{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PIyoZFtZJ0zv",
        "outputId": "008e9a08-f700-4b45-e7d9-9628bfab98ca"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Collecting PyPDF2\n",
            "  Downloading pypdf2-3.0.1-py3-none-any.whl.metadata (6.8 kB)\n",
            "Downloading pypdf2-3.0.1-py3-none-any.whl (232 kB)\n",
            "Installing collected packages: PyPDF2\n",
            "Successfully installed PyPDF2-3.0.1\n",
            "Note: you may need to restart the kernel to use updated packages.\n"
          ]
        }
      ],
      "source": [
        "pip install PyPDF2"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "5LMFme6UJVwl"
      },
      "outputs": [],
      "source": [
        "# Data read/write\n",
        "import PyPDF2\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "from PyPDF2 import PdfReader\n",
        "\n",
        "# Data Visualization\n",
        "from wordcloud import WordCloud\n",
        "import matplotlib.pyplot as plt\n",
        "from collections import Counter"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "Read pdf file by through PyPDF2 package"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "oaAuF8c6K1Ks"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "1874\n"
          ]
        }
      ],
      "source": [
        "\n",
        "path = r\"C:\\\\Users\\\\HP\\\\OneDrive\\\\Desktop\\\\Diagnosis\\\\2022, CURRENT Medical Diagnosis and Treatment- Original.pdf\"\n",
        "text_file = open( path ,\"rb\")\n",
        "# open file and read it through PyPDF2 packages\n",
        "reader = PdfReader(text_file)\n",
        "total_page = len(reader.pages)\n",
        "print(total_page)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 13,
      "metadata": {},
      "outputs": [],
      "source": [
        "def extract_articles_from_pdf(reader, start_page, end_page):\n",
        "    article_text = \"\"\n",
        "    for page_num in range(start_page, end_page):\n",
        "        pageObj = reader.pages[page_num]\n",
        "        extract = pageObj.extract_text().split(\"\\n\")\n",
        "        article_text += ' '.join(extract)\n",
        "        list_from_pdf.append(extract)\n",
        "    return article_text\n",
        "\n",
        "list_from_pdf = []\n",
        "\n",
        "# Extracting each article\n",
        "article1 = extract_articles_from_pdf(reader, 1632, 1696)\n",
        "article2 = extract_articles_from_pdf(reader, 1232, 1276)\n",
        "article3 = extract_articles_from_pdf(reader, 998, 1074)\n",
        "article4 = extract_articles_from_pdf(reader, 932, 972)\n",
        "article5 = extract_articles_from_pdf(reader, 463, 522)\n",
        "article6 = extract_articles_from_pdf(reader, 187, 221)\n",
        "\n",
        "# Creating a DataFrame\n",
        "articles = [article1, article2, article3, article4, article5, article6]\n",
        "df = pd.DataFrame(articles, columns=['string_values'])\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "metadata": {},
      "outputs": [],
      "source": [
        "article= article1 + \" \" + article2 + \" \" + article3 + \" \" + article4  + \" \" +article5 + \" \" + article6 \n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 14,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 638
        },
        "id": "hsovYBWZS-vJ",
        "outputId": "49140c66-d454-41b4-e7ac-bffc4918bcb6"
      },
      "outputs": [
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 1500x1000 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "\n",
        "word_cloud2 = WordCloud(collocations = False, background_color = 'white').generate(article)\n",
        "plt.figure(figsize=(15,10))\n",
        "plt.imshow(word_cloud2, interpolation='bilinear')\n",
        "plt.axis(\"off\")\n",
        "plt.show()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 15,
      "metadata": {},
      "outputs": [],
      "source": [
        "def get_freq_word(TEXT_list):\n",
        "    \"\"\"This method get count the frequency of each word in the passed parameter\"\"\"\n",
        "    Vocab_list = ' '.join(TEXT_list)\n",
        "    temp_dict = Counter(Vocab_list.split()).items()\n",
        "    freq_df = pd.DataFrame(temp_dict)\n",
        "    freq_df = freq_df.sort_values(1, ascending = False)\n",
        "    return freq_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 17,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 591
        },
        "id": "Zb2Psb8BTnDs",
        "outputId": "67a344c7-e797-48d3-be06-1f865c976ed4"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "c:\\Users\\HP\\anaconda3\\envs\\diagnosis\\Lib\\site-packages\\IPython\\core\\pylabtools.py:170: UserWarning: Glyph 57403 (\\ue03b) missing from font(s) DejaVu Sans.\n",
            "  fig.canvas.print_figure(bytes_io, **kw)\n"
          ]
        },
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 1500x1000 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "\n",
        "freq_words = get_freq_word(df.string_values)\n",
        "freq_words.columns = ['WORD', 'COUNT']\n",
        "\n",
        "plt.figure(figsize=(15,10))\n",
        "plt.bar(freq_words.WORD[:40], freq_words.COUNT[:40], color ='#ceeffa',\n",
        "        width = 0.4)\n",
        "plt.xticks(rotation=90 ,fontsize = 15)\n",
        "plt.yticks(fontsize = 15)\n",
        "plt.xlabel(\"Words\" , fontsize = 25)\n",
        "plt.ylabel(\"Repetition\", fontsize = 25)\n",
        "plt.title(\"Most Frequent Word\", fontsize = 30)\n",
        "plt.show();"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 18,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "showing info https://raw.githubusercontent.com/nltk/nltk_data/gh-pages/index.xml\n"
          ]
        },
        {
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "execution_count": 18,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "import nltk\n",
        "nltk.download()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "W-WLulpYJdLE",
        "outputId": "d729fc87-962f-455f-d979-b4c22cca3231"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "[nltk_data] Downloading package punkt to\n",
            "[nltk_data]     C:\\Users\\HP\\AppData\\Roaming\\nltk_data...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n",
            "[nltk_data] Downloading package stopwords to\n",
            "[nltk_data]     C:\\Users\\HP\\AppData\\Roaming\\nltk_data...\n",
            "[nltk_data]   Unzipping corpora\\stopwords.zip.\n",
            "[nltk_data] Downloading package wordnet to\n",
            "[nltk_data]     C:\\Users\\HP\\AppData\\Roaming\\nltk_data...\n",
            "[nltk_data]   Package wordnet is already up-to-date!\n"
          ]
        }
      ],
      "source": [
        "import ssl\n",
        "from nltk.tokenize import sent_tokenize\n",
        "from nltk.tokenize import word_tokenize\n",
        "ssl._create_default_https_context = ssl._create_unverified_context\n",
        "\n",
        "import nltk\n",
        "nltk.download('punkt')\n",
        "nltk.download('stopwords')\n",
        "nltk.download('wordnet')\n",
        "\n",
        "# Import WordNetLemmatizer, and stopwords\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "from nltk.corpus import stopwords\n",
        "\n",
        "# import spcay framework\n",
        "import spacy\n",
        "nlp = spacy.load('en_core_web_sm')\n",
        "from spacy.symbols import amod\n",
        "# Import Counter\n",
        "from collections import Counter\n",
        "nltk.download('punkt_tab')\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 27,
      "metadata": {},
      "outputs": [],
      "source": [
        "df['spacy_doc'] = list(nlp.pipe(df.string_values))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 73,
      "metadata": {},
      "outputs": [],
      "source": [
        "# Create an empty list to store the processed docs\n",
        "processed_docs = []\n",
        "\n",
        "# Process each text and split long ones\n",
        "for text in df['string_values']:\n",
        "        processed_docs.append(nlp(text))\n",
        "\n",
        "\n",
        "\n",
        "# Assign the processed docs back to the DataFrame\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 74,
      "metadata": {},
      "outputs": [],
      "source": [
        "df['spacy_doc'] = processed_docs"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 75,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "application/vnd.microsoft.datawrangler.viewer.v0+json": {
              "columns": [
                {
                  "name": "index",
                  "rawType": "int64",
                  "type": "integer"
                },
                {
                  "name": "string_values",
                  "rawType": "object",
                  "type": "string"
                },
                {
                  "name": "spacy_doc",
                  "rawType": "object",
                  "type": "unknown"
                }
              ],
              "conversionMethod": "pd.DataFrame",
              "ref": "7180a854-08e1-4e8e-b658-686eb61565fc",
              "rows": [
                [
                  "0",
                  "CANCER1613 CMDT 2022Office  of Disease Prevention and Health Promotion. Healthy People 2030. Tobacco use objectives: reduce tobacco use in adults. https://health.gov/healthypeople/objectives-and-data/ browse-objectives/tobacco-use/reduce-current-tobacco- use-adults-tu-01Table 39–1. Estimated 10 most common cancer cases in the United States in males and females (all races).R ankMales Females Total Cases [N] = 970,250 (100 percent)Total Cases [N] = 927,910 (100 percent) 1 Prostate 248,530 (26)Breast 281,550 (30) 2 Lung and bronchus 119,100 (12)Lung and bronchus 116,660 (13) 3 Colon and rectum 79,520 (8)Colon and rectum 69,980 (8) 4 Urinary bladder 64,280 (7)Uterine corpus 66,570 (7) 5 Melanoma 62,260 (6)Melanoma 43,850 (5) 6 Kidney and renal pelvis 48,780 (5)Non-Hodgkin lymphoma 35,930 (4) 7 Non-Hodgkin lymphoma 45,630 (5)Thyroid 32,130 (3) 8 Oral cavity and pharynx 38,800 (4)Pancreas 28,480 (3) 9 Leukemia 35,530 (4)Kidney and renal pelvis 27,300 (3) 10 Pancreas 31,950 (3)Leukemia 25,560 (3) Other sites 195,870 (20)Other sites 199,900 (21) Data from the American Cancer Society, 2021.Klein WMP et al. Alcohol and cancer risk: clinical and research implications. JAMA. 2020;323:23. [PMID: 31834355] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71:7. [PMID: 33433946] »StagingThe  TNM system is the commonly used classification to stage cancer. Staging is important not only because it cor- relates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Certain characteristics of cancers, not reflected in the TNM stage, may be used to indicate prognosis and guide treat- ment. Pathologic features seen on routine histologic examina- tion for some cancers are very important; examples include the Gleason score for prostate cancer, human papillomavirus (HPV) status of oropharyngeal cancer, and grade of sarcomas. Cancer specimens should also be sent for molecular diagnostic testing and programmed death-ligand 1 (PD-L1) expression testing when appropriate. Some examples of targeted molecu- lar testing include HER2 in breast and gastric cancer, K-ras and BRAF mutations in colorectal cancer and melanoma, and epidermal growth factor receptor (EGFR) and fusion genes (ALK andROS1 ) in lung cancer.Machczyńs ki P et al. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Otorhinolaryngol. 2020;277:2407. [PMID: 32342197] »TreatmentSee  Primary Cancer Treatment section below. Table 39–2 outlines treatment choices by cancer type for those respon- sive to systemic agents, and Table 39–3 provides a listing of common chemotherapeutic agents. Table 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Acute lymphoblastic leukemia (ALL)Induction combination cemoterapy (Piladelpia cromosome–positive): Cyclophosphamide, vincristine, doxorubicin/daunorubicin, dexamethasone (hyper-CVAD) alternating with cytarabine, methotrexate; add imatinib or dasatinib or nilotinib Induction combination cemoterapy (Piladelpia cromosome–negative): Daunorubicin, vincristine, prednisone, pegaspargase, cyclophosphamide; or hyper-CVAD alternating with methotrexate and cytarabine Maintenance cemoterapy: Methotrexate, 6-mercaptopurine, vincristine, prednisone Acute myeloid leukemia (AML) Induction combination cemoterapy: Cytarabine with daunorubicin or idarubicin, with gemtuzumab ozogamicin (CD33-positive), or with midostaurin ( FLT3-mutated), or with fludarabine Alternative cemoterapy for ≥ 60 years old: Azacitidine, decitabine, or low-dose cytarabine with or without venetoclax; or Liposomal encapsulation of cytarabine and daunorubicin (therapy-related or myelodysplasia-related changes) Ivosidenib ( IDH1 mutation); or Enasidenib ( IDH2 mutation) (continued )CMDT22_Ch39_p1612-p1675.indd  1613 02/07/21 2:44 PMChAPTER 391614 CMDT 2022T able 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Chronic myeloid leukemia (CML)Nilotinib or dasatinib or imatinib or bosutinib Chronic lymphocytic leukemia (CLL)Venetoclax with obinutuzumab, or acalabrutinib with or without obinutuzumab, or ibrutinib Hairy cell leukemia Cladribine with or without rituximab1or pentostatin Hodgkin lymphoma Combination cemoterapy: Doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), or Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) Non-Hodgkin lymphoma (intermediate and high grade)Combination cemoterapy: Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab1 (CHOP-R), or Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab1(dose-adjusted R-EPOCH) (for double-/triple-hit) Non-Hodgkin lymphoma (low grade)Combination cemoterapy: Bendamustine plus obinutuzumab or rituximab1, or Cyclophosphamide, vincristine, doxorubicin, prednisone, rituximab1(CHOP-R), or Cyclophosphamide, vincristine, prednisone, rituximab1(CVP-R), or Lenalidomide, rituximab1Plasma  cell myeloma Combination cemoterapy (transplant candidates): Bortezomib, dexamethasone, cyclophosphamide, or Bortezomib, dexamethasone, lenalidomide Followed by autologous or mini-allogeneic stem cell transplantation Combination cemoterapy (non-transplant candidates): Bortezomib, lenalidomide, dexamethasone, or Daratumumab, lenalidomide, dexamethasone, or Lenalidomide, dexamethasone, or Bortezomib, cyclophosphamide, dexamethasone Waldenström macroglobulinemiaPlasmaperesis alone or followed by combination cemoterapy: Ibrutinib with or without rituximab1Bortezomib,  dexamethasone, rituximab1, or Cyclophosphamide, dexamethasone, rituximab1, or Bendamustine, rituximab1Poly cythemia vera Phlebotomy or hydroxyurea or aspirin Non–small cell lung cancer Combination terapy: Cisplatin, etoposide, or Paclitaxel, carboplatin, or Cisplatin, gemcitabine or docetaxel (squamous histology), or Cisplatin, pemetrexed (nonsquamous histology), or Carboplatin, albumin-bound paclitaxel, or Dabrafenib/trametinib ( BRAF V600F mutation), or Carboplatin or cisplatin/pemetrexed/pembrolizumab (nonsquamous); carboplatin/paclitaxel or albumin-bound paclitaxel/pembrolizumab (squamous) Single-agent terapy: Erlotinib, gefitinib, osimertinib, afatinib, or dacomitinib ( EGFR mutation positive) Crizotinib, alectinib, ceritinib, or brigatinib ( ALKmutation positive) Ceritinib, crizotinib, or entrectinib ( ROS1 rearrangement) Larotrectinib or entrectinib ( NTRK gene fusion positive) Pembrolizumab (PD-L1 ≥ 1%) or atezolizumab (PD-L1 ≥ 50%) Small cell lung cancer Combination terapy: Cisplatin, etoposide (limited stage), or Cisplatin, etoposide, durvalumab (extensive stage), or Carboplatin, etoposide, atezolizumab or durvalumab (extensive stage) Mesothelioma Combination terapy: Cisplatin or carboplatin/pemetrexed with or without bevacizumab, or Nivolumab/ipilimumab (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1614 02/07/21 2:44 PMCANCER1615 CMDT 2022T able 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Head and neck cancer Cisplatin with radiation therapy, or Carboplatin with 5-fluorouracil with radiation therapy, or Docetaxel, cisplatin, 5-fluorouracil, or Cisplatin or carboplatin/5-fluorouracil/cetuximab, or Pembrolizumab (PD-L1 ≥ 1%), or Pembrolizumab/cisplatin or carboplatin/5-fluorouracil Esophageal and esophagogastric junction cancerCombination terapy: Cisplatin, 5-fluorouracil or capecitabine, or Paclitaxel, carboplatin, or Oxaliplatin, 5-fluorouracil or capecitabine, or 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) Add trastuzumab for HER2 -overexpressing metastatic adenocarcinoma Uterine cancer hormone terapy: Progestins, tamoxifen, aromatase inhibitors, or fulvestrant Combination cemoterapy: Carboplatin, paclitaxel Carboplatin, paclitaxel, trastuzumab ( HER2 positive) Ovarian cancer Combination cemoterapy: Paclitaxel, carboplatin, with or without bevacizumab, or 5-Fluorouracil/leucovorin or capecitabine, oxaliplatin Cervical cancer Wit radiation: Cisplatin or carboplatin Combination cemoterapy: Cisplatin or carboplatin, paclitaxel with or without bevacizumab Breast cancer Adjuvant ormone terapy: Premenopausal: Tamoxifen Postmenopausal: Aromatase inhibitors (anastrozole, letrozole, exemestane) Adjuvant cemoterapy ( HER2 negative): Doxorubicin, cyclophosphamide, followed by paclitaxel, or Docetaxel, cyclophosphamide Adjuvant cemoterapy ( HER2 positive): Doxorubicin, cyclophosphamide, followed by paclitaxel, trastuzumab with or without pertuzumab, or Docetaxel, carboplatin, trastuzumab with or without pertuzumab, or Paclitaxel, trastuzumab Gestational trophoblastic neoplasiaSingle-agent cemoterapy: Methotrexate or dactinomycin for low-risk disease Combination cemoterapy: Etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine (EMA-CO) for high-risk disease Testicular cancer Combination cemoterapy: Cisplatin, etoposide (EP), or Bleomycin, etoposide, cisplatin (BEP), or Etoposide, mesna, ifosfamide, cisplatin (VIP) Kidney (renal cell) cancer Clear cell istology: Axitinib plus pembrolizumab, ipilimumab plus nivolumab, pazopanib, sunitinib, or cabozantinib Non–clear cell istology: Sunitinib Bladder cancer Combination cemoterapy: Gemcitabine, cisplatin, or Methotrexate, vinblastine, doxorubicin, cisplatin (MVAC), or Atezolizumab, or pembrolizumab, or gemcitabine plus carboplatin (cisplatin ineligible) Prostate cancer hormone terapy: Luteinizing hormone–releasing agonist (leuprolide, goserelin, triptorelin, histrelin), or degarelix with or without an antiandrogen (flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide) or abiraterone Cemoterapy: Docetaxel or cabazitaxel or mitoxantrone with corticosteroid Brain cancer (anaplastic astro- cytoma and glioblastoma multiforme)Single-agent cemoterapy wit radiation terapy: Temozolomide Neuroblastoma Combination cemoterapy: Cyclophosphamide, doxorubicin, cisplatin, etoposide Thyroid cancer Single-agent terapy: Radioiodine (131I) or sorafenib, lenvatinib, vandetanib (medullary thyroid cancer) or cabozantinib (medullary thyroid cancer) Adrenal cancer Cisplatin or carboplatin with etoposide, with or without doxorubicin, with or without mitotane (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1615 02/07/21 2:44 PMChAPTER 391616 CMDT 2022T able 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Stomach (gastric) cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) (perioperative) 5-Fluorouracil or capecitabine with oxaliplatin or cisplatin Add trastuzumab for HER2 -overexpressing adenocarcinomas Pancreatic cancer Combination cemoterapy: Gemcitabine, nab-paclitaxel, or 5-Fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX), or Gemcitabine, capecitabine, or Gemcitabine, cisplatin (for BRCA1/2 orPALB2 mutation) Single-agent cemoterapy: Gemcitabine Colon cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin (FOLFOX) with or without bevacizumab, or Capecitabine, oxaliplatin (CAPEOX) with or without bevacizumab, or 5-Fluorouracil, leucovorin, irinotecan (FOLFIRI) with or without bevacizumab 5-Fluorouracil, leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) with or without bevacizumab Cetuximab or panitumumab added to FOLFOX or FOLFIRI for KRAS/NRAS/BRAF wild-type and left-sided tumors Capecitabine or 5-fluorouracil/leucovorin with or without bevacizumab Single-agent terapy: Nivolumab or pembrolizumab (deficient mismatch repair [dMMR]/high-level microsatellite instability [MSI-H]) Rectal cancer 5-Fluorouracil or capecitabine or FOLFOX or CAPEOX Anal cancer Mitomycin with 5-fluorouracil or capecitabine with radiation Carboplatin, paclitaxel with or without radiation therapy Carcinoid Octreotide LAR or lanreotide or everolimus or lutetium Lu 177-dotatate Osteosarcoma Combination cemoterapy: Cisplatin, doxorubicin, or Methotrexate, doxorubicin, cisplatin (MAP) Soft tissue sarcomas Combination cemoterapy: Doxorubicin, dacarbazine (AD), or Doxorubicin, ifosfamide, mesna (AIM), or Ifosfamide, epirubicin, mesna Single-agent terapy: Imatinib or sunitinib or regorafenib (gastrointestinal stromal tumors) Doxorubicin or epirubicin or liposomal doxorubicin Melanoma Pembrolizumab or nivolumab or nivolumab/ipilimumab (non- BRAF mutation) Dabrafenib/trametinib or vemurafenib/cobimetinib or encorafenib/binimetinib ( BRAF mutation) Hepatocellular cancer Sorafenib or lenvatinib or atezolizumab with bevacizumab Kaposi sarcoma Liposomal doxorubicin1 In patients with past hepatitis B virus (HBV) infection, rituximab should be used with anti-HBV agent (eg, entecavir) prophylax is since HBV reactivation, fulminant hepatitis, and, rarely, death can occur otherwise.T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating Agents—Nitrogen Mustards Bendamustine (Treanda) 100–120 mg/m2intravenously every 3–4 weeks Acute: hypersensitivity, nausea, vomiting Delayed: myelosuppression, rash, pyrexia, fatigue Cyclophosphamide (Cytoxan)500–1000 mg/m2intravenously every 3 weeks; 100 mg/m2/day orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, alopecia, hemorrhagic cystitis, cardiotoxicity (high dose) Ifosfamide (Ifex) 1200 mg/m2intravenously daily for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: alopecia, myelosuppression, hemorrhagic cystitis, neurotoxicity (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1616 02/07/21 2:44 PMCANCER1617 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating Agents—Platinum Analogs Carboplatin (Paraplatin) Area under the curve (AUC)–based dosing use Calvert equation [Dose (mg) = AUC × (GFR + 25)] AUC = 2–7 mg/mL/min every 2–4 weeksAcute: nausea and vomiting Delayed: myelosuppression, electrolyte disturbances, peripheral neuropathy, nephrotoxicity, hypersensitivity Cisplatin (Platinol) 50–100 mg/m2intravenously every 3–4 weeks; 20 mg/m2/day intravenously for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression, electrolyte disturbances Oxaliplatin (Eloxatin) 85–130 mg/m2intravenously every 2–3 weeks Acute: peripheral neuropathy exacerbated by cold, nausea, vomiting, diarrhea Delayed: myelosuppression, elevated transaminases Alkylating Agents—Triazenes Dacarbazine (DTIC-Dome) 375 mg/m2intravenously on days 1 and 15 every 4 weeks; 900–1000 mg/m2intrave- nously over 3 to 4 days; various dosesAcute: nausea, vomiting, photosensitivity Delayed: myelosuppression, anorexia, hypotension, flu-like syndrome Procarbazine (Matulane) 60–100 mg/m2orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, disulfiram-like reaction, MAO inhibition, rash Temozolomide (Temodar) 75 mg/m2orally daily during radiation for 42 days; 150–200 mg/m2orally for 5 days every 4 weeksAcute: nausea, vomiting, constipation Delayed: myelosuppression, fatigue Antimetabolites—Folate Antagonists Methotrexate (MTX; Trexall)Intratecal: 12 mg hig dose: 1000–12,000 mg/m2intravenously every 2–3 weeksAcute: nausea, vomiting, mucositis Delayed: myelosuppression, nephrotoxicity, hepatotoxicity, neurotoxicity, photosensitivity, pulmonary toxicity Pemetrexed (Alimta) 500 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, fatigue, mucositis Antimetabolites—Purine Analogs Fludarabine (Fludara) 25 mg/m2intravenously for 5 days every 4 weeksAcute: fever, nausea, vomiting Delayed: asthenia, myelosuppression, immunosuppression, neurotoxicity, anorexia Mercaptopurine (6-MP; Purinethol)Induction: 2.5–5 mg/kg/day orally Maintenance: 1.5–2.5 mg/kg/day orallyAcute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, immunosuppression, hepatotoxicity, mucositis Antimetabolites—Pyrimidine Analogs Azacitidine (Vidaza) 75–100 mg/m2subcutaneously or intravenously for 7 days every 4 weeksAcute: injection site reaction (subcutaneously), nausea, diarrhea, fever Delayed: myelosuppression, dyspnea, arthralgia Capecitabine (Xeloda) 1000–1250 mg/m2orally twice a day for 14 days every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: hand-foot syndrome, mucositis, hyperbilirubinemia, myelosuppression Cytarabine (Ara-C, Cytosar U)Standard dose: 100 mg/m2/day intravenously via continuous infusion for 7 days hig dose: 1000–3000 mg/m2intravenously every 12 hours for 2–6 daysAcute: nausea, vomiting, rash, flu-like syndrome Delayed: myelosuppression High-dose: neurotoxicity, ocular toxicities Decitabine (Dacogen) 15 mg/m2intravenously every 8 hours for 3 days every 8 weeks; 20 mg/m2intravenously daily for 5 daysAcute: nausea, vomiting, hyperglycemia Delayed: myelosuppression, fever, fatigue, cough Fluorouracil (Adrucil) 400 mg/m2intravenous bolus followed by 2400 mg/m2intravenously over 46 hours every 2 weeks; 1000 mg/m2intravenously via continuous infusion for 4–5 days every 3–4 weeks; various dosesAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, hand-foot syndrome, mucositis, photosensitivity, cardiotoxicity (rare) (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1617 02/07/21 2:44 PMChAPTER 391618 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Antimetabolites—Pyrimidine Analogs (cont.) Gemcitabine (Gemzar) 1000–1250 mg/m2intravenously on days 1 and 8 every 3 weeks or days 1, 8, 15 every 4 weeksAcute: nausea, vomiting, rash, flu-like symptoms, fever, diarrhea Delayed: myelosuppression, edema, elevated transaminases Antimicrotubules—Vinca Alkaloids Vinblastine (Velban) 6 mg/m2intravenously on days 1 and 15 every 4 weeks; various dosesAcute: constipation Delayed: myelosuppression, alopecia, bone pain, malaise Vincristine (Oncovin) 0.5–1.4 mg/m2intravenously every 3 weeks; various doses; maximum single dose usually limited to 2 mgAcute: constipation, nausea Delayed: peripheral neuropathy, alopecia Antimicrotubules—Taxanes Docetaxel (Taxotere) 60–100 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, hypersensitivity, rash Delayed: myelosuppression, asthenia, peripheral neuropathy, alopecia, edema, mucositis Paclitaxel (Taxol) 135–175 mg/m2intravenously every 3 weeks; 50–80 mg/m2intravenously weekly; various dosesAcute: diarrhea, nausea, vomiting, hypersensitivity Delayed: myelosuppression, peripheral neuropathy, alopecia, mucositis, arthralgia Paclitaxel protein-bound (Abraxane)100–125 mg/m2on days 1, 8, 15 every 3–4 weeks; 260 mg/m2intravenously every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, peripheral neuropathy, alopecia, asthenia Enzyme Inibitors—Antracyclines Daunorubicin (Cerubidine) 30–60 mg/m2intravenously for 3 days Acute: nausea, vomiting, diarrhea, red/orange discoloration of urine, infusion-related reactions (liposomal products) Delayed: myelosuppression, mucositis, alopecia, hand-foot syndrome (liposomal doxorubicin), cardiotoxicity (dose related) Doxorubicin (Adriamycin) 45–75 mg/m2intravenously every 3 weeks; various doses Epirubicin (Ellence) 60–120 mg/m2intravenously every 3–4 weeks Idarubicin (Idamycin) 10–12 mg/m2intravenously for 3 days Liposomal doxorubicin (Doxil, Lipodox)20–50 mg/m2intravenously every 3–4 weeks Enzyme Inibitors—Topoisomerase Inibitors Etoposide (Vepesid) 50–100 mg/m2intravenously for 3–5 days every 3 weeksAcute: nausea, vomiting, diarrhea, hypersensitivity, fever, hypotension Delayed: myelosuppression, alopecia, fatigue Irinotecan (Camptosar) 180 mg/m2intravenously every other week; various dosesAcute: diarrhea, cholinergic syndrome, nausea, vomiting Delayed: myelosuppression, alopecia, asthenia Targeted Terapy—Monoclonal Antibodies Atezolizumab (Tecentriq) 1200 mg intravenously every 3 weeks Acute: infusion-related reaction Delayed: immune-mediated reactions, fatigue, decreased appetite Bevacizumab (Avastin) 5–15 mg/kg intravenously every 2–3 weeks Acute: infusion-related reaction Delayed: hypertension, proteinuria, wound healing compli- cations, gastrointestinal perforation, hemorrhage Cetuximab (Erbitux) Loading dose 400 mg/m2intravenously, maintenance dose 250 mg/m2intravenously weeklyAcute: infusion-related reaction, nausea, diarrhea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychial inflammation, dyspnea Daratumumab (Darzalex) 16 mg/kg intravenously weekly for weeks 1–8, every 2 weeks for weeks 9–24, and every 4 weeks from week 25 until disease progressionAcute: infusion-related reaction, nausea Delayed: myelosuppression, fatigue, upper respiratory tract infection (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1618 02/07/21 2:44 PMCANCER1619 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted Terapy—Monoclonal Antibodies (cont.) Ipilimumab (Yervoy) 1–10 mg/kg intravenously every 3 weeks for a total of four dosesAcute: infusion-related reaction Delayed: immune-related reactions, fatigue Nivolumab (Opdivo) 240 mg intravenously every 2 weeks or 480 mg every 4 weeksAcute: vomiting Delayed: fatigue, musculoskeletal pain, rash, pruritus, cough, elevated transaminases Obinutuzumab (Gazyva) Cycle 1: 100 mg intravenously on day 1, 900 mg on day 2, 1000 mg on days 8 and 15 of a 28-day cycle; cycles 2–6: 1000 mg intrave- nously on day 1Acute: infusion-related reaction, tumor lysis syndrome Delayed: myelosuppression, pyrexia, cough, musculoskeletal disorder, potential hepatitis B reactivation Panitumumab (Vectibix) 6 mg/kg intravenously every 2 weeks Acute: infusion-related reaction, nausea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychia, fatigue, dyspnea Pembrolizumab (Keytruda) 200 mg intravenously every 3 weeks or 400 mg every 6 weeksAcute: infusion-related reaction, nausea Delayed: immune-mediated reactions, fatigue, cough Pertuzumab (Perjeta) 840 mg intravenously once followed by 420 mg intravenously every 3 weeksAcute: infusion-related reaction, diarrhea, nausea Delayed: fatigue, alopecia, neutropenia, rash, peripheral neuropathy, cardiomyopathy Rituximab (Rituxan) 375 mg/m2intravenously weekly for 4 weeks, or every 3–4 weeksAcute: infusion-related reaction, tumor lysis syndrome Delayed: lymphopenia, asthenia, rash, potential hepatitis B reactivation Trastuzumab (Herceptin) Initial dose 4 mg/kg intravenously, then 2 mg/kg intravenously weekly; or initial dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeksAcute: headache, nausea, diarrhea, infusion-related reaction Delayed: myelosuppression, pyrexia, cardiomyopathy, pulmonary toxicity (rare) Targeted Terapy—Kinase Inibitors Acalabrutinib 100 mg orally twice daily Acute: diarrhea Delayed: myelosuppression, upper respiratory infection, musculoskeletal pain Afatinib (Gilotrif) 40 mg orally once daily without food Acute: diarrhea Delayed: acneiform rash, stomatitis, paronychia Alectinib (Alecensa) 600 mg orally twice daily with food Acute: none Delayed: myelosuppression, fatigue, edema, myalgia, dyspnea, elevated transaminases Axitinib (Inlyta) 5–10 mg orally twice daily Acute: diarrhea, nausea, vomiting Delayed: hypertension, fatigue, dysphonia, hand-foot syndrome, elevated transaminases Bosutinib (Bosulif) 500–600 mg orally once daily with food Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, rash, abdominal pain, hepatotoxicity, fluid retention Ceritinib (Zykadia) 740 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: elevated transaminases, abdominal pain, fatigue, decreased appetite Cobimetinib (Cotellic) 60 mg orally once daily on days 1–21 of a 28-day cycleAcute: diarrhea, photosensitivity reaction, nausea, vomiting Delayed: myelosuppression, hepatotoxicity, rash, cardiomyopathy (with vemurafenib) Crizotinib (Xalkori) 250 mg orally twice daily Acute: nausea, vomiting, diarrhea, constipation Delayed: vision disorder, edema, elevated transaminases, fatigue Dabrafenib (Tafinlar) 150 mg orally twice daily without food Acute: headache Delayed: hyperkeratosis, fever, hand-foot syndrome, hyperglycemia, hypophosphatemia Dacomitinib (Vizimpro) 45 mg orally once daily Acute: diarrhea Delayed: rash, paronychia, mucositis, cough, interstitial lung disease (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1619 02/07/21 2:44 PMChAPTER 391620 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted Terapy—Kinase Inibitors (cont.) Dasatinib (Sprycel) 100–180 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, fluid retention, fatigue, dyspnea, musculoskeletal pain, rash Entrectinib (Rozlytrek) 600 mg orally daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, heart failure, potential for birth defects, hepatotoxicity, vision disorder, prolonged QT interval (rare) Erlotinib (Tarceva) 100 or 150 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: acneiform skin rash, fatigue, anorexia, dyspnea Gefitinib (Iressa) 250 mg orally once daily Acute: diarrhea Delayed: acneiform skin rash Ibrutinib (Imbruvica) 420 or 560 mg orally once daily Acute: diarrhea, nausea Delayed: myelosuppression, fatigue, edema, rash, elevated serum creatinine, hemorrhage Imatinib (Gleevec) 100–800 mg orally once daily with food Acute: nausea, vomiting, diarrhea Delayed: edema, muscle cramps, rash, myelosuppression, hepatotoxicity Larotrectinib (Vitrakvi) 100 mg orally twice daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, potential for birth defects, hepatotoxicity Lenvatinib (Lenvima) 24 mg orally daily Acute: hypertension, nausea, vomiting, diarrhea Delayed: fatigue, arthralgia/myalgia, stomatitis, hand-foot syndrome Nilotinib (Tasigna) 300 or 400 mg orally twice daily without food Acute: nausea, vomiting, diarrhea Delayed: rash, fatigue, myelosuppression, prolonged QT interval (rare) Osimertinib (Tagrisso) 80 mg orally once daily Acute: diarrhea Delayed: myelosuppression, rash, dry skin, nail toxicity, cardiomyopathy (rare), QTc interval prolongation (rare) Pazopanib (Votrient) 800 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: hypertension, hair color changes, hepatotoxicity, hemorrhage Regorafenib (Stivarga) 160 mg orally once daily with food (low-fat breakfast)Acute: diarrhea Delayed: asthenia, hand-foot syndrome, anorexia, hyperten- sion, mucositis, myelosuppression, hepatotoxicity Sorafenib (Nexavar) 400 mg orally twice daily without food Acute: diarrhea and nausea Delayed: fatigue, hand-foot syndrome, rash, hypertension, hemorrhage Sunitinib (Sutent) 50 mg orally once daily for 4 weeks followed by 2 weeks rest; 37.5 mg orally dailyAcute: diarrhea and nausea Delayed: hypertension, hand-foot syndrome, rash, yellow discoloration of skin, fatigue, hypothyroidism, mucositis, left ventricular dysfunction, bleeding, hepatotoxicity Trametinib (Mekinist) 2 mg orally once daily without food Acute: rash, diarrhea Delayed: elevated transaminases, lymphedema, cardiomyopathy Vemurafenib (Zelboraf) 960 mg orally twice daily Acute: nausea, hypersensitivity (rare) Delayed: photosensitivity, rash, arthralgia, alopecia, fatigue, prolonged QT interval, cutaneous squamous cell carcinoma (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1620 02/07/21 2:44 PMCANCER1621 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Miscellaneous Agents Abiraterone (Zytiga) 1000 mg orally once daily Acute: diarrhea, edema Delayed: adrenal insufficiency, hepatotoxicity, joint pain, hypokalemia Bleomycin (Blenoxane) 10 units/m2intravenously on days 1 and 15 every 28 days; 30 units intravenously on days 2, 9, and 16 every 21 daysAcute: hypersensitivity, fever Delayed: skin reaction (rash, hyperpigmentation of skin, striae), mucositis, pneumonitis Bortezomib (Velcade) 1.3 mg/m2intravenous bolus or subcutaneously on days 1, 4, 8, 11 followed by a 10-day rest, or weekly for 4 weeks followed by 13-day restAcute: nausea, vomiting, diarrhea Delayed: peripheral neuropathy, fatigue, myelosuppression Hydroxyurea (Hydrea) 20–30 mg/kg orally daily Acute: none Delayed: myelosuppression Lenalidomide (Revlimid) 5–25 mg orally once daily on days 1–21 of 28-day cycle; or continuouslyAcute: diarrhea, rash Delayed: myelosuppression, fatigue, venous thromboembolism, potential for birth defects Mitomycin (Mutamycin) 10–20 mg/m2intravenously every 4–8 weeks; 20–40 mg intravesicallyAcute: cystitis (intravesically), nausea, vomiting Delayed: myelosuppression, mucositis, anorexia Pegaspargase (Oncaspar) 2000–2500 international units/m2intramuscu- larly every 14 daysAcute: hypersensitivity Delayed: febrile neutropenia, coagulation abnormalities, hepatotoxicity, pancreatitis Venetoclax (Venclexta) 20 mg orally daily during week 1; 50 mg daily during week 2; 100 mg daily during week 3; 200 mg daily during week 4; then 400 mg orally daily thereafterAcute: diarrhea, nausea, vomiting, tumor lysis syndrome Delayed: myelosuppression, upper respiratory infections, fatigue Antiandrogens Apalutamide (Erleada) 240 mg orally daily Acute: fatigue, diarrhea Delayed: arthralgia, hot flashes, falls, peripheral edema, seizure (rare) Bicalutamide (Casodex) 50 mg orally once daily Acute: none Delayed: hot flashes, back pain, asthenia Enzalutamide (Xtandi) 160 mg orally once daily Acute: asthenia, diarrhea Delayed: hot flashes, arthralgia, peripheral edema, seizure (rare) Flutamide (Eulexin) 250 mg orally every 8 hours Acute: diarrhea Delayed: hot flashes, hepatotoxicity Nilutamide (Nilandron) 300 mg orally for 30 days, then 150 mg orally once dailyAcute: none Delayed: visual disturbances (impaired adaptation to dark), hot flashes, disulfiram-like reaction Selective Estrogen Receptor Modulators Tamoxifen (Nolvadex) 20–40 mg orally once daily Acute: none Delayed: hot flashes, vaginal discharge, menstrual irregularities, arthralgia Aromatase Inibitors Anastrozole (Arimidex) 1 mg orally once daily Acute: nausea Delayed: hot flashes, peripheral edema, asthenia, hypercholesterolemia, arthralgia/myalgia, osteoporosis Exemestane (Aromasin) 25 mg orally once daily Letrozole (Femara) 2.5 mg orally once daily (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1621 02/07/21 2:44 PMChAPTER 391622 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Pure Estrogen Receptor Antagonist Fulvestrant (Faslodex) 500 mg intramuscularly on days 1, 15, 29, then monthlyAcute: injection site reaction, nausea Delayed: hot flashes, bone pain, elevated transaminases LhRh Analogs Goserelin acetate (Zoladex)3.6 mg subcutaneously every month; 10.8 mg subcutaneously every 3 monthsAcute: injection site discomfort Delayed: hot flashes, tumor flare, edema, decreased libido, erectile dysfunction, osteoporosis Leuprolide (Lupron) 7.5 mg intramuscularly or subcutaneously every month; 22.5 mg intramuscularly or subcuta- neously every 3 months; 30 mg intramuscu- larly or subcutaneously every 4 months; 45 mg intramuscularly or subcutaneously every 6 months Triptorelin pamoate (Trelstar)3.75 mg intramuscularly every 4 weeks; 11.25 mg intramuscularly every 12 weeks; 22.5 mg intramuscularly every 24 weeks LhRh Antagonist Degarelix (Firmagon) 240 mg subcutaneously once, then 80 mg subcutaneously every 28 daysAcute: injection site reaction Delayed: hot flashes, weight gain, elevated transaminases, QT prolongation AV, atrioventricular; GFR, glomerular filtration rate; LHRH, luteinizing hormone–releasing hormone; MAO, monoamine oxidase; MCV , mean corpuscular volume. ºTYPES OF CANCER LUNG CANCER Sunny Wang, MD BRONCHOGENIC CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »New cough or change in chronic cough. »Dyspnea, hemoptysis, anorexia, weight loss. »Enlarging lung nodule or mass; persistent opacity, atelectasis, or pleural effusion on chest radiograph or CT scan. »Cytologic or histologic findings of lung cancer in sputum, pleural fluid, or biopsy specimen. »General ConsiderationsLung  cancer is the leading cause of cancer deaths in both men and women. The American Cancer Society estimates 228,820 new diagnoses and 135,720 deaths from lung can- cer in the United States in 2020, accounting for approxi- mately 13% of new cancer diagnoses and 22% of all cancer deaths. More Americans die of lung cancer than of colorec- tal, breast, and prostate cancers combined.Cigarette smoking causes 85–90% of cases of lung cancer. The causal connection between cigarettes and lung cancer is established not only epidemiologically but also through identification of carcinogens in tobacco smoke and analysis of the effect of these carcinogens on specific oncogenes expressed in lung cancer. Other environmental risk factors for the development of lung cancer include exposure to environmental tobacco smoke, radon, asbestos, diesel exhaust, ionizing radiation, metals (arsenic, chromium, nickel, iron oxide), and indus- trial carcinogens. A familial predisposition to lung cancer is recognized. Certain diseases are associated with an increased risk of lung cancer, including pulmonary fibrosis, chronic obstructive pulmonary disease, and sarcoidosis. The median age at diagnosis of lung cancer in the United States is 70; it is unusual under the age of 40. The combined relative 5-year survival rate for all stages of lung cancer is currently 21%. There are five main histologic categories of broncho- genic carcinoma. Squamous cell carcinomas (23% of cases, based on US SEER data 2013–2017) arise from the bronchial epithelium and often present as intraluminal masses. They are usually centrally located and can present with hemoptysis. Adenocarcinomas (50% of cases) arise from mucous glands or from any epithelial cell within or distal to the terminal bronchioles. They usually present as peripheral nodules or masses. Adenocarcinomas in situ (formerly bronchioloalveolar cell carcinomas) spread along preexisting alveolar structures (lepidic growth) with- out evidence of invasion. Large cell carcinomas (1.3% of(continued)CMDT22_Ch39_p1612-p1675.indd  1622 02/07/21 2:44 PMCANCER1623 CMDT 2022cases)  are a heterogeneous group of undifferentiated can- cers that share large cells and do not fit into other catego- ries. Large cell carcinomas are typically aggressive and have rapid doubling times. They present as central or peripheral masses. Cancers that are not better differentiated on patho- logic review other than non–small cell carcinomas (NSCLC) or carcinomas not otherwise specified make up about 13% of cases. Small cell carcinomas (13% of cases) are tumors of bronchial origin that typically begin cen- trally, infiltrating submucosally to cause narrowing of the bronchus without a discrete luminal mass. They are aggres- sive cancers that often involve regional or distant metastasis on presentation. For purposes of staging and treatment, bronchogenic carcinomas are divided into small cell lung cancer (SCLC) and the other four types, labeled NSCLC. This practical classification reflects different natural histories and differ- ent treatment. SCLC is prone to early hematogenous spread and has a more aggressive course with a median survival (untreated) of 6–18 weeks. »Clinical FindingsLun g cancer is symptomatic at diagnosis in a majority of patients. The clinical presentation depends on the type and location of the primary tumor, the extent of local spread, and the presence of distant metastases and any paraneo- plastic syndromes.A.  Symptoms and SignsAnor exia, weight loss, or asthenia occurs in 55–90% of patients presenting with a new diagnosis of lung cancer. Up to 60% of patients have a new cough or a change in a chronic cough; 6–31% have hemoptysis; and 25–40% com- plain of pain, either nonspecific chest pain or pain from bony metastases to the vertebrae, ribs, or pelvis. Local spread may cause endobronchial obstruction with atelectasis and postobstructive pneumonia, pleural effusion (12–33%), change in voice (compromise of the recurrent laryngeal nerve), superior vena cava syndrome (obstruc- tion of the superior vena cava with supraclavicular venous engorgement), and Horner syndrome (ipsilateral ptosis, miosis, and anhidrosis from involvement of the inferior cervical ganglion and the paravertebral sympathetic chain). Distant metastases to the liver are associated with asthenia and weight loss. Brain metastases (10% in NSCLC, more common in adenocarcinoma, and 20–30% in SCLC) may present with headache, nausea, vomiting, seizures, dizzi- ness, or altered mental status. Paraneoplastic syndromes are patterns of organ dys- function related to immune-mediated or secretory effects of neoplasms. These syndromes occur in 10–20% of lung cancer patients. They may precede, accompany, or follow the diagnosis of lung cancer. In patients with small cell carcinoma, the syndrome of inappropriate antidiuretic hormone (SIADH) can develop in 10–15%; in those with squamous cell carcinoma, hypercalcemia can develop in 10%. Digital clubbing is seen in up to 20% of patients at diagnosis (see Figure 6–42). Other common paraneoplastic syndromes include increased ACTH production, anemia,hypercoagulability, peripheral neuropathy, and the Lambert- Eaton myasthenic syndrome. Their recognition is important because treatment of the primary tumor may improve or resolve symptoms even when the cancer is not curable.B.  Laboratory FindingsThe diagnosis of lu ng cancer rests on examination of a tis- sue or cytology specimen. Sputum cytology is highly spe- cific but insensitive; the yield is highest when there are lesions in the central airways. While the diagnostic yield of CT-guided biopsy of peripheral nodules approaches 80–90%, the rates of pneumothorax are significant (15–30%), especially in those with emphysema. Thoracentesis (sensi- tivity 50–65%) can be used to establish a diagnosis of lung cancer in patients with malignant pleural effusions. Fine-needle aspiration (FNA) of palpable supraclavicular or cervical lymph nodes is frequently diagnostic. Fiberoptic bronchoscopy allows visualization of the major airways, cytology brushing of visible lesions or lavage of lung segments with cytologic evaluation of speci- mens, direct biopsy of endobronchial abnormalities, blind transbronchial biopsy of the pulmonary parenchyma or peripheral nodules, and FNA biopsy of mediastinal lymph nodes. The use of fluorescence bronchoscopy improves the ability to identify early endobronchial lesions, and endo- bronchial and transesophageal endoscopic ultrasound enhance the direction and yield of FNA of mediastinal nodes. Electromagnetic navigational bronchoscopy allows bronchoscopic approaches to small peripheral nodules. Mediastinoscopy, video-assisted thoracoscopic surgery (VATS), and thoracotomy may be necessary in cases where less invasive techniques fail to yield a diagnosis.C.  ImagingNear ly all patients with lung cancer have abnormal find- ings on chest radiography or CT scan (Figure 39–1). These findings are rarely specific for a particular diagnosis. Inter- pretation of characteristic findings in isolated nodules is described in Chapter 9.D . Special Examinations1. Staging—  Accurate staging is crucial (1) to provide the clinician with information to guide treatment, (2) to pro- vide the patient with accurate information regarding prog- nosis, and (3) to standardize entry criteria for clinical trials to allow interpretation of results. Staging of NSCLC uses two integrated systems and is continuously updated with the eighth edition of the AJCC/ Union for International Cancer Control (UICC) stage classification for lung cancer in effect since January 2018. TheAJCC TNM international staging system attempts a physical description of the neoplasm: T describes the size and location of the primary tumor; N describes the pres- ence and location of nodal metastases; and M refers to the presence or absence of distant metastases. These TNM stages are grouped into summary stages I–IV , and these are used to guide therapy. Many patients with stage I and stage II disease are cured through surgery. Patients with stage IIIB and stage IV disease do not benefit from surgeryCMDT22_Ch39_p1612-p1675.indd  1623 02/07/21 2:44 PMChAPTER 391624 CMDT 2022 ▲Figure 39–1. Squamous cell carcinoma of the right lung on chest radiograph (A)and CT scan (B).(Repro- duced, with permission, from Elsayes KM, Oldham SA. Introduction to Diagnostic Radiology. McGraw-Hill, 2014.) A B(T able 39–4). Patients with stage IIIA disease have locally invasive disease that may benefit from surgery in selected cases as part of multimodality therapy. SCLC is traditionally divided into two categories: limited disease (30%), when the tumor is limited to the unilateral hemithorax (including contralateral mediastinal nodes); or extensive disease (70%), when the tumor extends beyond the hemithorax (including pleural effu- sion). It is also recommended to stage SCLC according to the TNM staging system. For both SCLC and NSCLC, a complete examination is essential to exclude obvious metastatic disease to lymph nodes, skin, and bone. A detailed history is essential because the patient’s performance status is a powerful pre- dictor of disease course. All patients should have measure- ment of a complete blood count (CBC), serum electrolytes, calcium, creatinine, liver biochemical tests, lactate dehy- drogenase, and albumin.NSCLC patients being considered for surgery require meticulous evaluation to identify those with resectable disease. CT imaging is key for staging candidates for resec- tion. The sensitivity and specificity of CT imaging for identifying lung cancer metastatic to the mediastinal lymph nodes are 57% (49–66%) and 82% (77–86%), respectively. Therefore, chest CT imaging alone does not provide definitive staging information. CT imaging helps determine where to biopsy, and how the mediastinum should be sampled. Positron emission tomography (PET) using 2-[18F] fluoro-2-deoxyglucose (FDG) is an important modality for identifying metastatic foci in the mediastinum or distant sites. The sensitivity and specificity of PET for detecting mediastinal spread of primary lung cancer depend on the size of mediastinal nodes or masses. When mediastinal lymph nodes smaller than 1 cm are present, the sensitivity and specificity of PET for tumor involvement of nodes are 74% and 96%, respectively. When CT shows lymph nodes larger than 1 cm, the sensitivity and specificity are 95% and 76%, respectively. The combination of PET and CT imaging has improved preoperative staging compared with CT or PET alone. Whole body fusion PET-CT imaging is most useful toTable 39–4. Five-year survival rates for non–small cell lung cancer, based on TNM staging.Stage TNM Subset5-Year Survival for Clinical TNM5-Year Survival for Pato- logic TNM 0 Carcinoma in situ 1A1 T1aN0M0 92% 90% 1A2 T1bN0M0 83% 85% IA3 T1cN0M0 77% 80% IB T2aN0M0 68% 73% IIA T2bN0M0 60% 65% IIB T1/T2, N1M0 T3N0M053% 56% IIIA T1/T2, N2M0 T3N1M0 T4, N0/N1, M036% 41% IIIB T1/T2, N3M0 T3/T4, N2M026% 24% IIIC T3/T4, N3M0 13% 12% IVA Any T, Any N, M1a/M1b10% — IVB Any T, Any N, M1c 0% — Data from multiple sources. Modified and reproduced, with per- mission, from Detterbeck FC et al. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017;151:193. Copyright © Elsevier; and data from Goldstraw P et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;11:39.CMDT22_Ch39_p1612-p1675.indd  1624 02/07/21 2:44 PMCANCER1625 CMDT 2022confirm  lack of regional or metastatic disease in NSCLC patients who are candidates for surgical resection. Obtaining an MRI of the brain is important to rule out brain metastases in patients with SCLC and in patients with NSCLC with at least stage II disease or poorly differ- entiated histologies. 2. Preoperative assessment— See Chapter 3. 3. Pulmonary function testing— Many patients with NSCLC have moderate to severe chronic lung disease that increases the risk of perioperative complications as well as long-term pulmonary insufficiency following lung resec- tion. All patients considered for surgery require spirome- try. In the absence of other comorbidities, patients with good lung function (preoperative FEV12 L or more) are at low risk for complications from lobectomy or pneumonec- tomy. High-risk patients include those with a predicted postoperative FEV1less than 700 mL (or less than 40% of predicted FEV1). 4. Screening— Screening with low-dose helical CT scans has been shown to improve mortality rates for lung cancer. The National Lung Screening Trial, a multicenter random- ized US trial involving over 53,000 current and former heavy smokers, showed that screening annually with low- dose helical CT for 3 years yielded a 20% relative reduction in lung cancer mortality and 6.7% reduction in all-cause mortality compared to chest radiography. Given these find- ings, US professional organizations have recommended annual screening with low-dose helical CT for lung cancer. The 2021 US Preventive Services Task Force (USPSTF) recommends annual low-dose CT for smokers aged 50–80 who have at least a 20 pack-year smoking history and who either currently smoke or have quit within the last 15 years. Smoking cessation policies and efforts should be integrated with any screening program. »TreatmentA.  Non–Small Cell Lung CarcinomaSurgic al resection offers the best chance for cure of NSCLC. Clinical features that preclude complete surgical resection include extrathoracic metastases or a malignant pleural effusion; or tumor involving the heart, pericar- dium, great vessels, esophagus, recurrent laryngeal or phrenic nerves, trachea, main carina, or contralateral mediastinal lymph nodes. Accordingly, stage I and stage II patients are treated with surgical resection where possible. Stage II and select cases of stage IB are additionally recom- mended to receive adjuvant chemotherapy. Stage IIIA patients have poor outcomes if treated with resection alone. They should undergo multimodality treatment that includes chemotherapy or radiotherapy, or both. Inopera- ble stage IIIA and stage IIIB patients treated with concur- rent chemotherapy and radiation therapy have improved survival. Stage IV patients are treated with systemic ther- apy (targeted therapy, chemotherapy, or immunotherapy) or symptom-based palliative therapy, or both. Surgical approach affects outcome. In 1994, the North American Lung Cancer Study Group conducted a prospec- tive trial of stage IA patients randomized to lobectomyversus limited resection. They reported a threefold increased rate of local recurrence in the limited resection group (P= 0.008) and a trend toward an increase in overall death rate (increase of 30%, P= 0.08) and increase in cancer- related death rate (increase of 50%, P= 0.09), compared with patients receiving lobectomy. However, for patients who cannot tolerate lobectomy, a sublobar resection (wedge resection or segmentectomy) may be considered. Patients with clinical stage I primary NSCLC, who are not candidates for surgery because of significant comor- bidity or other surgical contraindication, are candidates for stereotactic body radiotherapy. Stereotactic body radio- therapy, which is composed of multiple non-parallel radia- tion beams that converge, allows the delivery of a relatively large dose of radiation to a small, well-defined target. For clinical stage I NSCLC, 3-year local control rates with ste- reotactic body radiotherapy exceed 90%, and large meta- analyses of nonrandomized data have shown 2-year survival of 70% and 5-year survival of 40%. Patients with locally advanced disease (stages IIIA and IIIB) who are not surgical candidates have improved survival when treated with concurrent chemotherapy and radiation therapy com- pared with no therapy, radiation alone, or even sequential chemotherapy and radiation. Neoadjuvant chemotherapy consists of giving antineo- plastic drugs in advance of surgery or radiation therapy. Neoadjuvant therapy can be used in select patients with stage IIIA or stage IIIB disease. Some studies suggest a survival advantage. Adjuvant chemotherapy consists of administering antineoplastic drugs following surgery or radiation ther- apy. Cisplatin-containing regimens have been shown to confer an overall survival benefit in at least stage II disease and a subset of stage IB disease where primary tumor size exceeds 4 cm. The Lung Adjuvant Cisplatin Evaluation Collaborative Group, a meta-analysis of the five largest cisplatin-based adjuvant trials, reported a 5% absolute ben- efit in 5-year overall survival with a cisplatin-containing doublet regimen following surgery ( P= 0.005) in patients with at least stage II disease. For stage IIIB and stage IV NSCLC, options for therapy include targeted therapy, cytotoxic chemotherapy, and immunotherapy (checkpoint inhibitors) (Tables 39–2 and 39–3). The approach to therapy is individualized based on molecular profiling and PD-L1 testing. Molecular profiling is offered as next-generation sequencing multi-gene assays. The key driver mutations in lung cancer currently include EGFR, ALK, BRAF, ROS1, NTRK ,MET, and RET muta- tions, but only a minority of all lung cancer cases harbor these mutations. K-ras mutation is more commonly found among smokers. Difficulties in testing may arise when only small fine-needle aspirate biopsies are obtained; to have sufficient tissue for analysis, it is recommended that clini- cians obtain core biopsies. PD-L1 expression is a flawed but actively used biomarker to assess possible response to checkpoint inhibitor therapy (specifically, programmed death-1 [PD-1] inhibitors). Targeted therapy has played a pivotal role in advanced NSCLC (Tables 39–2 and 39–3). Activating EGFR muta- tions are found in approximately 10–20% of the WhiteCMDT22_Ch39_p1612-p1675.indd  1625 02/07/21 2:44 PMChAPTER 391626 CMDT 2022popula tion and 30–48% of the Asian population and are usually found among nonsmokers to light smokers, females, and persons with nonsquamous histologies (particularly adenocarcinomas). For patients with EGFR mutations, an EGFR tyrosine kinase inhibitor (osimertinib, erlotinib, gefi- tinib, afatinib, or dacomitinib) rather than platinum-based chemotherapy is the first-line treatment. Response rates with EGFR tyrosine kinase inhibitors in patients with EGFR mutation are at least 70%, and median overall survival is estimated to be 21–33 months. Osimertinib (a third-gener- ation irreversible EGFR tyrosine kinase inhibitor) is recom- mended as first-line treatment of EGFR -mutated lung cancers. Phase 3 data show that osimertinib leads to a lon- ger duration of response, longer progression-free survival, and lower rates of severe adverse events compared to earlier generation EGFR tyrosine kinase inhibitors. Approximately 5% of all patients with NSCLC carry translocations of ALK resulting in novel fusion gene prod- ucts with oncogenic activity. For patients with ALK- rearranged lung cancers, ALK tyrosine kinase inhibitors (alectinib, ceritinib, crizotinib, brigatinib, and lorlatinib) are recommended therapeutic agents. Alectinib and briga- tinib are recommended as first-line agents in ALK - rearranged lung cancers with response rates ranging from 74% to 83%. For patients who have developed resistance to either first- or second-generation ALK inhibitors, lorlati- nib (a third-generation ALK and ROS1 tyrosine kinase inhibitor) has shown a response rate of 47%. Approxi- mately 1–2% of NSCLC harbor ROS1 rearrangements and they are usually lung adenocarcinomas found among non- smokers or light smokers. ROS1 -rearranged lung cancers respond to crizotinib ( ALK,cMET , and ROS1 tyrosine kinase inhibitor) and entrectinib (multikinase inhibitor, including ROS-1) with response rates over 70%. MET exon 14 (METex14) skipping mutations are found in 3% of lung adenocarcinomas. Capmatinib (MET inhibitor) is recom- mended as first-line treatment for patients with METex14 skipping mutation. BRAF mutations have been found in 2% of NSCLC patients. The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) has shown response rates of over 60% in patients with BRAF V600E mutations. Treatment with larotrectinib (TRKA/ B/C inhibitor) or entrectinib (multikinase inhibitor, including TRKA/B/C) is recommended for patients whose tumors reveal NTRK 1/2/3 gene fusion. Selpercatinib and pralsetinib (RET inhibitors) are recommended first-line treatments for RET fusion–positive NSCLC. Finally, K-ras mutations are found among 30% of patients with adenocar- cinomas, are associated with smoking, and indicate a poor prognosis. Early clinical trials are already under way evalu- ating the role of novel K-ras inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), in treating K-ras G12C mutated lung cancers. Immune checkpoint inhibition using PD-1 or PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab, and durvalumab) has an important role in the treatment of NSCLC (Tables 39–2 and 39–3). Checkpoint inhibitors release T cells from the inhibitory signals they receive from tumor cells via the PD-1 pathway, restoring antitumor immunity. For patients with tumors staining greater than50% for PDL-1, pembrolizumab outperforms first-line platinum-based chemotherapy, with response rates of 45% vs 28% and median progression-free survival of 10 months vs 6 months. Phase 3 trials have shown improved survival outcomes with adding pembrolizumab to platinum- doublet chemotherapy as first-line therapy for patients with advanced NSCLC regardless of PD-L1 status. If patients received chemotherapy alone as first-line treatment, PD-1 inhibitors are recommended as second-line treatment of NSCLC, regardless of PD-L1 staining intensity. However, significant side effects and toxicity have been reported with checkpoint inhibitors, especially autoimmune manifesta- tions such as hepatitis, thyroiditis, hypophysitis, colitis, pneumonitis, and type 1 diabetes mellitus. Recently, a ran- domized phase 3 trial has shown improved survival out- comes by adding durvalumab as consolidation therapy post-definitive chemoradiation for stage III NSCLCs. If no targetable mutations are found and there is inad- equate PD-L1 expression on tumor cells, patients are either offered combination immunotherapy with cytotoxic che- motherapy or cytotoxic chemotherapy alone (Table 39–2). Although not curative, chemotherapy has been shown in multiple clinical trials to provide a modest increase in over- all survival in patients with stage IIIB and stage IV NSCLC compared with supportive care alone, with the median survival increased from 5 months to a range of 8–12 months and 1-year survival rate of 30–40%. Palliative chemother- apy also leads to improved quality of life and symptom control, with first-line therapy involving a platinum-based regimen.B.  Small Cell Lung CarcinomaResponse  rates of SCLC to cisplatin and etoposide (Table 39–2) are excellent with 80–90% response in limited-stage disease (50–60% complete response), and 60–80% response in extensive-stage disease (15–20% complete response). However, remissions tend to be short-lived with a median duration of 6–8 months. Once the disease has recurred, median survival is 3–4 months. Overall 2-year survival is 20–40% in limited-stage disease and 5% in extensive-stage disease (Table 39–5). Modest improvement in survival has been achieved with the addition of a checkpoint inhibitor (atezolizumab or durvalumab) to cisplatin or carboplatin and etoposide therapy in extensive stage disease. Thoracic radiation therapy improves survival in patients with lim- ited SCLC and is given concurrently with chemotherapy. There is a high rate of brain metastasis in patients with SCLC, even following a good response to chemotherapy. Table 39–5. Median survival for small cell lung carci- noma following treatment.Stage Mean 2-Year Survival Median Survival Limited 20–40% 15–20 months Extensive 5% 8–13 months Data from multiple sources, including Van Meerbeeck JP et al. Small-cell lung cancer. Lancet. 2011;378:1741.CMDT22_Ch39_p1612-p1675.indd  1626 02/07/21 2:44 PMCANCER1627 CMDT 2022Pro phylactic cranial irradiation may be considered for patients with limited-stage disease who respond to chemo- therapy and in a subset of patients with extensive-stage disease who have had an excellent response to chemotherapy.C.  Palliative TherapyPhoto resection with the Nd:YAG laser is sometimes per- formed on central tumors to relieve endobronchial obstruc- tion, improve dyspnea, and control hemoptysis. External beam radiation therapy is also used to control dyspnea, hemoptysis, endobronchial obstruction, pain from bony metastases, obstruction from superior vena cava syn- drome, and symptomatic brain metastases. Resection of a solitary brain metastasis improves quality of life and sur- vival when combined with radiation therapy if there is no evidence of other metastatic disease. Stereotactic radia- tion therapy is offered for limited brain metastases. Repeated thoracenteses, pleurodesis, and PleurX catheter tube placement are key interventions for palliation of symptomatic malignant pleural effusions. Pain is very common in advanced disease. Meticulous efforts at pain control are essential (see Chapter 5). In addition to standard oncologic care, early referral to a palliative care specialist is recommended in advanced disease to aid in pain and other symptom management. Such palliative care can modestly improve survival. »PrognosisThe  overall 5-year survival rate for lung cancer is approxi- mately 20%. Predictors of survival include the tumor type (SCLC versus NSCLC), molecular profiling, and stage, and the patient’s performance status and weight loss in the prior 6 months. Patients with targetable mutations have better overall survival when compared with those without muta- tions due to superior efficacy of targeted drug therapy.Camidg e DR et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: sec- ond interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38:3592. [PMID: 32780660] Drilon A et al. Entrectinib in ROS1 fusion-positive non-small- cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:262. [PMID: 31838015] Ghimessy A et al. Current therapy of KRAS -mutant lung cancer. Cancer Metastasis Rev. 2020;39:1159. [PMID: 32548736] Ramalingam SS et al; FLAURA Investigators. Overall survival with osimertinib in untreated EGFR -mutated advanced NSCLC. N Engl J Med. 2020;382:41. [PMID: 31751012] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7. [PMID: 33433946] US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325:962. [PMID: 33687470]PU LMONARY METASTASISPulmonary metastasis  results from the spread of an extra- pulmonary malignant tumor through vascular or lym- phatic channels or by direct extension. Metastases usually occur via the pulmonary artery and typically present asmultiple nodules or masses on chest radiography. The radiographic differential diagnosis of multiple pulmonary nodules also includes pulmonary arteriovenous malforma- tion, infections (including abscesses, septic emboli, and atypical infections), sarcoidosis, rheumatoid nodules, and granulomatosis with polyangiitis. Metastases to the lungs are found in 20–55% of patients with various metastatic malignancies. Carcinomas of the kidney, breast, rectum, colon, and cervix and malignant melanoma are the most likely primary tumors. Lymphangitic carcinomatosis denotes diffuse involve- ment of the pulmonary lymphatic network by primary or metastatic lung cancer, probably a result of extension of tumor from lung capillaries to the lymphatics. Tumor embolization from extrapulmonary cancer (renal cell car- cinoma, hepatocellular carcinoma, choriocarcinoma) is an uncommon route for tumor spread to the lungs. Metastatic cancer may also present as a malignant pleural effusion. »Clinical FindingsA.  Symptoms and SignsSymp toms are uncommon but include cough, hemoptysis and, in advanced cases, dyspnea and hypoxemia. Symp- toms are more often referable to the site of the primary tumor.B.  Laboratory FindingsThe  diagnosis of metastatic cancer involving the lungs is usually established by identifying a primary tumor. Appro- priate studies should be ordered if there is a suspicion of any primary cancer, such as breast, thyroid, testis, colorec- tal, or prostate, for which specific treatment is available. If the history, physical examination, and initial studies fail to reveal the site of the primary tumor, attention is better focused on the lung, where tissue samples obtained by bronchoscopy, percutaneous needle biopsy, video-assisted thoracoscopic surgery (V ATS), or thoracotomy may estab- lish the histologic diagnosis and suggest the most likely primary cancer. Occasionally, cytologic studies of pleural fluid or pleural biopsy reveals the diagnosis.C.  ImagingChest  radiographs usually show multiple spherical densi- ties with sharp margins. The lesions are usually bilateral, pleural, or subpleural in location, and more common in lower lung zones. Lymphangitic spread and solitary pul- monary nodule are less common radiographic presenta- tions of pulmonary metastasis. CT imaging of the chest, abdomen, and pelvis may reveal the site of a primary tumor and will help determine feasibility of surgical resection of the metastatic lung tumors. FDG PET-CT scan is helpful in identifying the site of a primary cancer and identifying other areas of extrathoracic metastasis. »TreatmentOnce  the diagnosis has been established, management consists of treatment of the primary neoplasm and any pulmonary complications. Surgical resection of a solitaryCMDT22_Ch39_p1612-p1675.indd  1627 02/07/21 2:44 PMChAPTER 391628 CMDT 2022pulmona ry nodule is often prudent in the patient with known current or previous extrapulmonary cancer. Local resection of one or more pulmonary metastases is feasible in a few carefully selected patients with various sarcomas and carcinomas (such as testis, colorectal, and kidney). About 15–25% of metastatic solid tumor patients have metastases limited to the lungs and are surgical candidates. Surgical resection should be considered only if (1) the pri- mary tumor is under control, (2) the patient has adequate cardiopulmonary reserve to tolerate resection, (3) all meta- static tumor can be resected, (4) effective nonsurgical approaches are not available, and (5) there is no evidence of extrathoracic metastases that are not controlled. Unfa- vorable prognostic factors also include shorter disease-free interval from primary tumor treatment to presentation of metastases and a larger number of metastases. Retrospec- tive data from the International Registry of Lung Metasta- ses report an overall 5-year survival rate of 36% and 10-year survival rate of 26% after complete resection of pulmonary metastases. Patients who are not surgical can- didates but have solitary or limited metastatic disease to the lungs may be candidates for stereotactic radiotherapy, radioablation, or cryotherapy. For patients with unresect- able progressive disease, chemotherapy tailored to the pri- mary tumor can be offered, and diligent attention to palliative care is essential (see Chapter 5).Ha ndy JR et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. 2019;107:631. [PMID: 30476477] Sudarshan M et al. Current indications for pulmonary metasta- sectomy. Surg Oncol Clin N Am. 2020;29:673. [PMID: 32883466]ME SOTHELIOMAE S S E N T I A L S  O F  D I A G N O S I S »Unilateral, nonpleuritic chest pain and dyspnea. »Distant (> 20 years earlier) history of exposure to asbestos. »Pleural effusion or pleural thickening or both on chest radiographs. »Malignant cells in pleural fluid or tissue biopsy. »General ConsiderationsMeso theliomas are primary tumors arising from the sur- face lining of the pleura (80% of cases) or peritoneum (20% of cases). Numerous studies have confirmed the associa- tion of malignant pleural mesothelioma with exposure to asbestos. The lifetime risk to asbestos workers of develop- ing malignant pleural mesothelioma is as high as 10%. The latent period between exposure and onset of symptoms ranges from 20 to 40 years. The clinician should inquire about asbestos exposure through mining, milling, manu- facturing, shipyard work, insulation, brake linings,building construction and demolition, roofing materials, and other asbestos products (pipes, textiles, paints, tiles, gaskets, panels). »Clinical FindingsA.  Symptoms and SignsThe  average interval between onset of symptoms and diagnosis is 2–3 months; the median age at diagnosis is 72–74 years in Western countries. Symptoms include the insidious onset of shortness of breath, nonpleuritic chest pain, and weight loss. Physical findings include dullness to percussion, diminished breath sounds and, in some cases, digital clubbing.B.  Laboratory FindingsPleural  fluid is exudative and often hemorrhagic. Cytologic tests of pleural fluid are often negative. VATS biopsy is usu- ally necessary to obtain an adequate specimen for histo- logic diagnosis. The histologic variants of malignant pleural mesothelioma are epithelial (50–60%), sarcomatoid (10%), and biphasic (30–40%). Since distinction from benign inflammatory conditions and metastatic adenocar- cinoma may be difficult, immunohistochemical stains are important to confirm the diagnosis.C.  ImagingRadiographic  abnormalities consist of nodular, irregular, unilateral pleural thickening and varying degrees of unilat- eral pleural effusion. Sixty percent of patients have right- sided disease, while only 5% have bilateral involvement. CT scans demonstrate the extent of pleural involvement. PET-CT is used to help differentiate benign from malig- nant pleural disease, improve staging accuracy, and iden- tify candidates for aggressive surgical approaches. »ComplicationsMalignan t pleural mesothelioma progresses rapidly as the tumor spreads along the pleural surface to involve the peri- cardium, mediastinum, and contralateral pleura. The tumor may eventually extend beyond the thorax to involve abdominal lymph nodes and organs. Progressive pain and dyspnea are characteristic. Local invasion of thoracic struc- tures may cause superior vena cava syndrome, hoarseness, Horner syndrome, arrhythmias, and dysphagia. »TreatmentChemothera py is the mainstay of treatment (Tables 39–2 and 39–3), with cytoreductive surgery included in multi- modality treatment only if there is localized disease that is amenable to complete macroscopic surgical resection. The optimal surgical approach is still under debate. For local- ized disease, surgical options include pleurectomy and decortication (surgical stripping of the pleura and pericar- dium from apex of the lung to diaphragm) or extrapleural pneumonectomy (a radical surgical procedure involving removal of the ipsilateral lung, parietal and visceral pleura,CMDT22_Ch39_p1612-p1675.indd  1628 02/07/21 2:44 PMCANCER1629 CMDT 2022pericardium,  and most of the hemidiaphragm). Surgical cytoreduction alone is not sufficient, and either chemo- therapy or radiation therapy (or both) should be included in a multimodality approach. In advanced unresectable disease, palliative chemotherapy with cisplatin and peme- trexed can achieve response rates of 30–40%, can extend median overall survival to 12 months, and can improve quality of life. Adding bevacizumab (a monoclonal anti- body to vascular endothelial growth factor [VEGF]) to cisplatin and pemetrexed has been shown to further improve overall survival. Nivolumab and ipilimumab (checkpoint inhibition therapy) can also be offered as first- line treatment, with improved outcomes among those with nonepithelioid tumors. Drainage of pleural effusions, pleurodesis, radiation therapy, and even surgical resection may offer palliative benefit to some patients. »PrognosisMos t patients die of respiratory failure and complications of local extension. Median survival time from diagnosis ranges from 7 months to 17 months. Five-year survival is 5–10%. Tumors that are predominantly sarcomatoid are more resistant to therapy and have a worse prognosis, with median survivals less than 1 year. Poor prognostic features include poor performance status, non-epithelioid histol- ogy, male gender, nodal involvement, elevated lactate dehy- drogenase, high white blood cell count, low hemoglobin, and high platelet count.Sch erpereel A et al; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239. [PMID: 30660609] Scherpereel A et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55:1900953. [PMID: 32451346] Waller DA et al. Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. J Thorac Cardiovasc Surg. 2020;S0022-5223 (20)32986-X . [PMID: 33223192]hE PATOBILIARY CANCERS Lawrence S. Friedman, MD HEPATOCELLULAR CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »Usually a complication of cirrhosis. »Characteristic CT and MRI features may obviate the need for a confirmatory biopsy. »General ConsiderationsMalignan t neoplasms of the liver that arise from parenchy- mal cells are called hepatocellular carcinomas (accountingfor 85% of liver cancers); those that originate in the ductu- lar cells are called cholangiocarcinomas (15% or less). Rare tumors of the liver include angiosarcoma and lymphoma. Worldwide, hepatocellular carcinomas are the fourth most common cause of cancer-related deaths and the sixth most common in incidence. They are associated with cir- rhosis in 85% of cases. In Africa and most of Asia, hepatitis B virus (HBV) infection (including “occult” HBV infection; see Chapter 16) is a major etiologic factor, and a family history of hepatocellular carcinoma increases the risk syn- ergistically. In the United States and other Western coun- tries, incidence rates rose over twofold after 1978, with slowing of the rate increase after 2006 except in men ages 55–64, presumably because of the increasing prevalence of cirrhosis caused by chronic hepatitis C virus (HCV) infec- tion and nonalcoholic fatty liver disease (NAFLD). Rates appear to have plateaued since 2010 because of improved treatment of viral hepatitis. In Western countries, risk fac- tors for hepatocellular carcinoma in patients known to have cirrhosis are male gender, age greater than 55 years (although there has been an increase in the number of younger cases), Hispanic or Asian ethnicity, family history in a first-degree relative, overweight, obesity (especially in early adulthood), alcohol use (especially in combination with obesity), tobacco use, diabetes mellitus, hypothyroid- ism (in women), a prolonged prothrombin time, a low platelet count, and an elevated serum transferrin satura- tion. The risk of hepatocellular carcinoma is higher in persons with a viral rather than nonviral cause of cirrhosis and may be increased in persons with autoimmune dis- eases. Other associations include high levels of HBV repli- cation; HBV genotype C; hepatitis D coinfection; elevated serum ALT levels in persons with chronic hepatitis B (in whom antiviral therapy to suppress HBV replication appears to reduce the risk); HCV genotypes 1b and 3; lack of response to antiviral therapy for HCV infection; hemo- chromatosis (and possibly the C282Y carrier state); afla- toxin exposure (associated with mutation of the TP53 gene); alpha-1-antiprotease (alpha-1-antitrypsin) defi- ciency; tyrosinemia; and radiation exposure. In patients with the metabolic syndrome and NAFLD, hepatocellular carcinoma may rarely arise from nonalcoholic steatohepa- titis in the absence of cirrhosis. Hepatocellular adenoma may be a precursor for hepatocellular carcinoma (see Chapter 16). Evidence for an association with long-term use of oral contraceptives is inconclusive. Whereas sulfo- nylurea and insulin use may increase the risk of hepatocel- lular carcinoma, consumption of coffee, vegetables, white meat, fish, and n-3 polyunsaturated fatty acids; use of aspirin; and use of lipophilic HMG-CoA reductase inhibi- tors (statins) (eg, atorvastatin, simvastatin) and, in diabetic patients, metformin appear to be protective. The fibrolamellar variant of hepatocellular carcinoma generally occurs in young women and is characterized by a distinctive histologic picture, absence of risk factors, unique genomic profiles, and indolent course. Vinyl chlo- ride exposure is associated with angiosarcoma of the liver. Hepatoblastoma, the most common malignant liver cancer in infants and young children, rarely occurs in adults.CMDT22_Ch39_p1612-p1675.indd  1629 02/07/21 2:44 PMChAPTER 391630 CMDT 2022 »Clinical FindingsA.  Symptoms and SignsThe pr esence of a hepatocellular carcinoma may be unsus- pected until there is deterioration in the condition of a cirrhotic patient who was formerly stable. Cachexia, weak- ness, and weight loss are associated symptoms. The sudden appearance of ascites, which may be bloody, suggests portal or hepatic vein thrombosis by cancer or bleeding from a necrotic cancer. Physical examination may show tender enlargement of the liver, occasionally with a palpable mass. In Africa, the typical presentation in young patients is a rapidly expand- ing abdominal mass. Auscultation may reveal a bruit over the tumor or a friction rub when the tumor has extended to the surface of the liver.B.  Laboratory FindingsLabora tory tests may reveal leukocytosis, as opposed to the leukopenia that is frequently encountered in cirrhotic patients. Anemia is common, but a normal or elevated hematocrit value may be found in up to one-third of patients owing to elaboration of erythropoietin by the tumor. Sudden and sustained elevation of the serum alka- line phosphatase in a patient who was formerly stable is a common finding. HBsAg is present in a majority of cases in endemic areas, whereas in the United States anti-HCV is found in up to 40% of cases. Serum alpha-fetoprotein (AFP) levels are elevated in up to 70% of patients with hepa- tocellular carcinoma in Western countries (although the sensitivity is lower in Blacks and levels are not elevated in patients with fibrolamellar hepatocellular carcinoma); how- ever, mild elevations (10–200 ng/mL [10–200 mcg/L]) are also often seen in patients with chronic hepatitis. Serum levels of des-gamma-carboxy prothrombin are elevated in up to 90% of patients with hepatocellular carcinoma, but they may also be elevated in patients with vitamin K defi- ciency, chronic hepatitis, and metastatic cancer. Cytologic study of ascitic fluid rarely reveals malignant cells.C.  ImagingM ultiphasic helical CT and MRI with contrast enhance- ment are the preferred imaging studies for determining the location and vascularity of the tumor; MRI may be more sensitive than CT, and imaging with gadoxetic acid increases sensitivity. Lesions smaller than 1 cm may be dif- ficult to characterize. Based on stringent criteria developed by the American College of Radiology through its Liver Imaging Reporting and Data System, the Organ Procure- ment and Transplantation Network, and the American Association for the Study of Liver Diseases, arterial phase enhancement of a lesion that is greater than or equal to 1 cm in diameter followed by delayed hypointensity (“washout”) has a 90% specificity for hepatocellular carci- noma. Ultrasonography is less sensitive and more operator dependent but is used to screen for hepatic nodules in high-risk patients. Contrast-enhanced ultrasonography has a sensitivity and specificity approaching those of arterial phase helical CT but, unlike CT and MRI, cannot image theentire liver during the short duration of the arterial phase and is thus associated with false-positive results. In selected cases, endoscopic ultrasonography (EUS) may be useful. PET is under study and appears to improve detection of extrahepatic metastases.D . Liver Biopsy and StagingLiver  biopsy is diagnostic, although seeding of the needle tract by cancer is a potential risk (1–3%). For lesions smaller than 1 cm, ultrasonography may be repeated every 3 months followed by further investigation of enlarging lesions. For lesions 1 cm or larger, biopsy can be deferred when characteristic arterial hypervascularity and delayed washout are demonstrated on either multiphasic helical CT or MRI with contrast enhancement (or both) in a patient with cirrhosis or if surgical resection is planned. The TNM system is the commonly used classification to stage hepatocellular carcinoma. Staging is important not only because it correlates with the patient’s long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. The Barcelona Clinic Liver Cancer (BCLC) staging system is preferred and includes the Child-Pugh class, tumor stage, and liver function and has the advantage of linking overall stage with preferred treatment modalities and with an estimation of life expectancy. »Screening & PreventionSurveillance (screening) fo r the development of hepatocel- lular carcinoma is recommended in patients with chronic hepatitis B (beginning as early as age 20 in Africans, age 40 in Asian males or Asians with a family history of hepatocel- lular carcinoma, and age 50 in others) or cirrhosis caused by HCV , HBV , or alcohol. There is some evidence that screening for hepatocellular carcinoma leads to a survival advantage over clinical diagnosis, but only a minority of cases are detected by screening. The standard screening approach is performing ultrasonography and obtaining serum AFP level every 6 months, although AFP testing has low sensitivity. A serum AFP level of 20 ng/mL (20 mcg/L) is generally the cutoff value that should trigger further evaluation. CT and MRI are considered too expensive for screening. The sensitivity of ultrasonography for detecting early hepatocellular carcinoma is only 63%. The risk of hepatocellular carcinoma developing in a patient with cirrhosis is 3–5% a year. Among patients with cirrhosis, over 60% of nodules smaller than 2 cm in diam- eter detected on a screening ultrasonography prove to be hepatocellular carcinoma. Patients with cancers detected by surveillance have a less advanced stage on average and greater likelihood that treatment will prolong survival than those whose cancers were not detected by surveillance. However, controversy persists about whether surveillance reduces cancer-related mortality. Mass vaccination programs against HBV in developing countries are leading to reduced rates of hepatocellular carcinoma. Successful treatment of hepatitis B and of hepatitis C in patients with cirrhosis also reduces the subsequent risk of hepatocellular carcinoma, and thusCMDT22_Ch39_p1612-p1675.indd  1630 02/07/21 2:44 PMCANCER1631 CMDT 2022hepatocellular carcino ma is considered a preventable neo- plasm. However, hepatocellular carcinoma may still occur after clearance of hepatitis B surface antigen or cure of HCV infection, thereby reducing the benefit of treatment for HBV and HCV infection. »TreatmentSurgical  resection of a solitary hepatocellular carcinoma may result in cure if liver function is preserved (Child- Pugh class A or possibly B) and portal vein thrombosis is not present. Laparoscopic liver resection has been per- formed in selected cases. Treatment of underlying chronic viral hepatitis, adjuvant chemotherapy, and adaptive immunotherapy may lower postsurgical recurrence rates. Liver transplantation may be appropriate for small unre- sectable tumors in a patient with advanced cirrhosis, with reported 5-year survival rates of up to 75%. The recurrence- free survival may be better for liver transplantation than for resection in patients with well-compensated cirrhosis and small tumors (one tumor less than 5 cm or three or fewer tumors each less than 3 cm in diameter [Milan criteria]) and in those with expanded (University of California, San Francisco) criteria of one tumor less than or equal to 6.5 cm or three or fewer tumors less than or equal to 4.5 cm (or a combined tumor diameter of 8.5 cm) without vascular invasion. The Extended Toronto criteria include tumor dif- ferentiation, cancer-related symptoms, confinement of tumor to the liver, and absence of vascular invasion, without regard to tumor number or size, to determine candidacy for liver transplantation and appear to predict outcomes as well as the Milan criteria. After 6 months on the waiting list, patients with stage 2 hepatocellular carcinoma meeting the Milan criteria are awarded a fixed score of 3 points lower than the median Model for End-Stage Liver Disease (MELD) score for patients transplanted in the area where the candidate is listed (see Chapter 16), thereby increasing their chances of undergoing transplantation. However, orthotopic liver transplantation is often impractical because of donor organ shortage, so living donor liver transplanta- tion may be considered in these cases. Patients with larger tumors (3–5 cm), a serum AFP level of 1000 ng/mL (1000 mcg/L) or higher, or a MELD score of 20 or higher have poor posttransplantation survival. In patients with a serum AFP level greater than 1000 ng/mL (1000 mcg/L), down- staging by locoregional therapy to an AFP level less than 500 ng/mL (500 mcg/L) improves survival following subse- quent liver transplantation. Chemotherapy, hormonal therapy with tamoxifen, and long-acting octreotide have not been shown to prolong life, but transarterial chemoembolization (TACE), TACE with drug-eluting beads, transarterial chemoinfusion (TACI), and transarterial radioembolization (TARE) via the hepatic artery are not only palliative but may also prolong survival in patients with a large or multifocal tumor in the absence of extrahepatic spread. TACI and TARE are suitable for patients with portal vein thrombosis. TARE with yttrium-90 has been shown to result in a longer time to progression than TACE. Microwave ablation, radiofrequency ablation, cryotherapy, or injection of absolute ethanol into tumors smaller than 2 cm may prolong survival in patients who arenot candidates for resection and have tumors that are accessible; these interventions, as well as stereotactic body radiation therapy, may also provide a “bridge” to liver transplantation. Microwave ablation is becoming the pre- ferred approach because it allows shorter treatment times and, like radiofrequency ablation, can be performed after TACE in select cases. Cryoablation may result in slower tumor progression than radiofrequency ablation for tumors that are 3.1–4 cm in diameter. Stereotactic body radiation therapy is also being used to treat unresectable hepatocel- lular carcinoma and may be effective in treating lesions larger than those treated with ablation techniques. Sorafenib (an oral multikinase inhibitor of Raf kinase, the VEGF receptor, and the platelet-derived growth factor receptor [and others]) prolongs median survival as well as the time to radiologic progression by 3 months in patients with advanced hepatocellular carcinoma and until recently was the standard care in these patients. Lenvatinib is another oral multikinase inhibitor that is FDA approved for the same indications as sorafenib. However, the combi- nation of atezolizumab, an immune checkpoint inhibitor, and bevacizumab, an antibody to the VEGF receptor, has been shown to be superior to sorafenib and has become standard first-line therapy. Regorafenib is an oral multiki- nase inhibitor that provides a survival benefit for patients whose disease progresses despite sorafenib therapy, and nivolumab and pembrolizumab are immune checkpoint inhibitors that have been approved for advanced hepatocel- lular carcinoma. The combination of nivolumab and ipili- mumab has been recommended as second-line therapy after failure of sorafenib. Cabozantinib, another multiki- nase inhibitor, has been approved by the FDA for the treat- ment of hepatocellular carcinoma after prior treatment with sorafenib, as has ramucirumab, an antibody to the VEGF receptor, which is approved for patients with an AFP level greater than or equal to 400 ng/mL (400 mcg/L) and previous treatment with sorafenib. The modified Response Evaluation Criteria in Solid Tumors (mRECIST) are used to assess treatment response based on tumor shrinkage and viability after locoregional and antiangiogenic treatment. Meticulous efforts at palliative care are essential for patients in whom disease progresses despite treatment or in whom advanced tumors, vascular invasion, or extrahepatic spread are present. Severe pain may develop in such patients due to expansion of the liver capsule by the tumor and requires concerted efforts at pain management, including the use of opioids (see Chapter 5). »PrognosisIn  the United States, overall 1- and 5-year survival rates for patients with hepatocellular carcinoma are 23% and 5%, respectively. Five-year survival rates rise to 56% for patients with localized resectable disease (T1, T2, selected T3 and T4; N0; M0) but are virtually nil for those with locally unresectable or advanced disease. In patients with HCV- related hepatocellular carcinoma, the serum AFP level at the time of diagnosis of cancer has been reported to be an independent predictor of mortality. A serum AFP level greater than or equal to 200 ng/mL (200 mcg/L) or increases of greater than 15 ng/mL/month predict worseCMDT22_Ch39_p1612-p1675.indd  1631 02/07/21 2:44 PMChAPTER 391632 CMDT 2022outco mes in patients awaiting liver transplantation. In patients who are not eligible for surgery, an elevated serum C-reactive protein level is associated with poor survival. Contrary to traditional opinion, the fibrolamellar variant does not have a better prognosis than conventional hepato- cellular carcinoma without cirrhosis. »When to ReferAll  patients with hepatocellular carcinoma should be referred to a specialist. »When to Admit• Complications of cirrhosis. •Severe pain. •For surgery and other interventions.Bangaru  S et al. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51:78. [PMID: 31747082] Bruix J et al (editors). The growing burden of liver cancer. Semin Liver Dis. 2020;40:101. [Full issue] Fanwal F et al. Surveillance for hepatocellular carcinoma: cur- rent best practice and future direction. Gastroenterology. 2019;157:54. [PMID: 30986389] Shiels MS et al. Recent decline in hepatocellular carcinoma rates in the United States. Gastroenterology. 2020;158:1503. [PMID: 31962125] Simon TG et al. Association of aspirin with hepatocellular carci- noma and liver-related mortality. N Engl J Med. 2020;382:1018. [PMID: 32160663]CA RCINOMA OF THE BILIARY TRACTE S S E N T I A L S  O F  D I A G N O S I S »Presents with obstructive jaundice, usually pain- less, often with dilated biliary tract. »Pain is more common in gallbladder carcinoma than cholangiocarcinoma. »A dilated gallbladder may be palpable (Cour- voisier sign). »Diagnosis by cholangiography with biopsy and brushings for cytology. »General ConsiderationsCarcino ma of the gallbladder occurs in approximately 2% of all people operated on for biliary tract disease; the inci- dence, like that of carcinoma of the bile ducts, had been decreasing in the United States but may be increasing again in some Western countries because of lifestyle changes. It is notoriously insidious, and the diagnosis is often made unexpectedly at surgery. Cholelithiasis (often large, symp- tomatic stones) is usually present. Other risk factors are chronic infection of the gallbladder with Salmonella typhi , adenomatous gallbladder polyps over 1 cm in diameter (particularly with hypoechoic foci on EUS), mucosalcalcification of the gallbladder (porcelain gallbladder), anomalous pancreaticobiliary ductal junction, high parity in women, and aflatoxin exposure. Genetic factors include K-ras andTP53 mutations. Spread of the cancer—by direct extension into the liver or to the peritoneal surface—may be seen on initial presentation. Carcinoma of the bile ducts (cholangiocarcinoma) accounts for 10–25% of all hepatobiliary malignancies and 3% of all cancer deaths in the United States. It is more prevalent in persons aged 50–70, with a slight male pre- dominance, and more common in Asia. About 50% arise at the confluence of the hepatic ducts (perihilar, or so-called Klatskin, tumors), and 40% arise in the distal extrahepatic bile duct (the incidence of which has risen since 1990); the remainder are intrahepatic (the incidence of which rose dramatically from the 1970s to the early 2000s). Mortality from intrahepatic cholangiocarcinoma has been increas- ing. The frequency of carcinoma in persons with a chole- dochal cyst has been reported to be over 14% at 20 years, and surgical excision is recommended. Most cases of chol- angiocarcinoma are sporadic. There is an increased inci- dence of cholangiocarcinoma in patients with bile duct adenoma; Caroli disease; a biliary-enteric anastomosis; ulcerative colitis, especially those with primary sclerosing cholangitis; biliary cirrhosis; diabetes mellitus; hyperthy- roidism; chronic pancreatitis; heavy alcohol consumption; smoking; and past exposure to Thorotrast, a contrast agent. Premalignant lesions of the bile duct include biliary intraepithelial neoplasia and intraductal papillary neopla- sia of the biliary system (biliary papillomatosis). Aspirin use and statin use are associated with a reduced risk of cholangiocarcinoma, and in diabetic patients, metformin use is associated with a reduced risk of intrahepatic cholan- giocarcinoma. In Southeast Asia, hepatolithiasis, chronic typhoid carriage, and infection of the bile ducts with hel- minths (Clonorchis sinensis, Opisthorchis viverrini) are associated with an increased risk of cholangiocarcinoma. Hepatitis C virus (and possibly hepatitis B virus) infection, cirrhosis, HIV infection, nonalcoholic fatty liver disease, diabetes mellitus, obesity, and tobacco smoking are risk factors for intrahepatic cholangiocarcinoma. The TNM system is the commonly used classification to stage carcinoma of the biliary tract, including gallblad- der carcinomas and perihilar and intrahepatic cholangio- carcinomas. Staging is important not only because it correlates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Other staging systems consider the patient’s age, perfor- mance status, tumor extent and form, perineural invasion, vascular encasement, hepatic lobe atrophy, underlying liver disease, and peritoneal metastasis. »Clinical FindingsA.  Symptoms and SignsProgres sive jaundice is the most common and usually the first sign of obstruction of the extrahepatic biliary system. Pain in the right upper abdomen with radiation into the back is usually present early in the course of gallbladderCMDT22_Ch39_p1612-p1675.indd  1632 02/07/21 2:44 PMCANCER1633 CMDT 2022carcino ma but occurs later in the course of bile duct carci- noma. Anorexia and weight loss are common and may be associated with fever and chills due to cholangitis. Rarely, hematemesis or melena results from erosion of cancer into a blood vessel (hemobilia). Fistula formation between the bili- ary system and adjacent organs may also occur. The course is usually one of rapid deterioration, with death occurring within a few months. Physical examination reveals profound jaundice. Pruritus and skin excoriations are common. A palpable gallbladder with obstructive jaundice usually is said to signify malignant disease (Courvoisier sign); however, this clinical generaliza- tion has been proven to be accurate only about 50% of the time. Hepatomegaly due to hypertrophy of the unobstructed liver lobe is usually present and is associated with liver ten- derness. Ascites may occur with peritoneal implants.B.  Laboratory FindingsW ith biliary obstruction, laboratory examination reveals predominantly conjugated hyperbilirubinemia, with total serum bilirubin values ranging from 5 to 30 mg/dL. There is usually concomitant elevation of the alkaline phosphatase and serum cholesterol. AST is normal or minimally elevated. The serum CA 19-9 level is elevated in up to 85% of patients and may help distinguish cholangiocarcinoma from a benign biliary stricture (in the absence of cholangitis), but this test is neither sensitive nor specific.C.  ImagingUl trasonography and contrast-enhanced, triple-phase, heli- cal CT may show a gallbladder mass in gallbladder carci- noma and intrahepatic mass or biliary dilatation in carcinoma of the bile ducts. CT may also show involved regional lymph nodes and atrophy of a hepatic lobe because of vascular encasement with compensatory hypertrophy of the unaffected lobe. MRI with magnetic resonance cholan- giopancreatography (MRCP) and gadolinium enhancement permits visualization of the entire biliary tract and detection of vascular invasion and obviates the need for angiography and, in some cases, direct cholangiography; it is the imaging procedure of choice but may understage malignant hilar strictures. The sensitivity and image quality can be increased with use of ferumoxide enhancement. The features of intra- hepatic cholangiocarcinoma on MRI appear to differ from those of hepatocellular carcinoma, with contrast washout in the latter but not the former. In indeterminate cases, PET can detect cholangiocarcinomas as small as 1 cm and lymph node and distant metastases, but false-positive results occur. The most helpful diagnostic studies before surgery are either endoscopic retrograde cholangiography or percutaneous transhepatic cholangiography with biopsy and cytologic specimens, although false-negative biopsy and cytology results are common. Digital image analysis and fluorescent in situ hybridization of cytologic specimens for polysomy improve sensitivity. EUS with FNA of tumors, peroral chol- angioscopy, confocal laser endomicroscopy, and intraductal ultrasonography may confirm a diagnosis of cholangiocarci- noma in a patient with bile duct stricture and an otherwise indeterminate evaluation, but FNA can result in cancerseeding and should be avoided if the cancer is potentially resectable. »TreatmentIn  young and fit patients, curative surgery for gallbladder carcinoma may be attempted if the cancer is well localized. The 5-year survival rate for carcinoma of the gallbladder invading the lamina propria or muscularis (stage 1, T1a or 1b, N0, M0) is as high as 85% with laparoscopic cholecys- tectomy but drops to 60%, even with a more extended open resection, if there is perimuscular invasion (T2). The role of radical surgery for T3 and T4 tumors is debatable. If the cancer is unresectable at laparotomy, biliary-enteric bypass (eg, Roux-en-Y hepaticojejunostomy) can be performed. Carcinoma of the bile ducts is curable by surgery in less than 10% of cases. If resection margins are negative, the 5-year survival rate may be as high as 47% for intrahepatic cholangiocarcinomas, 41% for hilar cholangiocarcinoma, and 37% for distal cholangiocarcinomas, but the perioper- ative mortality rate may be as high as 10%. Factors predicting shorter survival for intrahepatic cholangiocarcinoma include large cancer size, multiple cancers, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy with capecitabine has been shown to result in superior overall survival compared with no adjuvant therapy. Pallia- tion can be achieved by placement of a self-expandable metal stent via an endoscopic or percutaneous transhepatic route. Covered metal stents may be more cost-effective than uncovered metal stents because of a longer duration of patency. However, they are associated with a higher rate of stent migration and cholecystitis due to occlusion of the cystic duct and are not associated with longer survival. For perihilar cancers, insertion of a unilateral stent rather than bilateral stents may suffice. Plastic stents are less expensive initially, but not in the long term, because they are more prone to occlude than metal ones; they may be considered in patients expected to survive only a few months. Photo- dynamic therapy in combination with stent placement prolongs survival when compared with stent placement alone in patients with nonresectable cholangiocarcinoma. Endoscopic retrograde cholangiopancreatography (ERCP)– directed radiofrequency ablation, TACE, and TARE are additional emerging options. Radiotherapy may relieve pain and contribute to biliary decompression. There is limited response to chemotherapy with gemcitabine alone, but the combination of cisplatin and gemcitabine or capecitabine and gemcitabine prolongs survival in patients with locally advanced or metastatic cholangiocarcinoma. Few patients survive for more than 24 months. Although cholangiocarcinoma is generally considered to be a contra- indication to liver transplantation because of rapid cancer recurrence, a 5-year survival rate of 75% has been reported in patients with stage I and II perihilar cholangiocarcinoma undergoing chemoradiation and exploratory laparotomy followed by liver transplantation, and a 5-year survival rate of 67% has been reported in those with intrahepatic cholangiocarcinoma. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5).CMDT22_Ch39_p1612-p1675.indd  1633 02/07/21 2:44 PMChAPTER 391634 CMDT 2022 »When to ReferAll  patients with carcinoma of the biliary tract should be referred to a specialist. »When to Admit• Biliary obstruction. •Cholangitis.Bertuccio  P et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104. [PMID: 30910538] De Martin E et al. Analysis of liver resection versus liver trans- plantation on outcome of small intrahepatic cholangiocarci- noma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020;26:785. [PMID: 32090444] Lavu S et al. Effect of statins on the risk of extrahepatic cholan- giocarcinoma. Hepatology. 2020;72:1298. [PMID: 32119126]CA RCINOMA OF THE PANCREAS & AMPULLA OF VATERE S S E N T I A L S  O F  D I A G N O S I S »Obstructive jaundice (may be painless). »Enlarged gallbladder (may be painful). »Upper abdominal pain with radiation to back, weight loss, and thrombophlebitis are usually late manifestations. »General ConsiderationsCarcino ma is the most common neoplasm of the pancreas. About 75% are in the head and 25% in the body and tail of the organ. Pancreatic carcinomas account for 2% of all cancers and 5% of cancer deaths. Ampullary carcinomas are much less common. Risk factors for pancreatic cancer include age, tobacco use (which is thought to cause 20–25% of cases), heavy alcohol use, obesity, chronic pan- creatitis, diabetes mellitus, prior abdominal radiation, fam- ily history, and possibly gastric ulcer and exposure to arsenic and cadmium. New-onset diabetes mellitus after age 45 years occasionally heralds the onset of pancreatic cancer. In diabetic patients, metformin use and possibly aspirin use may reduce the risk of pancreatic cancer slightly, but insulin use and glucagon-like peptide-1–based therapy (eg, sitagliptin) may increase the risk. About 7% of patients with pancreatic cancer have a family history of pancreatic cancer in a first-degree relative, compared with 0.6% of control subjects. The majority of pancreatic can- cers originate from pancreatic intraepithelial neoplasias, which measure less than 5 mm in diameter and can only be seen with a microscope. In 5–10% of cases, pancreatic cancer occurs as part of a hereditary syndrome, including familial breast cancer (car- riers of BRCA2 have a 7% lifetime risk of pancreatic can- cer), hereditary pancreatitis ( PSS1 mutation), familialatypical multiple mole melanoma ( p16/CDKN2A muta- tion), Peutz-Jeghers syndrome ( STK11 /LKB1 mutation), ataxia-telangiectasia ( ATM mutation), and Lynch syn- drome (hereditary nonpolyposis colorectal cancer [ MLH1 , MSH2 ,MSH6 mutations]). Neuroendocrine tumors account for 1–2% of pancreatic neoplasms and may be functional (producing gastrin, insu- lin, glucagon, vasoactive intestinal peptide, somatostatin, growth hormone–releasing hormone, adrenocorticotropic hormone, and others) or nonfunctional. Cystic neoplasms account for only 1% of pancreatic cancers, but they are important because pancreatic cysts are common and may be mistaken for pseudocysts. A cystic neoplasm should be suspected when a cystic lesion in the pancreas is found in the absence of a history of pancreatitis. At least 15% of all pancreatic cysts are neoplasms. Serous cystadenomas (which account for 32–39% of cystic pancreatic neoplasms and also occur in patients with von Hippel-Lindau disease) are benign. However, mucinous cystic neoplasms (defined by the presence of ovarian stroma and accounting for 10–45% of cystic pancreatic neoplasms), intraductal papil- lary mucinous neoplasms (21–33% of cystic pancreatic neoplasms), solid pseudopapillary tumors (less than 5%, primarily in young women), and cystic islet cell tumors (3–5%) may be malignant. Their prognoses are better than the prognosis of pancreatic adenocarcinoma, unless the cystic neoplasm is at least locally advanced. Mucinous cystic neoplasms and intraductal papillary mucinous neoplasms account for 15–30% of pancreatic cancers. »Clinical FindingsA.  Symptoms and SignsPai n is present in over 70% of cases and is often vague, dif- fuse, and located in the epigastrium or, when the lesion is in the tail, located in the left upper quadrant of the abdo- men. Radiation of pain into the back is common and some- times predominates. Sitting up and leaning forward may afford some relief, and this usually indicates that the lesion has spread beyond the pancreas and is inoperable. Diar- rhea, perhaps due to maldigestion, is an occasional early symptom. Migratory thrombophlebitis is a rare sign. Weight loss is a common but late finding and may be asso- ciated with depression. Hyperglycemia and decreases in subcutaneous abdominal fat and serum lipid levels have been reported to precede a diagnosis of pancreatic cancer. Occasional patients (often aged 40 years or older) present with acute pancreatitis in the absence of an alternative cause. Jaundice is usually due to biliary obstruction by a cancer in the pancreatic head. A palpable gallbladder is also indicative of obstruction by a neoplasm (Courvoisier sign), but there are frequent exceptions. A hard, fixed, occasionally tender mass may be present. In advanced cases, a hard periumbilical (Sister Mary Joseph’s) nodule may be palpable.B.  Laboratory FindingsThere  may be mild anemia. Glycosuria, hyperglycemia, and impaired glucose tolerance or true diabetes mellitus are found in 10–20% of cases. The serum amylase or lipaseCMDT22_Ch39_p1612-p1675.indd  1634 02/07/21 2:44 PMCANCER1635 CMDT 2022level  is occasionally elevated. Liver biochemical tests may suggest obstructive jaundice. Steatorrhea in the absence of jaundice is uncommon. Occult blood in the stool is sugges- tive of carcinoma of the ampulla of Vater (the combination of biliary obstruction and bleeding may give the stools a distinctive silver appearance). CA 19-9, with a sensitivity of 70% and a specificity of 87%, has not proven useful for early detection of pancreatic cancer; increased values are also found in acute and chronic pancreatitis and cholangi- tis. Plasma chromogranin A levels are elevated in 88–100% of patients with pancreatic neuroendocrine tumors (NETs).C.  ImagingM ultiphase thin-cut helical CT is generally the initial diag- nostic procedure and detects a mass in over 80% of cases. CT identifies metastases, delineates the extent of the tumor, and allows percutaneous FNA for cytologic studies and tumor markers. MRI is an alternative to CT. Ultraso- nography is not reliable because of interference by intesti- nal gas. PET is a sensitive technique for detecting pancreatic cancer and metastases, but PET-CT is not a routine staging procedure. Selective celiac and superior mesenteric arteri- ography may demonstrate vessel invasion by cancer, a find- ing that would preclude attempts at surgical resection, but it is used uncommonly since the advent of multiphase helical CT. EUS is more sensitive than CT for detecting pancreatic cancer and is equivalent to CT for determining nodal involvement and resectability; contrast-enhanced EUS improves accuracy. A normal EUS excludes pancre- atic cancer. EUS may also be used to guide FNA or biopsy for tissue diagnosis, tumor markers, and DNA analysis. ERCP may clarify an ambiguous CT or MRI study by delineating the pancreatic duct system or confirming an ampullary or biliary neoplasm. MRCP appears to be at least as sensitive as ERCP in diagnosing pancreatic cancer. In some centers, pancreatoscopy or intraductal ultrasonog- raphy is used to evaluate filling defects in the pancreatic duct and assess resectability of intraductal papillary muci- nous cancers. With obstruction of the splenic vein, spleno- megaly or gastric varices are present, the latter detected by endoscopy, EUS, or angiography. Cystic neoplasms can be distinguished by their appear- ance on CT, EUS, and ERCP and features of the cyst fluid on gross, cytologic, and genetic analysis. For example, serous cystadenomas may have a central scar or honey- comb appearance; mucinous cystadenomas are unilocular or multilocular and contain mucin-rich fluid with high carcinoembryonic antigen levels (greater than 200 ng/mL [200 mcg/L]) and K-ras mutations; and intraductal papil- lary mucinous neoplasms are associated with a dilated pancreatic duct and extrusion of gelatinous material from the ampulla. »StagingThe  TNM system is the commonly used classification to stage pancreatic cancer. Staging is important not only because it correlates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy.»TreatmentAbdo minal exploration is usually necessary when cytologic diagnosis cannot be made or if resection is to be attempted (in up to 30% of patients with pancreatic carcinoma). In a patient with a localized mass in the head of the pancreas and without jaundice, laparoscopy may detect tiny perito- neal or liver metastases and thereby avoid resection in 4–13% of patients. Radical pancreaticoduodenal (Whipple) resection is indicated for cancers strictly limited to the head of the pancreas, periampullary area, and duodenum (T1, N0, M0). Five-year survival rates are 20–25% in this group and as high as 40% in those with negative resection margins and without lymph node involvement. Preopera- tive endoscopic decompression of an obstructed bile duct is often achieved with a plastic stent or short metal stent but does not reduce operative mortality and is associated with complications. The best surgical results are achieved at centers that specialize in the multidisciplinary treatment of pancreatic cancer. Adjuvant chemotherapy with gemcitabine, 5-fluo- rouracil, or gemcitabine with capecitabine is superior to no adjuvant therapy. Gemcitabine with capecitabine and a modified FOLFIRINOX (5-fluorouracil, leucovorin, irino- tecan, oxaliplatin) regimen have been found to be superior to gemcitabine alone. The role of adjuvant chemoradiation is controversial but often used in the United States. Neoad- juvant chemotherapy with or without radiation is increas- ingly being used to downstage patients and in those with resectable cancer. Common chemotherapy regimens for this purpose include FOLFIRINOX and gemcitabine with nanoparticle albumin-bound (nab)-paclitaxel. Chemora- diotherapy downstages about 30% of patients with locally advanced disease to allow resection. When resection is not feasible, endoscopic stenting of the bile duct is performed to relieve jaundice. A plastic stent is generally placed if the patient’s anticipated survival is less than 6 months (or if surgery is planned). A metal stent is preferred when anticipated survival is 6 months or greater. Whether covered metal stents designed to prevent cancer ingrowth offer an advantage over uncovered stents is uncertain because covered stents are associated with higher rates of migration and acute cholecystitis due to occlusion of the cystic duct. Surgical biliary bypass may be considered in patients expected to survive at least 6 months. Surgical duodenal bypass may be considered in patients in whom duodenal obstruction is expected to develop; alternatively, endoscopic placement of a self- expandable duodenal stent may be feasible. Chemoradia- tion may be used for palliation of unresectable cancer confined to the pancreas. Chemotherapy has been disappointing in metastatic pancreatic cancer, although improved response rates have been reported with FOLFIRINOX and with the combination of gemcitabine and nab-paclitaxel. In patients who have received prior chemotherapy, a regimen of 5-fluorouracil and leucovorin in combination with nanoliposomal irinotecan has resulted in improved survival compared with 5-fluorouracil and leucovorin alone. Celiac plexus nerve block (under CT or endoscopic ultrasound guidance) or thoracoscopic splanchnicectomy may improve pain control.CMDT22_Ch39_p1612-p1675.indd  1635 02/07/21 2:44 PMChAPTER 391636 CMDT 2022Surgical  resection is the treatment of choice for NETs, when feasible. Lesions that are less than 1 cm in diameter and nonfunctioning without evidence of local invasion or metastasis may be followed expectantly. Metastatic disease may be controlled with long-acting somatostatin analogs, interferon, chemotherapy, peptide-receptor radionuclide therapy, and chemoembolization. There is a consensus that asymptomatic incidental pan- creatic cysts 2 cm or smaller are at low risk for harboring invasive carcinoma. The cysts may be monitored by imag- ing tests (MRI) in 1 year and then every 2 years for 5 years and probably longer if no changes are observed, with EUS and FNA performed if a cyst enlarges to 3 cm and another high-risk feature (dilated main pancreatic duct, presence of a solid component) develops. The optimal approach is uncertain, however, and other guidelines have been pro- posed. Surgical resection is indicated for mucinous cystic neoplasms, symptomatic serous cystadenomas, solid pseu- dopapillary tumors (which have a 15% risk of malignant transformation), and cystic tumors larger than 2 cm in diameter that remain undefined after helical CT, EUS, and diagnostic aspiration. All intraductal papillary mucinous neoplasms of the main pancreatic duct should be resected, but those of branch ducts may be monitored with serial imaging if they (1) are asymptomatic and exhibit benign features; (2) have a diameter less than 3 cm (some authori- ties recommend a diameter of 1.5 cm or smaller, but even lesions 3 cm or larger may be monitored in elderly persons with no other worrisome cyst features); and (3) lack non- enhancing mural nodules, or thick wall, or abrupt change in the caliber of the pancreatic duct with distal pancreatic atrophy, or possibly bile duct dilatation and gallbladder adenomyomatosis. Most lesions with such benign features remain stable on follow-up, but a risk of malignancy per- sists for more than 10 years. Moreover, the risk of pancre- atic ductal carcinoma and of nonpancreatic cancers is also increased in this group of patients. In the absence of locally advanced disease, survival is higher for malignant cystic neoplasms than for adenocarcinomas. The role of EUS- guided ablative treatment of potentially premalignant pancreatic cysts is under study. Endoscopic resection or ablation, with temporary placement of a pancreatic duct stent, may be feasible for ampullary adenomas, but patients must be followed for recurrence. »PrognosisCarcino ma of the pancreas, especially in the body or tail, has a poor prognosis; 80–85% of patients present with advanced unresectable disease, and reported 5-year sur- vival rates range from 2% to 5%. From 1980 to 2010, mor- tality from pancreatic cancer did not decrease, but it has since started to improve. Obesity may adversely affect mortality in Western countries. Metformin may improve survival in diabetic patients with pancreatic adenocarci- noma, and use of statins preceding a diagnosis of pancre- atic cancer may improve survival. Tumors of the ampulla have a better prognosis, with reported 5-year survival rates of 20–40% after resection; jaundice and lymph node involvement are adverse prognostic factors. In carefully selected patients, resection of cancer of the pancreatic headis feasible and results in reasonable survival. In persons with a family history of pancreatic cancer in at least two first-degree relatives, or with a genetic syndrome associ- ated with an increased risk of pancreatic cancer, screening with EUS and helical CT or MRI/MRCP should be consid- ered beginning at age 50 (age 40 in CKDN2A orPRSS1 mutation carriers and age 35 in those with Peutz-Jeghers syndrome) or 10 years before the age at which pancreatic cancer was first diagnosed in a family member. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5). »When to ReferAll pa tients with carcinoma involving the pancreas and the ampulla of Vater should be referred to a specialist. »When to AdmitPatients  who require surgery and other interventions should be hospitalized.Aslanian  HR et al. AGA Clinical Practice Update on pancreas cancer screening in high-risk individuals: expert review. Gas- troenterology. 2020;159:358. [PMID: 32416142] Elta GH et al. ACG Clinical Guideline: diagnosis and manage- ment of pancreatic cysts. Am J Gastroenterol. 2018;113:464. [PMID: 29485131] US Preventive Services Task Force; Owens DK et al. Screening for pancreatic cancer: US Preventive Services Task Force reaf- firmation recommendation statement. JAMA. 2019;322:438. [PMID: 31386141]AL IMENTARY TRACT CANCERS Carling Ursem, MD Kenneth R. McQuaid, MD ESOPHAGEAL CANCERE S S E N T I A L S  O F  D I A G N O S I S »Progressive dysphagia to solid food. »Weight loss common. »Endoscopy with biopsy establishes diagnosis. »General ConsiderationsEsophageal cancer usually develo ps in persons between 50 and 70 years of age. There were an estimated 18,440 new cases of esophageal cancer in the United States in 2020. The overall ratio of men to women is 3:1. There are two histo- logic types: squamous cell carcinoma and adenocarcinoma, and their incidence has significant geographic variation. Squamous cell carcinoma is associated with smoking, alco- hol, poor nutritional status, and drinking hot beverages. It accounts for over 90% of cases of esophageal cancer inCMDT22_Ch39_p1612-p1675.indd  1636 02/07/21 2:44 PMCANCER1637 CMDT 2022Eastern  and Southeast Asia and sub-Saharan Africa. Ade- nocarcinoma is associated with obesity and gastroesopha- geal reflux disease, with the majority of cases developing as a complication of Barrett metaplasia due to chronic gastro- esophageal reflux. Adenocarcinomas make up the majority of new cases of esophageal cancer in North America and Northern and Western Europe. »Clinical FindingsA.  Symptoms and SignsThe  majority (50–60%) of patients with esophageal cancer present with advanced, incurable disease. While early symptoms are nonspecific and subtle, over 90% eventually have solid food dysphagia, which progresses over weeks to months. Odynophagia is sometimes present. Significant weight loss is common. Local tumor extension into the tracheobronchial tree may result in a tracheo-esophageal fistula, characterized by coughing on swallowing or by pneumonia. Chest or back pain suggests mediastinal exten- sion. Recurrent laryngeal nerve involvement may produce hoarseness. Physical examination is often unrevealing. The presence of supraclavicular or cervical lymphadenopathy or of hepatomegaly implies metastatic disease.B.  Laboratory FindingsLaborato ry findings are nonspecific. Anemia related to chronic disease or occult blood loss is common. Elevated aminotransferase or alkaline phosphatase concentrations suggest hepatic or bony metastases. Hypoalbuminemia may result from malnutrition.C.  ImagingA  barium esophagogram may be the first study obtained to evaluate dysphagia. The appearance of a polypoid, obstruc- tive, or ulcerative lesion is suggestive of carcinoma and requires endoscopic evaluation. However, even lesions believed to be benign by radiography warrant endoscopic evaluation. Chest radiographs may show adenopathy, a widened mediastinum, pulmonary or bony metastases, or signs of tracheo-esophageal fistula such as pneumonia.D . Upper EndoscopyEndoscopy  with biopsy establishes the diagnosis of esopha- geal carcinoma with a high degree of reliability. In some cases, significant submucosal spread of the tumor may yield nondiagnostic mucosal biopsies. Repeat biopsy may be necessary. »StagingAfter  confirmation of the diagnosis of esophageal carci- noma, the stage of the disease should be determined since doing so influences the choice of therapy. Patients should undergo evaluation with contrast CT of the chest and abdomen to look for evidence of pulmonary or hepatic metastases, lymphadenopathy, and local tumor extension. If there is no evidence of distant metastases or extensive local spread on CT, then EUS with guided FNA biopsy of suspicious lymph nodes should be performed to evaluatethe locoregional stage. EUS is superior to CT in demon- strating the level of local mediastinal extension and local lymph node involvement. PET with fluorodeoxyglucose or integrated PET-CT imaging is indicated to look for regional or distant spread in patients thought to have localized dis- ease after other diagnostic studies, prior to invasive sur- gery. Bronchoscopy is sometimes required in esophageal cancers above the carina to exclude tracheobronchial extension. Laparoscopy to exclude occult peritoneal carci- nomatosis should be considered in patients with tumors at or near the gastroesophageal junction (see Gastric Adenocarcinoma). »Differential DiagnosisEsophageal  carcinoma must be distinguished from other causes of progressive dysphagia, including peptic stricture, achalasia, and adenocarcinoma of the gastric cardia with esophageal involvement. Benign-appearing peptic stric- tures should be biopsied at presentation to exclude occult malignancy. »TreatmentThe appr oach to esophageal cancer depends on the tumor stage, tumor location, patient preference and functional status, and the expertise of the gastroenterologists, sur- geons, oncologists, and radiation oncologists. It is helpful to classify patients into two general categories: those with early stage (curable) disease and those with advanced stage (incurable) disease.A.  Therapy for “Curable” DiseaseSuperficial  esophageal cancers confined to the epithelium (high-grade dysplasia or carcinoma in situ [Tis]), lamina propria (T1a), or submucosal (T1b) are increasingly recog- nized in endoscopic screening and surveillance programs. Esophagectomy achieves high cure rates for superficial tumors but is associated with mortality (2%) and morbid- ity. If performed by experienced clinicians, endoscopic mucosal resection of Tis and T1a cancers achieves equiva- lent long-term survival with less morbidity (see Barrett Esophagus, Chapter 15). Esophagectomy is recommended for superficial tumors that are invasive to the submucosa (T1b) because of higher rates of lymph node metastasis. 1. Surgery with or without neoadjuvant chemoradiation therapy— There are multiple surgical approaches to the resection of invasive but potentially “curable” esophageal cancers (stage Ib, II, IIIA, or IIIB). Accepted techniques include en bloc transthoracic excision of the esophagus with extended lymph node dissection, transhiatal esopha- gogastrectomy (entailing laparotomy with cervical anasto- mosis), and minimally invasive esophagectomy techniques. Meta-analysis data suggest equivalent oncologic outcomes from minimally invasive esophagectomy and conventional open techniques, although there are fewer postoperative complications and shorter hospital stays with the laparo- scopic approach. Multiple meta-analyses have shown that regardless of surgery type, surgery at a high-volume hospi- tal is associated with decreased perioperative mortality.CMDT22_Ch39_p1612-p1675.indd  1637 02/07/21 2:44 PMChAPTER 391638 CMDT 2022Pa tients with stage I tumors have high cure rates with surgery alone and do not require radiation or chemother- apy. Whether radiation or chemotherapy or both are required in addition to surgery for T2N0 stage II tumors is a subject of ongoing debate. If regional lymph node metas- tases have occurred (stages IIB and III), the rate of cure with surgery alone is reduced to less than 20%. Meta- analysis of trials comparing neoadjuvant (preoperative) therapy followed by surgery with surgery alone suggests a 13% absolute improvement in 2-year survival with com- bined therapy. Preoperative (neoadjuvant) chemoradiation therapy is recommended for stage IIB and III tumors in fit patients. The preferred neoadjuvant chemotherapy regi- men used with radiation is weekly carboplatin plus pacli- taxel (Table 39–2). As an alternative, a combination of cisplatin plus 5-fluorouracil may be used along with radia- tion. When radiation therapy is considered, techniques that are less toxic such as intensity-modulated radiation therapy (IMRT) or proton beam therapy may be consid- ered. Perioperative chemotherapy without radiation may also be considered for tumors of the gastroesophageal junction based on the randomized, multicenter, phase III MAGIC trial. 2. Chemotherapy plus radiation therapy without surgery— Combined treatment with chemotherapy and radiation achieves long-term survival rates in up to 25% of patients and is superior to radiation alone. Chemoradia- tion alone should be considered in patients with localized disease (stage II or IIIA) who are poor surgical candidates due to serious medical illness or poor functional status (Eastern Cooperative Oncology Group score greater than 2). Patients with cervical esophageal cancers, which appear similar biologically to head and neck cancers and in whom surgery is highly morbid and typically not recommended, also should be considered for chemoradiation. 3. Supportive care during definitive therapy— Patients with significant tumor obstruction may require percutane- ous gastric or jejunal tube placement to maintain adequate hydration and nutrition during neoadjuvant chemoradia- tion or chemotherapy. Multidisciplinary consultation is required to determine the optimal procedure and to opti- mize perioperative nutrition.B.  Therapy for Incurable DiseaseMo re than half of patients have either locally extensive tumor spread (T4b) that is unresectable or distant metasta- ses (M1) at the time of diagnosis. Surgery is not warranted in these patients. Since prolonged survival can be achieved in few patients, the primary goal is to provide relief from dysphagia and pain, optimize quality of life, and minimize treatment side effects. The optimal palliative approach depends on the presence or absence of metastatic disease, expected survival, patient preference, and institutional experience. 1. Chemotherapy or chemoradiation— Combined radia- tion therapy and chemotherapy may achieve palliation in two-thirds of patients but is associated with significant side effects. It should be considered for patients with locallyadvanced tumors without distant metastases who have good functional status and no significant medical prob- lems, in whom prolonged survival may be achieved. Com- bination chemotherapy may be considered in patients with metastatic disease who still have good functional status and expected survival of at least several months. The systemic therapy treatment options are the same for metastatic esophageal, gastroesophageal junction, and gastric cancers (Table 39–2). Choice of treatment is increas- ingly influenced by the results of molecular testing, includ- ing PD-L1 expression, mismatch repair/microsatellite instability (MSI) and, for adenocarcinomas, HER2 amplifi- cation testing. Because of the number of targetable altera- tions, a next generation sequencing panel should be considered. In patients with amplification of the HER2 gene (approximately 15% of cases), addition of the mono- clonal antibody trastuzumab (see Chapter 17) to chemo- therapy is associated with prolonged survival. For patients without HER2 amplification who have increased PD-L1 expression, the addition of a PD-1 or PD-L1 targeted anti- body to chemotherapy may improve overall survival. Immunotherapy with pembrolizumab should be consid- ered for tumors with either microsatellite instability-high (MSI-H) or deficient mismatch repair protein expression (dMMR). For patients with poor functional status, single- agent therapy with a fluoropyrimidine, a taxane, or irinote- can may be used. 2. Local therapy for esophageal obstruction— Patients with advanced esophageal cancer often have a poor func- tional and nutritional status. Radiation therapy alone to the area of esophageal obstruction may afford short-term relief of pain and dysphagia. Rapid palliation of dysphagia may be achieved by peroral placement of permanent expand- able wire stents (alone or followed by radiation). However, placement of these stents is complicated by perforation, migration, or tumor ingrowth in up to 40% of cases. »PrognosisThe ov erall 5-year survival rate of esophageal carcinoma is less than 20%. Apart from distant metastasis (M1b), the two most important predictors of poor survival are adja- cent mediastinal spread (T4) and lymph node involvement. Whereas cure may be achieved in patients with regional lymph node involvement (stages IIB and III), involvement of nodes outside the chest (M1a) is indicative of metastatic disease (stage IV) that is incurable. For those patients whose disease progresses despite chemotherapy, meticu- lous efforts at palliative care are essential (see Chapter 5). »When to Refer• Patients should be referred to a gastroenterologist for evaluation and staging (endoscopy with biopsy, EUS) and palliative endoscopic stenting. •Patients with curable and resectable disease for whom neoadjuvant therapy may be appropriate (stage IIB or IIIA) should be referred to medical, radiation, and sur- gical oncologists for consideration of neoadjuvant che- motherapy, chemoradiotherapy, and surgical resection.CMDT22_Ch39_p1612-p1675.indd  1638 02/07/21 2:44 PMCANCER1639 CMDT 2022• Patients with metastatic disease should be referred to medical and radiation oncologists for consideration of palliative chemotherapy or chemoradiation. •Patients with metastatic disease and obstructive tumors not amenable to or refractory to palliative radiation or stenting may require referral to an interventional radi- ologist, gastroenterologist, or surgeon for gastric or jejunal tube placement for liquid artificial nutrition. Early referral to palliative care services may improve symptom management in patients with advanced or metastatic disease. »When to AdmitP atients with high-grade esophageal obstruction with inabil- ity to manage oral secretions or maintain hydration should be admitted. Acute complications such as perforation, bleeding, aspiration, or fistula also may require admission.Boku  N et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previ- ously untreated, unresectable, advanced, or recurrent gastric/ gastroesophageal junction cancer: interim results of a ran- domized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250. [PMID: 30566590] Gottlieb-Vedi E et al. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. Ann Surg 2019;270:1005. [PMID: 30817355] Mariette C et al; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152. [PMID: 30625052] National Cancer Institute. SEER Cancer Statistics Factsheets: Esophageal Cancer, 2020. https://seer.cancer.gov/statfacts/ html/esoph.html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. Version5.2020. 2020 December 23. https:// www.nccn.org/professionals/physician_gls/pdf/esophageal. pdfGA STRIC ADENOCARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »Dyspeptic symptoms with weight loss in patients over age 40 years. »Iron deficiency anemia: occult blood in stools. »Abnormality detected on upper gastrointestinal series or endoscopy. »General ConsiderationsGastric  adenocarcinoma is the third most common cause of cancer death worldwide. However, its incidence has declined rapidly over the last 70 years, especially in Western countries, which may be attributable to changes in diet (more fruits and vegetables), food refrigeration (allowingmore fresh foods and reduced salted, smoked, and pre- served foods), reduced toxic environmental exposures, and a decline in Helicobacter pylori infections. The incidence of gastric cancer remains high (62/100,000 males) in Japan and many developing regions, including eastern Asia, Eastern Europe, Chile, Colombia, and Central America. In the United States, there were an estimated 27,600 new cases and 11,010 deaths in 2020. The incidence is higher in Asian Americans, Hispanics, African Americans, and Native Americans (including Native Alaskans). There are two main histologic variants of gastric cancer: “intestinal-type” (which resembles intestinal cancers in forming glandular structures) and “diffuse” (which is poorly differentiated, has signet-ring cells, and lacks glan- dular formation). The incidence of intestinal-type gastric cancer has declined significantly, but it is still the more common type (70–80%); it occurs twice as often in men as women, primarily affects older people (mean age 68 years), and is more strongly associated with environmental fac- tors. It is believed to arise through a gradual, multi-step progression from inflammation (most commonly due to H pylori ), to atrophic gastritis, to intestinal metaplasia, and finally to dysplasia and cancer. Chronic H pylori gastritis is the strongest risk factor for gastric carcinoma, increasing the relative risk 3.5- to 20-fold. It is estimated that 60–90% of cases of gastric carcinomas may be attributable to H pylori. Other risk factors for intestinal-type gastric cancer include pernicious anemia, a history of partial gastric resection more than 15 years previously, smoking, and diets that are high in nitrates or salt and low in vitamin C. Diffuse gastric cancer accounts for 20–30% of gastric can- cer cases. In contrast to intestinal-type cancer, it affects men and women equally, occurs more commonly in young people, is not as strongly related to H pylori infection, and has a worse prognosis than intestinal-type cancer due to early metastasis. Most diffuse gastric cancers are attribut- able to acquired or hereditary mutations in the genes regulating the E-cadherin cell adhesion protein. Hereditary diffuse gastric cancer accounts for 1–3% of gastric cancers. The cancer may arise at a young age, is often multifocal and infiltrating with signet ring cell histology, and confers poor prognosis. Many of these families have a germline muta- tion of E-cadherin CDH1, which is inherited in an autoso- mal dominant pattern and carries a greater than 60% lifetime risk of gastric cancer. Prophylactic gastrectomy should be considered in patients known to carry this mutation. Most gastric cancers arise in the body and antrum. These may occur in a variety of morphologic types: (1) polypoid or fungating intraluminal masses; (2) ulcerating masses; (3) diffusely spreading ( linitis plastica ), in which the tumor spreads through the submucosa, resulting in a rigid, atonic stomach with thickened folds (prognosis dis- mal); and (4) superficially spreading or “early” gastric cancer—confined to the mucosa or submucosa (with or without lymph node metastases) and associated with a favorable prognosis. HER2 amplification and overexpres- sion is seen in 10–25% of gastric adenocarcinoma cases and is more commonly observed in intestinal histology and moderately differentiated disease. Testing for MSI,CMDT22_Ch39_p1612-p1675.indd  1639 02/07/21 2:44 PMChAPTER 391640 CMDT 2022defici ency in mismatch repair proteins (dMMR), and PD-L1 is recommended in advanced disease to identify tumors that may respond to immunotherapy. For gastric adenocarcinoma, MSI-H/dMMR is found in 8–16% of cases. In contrast to the dramatic decline in cancers of the distal stomach, a rise in incidence of tumors of the gastric cardia has been noted. These tumors have demographic and pathologic features that resemble Barrett-associated esoph- ageal adenocarcinomas (see Esophageal Cancer). »Clinical FindingsA.  Symptoms and SignsGastri c carcinoma is generally asymptomatic until the dis- ease is quite advanced. Symptoms are nonspecific and are determined in part by the location of the tumor. Dyspepsia, vague epigastric pain, anorexia, early satiety, and weight loss are the presenting symptoms in most patients. Patients may derive initial symptomatic relief from over-the-counter rem- edies, further delaying diagnosis. Ulcerating lesions can lead to acute gastrointestinal bleeding with hematemesis or melena. Pyloric obstruction results in postprandial vomiting. Lower esophageal obstruction causes progressive dysphagia. Physical examination is rarely helpful. Stools may be guaiac positive.B.  Laboratory FindingsIr on deficiency anemia due to chronic blood loss or anemia of chronic disease is common. Circulating tumor markers do not have established clinical validity in screening or diagnosis of gastric cancer. However, when checked serially, tumor markers can assist in monitoring treatment response.C.  EndoscopyU pper endoscopy should be obtained in all patients over age 60 years with new onset of epigastric symptoms (dyspepsia) and young patients with “alarm” symptoms (dysphagia, recur- rent vomiting, significant weight loss), especially in immi- grants from countries with a high prevalence of gastric cancer. Endoscopy with biopsies of suspicious lesions is highly sensi- tive for detecting gastric carcinoma. It can be difficult to obtain adequate biopsy specimens in diffuse type gastric cancer.D . ImagingOnce  a gastric cancer is diagnosed, preoperative evaluation with contrast CT of chest, abdomen, and pelvis and EUS is indicated to delineate the local extent of the primary tumor as well as to evaluate for nodal or distant metastases. EUS is superior to CT in determining the depth of tumor pen- etration and is useful for evaluation of early gastric cancers that may be removed by endoscopic mucosal resection. PET or combined PET-CT imaging is recommended for detection of distant metastasis. »ScreeningBecause  of its unproven efficacy and cost-effectiveness, screening for H pylori infection and treating it to preventgastric cancer is not recommended for asymptomatic adults in the general population but may be considered in patients who have immigrated from regions with a high incidence of gastric cancer or who have a family history of gastric cancer. Because of the high incidence of gastric carcinoma in Japan, screening upper endoscopy is per- formed there to detect early gastric carcinoma. Approxi- mately 40% of tumors detected by screening are early, with a 5-year survival rate of almost 90%. Screening is not rec- ommended in the United States. »StagingThe  TNM system is the commonly used classification to stage gastric adenocarcinoma. Staging is important not only because it correlates with the patient’s long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. A staging laparoscopy prior to definitive surgery to exclude peritoneal carcinomatosis should be considered in patients with stage T1b or greater disease without radio- graphic evidence of distant metastases. Pathologic review should include (1) grade of tumor, (2) histologic subtype, (3) depth of invasion, (4) whether lymphatic or vascular inva- sion is present, and (5) if there is known metastatic disease, the status of HER2 protein expression by immunohisto- chemistry or fluorescent in situ hybridization or both, along with MMR or MSI testing and PD-L1 protein expression. »Differential DiagnosisUlce rating gastric adenocarcinomas are distinguished from benign gastric ulcers by biopsies. Approximately 3% of gastric ulcers initially believed to be benign later prove to be malignant. All gastric ulcers identified at endoscopy should be biopsied to exclude malignancy. Ulcers that are suspicious for malignancy to the endoscopist or that have atypia or dysplasia on histologic examination warrant repeat endoscopy in 2–3 months to verify healing and exclude malignancy. Nonhealing ulcers should be consid- ered for resection. Infiltrative carcinoma with thickened gastric folds must be distinguished from lymphoma and other hypertrophic gastropathies. »TreatmentA.  Curative Surgical ResectionSurgical resecti on is the only therapy with curative poten- tial. Laparoscopic techniques achieve similar outcomes and lower overall complication rates as open gastrectomy. In Japan and in specialized centers in the United States, endo- scopic mucosal resection is performed in select patients with small (less than 1–2 cm), early (intramucosal or T1aN0) gastric cancers after careful staging with EUS. Approximately 25% of patients undergoing surgery will be found to have locally unresectable tumors or peritoneal, hepatic, or distant lymph node metastases that are incur- able. The remaining patients with confirmed localized disease should undergo radical surgical resection. For adenocarcinoma localized to the distal two-thirds of the stomach, a subtotal gastrectomy should be performed. ForCMDT22_Ch39_p1612-p1675.indd  1640 02/07/21 2:44 PMCANCER1641 CMDT 2022pro ximal gastric cancer or diffusely infiltrating disease, total gastrectomy is necessary. The ultimate goal of surgery is obtaining negative surgical margins. Vitamin B12supple- mentation is required after gastrectomy. For patients with localized gastric cancer that is resectable, current National Comprehensive Cancer Network (NCCN) treatment guidelines recommend gastrectomy with extended (D1), or modified regional (D2), lymph node dissection and sam- pling of 15 or more lymph nodes. D2 lymphadenectomy has been shown to improve disease-specific survival but is associated with increased postoperative mortality.B.  Perioperative Chemotherapy or ChemoradiationThe  use of perioperative chemotherapy or adjuvant chemo- radiation is associated with improved survival in patients with localized or locoregional gastric adenocarcinoma who undergo surgical resection. The choice of treatment depends on the location and extent of tumor, type of sur- gery, patient comorbidities and performance status, and institutional experience. Tumors arising in the gastro- esophageal junction are treated following algorithms for esophageal primary tumors. Multidisciplinary treatment decision making involving the surgeon, radiation oncolo- gist, and medical oncologist is imperative.C.  Palliative ModalitiesMan y patients will be found either preoperatively or at the time of surgical exploration to have advanced disease that is not amenable to curative intent surgery due to peritoneal or distant metastases or local invasion of other organs. In some of these cases, palliative resection of the tumor none- theless may be indicated to alleviate pain, bleeding, or obstruction. For patients with unresectable disease, a surgi- cal diversion with gastrojejunostomy may be indicated to prevent obstruction. Alternatively, unresected tumors may be treated with endoscopic stent therapy, radiation therapy, or angiographic embolization to relieve bleeding or obstruction. Systemic therapy may be considered in patients with metastatic disease who still have good func- tional status and expected survival of at least several months. The regimens used are the same as those for esophageal and gastroesophageal junction tumors dis- cussed above (Table 39–2). »PrognosisThe  5-year survival for gastric cancer varies greatly by stage, location, and histologic features. The 5-year survival is approximately 90% for early-stage cancer (T1b or less), 80% for stage II after curative intent treatment, but less than 20% for stage IIIC. Even with apparently localized disease, proxi- mal tumors have a 5-year survival of less than 15%. For those whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). »When to Refer• Patients with dysphagia, weight loss, protracted vomit- ing, iron deficiency anemia, melena, or new-onset dys- pepsia (especially if aged 60 years or older or associatedwith other alarm symptoms) in whom gastric cancer is suspected should be referred for endoscopy. •Patients should be referred to a surgeon for attempt at curative resection in stage I, II, or III cancer, including staging laparoscopy if indicated. •Prior to surgery, patients should be referred to an oncolo- gist to determine the role for perioperative chemother- apy or adjuvant chemoradiation or chemotherapy. •Patients who have undergone gastrectomy require con- sultation with a nutritionist due to propensity for mal- nutrition and complications, such as dumping syndrome and vitamin B12deficiency, postoperatively. •Patients with unresectable or metastatic disease should be referred to an oncologist for consideration of pallia- tive chemotherapy or chemoradiation. Early referral to palliative care services may also be considered for symptom management in patients with advanced and metastatic disease. »When to AdmitPa tients with acute bleeding, protracted vomiting, or inabil- ity to maintain hydration or nutrition.Ja ng S et al. Superiority of gastrojejunostomy over endoscopic stenting for palliation of malignant gastric outlet obstruction. Clin Gastroenterol Hepatol. 2019;17:1295. [PMID: 30391433] Katai H et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open-distal gastrectomy with nodal dis- section for clinical stage IA or IB gastric cancer: a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5:142. [PMID: 31757656] National Cancer Institute. SEER Cancer Stat Facts: Stomach Cancer, 2020. https://seer.cancer.gov/statfacts/html/stomach. html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 4.2020. 2020 December 23. https://www.nccn.org/professionals/physician_ gls/pdf/gastric.pdfGA STRIC LYMPHOMAE S S E N T I A L S  O F  D I A G N O S I S »Symptoms of dyspepsia, weight loss, or anemia. »Variable abnormalities on upper gastrointestinal series or endoscopy including thickened folds, ulcer, mass, or infiltrating lesions; diagnosis estab- lished by endoscopic biopsy. »Abdominal CT and EUS required for staging. »General ConsiderationsGastric lympho mas may be primary (arising from the gas- tric mucosa) or may represent a site of secondary involve- ment in patients with nodal lymphomas. Distinguishing advanced primary gastric lymphoma with adjacent nodal spread from advanced nodal lymphoma with secondaryCMDT22_Ch39_p1612-p1675.indd  1641 02/07/21 2:44 PMChAPTER 391642 CMDT 2022gastric spread is essential  because the prognosis and treat- ment of primary and secondary gastric lymphomas are different. Primary gastric lymphoma is the second most common gastric malignancy, accounting for 3–5% of gas- tric cancers. More than 95% of these are non-Hodgkin B-cell lymphomas mainly consisting of either mucosa- associated lymphoid tissue (MALT)-type lymphoma and diffuse large B-cell lymphoma. Over 90% of low-grade primary gastric MALT-type lymphomas are associated with H pylori infection. Gastric T-cell lymphoma, which is associated with HTLV-1 infection, is rare and makes up 7% of primary gastric lymphomas. »Clinical Findings & StagingThe  clinical presentation and endoscopic appearance of gastric lymphoma are similar to those of adenocarcinoma. Most patients have abdominal pain, weight loss, or bleed- ing. Patients with diffuse large B-cell lymphoma are more likely to have systemic symptoms and advanced tumor stage. At endoscopy, lymphoma may appear as an ulcer, mass, or diffusely infiltrating lesion. It tends to have hori- zontal infiltration as opposed to the vertical extension seen in adenocarcinoma. The diagnosis is established with endoscopic biopsy; FNA is not adequate. Since the disease can be multifocal, biopsies of both suspicious and normal- appearing areas are recommended. Biopsy specimens should be tested for H pylori and, if positive, for t(11;18) via PCR or FISH. EUS is the most sensitive test for determin- ing the level of invasion and presence of perigastric lymph- adenopathy and should be performed for accurate staging, if available. All patients should undergo staging with CT scanning of chest, abdomen, and pelvis. For gastric MALT lymphomas, the Lugano staging system is most frequently used. Stage I is confined to the gastrointestinal tract, stage II involves local or regional lymph nodes, stage IIE has invasion of adjacent organs or tissues, and stage IV has distant metastases. There is no stage III. For patients with diffuse large B-cell lymphomas involving the stomach, combination PET-CT imaging, bone marrow biopsy with aspirate, tumor lysis laboratory tests, and hepatitis B and HIV serologies also may be required for staging and treat- ment planning (see Chapter 13). »TreatmentT reatment of primary gastric lymphomas depends on the tumor histology, grade, and stage. Marginal B-cell lympho- mas of the MALT type that are low-grade and localized to the stomach wall (stage I) or perigastric lymph nodes (stage IIE1) have an excellent prognosis. Patients with pri- mary gastric MALT-lymphoma should be tested for H pylori infection and treated if positive. Complete lym- phoma regression after successful H pylori eradication occurs in approximately 75% of cases of stage I and approx- imately 55% with stage IIE low-grade lymphoma. However, 95% of cancers positive for t(11;18) do not respond to antibiotics. Remission may take as long as a year, and relapse occurs in about 2% of cases per year. Many patients with minimal disease after successful H pylori eradication may be observed closely without further therapy. Restagingwith endoscopy and biopsy is recommended 3 months after antibiotic treatment and 3–6 months following radia- tion therapy. Ultimately, endoscopic surveillance after treatment is recommended every 3–6 months for 5 years to evaluate for recurrence. In patients whose tumors harbor specific gene translo- cations, including t(11;18) (API2-MALT1), t(1;14), or t(14;18), rates of remission after H pylori eradication are lower, and treatment with radiation is often required. The long-term survival of low-grade MALT lymphoma for stage I is over 90% and for stage II is 35–65%. Surgical resection is not recommended. Diffuse large B-cell or other higher-grade lymphomas with secondary gastrointestinal involvement usually present at an advanced stage with widely disseminated disease and are treated according to stage and subtype of lymphoma (see Chapter 13).A vilés A et al. Primary gastric diffuse large B-cell lymphoma: the role of dose-dense chemotherapy. J Oncol Pharm Pract. 2019; 25:1682. [PMID: 30370804] Juárez-Salcedo LM et al. Primary gastric lymphoma, epidemiol- ogy, clinical diagnosis, and treatment. Cancer Control. 2018;25: 1073274818778256. [PMID: 29779412] Lin JL et al. Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study. BMC Cancer. 2019;19:873. [PMID: 31481021] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell. pdf” https://www.nccn.org/professionals/physician_gls/pdf/b- cell.pdf Tian C et al. A retrospective analysis of primary gastrointestinal non-Hodgkin lymphomas: clinical features, prognostic fac- tors and treatment outcomes. Onco Targets Ther. 2020;13: 5345. [PMID: 32606752]GA STRIC NEUROENDOCRINE TUMORSGastric  NETs make up less than 1% of gastric neoplasms. They may occur sporadically or secondary to chronic hypergastrinemia that results in hyperplasia and transfor- mation of enterochromaffin cells in the gastric fundus. The majority of NETs are caused by hypergastrinemia and occur in association with either pernicious anemia (75%) (type 1) or Zollinger-Ellison syndrome (5%) (type 2). Type 1 tumors are associated with chronic atrophic gastritis, gas- tric achlorhydria, and secondary hypergastrinemia. Initial diagnostic workup includes serum gastrin level, upper endoscopy, and EUS. Gastrin level should be obtained 1 week after the patient has stopped taking protein pump inhibitors. For low-grade tumors (Ki-67 less than 3% or less than 2 mitoses/10 high-power fields [HPF]), soma- tostatin receptor–based imaging (somatostatin receptor scintigraphy or gallium-68 dotatate PET/CT) should be performed. For high-grade tumors (Ki-67 greater than 20% or greater than 20 mitoses/10 HPF), FDG-PET/CT is pre- ferred to evaluate the extent of disease. For patients with hypergastrinemia (suspected of type 1 or type 2 carcinoid), serum vitamin B12and intrinsic factor antibody levels should be obtained to exclude pernicious anemia. Gastric NETs associated with Zollinger-EllisonCMDT22_Ch39_p1612-p1675.indd  1642 02/07/21 2:44 PMCANCER1643 CMDT 2022syndrom e occur almost exclusively in patients with multi- ple endocrine neoplasia type 1 (MEN 1), in which chromo- somal loss of 11q13 has been reported. Gastric NETs caused by hypergastrinemia tend to be multifocal, be smaller than 1 cm, have a low potential for metastatic spread, and thus are unlikely to cause development of the carcinoid syn- drome. Small lesions may be successfully treated with endo- scopic resection followed by endoscopic surveillance every 6–12 months, or with observation. Antrectomy reduces serum gastrin levels and may lead to regression of small tumors. It can be considered in patients with type 1 gastric NETs to reduce recurrence risk and frequency of post- therapy monitoring. Octreotide therapy may be appropriate for patients with underlying gastrinoma and Zollinger- Ellison syndrome. Patients with tumors larger than 2 cm should undergo endoscopic or surgical resection (see Small Intestinal Adenocarcinomas below). Type 3 gastric NETs arise sporadically, independent of gastrin production, and account for up to 20% of gastric NETs. Most sporadic gastric NETs are solitary, larger than 2 cm, and have a strong propensity for hepatic or pulmo- nary metastases and thus the carcinoid syndrome at initial presentation. CT or MRI should be obtained to evaluate for metastatic disease. Localized sporadic NETs should be treated with partial or total gastrectomy and regional lymphadenectomy. Advanced, low-grade gastric NETs can be monitored with serial scans, if asymptomatic. Soma- tostatin analogs may provide symptomatic relief for patients with functional gastric NETs. Advanced high- grade gastric neuroendocrine carcinomas are treated in a fashion similar to SCLCs.Algashaam y K et al. Multifocal G1-G2 gastric neuroendocrine tumors: differentiating between type I, II and III, a clinico- pathologic review. World J Clin Cases. 2019;7:2413. [PMID: 31559277] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors. Version 2.2020. 2020 July 24. https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine.pdfGA STROINTESTINAL MESENCHYMAL TUMORS »Pathobiology & DiagnosisGastroin testinal mesenchymal tumors (which include stro- mal tumors, leiomyomas, and schwannomas) derive from mesenchymal stem cells and have an epithelioid or spindle cell histologic pattern, resembling smooth muscle. The most common stromal tumors are gastrointestinal stromal tumors (“GISTs”), which originate from interstitial cells of Cajal. GISTs occur throughout the gastrointestinal tract, but most commonly in the stomach (60%) and small intes- tine (30%). Approximately 80% of GISTs have mutations in KIT. A percentage of the KIT wild type tumors have a mutation in PDGFRA , and only a minority of patients are wild type for both genes. Mesenchymal tumors may be discovered incidentally on imaging studies or endoscopy or may cause symptoms (most commonly bleeding, pain, or obstruction). At endoscopy, they appear as a submucosalmass that may have central umbilication or ulceration. EUS with guided FNA biopsy is the optimal study for diagnos- ing gastric mesenchymal tumors and distinguishing them from other submucosal lesions. Percutaneous biopsy may confer risk of bleeding or intra-abdominal seeding. CT of the abdomen and pelvis with contrast, MRI, and PET imaging are useful in the diagnosis and staging. PET imaging also may be useful to monitor response to treatment. While almost all GISTs have malignant potential, the risk of developing metastasis is increased with tumor size greater than 2 cm, nongastric location, and mitotic index greater than 5 mitoses per 50 HPF. It is difficult to distinguish benign from malignant tumors by EUS appearance or by FNA. But, in general, lesions are more likely benign if they are smaller than 2 cm, have a smooth border, and have a homogeneous echo pattern on EUS. Resection settles the issue. »TreatmentA.  Localized TreatmentSu rgery is recommended for all patients with tumors that are 2 cm or larger, increasing in size, have an EUS appearance suspicious for malignancy, or are symptomatic. The man- agement of asymptomatic gastric lesions 2 cm or smaller in size depends on the EUS features. Tumors with high-risk EUS features can be surgically resected. If no high-risk fea- tures are noted, endoscopic surveillance can be performed. Because of the low but real long-term risk of malignancy, surgical resection should be considered in younger, other- wise healthy patients. However, other patients may be moni- tored with serial endoscopic ultrasonographic examinations or, in select cases, endoscopic resections. After complete surgical resection, the risk of GIST recurrence can be calcu- lated based on tumor location, size, and mitotic index. The majority of recurrences occur within the first 3 years.B.  Systemic TreatmentBecause  the majority of GISTs are driven by mutations in KIT orPDGFRA , the tyrosine kinase inhibitor, imatinib, which blocks signaling through this pathway, is used across disease stages. Neoadjuvant therapy with imatinib may be considered for patients with localized GIST tumors who are deemed to be at high risk for resection because of comorbidities, tumor size, or tumor location. A biopsy is required to confirm the diagnosis of GIST prior to initia- tion of neoadjuvant imatinib. Adjuvant therapy with ima- tinib delays recurrence and prolongs survival, but it is not likely to be curative. Untreated metastatic GIST tumors are aggressive and carry a poor prognosis. However, imatinib induces disease control in up to 85% of patients with metastatic disease with a progression-free survival of 20–24 months and median overall survival of almost 5 years. Additionally, imatinib is associated with long-term survival in some patients. One study reported that 18% of patients contin- ued treatment after a median follow-up of 9 years. For patients with imatinib-resistant cancers, high-dose imatinib or other approved tyrosine kinase inhibitors (eg, sunitinib or regorafenib) are options.CMDT22_Ch39_p1612-p1675.indd  1643 02/07/21 2:44 PMChAPTER 391644 CMDT 2022H einrich MC et al. Avapritinib in advanced PDGFRA D842V- mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21: 935. [PMID: 32615108] Patel DJ et al. Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): is there a survival benefit following margin negative surgical resection? Am J Surg. 2020;219:436. [PMID: 31679654] von Mehren M et al. Gastrointestinal stromal tumors. J Clin Oncol. 2018;36:136. [PMID: 29220298] Wang C et al. Safety and efficiency of endoscopic resection versus laparoscopic resection in gastrointestinal stromal tumours: a systematic review and meta-analysis. Eur J Surg Oncol. 2020; 46:667. [PMID: 31864827]MA LIGNANCIES OF THE SMALL INTESTINEThe  frequency of different tumor types varies by location within the small intestine. Adenocarcinomas are most common in the duodenum and jejunum and neuroendo- crine tumors, in the ileum. Lymphomas and sarcomas each have similar incidences in the various segments of the small intestine.1.  Small Intestinal AdenocarcinomasThese  tumors often present with nonspecific symptoms such as abdominal pain and nausea. The incidence is rare, with 11,110 new diagnoses estimated in 2020 in the United States. These adenocarcinomas are most often diag- nosed at stage III or IV , but their prognosis is slightly worse than for similar stage colon adenocarcinoma. The duode- num is the most common site of small bowel adenocarci- noma, specifically in the periampullary region. Ampullary carcinoma may present with jaundice due to bile duct obstruction or bleeding. Surgical resection of early lesions is curative in up to 40% of patients. The management of nonampullary small intestinal adenocarcinoma is extrapolated from data available for the management of colon adenocarcinoma.2.  Small Intestinal LympomasL ymphomas may arise primarily in the gastrointestinal tract or may involve it secondarily in patients with dissemi- nated disease. In Western countries, primary gastrointesti- nal lymphomas account for 5% of lymphomas and 20% of small bowel malignancies. There is an increased incidence of small intestinal lymphomas in patients with AIDS, Crohn disease, and those receiving immunosuppressive therapy. The most common histologic subtype is non- Hodgkin extranodal marginal zone (MALT) B-cell lymphoma. That said, enteropathy-associated T-cell lym- phomas appear to be increasing in incidence in the United States. They are associated with the diagnosis of celiac disease. In the Middle East, lymphomas may arise in the setting of immunoproliferative small intestinal disease. Other types of intestinal lymphomas include primary intestinal follicular cell lymphoma, mantle cell lymphoma, and Burkitt lymphoma (see Chapter 13). Presenting symptoms or signs of primary small bowel lymphoma include abdominal pain, weight loss, nausea and vomiting, distention, anemia, and occult blood in thestool. Fevers are unusual. Protein-losing enteropathy may result in hypoalbuminemia, but other signs of malabsorption are unusual. Barium radiography or CT enterography helps localize the site of the lesion. The diagnosis requires endo- scopic, percutaneous, or laparoscopic biopsy. Imaging and possibly bone marrow biopsy are required to determine stage. Treatment depends on the tumor histologic subtype and stage of disease (see Chapter 13). If feasible, surgical resec- tion of primary intestinal lymphoma, may be appropriate for localized tumors. In patients with limited disease (stage IE) in whom resection is performed with negative margins, the role of adjuvant chemotherapy is unclear. Locoregional radiation should be considered if surgical margins are posi- tive. Patients with more extensive disease generally are treated according to the tumor histology.3.  Intestinal Neuroendocrine TumorsE S S E N T I A L S  O F  D I A G N O S I S »Majority are asymptomatic and discovered inci- dentally at endoscopy or surgery. »Carcinoid syndrome occurs in < 10%; hepatic metastases are generally present. »Risk of metastasis is related to tumor size and location. »General ConsiderationsNeur oendocrine tumors are the most common type of tumor arising in the small bowel. Gastrointestinal NETs (also called carcinoids) most commonly occur in the small intestine (45%) but are also found in the rectum (20%), appendix (17%), and colon (11%), with the remainder occurring in the stomach (less than 10%; see Gastric Neu- roendocrine Tumors above). Carcinoid tumors are well- differentiated neuroendocrine tumors that may secrete a variety of hormones, including serotonin, somatostatin, gastrin, and substance P . Small intestinal carcinoids most commonly arise in the distal ileum within 60 cm of the ileocecal valve. Up to 30% are multicentric. The risk of metastatic spread increases when the tumor is 1 cm or larger and when it is larger than 2 cm with invasion beyond the muscularis propria. Appen- diceal carcinoids are identified in 0.3% of appendectomies, usually as an incidental finding. Almost 80% of these tumors are smaller than 1 cm, and 90% are smaller than 2 cm. However, in patients with appendiceal carcinoid tumors larger than 2 cm, approximately 90% develop nodal and distant metastases; right hemicolectomy is recom- mended in these cases. Rectal carcinoids are usually detected incidentally as submucosal nodules during proctoscopic examination and often locally excised by biopsy or snare polypectomy before the histologic diagnosis is known. Rectal carcinoids smaller than 1 cm virtually never metastasize and are treated effec- tively with local endoscopic or transanal excision. Larger tumors are associated with the development of metastasisCMDT22_Ch39_p1612-p1675.indd  1644 02/07/21 2:44 PMCANCER1645 CMDT 2022in  10%. Hence, a more extensive cancer resection operation is warranted in fit patients with rectal carcinoid tumors larger than 1–2 cm or with high-risk features (such as inva- sion of muscularis propria or evidence of nodal involve- ment), or both. »Clinical FindingsA.  Symptoms and SignsMos t lesions smaller than 1–2 cm are asymptomatic and difficult to detect by endoscopy or imaging studies. Small intestinal carcinoids may present with intermittent abdom- inal pain, bowel obstruction, bleeding, or bowel infarction. Appendiceal and rectal carcinoids usually are small and asymptomatic, but large lesions can cause bleeding, obstruction, or altered bowel habits. Carcinoid syndrome occurs in less than 10% of patients. More than 90% of patients with carcinoid syndrome have hepatic metastases, usually from carcinoids of small bowel origin. About 10% of patients with carcinoid syndrome have primary bron- chial or ovarian tumors without hepatic metastases. Carci- noid syndrome is caused by tumor secretion of hormonal mediators. The manifestations include facial flushing, edema of the head and neck (especially with bronchial carcinoid), abdominal cramps and diarrhea, broncho- spasm, cardiac lesions (pulmonary or tricuspid stenosis or regurgitation in 10–30%), and telangiectases.B.  Laboratory FindingsSerum  chromogranin A is elevated in the majority of NETs, although its sensitivity for small, localized carcinoid tumors is unknown. Serum chromogranin A is elevated in almost 90% of patients with advanced small bowel carcinoid. Urinary 5-hydroxyindoleacetic acid (5-HIAA) and platelet serotonin levels are also elevated in patients with metastatic carcinoid; however, these tests are less sensitive than serum chromogranin A. There is increased urinary 5-HIAA in carcinoid syndrome; symptomatic patients usually excrete more than 25 mg of 5-HIAA per day in the urine. Because certain foods and medications can interfere with 5-HIAA levels, these should be withheld for 48 hours prior to a 24-hour urine collection.C.  ImagingAbdo minal CT may demonstrate a mesenteric mass with tethering of the bowel, lymphadenopathy, and hepatic metastasis. Abdominal CT or enterography may reveal kinking of the bowel, but because the lesion is extralumi- nal, the diagnosis may be overlooked for several years. Gallium Ga-68 DOTATATE PET scan has replaced soma- tostatin receptor scintigraphy as the standard of care for staging; however, both may help identify disease that may benefit from treatment with somatostatin analogs or pep- tide receptor radionuclide therapy (PRRT). »Treatment & OutcomesSmall  intestinal carcinoids generally are indolent tumors with slow spread. Patients with disease confined to the small intestine should be treated with surgical excision.There is no proven role for adjuvant therapy after complete resection. Five-year survival rates for patients with stage I and II disease are 96% and 87%, respectively. In patients with resectable disease who have lymph node involvement (stage III), the 5-year survival rate is 74%; however, by 25 years, less than 25% remain disease free. Across stages, prognosis is strongly associated with histologic differentia- tion and grade. Patients with grade 1 disease may not require treatment for many years even with metastatic disease. However, patients with a grade 3 neuroendocrine tumor may have a clinical course more similar to a high- grade neuroendocrine carcinoma. In patients with advanced disease, therapy historically has been deferred until the patient is symptomatic. Con- ventional cytotoxic chemotherapy agents do not achieve significant responses in carcinoid tumors and have not been associated with improved outcomes. For patients who are symptomatic either from tumor bulk or carcinoid syn- drome, the cornerstone of therapy is typically a long-acting somatostatin analog, which inhibits hormone secretion from the carcinoid tumor. In 90% of patients, this results in dramatic relief of symptoms of carcinoid syndrome, includ- ing diarrhea or flushing, and may also control tumor growth for a median period of 1 year. Options at disease progression include octreotide dose escalation, or addition of everolimus, a mammalian target of rapamycin (mTOR) inhibitor. For patients with somatostatin receptor–positive disease based on imaging, another option after progression is treatment with PRRT. PRRT consists of a somatostatin analog conjugated to a radioactive isotope such as yttrium-90 or lutetium-177. Studies of anti-angiogenic kinase inhibitors have shown some benefit; currently, suni- tinib is approved in the United States for pancreatic neuro- endocrine tumors. In selected patients with hepatic-dominant disease, resection of hepatic metastases may provide dramatic improvement in carcinoid syndrome symptoms. Tumor debulking with liver-directed chemoembolization or radio- embolization may also provide symptomatic improvement in some of these patients. Patients with advanced, poorly differentiated intestinal NETs are treated in a similar fashion to those with small cell carcinomas. They have a poor prognosis.4.  Small Intestine SarcomaSarco mas constitute approximately 10% of small bowel neoplasms and are commonly found in the jejunum and ileum (and in a Meckel diverticulum, if present). Most arise from stromal tumors (GISTs) that stain positive for CD117; a minority arise from smooth muscle tumors (leiomyosar- comas) (see Gastrointestinal Mesenchymal Tumors above). Common symptoms of small intestine sarcoma include pain, weight loss, bleeding, and perforation. As the lesions tend to enlarge extraluminally, obstruction is rare. Kaposi sarcoma was at one time a common complica- tion in AIDS, but the incidence is declining with antiretro- viral therapy. It can also occur in the setting of immunosuppression after organ transplantation. It is caused by infection with human herpesvirus 8 (HHV8). Lesions may be present anywhere in the intestinal tract.CMDT22_Ch39_p1612-p1675.indd  1645 02/07/21 2:44 PMChAPTER 391646 CMDT 2022V isceral involvement usually is associated with cutaneous disease. Most lesions are clinically silent; however, large lesions may be symptomatic. Widespread involvement may be best treated by systemic chemotherapy using single- agent therapy or combinations of pegylated-doxorubicin, paclitaxel, vincristine, bleomycin, or etoposide. Surgery or radiation may be indicated for isolated high-risk lesions.Akce  M et al. Clinical outcomes of small bowel adenocarcinoma. Clin Colorectal Cancer. 2019;18:257. [PMID: 31606297] Bonds M et al. Neuroendocrine tumors of the pancreaticobiliary and gastrointestinal tracts. Surg Clin North Am. 2020;100:635. [PMID: 32402306] Lee MR et al. Incidence trends of gastroenteropancreatic neuro- endocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17:2212. [PMID: 30580091] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Small Bowel Adenocarcinoma. Ver- sion 2.2020. 2020 May 6. https://www.nccn.org/professionals/ physician_gls/pdf/small_bowel.pdf Scott AT et al. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14:471. [PMID: 30096273]COLOR ECTAL CANCERE S S E N T I A L S  O F  D I A G N O S I S »Personal or family history of adenomatous or ser- rated polyps or colorectal cancer are important risk factors. »Symptoms or signs depend on tumor location. »Proximal colon: fecal occult blood, anemia. »Distal colon: change in bowel habits, hematochezia. »Diagnosis established with colonoscopy. »General ConsiderationsColor ectal cancer is the second leading cause of death due to malignancy in the United States. Colorectal cancer will develop in approximately 4.2% of Americans and has a 5-year survival rate of 65%. In 2020, there were an estimated 147,950 new cases of colorectal cancer in the United States, with an estimated 53,200 deaths. Between 1996 and 2010, its mortality rate decreased by 46%. A 2015 National Health Interview Survey estimated that 62% of US adults have undergone recommended screening. On average, new cases have been falling 3.2% each year over the last 10 years. Colorectal cancers are almost all adenocarcinomas, which tend to form bulky exophytic masses or annular constricting lesions. The majority of colorectal cancers are thought to arise from malignant transformation of an adenomatous polyp (tubular, tubulovillous, or villous ade- noma) or serrated polyp (hyperplastic polyp, traditional serrated adenoma, or sessile serrated adenoma). Polyps that are “advanced” (ie, polyps at least 1 cm in size, adeno- mas with villous features or high-grade dysplasia, or ser- rated polyps with dysplasia) are associated with a greaterrisk of cancer. Approximately 85% of sporadic colorectal cancers arise from adenomatous polyps. They have loss of function of one or more tumor suppressor genes (eg, p53, APC, orDCC ) due to a combination of spontaneous muta- tion of one allele combined with chromosomal instability and aneuploidy (abnormal DNA content) that leads to dele- tion and loss of heterozygosity of the other allele (eg, 5q, 17q, or 18p deletion). Activation of oncogenes such as KRAS and BRAF is present in a subset of colorectal cancers with prog- nostic and therapeutic implications discussed further below. Approximately 10–20% of colorectal cancers arise from serrated polyps, most of which have hypermethylation of CpG-rich promoter regions that leads to inactivation of the DNA mismatch repair gene MLH1, resulting in MSI, and activation of mutations of the BRAF gene. Serrated colon cancers have distinct clinical and pathologic characteris- tics, including diploid DNA content, predominance in the proximal colon, poor differentiation, and more favorable prognosis. Up to 5% of colorectal cancers are caused by inherited germline mutations resulting in polyposis syndromes (eg, familial adenomatous polyposis) or hereditary nonpolypo- sis colorectal cancer (HNPCC or Lynch syndrome). These conditions are discussed further in Chapter 15. »Risk FactorsA n umber of factors increase the risk of developing colorec- tal cancer. Some of these factors include smoking, consump- tion of red and processed meats, alcohol intake, diabetes mellitus, physical inactivity, obesity, and history of inflam- matory bowel disease. Recognition of these factors has had an impact on screening strategies. However, 75% of all cases occur in people with no known predisposing factors.A.  AgeThe  incidence of colorectal cancer rises sharply after age 45 years, and 90% of cases occur in persons over the age of 50 years. The median age at diagnosis is 68 for men and 72 for women. Over the past two decades there has been a 20% decrease in incidence among adults over age 50 (likely due to colorectal cancer screening programs) but a 50% increase in incidence among adults under age 50 (espe- cially in the distal colon and rectum). The incidence of young adult–onset colorectal cancer is rising in all racial and ethnic groups but is highest in Blacks. In the United States, the colorectal cancer incidence rates in adults over age 50 is 40/100,000 and is 12.2/100,000 in adults younger than age 50. It is estimated that by 2030, 10% of colon cancer and 20% of rectal cancers will occur in patients under the age of 50. The reason for the increase in colorectal cancer incidence among adults under age 50 is uncertain.B.  Family History of NeoplasiaA family history of colorectal cancer is presen t in approxi- mately 20% of patients with colon cancer. Hereditary fac- tors are believed to contribute to 20–30% of colorectal cancers; however, the genes responsible for most of these cases have not yet been identified. Hereditary cancerCMDT22_Ch39_p1612-p1675.indd  1646 02/07/21 2:44 PMCANCER1647 CMDT 2022syndromes  (Lynch syndrome or polyposis syndromes) account for approximately 3–4% of colorectal cancers in patients 50 years or older but 10–15% of patients with young adult–onset colorectal cancer (see Chapter 15). Approximately 6% of the Ashkenazi Jewish population has a missense mutation in the APC gene (APC I1307K) that confers a modestly increased lifetime risk of developing colorectal cancer (odds ratio [OR] 1.4–1.9) that phenotypi- cally resembles sporadic colorectal cancer rather than familial adenomatous polyposis. Genetic screening is avail- able, and patients harboring the mutation merit more intensive colorectal screening. A family history of colorectal cancer or adenomatous polyps is one of the most important risk factors for colorec- tal cancer. The risk of colon cancer is proportionate to the number and age of affected first-degree family members with colon neoplasia. People with one first-degree family member with colorectal cancer have an increased risk approximately two times that of the general population; however, the risk is almost four times if the family member was younger than 45 years when the cancer was diagnosed. Patients with two first-degree relatives have a fourfold increased, or 25–30% lifetime, risk of developing colon can- cer. First-degree relatives of patients with adenomatous pol- yps also have a twofold increased risk for colorectal neoplasia, especially if they were younger than 60 years when the polyp was detected or if the polyp was 10 mm or larger.C.  Inflammatory Bowel DiseaseThe  risk of adenocarcinoma of the colon begins to rise 8 years after disease onset in patients with ulcerative colitis and Crohn colitis (see Chapter 15). For this reason, initia- tion of surveillance with colonoscopy is recommended at 8–10 years after onset of inflammatory bowel disease symptoms.D . Dietary and Lifestyle Factors and ChemopreventionIn  epidemiologic studies, diets rich in fats and red meat are associated with an increased risk of colorectal adenomas and cancer, whereas diets high in fruits, vegetables, and fiber are associated with a decreased risk. However, pro- spective studies have not shown a reduction in colon can- cer or recurrence of adenomatous polyps with diets that are low in fat; that are high in fiber, fruits or vegetables; or that include calcium, folate, beta-carotene, or vitamin A, C, D, or E supplements. Meta-analyses suggest that individuals with increased physical activity are up to 27% less likely to develop colon cancer. There also is a correlation between increasing body mass index and cancer risk, such that for each increase of 5 kg/m2in BMI, there is a 5% increased cancer risk. Patients with higher levels of pre- and post-diagnosis physical activ- ity experience reduced colorectal cancer–specific mortality and all-cause mortality. Maintaining a healthy body weight, a healthy diet, and a physically active lifestyle are recom- mended in colorectal cancer survivors. Low-dose aspirin has been associated with a reduced risk of colorectal adenomas and cancer in multiple studies.A 2016 USPSTF systematic review of controlled trials con- cluded that prolonged regular use of low-dose aspirin (81 mg/day) is associated with a 40% reduction in colorectal cancer incidence after 10 years and a 33% reduction in colorectal cancer mortality after 20 years. Because long- term aspirin use is associated with a low incidence of seri- ous complications (gastrointestinal hemorrhage, stroke), low-dose aspirin should not be routinely administered as a chemopreventive agent without other medical indications. Low-dose aspirin may also be considered in patients with a personal or family history of colorectal cancer or advanced adenomas; however, its administration does not obviate the need for colonoscopy screening and surveillance.E.  Other FactorsThe  overall incidence of colorectal cancer is similar in men and women; however, similar incidence rates are reached in women about 4–6 years later than in men. A higher proportion of cancers are located in the proximal colon in women (46%) than men (37%). The incidence and mortal- ity of colon adenocarcinoma is higher in Blacks and Native Americans than in Whites. It is unclear whether this is due to genetic or socioeconomic factors (eg, diet or reduced access to medical care). »Clinical FindingsA.  Symptoms and SignsAdenocar cinomas grow slowly and may be present for several years before symptoms appear. However, some asymptomatic tumors may be detected by the presence of fecal occult blood (see Screening for Colorectal Neo- plasms, below). Symptoms depend on the location of the carcinoma. Chronic blood loss from right-sided colonic cancers may cause iron deficiency anemia, manifested by fatigue and weakness. Obstruction, however, is uncommon because of the large diameter of the right colon and the liquid consistency of the fecal material. Lesions of the left colon often involve the bowel circumferentially. Because the left colon has a smaller diameter and the fecal matter is solid, obstructive symptoms may develop with colicky abdominal pain and a change in bowel habits. Constipation may alternate with periods of increased frequency and loose stools. The stool may be streaked with blood, though marked bleeding is unusual. With rectal cancers, patients note tenesmus, urgency, and recurrent hematochezia. Physical examination is usually normal except in advanced disease. The liver should be examined for hepatomegaly, suggesting metastatic spread. For cancers of the distal rec- tum, digital examination is necessary to determine whether there is extension into the anal sphincter or fixation, sug- gesting extension to the pelvic floor.B.  Laboratory FindingsA  CBC should be obtained to look for anemia. Elevated liver biochemical tests raise suspicion of metastatic disease. The serum carcinoembryonic antigen (CEA) should be measured in all patients with proven colorectal cancer but is not appropriate for screening. The CEA is not elevated inCMDT22_Ch39_p1612-p1675.indd  1647 02/07/21 2:44 PMChAPTER 391648 CMDT 2022man y patients with confirmed colorectal cancer; con- versely, the CEA may be elevated in active smokers and those with a variety of other nonmalignant conditions. A preoperative CEA level greater than 5 ng/mL is a poor prognostic indicator. After complete surgical resection, CEA levels should normalize; persistently elevated levels suggest the presence of persistent disease and warrant fur- ther evaluation. CEA is routinely monitored at the time of adjuvant therapy and during postoperative surveillance for patients who had elevated levels before resection.C.  ColonoscopyColo noscopy is the required diagnostic procedure in patients with a clinical history suggestive of colorectal cancer or in patients with an abnormality suspicious for cancer detected on radiographic imaging. Colonoscopy and upper endos- copy should be considered in all adults with new-onset iron deficiency anemia. Colonoscopy permits biopsy for patho- logic confirmation of malignancy.D . ImagingChes t, abdominal, and pelvic CT scans with contrast are required for preoperative staging. CT scans may demon- strate distant metastases but are less accurate in the determi- nation of the level of local tumor extension (T stage) or lymphatic spread (N stage). Intraoperative assessment of the liver by direct palpation and ultrasonography can be per- formed to detect hepatic metastases (M stage). For rectal cancers (generally defined as tumors arising 12 cm or less proximal to the anal verge), pelvic MRI or endorectal ultra- sonography is required to determine the depth of penetra- tion of the cancer through the rectal wall (T stage) and perirectal lymph nodes (N stage), informing decisions about preoperative (neoadjuvant) chemoradiotherapy and opera- tive management. PET is not routinely used for staging or surveillance in colorectal cancers. »StagingThe  TNM system is the commonly used classification to stage colorectal cancer. Staging is important not only because it correlates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. »Differential DiagnosisThe  nonspecific symptoms of colorectal cancer may be con- fused with those of irritable bowel syndrome, diverticular disease, ischemic colitis, inflammatory bowel disease, infec- tious colitis, and hemorrhoids. Neoplasm must be excluded in any patient over age 40 years who reports a change in bowel habits or hematochezia or who has an unexplained iron deficiency anemia or occult blood in stool samples. »TreatmentA.  Colon CancerSurgical resection  of the colonic tumor is the treatment of choice for almost all patients. It may be curative in patientswith stage I, II, and III disease and even some patients with metastatic (stage IV) disease. Multiple studies demonstrate that minimally invasive, laparoscopically assisted colec- tomy results in similar outcomes and rates of recurrence to open colectomy. Regional dissection of at least 12 lymph nodes should be performed to determine staging, which guides decisions about adjuvant therapy. Following com- plete endoscopic removal of an adenomatous polyp (polyp- ectomy) that is found on pathologic review to contain a focus of cancer (malignant polyp), observation is a reason- able alternative to further surgical resection in carefully selected patients with invasion into the submucosa (T1 disease). Pathology review of colorectal cancers should include testing for mismatch repair proteins for all patients. Tumors of patients with metastatic colorectal cancer should also be tested for extended RAS andBRAF mutations. Following surgical resection, chemotherapy has been demonstrated to improve overall and tumor-free survival in select patients with colon cancer depending on stage (Table 39–2). 1. Stage I— Because of the excellent 5-year survival rate (approximately 92%), no adjuvant therapy is recommended for stage I colon cancer. 2. Stage II node-negative disease— The 5-year survival rate is approximately 87% for stage IIA disease and 63% for stage IIB disease. A significant survival benefit from adju- vant chemotherapy has not been demonstrated in most randomized clinical trials for stage II colon cancer (see discussion for stage III disease). However, otherwise healthy patients with stage II disease who are at higher risk for recurrence (perforation; obstruction; close or indeter- minate margins; poorly differentiated histology; lymphatic, vascular, or perineural invasion; T4 tumors; or fewer than 12 lymph nodes sampled) may benefit from adjuvant che- motherapy. Patients whose tumors reveal MSI have a more favorable prognosis and do not benefit from 5-fluorouracil- based adjuvant therapy. 3. Stage III node-positive disease— With surgical resec- tion alone, the expected 5-year survival rate is 30–50%. Postoperative adjuvant chemotherapy significantly increases disease-free survival as well as overall survival by up to 30% and is recommended for all fit patients (Table 39–2). Multiple large, well-designed studies of adjuvant therapy for stage III colorectal cancer have reported a higher rate of disease-free survival at 5 years for patients treated for 6 months postoperatively with a combination of oxalipla- tin, 5-fluorouracil, and leucovorin (FOLFOX) (73.3%) than with 5-fluorouracil and leucovorin (FL) alone (67.4%). Similar benefit was reported for patients treated with oxali- platin and capecitabine (orally active fluoropyrimidine). A large international randomized controlled trial com- paring 3 months with 6 months of adjuvant therapy for colon cancer found that 3 months of adjuvant therapy resulted in equivalent disease-free survival for patients with earlier stage T1, T2, or T3, and N1 disease but not with more advanced T4 or N2 disease. For patients with high-risk disease (T4 or N2), 6 months of adjuvant che- motherapy are still recommended. The addition of aCMDT22_Ch39_p1612-p1675.indd  1648 02/07/21 2:44 PMCANCER1649 CMDT 2022biologic  agent (bevacizumab or cetuximab) to adjuvant chemotherapy does not improve outcomes. 4. Stage IV metastatic disease— Approximately 20% of patients have metastatic disease at the time of initial diag- nosis, and an additional 30% eventually develop metastasis. A subset of these patients has limited disease that is poten- tially curable with surgical resection. Surgery may also be warranted to provide palliation of tumor bleeding or obstruction. Resection of isolated liver metastases may result in long-term (over 5 years) survival in 35–55% of cases. For those with unresectable hepatic metastases, local ablative techniques (cryosurgery, radiofrequency or micro- wave coagulation, embolization, hepatic intra-arterial che- motherapy) or radiation may provide long-term tumor control. A subset of patients who have isolated pulmonary metastases may undergo resection or radiation with poten- tial cure. In the absence of other treatment, the median survival is less than 12 months; however, with current therapies, median survival approaches 30 months. Primary cancer location has been found to have a potential prog- nostic importance: median survival times are 33.3 months for patients with left-sided colon cancers compared to 19.4 months for those with right-sided cancers. The goals of therapy for patients with metastatic colorectal cancer are to slow tumor progression while maintaining a reasonable quality of life for as long as pos- sible. Currently, either FOLFOX (the addition of oxalipla- tin to 5-fluorouracil and folinic acid) or FOLFIRI (the addition of irinotecan to 5-fluorouracil and folinic acid) is the preferred first-line treatment regimen for fit patients. For convenience, oral capecitabine (instead of intravenous 5-fluorouracil and leucovorin) can be used in combination with oxaliplatin since it has similar efficacy to 5-fluorouracil; however, combination with irinotecan is not recommended due to increased toxicity (diarrhea). Addition of a biologic agent to combination chemotherapy improves response rates and overall survival and is recommended in the first line of treatment in suitable patients. Bevacizumab is a monoclonal antibody targeting VEGF. Combination of bevacizumab with FOLFOX or FOLFIRI prolongs mean survival by 2–5 months compared with either regimen alone. Cetuximab and panitumumab are monoclonal anti- bodies targeting EGFR. Activating K-ras gene mutations downstream of EGFR are present in approximately 35% of patients with metastatic colorectal cancer and are a bio- marker for nonresponse to cetuximab and panitumumab, for which reason the use of these agents is restricted to patients with tumors wild-type for K-ras. Mutations in N-ras and BRAF are also predictive of nonresponse to EGFR inhibition alone. In stage IV patients with K-ras wild-type cancers, the addition of panitumumab or cetux- imab to FOLFOX or FOLFIRI prolongs survival by approx- imately 4 months. When disease progresses despite treatment either with FOLFOX or with FOLFIRI (often in conjunction with bevacizumab or an EGFR-targeted antibody), therapy is switched to the alternate regimen. Although the ideal sequence of agents is not known, patients do benefit from exposure to all available therapies. Clinical trial participa- tion should be considered for eligible patients who areintolerant of or ineligible for standard therapies or in whom disease has progressed.B.  Rectal CancerThe  treatment approach to rectal cancer is guided by clinical staging as determined by colonoscopy and endorectal ultrasound or MRI with endorectal coil. In carefully selected patients with small (less than 4 cm), mobile, well-differentiated T1 rectal cancers that are less than 8 cm from the anal verge, transanal endoscopic or surgical excision may be considered. All other patients with rectal cancer require either a low anterior resection with a colorectal anastomosis or an abdominoperineal resection with a colostomy, depending on how far above the anal verge the cancer is located and the extent of local tumor spread. For invasive rectal carcinoma, preoperative (neoadju- vant) therapy with radiation or chemoradiation, with or without postoperative (adjuvant) therapy with chemother- apy or chemoradiation, is generally recommended in all node-positive tumors and in T3 and greater tumors due to increased risk of local recurrence. The choice and timing of radiation and chemotherapy depend on a host of factors. Neoadjuvant chemoradiation has become the preferred standard in many centers because chemotherapy is more tolerable prior to surgery, leads to improved local control, and may result in improved long-term survival. For patients with clinical node-positive disease, a bulky primary cancer (T4), or a low-lying cancer that will require a permanent colostomy, giving all chemotherapy in the neoadjuvant set- ting (total neoadjuvant therapy) is now an option in NCCN guidelines. After neoadjuvant therapy, the operative approach (low anterior resection versus abdominoperineal resection with colostomy) depends on how far above the anal verge the cancer is located, its size and depth of penetration, and the patient’s overall condition. Careful dissection of the entire mesorectum by either open or laparoscopic surgery reduces local recurrence to 5%. Although low anterior resections obviate a colostomy, they are associated with increased immediate postsurgical complications (eg, leak, dehis- cence, stricture) and long-term defecatory complaints (eg, increased stool frequency, and incontinence). With unre- sectable rectal cancer, the patient may be palliated with a diverting colostomy. »Follow-Up After SurgeryColorectal cancer p atients who have undergone resections for cure are monitored closely to look for evidence of symptomatic or asymptomatic tumor recurrence that may occasionally be amenable to curative resection. Patients should be evaluated every 3–6 months for 2 years and then every 6 months for a total of 5 years with history, physical examination, and laboratory surveillance, including serum CEA levels if baseline levels are elevated. The NCCN and ASCO guidelines recommend surveillance contrast CT scans of chest, abdomen, and pelvis up to every 6–12 months for up to 5 years post-resection in high-risk stage II and all stage III patients. Patients who had aCMDT22_Ch39_p1612-p1675.indd  1649 02/07/21 2:44 PMChAPTER 391650 CMDT 2022comple te preoperative colonoscopy should undergo another colonoscopy 1 year after surgical resection. Patients who did not undergo full colonoscopy preopera- tively also should undergo a full colonoscopy after comple- tion of all adjuvant therapy to exclude other synchronous colorectal neoplasms. If a colonoscopy does not detect new adenomatous polyps 1 year postoperatively, surveillance colonoscopy should be performed every 3–5 years thereaf- ter to look for metachronous polyps or cancer. New onset of symptoms or a rising CEA warrants investigation with chest, abdominal, and pelvic CT and colonoscopy to look for a new primary tumor or recurrence, or metachronous metastatic disease that may be amenable to curative or pal- liative therapy. The majority of colorectal cancer recur- rences occur within 3 years of the conclusion of treatment, and almost all (greater than 90%) occur within 5 years. »PrognosisThe  stage of disease at presentation remains the most important determinant of 5-year survival in colorectal cancer, which is estimated in older registries as: stage I, greater than 90%; stage II, 70–85%; stage III with fewer than 4 positive lymph nodes, 67%; stage III with more than 4 positive lymph nodes, 33%; and stage IV , 5–7%. Long- term registry follow-up data from the modern chemo- therapy era are not yet available. For each stage, rectal cancers have a worse prognosis. For those patients whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). »Screening for Colorectal NeoplasmsColorectal can cer is ideal for screening because it is a com- mon disease that is fatal in almost 50% of cases and yet is curable if detected at an earlier stage. Furthermore, most cases arise from benign adenomatous or serrated polyps that progress over many years to cancer, and removal of these polyps has been shown to prevent the majority of cancers. Colorectal cancer screening is endorsed by the USPSTF, the Agency for Health Care Policy and Research, the American Cancer Society, and every professional gas- troenterology and colorectal surgery society. Although there is continued debate about the optimal cost-effective means of providing population screening, there is now almost unanimous consent that screening of some kind should be offered to all adults ages 45–75 years. The 2018 American Cancer Society recommendations for screening and 2020 USPSTF draft recommendations for screening are listed in Table 39–6. Due to a rising incidence of colorectal cancer in adults younger than 50 years, the 2020 USPSTF and 2018 American Cancer Society guidelines both endorse consideration of screening in asymptomatic, average-risk adults beginning at age 45; however, the cost- effectiveness of this strategy is uncertain. It is important for primary care providers to understand the relative merits of various options and to discuss them with their patients. The potential for harm from screening must be weighed against the likelihood of benefit, especially in elderly patients with comorbid illnesses and shorter life expec- tancy. Although routine screening is not recommended inadults above age 75, it may be considered on a case-by-case basis in adults age 76 through 85 years who have excellent health and functional status. Patients with first-degree relatives with colorectal neo- plasms (cancer or adenomatous polyps) are at increased risk. Therefore, most guidelines recommend initiating screening at age 40–50 years (or 10 years younger than the familial diagnosis) in individuals with first-degree relatives with colorectal cancer or with advanced adenomas. Rec- ommendations for screening in families with inherited cancer syndromes or inflammatory bowel disease are pro- vided in Chapter 15. Screening tests may be classified into two broad catego- ries: stool-based tests and examinations that visualize the structure of the colon by direct endoscopic inspection or radiographic imaging.A.  Stool-Based Tests1.  Fecal occult blood test— Most colorectal cancers and some large adenomas result in increased chronic blood loss. A variety of tests for fecal occult blood are commer- cially available that have varying sensitivities and specifici- ties for colorectal neoplasia. These include guaiac-based fecal occult blood tests (gFOBT) (eg, Hemoccult I and II and Hemoccult SENSA) that detect the pseudoperoxidase activity of heme or hemoglobin and fecal immunochemical tests (FITs) that detect human globin. In clinical trials, FITsTable 39–6. Recommendations for colorectal cancer screening,1based on updated draft 2020 US Preventive Services Task Force and 2018 American Cancer Society recommendations.2Av erage-risk individuals ≥ 45 years old2 Annual fecal occult blood testing using higher sensitivity tests (Hemoccult SENSA) Annual fecal immunochemical test (FIT) Fecal DNA test (interval uncertain) Flexible sigmoidoscopy every 5 years Colonoscopy every 10 years CT colonography every 5 years Individuals wit a family istory of a first-degree member wit colorectal neoplasia3 Single first-degree relative wit colorectal cancer diagnosed at age 60 years or older: Begin screening at age 40. Screen- ing guidelines same as average-risk individual; however, preferred method is colonoscopy every 10 years. Single first-degree relative wit colorectal cancer or advanced adenoma diagnosed before age 60 years, or two first-degree relatives: Begin screening at age 40 or at age 10 years younger than age at diagnosis of the youngest affected relative, whichever is first in time. Recommended screening: colonoscopy every 5 years.1 For recommendations for families with inherited polyposis syn- dromes or hereditary nonpolyposis colon cancer, see Chapter 15.2 The American Cancer Society recommends screening of average- risk adults from age 45 to 75; the US Preventive Services Task Force recommends screening of all adults ages 50–75 (Grade A recom- mendation) and ages 45–59 (Grade B). Both recommend screen- ing in selected patients ages 76–85 based on life expectancy, patient preferences, overall health, and prior screening results.CMDT22_Ch39_p1612-p1675.indd  1650 02/07/21 2:44 PMCANCER1651 CMDT 2022have  proven superior to gFOBT in sensitivity for detection of colorectal cancer and advanced adenomas with similar specificity. Because FITs are not affected by diet or medica- tions and have superior accuracy, the USMSTF now rec- ommends their use instead of gFOBT. In 19 clinical studies, the pooled sensitivity and specificity of FIT for colorectal cancer in average-risk patients were 79% and 94%, respectively. FIT testing is the preferred option for population-based screening in various European and Australian programs. In the United States, it is offered as the preferred option by many health care plans. For health care systems in which screening colonoscopy is readily available, FIT is a suitable option for patients seeking a noninvasive screening test who are willing to undertake annual fecal testing. The opti- mal interval (yearly or every 2 years) and number of stool samples (one or two) required for optimal FIT testing is as yet undetermined, but currently annual testing is recom- mended. Patients with a positive FIT test must undergo further evaluation with colonoscopy. 2. Multitarget DNA assay— Stool DNA tests measure a variety of mutated genes and methylated gene markers from exfoliated tumor cells. A newer-generation assay (Cologuard) combines a fecal DNA panel with a FIT. In a prospective comparative trial conducted in persons at aver- age risk for colorectal cancer undergoing colonoscopy, the sensitivity for colorectal cancer for Cologuard was 92.3% vs 73.8% for FIT alone and the sensitivity for adenomas larger than 1 cm or serrated polyps for Cologuard was 42.4% vs 23.8% for FIT alone. A positive stool DNA test requires colonoscopy evaluation. Compared with FIT testing alone, FIT-fecal DNA testing has disadvantages including higher cost, lower specificity, lower cost-effectiveness, and cum- bersome requirements for stool collection and mailing.B.  Endoscopic Examinations of the Colon1.  Colonoscopy— Colonoscopy permits examination of the entire colon. In addition to detecting early cancers, colo- noscopy allows removal of adenomatous polyps by biopsy or polypectomy, which is believed to reduce the risk of subsequent cancer. Over the past decade, there has been a dramatic increase in screening colonoscopy, with over 60% of US adults screened in the past 10 years. In asymptomatic individuals between 50 and 75 years of age undergoing screening colonoscopy, the prevalence of advanced colonic neoplasia is 4–11% and of colon cancer is 0.1–1%. Although colonoscopy is believed to be the most sensi- tive test for detecting adenomas and cancer, it has several disadvantages. Adequate visualization of the entire colonic mucosa requires thorough bowel cleansing the evening and morning prior to the examination. To alleviate discomfort during the procedure, intravenous sedation is used for most patients, necessitating a companion to transport the patient home post-procedure. Serious complications occur uncommonly; they include perforation (0.1%), bleeding (0.25%), and death (2.9/100,000). The skill of the operator has a major impact upon the quality of the colonoscopy examination. In several studies, the rate of colorectal cancer within 3 years of a screeningcolonoscopy was 0.7–0.9%, ie, approximately 1 in 110 patients. Population-based case-control and cohort studies suggest that colonoscopy is associated with greater reduc- tion in colorectal cancer incidence and mortality in the distal colon (80%) than the proximal colon (40–60%). This may be attributable to incomplete examination of the proximal colon, and differences between the proximal and distal colon that include worse bowel preparation, subopti- mal colonoscopic technique, and a higher prevalence of serrated polyps and flat adenomas, which are more diffi- cult to identify than raised (sessile or pedunculated) polyps. To optimize diagnostic accuracy as well as patient safety and comfort, colonoscopy should be performed after optimal bowel preparation by a well-trained endoscopist who spends sufficient time (at least 7 minutes) carefully examining the colon (especially the proximal colon) while withdrawing the endoscope. 2. Flexible sigmoidoscopy— Use of a 60-cm flexible sig- moidoscope permits visualization of the rectosigmoid and descending colon. Adenomatous polyps are identi- fied in 10–20% and colorectal cancers in 1% of patients. The finding at sigmoidoscopy of an adenomatous polyp in the distal colon increases the likelihood at least twofold that an advanced neoplasm is present in the proximal colon. The chief disadvantage of screening with flexible sig- moidoscopy is that it requires some bowel cleansing, it may be associated with some discomfort (since intravenous sedation is not used), and it does not examine the proximal colon. The prevalence of proximal versus distal neoplasia is higher in persons older than age 65 years, in Blacks, and in women.C.  Radiographic and Other Imaging of the Colon1. CT colonograph y— CT colonography requires a similar bowel cleansing regimen as colonoscopy as well as insuffla- tion of air into the colon through a rectal tube, which may be associated with discomfort. Using current imaging soft- ware with multidetector helical scanners, the sensitivity is greater than 95% for the detection of cancer and greater than 84–92% for the detection of polyps 10 mm or larger. CT colonography is less sensitive than colonoscopy for the detection of polyps smaller than 1 cm, flat adenomas, and serrated polyps. The chief disadvantages of CT colonography are the need for a bowel preparation, limited availability in many health care systems, a possible increased risk of neoplasia due to radiation exposure, and the potential for finding incidental extracolonic findings that may lead to further evaluations. CT colonography is an excellent screening option in patients who do not wish to undergo or are unsuitable for colonoscopy and in patients in whom colo- noscopy could not be completed. 2. Capsule colonoscopy— Imaging of the colon can be accomplished by oral ingestion of a capsule that captures video images of the colon. Compared with colonoscopy, the colon capsule has reduced sensitivity for polyps greater than 6 mm (64% vs 84%) and for colorectal cancers (74% vs 100%). At present, it is approved by the FDA forCMDT22_Ch39_p1612-p1675.indd  1651 02/07/21 2:44 PMChAPTER 391652 CMDT 2022evaluation  in patients who are not suitable candidates for colonoscopy or in whom colonoscopy could not evaluate the proximal colon. In addition to its suboptimal sensitivity for neoplasia, the main disadvantages of capsule colonos- copy are its cost, need for extensive bowel preparation, lack of reimbursement by most insurance carriers, and small risk of small bowel obstruction. »When to Refer• Patients with symptoms (change in bowel habits, hema- tochezia), signs (mass on abdominal examination or digital rectal examination), or laboratory tests (iron deficiency anemia) suggestive of colorectal neoplasia should be referred for colonoscopy. •Patients with suspected colorectal cancer or adenoma- tous polyps of any size should be referred for colonoscopy. •Virtually all patients with proven colorectal cancer should be referred to a surgeon for resection. Patients with clinical stage T3 or node-positive rectal tumors (or both) also should be referred to medical and radiation oncologists preoperatively for neoadjuvant therapy. Patients with stage II, III, or IV colorectal tumors should be referred to a medical oncologist. »When to Admit• Patients with complications of colorectal cancer (obstruction, acute bleeding) requiring urgent evalua- tion and intervention. •Patients with advanced metastatic disease requiring palliative care.Biller LH et a l. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669. [PMID: 33591350] Ladabaum U et al. Strategies for colorectal cancer screening. Gastroenterology. 2020;158:418. [PMID: 31394083] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2021. 2021 Jan 21. https://www.nccn.org/professionals/physician_gls/ pdf/colon.pdf National Comprehensive Cancer Network. Clinical Practice Guide- lines in Oncology. Rectal Cancer. Version 1.2021. 2020 Dec 22. https://www.nccn.org/professionals/physician_gls/pdf/rectal. pdf National Institutes of Health. SEER Cancer Stat Facts: Colorectal Cancer, 2020. https://seer.cancer.gov/statfacts/html/colorect. html Petrelli F et al. Total neoadjuvant therapy in rectal cancer: a system- atic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271:440. [PMID: 31318794] Ran T et al. Cost-effectiveness of colorectal cancer screening strategies: a systematic review. Clin Gastroenterol Hepatol. 2019; 17:1969. [PMID: 30659991] Stoffel EM et al. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroen- terology. 2020;158:341. [PMID: 31394082] US Preventive Services Task Force. Colorectal Cancer: Screening 2021 May 18. https://www.uspreventiveservicestaskforce.org/ uspstf/recommendation/colorectal-cancer-screeningCARCINOMA OF THE ANUSThe an al canal is lined from its proximal to distal extent by columnar, transitional, and non-keratinized squamous epi- thelium, which merges at the anal verge with the keratin- ized perianal skin. Cancers arising from the mucosa of the anal canal are relatively rare, comprising only 1–2% of all cancers of the anus and large intestine. Squamous cancers make up the majority of anal cancers. Anal cancer is increased among people practicing receptive anal inter- course and those with a history of anorectal warts. In over 80% of cases, HPV may be detected, suggesting that this virus is a major causal factor. In a large controlled trial, HPV vaccination of healthy men (16 to 26 years old) who have sex with men decreased the incidence of anal intraepi- thelial neoplasia by 50%. Women with anal cancer are at increased risk for cervical cancer (which may be due to a field effect of oncogenic HPV infection) and require gyne- cologic screening and monitoring. Anal cancer is increased in HIV-infected individuals, possibly due to interaction with HPV . Nine-valent HPV (9vHPV) vaccine is recom- mended for boys and girls starting at age 11 or 12 and for individuals up to age 26 who have not been previously vac- cinated. Thereafter, shared clinical decision-making regard- ing HPV vaccination is recommended for some adults aged 27 through 45 years who are not adequately vaccinated. Bleeding, pain, and local mass are the most common symptoms. The lesion is often confused with hemorrhoids or other common anal disorders. These tumors tend to become annular, invade the sphincter, and spread upward via the lymphatics into the perirectal mesenteric lymphatic nodes. CT or MRI scans of the abdomen and pelvis are required to identify regional lymphadenopathy or meta- static disease at diagnosis. PET imaging may be used in conjunction. Treatment depends on the tumor location and histo- logic stage. Well-differentiated and small (less than 2 cm) superficial lesions of the perianal skin may be treated with wide local excision. Adenocarcinoma of the anal canal is treated in similar fashion to rectal cancer (see above), commonly by abdomi- noperineal resection with neoadjuvant chemoradiotherapy and adjuvant chemotherapy. The more common squa- mous cell cancer of the anal canal and large perianal tumors invading the sphincter or rectum are treated with combined-modality therapy that includes external radia- tion with simultaneous chemotherapy (5-fluorouracil plus mitomycin). Local control is achieved in approximately 80% of patients. Radical surgery (abdominoperineal resec- tion) is reserved for patients who fail chemotherapy and radiation therapy. Metastatic disease is generally treated with carboplatin and paclitaxel. The 5-year survival rate is 81% for localized tumors and approximately 30% for meta- static (stage IV) disease.Mahal  AR et al. An update to changing patterns of anal carci- noma in the United States. Am J Clin Oncol. 2020;42:887. [PMID: 31651454] National Cancer Institute. SEER Cancer Stat Facts: Anal Cancer, 2020. https://seer.cancer.gov/statfacts/html/anus.htmlCMDT22_Ch39_p1612-p1675.indd  1652 02/07/21 2:44 PMCANCER1653 CMDT 2022Na tional Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Anal Carcinoma. Version 2.2020. 2020 May 6. https://www.nccn.org/professionals/physician_ gls/pdf/anal.pdf Parwaiz I et al. A systematic review and meta-analysis of prog- nostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy. Clin Oncol (R Coll Radiol). 2019;31:e1. [PMID: 31301958]CA NCERS OF ThE GENITOURINARY TRACT George R. Schade, MD PROSTATE CANCERE S S E N T I A L S  O F  D I A G N O S I S »Prostatic induration on digital rectal examination (DRE) or elevation of PSA. »Most often asymptomatic. »Rarely: systemic symptoms (weight loss, bone pain). »General ConsiderationsProsta te cancer is the most common noncutaneous cancer and the second leading cause of cancer-related death in American men with an estimated 191,930 new prostate cancer diagnoses and 33,330 prostate cancer deaths in 2020. The clinical incidence, however, does not match the prevalence of the disease. Autopsy studies have demon- strated that more than 40% of men over age 50 years have prostate cancer, and its prevalence increases with age with 30% of men aged 60–69 years and 67% of men aged 80–89 years harboring the disease at autopsy. Most of these occult cancers are small indolent organ-confined cancers with few representing regional or metastatic disease. Although the global prevalence of prostatic cancer at autopsy is relatively consistent, the clinical incidence varies consider- ably (high in North America and European countries, inter- mediate in South America, and low in the Far East). A 50-year-old American man has a lifetime risk of 40% for latent cancer, a 16% risk for developing clinically apparent cancer, and a 2.9% risk of death due to prostatic cancer. Black race, family history of prostatic cancer, and history of high dietary fat intake are risk factors for prostate cancer. »Clinical FindingsA.  Symptoms and SignsPresen tly, most prostate cancers are asymptomatic and are diagnosed because of elevations in serum PSA. However, some men will be diagnosed based on discrete nodules or areas of induration within the prostate on a DRE. Obstruc- tive voiding symptoms are most often due to benign pros- tatic hyperplasia, which occurs in the same age group. Nevertheless, large or locally extensive prostatic cancers can cause obstructive voiding symptoms, including urinaryretention. Lymph node metastases can lead to lower extremity lymphedema. Because the axial skeleton is the most common site of metastases, patients may present with back pain, pathologic fractures, or rarely neurologic symp- toms from epidural metastases and cord compression.B.  Laboratory Findings1.  Serum tumor markers— PSA is a glycoprotein produced only by prostatic cells, either benign or malignant. The serum level is typically low and correlates with the total volume of prostate tissue and tends to increase with age. Measurement of serum PSA is useful in detecting and stag- ing prostate cancer, monitoring response to treatment, and identifying recurrence before it becomes clinically evident. As a screening test, PSA is elevated (greater than 4.0 ng/mL [4.0 mcg/L]) in 10–15% of men. Prostate cancer will be diagnosed in approximately 18–30% of men with PSA 4.1–10 ng/mL (4.1–10 mcg/L) and 50–70% of men with PSA greater than 10 ng/mL (10 mcg/L). However, no PSA threshold excludes the diagnosis of prostate cancer. In untreated patients with prostate cancer, the level of PSA correlates with the volume and stage of disease. Patients with PSA levels less than 10 ng/mL (10 mcg/L) usually have localized and therefore potentially curable cancers, while those with PSA levels in excess of 40 ng/mL (40 mcg/L) are more likely to have advanced disease (semi- nal vesicle invasion, lymph node involvement, or occult distant metastases). Approximately 98% of patients with metastatic prostate cancer will have an elevated PSA level. However, there are rare cancers that are localized despite substantial elevations in PSA. Therefore, initial treatment decisions cannot be made on the basis of PSA testing alone. A rising PSA after therapy is usually consistent with pro- gressive disease, either locally recurrent or metastatic. 2. Miscellaneous laboratory testing— Patients with uri- nary retention or with ureteral obstruction due to loco- regionally advanced prostate cancers may present with elevations in blood urea nitrogen or serum creatinine. Patients with bony metastases may have elevations in serum alkaline phosphatase or calcium. Laboratory and clinical evidence of disseminated intravascular coagulation can occur in patients with advanced prostate cancers. 3. Prostate biopsy— Transrectal ultrasound-guided biopsy is the standard method for detection of prostate cancer. The use of a spring-loaded, 18-gauge biopsy needle has allowed transrectal biopsy to be performed with minimal patient discomfort and morbidity. Local anesthesia is standard and increases the tolerability of the procedure. The specimen preserves glandular architecture and permits accurate grad- ing. Prostate biopsy specimens are taken from the apex, mid-portion, and base in men who have an abnormal DRE or an elevated serum PSA, or both. Extended-pattern biop- sies, including a total of at least 10 biopsies, are associated with improved cancer detection and risk stratification of patients with newly diagnosed disease. In addition, suspi- cious hypoechoic prostatic lesions seen on transrectal ultra- sound may be targeted for biopsy. Patients with abnormalities of the seminal vesicles can have these struc- tures specifically biopsied to identify local tumor invasion.CMDT22_Ch39_p1612-p1675.indd  1653 02/07/21 2:44 PMChAPTER 391654 CMDT 2022C.  ImagingU se of imaging for staging should be tailored to the likeli- hood of advanced disease in newly diagnosed cases. CTof the abdomen and pelvis and radionuclide (99-techne- tium) bone scans are generally the first-line staging studies performed, when indicated, to assess for nodal and bony metastases, respectively. MRI allows for evaluation of the prostate as well as regional lymph nodes. The positive predictive value for detec- tion of both capsular penetration and seminal vesicle invasion is similar for transrectal ultrasound and MRI, although newer multi-parametric MRI techniques may better stage patients considering treatment or, alternatively, active surveillance. Additionally, there is a growing role for multi-parametric MRI in prostate cancer diagnosis, particularly among men with previous negative prostate biopsies, to evaluate for suspi- cious prostatic lesions. Such lesions may then be sampled via MRI-guided needle biopsy or via MR Fusion (in which pros- tate MRI images are fused in real-time with images from an ultrasound-guided needle biopsy). Such an approach may improve not only overall cancer detection but discovery of clinically relevant disease, and its use in routine clinical prac- tice has increased and continues to evolve. Conventional radionuclide (99-technetium) bone scans are superior to conventional plain skeletal radio- graphs in detecting bony metastases. Prostate cancer bony metastases tend to be multiple and most commonly occur in the axial skeleton. Men with more advanced local lesions, symptoms of metastases (eg, bone pain), high- grade disease, or elevations in PSA greater than 20 ng/mL (20 mcg/L) should undergo radionuclide bone scan. PET (eg,18F-sodium fluoride [18F-NaF] PET ) and18F-NaF PET/CT hybrid imaging are more sensitive than con- ventional bone scans. However, a high frequency of abnormal scans with18F-NaF PET/CT resulting from degenerative joint disease has limited their usefulness. Fluciclovine (Axumin) PET imaging has been approved for suspected cancer recurrence based on elevated PSA after prior treatment. PSMA (prostate-specific membrane antigen) PET, using small-molecule radiotracers target- ing PSMA (eg,18F-DCFBC [N-[N-[(S)-1,3-dicarboxypro- pyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine]) has shown significant promise as a next-generation imaging method and may replace traditional imaging modalities in the future. Despite application of modern, sophisticated tech- niques, understaging of prostate cancer occurs in at least 20% of patients.D . Genetic TestingThe role of gene tics in prostate cancer diagnosis and man- agement is evolving. A family history of prostate cancer increases the risk of prostate cancer. Additionally, prostate cancer has been associated with several hereditary cancer syndromes (eg, Lynch syndrome, hereditary breast and ovarian cancer syndrome, etc.) with approximately 11% of prostate cancer patients with at least one additional primary cancer carrying germline mutations. Consequently, some patients with prostate cancer and their families may haveelevated risk for other cancers. Further, data suggest that some germline mutations, such as BRCA1/2 , are associated with lower PSA at diagnosis and increased risk of progres- sion and death; approximately 12% of patients with metastatic prostate cancer have germline mutations in homologous DNA repair genes. Finally, germline mutations in DNA repair genes can have implications for treatment and, as a result, play a role in personalized treatment. Patients with prostate cancer should have a thorough review of their family history and those with a concerning family history should be referred for genetic counselling and possible testing. Additionally, patients with high-risk disease or metastatic disease should undergo genetic evalu- ation as well. »Screening for Prostate CancerThe  impact of prostate cancer screening on mortality remains controversial. The screening tests currently avail- able include DRE, PSA testing, and transrectal ultrasound. Prostate cancer detection rates using DRE alone vary from 1.5% to 7%, but unfortunately, most of these cancers are advanced (stage T3 or greater). Transrectal ultrasound should not be used as a first-line screening tool due to its expense, low specificity, and minimal improvement in detec- tion rate versus the combined use of DRE and PSA testing. PSA testing increases the detection rate of prostate can- cers compared with DRE. Approximately 2–2.5% of men older than 50 years of age will be found to have prostate cancer using PSA testing compared with a rate of approxi- mately 1.5% using DRE alone. The sensitivity, specificity, and positive predictive value of PSA and DRE are listed in Table 39–7. PSA-detected cancers are more likely to be localized compared with those detected by DRE alone. The Prostate Cancer Prevention Trial provided data demon- strating a significant risk of prostate cancer even in men with PSA less than 4.0 ng/mL (4.0 mcg/L) (Table 39–8) and a web-based calculator has been developed to estimate the risk of harboring both prostate cancer and high-grade cancer (http://riskcalc.org/PBCG). Table 39–7. Screening for prostatic cancer: test performance.T est Sensitivity SpecificityPositive Pre- dictive Value Abnormal PSA (> 4 ng/mL [mcg/L])0.67 0.97 0.43 Abnormal DRE 0.50 0.94 0.24 Abnormal PSA or DRE0.84 0.92 0.28 Abnormal PSA and DRE0.34 0.995 0.49 DRE, digital rectal examination; PSA, prostate-specific antigen. Modified, with permission, from Kramer BS et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914. Copyright © 1993 American College of Physicians. All rights reserved.CMDT22_Ch39_p1612-p1675.indd  1654 02/07/21 2:44 PMCANCER1655 CMDT 2022T o improve the performance of PSA as a screening test, several investigators have developed alternative methods for its use. These include establishment of age- and race- specific reference ranges, measurement of free serum and protein-bound levels of PSA ( percent free PSA ), and cal- culation of changes in PSA over time ( PSA velocity ). Gen- erally, men with PSA free fractions exceeding 25% are unlikely to have prostate cancer, whereas those with free fractions less than 10% have an approximately 50% chance of having prostate cancer. Newer tests, including the Pros- tate Health Index (PHI) and 4kscore (https://4kscore.com), may better identify not only men at greater risk for prostate cancer but those with more aggressive disease. The frequency of PSA testing also remains a matter of debate. The traditional yearly screening approach may not be the most efficient; rather, earlier PSA testing at younger age may allow less frequent testing later as well as provide information regarding PSA velocity. Men with PSA above the age-based median when tested between 40 and 60 years are at significantly increased risk for subsequent cancer detection over 25 years. Men aged 40–50 with PSA below 0.6 ng/mL (0.6 mcg/L) and aged 50–60 with PSA below 0.71 ng/mL (0.71 mcg/L) may require less frequent PSA tests. In addition, men with PSA velocity greater than 0.35 ng/mL (0.35 mcg/L) per year measured 10–15 years before diagnosis had significantly worse cancer-specific survival compared with those with lower PSA velocity. The NCCN guidelines (https://www.nccn.org/professionals/physician_ gls/f_guidelines.asp) for prostate cancer early detection incorporate many of these factors. The European Associa- tion of Urology (EAU) recommends offering PSA screening to men beginning at age 40–50 years, dependent on risk factors, and subsequently initiating a risk-adapted strategy. Two large, randomized trials have evaluated the benefit of PSA screening for early detection of prostate cancer. In the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, no mortality benefit was observed after combined screening with PSA testing and DRE dur- ing 15-year follow-up. Although screening resulted in a 12% increase in prostate cancer detection, the cancer-specific mortality rate was similar in the screening and controlarms (2.55 and 2.44 deaths per 10,000 person-years, respectively). However, an estimated 86% of control patients received at least one screening PSA test and 46% of control patients received yearly PSA screening during the trial. Conversely, the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial demonstrated a significant 20% reduction in prostate cancer mortality with an absolute reduction of 1.75 deaths per 1000 men screened at 16 years. The number of men needed to be invited for screening to prevent one prostate cancer death was 570 at 16 years compared with 742 at 13 years, while the number of prostate cancers needing to be diagnosed to prevent one prostate cancer death was reduced from 26 to 18, underscoring the importance of adequate long-term follow-up for prostate cancer. In 2018, the USPSTF issued a revised (Grade C) recom- mendation for men aged 55 to 69 years that the decision to undergo periodic PSA–based screening should be an indi- vidual one. Before deciding about screening, men should discuss its potential benefits and harms with their clinician, incorporating their own values and preferences in the deci- sion. The revised recommendation acknowledges that, while screening offers some men a small potential benefit of reducing the chance of dying from prostate cancer, many other men will experience potential harms from screening. These include false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether screening is appropriate in individual cases, the individual patient’s family history, race/ethnicity, comorbid medical conditions, values about the benefits and harms of screening and treatment-specific outcomes, and other health needs should be considered. Clinicians should not screen men who do not express a preference for screening. For men age 70 years and older, the USPSTF recommends against PSA-based screening (Grade D recommendation). »StagingThe  majority of prostate cancers are adenocarcinomas. Most arise in the peripheral zone of the prostate, though a small percentage arise in the central (5–10%) and transi- tion zones (20%) of the gland. Pathologists utilize the Gleason grading system whereby a “primary” grade is applied to the architectural pattern of malignant glands occupying the largest area of the specimen and a “second- ary” grade is assigned to the next largest area of cancer. Grading is based on architectural rather than histologic criteria, and five “grades” are possible. Adding the score of the primary and secondary grades gives a Gleason score from 2 to 10. Gleason score correlates with tumor volume, pathologic stage, and prognosis. A simplified five-grade group system has been introduced by the International Society of Urological Pathologists. »TreatmentA.  General MeasuresThe  optimal management of localized prostate cancer remains controversial owing to the plethora of treatmentTable 39–8. Risk of prostate cancer in men with PSA ≤ 4.0 ng/mL (or mcg/L).PSA  Level (ng/mL [or mcg/L])Percentage wit Prostate CancerPercentage wit hig-Grade1 Prostate Cancer ≤ 0.5 6.6 12.5 0.6–1.0 10.1 10.0 1.1–2.0 17.0 11.8 2.1–3.0 23.9 19.1 3.1–4.0 26.9 25.01 High-grade cancer was defined as Gleason score ≥ 7. Data from Thompson IM et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med. 2004;350:2239.CMDT22_Ch39_p1612-p1675.indd  1655 02/07/21 2:44 PMChAPTER 391656 CMDT 2022optio ns, side effects of the various options, and indolent nature of many prostate cancers. These factors have contrib- uted to uncertainty regarding a definitive survival benefit of treating localized prostate cancer. To help guide treatment decision making, patients are risk stratified according to their PSA level at diagnosis, DRE, and prostate cancer grade (Gleason score). Additionally, patients should have an assessment of life expectancy prior to treatment decision- making since all patients with low-risk disease and many with intermediate-risk disease with less than 10-year life expectancy will not benefit from treatment.B.  Active SurveillanceThe g oal of active surveillance is to avoid treatment in men who may never require it while recognizing and definitively treating men harboring higher-risk disease in order to bal- ance cancer risk with the morbidity of treatment. Treatment decisions are made based on stage, PSA, and cancer grade (Gleason score) as well as the age and health of the patient. Active surveillance alone may be effective management for appropriately selected patients, typically those with low PSA, small volume, well-differentiated cancers, and life expectancy less than 10–15 years. For such patients, active surveillance involves serial PSA levels, DREs, and periodic prostate biopsies to reassess grade and extent of cancer. Endpoints for intervention in patients on active surveil- lance, particularly PSA changes, have not been clearly defined and surveillance regimens remain an active area of research. Nonetheless, they are increasingly accepted by patients and clinicians with contemporary series demon- strating freedom from definitive treatment in greater than half of patients at 5 years, and risk of developing metastases and suffering cancer-specific death in less than 3% and 2%, respectively, at 10 years. Active surveillance, which is distin- guished from mere observation (watchful waiting), is fea- tured prominently in the NCCN and EAU guidelines and is the preferred management in most men with very low risk prostate cancer. This approach is increasingly accepted and incorporated in routine clinical practice.C.  Radical ProstatectomyDuring  radical prostatectomy, the seminal vesicles, prostate, and ampullae of the vas deferens are removed. Refinements in technique have allowed preservation of urinary conti- nence in most patients and erectile function in selected patients. Radical prostatectomy can be performed via open retropubic, transperineal, or laparoscopic (with or without robotic assistance) surgery. Local recurrence is uncommon after radical prostatectomy and related to pathologic stage. Organ-confined cancers rarely recur; however, cancers with adverse pathologic features (capsular penetration, seminal vesicle invasion) are associated with higher local (10–25%) and distant (20–50%) relapse rates. Ideal candidates for radical prostatectomy include healthy patients with stages T1 and T2 prostate cancers. Patients with advanced local tumors (T4) or lymph node metastases are rarely candidates for prostatectomy alone, although surgery is sometimes used in combination with hormonal therapy and postoperative radiation therapy for select high-risk patients.D. Radiation TherapyRadiatio n can be delivered by a variety of techniques to the prostate and, when clinically indicated, to the pelvic lymph nodes. Conformal techniques, including three-dimensional conformal radiation, intensity modulated radiotherapy, and image-guided radiotherapy, have become the standard of care for external photon-based radiotherapy, while proton beam therapy has gained acceptance as an alternative exter- nal beam therapy that theoretically may reduce toxicities. Additionally, hypofractionated and ultra-hypofractionated (ie, stereotactic radiotherapy) regimens have shown prom- ising short- and intermediate-term outcomes vs conven- tionally dosed regimens. Brachytherapy—the implantation of permanent or temporary radioactive sources (palladium, iodine, or iridium) into the prostate—can be used as mono- therapy in those with low-grade or low-volume malignan- cies or combined with external beam radiation in patients with higher-grade or higher-volume disease. The PSA may rise after brachytherapy because of prostate inflammation and necrosis. This transient elevation (PSA bounce) should not be mistaken for recurrence and may occur up to 20 months after treatment. Patients with intermediate- and high-risk disease benefit from concomitant androgen deprivation therapy. As with surgery, the likelihood of local failure fol- lowing radiation correlates with technique and cancer char- acteristics. The likelihood of a positive prostate biopsy more than 18 months after radiation varies between 20% and 60%. Patients with local recurrence are at an increased risk of cancer progression and cancer death compared with those who have negative biopsies. Survival of patients with localized cancers (T1, T2, and selected T3) approaches 65% at 10 years. Ambiguous target definitions, inadequate radia- tion doses, and understaging of the cancer may be respon- sible for the failure noted in some series.E.  Focal TherapyT o reduce the morbidity of localized prostate cancer treat- ment, there has been a growing interest in focal therapy. Focal therapy delivers energy to the prostate, destroying the tumor(s) and a margin of normal prostate tissue while avoiding collateral damage to the neurovascular bundles, external urinary sphincter, bladder, and rectum. To date, several energy sources (cryotherapy, high intensity focused ultrasound, lasers, etc) have been evaluated and several others are under development. The multifocal nature and the difficulty of localizing the prostate cancer with contem- porary imaging techniques combined with the prolonged disease course, lack of clearly defined endpoints, and ran- domized prospective data have limited the widespread adoption of focal therapies as well as a clear understanding of which are the ideal candidates.F . Localized DiseaseAlthough  selected patients may be candidates for active surveillance based on age or health and evidence of small- volume or well-differentiated cancers, most men with an anticipated life expectancy of longer than 10 years should be considered for treatment. Newly introduced genomic tests may provide important information to help guideCMDT22_Ch39_p1612-p1675.indd  1656 02/07/21 2:44 PMCANCER1657 CMDT 2022tr eatment decisions. Both radiation therapy and radical pros- tatectomy result in acceptable levels of local control. A large, prospective, randomized trial compared watchful waiting with radical prostatectomy in 695 men with clinically local- ized and well-differentiated to moderately differentiated cancers. Radical prostatectomy significantly reduced disease- specific mortality, overall mortality, and risks of metastasis and local progression. The relative reduction in the risk of death at 23 years was 0.56 in the prostatectomy group, with the number needed to treat to avert one death (NNT) = 8 patients; the benefit was largest in men younger than age 65 years (relative risk [RR] = 0.45) and with intermediate- risk prostate cancer (RR = 0.38). Surgery also reduced the risk of metastases in older men (RR = 0.68).G.  Locally and Regionally Advanced DiseasePa tients with advanced pathologic stage or positive surgical margins are at an increased risk for local and distant tumor relapse. Due to these risks, such patients have been consid- ered for adjuvant therapy (radiation for positive margins and seminal vesicle invasion or androgen deprivation and/ or radiation for lymph node metastases). Two randomized clinical trials (EORTC 22911 and SWOG 8794) demon- strated improved progression-free and metastasis-free sur- vival with early radiotherapy in these men, and subsequent analysis of SWOG 8794 showed improved overall survival in men receiving adjuvant radiation therapy. However, the publication of two trials comparing adjuvant radiotherapy with early-salvage therapy using contemporary radiother- apy techniques (GETUG-AFU17 and RAVES) demon- strated no difference in 5-year biochemical progression-free survival casting doubt on the benefit of adjuvant radio- therapy in the contemporary era.H.  Metastatic DiseaseSince death due to prosta te carcinoma is almost invariably the result of failure to control metastatic disease, research has emphasized efforts to improve control of distant dis- ease. Most prostate carcinomas are hormone dependent and approximately 70–80% of men with metastatic prostate carcinoma will respond to various forms of androgen deprivation. Androgen deprivation therapy may be effec- tive at several levels along the pituitary–gonadal axis using a variety of methods or agents (Table 39–9). Use of lutein- izing hormone-releasing hormone (LHRH) agonists (leup- rolide, goserelin) achieves medical castration without orchiectomy and is the most common method of reducing testosterone levels. A single LHRH antagonist (degarelix) is FDA approved and has no short-term testosterone “flare” associated with LHRH agonists. Because of its rapid onset of action, ketoconazole should be considered in patients with advanced prostate cancer who present with spinal cord compression, bilateral ureteral obstruction, or dis- seminated intravascular coagulation. Although testoster- one is the major circulating androgen, the adrenal gland secretes the androgens dehydroepiandrosterone, dehy- droepiandrosterone sulfate, and androstenedione. This led to the development of abiraterone acetate (an inhibi- tor of CYP17, a key enzyme in androgen synthesis) to block both testicular and adrenal androgens. Nonsteroidalantiandrogen agents act by competitively binding the receptor for dihydrotestosterone, the intracellular andro- gen responsible for prostate cell growth and development. In addition to immediate side effects of androgen depriva- tion (sexual dysfunction and hot flashes), the chronic sup- pression of testosterone leads to osteoporosis and risk of fractures, cardiovascular disease and diabetes mellitus, and decreased muscle and increased fat. Bisphosphonates can prevent osteoporosis associated with androgen depriva- tion, decrease bone pain from metastases, and reduce skeletal-related events. Denosumab , a RANK ligand inhib- itor, is approved for the prevention of skeletal-related events in patients with bone metastases from prostate cancer and also appears to delay the development of these metastases in patients with castration-resistant prostate cancer. In addition, enzalutamide definitively improves metastasis-free survival in men with nonmetastatic castrate- resistant prostate cancer and rapidly rising PSAs. The management of advanced prostate cancer is rapidly evolving. Contemporary management consists of initiating androgen deprivation therapy with orchiectomy, LHRH agonist, or LHRH antagonist. A meta-analysis compared using an LHRH agonist or orchiectomy alone with an LHRH agonist or orchiectomy plus an antiandrogen agent; results showed little benefit of combination therapy. However, patients at risk for disease-related symptoms (bone pain, obstructive voiding symptoms) should receive concurrent antiandrogens due to the initial elevation of serum testoster- one that accompanies LHRH agonists. For patients with elevated PSAs only (indicating recurrent, but nonmetastatic, cancer), nonsteroidal antiandrogen agents may be useful. Further androgen manipulations, initiation of cytotoxic chemotherapy, and local therapy (eg, radiation) is defined by the cancer’s androgen sensitivity status. For patients with hormone-sensitive metastatic prostate cancer, the addition of systemic cytotoxic chemotherapy with docetaxol to androgen deprivation therapy results in improved survival compared to androgen deprivation therapy alone. Similarly, the addition, of abiraterone acetate plus prednisone to androgen deprivation therapy, results in superior survival compared to androgen deprivation therapy alone. Patients with castrate-resistant disease or prostate can- cer that demonstrates rising PSA or progression of disease despite castrate levels of serum testosterone (less than 50 ng/dL) should continue their LHRH agonist/antagonist regimen. Additional treatment options are stratified based on the presence of metastatic disease. Patients with non- metastatic castrate-resistant disease and long PSA doubling time (longer than10 months) can simply be observed due to their relatively indolent disease. Conversely, nonmeta- static castrate-resistant patients with short doubling times (10 months or less) have demonstrated improved metastasis- free survival with the addition of the potent nonsteroidal androgen receptor antagonists enzalutamide ,apalu- tamide , and darolutamide to androgen deprivation therapy. For patients with metastatic castrate-resistant prostate cancer, docetaxol was the first cytotoxic chemo- therapy agent to improve survival. Enzalutamide and abiraterone improve overall survival in men with meta- static castrate prostate cancer in both the docetaxol naïve and non-naïve setting. Cabazitaxel is a second-line taxaneCMDT22_Ch39_p1612-p1675.indd  1657 02/07/21 2:44 PMChAPTER 391658 CMDT 2022chemothera py that improves overall survival in men who have received docetaxel. Sipuleucel-T, an autologous cel- lular immunotherapy, is FDA approved in asymptomatic or minimally symptomatic men with metastatic castration- resistant prostate cancer. Radium-223 dichloride is approved for the treatment of men with castration-resistant, symptomatic bone metastases, with significant improve- ments in both overall survival and time to skeletal-related events (eg, fractures and spinal cord compression). Finally, patients who have undergone a genetics evaluation and are found to have specific germline or somatic mutations may benefit from personalized treatment strategies. »PrognosisTh e likelihood of success of active surveillance or treatment can be predicted using risk assessment tools that usuallyTable 39–9. Androgen deprivation for prostatic cancer.Lev el Agent Dose Sequelae Pituitary, hypothalamus Diethylstilbestrol 1–3 mg orally daily Gynecomastia, hot flushes, thromboembolic disease, erectile dysfunction LhRh agonists Leuprolide Goserelin Triptorelin HistrelinDaily subcutaneous injection Monthly to quarterly depot injection Monthly depot injection Annual subcutaneous implantErectile dysfunction, hot flushes, gynecomastia, rarely anemia LhRh antagonist Degarelix 240 mg subcutaneously initial dose, then 80 mg subcutaneously monthlyHot flushes, weight gain, erectile dysfunction, increased liver tests Adrenal Ketoconazole 400 mg three times orally daily Adrenal insufficiency, nausea, rash, ataxia Aminoglutethimide 250 mg four times orally daily Adrenal insufficiency, nausea, rash, ataxia Corticosteroid Prednisone 20–40 mg orally daily Gastrointestinal bleeding, fluid retention CYP17a1 inibitor Abiraterone 1000 mg orally daily (with predni- sone 5 mg orally twice daily)Weight gain, fluid retention, hypokalemia, hypertension Testis Orchiectomy  Gynecomastia, hot flushes, erectile dysfunction Prostate cell Antiandrogens Flutamide 250 mg three times orally daily No erectile dysfunction when used alone; nausea, diarrhea Bicalutamide 50 mg orally daily Liver, cardiac, and pulmonary toxicity Enzalutamide 160 mg orally daily Seizures, dizziness, asthenia Apalutamide 240 mg orally daily Fatigue, leukopenia, hyperlipidemia, hyperglycemia, hyperkalemia, seizures (rare) Doralutamide 600 mg orally twice daily Fatigue, extremity pain, rash Cytotoxic cemotera- peutic agentsBone marrow, skin, pulmonary, cardiac, gastrointestinal, hepatic toxicities possible Docetaxel 75 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) Cabazitaxel 20 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) LHRH, luteinizing hormone-releasing hormone.co mbine stage, grade, PSA level, and number and extent of positive prostate biopsies. Several web-based tools are avail- able (eg, https://www.mskcc.org/nomograms/prostate). Widely used nomograms include the Kattan nomogram and theCAPRA nomogram. CAPRA uses serum PSA, Gleason score, clinical stage, percent positive biopsies, and patient age in a point system to risk stratify and predict the likelihood of PSA recurrence 3 and 5 years after radical prostatectomy (Tables 39–10 and 39–11) as well as metastasis and prostate cancer-specific and overall survival. The CAPRA nomogram has been validated on large multicenter and international radical prostatectomy and radiation-treated cohorts. The patterns of prostate cancer progression have been well defined. Small and well-differentiated cancers (Gleason grade 3) are usually confined within the prostate, whereas large-volume (greater than 4 mL) or poorly differentiatedCMDT22_Ch39_p1612-p1675.indd  1658 02/07/21 2:44 PMCANCER1659 CMDT 2022T able 39–11. CAPRA: Probability of freedom from PSA recurrence after radical prostatectomy by CAPRA point total.CA PRA Score3-Year Recurrence-Free Survival (%) (95% CI)5-Year Recurrence-Free Survival (%) (95% CI) 0–1 91 (85–95) 85 (73–92) 2 89 (83–94) 81 (69–89) 3 81 (73–87) 66 (54–76) 4 81 (69–89) 59 (40–74) 5 69 (51–82) 60 (37–77) 6 54 (27–75) 34 (12–57) 7+ 24 (9–43) 8 (0–28) PSA, prostate-specific antigen. Source: https://urology.ucsf.edu/research/cancer/prostate-cancer- risk-assessment-and-the-ucsf-capra-score.Table 39–10. The UCSF Cancer of the Prostate Risk Assessment (CAPRA).V ariable Level Points PSA (ng/mL [or mcg/L]) at diagnosis 0–6 0 6.1–10 1 10.1–20 2 20.1–30 3 > 30 4 Gleason grade, primary/secondary 1–3/1–3 0 1–3/4–5 1 4–5/1–5 3 T stage T1 or T2 0 T3a 1 % positive biopsies (biopsy cores posi- tive divided by the number of biop- sies obtained)< 34% 0 ≥ 34% 1 Age < 50 years 0 ≥ 50 years 1 Source: https://urology.ucsf.edu/research/cancer/prostate- cancer-risk-assessment-and-the-ucsf-capra-score.(G leason grades 4 and 5) cancers are more often locally exten- sive or metastatic to regional lymph nodes or bone. Penetra- tion of the prostate capsule by cancer is common and occurs along perineural spaces. Seminal vesicle invasion is associ- ated with a high likelihood of regional or distant disease and disease recurrence. The most common sites of lymph node metastases are the obturator and internal iliac lymph node chains and of distant metastases, the axial skeleton.»When to Refer• Refer all patients to a urologist for management of localized disease or for active surveillance. •For metastatic disease, medical oncology should be consulted for consideration of systemic treatments. •Active surveillance may be appropriate in selected patients with very low-volume, low-grade prostate cancer. •Localized disease may be managed by active surveil- lance, surgery, or radiation therapy. •Locally extensive, regionally advanced, and metastatic disease often require multimodal treatment strategies.Bill-Ax elson A et al. Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up. N Engl J Med. 2018;379: 2319. [PMID: 30575473] Gourd E. New advances in prostate cancer screening and moni- toring. Lancet Oncol. 2020;21:887. [PMID: 32534632] Hoffman KE et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323:149. [PMID: 31935027] Hugosson J et al; ERSPC investigators. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2019;76:43. [PMID: 30824296] Hussain M et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018; 378:2465. [PMID: 29949494] Kneebone A et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ ANZUP RAVES): a randomised, controlled, phase 3, non- inferiority trial. Lancet Oncol. 2020;21:1331. [PMID: 33002437] Parker CC et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a ran- domised controlled phase 3 trial. Lancet. 2018;392:2353. [PMID: 30355464] Sargos P et al. Adjuvant radiotherapy versus early salvage radio- therapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341. [PMID: 33002438] Shoag JE et al. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465. [PMID: 32558473]BL ADDER CANCERE S S E N T I A L S  O F  D I A G N O S I S »Gross or microscopic hematuria. »Irritative voiding symptoms. »Positive urinary cytology in most patients. »Filling defect within bladder noted on imaging. »General ConsiderationsBladder  cancer is the second most common urologic can- cer; it occurs more commonly in men than women (3.1:1), and the mean age at diagnosis is 73 years. Cigarette smok- ing and exposure to industrial dyes or solvents are risk factors for the disease and account for approximately 60%CMDT22_Ch39_p1612-p1675.indd  1659 02/07/21 2:44 PMChAPTER 391660 CMDT 2022and  15% of new cases, respectively. In the United States, almost all primary bladder cancers (98%) are epithelial malignancies, usually urothelial cell carcinomas (90%). Adenocarcinomas and squamous cell cancers account for approximately 2% and 7%, respectively. The latter is often associated with schistosomiasis, vesical calculi, or pro- longed catheter use. »Clinical FindingsA.  Symptoms and SignsH ematuria—gross or microscopic, chronic or intermittent— is the presenting symptom in 85–90% of patients with bladder cancer. Irritative voiding symptoms (urinary fre- quency and urgency) occur in a small percentage of patients as a result of the location or size of the cancer. Most patients with bladder cancer do not have signs of the disease because of its superficial nature. Abdominal masses detected on bimanual examination may be present in patients with large-volume or deeply infiltrating cancers. Hepatomegaly or palpable lymphadenopathy may be pres- ent in patients with metastatic disease, and lymphedema of the lower extremities results from locally advanced cancers or metastases to pelvic lymph nodes.B.  Laboratory FindingsU rinalysis reveals microscopic or gross hematuria in the majority of cases. On occasion, hematuria is accompanied by pyuria. Azotemia may be present in a small number of cases associated with ureteral obstruction. Anemia may occasionally be due to chronic blood loss or to bone mar- row metastases. Exfoliated cells from normal and abnormal urothelium can be readily detected in voided urine speci- mens. Cytology can be useful to detect the disease initially or to detect its recurrence. Cytology is sensitive in detect- ing cancers of higher grade and stage (80–90%), but less so in detecting superficial or well-differentiated lesions (50%). There are numerous urinary tumor markers under investi- gation for screening or assessing recurrence, progression, prognosis, or response to therapy.C.  ImagingBladder  cancers may be identified as masses within the bladder using ultrasound, CT, or MRI. However, the pres- ence of cancer is confirmed by cystoscopy and biopsy, with imaging primarily used to evaluate the upper urinary tract and to stage more advanced lesions.D . Cystourethroscopy and BiopsyThe  diagnosis and staging of bladder cancers are made by cystoscopy and transurethral resection. If cystoscopy— usually performed under local anesthesia—confirms the presence of a bladder tumor, the patient is scheduled for transurethral resection under general or regional anesthe- sia. Random bladder and transurethral prostate biopsies are occasionally performed to detect occult disease and potentially identify patients at greater risk for cancer recur- rence and progression.»Pathology & StagingGrading  is based on cellular features: size, pleomorphism, mitotic rate, and hyperchromatism. Bladder cancer staging is based on the extent (depth) of bladder wall penetration and the presence of regional or distant metastases. Both cancer grade and stage influence the natural history of bladder cancer including local recurrence within the blad- der and progression to higher-stage disease. »TreatmentPa tients with superficial non–muscle invasive cancers (Tis, Ta, T1) are treated with complete transurethral resection with selective use of a single dose intravesical chemother- apy immediately following resection. The subset of patients with carcinoma in situ (Tis) and those undergoing resec- tion of large, high-grade, recurrent Ta lesions or T1 cancers (or both) are good candidates for additional intravesical therapy. Patients with muscle invasive (T2+) but still localized cancers are at risk for both nodal metastases and progres- sion and require more aggressive treatment. The gold standard treatment is neoadjuvant chemotherapy followed by radical cystectomy, which confers a survival advantage versus cystectomy alone. This is particularly important for higher-stage or bulky tumors to improve their surgical resectability. Trimodal bladder preservation therapy con- sisting of complete transurethral resection, sensitizing sys- temic chemotherapy, and external beam radiotherapy can offer similar outcomes in optimally selected patients.A.  Intravesical TherapyImm unotherapeutic or chemotherapeutic agents delivered directly into the bladder via a urethral catheter can reduce the likelihood of recurrence in those who have undergone complete transurethral resection. Most agents are adminis- tered weekly for 6–12 weeks. Efficacy may be increased by prolonging contact time to 2 hours. The use of main- tenance therapy after the initial induction regimen is beneficial. Common agents include gemcitabine, mito- mycin, doxorubicin, valrubicin, and bacillus Calmette– Guérin (BCG), with the last being the only agent effective in reducing disease progression. Side effects of intravesical chemotherapy include irritative voiding symptoms and hemorrhagic cystitis. Patients in whom symptoms or infection develop from BCG may require antituberculous therapy.B.  Surgical TreatmentAlthough  transurethral resection is the initial form of treatment for all bladder tumors (since it is diagnostic, allows for proper staging, and controls superficial cancers), muscle-invasive cancers require more aggressive treat- ment. Partial cystectomy can be considered in selected patients with solitary lesions at the bladder dome or those with cancer in a bladder diverticulum. Radical cystectomy in men entails removal of the bladder, prostate, seminal vesicles, and surrounding fat and peritoneal attachments and in women removal of the bladder, uterus, cervix,CMDT22_Ch39_p1612-p1675.indd  1660 02/07/21 2:44 PMCANCER1661 CMDT 2022urethra,  anterior vaginal vault, and usually the ovaries. In women with anterior tumors, vaginal and reproductive organ-sparing surgery can be considered. Bilateral pelvic lymph node dissection is performed in all patients. Urinary diversion is performed in all. In most patients, it uses a conduit of ileum or colon. However, continent forms of diversion avoid the necessity of an external appliance; it can be considered in a significant percentage of patients.C.  RadiotherapyExternal  beam radiotherapy delivered in fractions over a 6- to 8-week period is generally well tolerated, but approxi- mately 10–15% of patients will develop bladder, bowel, or rectal complications. Local recurrence is common after radiotherapy alone (30–70%) and it is therefore combined with radiosensitizing systemic chemotherapy to improve complete response and to decrease recurrence rates. Bladder- preserving chemoradiation can be offered to those patients seeking to keep their bladder and is best suited for those with solitary T2 or limited T3 tumors without ureteral obstruction. Radiation with or without chemotherapy can be offered to patients with localized cancers and to patients who are poor candidates for radical cystectomy or to patients with metastatic disease seeking palliation of local symptoms.D . ChemotherapyMetas tatic disease is present in 15% of patients with newly diagnosed bladder cancer. Furthermore, metastases develop in up to 40% of patients within 2 years of cystec- tomy, including those patients who were believed to have localized disease at the time of treatment. Cisplatin-based combination chemotherapy results in partial or complete responses in 15–45% of patients (see Table 39–2) and is the preferred approach. Combination chemotherapy has been used to decrease recurrence rates in patients treated both with surgery and with radiotherapy. Neoadjuvant chemotherapy appears to benefit all patients with muscle-invasive disease prior to planned cystectomy. Chemotherapy should also be consid- ered before surgery in those with bulky lesions or those in whom regional metastases are suspected. Alternatively, adjuvant chemotherapy has been used after cystectomy in patients at high risk for recurrence, such as those who have lymph node involvement or extravesical local invasion.E.  ImmunotherapyThe  FDA has now approved several checkpoint inhibitors as immunotherapy for metastatic urothelial cancer. Approved anti–PDL-1 inhibitors include atezolizumab, durvalumab , and avelumab (Table 39–2). Approved anti- PD1 inhibitors include nivolumab andpembrolizumab. All are approved for second-line treatment of locally advanced or metastatic urothelial cancer that progressed during or after platinum-based chemotherapy. Addition- ally, atezolizumab and pembrolizumab are approved as first-line therapy in cisplatin-ineligible patients whose tumors express PD-L1 or in patients ineligible for any platinum-based chemotherapy regardless of PD-L1expression status. Overall response rates of these agents are similar and range from 17% to 25% in locally advanced and metastatic urothelial bladder cancer. »PrognosisThe  frequency of recurrence and progression are correlated with grade. Whereas progression may be noted in few low- grade cancers (19–37%), it is common with poorly differ- entiated lesions (33–67%). Carcinoma in situ is most often found in association with papillary bladder cancers. Its presence identifies patients at increased risk for recurrence and progression. At initial presentation, approximately 50–80% of blad- der cancers are superficial: stage Ta, Tis, or T1. When properly treated, lymph node metastases and progression are uncommon in such patients and survival is excellent (81%). Five-year survival of patients with T2 and T3 dis- ease ranges from 50% to 75% after radical cystectomy. Long-term survival for patients with metastatic disease at presentation is rare. »When to Refer• Refer all patients to a urologist. Hematuria often deserves evaluation with both upper urinary tract imaging and cystoscopy, particularly in a high-risk group (eg, older men). •Refer when histologic diagnosis and staging require endoscopic resection of cancer. •Metastatic urothelial cancer should be managed by a medical oncologist.Babjuk  M et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)–2019 update. Eur Urol. 2019;76:639. [PMID: 31443960] Faba OR et al. Update of the ICUD-SIU International Consulta- tion on Bladder Cancer 2018: urinary diversion. World J Urol. 2019;37:85. [PMID: 30238399] Flaig TW et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329. [PMID: 32135513] Hussain SA et al. From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. Eur Urol Oncol. 2018;1:486. [PMID: 31158093] Nadal R et al. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10. [PMID: 31030123]C ANCERS OF THE URETER & RENAL PELVISCancers  of the ureter and renal pelvis are rare and occur more commonly in patients who have bladder cancer, Bal- kan nephropathy, or Lynch syndrome, who smoke, or who have a long history of analgesic abuse. The majority are urothelial cell carcinomas. Gross or microscopic hematuria is present in most patients; flank pain secondary to bleed- ing and obstruction occurs less commonly. As with bladder cancers, urinary cytology is often positive in high-grade cancers. The most common signs identified at the time of CT or intravenous urography include an intraluminal fill- ing defect, unilateral nonvisualization of the collectingCMDT22_Ch39_p1612-p1675.indd  1661 02/07/21 2:44 PMChAPTER 391662 CMDT 2022system,  and hydronephrosis. Ureteral and renal pelvic tumors must be differentiated from calculi, blood clots, papillary necrosis, or inflammatory and infectious lesions. On occasion, upper urinary tract lesions are accessible for biopsy, fulguration, or resection using a ureteroscope. Treatment is based on the site, size, grade, depth of pene- tration, and number of cancers present. Most are excised with laparoscopic or open nephroureterectomy (renal pel- vic and upper ureteral lesions) or segmental excision of the ureter (distal ureteral lesions). Endoscopic resection may be indicated in patients with limited renal function or focal, low-grade, cancers. Similar to urothelial bladder cancers, use of chemotherapy prior to surgery may improve outcomes.Kim  HS et al. Immune checkpoint inhibitors for urothelial carci- noma. Investig Clin Urol. 2018;59:285. [PMID: 30182073] Leow JJ et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79:635. [PMID: 32798146] Scotland KB et al. Long term outcomes of ureteroscopic man- agement of upper tract urothelial carcinoma. Urol Oncol. 2020;38:850.e17. [PMID: 32773230]RE NAL CELL CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »Gross or microscopic hematuria. »Flank pain or mass in some patients. »Systemic symptoms such as fever, weight loss may be prominent. »Solid renal mass on imaging. »General ConsiderationsKidney  (renal cell) and renal pelvis carcinomas account for 3.8% of all adult cancers. In 2019 in the United States, it is estimated that approximately 73,820 cases of renal cell car- cinoma will be diagnosed and 14,770 deaths will result. Renal cell carcinoma has a peak incidence in the sixth decade of life and a male-to-female ratio of 2:1. It may be associated with a number of paraneoplastic syndromes. Risk factors include physical inactivity, obesity, and diabetes mellitus. Cigarette smoking is the only known significant environmental risk factor. Familial causes of renal cell carcinoma have been identified (von Hippel– Lindau syndrome, hereditary papillary renal cell carci- noma, hereditary leiomyoma-renal cell carcinoma, and Birt-Hogg-Dubé syndrome). There is an association with dialysis-related acquired cystic disease and specific genetic aberrations (eg, Xp11.2 translocation). But sporadic carci- nomas are far more common. Renal cell carcinoma originates from the proximal tubule cells. Various histologic cell types are recognized (clear cell, papillary, chromophobe, collecting duct, and sarcomatoid).»Clinical FindingsA.  Symptoms and SignsHisto rically, 60% of patients presented with gross or micro- scopic hematuria. Flank pain or an abdominal mass was detected in approximately 30% of cases. The triad of flank pain, hematuria, and mass, found in only 10% of patients, is often a sign of advanced disease. Fever can occur as a paraneoplastic symptom. Symptoms of metastatic disease (cough, bone pain) occur in 20–30% of patients at presenta- tion. Due to the widespread use of ultrasound and cross- sectional imaging, renal tumors are frequently detected incidentally in individuals with no urologic symptoms. Consequently, there has been profound stage migration toward lower stages of disease over the last 20 years. How- ever, population mortality rates have remained stable.B.  Laboratory FindingsCon temporary studies suggest hematuria is present in less than 50% of patients. Erythrocytosis from increased eryth- ropoietin production occurs in 5%, though anemia is more common; hypercalcemia may be present in up to 10% of patients. Stauffer syndrome is a reversible syndrome of hepatic dysfunction (with elevated liver tests) in the absence of metastatic disease.C.  ImagingSolid  renal masses are often first identified by abdominal ultrasonography or CT. CT and MRI scanning are the most valuable imaging tests for renal cell carcinoma. These scans confirm the character of the mass and provide valuable stag- ing information with respect to regional lymph nodes, renal vein or vena cava tumor thrombus, and adrenal or liver metastases. CT and MRI also provide valuable information regarding the contralateral kidney (function, bilaterality of neoplasm). Chest radiographs or CT exclude pulmonary metastases. Bone scans should be performed for large tumors and in patients with bone pain or elevated serum alkaline phosphatase levels. Brain imaging should be obtained in patients with high metastatic burden or in those with neurologic deficits. »Differential DiagnosisSolid  renal masses are renal cell carcinoma until proven otherwise. Other solid masses include renal angiomyoli- pomas (fat density usually detectable by CT), renal pelvis urothelial cancers (more central location, involvement of the collecting system, positive urinary cytology), renal oncocytomas (indistinguishable from renal cell carcinoma preoperatively), renal abscesses, and adrenal tumors (superoanterior to the kidney). »TreatmentSu rgical extirpation is the primary treatment for localized renal cell carcinoma. Patients with a single kidney, bilateral lesions, or significant medical renal disease should be con- sidered for partial nephrectomy. Patients harboring a small tumor with a normal contralateral kidney and good kidneyCMDT22_Ch39_p1612-p1675.indd  1662 02/07/21 2:44 PMCANCER1663 CMDT 2022funct ion are also candidates for partial nephrectomy, while radical nephrectomy is indicated in patients with cancers larger than 7 cm and those in whom partial nephrectomy is not technically feasible. Radiofrequency and cryosurgical ablation are alternative options instead of surgery in select patients with tumors less than 3–4 cm with similar risk of metastatic progression but higher risk of local recurrence. Active surveillance is warranted in select patients (signifi- cant comorbidity, short life expectancy) and appears safe with low risk of 5-year systemic progression. Percutaneous biopsy can provide tumor histology and grade to help guide treatment decisions. Cytotoxic chemotherapy has no role in the treatment of metastatic renal cell carcinoma. Historically, cytokine-based immunotherapies, such as interferon-alpha and interleukin-2, produced partial response rates of 15–20% and 15–35%, respectively (Table 39–2). Responders tended to have lower tumor burden, metastatic disease confined to the lung, and a high-performance status. Two randomized trials demonstrat- ing a survival benefit of cytoreductive nephrectomy followed by systemic interferon-alpha compared with the use of sys- temic therapy alone led to the widespread adoption of cytore- ductive nephrectomy. Patients most likely to benefit from cytoreduction were those with good performance status, lung only metastases, and good prognostic features. Presently, management strategies are based on tumor histology and patient risk (favorable, intermediate, or poor). Several targeted medications, specifically VEGF, Raf- kinase, and mTOR inhibitors, are effective (40–60% response rates) in patients with advanced kidney cancer (Table 39–2). These oral agents, which include sunitinib, pazopanib, cabozantinib, axitinib, and sorafenib, are generally well tolerated and particularly active for clear cell carcinoma. The optimal timing and combination of these agents remain to be determined. Sunitinib is approved for adjuvant use after complete surgical resection in patients with adverse pathologic features. The mTOR inhibitors everolimus and temsirolimus are approved for use in patients with prior anti-VEGF therapy, as is the combina- tion of lenvatinib and everolimus. Nivolumab is an approved anti-PD-1 immunotherapy for treating metastatic disease that has progressed despite antiangiogenic therapy. Nivolumab in combination with the anti-CTLA4 immuno- therapy ipilimumab and pembrolizumab (anti-PD-1) in combination with the VEGF inhibitor axitinib have proved superior to sunitinib in previously untreated intermediate- and poor-risk metastatic clear cell renal cell carcinoma and are considered the standard first-line treatment for this patient population (Table 39–2). The utilization of cytoreductive nephrectomy in combi- nation with contemporary agents has decreased in response to the results of CARMENA and adoption of combination immunotherapy regimens (nivolumab plus ipilimumab, pembrolizumab plus axitinib). Still, there remains a role for cytoreductive surgery in select patients with intermediate- risk disease. »PrognosisAfter  radical or partial nephrectomy, tumors confined to the renal capsule (T1–T2) demonstrate 5-year disease-freesurvivals of 90–100%. Tumors extending beyond the renal capsule (T3 or T4) and node-positive tumors have 5-year disease-free survivals of 50–60% and 0–15%, respectively. One subgroup of patients with nonlocalized disease has reasonable long-term survival, namely, those with solitary resectable metastases. In this setting, radical nephrectomy with resection of the solitary metastasis results in 5-year disease-free survival rates of 15–30%. »When to Refer• Refer patients with solid renal masses or complex cysts to a urologist for further evaluation. •Refer patients with renal cell carcinoma to a urologic surgeon for surgical excision. •Refer patients with metastatic disease to an oncologist and urologist.Lalani AA et  al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immuno- therapy, and future directions. Eur Urol. 2019;75:100. [PMID: 30327274] Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277. [PMID: 29562145] Rini BI et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116. [PMID: 30779529] Sanchez A et al. Current management of small renal masses, including patient selection, renal tumor biopsy, active surveil- lance, and thermal ablation. J Clin Oncol. 2018;36:3591. [PMID: 30372390]OTH ER PRIMARY TUMORS OF THE KIDNEYOncocytomas  account for 3–5% of renal tumors, are usu- ally benign, and are indistinguishable from renal cell carci- noma on preoperative imaging. These tumors are seen in other organs, including the adrenals, salivary glands, and thyroid and parathyroid glands. Angiomyolipomas are rare benign tumors composed of fat, smooth muscle, and blood vessels. They are most com- monly seen in patients with tuberous sclerosis (often mul- tiple and bilateral) or in young to middle-aged women. CT scanning may identify the fat component, which is diagnos- tic for angiomyolipoma. Asymptomatic lesions less than 5 cm in diameter usually do not require intervention; large lesions can spontaneously bleed. Acute bleeding can be treated by angiographic embolization or, in rare cases, nephrectomy. Lesions over 5 cm are often prophylacti- cally treated with angioembolization to reduce the risk of bleeding.SE CONDARY CANCERS OF THE KIDNEYThe kidney is not an infrequent site fo r metastatic disease. Of the solid tumors, lung cancer is the most common (20%), followed by breast (10%), stomach (10%), and the contralateral kidney (10%). Lymphoma, both Hodgkin and non-Hodgkin, may also involve the kidney, although it tends to appear as a diffusely infiltrative process resulting in renal enlargement rather than a discrete mass.CMDT22_Ch39_p1612-p1675.indd  1663 02/07/21 2:44 PMChAPTER 391664 CMDT 2022TE STICULAR CANCERS (Germ Cell Tumors)E S S E N T I A L S  O F  D I A G N O S I S »Most common neoplasm in men aged 20–35 years. »Patient typically discovers a painless nodule. »Orchiectomy necessary for diagnosis. »General ConsiderationsMalignan t tumors of the testis are rare, with approximately five to six cases per 100,000 males reported in the United States each year. Ninety to 95 percent of all primary testicu- lar tumors are germ cell tumors and can be divided into two major categories: nonseminomas, including embryo- nal cell carcinoma (20%), teratoma (5%), choriocarcinoma (less than 1%), and mixed cell types (40%); and semino- mas (35%). The lifetime probability of developing testicu- lar cancer is 0.3% for an American male. Approximately 5% of testicular cancers develop in a patient with a history of cryptorchism, with seminoma being the most common. However, 5–10% of these tumors occur in the contralateral, normally descended testis. The relative risk of development of malignancy is higher for the intra- abdominal testis (1:20) and lower for the inguinal testis (1:80). Placement of the cryptorchid testis into the scrotum (orchidopexy) does not alter its malignant potential but does facilitate routine examination and cancer detection. Testicular cancer is slightly more common on the right than the left, paralleling the increased incidence of cryptor- chidism on the right side. One to 2 percent of primary tes- ticular cancers are bilateral and up to 50% of these men have a history of unilateral or bilateral cryptorchidism. Primary bilateral testicular cancers may occur synchronously or asynchronously but tend to be of the same histology. Semi- noma is the most common histologic finding in bilateral primary testicular cancers, while malignant lymphoma is the most common bilateral testicular tumor overall. »Clinical FindingsA.  Symptoms and SignsThe  most common symptom of testicular cancer is painless enlargement of the testis. Sensations of heaviness are not unusual. Patients are usually the first to recognize an abnormality, yet often delay in seeking medical attention ranges from 3 to 6 months. Acute testicular pain resulting from intratesticular hemorrhage occurs in approximately 10% of cases. Ten percent of patients are asymptomatic at presentation, and 10% manifest symptoms relating to metastatic disease such as back pain (retroperitoneal metastases), cough (pulmonary metastases), or lower extremity edema (vena cava obstruction). A discrete mass or diffuse testicular enlargement is noted in most cases. Secondary hydroceles may be present in 5–10% of cases. In advanced disease, supraclavicular adenop- athy may be present, and abdominal examination may reveal a mass. Gynecomastia is seen in 5% of germ cell tumors.B. Laboratory FindingsSeveral  serum markers are important in the diagnosis and monitoring of testicular carcinoma, including human cho- rionic gonadotropin (hCG), alpha-fetoprotein, and lactate dehydrogenase. Alpha-fetoprotein is never elevated with pure seminomas, and while hCG is occasionally elevated in seminomas, levels tend to be lower than those seen with nonseminomas. Lactate dehydrogenase may be elevated with either type of tumor and is a marker for disease bur- den. Liver tests may be elevated in the presence of hepatic metastases, and anemia may be present in advanced disease.C.  ImagingScrotal  ultrasound can readily determine whether a mass is intratesticular or extratesticular. Once the diagnosis of testicular cancer has been established by inguinal orchiec- tomy, clinical staging of the disease is accomplished by chest, abdominal, and pelvic CT scanning. »StagingT esticular cancer is staged using the TNM system created based on extent of cancer in the testis, status of regional lymph nodes, the presence of metastases in distant lymph nodes or other viscera, and serum levels of tumor markers. Based on these features, germ cell tumors can be grouped to assign an overall stage: stage I lesion is confined to the testis; stage II demonstrates regional lymph node involve- ment in the retroperitoneum; and stage III indicates distant metastasis. »Differential DiagnosisAn  incorrect diagnosis is made at the initial examination in up to 25% of patients with testicular tumors. Scrotal ultra- sonography should be performed if any uncertainty exists with respect to the diagnosis. Although most intratesticu- lar masses are malignant, a benign lesion—epidermoid cyst—may rarely be seen. Epidermoid cysts are usually very small benign nodules located just underneath the tunica albuginea; occasionally, however, they can be large. Testicular lymphoma is discussed below. »TreatmentIn guinal exploration with early vascular control of the sper- matic cord structures is the initial intervention. If cancer cannot be excluded by examination of the testis, radical orchiectomy is warranted. Scrotal approaches and open tes- ticular biopsies should be avoided. Further therapy depends on the histology of the tumor as well as the clinical stage. Patients with clinical stage I seminomas are candidates for surveillance (preferred), single-agent carboplatin, or adjuvant radiotherapy. Stage IIa and IIb seminomas (retro- peritoneal disease less than 2 cm diameter in IIa and 2–5 cm in IIb) are treated by radical orchiectomy plus retroperito- neal irradiation or primary systemic chemotherapy (etoposide and cisplatin or cisplatin, etoposide, and bleo- mycin) (Table 39–2). Seminomas of stage IIc (greater than 5-cm-diameter retroperitoneal nodes) and stage III receiveCMDT22_Ch39_p1612-p1675.indd  1664 02/07/21 2:44 PMCANCER1665 CMDT 2022primary systemic chemotherap y. After chemotherapy, sur- gical resection of residual retroperitoneal nodes is war- ranted if the node is greater than 3 cm in diameter and positive on PET scan, since 40% will harbor residual carcinoma. Up to 75% of clinical stage I nonseminomas are cured by orchiectomy alone. Selected patients without specific risk factors have low-risk of recurrence and are generally offered surveillance after orchiectomy. These criteria include (1) cancer is confined within the tunica albuginea; (2) cancer does not demonstrate vascular invasion; (3) tumor markers normalize after orchiectomy; (4) radio- graphic imaging of the chest and abdomen shows no evi- dence of disease; and (5) the patient is reliable. Patients most likely to experience relapse on a surveillance regimen include those with predominantly embryonal cancer and those with vascular or lymphatic invasion identified in the orchiectomy specimen. Alternatives to surveillance for clinical stage I nonseminomas include adjuvant chemo- therapy (bleomycin, etoposide, cisplatin) (see Table 39–2) or retroperitoneal lymph node dissection. Following orchiectomy, patients with bulky retroperito- neal disease (greater than 5-cm nodes) or metastatic non- seminomas are treated with combination chemotherapy (cisplatin and etoposide or cisplatin, etoposide, and bleo- mycin) (Table 39–2). If tumor markers normalize and a residual mass greater than 1 cm persists on imaging stud- ies, it is resected because 15–20% will harbor residual cancer and 40% will harbor teratomas. Even if patients have a complete response to chemotherapy, some clinicians advocate retroperitoneal lymphadenectomy since 10% of patients may harbor residual carcinoma and 10%, retro- peritoneal teratoma. If tumor markers fail to normalize following primary chemotherapy, salvage chemotherapy is required (cisplatin, etoposide, and ifosfamide). Postoperative active surveillance by the clinician and patient means patients are followed up every 2–6 months for the first 2 years and every 4–6 months in the third year. For nonseminomas, tumor markers are obtained at each visit, and chest radiographs and abdominal and pelvic CT scans are obtained every 4–6 months. For seminomas, serum tumor markers may be obtained (optional), chest imaging is obtained only as clinically indicated, and abdominal and pelvic CT scans are performed every 3–6 months. Follow-up continues beyond the initial 3 years; however, 80% of relapses will occur within the first 2 years. With rare exceptions, patients who relapse can be cured by chemotherapy or surgery. »PrognosisThe  5-year disease-free survival rates for stage I and IIa seminomas (retroperitoneal disease less than 2 cm in diameter) treated by radical orchiectomy and retroperito- neal irradiation are 98% and 92–94%, respectively. Ninety- five percent of patients with stage III disease attain a complete response following orchiectomy and chemother- apy. The 5-year disease-free survival for patients with stage I nonseminomas (includes all treatments) ranges from 96% to 100%. For low-volume stage II disease, a 5-year disease- free survival of 90% is expected. Patients withbulky retroperitoneal or disseminated disease treated with primary chemotherapy followed by surgery have a 5-year disease-free survival rate of 55–80%. »When to ReferRef er all patients with solid masses of the testis to a urologist and a medical oncologist if metastatic disease is suspected.Goldber g H et al. Germ cell testicular tumors—contemporary diagnosis, staging and management of localized and advanced disease. Urology. 2019;125:8. [PMID: 30597167] King J et al. Management of residual disease after chemotherapy in germ cell tumors. Curr Opin Oncol. 2020;32:250. [PMID: 32168037] Pierorazio PM et al. Performance characteristics of clinical stag- ing modalities for early stage testicular germ cell tumors: a systematic review. J Urol. 2020;203:894. [PMID: 31609176]SE CONDARY CANCERS OF THE TESTISSecondary  cancers of the testis are rare. In men over the age of 50 years, lymphoma is the most common. Overall, it is the most common secondary neoplasm of the testis, accounting for 5% of all testicular cancers. It may be seen in three clinical settings: (1) late manifestation of wide- spread lymphoma, (2) the initial presentation of clinically occult disease, and (3) primary extranodal disease. Radical orchiectomy is indicated to make the diagnosis. Prognosis is related to the stage of disease. Metastasis to the testis is rare. The most common pri- mary site of origin is the prostate, followed by the lung, gastrointestinal tract, melanoma, and kidney.CA NCER COMPLICATIONS & EMERGENCIESSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSP INAL CORD COMPRESSIONE S S E N T I A L S  O F  D I A G N O S I S »Complication of metastatic solid tumor, lym- phoma, or plasma cell myeloma. »Back pain is most common presenting symptom. »Prompt diagnosis is essential because once a severe neurologic deficit develops, it is often irreversible. »Emergent treatment may prevent or potentially reverse paresis and urinary and bowel incontinence. »General ConsiderationsCancers  that cause spinal cord compression most com- monly metastasize to the vertebral bodies, resulting in physical damage to the spinal cord from edema, hemorrhage,CMDT22_Ch39_p1612-p1675.indd  1665 02/07/21 2:44 PMChAPTER 391666 CMDT 2022and  pressure-induced ischemia to its vasculature. Persis- tent compression can result in irreversible changes to the myelin sheaths resulting in permanent neurologic impairment. Prompt diagnosis and therapeutic intervention are essential, since the probability of reversing neurologic symptoms largely depends on the duration of symptoms. Patients who are treated promptly after symptoms appear may have partial or complete return of function and, depending on tumor sensitivity to specific treatment, may respond favorably to subsequent anticancer therapy. »Clinical FindingsA.  Symptoms and SignsBack  pain at the level of the tumor mass occurs in over 80% of cases and may be aggravated by lying down, weight bear- ing, sneezing, or coughing; it usually precedes the develop- ment of neurologic symptoms or signs. Since involvement is usually epidural, a mixture of nerve root and spinal cord symptoms often develops. Progressive weakness and sen- sory changes commonly occur. Bowel and bladder symp- toms progressing to incontinence are late findings. The initial findings of impending cord compression may be quite subtle, and there should be a high index of suspicion when back pain or weakness of the lower extrem- ities develops in a cancer patient.B.  ImagingMRI is usually the initial imaging procedure o f choice in a cancer patient with new-onset back pain. If the back pain symptom is nonspecific, a whole-body PET-CT scan with18 F-2-deoxyglucose may be a useful screening procedure. Bone radiographs are neither sensitive nor specific for the evaluation of a cancer patient with back pain. When neu- rologic findings suggest spinal cord compression, an emer- gent MRI should be obtained; the MRI should survey the entire spine to define all areas of tumor involvement for treatment planning purposes. MRI has a sensitivity of 93% and a specificity of 97% for diagnosis of metastatic spinal cord compression. »TreatmentPa tients with a known cancer diagnosis found to have epi- dural impingement of the spinal cord should be given corticosteroids immediately. The initial dexamethasone dose is 10 mg intravenously followed by 4–6 mg every 6 hours intravenously or orally. Patients without a known diagnosis of cancer should have emergent surgery to relieve the impingement and obtain a pathologic speci- men; preoperative corticosteroids should not be given since they might compromise the pathology results. Patients with solid tumors who have a single area of com- pression and who are considered candidates for surgery are best treated first with surgical decompression followed by radiation therapy. Better outcomes (ie, improved ability to ambulate and improved bladder and bowel function) occur in patients who undergo surgery followed byradiation therapy than in those who receive radiation alone. If multiple vertebral body levels are involved with cancer, fractionated radiation therapy is the preferred treatment option. Corticosteroids are generally tapered toward the end of radiation therapy. A scoring system exists for patients presenting with spinal cord metastases to identify those with poor survival times who would be best managed with supportive care or single fraction palliative radiation.Boussios S et  al. Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges. Anticancer Res. 2018;38:4987. [PMID: 30194142] Hoskin PJ et al. Effect of single-fraction vs multifraction radio- therapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322:2084. [PMID: 31794625] Lawton AJ et al. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol. 2019;37:61. [PMID: 30395488]MA LIGNANT EFFUSIONSE S S E N T I A L S  O F  D I A G N O S I S »Occur in pleural, pericardial, and peritoneal spaces. »Caused by direct neoplastic involvement of serous surface or obstruction of lymphatic drainage. »Half of undiagnosed effusions in patients not known to have cancer are malignant. »General ConsiderationsThe developme nt of an effusion in the pleural, pericardial, or peritoneal space may be the initial finding in a patient with cancer, or an effusion may appear during the course of disease progression. Direct involvement of the serous sur- face with tumor is the most frequent initiating cause of the accumulation of fluid. The most common malignancies causing pleural and pericardial effusions are lung and breast cancers; the most common malignancies associated with malignant ascites are ovarian, colorectal, stomach, and pancreatic cancers. »Clinical FindingsA.  Symptoms and SignsPa tients with pleural and pericardial effusions complain of shortness of breath and orthopnea. Patients with ascites complain of abdominal distention and discomfort. Cardiac tamponade causing pressure equalization in the chambers impairs both filling and cardiac output and can be life- threatening. Signs of tamponade include tachycardia, muf- fled heart sounds, pulsus paradoxus, and hypotension. Signs of pleural effusions include decreased breath sounds, egophony, and percussion dullness.CMDT22_Ch39_p1612-p1675.indd  1666 02/07/21 2:44 PMCANCER1667 CMDT 2022B.  Laboratory FindingsMalignancy is confirmed  as the cause of an effusion when analysis of the fluid specimen shows malignant cells in either the cytology or cell block specimen.C.  ImagingThe  presence of effusions can be confirmed with radio- graphic studies or ultrasonography. »Differential DiagnosisThe  differential diagnosis of a malignant pleural or pericar- dial effusion includes nonmalignant processes, such as infection, pulmonary embolism, heart failure, and trauma. The differential diagnosis of malignant ascites includes similar benign processes, such as heart failure, cirrhosis, peritonitis, and pancreatic ascites. Bloody effusions are usually due to cancer, but a bloody pleural effusion can also be due to pulmonary embolism, trauma and, occasionally, infection. Chylous pleural or ascitic fluid is generally asso- ciated with obstruction of lymphatic drainage as might occur in lymphoma. »TreatmentThe  development of a malignant effusion is a late-stage manifestation of the cancer. Treatment is tailored to the underlying cancer, whether with targeted therapy, chemo- therapy, or immunotherapy, depending on tumor testing results. Effective systemic treatment can lead to regression of the effusion. Acute symptoms related to the effusion often require urgent intervention with drainage of the effu- sion. Decisions regarding palliative management of malig- nant effusion are in large part dictated by the patient’s symptoms and goals of care.A.  Pleural EffusionA  pleural effusion that is symptomatic may be managed initially with a large volume thoracentesis. In some patients, the effusion slowly reaccumulates, which allows for periodic thoracentesis when the patient becomes symp- tomatic. However, in many patients, the effusion reaccu- mulates quickly, causing rapid return of shortness of breath. For those patients, two other management options exist: pleurodesis or indwelling pleural catheter (eg, PleurX). Chest tube drainage followed by pleurodesis involves placement of a chest tube that is connected to closed water seal drainage. After lung expansion is con- firmed on a chest radiograph, a sclerosing agent (such as talc slurry or doxycycline) is injected into the catheter. Patients should be premedicated with analgesics. Pleurode- sis will not be successful if the lung cannot be reexpanded. These patients are better managed with placement of an indwelling catheter that can be drained by a family mem- ber or a visiting nurse. This procedure is often preferable for patients with short life expectancies or for those who do not respond to pleurodesis. In a meta-analysis of random- ized controlled trials comparing indwelling pleural cathe- ter with pleurodesis, indwelling pleural catheters resultedin shorter hospital stays and fewer repeat pleural interven- tions, but increased rates of cellulitis.B.  Pericardial EffusionFluid  may be removed by a needle aspiration or by place- ment of a catheter for more thorough drainage. As with pleural effusions, most pericardial effusions will reaccu- mulate. Management options for recurrent, symptomatic effusions include prolonged catheter drainage (for several days until drainage has decreased to 20–30 mL/day) or surgical intervention such as a pericardiotomy or pericardiectomy.C.  Malignant AscitesPa tients with malignant ascites not responsive to chemo- therapy are generally treated with repeated large-volume paracenteses. Since the frequency of drainage to maintain comfort can compromise the patient’s quality of life, other alternatives include placement of a catheter or port so that the patient, family member, or visiting nurse can drain fluid as needed at home. For patients with portal hyper- tension from large hepatic masses, diuretics (such as spi- ronolactone 100 mg with furosemide 20–40 mg orally daily) may be useful to decrease the need for repeated paracentesis.As ciak R et al. Malignant pleural effusion: from diagnostics to therapeutics. Clin Chest Med. 2018;39:181. [PMID: 29433714] Feller-Kopman DJ et al. Management of malignant pleural effu- sions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198:839. [PMID: 30272503] Iyer NP et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta- analysis. Ann Am Thorac Soc. 2019;16:124. [PMID: 30272486] Walker S et al. Malignant pleural effusion management: keeping the flood gates shut. Lancet Respir Med. 2020;8:609. [PMID: 31669226]HYP ERCALCEMIAE S S E N T I A L S  O F  D I A G N O S I S »Most common paraneoplastic endocrine syndrome. »Usually symptomatic and severe (≥ 15 mg/dL [3.75 mmol/L]); accounts for most inpatients with hypercalcemia. »The neoplasm is clinically apparent in nearly all cases when hypercalcemia is detected. »General ConsiderationsH ypercalcemia affects 20–30% of cancer patients at some point during their illness. The most common cancers causing hypercalcemia are myeloma, breast carcinoma, and NSCLC. Hypercalcemia is caused by one of three mechanisms: sys- temic effects of tumor-released proteins, direct osteolysis of bone by tumor, or vitamin D–mediated osteoabsorption.CMDT22_Ch39_p1612-p1675.indd  1667 02/07/21 2:44 PMChAPTER 391668 CMDT 2022 »Clinical FindingsA.  Symptoms and SignsSy mptoms and signs of hypercalcemia can be subtle; more severe symptoms occur with higher levels of hypercalcemia and with a rapidly rising calcium level. Early symptoms typi- cally include anorexia, nausea, fatigue, constipation, and polyuria; later findings may include muscular weakness and hyporeflexia, confusion, psychosis, tremor, and lethargy.B.  Laboratory FindingsSym ptoms and signs are caused by free calcium; as calcium is bound by protein in the serum, the measured serum calcium will underestimate the free or ionized calcium in patients with low albumin levels. Free ionized calcium can be measured. When the corrected serum calcium rises above 12 mg/dL (3 mmol/L), especially if the rise occurs rapidly, sudden death due to cardiac arrhythmia or asystole may occur. Initial work-up for hypercalcemia includes obtaining serum PTH, PTHrP , and calcitriol levels. The presence of hypercalcemia does not invariably indicate a dismal prognosis, especially in patients with breast cancer, myeloma, or lymphoma.C.  ECGElectrocardiograph y in hypercalcemia often shows a short- ening of the QT interval. »TreatmentEme rgency management should begin with the initiation of intravenous fluids with 0.9% saline at 100–300 mL/h to ensure rehydration with brisk urinary output of the often volume-depleted patient. If kidney function is normal or only marginally impaired, a bisphosphonate should be given. Choices include pamidronate, 60–90 mg intravenously over 2–4 hours, or zoledronic acid, 4 mg intravenously over 15 minutes. Zoledronic acid is more potent than pamidro- nate and has the advantage of a shorter administration time as well as a longer duration of effect. Once hypercalcemia is controlled, treatment directed at the cancer should be initi- ated if possible. In the event that the hypercalcemia becomes refractory to repeated doses of bisphosphonates, other agents that can help control hypercalcemia (at least temporarily) include calcitonin and denosumab; corticosteroids can be useful in patients with myeloma and lymphoma. Salmon calcitonin, 4–8 international units/kg given subcutaneously or intramuscularly every 12 hours, can be used in patients with severe, symptomatic hypercalcemia; its onset of action is within hours but its hypocalcemic effect wanes in 2–3 days. Denosumab, 120 mg given subcutaneously weekly for 4 weeks followed by monthly administration, is a choice for long-term management of bisphosphonate-refractory hyper- calcemia or for patients with kidney dysfunction that pre- cludes use of a bisphosphonate.Asoni tis N et al. Diagnosis, pathophysiology, and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019;51:770. [PMID: 31826272]Zagzag J et al. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin. 2018;68:377. [PMID: 30240520]HYP ERURICEMIA & TUMOR LYSIS SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S »Complication of treatment-associated tumor lysis of hematologic and rapidly proliferating malignancies. »May be worsened by thiazide diuretics. »Rapid increase in serum uric acid can cause acute urate nephropathy from uric acid crystallization. »Reducing pre-chemotherapy serum uric acid is fundamental to preventing urate nephropathy. »General ConsiderationsT umor lysis syndrome (TLS) is seen most commonly fol- lowing treatment of hematologic malignancies, such as acute lymphoblastic leukemia and Burkitt lymphoma. However, TLS can develop from any tumor highly sensitive to chemotherapy. TLS is caused by the massive release of cellular material including nucleic acids, proteins, phos- phorus, and potassium. If both the metabolism and excre- tion of these breakdown products are impaired, hyperuricemia, hyperphosphatemia, and hyperkalemia will develop abruptly. Acute kidney injury may then develop from the crystallization and deposition of uric acid and calcium phosphate within the renal tubules, further exacerbating the hyperphosphatemia and hyperkalemia. »Clinical FindingsA.  Symptoms and SignsSymp toms of hyperphosphatemia include nausea, vomit- ing, anorexia, muscle cramps, tetany, and seizures. High levels of phosphorus and co-precipitation with calcium can cause renal tubule blockage, further exacerbating the kid- ney injury. Hyperkalemia, due to release of intracellular potassium and impaired kidney excretion, can cause arrhythmias and sudden death.B.  Laboratory FindingsThe laborat ory diagnosis of TLS include at least two of the following criteria observed within a 24-hour period: uric acid 8 mg/dL or higher (476 mcmol/L or higher), phos- phate 4.5 mg/dL or higher (1.45 mmol/L or higher), potas- sium 6.0 mEq/L or more (6 mmol/L or more) (or a 25% increase from baseline for these parameters), and corrected serum calcium 7 mg/dL or lower (1.75 mmol/L or lower). A clinical diagnosis of TLS includes meeting the laboratory criteria and at least one clinical criterion: acute kidney injury (creatinine greater than or equal to 1.5 × upper limit of normal or increase greater than 0.3 g/dL or urinaryCMDT22_Ch39_p1612-p1675.indd  1668 02/07/21 2:44 PMCANCER1669 CMDT 2022out put greater than 0.5 mL/kg/h for 6 hours) or cardiac arrhythmia, sudden cardiac death, or seizure. »TreatmentPreven tion is the most important factor in the manage- ment of TLS. Aggressive hydration at least 24 hours prior to chemotherapy as well as 24–48 hours after chemotherapy completion helps keep urine flowing and facilitates excre- tion of uric acid and phosphorus. It is recommended to maintain a urinary output of at least 100 mL/h, and a daily urine volume of at least 3 L/day. If evidence of volume over- load or inadequate urinary output develops, loop diuretics can be used. Thiazide diuretics are contraindicated because they increase uric acid levels and can interact with allopuri- nol. For patients at moderate risk of developing TLS, eg, those with intermediate-grade lymphomas and acute leuke- mias, allopurinol should be given before starting chemo- therapy with dose reductions for impaired kidney function. Rasburicase is given intravenously to patients at high risk for developing TLS, eg, those with high-grade lymphomas or acute leukemias with markedly elevated white blood cell counts. Rasburicase may also be considered for patients with baseline elevated uric acid who are being treated with venetoclax (Bcl-2 inhibitor) for chronic lymphocytic leuke- mia or in any patient in whom uric acid levels reach levels greater than 8 mg/dL despite treatment with allopurinol. Rasburicase cannot be given to patients with known glucose 6-phosphate dehydrogenase (G6PD) deficiency nor can it be given to pregnant or lactating women. »When to ReferShould  urinary output drop, serum creatinine or potas- sium levels rise, or hyperphosphatemia persist, a nephrolo- gist should be immediately consulted to evaluate the need for dialysis.Durani  U et al. Emergencies in haematology: tumor lysis syn- drome. Br J Haematol. 2020;188:494. [PMID: 31774551] Matuszkiewicz-Rowinska J et al. Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res. 2020;45:645. [PMID: 32998135]IN FECTIONSChapt ers 30 and 31 provide more detailed discussions of infections in the immunocompromised patient.E S S E N T I A L S  O F  D I A G N O S I S »In patients with neutropenia, infection is a medi- cal emergency. »Although sometimes attributable to other causes, the presence of fever, defined as a single tempera- ture > 38.3°C (101°F) or a temperature of > 38°C (100.4°F) for > 1 hour, must be assumed to be due to an infection.»General ConsiderationsMa ny patients with disseminated neoplasms have increased susceptibility to infection. In some patients, this results from impaired defense mechanisms (eg, acute leukemia, Hodgkin lymphoma, plasma cell myeloma, chronic lymphocytic leu- kemia); in others, it results from the myelosuppressive and immunosuppressive effects of cancer chemotherapy or a combination of these factors. Complicating impaired defense mechanisms are the frequent presence of indwelling cathe- ters, impaired mucosal surfaces, and colonization with more virulent hospital-acquired pathogens. The source of a neutropenic febrile episode is deter- mined in about 30% of cases through blood, urine, or sputum cultures. The bacterial organisms accounting for the majority of infections in cancer patients include gram- positive bacteria (coagulase-negative Staphylococcus, Staphylococcus aureus, Streptococcus pneumoniae, Coryne- bacterium, and streptococci) and gram-negative bacteria (Escherichia coli, Klebsiella, Pseudomonas, Enterobacter ). Gram-positive organism infections are more common, but gram-negative infections are more serious and life- threatening. The risk of bacterial infections rises when the neutrophil count is below 500/mcL (0.5 × 109/L); the risk markedly increases when the count falls below 100/mcL (0.1 × 109/L) or when there is a prolonged duration of neu- tropenia, typically greater than 7 days. »Clinical FindingsA  thorough physical examination should be performed. Appropriate cultures (eg, blood, sputum, urine and, if indi- cated, cerebrospinal fluid) should always be obtained. Two sets of blood cultures should be drawn before starting antibiotics; if the patient has an indwelling catheter, one of the cultures should be drawn from the line. A chest radio- graph should also be obtained. »TreatmentEmpiric  antibiotic therapy needs to be initiated within 1 hour of presentation and following the collection of blood cultures in the febrile neutropenic patient. The choice of antibiotics depends on a number of different factors includ- ing the patient’s clinical status and any localizing source of infection. If the patient is clinically well, monotherapy with an intravenous beta-lactam with anti- Pseudomonas activity (cefepime, ceftazidime, imipenem/cilastatin, piperacillin/ tazobactam) should be started (see Infections in the Immu- nocompromised Patient, Chapter 30). If the patient is clini- cally ill with hypotension or hypoxia, an intravenous aminoglycoside or fluoroquinolone should be added for “double” gram-negative bacteria coverage. If there is a strong suspicion of a gram-positive organism, such as from aS aureus catheter infection, intravenous vancomycin can be given empirically. Low-risk patients may be treated with oral antibiotics in the outpatient setting. Antibiotics should be continued until the neutrophil count is rising and greater than 500/mcL (0.5 × 109/L) for at least 1 day and the patient has been afebrile for 2 days. If an organism is identified through the cultures, theCMDT22_Ch39_p1612-p1675.indd  1669 02/07/21 2:44 PMChAPTER 391670 CMDT 2022antib iotics should be adjusted to the antibiotic sensitivities of the isolate; treatment should be continued for the appro- priate period of time and at least until the neutrophil count recovers and fever resolves. For the neutropenic patient who is persistently febrile despite broad-spectrum antibiotics, an empiric antifungal drug should be added (amphotericin B, caspofungin, itra- conazole, voriconazole, or liposomal amphotericin B).Braga  CC et al. Clinical implications of febrile neutropenia guidelines in the cancer patient population. J Clin Oncol. 2019;15:25. [PMID: 30629901] Taplitz A et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443. [PMID: 29461916] ºPRIMARY CANCER TREATMENTSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSYS TEMIC CANCER THERAPYDetailed  guidelines from the NCCN for cancer treatment can be found at www.nccn.org. Use of cytotoxic drugs, hormones, antihormones, and biologic agents has become a highly specialized and increasingly effective means of treating cancer, with therapyadministered and monitored by a medical oncologist or hematologist. Selection of specific drugs or protocols for various types of cancer is usually based on results of clini- cal trials. Increasingly, newer agents are being identified that target specific molecular pathways. Yet both initial and acquired drug resistance remains a challenge. Described mechanisms of drug resistance include impaired mem- brane transport of drugs, enhanced drug metabolism, mutated target proteins, and blockage of apoptosis due to mutations in cellular proteins (see Table 39–2 for suggested agents for various cancers).TOXI CITY & DOSE MODIFICATION OF CHEMOTHERAPEUTIC AGENTSU se of chemotherapy to treat cancer is generally guided by results from clinical trials in individual tumor types. The complexity of treating cancer has increased over the last decade as more drugs, including those with targeted mechanisms of action, have been approved by the US Food and Drug Administration (FDA) and introduced into gen- eral practice. Drug side effects and toxicities must be anticipated and carefully monitored. The short- and long- term toxicities of individual drugs are listed in Tables 39–3 and 39–12. Decisions on dose modifications for toxicities should be guided by the intent of therapy. In the palliative setting where the aim of therapy is to improve symptoms and quality of life, lowering doses to minimize toxicity is commonly done. However, when the goal of treatment is cure, dosing frequency and intensity should be maintained whenever possible. Table 39–12. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Allopurinol (Xyloprim) Prevent hyperuricemia from tumor lysis syndrome600–800 mg/day orally Acute: none Delayed: rash Dexrazoxane (Zinecard) Prevent cardiomyopathy second- ary to doxorubicin; anthracy- cline-induced injection site extravasation10 times the doxorubicin dose intravenously before doxorubi- cin; 1000 mg/m2intravenously on days 1 and 2, then 500 mg/m2 intravenously on day 3Acute: nausea Delayed: myelosuppression, elevated transaminases Leucovorin Rescue after high-dose metho- trexate; in combination with 5-fluorouracil for colon cancer10 mg/m2intravenously or orally every 6 hours; 20 mg/m2or 200– 500 mg/m2intravenously before 5-fluorouracil; various dosesAcute: nausea, vomiting, diarrhea Delayed: stomatitis, fatigue Mesna (Mesnex) Prevent ifosfamide-induced hemorrhagic cystitis20% of ifosfamide dose intrave- nously at 0, 4, and 8 hours; various dosesAcute: nausea, vomiting Delayed: fatigue Palifermin (Kepivance) Prevent mucositis following chemotherapy60 mcg/kg/day intravenously for 3 days before and 3 days after chemotherapyAcute: none Delayed: rash, fever, elevated serum amylase, erythema, edema Radium (Ra)-223 dichloride (Xofigo)Symptomatic bone metastases 50 kilobecquerel/kg (1.35 microCurie/kg) intrave- nously every 4 weeks for 6 cyclesAcute: nausea, vomiting, diarrhea, peripheral edema Delayed: myelosuppression Rasburicase (Elitek) Prevent hyperuricemia from tumor lysis syndrome3–6 mg intravenously once Acute: hypersensitivity, nausea, vomiting, diarrhea, fever, headache Delayed: rash, peripheral edema (continued )CMDT22_Ch39_p1612-p1675.indd  1670 02/07/21 2:44 PMCANCER1671 CMDT 2022T able 39–12. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Bone-Modifying Agents Denosumab (Xgeva) Osteolytic bone metastasis 120 mg subcutaneously every 4 weeksAcute: nausea Delayed: hypocalcemia, hypophos- phatemia, fatigue, osteonecrosis of the jaw Pamidronate (Aredia) Osteolytic bone metastasis, hypercalcemia of malignancy90 mg intravenously every 3–4 weeks; 60–90 mg intrave- nously, may repeat after 7 daysAcute: nausea Delayed: dyspnea, arthralgia, bone pain, osteonecrosis of the jaw, nephrotoxicity, hypocalcemia Zoledronic acid (Zometa) Osteolytic bone metastasis, hypercalcemia of malignancy4 mg intravenously every 3–4 weeks; 4 mg intravenously once, may repeat after 7 days— Growt Factors Darbepoetin alfa (Aranesp)Chemotherapy-induced anemia 2.25 mcg/kg subcutaneously weekly; 500 mcg subcutaneously every 3 weeks— Epoetin alfa (Epogen, Procrit)Chemotherapy-induced anemia 40,000 units subcutaneously once weekly; 150 units/kg subcutane- ously three times a weekAcute: injection site reaction Delayed: hypertension, thromboem- bolic events, increased risk of tumor progression or recurrence Filgrastim (Neupogen) Febrile neutropenia prophylaxis, mobilization of peripheral stem cells5–10 mcg/kg/day subcutaneously or intravenously once daily, treat past nadirAcute: injection site reaction Delayed: bone pain Pegfilgrastim (Neulasta) Febrile neutropenia prophylaxis 6 mg subcutaneously once per chemotherapy cycle— Sargramostim (Leukine) Myeloid reconstitution following bone marrow transplant, mobilization of peripheral blood stem cells250 mcg/m2intravenously daily until the absolute neutrophil count is > 1500 cells/mcL (1.5 × 109/L) for 3 consecutive daysAcute: fever, rash, pruritus, nausea, vomiting, diarrhea, injection site reaction, dyspnea Delayed: asthenia, bone pain, mucositis, edema, arrhythmia1 For amifostine, levoleucovorin, pilocarpine, samarium, strontium, filgrastim-sndz, and tbo-filgrastim, see Table 39–12 in CMDT Online at www.accessmedicine.com.A  CBC including a differential count, with absolute neutrophil count and platelet count, and liver and kid- ney tests should be obtained before the initiation of chemotherapy. In patients with good performance sta- tus, normal CBCs, as well as normal liver and kidney function, drugs are started at their full dose. When the intent of chemotherapy is cure, including treatment in the adjuvant setting, every attempt should be made to schedule chemotherapy on time and at full dose. A CBC with differential may be checked at mid cycle (to determine the nadir of the absolute neutrophil and platelet counts), and liver and kidney function tests should be obtained immediately before the next cycle of chemotherapy. Dose reductions may be necessary for patients with impaired kidney or liver function depending on the clear- ance mechanism of the drug. For patients receiving chemo- therapy for palliation, bone marrow toxicity can be managed with dose reductions or delaying the next treat- ment cycle. A schema for dose modification is shown in Table 39–13.1. Bone Marrow ToxicityA.  NeutropeniaGra nulocyte colony-stimulating factor (G-CSF), given as either daily subcutaneous injections (eg, filgrastim, 300 mcg Table 39–13. A common scheme for dose modifica- tion of cancer chemotherapeutic agents.Granulocyte Count Platelet CountSuggested Drug Dosage (% of Full Dose) > 2000 cells/mcL (2 × 109/L)> 100,000/mcL (100 × 109/L)100% 1000–2000 cells/mcL (1–2 × 109/L)75,000–100,000/ mcL (75–100 × 109/L)50% < 1000 cells/mcL (1 × 109/L)< 50,000/mcL (50 × 109/L)0%(continued)CMDT22_Ch39_p1612-p1675.indd  1671 02/07/21 2:44 PMChAPTER 391672 CMDT 2022or  480 mcg) or as a one-time dose (pegfilgrastim, 6 mg) beginning 24 hours after cytotoxic chemotherapy is com- pleted, reduces the duration and severity of granulocytope- nia following cytotoxic chemotherapy (Table 39–12). The American Society of Clinical Oncology and NCCN guide- lines recommend primary prophylaxis with G-CSF when there is at least a 20% risk of febrile neutropenia or when age, medical history, and disease characteristics put the patient at high risk for complications related to myelosuppression.B.  AnemiaErythropoiesis-stimulatin g agents (ESAs) ameliorate the anemia and its associated symptoms caused by cancer che- motherapy but these drugs have untoward effects, includ- ing an increased risk of thromboembolism, and possibly a decreased survival due to cancer-related deaths as well as a shortened time to tumor progression. The FDA recom- mends that these drugs should not be used when the intent of chemotherapy is curative. Administration of red blood cell transfusions is an alternative for managing symptom- atic anemia in chemotherapy patients. ESAs can be an option in cancer patients with symptom- atic anemia undergoing palliative treatment; patient prefer- ence is important in determining when to use ESAs or transfusions. When using ESAs, treatment should not be initiated until the hemoglobin is less than 10 g/dL (100 g/L) and the ESA held when the hemoglobin is greater than 12 g/dL (120 g/L). Epoetin alfa can be given subcutaneously at a dose of 40,000 units weekly or 150 units/kg three times weekly with a target hemoglobin of 11–12 g/dL (110–120 g/L). Darbepoetin alfa is given subcutaneously at a dose of 300–500 mcg every 3 weeks or 2.25 mcg weekly with the same target hemoglobin (see Table 39–12). To have maxi- mum therapeutic effect, patients need to be iron replete. Uncontrolled hypertension is a contraindication to the use of ESAs; blood pressure must be controlled prior to initia- tion of this therapy.C.  ThrombocytopeniaDrug  management of chemotherapy-induced thrombocyto- penia is more limited. Two drugs that activate the thrombo- poietin receptor, romiplostim and eltrombopag, are FDA approved for use in idiopathic thrombocytopenia, thrombo- cytopenia related to interferon therapy of hepatitis C, and thrombocytopenia in aplastic anemia. While these agents have been used in selected cases of refractory chemotherapy- related thrombocytopenia with some reports of success, trials to date have not demonstrated convincing efficacy in patients with chemotherapy-induced thrombocytopenia and neither agent is FDA approved for this indication.2.  Cemoterapy-Induced Nausea & VomitingA numbe r of cytotoxic anticancer drugs can induce nau- sea and vomiting, which can be the most anticipated and stressful side effects for patients. Chemotherapy-induced nausea and vomiting is mediated in part by the stimulation of at least two central nervous system receptors, 5-hydroxy- tryptamine subtype 3 (5HT3) and neurokinin subtype 1 (NK1). Chemotherapy-induced nausea and vomiting can beanticipatory, occurring even before chemotherapy adminis- tration; acute, occurring within minutes to hours of chemo- therapy administration; or delayed, lasting up to 7 days. Chemotherapy drugs are classified into high, moderate, low, and minimal likelihoods of causing emesis (90%, 30–90%, 10–30%, less than 10%, respectively). Highly emetogenic chemotherapy drugs include carmustine, cisplatin, cyclo- phosphamide (at doses over 1.5 g/m2), dacarbazine, and streptozocin, or a combination of regularly dosed anthracy- clines and cyclophosphamide. Moderately emetogenic che- motherapy drugs include azacitadine, bendamustine, carboplatin, crizotinib, cyclophosphamide, cytarabine, doxo- rubicin, epirubicin, ifosfamide, irinotecan, oxaliplatin, and temozolomide. Low emetogenic drugs include bortezomib, capecitabine, dabrafenib, dasatinib, docetaxel, erlotinib, eto- poside, 5-fluorouracil, gemcitabine, hydroxyurea, lenalido- mide, methotrexate, mitomycin, paclitaxel, pemetrexed, pomalidomide, and topotecan. Drugs with minimal risk of emesis include bevacizumab, bleomycin, cetuximab, decitabine, panitumumab, rituximab, trastuzumab, and vincristine. Major advances have occurred in the development of highly effective antiemetic drugs. Antagonists to the 5HT3-receptor include alosetron, dolasetron, granisetron, ondansetron, and palonosetron, as well as ramosetron and tropisetron (neither yet available in the United States). Ondansetron can be given either intravenously (8 mg or 0.15 mg/kg) or orally (24 mg once before highly emeto- genic chemotherapy, 8 mg twice daily for moderately emetogenic chemotherapy). Doses of 8 mg can be repeated parenterally or orally every 8 hours. Dosing of granisetron is 1 mg or 0.01 mg/kg intravenously or 1–2 mg orally. Dola- setron is given once as an oral 100-mg dose. Palonosetron, a long-acting 5HT3-receptor antagonist with high affinity for the receptor, is given once at a dose of 0.25 mg intravenously, both for acute and delayed emesis. As a class of drugs, the 5HT3-receptor antagonists have the potential to cause elec- trocardiogram changes, including QT prolongation. Antagonists to the NK1-receptor are aprepitant, fosa- prepitant, and netupitant. Aprepitant is given as a 125-mg oral dose followed by an 80-mg dose on the second and third day along with a 5HT3-receptor antagonist and dexa- methasone to increase its immediate and delayed protective effect for highly emetogenic chemotherapy. Fosaprepitant, the intravenous formulation of the prodrug to aprepitant, can be given at a dose of 115 mg if followed by 2 days of aprepitant or at a dose of 150 mg if given alone. NEPA is a single-dose capsule consisting of a combination of netupitant and palonosetron. For highly emetogenic chemotherapy (eg, cisplatin), patients should be offered a four-drug regimen (a 5HT3- antagonist, dexamethasone, NK1-receptor antagonist, and olanzapine), all given on the first day (and if used, aprepi- tant given again on the second and third days with dexa- methasone and olanzapine continued on days 2–4. For moderately emetogenic chemotherapy, standard regimens include both three-drug regimens (an NK1-antagonist, a 5HT3-antagonist, and dexamethasone) or a two-drug combination (5HT3-antagonist and dexamethasone). Palonosetron is the preferred 5HT3-blocker due to its greaterCMDT22_Ch39_p1612-p1675.indd  1672 02/07/21 2:44 PMCANCER1673 CMDT 2022affinity  for the 5HT3-receptor and its longer half-life. For low emetogenic chemotherapy drugs, a single agent such as a 5HT3-antagonist or prochlorperazine or dexamethasone can be given. A 25-mg suppository form of prochlorpera- zine may be used for patients unable to swallow oral medi- cations. Another medication that is helpful for anticipatory or refractory nausea and vomiting is olanzapine, 10 mg given orally once. The importance of treating chemotherapy-induced nau- sea and vomiting expectantly and aggressively beginning with the first course of chemotherapy cannot be overem- phasized. Patients being treated in the clinic setting should always be given antiemetics for home use with written instructions as well as contact numbers to call for advice.3.  Gastrointestinal ToxicityU ntoward effects of cancer chemotherapy include damage to the more rapidly growing cells of the body such as the mucosal lining from the mouth through the gastrointesti- nal tract. Oral symptoms range from mild mouth soreness to frank ulcerations. Not uncommonly, mouth ulcerations will have superimposed candida or herpes simplex infec- tions. In addition to receiving cytotoxic chemotherapy, a significant risk factor for development of oral mucositis is poor oral hygiene and existing caries or periodontal dis- ease. Toxicity in the gastrointestinal tract usually manifests as diarrhea. Gastrointestinal symptoms can range from mild symptoms of loose stools to life-threatening diar- rhea leading to dehydration and electrolyte imbalances. Drugs most commonly associated with causing mucositis in the mouth and the gastrointestinal tract are cytarabine, 5-fluorouracil, and methotrexate. Patients undergoing treatment for head and neck can- cer with concurrent chemotherapy and radiation therapy have a very high risk of developing severe mucositis. Preventive strategies for oral mucositis include pretreat- ment dental care, particularly for all head and neck cancer patients and any cancer patient with poor dental hygiene who will be receiving chemotherapy. For patients receiving 5-fluorouracil, simple measures such as ice chips in the mouth for 30 minutes during infusion can reduce the inci- dence and severity of mucositis. Once mucositis is encoun- tered, superimposed fungal infections should be treated with topical antifungal medications (oral nystatin mouth suspensions, or clotrimazole troches) or systemic therapy (fluconazole 100–400 mg orally daily). Suspected herpetic infections can be treated with acyclovir (up to 800 mg orally five times daily) or valacyclovir (1 g orally twice daily). Mucositis may also be managed with mouthwashes; it is also important to provide adequate pain medication. Another strategy for prevention of oral mucositis is the use of palifermin, the recombinant keratinocyte growth factor inhibitor. Prophylaxis with intravenous palifermin (60 mcg/kg/day) for patients receiving high-dose chemo- therapy can reduce the incidence and duration of mucositis (Table 39–12). Diarrhea is most associated with 5-fluorouracil, capecitabine, and irinotecan as well as the tyrosine kinase inhibitors (dasatinib, imatinib, nilotinib, regorafenib, sorafenib, sunitinib) and epithelial growth factor inhibitors(cetuximab, erlotinib, panitumumab). Mild to moderate diarrhea can be managed with oral antidiarrheal medica- tion (loperamide, 4 mg initially followed by 2 mg every 2–4 hours until bowel movements are formed). Occasion- ally, severe diarrhea will cause dehydration, electrolyte imbalances, and acute kidney injury; these patients require inpatient management with aggressive intravenous hydra- tion and electrolyte replacement. Octreotide, 100–150 mcg subcutaneously three times daily, can be useful.4.  Skin ToxicityDerm atologic complications from cancer chemotherapy can include hyperpigmentation (busulfan, hydroxyurea, liposomal doxorubicin), alopecia, photosensitivity, nail changes, acral erythema, and generalized rashes. Acral erythema (hand-foot syndrome), most commonly associ- ated with administration of capecitabine, 5-fluorouracil, and liposomal doxorubicin, manifests as painful palms or soles accompanied by erythema, progressing to blistering, desquamation, and ulceration in its worst forms. Strate- gies for prevention of acral erythema include oral pyri- doxine, 200 mg daily, and applying cold packs to the extremities during chemotherapy administration. Agents targeting the epidermal growth factor pathway can cause an acne-like rash; the development of the rash may iden- tify those who will respond to the drug. Inhibitors of the tyrosine kinase pathway are also associated with a high incidence of dermatologic complications, such as rash and acral erythema.5.  Miscellaneous Drug-Specific ToxicitiesThe  toxicities of individual drugs are summarized in Tables 39–3 and 39–12; however, several of these toxicities war- rant additional mention, since they occur with frequently administered agents, and special measures are often indicated.A.  Hemorrhagic Cystitis Induced by Cyclophosphamide or IfosfamidePa tients receiving cyclophosphamide must maintain a high fluid intake prior to and following the administration of the drug and be counseled to empty their bladders fre- quently. Early symptoms suggesting bladder toxicity include dysuria and increased frequency of urination. Should microscopic hematuria develop, it is advisable to stop the drug temporarily or switch to a different alkylating agent, to increase fluid intake, and to administer a urinary analgesic such as phenazopyridine. The neutralizing agent, mesna, can be used for patients in whom cystitis develops. With severe cystitis, large segments of bladder mucosa may be shed, resulting in prolonged gross hematuria. Such patients should be observed for signs of urinary obstruc- tion and may require cystoscopy for removal of obstructing blood clots. The cyclophosphamide analog ifosfamide can cause severe hemorrhagic cystitis when used alone. How- ever, when its use is followed by a series of doses of the neutralizing agent mesna, bladder toxicity can be pre- vented (Table 39–12).CMDT22_Ch39_p1612-p1675.indd  1673 02/07/21 2:44 PMChAPTER 391674 CMDT 2022B.  Neuropathy Due to Vinca Alkaloids and Other Chemotherapy DrugsNeur opathy is caused by a number of different chemo- therapy drugs, the most common being vincristine. The peripheral neuropathy can be sensory, motor, autonomic, or a combination of these types. In its mildest form, it con- sists of paresthesias of the fingers and toes. Occasionally, acute jaw or throat pain can develop as a form of trigeminal or glossopharyngeal neuralgia. With continued vincristine therapy, the paresthesias extend to the proximal interpha- langeal joints, hyporeflexia appears in the lower extremi- ties, and significant weakness can develop. Other drugs in the vinca alkaloid class as well as the taxane drugs (docetaxel and paclitaxel) and agents to treat myeloma (bortezomib and thalidomide) cause similar toxicity. Constipation is the most common symptom of auto- nomic neuropathy associated with the vinca alkaloids. Patients receiving these drugs should be started on mild cathartics and other agents (Table 15–4); otherwise, severe impaction may result from an atonic bowel. More serious autonomic involvement can lead to acute intestinal obstruction with signs indistinguishable from those of an acute abdomen. Bladder neuropathies are uncommon but may be severe. These two complications are absolute con- traindications to continued vincristine therapy.C.  Methotrexate ToxicityMethotr exate, a folate antagonist, is a commonly used component of regimens to treat patients with leptomenin- geal disease, acute lymphoblastic leukemia, and sarcomas. Methotrexate is almost entirely eliminated by the kidney. Methotrexate toxicity affects cells with rapid turnover, including the bone marrow and mucosa resulting in myelosuppression and mucositis. Methotrexate can also damage the liver and kidney manifesting as elevated serum liver enzymes and creatinine. High-dose methotrexate, usually defined as a dose of 500 mg/m2or more given over 4–36 hours, would be lethal without “rescue” of the normal tissues. Leucovorin, a form of folate, will reverse the toxic effects of methotrexate and is given until serum methotrex- ate levels are in the safe range (less than 0.05 mmol/L). It is crucial that high-dose methotrexate and leucovorin are given precisely according to protocol as deviations of the timing of methotrexate delivery or delay in rescue can result in death. In a patient with kidney disease or an effu- sion, prolonged rescue with leucovorin is necessary. Vigorous hydration and bicarbonate loading can help prevent crystallization of high-dose methotrexate in the renal tubular epithelium and consequent nephrotoxicity. Daily monitoring of the serum creatinine is mandatory. If possible, drugs impairing methotrexate excretion, such as aspirin, nonsteroidal anti-inflammatory drugs, amio- darone, omeprazole, penicillin, phenytoin, and sulfa, should be stopped before methotrexate administration.D . Cardiotoxicity from Anthracyclines and Other Chemotherapy DrugsA  number of cancer chemotherapy drugs are associated with cardiovascular complications including traditionaldrugs such as anthracyclines as well as new targeted agents. The anthracycline drugs, including doxorubicin, daunomycin, epirubicin, and idarubicin, can produce acute (during administration), subacute (days to months following administration), and delayed (years following administration) cardiac toxicity. The most feared compli- cation is the delayed development of heart failure. Risk factors for this debilitating toxicity include the anthracy- cline cumulative dose, age over 70, previous or concurrent irradiation of the chest, preexisting cardiac disease, and concurrent administration of chemotherapy drugs such as trastuzumab. The problem is greatest with doxorubicin because it is the most commonly administered anthracy- cline due to its major role in the treatment of lymphomas, sarcomas, breast cancer, and certain other solid tumors. Patients receiving anthracyclines should have an assessment of left ventricular ejection fraction (LVEF). If the LVEF is greater than 50%, anthracyclines can be administered; if the LVEF is less than 30%, these drugs should not be given. For patients with intermediate values, anthracyclines can be cautiously given, if necessary, at lower doses with LVEF monitoring between doses. In general, patients should not receive doses in excess of 450 mg/m2; the dose should be lower if prior chest radiotherapy has been given. Unfortu- nately, toxicity may be irreversible and frequently fatal at total dosage levels above 550 mg/m2. At lower doses (eg, 350 mg/m2), the symptoms and signs of cardiac failure gen- erally respond well to medical therapy and discontinuation of the anthracycline. Doxorubicin and daunomycin have been formulated as liposomal products; these drugs, approved for use in patients with Kaposi sarcoma and sometimes in other cancers as a substitute for the conventional anthracy- clines, appear to have less potential for cardiac toxicity. As molecular mechanisms for cancer have been increas- ingly delineated, therapies have been developed that better target these mechanisms. Therapies targeting oncogenic pathways include (1) HER2 inhibitors (lapatinib, pertu- zumab, trastuzumab, ado-trastuzumab emtansine); (2) VEGF signaling pathway inhibitors (afilbercept, axitinib, bevacizumab, cabozantinib, lenvatinib, pazopanib, ramuci- rumab, regorafenib, sorafenib, sunitinib, vandetanib); (3) multitargeted tyrosine kinase inhibitors (dasatinib, nilo- tinib, ponatinib); (4) proteasome inhibitors (bortezomib, carfilzomib); and (5) immune checkpoint inhibitors (atezolizumab, durvalumab, ipilimumab, nivolumab, pem- brolizumab). Many of the pathways targeted by these drugs share a common biologic pathway in cardiac tissue. Untow- ard cardiac events are being increasingly reported with these agents, including arrhythmias, cardiac ischemia, myocarditis, thrombosis, and heart failure.E.  Cisplatin Nephrotoxicity and NeurotoxicityCispla tin is effective in treating testicular, bladder, head and neck, lung, and ovarian cancers. With cisplatin, the serious side effects of nephrotoxicity and neurotoxicity must be anticipated and aggressively managed. Patients must be vigorously hydrated prior to, during, and after cis- platin administration. Both kidney function and electro- lytes must be monitored. Low serum magnesium, potassium, and sodium levels can develop. The neurotoxicity is usuallyCMDT22_Ch39_p1612-p1675.indd  1674 02/07/21 2:44 PMCANCER1675 CMDT 2022mani fested as a peripheral neuropathy of mixed sensorimo- tor type and may be associated with painful paresthesias. Development of neuropathy typically occurs after cumula- tive doses of 300 mg/m2. Ototoxicity is a potentially serious manifestation of neurotoxicity and can progress to deafness. The second-generation platinum analog, carboplatin, is non-nephrotoxic, although it is myelosuppressive. In the setting of preexisting kidney disease or neuropathy, carbo- platin is occasionally substituted for cisplatin.F . Bleomycin ToxicitySee online text at www .accessmedicine.com/cmdt.PR OGNOSISPa tients receiving chemotherapy for curative intent will often tolerate side effects with the knowledge that the treat- ment may result in eradication of their cancer. Patients receiving therapy for palliative intent often have their therapy tailored to improve quality of life while minimizingmajor side effects. A valuable sign of clinical improvement is the general well-being of the patient. Although general well-being is a combination of subjective factors (possibly partly a placebo effect) and objective factors, it nonetheless serves as a sign of clinical improvement along with improved appetite and weight gain and increased “performance status” (eg, ambulatory versus bedridden). Evaluation of factors such as activity status enables the clinician to judge whether the net effect of chemotherapy is worthwhile pal- liation (see Chapter 5).Babiker  HM et al. Cardiotoxic effects of chemotherapy: a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018;126:186. [PMID: 29759560] Okada Y et al. One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemo- therapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist. 2019;24:1593. [PMID: 31217343]CMDT22_Ch39_p1612-p1675.indd  1675 02/07/21 2:44 PM1676 CMDT 2022ACU TE INTERMITTENT PORPHYRIAE S S E N T I A L S  O F  D I A G N O S I S »Unexplained abdominal crisis, generally in young women. »Acute peripheral or central nervous system dys- function; recurrent psychiatric illnesses. »Hyponatremia. »Porphobilinogen in the urine during an attack. »General ConsiderationsTho ugh there are several different types of porphyrias, the one with the most serious consequences and the one that usually presents in adulthood is acute intermittent porphyria (AIP), which is inherited as an autosomal dominant condi- tion, though it remains clinically silent in most patients who carry a mutation in HMBS . Clinical illness usually develops in women. Symptoms begin in the teens or 20s, but onset can begin after menopause in rare cases. The disorder is caused by partial deficiency of hydroxymethylbilane synthase activ- ity, leading to increased excretion of aminolevulinic acid and porphobilinogen in the urine. The diagnosis may be elusive if not specifically considered. The characteristic abdominal pain may be due to abnormalities in autonomic innervation in the gut. In contrast to other forms of porphyria, cutaneous photosensitivity is absent in AIP . Attacks are precipitated by numerous factors, including drugs and intercurrent infec- tions. Harmful and relatively safe drugs for use in treatment are listed in Table 40–1. Hyponatremia may be seen, due in part to inappropriate release of antidiuretic hormone, although gastrointestinal loss of sodium in some patients may be a contributing factor. »Clinical FindingsA.  Symptoms and SignsPa tients show intermittent abdominal pain of varying severity, and in some instances, it may so simulate an acuteabdomen as to lead to exploratory laparotomy. Because the origin of the abdominal pain is neurologic, there is an absence of fever and leukocytosis. Complete recovery between attacks is usual. Any part of the nervous system may be involved, with evidence for autonomic and periph- eral neuropathy. Peripheral neuropathy may be symmetric or asymmetric and mild or profound; in the latter instance, it can even lead to quadriplegia with respiratory paralysis. Other central nervous system manifestations include sei- zures, altered consciousness, psychosis, and abnormalities of the basal ganglia. Hyponatremia may further cause or exacerbate central nervous system manifestations.B.  Laboratory FindingsOften  there is profound hyponatremia. The diagnosis can be confirmed by demonstrating an increased amount of porphobilinogen in the urine during an acute attack. Freshly voided urine is of normal color but may turn dark upon standing in light and air. Most families have different mutations in HMBS caus- ing AIP . Mutations can be detected in 90% of patients and used for presymptomatic and prenatal diagnosis. »PreventionA voidance of factors known to precipitate attacks of AIP— especially drugs—can reduce morbidity. Sulfonamides and barbiturates are the most common culprits; others are listed in Table 40–1 and on the Internet (www.drugs- porphyria.org). Starvation diets and prolonged fasting also cause attacks and so must be avoided. Hormonal changes during pregnancy can precipitate crises. »TreatmentT reatment with a high-carbohydrate diet diminishes the number of attacks in some patients and is a reasonable empiric gesture considering its benignity. Acute attacks may be life-threatening and require prompt diagnosis, withdrawal of the inciting agent (if possible), and treat- ment with analgesics and intravenous glucose in saline and hematin. A minimum of 300 g of carbohydrate per day should be provided orally or intravenously. Electrolyte40Reed E. Pyeritz, MD, PhDGenetic & Genomic DisordersCMDT22_Ch40_p1676-p1684.indd  1676 02/07/21 2:45 PM",
                  "CANCER1613 CMDT 2022Office  of Disease Prevention and Health Promotion. Healthy People 2030. Tobacco use objectives: reduce tobacco use in adults. https://health.gov/healthypeople/objectives-and-data/ browse-objectives/tobacco-use/reduce-current-tobacco- use-adults-tu-01Table 39–1. Estimated 10 most common cancer cases in the United States in males and females (all races).R ankMales Females Total Cases [N] = 970,250 (100 percent)Total Cases [N] = 927,910 (100 percent) 1 Prostate 248,530 (26)Breast 281,550 (30) 2 Lung and bronchus 119,100 (12)Lung and bronchus 116,660 (13) 3 Colon and rectum 79,520 (8)Colon and rectum 69,980 (8) 4 Urinary bladder 64,280 (7)Uterine corpus 66,570 (7) 5 Melanoma 62,260 (6)Melanoma 43,850 (5) 6 Kidney and renal pelvis 48,780 (5)Non-Hodgkin lymphoma 35,930 (4) 7 Non-Hodgkin lymphoma 45,630 (5)Thyroid 32,130 (3) 8 Oral cavity and pharynx 38,800 (4)Pancreas 28,480 (3) 9 Leukemia 35,530 (4)Kidney and renal pelvis 27,300 (3) 10 Pancreas 31,950 (3)Leukemia 25,560 (3) Other sites 195,870 (20)Other sites 199,900 (21) Data from the American Cancer Society, 2021.Klein WMP et al. Alcohol and cancer risk: clinical and research implications. JAMA. 2020;323:23. [PMID: 31834355] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71:7. [PMID: 33433946] »StagingThe  TNM system is the commonly used classification to stage cancer. Staging is important not only because it cor- relates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Certain characteristics of cancers, not reflected in the TNM stage, may be used to indicate prognosis and guide treat- ment. Pathologic features seen on routine histologic examina- tion for some cancers are very important; examples include the Gleason score for prostate cancer, human papillomavirus (HPV) status of oropharyngeal cancer, and grade of sarcomas. Cancer specimens should also be sent for molecular diagnostic testing and programmed death-ligand 1 (PD-L1) expression testing when appropriate. Some examples of targeted molecu- lar testing include HER2 in breast and gastric cancer, K-ras and BRAF mutations in colorectal cancer and melanoma, and epidermal growth factor receptor (EGFR) and fusion genes (ALK andROS1 ) in lung cancer.Machczyńs ki P et al. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Otorhinolaryngol. 2020;277:2407. [PMID: 32342197] »TreatmentSee  Primary Cancer Treatment section below. Table 39–2 outlines treatment choices by cancer type for those respon- sive to systemic agents, and Table 39–3 provides a listing of common chemotherapeutic agents. Table 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Acute lymphoblastic leukemia (ALL)Induction combination cemoterapy (Piladelpia cromosome–positive): Cyclophosphamide, vincristine, doxorubicin/daunorubicin, dexamethasone (hyper-CVAD) alternating with cytarabine, methotrexate; add imatinib or dasatinib or nilotinib Induction combination cemoterapy (Piladelpia cromosome–negative): Daunorubicin, vincristine, prednisone, pegaspargase, cyclophosphamide; or hyper-CVAD alternating with methotrexate and cytarabine Maintenance cemoterapy: Methotrexate, 6-mercaptopurine, vincristine, prednisone Acute myeloid leukemia (AML) Induction combination cemoterapy: Cytarabine with daunorubicin or idarubicin, with gemtuzumab ozogamicin (CD33-positive), or with midostaurin ( FLT3-mutated), or with fludarabine Alternative cemoterapy for ≥ 60 years old: Azacitidine, decitabine, or low-dose cytarabine with or without venetoclax; or Liposomal encapsulation of cytarabine and daunorubicin (therapy-related or myelodysplasia-related changes) Ivosidenib ( IDH1 mutation); or Enasidenib ( IDH2 mutation) (continued )CMDT22_Ch39_p1612-p1675.indd  1613 02/07/21 2:44 PMChAPTER 391614 CMDT 2022T able 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Chronic myeloid leukemia (CML)Nilotinib or dasatinib or imatinib or bosutinib Chronic lymphocytic leukemia (CLL)Venetoclax with obinutuzumab, or acalabrutinib with or without obinutuzumab, or ibrutinib Hairy cell leukemia Cladribine with or without rituximab1or pentostatin Hodgkin lymphoma Combination cemoterapy: Doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), or Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) Non-Hodgkin lymphoma (intermediate and high grade)Combination cemoterapy: Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab1 (CHOP-R), or Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab1(dose-adjusted R-EPOCH) (for double-/triple-hit) Non-Hodgkin lymphoma (low grade)Combination cemoterapy: Bendamustine plus obinutuzumab or rituximab1, or Cyclophosphamide, vincristine, doxorubicin, prednisone, rituximab1(CHOP-R), or Cyclophosphamide, vincristine, prednisone, rituximab1(CVP-R), or Lenalidomide, rituximab1Plasma  cell myeloma Combination cemoterapy (transplant candidates): Bortezomib, dexamethasone, cyclophosphamide, or Bortezomib, dexamethasone, lenalidomide Followed by autologous or mini-allogeneic stem cell transplantation Combination cemoterapy (non-transplant candidates): Bortezomib, lenalidomide, dexamethasone, or Daratumumab, lenalidomide, dexamethasone, or Lenalidomide, dexamethasone, or Bortezomib, cyclophosphamide, dexamethasone Waldenström macroglobulinemiaPlasmaperesis alone or followed by combination cemoterapy: Ibrutinib with or without rituximab1Bortezomib,  dexamethasone, rituximab1, or Cyclophosphamide, dexamethasone, rituximab1, or Bendamustine, rituximab1Poly cythemia vera Phlebotomy or hydroxyurea or aspirin Non–small cell lung cancer Combination terapy: Cisplatin, etoposide, or Paclitaxel, carboplatin, or Cisplatin, gemcitabine or docetaxel (squamous histology), or Cisplatin, pemetrexed (nonsquamous histology), or Carboplatin, albumin-bound paclitaxel, or Dabrafenib/trametinib ( BRAF V600F mutation), or Carboplatin or cisplatin/pemetrexed/pembrolizumab (nonsquamous); carboplatin/paclitaxel or albumin-bound paclitaxel/pembrolizumab (squamous) Single-agent terapy: Erlotinib, gefitinib, osimertinib, afatinib, or dacomitinib ( EGFR mutation positive) Crizotinib, alectinib, ceritinib, or brigatinib ( ALKmutation positive) Ceritinib, crizotinib, or entrectinib ( ROS1 rearrangement) Larotrectinib or entrectinib ( NTRK gene fusion positive) Pembrolizumab (PD-L1 ≥ 1%) or atezolizumab (PD-L1 ≥ 50%) Small cell lung cancer Combination terapy: Cisplatin, etoposide (limited stage), or Cisplatin, etoposide, durvalumab (extensive stage), or Carboplatin, etoposide, atezolizumab or durvalumab (extensive stage) Mesothelioma Combination terapy: Cisplatin or carboplatin/pemetrexed with or without bevacizumab, or Nivolumab/ipilimumab (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1614 02/07/21 2:44 PMCANCER1615 CMDT 2022T able 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Head and neck cancer Cisplatin with radiation therapy, or Carboplatin with 5-fluorouracil with radiation therapy, or Docetaxel, cisplatin, 5-fluorouracil, or Cisplatin or carboplatin/5-fluorouracil/cetuximab, or Pembrolizumab (PD-L1 ≥ 1%), or Pembrolizumab/cisplatin or carboplatin/5-fluorouracil Esophageal and esophagogastric junction cancerCombination terapy: Cisplatin, 5-fluorouracil or capecitabine, or Paclitaxel, carboplatin, or Oxaliplatin, 5-fluorouracil or capecitabine, or 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) Add trastuzumab for HER2 -overexpressing metastatic adenocarcinoma Uterine cancer hormone terapy: Progestins, tamoxifen, aromatase inhibitors, or fulvestrant Combination cemoterapy: Carboplatin, paclitaxel Carboplatin, paclitaxel, trastuzumab ( HER2 positive) Ovarian cancer Combination cemoterapy: Paclitaxel, carboplatin, with or without bevacizumab, or 5-Fluorouracil/leucovorin or capecitabine, oxaliplatin Cervical cancer Wit radiation: Cisplatin or carboplatin Combination cemoterapy: Cisplatin or carboplatin, paclitaxel with or without bevacizumab Breast cancer Adjuvant ormone terapy: Premenopausal: Tamoxifen Postmenopausal: Aromatase inhibitors (anastrozole, letrozole, exemestane) Adjuvant cemoterapy ( HER2 negative): Doxorubicin, cyclophosphamide, followed by paclitaxel, or Docetaxel, cyclophosphamide Adjuvant cemoterapy ( HER2 positive): Doxorubicin, cyclophosphamide, followed by paclitaxel, trastuzumab with or without pertuzumab, or Docetaxel, carboplatin, trastuzumab with or without pertuzumab, or Paclitaxel, trastuzumab Gestational trophoblastic neoplasiaSingle-agent cemoterapy: Methotrexate or dactinomycin for low-risk disease Combination cemoterapy: Etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine (EMA-CO) for high-risk disease Testicular cancer Combination cemoterapy: Cisplatin, etoposide (EP), or Bleomycin, etoposide, cisplatin (BEP), or Etoposide, mesna, ifosfamide, cisplatin (VIP) Kidney (renal cell) cancer Clear cell istology: Axitinib plus pembrolizumab, ipilimumab plus nivolumab, pazopanib, sunitinib, or cabozantinib Non–clear cell istology: Sunitinib Bladder cancer Combination cemoterapy: Gemcitabine, cisplatin, or Methotrexate, vinblastine, doxorubicin, cisplatin (MVAC), or Atezolizumab, or pembrolizumab, or gemcitabine plus carboplatin (cisplatin ineligible) Prostate cancer hormone terapy: Luteinizing hormone–releasing agonist (leuprolide, goserelin, triptorelin, histrelin), or degarelix with or without an antiandrogen (flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide) or abiraterone Cemoterapy: Docetaxel or cabazitaxel or mitoxantrone with corticosteroid Brain cancer (anaplastic astro- cytoma and glioblastoma multiforme)Single-agent cemoterapy wit radiation terapy: Temozolomide Neuroblastoma Combination cemoterapy: Cyclophosphamide, doxorubicin, cisplatin, etoposide Thyroid cancer Single-agent terapy: Radioiodine (131I) or sorafenib, lenvatinib, vandetanib (medullary thyroid cancer) or cabozantinib (medullary thyroid cancer) Adrenal cancer Cisplatin or carboplatin with etoposide, with or without doxorubicin, with or without mitotane (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1615 02/07/21 2:44 PMChAPTER 391616 CMDT 2022T able 39–2. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Stomach (gastric) cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) (perioperative) 5-Fluorouracil or capecitabine with oxaliplatin or cisplatin Add trastuzumab for HER2 -overexpressing adenocarcinomas Pancreatic cancer Combination cemoterapy: Gemcitabine, nab-paclitaxel, or 5-Fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX), or Gemcitabine, capecitabine, or Gemcitabine, cisplatin (for BRCA1/2 orPALB2 mutation) Single-agent cemoterapy: Gemcitabine Colon cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin (FOLFOX) with or without bevacizumab, or Capecitabine, oxaliplatin (CAPEOX) with or without bevacizumab, or 5-Fluorouracil, leucovorin, irinotecan (FOLFIRI) with or without bevacizumab 5-Fluorouracil, leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) with or without bevacizumab Cetuximab or panitumumab added to FOLFOX or FOLFIRI for KRAS/NRAS/BRAF wild-type and left-sided tumors Capecitabine or 5-fluorouracil/leucovorin with or without bevacizumab Single-agent terapy: Nivolumab or pembrolizumab (deficient mismatch repair [dMMR]/high-level microsatellite instability [MSI-H]) Rectal cancer 5-Fluorouracil or capecitabine or FOLFOX or CAPEOX Anal cancer Mitomycin with 5-fluorouracil or capecitabine with radiation Carboplatin, paclitaxel with or without radiation therapy Carcinoid Octreotide LAR or lanreotide or everolimus or lutetium Lu 177-dotatate Osteosarcoma Combination cemoterapy: Cisplatin, doxorubicin, or Methotrexate, doxorubicin, cisplatin (MAP) Soft tissue sarcomas Combination cemoterapy: Doxorubicin, dacarbazine (AD), or Doxorubicin, ifosfamide, mesna (AIM), or Ifosfamide, epirubicin, mesna Single-agent terapy: Imatinib or sunitinib or regorafenib (gastrointestinal stromal tumors) Doxorubicin or epirubicin or liposomal doxorubicin Melanoma Pembrolizumab or nivolumab or nivolumab/ipilimumab (non- BRAF mutation) Dabrafenib/trametinib or vemurafenib/cobimetinib or encorafenib/binimetinib ( BRAF mutation) Hepatocellular cancer Sorafenib or lenvatinib or atezolizumab with bevacizumab Kaposi sarcoma Liposomal doxorubicin1 In patients with past hepatitis B virus (HBV) infection, rituximab should be used with anti-HBV agent (eg, entecavir) prophylax is since HBV reactivation, fulminant hepatitis, and, rarely, death can occur otherwise.T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating Agents—Nitrogen Mustards Bendamustine (Treanda) 100–120 mg/m2intravenously every 3–4 weeks Acute: hypersensitivity, nausea, vomiting Delayed: myelosuppression, rash, pyrexia, fatigue Cyclophosphamide (Cytoxan)500–1000 mg/m2intravenously every 3 weeks; 100 mg/m2/day orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, alopecia, hemorrhagic cystitis, cardiotoxicity (high dose) Ifosfamide (Ifex) 1200 mg/m2intravenously daily for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: alopecia, myelosuppression, hemorrhagic cystitis, neurotoxicity (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1616 02/07/21 2:44 PMCANCER1617 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating Agents—Platinum Analogs Carboplatin (Paraplatin) Area under the curve (AUC)–based dosing use Calvert equation [Dose (mg) = AUC × (GFR + 25)] AUC = 2–7 mg/mL/min every 2–4 weeksAcute: nausea and vomiting Delayed: myelosuppression, electrolyte disturbances, peripheral neuropathy, nephrotoxicity, hypersensitivity Cisplatin (Platinol) 50–100 mg/m2intravenously every 3–4 weeks; 20 mg/m2/day intravenously for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression, electrolyte disturbances Oxaliplatin (Eloxatin) 85–130 mg/m2intravenously every 2–3 weeks Acute: peripheral neuropathy exacerbated by cold, nausea, vomiting, diarrhea Delayed: myelosuppression, elevated transaminases Alkylating Agents—Triazenes Dacarbazine (DTIC-Dome) 375 mg/m2intravenously on days 1 and 15 every 4 weeks; 900–1000 mg/m2intrave- nously over 3 to 4 days; various dosesAcute: nausea, vomiting, photosensitivity Delayed: myelosuppression, anorexia, hypotension, flu-like syndrome Procarbazine (Matulane) 60–100 mg/m2orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, disulfiram-like reaction, MAO inhibition, rash Temozolomide (Temodar) 75 mg/m2orally daily during radiation for 42 days; 150–200 mg/m2orally for 5 days every 4 weeksAcute: nausea, vomiting, constipation Delayed: myelosuppression, fatigue Antimetabolites—Folate Antagonists Methotrexate (MTX; Trexall)Intratecal: 12 mg hig dose: 1000–12,000 mg/m2intravenously every 2–3 weeksAcute: nausea, vomiting, mucositis Delayed: myelosuppression, nephrotoxicity, hepatotoxicity, neurotoxicity, photosensitivity, pulmonary toxicity Pemetrexed (Alimta) 500 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, fatigue, mucositis Antimetabolites—Purine Analogs Fludarabine (Fludara) 25 mg/m2intravenously for 5 days every 4 weeksAcute: fever, nausea, vomiting Delayed: asthenia, myelosuppression, immunosuppression, neurotoxicity, anorexia Mercaptopurine (6-MP; Purinethol)Induction: 2.5–5 mg/kg/day orally Maintenance: 1.5–2.5 mg/kg/day orallyAcute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, immunosuppression, hepatotoxicity, mucositis Antimetabolites—Pyrimidine Analogs Azacitidine (Vidaza) 75–100 mg/m2subcutaneously or intravenously for 7 days every 4 weeksAcute: injection site reaction (subcutaneously), nausea, diarrhea, fever Delayed: myelosuppression, dyspnea, arthralgia Capecitabine (Xeloda) 1000–1250 mg/m2orally twice a day for 14 days every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: hand-foot syndrome, mucositis, hyperbilirubinemia, myelosuppression Cytarabine (Ara-C, Cytosar U)Standard dose: 100 mg/m2/day intravenously via continuous infusion for 7 days hig dose: 1000–3000 mg/m2intravenously every 12 hours for 2–6 daysAcute: nausea, vomiting, rash, flu-like syndrome Delayed: myelosuppression High-dose: neurotoxicity, ocular toxicities Decitabine (Dacogen) 15 mg/m2intravenously every 8 hours for 3 days every 8 weeks; 20 mg/m2intravenously daily for 5 daysAcute: nausea, vomiting, hyperglycemia Delayed: myelosuppression, fever, fatigue, cough Fluorouracil (Adrucil) 400 mg/m2intravenous bolus followed by 2400 mg/m2intravenously over 46 hours every 2 weeks; 1000 mg/m2intravenously via continuous infusion for 4–5 days every 3–4 weeks; various dosesAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, hand-foot syndrome, mucositis, photosensitivity, cardiotoxicity (rare) (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1617 02/07/21 2:44 PMChAPTER 391618 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Antimetabolites—Pyrimidine Analogs (cont.) Gemcitabine (Gemzar) 1000–1250 mg/m2intravenously on days 1 and 8 every 3 weeks or days 1, 8, 15 every 4 weeksAcute: nausea, vomiting, rash, flu-like symptoms, fever, diarrhea Delayed: myelosuppression, edema, elevated transaminases Antimicrotubules—Vinca Alkaloids Vinblastine (Velban) 6 mg/m2intravenously on days 1 and 15 every 4 weeks; various dosesAcute: constipation Delayed: myelosuppression, alopecia, bone pain, malaise Vincristine (Oncovin) 0.5–1.4 mg/m2intravenously every 3 weeks; various doses; maximum single dose usually limited to 2 mgAcute: constipation, nausea Delayed: peripheral neuropathy, alopecia Antimicrotubules—Taxanes Docetaxel (Taxotere) 60–100 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, hypersensitivity, rash Delayed: myelosuppression, asthenia, peripheral neuropathy, alopecia, edema, mucositis Paclitaxel (Taxol) 135–175 mg/m2intravenously every 3 weeks; 50–80 mg/m2intravenously weekly; various dosesAcute: diarrhea, nausea, vomiting, hypersensitivity Delayed: myelosuppression, peripheral neuropathy, alopecia, mucositis, arthralgia Paclitaxel protein-bound (Abraxane)100–125 mg/m2on days 1, 8, 15 every 3–4 weeks; 260 mg/m2intravenously every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, peripheral neuropathy, alopecia, asthenia Enzyme Inibitors—Antracyclines Daunorubicin (Cerubidine) 30–60 mg/m2intravenously for 3 days Acute: nausea, vomiting, diarrhea, red/orange discoloration of urine, infusion-related reactions (liposomal products) Delayed: myelosuppression, mucositis, alopecia, hand-foot syndrome (liposomal doxorubicin), cardiotoxicity (dose related) Doxorubicin (Adriamycin) 45–75 mg/m2intravenously every 3 weeks; various doses Epirubicin (Ellence) 60–120 mg/m2intravenously every 3–4 weeks Idarubicin (Idamycin) 10–12 mg/m2intravenously for 3 days Liposomal doxorubicin (Doxil, Lipodox)20–50 mg/m2intravenously every 3–4 weeks Enzyme Inibitors—Topoisomerase Inibitors Etoposide (Vepesid) 50–100 mg/m2intravenously for 3–5 days every 3 weeksAcute: nausea, vomiting, diarrhea, hypersensitivity, fever, hypotension Delayed: myelosuppression, alopecia, fatigue Irinotecan (Camptosar) 180 mg/m2intravenously every other week; various dosesAcute: diarrhea, cholinergic syndrome, nausea, vomiting Delayed: myelosuppression, alopecia, asthenia Targeted Terapy—Monoclonal Antibodies Atezolizumab (Tecentriq) 1200 mg intravenously every 3 weeks Acute: infusion-related reaction Delayed: immune-mediated reactions, fatigue, decreased appetite Bevacizumab (Avastin) 5–15 mg/kg intravenously every 2–3 weeks Acute: infusion-related reaction Delayed: hypertension, proteinuria, wound healing compli- cations, gastrointestinal perforation, hemorrhage Cetuximab (Erbitux) Loading dose 400 mg/m2intravenously, maintenance dose 250 mg/m2intravenously weeklyAcute: infusion-related reaction, nausea, diarrhea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychial inflammation, dyspnea Daratumumab (Darzalex) 16 mg/kg intravenously weekly for weeks 1–8, every 2 weeks for weeks 9–24, and every 4 weeks from week 25 until disease progressionAcute: infusion-related reaction, nausea Delayed: myelosuppression, fatigue, upper respiratory tract infection (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1618 02/07/21 2:44 PMCANCER1619 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted Terapy—Monoclonal Antibodies (cont.) Ipilimumab (Yervoy) 1–10 mg/kg intravenously every 3 weeks for a total of four dosesAcute: infusion-related reaction Delayed: immune-related reactions, fatigue Nivolumab (Opdivo) 240 mg intravenously every 2 weeks or 480 mg every 4 weeksAcute: vomiting Delayed: fatigue, musculoskeletal pain, rash, pruritus, cough, elevated transaminases Obinutuzumab (Gazyva) Cycle 1: 100 mg intravenously on day 1, 900 mg on day 2, 1000 mg on days 8 and 15 of a 28-day cycle; cycles 2–6: 1000 mg intrave- nously on day 1Acute: infusion-related reaction, tumor lysis syndrome Delayed: myelosuppression, pyrexia, cough, musculoskeletal disorder, potential hepatitis B reactivation Panitumumab (Vectibix) 6 mg/kg intravenously every 2 weeks Acute: infusion-related reaction, nausea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychia, fatigue, dyspnea Pembrolizumab (Keytruda) 200 mg intravenously every 3 weeks or 400 mg every 6 weeksAcute: infusion-related reaction, nausea Delayed: immune-mediated reactions, fatigue, cough Pertuzumab (Perjeta) 840 mg intravenously once followed by 420 mg intravenously every 3 weeksAcute: infusion-related reaction, diarrhea, nausea Delayed: fatigue, alopecia, neutropenia, rash, peripheral neuropathy, cardiomyopathy Rituximab (Rituxan) 375 mg/m2intravenously weekly for 4 weeks, or every 3–4 weeksAcute: infusion-related reaction, tumor lysis syndrome Delayed: lymphopenia, asthenia, rash, potential hepatitis B reactivation Trastuzumab (Herceptin) Initial dose 4 mg/kg intravenously, then 2 mg/kg intravenously weekly; or initial dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeksAcute: headache, nausea, diarrhea, infusion-related reaction Delayed: myelosuppression, pyrexia, cardiomyopathy, pulmonary toxicity (rare) Targeted Terapy—Kinase Inibitors Acalabrutinib 100 mg orally twice daily Acute: diarrhea Delayed: myelosuppression, upper respiratory infection, musculoskeletal pain Afatinib (Gilotrif) 40 mg orally once daily without food Acute: diarrhea Delayed: acneiform rash, stomatitis, paronychia Alectinib (Alecensa) 600 mg orally twice daily with food Acute: none Delayed: myelosuppression, fatigue, edema, myalgia, dyspnea, elevated transaminases Axitinib (Inlyta) 5–10 mg orally twice daily Acute: diarrhea, nausea, vomiting Delayed: hypertension, fatigue, dysphonia, hand-foot syndrome, elevated transaminases Bosutinib (Bosulif) 500–600 mg orally once daily with food Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, rash, abdominal pain, hepatotoxicity, fluid retention Ceritinib (Zykadia) 740 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: elevated transaminases, abdominal pain, fatigue, decreased appetite Cobimetinib (Cotellic) 60 mg orally once daily on days 1–21 of a 28-day cycleAcute: diarrhea, photosensitivity reaction, nausea, vomiting Delayed: myelosuppression, hepatotoxicity, rash, cardiomyopathy (with vemurafenib) Crizotinib (Xalkori) 250 mg orally twice daily Acute: nausea, vomiting, diarrhea, constipation Delayed: vision disorder, edema, elevated transaminases, fatigue Dabrafenib (Tafinlar) 150 mg orally twice daily without food Acute: headache Delayed: hyperkeratosis, fever, hand-foot syndrome, hyperglycemia, hypophosphatemia Dacomitinib (Vizimpro) 45 mg orally once daily Acute: diarrhea Delayed: rash, paronychia, mucositis, cough, interstitial lung disease (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1619 02/07/21 2:44 PMChAPTER 391620 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted Terapy—Kinase Inibitors (cont.) Dasatinib (Sprycel) 100–180 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, fluid retention, fatigue, dyspnea, musculoskeletal pain, rash Entrectinib (Rozlytrek) 600 mg orally daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, heart failure, potential for birth defects, hepatotoxicity, vision disorder, prolonged QT interval (rare) Erlotinib (Tarceva) 100 or 150 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: acneiform skin rash, fatigue, anorexia, dyspnea Gefitinib (Iressa) 250 mg orally once daily Acute: diarrhea Delayed: acneiform skin rash Ibrutinib (Imbruvica) 420 or 560 mg orally once daily Acute: diarrhea, nausea Delayed: myelosuppression, fatigue, edema, rash, elevated serum creatinine, hemorrhage Imatinib (Gleevec) 100–800 mg orally once daily with food Acute: nausea, vomiting, diarrhea Delayed: edema, muscle cramps, rash, myelosuppression, hepatotoxicity Larotrectinib (Vitrakvi) 100 mg orally twice daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, potential for birth defects, hepatotoxicity Lenvatinib (Lenvima) 24 mg orally daily Acute: hypertension, nausea, vomiting, diarrhea Delayed: fatigue, arthralgia/myalgia, stomatitis, hand-foot syndrome Nilotinib (Tasigna) 300 or 400 mg orally twice daily without food Acute: nausea, vomiting, diarrhea Delayed: rash, fatigue, myelosuppression, prolonged QT interval (rare) Osimertinib (Tagrisso) 80 mg orally once daily Acute: diarrhea Delayed: myelosuppression, rash, dry skin, nail toxicity, cardiomyopathy (rare), QTc interval prolongation (rare) Pazopanib (Votrient) 800 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: hypertension, hair color changes, hepatotoxicity, hemorrhage Regorafenib (Stivarga) 160 mg orally once daily with food (low-fat breakfast)Acute: diarrhea Delayed: asthenia, hand-foot syndrome, anorexia, hyperten- sion, mucositis, myelosuppression, hepatotoxicity Sorafenib (Nexavar) 400 mg orally twice daily without food Acute: diarrhea and nausea Delayed: fatigue, hand-foot syndrome, rash, hypertension, hemorrhage Sunitinib (Sutent) 50 mg orally once daily for 4 weeks followed by 2 weeks rest; 37.5 mg orally dailyAcute: diarrhea and nausea Delayed: hypertension, hand-foot syndrome, rash, yellow discoloration of skin, fatigue, hypothyroidism, mucositis, left ventricular dysfunction, bleeding, hepatotoxicity Trametinib (Mekinist) 2 mg orally once daily without food Acute: rash, diarrhea Delayed: elevated transaminases, lymphedema, cardiomyopathy Vemurafenib (Zelboraf) 960 mg orally twice daily Acute: nausea, hypersensitivity (rare) Delayed: photosensitivity, rash, arthralgia, alopecia, fatigue, prolonged QT interval, cutaneous squamous cell carcinoma (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1620 02/07/21 2:44 PMCANCER1621 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Miscellaneous Agents Abiraterone (Zytiga) 1000 mg orally once daily Acute: diarrhea, edema Delayed: adrenal insufficiency, hepatotoxicity, joint pain, hypokalemia Bleomycin (Blenoxane) 10 units/m2intravenously on days 1 and 15 every 28 days; 30 units intravenously on days 2, 9, and 16 every 21 daysAcute: hypersensitivity, fever Delayed: skin reaction (rash, hyperpigmentation of skin, striae), mucositis, pneumonitis Bortezomib (Velcade) 1.3 mg/m2intravenous bolus or subcutaneously on days 1, 4, 8, 11 followed by a 10-day rest, or weekly for 4 weeks followed by 13-day restAcute: nausea, vomiting, diarrhea Delayed: peripheral neuropathy, fatigue, myelosuppression Hydroxyurea (Hydrea) 20–30 mg/kg orally daily Acute: none Delayed: myelosuppression Lenalidomide (Revlimid) 5–25 mg orally once daily on days 1–21 of 28-day cycle; or continuouslyAcute: diarrhea, rash Delayed: myelosuppression, fatigue, venous thromboembolism, potential for birth defects Mitomycin (Mutamycin) 10–20 mg/m2intravenously every 4–8 weeks; 20–40 mg intravesicallyAcute: cystitis (intravesically), nausea, vomiting Delayed: myelosuppression, mucositis, anorexia Pegaspargase (Oncaspar) 2000–2500 international units/m2intramuscu- larly every 14 daysAcute: hypersensitivity Delayed: febrile neutropenia, coagulation abnormalities, hepatotoxicity, pancreatitis Venetoclax (Venclexta) 20 mg orally daily during week 1; 50 mg daily during week 2; 100 mg daily during week 3; 200 mg daily during week 4; then 400 mg orally daily thereafterAcute: diarrhea, nausea, vomiting, tumor lysis syndrome Delayed: myelosuppression, upper respiratory infections, fatigue Antiandrogens Apalutamide (Erleada) 240 mg orally daily Acute: fatigue, diarrhea Delayed: arthralgia, hot flashes, falls, peripheral edema, seizure (rare) Bicalutamide (Casodex) 50 mg orally once daily Acute: none Delayed: hot flashes, back pain, asthenia Enzalutamide (Xtandi) 160 mg orally once daily Acute: asthenia, diarrhea Delayed: hot flashes, arthralgia, peripheral edema, seizure (rare) Flutamide (Eulexin) 250 mg orally every 8 hours Acute: diarrhea Delayed: hot flashes, hepatotoxicity Nilutamide (Nilandron) 300 mg orally for 30 days, then 150 mg orally once dailyAcute: none Delayed: visual disturbances (impaired adaptation to dark), hot flashes, disulfiram-like reaction Selective Estrogen Receptor Modulators Tamoxifen (Nolvadex) 20–40 mg orally once daily Acute: none Delayed: hot flashes, vaginal discharge, menstrual irregularities, arthralgia Aromatase Inibitors Anastrozole (Arimidex) 1 mg orally once daily Acute: nausea Delayed: hot flashes, peripheral edema, asthenia, hypercholesterolemia, arthralgia/myalgia, osteoporosis Exemestane (Aromasin) 25 mg orally once daily Letrozole (Femara) 2.5 mg orally once daily (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1621 02/07/21 2:44 PMChAPTER 391622 CMDT 2022T able 39–3. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Pure Estrogen Receptor Antagonist Fulvestrant (Faslodex) 500 mg intramuscularly on days 1, 15, 29, then monthlyAcute: injection site reaction, nausea Delayed: hot flashes, bone pain, elevated transaminases LhRh Analogs Goserelin acetate (Zoladex)3.6 mg subcutaneously every month; 10.8 mg subcutaneously every 3 monthsAcute: injection site discomfort Delayed: hot flashes, tumor flare, edema, decreased libido, erectile dysfunction, osteoporosis Leuprolide (Lupron) 7.5 mg intramuscularly or subcutaneously every month; 22.5 mg intramuscularly or subcuta- neously every 3 months; 30 mg intramuscu- larly or subcutaneously every 4 months; 45 mg intramuscularly or subcutaneously every 6 months Triptorelin pamoate (Trelstar)3.75 mg intramuscularly every 4 weeks; 11.25 mg intramuscularly every 12 weeks; 22.5 mg intramuscularly every 24 weeks LhRh Antagonist Degarelix (Firmagon) 240 mg subcutaneously once, then 80 mg subcutaneously every 28 daysAcute: injection site reaction Delayed: hot flashes, weight gain, elevated transaminases, QT prolongation AV, atrioventricular; GFR, glomerular filtration rate; LHRH, luteinizing hormone–releasing hormone; MAO, monoamine oxidase; MCV , mean corpuscular volume. ºTYPES OF CANCER LUNG CANCER Sunny Wang, MD BRONCHOGENIC CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »New cough or change in chronic cough. »Dyspnea, hemoptysis, anorexia, weight loss. »Enlarging lung nodule or mass; persistent opacity, atelectasis, or pleural effusion on chest radiograph or CT scan. »Cytologic or histologic findings of lung cancer in sputum, pleural fluid, or biopsy specimen. »General ConsiderationsLung  cancer is the leading cause of cancer deaths in both men and women. The American Cancer Society estimates 228,820 new diagnoses and 135,720 deaths from lung can- cer in the United States in 2020, accounting for approxi- mately 13% of new cancer diagnoses and 22% of all cancer deaths. More Americans die of lung cancer than of colorec- tal, breast, and prostate cancers combined.Cigarette smoking causes 85–90% of cases of lung cancer. The causal connection between cigarettes and lung cancer is established not only epidemiologically but also through identification of carcinogens in tobacco smoke and analysis of the effect of these carcinogens on specific oncogenes expressed in lung cancer. Other environmental risk factors for the development of lung cancer include exposure to environmental tobacco smoke, radon, asbestos, diesel exhaust, ionizing radiation, metals (arsenic, chromium, nickel, iron oxide), and indus- trial carcinogens. A familial predisposition to lung cancer is recognized. Certain diseases are associated with an increased risk of lung cancer, including pulmonary fibrosis, chronic obstructive pulmonary disease, and sarcoidosis. The median age at diagnosis of lung cancer in the United States is 70; it is unusual under the age of 40. The combined relative 5-year survival rate for all stages of lung cancer is currently 21%. There are five main histologic categories of broncho- genic carcinoma. Squamous cell carcinomas (23% of cases, based on US SEER data 2013–2017) arise from the bronchial epithelium and often present as intraluminal masses. They are usually centrally located and can present with hemoptysis. Adenocarcinomas (50% of cases) arise from mucous glands or from any epithelial cell within or distal to the terminal bronchioles. They usually present as peripheral nodules or masses. Adenocarcinomas in situ (formerly bronchioloalveolar cell carcinomas) spread along preexisting alveolar structures (lepidic growth) with- out evidence of invasion. Large cell carcinomas (1.3% of(continued)CMDT22_Ch39_p1612-p1675.indd  1622 02/07/21 2:44 PMCANCER1623 CMDT 2022cases)  are a heterogeneous group of undifferentiated can- cers that share large cells and do not fit into other catego- ries. Large cell carcinomas are typically aggressive and have rapid doubling times. They present as central or peripheral masses. Cancers that are not better differentiated on patho- logic review other than non–small cell carcinomas (NSCLC) or carcinomas not otherwise specified make up about 13% of cases. Small cell carcinomas (13% of cases) are tumors of bronchial origin that typically begin cen- trally, infiltrating submucosally to cause narrowing of the bronchus without a discrete luminal mass. They are aggres- sive cancers that often involve regional or distant metastasis on presentation. For purposes of staging and treatment, bronchogenic carcinomas are divided into small cell lung cancer (SCLC) and the other four types, labeled NSCLC. This practical classification reflects different natural histories and differ- ent treatment. SCLC is prone to early hematogenous spread and has a more aggressive course with a median survival (untreated) of 6–18 weeks. »Clinical FindingsLun g cancer is symptomatic at diagnosis in a majority of patients. The clinical presentation depends on the type and location of the primary tumor, the extent of local spread, and the presence of distant metastases and any paraneo- plastic syndromes.A.  Symptoms and SignsAnor exia, weight loss, or asthenia occurs in 55–90% of patients presenting with a new diagnosis of lung cancer. Up to 60% of patients have a new cough or a change in a chronic cough; 6–31% have hemoptysis; and 25–40% com- plain of pain, either nonspecific chest pain or pain from bony metastases to the vertebrae, ribs, or pelvis. Local spread may cause endobronchial obstruction with atelectasis and postobstructive pneumonia, pleural effusion (12–33%), change in voice (compromise of the recurrent laryngeal nerve), superior vena cava syndrome (obstruc- tion of the superior vena cava with supraclavicular venous engorgement), and Horner syndrome (ipsilateral ptosis, miosis, and anhidrosis from involvement of the inferior cervical ganglion and the paravertebral sympathetic chain). Distant metastases to the liver are associated with asthenia and weight loss. Brain metastases (10% in NSCLC, more common in adenocarcinoma, and 20–30% in SCLC) may present with headache, nausea, vomiting, seizures, dizzi- ness, or altered mental status. Paraneoplastic syndromes are patterns of organ dys- function related to immune-mediated or secretory effects of neoplasms. These syndromes occur in 10–20% of lung cancer patients. They may precede, accompany, or follow the diagnosis of lung cancer. In patients with small cell carcinoma, the syndrome of inappropriate antidiuretic hormone (SIADH) can develop in 10–15%; in those with squamous cell carcinoma, hypercalcemia can develop in 10%. Digital clubbing is seen in up to 20% of patients at diagnosis (see Figure 6–42). Other common paraneoplastic syndromes include increased ACTH production, anemia,hypercoagulability, peripheral neuropathy, and the Lambert- Eaton myasthenic syndrome. Their recognition is important because treatment of the primary tumor may improve or resolve symptoms even when the cancer is not curable.B.  Laboratory FindingsThe diagnosis of lu ng cancer rests on examination of a tis- sue or cytology specimen. Sputum cytology is highly spe- cific but insensitive; the yield is highest when there are lesions in the central airways. While the diagnostic yield of CT-guided biopsy of peripheral nodules approaches 80–90%, the rates of pneumothorax are significant (15–30%), especially in those with emphysema. Thoracentesis (sensi- tivity 50–65%) can be used to establish a diagnosis of lung cancer in patients with malignant pleural effusions. Fine-needle aspiration (FNA) of palpable supraclavicular or cervical lymph nodes is frequently diagnostic. Fiberoptic bronchoscopy allows visualization of the major airways, cytology brushing of visible lesions or lavage of lung segments with cytologic evaluation of speci- mens, direct biopsy of endobronchial abnormalities, blind transbronchial biopsy of the pulmonary parenchyma or peripheral nodules, and FNA biopsy of mediastinal lymph nodes. The use of fluorescence bronchoscopy improves the ability to identify early endobronchial lesions, and endo- bronchial and transesophageal endoscopic ultrasound enhance the direction and yield of FNA of mediastinal nodes. Electromagnetic navigational bronchoscopy allows bronchoscopic approaches to small peripheral nodules. Mediastinoscopy, video-assisted thoracoscopic surgery (VATS), and thoracotomy may be necessary in cases where less invasive techniques fail to yield a diagnosis.C.  ImagingNear ly all patients with lung cancer have abnormal find- ings on chest radiography or CT scan (Figure 39–1). These findings are rarely specific for a particular diagnosis. Inter- pretation of characteristic findings in isolated nodules is described in Chapter 9.D . Special Examinations1. Staging—  Accurate staging is crucial (1) to provide the clinician with information to guide treatment, (2) to pro- vide the patient with accurate information regarding prog- nosis, and (3) to standardize entry criteria for clinical trials to allow interpretation of results. Staging of NSCLC uses two integrated systems and is continuously updated with the eighth edition of the AJCC/ Union for International Cancer Control (UICC) stage classification for lung cancer in effect since January 2018. TheAJCC TNM international staging system attempts a physical description of the neoplasm: T describes the size and location of the primary tumor; N describes the pres- ence and location of nodal metastases; and M refers to the presence or absence of distant metastases. These TNM stages are grouped into summary stages I–IV , and these are used to guide therapy. Many patients with stage I and stage II disease are cured through surgery. Patients with stage IIIB and stage IV disease do not benefit from surgeryCMDT22_Ch39_p1612-p1675.indd  1623 02/07/21 2:44 PMChAPTER 391624 CMDT 2022 ▲Figure 39–1. Squamous cell carcinoma of the right lung on chest radiograph (A)and CT scan (B).(Repro- duced, with permission, from Elsayes KM, Oldham SA. Introduction to Diagnostic Radiology. McGraw-Hill, 2014.) A B(T able 39–4). Patients with stage IIIA disease have locally invasive disease that may benefit from surgery in selected cases as part of multimodality therapy. SCLC is traditionally divided into two categories: limited disease (30%), when the tumor is limited to the unilateral hemithorax (including contralateral mediastinal nodes); or extensive disease (70%), when the tumor extends beyond the hemithorax (including pleural effu- sion). It is also recommended to stage SCLC according to the TNM staging system. For both SCLC and NSCLC, a complete examination is essential to exclude obvious metastatic disease to lymph nodes, skin, and bone. A detailed history is essential because the patient’s performance status is a powerful pre- dictor of disease course. All patients should have measure- ment of a complete blood count (CBC), serum electrolytes, calcium, creatinine, liver biochemical tests, lactate dehy- drogenase, and albumin.NSCLC patients being considered for surgery require meticulous evaluation to identify those with resectable disease. CT imaging is key for staging candidates for resec- tion. The sensitivity and specificity of CT imaging for identifying lung cancer metastatic to the mediastinal lymph nodes are 57% (49–66%) and 82% (77–86%), respectively. Therefore, chest CT imaging alone does not provide definitive staging information. CT imaging helps determine where to biopsy, and how the mediastinum should be sampled. Positron emission tomography (PET) using 2-[18F] fluoro-2-deoxyglucose (FDG) is an important modality for identifying metastatic foci in the mediastinum or distant sites. The sensitivity and specificity of PET for detecting mediastinal spread of primary lung cancer depend on the size of mediastinal nodes or masses. When mediastinal lymph nodes smaller than 1 cm are present, the sensitivity and specificity of PET for tumor involvement of nodes are 74% and 96%, respectively. When CT shows lymph nodes larger than 1 cm, the sensitivity and specificity are 95% and 76%, respectively. The combination of PET and CT imaging has improved preoperative staging compared with CT or PET alone. Whole body fusion PET-CT imaging is most useful toTable 39–4. Five-year survival rates for non–small cell lung cancer, based on TNM staging.Stage TNM Subset5-Year Survival for Clinical TNM5-Year Survival for Pato- logic TNM 0 Carcinoma in situ 1A1 T1aN0M0 92% 90% 1A2 T1bN0M0 83% 85% IA3 T1cN0M0 77% 80% IB T2aN0M0 68% 73% IIA T2bN0M0 60% 65% IIB T1/T2, N1M0 T3N0M053% 56% IIIA T1/T2, N2M0 T3N1M0 T4, N0/N1, M036% 41% IIIB T1/T2, N3M0 T3/T4, N2M026% 24% IIIC T3/T4, N3M0 13% 12% IVA Any T, Any N, M1a/M1b10% — IVB Any T, Any N, M1c 0% — Data from multiple sources. Modified and reproduced, with per- mission, from Detterbeck FC et al. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017;151:193. Copyright © Elsevier; and data from Goldstraw P et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;11:39.CMDT22_Ch39_p1612-p1675.indd  1624 02/07/21 2:44 PMCANCER1625 CMDT 2022confirm  lack of regional or metastatic disease in NSCLC patients who are candidates for surgical resection. Obtaining an MRI of the brain is important to rule out brain metastases in patients with SCLC and in patients with NSCLC with at least stage II disease or poorly differ- entiated histologies. 2. Preoperative assessment— See Chapter 3. 3. Pulmonary function testing— Many patients with NSCLC have moderate to severe chronic lung disease that increases the risk of perioperative complications as well as long-term pulmonary insufficiency following lung resec- tion. All patients considered for surgery require spirome- try. In the absence of other comorbidities, patients with good lung function (preoperative FEV12 L or more) are at low risk for complications from lobectomy or pneumonec- tomy. High-risk patients include those with a predicted postoperative FEV1less than 700 mL (or less than 40% of predicted FEV1). 4. Screening— Screening with low-dose helical CT scans has been shown to improve mortality rates for lung cancer. The National Lung Screening Trial, a multicenter random- ized US trial involving over 53,000 current and former heavy smokers, showed that screening annually with low- dose helical CT for 3 years yielded a 20% relative reduction in lung cancer mortality and 6.7% reduction in all-cause mortality compared to chest radiography. Given these find- ings, US professional organizations have recommended annual screening with low-dose helical CT for lung cancer. The 2021 US Preventive Services Task Force (USPSTF) recommends annual low-dose CT for smokers aged 50–80 who have at least a 20 pack-year smoking history and who either currently smoke or have quit within the last 15 years. Smoking cessation policies and efforts should be integrated with any screening program. »TreatmentA.  Non–Small Cell Lung CarcinomaSurgic al resection offers the best chance for cure of NSCLC. Clinical features that preclude complete surgical resection include extrathoracic metastases or a malignant pleural effusion; or tumor involving the heart, pericar- dium, great vessels, esophagus, recurrent laryngeal or phrenic nerves, trachea, main carina, or contralateral mediastinal lymph nodes. Accordingly, stage I and stage II patients are treated with surgical resection where possible. Stage II and select cases of stage IB are additionally recom- mended to receive adjuvant chemotherapy. Stage IIIA patients have poor outcomes if treated with resection alone. They should undergo multimodality treatment that includes chemotherapy or radiotherapy, or both. Inopera- ble stage IIIA and stage IIIB patients treated with concur- rent chemotherapy and radiation therapy have improved survival. Stage IV patients are treated with systemic ther- apy (targeted therapy, chemotherapy, or immunotherapy) or symptom-based palliative therapy, or both. Surgical approach affects outcome. In 1994, the North American Lung Cancer Study Group conducted a prospec- tive trial of stage IA patients randomized to lobectomyversus limited resection. They reported a threefold increased rate of local recurrence in the limited resection group (P= 0.008) and a trend toward an increase in overall death rate (increase of 30%, P= 0.08) and increase in cancer- related death rate (increase of 50%, P= 0.09), compared with patients receiving lobectomy. However, for patients who cannot tolerate lobectomy, a sublobar resection (wedge resection or segmentectomy) may be considered. Patients with clinical stage I primary NSCLC, who are not candidates for surgery because of significant comor- bidity or other surgical contraindication, are candidates for stereotactic body radiotherapy. Stereotactic body radio- therapy, which is composed of multiple non-parallel radia- tion beams that converge, allows the delivery of a relatively large dose of radiation to a small, well-defined target. For clinical stage I NSCLC, 3-year local control rates with ste- reotactic body radiotherapy exceed 90%, and large meta- analyses of nonrandomized data have shown 2-year survival of 70% and 5-year survival of 40%. Patients with locally advanced disease (stages IIIA and IIIB) who are not surgical candidates have improved survival when treated with concurrent chemotherapy and radiation therapy com- pared with no therapy, radiation alone, or even sequential chemotherapy and radiation. Neoadjuvant chemotherapy consists of giving antineo- plastic drugs in advance of surgery or radiation therapy. Neoadjuvant therapy can be used in select patients with stage IIIA or stage IIIB disease. Some studies suggest a survival advantage. Adjuvant chemotherapy consists of administering antineoplastic drugs following surgery or radiation ther- apy. Cisplatin-containing regimens have been shown to confer an overall survival benefit in at least stage II disease and a subset of stage IB disease where primary tumor size exceeds 4 cm. The Lung Adjuvant Cisplatin Evaluation Collaborative Group, a meta-analysis of the five largest cisplatin-based adjuvant trials, reported a 5% absolute ben- efit in 5-year overall survival with a cisplatin-containing doublet regimen following surgery ( P= 0.005) in patients with at least stage II disease. For stage IIIB and stage IV NSCLC, options for therapy include targeted therapy, cytotoxic chemotherapy, and immunotherapy (checkpoint inhibitors) (Tables 39–2 and 39–3). The approach to therapy is individualized based on molecular profiling and PD-L1 testing. Molecular profiling is offered as next-generation sequencing multi-gene assays. The key driver mutations in lung cancer currently include EGFR, ALK, BRAF, ROS1, NTRK ,MET, and RET muta- tions, but only a minority of all lung cancer cases harbor these mutations. K-ras mutation is more commonly found among smokers. Difficulties in testing may arise when only small fine-needle aspirate biopsies are obtained; to have sufficient tissue for analysis, it is recommended that clini- cians obtain core biopsies. PD-L1 expression is a flawed but actively used biomarker to assess possible response to checkpoint inhibitor therapy (specifically, programmed death-1 [PD-1] inhibitors). Targeted therapy has played a pivotal role in advanced NSCLC (Tables 39–2 and 39–3). Activating EGFR muta- tions are found in approximately 10–20% of the WhiteCMDT22_Ch39_p1612-p1675.indd  1625 02/07/21 2:44 PMChAPTER 391626 CMDT 2022popula tion and 30–48% of the Asian population and are usually found among nonsmokers to light smokers, females, and persons with nonsquamous histologies (particularly adenocarcinomas). For patients with EGFR mutations, an EGFR tyrosine kinase inhibitor (osimertinib, erlotinib, gefi- tinib, afatinib, or dacomitinib) rather than platinum-based chemotherapy is the first-line treatment. Response rates with EGFR tyrosine kinase inhibitors in patients with EGFR mutation are at least 70%, and median overall survival is estimated to be 21–33 months. Osimertinib (a third-gener- ation irreversible EGFR tyrosine kinase inhibitor) is recom- mended as first-line treatment of EGFR -mutated lung cancers. Phase 3 data show that osimertinib leads to a lon- ger duration of response, longer progression-free survival, and lower rates of severe adverse events compared to earlier generation EGFR tyrosine kinase inhibitors. Approximately 5% of all patients with NSCLC carry translocations of ALK resulting in novel fusion gene prod- ucts with oncogenic activity. For patients with ALK- rearranged lung cancers, ALK tyrosine kinase inhibitors (alectinib, ceritinib, crizotinib, brigatinib, and lorlatinib) are recommended therapeutic agents. Alectinib and briga- tinib are recommended as first-line agents in ALK - rearranged lung cancers with response rates ranging from 74% to 83%. For patients who have developed resistance to either first- or second-generation ALK inhibitors, lorlati- nib (a third-generation ALK and ROS1 tyrosine kinase inhibitor) has shown a response rate of 47%. Approxi- mately 1–2% of NSCLC harbor ROS1 rearrangements and they are usually lung adenocarcinomas found among non- smokers or light smokers. ROS1 -rearranged lung cancers respond to crizotinib ( ALK,cMET , and ROS1 tyrosine kinase inhibitor) and entrectinib (multikinase inhibitor, including ROS-1) with response rates over 70%. MET exon 14 (METex14) skipping mutations are found in 3% of lung adenocarcinomas. Capmatinib (MET inhibitor) is recom- mended as first-line treatment for patients with METex14 skipping mutation. BRAF mutations have been found in 2% of NSCLC patients. The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) has shown response rates of over 60% in patients with BRAF V600E mutations. Treatment with larotrectinib (TRKA/ B/C inhibitor) or entrectinib (multikinase inhibitor, including TRKA/B/C) is recommended for patients whose tumors reveal NTRK 1/2/3 gene fusion. Selpercatinib and pralsetinib (RET inhibitors) are recommended first-line treatments for RET fusion–positive NSCLC. Finally, K-ras mutations are found among 30% of patients with adenocar- cinomas, are associated with smoking, and indicate a poor prognosis. Early clinical trials are already under way evalu- ating the role of novel K-ras inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), in treating K-ras G12C mutated lung cancers. Immune checkpoint inhibition using PD-1 or PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab, and durvalumab) has an important role in the treatment of NSCLC (Tables 39–2 and 39–3). Checkpoint inhibitors release T cells from the inhibitory signals they receive from tumor cells via the PD-1 pathway, restoring antitumor immunity. For patients with tumors staining greater than50% for PDL-1, pembrolizumab outperforms first-line platinum-based chemotherapy, with response rates of 45% vs 28% and median progression-free survival of 10 months vs 6 months. Phase 3 trials have shown improved survival outcomes with adding pembrolizumab to platinum- doublet chemotherapy as first-line therapy for patients with advanced NSCLC regardless of PD-L1 status. If patients received chemotherapy alone as first-line treatment, PD-1 inhibitors are recommended as second-line treatment of NSCLC, regardless of PD-L1 staining intensity. However, significant side effects and toxicity have been reported with checkpoint inhibitors, especially autoimmune manifesta- tions such as hepatitis, thyroiditis, hypophysitis, colitis, pneumonitis, and type 1 diabetes mellitus. Recently, a ran- domized phase 3 trial has shown improved survival out- comes by adding durvalumab as consolidation therapy post-definitive chemoradiation for stage III NSCLCs. If no targetable mutations are found and there is inad- equate PD-L1 expression on tumor cells, patients are either offered combination immunotherapy with cytotoxic che- motherapy or cytotoxic chemotherapy alone (Table 39–2). Although not curative, chemotherapy has been shown in multiple clinical trials to provide a modest increase in over- all survival in patients with stage IIIB and stage IV NSCLC compared with supportive care alone, with the median survival increased from 5 months to a range of 8–12 months and 1-year survival rate of 30–40%. Palliative chemother- apy also leads to improved quality of life and symptom control, with first-line therapy involving a platinum-based regimen.B.  Small Cell Lung CarcinomaResponse  rates of SCLC to cisplatin and etoposide (Table 39–2) are excellent with 80–90% response in limited-stage disease (50–60% complete response), and 60–80% response in extensive-stage disease (15–20% complete response). However, remissions tend to be short-lived with a median duration of 6–8 months. Once the disease has recurred, median survival is 3–4 months. Overall 2-year survival is 20–40% in limited-stage disease and 5% in extensive-stage disease (Table 39–5). Modest improvement in survival has been achieved with the addition of a checkpoint inhibitor (atezolizumab or durvalumab) to cisplatin or carboplatin and etoposide therapy in extensive stage disease. Thoracic radiation therapy improves survival in patients with lim- ited SCLC and is given concurrently with chemotherapy. There is a high rate of brain metastasis in patients with SCLC, even following a good response to chemotherapy. Table 39–5. Median survival for small cell lung carci- noma following treatment.Stage Mean 2-Year Survival Median Survival Limited 20–40% 15–20 months Extensive 5% 8–13 months Data from multiple sources, including Van Meerbeeck JP et al. Small-cell lung cancer. Lancet. 2011;378:1741.CMDT22_Ch39_p1612-p1675.indd  1626 02/07/21 2:44 PMCANCER1627 CMDT 2022Pro phylactic cranial irradiation may be considered for patients with limited-stage disease who respond to chemo- therapy and in a subset of patients with extensive-stage disease who have had an excellent response to chemotherapy.C.  Palliative TherapyPhoto resection with the Nd:YAG laser is sometimes per- formed on central tumors to relieve endobronchial obstruc- tion, improve dyspnea, and control hemoptysis. External beam radiation therapy is also used to control dyspnea, hemoptysis, endobronchial obstruction, pain from bony metastases, obstruction from superior vena cava syn- drome, and symptomatic brain metastases. Resection of a solitary brain metastasis improves quality of life and sur- vival when combined with radiation therapy if there is no evidence of other metastatic disease. Stereotactic radia- tion therapy is offered for limited brain metastases. Repeated thoracenteses, pleurodesis, and PleurX catheter tube placement are key interventions for palliation of symptomatic malignant pleural effusions. Pain is very common in advanced disease. Meticulous efforts at pain control are essential (see Chapter 5). In addition to standard oncologic care, early referral to a palliative care specialist is recommended in advanced disease to aid in pain and other symptom management. Such palliative care can modestly improve survival. »PrognosisThe  overall 5-year survival rate for lung cancer is approxi- mately 20%. Predictors of survival include the tumor type (SCLC versus NSCLC), molecular profiling, and stage, and the patient’s performance status and weight loss in the prior 6 months. Patients with targetable mutations have better overall survival when compared with those without muta- tions due to superior efficacy of targeted drug therapy.Camidg e DR et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: sec- ond interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38:3592. [PMID: 32780660] Drilon A et al. Entrectinib in ROS1 fusion-positive non-small- cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:262. [PMID: 31838015] Ghimessy A et al. Current therapy of KRAS -mutant lung cancer. Cancer Metastasis Rev. 2020;39:1159. [PMID: 32548736] Ramalingam SS et al; FLAURA Investigators. Overall survival with osimertinib in untreated EGFR -mutated advanced NSCLC. N Engl J Med. 2020;382:41. [PMID: 31751012] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7. [PMID: 33433946] US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325:962. [PMID: 33687470]PU LMONARY METASTASISPulmonary metastasis  results from the spread of an extra- pulmonary malignant tumor through vascular or lym- phatic channels or by direct extension. Metastases usually occur via the pulmonary artery and typically present asmultiple nodules or masses on chest radiography. The radiographic differential diagnosis of multiple pulmonary nodules also includes pulmonary arteriovenous malforma- tion, infections (including abscesses, septic emboli, and atypical infections), sarcoidosis, rheumatoid nodules, and granulomatosis with polyangiitis. Metastases to the lungs are found in 20–55% of patients with various metastatic malignancies. Carcinomas of the kidney, breast, rectum, colon, and cervix and malignant melanoma are the most likely primary tumors. Lymphangitic carcinomatosis denotes diffuse involve- ment of the pulmonary lymphatic network by primary or metastatic lung cancer, probably a result of extension of tumor from lung capillaries to the lymphatics. Tumor embolization from extrapulmonary cancer (renal cell car- cinoma, hepatocellular carcinoma, choriocarcinoma) is an uncommon route for tumor spread to the lungs. Metastatic cancer may also present as a malignant pleural effusion. »Clinical FindingsA.  Symptoms and SignsSymp toms are uncommon but include cough, hemoptysis and, in advanced cases, dyspnea and hypoxemia. Symp- toms are more often referable to the site of the primary tumor.B.  Laboratory FindingsThe  diagnosis of metastatic cancer involving the lungs is usually established by identifying a primary tumor. Appro- priate studies should be ordered if there is a suspicion of any primary cancer, such as breast, thyroid, testis, colorec- tal, or prostate, for which specific treatment is available. If the history, physical examination, and initial studies fail to reveal the site of the primary tumor, attention is better focused on the lung, where tissue samples obtained by bronchoscopy, percutaneous needle biopsy, video-assisted thoracoscopic surgery (V ATS), or thoracotomy may estab- lish the histologic diagnosis and suggest the most likely primary cancer. Occasionally, cytologic studies of pleural fluid or pleural biopsy reveals the diagnosis.C.  ImagingChest  radiographs usually show multiple spherical densi- ties with sharp margins. The lesions are usually bilateral, pleural, or subpleural in location, and more common in lower lung zones. Lymphangitic spread and solitary pul- monary nodule are less common radiographic presenta- tions of pulmonary metastasis. CT imaging of the chest, abdomen, and pelvis may reveal the site of a primary tumor and will help determine feasibility of surgical resection of the metastatic lung tumors. FDG PET-CT scan is helpful in identifying the site of a primary cancer and identifying other areas of extrathoracic metastasis. »TreatmentOnce  the diagnosis has been established, management consists of treatment of the primary neoplasm and any pulmonary complications. Surgical resection of a solitaryCMDT22_Ch39_p1612-p1675.indd  1627 02/07/21 2:44 PMChAPTER 391628 CMDT 2022pulmona ry nodule is often prudent in the patient with known current or previous extrapulmonary cancer. Local resection of one or more pulmonary metastases is feasible in a few carefully selected patients with various sarcomas and carcinomas (such as testis, colorectal, and kidney). About 15–25% of metastatic solid tumor patients have metastases limited to the lungs and are surgical candidates. Surgical resection should be considered only if (1) the pri- mary tumor is under control, (2) the patient has adequate cardiopulmonary reserve to tolerate resection, (3) all meta- static tumor can be resected, (4) effective nonsurgical approaches are not available, and (5) there is no evidence of extrathoracic metastases that are not controlled. Unfa- vorable prognostic factors also include shorter disease-free interval from primary tumor treatment to presentation of metastases and a larger number of metastases. Retrospec- tive data from the International Registry of Lung Metasta- ses report an overall 5-year survival rate of 36% and 10-year survival rate of 26% after complete resection of pulmonary metastases. Patients who are not surgical can- didates but have solitary or limited metastatic disease to the lungs may be candidates for stereotactic radiotherapy, radioablation, or cryotherapy. For patients with unresect- able progressive disease, chemotherapy tailored to the pri- mary tumor can be offered, and diligent attention to palliative care is essential (see Chapter 5).Ha ndy JR et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. 2019;107:631. [PMID: 30476477] Sudarshan M et al. Current indications for pulmonary metasta- sectomy. Surg Oncol Clin N Am. 2020;29:673. [PMID: 32883466]ME SOTHELIOMAE S S E N T I A L S  O F  D I A G N O S I S »Unilateral, nonpleuritic chest pain and dyspnea. »Distant (> 20 years earlier) history of exposure to asbestos. »Pleural effusion or pleural thickening or both on chest radiographs. »Malignant cells in pleural fluid or tissue biopsy. »General ConsiderationsMeso theliomas are primary tumors arising from the sur- face lining of the pleura (80% of cases) or peritoneum (20% of cases). Numerous studies have confirmed the associa- tion of malignant pleural mesothelioma with exposure to asbestos. The lifetime risk to asbestos workers of develop- ing malignant pleural mesothelioma is as high as 10%. The latent period between exposure and onset of symptoms ranges from 20 to 40 years. The clinician should inquire about asbestos exposure through mining, milling, manu- facturing, shipyard work, insulation, brake linings,building construction and demolition, roofing materials, and other asbestos products (pipes, textiles, paints, tiles, gaskets, panels). »Clinical FindingsA.  Symptoms and SignsThe  average interval between onset of symptoms and diagnosis is 2–3 months; the median age at diagnosis is 72–74 years in Western countries. Symptoms include the insidious onset of shortness of breath, nonpleuritic chest pain, and weight loss. Physical findings include dullness to percussion, diminished breath sounds and, in some cases, digital clubbing.B.  Laboratory FindingsPleural  fluid is exudative and often hemorrhagic. Cytologic tests of pleural fluid are often negative. VATS biopsy is usu- ally necessary to obtain an adequate specimen for histo- logic diagnosis. The histologic variants of malignant pleural mesothelioma are epithelial (50–60%), sarcomatoid (10%), and biphasic (30–40%). Since distinction from benign inflammatory conditions and metastatic adenocar- cinoma may be difficult, immunohistochemical stains are important to confirm the diagnosis.C.  ImagingRadiographic  abnormalities consist of nodular, irregular, unilateral pleural thickening and varying degrees of unilat- eral pleural effusion. Sixty percent of patients have right- sided disease, while only 5% have bilateral involvement. CT scans demonstrate the extent of pleural involvement. PET-CT is used to help differentiate benign from malig- nant pleural disease, improve staging accuracy, and iden- tify candidates for aggressive surgical approaches. »ComplicationsMalignan t pleural mesothelioma progresses rapidly as the tumor spreads along the pleural surface to involve the peri- cardium, mediastinum, and contralateral pleura. The tumor may eventually extend beyond the thorax to involve abdominal lymph nodes and organs. Progressive pain and dyspnea are characteristic. Local invasion of thoracic struc- tures may cause superior vena cava syndrome, hoarseness, Horner syndrome, arrhythmias, and dysphagia. »TreatmentChemothera py is the mainstay of treatment (Tables 39–2 and 39–3), with cytoreductive surgery included in multi- modality treatment only if there is localized disease that is amenable to complete macroscopic surgical resection. The optimal surgical approach is still under debate. For local- ized disease, surgical options include pleurectomy and decortication (surgical stripping of the pleura and pericar- dium from apex of the lung to diaphragm) or extrapleural pneumonectomy (a radical surgical procedure involving removal of the ipsilateral lung, parietal and visceral pleura,CMDT22_Ch39_p1612-p1675.indd  1628 02/07/21 2:44 PMCANCER1629 CMDT 2022pericardium,  and most of the hemidiaphragm). Surgical cytoreduction alone is not sufficient, and either chemo- therapy or radiation therapy (or both) should be included in a multimodality approach. In advanced unresectable disease, palliative chemotherapy with cisplatin and peme- trexed can achieve response rates of 30–40%, can extend median overall survival to 12 months, and can improve quality of life. Adding bevacizumab (a monoclonal anti- body to vascular endothelial growth factor [VEGF]) to cisplatin and pemetrexed has been shown to further improve overall survival. Nivolumab and ipilimumab (checkpoint inhibition therapy) can also be offered as first- line treatment, with improved outcomes among those with nonepithelioid tumors. Drainage of pleural effusions, pleurodesis, radiation therapy, and even surgical resection may offer palliative benefit to some patients. »PrognosisMos t patients die of respiratory failure and complications of local extension. Median survival time from diagnosis ranges from 7 months to 17 months. Five-year survival is 5–10%. Tumors that are predominantly sarcomatoid are more resistant to therapy and have a worse prognosis, with median survivals less than 1 year. Poor prognostic features include poor performance status, non-epithelioid histol- ogy, male gender, nodal involvement, elevated lactate dehy- drogenase, high white blood cell count, low hemoglobin, and high platelet count.Sch erpereel A et al; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239. [PMID: 30660609] Scherpereel A et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55:1900953. [PMID: 32451346] Waller DA et al. Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. J Thorac Cardiovasc Surg. 2020;S0022-5223 (20)32986-X . [PMID: 33223192]hE PATOBILIARY CANCERS Lawrence S. Friedman, MD HEPATOCELLULAR CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »Usually a complication of cirrhosis. »Characteristic CT and MRI features may obviate the need for a confirmatory biopsy. »General ConsiderationsMalignan t neoplasms of the liver that arise from parenchy- mal cells are called hepatocellular carcinomas (accountingfor 85% of liver cancers); those that originate in the ductu- lar cells are called cholangiocarcinomas (15% or less). Rare tumors of the liver include angiosarcoma and lymphoma. Worldwide, hepatocellular carcinomas are the fourth most common cause of cancer-related deaths and the sixth most common in incidence. They are associated with cir- rhosis in 85% of cases. In Africa and most of Asia, hepatitis B virus (HBV) infection (including “occult” HBV infection; see Chapter 16) is a major etiologic factor, and a family history of hepatocellular carcinoma increases the risk syn- ergistically. In the United States and other Western coun- tries, incidence rates rose over twofold after 1978, with slowing of the rate increase after 2006 except in men ages 55–64, presumably because of the increasing prevalence of cirrhosis caused by chronic hepatitis C virus (HCV) infec- tion and nonalcoholic fatty liver disease (NAFLD). Rates appear to have plateaued since 2010 because of improved treatment of viral hepatitis. In Western countries, risk fac- tors for hepatocellular carcinoma in patients known to have cirrhosis are male gender, age greater than 55 years (although there has been an increase in the number of younger cases), Hispanic or Asian ethnicity, family history in a first-degree relative, overweight, obesity (especially in early adulthood), alcohol use (especially in combination with obesity), tobacco use, diabetes mellitus, hypothyroid- ism (in women), a prolonged prothrombin time, a low platelet count, and an elevated serum transferrin satura- tion. The risk of hepatocellular carcinoma is higher in persons with a viral rather than nonviral cause of cirrhosis and may be increased in persons with autoimmune dis- eases. Other associations include high levels of HBV repli- cation; HBV genotype C; hepatitis D coinfection; elevated serum ALT levels in persons with chronic hepatitis B (in whom antiviral therapy to suppress HBV replication appears to reduce the risk); HCV genotypes 1b and 3; lack of response to antiviral therapy for HCV infection; hemo- chromatosis (and possibly the C282Y carrier state); afla- toxin exposure (associated with mutation of the TP53 gene); alpha-1-antiprotease (alpha-1-antitrypsin) defi- ciency; tyrosinemia; and radiation exposure. In patients with the metabolic syndrome and NAFLD, hepatocellular carcinoma may rarely arise from nonalcoholic steatohepa- titis in the absence of cirrhosis. Hepatocellular adenoma may be a precursor for hepatocellular carcinoma (see Chapter 16). Evidence for an association with long-term use of oral contraceptives is inconclusive. Whereas sulfo- nylurea and insulin use may increase the risk of hepatocel- lular carcinoma, consumption of coffee, vegetables, white meat, fish, and n-3 polyunsaturated fatty acids; use of aspirin; and use of lipophilic HMG-CoA reductase inhibi- tors (statins) (eg, atorvastatin, simvastatin) and, in diabetic patients, metformin appear to be protective. The fibrolamellar variant of hepatocellular carcinoma generally occurs in young women and is characterized by a distinctive histologic picture, absence of risk factors, unique genomic profiles, and indolent course. Vinyl chlo- ride exposure is associated with angiosarcoma of the liver. Hepatoblastoma, the most common malignant liver cancer in infants and young children, rarely occurs in adults.CMDT22_Ch39_p1612-p1675.indd  1629 02/07/21 2:44 PMChAPTER 391630 CMDT 2022 »Clinical FindingsA.  Symptoms and SignsThe pr esence of a hepatocellular carcinoma may be unsus- pected until there is deterioration in the condition of a cirrhotic patient who was formerly stable. Cachexia, weak- ness, and weight loss are associated symptoms. The sudden appearance of ascites, which may be bloody, suggests portal or hepatic vein thrombosis by cancer or bleeding from a necrotic cancer. Physical examination may show tender enlargement of the liver, occasionally with a palpable mass. In Africa, the typical presentation in young patients is a rapidly expand- ing abdominal mass. Auscultation may reveal a bruit over the tumor or a friction rub when the tumor has extended to the surface of the liver.B.  Laboratory FindingsLabora tory tests may reveal leukocytosis, as opposed to the leukopenia that is frequently encountered in cirrhotic patients. Anemia is common, but a normal or elevated hematocrit value may be found in up to one-third of patients owing to elaboration of erythropoietin by the tumor. Sudden and sustained elevation of the serum alka- line phosphatase in a patient who was formerly stable is a common finding. HBsAg is present in a majority of cases in endemic areas, whereas in the United States anti-HCV is found in up to 40% of cases. Serum alpha-fetoprotein (AFP) levels are elevated in up to 70% of patients with hepa- tocellular carcinoma in Western countries (although the sensitivity is lower in Blacks and levels are not elevated in patients with fibrolamellar hepatocellular carcinoma); how- ever, mild elevations (10–200 ng/mL [10–200 mcg/L]) are also often seen in patients with chronic hepatitis. Serum levels of des-gamma-carboxy prothrombin are elevated in up to 90% of patients with hepatocellular carcinoma, but they may also be elevated in patients with vitamin K defi- ciency, chronic hepatitis, and metastatic cancer. Cytologic study of ascitic fluid rarely reveals malignant cells.C.  ImagingM ultiphasic helical CT and MRI with contrast enhance- ment are the preferred imaging studies for determining the location and vascularity of the tumor; MRI may be more sensitive than CT, and imaging with gadoxetic acid increases sensitivity. Lesions smaller than 1 cm may be dif- ficult to characterize. Based on stringent criteria developed by the American College of Radiology through its Liver Imaging Reporting and Data System, the Organ Procure- ment and Transplantation Network, and the American Association for the Study of Liver Diseases, arterial phase enhancement of a lesion that is greater than or equal to 1 cm in diameter followed by delayed hypointensity (“washout”) has a 90% specificity for hepatocellular carci- noma. Ultrasonography is less sensitive and more operator dependent but is used to screen for hepatic nodules in high-risk patients. Contrast-enhanced ultrasonography has a sensitivity and specificity approaching those of arterial phase helical CT but, unlike CT and MRI, cannot image theentire liver during the short duration of the arterial phase and is thus associated with false-positive results. In selected cases, endoscopic ultrasonography (EUS) may be useful. PET is under study and appears to improve detection of extrahepatic metastases.D . Liver Biopsy and StagingLiver  biopsy is diagnostic, although seeding of the needle tract by cancer is a potential risk (1–3%). For lesions smaller than 1 cm, ultrasonography may be repeated every 3 months followed by further investigation of enlarging lesions. For lesions 1 cm or larger, biopsy can be deferred when characteristic arterial hypervascularity and delayed washout are demonstrated on either multiphasic helical CT or MRI with contrast enhancement (or both) in a patient with cirrhosis or if surgical resection is planned. The TNM system is the commonly used classification to stage hepatocellular carcinoma. Staging is important not only because it correlates with the patient’s long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. The Barcelona Clinic Liver Cancer (BCLC) staging system is preferred and includes the Child-Pugh class, tumor stage, and liver function and has the advantage of linking overall stage with preferred treatment modalities and with an estimation of life expectancy. »Screening & PreventionSurveillance (screening) fo r the development of hepatocel- lular carcinoma is recommended in patients with chronic hepatitis B (beginning as early as age 20 in Africans, age 40 in Asian males or Asians with a family history of hepatocel- lular carcinoma, and age 50 in others) or cirrhosis caused by HCV , HBV , or alcohol. There is some evidence that screening for hepatocellular carcinoma leads to a survival advantage over clinical diagnosis, but only a minority of cases are detected by screening. The standard screening approach is performing ultrasonography and obtaining serum AFP level every 6 months, although AFP testing has low sensitivity. A serum AFP level of 20 ng/mL (20 mcg/L) is generally the cutoff value that should trigger further evaluation. CT and MRI are considered too expensive for screening. The sensitivity of ultrasonography for detecting early hepatocellular carcinoma is only 63%. The risk of hepatocellular carcinoma developing in a patient with cirrhosis is 3–5% a year. Among patients with cirrhosis, over 60% of nodules smaller than 2 cm in diam- eter detected on a screening ultrasonography prove to be hepatocellular carcinoma. Patients with cancers detected by surveillance have a less advanced stage on average and greater likelihood that treatment will prolong survival than those whose cancers were not detected by surveillance. However, controversy persists about whether surveillance reduces cancer-related mortality. Mass vaccination programs against HBV in developing countries are leading to reduced rates of hepatocellular carcinoma. Successful treatment of hepatitis B and of hepatitis C in patients with cirrhosis also reduces the subsequent risk of hepatocellular carcinoma, and thusCMDT22_Ch39_p1612-p1675.indd  1630 02/07/21 2:44 PMCANCER1631 CMDT 2022hepatocellular carcino ma is considered a preventable neo- plasm. However, hepatocellular carcinoma may still occur after clearance of hepatitis B surface antigen or cure of HCV infection, thereby reducing the benefit of treatment for HBV and HCV infection. »TreatmentSurgical  resection of a solitary hepatocellular carcinoma may result in cure if liver function is preserved (Child- Pugh class A or possibly B) and portal vein thrombosis is not present. Laparoscopic liver resection has been per- formed in selected cases. Treatment of underlying chronic viral hepatitis, adjuvant chemotherapy, and adaptive immunotherapy may lower postsurgical recurrence rates. Liver transplantation may be appropriate for small unre- sectable tumors in a patient with advanced cirrhosis, with reported 5-year survival rates of up to 75%. The recurrence- free survival may be better for liver transplantation than for resection in patients with well-compensated cirrhosis and small tumors (one tumor less than 5 cm or three or fewer tumors each less than 3 cm in diameter [Milan criteria]) and in those with expanded (University of California, San Francisco) criteria of one tumor less than or equal to 6.5 cm or three or fewer tumors less than or equal to 4.5 cm (or a combined tumor diameter of 8.5 cm) without vascular invasion. The Extended Toronto criteria include tumor dif- ferentiation, cancer-related symptoms, confinement of tumor to the liver, and absence of vascular invasion, without regard to tumor number or size, to determine candidacy for liver transplantation and appear to predict outcomes as well as the Milan criteria. After 6 months on the waiting list, patients with stage 2 hepatocellular carcinoma meeting the Milan criteria are awarded a fixed score of 3 points lower than the median Model for End-Stage Liver Disease (MELD) score for patients transplanted in the area where the candidate is listed (see Chapter 16), thereby increasing their chances of undergoing transplantation. However, orthotopic liver transplantation is often impractical because of donor organ shortage, so living donor liver transplanta- tion may be considered in these cases. Patients with larger tumors (3–5 cm), a serum AFP level of 1000 ng/mL (1000 mcg/L) or higher, or a MELD score of 20 or higher have poor posttransplantation survival. In patients with a serum AFP level greater than 1000 ng/mL (1000 mcg/L), down- staging by locoregional therapy to an AFP level less than 500 ng/mL (500 mcg/L) improves survival following subse- quent liver transplantation. Chemotherapy, hormonal therapy with tamoxifen, and long-acting octreotide have not been shown to prolong life, but transarterial chemoembolization (TACE), TACE with drug-eluting beads, transarterial chemoinfusion (TACI), and transarterial radioembolization (TARE) via the hepatic artery are not only palliative but may also prolong survival in patients with a large or multifocal tumor in the absence of extrahepatic spread. TACI and TARE are suitable for patients with portal vein thrombosis. TARE with yttrium-90 has been shown to result in a longer time to progression than TACE. Microwave ablation, radiofrequency ablation, cryotherapy, or injection of absolute ethanol into tumors smaller than 2 cm may prolong survival in patients who arenot candidates for resection and have tumors that are accessible; these interventions, as well as stereotactic body radiation therapy, may also provide a “bridge” to liver transplantation. Microwave ablation is becoming the pre- ferred approach because it allows shorter treatment times and, like radiofrequency ablation, can be performed after TACE in select cases. Cryoablation may result in slower tumor progression than radiofrequency ablation for tumors that are 3.1–4 cm in diameter. Stereotactic body radiation therapy is also being used to treat unresectable hepatocel- lular carcinoma and may be effective in treating lesions larger than those treated with ablation techniques. Sorafenib (an oral multikinase inhibitor of Raf kinase, the VEGF receptor, and the platelet-derived growth factor receptor [and others]) prolongs median survival as well as the time to radiologic progression by 3 months in patients with advanced hepatocellular carcinoma and until recently was the standard care in these patients. Lenvatinib is another oral multikinase inhibitor that is FDA approved for the same indications as sorafenib. However, the combi- nation of atezolizumab, an immune checkpoint inhibitor, and bevacizumab, an antibody to the VEGF receptor, has been shown to be superior to sorafenib and has become standard first-line therapy. Regorafenib is an oral multiki- nase inhibitor that provides a survival benefit for patients whose disease progresses despite sorafenib therapy, and nivolumab and pembrolizumab are immune checkpoint inhibitors that have been approved for advanced hepatocel- lular carcinoma. The combination of nivolumab and ipili- mumab has been recommended as second-line therapy after failure of sorafenib. Cabozantinib, another multiki- nase inhibitor, has been approved by the FDA for the treat- ment of hepatocellular carcinoma after prior treatment with sorafenib, as has ramucirumab, an antibody to the VEGF receptor, which is approved for patients with an AFP level greater than or equal to 400 ng/mL (400 mcg/L) and previous treatment with sorafenib. The modified Response Evaluation Criteria in Solid Tumors (mRECIST) are used to assess treatment response based on tumor shrinkage and viability after locoregional and antiangiogenic treatment. Meticulous efforts at palliative care are essential for patients in whom disease progresses despite treatment or in whom advanced tumors, vascular invasion, or extrahepatic spread are present. Severe pain may develop in such patients due to expansion of the liver capsule by the tumor and requires concerted efforts at pain management, including the use of opioids (see Chapter 5). »PrognosisIn  the United States, overall 1- and 5-year survival rates for patients with hepatocellular carcinoma are 23% and 5%, respectively. Five-year survival rates rise to 56% for patients with localized resectable disease (T1, T2, selected T3 and T4; N0; M0) but are virtually nil for those with locally unresectable or advanced disease. In patients with HCV- related hepatocellular carcinoma, the serum AFP level at the time of diagnosis of cancer has been reported to be an independent predictor of mortality. A serum AFP level greater than or equal to 200 ng/mL (200 mcg/L) or increases of greater than 15 ng/mL/month predict worseCMDT22_Ch39_p1612-p1675.indd  1631 02/07/21 2:44 PMChAPTER 391632 CMDT 2022outco mes in patients awaiting liver transplantation. In patients who are not eligible for surgery, an elevated serum C-reactive protein level is associated with poor survival. Contrary to traditional opinion, the fibrolamellar variant does not have a better prognosis than conventional hepato- cellular carcinoma without cirrhosis. »When to ReferAll  patients with hepatocellular carcinoma should be referred to a specialist. »When to Admit• Complications of cirrhosis. •Severe pain. •For surgery and other interventions.Bangaru  S et al. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51:78. [PMID: 31747082] Bruix J et al (editors). The growing burden of liver cancer. Semin Liver Dis. 2020;40:101. [Full issue] Fanwal F et al. Surveillance for hepatocellular carcinoma: cur- rent best practice and future direction. Gastroenterology. 2019;157:54. [PMID: 30986389] Shiels MS et al. Recent decline in hepatocellular carcinoma rates in the United States. Gastroenterology. 2020;158:1503. [PMID: 31962125] Simon TG et al. Association of aspirin with hepatocellular carci- noma and liver-related mortality. N Engl J Med. 2020;382:1018. [PMID: 32160663]CA RCINOMA OF THE BILIARY TRACTE S S E N T I A L S  O F  D I A G N O S I S »Presents with obstructive jaundice, usually pain- less, often with dilated biliary tract. »Pain is more common in gallbladder carcinoma than cholangiocarcinoma. »A dilated gallbladder may be palpable (Cour- voisier sign). »Diagnosis by cholangiography with biopsy and brushings for cytology. »General ConsiderationsCarcino ma of the gallbladder occurs in approximately 2% of all people operated on for biliary tract disease; the inci- dence, like that of carcinoma of the bile ducts, had been decreasing in the United States but may be increasing again in some Western countries because of lifestyle changes. It is notoriously insidious, and the diagnosis is often made unexpectedly at surgery. Cholelithiasis (often large, symp- tomatic stones) is usually present. Other risk factors are chronic infection of the gallbladder with Salmonella typhi , adenomatous gallbladder polyps over 1 cm in diameter (particularly with hypoechoic foci on EUS), mucosalcalcification of the gallbladder (porcelain gallbladder), anomalous pancreaticobiliary ductal junction, high parity in women, and aflatoxin exposure. Genetic factors include K-ras andTP53 mutations. Spread of the cancer—by direct extension into the liver or to the peritoneal surface—may be seen on initial presentation. Carcinoma of the bile ducts (cholangiocarcinoma) accounts for 10–25% of all hepatobiliary malignancies and 3% of all cancer deaths in the United States. It is more prevalent in persons aged 50–70, with a slight male pre- dominance, and more common in Asia. About 50% arise at the confluence of the hepatic ducts (perihilar, or so-called Klatskin, tumors), and 40% arise in the distal extrahepatic bile duct (the incidence of which has risen since 1990); the remainder are intrahepatic (the incidence of which rose dramatically from the 1970s to the early 2000s). Mortality from intrahepatic cholangiocarcinoma has been increas- ing. The frequency of carcinoma in persons with a chole- dochal cyst has been reported to be over 14% at 20 years, and surgical excision is recommended. Most cases of chol- angiocarcinoma are sporadic. There is an increased inci- dence of cholangiocarcinoma in patients with bile duct adenoma; Caroli disease; a biliary-enteric anastomosis; ulcerative colitis, especially those with primary sclerosing cholangitis; biliary cirrhosis; diabetes mellitus; hyperthy- roidism; chronic pancreatitis; heavy alcohol consumption; smoking; and past exposure to Thorotrast, a contrast agent. Premalignant lesions of the bile duct include biliary intraepithelial neoplasia and intraductal papillary neopla- sia of the biliary system (biliary papillomatosis). Aspirin use and statin use are associated with a reduced risk of cholangiocarcinoma, and in diabetic patients, metformin use is associated with a reduced risk of intrahepatic cholan- giocarcinoma. In Southeast Asia, hepatolithiasis, chronic typhoid carriage, and infection of the bile ducts with hel- minths (Clonorchis sinensis, Opisthorchis viverrini) are associated with an increased risk of cholangiocarcinoma. Hepatitis C virus (and possibly hepatitis B virus) infection, cirrhosis, HIV infection, nonalcoholic fatty liver disease, diabetes mellitus, obesity, and tobacco smoking are risk factors for intrahepatic cholangiocarcinoma. The TNM system is the commonly used classification to stage carcinoma of the biliary tract, including gallblad- der carcinomas and perihilar and intrahepatic cholangio- carcinomas. Staging is important not only because it correlates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Other staging systems consider the patient’s age, perfor- mance status, tumor extent and form, perineural invasion, vascular encasement, hepatic lobe atrophy, underlying liver disease, and peritoneal metastasis. »Clinical FindingsA.  Symptoms and SignsProgres sive jaundice is the most common and usually the first sign of obstruction of the extrahepatic biliary system. Pain in the right upper abdomen with radiation into the back is usually present early in the course of gallbladderCMDT22_Ch39_p1612-p1675.indd  1632 02/07/21 2:44 PMCANCER1633 CMDT 2022carcino ma but occurs later in the course of bile duct carci- noma. Anorexia and weight loss are common and may be associated with fever and chills due to cholangitis. Rarely, hematemesis or melena results from erosion of cancer into a blood vessel (hemobilia). Fistula formation between the bili- ary system and adjacent organs may also occur. The course is usually one of rapid deterioration, with death occurring within a few months. Physical examination reveals profound jaundice. Pruritus and skin excoriations are common. A palpable gallbladder with obstructive jaundice usually is said to signify malignant disease (Courvoisier sign); however, this clinical generaliza- tion has been proven to be accurate only about 50% of the time. Hepatomegaly due to hypertrophy of the unobstructed liver lobe is usually present and is associated with liver ten- derness. Ascites may occur with peritoneal implants.B.  Laboratory FindingsW ith biliary obstruction, laboratory examination reveals predominantly conjugated hyperbilirubinemia, with total serum bilirubin values ranging from 5 to 30 mg/dL. There is usually concomitant elevation of the alkaline phosphatase and serum cholesterol. AST is normal or minimally elevated. The serum CA 19-9 level is elevated in up to 85% of patients and may help distinguish cholangiocarcinoma from a benign biliary stricture (in the absence of cholangitis), but this test is neither sensitive nor specific.C.  ImagingUl trasonography and contrast-enhanced, triple-phase, heli- cal CT may show a gallbladder mass in gallbladder carci- noma and intrahepatic mass or biliary dilatation in carcinoma of the bile ducts. CT may also show involved regional lymph nodes and atrophy of a hepatic lobe because of vascular encasement with compensatory hypertrophy of the unaffected lobe. MRI with magnetic resonance cholan- giopancreatography (MRCP) and gadolinium enhancement permits visualization of the entire biliary tract and detection of vascular invasion and obviates the need for angiography and, in some cases, direct cholangiography; it is the imaging procedure of choice but may understage malignant hilar strictures. The sensitivity and image quality can be increased with use of ferumoxide enhancement. The features of intra- hepatic cholangiocarcinoma on MRI appear to differ from those of hepatocellular carcinoma, with contrast washout in the latter but not the former. In indeterminate cases, PET can detect cholangiocarcinomas as small as 1 cm and lymph node and distant metastases, but false-positive results occur. The most helpful diagnostic studies before surgery are either endoscopic retrograde cholangiography or percutaneous transhepatic cholangiography with biopsy and cytologic specimens, although false-negative biopsy and cytology results are common. Digital image analysis and fluorescent in situ hybridization of cytologic specimens for polysomy improve sensitivity. EUS with FNA of tumors, peroral chol- angioscopy, confocal laser endomicroscopy, and intraductal ultrasonography may confirm a diagnosis of cholangiocarci- noma in a patient with bile duct stricture and an otherwise indeterminate evaluation, but FNA can result in cancerseeding and should be avoided if the cancer is potentially resectable. »TreatmentIn  young and fit patients, curative surgery for gallbladder carcinoma may be attempted if the cancer is well localized. The 5-year survival rate for carcinoma of the gallbladder invading the lamina propria or muscularis (stage 1, T1a or 1b, N0, M0) is as high as 85% with laparoscopic cholecys- tectomy but drops to 60%, even with a more extended open resection, if there is perimuscular invasion (T2). The role of radical surgery for T3 and T4 tumors is debatable. If the cancer is unresectable at laparotomy, biliary-enteric bypass (eg, Roux-en-Y hepaticojejunostomy) can be performed. Carcinoma of the bile ducts is curable by surgery in less than 10% of cases. If resection margins are negative, the 5-year survival rate may be as high as 47% for intrahepatic cholangiocarcinomas, 41% for hilar cholangiocarcinoma, and 37% for distal cholangiocarcinomas, but the perioper- ative mortality rate may be as high as 10%. Factors predicting shorter survival for intrahepatic cholangiocarcinoma include large cancer size, multiple cancers, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy with capecitabine has been shown to result in superior overall survival compared with no adjuvant therapy. Pallia- tion can be achieved by placement of a self-expandable metal stent via an endoscopic or percutaneous transhepatic route. Covered metal stents may be more cost-effective than uncovered metal stents because of a longer duration of patency. However, they are associated with a higher rate of stent migration and cholecystitis due to occlusion of the cystic duct and are not associated with longer survival. For perihilar cancers, insertion of a unilateral stent rather than bilateral stents may suffice. Plastic stents are less expensive initially, but not in the long term, because they are more prone to occlude than metal ones; they may be considered in patients expected to survive only a few months. Photo- dynamic therapy in combination with stent placement prolongs survival when compared with stent placement alone in patients with nonresectable cholangiocarcinoma. Endoscopic retrograde cholangiopancreatography (ERCP)– directed radiofrequency ablation, TACE, and TARE are additional emerging options. Radiotherapy may relieve pain and contribute to biliary decompression. There is limited response to chemotherapy with gemcitabine alone, but the combination of cisplatin and gemcitabine or capecitabine and gemcitabine prolongs survival in patients with locally advanced or metastatic cholangiocarcinoma. Few patients survive for more than 24 months. Although cholangiocarcinoma is generally considered to be a contra- indication to liver transplantation because of rapid cancer recurrence, a 5-year survival rate of 75% has been reported in patients with stage I and II perihilar cholangiocarcinoma undergoing chemoradiation and exploratory laparotomy followed by liver transplantation, and a 5-year survival rate of 67% has been reported in those with intrahepatic cholangiocarcinoma. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5).CMDT22_Ch39_p1612-p1675.indd  1633 02/07/21 2:44 PMChAPTER 391634 CMDT 2022 »When to ReferAll  patients with carcinoma of the biliary tract should be referred to a specialist. »When to Admit• Biliary obstruction. •Cholangitis.Bertuccio  P et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104. [PMID: 30910538] De Martin E et al. Analysis of liver resection versus liver trans- plantation on outcome of small intrahepatic cholangiocarci- noma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020;26:785. [PMID: 32090444] Lavu S et al. Effect of statins on the risk of extrahepatic cholan- giocarcinoma. Hepatology. 2020;72:1298. [PMID: 32119126]CA RCINOMA OF THE PANCREAS & AMPULLA OF VATERE S S E N T I A L S  O F  D I A G N O S I S »Obstructive jaundice (may be painless). »Enlarged gallbladder (may be painful). »Upper abdominal pain with radiation to back, weight loss, and thrombophlebitis are usually late manifestations. »General ConsiderationsCarcino ma is the most common neoplasm of the pancreas. About 75% are in the head and 25% in the body and tail of the organ. Pancreatic carcinomas account for 2% of all cancers and 5% of cancer deaths. Ampullary carcinomas are much less common. Risk factors for pancreatic cancer include age, tobacco use (which is thought to cause 20–25% of cases), heavy alcohol use, obesity, chronic pan- creatitis, diabetes mellitus, prior abdominal radiation, fam- ily history, and possibly gastric ulcer and exposure to arsenic and cadmium. New-onset diabetes mellitus after age 45 years occasionally heralds the onset of pancreatic cancer. In diabetic patients, metformin use and possibly aspirin use may reduce the risk of pancreatic cancer slightly, but insulin use and glucagon-like peptide-1–based therapy (eg, sitagliptin) may increase the risk. About 7% of patients with pancreatic cancer have a family history of pancreatic cancer in a first-degree relative, compared with 0.6% of control subjects. The majority of pancreatic can- cers originate from pancreatic intraepithelial neoplasias, which measure less than 5 mm in diameter and can only be seen with a microscope. In 5–10% of cases, pancreatic cancer occurs as part of a hereditary syndrome, including familial breast cancer (car- riers of BRCA2 have a 7% lifetime risk of pancreatic can- cer), hereditary pancreatitis ( PSS1 mutation), familialatypical multiple mole melanoma ( p16/CDKN2A muta- tion), Peutz-Jeghers syndrome ( STK11 /LKB1 mutation), ataxia-telangiectasia ( ATM mutation), and Lynch syn- drome (hereditary nonpolyposis colorectal cancer [ MLH1 , MSH2 ,MSH6 mutations]). Neuroendocrine tumors account for 1–2% of pancreatic neoplasms and may be functional (producing gastrin, insu- lin, glucagon, vasoactive intestinal peptide, somatostatin, growth hormone–releasing hormone, adrenocorticotropic hormone, and others) or nonfunctional. Cystic neoplasms account for only 1% of pancreatic cancers, but they are important because pancreatic cysts are common and may be mistaken for pseudocysts. A cystic neoplasm should be suspected when a cystic lesion in the pancreas is found in the absence of a history of pancreatitis. At least 15% of all pancreatic cysts are neoplasms. Serous cystadenomas (which account for 32–39% of cystic pancreatic neoplasms and also occur in patients with von Hippel-Lindau disease) are benign. However, mucinous cystic neoplasms (defined by the presence of ovarian stroma and accounting for 10–45% of cystic pancreatic neoplasms), intraductal papil- lary mucinous neoplasms (21–33% of cystic pancreatic neoplasms), solid pseudopapillary tumors (less than 5%, primarily in young women), and cystic islet cell tumors (3–5%) may be malignant. Their prognoses are better than the prognosis of pancreatic adenocarcinoma, unless the cystic neoplasm is at least locally advanced. Mucinous cystic neoplasms and intraductal papillary mucinous neoplasms account for 15–30% of pancreatic cancers. »Clinical FindingsA.  Symptoms and SignsPai n is present in over 70% of cases and is often vague, dif- fuse, and located in the epigastrium or, when the lesion is in the tail, located in the left upper quadrant of the abdo- men. Radiation of pain into the back is common and some- times predominates. Sitting up and leaning forward may afford some relief, and this usually indicates that the lesion has spread beyond the pancreas and is inoperable. Diar- rhea, perhaps due to maldigestion, is an occasional early symptom. Migratory thrombophlebitis is a rare sign. Weight loss is a common but late finding and may be asso- ciated with depression. Hyperglycemia and decreases in subcutaneous abdominal fat and serum lipid levels have been reported to precede a diagnosis of pancreatic cancer. Occasional patients (often aged 40 years or older) present with acute pancreatitis in the absence of an alternative cause. Jaundice is usually due to biliary obstruction by a cancer in the pancreatic head. A palpable gallbladder is also indicative of obstruction by a neoplasm (Courvoisier sign), but there are frequent exceptions. A hard, fixed, occasionally tender mass may be present. In advanced cases, a hard periumbilical (Sister Mary Joseph’s) nodule may be palpable.B.  Laboratory FindingsThere  may be mild anemia. Glycosuria, hyperglycemia, and impaired glucose tolerance or true diabetes mellitus are found in 10–20% of cases. The serum amylase or lipaseCMDT22_Ch39_p1612-p1675.indd  1634 02/07/21 2:44 PMCANCER1635 CMDT 2022level  is occasionally elevated. Liver biochemical tests may suggest obstructive jaundice. Steatorrhea in the absence of jaundice is uncommon. Occult blood in the stool is sugges- tive of carcinoma of the ampulla of Vater (the combination of biliary obstruction and bleeding may give the stools a distinctive silver appearance). CA 19-9, with a sensitivity of 70% and a specificity of 87%, has not proven useful for early detection of pancreatic cancer; increased values are also found in acute and chronic pancreatitis and cholangi- tis. Plasma chromogranin A levels are elevated in 88–100% of patients with pancreatic neuroendocrine tumors (NETs).C.  ImagingM ultiphase thin-cut helical CT is generally the initial diag- nostic procedure and detects a mass in over 80% of cases. CT identifies metastases, delineates the extent of the tumor, and allows percutaneous FNA for cytologic studies and tumor markers. MRI is an alternative to CT. Ultraso- nography is not reliable because of interference by intesti- nal gas. PET is a sensitive technique for detecting pancreatic cancer and metastases, but PET-CT is not a routine staging procedure. Selective celiac and superior mesenteric arteri- ography may demonstrate vessel invasion by cancer, a find- ing that would preclude attempts at surgical resection, but it is used uncommonly since the advent of multiphase helical CT. EUS is more sensitive than CT for detecting pancreatic cancer and is equivalent to CT for determining nodal involvement and resectability; contrast-enhanced EUS improves accuracy. A normal EUS excludes pancre- atic cancer. EUS may also be used to guide FNA or biopsy for tissue diagnosis, tumor markers, and DNA analysis. ERCP may clarify an ambiguous CT or MRI study by delineating the pancreatic duct system or confirming an ampullary or biliary neoplasm. MRCP appears to be at least as sensitive as ERCP in diagnosing pancreatic cancer. In some centers, pancreatoscopy or intraductal ultrasonog- raphy is used to evaluate filling defects in the pancreatic duct and assess resectability of intraductal papillary muci- nous cancers. With obstruction of the splenic vein, spleno- megaly or gastric varices are present, the latter detected by endoscopy, EUS, or angiography. Cystic neoplasms can be distinguished by their appear- ance on CT, EUS, and ERCP and features of the cyst fluid on gross, cytologic, and genetic analysis. For example, serous cystadenomas may have a central scar or honey- comb appearance; mucinous cystadenomas are unilocular or multilocular and contain mucin-rich fluid with high carcinoembryonic antigen levels (greater than 200 ng/mL [200 mcg/L]) and K-ras mutations; and intraductal papil- lary mucinous neoplasms are associated with a dilated pancreatic duct and extrusion of gelatinous material from the ampulla. »StagingThe  TNM system is the commonly used classification to stage pancreatic cancer. Staging is important not only because it correlates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy.»TreatmentAbdo minal exploration is usually necessary when cytologic diagnosis cannot be made or if resection is to be attempted (in up to 30% of patients with pancreatic carcinoma). In a patient with a localized mass in the head of the pancreas and without jaundice, laparoscopy may detect tiny perito- neal or liver metastases and thereby avoid resection in 4–13% of patients. Radical pancreaticoduodenal (Whipple) resection is indicated for cancers strictly limited to the head of the pancreas, periampullary area, and duodenum (T1, N0, M0). Five-year survival rates are 20–25% in this group and as high as 40% in those with negative resection margins and without lymph node involvement. Preopera- tive endoscopic decompression of an obstructed bile duct is often achieved with a plastic stent or short metal stent but does not reduce operative mortality and is associated with complications. The best surgical results are achieved at centers that specialize in the multidisciplinary treatment of pancreatic cancer. Adjuvant chemotherapy with gemcitabine, 5-fluo- rouracil, or gemcitabine with capecitabine is superior to no adjuvant therapy. Gemcitabine with capecitabine and a modified FOLFIRINOX (5-fluorouracil, leucovorin, irino- tecan, oxaliplatin) regimen have been found to be superior to gemcitabine alone. The role of adjuvant chemoradiation is controversial but often used in the United States. Neoad- juvant chemotherapy with or without radiation is increas- ingly being used to downstage patients and in those with resectable cancer. Common chemotherapy regimens for this purpose include FOLFIRINOX and gemcitabine with nanoparticle albumin-bound (nab)-paclitaxel. Chemora- diotherapy downstages about 30% of patients with locally advanced disease to allow resection. When resection is not feasible, endoscopic stenting of the bile duct is performed to relieve jaundice. A plastic stent is generally placed if the patient’s anticipated survival is less than 6 months (or if surgery is planned). A metal stent is preferred when anticipated survival is 6 months or greater. Whether covered metal stents designed to prevent cancer ingrowth offer an advantage over uncovered stents is uncertain because covered stents are associated with higher rates of migration and acute cholecystitis due to occlusion of the cystic duct. Surgical biliary bypass may be considered in patients expected to survive at least 6 months. Surgical duodenal bypass may be considered in patients in whom duodenal obstruction is expected to develop; alternatively, endoscopic placement of a self- expandable duodenal stent may be feasible. Chemoradia- tion may be used for palliation of unresectable cancer confined to the pancreas. Chemotherapy has been disappointing in metastatic pancreatic cancer, although improved response rates have been reported with FOLFIRINOX and with the combination of gemcitabine and nab-paclitaxel. In patients who have received prior chemotherapy, a regimen of 5-fluorouracil and leucovorin in combination with nanoliposomal irinotecan has resulted in improved survival compared with 5-fluorouracil and leucovorin alone. Celiac plexus nerve block (under CT or endoscopic ultrasound guidance) or thoracoscopic splanchnicectomy may improve pain control.CMDT22_Ch39_p1612-p1675.indd  1635 02/07/21 2:44 PMChAPTER 391636 CMDT 2022Surgical  resection is the treatment of choice for NETs, when feasible. Lesions that are less than 1 cm in diameter and nonfunctioning without evidence of local invasion or metastasis may be followed expectantly. Metastatic disease may be controlled with long-acting somatostatin analogs, interferon, chemotherapy, peptide-receptor radionuclide therapy, and chemoembolization. There is a consensus that asymptomatic incidental pan- creatic cysts 2 cm or smaller are at low risk for harboring invasive carcinoma. The cysts may be monitored by imag- ing tests (MRI) in 1 year and then every 2 years for 5 years and probably longer if no changes are observed, with EUS and FNA performed if a cyst enlarges to 3 cm and another high-risk feature (dilated main pancreatic duct, presence of a solid component) develops. The optimal approach is uncertain, however, and other guidelines have been pro- posed. Surgical resection is indicated for mucinous cystic neoplasms, symptomatic serous cystadenomas, solid pseu- dopapillary tumors (which have a 15% risk of malignant transformation), and cystic tumors larger than 2 cm in diameter that remain undefined after helical CT, EUS, and diagnostic aspiration. All intraductal papillary mucinous neoplasms of the main pancreatic duct should be resected, but those of branch ducts may be monitored with serial imaging if they (1) are asymptomatic and exhibit benign features; (2) have a diameter less than 3 cm (some authori- ties recommend a diameter of 1.5 cm or smaller, but even lesions 3 cm or larger may be monitored in elderly persons with no other worrisome cyst features); and (3) lack non- enhancing mural nodules, or thick wall, or abrupt change in the caliber of the pancreatic duct with distal pancreatic atrophy, or possibly bile duct dilatation and gallbladder adenomyomatosis. Most lesions with such benign features remain stable on follow-up, but a risk of malignancy per- sists for more than 10 years. Moreover, the risk of pancre- atic ductal carcinoma and of nonpancreatic cancers is also increased in this group of patients. In the absence of locally advanced disease, survival is higher for malignant cystic neoplasms than for adenocarcinomas. The role of EUS- guided ablative treatment of potentially premalignant pancreatic cysts is under study. Endoscopic resection or ablation, with temporary placement of a pancreatic duct stent, may be feasible for ampullary adenomas, but patients must be followed for recurrence. »PrognosisCarcino ma of the pancreas, especially in the body or tail, has a poor prognosis; 80–85% of patients present with advanced unresectable disease, and reported 5-year sur- vival rates range from 2% to 5%. From 1980 to 2010, mor- tality from pancreatic cancer did not decrease, but it has since started to improve. Obesity may adversely affect mortality in Western countries. Metformin may improve survival in diabetic patients with pancreatic adenocarci- noma, and use of statins preceding a diagnosis of pancre- atic cancer may improve survival. Tumors of the ampulla have a better prognosis, with reported 5-year survival rates of 20–40% after resection; jaundice and lymph node involvement are adverse prognostic factors. In carefully selected patients, resection of cancer of the pancreatic headis feasible and results in reasonable survival. In persons with a family history of pancreatic cancer in at least two first-degree relatives, or with a genetic syndrome associ- ated with an increased risk of pancreatic cancer, screening with EUS and helical CT or MRI/MRCP should be consid- ered beginning at age 50 (age 40 in CKDN2A orPRSS1 mutation carriers and age 35 in those with Peutz-Jeghers syndrome) or 10 years before the age at which pancreatic cancer was first diagnosed in a family member. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5). »When to ReferAll pa tients with carcinoma involving the pancreas and the ampulla of Vater should be referred to a specialist. »When to AdmitPatients  who require surgery and other interventions should be hospitalized.Aslanian  HR et al. AGA Clinical Practice Update on pancreas cancer screening in high-risk individuals: expert review. Gas- troenterology. 2020;159:358. [PMID: 32416142] Elta GH et al. ACG Clinical Guideline: diagnosis and manage- ment of pancreatic cysts. Am J Gastroenterol. 2018;113:464. [PMID: 29485131] US Preventive Services Task Force; Owens DK et al. Screening for pancreatic cancer: US Preventive Services Task Force reaf- firmation recommendation statement. JAMA. 2019;322:438. [PMID: 31386141]AL IMENTARY TRACT CANCERS Carling Ursem, MD Kenneth R. McQuaid, MD ESOPHAGEAL CANCERE S S E N T I A L S  O F  D I A G N O S I S »Progressive dysphagia to solid food. »Weight loss common. »Endoscopy with biopsy establishes diagnosis. »General ConsiderationsEsophageal cancer usually develo ps in persons between 50 and 70 years of age. There were an estimated 18,440 new cases of esophageal cancer in the United States in 2020. The overall ratio of men to women is 3:1. There are two histo- logic types: squamous cell carcinoma and adenocarcinoma, and their incidence has significant geographic variation. Squamous cell carcinoma is associated with smoking, alco- hol, poor nutritional status, and drinking hot beverages. It accounts for over 90% of cases of esophageal cancer inCMDT22_Ch39_p1612-p1675.indd  1636 02/07/21 2:44 PMCANCER1637 CMDT 2022Eastern  and Southeast Asia and sub-Saharan Africa. Ade- nocarcinoma is associated with obesity and gastroesopha- geal reflux disease, with the majority of cases developing as a complication of Barrett metaplasia due to chronic gastro- esophageal reflux. Adenocarcinomas make up the majority of new cases of esophageal cancer in North America and Northern and Western Europe. »Clinical FindingsA.  Symptoms and SignsThe  majority (50–60%) of patients with esophageal cancer present with advanced, incurable disease. While early symptoms are nonspecific and subtle, over 90% eventually have solid food dysphagia, which progresses over weeks to months. Odynophagia is sometimes present. Significant weight loss is common. Local tumor extension into the tracheobronchial tree may result in a tracheo-esophageal fistula, characterized by coughing on swallowing or by pneumonia. Chest or back pain suggests mediastinal exten- sion. Recurrent laryngeal nerve involvement may produce hoarseness. Physical examination is often unrevealing. The presence of supraclavicular or cervical lymphadenopathy or of hepatomegaly implies metastatic disease.B.  Laboratory FindingsLaborato ry findings are nonspecific. Anemia related to chronic disease or occult blood loss is common. Elevated aminotransferase or alkaline phosphatase concentrations suggest hepatic or bony metastases. Hypoalbuminemia may result from malnutrition.C.  ImagingA  barium esophagogram may be the first study obtained to evaluate dysphagia. The appearance of a polypoid, obstruc- tive, or ulcerative lesion is suggestive of carcinoma and requires endoscopic evaluation. However, even lesions believed to be benign by radiography warrant endoscopic evaluation. Chest radiographs may show adenopathy, a widened mediastinum, pulmonary or bony metastases, or signs of tracheo-esophageal fistula such as pneumonia.D . Upper EndoscopyEndoscopy  with biopsy establishes the diagnosis of esopha- geal carcinoma with a high degree of reliability. In some cases, significant submucosal spread of the tumor may yield nondiagnostic mucosal biopsies. Repeat biopsy may be necessary. »StagingAfter  confirmation of the diagnosis of esophageal carci- noma, the stage of the disease should be determined since doing so influences the choice of therapy. Patients should undergo evaluation with contrast CT of the chest and abdomen to look for evidence of pulmonary or hepatic metastases, lymphadenopathy, and local tumor extension. If there is no evidence of distant metastases or extensive local spread on CT, then EUS with guided FNA biopsy of suspicious lymph nodes should be performed to evaluatethe locoregional stage. EUS is superior to CT in demon- strating the level of local mediastinal extension and local lymph node involvement. PET with fluorodeoxyglucose or integrated PET-CT imaging is indicated to look for regional or distant spread in patients thought to have localized dis- ease after other diagnostic studies, prior to invasive sur- gery. Bronchoscopy is sometimes required in esophageal cancers above the carina to exclude tracheobronchial extension. Laparoscopy to exclude occult peritoneal carci- nomatosis should be considered in patients with tumors at or near the gastroesophageal junction (see Gastric Adenocarcinoma). »Differential DiagnosisEsophageal  carcinoma must be distinguished from other causes of progressive dysphagia, including peptic stricture, achalasia, and adenocarcinoma of the gastric cardia with esophageal involvement. Benign-appearing peptic stric- tures should be biopsied at presentation to exclude occult malignancy. »TreatmentThe appr oach to esophageal cancer depends on the tumor stage, tumor location, patient preference and functional status, and the expertise of the gastroenterologists, sur- geons, oncologists, and radiation oncologists. It is helpful to classify patients into two general categories: those with early stage (curable) disease and those with advanced stage (incurable) disease.A.  Therapy for “Curable” DiseaseSuperficial  esophageal cancers confined to the epithelium (high-grade dysplasia or carcinoma in situ [Tis]), lamina propria (T1a), or submucosal (T1b) are increasingly recog- nized in endoscopic screening and surveillance programs. Esophagectomy achieves high cure rates for superficial tumors but is associated with mortality (2%) and morbid- ity. If performed by experienced clinicians, endoscopic mucosal resection of Tis and T1a cancers achieves equiva- lent long-term survival with less morbidity (see Barrett Esophagus, Chapter 15). Esophagectomy is recommended for superficial tumors that are invasive to the submucosa (T1b) because of higher rates of lymph node metastasis. 1. Surgery with or without neoadjuvant chemoradiation therapy— There are multiple surgical approaches to the resection of invasive but potentially “curable” esophageal cancers (stage Ib, II, IIIA, or IIIB). Accepted techniques include en bloc transthoracic excision of the esophagus with extended lymph node dissection, transhiatal esopha- gogastrectomy (entailing laparotomy with cervical anasto- mosis), and minimally invasive esophagectomy techniques. Meta-analysis data suggest equivalent oncologic outcomes from minimally invasive esophagectomy and conventional open techniques, although there are fewer postoperative complications and shorter hospital stays with the laparo- scopic approach. Multiple meta-analyses have shown that regardless of surgery type, surgery at a high-volume hospi- tal is associated with decreased perioperative mortality.CMDT22_Ch39_p1612-p1675.indd  1637 02/07/21 2:44 PMChAPTER 391638 CMDT 2022Pa tients with stage I tumors have high cure rates with surgery alone and do not require radiation or chemother- apy. Whether radiation or chemotherapy or both are required in addition to surgery for T2N0 stage II tumors is a subject of ongoing debate. If regional lymph node metas- tases have occurred (stages IIB and III), the rate of cure with surgery alone is reduced to less than 20%. Meta- analysis of trials comparing neoadjuvant (preoperative) therapy followed by surgery with surgery alone suggests a 13% absolute improvement in 2-year survival with com- bined therapy. Preoperative (neoadjuvant) chemoradiation therapy is recommended for stage IIB and III tumors in fit patients. The preferred neoadjuvant chemotherapy regi- men used with radiation is weekly carboplatin plus pacli- taxel (Table 39–2). As an alternative, a combination of cisplatin plus 5-fluorouracil may be used along with radia- tion. When radiation therapy is considered, techniques that are less toxic such as intensity-modulated radiation therapy (IMRT) or proton beam therapy may be consid- ered. Perioperative chemotherapy without radiation may also be considered for tumors of the gastroesophageal junction based on the randomized, multicenter, phase III MAGIC trial. 2. Chemotherapy plus radiation therapy without surgery— Combined treatment with chemotherapy and radiation achieves long-term survival rates in up to 25% of patients and is superior to radiation alone. Chemoradia- tion alone should be considered in patients with localized disease (stage II or IIIA) who are poor surgical candidates due to serious medical illness or poor functional status (Eastern Cooperative Oncology Group score greater than 2). Patients with cervical esophageal cancers, which appear similar biologically to head and neck cancers and in whom surgery is highly morbid and typically not recommended, also should be considered for chemoradiation. 3. Supportive care during definitive therapy— Patients with significant tumor obstruction may require percutane- ous gastric or jejunal tube placement to maintain adequate hydration and nutrition during neoadjuvant chemoradia- tion or chemotherapy. Multidisciplinary consultation is required to determine the optimal procedure and to opti- mize perioperative nutrition.B.  Therapy for Incurable DiseaseMo re than half of patients have either locally extensive tumor spread (T4b) that is unresectable or distant metasta- ses (M1) at the time of diagnosis. Surgery is not warranted in these patients. Since prolonged survival can be achieved in few patients, the primary goal is to provide relief from dysphagia and pain, optimize quality of life, and minimize treatment side effects. The optimal palliative approach depends on the presence or absence of metastatic disease, expected survival, patient preference, and institutional experience. 1. Chemotherapy or chemoradiation— Combined radia- tion therapy and chemotherapy may achieve palliation in two-thirds of patients but is associated with significant side effects. It should be considered for patients with locallyadvanced tumors without distant metastases who have good functional status and no significant medical prob- lems, in whom prolonged survival may be achieved. Com- bination chemotherapy may be considered in patients with metastatic disease who still have good functional status and expected survival of at least several months. The systemic therapy treatment options are the same for metastatic esophageal, gastroesophageal junction, and gastric cancers (Table 39–2). Choice of treatment is increas- ingly influenced by the results of molecular testing, includ- ing PD-L1 expression, mismatch repair/microsatellite instability (MSI) and, for adenocarcinomas, HER2 amplifi- cation testing. Because of the number of targetable altera- tions, a next generation sequencing panel should be considered. In patients with amplification of the HER2 gene (approximately 15% of cases), addition of the mono- clonal antibody trastuzumab (see Chapter 17) to chemo- therapy is associated with prolonged survival. For patients without HER2 amplification who have increased PD-L1 expression, the addition of a PD-1 or PD-L1 targeted anti- body to chemotherapy may improve overall survival. Immunotherapy with pembrolizumab should be consid- ered for tumors with either microsatellite instability-high (MSI-H) or deficient mismatch repair protein expression (dMMR). For patients with poor functional status, single- agent therapy with a fluoropyrimidine, a taxane, or irinote- can may be used. 2. Local therapy for esophageal obstruction— Patients with advanced esophageal cancer often have a poor func- tional and nutritional status. Radiation therapy alone to the area of esophageal obstruction may afford short-term relief of pain and dysphagia. Rapid palliation of dysphagia may be achieved by peroral placement of permanent expand- able wire stents (alone or followed by radiation). However, placement of these stents is complicated by perforation, migration, or tumor ingrowth in up to 40% of cases. »PrognosisThe ov erall 5-year survival rate of esophageal carcinoma is less than 20%. Apart from distant metastasis (M1b), the two most important predictors of poor survival are adja- cent mediastinal spread (T4) and lymph node involvement. Whereas cure may be achieved in patients with regional lymph node involvement (stages IIB and III), involvement of nodes outside the chest (M1a) is indicative of metastatic disease (stage IV) that is incurable. For those patients whose disease progresses despite chemotherapy, meticu- lous efforts at palliative care are essential (see Chapter 5). »When to Refer• Patients should be referred to a gastroenterologist for evaluation and staging (endoscopy with biopsy, EUS) and palliative endoscopic stenting. •Patients with curable and resectable disease for whom neoadjuvant therapy may be appropriate (stage IIB or IIIA) should be referred to medical, radiation, and sur- gical oncologists for consideration of neoadjuvant che- motherapy, chemoradiotherapy, and surgical resection.CMDT22_Ch39_p1612-p1675.indd  1638 02/07/21 2:44 PMCANCER1639 CMDT 2022• Patients with metastatic disease should be referred to medical and radiation oncologists for consideration of palliative chemotherapy or chemoradiation. •Patients with metastatic disease and obstructive tumors not amenable to or refractory to palliative radiation or stenting may require referral to an interventional radi- ologist, gastroenterologist, or surgeon for gastric or jejunal tube placement for liquid artificial nutrition. Early referral to palliative care services may improve symptom management in patients with advanced or metastatic disease. »When to AdmitP atients with high-grade esophageal obstruction with inabil- ity to manage oral secretions or maintain hydration should be admitted. Acute complications such as perforation, bleeding, aspiration, or fistula also may require admission.Boku  N et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previ- ously untreated, unresectable, advanced, or recurrent gastric/ gastroesophageal junction cancer: interim results of a ran- domized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250. [PMID: 30566590] Gottlieb-Vedi E et al. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. Ann Surg 2019;270:1005. [PMID: 30817355] Mariette C et al; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152. [PMID: 30625052] National Cancer Institute. SEER Cancer Statistics Factsheets: Esophageal Cancer, 2020. https://seer.cancer.gov/statfacts/ html/esoph.html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. Version5.2020. 2020 December 23. https:// www.nccn.org/professionals/physician_gls/pdf/esophageal. pdfGA STRIC ADENOCARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »Dyspeptic symptoms with weight loss in patients over age 40 years. »Iron deficiency anemia: occult blood in stools. »Abnormality detected on upper gastrointestinal series or endoscopy. »General ConsiderationsGastric  adenocarcinoma is the third most common cause of cancer death worldwide. However, its incidence has declined rapidly over the last 70 years, especially in Western countries, which may be attributable to changes in diet (more fruits and vegetables), food refrigeration (allowingmore fresh foods and reduced salted, smoked, and pre- served foods), reduced toxic environmental exposures, and a decline in Helicobacter pylori infections. The incidence of gastric cancer remains high (62/100,000 males) in Japan and many developing regions, including eastern Asia, Eastern Europe, Chile, Colombia, and Central America. In the United States, there were an estimated 27,600 new cases and 11,010 deaths in 2020. The incidence is higher in Asian Americans, Hispanics, African Americans, and Native Americans (including Native Alaskans). There are two main histologic variants of gastric cancer: “intestinal-type” (which resembles intestinal cancers in forming glandular structures) and “diffuse” (which is poorly differentiated, has signet-ring cells, and lacks glan- dular formation). The incidence of intestinal-type gastric cancer has declined significantly, but it is still the more common type (70–80%); it occurs twice as often in men as women, primarily affects older people (mean age 68 years), and is more strongly associated with environmental fac- tors. It is believed to arise through a gradual, multi-step progression from inflammation (most commonly due to H pylori ), to atrophic gastritis, to intestinal metaplasia, and finally to dysplasia and cancer. Chronic H pylori gastritis is the strongest risk factor for gastric carcinoma, increasing the relative risk 3.5- to 20-fold. It is estimated that 60–90% of cases of gastric carcinomas may be attributable to H pylori. Other risk factors for intestinal-type gastric cancer include pernicious anemia, a history of partial gastric resection more than 15 years previously, smoking, and diets that are high in nitrates or salt and low in vitamin C. Diffuse gastric cancer accounts for 20–30% of gastric can- cer cases. In contrast to intestinal-type cancer, it affects men and women equally, occurs more commonly in young people, is not as strongly related to H pylori infection, and has a worse prognosis than intestinal-type cancer due to early metastasis. Most diffuse gastric cancers are attribut- able to acquired or hereditary mutations in the genes regulating the E-cadherin cell adhesion protein. Hereditary diffuse gastric cancer accounts for 1–3% of gastric cancers. The cancer may arise at a young age, is often multifocal and infiltrating with signet ring cell histology, and confers poor prognosis. Many of these families have a germline muta- tion of E-cadherin CDH1, which is inherited in an autoso- mal dominant pattern and carries a greater than 60% lifetime risk of gastric cancer. Prophylactic gastrectomy should be considered in patients known to carry this mutation. Most gastric cancers arise in the body and antrum. These may occur in a variety of morphologic types: (1) polypoid or fungating intraluminal masses; (2) ulcerating masses; (3) diffusely spreading ( linitis plastica ), in which the tumor spreads through the submucosa, resulting in a rigid, atonic stomach with thickened folds (prognosis dis- mal); and (4) superficially spreading or “early” gastric cancer—confined to the mucosa or submucosa (with or without lymph node metastases) and associated with a favorable prognosis. HER2 amplification and overexpres- sion is seen in 10–25% of gastric adenocarcinoma cases and is more commonly observed in intestinal histology and moderately differentiated disease. Testing for MSI,CMDT22_Ch39_p1612-p1675.indd  1639 02/07/21 2:44 PMChAPTER 391640 CMDT 2022defici ency in mismatch repair proteins (dMMR), and PD-L1 is recommended in advanced disease to identify tumors that may respond to immunotherapy. For gastric adenocarcinoma, MSI-H/dMMR is found in 8–16% of cases. In contrast to the dramatic decline in cancers of the distal stomach, a rise in incidence of tumors of the gastric cardia has been noted. These tumors have demographic and pathologic features that resemble Barrett-associated esoph- ageal adenocarcinomas (see Esophageal Cancer). »Clinical FindingsA.  Symptoms and SignsGastri c carcinoma is generally asymptomatic until the dis- ease is quite advanced. Symptoms are nonspecific and are determined in part by the location of the tumor. Dyspepsia, vague epigastric pain, anorexia, early satiety, and weight loss are the presenting symptoms in most patients. Patients may derive initial symptomatic relief from over-the-counter rem- edies, further delaying diagnosis. Ulcerating lesions can lead to acute gastrointestinal bleeding with hematemesis or melena. Pyloric obstruction results in postprandial vomiting. Lower esophageal obstruction causes progressive dysphagia. Physical examination is rarely helpful. Stools may be guaiac positive.B.  Laboratory FindingsIr on deficiency anemia due to chronic blood loss or anemia of chronic disease is common. Circulating tumor markers do not have established clinical validity in screening or diagnosis of gastric cancer. However, when checked serially, tumor markers can assist in monitoring treatment response.C.  EndoscopyU pper endoscopy should be obtained in all patients over age 60 years with new onset of epigastric symptoms (dyspepsia) and young patients with “alarm” symptoms (dysphagia, recur- rent vomiting, significant weight loss), especially in immi- grants from countries with a high prevalence of gastric cancer. Endoscopy with biopsies of suspicious lesions is highly sensi- tive for detecting gastric carcinoma. It can be difficult to obtain adequate biopsy specimens in diffuse type gastric cancer.D . ImagingOnce  a gastric cancer is diagnosed, preoperative evaluation with contrast CT of chest, abdomen, and pelvis and EUS is indicated to delineate the local extent of the primary tumor as well as to evaluate for nodal or distant metastases. EUS is superior to CT in determining the depth of tumor pen- etration and is useful for evaluation of early gastric cancers that may be removed by endoscopic mucosal resection. PET or combined PET-CT imaging is recommended for detection of distant metastasis. »ScreeningBecause  of its unproven efficacy and cost-effectiveness, screening for H pylori infection and treating it to preventgastric cancer is not recommended for asymptomatic adults in the general population but may be considered in patients who have immigrated from regions with a high incidence of gastric cancer or who have a family history of gastric cancer. Because of the high incidence of gastric carcinoma in Japan, screening upper endoscopy is per- formed there to detect early gastric carcinoma. Approxi- mately 40% of tumors detected by screening are early, with a 5-year survival rate of almost 90%. Screening is not rec- ommended in the United States. »StagingThe  TNM system is the commonly used classification to stage gastric adenocarcinoma. Staging is important not only because it correlates with the patient’s long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. A staging laparoscopy prior to definitive surgery to exclude peritoneal carcinomatosis should be considered in patients with stage T1b or greater disease without radio- graphic evidence of distant metastases. Pathologic review should include (1) grade of tumor, (2) histologic subtype, (3) depth of invasion, (4) whether lymphatic or vascular inva- sion is present, and (5) if there is known metastatic disease, the status of HER2 protein expression by immunohisto- chemistry or fluorescent in situ hybridization or both, along with MMR or MSI testing and PD-L1 protein expression. »Differential DiagnosisUlce rating gastric adenocarcinomas are distinguished from benign gastric ulcers by biopsies. Approximately 3% of gastric ulcers initially believed to be benign later prove to be malignant. All gastric ulcers identified at endoscopy should be biopsied to exclude malignancy. Ulcers that are suspicious for malignancy to the endoscopist or that have atypia or dysplasia on histologic examination warrant repeat endoscopy in 2–3 months to verify healing and exclude malignancy. Nonhealing ulcers should be consid- ered for resection. Infiltrative carcinoma with thickened gastric folds must be distinguished from lymphoma and other hypertrophic gastropathies. »TreatmentA.  Curative Surgical ResectionSurgical resecti on is the only therapy with curative poten- tial. Laparoscopic techniques achieve similar outcomes and lower overall complication rates as open gastrectomy. In Japan and in specialized centers in the United States, endo- scopic mucosal resection is performed in select patients with small (less than 1–2 cm), early (intramucosal or T1aN0) gastric cancers after careful staging with EUS. Approximately 25% of patients undergoing surgery will be found to have locally unresectable tumors or peritoneal, hepatic, or distant lymph node metastases that are incur- able. The remaining patients with confirmed localized disease should undergo radical surgical resection. For adenocarcinoma localized to the distal two-thirds of the stomach, a subtotal gastrectomy should be performed. ForCMDT22_Ch39_p1612-p1675.indd  1640 02/07/21 2:44 PMCANCER1641 CMDT 2022pro ximal gastric cancer or diffusely infiltrating disease, total gastrectomy is necessary. The ultimate goal of surgery is obtaining negative surgical margins. Vitamin B12supple- mentation is required after gastrectomy. For patients with localized gastric cancer that is resectable, current National Comprehensive Cancer Network (NCCN) treatment guidelines recommend gastrectomy with extended (D1), or modified regional (D2), lymph node dissection and sam- pling of 15 or more lymph nodes. D2 lymphadenectomy has been shown to improve disease-specific survival but is associated with increased postoperative mortality.B.  Perioperative Chemotherapy or ChemoradiationThe  use of perioperative chemotherapy or adjuvant chemo- radiation is associated with improved survival in patients with localized or locoregional gastric adenocarcinoma who undergo surgical resection. The choice of treatment depends on the location and extent of tumor, type of sur- gery, patient comorbidities and performance status, and institutional experience. Tumors arising in the gastro- esophageal junction are treated following algorithms for esophageal primary tumors. Multidisciplinary treatment decision making involving the surgeon, radiation oncolo- gist, and medical oncologist is imperative.C.  Palliative ModalitiesMan y patients will be found either preoperatively or at the time of surgical exploration to have advanced disease that is not amenable to curative intent surgery due to peritoneal or distant metastases or local invasion of other organs. In some of these cases, palliative resection of the tumor none- theless may be indicated to alleviate pain, bleeding, or obstruction. For patients with unresectable disease, a surgi- cal diversion with gastrojejunostomy may be indicated to prevent obstruction. Alternatively, unresected tumors may be treated with endoscopic stent therapy, radiation therapy, or angiographic embolization to relieve bleeding or obstruction. Systemic therapy may be considered in patients with metastatic disease who still have good func- tional status and expected survival of at least several months. The regimens used are the same as those for esophageal and gastroesophageal junction tumors dis- cussed above (Table 39–2). »PrognosisThe  5-year survival for gastric cancer varies greatly by stage, location, and histologic features. The 5-year survival is approximately 90% for early-stage cancer (T1b or less), 80% for stage II after curative intent treatment, but less than 20% for stage IIIC. Even with apparently localized disease, proxi- mal tumors have a 5-year survival of less than 15%. For those whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). »When to Refer• Patients with dysphagia, weight loss, protracted vomit- ing, iron deficiency anemia, melena, or new-onset dys- pepsia (especially if aged 60 years or older or associatedwith other alarm symptoms) in whom gastric cancer is suspected should be referred for endoscopy. •Patients should be referred to a surgeon for attempt at curative resection in stage I, II, or III cancer, including staging laparoscopy if indicated. •Prior to surgery, patients should be referred to an oncolo- gist to determine the role for perioperative chemother- apy or adjuvant chemoradiation or chemotherapy. •Patients who have undergone gastrectomy require con- sultation with a nutritionist due to propensity for mal- nutrition and complications, such as dumping syndrome and vitamin B12deficiency, postoperatively. •Patients with unresectable or metastatic disease should be referred to an oncologist for consideration of pallia- tive chemotherapy or chemoradiation. Early referral to palliative care services may also be considered for symptom management in patients with advanced and metastatic disease. »When to AdmitPa tients with acute bleeding, protracted vomiting, or inabil- ity to maintain hydration or nutrition.Ja ng S et al. Superiority of gastrojejunostomy over endoscopic stenting for palliation of malignant gastric outlet obstruction. Clin Gastroenterol Hepatol. 2019;17:1295. [PMID: 30391433] Katai H et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open-distal gastrectomy with nodal dis- section for clinical stage IA or IB gastric cancer: a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5:142. [PMID: 31757656] National Cancer Institute. SEER Cancer Stat Facts: Stomach Cancer, 2020. https://seer.cancer.gov/statfacts/html/stomach. html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 4.2020. 2020 December 23. https://www.nccn.org/professionals/physician_ gls/pdf/gastric.pdfGA STRIC LYMPHOMAE S S E N T I A L S  O F  D I A G N O S I S »Symptoms of dyspepsia, weight loss, or anemia. »Variable abnormalities on upper gastrointestinal series or endoscopy including thickened folds, ulcer, mass, or infiltrating lesions; diagnosis estab- lished by endoscopic biopsy. »Abdominal CT and EUS required for staging. »General ConsiderationsGastric lympho mas may be primary (arising from the gas- tric mucosa) or may represent a site of secondary involve- ment in patients with nodal lymphomas. Distinguishing advanced primary gastric lymphoma with adjacent nodal spread from advanced nodal lymphoma with secondaryCMDT22_Ch39_p1612-p1675.indd  1641 02/07/21 2:44 PMChAPTER 391642 CMDT 2022gastric spread is essential  because the prognosis and treat- ment of primary and secondary gastric lymphomas are different. Primary gastric lymphoma is the second most common gastric malignancy, accounting for 3–5% of gas- tric cancers. More than 95% of these are non-Hodgkin B-cell lymphomas mainly consisting of either mucosa- associated lymphoid tissue (MALT)-type lymphoma and diffuse large B-cell lymphoma. Over 90% of low-grade primary gastric MALT-type lymphomas are associated with H pylori infection. Gastric T-cell lymphoma, which is associated with HTLV-1 infection, is rare and makes up 7% of primary gastric lymphomas. »Clinical Findings & StagingThe  clinical presentation and endoscopic appearance of gastric lymphoma are similar to those of adenocarcinoma. Most patients have abdominal pain, weight loss, or bleed- ing. Patients with diffuse large B-cell lymphoma are more likely to have systemic symptoms and advanced tumor stage. At endoscopy, lymphoma may appear as an ulcer, mass, or diffusely infiltrating lesion. It tends to have hori- zontal infiltration as opposed to the vertical extension seen in adenocarcinoma. The diagnosis is established with endoscopic biopsy; FNA is not adequate. Since the disease can be multifocal, biopsies of both suspicious and normal- appearing areas are recommended. Biopsy specimens should be tested for H pylori and, if positive, for t(11;18) via PCR or FISH. EUS is the most sensitive test for determin- ing the level of invasion and presence of perigastric lymph- adenopathy and should be performed for accurate staging, if available. All patients should undergo staging with CT scanning of chest, abdomen, and pelvis. For gastric MALT lymphomas, the Lugano staging system is most frequently used. Stage I is confined to the gastrointestinal tract, stage II involves local or regional lymph nodes, stage IIE has invasion of adjacent organs or tissues, and stage IV has distant metastases. There is no stage III. For patients with diffuse large B-cell lymphomas involving the stomach, combination PET-CT imaging, bone marrow biopsy with aspirate, tumor lysis laboratory tests, and hepatitis B and HIV serologies also may be required for staging and treat- ment planning (see Chapter 13). »TreatmentT reatment of primary gastric lymphomas depends on the tumor histology, grade, and stage. Marginal B-cell lympho- mas of the MALT type that are low-grade and localized to the stomach wall (stage I) or perigastric lymph nodes (stage IIE1) have an excellent prognosis. Patients with pri- mary gastric MALT-lymphoma should be tested for H pylori infection and treated if positive. Complete lym- phoma regression after successful H pylori eradication occurs in approximately 75% of cases of stage I and approx- imately 55% with stage IIE low-grade lymphoma. However, 95% of cancers positive for t(11;18) do not respond to antibiotics. Remission may take as long as a year, and relapse occurs in about 2% of cases per year. Many patients with minimal disease after successful H pylori eradication may be observed closely without further therapy. Restagingwith endoscopy and biopsy is recommended 3 months after antibiotic treatment and 3–6 months following radia- tion therapy. Ultimately, endoscopic surveillance after treatment is recommended every 3–6 months for 5 years to evaluate for recurrence. In patients whose tumors harbor specific gene translo- cations, including t(11;18) (API2-MALT1), t(1;14), or t(14;18), rates of remission after H pylori eradication are lower, and treatment with radiation is often required. The long-term survival of low-grade MALT lymphoma for stage I is over 90% and for stage II is 35–65%. Surgical resection is not recommended. Diffuse large B-cell or other higher-grade lymphomas with secondary gastrointestinal involvement usually present at an advanced stage with widely disseminated disease and are treated according to stage and subtype of lymphoma (see Chapter 13).A vilés A et al. Primary gastric diffuse large B-cell lymphoma: the role of dose-dense chemotherapy. J Oncol Pharm Pract. 2019; 25:1682. [PMID: 30370804] Juárez-Salcedo LM et al. Primary gastric lymphoma, epidemiol- ogy, clinical diagnosis, and treatment. Cancer Control. 2018;25: 1073274818778256. [PMID: 29779412] Lin JL et al. Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study. BMC Cancer. 2019;19:873. [PMID: 31481021] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell. pdf” https://www.nccn.org/professionals/physician_gls/pdf/b- cell.pdf Tian C et al. A retrospective analysis of primary gastrointestinal non-Hodgkin lymphomas: clinical features, prognostic fac- tors and treatment outcomes. Onco Targets Ther. 2020;13: 5345. [PMID: 32606752]GA STRIC NEUROENDOCRINE TUMORSGastric  NETs make up less than 1% of gastric neoplasms. They may occur sporadically or secondary to chronic hypergastrinemia that results in hyperplasia and transfor- mation of enterochromaffin cells in the gastric fundus. The majority of NETs are caused by hypergastrinemia and occur in association with either pernicious anemia (75%) (type 1) or Zollinger-Ellison syndrome (5%) (type 2). Type 1 tumors are associated with chronic atrophic gastritis, gas- tric achlorhydria, and secondary hypergastrinemia. Initial diagnostic workup includes serum gastrin level, upper endoscopy, and EUS. Gastrin level should be obtained 1 week after the patient has stopped taking protein pump inhibitors. For low-grade tumors (Ki-67 less than 3% or less than 2 mitoses/10 high-power fields [HPF]), soma- tostatin receptor–based imaging (somatostatin receptor scintigraphy or gallium-68 dotatate PET/CT) should be performed. For high-grade tumors (Ki-67 greater than 20% or greater than 20 mitoses/10 HPF), FDG-PET/CT is pre- ferred to evaluate the extent of disease. For patients with hypergastrinemia (suspected of type 1 or type 2 carcinoid), serum vitamin B12and intrinsic factor antibody levels should be obtained to exclude pernicious anemia. Gastric NETs associated with Zollinger-EllisonCMDT22_Ch39_p1612-p1675.indd  1642 02/07/21 2:44 PMCANCER1643 CMDT 2022syndrom e occur almost exclusively in patients with multi- ple endocrine neoplasia type 1 (MEN 1), in which chromo- somal loss of 11q13 has been reported. Gastric NETs caused by hypergastrinemia tend to be multifocal, be smaller than 1 cm, have a low potential for metastatic spread, and thus are unlikely to cause development of the carcinoid syn- drome. Small lesions may be successfully treated with endo- scopic resection followed by endoscopic surveillance every 6–12 months, or with observation. Antrectomy reduces serum gastrin levels and may lead to regression of small tumors. It can be considered in patients with type 1 gastric NETs to reduce recurrence risk and frequency of post- therapy monitoring. Octreotide therapy may be appropriate for patients with underlying gastrinoma and Zollinger- Ellison syndrome. Patients with tumors larger than 2 cm should undergo endoscopic or surgical resection (see Small Intestinal Adenocarcinomas below). Type 3 gastric NETs arise sporadically, independent of gastrin production, and account for up to 20% of gastric NETs. Most sporadic gastric NETs are solitary, larger than 2 cm, and have a strong propensity for hepatic or pulmo- nary metastases and thus the carcinoid syndrome at initial presentation. CT or MRI should be obtained to evaluate for metastatic disease. Localized sporadic NETs should be treated with partial or total gastrectomy and regional lymphadenectomy. Advanced, low-grade gastric NETs can be monitored with serial scans, if asymptomatic. Soma- tostatin analogs may provide symptomatic relief for patients with functional gastric NETs. Advanced high- grade gastric neuroendocrine carcinomas are treated in a fashion similar to SCLCs.Algashaam y K et al. Multifocal G1-G2 gastric neuroendocrine tumors: differentiating between type I, II and III, a clinico- pathologic review. World J Clin Cases. 2019;7:2413. [PMID: 31559277] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors. Version 2.2020. 2020 July 24. https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine.pdfGA STROINTESTINAL MESENCHYMAL TUMORS »Pathobiology & DiagnosisGastroin testinal mesenchymal tumors (which include stro- mal tumors, leiomyomas, and schwannomas) derive from mesenchymal stem cells and have an epithelioid or spindle cell histologic pattern, resembling smooth muscle. The most common stromal tumors are gastrointestinal stromal tumors (“GISTs”), which originate from interstitial cells of Cajal. GISTs occur throughout the gastrointestinal tract, but most commonly in the stomach (60%) and small intes- tine (30%). Approximately 80% of GISTs have mutations in KIT. A percentage of the KIT wild type tumors have a mutation in PDGFRA , and only a minority of patients are wild type for both genes. Mesenchymal tumors may be discovered incidentally on imaging studies or endoscopy or may cause symptoms (most commonly bleeding, pain, or obstruction). At endoscopy, they appear as a submucosalmass that may have central umbilication or ulceration. EUS with guided FNA biopsy is the optimal study for diagnos- ing gastric mesenchymal tumors and distinguishing them from other submucosal lesions. Percutaneous biopsy may confer risk of bleeding or intra-abdominal seeding. CT of the abdomen and pelvis with contrast, MRI, and PET imaging are useful in the diagnosis and staging. PET imaging also may be useful to monitor response to treatment. While almost all GISTs have malignant potential, the risk of developing metastasis is increased with tumor size greater than 2 cm, nongastric location, and mitotic index greater than 5 mitoses per 50 HPF. It is difficult to distinguish benign from malignant tumors by EUS appearance or by FNA. But, in general, lesions are more likely benign if they are smaller than 2 cm, have a smooth border, and have a homogeneous echo pattern on EUS. Resection settles the issue. »TreatmentA.  Localized TreatmentSu rgery is recommended for all patients with tumors that are 2 cm or larger, increasing in size, have an EUS appearance suspicious for malignancy, or are symptomatic. The man- agement of asymptomatic gastric lesions 2 cm or smaller in size depends on the EUS features. Tumors with high-risk EUS features can be surgically resected. If no high-risk fea- tures are noted, endoscopic surveillance can be performed. Because of the low but real long-term risk of malignancy, surgical resection should be considered in younger, other- wise healthy patients. However, other patients may be moni- tored with serial endoscopic ultrasonographic examinations or, in select cases, endoscopic resections. After complete surgical resection, the risk of GIST recurrence can be calcu- lated based on tumor location, size, and mitotic index. The majority of recurrences occur within the first 3 years.B.  Systemic TreatmentBecause  the majority of GISTs are driven by mutations in KIT orPDGFRA , the tyrosine kinase inhibitor, imatinib, which blocks signaling through this pathway, is used across disease stages. Neoadjuvant therapy with imatinib may be considered for patients with localized GIST tumors who are deemed to be at high risk for resection because of comorbidities, tumor size, or tumor location. A biopsy is required to confirm the diagnosis of GIST prior to initia- tion of neoadjuvant imatinib. Adjuvant therapy with ima- tinib delays recurrence and prolongs survival, but it is not likely to be curative. Untreated metastatic GIST tumors are aggressive and carry a poor prognosis. However, imatinib induces disease control in up to 85% of patients with metastatic disease with a progression-free survival of 20–24 months and median overall survival of almost 5 years. Additionally, imatinib is associated with long-term survival in some patients. One study reported that 18% of patients contin- ued treatment after a median follow-up of 9 years. For patients with imatinib-resistant cancers, high-dose imatinib or other approved tyrosine kinase inhibitors (eg, sunitinib or regorafenib) are options.CMDT22_Ch39_p1612-p1675.indd  1643 02/07/21 2:44 PMChAPTER 391644 CMDT 2022H einrich MC et al. Avapritinib in advanced PDGFRA D842V- mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21: 935. [PMID: 32615108] Patel DJ et al. Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): is there a survival benefit following margin negative surgical resection? Am J Surg. 2020;219:436. [PMID: 31679654] von Mehren M et al. Gastrointestinal stromal tumors. J Clin Oncol. 2018;36:136. [PMID: 29220298] Wang C et al. Safety and efficiency of endoscopic resection versus laparoscopic resection in gastrointestinal stromal tumours: a systematic review and meta-analysis. Eur J Surg Oncol. 2020; 46:667. [PMID: 31864827]MA LIGNANCIES OF THE SMALL INTESTINEThe  frequency of different tumor types varies by location within the small intestine. Adenocarcinomas are most common in the duodenum and jejunum and neuroendo- crine tumors, in the ileum. Lymphomas and sarcomas each have similar incidences in the various segments of the small intestine.1.  Small Intestinal AdenocarcinomasThese  tumors often present with nonspecific symptoms such as abdominal pain and nausea. The incidence is rare, with 11,110 new diagnoses estimated in 2020 in the United States. These adenocarcinomas are most often diag- nosed at stage III or IV , but their prognosis is slightly worse than for similar stage colon adenocarcinoma. The duode- num is the most common site of small bowel adenocarci- noma, specifically in the periampullary region. Ampullary carcinoma may present with jaundice due to bile duct obstruction or bleeding. Surgical resection of early lesions is curative in up to 40% of patients. The management of nonampullary small intestinal adenocarcinoma is extrapolated from data available for the management of colon adenocarcinoma.2.  Small Intestinal LympomasL ymphomas may arise primarily in the gastrointestinal tract or may involve it secondarily in patients with dissemi- nated disease. In Western countries, primary gastrointesti- nal lymphomas account for 5% of lymphomas and 20% of small bowel malignancies. There is an increased incidence of small intestinal lymphomas in patients with AIDS, Crohn disease, and those receiving immunosuppressive therapy. The most common histologic subtype is non- Hodgkin extranodal marginal zone (MALT) B-cell lymphoma. That said, enteropathy-associated T-cell lym- phomas appear to be increasing in incidence in the United States. They are associated with the diagnosis of celiac disease. In the Middle East, lymphomas may arise in the setting of immunoproliferative small intestinal disease. Other types of intestinal lymphomas include primary intestinal follicular cell lymphoma, mantle cell lymphoma, and Burkitt lymphoma (see Chapter 13). Presenting symptoms or signs of primary small bowel lymphoma include abdominal pain, weight loss, nausea and vomiting, distention, anemia, and occult blood in thestool. Fevers are unusual. Protein-losing enteropathy may result in hypoalbuminemia, but other signs of malabsorption are unusual. Barium radiography or CT enterography helps localize the site of the lesion. The diagnosis requires endo- scopic, percutaneous, or laparoscopic biopsy. Imaging and possibly bone marrow biopsy are required to determine stage. Treatment depends on the tumor histologic subtype and stage of disease (see Chapter 13). If feasible, surgical resec- tion of primary intestinal lymphoma, may be appropriate for localized tumors. In patients with limited disease (stage IE) in whom resection is performed with negative margins, the role of adjuvant chemotherapy is unclear. Locoregional radiation should be considered if surgical margins are posi- tive. Patients with more extensive disease generally are treated according to the tumor histology.3.  Intestinal Neuroendocrine TumorsE S S E N T I A L S  O F  D I A G N O S I S »Majority are asymptomatic and discovered inci- dentally at endoscopy or surgery. »Carcinoid syndrome occurs in < 10%; hepatic metastases are generally present. »Risk of metastasis is related to tumor size and location. »General ConsiderationsNeur oendocrine tumors are the most common type of tumor arising in the small bowel. Gastrointestinal NETs (also called carcinoids) most commonly occur in the small intestine (45%) but are also found in the rectum (20%), appendix (17%), and colon (11%), with the remainder occurring in the stomach (less than 10%; see Gastric Neu- roendocrine Tumors above). Carcinoid tumors are well- differentiated neuroendocrine tumors that may secrete a variety of hormones, including serotonin, somatostatin, gastrin, and substance P . Small intestinal carcinoids most commonly arise in the distal ileum within 60 cm of the ileocecal valve. Up to 30% are multicentric. The risk of metastatic spread increases when the tumor is 1 cm or larger and when it is larger than 2 cm with invasion beyond the muscularis propria. Appen- diceal carcinoids are identified in 0.3% of appendectomies, usually as an incidental finding. Almost 80% of these tumors are smaller than 1 cm, and 90% are smaller than 2 cm. However, in patients with appendiceal carcinoid tumors larger than 2 cm, approximately 90% develop nodal and distant metastases; right hemicolectomy is recom- mended in these cases. Rectal carcinoids are usually detected incidentally as submucosal nodules during proctoscopic examination and often locally excised by biopsy or snare polypectomy before the histologic diagnosis is known. Rectal carcinoids smaller than 1 cm virtually never metastasize and are treated effec- tively with local endoscopic or transanal excision. Larger tumors are associated with the development of metastasisCMDT22_Ch39_p1612-p1675.indd  1644 02/07/21 2:44 PMCANCER1645 CMDT 2022in  10%. Hence, a more extensive cancer resection operation is warranted in fit patients with rectal carcinoid tumors larger than 1–2 cm or with high-risk features (such as inva- sion of muscularis propria or evidence of nodal involve- ment), or both. »Clinical FindingsA.  Symptoms and SignsMos t lesions smaller than 1–2 cm are asymptomatic and difficult to detect by endoscopy or imaging studies. Small intestinal carcinoids may present with intermittent abdom- inal pain, bowel obstruction, bleeding, or bowel infarction. Appendiceal and rectal carcinoids usually are small and asymptomatic, but large lesions can cause bleeding, obstruction, or altered bowel habits. Carcinoid syndrome occurs in less than 10% of patients. More than 90% of patients with carcinoid syndrome have hepatic metastases, usually from carcinoids of small bowel origin. About 10% of patients with carcinoid syndrome have primary bron- chial or ovarian tumors without hepatic metastases. Carci- noid syndrome is caused by tumor secretion of hormonal mediators. The manifestations include facial flushing, edema of the head and neck (especially with bronchial carcinoid), abdominal cramps and diarrhea, broncho- spasm, cardiac lesions (pulmonary or tricuspid stenosis or regurgitation in 10–30%), and telangiectases.B.  Laboratory FindingsSerum  chromogranin A is elevated in the majority of NETs, although its sensitivity for small, localized carcinoid tumors is unknown. Serum chromogranin A is elevated in almost 90% of patients with advanced small bowel carcinoid. Urinary 5-hydroxyindoleacetic acid (5-HIAA) and platelet serotonin levels are also elevated in patients with metastatic carcinoid; however, these tests are less sensitive than serum chromogranin A. There is increased urinary 5-HIAA in carcinoid syndrome; symptomatic patients usually excrete more than 25 mg of 5-HIAA per day in the urine. Because certain foods and medications can interfere with 5-HIAA levels, these should be withheld for 48 hours prior to a 24-hour urine collection.C.  ImagingAbdo minal CT may demonstrate a mesenteric mass with tethering of the bowel, lymphadenopathy, and hepatic metastasis. Abdominal CT or enterography may reveal kinking of the bowel, but because the lesion is extralumi- nal, the diagnosis may be overlooked for several years. Gallium Ga-68 DOTATATE PET scan has replaced soma- tostatin receptor scintigraphy as the standard of care for staging; however, both may help identify disease that may benefit from treatment with somatostatin analogs or pep- tide receptor radionuclide therapy (PRRT). »Treatment & OutcomesSmall  intestinal carcinoids generally are indolent tumors with slow spread. Patients with disease confined to the small intestine should be treated with surgical excision.There is no proven role for adjuvant therapy after complete resection. Five-year survival rates for patients with stage I and II disease are 96% and 87%, respectively. In patients with resectable disease who have lymph node involvement (stage III), the 5-year survival rate is 74%; however, by 25 years, less than 25% remain disease free. Across stages, prognosis is strongly associated with histologic differentia- tion and grade. Patients with grade 1 disease may not require treatment for many years even with metastatic disease. However, patients with a grade 3 neuroendocrine tumor may have a clinical course more similar to a high- grade neuroendocrine carcinoma. In patients with advanced disease, therapy historically has been deferred until the patient is symptomatic. Con- ventional cytotoxic chemotherapy agents do not achieve significant responses in carcinoid tumors and have not been associated with improved outcomes. For patients who are symptomatic either from tumor bulk or carcinoid syn- drome, the cornerstone of therapy is typically a long-acting somatostatin analog, which inhibits hormone secretion from the carcinoid tumor. In 90% of patients, this results in dramatic relief of symptoms of carcinoid syndrome, includ- ing diarrhea or flushing, and may also control tumor growth for a median period of 1 year. Options at disease progression include octreotide dose escalation, or addition of everolimus, a mammalian target of rapamycin (mTOR) inhibitor. For patients with somatostatin receptor–positive disease based on imaging, another option after progression is treatment with PRRT. PRRT consists of a somatostatin analog conjugated to a radioactive isotope such as yttrium-90 or lutetium-177. Studies of anti-angiogenic kinase inhibitors have shown some benefit; currently, suni- tinib is approved in the United States for pancreatic neuro- endocrine tumors. In selected patients with hepatic-dominant disease, resection of hepatic metastases may provide dramatic improvement in carcinoid syndrome symptoms. Tumor debulking with liver-directed chemoembolization or radio- embolization may also provide symptomatic improvement in some of these patients. Patients with advanced, poorly differentiated intestinal NETs are treated in a similar fashion to those with small cell carcinomas. They have a poor prognosis.4.  Small Intestine SarcomaSarco mas constitute approximately 10% of small bowel neoplasms and are commonly found in the jejunum and ileum (and in a Meckel diverticulum, if present). Most arise from stromal tumors (GISTs) that stain positive for CD117; a minority arise from smooth muscle tumors (leiomyosar- comas) (see Gastrointestinal Mesenchymal Tumors above). Common symptoms of small intestine sarcoma include pain, weight loss, bleeding, and perforation. As the lesions tend to enlarge extraluminally, obstruction is rare. Kaposi sarcoma was at one time a common complica- tion in AIDS, but the incidence is declining with antiretro- viral therapy. It can also occur in the setting of immunosuppression after organ transplantation. It is caused by infection with human herpesvirus 8 (HHV8). Lesions may be present anywhere in the intestinal tract.CMDT22_Ch39_p1612-p1675.indd  1645 02/07/21 2:44 PMChAPTER 391646 CMDT 2022V isceral involvement usually is associated with cutaneous disease. Most lesions are clinically silent; however, large lesions may be symptomatic. Widespread involvement may be best treated by systemic chemotherapy using single- agent therapy or combinations of pegylated-doxorubicin, paclitaxel, vincristine, bleomycin, or etoposide. Surgery or radiation may be indicated for isolated high-risk lesions.Akce  M et al. Clinical outcomes of small bowel adenocarcinoma. Clin Colorectal Cancer. 2019;18:257. [PMID: 31606297] Bonds M et al. Neuroendocrine tumors of the pancreaticobiliary and gastrointestinal tracts. Surg Clin North Am. 2020;100:635. [PMID: 32402306] Lee MR et al. Incidence trends of gastroenteropancreatic neuro- endocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17:2212. [PMID: 30580091] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Small Bowel Adenocarcinoma. Ver- sion 2.2020. 2020 May 6. https://www.nccn.org/professionals/ physician_gls/pdf/small_bowel.pdf Scott AT et al. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14:471. [PMID: 30096273]COLOR ECTAL CANCERE S S E N T I A L S  O F  D I A G N O S I S »Personal or family history of adenomatous or ser- rated polyps or colorectal cancer are important risk factors. »Symptoms or signs depend on tumor location. »Proximal colon: fecal occult blood, anemia. »Distal colon: change in bowel habits, hematochezia. »Diagnosis established with colonoscopy. »General ConsiderationsColor ectal cancer is the second leading cause of death due to malignancy in the United States. Colorectal cancer will develop in approximately 4.2% of Americans and has a 5-year survival rate of 65%. In 2020, there were an estimated 147,950 new cases of colorectal cancer in the United States, with an estimated 53,200 deaths. Between 1996 and 2010, its mortality rate decreased by 46%. A 2015 National Health Interview Survey estimated that 62% of US adults have undergone recommended screening. On average, new cases have been falling 3.2% each year over the last 10 years. Colorectal cancers are almost all adenocarcinomas, which tend to form bulky exophytic masses or annular constricting lesions. The majority of colorectal cancers are thought to arise from malignant transformation of an adenomatous polyp (tubular, tubulovillous, or villous ade- noma) or serrated polyp (hyperplastic polyp, traditional serrated adenoma, or sessile serrated adenoma). Polyps that are “advanced” (ie, polyps at least 1 cm in size, adeno- mas with villous features or high-grade dysplasia, or ser- rated polyps with dysplasia) are associated with a greaterrisk of cancer. Approximately 85% of sporadic colorectal cancers arise from adenomatous polyps. They have loss of function of one or more tumor suppressor genes (eg, p53, APC, orDCC ) due to a combination of spontaneous muta- tion of one allele combined with chromosomal instability and aneuploidy (abnormal DNA content) that leads to dele- tion and loss of heterozygosity of the other allele (eg, 5q, 17q, or 18p deletion). Activation of oncogenes such as KRAS and BRAF is present in a subset of colorectal cancers with prog- nostic and therapeutic implications discussed further below. Approximately 10–20% of colorectal cancers arise from serrated polyps, most of which have hypermethylation of CpG-rich promoter regions that leads to inactivation of the DNA mismatch repair gene MLH1, resulting in MSI, and activation of mutations of the BRAF gene. Serrated colon cancers have distinct clinical and pathologic characteris- tics, including diploid DNA content, predominance in the proximal colon, poor differentiation, and more favorable prognosis. Up to 5% of colorectal cancers are caused by inherited germline mutations resulting in polyposis syndromes (eg, familial adenomatous polyposis) or hereditary nonpolypo- sis colorectal cancer (HNPCC or Lynch syndrome). These conditions are discussed further in Chapter 15. »Risk FactorsA n umber of factors increase the risk of developing colorec- tal cancer. Some of these factors include smoking, consump- tion of red and processed meats, alcohol intake, diabetes mellitus, physical inactivity, obesity, and history of inflam- matory bowel disease. Recognition of these factors has had an impact on screening strategies. However, 75% of all cases occur in people with no known predisposing factors.A.  AgeThe  incidence of colorectal cancer rises sharply after age 45 years, and 90% of cases occur in persons over the age of 50 years. The median age at diagnosis is 68 for men and 72 for women. Over the past two decades there has been a 20% decrease in incidence among adults over age 50 (likely due to colorectal cancer screening programs) but a 50% increase in incidence among adults under age 50 (espe- cially in the distal colon and rectum). The incidence of young adult–onset colorectal cancer is rising in all racial and ethnic groups but is highest in Blacks. In the United States, the colorectal cancer incidence rates in adults over age 50 is 40/100,000 and is 12.2/100,000 in adults younger than age 50. It is estimated that by 2030, 10% of colon cancer and 20% of rectal cancers will occur in patients under the age of 50. The reason for the increase in colorectal cancer incidence among adults under age 50 is uncertain.B.  Family History of NeoplasiaA family history of colorectal cancer is presen t in approxi- mately 20% of patients with colon cancer. Hereditary fac- tors are believed to contribute to 20–30% of colorectal cancers; however, the genes responsible for most of these cases have not yet been identified. Hereditary cancerCMDT22_Ch39_p1612-p1675.indd  1646 02/07/21 2:44 PMCANCER1647 CMDT 2022syndromes  (Lynch syndrome or polyposis syndromes) account for approximately 3–4% of colorectal cancers in patients 50 years or older but 10–15% of patients with young adult–onset colorectal cancer (see Chapter 15). Approximately 6% of the Ashkenazi Jewish population has a missense mutation in the APC gene (APC I1307K) that confers a modestly increased lifetime risk of developing colorectal cancer (odds ratio [OR] 1.4–1.9) that phenotypi- cally resembles sporadic colorectal cancer rather than familial adenomatous polyposis. Genetic screening is avail- able, and patients harboring the mutation merit more intensive colorectal screening. A family history of colorectal cancer or adenomatous polyps is one of the most important risk factors for colorec- tal cancer. The risk of colon cancer is proportionate to the number and age of affected first-degree family members with colon neoplasia. People with one first-degree family member with colorectal cancer have an increased risk approximately two times that of the general population; however, the risk is almost four times if the family member was younger than 45 years when the cancer was diagnosed. Patients with two first-degree relatives have a fourfold increased, or 25–30% lifetime, risk of developing colon can- cer. First-degree relatives of patients with adenomatous pol- yps also have a twofold increased risk for colorectal neoplasia, especially if they were younger than 60 years when the polyp was detected or if the polyp was 10 mm or larger.C.  Inflammatory Bowel DiseaseThe  risk of adenocarcinoma of the colon begins to rise 8 years after disease onset in patients with ulcerative colitis and Crohn colitis (see Chapter 15). For this reason, initia- tion of surveillance with colonoscopy is recommended at 8–10 years after onset of inflammatory bowel disease symptoms.D . Dietary and Lifestyle Factors and ChemopreventionIn  epidemiologic studies, diets rich in fats and red meat are associated with an increased risk of colorectal adenomas and cancer, whereas diets high in fruits, vegetables, and fiber are associated with a decreased risk. However, pro- spective studies have not shown a reduction in colon can- cer or recurrence of adenomatous polyps with diets that are low in fat; that are high in fiber, fruits or vegetables; or that include calcium, folate, beta-carotene, or vitamin A, C, D, or E supplements. Meta-analyses suggest that individuals with increased physical activity are up to 27% less likely to develop colon cancer. There also is a correlation between increasing body mass index and cancer risk, such that for each increase of 5 kg/m2in BMI, there is a 5% increased cancer risk. Patients with higher levels of pre- and post-diagnosis physical activ- ity experience reduced colorectal cancer–specific mortality and all-cause mortality. Maintaining a healthy body weight, a healthy diet, and a physically active lifestyle are recom- mended in colorectal cancer survivors. Low-dose aspirin has been associated with a reduced risk of colorectal adenomas and cancer in multiple studies.A 2016 USPSTF systematic review of controlled trials con- cluded that prolonged regular use of low-dose aspirin (81 mg/day) is associated with a 40% reduction in colorectal cancer incidence after 10 years and a 33% reduction in colorectal cancer mortality after 20 years. Because long- term aspirin use is associated with a low incidence of seri- ous complications (gastrointestinal hemorrhage, stroke), low-dose aspirin should not be routinely administered as a chemopreventive agent without other medical indications. Low-dose aspirin may also be considered in patients with a personal or family history of colorectal cancer or advanced adenomas; however, its administration does not obviate the need for colonoscopy screening and surveillance.E.  Other FactorsThe  overall incidence of colorectal cancer is similar in men and women; however, similar incidence rates are reached in women about 4–6 years later than in men. A higher proportion of cancers are located in the proximal colon in women (46%) than men (37%). The incidence and mortal- ity of colon adenocarcinoma is higher in Blacks and Native Americans than in Whites. It is unclear whether this is due to genetic or socioeconomic factors (eg, diet or reduced access to medical care). »Clinical FindingsA.  Symptoms and SignsAdenocar cinomas grow slowly and may be present for several years before symptoms appear. However, some asymptomatic tumors may be detected by the presence of fecal occult blood (see Screening for Colorectal Neo- plasms, below). Symptoms depend on the location of the carcinoma. Chronic blood loss from right-sided colonic cancers may cause iron deficiency anemia, manifested by fatigue and weakness. Obstruction, however, is uncommon because of the large diameter of the right colon and the liquid consistency of the fecal material. Lesions of the left colon often involve the bowel circumferentially. Because the left colon has a smaller diameter and the fecal matter is solid, obstructive symptoms may develop with colicky abdominal pain and a change in bowel habits. Constipation may alternate with periods of increased frequency and loose stools. The stool may be streaked with blood, though marked bleeding is unusual. With rectal cancers, patients note tenesmus, urgency, and recurrent hematochezia. Physical examination is usually normal except in advanced disease. The liver should be examined for hepatomegaly, suggesting metastatic spread. For cancers of the distal rec- tum, digital examination is necessary to determine whether there is extension into the anal sphincter or fixation, sug- gesting extension to the pelvic floor.B.  Laboratory FindingsA  CBC should be obtained to look for anemia. Elevated liver biochemical tests raise suspicion of metastatic disease. The serum carcinoembryonic antigen (CEA) should be measured in all patients with proven colorectal cancer but is not appropriate for screening. The CEA is not elevated inCMDT22_Ch39_p1612-p1675.indd  1647 02/07/21 2:44 PMChAPTER 391648 CMDT 2022man y patients with confirmed colorectal cancer; con- versely, the CEA may be elevated in active smokers and those with a variety of other nonmalignant conditions. A preoperative CEA level greater than 5 ng/mL is a poor prognostic indicator. After complete surgical resection, CEA levels should normalize; persistently elevated levels suggest the presence of persistent disease and warrant fur- ther evaluation. CEA is routinely monitored at the time of adjuvant therapy and during postoperative surveillance for patients who had elevated levels before resection.C.  ColonoscopyColo noscopy is the required diagnostic procedure in patients with a clinical history suggestive of colorectal cancer or in patients with an abnormality suspicious for cancer detected on radiographic imaging. Colonoscopy and upper endos- copy should be considered in all adults with new-onset iron deficiency anemia. Colonoscopy permits biopsy for patho- logic confirmation of malignancy.D . ImagingChes t, abdominal, and pelvic CT scans with contrast are required for preoperative staging. CT scans may demon- strate distant metastases but are less accurate in the determi- nation of the level of local tumor extension (T stage) or lymphatic spread (N stage). Intraoperative assessment of the liver by direct palpation and ultrasonography can be per- formed to detect hepatic metastases (M stage). For rectal cancers (generally defined as tumors arising 12 cm or less proximal to the anal verge), pelvic MRI or endorectal ultra- sonography is required to determine the depth of penetra- tion of the cancer through the rectal wall (T stage) and perirectal lymph nodes (N stage), informing decisions about preoperative (neoadjuvant) chemoradiotherapy and opera- tive management. PET is not routinely used for staging or surveillance in colorectal cancers. »StagingThe  TNM system is the commonly used classification to stage colorectal cancer. Staging is important not only because it correlates with the patient’s long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. »Differential DiagnosisThe  nonspecific symptoms of colorectal cancer may be con- fused with those of irritable bowel syndrome, diverticular disease, ischemic colitis, inflammatory bowel disease, infec- tious colitis, and hemorrhoids. Neoplasm must be excluded in any patient over age 40 years who reports a change in bowel habits or hematochezia or who has an unexplained iron deficiency anemia or occult blood in stool samples. »TreatmentA.  Colon CancerSurgical resection  of the colonic tumor is the treatment of choice for almost all patients. It may be curative in patientswith stage I, II, and III disease and even some patients with metastatic (stage IV) disease. Multiple studies demonstrate that minimally invasive, laparoscopically assisted colec- tomy results in similar outcomes and rates of recurrence to open colectomy. Regional dissection of at least 12 lymph nodes should be performed to determine staging, which guides decisions about adjuvant therapy. Following com- plete endoscopic removal of an adenomatous polyp (polyp- ectomy) that is found on pathologic review to contain a focus of cancer (malignant polyp), observation is a reason- able alternative to further surgical resection in carefully selected patients with invasion into the submucosa (T1 disease). Pathology review of colorectal cancers should include testing for mismatch repair proteins for all patients. Tumors of patients with metastatic colorectal cancer should also be tested for extended RAS andBRAF mutations. Following surgical resection, chemotherapy has been demonstrated to improve overall and tumor-free survival in select patients with colon cancer depending on stage (Table 39–2). 1. Stage I— Because of the excellent 5-year survival rate (approximately 92%), no adjuvant therapy is recommended for stage I colon cancer. 2. Stage II node-negative disease— The 5-year survival rate is approximately 87% for stage IIA disease and 63% for stage IIB disease. A significant survival benefit from adju- vant chemotherapy has not been demonstrated in most randomized clinical trials for stage II colon cancer (see discussion for stage III disease). However, otherwise healthy patients with stage II disease who are at higher risk for recurrence (perforation; obstruction; close or indeter- minate margins; poorly differentiated histology; lymphatic, vascular, or perineural invasion; T4 tumors; or fewer than 12 lymph nodes sampled) may benefit from adjuvant che- motherapy. Patients whose tumors reveal MSI have a more favorable prognosis and do not benefit from 5-fluorouracil- based adjuvant therapy. 3. Stage III node-positive disease— With surgical resec- tion alone, the expected 5-year survival rate is 30–50%. Postoperative adjuvant chemotherapy significantly increases disease-free survival as well as overall survival by up to 30% and is recommended for all fit patients (Table 39–2). Multiple large, well-designed studies of adjuvant therapy for stage III colorectal cancer have reported a higher rate of disease-free survival at 5 years for patients treated for 6 months postoperatively with a combination of oxalipla- tin, 5-fluorouracil, and leucovorin (FOLFOX) (73.3%) than with 5-fluorouracil and leucovorin (FL) alone (67.4%). Similar benefit was reported for patients treated with oxali- platin and capecitabine (orally active fluoropyrimidine). A large international randomized controlled trial com- paring 3 months with 6 months of adjuvant therapy for colon cancer found that 3 months of adjuvant therapy resulted in equivalent disease-free survival for patients with earlier stage T1, T2, or T3, and N1 disease but not with more advanced T4 or N2 disease. For patients with high-risk disease (T4 or N2), 6 months of adjuvant che- motherapy are still recommended. The addition of aCMDT22_Ch39_p1612-p1675.indd  1648 02/07/21 2:44 PMCANCER1649 CMDT 2022biologic  agent (bevacizumab or cetuximab) to adjuvant chemotherapy does not improve outcomes. 4. Stage IV metastatic disease— Approximately 20% of patients have metastatic disease at the time of initial diag- nosis, and an additional 30% eventually develop metastasis. A subset of these patients has limited disease that is poten- tially curable with surgical resection. Surgery may also be warranted to provide palliation of tumor bleeding or obstruction. Resection of isolated liver metastases may result in long-term (over 5 years) survival in 35–55% of cases. For those with unresectable hepatic metastases, local ablative techniques (cryosurgery, radiofrequency or micro- wave coagulation, embolization, hepatic intra-arterial che- motherapy) or radiation may provide long-term tumor control. A subset of patients who have isolated pulmonary metastases may undergo resection or radiation with poten- tial cure. In the absence of other treatment, the median survival is less than 12 months; however, with current therapies, median survival approaches 30 months. Primary cancer location has been found to have a potential prog- nostic importance: median survival times are 33.3 months for patients with left-sided colon cancers compared to 19.4 months for those with right-sided cancers. The goals of therapy for patients with metastatic colorectal cancer are to slow tumor progression while maintaining a reasonable quality of life for as long as pos- sible. Currently, either FOLFOX (the addition of oxalipla- tin to 5-fluorouracil and folinic acid) or FOLFIRI (the addition of irinotecan to 5-fluorouracil and folinic acid) is the preferred first-line treatment regimen for fit patients. For convenience, oral capecitabine (instead of intravenous 5-fluorouracil and leucovorin) can be used in combination with oxaliplatin since it has similar efficacy to 5-fluorouracil; however, combination with irinotecan is not recommended due to increased toxicity (diarrhea). Addition of a biologic agent to combination chemotherapy improves response rates and overall survival and is recommended in the first line of treatment in suitable patients. Bevacizumab is a monoclonal antibody targeting VEGF. Combination of bevacizumab with FOLFOX or FOLFIRI prolongs mean survival by 2–5 months compared with either regimen alone. Cetuximab and panitumumab are monoclonal anti- bodies targeting EGFR. Activating K-ras gene mutations downstream of EGFR are present in approximately 35% of patients with metastatic colorectal cancer and are a bio- marker for nonresponse to cetuximab and panitumumab, for which reason the use of these agents is restricted to patients with tumors wild-type for K-ras. Mutations in N-ras and BRAF are also predictive of nonresponse to EGFR inhibition alone. In stage IV patients with K-ras wild-type cancers, the addition of panitumumab or cetux- imab to FOLFOX or FOLFIRI prolongs survival by approx- imately 4 months. When disease progresses despite treatment either with FOLFOX or with FOLFIRI (often in conjunction with bevacizumab or an EGFR-targeted antibody), therapy is switched to the alternate regimen. Although the ideal sequence of agents is not known, patients do benefit from exposure to all available therapies. Clinical trial participa- tion should be considered for eligible patients who areintolerant of or ineligible for standard therapies or in whom disease has progressed.B.  Rectal CancerThe  treatment approach to rectal cancer is guided by clinical staging as determined by colonoscopy and endorectal ultrasound or MRI with endorectal coil. In carefully selected patients with small (less than 4 cm), mobile, well-differentiated T1 rectal cancers that are less than 8 cm from the anal verge, transanal endoscopic or surgical excision may be considered. All other patients with rectal cancer require either a low anterior resection with a colorectal anastomosis or an abdominoperineal resection with a colostomy, depending on how far above the anal verge the cancer is located and the extent of local tumor spread. For invasive rectal carcinoma, preoperative (neoadju- vant) therapy with radiation or chemoradiation, with or without postoperative (adjuvant) therapy with chemother- apy or chemoradiation, is generally recommended in all node-positive tumors and in T3 and greater tumors due to increased risk of local recurrence. The choice and timing of radiation and chemotherapy depend on a host of factors. Neoadjuvant chemoradiation has become the preferred standard in many centers because chemotherapy is more tolerable prior to surgery, leads to improved local control, and may result in improved long-term survival. For patients with clinical node-positive disease, a bulky primary cancer (T4), or a low-lying cancer that will require a permanent colostomy, giving all chemotherapy in the neoadjuvant set- ting (total neoadjuvant therapy) is now an option in NCCN guidelines. After neoadjuvant therapy, the operative approach (low anterior resection versus abdominoperineal resection with colostomy) depends on how far above the anal verge the cancer is located, its size and depth of penetration, and the patient’s overall condition. Careful dissection of the entire mesorectum by either open or laparoscopic surgery reduces local recurrence to 5%. Although low anterior resections obviate a colostomy, they are associated with increased immediate postsurgical complications (eg, leak, dehis- cence, stricture) and long-term defecatory complaints (eg, increased stool frequency, and incontinence). With unre- sectable rectal cancer, the patient may be palliated with a diverting colostomy. »Follow-Up After SurgeryColorectal cancer p atients who have undergone resections for cure are monitored closely to look for evidence of symptomatic or asymptomatic tumor recurrence that may occasionally be amenable to curative resection. Patients should be evaluated every 3–6 months for 2 years and then every 6 months for a total of 5 years with history, physical examination, and laboratory surveillance, including serum CEA levels if baseline levels are elevated. The NCCN and ASCO guidelines recommend surveillance contrast CT scans of chest, abdomen, and pelvis up to every 6–12 months for up to 5 years post-resection in high-risk stage II and all stage III patients. Patients who had aCMDT22_Ch39_p1612-p1675.indd  1649 02/07/21 2:44 PMChAPTER 391650 CMDT 2022comple te preoperative colonoscopy should undergo another colonoscopy 1 year after surgical resection. Patients who did not undergo full colonoscopy preopera- tively also should undergo a full colonoscopy after comple- tion of all adjuvant therapy to exclude other synchronous colorectal neoplasms. If a colonoscopy does not detect new adenomatous polyps 1 year postoperatively, surveillance colonoscopy should be performed every 3–5 years thereaf- ter to look for metachronous polyps or cancer. New onset of symptoms or a rising CEA warrants investigation with chest, abdominal, and pelvic CT and colonoscopy to look for a new primary tumor or recurrence, or metachronous metastatic disease that may be amenable to curative or pal- liative therapy. The majority of colorectal cancer recur- rences occur within 3 years of the conclusion of treatment, and almost all (greater than 90%) occur within 5 years. »PrognosisThe  stage of disease at presentation remains the most important determinant of 5-year survival in colorectal cancer, which is estimated in older registries as: stage I, greater than 90%; stage II, 70–85%; stage III with fewer than 4 positive lymph nodes, 67%; stage III with more than 4 positive lymph nodes, 33%; and stage IV , 5–7%. Long- term registry follow-up data from the modern chemo- therapy era are not yet available. For each stage, rectal cancers have a worse prognosis. For those patients whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). »Screening for Colorectal NeoplasmsColorectal can cer is ideal for screening because it is a com- mon disease that is fatal in almost 50% of cases and yet is curable if detected at an earlier stage. Furthermore, most cases arise from benign adenomatous or serrated polyps that progress over many years to cancer, and removal of these polyps has been shown to prevent the majority of cancers. Colorectal cancer screening is endorsed by the USPSTF, the Agency for Health Care Policy and Research, the American Cancer Society, and every professional gas- troenterology and colorectal surgery society. Although there is continued debate about the optimal cost-effective means of providing population screening, there is now almost unanimous consent that screening of some kind should be offered to all adults ages 45–75 years. The 2018 American Cancer Society recommendations for screening and 2020 USPSTF draft recommendations for screening are listed in Table 39–6. Due to a rising incidence of colorectal cancer in adults younger than 50 years, the 2020 USPSTF and 2018 American Cancer Society guidelines both endorse consideration of screening in asymptomatic, average-risk adults beginning at age 45; however, the cost- effectiveness of this strategy is uncertain. It is important for primary care providers to understand the relative merits of various options and to discuss them with their patients. The potential for harm from screening must be weighed against the likelihood of benefit, especially in elderly patients with comorbid illnesses and shorter life expec- tancy. Although routine screening is not recommended inadults above age 75, it may be considered on a case-by-case basis in adults age 76 through 85 years who have excellent health and functional status. Patients with first-degree relatives with colorectal neo- plasms (cancer or adenomatous polyps) are at increased risk. Therefore, most guidelines recommend initiating screening at age 40–50 years (or 10 years younger than the familial diagnosis) in individuals with first-degree relatives with colorectal cancer or with advanced adenomas. Rec- ommendations for screening in families with inherited cancer syndromes or inflammatory bowel disease are pro- vided in Chapter 15. Screening tests may be classified into two broad catego- ries: stool-based tests and examinations that visualize the structure of the colon by direct endoscopic inspection or radiographic imaging.A.  Stool-Based Tests1.  Fecal occult blood test— Most colorectal cancers and some large adenomas result in increased chronic blood loss. A variety of tests for fecal occult blood are commer- cially available that have varying sensitivities and specifici- ties for colorectal neoplasia. These include guaiac-based fecal occult blood tests (gFOBT) (eg, Hemoccult I and II and Hemoccult SENSA) that detect the pseudoperoxidase activity of heme or hemoglobin and fecal immunochemical tests (FITs) that detect human globin. In clinical trials, FITsTable 39–6. Recommendations for colorectal cancer screening,1based on updated draft 2020 US Preventive Services Task Force and 2018 American Cancer Society recommendations.2Av erage-risk individuals ≥ 45 years old2 Annual fecal occult blood testing using higher sensitivity tests (Hemoccult SENSA) Annual fecal immunochemical test (FIT) Fecal DNA test (interval uncertain) Flexible sigmoidoscopy every 5 years Colonoscopy every 10 years CT colonography every 5 years Individuals wit a family istory of a first-degree member wit colorectal neoplasia3 Single first-degree relative wit colorectal cancer diagnosed at age 60 years or older: Begin screening at age 40. Screen- ing guidelines same as average-risk individual; however, preferred method is colonoscopy every 10 years. Single first-degree relative wit colorectal cancer or advanced adenoma diagnosed before age 60 years, or two first-degree relatives: Begin screening at age 40 or at age 10 years younger than age at diagnosis of the youngest affected relative, whichever is first in time. Recommended screening: colonoscopy every 5 years.1 For recommendations for families with inherited polyposis syn- dromes or hereditary nonpolyposis colon cancer, see Chapter 15.2 The American Cancer Society recommends screening of average- risk adults from age 45 to 75; the US Preventive Services Task Force recommends screening of all adults ages 50–75 (Grade A recom- mendation) and ages 45–59 (Grade B). Both recommend screen- ing in selected patients ages 76–85 based on life expectancy, patient preferences, overall health, and prior screening results.CMDT22_Ch39_p1612-p1675.indd  1650 02/07/21 2:44 PMCANCER1651 CMDT 2022have  proven superior to gFOBT in sensitivity for detection of colorectal cancer and advanced adenomas with similar specificity. Because FITs are not affected by diet or medica- tions and have superior accuracy, the USMSTF now rec- ommends their use instead of gFOBT. In 19 clinical studies, the pooled sensitivity and specificity of FIT for colorectal cancer in average-risk patients were 79% and 94%, respectively. FIT testing is the preferred option for population-based screening in various European and Australian programs. In the United States, it is offered as the preferred option by many health care plans. For health care systems in which screening colonoscopy is readily available, FIT is a suitable option for patients seeking a noninvasive screening test who are willing to undertake annual fecal testing. The opti- mal interval (yearly or every 2 years) and number of stool samples (one or two) required for optimal FIT testing is as yet undetermined, but currently annual testing is recom- mended. Patients with a positive FIT test must undergo further evaluation with colonoscopy. 2. Multitarget DNA assay— Stool DNA tests measure a variety of mutated genes and methylated gene markers from exfoliated tumor cells. A newer-generation assay (Cologuard) combines a fecal DNA panel with a FIT. In a prospective comparative trial conducted in persons at aver- age risk for colorectal cancer undergoing colonoscopy, the sensitivity for colorectal cancer for Cologuard was 92.3% vs 73.8% for FIT alone and the sensitivity for adenomas larger than 1 cm or serrated polyps for Cologuard was 42.4% vs 23.8% for FIT alone. A positive stool DNA test requires colonoscopy evaluation. Compared with FIT testing alone, FIT-fecal DNA testing has disadvantages including higher cost, lower specificity, lower cost-effectiveness, and cum- bersome requirements for stool collection and mailing.B.  Endoscopic Examinations of the Colon1.  Colonoscopy— Colonoscopy permits examination of the entire colon. In addition to detecting early cancers, colo- noscopy allows removal of adenomatous polyps by biopsy or polypectomy, which is believed to reduce the risk of subsequent cancer. Over the past decade, there has been a dramatic increase in screening colonoscopy, with over 60% of US adults screened in the past 10 years. In asymptomatic individuals between 50 and 75 years of age undergoing screening colonoscopy, the prevalence of advanced colonic neoplasia is 4–11% and of colon cancer is 0.1–1%. Although colonoscopy is believed to be the most sensi- tive test for detecting adenomas and cancer, it has several disadvantages. Adequate visualization of the entire colonic mucosa requires thorough bowel cleansing the evening and morning prior to the examination. To alleviate discomfort during the procedure, intravenous sedation is used for most patients, necessitating a companion to transport the patient home post-procedure. Serious complications occur uncommonly; they include perforation (0.1%), bleeding (0.25%), and death (2.9/100,000). The skill of the operator has a major impact upon the quality of the colonoscopy examination. In several studies, the rate of colorectal cancer within 3 years of a screeningcolonoscopy was 0.7–0.9%, ie, approximately 1 in 110 patients. Population-based case-control and cohort studies suggest that colonoscopy is associated with greater reduc- tion in colorectal cancer incidence and mortality in the distal colon (80%) than the proximal colon (40–60%). This may be attributable to incomplete examination of the proximal colon, and differences between the proximal and distal colon that include worse bowel preparation, subopti- mal colonoscopic technique, and a higher prevalence of serrated polyps and flat adenomas, which are more diffi- cult to identify than raised (sessile or pedunculated) polyps. To optimize diagnostic accuracy as well as patient safety and comfort, colonoscopy should be performed after optimal bowel preparation by a well-trained endoscopist who spends sufficient time (at least 7 minutes) carefully examining the colon (especially the proximal colon) while withdrawing the endoscope. 2. Flexible sigmoidoscopy— Use of a 60-cm flexible sig- moidoscope permits visualization of the rectosigmoid and descending colon. Adenomatous polyps are identi- fied in 10–20% and colorectal cancers in 1% of patients. The finding at sigmoidoscopy of an adenomatous polyp in the distal colon increases the likelihood at least twofold that an advanced neoplasm is present in the proximal colon. The chief disadvantage of screening with flexible sig- moidoscopy is that it requires some bowel cleansing, it may be associated with some discomfort (since intravenous sedation is not used), and it does not examine the proximal colon. The prevalence of proximal versus distal neoplasia is higher in persons older than age 65 years, in Blacks, and in women.C.  Radiographic and Other Imaging of the Colon1. CT colonograph y— CT colonography requires a similar bowel cleansing regimen as colonoscopy as well as insuffla- tion of air into the colon through a rectal tube, which may be associated with discomfort. Using current imaging soft- ware with multidetector helical scanners, the sensitivity is greater than 95% for the detection of cancer and greater than 84–92% for the detection of polyps 10 mm or larger. CT colonography is less sensitive than colonoscopy for the detection of polyps smaller than 1 cm, flat adenomas, and serrated polyps. The chief disadvantages of CT colonography are the need for a bowel preparation, limited availability in many health care systems, a possible increased risk of neoplasia due to radiation exposure, and the potential for finding incidental extracolonic findings that may lead to further evaluations. CT colonography is an excellent screening option in patients who do not wish to undergo or are unsuitable for colonoscopy and in patients in whom colo- noscopy could not be completed. 2. Capsule colonoscopy— Imaging of the colon can be accomplished by oral ingestion of a capsule that captures video images of the colon. Compared with colonoscopy, the colon capsule has reduced sensitivity for polyps greater than 6 mm (64% vs 84%) and for colorectal cancers (74% vs 100%). At present, it is approved by the FDA forCMDT22_Ch39_p1612-p1675.indd  1651 02/07/21 2:44 PMChAPTER 391652 CMDT 2022evaluation  in patients who are not suitable candidates for colonoscopy or in whom colonoscopy could not evaluate the proximal colon. In addition to its suboptimal sensitivity for neoplasia, the main disadvantages of capsule colonos- copy are its cost, need for extensive bowel preparation, lack of reimbursement by most insurance carriers, and small risk of small bowel obstruction. »When to Refer• Patients with symptoms (change in bowel habits, hema- tochezia), signs (mass on abdominal examination or digital rectal examination), or laboratory tests (iron deficiency anemia) suggestive of colorectal neoplasia should be referred for colonoscopy. •Patients with suspected colorectal cancer or adenoma- tous polyps of any size should be referred for colonoscopy. •Virtually all patients with proven colorectal cancer should be referred to a surgeon for resection. Patients with clinical stage T3 or node-positive rectal tumors (or both) also should be referred to medical and radiation oncologists preoperatively for neoadjuvant therapy. Patients with stage II, III, or IV colorectal tumors should be referred to a medical oncologist. »When to Admit• Patients with complications of colorectal cancer (obstruction, acute bleeding) requiring urgent evalua- tion and intervention. •Patients with advanced metastatic disease requiring palliative care.Biller LH et a l. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669. [PMID: 33591350] Ladabaum U et al. Strategies for colorectal cancer screening. Gastroenterology. 2020;158:418. [PMID: 31394083] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2021. 2021 Jan 21. https://www.nccn.org/professionals/physician_gls/ pdf/colon.pdf National Comprehensive Cancer Network. Clinical Practice Guide- lines in Oncology. Rectal Cancer. Version 1.2021. 2020 Dec 22. https://www.nccn.org/professionals/physician_gls/pdf/rectal. pdf National Institutes of Health. SEER Cancer Stat Facts: Colorectal Cancer, 2020. https://seer.cancer.gov/statfacts/html/colorect. html Petrelli F et al. Total neoadjuvant therapy in rectal cancer: a system- atic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271:440. [PMID: 31318794] Ran T et al. Cost-effectiveness of colorectal cancer screening strategies: a systematic review. Clin Gastroenterol Hepatol. 2019; 17:1969. [PMID: 30659991] Stoffel EM et al. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroen- terology. 2020;158:341. [PMID: 31394082] US Preventive Services Task Force. Colorectal Cancer: Screening 2021 May 18. https://www.uspreventiveservicestaskforce.org/ uspstf/recommendation/colorectal-cancer-screeningCARCINOMA OF THE ANUSThe an al canal is lined from its proximal to distal extent by columnar, transitional, and non-keratinized squamous epi- thelium, which merges at the anal verge with the keratin- ized perianal skin. Cancers arising from the mucosa of the anal canal are relatively rare, comprising only 1–2% of all cancers of the anus and large intestine. Squamous cancers make up the majority of anal cancers. Anal cancer is increased among people practicing receptive anal inter- course and those with a history of anorectal warts. In over 80% of cases, HPV may be detected, suggesting that this virus is a major causal factor. In a large controlled trial, HPV vaccination of healthy men (16 to 26 years old) who have sex with men decreased the incidence of anal intraepi- thelial neoplasia by 50%. Women with anal cancer are at increased risk for cervical cancer (which may be due to a field effect of oncogenic HPV infection) and require gyne- cologic screening and monitoring. Anal cancer is increased in HIV-infected individuals, possibly due to interaction with HPV . Nine-valent HPV (9vHPV) vaccine is recom- mended for boys and girls starting at age 11 or 12 and for individuals up to age 26 who have not been previously vac- cinated. Thereafter, shared clinical decision-making regard- ing HPV vaccination is recommended for some adults aged 27 through 45 years who are not adequately vaccinated. Bleeding, pain, and local mass are the most common symptoms. The lesion is often confused with hemorrhoids or other common anal disorders. These tumors tend to become annular, invade the sphincter, and spread upward via the lymphatics into the perirectal mesenteric lymphatic nodes. CT or MRI scans of the abdomen and pelvis are required to identify regional lymphadenopathy or meta- static disease at diagnosis. PET imaging may be used in conjunction. Treatment depends on the tumor location and histo- logic stage. Well-differentiated and small (less than 2 cm) superficial lesions of the perianal skin may be treated with wide local excision. Adenocarcinoma of the anal canal is treated in similar fashion to rectal cancer (see above), commonly by abdomi- noperineal resection with neoadjuvant chemoradiotherapy and adjuvant chemotherapy. The more common squa- mous cell cancer of the anal canal and large perianal tumors invading the sphincter or rectum are treated with combined-modality therapy that includes external radia- tion with simultaneous chemotherapy (5-fluorouracil plus mitomycin). Local control is achieved in approximately 80% of patients. Radical surgery (abdominoperineal resec- tion) is reserved for patients who fail chemotherapy and radiation therapy. Metastatic disease is generally treated with carboplatin and paclitaxel. The 5-year survival rate is 81% for localized tumors and approximately 30% for meta- static (stage IV) disease.Mahal  AR et al. An update to changing patterns of anal carci- noma in the United States. Am J Clin Oncol. 2020;42:887. [PMID: 31651454] National Cancer Institute. SEER Cancer Stat Facts: Anal Cancer, 2020. https://seer.cancer.gov/statfacts/html/anus.htmlCMDT22_Ch39_p1612-p1675.indd  1652 02/07/21 2:44 PMCANCER1653 CMDT 2022Na tional Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Anal Carcinoma. Version 2.2020. 2020 May 6. https://www.nccn.org/professionals/physician_ gls/pdf/anal.pdf Parwaiz I et al. A systematic review and meta-analysis of prog- nostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy. Clin Oncol (R Coll Radiol). 2019;31:e1. [PMID: 31301958]CA NCERS OF ThE GENITOURINARY TRACT George R. Schade, MD PROSTATE CANCERE S S E N T I A L S  O F  D I A G N O S I S »Prostatic induration on digital rectal examination (DRE) or elevation of PSA. »Most often asymptomatic. »Rarely: systemic symptoms (weight loss, bone pain). »General ConsiderationsProsta te cancer is the most common noncutaneous cancer and the second leading cause of cancer-related death in American men with an estimated 191,930 new prostate cancer diagnoses and 33,330 prostate cancer deaths in 2020. The clinical incidence, however, does not match the prevalence of the disease. Autopsy studies have demon- strated that more than 40% of men over age 50 years have prostate cancer, and its prevalence increases with age with 30% of men aged 60–69 years and 67% of men aged 80–89 years harboring the disease at autopsy. Most of these occult cancers are small indolent organ-confined cancers with few representing regional or metastatic disease. Although the global prevalence of prostatic cancer at autopsy is relatively consistent, the clinical incidence varies consider- ably (high in North America and European countries, inter- mediate in South America, and low in the Far East). A 50-year-old American man has a lifetime risk of 40% for latent cancer, a 16% risk for developing clinically apparent cancer, and a 2.9% risk of death due to prostatic cancer. Black race, family history of prostatic cancer, and history of high dietary fat intake are risk factors for prostate cancer. »Clinical FindingsA.  Symptoms and SignsPresen tly, most prostate cancers are asymptomatic and are diagnosed because of elevations in serum PSA. However, some men will be diagnosed based on discrete nodules or areas of induration within the prostate on a DRE. Obstruc- tive voiding symptoms are most often due to benign pros- tatic hyperplasia, which occurs in the same age group. Nevertheless, large or locally extensive prostatic cancers can cause obstructive voiding symptoms, including urinaryretention. Lymph node metastases can lead to lower extremity lymphedema. Because the axial skeleton is the most common site of metastases, patients may present with back pain, pathologic fractures, or rarely neurologic symp- toms from epidural metastases and cord compression.B.  Laboratory Findings1.  Serum tumor markers— PSA is a glycoprotein produced only by prostatic cells, either benign or malignant. The serum level is typically low and correlates with the total volume of prostate tissue and tends to increase with age. Measurement of serum PSA is useful in detecting and stag- ing prostate cancer, monitoring response to treatment, and identifying recurrence before it becomes clinically evident. As a screening test, PSA is elevated (greater than 4.0 ng/mL [4.0 mcg/L]) in 10–15% of men. Prostate cancer will be diagnosed in approximately 18–30% of men with PSA 4.1–10 ng/mL (4.1–10 mcg/L) and 50–70% of men with PSA greater than 10 ng/mL (10 mcg/L). However, no PSA threshold excludes the diagnosis of prostate cancer. In untreated patients with prostate cancer, the level of PSA correlates with the volume and stage of disease. Patients with PSA levels less than 10 ng/mL (10 mcg/L) usually have localized and therefore potentially curable cancers, while those with PSA levels in excess of 40 ng/mL (40 mcg/L) are more likely to have advanced disease (semi- nal vesicle invasion, lymph node involvement, or occult distant metastases). Approximately 98% of patients with metastatic prostate cancer will have an elevated PSA level. However, there are rare cancers that are localized despite substantial elevations in PSA. Therefore, initial treatment decisions cannot be made on the basis of PSA testing alone. A rising PSA after therapy is usually consistent with pro- gressive disease, either locally recurrent or metastatic. 2. Miscellaneous laboratory testing— Patients with uri- nary retention or with ureteral obstruction due to loco- regionally advanced prostate cancers may present with elevations in blood urea nitrogen or serum creatinine. Patients with bony metastases may have elevations in serum alkaline phosphatase or calcium. Laboratory and clinical evidence of disseminated intravascular coagulation can occur in patients with advanced prostate cancers. 3. Prostate biopsy— Transrectal ultrasound-guided biopsy is the standard method for detection of prostate cancer. The use of a spring-loaded, 18-gauge biopsy needle has allowed transrectal biopsy to be performed with minimal patient discomfort and morbidity. Local anesthesia is standard and increases the tolerability of the procedure. The specimen preserves glandular architecture and permits accurate grad- ing. Prostate biopsy specimens are taken from the apex, mid-portion, and base in men who have an abnormal DRE or an elevated serum PSA, or both. Extended-pattern biop- sies, including a total of at least 10 biopsies, are associated with improved cancer detection and risk stratification of patients with newly diagnosed disease. In addition, suspi- cious hypoechoic prostatic lesions seen on transrectal ultra- sound may be targeted for biopsy. Patients with abnormalities of the seminal vesicles can have these struc- tures specifically biopsied to identify local tumor invasion.CMDT22_Ch39_p1612-p1675.indd  1653 02/07/21 2:44 PMChAPTER 391654 CMDT 2022C.  ImagingU se of imaging for staging should be tailored to the likeli- hood of advanced disease in newly diagnosed cases. CTof the abdomen and pelvis and radionuclide (99-techne- tium) bone scans are generally the first-line staging studies performed, when indicated, to assess for nodal and bony metastases, respectively. MRI allows for evaluation of the prostate as well as regional lymph nodes. The positive predictive value for detec- tion of both capsular penetration and seminal vesicle invasion is similar for transrectal ultrasound and MRI, although newer multi-parametric MRI techniques may better stage patients considering treatment or, alternatively, active surveillance. Additionally, there is a growing role for multi-parametric MRI in prostate cancer diagnosis, particularly among men with previous negative prostate biopsies, to evaluate for suspi- cious prostatic lesions. Such lesions may then be sampled via MRI-guided needle biopsy or via MR Fusion (in which pros- tate MRI images are fused in real-time with images from an ultrasound-guided needle biopsy). Such an approach may improve not only overall cancer detection but discovery of clinically relevant disease, and its use in routine clinical prac- tice has increased and continues to evolve. Conventional radionuclide (99-technetium) bone scans are superior to conventional plain skeletal radio- graphs in detecting bony metastases. Prostate cancer bony metastases tend to be multiple and most commonly occur in the axial skeleton. Men with more advanced local lesions, symptoms of metastases (eg, bone pain), high- grade disease, or elevations in PSA greater than 20 ng/mL (20 mcg/L) should undergo radionuclide bone scan. PET (eg,18F-sodium fluoride [18F-NaF] PET ) and18F-NaF PET/CT hybrid imaging are more sensitive than con- ventional bone scans. However, a high frequency of abnormal scans with18F-NaF PET/CT resulting from degenerative joint disease has limited their usefulness. Fluciclovine (Axumin) PET imaging has been approved for suspected cancer recurrence based on elevated PSA after prior treatment. PSMA (prostate-specific membrane antigen) PET, using small-molecule radiotracers target- ing PSMA (eg,18F-DCFBC [N-[N-[(S)-1,3-dicarboxypro- pyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine]) has shown significant promise as a next-generation imaging method and may replace traditional imaging modalities in the future. Despite application of modern, sophisticated tech- niques, understaging of prostate cancer occurs in at least 20% of patients.D . Genetic TestingThe role of gene tics in prostate cancer diagnosis and man- agement is evolving. A family history of prostate cancer increases the risk of prostate cancer. Additionally, prostate cancer has been associated with several hereditary cancer syndromes (eg, Lynch syndrome, hereditary breast and ovarian cancer syndrome, etc.) with approximately 11% of prostate cancer patients with at least one additional primary cancer carrying germline mutations. Consequently, some patients with prostate cancer and their families may haveelevated risk for other cancers. Further, data suggest that some germline mutations, such as BRCA1/2 , are associated with lower PSA at diagnosis and increased risk of progres- sion and death; approximately 12% of patients with metastatic prostate cancer have germline mutations in homologous DNA repair genes. Finally, germline mutations in DNA repair genes can have implications for treatment and, as a result, play a role in personalized treatment. Patients with prostate cancer should have a thorough review of their family history and those with a concerning family history should be referred for genetic counselling and possible testing. Additionally, patients with high-risk disease or metastatic disease should undergo genetic evalu- ation as well. »Screening for Prostate CancerThe  impact of prostate cancer screening on mortality remains controversial. The screening tests currently avail- able include DRE, PSA testing, and transrectal ultrasound. Prostate cancer detection rates using DRE alone vary from 1.5% to 7%, but unfortunately, most of these cancers are advanced (stage T3 or greater). Transrectal ultrasound should not be used as a first-line screening tool due to its expense, low specificity, and minimal improvement in detec- tion rate versus the combined use of DRE and PSA testing. PSA testing increases the detection rate of prostate can- cers compared with DRE. Approximately 2–2.5% of men older than 50 years of age will be found to have prostate cancer using PSA testing compared with a rate of approxi- mately 1.5% using DRE alone. The sensitivity, specificity, and positive predictive value of PSA and DRE are listed in Table 39–7. PSA-detected cancers are more likely to be localized compared with those detected by DRE alone. The Prostate Cancer Prevention Trial provided data demon- strating a significant risk of prostate cancer even in men with PSA less than 4.0 ng/mL (4.0 mcg/L) (Table 39–8) and a web-based calculator has been developed to estimate the risk of harboring both prostate cancer and high-grade cancer (http://riskcalc.org/PBCG). Table 39–7. Screening for prostatic cancer: test performance.T est Sensitivity SpecificityPositive Pre- dictive Value Abnormal PSA (> 4 ng/mL [mcg/L])0.67 0.97 0.43 Abnormal DRE 0.50 0.94 0.24 Abnormal PSA or DRE0.84 0.92 0.28 Abnormal PSA and DRE0.34 0.995 0.49 DRE, digital rectal examination; PSA, prostate-specific antigen. Modified, with permission, from Kramer BS et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914. Copyright © 1993 American College of Physicians. All rights reserved.CMDT22_Ch39_p1612-p1675.indd  1654 02/07/21 2:44 PMCANCER1655 CMDT 2022T o improve the performance of PSA as a screening test, several investigators have developed alternative methods for its use. These include establishment of age- and race- specific reference ranges, measurement of free serum and protein-bound levels of PSA ( percent free PSA ), and cal- culation of changes in PSA over time ( PSA velocity ). Gen- erally, men with PSA free fractions exceeding 25% are unlikely to have prostate cancer, whereas those with free fractions less than 10% have an approximately 50% chance of having prostate cancer. Newer tests, including the Pros- tate Health Index (PHI) and 4kscore (https://4kscore.com), may better identify not only men at greater risk for prostate cancer but those with more aggressive disease. The frequency of PSA testing also remains a matter of debate. The traditional yearly screening approach may not be the most efficient; rather, earlier PSA testing at younger age may allow less frequent testing later as well as provide information regarding PSA velocity. Men with PSA above the age-based median when tested between 40 and 60 years are at significantly increased risk for subsequent cancer detection over 25 years. Men aged 40–50 with PSA below 0.6 ng/mL (0.6 mcg/L) and aged 50–60 with PSA below 0.71 ng/mL (0.71 mcg/L) may require less frequent PSA tests. In addition, men with PSA velocity greater than 0.35 ng/mL (0.35 mcg/L) per year measured 10–15 years before diagnosis had significantly worse cancer-specific survival compared with those with lower PSA velocity. The NCCN guidelines (https://www.nccn.org/professionals/physician_ gls/f_guidelines.asp) for prostate cancer early detection incorporate many of these factors. The European Associa- tion of Urology (EAU) recommends offering PSA screening to men beginning at age 40–50 years, dependent on risk factors, and subsequently initiating a risk-adapted strategy. Two large, randomized trials have evaluated the benefit of PSA screening for early detection of prostate cancer. In the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, no mortality benefit was observed after combined screening with PSA testing and DRE dur- ing 15-year follow-up. Although screening resulted in a 12% increase in prostate cancer detection, the cancer-specific mortality rate was similar in the screening and controlarms (2.55 and 2.44 deaths per 10,000 person-years, respectively). However, an estimated 86% of control patients received at least one screening PSA test and 46% of control patients received yearly PSA screening during the trial. Conversely, the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial demonstrated a significant 20% reduction in prostate cancer mortality with an absolute reduction of 1.75 deaths per 1000 men screened at 16 years. The number of men needed to be invited for screening to prevent one prostate cancer death was 570 at 16 years compared with 742 at 13 years, while the number of prostate cancers needing to be diagnosed to prevent one prostate cancer death was reduced from 26 to 18, underscoring the importance of adequate long-term follow-up for prostate cancer. In 2018, the USPSTF issued a revised (Grade C) recom- mendation for men aged 55 to 69 years that the decision to undergo periodic PSA–based screening should be an indi- vidual one. Before deciding about screening, men should discuss its potential benefits and harms with their clinician, incorporating their own values and preferences in the deci- sion. The revised recommendation acknowledges that, while screening offers some men a small potential benefit of reducing the chance of dying from prostate cancer, many other men will experience potential harms from screening. These include false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether screening is appropriate in individual cases, the individual patient’s family history, race/ethnicity, comorbid medical conditions, values about the benefits and harms of screening and treatment-specific outcomes, and other health needs should be considered. Clinicians should not screen men who do not express a preference for screening. For men age 70 years and older, the USPSTF recommends against PSA-based screening (Grade D recommendation). »StagingThe  majority of prostate cancers are adenocarcinomas. Most arise in the peripheral zone of the prostate, though a small percentage arise in the central (5–10%) and transi- tion zones (20%) of the gland. Pathologists utilize the Gleason grading system whereby a “primary” grade is applied to the architectural pattern of malignant glands occupying the largest area of the specimen and a “second- ary” grade is assigned to the next largest area of cancer. Grading is based on architectural rather than histologic criteria, and five “grades” are possible. Adding the score of the primary and secondary grades gives a Gleason score from 2 to 10. Gleason score correlates with tumor volume, pathologic stage, and prognosis. A simplified five-grade group system has been introduced by the International Society of Urological Pathologists. »TreatmentA.  General MeasuresThe  optimal management of localized prostate cancer remains controversial owing to the plethora of treatmentTable 39–8. Risk of prostate cancer in men with PSA ≤ 4.0 ng/mL (or mcg/L).PSA  Level (ng/mL [or mcg/L])Percentage wit Prostate CancerPercentage wit hig-Grade1 Prostate Cancer ≤ 0.5 6.6 12.5 0.6–1.0 10.1 10.0 1.1–2.0 17.0 11.8 2.1–3.0 23.9 19.1 3.1–4.0 26.9 25.01 High-grade cancer was defined as Gleason score ≥ 7. Data from Thompson IM et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med. 2004;350:2239.CMDT22_Ch39_p1612-p1675.indd  1655 02/07/21 2:44 PMChAPTER 391656 CMDT 2022optio ns, side effects of the various options, and indolent nature of many prostate cancers. These factors have contrib- uted to uncertainty regarding a definitive survival benefit of treating localized prostate cancer. To help guide treatment decision making, patients are risk stratified according to their PSA level at diagnosis, DRE, and prostate cancer grade (Gleason score). Additionally, patients should have an assessment of life expectancy prior to treatment decision- making since all patients with low-risk disease and many with intermediate-risk disease with less than 10-year life expectancy will not benefit from treatment.B.  Active SurveillanceThe g oal of active surveillance is to avoid treatment in men who may never require it while recognizing and definitively treating men harboring higher-risk disease in order to bal- ance cancer risk with the morbidity of treatment. Treatment decisions are made based on stage, PSA, and cancer grade (Gleason score) as well as the age and health of the patient. Active surveillance alone may be effective management for appropriately selected patients, typically those with low PSA, small volume, well-differentiated cancers, and life expectancy less than 10–15 years. For such patients, active surveillance involves serial PSA levels, DREs, and periodic prostate biopsies to reassess grade and extent of cancer. Endpoints for intervention in patients on active surveil- lance, particularly PSA changes, have not been clearly defined and surveillance regimens remain an active area of research. Nonetheless, they are increasingly accepted by patients and clinicians with contemporary series demon- strating freedom from definitive treatment in greater than half of patients at 5 years, and risk of developing metastases and suffering cancer-specific death in less than 3% and 2%, respectively, at 10 years. Active surveillance, which is distin- guished from mere observation (watchful waiting), is fea- tured prominently in the NCCN and EAU guidelines and is the preferred management in most men with very low risk prostate cancer. This approach is increasingly accepted and incorporated in routine clinical practice.C.  Radical ProstatectomyDuring  radical prostatectomy, the seminal vesicles, prostate, and ampullae of the vas deferens are removed. Refinements in technique have allowed preservation of urinary conti- nence in most patients and erectile function in selected patients. Radical prostatectomy can be performed via open retropubic, transperineal, or laparoscopic (with or without robotic assistance) surgery. Local recurrence is uncommon after radical prostatectomy and related to pathologic stage. Organ-confined cancers rarely recur; however, cancers with adverse pathologic features (capsular penetration, seminal vesicle invasion) are associated with higher local (10–25%) and distant (20–50%) relapse rates. Ideal candidates for radical prostatectomy include healthy patients with stages T1 and T2 prostate cancers. Patients with advanced local tumors (T4) or lymph node metastases are rarely candidates for prostatectomy alone, although surgery is sometimes used in combination with hormonal therapy and postoperative radiation therapy for select high-risk patients.D. Radiation TherapyRadiatio n can be delivered by a variety of techniques to the prostate and, when clinically indicated, to the pelvic lymph nodes. Conformal techniques, including three-dimensional conformal radiation, intensity modulated radiotherapy, and image-guided radiotherapy, have become the standard of care for external photon-based radiotherapy, while proton beam therapy has gained acceptance as an alternative exter- nal beam therapy that theoretically may reduce toxicities. Additionally, hypofractionated and ultra-hypofractionated (ie, stereotactic radiotherapy) regimens have shown prom- ising short- and intermediate-term outcomes vs conven- tionally dosed regimens. Brachytherapy—the implantation of permanent or temporary radioactive sources (palladium, iodine, or iridium) into the prostate—can be used as mono- therapy in those with low-grade or low-volume malignan- cies or combined with external beam radiation in patients with higher-grade or higher-volume disease. The PSA may rise after brachytherapy because of prostate inflammation and necrosis. This transient elevation (PSA bounce) should not be mistaken for recurrence and may occur up to 20 months after treatment. Patients with intermediate- and high-risk disease benefit from concomitant androgen deprivation therapy. As with surgery, the likelihood of local failure fol- lowing radiation correlates with technique and cancer char- acteristics. The likelihood of a positive prostate biopsy more than 18 months after radiation varies between 20% and 60%. Patients with local recurrence are at an increased risk of cancer progression and cancer death compared with those who have negative biopsies. Survival of patients with localized cancers (T1, T2, and selected T3) approaches 65% at 10 years. Ambiguous target definitions, inadequate radia- tion doses, and understaging of the cancer may be respon- sible for the failure noted in some series.E.  Focal TherapyT o reduce the morbidity of localized prostate cancer treat- ment, there has been a growing interest in focal therapy. Focal therapy delivers energy to the prostate, destroying the tumor(s) and a margin of normal prostate tissue while avoiding collateral damage to the neurovascular bundles, external urinary sphincter, bladder, and rectum. To date, several energy sources (cryotherapy, high intensity focused ultrasound, lasers, etc) have been evaluated and several others are under development. The multifocal nature and the difficulty of localizing the prostate cancer with contem- porary imaging techniques combined with the prolonged disease course, lack of clearly defined endpoints, and ran- domized prospective data have limited the widespread adoption of focal therapies as well as a clear understanding of which are the ideal candidates.F . Localized DiseaseAlthough  selected patients may be candidates for active surveillance based on age or health and evidence of small- volume or well-differentiated cancers, most men with an anticipated life expectancy of longer than 10 years should be considered for treatment. Newly introduced genomic tests may provide important information to help guideCMDT22_Ch39_p1612-p1675.indd  1656 02/07/21 2:44 PMCANCER1657 CMDT 2022tr eatment decisions. Both radiation therapy and radical pros- tatectomy result in acceptable levels of local control. A large, prospective, randomized trial compared watchful waiting with radical prostatectomy in 695 men with clinically local- ized and well-differentiated to moderately differentiated cancers. Radical prostatectomy significantly reduced disease- specific mortality, overall mortality, and risks of metastasis and local progression. The relative reduction in the risk of death at 23 years was 0.56 in the prostatectomy group, with the number needed to treat to avert one death (NNT) = 8 patients; the benefit was largest in men younger than age 65 years (relative risk [RR] = 0.45) and with intermediate- risk prostate cancer (RR = 0.38). Surgery also reduced the risk of metastases in older men (RR = 0.68).G.  Locally and Regionally Advanced DiseasePa tients with advanced pathologic stage or positive surgical margins are at an increased risk for local and distant tumor relapse. Due to these risks, such patients have been consid- ered for adjuvant therapy (radiation for positive margins and seminal vesicle invasion or androgen deprivation and/ or radiation for lymph node metastases). Two randomized clinical trials (EORTC 22911 and SWOG 8794) demon- strated improved progression-free and metastasis-free sur- vival with early radiotherapy in these men, and subsequent analysis of SWOG 8794 showed improved overall survival in men receiving adjuvant radiation therapy. However, the publication of two trials comparing adjuvant radiotherapy with early-salvage therapy using contemporary radiother- apy techniques (GETUG-AFU17 and RAVES) demon- strated no difference in 5-year biochemical progression-free survival casting doubt on the benefit of adjuvant radio- therapy in the contemporary era.H.  Metastatic DiseaseSince death due to prosta te carcinoma is almost invariably the result of failure to control metastatic disease, research has emphasized efforts to improve control of distant dis- ease. Most prostate carcinomas are hormone dependent and approximately 70–80% of men with metastatic prostate carcinoma will respond to various forms of androgen deprivation. Androgen deprivation therapy may be effec- tive at several levels along the pituitary–gonadal axis using a variety of methods or agents (Table 39–9). Use of lutein- izing hormone-releasing hormone (LHRH) agonists (leup- rolide, goserelin) achieves medical castration without orchiectomy and is the most common method of reducing testosterone levels. A single LHRH antagonist (degarelix) is FDA approved and has no short-term testosterone “flare” associated with LHRH agonists. Because of its rapid onset of action, ketoconazole should be considered in patients with advanced prostate cancer who present with spinal cord compression, bilateral ureteral obstruction, or dis- seminated intravascular coagulation. Although testoster- one is the major circulating androgen, the adrenal gland secretes the androgens dehydroepiandrosterone, dehy- droepiandrosterone sulfate, and androstenedione. This led to the development of abiraterone acetate (an inhibi- tor of CYP17, a key enzyme in androgen synthesis) to block both testicular and adrenal androgens. Nonsteroidalantiandrogen agents act by competitively binding the receptor for dihydrotestosterone, the intracellular andro- gen responsible for prostate cell growth and development. In addition to immediate side effects of androgen depriva- tion (sexual dysfunction and hot flashes), the chronic sup- pression of testosterone leads to osteoporosis and risk of fractures, cardiovascular disease and diabetes mellitus, and decreased muscle and increased fat. Bisphosphonates can prevent osteoporosis associated with androgen depriva- tion, decrease bone pain from metastases, and reduce skeletal-related events. Denosumab , a RANK ligand inhib- itor, is approved for the prevention of skeletal-related events in patients with bone metastases from prostate cancer and also appears to delay the development of these metastases in patients with castration-resistant prostate cancer. In addition, enzalutamide definitively improves metastasis-free survival in men with nonmetastatic castrate- resistant prostate cancer and rapidly rising PSAs. The management of advanced prostate cancer is rapidly evolving. Contemporary management consists of initiating androgen deprivation therapy with orchiectomy, LHRH agonist, or LHRH antagonist. A meta-analysis compared using an LHRH agonist or orchiectomy alone with an LHRH agonist or orchiectomy plus an antiandrogen agent; results showed little benefit of combination therapy. However, patients at risk for disease-related symptoms (bone pain, obstructive voiding symptoms) should receive concurrent antiandrogens due to the initial elevation of serum testoster- one that accompanies LHRH agonists. For patients with elevated PSAs only (indicating recurrent, but nonmetastatic, cancer), nonsteroidal antiandrogen agents may be useful. Further androgen manipulations, initiation of cytotoxic chemotherapy, and local therapy (eg, radiation) is defined by the cancer’s androgen sensitivity status. For patients with hormone-sensitive metastatic prostate cancer, the addition of systemic cytotoxic chemotherapy with docetaxol to androgen deprivation therapy results in improved survival compared to androgen deprivation therapy alone. Similarly, the addition, of abiraterone acetate plus prednisone to androgen deprivation therapy, results in superior survival compared to androgen deprivation therapy alone. Patients with castrate-resistant disease or prostate can- cer that demonstrates rising PSA or progression of disease despite castrate levels of serum testosterone (less than 50 ng/dL) should continue their LHRH agonist/antagonist regimen. Additional treatment options are stratified based on the presence of metastatic disease. Patients with non- metastatic castrate-resistant disease and long PSA doubling time (longer than10 months) can simply be observed due to their relatively indolent disease. Conversely, nonmeta- static castrate-resistant patients with short doubling times (10 months or less) have demonstrated improved metastasis- free survival with the addition of the potent nonsteroidal androgen receptor antagonists enzalutamide ,apalu- tamide , and darolutamide to androgen deprivation therapy. For patients with metastatic castrate-resistant prostate cancer, docetaxol was the first cytotoxic chemo- therapy agent to improve survival. Enzalutamide and abiraterone improve overall survival in men with meta- static castrate prostate cancer in both the docetaxol naïve and non-naïve setting. Cabazitaxel is a second-line taxaneCMDT22_Ch39_p1612-p1675.indd  1657 02/07/21 2:44 PMChAPTER 391658 CMDT 2022chemothera py that improves overall survival in men who have received docetaxel. Sipuleucel-T, an autologous cel- lular immunotherapy, is FDA approved in asymptomatic or minimally symptomatic men with metastatic castration- resistant prostate cancer. Radium-223 dichloride is approved for the treatment of men with castration-resistant, symptomatic bone metastases, with significant improve- ments in both overall survival and time to skeletal-related events (eg, fractures and spinal cord compression). Finally, patients who have undergone a genetics evaluation and are found to have specific germline or somatic mutations may benefit from personalized treatment strategies. »PrognosisTh e likelihood of success of active surveillance or treatment can be predicted using risk assessment tools that usuallyTable 39–9. Androgen deprivation for prostatic cancer.Lev el Agent Dose Sequelae Pituitary, hypothalamus Diethylstilbestrol 1–3 mg orally daily Gynecomastia, hot flushes, thromboembolic disease, erectile dysfunction LhRh agonists Leuprolide Goserelin Triptorelin HistrelinDaily subcutaneous injection Monthly to quarterly depot injection Monthly depot injection Annual subcutaneous implantErectile dysfunction, hot flushes, gynecomastia, rarely anemia LhRh antagonist Degarelix 240 mg subcutaneously initial dose, then 80 mg subcutaneously monthlyHot flushes, weight gain, erectile dysfunction, increased liver tests Adrenal Ketoconazole 400 mg three times orally daily Adrenal insufficiency, nausea, rash, ataxia Aminoglutethimide 250 mg four times orally daily Adrenal insufficiency, nausea, rash, ataxia Corticosteroid Prednisone 20–40 mg orally daily Gastrointestinal bleeding, fluid retention CYP17a1 inibitor Abiraterone 1000 mg orally daily (with predni- sone 5 mg orally twice daily)Weight gain, fluid retention, hypokalemia, hypertension Testis Orchiectomy  Gynecomastia, hot flushes, erectile dysfunction Prostate cell Antiandrogens Flutamide 250 mg three times orally daily No erectile dysfunction when used alone; nausea, diarrhea Bicalutamide 50 mg orally daily Liver, cardiac, and pulmonary toxicity Enzalutamide 160 mg orally daily Seizures, dizziness, asthenia Apalutamide 240 mg orally daily Fatigue, leukopenia, hyperlipidemia, hyperglycemia, hyperkalemia, seizures (rare) Doralutamide 600 mg orally twice daily Fatigue, extremity pain, rash Cytotoxic cemotera- peutic agentsBone marrow, skin, pulmonary, cardiac, gastrointestinal, hepatic toxicities possible Docetaxel 75 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) Cabazitaxel 20 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) LHRH, luteinizing hormone-releasing hormone.co mbine stage, grade, PSA level, and number and extent of positive prostate biopsies. Several web-based tools are avail- able (eg, https://www.mskcc.org/nomograms/prostate). Widely used nomograms include the Kattan nomogram and theCAPRA nomogram. CAPRA uses serum PSA, Gleason score, clinical stage, percent positive biopsies, and patient age in a point system to risk stratify and predict the likelihood of PSA recurrence 3 and 5 years after radical prostatectomy (Tables 39–10 and 39–11) as well as metastasis and prostate cancer-specific and overall survival. The CAPRA nomogram has been validated on large multicenter and international radical prostatectomy and radiation-treated cohorts. The patterns of prostate cancer progression have been well defined. Small and well-differentiated cancers (Gleason grade 3) are usually confined within the prostate, whereas large-volume (greater than 4 mL) or poorly differentiatedCMDT22_Ch39_p1612-p1675.indd  1658 02/07/21 2:44 PMCANCER1659 CMDT 2022T able 39–11. CAPRA: Probability of freedom from PSA recurrence after radical prostatectomy by CAPRA point total.CA PRA Score3-Year Recurrence-Free Survival (%) (95% CI)5-Year Recurrence-Free Survival (%) (95% CI) 0–1 91 (85–95) 85 (73–92) 2 89 (83–94) 81 (69–89) 3 81 (73–87) 66 (54–76) 4 81 (69–89) 59 (40–74) 5 69 (51–82) 60 (37–77) 6 54 (27–75) 34 (12–57) 7+ 24 (9–43) 8 (0–28) PSA, prostate-specific antigen. Source: https://urology.ucsf.edu/research/cancer/prostate-cancer- risk-assessment-and-the-ucsf-capra-score.Table 39–10. The UCSF Cancer of the Prostate Risk Assessment (CAPRA).V ariable Level Points PSA (ng/mL [or mcg/L]) at diagnosis 0–6 0 6.1–10 1 10.1–20 2 20.1–30 3 > 30 4 Gleason grade, primary/secondary 1–3/1–3 0 1–3/4–5 1 4–5/1–5 3 T stage T1 or T2 0 T3a 1 % positive biopsies (biopsy cores posi- tive divided by the number of biop- sies obtained)< 34% 0 ≥ 34% 1 Age < 50 years 0 ≥ 50 years 1 Source: https://urology.ucsf.edu/research/cancer/prostate- cancer-risk-assessment-and-the-ucsf-capra-score.(G leason grades 4 and 5) cancers are more often locally exten- sive or metastatic to regional lymph nodes or bone. Penetra- tion of the prostate capsule by cancer is common and occurs along perineural spaces. Seminal vesicle invasion is associ- ated with a high likelihood of regional or distant disease and disease recurrence. The most common sites of lymph node metastases are the obturator and internal iliac lymph node chains and of distant metastases, the axial skeleton.»When to Refer• Refer all patients to a urologist for management of localized disease or for active surveillance. •For metastatic disease, medical oncology should be consulted for consideration of systemic treatments. •Active surveillance may be appropriate in selected patients with very low-volume, low-grade prostate cancer. •Localized disease may be managed by active surveil- lance, surgery, or radiation therapy. •Locally extensive, regionally advanced, and metastatic disease often require multimodal treatment strategies.Bill-Ax elson A et al. Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up. N Engl J Med. 2018;379: 2319. [PMID: 30575473] Gourd E. New advances in prostate cancer screening and moni- toring. Lancet Oncol. 2020;21:887. [PMID: 32534632] Hoffman KE et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323:149. [PMID: 31935027] Hugosson J et al; ERSPC investigators. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2019;76:43. [PMID: 30824296] Hussain M et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018; 378:2465. [PMID: 29949494] Kneebone A et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ ANZUP RAVES): a randomised, controlled, phase 3, non- inferiority trial. Lancet Oncol. 2020;21:1331. [PMID: 33002437] Parker CC et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a ran- domised controlled phase 3 trial. Lancet. 2018;392:2353. [PMID: 30355464] Sargos P et al. Adjuvant radiotherapy versus early salvage radio- therapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341. [PMID: 33002438] Shoag JE et al. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465. [PMID: 32558473]BL ADDER CANCERE S S E N T I A L S  O F  D I A G N O S I S »Gross or microscopic hematuria. »Irritative voiding symptoms. »Positive urinary cytology in most patients. »Filling defect within bladder noted on imaging. »General ConsiderationsBladder  cancer is the second most common urologic can- cer; it occurs more commonly in men than women (3.1:1), and the mean age at diagnosis is 73 years. Cigarette smok- ing and exposure to industrial dyes or solvents are risk factors for the disease and account for approximately 60%CMDT22_Ch39_p1612-p1675.indd  1659 02/07/21 2:44 PMChAPTER 391660 CMDT 2022and  15% of new cases, respectively. In the United States, almost all primary bladder cancers (98%) are epithelial malignancies, usually urothelial cell carcinomas (90%). Adenocarcinomas and squamous cell cancers account for approximately 2% and 7%, respectively. The latter is often associated with schistosomiasis, vesical calculi, or pro- longed catheter use. »Clinical FindingsA.  Symptoms and SignsH ematuria—gross or microscopic, chronic or intermittent— is the presenting symptom in 85–90% of patients with bladder cancer. Irritative voiding symptoms (urinary fre- quency and urgency) occur in a small percentage of patients as a result of the location or size of the cancer. Most patients with bladder cancer do not have signs of the disease because of its superficial nature. Abdominal masses detected on bimanual examination may be present in patients with large-volume or deeply infiltrating cancers. Hepatomegaly or palpable lymphadenopathy may be pres- ent in patients with metastatic disease, and lymphedema of the lower extremities results from locally advanced cancers or metastases to pelvic lymph nodes.B.  Laboratory FindingsU rinalysis reveals microscopic or gross hematuria in the majority of cases. On occasion, hematuria is accompanied by pyuria. Azotemia may be present in a small number of cases associated with ureteral obstruction. Anemia may occasionally be due to chronic blood loss or to bone mar- row metastases. Exfoliated cells from normal and abnormal urothelium can be readily detected in voided urine speci- mens. Cytology can be useful to detect the disease initially or to detect its recurrence. Cytology is sensitive in detect- ing cancers of higher grade and stage (80–90%), but less so in detecting superficial or well-differentiated lesions (50%). There are numerous urinary tumor markers under investi- gation for screening or assessing recurrence, progression, prognosis, or response to therapy.C.  ImagingBladder  cancers may be identified as masses within the bladder using ultrasound, CT, or MRI. However, the pres- ence of cancer is confirmed by cystoscopy and biopsy, with imaging primarily used to evaluate the upper urinary tract and to stage more advanced lesions.D . Cystourethroscopy and BiopsyThe  diagnosis and staging of bladder cancers are made by cystoscopy and transurethral resection. If cystoscopy— usually performed under local anesthesia—confirms the presence of a bladder tumor, the patient is scheduled for transurethral resection under general or regional anesthe- sia. Random bladder and transurethral prostate biopsies are occasionally performed to detect occult disease and potentially identify patients at greater risk for cancer recur- rence and progression.»Pathology & StagingGrading  is based on cellular features: size, pleomorphism, mitotic rate, and hyperchromatism. Bladder cancer staging is based on the extent (depth) of bladder wall penetration and the presence of regional or distant metastases. Both cancer grade and stage influence the natural history of bladder cancer including local recurrence within the blad- der and progression to higher-stage disease. »TreatmentPa tients with superficial non–muscle invasive cancers (Tis, Ta, T1) are treated with complete transurethral resection with selective use of a single dose intravesical chemother- apy immediately following resection. The subset of patients with carcinoma in situ (Tis) and those undergoing resec- tion of large, high-grade, recurrent Ta lesions or T1 cancers (or both) are good candidates for additional intravesical therapy. Patients with muscle invasive (T2+) but still localized cancers are at risk for both nodal metastases and progres- sion and require more aggressive treatment. The gold standard treatment is neoadjuvant chemotherapy followed by radical cystectomy, which confers a survival advantage versus cystectomy alone. This is particularly important for higher-stage or bulky tumors to improve their surgical resectability. Trimodal bladder preservation therapy con- sisting of complete transurethral resection, sensitizing sys- temic chemotherapy, and external beam radiotherapy can offer similar outcomes in optimally selected patients.A.  Intravesical TherapyImm unotherapeutic or chemotherapeutic agents delivered directly into the bladder via a urethral catheter can reduce the likelihood of recurrence in those who have undergone complete transurethral resection. Most agents are adminis- tered weekly for 6–12 weeks. Efficacy may be increased by prolonging contact time to 2 hours. The use of main- tenance therapy after the initial induction regimen is beneficial. Common agents include gemcitabine, mito- mycin, doxorubicin, valrubicin, and bacillus Calmette– Guérin (BCG), with the last being the only agent effective in reducing disease progression. Side effects of intravesical chemotherapy include irritative voiding symptoms and hemorrhagic cystitis. Patients in whom symptoms or infection develop from BCG may require antituberculous therapy.B.  Surgical TreatmentAlthough  transurethral resection is the initial form of treatment for all bladder tumors (since it is diagnostic, allows for proper staging, and controls superficial cancers), muscle-invasive cancers require more aggressive treat- ment. Partial cystectomy can be considered in selected patients with solitary lesions at the bladder dome or those with cancer in a bladder diverticulum. Radical cystectomy in men entails removal of the bladder, prostate, seminal vesicles, and surrounding fat and peritoneal attachments and in women removal of the bladder, uterus, cervix,CMDT22_Ch39_p1612-p1675.indd  1660 02/07/21 2:44 PMCANCER1661 CMDT 2022urethra,  anterior vaginal vault, and usually the ovaries. In women with anterior tumors, vaginal and reproductive organ-sparing surgery can be considered. Bilateral pelvic lymph node dissection is performed in all patients. Urinary diversion is performed in all. In most patients, it uses a conduit of ileum or colon. However, continent forms of diversion avoid the necessity of an external appliance; it can be considered in a significant percentage of patients.C.  RadiotherapyExternal  beam radiotherapy delivered in fractions over a 6- to 8-week period is generally well tolerated, but approxi- mately 10–15% of patients will develop bladder, bowel, or rectal complications. Local recurrence is common after radiotherapy alone (30–70%) and it is therefore combined with radiosensitizing systemic chemotherapy to improve complete response and to decrease recurrence rates. Bladder- preserving chemoradiation can be offered to those patients seeking to keep their bladder and is best suited for those with solitary T2 or limited T3 tumors without ureteral obstruction. Radiation with or without chemotherapy can be offered to patients with localized cancers and to patients who are poor candidates for radical cystectomy or to patients with metastatic disease seeking palliation of local symptoms.D . ChemotherapyMetas tatic disease is present in 15% of patients with newly diagnosed bladder cancer. Furthermore, metastases develop in up to 40% of patients within 2 years of cystec- tomy, including those patients who were believed to have localized disease at the time of treatment. Cisplatin-based combination chemotherapy results in partial or complete responses in 15–45% of patients (see Table 39–2) and is the preferred approach. Combination chemotherapy has been used to decrease recurrence rates in patients treated both with surgery and with radiotherapy. Neoadjuvant chemotherapy appears to benefit all patients with muscle-invasive disease prior to planned cystectomy. Chemotherapy should also be consid- ered before surgery in those with bulky lesions or those in whom regional metastases are suspected. Alternatively, adjuvant chemotherapy has been used after cystectomy in patients at high risk for recurrence, such as those who have lymph node involvement or extravesical local invasion.E.  ImmunotherapyThe  FDA has now approved several checkpoint inhibitors as immunotherapy for metastatic urothelial cancer. Approved anti–PDL-1 inhibitors include atezolizumab, durvalumab , and avelumab (Table 39–2). Approved anti- PD1 inhibitors include nivolumab andpembrolizumab. All are approved for second-line treatment of locally advanced or metastatic urothelial cancer that progressed during or after platinum-based chemotherapy. Addition- ally, atezolizumab and pembrolizumab are approved as first-line therapy in cisplatin-ineligible patients whose tumors express PD-L1 or in patients ineligible for any platinum-based chemotherapy regardless of PD-L1expression status. Overall response rates of these agents are similar and range from 17% to 25% in locally advanced and metastatic urothelial bladder cancer. »PrognosisThe  frequency of recurrence and progression are correlated with grade. Whereas progression may be noted in few low- grade cancers (19–37%), it is common with poorly differ- entiated lesions (33–67%). Carcinoma in situ is most often found in association with papillary bladder cancers. Its presence identifies patients at increased risk for recurrence and progression. At initial presentation, approximately 50–80% of blad- der cancers are superficial: stage Ta, Tis, or T1. When properly treated, lymph node metastases and progression are uncommon in such patients and survival is excellent (81%). Five-year survival of patients with T2 and T3 dis- ease ranges from 50% to 75% after radical cystectomy. Long-term survival for patients with metastatic disease at presentation is rare. »When to Refer• Refer all patients to a urologist. Hematuria often deserves evaluation with both upper urinary tract imaging and cystoscopy, particularly in a high-risk group (eg, older men). •Refer when histologic diagnosis and staging require endoscopic resection of cancer. •Metastatic urothelial cancer should be managed by a medical oncologist.Babjuk  M et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)–2019 update. Eur Urol. 2019;76:639. [PMID: 31443960] Faba OR et al. Update of the ICUD-SIU International Consulta- tion on Bladder Cancer 2018: urinary diversion. World J Urol. 2019;37:85. [PMID: 30238399] Flaig TW et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329. [PMID: 32135513] Hussain SA et al. From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. Eur Urol Oncol. 2018;1:486. [PMID: 31158093] Nadal R et al. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10. [PMID: 31030123]C ANCERS OF THE URETER & RENAL PELVISCancers  of the ureter and renal pelvis are rare and occur more commonly in patients who have bladder cancer, Bal- kan nephropathy, or Lynch syndrome, who smoke, or who have a long history of analgesic abuse. The majority are urothelial cell carcinomas. Gross or microscopic hematuria is present in most patients; flank pain secondary to bleed- ing and obstruction occurs less commonly. As with bladder cancers, urinary cytology is often positive in high-grade cancers. The most common signs identified at the time of CT or intravenous urography include an intraluminal fill- ing defect, unilateral nonvisualization of the collectingCMDT22_Ch39_p1612-p1675.indd  1661 02/07/21 2:44 PMChAPTER 391662 CMDT 2022system,  and hydronephrosis. Ureteral and renal pelvic tumors must be differentiated from calculi, blood clots, papillary necrosis, or inflammatory and infectious lesions. On occasion, upper urinary tract lesions are accessible for biopsy, fulguration, or resection using a ureteroscope. Treatment is based on the site, size, grade, depth of pene- tration, and number of cancers present. Most are excised with laparoscopic or open nephroureterectomy (renal pel- vic and upper ureteral lesions) or segmental excision of the ureter (distal ureteral lesions). Endoscopic resection may be indicated in patients with limited renal function or focal, low-grade, cancers. Similar to urothelial bladder cancers, use of chemotherapy prior to surgery may improve outcomes.Kim  HS et al. Immune checkpoint inhibitors for urothelial carci- noma. Investig Clin Urol. 2018;59:285. [PMID: 30182073] Leow JJ et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79:635. [PMID: 32798146] Scotland KB et al. Long term outcomes of ureteroscopic man- agement of upper tract urothelial carcinoma. Urol Oncol. 2020;38:850.e17. [PMID: 32773230]RE NAL CELL CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S »Gross or microscopic hematuria. »Flank pain or mass in some patients. »Systemic symptoms such as fever, weight loss may be prominent. »Solid renal mass on imaging. »General ConsiderationsKidney  (renal cell) and renal pelvis carcinomas account for 3.8% of all adult cancers. In 2019 in the United States, it is estimated that approximately 73,820 cases of renal cell car- cinoma will be diagnosed and 14,770 deaths will result. Renal cell carcinoma has a peak incidence in the sixth decade of life and a male-to-female ratio of 2:1. It may be associated with a number of paraneoplastic syndromes. Risk factors include physical inactivity, obesity, and diabetes mellitus. Cigarette smoking is the only known significant environmental risk factor. Familial causes of renal cell carcinoma have been identified (von Hippel– Lindau syndrome, hereditary papillary renal cell carci- noma, hereditary leiomyoma-renal cell carcinoma, and Birt-Hogg-Dubé syndrome). There is an association with dialysis-related acquired cystic disease and specific genetic aberrations (eg, Xp11.2 translocation). But sporadic carci- nomas are far more common. Renal cell carcinoma originates from the proximal tubule cells. Various histologic cell types are recognized (clear cell, papillary, chromophobe, collecting duct, and sarcomatoid).»Clinical FindingsA.  Symptoms and SignsHisto rically, 60% of patients presented with gross or micro- scopic hematuria. Flank pain or an abdominal mass was detected in approximately 30% of cases. The triad of flank pain, hematuria, and mass, found in only 10% of patients, is often a sign of advanced disease. Fever can occur as a paraneoplastic symptom. Symptoms of metastatic disease (cough, bone pain) occur in 20–30% of patients at presenta- tion. Due to the widespread use of ultrasound and cross- sectional imaging, renal tumors are frequently detected incidentally in individuals with no urologic symptoms. Consequently, there has been profound stage migration toward lower stages of disease over the last 20 years. How- ever, population mortality rates have remained stable.B.  Laboratory FindingsCon temporary studies suggest hematuria is present in less than 50% of patients. Erythrocytosis from increased eryth- ropoietin production occurs in 5%, though anemia is more common; hypercalcemia may be present in up to 10% of patients. Stauffer syndrome is a reversible syndrome of hepatic dysfunction (with elevated liver tests) in the absence of metastatic disease.C.  ImagingSolid  renal masses are often first identified by abdominal ultrasonography or CT. CT and MRI scanning are the most valuable imaging tests for renal cell carcinoma. These scans confirm the character of the mass and provide valuable stag- ing information with respect to regional lymph nodes, renal vein or vena cava tumor thrombus, and adrenal or liver metastases. CT and MRI also provide valuable information regarding the contralateral kidney (function, bilaterality of neoplasm). Chest radiographs or CT exclude pulmonary metastases. Bone scans should be performed for large tumors and in patients with bone pain or elevated serum alkaline phosphatase levels. Brain imaging should be obtained in patients with high metastatic burden or in those with neurologic deficits. »Differential DiagnosisSolid  renal masses are renal cell carcinoma until proven otherwise. Other solid masses include renal angiomyoli- pomas (fat density usually detectable by CT), renal pelvis urothelial cancers (more central location, involvement of the collecting system, positive urinary cytology), renal oncocytomas (indistinguishable from renal cell carcinoma preoperatively), renal abscesses, and adrenal tumors (superoanterior to the kidney). »TreatmentSu rgical extirpation is the primary treatment for localized renal cell carcinoma. Patients with a single kidney, bilateral lesions, or significant medical renal disease should be con- sidered for partial nephrectomy. Patients harboring a small tumor with a normal contralateral kidney and good kidneyCMDT22_Ch39_p1612-p1675.indd  1662 02/07/21 2:44 PMCANCER1663 CMDT 2022funct ion are also candidates for partial nephrectomy, while radical nephrectomy is indicated in patients with cancers larger than 7 cm and those in whom partial nephrectomy is not technically feasible. Radiofrequency and cryosurgical ablation are alternative options instead of surgery in select patients with tumors less than 3–4 cm with similar risk of metastatic progression but higher risk of local recurrence. Active surveillance is warranted in select patients (signifi- cant comorbidity, short life expectancy) and appears safe with low risk of 5-year systemic progression. Percutaneous biopsy can provide tumor histology and grade to help guide treatment decisions. Cytotoxic chemotherapy has no role in the treatment of metastatic renal cell carcinoma. Historically, cytokine-based immunotherapies, such as interferon-alpha and interleukin-2, produced partial response rates of 15–20% and 15–35%, respectively (Table 39–2). Responders tended to have lower tumor burden, metastatic disease confined to the lung, and a high-performance status. Two randomized trials demonstrat- ing a survival benefit of cytoreductive nephrectomy followed by systemic interferon-alpha compared with the use of sys- temic therapy alone led to the widespread adoption of cytore- ductive nephrectomy. Patients most likely to benefit from cytoreduction were those with good performance status, lung only metastases, and good prognostic features. Presently, management strategies are based on tumor histology and patient risk (favorable, intermediate, or poor). Several targeted medications, specifically VEGF, Raf- kinase, and mTOR inhibitors, are effective (40–60% response rates) in patients with advanced kidney cancer (Table 39–2). These oral agents, which include sunitinib, pazopanib, cabozantinib, axitinib, and sorafenib, are generally well tolerated and particularly active for clear cell carcinoma. The optimal timing and combination of these agents remain to be determined. Sunitinib is approved for adjuvant use after complete surgical resection in patients with adverse pathologic features. The mTOR inhibitors everolimus and temsirolimus are approved for use in patients with prior anti-VEGF therapy, as is the combina- tion of lenvatinib and everolimus. Nivolumab is an approved anti-PD-1 immunotherapy for treating metastatic disease that has progressed despite antiangiogenic therapy. Nivolumab in combination with the anti-CTLA4 immuno- therapy ipilimumab and pembrolizumab (anti-PD-1) in combination with the VEGF inhibitor axitinib have proved superior to sunitinib in previously untreated intermediate- and poor-risk metastatic clear cell renal cell carcinoma and are considered the standard first-line treatment for this patient population (Table 39–2). The utilization of cytoreductive nephrectomy in combi- nation with contemporary agents has decreased in response to the results of CARMENA and adoption of combination immunotherapy regimens (nivolumab plus ipilimumab, pembrolizumab plus axitinib). Still, there remains a role for cytoreductive surgery in select patients with intermediate- risk disease. »PrognosisAfter  radical or partial nephrectomy, tumors confined to the renal capsule (T1–T2) demonstrate 5-year disease-freesurvivals of 90–100%. Tumors extending beyond the renal capsule (T3 or T4) and node-positive tumors have 5-year disease-free survivals of 50–60% and 0–15%, respectively. One subgroup of patients with nonlocalized disease has reasonable long-term survival, namely, those with solitary resectable metastases. In this setting, radical nephrectomy with resection of the solitary metastasis results in 5-year disease-free survival rates of 15–30%. »When to Refer• Refer patients with solid renal masses or complex cysts to a urologist for further evaluation. •Refer patients with renal cell carcinoma to a urologic surgeon for surgical excision. •Refer patients with metastatic disease to an oncologist and urologist.Lalani AA et  al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immuno- therapy, and future directions. Eur Urol. 2019;75:100. [PMID: 30327274] Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277. [PMID: 29562145] Rini BI et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116. [PMID: 30779529] Sanchez A et al. Current management of small renal masses, including patient selection, renal tumor biopsy, active surveil- lance, and thermal ablation. J Clin Oncol. 2018;36:3591. [PMID: 30372390]OTH ER PRIMARY TUMORS OF THE KIDNEYOncocytomas  account for 3–5% of renal tumors, are usu- ally benign, and are indistinguishable from renal cell carci- noma on preoperative imaging. These tumors are seen in other organs, including the adrenals, salivary glands, and thyroid and parathyroid glands. Angiomyolipomas are rare benign tumors composed of fat, smooth muscle, and blood vessels. They are most com- monly seen in patients with tuberous sclerosis (often mul- tiple and bilateral) or in young to middle-aged women. CT scanning may identify the fat component, which is diagnos- tic for angiomyolipoma. Asymptomatic lesions less than 5 cm in diameter usually do not require intervention; large lesions can spontaneously bleed. Acute bleeding can be treated by angiographic embolization or, in rare cases, nephrectomy. Lesions over 5 cm are often prophylacti- cally treated with angioembolization to reduce the risk of bleeding.SE CONDARY CANCERS OF THE KIDNEYThe kidney is not an infrequent site fo r metastatic disease. Of the solid tumors, lung cancer is the most common (20%), followed by breast (10%), stomach (10%), and the contralateral kidney (10%). Lymphoma, both Hodgkin and non-Hodgkin, may also involve the kidney, although it tends to appear as a diffusely infiltrative process resulting in renal enlargement rather than a discrete mass.CMDT22_Ch39_p1612-p1675.indd  1663 02/07/21 2:44 PMChAPTER 391664 CMDT 2022TE STICULAR CANCERS (Germ Cell Tumors)E S S E N T I A L S  O F  D I A G N O S I S »Most common neoplasm in men aged 20–35 years. »Patient typically discovers a painless nodule. »Orchiectomy necessary for diagnosis. »General ConsiderationsMalignan t tumors of the testis are rare, with approximately five to six cases per 100,000 males reported in the United States each year. Ninety to 95 percent of all primary testicu- lar tumors are germ cell tumors and can be divided into two major categories: nonseminomas, including embryo- nal cell carcinoma (20%), teratoma (5%), choriocarcinoma (less than 1%), and mixed cell types (40%); and semino- mas (35%). The lifetime probability of developing testicu- lar cancer is 0.3% for an American male. Approximately 5% of testicular cancers develop in a patient with a history of cryptorchism, with seminoma being the most common. However, 5–10% of these tumors occur in the contralateral, normally descended testis. The relative risk of development of malignancy is higher for the intra- abdominal testis (1:20) and lower for the inguinal testis (1:80). Placement of the cryptorchid testis into the scrotum (orchidopexy) does not alter its malignant potential but does facilitate routine examination and cancer detection. Testicular cancer is slightly more common on the right than the left, paralleling the increased incidence of cryptor- chidism on the right side. One to 2 percent of primary tes- ticular cancers are bilateral and up to 50% of these men have a history of unilateral or bilateral cryptorchidism. Primary bilateral testicular cancers may occur synchronously or asynchronously but tend to be of the same histology. Semi- noma is the most common histologic finding in bilateral primary testicular cancers, while malignant lymphoma is the most common bilateral testicular tumor overall. »Clinical FindingsA.  Symptoms and SignsThe  most common symptom of testicular cancer is painless enlargement of the testis. Sensations of heaviness are not unusual. Patients are usually the first to recognize an abnormality, yet often delay in seeking medical attention ranges from 3 to 6 months. Acute testicular pain resulting from intratesticular hemorrhage occurs in approximately 10% of cases. Ten percent of patients are asymptomatic at presentation, and 10% manifest symptoms relating to metastatic disease such as back pain (retroperitoneal metastases), cough (pulmonary metastases), or lower extremity edema (vena cava obstruction). A discrete mass or diffuse testicular enlargement is noted in most cases. Secondary hydroceles may be present in 5–10% of cases. In advanced disease, supraclavicular adenop- athy may be present, and abdominal examination may reveal a mass. Gynecomastia is seen in 5% of germ cell tumors.B. Laboratory FindingsSeveral  serum markers are important in the diagnosis and monitoring of testicular carcinoma, including human cho- rionic gonadotropin (hCG), alpha-fetoprotein, and lactate dehydrogenase. Alpha-fetoprotein is never elevated with pure seminomas, and while hCG is occasionally elevated in seminomas, levels tend to be lower than those seen with nonseminomas. Lactate dehydrogenase may be elevated with either type of tumor and is a marker for disease bur- den. Liver tests may be elevated in the presence of hepatic metastases, and anemia may be present in advanced disease.C.  ImagingScrotal  ultrasound can readily determine whether a mass is intratesticular or extratesticular. Once the diagnosis of testicular cancer has been established by inguinal orchiec- tomy, clinical staging of the disease is accomplished by chest, abdominal, and pelvic CT scanning. »StagingT esticular cancer is staged using the TNM system created based on extent of cancer in the testis, status of regional lymph nodes, the presence of metastases in distant lymph nodes or other viscera, and serum levels of tumor markers. Based on these features, germ cell tumors can be grouped to assign an overall stage: stage I lesion is confined to the testis; stage II demonstrates regional lymph node involve- ment in the retroperitoneum; and stage III indicates distant metastasis. »Differential DiagnosisAn  incorrect diagnosis is made at the initial examination in up to 25% of patients with testicular tumors. Scrotal ultra- sonography should be performed if any uncertainty exists with respect to the diagnosis. Although most intratesticu- lar masses are malignant, a benign lesion—epidermoid cyst—may rarely be seen. Epidermoid cysts are usually very small benign nodules located just underneath the tunica albuginea; occasionally, however, they can be large. Testicular lymphoma is discussed below. »TreatmentIn guinal exploration with early vascular control of the sper- matic cord structures is the initial intervention. If cancer cannot be excluded by examination of the testis, radical orchiectomy is warranted. Scrotal approaches and open tes- ticular biopsies should be avoided. Further therapy depends on the histology of the tumor as well as the clinical stage. Patients with clinical stage I seminomas are candidates for surveillance (preferred), single-agent carboplatin, or adjuvant radiotherapy. Stage IIa and IIb seminomas (retro- peritoneal disease less than 2 cm diameter in IIa and 2–5 cm in IIb) are treated by radical orchiectomy plus retroperito- neal irradiation or primary systemic chemotherapy (etoposide and cisplatin or cisplatin, etoposide, and bleo- mycin) (Table 39–2). Seminomas of stage IIc (greater than 5-cm-diameter retroperitoneal nodes) and stage III receiveCMDT22_Ch39_p1612-p1675.indd  1664 02/07/21 2:44 PMCANCER1665 CMDT 2022primary systemic chemotherap y. After chemotherapy, sur- gical resection of residual retroperitoneal nodes is war- ranted if the node is greater than 3 cm in diameter and positive on PET scan, since 40% will harbor residual carcinoma. Up to 75% of clinical stage I nonseminomas are cured by orchiectomy alone. Selected patients without specific risk factors have low-risk of recurrence and are generally offered surveillance after orchiectomy. These criteria include (1) cancer is confined within the tunica albuginea; (2) cancer does not demonstrate vascular invasion; (3) tumor markers normalize after orchiectomy; (4) radio- graphic imaging of the chest and abdomen shows no evi- dence of disease; and (5) the patient is reliable. Patients most likely to experience relapse on a surveillance regimen include those with predominantly embryonal cancer and those with vascular or lymphatic invasion identified in the orchiectomy specimen. Alternatives to surveillance for clinical stage I nonseminomas include adjuvant chemo- therapy (bleomycin, etoposide, cisplatin) (see Table 39–2) or retroperitoneal lymph node dissection. Following orchiectomy, patients with bulky retroperito- neal disease (greater than 5-cm nodes) or metastatic non- seminomas are treated with combination chemotherapy (cisplatin and etoposide or cisplatin, etoposide, and bleo- mycin) (Table 39–2). If tumor markers normalize and a residual mass greater than 1 cm persists on imaging stud- ies, it is resected because 15–20% will harbor residual cancer and 40% will harbor teratomas. Even if patients have a complete response to chemotherapy, some clinicians advocate retroperitoneal lymphadenectomy since 10% of patients may harbor residual carcinoma and 10%, retro- peritoneal teratoma. If tumor markers fail to normalize following primary chemotherapy, salvage chemotherapy is required (cisplatin, etoposide, and ifosfamide). Postoperative active surveillance by the clinician and patient means patients are followed up every 2–6 months for the first 2 years and every 4–6 months in the third year. For nonseminomas, tumor markers are obtained at each visit, and chest radiographs and abdominal and pelvic CT scans are obtained every 4–6 months. For seminomas, serum tumor markers may be obtained (optional), chest imaging is obtained only as clinically indicated, and abdominal and pelvic CT scans are performed every 3–6 months. Follow-up continues beyond the initial 3 years; however, 80% of relapses will occur within the first 2 years. With rare exceptions, patients who relapse can be cured by chemotherapy or surgery. »PrognosisThe  5-year disease-free survival rates for stage I and IIa seminomas (retroperitoneal disease less than 2 cm in diameter) treated by radical orchiectomy and retroperito- neal irradiation are 98% and 92–94%, respectively. Ninety- five percent of patients with stage III disease attain a complete response following orchiectomy and chemother- apy. The 5-year disease-free survival for patients with stage I nonseminomas (includes all treatments) ranges from 96% to 100%. For low-volume stage II disease, a 5-year disease- free survival of 90% is expected. Patients withbulky retroperitoneal or disseminated disease treated with primary chemotherapy followed by surgery have a 5-year disease-free survival rate of 55–80%. »When to ReferRef er all patients with solid masses of the testis to a urologist and a medical oncologist if metastatic disease is suspected.Goldber g H et al. Germ cell testicular tumors—contemporary diagnosis, staging and management of localized and advanced disease. Urology. 2019;125:8. [PMID: 30597167] King J et al. Management of residual disease after chemotherapy in germ cell tumors. Curr Opin Oncol. 2020;32:250. [PMID: 32168037] Pierorazio PM et al. Performance characteristics of clinical stag- ing modalities for early stage testicular germ cell tumors: a systematic review. J Urol. 2020;203:894. [PMID: 31609176]SE CONDARY CANCERS OF THE TESTISSecondary  cancers of the testis are rare. In men over the age of 50 years, lymphoma is the most common. Overall, it is the most common secondary neoplasm of the testis, accounting for 5% of all testicular cancers. It may be seen in three clinical settings: (1) late manifestation of wide- spread lymphoma, (2) the initial presentation of clinically occult disease, and (3) primary extranodal disease. Radical orchiectomy is indicated to make the diagnosis. Prognosis is related to the stage of disease. Metastasis to the testis is rare. The most common pri- mary site of origin is the prostate, followed by the lung, gastrointestinal tract, melanoma, and kidney.CA NCER COMPLICATIONS & EMERGENCIESSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSP INAL CORD COMPRESSIONE S S E N T I A L S  O F  D I A G N O S I S »Complication of metastatic solid tumor, lym- phoma, or plasma cell myeloma. »Back pain is most common presenting symptom. »Prompt diagnosis is essential because once a severe neurologic deficit develops, it is often irreversible. »Emergent treatment may prevent or potentially reverse paresis and urinary and bowel incontinence. »General ConsiderationsCancers  that cause spinal cord compression most com- monly metastasize to the vertebral bodies, resulting in physical damage to the spinal cord from edema, hemorrhage,CMDT22_Ch39_p1612-p1675.indd  1665 02/07/21 2:44 PMChAPTER 391666 CMDT 2022and  pressure-induced ischemia to its vasculature. Persis- tent compression can result in irreversible changes to the myelin sheaths resulting in permanent neurologic impairment. Prompt diagnosis and therapeutic intervention are essential, since the probability of reversing neurologic symptoms largely depends on the duration of symptoms. Patients who are treated promptly after symptoms appear may have partial or complete return of function and, depending on tumor sensitivity to specific treatment, may respond favorably to subsequent anticancer therapy. »Clinical FindingsA.  Symptoms and SignsBack  pain at the level of the tumor mass occurs in over 80% of cases and may be aggravated by lying down, weight bear- ing, sneezing, or coughing; it usually precedes the develop- ment of neurologic symptoms or signs. Since involvement is usually epidural, a mixture of nerve root and spinal cord symptoms often develops. Progressive weakness and sen- sory changes commonly occur. Bowel and bladder symp- toms progressing to incontinence are late findings. The initial findings of impending cord compression may be quite subtle, and there should be a high index of suspicion when back pain or weakness of the lower extrem- ities develops in a cancer patient.B.  ImagingMRI is usually the initial imaging procedure o f choice in a cancer patient with new-onset back pain. If the back pain symptom is nonspecific, a whole-body PET-CT scan with18 F-2-deoxyglucose may be a useful screening procedure. Bone radiographs are neither sensitive nor specific for the evaluation of a cancer patient with back pain. When neu- rologic findings suggest spinal cord compression, an emer- gent MRI should be obtained; the MRI should survey the entire spine to define all areas of tumor involvement for treatment planning purposes. MRI has a sensitivity of 93% and a specificity of 97% for diagnosis of metastatic spinal cord compression. »TreatmentPa tients with a known cancer diagnosis found to have epi- dural impingement of the spinal cord should be given corticosteroids immediately. The initial dexamethasone dose is 10 mg intravenously followed by 4–6 mg every 6 hours intravenously or orally. Patients without a known diagnosis of cancer should have emergent surgery to relieve the impingement and obtain a pathologic speci- men; preoperative corticosteroids should not be given since they might compromise the pathology results. Patients with solid tumors who have a single area of com- pression and who are considered candidates for surgery are best treated first with surgical decompression followed by radiation therapy. Better outcomes (ie, improved ability to ambulate and improved bladder and bowel function) occur in patients who undergo surgery followed byradiation therapy than in those who receive radiation alone. If multiple vertebral body levels are involved with cancer, fractionated radiation therapy is the preferred treatment option. Corticosteroids are generally tapered toward the end of radiation therapy. A scoring system exists for patients presenting with spinal cord metastases to identify those with poor survival times who would be best managed with supportive care or single fraction palliative radiation.Boussios S et  al. Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges. Anticancer Res. 2018;38:4987. [PMID: 30194142] Hoskin PJ et al. Effect of single-fraction vs multifraction radio- therapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322:2084. [PMID: 31794625] Lawton AJ et al. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol. 2019;37:61. [PMID: 30395488]MA LIGNANT EFFUSIONSE S S E N T I A L S  O F  D I A G N O S I S »Occur in pleural, pericardial, and peritoneal spaces. »Caused by direct neoplastic involvement of serous surface or obstruction of lymphatic drainage. »Half of undiagnosed effusions in patients not known to have cancer are malignant. »General ConsiderationsThe developme nt of an effusion in the pleural, pericardial, or peritoneal space may be the initial finding in a patient with cancer, or an effusion may appear during the course of disease progression. Direct involvement of the serous sur- face with tumor is the most frequent initiating cause of the accumulation of fluid. The most common malignancies causing pleural and pericardial effusions are lung and breast cancers; the most common malignancies associated with malignant ascites are ovarian, colorectal, stomach, and pancreatic cancers. »Clinical FindingsA.  Symptoms and SignsPa tients with pleural and pericardial effusions complain of shortness of breath and orthopnea. Patients with ascites complain of abdominal distention and discomfort. Cardiac tamponade causing pressure equalization in the chambers impairs both filling and cardiac output and can be life- threatening. Signs of tamponade include tachycardia, muf- fled heart sounds, pulsus paradoxus, and hypotension. Signs of pleural effusions include decreased breath sounds, egophony, and percussion dullness.CMDT22_Ch39_p1612-p1675.indd  1666 02/07/21 2:44 PMCANCER1667 CMDT 2022B.  Laboratory FindingsMalignancy is confirmed  as the cause of an effusion when analysis of the fluid specimen shows malignant cells in either the cytology or cell block specimen.C.  ImagingThe  presence of effusions can be confirmed with radio- graphic studies or ultrasonography. »Differential DiagnosisThe  differential diagnosis of a malignant pleural or pericar- dial effusion includes nonmalignant processes, such as infection, pulmonary embolism, heart failure, and trauma. The differential diagnosis of malignant ascites includes similar benign processes, such as heart failure, cirrhosis, peritonitis, and pancreatic ascites. Bloody effusions are usually due to cancer, but a bloody pleural effusion can also be due to pulmonary embolism, trauma and, occasionally, infection. Chylous pleural or ascitic fluid is generally asso- ciated with obstruction of lymphatic drainage as might occur in lymphoma. »TreatmentThe  development of a malignant effusion is a late-stage manifestation of the cancer. Treatment is tailored to the underlying cancer, whether with targeted therapy, chemo- therapy, or immunotherapy, depending on tumor testing results. Effective systemic treatment can lead to regression of the effusion. Acute symptoms related to the effusion often require urgent intervention with drainage of the effu- sion. Decisions regarding palliative management of malig- nant effusion are in large part dictated by the patient’s symptoms and goals of care.A.  Pleural EffusionA  pleural effusion that is symptomatic may be managed initially with a large volume thoracentesis. In some patients, the effusion slowly reaccumulates, which allows for periodic thoracentesis when the patient becomes symp- tomatic. However, in many patients, the effusion reaccu- mulates quickly, causing rapid return of shortness of breath. For those patients, two other management options exist: pleurodesis or indwelling pleural catheter (eg, PleurX). Chest tube drainage followed by pleurodesis involves placement of a chest tube that is connected to closed water seal drainage. After lung expansion is con- firmed on a chest radiograph, a sclerosing agent (such as talc slurry or doxycycline) is injected into the catheter. Patients should be premedicated with analgesics. Pleurode- sis will not be successful if the lung cannot be reexpanded. These patients are better managed with placement of an indwelling catheter that can be drained by a family mem- ber or a visiting nurse. This procedure is often preferable for patients with short life expectancies or for those who do not respond to pleurodesis. In a meta-analysis of random- ized controlled trials comparing indwelling pleural cathe- ter with pleurodesis, indwelling pleural catheters resultedin shorter hospital stays and fewer repeat pleural interven- tions, but increased rates of cellulitis.B.  Pericardial EffusionFluid  may be removed by a needle aspiration or by place- ment of a catheter for more thorough drainage. As with pleural effusions, most pericardial effusions will reaccu- mulate. Management options for recurrent, symptomatic effusions include prolonged catheter drainage (for several days until drainage has decreased to 20–30 mL/day) or surgical intervention such as a pericardiotomy or pericardiectomy.C.  Malignant AscitesPa tients with malignant ascites not responsive to chemo- therapy are generally treated with repeated large-volume paracenteses. Since the frequency of drainage to maintain comfort can compromise the patient’s quality of life, other alternatives include placement of a catheter or port so that the patient, family member, or visiting nurse can drain fluid as needed at home. For patients with portal hyper- tension from large hepatic masses, diuretics (such as spi- ronolactone 100 mg with furosemide 20–40 mg orally daily) may be useful to decrease the need for repeated paracentesis.As ciak R et al. Malignant pleural effusion: from diagnostics to therapeutics. Clin Chest Med. 2018;39:181. [PMID: 29433714] Feller-Kopman DJ et al. Management of malignant pleural effu- sions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198:839. [PMID: 30272503] Iyer NP et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta- analysis. Ann Am Thorac Soc. 2019;16:124. [PMID: 30272486] Walker S et al. Malignant pleural effusion management: keeping the flood gates shut. Lancet Respir Med. 2020;8:609. [PMID: 31669226]HYP ERCALCEMIAE S S E N T I A L S  O F  D I A G N O S I S »Most common paraneoplastic endocrine syndrome. »Usually symptomatic and severe (≥ 15 mg/dL [3.75 mmol/L]); accounts for most inpatients with hypercalcemia. »The neoplasm is clinically apparent in nearly all cases when hypercalcemia is detected. »General ConsiderationsH ypercalcemia affects 20–30% of cancer patients at some point during their illness. The most common cancers causing hypercalcemia are myeloma, breast carcinoma, and NSCLC. Hypercalcemia is caused by one of three mechanisms: sys- temic effects of tumor-released proteins, direct osteolysis of bone by tumor, or vitamin D–mediated osteoabsorption.CMDT22_Ch39_p1612-p1675.indd  1667 02/07/21 2:44 PMChAPTER 391668 CMDT 2022 »Clinical FindingsA.  Symptoms and SignsSy mptoms and signs of hypercalcemia can be subtle; more severe symptoms occur with higher levels of hypercalcemia and with a rapidly rising calcium level. Early symptoms typi- cally include anorexia, nausea, fatigue, constipation, and polyuria; later findings may include muscular weakness and hyporeflexia, confusion, psychosis, tremor, and lethargy.B.  Laboratory FindingsSym ptoms and signs are caused by free calcium; as calcium is bound by protein in the serum, the measured serum calcium will underestimate the free or ionized calcium in patients with low albumin levels. Free ionized calcium can be measured. When the corrected serum calcium rises above 12 mg/dL (3 mmol/L), especially if the rise occurs rapidly, sudden death due to cardiac arrhythmia or asystole may occur. Initial work-up for hypercalcemia includes obtaining serum PTH, PTHrP , and calcitriol levels. The presence of hypercalcemia does not invariably indicate a dismal prognosis, especially in patients with breast cancer, myeloma, or lymphoma.C.  ECGElectrocardiograph y in hypercalcemia often shows a short- ening of the QT interval. »TreatmentEme rgency management should begin with the initiation of intravenous fluids with 0.9% saline at 100–300 mL/h to ensure rehydration with brisk urinary output of the often volume-depleted patient. If kidney function is normal or only marginally impaired, a bisphosphonate should be given. Choices include pamidronate, 60–90 mg intravenously over 2–4 hours, or zoledronic acid, 4 mg intravenously over 15 minutes. Zoledronic acid is more potent than pamidro- nate and has the advantage of a shorter administration time as well as a longer duration of effect. Once hypercalcemia is controlled, treatment directed at the cancer should be initi- ated if possible. In the event that the hypercalcemia becomes refractory to repeated doses of bisphosphonates, other agents that can help control hypercalcemia (at least temporarily) include calcitonin and denosumab; corticosteroids can be useful in patients with myeloma and lymphoma. Salmon calcitonin, 4–8 international units/kg given subcutaneously or intramuscularly every 12 hours, can be used in patients with severe, symptomatic hypercalcemia; its onset of action is within hours but its hypocalcemic effect wanes in 2–3 days. Denosumab, 120 mg given subcutaneously weekly for 4 weeks followed by monthly administration, is a choice for long-term management of bisphosphonate-refractory hyper- calcemia or for patients with kidney dysfunction that pre- cludes use of a bisphosphonate.Asoni tis N et al. Diagnosis, pathophysiology, and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019;51:770. [PMID: 31826272]Zagzag J et al. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin. 2018;68:377. [PMID: 30240520]HYP ERURICEMIA & TUMOR LYSIS SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S »Complication of treatment-associated tumor lysis of hematologic and rapidly proliferating malignancies. »May be worsened by thiazide diuretics. »Rapid increase in serum uric acid can cause acute urate nephropathy from uric acid crystallization. »Reducing pre-chemotherapy serum uric acid is fundamental to preventing urate nephropathy. »General ConsiderationsT umor lysis syndrome (TLS) is seen most commonly fol- lowing treatment of hematologic malignancies, such as acute lymphoblastic leukemia and Burkitt lymphoma. However, TLS can develop from any tumor highly sensitive to chemotherapy. TLS is caused by the massive release of cellular material including nucleic acids, proteins, phos- phorus, and potassium. If both the metabolism and excre- tion of these breakdown products are impaired, hyperuricemia, hyperphosphatemia, and hyperkalemia will develop abruptly. Acute kidney injury may then develop from the crystallization and deposition of uric acid and calcium phosphate within the renal tubules, further exacerbating the hyperphosphatemia and hyperkalemia. »Clinical FindingsA.  Symptoms and SignsSymp toms of hyperphosphatemia include nausea, vomit- ing, anorexia, muscle cramps, tetany, and seizures. High levels of phosphorus and co-precipitation with calcium can cause renal tubule blockage, further exacerbating the kid- ney injury. Hyperkalemia, due to release of intracellular potassium and impaired kidney excretion, can cause arrhythmias and sudden death.B.  Laboratory FindingsThe laborat ory diagnosis of TLS include at least two of the following criteria observed within a 24-hour period: uric acid 8 mg/dL or higher (476 mcmol/L or higher), phos- phate 4.5 mg/dL or higher (1.45 mmol/L or higher), potas- sium 6.0 mEq/L or more (6 mmol/L or more) (or a 25% increase from baseline for these parameters), and corrected serum calcium 7 mg/dL or lower (1.75 mmol/L or lower). A clinical diagnosis of TLS includes meeting the laboratory criteria and at least one clinical criterion: acute kidney injury (creatinine greater than or equal to 1.5 × upper limit of normal or increase greater than 0.3 g/dL or urinaryCMDT22_Ch39_p1612-p1675.indd  1668 02/07/21 2:44 PMCANCER1669 CMDT 2022out put greater than 0.5 mL/kg/h for 6 hours) or cardiac arrhythmia, sudden cardiac death, or seizure. »TreatmentPreven tion is the most important factor in the manage- ment of TLS. Aggressive hydration at least 24 hours prior to chemotherapy as well as 24–48 hours after chemotherapy completion helps keep urine flowing and facilitates excre- tion of uric acid and phosphorus. It is recommended to maintain a urinary output of at least 100 mL/h, and a daily urine volume of at least 3 L/day. If evidence of volume over- load or inadequate urinary output develops, loop diuretics can be used. Thiazide diuretics are contraindicated because they increase uric acid levels and can interact with allopuri- nol. For patients at moderate risk of developing TLS, eg, those with intermediate-grade lymphomas and acute leuke- mias, allopurinol should be given before starting chemo- therapy with dose reductions for impaired kidney function. Rasburicase is given intravenously to patients at high risk for developing TLS, eg, those with high-grade lymphomas or acute leukemias with markedly elevated white blood cell counts. Rasburicase may also be considered for patients with baseline elevated uric acid who are being treated with venetoclax (Bcl-2 inhibitor) for chronic lymphocytic leuke- mia or in any patient in whom uric acid levels reach levels greater than 8 mg/dL despite treatment with allopurinol. Rasburicase cannot be given to patients with known glucose 6-phosphate dehydrogenase (G6PD) deficiency nor can it be given to pregnant or lactating women. »When to ReferShould  urinary output drop, serum creatinine or potas- sium levels rise, or hyperphosphatemia persist, a nephrolo- gist should be immediately consulted to evaluate the need for dialysis.Durani  U et al. Emergencies in haematology: tumor lysis syn- drome. Br J Haematol. 2020;188:494. [PMID: 31774551] Matuszkiewicz-Rowinska J et al. Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res. 2020;45:645. [PMID: 32998135]IN FECTIONSChapt ers 30 and 31 provide more detailed discussions of infections in the immunocompromised patient.E S S E N T I A L S  O F  D I A G N O S I S »In patients with neutropenia, infection is a medi- cal emergency. »Although sometimes attributable to other causes, the presence of fever, defined as a single tempera- ture > 38.3°C (101°F) or a temperature of > 38°C (100.4°F) for > 1 hour, must be assumed to be due to an infection.»General ConsiderationsMa ny patients with disseminated neoplasms have increased susceptibility to infection. In some patients, this results from impaired defense mechanisms (eg, acute leukemia, Hodgkin lymphoma, plasma cell myeloma, chronic lymphocytic leu- kemia); in others, it results from the myelosuppressive and immunosuppressive effects of cancer chemotherapy or a combination of these factors. Complicating impaired defense mechanisms are the frequent presence of indwelling cathe- ters, impaired mucosal surfaces, and colonization with more virulent hospital-acquired pathogens. The source of a neutropenic febrile episode is deter- mined in about 30% of cases through blood, urine, or sputum cultures. The bacterial organisms accounting for the majority of infections in cancer patients include gram- positive bacteria (coagulase-negative Staphylococcus, Staphylococcus aureus, Streptococcus pneumoniae, Coryne- bacterium, and streptococci) and gram-negative bacteria (Escherichia coli, Klebsiella, Pseudomonas, Enterobacter ). Gram-positive organism infections are more common, but gram-negative infections are more serious and life- threatening. The risk of bacterial infections rises when the neutrophil count is below 500/mcL (0.5 × 109/L); the risk markedly increases when the count falls below 100/mcL (0.1 × 109/L) or when there is a prolonged duration of neu- tropenia, typically greater than 7 days. »Clinical FindingsA  thorough physical examination should be performed. Appropriate cultures (eg, blood, sputum, urine and, if indi- cated, cerebrospinal fluid) should always be obtained. Two sets of blood cultures should be drawn before starting antibiotics; if the patient has an indwelling catheter, one of the cultures should be drawn from the line. A chest radio- graph should also be obtained. »TreatmentEmpiric  antibiotic therapy needs to be initiated within 1 hour of presentation and following the collection of blood cultures in the febrile neutropenic patient. The choice of antibiotics depends on a number of different factors includ- ing the patient’s clinical status and any localizing source of infection. If the patient is clinically well, monotherapy with an intravenous beta-lactam with anti- Pseudomonas activity (cefepime, ceftazidime, imipenem/cilastatin, piperacillin/ tazobactam) should be started (see Infections in the Immu- nocompromised Patient, Chapter 30). If the patient is clini- cally ill with hypotension or hypoxia, an intravenous aminoglycoside or fluoroquinolone should be added for “double” gram-negative bacteria coverage. If there is a strong suspicion of a gram-positive organism, such as from aS aureus catheter infection, intravenous vancomycin can be given empirically. Low-risk patients may be treated with oral antibiotics in the outpatient setting. Antibiotics should be continued until the neutrophil count is rising and greater than 500/mcL (0.5 × 109/L) for at least 1 day and the patient has been afebrile for 2 days. If an organism is identified through the cultures, theCMDT22_Ch39_p1612-p1675.indd  1669 02/07/21 2:44 PMChAPTER 391670 CMDT 2022antib iotics should be adjusted to the antibiotic sensitivities of the isolate; treatment should be continued for the appro- priate period of time and at least until the neutrophil count recovers and fever resolves. For the neutropenic patient who is persistently febrile despite broad-spectrum antibiotics, an empiric antifungal drug should be added (amphotericin B, caspofungin, itra- conazole, voriconazole, or liposomal amphotericin B).Braga  CC et al. Clinical implications of febrile neutropenia guidelines in the cancer patient population. J Clin Oncol. 2019;15:25. [PMID: 30629901] Taplitz A et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443. [PMID: 29461916] ºPRIMARY CANCER TREATMENTSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSYS TEMIC CANCER THERAPYDetailed  guidelines from the NCCN for cancer treatment can be found at www.nccn.org. Use of cytotoxic drugs, hormones, antihormones, and biologic agents has become a highly specialized and increasingly effective means of treating cancer, with therapyadministered and monitored by a medical oncologist or hematologist. Selection of specific drugs or protocols for various types of cancer is usually based on results of clini- cal trials. Increasingly, newer agents are being identified that target specific molecular pathways. Yet both initial and acquired drug resistance remains a challenge. Described mechanisms of drug resistance include impaired mem- brane transport of drugs, enhanced drug metabolism, mutated target proteins, and blockage of apoptosis due to mutations in cellular proteins (see Table 39–2 for suggested agents for various cancers).TOXI CITY & DOSE MODIFICATION OF CHEMOTHERAPEUTIC AGENTSU se of chemotherapy to treat cancer is generally guided by results from clinical trials in individual tumor types. The complexity of treating cancer has increased over the last decade as more drugs, including those with targeted mechanisms of action, have been approved by the US Food and Drug Administration (FDA) and introduced into gen- eral practice. Drug side effects and toxicities must be anticipated and carefully monitored. The short- and long- term toxicities of individual drugs are listed in Tables 39–3 and 39–12. Decisions on dose modifications for toxicities should be guided by the intent of therapy. In the palliative setting where the aim of therapy is to improve symptoms and quality of life, lowering doses to minimize toxicity is commonly done. However, when the goal of treatment is cure, dosing frequency and intensity should be maintained whenever possible. Table 39–12. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Allopurinol (Xyloprim) Prevent hyperuricemia from tumor lysis syndrome600–800 mg/day orally Acute: none Delayed: rash Dexrazoxane (Zinecard) Prevent cardiomyopathy second- ary to doxorubicin; anthracy- cline-induced injection site extravasation10 times the doxorubicin dose intravenously before doxorubi- cin; 1000 mg/m2intravenously on days 1 and 2, then 500 mg/m2 intravenously on day 3Acute: nausea Delayed: myelosuppression, elevated transaminases Leucovorin Rescue after high-dose metho- trexate; in combination with 5-fluorouracil for colon cancer10 mg/m2intravenously or orally every 6 hours; 20 mg/m2or 200– 500 mg/m2intravenously before 5-fluorouracil; various dosesAcute: nausea, vomiting, diarrhea Delayed: stomatitis, fatigue Mesna (Mesnex) Prevent ifosfamide-induced hemorrhagic cystitis20% of ifosfamide dose intrave- nously at 0, 4, and 8 hours; various dosesAcute: nausea, vomiting Delayed: fatigue Palifermin (Kepivance) Prevent mucositis following chemotherapy60 mcg/kg/day intravenously for 3 days before and 3 days after chemotherapyAcute: none Delayed: rash, fever, elevated serum amylase, erythema, edema Radium (Ra)-223 dichloride (Xofigo)Symptomatic bone metastases 50 kilobecquerel/kg (1.35 microCurie/kg) intrave- nously every 4 weeks for 6 cyclesAcute: nausea, vomiting, diarrhea, peripheral edema Delayed: myelosuppression Rasburicase (Elitek) Prevent hyperuricemia from tumor lysis syndrome3–6 mg intravenously once Acute: hypersensitivity, nausea, vomiting, diarrhea, fever, headache Delayed: rash, peripheral edema (continued )CMDT22_Ch39_p1612-p1675.indd  1670 02/07/21 2:44 PMCANCER1671 CMDT 2022T able 39–12. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Bone-Modifying Agents Denosumab (Xgeva) Osteolytic bone metastasis 120 mg subcutaneously every 4 weeksAcute: nausea Delayed: hypocalcemia, hypophos- phatemia, fatigue, osteonecrosis of the jaw Pamidronate (Aredia) Osteolytic bone metastasis, hypercalcemia of malignancy90 mg intravenously every 3–4 weeks; 60–90 mg intrave- nously, may repeat after 7 daysAcute: nausea Delayed: dyspnea, arthralgia, bone pain, osteonecrosis of the jaw, nephrotoxicity, hypocalcemia Zoledronic acid (Zometa) Osteolytic bone metastasis, hypercalcemia of malignancy4 mg intravenously every 3–4 weeks; 4 mg intravenously once, may repeat after 7 days— Growt Factors Darbepoetin alfa (Aranesp)Chemotherapy-induced anemia 2.25 mcg/kg subcutaneously weekly; 500 mcg subcutaneously every 3 weeks— Epoetin alfa (Epogen, Procrit)Chemotherapy-induced anemia 40,000 units subcutaneously once weekly; 150 units/kg subcutane- ously three times a weekAcute: injection site reaction Delayed: hypertension, thromboem- bolic events, increased risk of tumor progression or recurrence Filgrastim (Neupogen) Febrile neutropenia prophylaxis, mobilization of peripheral stem cells5–10 mcg/kg/day subcutaneously or intravenously once daily, treat past nadirAcute: injection site reaction Delayed: bone pain Pegfilgrastim (Neulasta) Febrile neutropenia prophylaxis 6 mg subcutaneously once per chemotherapy cycle— Sargramostim (Leukine) Myeloid reconstitution following bone marrow transplant, mobilization of peripheral blood stem cells250 mcg/m2intravenously daily until the absolute neutrophil count is > 1500 cells/mcL (1.5 × 109/L) for 3 consecutive daysAcute: fever, rash, pruritus, nausea, vomiting, diarrhea, injection site reaction, dyspnea Delayed: asthenia, bone pain, mucositis, edema, arrhythmia1 For amifostine, levoleucovorin, pilocarpine, samarium, strontium, filgrastim-sndz, and tbo-filgrastim, see Table 39–12 in CMDT Online at www.accessmedicine.com.A  CBC including a differential count, with absolute neutrophil count and platelet count, and liver and kid- ney tests should be obtained before the initiation of chemotherapy. In patients with good performance sta- tus, normal CBCs, as well as normal liver and kidney function, drugs are started at their full dose. When the intent of chemotherapy is cure, including treatment in the adjuvant setting, every attempt should be made to schedule chemotherapy on time and at full dose. A CBC with differential may be checked at mid cycle (to determine the nadir of the absolute neutrophil and platelet counts), and liver and kidney function tests should be obtained immediately before the next cycle of chemotherapy. Dose reductions may be necessary for patients with impaired kidney or liver function depending on the clear- ance mechanism of the drug. For patients receiving chemo- therapy for palliation, bone marrow toxicity can be managed with dose reductions or delaying the next treat- ment cycle. A schema for dose modification is shown in Table 39–13.1. Bone Marrow ToxicityA.  NeutropeniaGra nulocyte colony-stimulating factor (G-CSF), given as either daily subcutaneous injections (eg, filgrastim, 300 mcg Table 39–13. A common scheme for dose modifica- tion of cancer chemotherapeutic agents.Granulocyte Count Platelet CountSuggested Drug Dosage (% of Full Dose) > 2000 cells/mcL (2 × 109/L)> 100,000/mcL (100 × 109/L)100% 1000–2000 cells/mcL (1–2 × 109/L)75,000–100,000/ mcL (75–100 × 109/L)50% < 1000 cells/mcL (1 × 109/L)< 50,000/mcL (50 × 109/L)0%(continued)CMDT22_Ch39_p1612-p1675.indd  1671 02/07/21 2:44 PMChAPTER 391672 CMDT 2022or  480 mcg) or as a one-time dose (pegfilgrastim, 6 mg) beginning 24 hours after cytotoxic chemotherapy is com- pleted, reduces the duration and severity of granulocytope- nia following cytotoxic chemotherapy (Table 39–12). The American Society of Clinical Oncology and NCCN guide- lines recommend primary prophylaxis with G-CSF when there is at least a 20% risk of febrile neutropenia or when age, medical history, and disease characteristics put the patient at high risk for complications related to myelosuppression.B.  AnemiaErythropoiesis-stimulatin g agents (ESAs) ameliorate the anemia and its associated symptoms caused by cancer che- motherapy but these drugs have untoward effects, includ- ing an increased risk of thromboembolism, and possibly a decreased survival due to cancer-related deaths as well as a shortened time to tumor progression. The FDA recom- mends that these drugs should not be used when the intent of chemotherapy is curative. Administration of red blood cell transfusions is an alternative for managing symptom- atic anemia in chemotherapy patients. ESAs can be an option in cancer patients with symptom- atic anemia undergoing palliative treatment; patient prefer- ence is important in determining when to use ESAs or transfusions. When using ESAs, treatment should not be initiated until the hemoglobin is less than 10 g/dL (100 g/L) and the ESA held when the hemoglobin is greater than 12 g/dL (120 g/L). Epoetin alfa can be given subcutaneously at a dose of 40,000 units weekly or 150 units/kg three times weekly with a target hemoglobin of 11–12 g/dL (110–120 g/L). Darbepoetin alfa is given subcutaneously at a dose of 300–500 mcg every 3 weeks or 2.25 mcg weekly with the same target hemoglobin (see Table 39–12). To have maxi- mum therapeutic effect, patients need to be iron replete. Uncontrolled hypertension is a contraindication to the use of ESAs; blood pressure must be controlled prior to initia- tion of this therapy.C.  ThrombocytopeniaDrug  management of chemotherapy-induced thrombocyto- penia is more limited. Two drugs that activate the thrombo- poietin receptor, romiplostim and eltrombopag, are FDA approved for use in idiopathic thrombocytopenia, thrombo- cytopenia related to interferon therapy of hepatitis C, and thrombocytopenia in aplastic anemia. While these agents have been used in selected cases of refractory chemotherapy- related thrombocytopenia with some reports of success, trials to date have not demonstrated convincing efficacy in patients with chemotherapy-induced thrombocytopenia and neither agent is FDA approved for this indication.2.  Cemoterapy-Induced Nausea & VomitingA numbe r of cytotoxic anticancer drugs can induce nau- sea and vomiting, which can be the most anticipated and stressful side effects for patients. Chemotherapy-induced nausea and vomiting is mediated in part by the stimulation of at least two central nervous system receptors, 5-hydroxy- tryptamine subtype 3 (5HT3) and neurokinin subtype 1 (NK1). Chemotherapy-induced nausea and vomiting can beanticipatory, occurring even before chemotherapy adminis- tration; acute, occurring within minutes to hours of chemo- therapy administration; or delayed, lasting up to 7 days. Chemotherapy drugs are classified into high, moderate, low, and minimal likelihoods of causing emesis (90%, 30–90%, 10–30%, less than 10%, respectively). Highly emetogenic chemotherapy drugs include carmustine, cisplatin, cyclo- phosphamide (at doses over 1.5 g/m2), dacarbazine, and streptozocin, or a combination of regularly dosed anthracy- clines and cyclophosphamide. Moderately emetogenic che- motherapy drugs include azacitadine, bendamustine, carboplatin, crizotinib, cyclophosphamide, cytarabine, doxo- rubicin, epirubicin, ifosfamide, irinotecan, oxaliplatin, and temozolomide. Low emetogenic drugs include bortezomib, capecitabine, dabrafenib, dasatinib, docetaxel, erlotinib, eto- poside, 5-fluorouracil, gemcitabine, hydroxyurea, lenalido- mide, methotrexate, mitomycin, paclitaxel, pemetrexed, pomalidomide, and topotecan. Drugs with minimal risk of emesis include bevacizumab, bleomycin, cetuximab, decitabine, panitumumab, rituximab, trastuzumab, and vincristine. Major advances have occurred in the development of highly effective antiemetic drugs. Antagonists to the 5HT3-receptor include alosetron, dolasetron, granisetron, ondansetron, and palonosetron, as well as ramosetron and tropisetron (neither yet available in the United States). Ondansetron can be given either intravenously (8 mg or 0.15 mg/kg) or orally (24 mg once before highly emeto- genic chemotherapy, 8 mg twice daily for moderately emetogenic chemotherapy). Doses of 8 mg can be repeated parenterally or orally every 8 hours. Dosing of granisetron is 1 mg or 0.01 mg/kg intravenously or 1–2 mg orally. Dola- setron is given once as an oral 100-mg dose. Palonosetron, a long-acting 5HT3-receptor antagonist with high affinity for the receptor, is given once at a dose of 0.25 mg intravenously, both for acute and delayed emesis. As a class of drugs, the 5HT3-receptor antagonists have the potential to cause elec- trocardiogram changes, including QT prolongation. Antagonists to the NK1-receptor are aprepitant, fosa- prepitant, and netupitant. Aprepitant is given as a 125-mg oral dose followed by an 80-mg dose on the second and third day along with a 5HT3-receptor antagonist and dexa- methasone to increase its immediate and delayed protective effect for highly emetogenic chemotherapy. Fosaprepitant, the intravenous formulation of the prodrug to aprepitant, can be given at a dose of 115 mg if followed by 2 days of aprepitant or at a dose of 150 mg if given alone. NEPA is a single-dose capsule consisting of a combination of netupitant and palonosetron. For highly emetogenic chemotherapy (eg, cisplatin), patients should be offered a four-drug regimen (a 5HT3- antagonist, dexamethasone, NK1-receptor antagonist, and olanzapine), all given on the first day (and if used, aprepi- tant given again on the second and third days with dexa- methasone and olanzapine continued on days 2–4. For moderately emetogenic chemotherapy, standard regimens include both three-drug regimens (an NK1-antagonist, a 5HT3-antagonist, and dexamethasone) or a two-drug combination (5HT3-antagonist and dexamethasone). Palonosetron is the preferred 5HT3-blocker due to its greaterCMDT22_Ch39_p1612-p1675.indd  1672 02/07/21 2:44 PMCANCER1673 CMDT 2022affinity  for the 5HT3-receptor and its longer half-life. For low emetogenic chemotherapy drugs, a single agent such as a 5HT3-antagonist or prochlorperazine or dexamethasone can be given. A 25-mg suppository form of prochlorpera- zine may be used for patients unable to swallow oral medi- cations. Another medication that is helpful for anticipatory or refractory nausea and vomiting is olanzapine, 10 mg given orally once. The importance of treating chemotherapy-induced nau- sea and vomiting expectantly and aggressively beginning with the first course of chemotherapy cannot be overem- phasized. Patients being treated in the clinic setting should always be given antiemetics for home use with written instructions as well as contact numbers to call for advice.3.  Gastrointestinal ToxicityU ntoward effects of cancer chemotherapy include damage to the more rapidly growing cells of the body such as the mucosal lining from the mouth through the gastrointesti- nal tract. Oral symptoms range from mild mouth soreness to frank ulcerations. Not uncommonly, mouth ulcerations will have superimposed candida or herpes simplex infec- tions. In addition to receiving cytotoxic chemotherapy, a significant risk factor for development of oral mucositis is poor oral hygiene and existing caries or periodontal dis- ease. Toxicity in the gastrointestinal tract usually manifests as diarrhea. Gastrointestinal symptoms can range from mild symptoms of loose stools to life-threatening diar- rhea leading to dehydration and electrolyte imbalances. Drugs most commonly associated with causing mucositis in the mouth and the gastrointestinal tract are cytarabine, 5-fluorouracil, and methotrexate. Patients undergoing treatment for head and neck can- cer with concurrent chemotherapy and radiation therapy have a very high risk of developing severe mucositis. Preventive strategies for oral mucositis include pretreat- ment dental care, particularly for all head and neck cancer patients and any cancer patient with poor dental hygiene who will be receiving chemotherapy. For patients receiving 5-fluorouracil, simple measures such as ice chips in the mouth for 30 minutes during infusion can reduce the inci- dence and severity of mucositis. Once mucositis is encoun- tered, superimposed fungal infections should be treated with topical antifungal medications (oral nystatin mouth suspensions, or clotrimazole troches) or systemic therapy (fluconazole 100–400 mg orally daily). Suspected herpetic infections can be treated with acyclovir (up to 800 mg orally five times daily) or valacyclovir (1 g orally twice daily). Mucositis may also be managed with mouthwashes; it is also important to provide adequate pain medication. Another strategy for prevention of oral mucositis is the use of palifermin, the recombinant keratinocyte growth factor inhibitor. Prophylaxis with intravenous palifermin (60 mcg/kg/day) for patients receiving high-dose chemo- therapy can reduce the incidence and duration of mucositis (Table 39–12). Diarrhea is most associated with 5-fluorouracil, capecitabine, and irinotecan as well as the tyrosine kinase inhibitors (dasatinib, imatinib, nilotinib, regorafenib, sorafenib, sunitinib) and epithelial growth factor inhibitors(cetuximab, erlotinib, panitumumab). Mild to moderate diarrhea can be managed with oral antidiarrheal medica- tion (loperamide, 4 mg initially followed by 2 mg every 2–4 hours until bowel movements are formed). Occasion- ally, severe diarrhea will cause dehydration, electrolyte imbalances, and acute kidney injury; these patients require inpatient management with aggressive intravenous hydra- tion and electrolyte replacement. Octreotide, 100–150 mcg subcutaneously three times daily, can be useful.4.  Skin ToxicityDerm atologic complications from cancer chemotherapy can include hyperpigmentation (busulfan, hydroxyurea, liposomal doxorubicin), alopecia, photosensitivity, nail changes, acral erythema, and generalized rashes. Acral erythema (hand-foot syndrome), most commonly associ- ated with administration of capecitabine, 5-fluorouracil, and liposomal doxorubicin, manifests as painful palms or soles accompanied by erythema, progressing to blistering, desquamation, and ulceration in its worst forms. Strate- gies for prevention of acral erythema include oral pyri- doxine, 200 mg daily, and applying cold packs to the extremities during chemotherapy administration. Agents targeting the epidermal growth factor pathway can cause an acne-like rash; the development of the rash may iden- tify those who will respond to the drug. Inhibitors of the tyrosine kinase pathway are also associated with a high incidence of dermatologic complications, such as rash and acral erythema.5.  Miscellaneous Drug-Specific ToxicitiesThe  toxicities of individual drugs are summarized in Tables 39–3 and 39–12; however, several of these toxicities war- rant additional mention, since they occur with frequently administered agents, and special measures are often indicated.A.  Hemorrhagic Cystitis Induced by Cyclophosphamide or IfosfamidePa tients receiving cyclophosphamide must maintain a high fluid intake prior to and following the administration of the drug and be counseled to empty their bladders fre- quently. Early symptoms suggesting bladder toxicity include dysuria and increased frequency of urination. Should microscopic hematuria develop, it is advisable to stop the drug temporarily or switch to a different alkylating agent, to increase fluid intake, and to administer a urinary analgesic such as phenazopyridine. The neutralizing agent, mesna, can be used for patients in whom cystitis develops. With severe cystitis, large segments of bladder mucosa may be shed, resulting in prolonged gross hematuria. Such patients should be observed for signs of urinary obstruc- tion and may require cystoscopy for removal of obstructing blood clots. The cyclophosphamide analog ifosfamide can cause severe hemorrhagic cystitis when used alone. How- ever, when its use is followed by a series of doses of the neutralizing agent mesna, bladder toxicity can be pre- vented (Table 39–12).CMDT22_Ch39_p1612-p1675.indd  1673 02/07/21 2:44 PMChAPTER 391674 CMDT 2022B.  Neuropathy Due to Vinca Alkaloids and Other Chemotherapy DrugsNeur opathy is caused by a number of different chemo- therapy drugs, the most common being vincristine. The peripheral neuropathy can be sensory, motor, autonomic, or a combination of these types. In its mildest form, it con- sists of paresthesias of the fingers and toes. Occasionally, acute jaw or throat pain can develop as a form of trigeminal or glossopharyngeal neuralgia. With continued vincristine therapy, the paresthesias extend to the proximal interpha- langeal joints, hyporeflexia appears in the lower extremi- ties, and significant weakness can develop. Other drugs in the vinca alkaloid class as well as the taxane drugs (docetaxel and paclitaxel) and agents to treat myeloma (bortezomib and thalidomide) cause similar toxicity. Constipation is the most common symptom of auto- nomic neuropathy associated with the vinca alkaloids. Patients receiving these drugs should be started on mild cathartics and other agents (Table 15–4); otherwise, severe impaction may result from an atonic bowel. More serious autonomic involvement can lead to acute intestinal obstruction with signs indistinguishable from those of an acute abdomen. Bladder neuropathies are uncommon but may be severe. These two complications are absolute con- traindications to continued vincristine therapy.C.  Methotrexate ToxicityMethotr exate, a folate antagonist, is a commonly used component of regimens to treat patients with leptomenin- geal disease, acute lymphoblastic leukemia, and sarcomas. Methotrexate is almost entirely eliminated by the kidney. Methotrexate toxicity affects cells with rapid turnover, including the bone marrow and mucosa resulting in myelosuppression and mucositis. Methotrexate can also damage the liver and kidney manifesting as elevated serum liver enzymes and creatinine. High-dose methotrexate, usually defined as a dose of 500 mg/m2or more given over 4–36 hours, would be lethal without “rescue” of the normal tissues. Leucovorin, a form of folate, will reverse the toxic effects of methotrexate and is given until serum methotrex- ate levels are in the safe range (less than 0.05 mmol/L). It is crucial that high-dose methotrexate and leucovorin are given precisely according to protocol as deviations of the timing of methotrexate delivery or delay in rescue can result in death. In a patient with kidney disease or an effu- sion, prolonged rescue with leucovorin is necessary. Vigorous hydration and bicarbonate loading can help prevent crystallization of high-dose methotrexate in the renal tubular epithelium and consequent nephrotoxicity. Daily monitoring of the serum creatinine is mandatory. If possible, drugs impairing methotrexate excretion, such as aspirin, nonsteroidal anti-inflammatory drugs, amio- darone, omeprazole, penicillin, phenytoin, and sulfa, should be stopped before methotrexate administration.D . Cardiotoxicity from Anthracyclines and Other Chemotherapy DrugsA  number of cancer chemotherapy drugs are associated with cardiovascular complications including traditionaldrugs such as anthracyclines as well as new targeted agents. The anthracycline drugs, including doxorubicin, daunomycin, epirubicin, and idarubicin, can produce acute (during administration), subacute (days to months following administration), and delayed (years following administration) cardiac toxicity. The most feared compli- cation is the delayed development of heart failure. Risk factors for this debilitating toxicity include the anthracy- cline cumulative dose, age over 70, previous or concurrent irradiation of the chest, preexisting cardiac disease, and concurrent administration of chemotherapy drugs such as trastuzumab. The problem is greatest with doxorubicin because it is the most commonly administered anthracy- cline due to its major role in the treatment of lymphomas, sarcomas, breast cancer, and certain other solid tumors. Patients receiving anthracyclines should have an assessment of left ventricular ejection fraction (LVEF). If the LVEF is greater than 50%, anthracyclines can be administered; if the LVEF is less than 30%, these drugs should not be given. For patients with intermediate values, anthracyclines can be cautiously given, if necessary, at lower doses with LVEF monitoring between doses. In general, patients should not receive doses in excess of 450 mg/m2; the dose should be lower if prior chest radiotherapy has been given. Unfortu- nately, toxicity may be irreversible and frequently fatal at total dosage levels above 550 mg/m2. At lower doses (eg, 350 mg/m2), the symptoms and signs of cardiac failure gen- erally respond well to medical therapy and discontinuation of the anthracycline. Doxorubicin and daunomycin have been formulated as liposomal products; these drugs, approved for use in patients with Kaposi sarcoma and sometimes in other cancers as a substitute for the conventional anthracy- clines, appear to have less potential for cardiac toxicity. As molecular mechanisms for cancer have been increas- ingly delineated, therapies have been developed that better target these mechanisms. Therapies targeting oncogenic pathways include (1) HER2 inhibitors (lapatinib, pertu- zumab, trastuzumab, ado-trastuzumab emtansine); (2) VEGF signaling pathway inhibitors (afilbercept, axitinib, bevacizumab, cabozantinib, lenvatinib, pazopanib, ramuci- rumab, regorafenib, sorafenib, sunitinib, vandetanib); (3) multitargeted tyrosine kinase inhibitors (dasatinib, nilo- tinib, ponatinib); (4) proteasome inhibitors (bortezomib, carfilzomib); and (5) immune checkpoint inhibitors (atezolizumab, durvalumab, ipilimumab, nivolumab, pem- brolizumab). Many of the pathways targeted by these drugs share a common biologic pathway in cardiac tissue. Untow- ard cardiac events are being increasingly reported with these agents, including arrhythmias, cardiac ischemia, myocarditis, thrombosis, and heart failure.E.  Cisplatin Nephrotoxicity and NeurotoxicityCispla tin is effective in treating testicular, bladder, head and neck, lung, and ovarian cancers. With cisplatin, the serious side effects of nephrotoxicity and neurotoxicity must be anticipated and aggressively managed. Patients must be vigorously hydrated prior to, during, and after cis- platin administration. Both kidney function and electro- lytes must be monitored. Low serum magnesium, potassium, and sodium levels can develop. The neurotoxicity is usuallyCMDT22_Ch39_p1612-p1675.indd  1674 02/07/21 2:44 PMCANCER1675 CMDT 2022mani fested as a peripheral neuropathy of mixed sensorimo- tor type and may be associated with painful paresthesias. Development of neuropathy typically occurs after cumula- tive doses of 300 mg/m2. Ototoxicity is a potentially serious manifestation of neurotoxicity and can progress to deafness. The second-generation platinum analog, carboplatin, is non-nephrotoxic, although it is myelosuppressive. In the setting of preexisting kidney disease or neuropathy, carbo- platin is occasionally substituted for cisplatin.F . Bleomycin ToxicitySee online text at www .accessmedicine.com/cmdt.PR OGNOSISPa tients receiving chemotherapy for curative intent will often tolerate side effects with the knowledge that the treat- ment may result in eradication of their cancer. Patients receiving therapy for palliative intent often have their therapy tailored to improve quality of life while minimizingmajor side effects. A valuable sign of clinical improvement is the general well-being of the patient. Although general well-being is a combination of subjective factors (possibly partly a placebo effect) and objective factors, it nonetheless serves as a sign of clinical improvement along with improved appetite and weight gain and increased “performance status” (eg, ambulatory versus bedridden). Evaluation of factors such as activity status enables the clinician to judge whether the net effect of chemotherapy is worthwhile pal- liation (see Chapter 5).Babiker  HM et al. Cardiotoxic effects of chemotherapy: a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018;126:186. [PMID: 29759560] Okada Y et al. One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemo- therapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist. 2019;24:1593. [PMID: 31217343]CMDT22_Ch39_p1612-p1675.indd  1675 02/07/21 2:44 PM1676 CMDT 2022ACU TE INTERMITTENT PORPHYRIAE S S E N T I A L S  O F  D I A G N O S I S »Unexplained abdominal crisis, generally in young women. »Acute peripheral or central nervous system dys- function; recurrent psychiatric illnesses. »Hyponatremia. »Porphobilinogen in the urine during an attack. »General ConsiderationsTho ugh there are several different types of porphyrias, the one with the most serious consequences and the one that usually presents in adulthood is acute intermittent porphyria (AIP), which is inherited as an autosomal dominant condi- tion, though it remains clinically silent in most patients who carry a mutation in HMBS . Clinical illness usually develops in women. Symptoms begin in the teens or 20s, but onset can begin after menopause in rare cases. The disorder is caused by partial deficiency of hydroxymethylbilane synthase activ- ity, leading to increased excretion of aminolevulinic acid and porphobilinogen in the urine. The diagnosis may be elusive if not specifically considered. The characteristic abdominal pain may be due to abnormalities in autonomic innervation in the gut. In contrast to other forms of porphyria, cutaneous photosensitivity is absent in AIP . Attacks are precipitated by numerous factors, including drugs and intercurrent infec- tions. Harmful and relatively safe drugs for use in treatment are listed in Table 40–1. Hyponatremia may be seen, due in part to inappropriate release of antidiuretic hormone, although gastrointestinal loss of sodium in some patients may be a contributing factor. »Clinical FindingsA.  Symptoms and SignsPa tients show intermittent abdominal pain of varying severity, and in some instances, it may so simulate an acuteabdomen as to lead to exploratory laparotomy. Because the origin of the abdominal pain is neurologic, there is an absence of fever and leukocytosis. Complete recovery between attacks is usual. Any part of the nervous system may be involved, with evidence for autonomic and periph- eral neuropathy. Peripheral neuropathy may be symmetric or asymmetric and mild or profound; in the latter instance, it can even lead to quadriplegia with respiratory paralysis. Other central nervous system manifestations include sei- zures, altered consciousness, psychosis, and abnormalities of the basal ganglia. Hyponatremia may further cause or exacerbate central nervous system manifestations.B.  Laboratory FindingsOften  there is profound hyponatremia. The diagnosis can be confirmed by demonstrating an increased amount of porphobilinogen in the urine during an acute attack. Freshly voided urine is of normal color but may turn dark upon standing in light and air. Most families have different mutations in HMBS caus- ing AIP . Mutations can be detected in 90% of patients and used for presymptomatic and prenatal diagnosis. »PreventionA voidance of factors known to precipitate attacks of AIP— especially drugs—can reduce morbidity. Sulfonamides and barbiturates are the most common culprits; others are listed in Table 40–1 and on the Internet (www.drugs- porphyria.org). Starvation diets and prolonged fasting also cause attacks and so must be avoided. Hormonal changes during pregnancy can precipitate crises. »TreatmentT reatment with a high-carbohydrate diet diminishes the number of attacks in some patients and is a reasonable empiric gesture considering its benignity. Acute attacks may be life-threatening and require prompt diagnosis, withdrawal of the inciting agent (if possible), and treat- ment with analgesics and intravenous glucose in saline and hematin. A minimum of 300 g of carbohydrate per day should be provided orally or intravenously. Electrolyte40Reed E. Pyeritz, MD, PhDGenetic & Genomic DisordersCMDT22_Ch40_p1676-p1684.indd  1676 02/07/21 2:45 PM"
                ],
                [
                  "1",
                  "DIABETES MELLITUS & HYPOGLYCEMIA1213 CMDT 2022Whih  envirnentl ftr is respnsible fr the inresed risk is nt knwn. Brestfeeding in the first 6 nths f life ppers t be prtetive. There is uu- lting evidene tht iprveents in publi helth nd redued infetins (espeilly prsiti) led t iune syste dysregultin nd develpent f utiune disrders suh s sth nd type 1 dibetes. Chek pint inhibitr iuntherpies fr dvned lignnies, suh s nivlub, pebrlizub, nd ipiliub, n preipitte utiune disrders, inlud- ing type 1 dibetes. The nset f dibetes n be rpid nd the ptients frequently hve dibeti ketidsis t pre- senttin. Autntibdies ginst islet ntigens re nly present in but 50% f ptients. Ptients reeiving these drugs shuld be refully nitred fr the develpent f dibetes. Apprxitely 5% f subjets hve n evidene f pn- reti B ell utiunity t explin their insulinpeni nd ketidsis. This subgrup hs been lssified s “idipthi type 1 dibetes” nd designted s “type 1B. ” Althugh nly  inrity f ptients with type 1 dibetes fll int this grup, st f these individuls re f Asin r Afrin rigin. Abut 4% f the West Afrins with ketsis-prne dibetes re hzygus fr  uttin in PAX-4 (Arg133Trp )— trnsriptin ftr tht is essentil fr the develpent f pnreti islets.B.  Type 2 Diabetes MellitusT ype 2 dibetes is due t nn-iune uses f pnreti B ell lss with vrible degree f tissue insensitivity t insulin, tht is, insulin resistne. The residul bet ell funtin is suffiient t prevent ketidsis but is inde- qute t prevent the hyperglyei. This fr f dibetes used t ur predinntly in dults, but it is nw re frequently enuntered in hildren nd dlesents.Geneti nd envirnentl ftrs bine t use bth the bet ell lss nd the insulin resistne. Mst epi- deilgi dt indite strng geneti influenes, sine in nzygti twins ver 40 yers f ge, nrdne develps in ver 70% f ses within  yer whenever type 2 dibetes develps in ne twin. Gene wide ssitin studies hve identified 143 risk vrints nd puttive regu- ltr ehniss fr type 2 dibetes. A signifint nuber f the identified li pper t de fr prteins tht hve  rle in bet ell funtin r develpent. One f the geneti li with the lrgest risk effet is TCF7L2 . This gene des fr  trnsriptin ftr invlved in the WNT sig- nling pthwy tht is required fr nrl pnreti develpent. Obesity is the most important environmental factor causing insulin resistance. The degree nd prevlene f besity vries ng different ril grups with type 2 dibetes. While besity is pprent in n re thn 30% f Chinese nd Jpnese ptients with type 2, it is fund in 60–70% f Nrth Aerins, Eurpens, r Afrins with type 2 nd pprhes 100% f ptients with type 2 ng Pi Indins r Pifi Islnders fr Nuru r S. Viserl besity, due t uultin f ft in the entl nd esenteri regins, rreltes with insulin resistne; subutneus bdinl ft sees t hve less f n ssitin with insulin insensitivity. There re ny ptients with type 2 dibetes wh, while nt vertly bese, hve inresed viserl ft; they re tered the “etbli- lly bese. ” Exerise y ffet the depsitin f viserl ft s suggested by CT sns f Jpnese wrestlers, whse extree besity is predinntly subutneus. Their dily vigrus exerise prgr prevents uultin f viserl ft, nd they hve nrl seru lipids nd eugly- ei despite dily intkes f 5000–7000 kl nd develp- ent f ssive subutneus besity.C.  Other Specific Types of Diabetes Mellitus1.  Maturityonset diabetes of the young (MODY)— This subgrup f ngeni disrders is hrterized by nn- insulin requiring dibetes with utsl dinnt inher- itne nd n ge t nset f 25 yers r yunger. Ptients re nnbese, nd their hyperglyei is due t ipired gluse-indued seretin f insulin. Six types f MODY hve been desribed (Tble 27–1). Exept fr MODY 2, in whih  glukinse gene is defetive, ll ther types invlve uttins f  nuler trnsriptin ftr tht regultes islet gene expressin. Ptients yunger thn 30 yers with endgenus insulin prdutin (urinry C-peptide/retinine rti f 0.2 nl/l r higher) nd negtive utntibdies re ndidtes fr geneti sreening fr MODY. The enzye glukinse is  rte- liiting step in glylysis nd deterines the rte f de- nsine triphsphte (ATP) prdutin fr gluse nd the insulin seretry respnse in the bet ell. MODY 2, due t glukinse uttins, is usully quite ild, ssi- ted with nly slight fsting hyperglyei nd few if ny irvsulr dibeti plitins. MODY 3, due t uttins in hepti nuler ftr 1 lph, is the st n fr, unting fr tw-thirds f ll MODY ses. Initilly, ptients with MODY 3 re respnsive tTable 27–1. Other specific types of diabetes mellitus.Genetic  defects of pancreatic B cell function MODY 1 (HNF-4alpha); rare MODY 2 (glucokinase); less rare MODY 3 (HNF-1alpha); accounts for two-thirds of all MODY MODY 4 (PDX1); very rare MODY 5 (HNF-1beta); very rare MODY 6 (neuroD1); very rare Mitochondrial DNA Wolfram syndrome Genetic defects in insulin action Type A insulin resistance Leprechaunism Rabson-Mendenhall syndrome Lipoatrophic diabetes Diseases of the exocrine pancreas Endocrinopathies Drug- or chemical-induced diabetes Other genetic syndromes (Down, Klinefelter, Turner, others) sometimes associated with diabetes HNF, hepatic nuclear factor; MODY, maturity-onset diabetes of the young; PDX1, pancreatic duodenal homeobox 1.CMDT22_Ch27_p1212-p1255.indd  1213 29/06/21 8:53 PMCHAPTEr 271214 CMDT 2022sulfn ylure therpy but the linil urse is f prgres- sive bet ell filure nd eventul need fr insulin therpy. Muttins in bth lleles f glukinse present with re severe nentl dibetes. Muttin in ne llele f the pn- reti dudenl hebx 1 (PDX1) uses dibetes usu- lly t  lter ge (~ 35 yers) thn ther frs f MODY; uttins in bth lleles f PDX1 use pnreti genesis. 2. Diabetes mellitus associated with a mutation of mito chondrial DNA— Sine sper d nt ntin ithn- dri, nly the ther trnsits ithndril genes t her ffspring. Dibetes due t uttins f ithndril DNA urs in less thn 2% f ptients with dibetes. The st n use is the A3243G uttin in the gene ding fr the tRNA (Leu, UUR). Dibetes usully devel- ps in these ptients in their lte 30s, nd hrteristilly, they ls hve hering lss (ternlly inherited dibetes nd defness [MIDD]). 3. Wolfram syndrome— Wlfr syndre is n uts- l reessive neurdegenertive disrder first evident in hildhd. It nsists f dibetes insipidus, dibetes elli- tus, pti trphy, nd defness, hene the rny DID- MOAD. It is due t uttins in  gene ned WFS1 , whih endes  100.3 KD trnsebrne prtein ll- ized in the endplsi retiulu. Crnil dibetes insipi- dus nd sensrineurl defness develp during the send dede in 60–75% f ptients. Ureterhydrnephrsis, neurgeni bldder, erebellr txi, peripherl neurp- thy, nd psyhitri illness develp lter in ny ptients. 4. Autosomal recessive syndromes— Hzygus ut- tins in  nuber f pnreti trnsriptin ftrs, NEU- ROG3, PTF1A, RFX6 , nd GLI-similar 3 (GLIS3) , use nentl r hildhd dibetes. Hzygus PTF1A uttins result in bsent pnres nd erebellr trphy; NEUROG3 uttins use severe lbsrptin nd dibetes befre puberty. Hzygus uttins in RFX6 use the Mithell-Riley syndre hrterized by bsene f ll islet ell types prt fr pnreti ply- peptide ells, hypplsi f the pnres nd gllbldder, nd intestinl tresi. GLIS3 gene plys  rle in trnsrip- tin f insulin gene, nd hzygus uttins use nentl dibetes nd ngenitl hypthyridis. The gene EIF2AK3 endes PKR-like ER kinse (PERK), whih ntrls ne f the pthwys f the unflded prtein respnse. Absene f PERK leds t indequte respnse t ER stress nd elerted bet ell pptsis. Ptients with uttin in this gene hve nentl dibetes, epiphysel dysplsi, develpentl dely, nd liver nd kidney dys- funtin (Wltt-Rllisn syndre). 5. Diabetes mellitus secondary to other causes— End- rine turs sereting grwth hrne, glurtiids, tehlines, glugn, r ststtin n use glu- se intlerne (Tble 27–2). In the first fur f these situ- tins, peripherl respnsiveness t insulin is ipired. With exess f glurtiids, tehlines, r glu- gn, inresed hepti utput f gluse is  ntributry ftr; in the se f tehlines, deresed insulin relese is n dditinl ftr in prduing rbhydrteintlerne, nd with ststtin, inhibitin f insulin seretin is the jr ftr. Dibetes inly urs in individuls with underlying defets in insulin seretin, nd hyperglyei typilly reslves when the hrne exess is reslved. High-titer nti-insulin reeptr ntibdies tht inhibit insulin binding use  linil syndre hrterized by severe insulin resistne, gluse intlerne r dibetes ellitus, nd nthsis nigrins. These ptients usully hve ther utiune disrders. There re reprts f spntneus reissin r reissin with yttxi therpy. Mny drugs re ssited with rbhydrte intler- ne r frnk dibetes (Tble 27–2). The drugs t by deresing insulin seretin r by inresing insulin resis- tne r bth. Cylsprine nd trlius ipir insulin seretin; sirlius priniplly inreses insulin resistne. These gents ntribute t the develpent f new-nset dibetes fter trnsplnttin. Crtisterids inrese insulin resistne but y ls hve n effet n bet ell funtin; in  se ntrl study nd  lrge ppultin hrt study, rl rtisterids dubled the risk fr develpent f dibetes. Thizide diuretis nd bet- blkers destly inrese the risk fr dibetes. Treting the hypklei due t thizides y reverse the hyper- glyei. Atypil ntipsyhtis, prtiulrly lnzpine nd lzpine, re ssited with inresed risk f gluse intlerne. These drugs use weight gin nd insulin resistne but y ls ipir bet ell funtin; n inrese in rtes f dibeti ketidsis (DKA) hs been reprted. Alpelisib is  phsphtidylinsitl-3-kinse (PI3K) inhibitr nd is pprved fr use in bintin with fulvestrnt fr hrne reeptr–psitive, HER2- negtive, PIK3CA -utted brest ner. PI3K is  p- nent f the insulin signling pthwy, nd hyperglyei is  n side effet f lpelisib tretent. Chrni pnretitis r subttl pnretety redues the nuber f funtining B ells nd n result in  etbli derngeent very siilr t tht f geneti type 1 dibetes exept tht  nitnt redu- tin in pnreti A ells y redue glugn seretin s tht reltively lwer dses f insulin repleent re needed.Table 27–2. Secondary causes of hyperglycemia.Hypeglycemia  due to tissue insensitivity to insulin Medications (corticosteroids, sympathomimetic drugs, niacin, alpelisib, sirolimus) Hormonal tumors (acromegaly, Cushing syndrome, glucagonoma, pheochromocytoma) Liver disease (cirrhosis, hemochromatosis) Muscle disorders (myotonic dystrophy) Adipose tissue disorders (lipodystrophy, truncal obesity) Hypeglycemia due to educed insulin secetion Medications (thiazide diuretics, phenytoin, pentamidine, calcineurin inhibitors, atypical antipsychotics) Hormonal tumors (somatostatinoma, pheochromocytoma) Pancreatic disorders (pancreatitis, hemosiderosis, hemochromatosis)CMDT22_Ch27_p1212-p1255.indd  1214 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1215 CMDT 2022 »Metabolic Syndrome (Insulin Resistance Syndrome)The  ter etbli syndre hs been dvted t iden- tify individuls wh were t higher risk fr develpent f dibetes nd rdivsulr disese. Criteri inluded wist iruferene, gluse levels, bld pressure, trigly- erides, nd HDL hlesterl. There is, hwever, n unify- ing pthphysilgi bsis fr the syndre, nd in 2010,  WHO expert ittee reprted tht the syndre lked utility s  dignsti r ngeent tl. They bserved tht there ws nly dest ssitin between etbli syndre nd rdivsulr disese, nd the definitin ws utperfred by trditinl rdivsulr risk preditin lgriths suh s the Fringh risk sre. Siilrly, fsting gluse nveys  greter risk f inident dibetes thn the etbli syndre. There is ls n evidene tht hyperinsulinei nd insulin resis- tne ply  diret rle in these etbli bnrlities. »Clinical Trials about Optimum Diabetic Glucose ControlFindings  f the Dibetes Cntrl nd Cplitins Tril nd f the United Kingd Prspetive Dibetes Study hve nfired the benefiil effets f iprved glyei ntrl in bth type 1 nd type 2 dibetes.A.  Type 1 DiabetesThe Dia betes Control and Complications Trial (DCCT),  lng-ter therpeuti study invlving 1441 ptients with type 1 dibetes ellitus, reprted tht “ner” nrliz- tin f bld gluse resulted in  dely in the nset nd  jr slwing f the prgressin f estblished irvs- ulr nd neurpthi plitins f dibetes. In hlf f the ptients,  en heglbin A1f 7.2% (nrl: less thn 6%) nd  en bld gluse f 155 g/dL (8.6 l/L) were hieved using intensive therpy, while in the nventinlly treted grup, HbA1 verged 8.9% with n verge bld gluse f 225 g/dL (12.5 l/L). Over the study perid, whih verged 7 yers, there ws n pprxitely 60% redutin in risk between the tw grups in regrd t dibeti retinpthy, nephrpthy, nd neurpthy. The intensively treted grup ls hd  nnsignifint redutin in the risk f rvsulr disese f 41% (95% CI, –10% t 68%). Intensively treted ptients hd  threefld greter risk f serius hypglyei s well s  greter tendeny twrd weight gin. Hwever, there were n deths definitely ttributble t hypglyei in ny persns in the DCCT study, nd n evidene f psthypglyei gnitive dge ws deteted. Prtiipnts in the DCCT study were subsequently enrlled in  fllw-up bservtinl study, the Epideil- gy f Dibetes Interventins nd Cplitins (EDIC) study. Even thugh the between-grup differenes in en HbA1nrrwed ver 4 yers, the grup ssigned t inten- sive therpy hd  lwer risk f retinpthy t 4 yers, irlbuinuri t 7–8 yers, nd ipired GFR (less thn 60 L/in/1.73 2) t 22 yers f ntinued studyfllw-up. Mrever, by the end f the 11-yer fllw-up perid, the intensive therpy grup hd signifintly redued their risk f ny rdivsulr disese events by 42% (95% CI, 9% t 23%; P= 0.02). Thus, it sees tht the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. The generl nsensus f the ADA is tht intensive insulin therpy ssited with prehensive self- ngeent trining shuld be stndrd therpy in ptients with type 1 dibetes ellitus fter the ge f puberty. Exeptins inlude thse with dvned hrni kidney disese nd lder dults sine the detrientl risks f hypglyei utweigh the benefits f tight glyei ntrl in these grups.B.  Type 2 DiabetesThe  United Kingdom Prospective Diabetes Study (UKPDS),  ultienter study, ws designed t estblish whether the risk f rvsulr r irvsulr - plitins uld be redued by intensive bld gluse ntrl with rl hypglyei gents r insulin nd whether ny prtiulr therpy ws re benefiil thn the ther in type 2 dibeti ptients. Intensive tretent with either sulfnylures, etfr- in, bintins f thse tw, r insulin hieved en HbA1levels f 7%. This level f glyei ntrl deresed the risk f irvsulr plitins (retinpthy nd nephrpthy) in prisn with nventinl therpy (stly diet lne), whih hieved en levels f HbA1 f 7.9%. Weight gin urred in intensively treted ptients exept when etfrin ws used s ntherpy. N dverse rdivsulr utes were nted regrdless f the therpeuti gent. In the verweight r bese sub- grup, etfrin therpy ws re benefiil thn diet lne in reduing the nuber f ptients wh suffered yrdil infrtins nd strkes. Hypglyei re- tins urred in the intensive tretent grups, but nly ne deth fr hypglyei ws duented during 27,000 ptient-yers f intensive therpy. Tight ntrl f bld pressure (edin vlue 144/82  Hg vs 154/87  Hg) substntilly redued the risk f irvsulr disese nd strke but nt y- rdil infrtin. In ft, reduing bld pressure by this unt hd substntilly greter ipt n irvsulr utes thn tht hieved by lwering HbA1fr 7.9% t 7%. An epideilgi nlysis f the UKPDS dt shwed tht every 10  Hg derese in en systli bld pressure ws ssited with 11% redutin in risk fr yrdil infrtin. Mre thn hlf f the ptients needed tw r re editins fr dequte therpy f their hypertensin, nd there ws n denstrble dvn- tge f ngitensin-nverting enzye (ACE) inhibitr therpy ver therpy with bet-blkers with regrd t dibetes end pints. Use f  liu hnnel blker dded t bth tretent grups ppered t be sfe ver the lng ter in this dibeti ppultin despite se ntrversy in the literture but its sfety in ptients with dibetes. Like the DCCT trilists, the UKPDS reserhers per- fred pst-tril nitring t deterine whether thereCMDT22_Ch27_p1212-p1255.indd  1215 29/06/21 8:53 PMCHAPTEr 271216 CMDT 2022were  lng-ter benefits f hving been in the intensively treted gluse nd bld pressure rs f the study. The intensively treted grup hd signifintly redued risk f yrdil infrtin (15%, P= 0.01) nd deth fr ny use (13%, P= 0.007) during the fllw-up perid. The subgrup f verweight r bese subjets wh were ini- tilly rndized t etfrin therpy shwed sustined redutin in risk f yrdil infrtin nd deth fr ny use in the fllw-up perid. Unlike the sustined benefits seen with gluse ntrl, there were n sustined benefits fr hving been in the re tightly ntrlled bld pressure grup. Bth bld pressure grups were t siilr risk fr irvsulr events nd dibetes-relted end pints during the fllw-up perid. Thus, the fllw-up f the UKPDS type 2 dibetes hrt shwed tht, s in type 1 dibetes, the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. Bld pressure benefits, hwever, lst nly s lng s the bld pressure is well ntrlled. »Diabetes Prevention TrialsA.  Prevention of Type 1 DiabetesAt  the tie f dignsis f type 1 dibetes, there reins signifint B ell pnreti funtin. This explins why sn fter dignsis, the dibetes ges int prtil linil reissin nd little r n insulin is required (“hneyn”). The linil reissin is shrt- lived, hwever, nd eventully ptients lse ll B ell fun- tin nd hve re lbile gluse ntrl. Studies hve been perfred t prlng this prtil linil reissin using iundultry gents. The CD3 plex is the jr signl-trnsduing eleent f the T ell reep- tr, nd the nti-CD3 ntibdies re believed t dulte the utiune respnse by seletively inhibiting the pthgeni T ells r by induing regultry T ells. Phse 1/2 nd 2/3 linil trils f hunized nlnl nti- bdies ginst CD3, hOKT3g (Al-Al) (tepli- zub), nd ChAglyCD3 (telixizub) delyed but did nt pletely rrest the deline in insulin prdutin in ptients with newly dignsed type 1 dibetes. A siilr phse 2 linil tril using teplizub ws undertken in nndibeti reltives f ptients with type 1 dibetes wh hd tw r re dibetes-relted ntibdies nd gluse intlerne. In the 5 yers fter rndiztin, 43% f the ptients reeiving teplizub nd 72% f the pleb grup develped dibetes.B.  Prevention of Type 2 DiabetesThe  Dibetes Preventin Prgr studied whether tret- ent with either diet nd exerise r etfrin uld prevent the nset f type 2 dibetes in verweight en nd wen ged 25–85 yers wh hd ipired gluse tler- ne. Interventin with  lw-ft diet nd 150 inutes f derte exerise (equivlent t  brisk wlk) per week redued the risk f prgressin t type 2 dibetes by 71%. Prtiipnts wh tk etfrin 850 g twie dily redued their risk f develping type 2 dibetes by 31%, but this interventin ws reltively ineffetive in thse wh were either less bese r in the lder ge grup.Eighty-eight perent f the persns in the Dibetes Preven- tin Prgr eleted t ntinue fllw up in the Dibetes Preventin Prgr Oute Study. At 15 yers f fllw up, the uultive inidene f dibetes ws 55% in the lifestyle grup nd 62% in the ntrl grup. »Clinical FindingsA.  Symptoms and Signs1.  Type 1 diabetes— A hrteristi sypt plex f hypersllity nd hyperketnei fr the uul- tin f irulting gluse nd ftty ids typilly presents in ptients with type 1 dibetes. When bslute insulin defiieny is f ute nset, there is brupt inrese in uri- ntin, thirst, blurred visin, weight lss, presthesis, nd ltered level f nsiusness. Ketidsis exerbtes the dehydrtin nd hypersllity by prduing nrexi nd nuse nd viting, interfering with rl fluid repleent. a. Increased urination and thirst— These sypts re nsequenes f sti diuresis sendry t sus- tined hyperglyei. The diuresis results in  lss f glu- se s well s free wter nd eletrlytes in the urine. b. Blurred vision— As the lenses re expsed t hyper- slr fluids, blurred visin ften develps. c. Weight loss— Despite nrl r inresed ppetite, weight lss is  n feture f type 1 when it develps subutely. The weight lss is initilly due t depletin f wter, glygen, nd triglyerides; therefter, redued us- le ss urs s in ids re diverted t fr gluse nd ketne bdies. Lss f subutneus ft nd usle wsting re fetures f re slwly develping insulin defiieny. Lwered pls vlue prdues sypts f psturl hyptensin, whih is  serius prgnsti sign. Ttl bdy ptssiu lss nd the generl tblis f usle prtein ntribute t the wekness. d. Paresthesias— Presthesis y be present t the tie f dignsis, prtiulrly when the nset is subute. They reflet  teprry dysfuntin f peripherl sensry nerves, whih lers s insulin repleent restres glye- i levels lser t nrl, suggesting neurtxiity fr sustined hyperglyei. e. The level of consciousness shown by the patient— The ptient’s level f nsiusness n vry depending n the degree f hypersllity. When insulin defiieny develps reltively slwly nd suffiient wter intke is intined, ptients rein reltively lert nd physil findings y be inil. When viting urs in respnse t wrsening ketidsis, dehydrtin pr- gresses nd penstry ehniss bee indequte t keep seru sllity belw 320–330 Os/L. Under these irustnes, stupr r even  y ur. The fruity breth dr f etne further suggests the dignsis f DKA. 2. Type 2 diabetes— While inresed urintin nd thirst y be presenting sypts in se ptients with type 2 dibetes, ny ther ptients hve n insidius nset fCMDT22_Ch27_p1212-p1255.indd  1216 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1217 CMDT 2022hypergly ei nd re syptti initilly. This is pr- tiulrly true in bese ptients, whse dibetes y be deteted nly fter glysuri r hyperglyei is nted during rutine lbrtry studies. Osinlly, when the disese hs been ult fr se tie, ptients y hve evidene f neurpthi r rdivsulr plitins t the tie f presenttin. Hyperglyei hyperslr  n ls be present when the seru sllity exeeds 320–330 Os/L; in these ses, ptients re pr- fundly dehydrted, hyptensive, lethrgi, r tse but withut the Kussul respirtins f ketidsis. a. Skin manifestations— Chrni skin infetins re n. Generlized pruritus nd sypts f vginitis re frequently the initil plints f wen. Dibetes shuld be suspeted in wen with hrni ndidl vul- vvginitis. Blnpsthitis (infltin f the freskin nd glns in uniruised les) y ur. Other skin findings inlude nthsis nigrins. whih is ssited with signifint insulin resistne. The skin in the xill, grin, nd bk f nek is hyperpigented nd hyperkertti (Figure 27–1). Eruptive xnths n the flexr surfe f the libs nd n the buttks nd lipei retinlis due t hyperhylirnei n ur in ptients with unntrlled type 2 dibetes wh ls hve  filil fr f hypertriglyeridei. b. Body habitus— Overweight r bese ptients fre- quently hve type 2 dibetes. Even thse wh re nt sig- nifintly bese ften hve hrteristi lliztin f ft depsits n the upper segent f the bdy (prtiulrly the bden, hest, nek, nd fe) nd reltively less ft n the ppendges, whih y be quite usulr. This en- tripetl ft distributin is hrterized by  high wist iruferene;  wist iruferene lrger thn 40 inhes (102 ) in en nd 35 inhes (88 ) in wen is ssi- ted with n inresed risk f dibetes. Mild hypertensin is ften present in bese ptients with dibetes. c. Obstetrical complications— Type 2 dibetes shuld be nsidered in wen wh hve delivered bbieslrger thn 9 lb (4.1 kg) r hve hd plyhydrnis, pre- elpsi, r unexplined fetl lsses.B.  Laboratory Findings1. Urine  glucose— A nvenient ethd t detet glus- uri is the pper strip ipregnted with gluse xidse nd  hrgen syste (Clinistix, Distix), whih is sen- sitive t s little s 100 g/dL (5.5 l) gluse in urine. A nrl renl threshld fr gluse s well s relible bldder eptying is essentil fr interprettin. Nndibeti glysuri (renl glysuri) is  benign syptti nditin wherein gluse ppers in the urine despite  nrl unt f gluse in the bld, either bslly r during  gluse tlerne test. Its use y vry fr uttins in the SGLT2 gene ding fr sdiu-gluse trnsprter 2 (filil renl glysuri) t ne ssited with dysfuntin f the prxil renl tubule (Fnni syndre, hrni kidney disese), r it y erely be  nsequene f the inresed ld f glu- se presented t the tubules by the elevted glerulr filtrtin rte (GFR) during pregnny. As ny s 50% f pregnnt wen nrlly hve denstrble sugr in the urine, espeilly during the third nd furth nths. This sugr is prtilly lwys gluse exept during the lte weeks f pregnny, when ltse y be present. 2. Urine and blood ketones— Qulittive detetin f ketne bdies n be plished by nitrprusside tests (Aetest r Ketstix). Althugh these tests d nt detet bet-hydrxybutyri id, whih lks  ketne grup, the seiquntittive estitin f ketnuri thus btined is nnetheless usully dequte fr linil purpses. Mny lbrtries esure bet-hydrxybutyri id, nd there re eters vilble (Preisin Xtr; Nv Mx Plus) fr ptient use tht esures bet-hydrxybutyri id levels in pillry gluse sples. Bet-hydrxybutyrte levels greter thn 0.6 l/L require evlutin. Ptients with levels greter thn 3.0 l/L, equivlent t very lrge urinry ketnes, require hspitliztin. 3. Plasma or serum glucose— The gluse nentrtin is 10–15% higher in pls r seru thn in whle bld beuse struturl pnents f bld ells re bsent. A pls gluse level f 126 g/dL (7 l/L) r higher n re thn ne sin fter t lest 8 hurs f fsting is dignsti f dibetes ellitus (Tble 27–3). Fsting pls gluse levels f 100–125 g/dL (5.6–6.9 l/L) re ssited with inresed risk f dibetes (ipired fsting gluse tlerne). 4. Oral glucose tolerance test— If the fsting pls glu- se level is less thn 126 g/dL (7 l/L) when dibetes is nnetheless suspeted, then  stndrdized rl gluse tlerne test y be dne (Tble 27–3). In rder t pti- ize insulin seretin nd effetiveness, espeilly when ptients hve been n  lw-rbhydrte diet,  iniu f 150–200 g f rbhydrte per dy shuld be inluded in the diet fr 3 dys preeding the test. The ptient shuld et nthing fter idnight prir t the test dy. On the rn- ing f the test, ptients re then given 75 g f gluse in 300 L f wter. The gluse ld is nsued within ▲Figure 27–1. Acanthosis nigricans of the nape of the neck, with typical dark and velvety appearance. (Used, with permission, from Umesh Masharani, MB, BS, MRCP [UK].)CMDT22_Ch27_p1212-p1255.indd  1217 29/06/21 8:53 PMCHAPTEr 271218 CMDT 20225  inutes. The test is perfred in the rning beuse f diurnl vritin in rl gluse tlerne; ptients shuld nt ske r be tive during the test. Bld sples fr pls gluse re btined t 0 nd 120 inutes fter ingestin f gluse. Tble 27–3 pr- vides dignsti riteri fr dibetes ellitus bsed n the rl gluse tlerne test. An rl gluse tlerne test is nrl if the fsting venus pls gluse vlue is less thn 100 g/dL (5.6 l/L) nd the 2-hur vlue flls belw 140 g/dL (7.8 l/L). A fsting vlue f 126 g/dL (7 l/L) r higher r  2-hur vlue f greter thn 200 g/dL (11.1 l/L) is dignsti f di- betes ellitus. Ptients with  2-hur vlue f 140–199 g/dL (7.8–11.1 l/L) hve ipired gluse tlerne. Flse- psitive results y ur in ptients wh re lnurished, bedridden, r fflited with n infetin r severe etinl stress. 5. Glycated hemoglobin (hemoglobin A1) measure ments— Heglbin bees glyted by ketine retins between gluse nd ther sugrs nd the free in grups n the lph nd bet hins. Only glytin f the N-terinl vline f the bet hin iprts suffi- ient negtive hrge t the heglbin leule t llw seprtin by hrge dependent tehniques. These hrge- seprted heglbins re lletively referred t s heglbin A1(HbA1). The jr fr f HbA1is he- glbin A1(HbA1) where gluse is the rbhydrte. HbA1prises 4–6% f ttl heglbin A. Sine HbA1irultes within red bld ells whse life spn lsts up t 120 dys, it generlly reflets the stte f glyei ver the preeding 8–12 weeks, thereby prviding n iprved ethd f ssessing dibeti ntrl. The HbA1vlue, hwever, is weighted t re reent gluse levels (previus nth) nd this explins why signifint hnges in HbA1re bserved with shrt-ter (1 nth) hnges in en pls gluse levels. Mesureents shuld be de in ptients with either type f dibetes ellitus t 3- t 4-nth intervls. In ptients nitring their wn bld gluse levels, HbA1vlues prvide  vluble hek n the ury f nitring. In ptientswh d nt nitr their wn bld gluse levels, HbA1 vlues re essentil fr djusting therpy. The A1Derived Averge Gluse Study reprted tht the reltinship between verge gluse in the previus 3 nths nd HbA1ws (28.7 × HbA1) – 46.7. There is, hwever, sub- stntil individul vribility; fr HbA1vlues between 6.9% nd 7.1%, the gluse levels rnge fr 125 g/dL t 205 g/dL (6.9–11.4 l/L; 95% CIs). Fr HbA1f 6%, the en gluse levels rnge fr 100 g/dL t 152 g/dL (5.5–8.5 l/L); nd fr 8% they rnge fr 147 g/dL t 217 g/dL (8.1–12.1 l/L). Fr this resn, utin shuld be exerised in estiting verge gluse levels fr esured HbA1. The ury f HbA1vlues n be ffeted by he- glbin vrints r trits. In ptients with high levels f he- glbin F, iunssys give flsely lw vlues f HbA1. The Ntinl Glyheglbin Stndrdiztin Prgr web- site (www.ngsp.rg) hs infrtin n the ipt f fre- quently enuntered heglbin vrints nd trits n the results btined with the nly used HbA1ssys. Any nditin tht shrtens erythryte survivl r dereses en erythryte ge (eg, revery fr ute bld lss, helyti nei) will flsely lwer HbA1, irrespetive f the ssy ethd used beuse f the extended tie tht it tkes irulting heglbin t be glysylted. Intrvenus irn nd erythrpietin therpy fr tretent f nei in hrni kidney disese ls flsely lwer HbA1levels. Alterntive ethds suh s frutsine (see belw) shuld be nsidered fr these ptients. Vitins C nd E re reprted t flsely lwer test results pssibly by inhibiting glytin f heglbin. Cnditins tht inrese erythryte survivl suh s sple- nety fr hereditry spherytsis will flsely rise HbA1levels. Irn defiieny nei is ls ssited with higher HbA1levels. HbA1is endrsed by the ADA s  dignsti test fr type 1 nd type 2 dibetes (Tble 27–3). A utff vlue f 6.5% (48 l/l) ws hsen beuse the risk fr reti- npthy inreses substntilly bve this vlue. The advantages of using the HbA1cto diagnose diabetes is that there is no need to fast; it hs lwer intrindividul vri- bility thn the fsting gluse test nd the rl gluse tlerne test; nd it prvides n estite f gluse n- trl fr the preeding 2–3 nths. Peple with HbA1lev- els f 5.7–6.4% (39–46 l/l) shuld be nsidered t high risk fr develping dibetes (predibetes). This test is nt pprprite t use in ppultins with high prevlene f heglbinpthies r in nditins with inresed red ell turnver. 6. Serum fructosamine— Seru frutsine is fred by nnenzyti glysyltin f seru prteins (pre- dinntly lbuin). Sine seru lbuin hs  uh shrter hlf-life thn heglbin, seru frutsine generlly reflets the stte f glyei ntrl fr nly the preeding 1–2 weeks. Redutins in seru lbuin (eg, nephrti stte, prtein-lsing enterpthy, r hepti dis- ese) will lwer the seru frutsine vlue. When bnrl heglbins r helyti sttes ffet the inter- prettin f glyheglbin r when  nrrwer tieTable 27–3. Criteria for the diagnosis of diabetes. Nomal Glucose Toleance1Impaied Glucose Toleance1Diabetes Mellitus2F asting plasma glucose mg/dL (mmol/L)< 100 (5.6) 100–125 (5.6–6.9)≥ 126 (7.0) 2 hours after glucose load mg/dL (mmol/L)< 140 (7.8) ≥ 140–199 (7.8–11.0)≥ 200 (11.1) HbA1c(%) < 5.7 5.7–6.4 ≥ 6.51 See text for the oral glucose tolerance test protocol.2 A fasting plasma glucose ≥ 126 mg/dL (7.0 mmol) is diagnostic of diabetes if confirmed by repeat testing. A fasting plasma glucose ≥ 126 mg/dL (7.0 mmol) and HbA1c≥ 6.5% on the same sample is also diagnostic of diabetes.CMDT22_Ch27_p1212-p1255.indd  1218 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1219 CMDT 2022fre  is required, suh s fr sertining glyei ntrl t the tie f neptin in  dibeti wn wh hs reently bee pregnnt, seru frutsine ssys ffer se dvntge. Nrl vlues vry in reltin t the seru lbuin nentrtin nd re 200–285 l/L when the seru lbuin level is 5 g/dL. HbA1vlues nd seru frutsine re highly rrelted. Seru fruts- ine levels f 300, 367, nd 430 l/L pprxite t HbA1vlues f 7%, 8%, nd 9%, respetively. Substntil individul vribility exists, thugh, when estiting the likely HbA1vlue fr the frutsine esureent. 7. Selfmonitoring of blood glucose— Cpillry bld gluse esureents perfred by ptients theselves, s utptients, re extreely useful. A lrge nuber f bld gluse eters re vilble. All re urte, but they vry with regrd t speed, nveniene, size f bld sples required, reprting pbility, nd st. Ppulr dels inlude thse nuftured by LifeSn (One Tuh), Byer Crprtin (Cntur), Rhe Dignstis (Au-Chek), nd Abbtt Lbrtries (Preisin, Free- Style). These bld gluse eters re reltively inexpen- sive, rnging fr $20 t $80 eh. Test strips rein  jr expense, sting but $0.25 t $1.50 piee. Eh gluse eter ls es with  lnet devie nd disps- ble 26- t 33-guge lnets. Mst eters n stre fr 100 t 1000 gluse vlues in their eries nd hve pbilities t dwnld the vlues int  puter r srtphne. Se eters re designed t unite with  speifi insulin pup. Cntur Next Link eter, fr exple, unites with the MiniMed Medtrni pup. The ury f dt btined by he gluse nitring des require edutin f the ptient in s- pling nd esuring predures. The liniin shuld be wre f the liittins f the self-nitring gluse systes. The strips hve liited lifespns nd iprper strge (high teperture; pen vil) n ffet their funtin. Ptients shuld ls be dvised nt t use expired strips. Inreses r dereses in hetrit n derese r inrese the esured glu- se vlues. Meters nd the test strips re librted ver the gluse nentrtins rnging fr 60 g/dL (3.3 l/L) t 160 g/dL (8.9 l/L) nd the ury is nt s gd fr higher nd lwer gluse levels. When the gluse is less thn 60 g/dL (3.3 l/L), the differ- ene between the eter nd the lbrtry vlue y be s uh s 20%. Gluse xidse–bsed peretri sys- tes underestite gluse levels in the presene f high xygen tensin. This y be iprtnt in the ritilly ill wh re reeiving suppleentl xygen; under these ir- ustnes,  gluse dehydrgense–bsed syste y be preferble. Gluse-dehydrgense pyrrlquin- line quinne (GDH-PQQ) systes y reprt flsely high gluse levels in ptients wh re reeiving prenterl prduts ntining nngluse sugrs suh s ltse, gltse, r xylse r their etblites. Se eters re pprved fr esuring gluse in bld sples btined t lterntive sites suh s the frer nd thigh. There is, hwever,  5- t 20-inute lg in the gluse respnse n the r with respet t the gluse respnse n the finger.Frer bld gluse esureents uld therefre result in  dely in detetin f rpidly develping hypgly- ei. Ipired irultin t the fingers (fr exple, in ptients with Rynud disese) will rtifiilly lwer fingerstik gluse esureents (pseudhypglyei). 8. Continuous glucose monitoring systems— A gluse xidse–bsed syste t esure gluse nentrtins in the interstitil fluid is used by ptients wh re inres- ingly using ntinuus gluse nitring systes. These systes, nuftured by Medtrni MiniMed, DexC systes, nd Abbtt Dignstis, invlve inserting  sub- utneus sensr (rther like  sll wire) tht esures gluse nentrtins ntinuusly in the interstitil fluid fr 7–14 dys. The DexC nd MiniMed systes trns- it gluse dt wirelessly t srtphnes r t the sreens f insulin pups. Diretinl rrws indite rte nd diretin f hnge f gluse levels, nd lerts n be set fr dngerusly lw r high gluse vlues. The werer ls gins insight int hw prtiulr fds nd tivities ffet their gluse level. The FreeStyle Libre (Abbtt Dig- nstis) sensr syste requires the ptient t hld  red- ing devie r  srtphne lse t the sensr pth fr but  send t see the rel tie gluse vlue. The MiniMed syste requires librtin with peridi finger- stik gluse levels, whih is nt neessry fr the Dex nd Freestyle Libre systes. The ftry librted systes use  librtin funtin tht uttilly rrets fr sensr drift ver the subsequent 10–14 dys. A 6-nth rndized ntrlled study f ptients with type 1 dibe- tes shwed tht dults (25 yers nd lder) using these ntinuus gluse nitring systes hd iprved glyei ntrl withut n inrese in the inidene f hypglyei. A rndized ntrlled study f ntinu- us gluse nitring during pregnny shwed iprved glyei ntrl in the third triester, lwer birth weight, nd redued risk f rsi. Suries f the ntinuus gluse nitring dt lleted ver 2–12 weeks n be very helpful. The perentge f “tie in rnge” (gluse levels 70–180 g/dy [3.9–10 l/L]), gluse levels tht re lw r high, nd their vribility n be ssessed. There is  strng rreltin between gluse levels tht re 70% “tie in rnge” nd n HbA1f pprx- itely 7%. Mny f these systes re vered by insurne. The initil st is but $800 t $1000, nd the sensr, whih hs t be hnged every 7 t 14 dys, sts $35 t $60; the ut-f-pket expense is but $4000 nnully. 9. Lipoprotein abnormalities in diabetes— Cirulting lipprteins re just s dependent n insulin s is the pls gluse. In type 1 dibetes, dertely defiient ntrl f hyperglyei is ssited with nly  slight elevtin f LDL hlesterl nd seru triglyerides nd little if ny hnge in HDL hlesterl. One the hypergly- ei is rreted, lipprtein levels re generlly nrl. Hwever, in ptients with type 2 dibetes,  distint “dibeti dyslipidei” is hrteristi f the insulin resistne syndre. Its fetures re  high seru tri- glyeride level (300–400 g/dL [3.4–4.5 l/L]),  lwCMDT22_Ch27_p1212-p1255.indd  1219 29/06/21 8:53 PMCHAPTEr 271220 CMDT 2022HDL h lesterl (less thn 30 g/dL [0.8 l/L]), nd  qulittive hnge in LDL prtiles, prduing  sller dense prtile whse ebrne rries suprnrl unts f free hlesterl. These sller dense LDL pr- tiles re re suseptible t xidtin, whih renders the re thergeni. Mesures designed t rret the besity nd hyperglyei, suh s exerise, diet, nd hypglyei therpy, re the tretent f hie fr di- beti dyslipidei, nd in sinl ptients in wh nrl weight ws hieved, ll fetures f the lipprtein bnrlities lered. Sine priry disrders f lipid etblis y exist with dibetes, persistene f lipid bnrlities fter restrtin f nrl weight nd bld gluse shuld prpt  dignsti wrkup nd pssible phrtherpy f the lipid disrder. Chpter 28 dis- usses these tters in detil.Aerin  Dibetes Assitin. 6. Glyei Trgets: Standards of Medical Care in Diabetes —2021. Dibetes Cre. 2021;44:S73. [PMID: 33298417] »TreatmentA.  DietA  well-blned, nutritius diet reins  fundentl eleent f therpy. There is n speifi reendtin n the perentge f lries tht shuld e fr rb- hydrte, prtein, nd ft. The rnutrient prprtins shuld be individulized bsed n the ptient’s eting pt- terns, preferenes, nd etbli gls. In generl, st ptients with dibetes nsue but 45% f their ttl dily lries in the fr f rbhydrtes, 25–35% in the fr f ft, nd 10–35% in the fr f prtein. In ptients with type 2 dibetes, liiting the rbhydrte intke nd substituting se f the lries with nunsturted fts, suh s live il, rpeseed (nl) il, r the ils in nuts nd vds, n lwer triglyerides nd inrese HDL hles- terl. A Mediterrnen-style eting pttern ( diet supple- ented with wlnuts, lnds, hzelnuts, nd live il) hs been shwn t iprve glyei ntrl nd lwer - bined endpints fr rdivsulr events nd strke. In thse ptients with besity nd type 2 dibetes, weight redutin by lri restritin is n iprtnt gl f the diet (see Chpter 29). Ptients with type 1 dibetes r type 2 dibetes wh tke insulin shuld be tught “rbhydrte unting, ” s they n dinister their insulin blus fr eh el bsed n its rbhydrte ntent. The urrent reendtins fr sturted fts nd dietry hlesterl intke fr peple with dibetes re the se s fr the generl ppultin. Sturted fts shuld be liited t less thn 10% f dily lries nd dietry h- lesterl intke shuld be less thn 300 g/dy. Fr thse ptients with kidney disese, dietry prtein shuld be intined t the reended dily llwne f 0.8 g/kg/dy. Exhnge lists fr el plnning n be btined fr the Aerin Dibetes Assitin nd its ffilite ssitins r fr the Aerin Dieteti Ass- itin (http://www.etright.rg), 216 W . Jksn Blvd., Chig, IL 60606 (312-899-0040).1. Dietary fiber— Plnt pnents suh s ellulse, gu, nd petin re indigestible by huns nd re tered dietry “fiber. ” Insluble fibers suh s ellulse r hei- ellulse, s fund in brn, tend t inrese intestinl trn- sit nd y hve benefiil effets n lni funtin. In ntrst, sluble fibers suh s gus nd petins, s fund in bens, tel, r pple skin, tend t retrd nutrient bsrptin rtes s tht gluse bsrptin is slwer nd hyperglyei y be slightly diinished. Althugh its reendtins d nt inlude insluble fiber supple- ents suh s dded brn, the ADA reends fd suh s tel, erels, nd bens with reltively high sluble fiber ntent s stple pnents f the diet in dibetis. High sluble fiber ntent in the diet y ls hve  fvrble effet n bld hlesterl levels. 2. Glycemic index— The glyei index f  rbhy- drte ntining fd is deterined by pring the gluse exursins fter nsuing 50 g f test fd with gluse exursins fter nsuing 50 g f referene fd (white bred): Glycemic indexBlood glucose area under the curve (3h) for test food Blood glucose area under the curve (3h) for reference food100 =  × Eting lw glyei index fds results in lwer glu- se levels fter els. Lw glyei index fds hve vlues f 55 r less nd inlude ny fruits, vegetbles, griny breds, pst, nd legues. High glyei index fds hve vlues f 70 r greter nd inlude bked ptt, white bred, nd white rie. Glyei index is lw- ered by the presene f fts nd prtein when fd is n- sued in  ixed el. Even thugh it y nt be pssible t urtely predit the glyei index f  prtiulr fd in the ntext f  el, it is resnble t hse fds with lw glyei index. 3. Artificial and other sweeteners— Shrin (Sweet N Lw), surlse (Splend), esulfe ptssiu (Sweet One), nd rebin (Truvi) re “rtifiil” sweeteners tht n be used in king nd bking. Asprte (NutrSweet) lks het stbility, s it nnt be used in king. Nne f these sweeteners rise bld gluse levels. Frutse represents  “nturl” sugr substne tht is  highly effetive sweetener, indues nly slight inreses in pls gluse levels, nd des nt require insulin fr its etblis. Hwever, beuse f ptentil dverse effets f lrge unts f frutse n rising seru hlesterl, triglyerides, nd LDL hlesterl, it des nt hve ny dvntge s  sweetening gent in the dibeti diet. This des nt prelude, hwever, ingestin f frutse-ntining fruits nd vegetbles r frutse-sweetened fds in dertin. Sugr lhls, ls knwn s plyls r plylhl, re nly used s sweeteners nd bulking gents. They ur nturlly in  vriety f fruits nd vegetbles but re ls erilly de fr surse, gluse, nd strh.CMDT22_Ch27_p1212-p1255.indd  1220 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1221 CMDT 2022Exp les re srbitl, xylitl, nnitl, ltitl, islt, ltitl, nd hydrgented strh hydrlystes (HSH). They re nt s esily bsrbed s sugr, s they d nt rise bld gluse levels s uh. Therefre, sugr l- hls re ften used in fd prduts tht re lbeled s “sugr free, ” suh s hewing gu, lzenges, hrd ndy, nd sugr-free ie re. Hwever, if nsued in lrge quntities, they will rise bld gluse nd n use blting nd dirrhe.B.  Medications for Treating HyperglycemiaThe  editins fr treting type 2 dibetes re listed in Tble 27–4. 1. Medications that primarily stimulate insulin secretion by binding to the sulfonylurea receptor on the beta cell— a. Sulfonylureas— The priry ehnis f tin f the sulfnylures is t stiulte insulin relese fr pn- reti B ells. Sulfnylures re used in ptients with type 2 but nt type 1 dibetes, sine these editins require funtin- ing pnreti B ells t prdue their effet n bld gluse. Sulfnylures re etblized by the liver nd prt fr ethexide, whse etblite is re tive thn the prent pund, the etblites f ll the ther sulfnylures re wekly tive r intive. The etblites re exreted by the kidney nd, in the se f the send-genertin sulfnylures, prtly exreted in the bile. Hypglyei is  n dverse retin with the sulfnylures. Weight gin is ls n, espeilly in the first yer f use. The ehniss f the weight gin inlude iprved gluse ntrl nd inresed fd intke in respnse t hypglyei. Idisynrti retins re rre, with skin rshes r hetlgi txiity (leukpeni, thrbytpeni) urring in less thn 0.1% f users. (1) First-generation oral sulfonylureas (tolbutamide, tolazamide, acetohexamide, chlorpropamide)— Tlbut- ide is prbbly best dinistered in divided dses (eg, 500 g befre eh el nd t bedtie); hwever, se ptients require nly ne r tw tblets dily with  xi- u dse f 3000 g/dy. Beuse f its shrt durtin f tin (but 6–10 hurs, whih is independent f kidney funtin), tlbutide is reltively sfe t use in kidney disese. Prlnged hypgly- ei hs been reprted rrely with tlbutide, stly in ptients reeiving ntibteril sulfnides (sulfisx- zle), phenylbutzne fr rthrlgis, r the rl zle ntifungl editins t tret ndidisis. Tlzide, ethexide, nd hlrprpide re rrely used. Chlrprpide hs  prlnged bilgi effet, nd severe hypglyei n ur espeilly in lder dults s their renl lerne delines with ging. Its ther side effets inlude lhl-indued flushing nd hypntrei due t its effet n vspressin seretin nd tin. (2) Second-generation sulfonylureas (glyburide, glipizide, gliclazide, glimepiride)— Glyburide, glipizide, glilzide, nd gliepiride re 100–200 ties re ptentthn tlbutide. These editins shuld be used with utin in ptients with rdivsulr disese r in elderly ptients, in wh prlnged hypglyei wuld be espe- illy dngerus. The usul strting dse f glyburide is 2.5 g/dy, nd the verge intenne dse is 5–10 g/dy given s  single rning dse; intenne dses higher thn 20 g/dy re nt reended. Se reprts suggest tht 10 g is  xiu dily therpeuti dse, with 15–20 g hving n dditinl benefit in pr respnders nd dses ver 20 g tully wrsening hyperglyei. A “Press Tb” frultin f “irnized” glyburide—esy t divide in hlf with slight pressure if neessry—is vil- ble. Glyburide is etblized in the liver nd the et- bli prduts f glyburide hve hypglyei tivity. This prbbly explins why ssys speifi fr the une- tblized pund suggest  pls hlf-life f nly 1–2 hurs, yet the bilgi effets f glyburide re lerly persistent 24 hurs fter  single rning dse in dibeti ptients. Glyburide hs few dverse effets ther thn its pten- til fr using hypglyei, whih t ties n be pr- lnged. Flushing hs rrely been reprted fter ethnl ingestin. It des nt use wter retentin, s hlrprp- ide des, but rther slightly enhnes free wter ler- ne. Glyburide shuld nt be used in ptients with liver filure nd hrni kidney disese beuse f the risk f hypglyei. Elderly ptients re t prtiulr risk fr hypglyei even with reltively sll dily dses. The reended strting dse f glipizide is 5 g/dy, with up t 15 g/dy given s  single dily dse befre brekfst. When higher dily dses re required, they shuld be divided nd given befre els. The xiu dse reended by the nufturer is 40 g/d, lthugh dses bve 10–15 g prbbly prvide little dditinl benefit in pr respnders nd y even be less effetive thn sller dses. Fr xi- u effet in reduing pstprndil hyperglyei, glipizide shuld be ingested 30 inutes befre els, sine rpid bsrptin is delyed when the editin is tken with fd. At lest 90% f glipizide is etblized in the liver t intive prduts, nd 10% is exreted unhnged in the urine. Glipizide therpy shuld therefre nt be used in ptients with liver filure. Beuse f its lwer pteny nd shrter durtin f tin, it is preferble t glyburide in elderly ptients nd fr thse ptients with kidney disese. Glutrl-XL prvides extended relese f glipizide during trnsit thrugh the gstrintestinl trt with greter effe- tiveness in lwering prebrekfst hyperglyei thn the shrter-durtin iedite-relese stndrd glipizide tb- lets. Hwever, this frultin ppers t hve srified its lwer prpensity fr severe hypglyei pred with lnger-ting glyburide withut shwing ny den- strble therpeuti dvntges ver glyburide. Gliclazide (nt vilble in the United Sttes) is nther interedite durtin sulfnylure with  durtin f tin f but 12 hurs. The reended strting dse is 40–80 g/dy with  xiu dse f 320 g. Dses f 160 g nd bve re given s divided dses befreCMDT22_Ch27_p1212-p1255.indd  1221 29/06/21 8:53 PMCHAPTEr 271222 CMDT 2022T able 27–4. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Sulfonylueas Acetohexamide (Dymelor) (not available in United States)250 and 500 mg 0.25–1.5 g as single dose or in two divided doses 8–24 hours Chlorpropamide (Diabinese) 100 and 250 mg 0.1–0.5 g as single dose 24–72 hours Gliclazide (not available in United States) 80 mg 40–80 mg as single dose; 160–320 mg as divided dose 12 hours Glimepiride (Amaryl) 1, 2, and 4 mg Usual dose: 1–4 mg once daily Maximal dose: 8 mg once dailyUp to 24 hours Glipizide (Glucotrol) 5 and 10 mg Usual dose: 2.5–10 mg twice daily 30 minutes before meals Maximal dose: 20 mg twice daily6–12 hours (Glucotrol XL) 2.5, 5, and 10 mg Usual dose: 2.5–10 mg once daily Maximal dose: 20 mg once dailyUp to 24 hours Glyburide (Dia Beta, Micronase) 1.25, 2.5, and 5 mg 1.25–20 mg as single dose or in two divided doses Up to 24 hours (Glynase) 1.5, 3, and 6 mg 1.5–12 mg as single dose or in two divided doses Up to 24 hours Tolazamide (Tolinase) 100, 250, and 500 mg 0.1–1 g as single dose or in two divided doses Up to 24 hours Tolbutamide (Orinase) 250 and 500 mg 0.5–2 g in two or three divided doses 6–10 hours Meglitinide Analogs Mitiglinide (available in Japan) 5 and 10 mg 5 or 10 mg three times daily before meals 2 hours Repaglinide (Prandin) 0.5, 1, and 2 mg Usual dose: 0.5 to 4 mg three times daily 15 minutes before meals Maximal dose: 16 mg daily3 hoursd -Phenylalanine Deivative Nateglinide (Starlix) 60 and 120 mg 60 or 120 mg three times daily before meals 4 hours Biguanides Metformin (Glucophage) 500, 850, and 1000 mg 500–850 mg with meals two or three times daily; 850–1000 mg with breakfast and dinner4 hours Metformin, extended release (Glucophage XR)1500, 750, and 1000 mg 500–2000 mg once daily Up to 24 hours Thiazolidinediones Pioglitazone (Actos) 15, 30, and 45 mg 15–45 mg daily Up to 24 hours Rosiglitazone (Avandia) 2, 4, and 8 mg 4–8 mg daily (can be divided) Up to 24 hours Alpha-Glucosidase Inhibitos Acarbose (Precose) 25, 50, and 100 mg 25–100 mg three times daily just before meals 4 hours Miglitol (Glyset) 25, 50, and 100 mg 25–100 mg three times daily just before meals 4 hours Voglibose (not available in United States) 0.2 and 0.3 mg 0.2–0.3 mg three times daily just before meals 4 hours GLP-1 recepto Agonists Dulaglutide (Trulicity) 0.75-, 1.5-mg single- dose pen or pre- filled syringeUsual dose: 0.75 mg subcutaneously once weekly Maximal dose: 1.5 mg subcutaneously once weekly1 week Exenatide (Byetta) 1.2 mL and 2.4 mL prefilled pens deliv- ering 5 mcg and 10 mcg doses5 mcg subcutaneously twice daily within 1 hour of breakfast and dinner. Increase to 10 mcg subcuta- neously twice daily after about a month. AVOID if eGFR < 30 mL/min/1.73 m26 hours Exenatide, long-acting release (Byetta LAR, Bydureon)2 mg (powder) Suspend in provided diluent and inject subcutaneously.1 week (continued )CMDT22_Ch27_p1212-p1255.indd  1222 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1223 CMDT 2022T able 27–4. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Liraglutide (Victoza) Prefilled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mgInitial dose: 0.6 mg subcutaneously once daily. Increase to 1.2 mg after a week if no adverse reactions. Maximal dose: 1.8 mg subcutaneously once daily24 hours Lixisenatide (Adlyxin, Lyxumia) 3-mL prefilled pens delivering 10- or 20-mcg dosesInitial dose: 10 mcg daily. Increase to 20 mcg daily after 2 weeks.24 hours Semaglutide (Ozempic, Rybelsus) Prefilled pens deliver- ing 0.25 mg or 0.5 mg 1-, 3-,7-, and 14-mg tabletsInitial dose: 0.25 mg weekly for 1 month and increase to 0.5 mg weekly if no adverse reactions. Maximal dose: 1 mg weekly Initial dose: 3 mg for 1 month and then increase to 7 mg. Take fasting daily with water and wait 30 min to eat. Maximal dose: 14 mg1 week Daily DPP-4 Inhibitos Alogliptin (Nesina) 6.25, 12.5, and 25 mg 25 mg once daily if eGFR ≥ 60 mL/min/1.73 m2; 12.5 mg daily if eGFR 30–59 mL/min/1.73 m2; 6.25 mg daily if eGFR < 30 mL/min/1.73 m224 hours Linagliptin (Tradjenta) 5 mg 5 mg daily 24 hours Saxagliptin (Onglyza) 2.5 and 5 mg 2.5 mg or 5 mg once daily if eGFR > 50 mL/min/1.73 m2. 2.5 mg daily if eGFR ≤ 50 mL/min/1.73 m2or if also taking drugs that are strong CYP3A4/5 inhibitors such as ketoconazole24 hours Sitagliptin (Januvia) 25, 50, and 100 mg 100 mg once daily if eGFR > 50 mL/min/1.73 m2; 50 mg once daily if eGFR 30–50 mL/min/1.73 m2; 25 mg once daily if eGFR < 30 mL/min/1.73 m224 hours Vildagliptin (Galvus) (not available in United States)50 mg 50 mg once or twice daily. AVOID if eGFR ≤ 60 mL/min/1.73 m2or AST/ALT three times upper limit of normal24 hours SGLT2 Inhibitos Canagliflozin (Invokana) 100 and 300 mg Usual dose: 100 mg daily. 300 mg can be used if normal eGFR, resulting in lowering the HbA1can additional ~ 0.1–0.25%. AVOID if eGFR < 45 mL/min/1.73 m2.24 hours Dapagliflozin (Farxiga) 5 and 10 mg 10 mg daily 24 hours Empagliflozin (Jardiance) 10 and 25 mg Usual dose: 10 mg daily Maximal dose: 25 mg24 hours Ertugliflozin (Steglatro) 5 and 15 mg Usual dose: 5 mg daily Maximal dose: 15 mg24 hours Othes Bromocriptine (Cycloset) 0.8 mg 0.8 mg daily. Increase weekly by 1 tablet until maxi- mal tolerated dose of 1.6–4.8 mg daily.24 hours Colesevelam (Welchol) 625 mg 3 tablets twice daily 24 hours Pramlintide (Symlin) 5-mL vial containing 0.6 mg/mL; also available as pre- filled pens. Symlin pen 60 or Symlin pen 120For insulin-treated type 2 patients, start at 60-mcg dose subcutaneously three times daily (10 units on U100 insulin syringe). Increase to 120 mcg three times daily (20 units on U100 insulin syringe) if no nausea for 3–7 days. Give immediately before meal. For type 1 patients, start at 15 mcg three times daily (2.5 units on U100 insulin syringe) and increase by increments of 15 mcg to a maximum of 60 mcg three times daily, as tolerated. To avoid hypoglycemia, lower insulin dose by 50% on initiation of therapy.2 hours AST/ALT, aspartate aminotransferase/alanine aminotransferase; eGFR, estimated glomerular filtration rate.(continued)CMDT22_Ch27_p1212-p1255.indd  1223 29/06/21 8:53 PMCHAPTEr 271224 CMDT 2022brekfst  nd dinner. The editin is etblized by the liver; the etblites nd njugtes hve n hypglyei effet. An extended-relese preprtin is vilble. Glimepiride hs  lng durtin f effet with  hlf- life f 5 hurs llwing ne r twie dily dsing. Gliepiride hieves bld gluse lwering with the lw- est dse f ny sulfnylure pund. A single dily dse f 1 g/dy hs been shwn t be effetive, nd the xi- l reended dse is 8 g. It is pletely etb- lized by the liver t reltively intive etbli prduts. b. Meglitinide analogs— Repglinide is struturlly siilr t glyburide but lks the sulfni id-ure iety. It ts by binding t the sulfnylure reeptr nd lsing the densine triphsphte (ATP)-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine nd then underges plete etblis in the liver t intive biliry prduts, giving it  pls hlf-life f less thn 1 hur. The editin therefre uses  brief but rpid pulse f insulin. The strting dse is 0.5 g three ties  dy 15 inutes befre eh el. The dse n be titrted t  xiu dily dse f 16 g. Like the sulfnylures, repglinide n be used in bintin with etfrin. Hypglyei is the in side effet. Like the sulfnyl- ures, repglinide uses weight gin. Metblis is by ythre P450 3A4 isenzye, nd ther editins tht indue r inhibit this isenzye y inrese r inhibit (respetively) the etblis f repglinide. The editin y be useful in ptients with kidney ipir- ent r in lder dults. Mitiglinide is  benzylsuini id derivtive tht binds t the sulfnylure reeptr nd is siilr t rep- glinide in its linil effets. It is pprved fr use in Jpn. c. D-phenylalanine derivative— Nteglinide stiu- ltes insulin seretin by binding t the sulfnylure reep- tr nd lsing the ATP-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine, rehing pek pls levels within 1 hur. It is etblized in the liver nd hs  pls hlf-life f but 1.5 hurs. Like repglinide, it uses  brief rpid pulse f insulin, nd when given befre  el it redues the pstprndil rise in bld gluse. Fr st ptients, the reended strting nd intenne dse is 120 g three ties  dy befre els. Use 60 g in ptients wh hve ild elevtins in HbA1. Like the ther insulin seretggues, its in side effets re hyp- glyei nd weight gin. 2. Medications that primarily lower glucose levels by their actions on the liver, muscle, and adipose tissue— a. Metformin— Metfrin is the first-line therpy fr ptients with type 2 dibetes. It n be used lne r in njuntin with ther rl gents r insulin in the tret- ent f ptients with type 2 dibetes. It is ineffetive in ptients with type 1 dibetes. Metfrin’s therpeuti effets pririly derive fr the inresing hepti densine nphsphte-tivted pr- tein kinse tivity, whih redues hepti glunegenesis nd lipgenesis. Metfrin hs  hlf-life f 1.5–3 hurs nd is nt bund t pls prteins r etblized, being exreted unhnged by the kidneys.The urrent reendtin is t strt etfrin t dignsis. A side benefit f etfrin therpy is its ten- deny t iprve bth fsting nd pstprndil hypergly- ei nd hypertriglyeridei in bese ptients with dibetes withut the weight gin ssited with insulin r sulfnylure therpy. Ptients with hrni kidney disese shuld nt be given this editin beuse filure t exrete it wuld prdue high bld nd tissue levels f etfrin tht uld stiulte lti id verprdutin. In the United Sttes, etfrin use is nt reended t r bve  seru retinine level f 1.4 g/dL in wen nd 1.5 g/dL in en. In the United Kingd, the re- endtins re t review etfrin use when the seru retinine exeeds 130 l/L (1.5 g/dL) r the esti- ted glerulr filtrtin rte (eGFR) flls belw 45 L/ in/1.73 2. The editin shuld be stpped if the seru retinine exeeds 150 l/L (1.7 g/dL) r the eGFR is belw 30 L/in/1.73 2. Ptients with liver fil- ure r persns with exessive lhl intke shuld nt reeive this editin beuse f the risk f lti idsis. The xiu dsge f etfrin is 2550 g, lthugh little benefit is seen bve  ttl dse f 2000 g. It is iprtnt t begin with  lw dse nd inrese the dsge very grdully in divided dses—tken with els—t redue inr gstrintestinl upsets (nrexi, nuse, viting, bdinl disfrt, dirrhe), whih ur in up t 20% f ptients. A n shedule wuld be ne 500-g tblet three ties  dy with els r ne 850- r 1000-g tblet twie dily t brekfst nd dinner. Up t 2000 g f the extended-relese preprtin n be given ne  dy. Lwer dses shuld be used in ptients with eGFRs between 30 nd 45 L/in/1.73 2nd in the elderly wh re t higher risk fr ute kidney injury fr redued renl funtinl reserve. The gstrintestinl side effets re dse-relted, tend t ur t nset f therpy, nd ften re trnsient. Hw- ever, in 3–5% f ptients, therpy y hve t be disntin- ued beuse f persistent dirrhel disfrt. Ptients swithing fr iedite-relese etfrin t pr- ble dse f extended-relese etfrin y experiene fewer gstrintestinl side effets. Hypglyei des nt ur with therpeuti dses f etfrin, whih perits its desriptin s  “euglyei” r “ntihyperglyei” editin rther thn n rl hypglyei gent. Dertlgi r hetlgi txiity is rre. Metfrin interferes with the liu dependent bsrptin f vitin B12-intrinsi plex in the terinl ileu; vitin B12defiieny n ur fter ny yers f etfrin use. Peridi sreening with vitin B12levels shuld be nsidered, espeilly in ptients with peripherl neurpthy (whih y be errneusly ttributed t di- beti neurpthy) r if  ryti nei develps. Inresed intke f dietry liu y prevent the et- frin-indued B12lbrptin. Lti idsis hs been reprted s  side effet but is unn with etfrin in ntrst t phenfrin. Alst ll reprted ses hve invlved persns with ssited risk ftrs tht shuld hve ntrindited its use (kidney, liver, r rdirespirtry insuffiieny ndCMDT22_Ch27_p1212-p1255.indd  1224 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1225 CMDT 2022lhlis).  Aute kidney injury n ur rrely in er- tin ptients tking etfrin wh reeive rdintrst gents. Metfrin therpy shuld therefre be teprrily hlted n the dy f rdintrst dinistrtin nd restrted  dy r tw lter fter nfirtin tht kidney funtin hs nt deterirted. b. Thiazolidinediones— Tw editins f this lss, rsiglitzne nd piglitzne, re vilble fr linil use. These editins sensitize peripherl tissues t insulin. They bind the nuler reeptr perxise prlifertr- tivted reeptr g (PPAR-g) nd ffet the expressin f  nuber f genes. Like the bigunides, this lss f editins des nt use hypglyei. Bth rsiglitzne nd piglitzne re effetive s ntherpy nd in bintin with sulfnylures r etfrin r insulin, lwering HbA1by 1–2%. When used in bintin with insulin, they n result in  30–50% redutin in insulin dsge, nd se ptients n e ff insulin pletely. The rl dsge f rsigli- tzne is 4–8 g dily nd f piglitzne, 15–45 g dily; the editins d nt hve t be tken with fd. Rsigli- tzne is pririly etblized by the CYP 2C8 isen- zye nd piglitzne is etblized by CYP 2C8 nd CYP 3A4. The bintin f  thizlidinedine nd etfr- in hs the dvntge f nt using hypglyei. Ptients indequtely nged n sulfnylures n d well n  bintin f sulfnylure nd rsiglitzne r piglitzne. These editins hve se dditinl effets prt fr gluse lwering. Rsiglitzne therpy is ssited with inreses in ttl hlesterl, LDL hlesterl (15%), nd HDL hlesterl (10%). There is  redutin in free ftty ids f but 8–15%. The hnges in triglyerides re generlly nt different fr pleb. Piglitzne in lini- l trils lwered triglyerides (9%) nd inresed HDL hlesterl (15%) but did nt use  nsistent hnge in ttl hlesterl nd LDL hlesterl levels. A prspetive rndized prisn f the etbli effets f pigli- tzne nd rsiglitzne shwed siilr effets n HbA1 nd weight gin. Sll prspetive studies hve den- strted tht tretent with these editins leds t iprveents in the biheil nd histlgi fetures f nnlhli ftty liver disese. The thizlidinedines ls y liit vsulr sth usle prlifertin fter injury, nd there re reprts tht piglitzne n redue neintil prlifertin fter rnry stent pleent. In ne duble-blind, pleb-ntrlled study, rsiglitzne ws shwn t be ssited with  derese in the rti f urinry lbuin t retinine exretin. Safety concerns nd se trublese side effets liit the use f this lss f editin. Rsiglitzne use delined when  et-nlysis f 42 rndized linil trils suggested tht this editin inreses the risk f ngin petris r yrdil infrtin; the Eurpen Mediines Ageny suspended the use f rsiglitzne in Eurpe. In the United Sttes, the FDA estblished  restrited distributin prgr. A subsequent lrge pr- spetive linil tril (the RECORD study) filed tnfir the et-nlysis finding nd the restritins were lifted in the United Sttes. Ede urs in but 3–4% f ptients reeiving ntherpy with rsiglitzne r piglitzne. The ede urs re frequently (10–15%) in ptients reeiv- ing nitnt insulin therpy nd y result in hert filure. The editins re ntrindited in dibeti individuls with New Yrk Hert Assitin lss III nd IV rdi sttus. Thizlidinedines hve ls been reprted s being ssited with new nset r wrsening ulr ede. Apprently, this is  rre side effet, nd st f these ptients ls hd peripherl ede. The ulr ede reslved r iprved ne the editin ws disntinued. Trglitzne, the first editin in this lss, ws with- drwn fr linil use beuse f editin-ssited ftl liver filure. Althugh rsiglitzne nd piglitzne hve nt been reprted t use liver injury, the FDA re- ends tht they shuld nt be used in ptients with linil evidene f tive liver disese r pretretent elevtin f the lnine intrnsferse (ALT) level tht is 2.5 ties greter thn the upper liit f nrl. Liver biheil tests shuld be perfred n ll ptients prir t inititin f tretent nd peridilly therefter. An inrese in frture risk in wen (but nt en) hs been reprted with bth rsiglitzne nd pigli- tzne. The frture risk is in the rnge f 1.9 per 100 ptient-yers with the thizlidinedine s ppsed t 1.1 per 100 ptient-yers n prisn tretent. In t lest ne study f rsiglitzne, the frture risk ws inresed in preenpusl s well s pstenpusl wen. Other side effets inlude nei, whih urs in 4% f ptients treted with these editins; it y be due t  dilutinl effet f inresed pls vlue rther thn  redutin in red ell ss. Weight gin urs, espeilly when the editin is bined with  sulfnylure r insulin. Se f the weight gin is fluid retentin, but there is ls n inrese in ttl ft ss. Clinil studies hve reprted nfliting results regrding n ssitin f bldder ner with piglitzne use. A 10-yer bserv- tinl hrt study f ptients tking piglitzne filed t find n ssitin with bldder ner. A lrge ultippu- ltin pled nlysis (1.01 illin persns ver 5.9 illin persn-yers) ls filed t find n ssitin between uultive expsure f piglitzne r rsiglitzne nd inidene f bldder ner. Anther ppultin-bsed study, hwever, generting 689,616 persn-yers f fllw- up did find tht piglitzne but nt rsiglitzne ws ssited with n inresed risk f bldder ner. 3. Medications that affect absorption of glucose— Alph- glusidse inhibitrs petitively inhibit the lph- glusidse enzyes in the gut tht digest dietry strh nd surse. Tw f these editins—rbse nd iglitl—re vilble fr linil use in the United Sttes. Vglibse, nther lph-glusidse inhibitr is vilble in Jpn, Kre, nd Indi. Arbse nd iglitl re ptent inhibitrs f gluylse, lph-ylse, nd surse but hve less effet n isltse nd hrdly ny n trehlse nd ltse.CMDT22_Ch27_p1212-p1255.indd  1225 29/06/21 8:53 PMCHAPTEr 271226 CMDT 2022a.  Acarbose— The reended strting dse f r- bse is 50 g rlly twie dily, grdully inresing t 100 g three ties dily. Fr xil benefit n pstprn- dil hyperglyei, rbse shuld be given with the first uthful f fd ingested. In dibeti ptients, it redues pstprndil hyperglyei by 30–50%, nd its verll effet is t lwer the HbA1by 0.5–1%. The prinipl dverse effet, seen in 20–30% f ptients, is fltulene. This is used by undigested rbhydrte rehing the lwer bwel, where gses re prdued by bteril flr. In 3% f ses, trublese dirrhe urs. This gstrintestinl disfrt tends t disur- ge exessive rbhydrte nsuptin nd prtes iprved pline f type 2 ptients with their diet presriptins. When rbse is given lne, there is n risk f hypglyei. Hwever, if bined with insulin r sulfnylures, it ight inrese the risk f hypglyei fr these gents. A slight rise in hepti intrnsfer- ses hs been nted in linil trils with rbse (5% vs 2% in pleb ntrls, nd prtiulrly with dses greter thn 300 g/dy). The levels generlly return t nrl n stpping the editin. b. Miglitol— Miglitl is siilr t rbse in ters f its linil effets. It is indited fr use in diet- r sulfnyl- ure-treted ptients with type 2 dibetes. Therpy is initi- ted t the lwest effetive dsge f 25 g rlly three ties  dy. The usul intenne dse is 50 g three ties  dy, lthugh se ptients y benefit fr inresing the dse t 100 g three ties  dy. Gstrin- testinl side effets ur s with rbse. The editin is nt etblized nd is exreted unhnged by the kidney. Miglitl shuld nt be used in end-stge hrni kidney disese, when its lerne wuld be ipired. 4. Incretins— Orl gluse prvkes  threefld t furfld higher insulin respnse thn n equivlent dse f gluse given intrvenusly. This is beuse the rl gluse uses  relese f gut hrnes, priniplly glugn-like pep- tide 1 (GLP-1) nd gluse-dependent insulintrpi ply- peptide (GIP1), tht plify the gluse-indued insulin relese. This “inretin effet” f GLP-1 seretin (but nt GIP1 seretin) is redued in ptients with type 2 dibetes; when GLP-1 is infused in ptients with type 2 dibetes, it stiultes insulin seretin nd lwers gluse levels. GLP-1, unlike the sulfnylures, hs nly  dest insulin stiul- try effet t nrglyei nentrtins. This ens tht GLP-1 hs  lwer risk fr hypglyei thn the sulfnylures. In dditin t its insulin stiultry effet, GLP-1 ls hs  nuber f ther pnreti nd extrpnreti effets. It suppresses glugn seretin nd s y e- lirte the hyperglugnei tht is present in peple with dibetes nd iprve pstprndil hyperglyei. GLP-1 ts n the sth delying gstri eptying; the iprtne f this effet n gluse lwering is illustrted by the bservtin tht ntgnizing the deelertin f gstri eptying rkedly redues the gluse lwering effet f GLP-1. GLP-1 reeptrs re present in the entrl nervus syste nd y ply  rle in the nreti effet f the drugs. Type 2 dibeti ptients underging GLP-1infusin re less hungry; it is unler whether this is inly due t  deelertin f gstri eptying r whether there is  entrl nervus syste effet s well. a. GLP-1 receptor agonists— GLP-1’s hlf-life is nly 1–2 inutes. It is rpidly prtelyzed by dipeptidyl pepti- dse 4 (DPP-4) nd by ther enzyes, suh s endpepti- dse 24.11, nd is ls lered quikly by the kidney. The ntive peptide, therefre, nnt be used therpeutilly. Five GLP-1 reeptr gnists with lnger hlf-lives, exen- tide, lirglutide, dulglutide, lixisentide, nd seglutide, re vilble fr linil use. Exenatide (Exendin 4) is  GLP-1 reeptr gnist is- lted fr the sliv f the Gil nster ( venus lizrd) tht is re resistnt t DPP-4 tin nd lered by the kidney. Its hlf-life is 2.4 hurs, nd its gluse lwering effet is but 6 hurs. Exentide is dispensed s tw fixed-dse pens (5 g nd 10 g). It is injeted 60 inutes befre brekfst nd befre dinner. Ptients with type 2 dibetes shuld be presribed the 5 g pen fr the first nth nd, if tlerted, the dse n then be inresed t 10 g twie  dy. The editin is nt reended in ptients with eGFR less thn 30 L/in/1.73 2. In linil trils, dding exentide therpy t ptients with type 2 dibetes lredy tking etfrin r  sulfnylure, r bth, further lwered the HbA1vlue by 0.4% t 0.6% ver  30-week perid. These ptients ls experiened  weight lss f 3–6 punds. Exentide LAR is  ne-weekly preprtin tht is dispensed s  pwder (2 g). It is suspended in the prvided diluent just prir t injetin. In prtive linil trils, the lng- ting drug lwers the HbA1level  little re thn the twie dily drug. Lw-titer ntibdies ginst exentide develp in ver ne-third (38%) f ptients, but the linil effets re nt ttenuted. High-titer ntibdies develp in  subset f ptients (~6%), nd in but hlf f these ses, n ttenu- tin f glyei respnse hs been seen. Liraglutide is  sluble ftty id ylted GLP-1 n- lg. The hlf-life is pprxitely 12 hurs, llwing the editin t be injeted ne  dy. The dsing is initi- ted t 0.6 g dily, inresed fter 1 week t 1.2 g dily. Se ptients y benefit fr inresing the dse t 1.8 g. In linil trils lsting 26 nd 52 weeks, dding lirglutide t the therpeuti regien (etfrin, sulf- nylure, thizlidinedine) f ptients with type 2 dibetes further lwered the HbA1vlue. Depending n the dse nd design f the study, the HbA1deline ws in the rnge f 0.6% t 1.5%. The ptients hd sustined weight lss f 1–6 punds. Lirglutide t  dse f 3 g dily hs been pprved fr weight lss. In  pstrketing ultintinl study f 9340 ptients with type 2 dibetes with knwn rdivsulr disese, the dditin f lirglutide ws ssited with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.87, P= 0.01). Ptients tking lirglutide hd lwer HbA1levels, weight lss f 2.3 kg, lwer systli bld pres- sure, nd fewer episdes f severe hypglyei. Dulaglutide nsists f tw GLP-1 nlg leules vlently linked t n F frgent f hun IgG4. The GLP-1 leule hs in id substitutins tht resistCMDT22_Ch27_p1212-p1255.indd  1226 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1227 CMDT 2022DPP -4 tin. The hlf-life f dulglutide is but 5 dys. The usul dse is 0.75 g weekly by subutneus inje- tin. The xiu reended dse is 1.5 g weekly. Dulglutide ntherpy nd bintin therpy lwers HbA1by but 0.7% t 1.6%. Weight lss rnged fr 2 punds t 7 punds. Lixisenatide is  syntheti nlg f exendin 4 (deletin f  prline nd dditin f 6 lysines t the C-terinl regin) with  hlf-life f 3 hurs. It is dispensed s tw fixed-dse pens (10 g nd 20 g). The 10-g dse is injeted ne dily befre brekfst fr the first 2 weeks, nd if tlerted, the dse is then inresed t 20 g dily. Its linil effet is but the se s exentide with HbA1 lwering in the 0.4–0.6% rnge. Weight lss rnges fr 2 punds t 6 punds. Antibdies t lixisentide ur frequently (70%) nd ~2.4% with the highest ntibdy titers hve ttenuted glyei respnse. Semaglutide is  syntheti nlg f GLP-1 with  drug hlf-life f but 1 week. It hs n lph-inisbutyri id substitutin t psitin 8 tht kes the leule resistnt t DPP4 tin nd  C-18 ftty di-id hin tthed t lysine t psitin 26 tht binds t lbuin, whih unts fr the drug’s lng hlf-life. Seglutide is dispensed either subutneusly r rlly. There re tw pens fr subutneus injetin: ne pen delivers  0.25-g r 0.5-g dse nd the ther pen delivers  1-g dse. The reended dsing is 0.25 g weekly fr 4 weeks nd if tlerted the dse is then inresed t 0.5 g per week. The 1-g per week dse n prvide dditinl gluse lwering effet. Seglutide ntherpy nd bin- tin therpy lwers HbA1fr 1.5% t 1.8%. The ptient ust tke rl seglutide fsting with  glss f wter nd then wit hlf n hur befre eting, drinking, r tking ther ediines. The reended strting dse is 3 g dily fr the first nth, with the dse inresed t 7–14 g dily s tlerted nd s needed fr gluse ntrl. Side effects— The st frequent dverse retins f the GLP-1 reeptr gnists re nuse (11–40%), vit- ing (4–13%), nd dirrhe (9–17%). The retins re re frequent t the higher dses. In linil trils but 1–5% f prtiipnts withdrew fr the studies beuse f the gstrintestinl sypts. The GLP-1 reeptr gnists hve been ssited with inresed risk f pnretitis. The pnretitis ws severe (herrhgi r nertizing) in 6 instnes, nd 2 f these ptients died. In the lirglutide nd dulglutide linil trils, there were 13 nd 5 ses f pnretitis in the drug- treted grups versus 1 nd 1 se in the prtr grups, respetively. This trnsltes t but 1.4–2.2 vs 0.6–0.9 ses f pnretitis per 1000 ptient-yers. Patients taking GLP-1 receptor agonists should be advised to seek immediate medical care if they experience unexplained per- sistent severe abdominal pain . There hve been rre reprts f ute kidney injury in ptients tking exentide. Se f these ptients hd pre- existing kidney disese, nd thers hd ne r re risk ftrs fr kidney disese. A nuber f the ptients reprted nuse, viting, nd dirrhe, nd it is ps- sible tht these side effets used vlue depletin ndntributed t the develpent f the kidney injury. Lir- glutide, seglutide, nd dulglutide re etblized by prtelysis nd re preferred hies in ptients with kid- ney filure. GLP-1 reeptr gnists stiulte C-ell neplsi nd use edullry thyrid rin in rts. Hun C-ells express very few GLP-1 reeptrs, nd the relevne t hun therpy is unler. The editins, hwever, shuld nt be used in ptients with persnl r fily his- try f edullry thyrid rin r ultiple endrine neplsi (MEN) syndre type 2. b. DPP-4 inhibitors— An lternte pprh t the use f GLP-1 reeptr gnists is t inhibit the enzye DPP-4 nd prlng the tin f endgenusly relesed GLP-1 nd GIP . Fur rl DPP-4 inhibitrs, sitgliptin, sx- gliptin, lingliptin, nd lgliptin, re vilble in the United Sttes fr the tretent f type 2 dibetes. An ddi- tinl DPP-4 inhibitr, vildgliptin, is vilble in Eurpe. Other DPP-4 inhibitrs—geigliptin, ngliptin, teneligliptin, trelgliptin, rigliptin, evgliptin, nd gsgliptin—hve been pprved utside the United Sttes nd Eurpen Unin (Kre, Indi, Thilnd, Jpn, Russi, nd severl Suth Aerin untries). Sitagliptin, when used lne r in bintin with ther dibetes editins, lwers HbA1by pprxi- tely 0.5%. The usul dse f sitgliptin is 100 g ne dily, but the dse is redued t 50 g dily if the lu- lted retinine lerne is 30–50 L/in nd t 25 g fr lernes less thn 30 L/in. Sxgliptin, when dded t the therpeuti regien (etfrin, sulfnyl- ure, thizlidinedine) f ptients with type 2 dibetes, further lwered the HbA1vlue by but 0.7–0.9%. The dse is 2.5 g r 5 g rlly ne  dy. The 2.5-g dse shuld be used in ptients with eGFR less thn 50 L/in/ 1.73 2. Alogliptin lwers HbA1by but 0.5–0.6% when dded t etfrin, sulfnylure, r piglitzne. The usul dse is 25 g rlly dily. The 12.5-g dse is used in ptients with eGFR f 30–60 L/in/1.73 2; nd 6.25 g fr lerne less thn 30 L/in/1.73 2. Lin- gliptin lwers HbA1by but 0.4–0.6% when dded t etfrin, sulfnylure, r piglitzne. The dse is 5 g rlly dily, nd sine, it is pririly exreted unetblized vi the bile, n dse djustent is needed in ptients with kidney disese. Vildgliptin lwers HbA1by but 0.5–1% when dded t the ther- peuti regien f ptients with type 2 dibetes. The dse is 50 g ne r twie dily. Side effects— The in dverse effet f DPP-4 inhibi- trs ppers t be  predispsitin t nsphryngitis r upper respirtry trt infetin. Hypersensitivity re- tins, inluding nphylxis, ngiede, nd exflitive skin nditins (suh s Stevens-Jhnsn syndre), hve been reprted. There hve ls been reprts f pnretitis, but the frequeny f the event is unler. Cses f liver filure hve been reprted with the use f lgliptin, but it is unertin if lgliptin ws the use. The editin, hwever, shuld be disntinued in the event f liver fil- ure. Rre ses f hepti dysfuntin, inluding heptitis,CMDT22_Ch27_p1212-p1255.indd  1227 29/06/21 8:53 PMCHAPTEr 271228 CMDT 2022hve  been reprted with the use f vildgliptin; nd liver biheil testing is reended qurterly during the first yer f use nd peridilly therefter. Sxgliptin y inrese the risk f hert filure. In  pst-rketing study f 16,492 ptients with type 2 dibetes, hert filure urred in 3.5% in the sxgliptin grup nd 2.8% in the pleb grup (hzrd rti 1.27). Ptients with the highest risk f hert filure were thse wh hd  histry f hert filure r hd elevted levels f N-terinl f the prhr- ne B-type ntriureti peptide (NT-pBNP) r hd kidney ipirent. In  lrge pst-rketing study, lgliptin, like sxgliptin, ws ssited with  slightly inresed rte f hert filure. The FDA hs issued  wrning tht the DPP-4 inhibitrs n sinlly use jint pins tht reslve fter stpping the drug. 5. Sodiumglucose cotransporter 2 inhibitors— Gluse is freely filtered by the kidney gleruli nd is rebsrbed in the prxil tubules by the tin f sdiu-gluse -trnsprters (SGLT). Sdiu-gluse -trnsprter 2 (SGLT2) unts fr but 90% f gluse rebsrptin nd its inhibitin uses glysuri in peple with dibetes, lwering pls gluse levels. The rl SGLT2 inhibitrs ngliflzin, dpgliflzin, epgliflzin, nd ertugli- flzin re pprved fr linil use in the United Sttes. These gents redue the threshld fr glysuri fr  pls gluse threshld f but  180 g/dL t but 40 g/dL; nd lwer HbA1by 0.5–1% when used lne r in bintin with ther rl gents r insulin. The effi- y is higher t higher HbA1levels when re gluse is exreted s  result f SGLT2 inhibitin. The lss f l- ries results in dest weight lss f 2–5 kg. Cngliflzin is dsed t 100 g dily but up t 300 g dily n be used in ptients with nrl kidney funtin. The dse f dpgliflzin is 10 g dily but 5 g dily is the reended initil dse in ptients with hepti fil- ure. The usul dsge f epgliflzin is 10 g dily but  higher dse f 25 g dily n be used. The reended strting dse f ertugliflzin is 5 g, but the dse n be inresed t 15 g dily if dditinl gluse lwering is needed. Empagliflozin ws evluted in  ultintinl study f 7020 ptients with type 2 dibetes with knwn rdi- vsulr disese; the dditin f epgliflzin ws ssi- ted with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infr- tin, r nnftl strke (hzrd rti 0.86, P= 0.04). The ehniss regrding the benefit rein unler. Weight lss, lwer bld pressure, nd diuresis y hve plyed  rle sine there were fewer deths fr hert filure in the treted grup wheres the rtes f yrdil infrtin were unltered. A siilr ultintinl study ws per- fred with the dditin f ngliflzin. This ws  study f 10,142 ptients with type 2 dibetes with knwn r t inresed risk fr rdivsulr disese. The ngliflzin treted grup hd  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.86, P= 0.02). In  2019 hert filure study f 4744 ptients with NYHA lss II, III, r IV hert filure nd ejetin frtin f less40%, dpgliflzin redued the uultive inidene f wrsening hert filure r rdivsulr deth (hzrd rti 0.74, P< 0.001). Frty-tw perent f the ptients hd dibetes; the findings in ptients with nd withut dibetes were the se. Bth epgliflzin nd ngliflzin shw benefit in ters f prgressin f lbuinuri nd kidney injury, pssibly by lwering glerulr hyperfiltrtin. In  2019 ultintinl study f 4401 ptients with type 2 dibetes nd lbuinuri hrni kidney disese (eGFR 30–89 L/in/1.73 2with lbuin [g] t retinine [g] rti > 300 t 5000) nd tking n ACE inhibitr r ngitensin reeptr blker, ngliflzin redued the risk f end-stge kidney disese, the dubling f seru reti- nine, nd f renl deth. In  2020 ultintinl study f 4304 ptients with hrni kidney disese, dpgliflzin redued the risk f end-stge kidney disese r deth fr renl nd rdivsulr uses. A third f the ptients in the study did nt hve dibetes nd hd benefit. Side effects— As ight be expeted, the effiy f the SGLT2 inhibitrs is redued in hrni kidney disese. They n ls inrese retinine nd derese eGFR, espe- illy in ptients with kidney ipirent. Their use is generlly nt reended in ptients with eGFR less thn 45 L/in/1.73 2nd re ntrindited in ptients with eGFR less thn 30 L/in/1.73 2. The study f dpgliflzin in hrni kidney disese, hwever, nted tht the drug is sfe nd benefiil in ptients with eGFR s lw s 25 L/in/1.73 2. The in side effets re inresed inidene f genitl yti infetins nd urinry trt infetins ffeting ~8–9% f ptients. Cses f nertizing fsiitis f the perineu (Furnier gn- grene) hve been reprted. There hve ls been reprts f ses f pyelnephritis nd septiei requiring hspitl- iztin. The glysuri n use intrvsulr vlue ntrtin nd hyptensin. One ultintinl study with ngliflzin shwed n inresed risk f puttins, espeilly f the tes (hzrd rti 1.97). This finding hs nt been bserved in ther studies using this drug r with the ther SGLT2 inhibitrs. Cngliflzin hs been reprted t use  derese in bne inerl density t the lubr spine nd the hip. In  pled nlysis f eight linil trils (en durtin 68 weeks),  30% inrese in frtures ws bserved in ptients tking ngliflzin. It is likely tht the effet n the bnes is  lss effet nd nt restrited t n- gliflzin. All the SGLT2 inhibitrs use  dest inrese in LDL hlesterl levels (3–8%). Als, in linil trils, ptients tking dpgliflzin hd higher rtes f brest ner (nine ses vs nne in prtr rs) nd bld- der ner (10 ses vs 1 in pleb r). These ner rtes exeeded the expeted rtes in ge-thed referene dibetes ppultin. Cses f DKA hve been reprted with ff-lbel use f SGLT2 inhibitrs in ptients with type 1 dibetes. Type 1 ptients re tught t give less insulin if their gluse levels re nt elevted. SGLT2 inhibitrs lwer gluse levels by hnging the renl threshld nd nt by insulin tin. Type 1 ptients tking n SGLT2 inhibitr, beuse the gluse levels re nt elevted, y either withhld rCMDT22_Ch27_p1212-p1255.indd  1228 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1229 CMDT 2022redue  their insulin dses t suh  degree s t indue ketidsis. SGLT2 inhibitors should not be used in patients with type 1 diabetes and in those patients labeled as having type 2 diabetes but who are very insulin deficient and ketosis-prone. 6. Others— Prlintide is  syntheti nlg f islet y- lid plypeptide (IAPP r ylin). When given subutne- usly, it delys gstri eptying, suppresses glugn seretin, nd dereses ppetite. It is pprved fr use bth in type 1 dibetes nd in insulin-treted type 2 dibe- tes. In 6-nth linil studies with type 1 nd insulin- treted type 2 ptients, thse tking the editin hd n pprxitely 0.4% redutin in HbA1nd but 1.7 kg weight lss pred with pleb. The HbA1redutin ws sustined fr 2 yers but se f the weight ws regined. The editin is given by injetin ieditely befre the el. Hypglyei n ur, nd it is re- ended tht the shrt-ting r preixed insulin dses be redued by 50% when the editin is strted. Sine the editin slws gstri eptying, revery fr hyp- glyei n be  prble beuse f dely in bsrptin f fst-ting rbhydrtes. Nuse is the ther in side effet, ffeting 30–50% f persns, but tends t iprve with tie. In ptients with type 1 dibetes, the initil dse f prlintide is 15 g befre eh el nd titrted up by 15-g inreents t  intenne dse f 30 g r 60 g befre eh el. In ptients with type 2 dibetes, the strting dse is 60 g preels inresed t 120 g in 3 t 7 dys if n signifint nuse urs. Brriptine,  dpine 2 reeptr gnist, hs been shwn t destly lwer HbA1by 0.1–0.5% when pred t bseline nd 0.4–0.5% pred t pleb. Cn side effets re nuse, viting, dizziness, nd hedhe. Clesevel, the bile id sequestrnt, when dded t etfrin r sulfnylure r insulin, lwered HbA10.3– 0.4% when pred t bseline nd 0.5–0.6% pred t pleb. HbA1lwering, hwever, ws nt bserved in  single ntherpy linil tril pring lesevel t pleb. Clesevel use is ssited with ~20% inrese in triglyeride levels. Other dverse effets inlude nstiptin nd dyspepsi.With their modest glucose lowering and significant side effects, using bromocriptine or colesevelam to treat diabetes is not recommended. 7. Medication combinations— Severl editin bi- ntins re vilble in different dse sizes, inluding glyburide nd etfrin (Gluvne); glipizide nd et- frin (Metglip); repglinide nd etfrin (Prndi-Met); rsiglitzne nd etfrin (Avndet); piglitzne nd etfrin (ACTOplusMet); rsiglitzne nd gliepiride (Avndryl); piglitzne nd gliepiride (Duett); sitgliptin nd etfrin (Jnuet); sx- gliptin nd etfrin XR (Kbiglyze XR); lingliptin nd etfrin (Jentduet); lgliptin nd etfrin (Kzn); lgliptin nd piglitzne (Oseni); dp- gliflzin nd etfrin (Xigdu); ngliflzin nd et- frin (Invket); epgliflzin nd etfrin (Synjrdy); epgliflzin nd lingliptin (Glyxbi); epgliflzin, lingliptin, nd etfrin (Trijrdy); ertugliflzin nd etfrin (Segluret); ertugliflzin nd sitgliptin (Steglujn); insulin deglude nd lirglutide (Xultphy); nd insulin glrgine nd lixisentide (Sliqu). These editin bintins, hwever, liit the lini- in’s bility t ptilly djust dsge f the individul editins nd fr tht resn re nt reended.C.  InsulinInsulin is indi ted fr type 1 dibetes s well s fr type 2 dibeti ptients with insulinpeni whse hyperglyei des nt respnd t diet therpy either lne r bined with ther hypglyei editins. 1. Characteristics of available insulin preparations— Hun insulin is dispensed s either regulr (R) r NPH (N) frultins. Six nlgs f hun insulin—three rpidly ting (insulin lispr, insulin sprt, insulin gluli- sine) nd three lng-ting (insulin glrgine, insulin deteir, nd insulin deglude)—re vilble fr linil use. Insulin preprtins differ with respet t the tie f nset nd durtin f their bilgi tin (Tble 27–5). All urrently vilble insulins ntin less thn 10 pp f prinsulin nd re lbeled s “purified. ” These purified insulins preserve their pteny, s tht refrigertin Table 27–5. Summary of bioavailability characteristics of the insulins.Insulin  Pepaations1Onset of Action Peak Action Effective Duation Insulins lispro, aspart,2,3glulisine 5–15 minutes 1–1.5 hours 3–4 hours Human regular 30–60 minutes 2 hours 6–8 hours Human NPH 2–4 hours 6–7 hours 10–20 hours Insulin glargine 0.5–1 hour Flat ~24 hours Insulin detemir 0.5–1 hour Flat 17 hours Insulin degludec 0.5–1.5 hours Flat More than 42 hours Technosphere inhaled insulin 5–15 minutes 1 hour 3 hours1 Insulin administered subcutaneously unless otherwise noted.2 Insulin aspart formulated with niacinamide (FiAsp has an ~10-minute faster onset of action).3 Insulin lispro formulated with treprostinil and citrate (Lyumjev has an 11-minute faster onset of action).CMDT22_Ch27_p1212-p1255.indd  1229 29/06/21 8:53 PMCHAPTEr 271230 CMDT 2022is  reended but nt ruil. During trvel, reserve supplies f insulin n be redily trnsprted fr weeks withut lsing pteny if prteted fr extrees f het r ld. All the insulins in the United Sttes re vilble in  nentrtin f 100 units/L (U100) nd dispensed in 10-L vils r 0.3-L rtridges r prefilled dispsble pens. Severl insulins re vilble t higher nentr- tins: insulin glrgine, 300 units/L (U300); insulin deglude, 200 units/L (U200); insulin lispr, 200 units/L (U200); nd regulr insulin, 500 units/L (U500). 2. Insulin preparations— See Tble 27–6. The rpidly t- ing insulin nlgs nd the lng-ting insulins re designed fr subutneus dinistrtin, while regulr insulin nd insulin sprt n ls be given intrvenusly. a. Short-acting insulin preparations— (1) Regular insulin— Regulr insulin is  shrt-ting sluble rystlline zin insulin whse effet ppers within 30 inutes fter subutneus injetin nd lsts 5–7 hurs when usul quntities re dinistered. Intrvenus infu- sins f regulr insulin re prtiulrly useful in the tret- ent f DKA nd during the peripertive ngeent f ptients with dibetes wh require insulin. Fr rkedly insulin-resistnt persns wh wuld therwise require lrge vlues f insulin slutin,  U500 preprtin f hun regulr insulin is vilble bth in  vil fr nd  dispsble pen. A U500 insulin syringe shuld be used if the vil fr is dispensed. U500 regulr insulin is uh re expensive thn the U100 nentrtin nd is rrely needed.(2) Rapidly acting insulin analogs— Insulin lispr (Hulg, Adelg) is n insulin nlg where the pr- line t psitin B28 is reversed with the lysine t B29. Insulin sprt (Nvlg) is  single substitutin f prline by sprti id t psitin B28. In insulin glulisine (Apidr) the sprgine t psitin B3 is repled by lysine nd the lysine in psitin B29 by gluti id. These three n- lgs hve less f  tendeny t fr hexers, in ntrst t hun insulin. When injeted subutneusly, the n- lgs quikly dissite int ners nd re bsrbed very rpidly, rehing pek seru vlues in s sn s 1 hur—in ntrst t regulr hun insulin, whse hex- ers require nsiderbly re tie t dissite nd bee bsrbed. The in id hnges in these nlgs d nt interfere with their binding t the insulin reeptr, with the irulting hlf-life, r with their iungeniity, whih re ll identil with thse f hun regulr insulin. An insulin sprt frultin (FiAsp) tht ntins niin- ide (vitin B3) hs  re rpid initil bsrptin nd its nset f tin is but 10 inutes fster thn the stndrd insulin sprt frultin. Beuse f this re rpid nset f tin, the 1-hur (but nt 2-hur) pstprndil gluse exursins re lwer pred t the stndrd frultin. Siilrly, n insulin lispr frultin (Lyujev) ntin- ing trepstinil t indue ll vsdiltin nd itrte t inrese vsulr perebility hs 11 inutes fster nset f tin nd lwer 1- nd 2-hur pstprndil gluse exur- sins pred t the stndrd insulin lispr frultin. Clinil trils hve denstrted tht the ptil ties f preprndil subutneus injetin f prble dses f the rpidly ting insulin nlgs nd f regulr hun insulin re 20 inutes nd 60 inutes, respetively, befre the el. The quiker nset f tin with the rpidly t- ing insulin nlgs llws the ptient t injet insulin just befre eting rther thn wit fr 60 inutes s needed fr regulr insulin. Anther desirble feture f rpidly ting insulin nlgs is tht their durtin f tin reins t but 4 hurs fr st nly used dsges. This n- trsts with regulr insulin, whse durtin f tin is sig- nifintly prlnged when lrger dses re used. The rpidly ting nlgs re nly used in pups. In  duble-blind rssver study pring insu- lin lispr with regulr insulin in insulin pups, persns using insulin lispr hd lwer HbA1vlues nd iprved pstprndil gluse ntrl with the se frequeny f hypglyei. In the event f pup filure, hwever, users f the rpidly ting insulin nlgs will hve re rpid nset f hyperglyei nd ketsis. While insulin sprt hs been pprved fr intrvenus use (eg, in hyperglyei eergenies), there is n dvn- tge in using insulin sprt ver regulr insulin by this rute. A U200 nentrtin f insulin lispr is vilble in  dispsble prefilled pen. The nly dvntge f the U200 ver the U100 insulin lispr preprtin is tht it delivers the se dse in hlf the vlue. b. Long-acting insulin preparations— (1) NPH (neutral protamine Hagedorn or isophane) insulin— NPH is n interedite-ting insulin whse nset f tin is delyed t 2–4 hurs, nd its pekTable 27–6. Insulin preparations available in the United States.1rapidly  acting human insulin analogs Insulin lispro (Humalog, Lyumjev, Lilly; Admelog, Sanofi) Insulin aspart (Novolog, FiAsp, Novo Nordisk) Insulin glulisine (Apidra, Sanofi Aventis) Shot-acting egula insulin Regular insulin (Lilly, Novo Nordisk) Technosphere inhaled regular insulin (Afrezza) Intemediate-acting insulins NPH insulin (Lilly, Novo Nordisk) Pemixed insulins 70% NPH/30% regular (70/30 insulin—Lilly, Novo Nordisk) 70% NPL/25% insulin lispro (Humalog Mix 75/25—Lilly) 50% NPL/50% insulin lispro (Humalog Mix 50/50—Lilly) 70% insulin aspart protamine/30% insulin aspart (Novolog Mix 70/30—Novo Nordisk) 70% insulin degludec/30 insulin aspart (Ryzodeg, Novo Nordisk) Long-acting human insulin analogs Insulin glargine (Lantus (U100), Toujeo (U300), Sanofi Aventis; Basaglar (U100), Lilly) Insulin detemir (Levemir, Novo Nordisk) Insulin degludec (Tresiba, Novo Nordisk)1 All insulins available in the United States are recombinant human or human insulin analog origin. All the above insulins are dis- pensed at U100 concentration. There is an additional U500 prepa- ration of regular insulin; U300 preparation of insulin glargine; U200 preparation of insulin lispro; U200 preparation of insulin degludec. NPH, neutral protamine Hagedorn.CMDT22_Ch27_p1212-p1255.indd  1230 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1231 CMDT 2022respn se is generlly rehed in but 6–7 hurs. The nset f tin is delyed by bining 2 prts sluble rystlline zin insulin with 1 prt prtine zin insulin. This prdues equivlent unts f insulin nd prt- ine, s tht neither is present in n unplexed fr (“isphne”). Beuse its durtin f tin is ften less thn 24 hurs (with  rnge f 10–20 hurs), st ptients require t lest tw injetins dily t intin  sustined insulin effet. Osinl vils f NPH insulin hve tended t shw unusul luping f their ntents r “frsting” f the ntiner, with nsiderble lss f bitivity. This instbility is rre nd urs less frequently if NPH hun insulin is refrigerted when nt in use nd if bttles re disrded fter 1 nth f use. (2) Insulin glargine— In this insulin, the sprgine t psitin 21 f the insulin A hin is repled by glyine nd tw rginines re dded t the rbxyl terinl f the B hin. The rginines rise the iseletri pint f the l- eule lser t neutrl king it re sluble in n idi envirnent. In ntrst, hun insulin hs n iseletri pint f pH 5.4. Insulin glrgine is  ler insulin, whih, when injeted int the neutrl pH envirnent f the sub- utneus tissue, frs irpreipittes tht slwly relese the insulin int the irultin. This insulin lsts fr but 24 hurs withut ny prnuned peks nd is given ne  dy t prvide bsl verge. This insulin nnt be ixed with the ther hun insulins beuse f its idi pH. When this insulin ws given s  single injetin t bedtie t type 1 ptients in linil trils, fsting hyper- glyei ws better ntrlled with less nturnl hyp- glyei when pred t NPH insulin. A re nentrted fr f insulin glrgine (U300) is vilble s n insulin pen. In linil trils in type 1 ptients, U300 use did nt result in better ntrl r redue the rtes f hypglyei. Althugh liited linil dt suggest tht insulin glrgine is sfe in pregnny, it is nt pprved fr this use. (3) Insulin detemir— In this insulin nlg, the thre- nine t psitin B30 hs been reved nd  14-C ftty id hin (tetrdeni id) is tthed t the lysine t psitin 29 by yltin. Its prlnged tin is due t dihexeriztin nd binding f hexers nd diers t lbuin t the injetin site s well s binding f the ner vi its ftty id side hin t lbuin in the irultin. The ffinity f insulin deteir is furfld t fivefld lwer thn tht f hun sluble insulin nd therefre the U100 frultin f insulin deteir hs n insulin nentrtin f 2400 nl/L pred with 600 nl/L fr NPH. The durtin f tin fr insulin deteir is but 17 hurs t therpeutilly relevnt dses. It is reended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. It hs been pprved fr use during pregnny. (4) Insulin degludec— In this insulin nlg, the thre- nine t psitin B30 hs been reved, nd the lysine t psitin B29 is njugted t hexdeni id vi  g-L-glutyl sper. In the vil, in the presene f phenl nd zin, the insulin is in the fr f dihexers but when injeted subutneusly, it self ssites int lrge ultihexeri hins nsisting f thusnds fdihexers. The hins slwly disslve in the subutne- us tissue nd insulin ners re stedily relesed int the systei irultin. The hlf-life f insulin deglude is 25 hurs. Its nset f tin is in 30–90 inutes nd its durtin f tin is re thn 42 hurs. It is re- ended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. Insulin deglude is vil- ble in tw nentrtins, U100 nd U200, nd dispensed in prefilled dispsble pens. (5) Insulin icodec— This is n insulin nlg tht is suit- ble fr ne weekly injetin nd is in phse 3 linil trils. c. Mixed insulin preparations— Ptients with type 2 dibetes n seties hieve resnble gluse ntrl with just prebrekfst nd predinner injetins f ixtures f shrt ting nd NPH insulins. The regulr insulin r rpidly ting insulin nlg is withdrwn first, then the NPH insulin nd then injeted ieditely. Stble pre- ixed insulins (70% NPH nd 30% regulr) re vilble s  nveniene t ptients wh hve diffiulty ixing insu- lin beuse f visul prbles r ipirent f nul dexterity (Tble 27–6). Preixed preprtins f insulin lispr nd NPH insulins re unstble; stbility is hieved by repling the NPH insulin with NPL (neutrl prtine lispr). This insulin hs the se durtin f tin s NPH insulin. Preixed bintins f NPL nd insulin lispr (75% NPL/25% insulin lispr ixture [Hulg Mix 75/25] nd 50% NPL/50% insulin lispr ixture [Hulg Mix 50/50]) re vilble fr linil use. Sii- lrly,  70% insulin sprt prtine/30% insulin sprt (NvLg Mix 70/30) is vilble. The in dvntges f these ixtures re tht they n be given within 15 inutes f strting  el nd they re superir in ntrlling the pstprndil gluse rise fter  rbhydrte-rih el. These benefits hve nt trnslted int iprveents in HbA1levels when pred with the usul 70% NPH/30% regulr ixture. The lnger-ting insulin nlgs, insulin glrgine nd insulin deteir, nnt be ixed with either regulr insulin r the rpidly ting insulin nlgs. Insulin deglude, hwever, n be ixed nd is vilble s 70% insulin deglude/30% insulin sprt nd is injeted ne r twie  dy. 3. Methods of insulin administration— a. Insulin syringes and needles— Plsti dispsble syringes re vilble in 1-L, 0.5-L, nd 0.3-L sizes. Three lengths f needles re vilble: 6 , 8 , nd 12.7 . Lng needles re preferble in bese ptients t redue vribility f insulin bsrptin. The needles re f 28, 30, nd 31 guges. The 31-guge needles re lst pinless. “Dispsble” syringes y be reused until blunt- ing f the needle urs (usully fter three t five inje- tins). Sterility dequte t vid infetin with reuse ppers t be intined by repping syringes between uses. Clensing the needle with lhl y nt be desir- ble sine it n disslve the siline ting nd n inrese the pin f skin punturing. b. Sites of injection— Any prt f the bdy vered by lse skin n be used, suh s the bden, thighs, upperCMDT22_Ch27_p1212-p1255.indd  1231 29/06/21 8:53 PMCHAPTEr 271232 CMDT 2022rs,  flnks, nd upper buttks. Preprtin with l- hl is nt required prir t injetin s lng s the skin is len. Rttin f sites is reended t vid delyed bsrptin when fibrsis r liphypertrphy urs fr repeted use f  single site. Regulr insulin is bsrbed re rpidly when injeted in the deltid r bden pred t thighs nd buttks. Exerise n inrese bsrptin when the injetin site is djent t the exer- ise usle. Fr st ptients, the bden is the re- end regin fr injetin beuse it prvides dequte re in whih t rtte sites. The effet f nti regins ppers t be uh less prnuned with the nlg insulins. c. Insulin pen injector devices— Insulin pens (Nv Nrdisk, nd Owen Mufrd) eliinte the need fr r- rying insulin vils nd syringes. Srt pens (Cpnin Medil) tht re linked t ell phnes n be used t reind the user t tke their insulin befre els, lulte dses, nd keep trk f tiing f the dses. Crtridges f insulin lispr nd insulin sprt re vilble fr the reus- ble pens. Dispsble prefilled pens re ls vilble fr regulr insulin (U100 nd U500), insulin lispr, insulin sprt, insulin glulisine, insulin deteir, insulin glrgine, insulin deglude, NPH, 70% NPH/30% regulr, 75% NPL/25% insulin lispr, 50% NPL/50% insulin lispr, 70% insulin sprt prtine/30% insulin sprt, nd 70% insulin deglude/30% insulin sprt. Pen needles re vil- ble in 29, 31, nd 32 guges nd 4-, 5-, 6-, 8-, nd 12.7- lengths (Nvfine; BD). d. Insulin pumps— In the United Sttes, Medtrni Mini- Med, Insulet, nd Tnde ke bttery perted ntinu- us subutneus insulin infusin (CSII) pups. These pups re sll (but the size f  pger) nd esy t prgr. They ffer ny fetures, inluding the bility t set  nuber f different bsl rtes thrughut the 24 hurs nd t djust the tie ver whih blus dses re given. They ls re ble t detet pressure build-up if the theter is kinked. The theter nneting the insulin reservir t the subutneus nnul n be disn- neted, llwing the ptient t reve the pup teprr- ily (eg, fr bthing). Oinpd (Insulet Crprtin) is n insulin infusin syste in whih the insulin reservir nd infusin set re integrted int ne unit (pd), s there is n theter (eletrni pth pup). The pd, pled n the skin, delivers subutneus bsl nd blus insulin bsed n wirelessly trnsitted instrutins fr  per- snl digitl ssistnt. The gret dvntge f ntinuus subutneus insulin infusin (CSII) is tht it llws fr estblishent f  bsl prfile tilred t the ptient llwing fr better vernight nd between els gluse ntrl. The bility t djust the bsl insulin infusin kes it esier fr the ptient t nge glyei exur- sins tht ur with exerise. The pups hve sftwre tht n ssist the ptient t lulte bluses bsed n gluse reding nd rbhydrtes t be nsued. They keep trk f the tie elpsed sine the lst insulin blus; the ptient is reinded f this when he r she ttepts t give dditinl rretin blus befre the effet f the previus blus hs wrn ff (“insulin n brd” feture).This feture redues the risk f verrreting nd subse- quent hypglyei. CSII therpy is pprprite fr ptients with type 1 dibetes wh re tivted, ehnilly inlined, edu- ted but dibetes (diet, insulin tin, tretent f hypglyei nd hyperglyei), nd willing t nitr their bld gluse fur t six ties  dy. Knwn pli- tins f CSII inlude ketidsis, whih n ur when insulin delivery is interrupted, nd skin infetins. Anther disdvntge is its st nd the tie needed f the liniin nd stff t initite therpy. Alst ll ptients use rpid- ting insulin nlgs in their pups. V-g (Vlerits) is  ehnil pth pup designed speifilly fr peple with type 2 dibetes wh use  bsl/ blus insulin regien. The devie is preset t deliver ne f three fixed nd flt bsl rtes (20, 30, r 40 units) fr 24 hurs (t whih pint it ust be repled) nd there is  buttn tht delivers tw units per press t help ver els. e. Closed loop systems— Algriths hve been devised t use gluse dt fr the ntinuus gluse nitr- ing systes t uttilly deliver insulin by ntinuus subutneus insulin infusin pup. These lsed lp systes (rtifiil pnres) hve been shwn in linil studies t iprve nighttie gluse ntrl, destly lwer HbA1levels, nd redue the risk f nturnl hyp- glyei. The MiniMed 670 G nd the Tnde Cntrl- IQ, hve been pprved fr linil use. The MiniMed 670 G lsed lp syste uses gluse dt fr  sensr t uttilly djust bsl insulin dses every 5 inutes, trgeting  sensr gluse level f 120 g/dL (6.7 l/L). Insulin delivery is suspended when the sensr gluse level flls belw r is predited t fll belw trget level. The gluse trget n be djusted up t 150 g/dL (8.3 l/L) fr physil tivity. The Tnde Cntrl-IQ trgets  sen- sr gluse level f 112.5 g/dL (6.25 l/L). The ptient is still respnsible fr blusing insulin fr els nd snks. There re ls D-It-Yurself lsed lp sys- tes using free pen-sure sftwre. One suh syste, lled the “Lp, ” uses the Dex G6 sensr, the iPhne, nd the Onipd insulin pup. The “Lp” ntrller is dwnlded n t the iPhne, nd it uses the Dex G6 sensr gluse esureents (ls n the iPhne) t ut- tilly djust bsl insulin delivery n the Onipd pup. Inresing nubers f type 1 ptients use these D- It-Yurself systes, but they re nt pprved fr use by the FDA. Suessful use f these systes requires prfi- ieny t using bth the insulin pup nd ntinuus gluse nitr. The systes re expensive; the insulin pup, whih needs t be repled every 4 yers, sts but $6000 nd the pup supplies re $1500 per yer. The ntinuus gluse nitring syste sts pprxitely $4000 per yer. f. Inhaled insulin— Tehnsphere insulin (Afrezz) is  dry-pwder frultin f rebinnt hun regulr insulin tht n be inhled. It nsists f 2- t 2.5- rystls f the exipient furyl diketpiperzine tht pr- vide  lrge surfe re fr dsrptin f prteins like insulin. The tehnsphere insulin is rpidly bsrbed with pek insulin levels rehed in 12–15 inutes nd deliningCMDT22_Ch27_p1212-p1255.indd  1232 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1233 CMDT 2022t bseline  in 3 hurs; the edin tie t xiu effet with inhled insulin is pprxitely 1 hur nd delines t bseline by but 3 hurs. In ntrst, the edin tie t xiu effet with subutneus insulin lispr is but 2 hurs nd delines t bseline by 4 hurs. In lini- l trils, tehnsphere insulin bined with bsl insu- lin ws s effetive in gluse lwering s rpid-ting insulin nlgs bined with bsl insulin. It is fru- lted s  single-use, lr-ded rtridge delivering 4, 8, r 12 units ieditely befre the el. The nufturer prvides  dse nversin tble; ptients injeting up t 4 units f rpid-ting insulin nlg shuld use the 4-unit rtridge. Thse injeting 5 t 8 units shuld use the 8-unit rtridge. If the dse is 9–12 units f rpid-ting insulin preel then ne 4-unit rtridge nd ne 8-unit rtridge r ne 12-unit rtridge shuld be used. The inhler is but the size f  referee’s whistle. The st n dverse retin f the inhled insulin is  ugh, ffeting but 27% f ptients. A sll derese in pulnry funtin (fred expirtry vlue in 1 send [FEV1]) is seen in the first 3 nths f use, whih persists ver 2 yers f fllw-up. Inhled insulin is ntrindited in ptients wh ske nd in thse with hrni lung disese, suh s sth nd hrni bstru- tive pulnry disese. Spiretry shuld be perfred t identify ptentil lung disese prir t inititing therpy. During linil trils, there were tw ses f lung ner in ptients wh were tking inhled insulin nd nne in the prtr-treted ptients. All the ptients in wh lung ner develped hd  histry f prir igrette sking. Cses f lung ner were ls reprted in igrette sk- ers using  previusly vilble inhled insulin preprtin (Exuber). The inidene rte in the Exuber-treted grup ws 0.13 per 1000 ptient-yers, wheres it ws 0.03 per 1000 ptient-yers in the prtr-treted grup.D . Transplantation1. Pancreas transplan tation— All ptients with end-stge kidney disese nd type 1 dibetes wh re ndidtes fr  kidney trnsplnt shuld be nsidered ptentil ndi- dtes fr  pnres trnsplnt. Eligibility riteri inlude ge yunger thn 55 nd inil rdivsulr risk. Cntrinditins inlude nnrretble rnry rtery disese, extensive peripherl vsulr disese, nd signifi- nt besity (weight greter thn 100 kg). The pnres trnsplnt y ur t the se tie s kidney trnsplnt r fter kidney trnsplnt. Ptients underging siultne- us pnres nd kidney trnsplnttin hve n 83% hne f pnreti grft survivl t 1 yer nd 69% t 5 yers. Slitry pnreti trnsplnttin in the bsene f  need fr kidney trnsplnttin is nsidered nly in thse rre ptients wh d nt respnd t ll ther insulin therpeuti pprhes nd wh hve frequent severe hypglyei, r wh hve life-thretening plitins relted t their lk f etbli ntrl. Slitry pnres trnsplnt grft survivl is 78% t 1 yer nd 54% t 5 yers. 2. Islet transplantation— Ttl pnretety is urtive fr severe pin syndre ssited with hrni pnre- titis. The pnretety, hwever, results in surgildibetes. Hrvesting islets fr the reved pnres nd uttrnsplnting the int the liver (vi prtl vein) n prevent the develpent f dibetes r result in “ild” dibetes (prtil islet funtin) tht is esier t nge. Sine the islets re utlgus, n iunsuppressin is required. The nuber f islets trnsplnted is the in preditr f insulin independene. Peple with type 1 dibetes n bee insulin inde- pendent fter reeiving islets islted fr  dnr pn- res (llislet trnsplnt). The islets re infused int the prtl vein using  perutneus trnshepti pprh, nd they ldge in the liver relesing insulin in respnse t physilgi stiuli. Lng-ter iunsuppressin is neessry t prevent llgrft rejetin nd t suppress the utiune press tht led t the disese in the first ple. Insulin independene fr re thn 5 yers hs been denstrted in ptients wh gt nti-CD3 nti- bdy r nti-thyyte glbulin indutin iunsup- pressin nd lineurin inhibitrs, Tr inhibitrs, nd yphenlte fetil s intenne iunsuppres- sin. One jr liittin is the need fr re thn ne islet infusin t hieve insulin independene. This is beuse f signifint lss f islets during isltin nd the perid prir t engrftent. Widespred llislet trnsplnttin will depend n iprving insulin inde- pendene rtes with ne infusin nd ls denstrting tht the lng-ter utes re s gd s thse f pn- res trnsplnt lne.Kristensen  SL et l. Crdivsulr, rtlity, nd kidney ut- es with GLP-1 reeptr gnists in ptients with type 2 dibetes:  systeti review nd et-nlysis f rdivs- ulr ute trils. Lnet Dibetes Endrinl. 2019;7:776. [PMID: 31422062] Leelrthn L et l. Hybrid lsed-lp therpy: where re we in 2021? Dibetes Obes Metb. 2021;23:655. [PMID: 33269551] MGuire DK et l. Assitin f SGLT2 inhibitrs with rdi- vsulr nd kidney utes in ptients with type 2 dibe- tes:  et-nlysis. JAMA Crdil. 2021;6:148. [PMID: 33031522] »Steps in the Management of DiabetesA.  Distinguishing the Types of DiabetesAn tt ept shuld be de t hrterize the dibetes s type 1 r type 2 r ther speifi types suh s MODY, bsed n the linil fetures present nd n whether r nt ketnuri pnies the glysuri. Fetures tht suggest end-rgn insulin insensitivity t insulin, suh s viserl besity, nthsis nigrins, r bth, ust be identified. The fily histry shuld duent nt nly the inidene f dibetes in ther ebers f the fily but ls the ge t nset, ssitin with besity, the need fr insulin, nd whether there were plitins. Fr the sinl ptient, esureent f GAD65, IAA, ICA 512, nd zin trnsprter 8 ntibdies n help distinguish between type 1 nd type 2 dibetes (Tble 27–7). Mny ptients with newly dignsed type 1 dibetes still hve signifint endgenus insulin prdutin, nd C peptide levels d nt relibly distinguish between type 1 nd type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1233 29/06/21 8:53 PMCHAPTEr 271234 CMDT 2022B.  Patient Education (SelfManagement Training)Since  diabetes is a lifelong disorder, education of the patient and the family is probably the most important obligation of the clinician who provides care. The best persns t nge  disese tht is ffeted s rkedly by dily flututins in envirnentl stress, exerise, diet, nd infetins re the ptients theselves nd their fi- lies. The “tehing urriulu” shuld inlude expln- tins by the liniin r nurse f the nture f dibetes nd its ptentil ute nd hrni hzrds nd hw they n be regnized erly nd prevented r treted. Self- nitring f bld gluse shuld be ephsized, espe- illy in insulin-requiring dibeti ptients, nd instrutins ust be given n prper testing nd rerding f dt. Ptients tking insulin shuld hve n understnding f the tins f bsl nd blus insulins. They shuld be tught t deterine whether the bsl dse is pprprite nd hw t djust the rpidly ting insulin dse fr the rbhydrte ntent f  el. Ptients nd their filies nd friends shuld be tught t regnize signs nd syp- ts f hypglyei nd hw t tret lw gluse re- tins. Strenuus exerise n preipitte hypglyei, nd ptients ust therefre be tught t redue their insulin dsge in ntiiptin f strenuus tivity r t tke supple- entl rbhydrte. Injetin f insulin int  site frthest wy fr the usles st invlved in the exerise y help elirte exerise-indued hypglyei, sine insu- lin injeted in the prxiity f exerising usle y be re rpidly bilized. Exerise trining ls inreses the effetiveness f insulin, nd insulin dses shuld be djusted rdingly. Infetins n use insulin resistne, nd ptients shuld be instruted n hw t nge the hyper- glyei with suppleentl rpidly ting insulin. Advie n persnl hygiene, inluding detiled instru- tins n ft nd dentl re, shuld be prvided. All infe- tins (espeilly pygeni nes) prvke the relese f high levels f insulin ntgnists, suh s tehlines r glugn, nd thus bring but  rked inrese in insu- lin requireents. Ptients wh re tking rl gents y depenste nd teprrily require insulin. Ptients shuld be tld but unity genies, suh s Dibetes Assitin hpters, tht n serve s  ntinuing sure f instrutin.Finlly, vigrus effrts shuld be de t persude ptients with newly dignsed dibetes wh ske t give up the hbit, sine lrge vessel peripherl vsulr disese nd debilitting retinpthy re less n in nnsk- ing dibeti ptients.C.  MedicationsT retent ust be individulized n the bsis f the type f dibetes nd speifi needs f eh ptient. Hwever, ertin generl priniples f ngeent n be utlined fr hyperglyei sttes f different types. 1. Type 1 diabetes— A bintin f rpidly ting insu- lin nlgs nd lng-ting insulin nlgs llws fr re physilgi insulin repleent. Tble 27–8 illustrtes  regien with  rpidly ting insulin nlg nd lng- ting bsl insulin tht ight be pprprite fr  70-kg persn with type 1 dibetes eting els prviding stn- drd rbhydrte intke nd derte t lw ft ntent. Insulin glrgine r insulin deglude is usully given ne in the evening t prvide 24-hur verge. There re sinl ptients in wh insulin glrgine des nt lst fr 24 hurs, nd in suh ses, it needs t be given twie  dy. Insulin deteir usully hs t be given twie  dy t get dequte 24-hur bsl verge. Altern- tively, sll dses f NPH (~3–4 units) n be given with eh el t prvide dytie bsl verge with  lrger dse t night. CSII by prtble bttery-perted “pen lp” devies llw the setting f different bsl rtes thrughut the 24 hurs nd perit blus dse djustents by s little s 0.05-unit inreents. The 24-hur bsl dsge is usully bsed n ge nd bdy weight. An dlesent ight need s uh s 0.4 unit/kg/dy;  yung dult (less thn 25 yers),Table 27–7. Diagnostic sensitivity and specificity of autoimmune markers in patients with newly diag- nosed type 1 diabetes mellitus. Sensitivity Specificity Islet cell antibodies (ICA) 44–100% 96% Glutamic acid decarboxylase (GAD65)70–90% 99% Insulin (IAA) 40–70% 99% Tyrosine phosphatase (IA-2, ICA 512)50–70% 99% Zinc transporter 8 (ZnT8) 50–70% 99%T able 27–8. Examples of intensive insulin regimens using rapidly acting insulin analogs (insulin lispro, aspart, or glulisine) and long-acting insulin analogs (insulin detemir, or insulin glargine or degludec) in a 70-kg man with type 1 diabetes.1–3 Pe- beakfastPe- lunchPe- dinneAt Bedtime Rapidly acting insulin analog5 units 4 units 6 units Insulin detemir36–7 units  8–9 units OR Rapidly acting insulin analog5 units 4 units 6 units — Insulin glargine or degludec3—  15–16 units1 Assumes that patient is consuming approximately 75 g carbohy- drate at breakfast, 60 g at lunch, and 90 g at dinner.2 The dose of rapidly acting insulin can be raised by 1 or 2 units if extra carbohydrate (15–30 g) is ingested or if premeal blood glu- cose is > 170 mg/dL (9.4 mmol/L).3 Insulin glargine or insulin detemir must be given as a separate injection.CMDT22_Ch27_p1212-p1255.indd  1234 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1235 CMDT 20220.35 unit p er/kg/dy; nd n lder dult, 0.25 unit/kg/dy. Fr exple,  70-kg, 30-yer-ld persn y require  bsl rte f 0.7 unit per hur thrughut the 24 hurs with the exeptin f 3 am t 8 am, when 0.8 unit per hur ight be pprprite (given the “ dawn phenomenon ”— redued tissue sensitivity t insulin between 5 am nd 8 am). The el blus vries bsed n the tie f dy nd the persn’s ge. Adlesents nd yung dults usully require 1 unit fr but 10 g f rbhydrte. Older dults usully require but 1 unit fr 15 g f rbhydrte. The rretin ftr—hw uh insulin is needed t lwer gluse levels by 50 g/dL—n be lulted fr the insulin-t-rbhydrte rtis. Fr exple, if 1 unit is required fr 15 g f rbhydrte, then 1 unit will lwer gluse levels by 50 g/dL. If 1.5 units f insulin re required fr 15 g f rbhydrte (tht is, 1 unit fr 10 g rbhydrte), then 1.5 units f insulin will lwer gluse levels by 50 g/dL (tht is, 1 unit will lwer gluse level by 33 g/dL). Fr  70-kg 30-yer-ld persn, blus rtis f 1 unit fr 12–15 g f rbhydrte plus 1 unit fr 50 g/dL f bld gluse ver  trget vlue f 120 g/dL wuld be resnble strting pint. Further djustents t bsl nd blus dsges wuld depend n the results f bld gluse nitring. One f the re diffiult ther- peuti prbles in nging ptients with type 1 dibetes is deterining the prper djustent f insulin dse when the prebrekfst bld gluse level is high. Osinlly, the prebrekfst hyperglyei is due t the Somogyi effect, in whih nturnl hypglyei leds t  surge f unterregultry hrnes t prdue high bld glu- se levels by 7 am. Hwever,  re n use fr prebrekfst hyperglyei is the wning f irulting insulin levels by the rning. The dignsis f the use f prebrekfst hyperglye- i n be filitted by self-nitring f bld gluse t 3 am in dditin t the usul bedtie nd 7 am e- sureents r by nlyzing dt fr the ntinuus glu- se nitr. This is required fr nly  few nights, nd when  prtiulr pttern eerges fr nitring bld gluse levels vernight, pprprite therpeuti esures n be tken. The Sgyi effet n be treted by lwer- ing the bsl insulin dse t bedtie r by eting  snk t bedtie. When  wning insulin level is the use, then either inresing the evening bsl insulin dse r shifting it fr dinnertie t bedtie (r bth) n be effetive. The urrently vilble lsed lp systes enble ptients t hieve lse t nrl gluse levels in the rning with  lw risk f nturnl hypglyei nd iprve verll gluse ntrl. All ptients with type 1 dibetes wh re skilled t using insulin pups shuld use these systes. 2. Type 2 diabetes— Therpeuti reendtins re bsed n the reltive ntributins f bet ell insuffi- ieny nd insulin insensitivity in individul ptients. The pssibility tht the individul ptient hs  speifi eti- lgi use fr their dibetes shuld lwys be nsidered, espeilly when the ptient des nt hve  fily histry f type 2 dibetes r des nt hve ny evidene f entrl besity r insulin resistne. Suh ptients shuld be evlu- ted fr ther types f dibetes suh s LADA r MODY(Tble 27–1). Ptients with LADA shuld be presribed insulin when the disese is dignsed nd treted like ptients with type 1 dibetes. It is ls iprtnt t nte tht ny ptients with type 2 dibetes ellitus hve  prgressive lss f bet ell funtin nd will require ddi- tinl therpeuti interventins with tie. a. Weight reduction— One f the priry des f therpy in the bese ptient with type 2 dibetes is weight redutin. Nrliztin f glyei n be hieved by weight lss nd iprveent in tissue sensitivity t insu- lin. A bintin f lri restritin, inresed exer- ise, nd behvir difitin is required if  weight redutin prgr is t be suessful. Understnding the risks ssited with the dignsis f dibetes y ti- vte the ptient t lse weight. Fr seleted ptients, edil r surgil ptins fr weight lss shuld be nsidered. Orlistt, phenterine/ tpirte, lrserin, nltrexne/extended-relese bupr- pin, nd high-dse lirglutide (3 g dily) re weight lss editins pprved fr use in bintin with diet nd exerise (see Chpter 29). Britri surgery (Rux-en-Y, gstri bnding, gstri sleeve, bilipnreti diversin/dudenl swith) typilly results in substntil weight lss nd iprveent in glu- se levels. A et-nlysis exining the ipt f br- itri surgery n ptients with dibetes nd BMI f 40 kg/2r greter nted tht 82% f ptients hd reslu- tin f linil nd lbrtry nifesttins f dibetes in the first 2 yers fter surgery nd 62% reined free f dibetes re thn 2 yers fter surgery. The iprveent ws st rked in the predure tht used the gretest weight lss (bilipnreti diversin/dudenl swith). There ws, hwever,  high ttritin f ptients vilble fr fllw-up, nd there ws little infrtin but differ- ent ethni types. Weight regin des ur fter britri surgery, nd it n be expeted tht 20–25% f the lst weight will be regined ver 10 yers. The ipt f this weight gin n dibetes reurrene depends priniplly n the degree f bet ell dysfuntin. Nnbese ptients with type 2 dibetes frequently hve inresed viserl dipsity—the s-lled etblilly bese nrl weight ptient. There is less ephsis n weight lss, but exerise reins n iprtnt spet f tretent. b. Glucose-lowering agents— Figure 27–2 utlines the tretent pprh bsed n the nsensus lgrith prpsed by the Aerin Dibetes Assitin nd the Eurpen Assitin fr the Study f Dibetes. The ur- rent reendtin is t strt etfrin therpy t dignsis nd nt wit t see whether the ptient n hieve trget glyei ntrl with weight ngeent nd exerise. See disussin f the individul editins, bve. When dibetes is nt well ntrlled with initil ther- py (usully etfrin), then  send gent shuld be dded. Presene f rdivsulr r kidney disese, r bth, will deterine the hie f the send gent. Lir- glutide, seglutide, epgliflzin, ngliflzin, nd dpgliflzin hve iprved rdivsulr utes.CMDT22_Ch27_p1212-p1255.indd  1235 29/06/21 8:53 PMCHAPTEr 271236 CMDT 2022The  SGLT2 inhibitrs re espeilly benefiil in ptients with hert filure r dibeti nephrpthy, r bth. The need fr weight lss shuld led t the use f GLP1- reeptr gnists in the bese ptient with r withut r- nry rtery disese. SGLT2 inhibitrs ls prte dest weight lss nd shuld be presribed in the ptient with hert filure r dibeti nephrpthy. Sulfnylures hve been vilble fr ny yers nd their use in bintin with etfrin is well estblished. They d, hwever, hve the prpensity f using hypglyei nd weight gin. In ptients wh experiene hyperglyei fter  rbhy- drte-rih el (suh s dinner),  shrt-ting seret- ggue (repglinide r nteglinide) befre els y suffie t get the gluse levels int the trget rnge. Ptients with severe insulin resistne y be ndidtes fr pigli- tzne. Piglitzne y ls redue the risk fr reurrent strke in ptients wh hve  histry f strke r trnsient ishei ttk. If tw gents re indequte, then  third gent is dded, lthugh dt regrding effiy f suh bined therpy re liited. When the bintin f rl gents (nd injetble GLP-1 reeptr gnists) fils t hieve euglyei in ptients with type 2 dibetes, then insulin tretent shuld be instituted. Vrius insulin regiens y be effetive. One prpsed regien is t ntinue the rl bintin therpy nd then siply dd  bedtie dse f NPH r lng-ting insulin nlg (insulin glrgine, deteir, r deglude) t redue exessive nturnl hepti gluse utput nd iprve fsting gluse levels. If the ptient des nt hieve trget gluse levels during the dy, then dytie insulin tretent n be initited. A nvenient insulin regien under these irustnes is  split dse f 70/30 NPH/regulr ixture (r Hulg Mix 75/25 r NvLgMix 70/30) befre brekfst nd befre dinner. If this regien fils t hieve stisftry glye- i gls r is ssited with uneptble frequeny f hypglyei episdes, then  re intensive regien f ultiple insulin injetins n be instituted s in ptients with type 1 dibetes. Metfrin priniplly redues hepti gluse utput, nd it is resnble t ntinue with this editin when insulin therpy is instituted. Piglitzne, whih iprves peripherl insulin sensitiv- ity, n be used tgether with insulin but this bintin is ssited with re weight gin nd peripherl ede. The sulfnylures, the GLP-1 reeptr gnists, the DPP-4 inhibitrs, nd the SGLT2 inhibitrs ls hve been shwn t be f ntinued benefit. Weight-reduing interventins shuld ntinue even fter inititin f insulin therpy nd y llw fr siplifitin f the therpeuti regi- en in the future.D . Acceptable Levels of Glycemic ControlA  resnble i f therpy is t pprh nrl glye- i exursins withut prvking severe r frequent hyp- glyei. Tble 27–9 surizes bld gluse nd HbA1 gls fr different ptient grups. The UKPDS study dem- onstrated that blood pressure control was as significant or more significant than glycemic control in patients with type 2 diabetes regarding the prevention of microvascular as well as macrovascular complications.Weight loss + exercise + metformin Metformin + another agent (noninsulin or insulin) Metformin + two other agents (noninsulin or insulin) Factors in Therapeutic Decision (single agent or combination)Seven main classes of agents • Metformin • Sulfonylureas (includes nateglinide, repaglinide) • Pioglitazone • GLP-1 receptor agonists • DPP-4 inhibitors • SGLT2 inhibitors • InsulinsIf HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reache d after ~ 3 months Efficacy • DPP-4 inhibitors are of moderate efficacy • All other agents are of high efficacy Cost • All agents except metformin and sulfonylureas are expensive • Insulins are expensive if the additional cost of monitoring is taken into considerationCardiovascular and renal effects • Metformin, liraglutide, semaglutide, empagliflozin, and canagliflozin have know n cardiovascular benefits • SGLT2 inhibitors reduce the risk of ESKD, doubling of serum creatinine and renal death in patients with diabetic nephropathy Hypoglycemic risk • Sulfonylureas and insulins have increased risk of hypoglycemia Effect on weight • Metformin and DPP-4 inhibitors are weight neutral • GLP-1 receptor agonists and SGLT2 inhibitor s promote weight loss • Sulfonylureas, insulins, and pioglitazone ar e associated with weight gain Major side effects • Metformin: lactic acidosis • Pioglitazone: fluid retention, fracture risk, macular edema, possible bladder cancer • GLP-1 receptor agonists: nausea, vomiting and pancreatitis • DPP-4 inhibitors: possible pancreatitis • SGLT2 inhibitors: urinary tract infection; genital mycotic infections; dehydration; cannot use if eGFR < 30 mL/min/1.73 m2Metformin + insulin ± other noninsulin agent ▲Figure 27–2. Algorithm for the treatment of type 2 diabetes based on the 2018 recommendations of the consensus panel of the American Diabetes Association/ European Association for the Study of Diabetes.CMDT22_Ch27_p1212-p1255.indd  1236 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1237 CMDT 2022E.  Complications of Insulin Therapy1.  Hypoglycemia— Hypglyei retins re the st n plitins tht ur in ptients with dibetes wh re treted with insulin. The signs nd sypts f hypglyei y be divided int thse resulting fr stiultin f the utni nervus syste nd thse fr neurglypeni (insuffiient gluse fr nrl entrl nervus syste funtin). When the bld gluse flls t rund 54 g/dL (3 l/L), the ptient strts t experiene bth syptheti (thyrdi, plpittins, sweting, treulusness) nd prsyptheti (nuse, hunger) nervus syste sypts. If these utni sypts re ignred nd the gluse levels fll further (t rund 50 g/dL [2.8 l/L]), then neurglypeni sypts pper, inluding irritbility, nfusin, blurred visin, tiredness, hedhe, nd diffiulty speking. A fur- ther deline in gluse n led t lss f nsiusness r even  seizure. With repeted episdes f hypglyei, there is dpttin, nd utni sypts d nt ur until the bld gluse levels re uh lwer nd s the first sypts re ften due t neurglypeni. This nditin is referred t s “hypglyei unwreness. ” It hs been shwn tht hypglyei unwreness n be reversed by keeping gluse levels high fr  perid f severl weeks. Exept fr sweting, st f the syptheti sypts f hypglyei re blunted in ptients reeiv- ing bet-blking gents. Thugh nt bslutely ntrin- dited, these editins ust be used with utin in ptients with dibetes wh require insulin, nd bet-1- seletive blking gents re preferred. Hypglyei n ur in  ptient tking sulfnyl- ures, repglinide, nd nteglinide, prtiulrly if the ptient is elderly, hs kidney r liver disese, r is tking ertin ther editins tht lter etblis f the sul- fnylures (eg, phenylbutzne, sulfnides, r wrf- rin). It urs re frequently with the use f lng-tingsulfnylures thn with shrter-ting gents. Otherwise, hypglyei in insulin-treted ptients urs s  nse- quene f three ftrs: behvirl issues, ipired un- terregultry systes, nd plitins f dibetes. Behvirl issues inlude injeting t uh insulin fr the unt f rbhydrtes ingested. Drinking lhl in exess, espeilly n n epty sth, n ls use hypglyei. In ptients with type 1 dibetes, hypglye- i n ur during r even severl hurs fter exerise, nd s gluse levels need t be nitred nd fd nd insulin djusted. Se ptients d nt like their gluse levels t be high, nd they tret every high gluse level ggressively. These individuls wh “stk” their insulin— tht is, give nther dse f insulin befre the first injetin hs hd its full tin—n develp hypglyei. Cunterregultry issues resulting in hypglyei inlude ipired glugn respnse, sypth-drenl respnses, nd rtisl defiieny. Ptients with dibetes f greter thn 5 yers in durtin lse their glugn respnse t hypglyei. As  result, they re t  signifi- nt disdvntge in prteting theselves ginst flling gluse levels. One the glugn respnse is lst, their sypth-drenl respnses tke n dded iprtne. Unfrtuntely, ging, utni neurpthy, r hypgly- ei unwreness due t repeted lw gluse levels fur- ther blunts the sypth-drenl respnses. Osinlly, Addisn disese develps in persns with type 1 dibetes ellitus; when this hppens, insulin requireents fll sig- nifintly, nd unless insulin dse is redued, reurrent hypglyei will develp. Cplitins f dibetes tht inrese the risk fr hypglyei inlude utni neurpthy, gstrpre- sis, nd end-stge hrni kidney disese. The syptheti nervus syste is n iprtnt syste lerting the indi- vidul tht the gluse level is flling by using sypts f thyrdi, plpittins, sweting, nd treulusness.Table 27–9. Glycemic targets for different groups of adults with diabetes. Blood Glucose Tagets (mg/dL [mmol/L]) HbA1cTaget (% [mmol/mol]) Nonpregnant healthy adults Premeal glucose 90–130 (5–7.2) 1-hour peak < 180 (10) 2-hour peak < 150 (8.3)< 7 (53). Aim for < 6.5 (48) if it can be achieved without significant hypoglycemia or polypharmacy Pregnancy Premeal glucose ≤ 95 (5.3) 1-hour peak ≤ 140 (7.8) 2-hour peak ≤ 120 (6.7)6–6.5 (42–48). Aim for < 6 (42) if possible without significant hypoglycemia Older adults Healthy Frail with limited life expectancyPremeal 90–130 (5–7.2) Bedtime 90–150 (5–8.3) Premeal 100–180 (5.6–10) Bedtime 110–200 (6.1–11.1)< 7.5 (58) < 8.5 (69) History of severe hypoglycemia Premeal 90–150 (5–8.3) Bedtime 100–180 (5.6–10)< 8 (64) Hospitalized patient 140–180 (7.8–10) — Chronic kidney disease (CKD) Glycemic targets in CKD are the same as those without CKD. HbA1cand fructosamine values may not be accu- rate in end-stage kidney disease, and greater reliance should be placed on the home glucose measurementsCMDT22_Ch27_p1212-p1255.indd  1237 29/06/21 8:53 PMCHAPTEr 271238 CMDT 2022Fil ure f the sypth-drenl respnses inreses the risk f hypglyei. In dditin, in ptients with gstr- presis, if insulin is given befre  el, the pek f insulin tin y ur befre the fd is bsrbed using the gluse levels t fll. Finlly, in end-stge hrni kidney disese, hypglyei n ur presubly beuse f deresed insulin lerne s well s lss f renl ntri- butin t glunegenesis in the pstbsrptive stte. T prevent nd tret insulin-indued hypglyei, the dibeti ptient shuld rry gluse tblets r juie t ll ties. Fr st episdes, ingestin f 15 grs f rb- hydrte is suffiient t reverse the hypglyei. The ptient shuld be instruted t hek the bld gluse in 15 inutes nd tret gin if the gluse level is still lw. A prenterl (1 g) r nsl inhltin (3 g) glugn eergeny kit shuld be prvided t every ptient with dibetes wh is reeiving insulin therpy. Fily r friends shuld be instruted hw t injet it subutneusly r intrusulrly int the buttk, r, r thigh r din- ister  nsl dse in the event tht the ptient is unn- sius r refuses fd. The editin n sinlly use viting, nd the unnsius ptient shuld be turned n his r her side t prtet the irwy. Glugn bilizes glygen fr the liver, rising the bld gluse by but 36 g/dL (2 l/L) in but 15 inutes. After the ptient revers nsiusness, dditinl rl rb- hydrte shuld be given. Peple with dibetes reeiving hypglyei editin therpy shuld ls wer n identifitin MediAlert brelet r nekle r rry  rd in his r her wllet (1-800-ID-ALERT, www.edi- lert.rg). Medil persnnel treting severe hypglyei n give 50 L f 50% gluse slutin by rpid intrvenus infusin. If intrvenus ess is nt vilble, 1 g f glugn n be injeted intrusulrly r 3 g given by nsl spry. 2. Immunopathology of insulin therapy— At lest five leulr lsses f insulin ntibdies re prdued dur- ing the urse f insulin therpy in dibetes, inluding IgA, IgD, IgE, IgG, nd IgM. With the swith t hun nd purified prk insulin, the vrius iunpthlgi syn- dres suh s insulin llergy, iune insulin resistne, nd liptrphy hve bee quite rre sine the titers nd vidity f these indued ntibdies re generlly quite lw. a. Insulin allergy— Insulin llergy, r iedite-type hypersensitivity, is  rre nditin in whih ll r sys- tei urtiri is due t histine relese fr tissue st ells sensitized by dherene f nti-insulin IgE ntibdies. In severe ses, nphylxis results. When nly hun insulin hs been used fr the nset f insulin therpy, insulin llergy is exeedingly rre. Antihistines, rti- sterids, nd even desensitiztin y be required, espe- illy fr systei hypersensitivity. b. Immune insulin resistance— A lw titer f irult- ing IgG nti-insulin ntibdies tht neutrlize the tin f insulin t  sll extent develps in st insulin-treted ptients. With the ld nil insulins,  high titer f iru- lting ntibdies seties develped, resulting inextreely high insulin requireents—ften re thn 200 units dily. This is nw rrely seen with the swith t hun r highly purified prk insulins nd hs nt been reprted with the nlgs. c. Lipodystrophy— Atrphy f subutneus ftty tissue leding t disfiguring exvtins nd depressed res y rrely ur t the site f injetin. This plitin results fr n iune retin, nd it hs bee rrer with the develpent f hun nd highly purified insu- lin preprtins. Liphypertrphy, n the ther hnd, is  nsequene f the phrlgi effets f insulin being depsited in the se ltin repetedly. It n ur with purified insulins s well. Rttin f injetin sites will prevent liphypertrphy.Rdriguez-Gutierrez  R et l. Benefits nd hrs f intensive glyei ntrl in ptients with type 2 dibetes. BMJ. 2019;367:l5887. [PMID: 31690574] »Chronic Complications of DiabetesLte  linil nifesttins f dibetes ellitus inlude  nuber f pthlgi hnges tht invlve sll nd lrge bld vessels, rnil nd peripherl nerves, the skin, nd the lens f the eye. These lesins led t hypertensin, end- stge hrni kidney disese, blindness, utni nd peripherl neurpthy, puttins f the lwer extrei- ties, yrdil infrtin, nd erebrvsulr idents. These lte nifesttins rrelte with the durtin f the dibeti stte subsequent t the nset f puberty. In type 1 dibetes, end-stge hrni kidney disese develps in up t 40% f ptients, pred with less thn 20% f ptients with type 2 dibetes. Prlifertive retinpthy ultitely develps in bth types f dibetes but hs  slightly higher prevlene in type 1 ptients (25% fter 15 yers’ durtin). In ptients with type 1 dibetes, plitins fr end- stge hrni kidney disese re  jr use f deth, wheres ptients with type 2 dibetes re re likely t hve rvsulr diseses leding t yrdil infr- tin nd strke s the in uses f deth. Cigrette use dds signifintly t the risk f bth irvsulr nd rvsulr plitins in dibeti ptients.A.  Ocular Complications1.  Diabetic cataracts— Preture trts ur in di- beti ptients nd see t rrelte with bth the durtin f dibetes nd the severity f hrni hyperglyei. Nnenzyti glysyltin f lens prtein is twie s high in dibeti ptients s in ge-thed nndibeti persns nd y ntribute t the preture urrene f trts. 2. Diabetic retinopathy— The tw in tegries f di- beti retinpthy, nnprlifertive nd prlifertive, re disussed in Chpter 7. 3. Glaucoma— Glu urs in pprxitely 6% f persns with dibetes. It is respnsive t the usul therpy fr pen-ngle disese. Nevsulriztin f the iris in ptients with dibetes n predispse t lsed-ngleCMDT22_Ch27_p1212-p1255.indd  1238 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1239 CMDT 2022glu,  but this is reltively unn exept fter trt extrtin, when grwth f new vessels hs been knwn t prgress rpidly, invlving the ngle f the iris nd bstruting utflw.B.  Diabetic NephropathyDibeti  nephrpthy is initilly nifested by lbuin- uri; subsequently, s kidney funtin delines, ure nd retinine uulte in the bld (see Chpter 22). An lbuin-retinine rti in n erly rning spt urine lleted upn wkening is the preferred ethd t ssess lbuin exretin. In the erly rning spt urine,  rti f lbuin (g/L) t retinine (g/L) f less thn 30 g/g retinine is nrl, nd  rti f 30–300 g/g retinine suggests bnrl irlbuinuri. At lest tw erly rning spt urine lletins ver  3- t 6-nth perid shuld be bnrl befre  dignsis f irlbuinuri is justified. Shrt-ter hyperglyei, exerise, urinry trt infetins, hert filure, nd ute febrile illness n use trnsient lbuinuri nd s test- ing fr irlbuinuri shuld be pstpned until res- lutin f these prbles. Subsequent end-stge hrni kidney disese n be predited by persistent urinry lbuin exretin rtes exeeding 30 g/g retinine. Glyei ntrl s well s  prtein diet f ~0.8 g/kg/dy y redue bth the hyperfiltrtin nd the elevted irlbuinuri in ptients in the erly stges f dibetes nd thse with inipient dibeti nephrpthy. Antihypertensive therpy ls dereses irlbuinuri. Evidene fr se studies supprts  speifi rle fr ACE inhibitrs in redu- ing intrglerulr pressure in dditin t their lwering f systei hypertensin. An ACE inhibitr (ptpril, 50 g twie dily) in nrtensive dibeti ptients ipedes prgressin t prteinuri nd prevents the inrese in lbuin exretin rte. SGLT2 therpy shuld be instituted in ptients with type 2 dibetes wh hve prgressin f kidney disese despite tking ptil nti- hypertensive therpy, whih inludes n ACE inhibitr r ngitensin reeptr blker.C.  Diabetic NeuropathyDibeti  neurpthies re the st n plitins f dibetes, ffeting up t 50% f lder ptients with type 2 dibetes. 1. Peripheral neuropathy— a. Distal symmetric polyneuropathy— This is the st n fr f dibeti peripherl neurpthy where lss f funtin ppers in  stking-glve pttern nd is due t n xnl neurpthi press. Lnger nerves re espeilly vulnerble, hene the ipt n the ft. Bth tr nd sensry nerve ndutin is delyed in the peripherl nerves, nd nkle jerks y be bsent. Sensry invlveent usully urs first nd is gener- lly bilterl, syetri, nd ssited with dulled per- eptin f vibrtin, pin, nd teperture. The pin n rnge fr ild disfrt t severe inpitting syp- ts. The sensry defiit y eventully be f suffiientdegree t prevent ptients fr feeling pin. Ptients wh hve  sensry neurpthy shuld therefre be exined with  5.07 Sees-Weinstein filent nd thse wh nnt feel the filent ust be nsidered t risk fr unpereived neurpthi injury. The denervtin f the sll usles f the ft n result in lwing f the tes nd displeent f the sub- ettrsl ft pds nterirly. These hnges, tgether with the jint nd nnetive tissue hnges, lter the biehnis f the ft nd inrese plntr pressures. This bintin f deresed pin threshld, bnr- lly high ft pressures, nd repetitive stress (suh s fr wlking) n led t lluses nd ulertins in the high-pressure res suh s ver the ettrsl heds (Figure 27–3). Peripherl neurpthy, utni neu- rpthy, nd tru ls predispses t the develpent fCharcot arthropathy. An ute se f Chrt ft rthrpthy presents with pin nd swelling, nd if left untreted, leds t  “rker btt” defrity nd ulertin. The erly rdilgi hnges shw jint sub- luxtin nd perirtiulr frtures. As the press pr- gresses, there is frnk stelsti destrutin leding t dernged nd unstble jints prtiulrly in the idft. Nt surprisingly, the key issue fr the heling f neur- pthi ulers in  ft with gd vsulr supply is ehnil unlding. In dditin, ny infetin shuld be treted with debrideent nd pprprite ntibitis; heling durtin f 8–10 weeks is typil. Osinlly, when heling ppers refrtry, pltelet-derived grwth ftr (beplerin [Regrnex]) shuld be nsidered fr ll pplitin. One ulers re heled, therpeuti ftwer is key t preventing reurrenes. Cust lded shes re reserved fr ptients with signifint ft defrities. Other ptients with neurpthy y require dtive insles tht distribute the ld ver s wide n re s pssible. Ptients with ft defr- ities nd lss f their prtetive threshld shuld get regulr re fr  pditrist. Ptients shuld be edu- ted n pprprite ftwer nd thse with lss f their ▲Figure 27–3. Diabetic foot ulcer over head of first metatarsal (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch27_p1212-p1255.indd  1239 29/06/21 8:53 PMCHAPTEr 271240 CMDT 2022prtet ive threshld shuld be instruted t inspet their feet dily fr reddened res, blisters, brsins, r lertins. In se ptients, hypersensitivity t light tuh nd sinlly severe “burning” pin, prtiulrly t night, n bee physilly nd etinlly disbling. Nrtrip- tyline r desiprine in dses f 25–150 g/dy rlly y prvide drti relief fr pin fr dibeti neu- rpthy, ften within 48–72 hurs. Ptients ften ttribute the benefit t hving  full night’s sleep. Mild t derte rning drwsiness is  side effet tht generlly iprves with tie r n be lessened by giving the editin sev- erl hurs befre bedtie. This editin shuld nt be ntinued if iprveent hs nt urred fter 5 dys f therpy. Aitriptyline, 25–75 g rlly t bedtie, n ls be used but hs re ntihlinergi effets. Triyli ntidepressnts, in bintin with fluphenzine (3 g dily in three divided dses) hve been shwn in tw stud- ies t be effiius in pinful neurpthy, with benefits unrelted t relief f depressin. Gbpentin (900–1800 g rlly dily in three divided dses) hs ls been shwn t be effetive in the tretent f pinful neurpthy nd shuld be tried if the triyli editins prve ineffe- tive. Pregblin,  ngener f gbpentin, hs been shwn in n 8-week study t be re effetive thn pleb in treting pinful dibeti peripherl neurpthy. Hwever, this editin ws nt pred with n tive ntrl. Als, beuse f its buse ptentil, it hs been tegrized s  shedule V ntrlled substne. Dulxetine (60–120 g),  sertnin nd nrepinephrine reuptke inhibitr, is pprved fr the tretent f pinful dibeti neurpthy. Cpsiin,  tpil irritnt, is effetive in reduing ll nerve pin; it is dispensed s  re (Zstrix 0.025%, Zstrix-HP 0.075%) t be rubbed int the skin ver the pinful regin tw t fur ties dily. Glves shuld be used fr pplitin sine hnd ntintin uld result in disfrt if the re es in ntt with eyes r sensitive res suh s the genitli. Appli- tin f  5% lidine pth ver n re f xil pin hs been reprted t be f benefit. It is pprved fr tret- ent f pstherpeti neurlgi. Diabetic neuropathic cachexia is  syndre hr- terized by  syetri peripherl neurpthy ssited with prfund weight lss (up t 60% f ttl bdy weight) nd pinful dysesthesis ffeting the prxil lwer libs, the hnds, r the lwer trunk. Tretent is usully with insulin nd nlgesis. The prgnsis is generlly gd, nd ptients typilly rever their bseline weight with reslutin f the pinful sensry sypts within 1 yer. b. Isolated peripheral neuropathy— Invlveent f the distributin f nly ne nerve (“nneurpthy”) r f severl nerves (“nneurpthy ultiplex”) is hr- terized by sudden nset with subsequent revery f ll r st f the funtin. This neurpthlgy hs been ttrib- uted t vsulr ishei r truti dge. Crnil nd ferl nerves re nly invlved, nd tr bnrlities predinte. The ptient with rnil nerve invlveent usully hs diplpi nd single third, furth, r sixth nerve wekness n exintin but the pupil isspred. A full revery f funtin urs in 6–12 weeks. Dibeti ytrphy presents with nset f severe pin in the frnt f the thigh. Within  few dys r weeks f the nset f pin, wekness nd wsting f the qudrieps develps. As the wekness ppers, the pin tends t iprve. Mngeent inludes nlgesi nd iprved dibetes ntrl. The sypts iprve ver 6–18 nths. 2. Autonomic neuropathy— Neurpthy f the utni syste urs priniplly in ptients with dibetes f lng durtin. It ffets ny diverse viserl funtins inlud- ing bld pressure nd pulse, gstrintestinl tivity, bld- der funtin, nd eretile dysfuntin. Tretent is direted speifilly t eh bnrlity. Insulin neuritis r tretent-indued neurpthy f dibetes urs - sinlly in ptients with pr gluse ntrl nd whse gluse levels iprve rpidly in dys r  few weeks. Sypts inlude severe sensry neurpthi pins nd seties utni funtins. These sypts iprve ver  few nths. a. Gastrointestinal system— Invlveent f the gs- trintestinl syste y be nifested by nuse, vit- ing, pstprndil fullness, reflux r dysphgi, nstiptin r dirrhe (r bth), nd fel inntinene. Gstrpre- sis shuld be nsidered in type 1 dibeti ptients in wh unexpeted flututins nd vribility in their bld gluse levels develps fter els. Metlpride hs been f se help in treting dibeti gstrpresis. It is given in  dse f 10 g rlly three r fur ties  dy, 30 inutes befre els nd t bedtie. Drwsiness, rest- lessness, ftigue, nd lssitude re n dverse effets. Trdive dyskinesi nd extrpyridl effets n ur, espeilly when used fr lnger thn 3 nths, nd the FDA hs utined ginst the lng-ter use f etlpride. Erythryin ppers t bind t tilin reeptrs in the sth nd hs been fund t iprve gstri epty- ing ver the shrt ter in dses f 250 g three ties dily, but its effetiveness sees t diinish ver tie. In seleted ptients, injetins f btulinu txin int the pylrus n redue pylrus sphinter resistne nd enhne gstri eptying. Gstri eletril stiultin hs been reprted t iprve sypts nd qulity f life indies in ptients with gstrpresis refrtry t phr- lgi therpy. Dirrhe ssited with utni neurpthy hs sinlly respnded t brd-spetru ntibiti ther- py (suh s rifxiin, etrnidzle, xiillin/lvul- nte, iprflxin, r dxyyline), lthugh it ften underges spntneus reissin. Refrtry dibeti dirrhe is ften ssited with ipired sphinter n- trl nd fel inntinene. Therpy with lperide, 4–8 g dily, r diphenxylte with trpine, tw tblets up t fur ties  dy, y prvide relief. In re severe ses, tinture f pregri r deine (60-g tblets) y be required t redue the frequeny f dirrhe nd iprve the nsisteny f the stls. Clnidine hs been reprted t lessen dibeti dirrhe; hwever, its usefulness is liited by its tendeny t lwer bld pressure in these ptients wh lredy hve utni neurpthy, resultingCMDT22_Ch27_p1212-p1255.indd  1240 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1241 CMDT 2022in  rthstti hyptensin. Cnstiptin usully respnds t stiulnt lxtives suh s senn. b. Genitourinary system— Inplete eptying f the bldder n seties ur. Bethnehl in dses f 10–50 g rlly three ties  dy hs sinlly iprved eptying f the tni urinry bldder. Ctheter depressin f the distended bldder hs been reprted t iprve its funtin, nd nsiderble benefit hs been reprted fter surgil severing f the internl vesile sphinter. Eretile dysfuntin n result fr neurlgi, psy- hlgil, r vsulr uses, r  bintin f these uses. The phsphdiesterse type 5 (PDE5) inhibitrs sildenfil (Vigr), vrdenfil (Levitr), nd tdlfil (Cilis) hve been shwn in pleb-ntrlled linil tri- ls t iprve eretins in respnse t sexul stiultin. The reended dse f sildenfil fr st ptients is ne 50-g tblet tken pprxitely 1 hur befre sexul tivity. The pek effet is t 1.5–2 hurs, with se effet persisting fr 4 hurs. Ptients with dibetes ellitus using sildenfil reprted 50–60% iprveent in eretile fun- tin. The xiu reended dse is 100 g. The reended dse f bth vrdenfil nd tdlfil is 10 g. The dses y be inresed t 20 g r deresed t 5 g bsed n effiy nd side effets. Tdlfil hs been shwn t iprve eretile funtin fr up t 36 hurs fter dsing. Lw dses re vilble fr dily use. In linil trils, nly  few dverse effets hve been reprted—trnsient ild hedhe, flushing, dyspepsi, nd se ltered lr visin. Pripis n ur with these editins, nd ptients shuld be dvised t seek iedite edil ttentin if n eretin persists fr lnger thn 4 hurs. The PDE5 inhibi- trs ptentite the hyptensive effets f nitrtes nd their use is ntrindited in ptients wh re nurrently using rgni nitrtes in ny fr. Cutin is dvised fr en wh hve suffered  hert ttk, strke, r life-thretening rrhythi within the previus 6 nths; en wh hve resting hyptensin r hypertensin; nd en wh hve  histry f hert filure r hve unstble ngin. Rrely,  derese in visin r pernent visul lss hs been reprted fter PDE5 inhibitr use. Intrrprel injetin f vstive editins uses penile engrgeent nd eretin. Meditins st nly used inlude ppverine lne, ppverine with phentline, nd lprstdil (prstglndin E1). Alprst- dil injetins re reltively pinless, but reful instrutin is essentil t prevent ll tru, pripis, nd fibrsis. Intrurethrl pellets f lprstdil vid the prble f injetin f the editin. Externl vuu therpy (Ere-Aid Syste) is  nnsur- gil tretent nsisting f  sutin hber perted by  hnd pup tht retes  vuu rund the penis. This drws bld int the penis t prdue n eretin tht is intined by  speilly designed tensin ring inserted rund the bse f the penis nd whih n be kept in ple fr up t 20–30 inutes. While this ethd is generlly effetive, its uberse nture liits its ppel. Surgil iplnts f penile prstheses rein n ptin fr thse ptients in wh the nnsurgil pprhes re ineffetive.c. Orthostatic hypotension— Use f Jbst fitted stkings, tilting the hed f the bed, nd rising slwly fr the supine psitin n be helpful in treting syp- ts f rthstti hyptensin. When suh esures re indequte, then tretent with fludrrtisne 0.1–0.2 g rlly dily n be nsidered. This editin, hwever, n result in supine hypertensin nd hypklei. The lph-gnist iddrine (10 g rlly three ties  dy) n ls be used.D . Cardiovascular Complications1.  Heart disease— Mirngipthy urs in the hert f ptients with dibetes nd y explin the etilgy f n- gestive rdiypthies in thse wh d nt hve den- strble rnry rtery disese. Mre nly, hwever, hert disese in ptients with dibetes is due t rnry therslersis. Myrdil infrtin is three t five ties re n in dibeti ptients nd is the leding use f deth in ptients with type 2 dibetes. Crdivsulr disese risk is inresed in ptients with type 1 dibetes s well, lthugh the bslute risk is lwer thn in ptients with type 2 dibetes. Preenpusl wen wh nrlly hve lwer rtes f rnry rtery disese lse this prte- tin ne dibetes develps. The inresed risk in ptients with type 2 dibetes reflets the bintin f hypergly- ei, hyperlipidei, bnrlities f pltelet dhesive- ness, gultin ftrs, hypertensin, xidtive stress, nd infltin. Lrge interventin studies f risk ftr redutin in dibetes re lking, but it is resnble t ssue tht reduing these risk ftrs wuld hve  ben- efiil effet. Lwering LDL hlesterl redues first events in ptients withut knwn rnry disese nd sendry events in ptients with knwn rnry disese. These interventin studies inluded se ptients with dibetes, nd the benefits f LDL hlesterl lwering ws pprent in this grup. The Ntinl Chlesterl Edutin Pr- gr linil prtie guidelines hve designted dibetes s  rnry risk equivlent nd hve reended tht ptients with dibetes shuld hve n LDL hlesterl gl f less thn 100 g/dL (2.6 l/L). Lwering LDL h- lesterl t 70 g/dL (1.8 l/L) y hve dditinl benefit nd is  resnble trget fr st ptients with type 2 dibetes wh hve ultiple risk ftrs fr rdi- vsulr disese. Aspirin t  dse f 81–325 g dily is effetive in reduing rdivsulr rbidity nd rtlity in ptients wh hve  histry f yrdil infrtin r strke (sendry preventin). Fr priry preventin,  2018 rndized study f 15,480 persns with dibetes but n evident rdivsulr disese bserved tht 100 g f spirin redued the first vsulr event f yrdil infrtin, strke r trnsient ishei ttk r deth fr vsulr event (exluding intrrnil herrhge) (rte rti 0.88; 95% nfidene intervl 0.79 t 0.97). There were, hwever, re jr bleeding events, espe- illy gstrintestinl, in the spirin grup (rte rti 1.29; 95% nfidene intervl 1.09 t 1.52). Thus, fr priry preventin, the use f spirin shuld nly be nsidered fr ptients with high rdivsulr risk nd lw bleeding risk nd generlly nt fr dults lder thn 70 yers. BsedCMDT22_Ch27_p1212-p1255.indd  1241 29/06/21 8:53 PMCHAPTEr 271242 CMDT 2022n  the Erly Tretent Dibeti Retinpthy Study (ETDRS), there des nt pper t be  ntrinditin t spirin use t hieve rdivsulr benefit in dibeti ptients wh hve prlifertive retinpthy. Aspirin ls des nt see t ffet the severity f vitreus/preretinl herrhges r their reslutin. 2. Hypertension— The ADA reends lwering systli bld pressure t less thn 140  Hg nd distli pres- sure t less thn 90  Hg in ptients with dibetes. The systli trget f 130  Hg r less nd distli trget f 80  Hg r less re reended fr the yunger ptient if they n be hieved withut undue tretent burden. The Systli Bld Pressure Interventin Tril (SPRINT) reprted tht treting t  systli bld pressure f less thn 120  Hg redued rdivsulr events by 25% nd deth fr rdivsulr uses by 43% during 3.26 yers f fllw-up. Peple with dibetes, hwever, were exluded fr this study, nd it is unler if the results re pplible t this ppultin. Ptients with type 2 dibetes wh lredy hve rdivsulr disese r irlbuinuri shuld be nsidered fr tretent with n ACE inhibitr. Mre lini- l studies re needed t ddress the questin f whether ptients with type 2 dibetes wh d nt hve rdivsulr disese r irlbuinuri wuld speifilly benefit fr ACE inhibitr tretent. 3. Peripheral vascular disease— Atherslersis is rk- edly elerted in the lrger rteries. It is ften diffuse, with llized enhneent in ertin res f turbulent bld flw, suh s t the bifurtin f the rt r ther lrge vessels. Clinil nifesttins f peripherl vsulr disese inlude ishei f the lwer extreities, eretile dysfuntin, nd intestinl ngin. The inidene f gangrene of the feet in ptients with dibetes is 30 ties tht in ge-thed ntrls. The f- trs respnsible fr its develpent, in dditin t periph- erl vsulr disese, re sll vessel disese, peripherl neurpthy with lss f bth pin senstin nd neur- geni infltry respnses, nd sendry infetin. In tw-thirds f ptients with ishei gngrene, pedl pulses re nt plpble. In the reining ne-third wh hve plpble pulses, redued bld flw thrugh these vessels n be denstrted by plethysgrphi r Dppler ultrsund exintin. Preventin f ft injury is ipertive. Agents tht redue peripherl bld flw suh s tb shuld be vided. Cntrl f ther risk ftrs suh s hypertensin is essentil. Bet-blkers re rel- tively ntrindited beuse f presued negtive peripherl hedyni nsequenes but dt tht sup- prt this re lking. Chlesterl-lwering gents re use- ful s djuntive therpy when erly ishei signs re deteted nd when dyslipidei is present. Ptients shuld be dvised t seek iedite edil re if  dibeti ft uler develps. Iprveent in peripherl bld flw with endrterety nd bypss pertins is pssible in er- tin ptients.E.  Skin and Mucous Membrane ComplicationsChrni  pygeni infetins f the skin y ur, espe- illy in prly ntrlled dibeti ptients. Cndidlinfetin n prdue erythe nd ede f intertrigi- nus res belw the brests, in the xills, nd between the fingers. It uses vulvvginitis in wen with hrnilly unntrlled dibetes wh hve persistent glusuri nd is  frequent use f pruritus. While ntifungl res ntining inzle r ltrizle ffer iedite relief f vulvvginitis, reurrene is frequent unless glu- suri is redued. In se ptients with type 2 dibetes, pr glyei ntrl n use severe hypertriglyei, whih n pres- ent s eruptive utneus xnths nd pnretitis. The skin lesins pper s yellw rbillifr eruptins 2–5  in dieter with erythetus rele. They ur n extensr surfes (elbws, knees, buttks) nd dispper fter triglyeride levels re redued. Nerbisis lipidi dibetiru is usully lted ver the nterir surfes f the legs r the drsl surfes f the nkles. They re vl r irregulrly shped plques with derted brders nd  glistening yellw surfe nd ur in wen tw t fur ties re frequently thn in en. Pthlgilly, the lesins shw degenertin f llgen, grnultus infltin f subutneus tissues nd bld vessels, pillry bseent ebrne thikening nd blitertin f vessel luin. The nditin is ssited with type 1 dibetes, lthugh it n ur in ptients with type 2 dibetes, nd ls in ptients withut dibetes. First-line therpy inludes tpil nd subutne- us rtisterids. Iprving glyei ntrl y help the nditin. “Shin spts” re nt unn in dults with dibetes. They re brwnish, runded, pinless trphi lesins f the skin in the pretibil re.F . Bone and Joint ComplicationsLng-stnding  dibetes n use prgressive stiffness f the hnd sendry t ntrture nd tightening f skin ver the jints (dibeti heirrthrpthy), frzen shul- der (dhesive psulitis), rpl tunnel syndre, nd Dupuytren ntrtures. These plitins re believed t be due t glysyltin f llgen nd perhps ther prteins in nnetive tissue. There y ls be n infl- try pnent. Dt n bne inerl density nd frture risk in peple with dibetes re ntrditry. Ptients with type 2 dibetes d pper t be t inresed risk fr nnvertebrl frtures. Wen with type 1 dibetes hve n inresed risk f fr- ture when pred with wen withut dibetes. Other ftrs, suh s durtin f dibetes, nd dibetes pli- tins, suh s neurpthy nd kidney disese, likely ffet bth the bne inerl density nd frture risk. Diffuse idipthi skeletl hyperstsis (DISH) is hr- terized by ssifitin f the nterir lngitudinl lig- ents f the spine nd vrius extrspinl ligents. It uses stiffness nd deresed rnge f spinl tin. The peripherl jints st nly ffeted re the etr- pphlngel jints, elbws, nd shulders. Dibetes, be- sity, hypertensin, nd dyslipidei re risk ftrs fr this nditin. Hyperuriei nd ute nd tpheus gut re re n in type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1242 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1243 CMDT 2022Bursitis,  prtiulrly f the shulders nd hips, urs re frequently thn expeted in ptients with dibetes.ASCEND Study Cllbrtive Gr up et l. Effets f spirin fr priry preventin in persns with dibetes ellitus. N Engl J Med. 2018;379:1529. [PMID: 30146931] Grennn D. Dibeti ft ulers. JAMA. 2019;321:114. [PMID: 30620372] Hinhliffe RJ et l; Interntinl Wrking Grup n the Dibeti Ft (IWGDF). Guidelines n dignsis, prgnsis, nd n- geent f peripherl rtery disese in ptients with ft ulers nd dibetes (IWGDF 2019 updte). Dibetes Metb Res Rev. 2020;36:e3276. [PMID: 31958217] Selvrjh D et l. Dibeti peripherl neurpthy: dvnes in dignsis nd strtegies fr sreening nd erly interventin. Lnet Dibetes Endrinl. 2019;7:938. [PMID: 31624024] Shen JI et l. Evidene fr nd ginst ACC/AHA 2017 guideline fr trget systli bld pressure f < 130  Hg in persns with type 2 dibetes. Curr Crdil Rep. 2019;21:149. [PMID: 31760494] »Special SituationsA.  Diabetes Management in the HospitalH spitlized ptients re generlly nt eting s usul nd they re ften fsting fr predures, whih kes it hl- lenging t use utptient rl r insulin regiens. There y be n inrese in the dverse retins f dibetes edi- ines (eg, thizlidinedines n use fluid retentin nd wrsen hert filure); etfrin shuld nt be used in ptients with signifint hrni kidney r liver disese r thse getting ntrst fr rdigrphi studies; nd SGLT2 inhibitrs y be ssited with inresed risk f dibeti ketidsis. The dt n the use f ntinuus gluse nitrs, insulin pups, nd hybrid lsed lp systes in hspitlized ptients re insuffiient. Whether ptients sty n these systes in the hspitl will depend n their severity f illness nd ess t speilist re. In generl, deisins regrding insulin dsing shuld be de bsed n pillry bld gluse esureents nd nt n the dt fr n- tinuus gluse nitrs. Ptients shuld be trnsitined t  nventinl bsl blus subutneus insulin regien if they re unble t nge their pup nd/r ntinuus gluse nitr beuse f their illness r if they refuse t fllw the institutinl guidelines n using the pup r ntinuus nitr (eg, giving theselves insulin bluses nd nt infring the linil stff). The systes hve t be reved if the ptient is getting n MRI. On the general medical and surgical inpatient ser- vices, st ptients re treted with subutneus insulin regiens. Liited rss-setinl nd prspetive studies suggest tht the best gluse ntrl is hieved n  - bintin f bsl nd blus regien with 50% f dily insulin needs prvided by interedite- r lng-ting insulins. Stndrdized rder sets n redue errrs, nd they ften inlude lgriths fr regnitin nd tret- ent f hypglyei (see http://usfinptientdibetes. pbwrks. fr exples). Orl ediines, espeilly etfrin nd sulfnylures, n be resued s the ptient is being prepred fr hspitl dishrge. In the intensive care units (ICUs), gluse levels re ntrlled st frequently using insulin infusins(http://usfinptientdibetes.pbwrks.). Ptients reeiv- ing ttl prenterl nutritin n hve insulin dded t the bg. Stndrd ttl prenterl nutritin ntins 25% dex- trse s n infusin rte f 50 L/h delivers 12.5 g f dextrse per hur. Bsed n the evidene vilble, ICU ptients with dibe- tes nd new-nset hyperglyei with bld gluse levels bve 180 g/dL (10 l/L) shuld be treted with insu- lin, iing fr trget gluse levels between 140 g/dL (7.8 l/L) nd 180 g/dL (10 l/L). In the ICU set- ting, iing fr bld gluse levels lse t 100 g/dL (5.6 l/L) is nt benefiil nd y even be hrful. When ptients leve the ICU, trget gluse vlues between 100 g/dL (5.6 l/L) nd 180 g/dL (10 l/L) y be pprprite, lthugh this view is bsed n linil bser- vtins rther thn nlusive evidene. Preoperative and perioperative diabetic management strtegies re disussed in Chpter 3. The rbidity nd rtlity in hspitlized dibeti ptients re twie thse f nndibeti ptients. Thse with new-nset hyperglyei (ie, thse withut  predis- sin dignsis f dibetes) hve even higher rtlity— lst eightfld tht f nndibeti ptients in ne study. These bservtins hve led t the questin f whether tight glyei ntrl in the hspitl iprves utes.B.  Pregnancy and the Diabetic PatientSee Chpt er 19. Tight glyei ntrl with nrl HbA1 levels is very iprtnt during pregnny. Erly in preg- nny, pr ntrl inreses the risk f spntneus br- tin nd ngenitl lfrtins. Lte in pregnny, pr ntrl n result in plyhydrnis, preter lbr, stillbirth, nd fetl rsi with its ssited prb- les. Dibetes plitins n ipt bth ternl nd fetl helth. Dibeti retinpthy n first develp during pregnny r retinpthy tht is lredy present n wrsen. Dibeti wen with irlbuinuri n hve wrsening lbuinuri during pregnny nd re t higher risk fr preelpsi. Lw-dse (81 g) spirin n redue the risk f preelpsi nd shuld be presribed fter 12 weeks f gesttin. Ptients wh hve preexisting kidney filure (prepregnny retinine lerne less thn 80 L/in) re t high risk fr further deline in kidney funtin during the pregnny, nd this y nt reverse fter delivery. Dibeti gstrpresis n severely exer- bte the nuse nd viting f pregnny nd se ptients y require fluid nd nutritinl supprt. Althugh there is evidene tht glyburide is sfe during pregnny, the urrent prtie is t ntrl dibetes with insulin therpy. Every effrt shuld be de, utilizing ul- tiple injetins f insulin r  ntinuus infusin f insu- lin by pup, t intin ner-nrliztin f fsting nd preprndil bld gluse vlues while viding hypglyei. Regulr nd NPH insulin nd the insulin nlgs lispr, sprt, nd deteir re lbeled pregnny tegry B. Insu- lin glrgine, glulisine, nd deglude re lbeled tegry C beuse f lk f linil sfety dt. A sll study using insulin glrgine in 32 pregnnies did nt revel ny prbles.CMDT22_Ch27_p1212-p1255.indd  1243 29/06/21 8:53 PMCHAPTEr 271244 CMDT 2022U nless there re fetl r ternl plitins, dibeti wen shuld be ble t rry the pregnny t full-ter, delivering t 38 t 41 weeks. Indutin f lbr befre 39 weeks y be nsidered if there is nern but inresing fetl weight. See Chpter 19 fr further detils.Aerin  Dibetes Assitin. Mngeent f dibetes in pregnny: Standards of Medical Care in Diabetes—2020 . Dibetes Cre. 2020;43:S183. [PMID: 31862757]DI ABETIC COMAC  y be due t uses nt diretly relted t dibetes. Dibeti  requires differentitin (Tble 27–10): (1) Hypglyei  fr exessive insulin r rl hyp- glyei gents. (2) Hyperglyei  with either severe insulin defiieny (DKA) r ild t derte insu- lin defiieny (hyperglyei hyperslr stte). (3) Lti idsis, prtiulrly when ptients with dibetes hve severe infetins r rdivsulr llpse.DI ABETIC KETOACIDOSISE S S E N T I A L S  O F  D I A G N O S I S »Hyperglycemia > than 250 mg/dL (13.9 mmol/L). »Metabolic acidosis with blood pH < 7.3; serum bicarbonate < 15 mEq/L. »Serum positive for ketones. »General ConsiderationsDibeti  ketidsis (DKA) is  disrder pririly in ptients with type 1 dibetes but n ur in ptients with type 2 dibetes wh hve severe illness, suh s sepsis r tru. DKA y be the initil nifesttin f type 1dibetes r y result fr inresed insulin requireents in type 1 dibetes ptients during the urse f infetin, tru, yrdil infrtin, r surgery. It is  life-thret- ening edil eergeny. The Ntinl Dt Grup reprts n nnul inidene f five t eight episdes f DKA per 1000 dibeti persns. DKA is ne f the re n serius plitins f insulin pup therpy, urring in pprxitely 1 per 80 ptient-nths f tretent. Mny ptients wh nitr pillry bld gluse regulrly ignre urine ketne esureents, whih signls the pssibility f insulin lekge r pup filure befre serius illness develps. Pr pline, either fr psyhlgil resns r beuse f indequte edutin, is ne f the st n uses f reurrent DKA. »Clinical FindingsA.  Symptoms and SignsThe  pperne f DKA is usully preeded by  dy r re f plyuri nd plydipsi ssited with rked ftigue, nuse, nd viting. If untreted, entl stupr ensues tht n prgress t . Drwsiness is firly n, but frnk  nly urs in but 10% f ptients. On physil exintin, evidene f dehydrtin in  stuprus ptient with rpid deep brething nd  “fruity” breth dr f etne strngly suggests the dignsis. Hyptensin with thy- rdi indites prfund fluid nd eletrlyte depletin, nd ild hyptheri is usully present. Abdinl pin nd even tenderness y be present in the bsene f bdinl disese. Cnversely, hleystitis r pnretitis y ur with inil sypts nd signs.B.  Laboratory FindingsT ypilly, the ptient with dertely severe DKA hs  pls gluse f 350–900 g/dL (19.4–50 l/L), seru ketnes t  dilutin f 1:8 r greter rTable 27–10. Laboratory diagnosis of coma in diabetic patients. Uine Glucose Uine Ketones Plasma Glucose Seum Bicabonate Seum Ketones related to Diabetes Hypoglycemia 010 or + Low Normal 0 Diabetic ketoacidosis ++++ ++++ High Low ++++ Hyperglycemic hyperosmolar state coma++++ 0 or + High Normal or slightly low 0 Lactic acidosis 0 or + 0 or + Normal or low or high Low 0 or + Unelated to Diabetes Alcohol or other toxic drugs 0 or + 0 or + May be low Normal or low20 or + Cerebrovascular accident or head trauma+ or 0 0 Often high Normal 0 Uremia 0 or + 0 High or normal Low 0 or +1 Leftover urine in bladder might still contain glucose from earlier hyperglycemia.2 Alcohol can elevate plasma lactate as well as keto acids to reduce pH.CMDT22_Ch27_p1212-p1255.indd  1244 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1245 CMDT 2022bet-hydr xybutyrte re thn 4 nl/L, hyperklei (seru ptssiu level f 5–8 Eq/L), ild hypntrei (seru sdiu f pprxitely 130 Eq/L), hyperphs- phtei (seru phsphte level f 6–7 g/dL [1.9–2.3 l/L]), nd elevted bld ure nitrgen nd seru retinine levels (Tble 27–10). Aidsis y be severe (pH rnging fr 6.9 t 7.2 nd seru birbnte rnging fr 5 Eq/L t 15 Eq/L); Pco2is lw (15–20  Hg) relted t penstry hyperventiltin. Fluid depletin is rked, typilly but 100 L/kg. In euglyei ketidsis, the ptient n hve severe id- sis nd fluid depletin but the pls gluse levels re nly destly elevted, usully less thn 250 g/dy (13.9 l/L). This nditin is seen in ptients in wh dibeti ketidsis develps while reeiving tretent with SGLT2 inhibitrs. Ketidsis with lwer gluse levels ls urs in pregnny nd y reflet the expnded pls vlue nd the inresed glerulr filtrtin rte. The differene between venus nd rteril pH is 0.02 t 0.15 pH units nd venus nd rteril birbnte is 1.88 Eq/L. These sll differenes will nt ffet either the dignsis r the ngeent f DKA, nd there is n need t llet rteril bld fr esuring the id-bse sttus. The hyperklei urs despite ttl bdy ptssiu depletin beuse f the shift f ptssiu fr the intr- ellulr t extrellulr spes tht urs in systei i- dsis. The verge ttl bdy ptssiu defiit resulting fr sti diuresis, idsis, nd gstrintestinl lsses is but 3–5 Eq/kg. Siilrly, despite the elevted seru phsphte, ttl bdy phsphte is generlly depleted. Seru sdiu is generlly redued due t lss f sdiu ins (7–10 Eq/kg) by plyuri nd viting nd beuse severe hyperglyei shifts intrellulr wter int the interstitil prtent. Fr every 100 g/dL f pls gluse, seru sdiu dereses by 1.6 Eq/L (5.56 l/L). The derese in seru sdiu y be greter when ptients hve re severe hyperglyei (greter thn 400 g/dL, 22.2 l/L) nd  rretin ftr f 2.4 Eq/L y be used. Hypertriglyeridei shuld be nsidered if the rreted sdiu is very lw. Seru sllity n be diretly esured by stndrd tests f freezing pint depressin r n be estited by lulting the lrity f sdiu, hlride, nd gluse in the seru. A nvenient ethd f estiting effetive seru sllity is s fllws (nrl vlues re 280–300 Os/kg): mOsm/kg  2 [measured Na ]Glucose (mg/dL) 18=  ++These lulted esti tes re usully 10–20 Os/kg lwer thn vlues esured by stndrd ryspi teh- niques. Centrl nervus syste depressin r  urs when the effetive seru sllity exeeds 320–330 Os/L. C in  dibeti ptient with  lwer sllity shuld prpt  serh fr the use f  ther thn hypersllity (see Tble 27–10 nd Chpter 24).Ketidei represents the effet f insulin lk t ultiple enzye li. Insulin lk ssited with elevted levels f grwth hrne, tehlines, nd glugn ntributes t inreses in liplysis fr dipse tissue nd in hepti ketgenesis. In dditin, redued ketlysis by insulin-defiient peripherl tissues ntributes t the ket- idei. The nly true “ket” id present in dibeti ketidsis is eteti id whih, lng with its by- prdut etne, is esured by nitrprusside regents (Aetest nd Ketstix). The sensitivity fr etne, hw- ever, is pr, requiring ver 10 l/L, whih is seld rehed in the pls f ketidti ptients—lthugh this detetble nentrtin is redily hieved in urine. Thus, in the pls f ketti ptients, nly etette is esured by these regents. The re prevlent bet- hydrxybutyri id hs n ketne grup nd is therefre nt deteted by nventinl nitrprusside tests. This tkes n speil iprtne in the presene f irultry l- lpse during DKA, wherein n inrese in lti id n shift the redx stte t inrese bet-hydrxybutyri id t the expense f the redily detetble eteti id. Bed- side dignsti regents re then unrelible, suggesting n ketnei in ses where bet-hydrxybutyri id is  jr ftr in prduing the idsis. Cbined gluse nd ketne eters (Preisin Xtr, Nv Mx Plus) tht esure bld bet-hydrxybutyrte nentr- tin n pillry bld re vilble. Mny linil lbrtries ls ffer diret bld bet-hydrxybutyrte esureent. Nnspeifi elevtins f seru ylse nd lipse urs in but 16–25% f ses f DKA, nd n iging study y be neessry if the dignsis f ute pnreti- tis is being seriusly nsidered. Leukytsis s high s 25,000/L (25 × 109/L) with  left shift y ur with r withut ssited infetin. The presene f n elevted r even  nrl teperture n suggest the presene f n infetin sine ptients with DKA re generlly hyp- theri if uninfeted. »TreatmentP tients with mild DKA re lert nd hve pH levels between 7.25 nd 7.30 nd bet-hydrxybutyrte levels f 3–4 l/L; thse with moderate ketoacidosis re either lert r  little drwsy nd hve pH levels between 7.0 nd 7.24 nd bet-hydrxybutyrte levels f 4–8 l/L; nd thse with severe ketoacidosis re stuprse nd hve  pH < 7.0 nd bet-hydrxybutyrte levels f greter thn 8 l/L. Ptients with ild ketidsis n be treted in the eergeny deprtent, but thse with derte r severe ketidsis require dissin t the ICU r step- dwn unit. Therpeuti gls re t restre pls vlue nd tissue perfusin, redue bld gluse nd sllity twrd nrl, rret idsis, replenish eletrlyte lsses, nd identify nd tret preipitting ftrs. Gstri intubtin is reended in the tse ptient t prevent viting nd spirtin tht y ur s  result f gstri tny,  n plitin f DKA. An indwelling urinry theter y ls be neessry. In ptients with preexisting hert r kidney filure r thse in severe rdivsulr llpse,  entrl venus pressureCMDT22_Ch27_p1212-p1255.indd  1245 29/06/21 8:53 PMCHAPTEr 271246 CMDT 2022the ter shuld be inserted t evlute the degree f hypvlei nd t nitr subsequent fluid dinistrtin. A prehensive flw sheet tht inludes vitl signs, seril lbrtry dt, nd therpeuti interventins (eg, fluids, insulin) shuld be etiulusly intined by the liniin respnsible fr the ptient’s re. Pls gluse shuld be rerded hurly nd eletrlytes nd pH t lest every 2–3 hurs during the initil tretent perid. Bed- side gluse eters shuld be used t titrte the insulin therpy. The ptient shuld nt reeive sedtives r piids in rder t vid sking signs nd sypts f ipeding erebrl ede.A.  Fluid ReplacementIn  st ptients, the fluid defiit is 4–5 L. Initilly, 0.9% sline slutin is the slutin f hie t help reexpnd the ntrted vsulr vlue nd shuld be strted in the eergeny deprtent s sn s the dignsis is estblished. The sline shuld be infused rpidly t prvide 1 L/h ver the first 1–2 hurs. After the first 2 L f fluid hve been given, the intrvenus infusin shuld be t the rte f 300–400 L/h. Use 0.9% (“nrl”) sline unless the seru sdiu is greter thn 150 Eq/L, when 0.45% (“hlf nrl”) sline slutin shuld be used. The vlue sttus shuld be refully nitred linilly. Filure t give enugh vlue repleent (t lest 3–4 L in 8 hurs) t restre nrl perfusin is ne f the st serius therpeuti shrtings dversely influening stisf- try revery. Exessive fluid repleent (re thn 5 L in 8 hurs) y ntribute t ute respirtry distress syndre r erebrl ede. When bld gluse flls t pprxitely 250 g/dL (13.9 l/L), the fluids shuld be hnged t  5% gluse-ntining slutin t in- tin seru gluse in the rnge f 250–300 g/dL (13.9–16.7 l/L). This will prevent the develpent f hypglyei nd will ls redue the likelihd f ere- brl ede, whih uld result fr t rpid deline f bld gluse.B.  Insulin ReplacementIedi tely fter inititin f fluid repleent, regulr insulin n be given intrvenusly in  lding dse f 0.1 unit/kg s  blus t prie the tissue insulin reeptrs. Fllwing the initil blus, intrvenus dses f insulin s lw s 0.1 unit/kg/h re ntinuusly infused r given hurly s n intrusulr injetin; this is suffiient t reple the insulin defiit in st ptients. A prspetive rndized study shwed tht  blus dse is nt required if ptients re given hurly insulin infusin t 0.14 unit/kg. Repleent f insulin defiieny helps rret the id- sis by reduing the flux f ftty ids t the liver, reduing ketne prdutin by the liver, nd ls iprving revl f ketnes fr the bld. Insulin tretent redues the hypersllity by reduing the hyperglyei. It - plishes this by inresing revl f gluse thrugh peripherl utiliztin s well s by deresing prdutin f gluse by the liver. This ltter effet is plished by diret inhibitin f glunegenesis nd glygenlysis swell s by lwered in id flux fr usle t liver nd redued hyperglugnei. The insulin infusin shuld be “piggy-bked” int the fluid line s the rte f fluid repleent n be hnged withut ltering the insulin delivery rte. If the pls gluse level fils t fll t lest 10% in the first hur,  repet lding dse (0.1 r 0.14 unit/kg) is reended. Rrely,  ptient with iune insulin resistne is enun- tered, nd this requires dubling the insulin dse every 2–4 hurs if hyperglyei des nt iprve fter the first tw dses f insulin. The insulin dse shuld be djusted t lwer the gluse nentrtin by but 50–70 g/dL/h (2.8–3.9 l/L). If linil irustnes prevent use f n insulin infusin, then the insulin n be given intrus- ulrly. An initil 0.15 unit/kg f regulr insulin is given intrvenusly, nd t the se tie, the se size dse is given intrusulrly. Subsequently, regulr insulin is given intrusulrly hurly t  dse f 0.1 unit/kg until the bld gluse flls t rund 250 g/dL, when the insulin n be given subutneusly. Ptients wh nrlly tke insulin glrgine r insulin deteir n be given their usul intenne dses during the initil tretent f their DKA. The ntinutin f their subutneus bsl insulins ens tht lwer dses f intrvenus insulin will be needed, nd there will be  sther trnsitin fr intr- venus insulin infusin t the subutneus regien.C.  PotassiumT tl bdy ptssiu lss fr plyuri nd viting y be s high s 200 Eq. Hwever, beuse f shifts f pts- siu fr ells int the extrellulr spe s  nse- quene f idsis, seru ptssiu is usully nrl t slightly elevted prir t institutin f tretent. As the idsis is rreted, ptssiu flws bk int the ells, nd hypklei n develp if ptssiu repleent is nt instituted. If the ptient is nt urei nd hs n de- qute urinry utput, ptssiu hlride in dses f 10–30 Eq/h shuld be infused during the send nd third hurs fter beginning therpy s sn s the idsis strts t reslve. Repleent shuld be strted sner if the initil seru ptssiu is inpprpritely nrl r lw nd shuld be delyed if seru ptssiu fils t respnd t initil therpy nd reins bve 5 Eq/L, s in ses f hrni kidney disese. Osinlly,  ptient y present with  seru ptssiu level less thn 3.5 Eq/L, in whih se insulin therpy shuld be delyed until the ptssiu level is rreted t greter thn 3.5 Eq/L. An ECG n help nitr the ptient’s pts- siu sttus: High peked T wves re  sign f hyperkle- i, nd flttened T wves with U wves re  sign f hypklei. Fds high in ptssiu ntent shuld be presribed when the ptient hs revered suffiiently t tke fd rlly. Tt juie hs 14 Eq f ptssiu per 240 L, nd  ediu-sized bnn prvides but 10 Eq.D . Sodium BicarbonateThe  use f sdiu birbnte in the ngeent f DKA hs been questined sine linil benefit ws ntCMDT22_Ch27_p1212-p1255.indd  1246 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1247 CMDT 2022denstr ted in ne prspetive rndized tril nd beuse f the fllwing ptentilly hrful nsequenes: (1) develpent f hypklei fr rpid shift f pts- siu int ells if the idsis is verrreted; (2) tissue nxi fr redued dissitin f xygen fr he- glbin when idsis is rpidly reversed (leftwrd shift f the xygen dissitin urve); nd (3) erebrl idsis resulting fr lwering f erebrspinl fluid pH. It ust be ephsized, hwever, tht these nsidertins re less iprtnt when very severe idsis exists. Therefre, it is reended tht birbnte be dinistered in DKA if the rteril bld pH is 7.0 r less, with reful nitring t prevent verrretin. One r tw pules f sdiu birbnte (ne pule ntins 44 Eq/50 L) shuld be dded t 1 L f 0.45% sline with 20 Eq KCl r t 400 L f sterile wter with 20 Eq KCl nd infused ver 1 t 2 hurs. ( Note: Additin f sdiu birbnte t 0.9% sline wuld prdue  rkedly hypertni slutin tht uld ggrvte the hyperslr stte lredy pres- ent.) It n be repeted until the rteril pH rehes 7.1, but it should not be given if the pH is 7.1 or greater sine ddi- tinl birbnte wuld inrese the risk f rebund etbli lklsis s ketnes re etblized. Alklsis shifts ptssiu fr seru int ells, whih uld pre- ipitte  ftl rdi rrhythi.E.  PhosphatePh sphte repleent is seld required in treting DKA. Hwever, if severe hypphsphtei f less thn 1 g/dL (0.32 l/L) develps during insulin therpy,  sll unt f phsphte n be repled per hur s the pts- siu slt. Three rndized studies, thugh, in whih phsphte ws repled in ptients with DKA did nt shw ny pprent linil benefit fr phsphte dinistr- tin. Mrever, ttepts t use ptssiu phsphte s the sle ens f repling ptssiu hve led t  nuber f reprted ses f severe hyplei with tetny. T ini- ize the risk f induing tetny fr t-rpid repleent f phsphte, the verge defiit f 40–50 l f phs- phte shuld be repled intrvenusly t  rte no greater than 3–4 mmol/h in  60- t 70-kg persn. A stk slutin (Abbtt) prvides  ixture f 1.12 g KH2PO4nd 1.18 g K2HPO4in  5-L single-dse vil (this equls 22 l f ptssiu nd 15 l f phsphte). One-hlf f this vil (2.5 L) shuld be dded t 1 L f either 0.45% sline r 5% dextrse in wter. Tw liters f this slutin, infused t  rte f 400 L/h, will rret the phsphte defiit t the ptil rte f 3 l/h while prviding 4.4 Eq f ptssiu per hur. (Additinl ptssiu shuld be dinistered s ptssiu hlride t prvide  ttl f 10–30 Eq f pts- siu per hur, s nted bve.) If the seru phsphte reins belw 2.5 g/dL (0.8 l/L) fter this infusin,  repet 5-hur infusin n be given.F . Hyperchloremic Acidosis During TherapyBeuse  f the nsiderble lss f ket ids in the urine during the initil phse f therpy, substrte fr subsequent regenertin f birbnte is lst nd rretin f the ttl birbnte defiit is hpered. A prtin f thebirbnte defiit is repled with hlride ins infused in lrge unts s sline t rret the dehydrtin. In st ptients, s the ketidsis lers during insulin reple- ent,  hyperhlrei, lw-birbnte pttern eerges with  nrl nin gp. This is  reltively benign ndi- tin tht reverses itself ver the subsequent 12–24 hurs ne intrvenus sline is n lnger being dinistered. Using  blned eletrlyte slutin with  pH f 7.4 nd 98 Eq/L hlride suh s Pls-lyte insted f nrl sline (pH ~5.5; hlride 154 Eq/L) hs been reprted t prevent the hyperhlrei idsis.G.  Treatment of Associated InfectionAntibi tis re presribed s indited (Tble 30–5). Ch- leystitis nd pyelnephritis y be prtiulrly severe in these ptients.H.  Transition to Subcutaneous Insulin RegimenOn e the DKA is ntrlled nd the ptient is wke nd ble t et, subutneus insulin therpy n be initited. The ptient with type 1 dibetes y hve persistent signifi- nt tissue insulin resistne nd y require  ttl dily insulin dse f pprxitely 0.6 unit/kg. The unt f insulin required in the previus 8 hurs n ls be helpful in estiting the initil insulin dses. Hlf the ttl dily dse n be given s  lng-ting bsl insulin nd the ther hlf s shrt-ting insulin preels. The ptient shuld reeive subutneus bsl insulin nd rpid-ting insulin nlg with the first el nd the insulin infusin disntin- ued n hur lter. The verlp f the subutneus insulin tin nd insulin infusin is neessry t prevent relpse f the DKA. In ptients with preexisting dibetes, giving their bsl insulin by subutneus injetin t inititin f tret- ent siplifies the trnsitin fr intrvenus t subut- neus regien. The inresed insulin resistne is nly present fr  few dys, nd it is iprtnt t redue bth the bsl nd blus insulins t vid hypglyei. A ptient with new-nset type 1 dibetes usully still hs signifint bet ell funtin nd y nt need ny bsl insulin nd nly very lw dses f rpid-ting insulin befre els fter revery fr the ketidsis. Ptients with type 2 dibetes nd DKA due t severe illness y initilly require insulin therpy but n ften trnsitin bk t rl gents during utptient fllw-up. »Complications & PrognosisLw- dse insulin infusin nd fluid nd eletrlyte repleent bined with reful nitring f ptients’ linil nd lbrtry respnses t therpy hve drti- lly redued the rtlity rtes f DKA t less thn 5% in individuls under 40 yers f ge. Hwever, this pli- tin reins  signifint risk in the ged wh hve r- tlity rtes greter thn 20% nd in ptients in prfund  in wh tretent hs been delyed. Aute yr- dil infrtin nd infrtin f the bwel fllwing pr- lnged hyptensin wrsen the utlk. A serius prgnsti sign is end-stge hrni kidney disese, nd prir kidney dysfuntin wrsens the prgnsis nsider- bly beuse the kidney plys  key rle in penstingCMDT22_Ch27_p1212-p1255.indd  1247 29/06/21 8:53 PMCHAPTEr 271248 CMDT 2022f r ssive pH nd eletrlyte bnrlities. Syptti erebrl ede urs pririly in the peditri ppultin. Risk ftrs fr its develpent inlude severe bseline i- dsis, rpid rretin f hyperglyei, nd exess vlue dinistrtin in the first 4 hurs. Onset f hedhe r deterirtin in entl sttus during tretent shuld led t nsidertin f this plitin. Intrvenus nnitl t  dsge f 1–2 g/kg given ver 15 inutes is the insty f tretent. Exess rystllid infusin n preipitte pul- nry ede. Aute respirtry distress syndre is  rre plitin f tretent f DKA. After revery nd stbiliztin, ptients shuld be instruted n hw t regnize the erly sypts nd signs f ketidsis. Urine ketnes r pillry bld bet-hydrxybutyrte shuld be esured in ptients with signs f infetin r in insulin pup-treted ptients when pillry bld gluse reins unexpetedly nd persis- tently high. When hevy ketnuri nd glysuri persist n severl suessive exintins, suppleentl rpid- ting insulin shuld be dinistered nd liquid fds suh s lightly slted tt juie nd brth shuld be ingested t replenish fluids nd eletrlytes. The ptient shuld be instruted t ntt the liniin if ketnuri persists, nd espeilly if there is viting nd inbility t keep dwn fluids. Reurrent episdes f severe ketid- sis ften indite pr pline with the insulin regi- en, nd these ptients will require intensive unseling.F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Isl T et l. Guidelines nd ntrversies in the ngeent f dibeti ketidsis— ini-review. Wrld J Dibetes. 2018;9:226. [PMID: 30588284] Krsliglu Frenh E et l. Dibeti ketidsis nd hypers- lr hyperglyei syndre: review f ute depensted dibetes in dult ptients. BMJ. 2019;365:l114. [PMID: 31142480] Mdi A et l. Euglyei dibeti letidsis:  review. Curr Dibetes Rev. 2017;13:315. [PMID: 27097605]HYP ERGLYCEMIC HYPEROSMOLAR STATEE S S E N T I A L S  O F  D I A G N O S I S »Hyperglycemia > 600 mg/dL (33.3 mmol/L). »Serum osmolality > 310 mOsm/kg. »No acidosis; blood pH > 7.3. »Serum bicarbonate > 15 mEq/L. »Normal anion gap (< 14 mEq/L). »General ConsiderationsTh is send st n fr f hyperglyei  is hrterized by severe hyperglyei in the bsene f sig- nifint ketsis, with hypersllity nd dehydrtin. It urs in ptients with ild r ult dibetes, nd stptients re typilly iddle-ged t elderly. Aurte figures re nt vilble s t its true inidene, but fr dt n hspitl dishrges it is rrer thn DKA even in lder ge grups. Underlying hrni kidney disese r hert filure is n, nd the presene f either wrsens the prgnsis. A preipitting event suh s infetin, yrdil infrtin, strke, r reent pertin is ften present. Certin edi- tins suh s phenytin, dizxide, rtisterids, nd diuret- is hve been iplited in its pthgenesis, s hve predures ssited with gluse lding suh s peritnel dilysis. »PathogenesisA prtil  r reltive insulin defiieny y initite the syn- dre by reduing gluse utiliztin f usle, ft, nd liver while induing hyperglugnei nd inresing hepti gluse utput. With ssive glysuri, bligtry wter lss ensues. If  ptient is unble t intin dequte fluid intke beuse f n ssited ute r hrni illness r hs suffered exessive fluid lss, rked dehydrtin results. As the pls vlue ntrts, kidney funtin bees ipired, liiting the urinry gluse lsses nd exerbting the hyperglyei. Severe hypersllity develps tht uses entl nfusin nd finlly . It is nt ler why ketsis is virtully bsent under these ndi- tins f insulin insuffiieny, lthugh redued levels f grwth hrne y be  ftr, lng with prtl vein insulin nentrtins suffiient t restrin ketgenesis. »Clinical FindingsA.  Symptoms and SignsOnset  y be insidius ver  perid f dys r weeks, with wekness, plyuri, nd plydipsi. The lk f fe- tures f DKA (eg, viting, rpid deep brething, etne dr) y retrd regnitin f the syndre nd dely therpy until dehydrtin bees re prfund thn in ketidsis. Redued intke f fluid is nt n unn histril feture, due t either inpprprite lk f thirst, nuse, r inessibility f fluids t elderly, bedridden ptients. A histry f ingestin f lrge quntities f gluse-ntining fluids, suh s sft drinks r rnge juie, n sinlly be btined. Lethrgy nd nfu- sin develp s seru sllity exeeds 310 Os/kg, nd nvulsins nd  n ur if sllity exeeds 320–330 Os/kg. Physil exintin nfirs the presene f prfund dehydrtin in  lethrgi r - tse ptient withut Kussul respirtins.B.  Laboratory FindingsSevere h yperglyei is present, with bld gluse vlues rnging fr 800 g/dL t 2400 g/dL (44.4 l/L t 133.2 l/L) (Tble 27–10). In ild ses, where dehy- drtin is less severe, dilutinl hypntrei s well s urinry sdiu lsses y redue seru sdiu t 120–125 Eq/L, whih prtets t se extent ginst extree hypersllity. Hwever, s dehydrtin pr- gresses, seru sdiu n exeed 140 Eq/L, prduing seru sllity redings f 330–440 Os/kg. Ketsis nd idsis re usully bsent r ild. Prerenl zteiCMDT22_Ch27_p1212-p1255.indd  1248 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1249 CMDT 2022is  the rule, with seru ure nitrgen elevtins ver 100 g/dL (35.7 l/L) being typil. »TreatmentA.  Fluid ReplacementFluid  repleent is f prunt iprtne in treting the nnketti hyperglyei stte. Fluid defiit y be s uh s 6–10 L. If hypvlei is present s evidened by hyptensin nd liguri, fluid therpy shuld be initited with 0.9% sline. In ll ther ses, 0.45% sline ppers t be prefer- ble s the initil repleent slutin beuse the bdy flu- ids f these ptients re rkedly hyperslr. As uh s 4–6 L f fluid y be required in the first 8–10 hurs. Cre- ful nitring f the ptient is required fr prper sdiu nd wter repleent. An iprtnt end pint f fluid therpy is t restre urinry utput t 50 L/h r re. One bld gluse rehes 250 g/dL (13.9 l/L), fluid repleent shuld inlude 5% dextrse in either wter, 0.45% sline slutin, r 0.9% sline slutin. The rte f dextrse infusin shuld be djusted t intin glyei levels f 250–300 g/dL (13.9–16.7 l/L) in rder t redue the risk f erebrl ede.B.  InsulinLess  insulin y be required t redue the hyperglyei in nnketti ptients s pred t thse with dibeti ket- idti . In ft, fluid repleent lne n redue hyperglyei nsiderbly by rreting the hypvlei, whih then inreses bth glerulr filtrtin nd renl exretin f gluse. Insulin tretent shuld therefre be delyed unless the ptient hs signifint ketnei (bet- hydrxybutyrte re thn 1 l/L). Strt the insulin infusin rte t 0.05 unit/kg/h (blus is nt needed) nd titrte t lwer bld gluse levels by 50–70 g/dL per hur (2.8–3.9 l/L/h). One the ptient hs stbilized nd the bld gluse flls t rund 250 g/dL (13.9 l/L), insulin n be given subutneusly.C.  PotassiumW ith the bsene f idsis, there y be n initil hyper- klei unless ssited end-stge hrni kidney disese is present. This results in less severe ttl ptssiu deple- tin thn in DKA, nd less ptssiu repleent is there- fre needed. Hwever, beuse initil seru ptssiu is usully nt elevted nd beuse it delines rpidly s  result f insulin’s effet n driving ptssiu intrellulrly, it is reended tht ptssiu repleent be initited erlier thn in ketti ptients, ssuing tht n hrni kidney disese r liguri is present. Ptssiu hlride (10 Eq/L) n be dded t the initil bttle f fluids din- istered if the ptient’s seru ptssiu is nt elevted.D . PhosphateIf  severe hypphsphtei (seru phsphte less thn 1 g/dL [0.32 l/L]) develps during insulin therpy, phsphte repleent n be given s desribed fr ket- idti ptients (t 3 l/h).»Complications & PrognosisThe  severe dehydrtin nd lw utput stte y predis- pse the ptient t plitins suh s yrdil infrtin, strke, pulnry eblis, esenteri vein thrbsis, nd disseinted intrvsulr gultin. Fluid repleent reins the priry pprh t the preventin f these plitins. Lw-dse heprin pr- phylxis is resnble but benefits f rutine ntigul- tin rein dubtful. Rhbdylysis is  regnized plitin nd shuld be lked fr nd treted. The verll rtlity rte f hyperglyei hypers- lr stte  is re thn ten ties tht f DKA, hiefly beuse f its higher inidene in lder ptients, wh y hve prised rdivsulr systes r ssited jr illnesses nd whse dehydrtin is ften exessive beuse f delys in regnitin nd tretent. (When ptients re thed fr ge, the prgnses f these tw hyperglyei eergenies re resnbly pr- ble.) When prpt therpy is instituted, the rtlity rte n be redued fr nerly 50% t tht relted t the severity f existent disrders. After the ptient is stbilized, the pprprite fr f lng-ter ngeent f the dibetes ust be deter- ined. Insulin tretent shuld be ntinued fr  few weeks but ptients usully rever suffiient endgenus insulin seretin t ke  tril f diet r diet plus rl gents wrthwhile. When the episde urs in  ptient wh hs knwn dibetes, then edutin f the ptient nd regivers shuld be instituted. They shuld be tught hw t regnize situtins (nuse nd viting, infetin) tht predispse t reurrene f the hyperglyei, hyper- slr stte, s well s detiled infrtin n hw t prevent the eslting dehydrtin tht ulintes in hyperslr  (sll sips f sugr-free liquids, inrese in usul hypglyei therpy, r erly ntt with the liniin).F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Stt AR; Jint British Dibetes Sieties (JBDS) fr Inptient Cre; JBDS hyperslr hyperglyei guidelines grup. Mngeent f hyperslr hyperglyei stte in dults with dibetes. Dibet Med. 2015;32:714. [PMID: 25980647]LAC TIC ACIDOSISE S S E N T I A L S  O F  D I A G N O S I S »Severe metabolic acidosis with compensatory hyperventilation. »Blood pH < 7.30. »Serum bicarbonate < 15 mEq/L. »Anion gap > 15 mEq/L. »Absent serum ketones. »Serum lactate > 5 mmol/L.CMDT22_Ch27_p1212-p1255.indd  1249 29/06/21 8:53 PMCHAPTEr 271250 CMDT 2022 »General ConsiderationsL ti idsis is hrterized by uultin f exess lti id in the bld. Nrlly, the prinipl sures f this id re the erythrytes (whih lk enzyes fr erbi xidtin), skeletl usle, skin, nd brin. Cn- versin f lti id t gluse nd its xidtin prini- plly by the liver but ls by the kidneys represent the hief pthwys fr its revl. Hyperlttei nd i- dsis ur when ltte prdutin exeeds ltte n- suptin. Cuses inlude tissue hypxi (glbl r ll), disrders tht inrese epinephrine levels (severe sth with exess bet-drenergi gnist use, rdigeni r herrhgi shk, phehryt), nd drugs tht ipir xidtive phsphryltin (ntiretrvirl gents nd prpfl). Mst ses f etfrin-ssited lti idsis ur in ptients in wh there were ntrindi- tins t the use f etfrin, in prtiulr kidney filure. Metfrin levels re usully greter thn 5 g/L when etfrin is iplited s the use f lti id- sis. Other uses f lti idsis inlude severl inbrn errrs f etblis nd the MELAS syndre (it- hndril enephlpthy, lti idsis, nd strke-like episdes). D-lti idsis n ur in ptients with shrt bwel syndre when unbsrbed rbhydrtes re presented s substrte fr ferenttin by lni bteri. »Clinical FindingsA.  Symptoms and SignsThe  in linil feture f lti idsis is rked hyperventiltin. When lti idsis is sendry t tissue hypxi r vsulr llpse, the linil present- tin is vrible, being tht f the previling tstrphi illness. Hwever, in the idipthi, r spntneus, vri- ety, the nset is rpid (usully ver  few hurs), bld pressure is nrl, peripherl irultin is gd, nd there is n ynsis.B.  Laboratory FindingsPl s birbnte nd bld pH re quite lw, indit- ing the presene f severe etbli idsis. Ketnes re usully bsent fr pls nd urine r t lest nt prinent. The first lue y be  high nin gp (seru sdiu inus the su f hlride nd birbn- te nins [in Eq/L] shuld be n greter thn 15). A higher vlue indites the existene f n bnrl - prtent f nins. If this nnt be linilly explined by n exess f ket ids (dibetes), inrgni ids (urei), r nins fr editin verdsge (sliy- ltes, ethyl lhl, ethylene glyl), then lti id- sis is prbbly the rret dignsis. (See ls Chpter 21.) In the bsene f ztei, hyperphsphtei y be  lue t the presene f lti idsis fr resns tht re nt ler. The dignsis is nfired by  pls lti id nentrtin f 5 l/L r higher (vlues s high s 30 l/L hve been reprted). Nrl pls vl- ues verge 1 l/L, with  nrl ltte/pyruvterti f 10:1. This rti is gretly exeeded in lti idsis.1 »TreatmentAggressiv e tretent f the preipitting use f lti idsis is the in pnent f therpy, suh s ensur- ing dequte xygentin nd vsulr perfusin f tissues. Epiri ntibiti verge fr sepsis shuld be given fter ulture sples re btined in ny ptient in wh the use f the lti idsis is nt pprent (Tble 30–5). Alkliniztin with intrvenus sdiu birbnte t keep the pH bve 7.2 hs been reended by se in the eergeny tretent f lti idsis; s uh s 2000 Eq in 24 hurs hs been used. Hwever, there is n evidene tht the rtlity rte is fvrbly ffeted by dinistering birbnte, nd its use reins ntrver- sil. Hedilysis y be useful in ses where lrge sdiu lds re prly tlerted nd in ses ssited with etfrin txiity. »PrognosisThe  rtlity rte f spntneus lti idsis is high. The prgnsis in st ses is tht f the priry disrder tht prdued the lti idsis.DeFr nz R et l. Metfrin-ssited lti idsis: urrent perspetives n uses nd risk. Metblis. 2016;65:20. [PMID: 26773926] ºTHE HYPOGLYCEMIC STATESSpn tneus hypglyei in dults is f tw prinipl types: fsting nd pstprndil. Sypts begin t pls gluse levels in the rnge f 60 g/dL (3.3 l/L) nd ipirent f brin funtin t pprxitely 50 g/dL (2.8 l/L). Fsting hypglyei is ften subute r hrni nd usully presents with neurglypeni s its prinipl nifesttin; pstprndil hypglyei is rel- tively ute nd is ften herlded by sypts f neur- geni utni dishrge (sweting, plpittins, nxiety, treulusness). »Differential Diagnosis (Table 27–11)Fstin g hypglyei y ur in ertin endrine dis- rders, suh s hyppituitris, Addisn disese, r yx- ede; in disrders relted t liver lfuntin, suh s ute lhlis r liver filure; nd in instnes f end- stge hrni kidney disese, prtiulrly in ptients requiring dilysis. These nditins re usully bvius, with hypglyei being nly  sendry feture. When fsting hypglyei is  priry nifesttin develp- ing in dults withut pprent endrine disrders r inbrn etbli diseses fr hildhd, the prinipl1 In lleting sples, it is essentil t rpidly hill nd seprte the bld in rder t reve red ells, whse ntinued glylysis t r teperture is  n sure f errr in reprts f high pls ltte. Frzen pls reins stble fr subsequent ssy.CMDT22_Ch27_p1212-p1255.indd  1250 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1251 CMDT 2022dignsti pssibili ties inlude (1) hyperinsulinis, due t either pnreti B ell turs, itrgeni r surreptitius dinistrtin f insulin r sulfnylure; nd (2) hypgly- ei due t extrpnreti turs. Pstprndil (retive) hypglyei y ur fter gstrintestinl surgery nd is prtiulrly ssited with the duping syndre fter gstrety nd Rux-en-Y gstri bypss surgery. Oult dibetes very sinlly presents with pstprndil hypglyei. Rrely, it urs with islet ell hyperplsi—the s-lled nninsulin pnretgenus hypglyei syndre. Alhl-relted hypglyei is due t hepti gly- gen depletin bined with lhl-edited inhibitin f glunegenesis. It is st n in lnurished individuls with exessive lhl intke but n ur in nyne wh is unble t ingest fd fter n ute lhli episde fllwed by gstritis nd viting. Iunpthlgi hypglyei is n extreely rre nditin in whih nti-insulin ntibdies r ntibdies t insulin reeptrs develp spntneusly.HYP OGLYCEMIA DUE TO PANCREATIC B CELL TUMORSE S S E N T I A L S  O F  D I A G N O S I S »Hypoglycemic symptoms—often neuroglycopenic (confusion, blurred vision, anxiety, convulsions). »Immediate recovery upon administration of glucose. »Blood glucose < 45 mg/dL (2.5 mmol/L) with a serum insulin level of ≥ 6 microunits/mL. »General ConsiderationsFsting  hypglyei in n therwise helthy, well- nurished dult is rre nd is st nly due t nden f the islets f Lngerhns. Ninety perent f suh turs re single nd benign, but ultiple dens n ur s well s lignnt turs with funtinl etstses. Adens y be filil, nd ultiple de- ns hve been fund in njuntin with turs f the prthyrids nd pituitry (MEN type 1 [MEN 1]). Abut 30% f sprdi insulin turs hve  sti ut- tin in the YY1 gene (T372R) tht endes the trnsrip- tinl repressr YY1. Over 99% f insulins re lted within the pnres nd less thn 1% in etpi pnreti tissue. »Clinical FindingsA.  Symptoms and SignsThe st ip rtnt prerequisite t dignsing n insulin-  is siply t nsider it, prtiulrly in reltively helthy-ppering persns wh hve fsting hypglyei ssited with se degree f entrl nervus syste dysfuntin suh s nfusin r bnrl behvir. A dely in dignsis n result in unneessry tretent fr psyhtr epilepsy r psyhitri disrders nd y use irreversible brin dge. In lng-stnding ses, besity n result s  nsequene f vereting t relieve sypts. The s-lled Whipple trid is hrteristi f hyp- glyei regrdless f the use. It nsists f (1)  histry f hypglyei sypts, (2) n ssited lw pls gluse level (40–50 g/dL), nd (3) relief f sypts upn ingesting fst-ting rbhydrtes in pprxitely 15 inutes. The hypglyei sypts in insulin ften develp in the erly rning r fter issing  el. Osinlly, they ur fter exerise. Ptients typilly plin f neurglypeni syp- ts suh s blurred visin r diplpi, hedhe, feelings f dethent, slurred speeh, nd wekness. Persnlity nd entl hnges vry fr nxiety t psyhti behv- ir, nd neurlgi deterirtin n result in nvulsins r . Hypglyei unwreness is very n nd drenergi sypts f plpittins nd sweting y be blunted. With the redy vilbility f he bld gluse– nitring systes, ptients seties present with d- uented fingerstik bld gluse levels in 40s nd 50s t tie f sypts. Aess t sulfnylures r insulin shuld be explred—des  fily eber hve dibetes, r des the ptient r fily eber wrk in the edil field? Meditin-dispensing errrs shuld be exluded—hs the ptient’s presriptin editin hnged in shpe r lr? Ptients with insulin r ftitius hypglyei usully hve  nrl physil exintin.B.  Laboratory FindingsB  ell dens d nt redue seretin f insulin in the presene f hypglyei, nd the ritil dignsti test is t denstrte inpprpritely elevted seru insulin, prinsulin, nd C-peptide levels, t  tie when pls gluse level is belw 45 g/dL. The dignsti riteri fr insulin fter  72-hur fst re listed in Tble 27–12. Other uses f hyperinsulin- ei hypglyei inlude ftitius dinistrtin fTable 27–11. Common causes of hypoglycemia in adults.1F asting hypoglycemia Pancreatic B cell tumor Surreptitious administration of insulin or sulfonylureas Extrapancreatic tumors Postpandial hypoglycemia Gastric surgery Occult diabetes mellitus Alcohol-elated hypoglycemia Immunopathologic hypoglycemia Idiopathic anti-insulin antibodies (which release their bound insulin) Antibodies to insulin receptors (which act as agonists) Dug-induced hypoglycemia1 In the absence of clinically obvious endocrine, kidney, or liver disorders and exclusive of diabetes mellitus treated with hypogly- cemic agents.CMDT22_Ch27_p1212-p1255.indd  1251 29/06/21 8:53 PMCHAPTEr 271252 CMDT 2022insulin  r sulfnylures. Ftitius use f insulin will result in suppressin f endgenus insulin seretin nd lw C-peptide levels. In ptients wh hve injeted insulin, the insulin/C-peptide rti (pl/L) will be greter thn 1. An elevted irulting prinsulin level in the presene f fst- ing hypglyei is hrteristi f st B ell dens nd des nt ur in ftitius hyperinsulinis. Thus, C-peptide levels (by iunheiluinetri ssys [ICMA]) f greter thn 200 pl/L nd prin- sulin levels (by rdiiunssy [RIA]) f greter thn 5 pl/L re hrteristi f insulins. In ptients with insulin, pls bet-hydrxybutyrte levels re suppressed t 2.7 l/L r less. N single hrne esureent (insulin, prinsulin, C-peptide) is 100% sensitive nd speifi fr the dignsis f insulin, nd insulin ses hve been reprted with insulin lev- els belw 3 irunits/L (ICMA ssy) r prinsulin level belw 5 pl/L. These hrnl ssys re ls nt stndrdized, nd there n be signifint vritin in the test results. Therefre, the dignsis shuld be bsed n ultiple biheil preters. In ptients with epigstri distress,  histry f renl luli, r enstrul r eretile dysfuntin,  seru l- iu, gstrin, r prltin level y be useful in sreening fr MEN 1 ssited with insulin.C.  Diagnostic TestsIf  the histry is nsistent with episdi spntneus hyp- glyei, ptients shuld be given  he bld gluse nitr nd dvised t nitr bld gluse levels t the tie f sypts nd befre nsuptin f rbhy- drtes, if this n be dne sfely. Ptients with insulins frequently reprt fingerstik bld gluse levels between 40 g/dL (2.2 l/L) nd 50 g/dL (2.8 l/L) t the tie f sypts. The dignsis, hwever, nnt be de bsed n  fingerstik bld gluse. It is neessry t hve  lw lbrtry gluse nitntly with ele- vted pls insulin, prinsulin, nd C-peptide levels nd  negtive sulfnylure sreen. When ptients give  his- try f sypts fter nly  shrt perid f fd with- drwl r with exerise, then n utptient ssessent nbe ttepted. The ptient shuld be brught by  fily eber t the ffie fter n vernight fst nd bserved in the ffie. Ativity suh s wlking shuld be enur- ged nd fingerstik bld gluse esured repetedly during bservtin. If sypts ur r fingerstik bld gluse is belw 50 g/dL (2.8 l/L), then sples fr pls gluse, insulin, C-peptide, prinsulin, sulfnyl- ure sreen, seru ketnes, nd ntibdies t insulin shuld be sent. If utptient bservtin des nt result in sypts r hypglyei nd if the linil suspiin reins high, then the ptient shuld underg n inptient supervised 72-hur fst. A suggested prtl fr the supervised fst is shwn in Tble 27–13. In 30% f ptients with insulin, the bld gluse levels ften drp belw 45 g/dL (2.5 l/L) fter n vernight fst, but se ptients require up t 72 hurs t develp syptti hypglyei. Hwever, the ter “72-hur fst” is tully  isner in st ses sine the fst shuld be ieditely terinted s sn s sypts pper nd lbrtry nfirtin f hypgly- ei is vilble. In nrl le subjets, the bld glu- se des nt fll belw 55–60 g/dL (3.1–3.3 l/L) during  3-dy fst. In ntrst, in nrl preenpusl wen, the pls gluse n reh vlues s lw s 35 g/dL (1.9 l/L). In these ses, hwever, the wen re nt syptti, presubly wing t the develpent f suffiient ketnei t supply energy needs t the brin. Insulin ptients, n the ther hnd,Table 27–12. Diagnostic criteria for insulinoma after a 72-hour fast.Laboatoy  Test result Plasma glucose < 45 mg/dL (2.5 mmol/L) Plasma insulin (RIA) ≥ 6 microunits/mL (36 pmol/L) Plasma insulin (ICMA) ≥ 3 microunits/mL (18 pmol/L) Plasma C-peptide ≥ 200 pmol/L (0.2 nmol/L, 0.6 ng/mL) Plasma proinsulin ≥ 5 pmol/L Beta-hydroxybutyrate ≤ 2.7 mmol/L Sulfonylurea screen (including repaglinide and nateglinide)Negative ICMA, immunochemiluminometric assays; RIA, radioimmunoassay.T able 27–13. Suggested hospital protocol for super- vised fast in diagnosis of insulinoma.(1)  Place intravenous cannula and obtain baseline plasma glucose, insulin, proinsulin, beta-hydroxybutyrate, and C-peptide measurements at onset of fast. (2) Permit only calorie-free and caffeine-free fluids and encourage supervised activity (such as walking). (3) Obtain fingerstick glucose measurements every 4 hours until values < 60 mg/dL are obtained. Then increase the frequency of fingersticks to 1–2 hours, and when capillary glucose value is < 45 mg/dL send a venous blood sample to the laboratory for plasma glucose.1Check frequently for manifestations of neuroglycopenia. (4) At 48 hours into the fast, send a venous blood sample for plasma glucose, insulin, proinsulin, C-peptide, beta- hydroxybutyrate, and sulfonylurea measurement. (5) If symptoms of hypoglycemia occur oif a laboratory value of serum glucose is < 45 mg/dL, oif 72 hours have elapsed, conclude the fast with a final blood sample for plasma glucose,1insulin, proinsulin, C-peptide, beta-hydroxybutyrate, and sulfonylurea measurements. Then give oral fast-acting carbohydrate followed by a meal. If the patient is confused or unable to take oral agents, administer 50 mL of 50% dextrose intravenously over 3–5 minutes. Do not conclude a fast based simply on a capillary blood glucose measurement—wait for the laboratory glucose value—unless the patient is very symptomatic and it would be dangerous to wait.1 Glucose sample should be collected in sodium fluoride contain- ing tube on ice to prevent glycolysis and the plasma separated immediately upon receipt at the laboratory. Arrange for the labora- tory to run the glucose samples “stat.”CMDT22_Ch27_p1212-p1255.indd  1252 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1253 CMDT 2022bee  syptti when pls gluse drps t sub- nrl levels, sine inpprprite insulin seretin restrits ketne frtin. Mrever, the denstrtin f  nn- suppressed insulin level f 3 irunits/L r re using n ICMA ssy (greter thn 6 irunits/L using n RIA ssy) in the presene f hypglyei suggests the dignsis f insulin. If hypglyei des nt develp in  le ptient fter fsting fr up t 72 hurs—nd pr- tiulrly when this prlnged fst is terinted with  perid f derte exerise—insulin ust be nsid- ered n unlikely dignsis. An rl gluse tlerne test is f n vlue in the dig- nsis f insulin-sereting turs. HbA1levels y be lw but there is nsiderble verlp with nrl ptients nd n prtiulr vlue is dignsti.D . Preoperative Localization of B Cell TumorsAfter  the dignsis f insulin hs been unequivlly de by linil nd lbrtry findings, studies t llize the tur shuld be initited. Mst turs re in the pn- res, nd etpi ses re rre. Beuse f the sll size f these turs (verging 1.5  in dieter in ne lrge series), iging studies d nt neessrily identify ll f the. A pnreti dul phse helil CT sn with thin setin n identify 82–94% f the lesins. MRI sns with gdliniu n be helpful in deteting  tur in 85% f ses. One se reprt suggests tht diffusin-weighted MRI n be useful fr deteting nd llizing sll insulins, espeilly fr thse with n hypervsulr pttern. PET/CT sns using glliu-lbeled ststtin nlgs suh s DOTA- 1-NI3-tretide (DOTA-NOC), whih hve  higher ffinity fr ststtin reeptr subtypes 2, 3, nd 5, hve been reprted t be useful in llizing the turs. Insuli- ns express GLP-1 reeptrs, nd rdilbeled GLP-1 reeptr gnists suh s Lys(40)(Ahx-hydrzinnitin- ide [HYNIC]-[(99)T)NH(2)]-exendin-4 fr SPECT/ CT hve ls been reprted t visulize the turs. If the iging study is nrl, then n endspi ultrsund shuld be perfred. In experiened hnds, but 80–90% f turs n be deteted with this predure. Fine-needle spirtin f the identified lesin n be ttepted t n- fir the presene f  neurendrine tur. If the tur is nt identified r the iging result is equivl, then the ptient shuld underg seletive liu-stiulted ngi- grphy, whih hs been reprted t llize the tur t  prtiulr regin f the pnres pprxitely 90% f the tie. In this test, ngigrphy is bined with inje- tins f liu glunte int the gstrdudenl, spleni, nd superir esenteri rteries, nd insulin levels re esured in the hepti vein effluent. The predure is perfred fter n vernight fst. Cliu stiultes insulin relese fr insulins but nt nrl islets, nd s  step-up fr bseline in insulin levels (twfld r greter) reginlizes the sure f the hyperinsulinis t the hed f the pnres fr the gstrdudenl rtery, the uninte press fr the superir esenteri rtery, nd the bdy nd til f the pnres fr the spleni rtery liu infusins. These studies bined with reful intrper- tive ultrsngrphy nd plptin by  surgenexperiened in insulin surgery identifies up t 98% f turs. »TreatmentThe  tretent f hie fr insulin-sereting turs is surgil resetin. While witing fr surgery, ptients shuld be given rl dizxide. Divided dses f 300–400 g/dy usully suffie, lthugh n sinl ptient y require up t 800 g/dy. Side effets inlude ede due t sdiu retentin, gstri irrittin, nd ild hirsutis. Hydrhlrthizide, 25–50 g dily, n be used t untert the sdiu retentin nd ede s well ptentite dizxide’s hyperglyei effet. In ptients with  single benign pnreti B ell de- n, 90–95% hve  suessful ure t the first surgil ttept when intrpertive ultrsund is used by  skilled surgen. Dizxide shuld be dinistered n the dy f the surgery beuse it redues the risk f hypglyei during surgery. Typilly, it des nt sk the glyei rise inditive f surgil ure. Bld gluse shuld be nitred thrughut surgery, nd 5% r 10% dextrse infusin shuld be used t intin euglyei. In ses where the dignsis hs been estblished but n den is lted fter reful plptin nd use f intrpertive ultrsund, it is n lnger dvisble t blindly reset the bdy nd til f the pnres, sine  nnplpble tur issed by ultrsund is st likely ebedded within the fleshy hed f the pnres tht is left behind with subttl resetins. Mst surgens prefer t lse the inisin nd shedule  seletive rteril liu stiultin with hepti venus spling t lte the tur site prir t  repet pertin. Lprspy using ultrsund nd enu- letin hs been suessful with  single tur f the bdy r til f the pnres, but pen surgery reins neessry fr turs in the hed f the pnres. In ptients with inperble funtining islet ell ri- n with nd withut hepti etstsis nd in pprxi- tely 5–10% f MEN 1 ses when subttl revl f the pnres hs filed t prdue ure, the tretent pprh is the se s fr ther types f pnreti neu- rendrine turs (pNETs). Dizxide is the tretent f hie in preventing hypglyei. Frequent rbhy- drte feedings (every 2–3 hurs) n ls be helpful, lthugh weight gin n bee  prble. Ststtin nlgs, tretide r lnretide, shuld be nsidered if dizxide is ineffetive r if there is tur prgressin. Surgery r ebliztin (blnd, he- nd rdi-) r ther- l bltin (rdifrequeny, irwve, nd rybltin) n be used t redue tur burden nd ls prvide syp- tti relief. Chetherpy regiens tht n be nsid- ered inlude bintin f streptzin, 5-flururil, nd dxrubiin; peitbine nd xlipltin; nd peitbine nd tezlide (Tble 39–3). Trgeted therpies ginst ultiple steps in the PI3K/AKT/Tr pth- wy hve been shwn t be helpful. Everlius, n inhibi- tr f Tr, is pprved fr tretent f dvned pNETs. Sunitinib hs been shwn t slw grwth f pNETs. Tret- ent with rdiistpes (indiu-111 r yttriu-90 r lutetiu-177) linked t  ststtin nlg hs been reprted t shw benefit in  prprtin f ptients.CMDT22_Ch27_p1212-p1255.indd  1253 29/06/21 8:53 PMCHAPTEr 271254 CMDT 2022NO NISLET CELL TUMOR HYPOGLYCEMIAThese  rre uses f hypglyei inlude esenhyl turs suh s retrperitnel srs, heptellulr rins, drenrtil rins, nd isellneus epithelil-type turs. The turs re frequently lrge nd redily plpted r visulized n CT sns r MRI. In ny ses the hypglyei is due t the expres- sin nd relese f n inpletely pressed insulin-like grwth ftr 2 (IGF-2) by the tur. The dignsis is supprted by lbrtry duent- tin f seru insulin levels belw 5 irunit/L with pls gluse levels f 45 g/dL (2.5 l/L) r lwer. Vlues fr grwth hrne nd IGF-1 re ls deresed. Levels f IGF-2 y be inresed but ften re “nrl” in quntity, despite the presene f the iture, higher- leulr-weight fr f IGF-2, whih n be deteted nly by speil lbrtry tehniques. Nt ll the ptients with nnislet ell tur hypglye- i hve elevted pr-IGF-2. Etpi insulin prdutin hs been desribed in brnhil rin, vrin rin, nd sll ell rin f the ervix. Hypglyei due t IgF-1 relesed fr  etstti lrge ell rin f the lung hs ls been reprted. GLP-1–sereting turs (vr- in nd pNETs) n ls use hypglyei by stiulting insulin relese fr nrl pnreti islets. The prgnsis fr these turs is generlly pr, nd surgil revl shuld be ttepted when fesible. Dietry ngeent f the hypglyei is the insty f edil tretent, sine dizxide is usully ineffetive.PO STPRANDIAL HYPOGLYCEMIA 1. Hypoglycemia Following Gastic SugeyH ypglyei seties develps in ptients wh hve undergne gstri surgery (eg, gstrety, vgty, pylrplsty, gstrjejunsty, Nissn fundplitin, Billrth II predure, nd Rux-en-Y), espeilly when they nsue fds ntining high levels f redily bsrbble rbhydrtes. This lte duping syndre urs but 1–3 hurs fter  el nd is  result f rpid delivery f high nentrtin f rbhydrtes in the prxil sll bwel nd rpid bsrptin f gluse. The hyperinsulinei respnse t the high rbhydrte ld uses hypglyei. Exessive relese f gstrintestinl hrnes suh s GLP-1 likely ply  rle in the hyperin- sulinei respnse. The sypts inlude lightheded- ness, sweting, nfusin nd even lss f nsiusness fter eting  high rbhydrte el. T duent hyp- glyei, the ptient shuld nsue  el tht leds t sypts during everydy life. An rl gluse tlerne test is nt reended beuse ny nrl persns hve flse-psitive test results. There hve been se reprts f insulin nd nninsulin pnretge- nus hypglyei syndre in ptients with hypglye- i pst Rux-en-Y surgery. It is unler hw ften this urs. A reful histry y identify ptients wh hve  histry f hypglyei with exerise r issed els, nd these individuls y require  frl 72-hur fst t rule ut n insulin.Tretent fr sendry duping inludes dietry difitin, but this y be diffiult t sustin. Ptients n try re frequent els with sller prtins f less rpidly digested rbhydrtes. Alph-glusidse therpy y be  useful djunt t  lw rbhydrte diet. Otre- tide 50 g dinistered subutneusly tw r three ties  dy 30 inutes prir t eh el hs been reprted t iprve sypts due t lte duping syndre. Tret- ent with exendin 9-39,  GLP-1 reeptr gnist, y prevent pst gstri bypss hypglyei. SGLT2 inhibitrs y elirte the pstprndil gluse rise, the subse- quent insulin respnse, nd hypglyei. There is  reprt f  ptient with Rux-en-Y surgery wh hd plete reslutin f bth hyperglyei nd hypglyei when she ws given ngliflzin. Vrius surgil predures t dely gstri eptying hve been reprted t iprve sypts but lng-ter effiy studies re lking.2.  Functional Alimentay HypoglycemiaP tients hve sypts suggestive f inresed syp- theti tivity, inluding nxiety, wekness, trer, swet- ing r plpittins fter els. Physil exintin nd lbrtry tests re nrl. It is nt reended tht ptients with sypts suggestive f inresed syp- theti tivity underg either  prlnged rl gluse tl- erne test r  ixed el test. Insted, the ptients shuld be given he bld gluse nitrs (with eries) nd instruted t nitr fingerstik gluse levels t the tie f sypts. Only ptients wh hve sypts when their fingerstik bld gluse is lw (less thn 50 g/dL) nd wh hve reslutin f sypts when the gluse is rised by eting rpidly relesed rb- hydrte need dditinl evlutin. Ptients wh d nt hve evidene fr lw gluse levels t tie f sypts re generlly ressured by their findings. Cunseling nd supprt shuld be the instys in therpy, with dietry nipultin nly n djunt.3.  Occult DiabetesThis  nditin is hrterized by  dely in erly insulin relese fr pnreti B ells, resulting in initil exgger- tin f hyperglyei during  gluse tlerne test. In respnse t this hyperglyei, n exggerted insulin relese prdues  lte hypglyei 4–5 hurs fter inges- tin f gluse. These ptients re ften bese nd fre- quently hve  fily histry f dibetes ellitus. Ptients with this type f pstprndil hypglyei ften respnd t redued intke f refined sugrs with ultiple, sped, sll feedings high in dietry fiber. In the bese, tretent is direted t weight redutin t hieve idel weight. These ptients shuld be nsidered t hve predibetes r erly dibetes (type 1 r 2) nd dvised t hve peridi edil evlutins.4.  Autoimmune HypoglycemiaP tients with utiune hypglyei hve erly pstprn- dil hyperglyei fllwed by hypglyei 3–4 hurs lter. The hypglyei is ttributed t  dissitin f insulin- ntibdy iune plexes, relesing free insulin.CMDT22_Ch27_p1212-p1255.indd  1254 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1255 CMDT 2022The  disrder is ssited with ethizle tretent fr Grves disese, lthugh it n ls ur in ptients treted with vrius ther sulfhydryl-ntining edi- tins (ptpril, peniilline) s well s ther drugs suh s hydrlzine, isnizid, nd prinide. In dditin, it hs been reprted in ptients with utiune disrders suh s rheutid rthritis, systei lupus erythetsus, nd plyysitis s well s in pls ell yel nd ther pls ell dysrsis where prprteins r ntibdies rss-ret with insulin. There is ls n ssitin with the HLA lss II lleles (DRB1*0406, DQA1*0301, nd DQB1*0302). These lleles re 10 t 20 ties re n in Jpnese nd Kren ppultins, whih explins why the disrder hs been reprted stly in Jpnese ptients. High titers f insulin utntibdies, usully IgG lss, n be deteted. Insulin, prinsulin, nd C-peptide levels y be elevted, but the results y be errneus beuse f the interferene f the insulin ntibdies with the iu- nssys fr these peptides. In st ses, the hypglyei is trnsient nd usully reslves spntneusly within 3–6 nths f dignsis, prtiulrly when the ffending editins re stpped. The st nsistent therpeuti benefit in ngeent f this syndre hs been hieved by dietry tretent with sll, frequent lw-rbhydrte els. Prednisne (30–60 g rlly dily) hs been used t lwer the titer f insulin ntibdies.F ACTITIOUS HYPOGLYCEMIAF titius hypglyei y be diffiult t duent. A suspiin f self-indued hypglyei is supprted when the ptient is ssited with the helth prfessins r hs ess t dibeti editins tken by  dibeti eber f the fily. The trid f hypglyei, high iunretive insulin, nd suppressed pls C-peptide iunretivity is pthgnni f exgenus insulin dinistrtin. Insu- lin nd C-peptide re sereted in  1:1 lr rti. A lrge frtin f the endgenus insulin is lered by the liver, wheres C-peptide, whih is lered by the kidney, hs  lwer etbli lerne rte. Fr this resn, the lr rti f insulin nd C-peptide in  hypglyei ptient shuld be less thn 1.0 in ses f insulin nd is greter thn 1.0 in ses f exgenus insulin dinistrtin (see Hypglyei Due t Pnreti B Cell Turs, bve). When sulfnylures, repglinide, nd nteglinide re sus- peted s  use f ftitius hypglyei,  pls level f these editins t detet their presene y be required t distinguish lbrtry findings fr thse f insulin.HYP OGLYCEMIA DUE TO INSULIN RECEPTOR ANTIBODIESH ypglyei due t insulin reeptr utntibdies is n extreely rre syndre; st ses hve urred in wen ften with  histry f utiune disese. Alst ll f these ptients hve ls hd episdes f insulin- resistnt dibetes nd nthsis nigrins. Their hypglye- i y be either fsting r pstprndil nd is ften severend is ttributed t n gnisti tin f the ntibdy n the insulin reeptr. Blne between the ntgnisti nd g- nisti effets f the ntibdies deterines whether insulin- resistnt dibetes r hypglyei urs. Hypglyei ws fund t respnd t rtisterid therpy but nt t plspheresis r iunsuppressin.ME DICATION- & ETHANOL-INDUCED HYPOGLYCEMIAA  nuber f editins prt fr dibeti editins n sinlly use hypglyei. Cn ffenders inlude the flurquinlnes suh s gtiflxin nd lev- flxin, pentidine, quinine, ACE inhibitrs, sliyltes nd bet-drenergi blking gents. The flurquinlnes, prtiulrly gtiflxin, hve been ssited with bth hypglyei nd hyperglyei. It is thught tht the drug ts n the ATP sensitive ptssiu hnnels in the bet ell. Hypglyei is n erly event, nd hyperglyei urs severl dys int therpy. Intrvenus pentidine is yt- txi t bet ells nd uses ute hyperinsulinei nd hypglyei fllwed by insulinpeni nd hyperglyei. Fsting ptients tking nnrdiseletive bet-blkers n hve n exggerted hypglyei respnse t strvtin. The bet-blkde inhibits ftty ids nd glunegenesis substrte relese nd redues pls glugn respnse. Therpy with ACE inhibitrs inreses the risk f hypgly- ei in ptients wh re tking insulin r sulfnylures presubly beuse these drugs inrese sensitivity t iru- lting insulin by inresing bld flw t the usle. Se piids use hypglyei. Trdl use hs been ssi- ted with inresed risk f hspitliztin fr hypglyei. Methdne verdse hs ls been reprted t use hyp- glyei nd  rpid dse esltin f ethdne in ner ptients n lwer gluse levels. Ethnl-ssited hypglyei y be due t hepti lhl dehydrgense tivity depleting NAD. The resul- tnt hnge in the redx stte—inrese in NADH t NAD+rti—uses  prtil blk t severl pints in the glunegeni pthwy. With prlnged strvtin, gly- gen reserves bee depleted within 18–24 hurs nd hepti gluse utput bees ttlly dependent n glu- negenesis. Under these irustnes,  bld nen- trtin f ethnl s lw s 45 g/dL (9.8 l/L) n indue prfund hypglyei by blking glunegen- esis. Neurglypeni in  ptient whse breth sells f lhl y be istken fr lhli stupr. Preventin nsists f dequte fd intke during ethnl ingestin. Therpy nsists f gluse dinistrtin t replenish glygen stres until glunegenesis resues. When sugr-ntining sft drinks re used s ixers t dilute lhl in beverges (gin nd tni, ru nd l), there sees t be  greter insulin relese thn when the sft drink lne is ingested nd  tendeny fr re f  lte hypglyei verswing t ur 3–4 hurs lter. Preventin wuld nsist f viding sugr ixers while ingesting lhl nd ensuring suppleentry fd intke t prvide sustined bsrptin.CMDT22_Ch27_p1212-p1255.indd  1255 29/06/21 8:53 PM1256 CMDT 2022Lipid Disorders 28Michael J. Blaha, MD, MPHThe  “Lipid Hypothesis” of cardiovascular disease (CVD)— stating that cholesterol is causal in the development of atherosclerotic cardiovascular disease (ASCVD) and that lowering of cholesterol is associated with lower cardiovas- cular event rates—is widely accepted throughout the medi- cal community. For patients with known CVD (secondary prevention), studies have shown that cholesterol lowering leads to a consistent reduction in total mortality and in recurrent cardiovascular events in men and women; other studies have documented lowered mortality and events in middle-aged and older patients. Among patients without CVD (primary prevention), the data are generally consis- tent, with rates of cardiovascular events, heart disease mortality, and all-cause mortality differing among studies. Treatment guidelines have been designed to assist clini- cians in selecting patients for cholesterol-lowering therapy based predominantly on their overall risk of developing CVD as well as their baseline cholesterol levels. There are several genetic disorders that provide insight into the pathogenesis of lipid-related diseases. Familial hypercholesterolemia, rare in the homozygous state (about one per million), causes markedly high low-density lipoprotein (LDL) levels and early CVD. The most common genetic defects involve absent or defective LDL receptors, resulting in unregulated LDL metabolism, genetic muta- tions of apolipoprotein B, or gain of function in proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates breakdown of LDL receptors. Patients with two abnormal genes (homozygotes) have extremely high levels—up to eight times normal—and present with ath- erosclerotic disease in childhood. Patients with two abnor- mal genes (homozygotes) may require liver transplantation or plasmapheresis to correct their severe lipid abnormali- ties; early treatment with statins appears to confer lifetime benefits in such patients. Those with one defective gene (heterozygotes) have LDL concentrations up to two or three times normal; persons with this condition may develop CVD in their 30s or 40s. Another rare condition is caused by an abnormality of lipoprotein lipase, the enzyme that enables peripheral tissues to take up triglyceride from chylomicrons and very- low-density lipoprotein (VLDL) particles. Patients with this condition, one cause of familial chylomicronemiasyndrome, have marked hypertriglyceridemia with recur- rent pancreatitis and hepatosplenomegaly in childhood. Numerous other genetic abnormalities of lipid metabo- lism are named for the abnormality noted when serum is electrophoresed (eg, dysbetalipoproteinemia, character- ized by elevated levels of remnant lipoproteins) or from polygenic combinations of lipid abnormalities in families (eg, familial combined hyperlipidemia). »When to Refer• Known genetic lipid disorders. •Striking family history of hyperlipidemia or premature atherosclerosis. •Extremely high serum LDL cholesterol or triglycerides, or extremely low serum high-density lipoprotein (HDL) cholesterol.Chyzh yk V et al. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30:80. [PMID: 31003756] Hegele RA et al. Rare dyslipidaemias, from phenotype to geno- type to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020;8:50. [PMID: 31582260] Khera AV et al. What is familial hypercholesterolemia, and why does it matter? Circulation. 2020;141:1760. [PMID: 32479201] Mortensen MB et al. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary pre- vention cohort. Lancet. 2020;396:1644. [PMID: 33186534] Sniderman AD et al. Apolipoprotein B particles and cardiovas- cular disease: a narrative review. JAMA Cardiol. 2019;4:1287. [PMID: 31642874]LI PID FRACTIONS & THE RISK OF CORONARY HEART DISEASEIn  serum, cholesterol is carried primarily on three different lipoproteins—the VLDL, LDL, and HDL molecules. Total cholesterol equals the sum of these three components: =  + +Total cholesterol  HDL cholesterol  VLDL cholesterol LDL cholesterolCMDT22_Ch28_p1256-p1266.indd  1256 29/06/21 8:55 PM",
                  "DIABETES MELLITUS & HYPOGLYCEMIA1213 CMDT 2022Whih  envirnentl ftr is respnsible fr the inresed risk is nt knwn. Brestfeeding in the first 6 nths f life ppers t be prtetive. There is uu- lting evidene tht iprveents in publi helth nd redued infetins (espeilly prsiti) led t iune syste dysregultin nd develpent f utiune disrders suh s sth nd type 1 dibetes. Chek pint inhibitr iuntherpies fr dvned lignnies, suh s nivlub, pebrlizub, nd ipiliub, n preipitte utiune disrders, inlud- ing type 1 dibetes. The nset f dibetes n be rpid nd the ptients frequently hve dibeti ketidsis t pre- senttin. Autntibdies ginst islet ntigens re nly present in but 50% f ptients. Ptients reeiving these drugs shuld be refully nitred fr the develpent f dibetes. Apprxitely 5% f subjets hve n evidene f pn- reti B ell utiunity t explin their insulinpeni nd ketidsis. This subgrup hs been lssified s “idipthi type 1 dibetes” nd designted s “type 1B. ” Althugh nly  inrity f ptients with type 1 dibetes fll int this grup, st f these individuls re f Asin r Afrin rigin. Abut 4% f the West Afrins with ketsis-prne dibetes re hzygus fr  uttin in PAX-4 (Arg133Trp )— trnsriptin ftr tht is essentil fr the develpent f pnreti islets.B.  Type 2 Diabetes MellitusT ype 2 dibetes is due t nn-iune uses f pnreti B ell lss with vrible degree f tissue insensitivity t insulin, tht is, insulin resistne. The residul bet ell funtin is suffiient t prevent ketidsis but is inde- qute t prevent the hyperglyei. This fr f dibetes used t ur predinntly in dults, but it is nw re frequently enuntered in hildren nd dlesents.Geneti nd envirnentl ftrs bine t use bth the bet ell lss nd the insulin resistne. Mst epi- deilgi dt indite strng geneti influenes, sine in nzygti twins ver 40 yers f ge, nrdne develps in ver 70% f ses within  yer whenever type 2 dibetes develps in ne twin. Gene wide ssitin studies hve identified 143 risk vrints nd puttive regu- ltr ehniss fr type 2 dibetes. A signifint nuber f the identified li pper t de fr prteins tht hve  rle in bet ell funtin r develpent. One f the geneti li with the lrgest risk effet is TCF7L2 . This gene des fr  trnsriptin ftr invlved in the WNT sig- nling pthwy tht is required fr nrl pnreti develpent. Obesity is the most important environmental factor causing insulin resistance. The degree nd prevlene f besity vries ng different ril grups with type 2 dibetes. While besity is pprent in n re thn 30% f Chinese nd Jpnese ptients with type 2, it is fund in 60–70% f Nrth Aerins, Eurpens, r Afrins with type 2 nd pprhes 100% f ptients with type 2 ng Pi Indins r Pifi Islnders fr Nuru r S. Viserl besity, due t uultin f ft in the entl nd esenteri regins, rreltes with insulin resistne; subutneus bdinl ft sees t hve less f n ssitin with insulin insensitivity. There re ny ptients with type 2 dibetes wh, while nt vertly bese, hve inresed viserl ft; they re tered the “etbli- lly bese. ” Exerise y ffet the depsitin f viserl ft s suggested by CT sns f Jpnese wrestlers, whse extree besity is predinntly subutneus. Their dily vigrus exerise prgr prevents uultin f viserl ft, nd they hve nrl seru lipids nd eugly- ei despite dily intkes f 5000–7000 kl nd develp- ent f ssive subutneus besity.C.  Other Specific Types of Diabetes Mellitus1.  Maturityonset diabetes of the young (MODY)— This subgrup f ngeni disrders is hrterized by nn- insulin requiring dibetes with utsl dinnt inher- itne nd n ge t nset f 25 yers r yunger. Ptients re nnbese, nd their hyperglyei is due t ipired gluse-indued seretin f insulin. Six types f MODY hve been desribed (Tble 27–1). Exept fr MODY 2, in whih  glukinse gene is defetive, ll ther types invlve uttins f  nuler trnsriptin ftr tht regultes islet gene expressin. Ptients yunger thn 30 yers with endgenus insulin prdutin (urinry C-peptide/retinine rti f 0.2 nl/l r higher) nd negtive utntibdies re ndidtes fr geneti sreening fr MODY. The enzye glukinse is  rte- liiting step in glylysis nd deterines the rte f de- nsine triphsphte (ATP) prdutin fr gluse nd the insulin seretry respnse in the bet ell. MODY 2, due t glukinse uttins, is usully quite ild, ssi- ted with nly slight fsting hyperglyei nd few if ny irvsulr dibeti plitins. MODY 3, due t uttins in hepti nuler ftr 1 lph, is the st n fr, unting fr tw-thirds f ll MODY ses. Initilly, ptients with MODY 3 re respnsive tTable 27–1. Other specific types of diabetes mellitus.Genetic  defects of pancreatic B cell function MODY 1 (HNF-4alpha); rare MODY 2 (glucokinase); less rare MODY 3 (HNF-1alpha); accounts for two-thirds of all MODY MODY 4 (PDX1); very rare MODY 5 (HNF-1beta); very rare MODY 6 (neuroD1); very rare Mitochondrial DNA Wolfram syndrome Genetic defects in insulin action Type A insulin resistance Leprechaunism Rabson-Mendenhall syndrome Lipoatrophic diabetes Diseases of the exocrine pancreas Endocrinopathies Drug- or chemical-induced diabetes Other genetic syndromes (Down, Klinefelter, Turner, others) sometimes associated with diabetes HNF, hepatic nuclear factor; MODY, maturity-onset diabetes of the young; PDX1, pancreatic duodenal homeobox 1.CMDT22_Ch27_p1212-p1255.indd  1213 29/06/21 8:53 PMCHAPTEr 271214 CMDT 2022sulfn ylure therpy but the linil urse is f prgres- sive bet ell filure nd eventul need fr insulin therpy. Muttins in bth lleles f glukinse present with re severe nentl dibetes. Muttin in ne llele f the pn- reti dudenl hebx 1 (PDX1) uses dibetes usu- lly t  lter ge (~ 35 yers) thn ther frs f MODY; uttins in bth lleles f PDX1 use pnreti genesis. 2. Diabetes mellitus associated with a mutation of mito chondrial DNA— Sine sper d nt ntin ithn- dri, nly the ther trnsits ithndril genes t her ffspring. Dibetes due t uttins f ithndril DNA urs in less thn 2% f ptients with dibetes. The st n use is the A3243G uttin in the gene ding fr the tRNA (Leu, UUR). Dibetes usully devel- ps in these ptients in their lte 30s, nd hrteristilly, they ls hve hering lss (ternlly inherited dibetes nd defness [MIDD]). 3. Wolfram syndrome— Wlfr syndre is n uts- l reessive neurdegenertive disrder first evident in hildhd. It nsists f dibetes insipidus, dibetes elli- tus, pti trphy, nd defness, hene the rny DID- MOAD. It is due t uttins in  gene ned WFS1 , whih endes  100.3 KD trnsebrne prtein ll- ized in the endplsi retiulu. Crnil dibetes insipi- dus nd sensrineurl defness develp during the send dede in 60–75% f ptients. Ureterhydrnephrsis, neurgeni bldder, erebellr txi, peripherl neurp- thy, nd psyhitri illness develp lter in ny ptients. 4. Autosomal recessive syndromes— Hzygus ut- tins in  nuber f pnreti trnsriptin ftrs, NEU- ROG3, PTF1A, RFX6 , nd GLI-similar 3 (GLIS3) , use nentl r hildhd dibetes. Hzygus PTF1A uttins result in bsent pnres nd erebellr trphy; NEUROG3 uttins use severe lbsrptin nd dibetes befre puberty. Hzygus uttins in RFX6 use the Mithell-Riley syndre hrterized by bsene f ll islet ell types prt fr pnreti ply- peptide ells, hypplsi f the pnres nd gllbldder, nd intestinl tresi. GLIS3 gene plys  rle in trnsrip- tin f insulin gene, nd hzygus uttins use nentl dibetes nd ngenitl hypthyridis. The gene EIF2AK3 endes PKR-like ER kinse (PERK), whih ntrls ne f the pthwys f the unflded prtein respnse. Absene f PERK leds t indequte respnse t ER stress nd elerted bet ell pptsis. Ptients with uttin in this gene hve nentl dibetes, epiphysel dysplsi, develpentl dely, nd liver nd kidney dys- funtin (Wltt-Rllisn syndre). 5. Diabetes mellitus secondary to other causes— End- rine turs sereting grwth hrne, glurtiids, tehlines, glugn, r ststtin n use glu- se intlerne (Tble 27–2). In the first fur f these situ- tins, peripherl respnsiveness t insulin is ipired. With exess f glurtiids, tehlines, r glu- gn, inresed hepti utput f gluse is  ntributry ftr; in the se f tehlines, deresed insulin relese is n dditinl ftr in prduing rbhydrteintlerne, nd with ststtin, inhibitin f insulin seretin is the jr ftr. Dibetes inly urs in individuls with underlying defets in insulin seretin, nd hyperglyei typilly reslves when the hrne exess is reslved. High-titer nti-insulin reeptr ntibdies tht inhibit insulin binding use  linil syndre hrterized by severe insulin resistne, gluse intlerne r dibetes ellitus, nd nthsis nigrins. These ptients usully hve ther utiune disrders. There re reprts f spntneus reissin r reissin with yttxi therpy. Mny drugs re ssited with rbhydrte intler- ne r frnk dibetes (Tble 27–2). The drugs t by deresing insulin seretin r by inresing insulin resis- tne r bth. Cylsprine nd trlius ipir insulin seretin; sirlius priniplly inreses insulin resistne. These gents ntribute t the develpent f new-nset dibetes fter trnsplnttin. Crtisterids inrese insulin resistne but y ls hve n effet n bet ell funtin; in  se ntrl study nd  lrge ppultin hrt study, rl rtisterids dubled the risk fr develpent f dibetes. Thizide diuretis nd bet- blkers destly inrese the risk fr dibetes. Treting the hypklei due t thizides y reverse the hyper- glyei. Atypil ntipsyhtis, prtiulrly lnzpine nd lzpine, re ssited with inresed risk f gluse intlerne. These drugs use weight gin nd insulin resistne but y ls ipir bet ell funtin; n inrese in rtes f dibeti ketidsis (DKA) hs been reprted. Alpelisib is  phsphtidylinsitl-3-kinse (PI3K) inhibitr nd is pprved fr use in bintin with fulvestrnt fr hrne reeptr–psitive, HER2- negtive, PIK3CA -utted brest ner. PI3K is  p- nent f the insulin signling pthwy, nd hyperglyei is  n side effet f lpelisib tretent. Chrni pnretitis r subttl pnretety redues the nuber f funtining B ells nd n result in  etbli derngeent very siilr t tht f geneti type 1 dibetes exept tht  nitnt redu- tin in pnreti A ells y redue glugn seretin s tht reltively lwer dses f insulin repleent re needed.Table 27–2. Secondary causes of hyperglycemia.Hypeglycemia  due to tissue insensitivity to insulin Medications (corticosteroids, sympathomimetic drugs, niacin, alpelisib, sirolimus) Hormonal tumors (acromegaly, Cushing syndrome, glucagonoma, pheochromocytoma) Liver disease (cirrhosis, hemochromatosis) Muscle disorders (myotonic dystrophy) Adipose tissue disorders (lipodystrophy, truncal obesity) Hypeglycemia due to educed insulin secetion Medications (thiazide diuretics, phenytoin, pentamidine, calcineurin inhibitors, atypical antipsychotics) Hormonal tumors (somatostatinoma, pheochromocytoma) Pancreatic disorders (pancreatitis, hemosiderosis, hemochromatosis)CMDT22_Ch27_p1212-p1255.indd  1214 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1215 CMDT 2022 »Metabolic Syndrome (Insulin Resistance Syndrome)The  ter etbli syndre hs been dvted t iden- tify individuls wh were t higher risk fr develpent f dibetes nd rdivsulr disese. Criteri inluded wist iruferene, gluse levels, bld pressure, trigly- erides, nd HDL hlesterl. There is, hwever, n unify- ing pthphysilgi bsis fr the syndre, nd in 2010,  WHO expert ittee reprted tht the syndre lked utility s  dignsti r ngeent tl. They bserved tht there ws nly dest ssitin between etbli syndre nd rdivsulr disese, nd the definitin ws utperfred by trditinl rdivsulr risk preditin lgriths suh s the Fringh risk sre. Siilrly, fsting gluse nveys  greter risk f inident dibetes thn the etbli syndre. There is ls n evidene tht hyperinsulinei nd insulin resis- tne ply  diret rle in these etbli bnrlities. »Clinical Trials about Optimum Diabetic Glucose ControlFindings  f the Dibetes Cntrl nd Cplitins Tril nd f the United Kingd Prspetive Dibetes Study hve nfired the benefiil effets f iprved glyei ntrl in bth type 1 nd type 2 dibetes.A.  Type 1 DiabetesThe Dia betes Control and Complications Trial (DCCT),  lng-ter therpeuti study invlving 1441 ptients with type 1 dibetes ellitus, reprted tht “ner” nrliz- tin f bld gluse resulted in  dely in the nset nd  jr slwing f the prgressin f estblished irvs- ulr nd neurpthi plitins f dibetes. In hlf f the ptients,  en heglbin A1f 7.2% (nrl: less thn 6%) nd  en bld gluse f 155 g/dL (8.6 l/L) were hieved using intensive therpy, while in the nventinlly treted grup, HbA1 verged 8.9% with n verge bld gluse f 225 g/dL (12.5 l/L). Over the study perid, whih verged 7 yers, there ws n pprxitely 60% redutin in risk between the tw grups in regrd t dibeti retinpthy, nephrpthy, nd neurpthy. The intensively treted grup ls hd  nnsignifint redutin in the risk f rvsulr disese f 41% (95% CI, –10% t 68%). Intensively treted ptients hd  threefld greter risk f serius hypglyei s well s  greter tendeny twrd weight gin. Hwever, there were n deths definitely ttributble t hypglyei in ny persns in the DCCT study, nd n evidene f psthypglyei gnitive dge ws deteted. Prtiipnts in the DCCT study were subsequently enrlled in  fllw-up bservtinl study, the Epideil- gy f Dibetes Interventins nd Cplitins (EDIC) study. Even thugh the between-grup differenes in en HbA1nrrwed ver 4 yers, the grup ssigned t inten- sive therpy hd  lwer risk f retinpthy t 4 yers, irlbuinuri t 7–8 yers, nd ipired GFR (less thn 60 L/in/1.73 2) t 22 yers f ntinued studyfllw-up. Mrever, by the end f the 11-yer fllw-up perid, the intensive therpy grup hd signifintly redued their risk f ny rdivsulr disese events by 42% (95% CI, 9% t 23%; P= 0.02). Thus, it sees tht the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. The generl nsensus f the ADA is tht intensive insulin therpy ssited with prehensive self- ngeent trining shuld be stndrd therpy in ptients with type 1 dibetes ellitus fter the ge f puberty. Exeptins inlude thse with dvned hrni kidney disese nd lder dults sine the detrientl risks f hypglyei utweigh the benefits f tight glyei ntrl in these grups.B.  Type 2 DiabetesThe  United Kingdom Prospective Diabetes Study (UKPDS),  ultienter study, ws designed t estblish whether the risk f rvsulr r irvsulr - plitins uld be redued by intensive bld gluse ntrl with rl hypglyei gents r insulin nd whether ny prtiulr therpy ws re benefiil thn the ther in type 2 dibeti ptients. Intensive tretent with either sulfnylures, etfr- in, bintins f thse tw, r insulin hieved en HbA1levels f 7%. This level f glyei ntrl deresed the risk f irvsulr plitins (retinpthy nd nephrpthy) in prisn with nventinl therpy (stly diet lne), whih hieved en levels f HbA1 f 7.9%. Weight gin urred in intensively treted ptients exept when etfrin ws used s ntherpy. N dverse rdivsulr utes were nted regrdless f the therpeuti gent. In the verweight r bese sub- grup, etfrin therpy ws re benefiil thn diet lne in reduing the nuber f ptients wh suffered yrdil infrtins nd strkes. Hypglyei re- tins urred in the intensive tretent grups, but nly ne deth fr hypglyei ws duented during 27,000 ptient-yers f intensive therpy. Tight ntrl f bld pressure (edin vlue 144/82  Hg vs 154/87  Hg) substntilly redued the risk f irvsulr disese nd strke but nt y- rdil infrtin. In ft, reduing bld pressure by this unt hd substntilly greter ipt n irvsulr utes thn tht hieved by lwering HbA1fr 7.9% t 7%. An epideilgi nlysis f the UKPDS dt shwed tht every 10  Hg derese in en systli bld pressure ws ssited with 11% redutin in risk fr yrdil infrtin. Mre thn hlf f the ptients needed tw r re editins fr dequte therpy f their hypertensin, nd there ws n denstrble dvn- tge f ngitensin-nverting enzye (ACE) inhibitr therpy ver therpy with bet-blkers with regrd t dibetes end pints. Use f  liu hnnel blker dded t bth tretent grups ppered t be sfe ver the lng ter in this dibeti ppultin despite se ntrversy in the literture but its sfety in ptients with dibetes. Like the DCCT trilists, the UKPDS reserhers per- fred pst-tril nitring t deterine whether thereCMDT22_Ch27_p1212-p1255.indd  1215 29/06/21 8:53 PMCHAPTEr 271216 CMDT 2022were  lng-ter benefits f hving been in the intensively treted gluse nd bld pressure rs f the study. The intensively treted grup hd signifintly redued risk f yrdil infrtin (15%, P= 0.01) nd deth fr ny use (13%, P= 0.007) during the fllw-up perid. The subgrup f verweight r bese subjets wh were ini- tilly rndized t etfrin therpy shwed sustined redutin in risk f yrdil infrtin nd deth fr ny use in the fllw-up perid. Unlike the sustined benefits seen with gluse ntrl, there were n sustined benefits fr hving been in the re tightly ntrlled bld pressure grup. Bth bld pressure grups were t siilr risk fr irvsulr events nd dibetes-relted end pints during the fllw-up perid. Thus, the fllw-up f the UKPDS type 2 dibetes hrt shwed tht, s in type 1 dibetes, the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. Bld pressure benefits, hwever, lst nly s lng s the bld pressure is well ntrlled. »Diabetes Prevention TrialsA.  Prevention of Type 1 DiabetesAt  the tie f dignsis f type 1 dibetes, there reins signifint B ell pnreti funtin. This explins why sn fter dignsis, the dibetes ges int prtil linil reissin nd little r n insulin is required (“hneyn”). The linil reissin is shrt- lived, hwever, nd eventully ptients lse ll B ell fun- tin nd hve re lbile gluse ntrl. Studies hve been perfred t prlng this prtil linil reissin using iundultry gents. The CD3 plex is the jr signl-trnsduing eleent f the T ell reep- tr, nd the nti-CD3 ntibdies re believed t dulte the utiune respnse by seletively inhibiting the pthgeni T ells r by induing regultry T ells. Phse 1/2 nd 2/3 linil trils f hunized nlnl nti- bdies ginst CD3, hOKT3g (Al-Al) (tepli- zub), nd ChAglyCD3 (telixizub) delyed but did nt pletely rrest the deline in insulin prdutin in ptients with newly dignsed type 1 dibetes. A siilr phse 2 linil tril using teplizub ws undertken in nndibeti reltives f ptients with type 1 dibetes wh hd tw r re dibetes-relted ntibdies nd gluse intlerne. In the 5 yers fter rndiztin, 43% f the ptients reeiving teplizub nd 72% f the pleb grup develped dibetes.B.  Prevention of Type 2 DiabetesThe  Dibetes Preventin Prgr studied whether tret- ent with either diet nd exerise r etfrin uld prevent the nset f type 2 dibetes in verweight en nd wen ged 25–85 yers wh hd ipired gluse tler- ne. Interventin with  lw-ft diet nd 150 inutes f derte exerise (equivlent t  brisk wlk) per week redued the risk f prgressin t type 2 dibetes by 71%. Prtiipnts wh tk etfrin 850 g twie dily redued their risk f develping type 2 dibetes by 31%, but this interventin ws reltively ineffetive in thse wh were either less bese r in the lder ge grup.Eighty-eight perent f the persns in the Dibetes Preven- tin Prgr eleted t ntinue fllw up in the Dibetes Preventin Prgr Oute Study. At 15 yers f fllw up, the uultive inidene f dibetes ws 55% in the lifestyle grup nd 62% in the ntrl grup. »Clinical FindingsA.  Symptoms and Signs1.  Type 1 diabetes— A hrteristi sypt plex f hypersllity nd hyperketnei fr the uul- tin f irulting gluse nd ftty ids typilly presents in ptients with type 1 dibetes. When bslute insulin defiieny is f ute nset, there is brupt inrese in uri- ntin, thirst, blurred visin, weight lss, presthesis, nd ltered level f nsiusness. Ketidsis exerbtes the dehydrtin nd hypersllity by prduing nrexi nd nuse nd viting, interfering with rl fluid repleent. a. Increased urination and thirst— These sypts re nsequenes f sti diuresis sendry t sus- tined hyperglyei. The diuresis results in  lss f glu- se s well s free wter nd eletrlytes in the urine. b. Blurred vision— As the lenses re expsed t hyper- slr fluids, blurred visin ften develps. c. Weight loss— Despite nrl r inresed ppetite, weight lss is  n feture f type 1 when it develps subutely. The weight lss is initilly due t depletin f wter, glygen, nd triglyerides; therefter, redued us- le ss urs s in ids re diverted t fr gluse nd ketne bdies. Lss f subutneus ft nd usle wsting re fetures f re slwly develping insulin defiieny. Lwered pls vlue prdues sypts f psturl hyptensin, whih is  serius prgnsti sign. Ttl bdy ptssiu lss nd the generl tblis f usle prtein ntribute t the wekness. d. Paresthesias— Presthesis y be present t the tie f dignsis, prtiulrly when the nset is subute. They reflet  teprry dysfuntin f peripherl sensry nerves, whih lers s insulin repleent restres glye- i levels lser t nrl, suggesting neurtxiity fr sustined hyperglyei. e. The level of consciousness shown by the patient— The ptient’s level f nsiusness n vry depending n the degree f hypersllity. When insulin defiieny develps reltively slwly nd suffiient wter intke is intined, ptients rein reltively lert nd physil findings y be inil. When viting urs in respnse t wrsening ketidsis, dehydrtin pr- gresses nd penstry ehniss bee indequte t keep seru sllity belw 320–330 Os/L. Under these irustnes, stupr r even  y ur. The fruity breth dr f etne further suggests the dignsis f DKA. 2. Type 2 diabetes— While inresed urintin nd thirst y be presenting sypts in se ptients with type 2 dibetes, ny ther ptients hve n insidius nset fCMDT22_Ch27_p1212-p1255.indd  1216 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1217 CMDT 2022hypergly ei nd re syptti initilly. This is pr- tiulrly true in bese ptients, whse dibetes y be deteted nly fter glysuri r hyperglyei is nted during rutine lbrtry studies. Osinlly, when the disese hs been ult fr se tie, ptients y hve evidene f neurpthi r rdivsulr plitins t the tie f presenttin. Hyperglyei hyperslr  n ls be present when the seru sllity exeeds 320–330 Os/L; in these ses, ptients re pr- fundly dehydrted, hyptensive, lethrgi, r tse but withut the Kussul respirtins f ketidsis. a. Skin manifestations— Chrni skin infetins re n. Generlized pruritus nd sypts f vginitis re frequently the initil plints f wen. Dibetes shuld be suspeted in wen with hrni ndidl vul- vvginitis. Blnpsthitis (infltin f the freskin nd glns in uniruised les) y ur. Other skin findings inlude nthsis nigrins. whih is ssited with signifint insulin resistne. The skin in the xill, grin, nd bk f nek is hyperpigented nd hyperkertti (Figure 27–1). Eruptive xnths n the flexr surfe f the libs nd n the buttks nd lipei retinlis due t hyperhylirnei n ur in ptients with unntrlled type 2 dibetes wh ls hve  filil fr f hypertriglyeridei. b. Body habitus— Overweight r bese ptients fre- quently hve type 2 dibetes. Even thse wh re nt sig- nifintly bese ften hve hrteristi lliztin f ft depsits n the upper segent f the bdy (prtiulrly the bden, hest, nek, nd fe) nd reltively less ft n the ppendges, whih y be quite usulr. This en- tripetl ft distributin is hrterized by  high wist iruferene;  wist iruferene lrger thn 40 inhes (102 ) in en nd 35 inhes (88 ) in wen is ssi- ted with n inresed risk f dibetes. Mild hypertensin is ften present in bese ptients with dibetes. c. Obstetrical complications— Type 2 dibetes shuld be nsidered in wen wh hve delivered bbieslrger thn 9 lb (4.1 kg) r hve hd plyhydrnis, pre- elpsi, r unexplined fetl lsses.B.  Laboratory Findings1. Urine  glucose— A nvenient ethd t detet glus- uri is the pper strip ipregnted with gluse xidse nd  hrgen syste (Clinistix, Distix), whih is sen- sitive t s little s 100 g/dL (5.5 l) gluse in urine. A nrl renl threshld fr gluse s well s relible bldder eptying is essentil fr interprettin. Nndibeti glysuri (renl glysuri) is  benign syptti nditin wherein gluse ppers in the urine despite  nrl unt f gluse in the bld, either bslly r during  gluse tlerne test. Its use y vry fr uttins in the SGLT2 gene ding fr sdiu-gluse trnsprter 2 (filil renl glysuri) t ne ssited with dysfuntin f the prxil renl tubule (Fnni syndre, hrni kidney disese), r it y erely be  nsequene f the inresed ld f glu- se presented t the tubules by the elevted glerulr filtrtin rte (GFR) during pregnny. As ny s 50% f pregnnt wen nrlly hve denstrble sugr in the urine, espeilly during the third nd furth nths. This sugr is prtilly lwys gluse exept during the lte weeks f pregnny, when ltse y be present. 2. Urine and blood ketones— Qulittive detetin f ketne bdies n be plished by nitrprusside tests (Aetest r Ketstix). Althugh these tests d nt detet bet-hydrxybutyri id, whih lks  ketne grup, the seiquntittive estitin f ketnuri thus btined is nnetheless usully dequte fr linil purpses. Mny lbrtries esure bet-hydrxybutyri id, nd there re eters vilble (Preisin Xtr; Nv Mx Plus) fr ptient use tht esures bet-hydrxybutyri id levels in pillry gluse sples. Bet-hydrxybutyrte levels greter thn 0.6 l/L require evlutin. Ptients with levels greter thn 3.0 l/L, equivlent t very lrge urinry ketnes, require hspitliztin. 3. Plasma or serum glucose— The gluse nentrtin is 10–15% higher in pls r seru thn in whle bld beuse struturl pnents f bld ells re bsent. A pls gluse level f 126 g/dL (7 l/L) r higher n re thn ne sin fter t lest 8 hurs f fsting is dignsti f dibetes ellitus (Tble 27–3). Fsting pls gluse levels f 100–125 g/dL (5.6–6.9 l/L) re ssited with inresed risk f dibetes (ipired fsting gluse tlerne). 4. Oral glucose tolerance test— If the fsting pls glu- se level is less thn 126 g/dL (7 l/L) when dibetes is nnetheless suspeted, then  stndrdized rl gluse tlerne test y be dne (Tble 27–3). In rder t pti- ize insulin seretin nd effetiveness, espeilly when ptients hve been n  lw-rbhydrte diet,  iniu f 150–200 g f rbhydrte per dy shuld be inluded in the diet fr 3 dys preeding the test. The ptient shuld et nthing fter idnight prir t the test dy. On the rn- ing f the test, ptients re then given 75 g f gluse in 300 L f wter. The gluse ld is nsued within ▲Figure 27–1. Acanthosis nigricans of the nape of the neck, with typical dark and velvety appearance. (Used, with permission, from Umesh Masharani, MB, BS, MRCP [UK].)CMDT22_Ch27_p1212-p1255.indd  1217 29/06/21 8:53 PMCHAPTEr 271218 CMDT 20225  inutes. The test is perfred in the rning beuse f diurnl vritin in rl gluse tlerne; ptients shuld nt ske r be tive during the test. Bld sples fr pls gluse re btined t 0 nd 120 inutes fter ingestin f gluse. Tble 27–3 pr- vides dignsti riteri fr dibetes ellitus bsed n the rl gluse tlerne test. An rl gluse tlerne test is nrl if the fsting venus pls gluse vlue is less thn 100 g/dL (5.6 l/L) nd the 2-hur vlue flls belw 140 g/dL (7.8 l/L). A fsting vlue f 126 g/dL (7 l/L) r higher r  2-hur vlue f greter thn 200 g/dL (11.1 l/L) is dignsti f di- betes ellitus. Ptients with  2-hur vlue f 140–199 g/dL (7.8–11.1 l/L) hve ipired gluse tlerne. Flse- psitive results y ur in ptients wh re lnurished, bedridden, r fflited with n infetin r severe etinl stress. 5. Glycated hemoglobin (hemoglobin A1) measure ments— Heglbin bees glyted by ketine retins between gluse nd ther sugrs nd the free in grups n the lph nd bet hins. Only glytin f the N-terinl vline f the bet hin iprts suffi- ient negtive hrge t the heglbin leule t llw seprtin by hrge dependent tehniques. These hrge- seprted heglbins re lletively referred t s heglbin A1(HbA1). The jr fr f HbA1is he- glbin A1(HbA1) where gluse is the rbhydrte. HbA1prises 4–6% f ttl heglbin A. Sine HbA1irultes within red bld ells whse life spn lsts up t 120 dys, it generlly reflets the stte f glyei ver the preeding 8–12 weeks, thereby prviding n iprved ethd f ssessing dibeti ntrl. The HbA1vlue, hwever, is weighted t re reent gluse levels (previus nth) nd this explins why signifint hnges in HbA1re bserved with shrt-ter (1 nth) hnges in en pls gluse levels. Mesureents shuld be de in ptients with either type f dibetes ellitus t 3- t 4-nth intervls. In ptients nitring their wn bld gluse levels, HbA1vlues prvide  vluble hek n the ury f nitring. In ptientswh d nt nitr their wn bld gluse levels, HbA1 vlues re essentil fr djusting therpy. The A1Derived Averge Gluse Study reprted tht the reltinship between verge gluse in the previus 3 nths nd HbA1ws (28.7 × HbA1) – 46.7. There is, hwever, sub- stntil individul vribility; fr HbA1vlues between 6.9% nd 7.1%, the gluse levels rnge fr 125 g/dL t 205 g/dL (6.9–11.4 l/L; 95% CIs). Fr HbA1f 6%, the en gluse levels rnge fr 100 g/dL t 152 g/dL (5.5–8.5 l/L); nd fr 8% they rnge fr 147 g/dL t 217 g/dL (8.1–12.1 l/L). Fr this resn, utin shuld be exerised in estiting verge gluse levels fr esured HbA1. The ury f HbA1vlues n be ffeted by he- glbin vrints r trits. In ptients with high levels f he- glbin F, iunssys give flsely lw vlues f HbA1. The Ntinl Glyheglbin Stndrdiztin Prgr web- site (www.ngsp.rg) hs infrtin n the ipt f fre- quently enuntered heglbin vrints nd trits n the results btined with the nly used HbA1ssys. Any nditin tht shrtens erythryte survivl r dereses en erythryte ge (eg, revery fr ute bld lss, helyti nei) will flsely lwer HbA1, irrespetive f the ssy ethd used beuse f the extended tie tht it tkes irulting heglbin t be glysylted. Intrvenus irn nd erythrpietin therpy fr tretent f nei in hrni kidney disese ls flsely lwer HbA1levels. Alterntive ethds suh s frutsine (see belw) shuld be nsidered fr these ptients. Vitins C nd E re reprted t flsely lwer test results pssibly by inhibiting glytin f heglbin. Cnditins tht inrese erythryte survivl suh s sple- nety fr hereditry spherytsis will flsely rise HbA1levels. Irn defiieny nei is ls ssited with higher HbA1levels. HbA1is endrsed by the ADA s  dignsti test fr type 1 nd type 2 dibetes (Tble 27–3). A utff vlue f 6.5% (48 l/l) ws hsen beuse the risk fr reti- npthy inreses substntilly bve this vlue. The advantages of using the HbA1cto diagnose diabetes is that there is no need to fast; it hs lwer intrindividul vri- bility thn the fsting gluse test nd the rl gluse tlerne test; nd it prvides n estite f gluse n- trl fr the preeding 2–3 nths. Peple with HbA1lev- els f 5.7–6.4% (39–46 l/l) shuld be nsidered t high risk fr develping dibetes (predibetes). This test is nt pprprite t use in ppultins with high prevlene f heglbinpthies r in nditins with inresed red ell turnver. 6. Serum fructosamine— Seru frutsine is fred by nnenzyti glysyltin f seru prteins (pre- dinntly lbuin). Sine seru lbuin hs  uh shrter hlf-life thn heglbin, seru frutsine generlly reflets the stte f glyei ntrl fr nly the preeding 1–2 weeks. Redutins in seru lbuin (eg, nephrti stte, prtein-lsing enterpthy, r hepti dis- ese) will lwer the seru frutsine vlue. When bnrl heglbins r helyti sttes ffet the inter- prettin f glyheglbin r when  nrrwer tieTable 27–3. Criteria for the diagnosis of diabetes. Nomal Glucose Toleance1Impaied Glucose Toleance1Diabetes Mellitus2F asting plasma glucose mg/dL (mmol/L)< 100 (5.6) 100–125 (5.6–6.9)≥ 126 (7.0) 2 hours after glucose load mg/dL (mmol/L)< 140 (7.8) ≥ 140–199 (7.8–11.0)≥ 200 (11.1) HbA1c(%) < 5.7 5.7–6.4 ≥ 6.51 See text for the oral glucose tolerance test protocol.2 A fasting plasma glucose ≥ 126 mg/dL (7.0 mmol) is diagnostic of diabetes if confirmed by repeat testing. A fasting plasma glucose ≥ 126 mg/dL (7.0 mmol) and HbA1c≥ 6.5% on the same sample is also diagnostic of diabetes.CMDT22_Ch27_p1212-p1255.indd  1218 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1219 CMDT 2022fre  is required, suh s fr sertining glyei ntrl t the tie f neptin in  dibeti wn wh hs reently bee pregnnt, seru frutsine ssys ffer se dvntge. Nrl vlues vry in reltin t the seru lbuin nentrtin nd re 200–285 l/L when the seru lbuin level is 5 g/dL. HbA1vlues nd seru frutsine re highly rrelted. Seru fruts- ine levels f 300, 367, nd 430 l/L pprxite t HbA1vlues f 7%, 8%, nd 9%, respetively. Substntil individul vribility exists, thugh, when estiting the likely HbA1vlue fr the frutsine esureent. 7. Selfmonitoring of blood glucose— Cpillry bld gluse esureents perfred by ptients theselves, s utptients, re extreely useful. A lrge nuber f bld gluse eters re vilble. All re urte, but they vry with regrd t speed, nveniene, size f bld sples required, reprting pbility, nd st. Ppulr dels inlude thse nuftured by LifeSn (One Tuh), Byer Crprtin (Cntur), Rhe Dignstis (Au-Chek), nd Abbtt Lbrtries (Preisin, Free- Style). These bld gluse eters re reltively inexpen- sive, rnging fr $20 t $80 eh. Test strips rein  jr expense, sting but $0.25 t $1.50 piee. Eh gluse eter ls es with  lnet devie nd disps- ble 26- t 33-guge lnets. Mst eters n stre fr 100 t 1000 gluse vlues in their eries nd hve pbilities t dwnld the vlues int  puter r srtphne. Se eters re designed t unite with  speifi insulin pup. Cntur Next Link eter, fr exple, unites with the MiniMed Medtrni pup. The ury f dt btined by he gluse nitring des require edutin f the ptient in s- pling nd esuring predures. The liniin shuld be wre f the liittins f the self-nitring gluse systes. The strips hve liited lifespns nd iprper strge (high teperture; pen vil) n ffet their funtin. Ptients shuld ls be dvised nt t use expired strips. Inreses r dereses in hetrit n derese r inrese the esured glu- se vlues. Meters nd the test strips re librted ver the gluse nentrtins rnging fr 60 g/dL (3.3 l/L) t 160 g/dL (8.9 l/L) nd the ury is nt s gd fr higher nd lwer gluse levels. When the gluse is less thn 60 g/dL (3.3 l/L), the differ- ene between the eter nd the lbrtry vlue y be s uh s 20%. Gluse xidse–bsed peretri sys- tes underestite gluse levels in the presene f high xygen tensin. This y be iprtnt in the ritilly ill wh re reeiving suppleentl xygen; under these ir- ustnes,  gluse dehydrgense–bsed syste y be preferble. Gluse-dehydrgense pyrrlquin- line quinne (GDH-PQQ) systes y reprt flsely high gluse levels in ptients wh re reeiving prenterl prduts ntining nngluse sugrs suh s ltse, gltse, r xylse r their etblites. Se eters re pprved fr esuring gluse in bld sples btined t lterntive sites suh s the frer nd thigh. There is, hwever,  5- t 20-inute lg in the gluse respnse n the r with respet t the gluse respnse n the finger.Frer bld gluse esureents uld therefre result in  dely in detetin f rpidly develping hypgly- ei. Ipired irultin t the fingers (fr exple, in ptients with Rynud disese) will rtifiilly lwer fingerstik gluse esureents (pseudhypglyei). 8. Continuous glucose monitoring systems— A gluse xidse–bsed syste t esure gluse nentrtins in the interstitil fluid is used by ptients wh re inres- ingly using ntinuus gluse nitring systes. These systes, nuftured by Medtrni MiniMed, DexC systes, nd Abbtt Dignstis, invlve inserting  sub- utneus sensr (rther like  sll wire) tht esures gluse nentrtins ntinuusly in the interstitil fluid fr 7–14 dys. The DexC nd MiniMed systes trns- it gluse dt wirelessly t srtphnes r t the sreens f insulin pups. Diretinl rrws indite rte nd diretin f hnge f gluse levels, nd lerts n be set fr dngerusly lw r high gluse vlues. The werer ls gins insight int hw prtiulr fds nd tivities ffet their gluse level. The FreeStyle Libre (Abbtt Dig- nstis) sensr syste requires the ptient t hld  red- ing devie r  srtphne lse t the sensr pth fr but  send t see the rel tie gluse vlue. The MiniMed syste requires librtin with peridi finger- stik gluse levels, whih is nt neessry fr the Dex nd Freestyle Libre systes. The ftry librted systes use  librtin funtin tht uttilly rrets fr sensr drift ver the subsequent 10–14 dys. A 6-nth rndized ntrlled study f ptients with type 1 dibe- tes shwed tht dults (25 yers nd lder) using these ntinuus gluse nitring systes hd iprved glyei ntrl withut n inrese in the inidene f hypglyei. A rndized ntrlled study f ntinu- us gluse nitring during pregnny shwed iprved glyei ntrl in the third triester, lwer birth weight, nd redued risk f rsi. Suries f the ntinuus gluse nitring dt lleted ver 2–12 weeks n be very helpful. The perentge f “tie in rnge” (gluse levels 70–180 g/dy [3.9–10 l/L]), gluse levels tht re lw r high, nd their vribility n be ssessed. There is  strng rreltin between gluse levels tht re 70% “tie in rnge” nd n HbA1f pprx- itely 7%. Mny f these systes re vered by insurne. The initil st is but $800 t $1000, nd the sensr, whih hs t be hnged every 7 t 14 dys, sts $35 t $60; the ut-f-pket expense is but $4000 nnully. 9. Lipoprotein abnormalities in diabetes— Cirulting lipprteins re just s dependent n insulin s is the pls gluse. In type 1 dibetes, dertely defiient ntrl f hyperglyei is ssited with nly  slight elevtin f LDL hlesterl nd seru triglyerides nd little if ny hnge in HDL hlesterl. One the hypergly- ei is rreted, lipprtein levels re generlly nrl. Hwever, in ptients with type 2 dibetes,  distint “dibeti dyslipidei” is hrteristi f the insulin resistne syndre. Its fetures re  high seru tri- glyeride level (300–400 g/dL [3.4–4.5 l/L]),  lwCMDT22_Ch27_p1212-p1255.indd  1219 29/06/21 8:53 PMCHAPTEr 271220 CMDT 2022HDL h lesterl (less thn 30 g/dL [0.8 l/L]), nd  qulittive hnge in LDL prtiles, prduing  sller dense prtile whse ebrne rries suprnrl unts f free hlesterl. These sller dense LDL pr- tiles re re suseptible t xidtin, whih renders the re thergeni. Mesures designed t rret the besity nd hyperglyei, suh s exerise, diet, nd hypglyei therpy, re the tretent f hie fr di- beti dyslipidei, nd in sinl ptients in wh nrl weight ws hieved, ll fetures f the lipprtein bnrlities lered. Sine priry disrders f lipid etblis y exist with dibetes, persistene f lipid bnrlities fter restrtin f nrl weight nd bld gluse shuld prpt  dignsti wrkup nd pssible phrtherpy f the lipid disrder. Chpter 28 dis- usses these tters in detil.Aerin  Dibetes Assitin. 6. Glyei Trgets: Standards of Medical Care in Diabetes —2021. Dibetes Cre. 2021;44:S73. [PMID: 33298417] »TreatmentA.  DietA  well-blned, nutritius diet reins  fundentl eleent f therpy. There is n speifi reendtin n the perentge f lries tht shuld e fr rb- hydrte, prtein, nd ft. The rnutrient prprtins shuld be individulized bsed n the ptient’s eting pt- terns, preferenes, nd etbli gls. In generl, st ptients with dibetes nsue but 45% f their ttl dily lries in the fr f rbhydrtes, 25–35% in the fr f ft, nd 10–35% in the fr f prtein. In ptients with type 2 dibetes, liiting the rbhydrte intke nd substituting se f the lries with nunsturted fts, suh s live il, rpeseed (nl) il, r the ils in nuts nd vds, n lwer triglyerides nd inrese HDL hles- terl. A Mediterrnen-style eting pttern ( diet supple- ented with wlnuts, lnds, hzelnuts, nd live il) hs been shwn t iprve glyei ntrl nd lwer - bined endpints fr rdivsulr events nd strke. In thse ptients with besity nd type 2 dibetes, weight redutin by lri restritin is n iprtnt gl f the diet (see Chpter 29). Ptients with type 1 dibetes r type 2 dibetes wh tke insulin shuld be tught “rbhydrte unting, ” s they n dinister their insulin blus fr eh el bsed n its rbhydrte ntent. The urrent reendtins fr sturted fts nd dietry hlesterl intke fr peple with dibetes re the se s fr the generl ppultin. Sturted fts shuld be liited t less thn 10% f dily lries nd dietry h- lesterl intke shuld be less thn 300 g/dy. Fr thse ptients with kidney disese, dietry prtein shuld be intined t the reended dily llwne f 0.8 g/kg/dy. Exhnge lists fr el plnning n be btined fr the Aerin Dibetes Assitin nd its ffilite ssitins r fr the Aerin Dieteti Ass- itin (http://www.etright.rg), 216 W . Jksn Blvd., Chig, IL 60606 (312-899-0040).1. Dietary fiber— Plnt pnents suh s ellulse, gu, nd petin re indigestible by huns nd re tered dietry “fiber. ” Insluble fibers suh s ellulse r hei- ellulse, s fund in brn, tend t inrese intestinl trn- sit nd y hve benefiil effets n lni funtin. In ntrst, sluble fibers suh s gus nd petins, s fund in bens, tel, r pple skin, tend t retrd nutrient bsrptin rtes s tht gluse bsrptin is slwer nd hyperglyei y be slightly diinished. Althugh its reendtins d nt inlude insluble fiber supple- ents suh s dded brn, the ADA reends fd suh s tel, erels, nd bens with reltively high sluble fiber ntent s stple pnents f the diet in dibetis. High sluble fiber ntent in the diet y ls hve  fvrble effet n bld hlesterl levels. 2. Glycemic index— The glyei index f  rbhy- drte ntining fd is deterined by pring the gluse exursins fter nsuing 50 g f test fd with gluse exursins fter nsuing 50 g f referene fd (white bred): Glycemic indexBlood glucose area under the curve (3h) for test food Blood glucose area under the curve (3h) for reference food100 =  × Eting lw glyei index fds results in lwer glu- se levels fter els. Lw glyei index fds hve vlues f 55 r less nd inlude ny fruits, vegetbles, griny breds, pst, nd legues. High glyei index fds hve vlues f 70 r greter nd inlude bked ptt, white bred, nd white rie. Glyei index is lw- ered by the presene f fts nd prtein when fd is n- sued in  ixed el. Even thugh it y nt be pssible t urtely predit the glyei index f  prtiulr fd in the ntext f  el, it is resnble t hse fds with lw glyei index. 3. Artificial and other sweeteners— Shrin (Sweet N Lw), surlse (Splend), esulfe ptssiu (Sweet One), nd rebin (Truvi) re “rtifiil” sweeteners tht n be used in king nd bking. Asprte (NutrSweet) lks het stbility, s it nnt be used in king. Nne f these sweeteners rise bld gluse levels. Frutse represents  “nturl” sugr substne tht is  highly effetive sweetener, indues nly slight inreses in pls gluse levels, nd des nt require insulin fr its etblis. Hwever, beuse f ptentil dverse effets f lrge unts f frutse n rising seru hlesterl, triglyerides, nd LDL hlesterl, it des nt hve ny dvntge s  sweetening gent in the dibeti diet. This des nt prelude, hwever, ingestin f frutse-ntining fruits nd vegetbles r frutse-sweetened fds in dertin. Sugr lhls, ls knwn s plyls r plylhl, re nly used s sweeteners nd bulking gents. They ur nturlly in  vriety f fruits nd vegetbles but re ls erilly de fr surse, gluse, nd strh.CMDT22_Ch27_p1212-p1255.indd  1220 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1221 CMDT 2022Exp les re srbitl, xylitl, nnitl, ltitl, islt, ltitl, nd hydrgented strh hydrlystes (HSH). They re nt s esily bsrbed s sugr, s they d nt rise bld gluse levels s uh. Therefre, sugr l- hls re ften used in fd prduts tht re lbeled s “sugr free, ” suh s hewing gu, lzenges, hrd ndy, nd sugr-free ie re. Hwever, if nsued in lrge quntities, they will rise bld gluse nd n use blting nd dirrhe.B.  Medications for Treating HyperglycemiaThe  editins fr treting type 2 dibetes re listed in Tble 27–4. 1. Medications that primarily stimulate insulin secretion by binding to the sulfonylurea receptor on the beta cell— a. Sulfonylureas— The priry ehnis f tin f the sulfnylures is t stiulte insulin relese fr pn- reti B ells. Sulfnylures re used in ptients with type 2 but nt type 1 dibetes, sine these editins require funtin- ing pnreti B ells t prdue their effet n bld gluse. Sulfnylures re etblized by the liver nd prt fr ethexide, whse etblite is re tive thn the prent pund, the etblites f ll the ther sulfnylures re wekly tive r intive. The etblites re exreted by the kidney nd, in the se f the send-genertin sulfnylures, prtly exreted in the bile. Hypglyei is  n dverse retin with the sulfnylures. Weight gin is ls n, espeilly in the first yer f use. The ehniss f the weight gin inlude iprved gluse ntrl nd inresed fd intke in respnse t hypglyei. Idisynrti retins re rre, with skin rshes r hetlgi txiity (leukpeni, thrbytpeni) urring in less thn 0.1% f users. (1) First-generation oral sulfonylureas (tolbutamide, tolazamide, acetohexamide, chlorpropamide)— Tlbut- ide is prbbly best dinistered in divided dses (eg, 500 g befre eh el nd t bedtie); hwever, se ptients require nly ne r tw tblets dily with  xi- u dse f 3000 g/dy. Beuse f its shrt durtin f tin (but 6–10 hurs, whih is independent f kidney funtin), tlbutide is reltively sfe t use in kidney disese. Prlnged hypgly- ei hs been reprted rrely with tlbutide, stly in ptients reeiving ntibteril sulfnides (sulfisx- zle), phenylbutzne fr rthrlgis, r the rl zle ntifungl editins t tret ndidisis. Tlzide, ethexide, nd hlrprpide re rrely used. Chlrprpide hs  prlnged bilgi effet, nd severe hypglyei n ur espeilly in lder dults s their renl lerne delines with ging. Its ther side effets inlude lhl-indued flushing nd hypntrei due t its effet n vspressin seretin nd tin. (2) Second-generation sulfonylureas (glyburide, glipizide, gliclazide, glimepiride)— Glyburide, glipizide, glilzide, nd gliepiride re 100–200 ties re ptentthn tlbutide. These editins shuld be used with utin in ptients with rdivsulr disese r in elderly ptients, in wh prlnged hypglyei wuld be espe- illy dngerus. The usul strting dse f glyburide is 2.5 g/dy, nd the verge intenne dse is 5–10 g/dy given s  single rning dse; intenne dses higher thn 20 g/dy re nt reended. Se reprts suggest tht 10 g is  xiu dily therpeuti dse, with 15–20 g hving n dditinl benefit in pr respnders nd dses ver 20 g tully wrsening hyperglyei. A “Press Tb” frultin f “irnized” glyburide—esy t divide in hlf with slight pressure if neessry—is vil- ble. Glyburide is etblized in the liver nd the et- bli prduts f glyburide hve hypglyei tivity. This prbbly explins why ssys speifi fr the une- tblized pund suggest  pls hlf-life f nly 1–2 hurs, yet the bilgi effets f glyburide re lerly persistent 24 hurs fter  single rning dse in dibeti ptients. Glyburide hs few dverse effets ther thn its pten- til fr using hypglyei, whih t ties n be pr- lnged. Flushing hs rrely been reprted fter ethnl ingestin. It des nt use wter retentin, s hlrprp- ide des, but rther slightly enhnes free wter ler- ne. Glyburide shuld nt be used in ptients with liver filure nd hrni kidney disese beuse f the risk f hypglyei. Elderly ptients re t prtiulr risk fr hypglyei even with reltively sll dily dses. The reended strting dse f glipizide is 5 g/dy, with up t 15 g/dy given s  single dily dse befre brekfst. When higher dily dses re required, they shuld be divided nd given befre els. The xiu dse reended by the nufturer is 40 g/d, lthugh dses bve 10–15 g prbbly prvide little dditinl benefit in pr respnders nd y even be less effetive thn sller dses. Fr xi- u effet in reduing pstprndil hyperglyei, glipizide shuld be ingested 30 inutes befre els, sine rpid bsrptin is delyed when the editin is tken with fd. At lest 90% f glipizide is etblized in the liver t intive prduts, nd 10% is exreted unhnged in the urine. Glipizide therpy shuld therefre nt be used in ptients with liver filure. Beuse f its lwer pteny nd shrter durtin f tin, it is preferble t glyburide in elderly ptients nd fr thse ptients with kidney disese. Glutrl-XL prvides extended relese f glipizide during trnsit thrugh the gstrintestinl trt with greter effe- tiveness in lwering prebrekfst hyperglyei thn the shrter-durtin iedite-relese stndrd glipizide tb- lets. Hwever, this frultin ppers t hve srified its lwer prpensity fr severe hypglyei pred with lnger-ting glyburide withut shwing ny den- strble therpeuti dvntges ver glyburide. Gliclazide (nt vilble in the United Sttes) is nther interedite durtin sulfnylure with  durtin f tin f but 12 hurs. The reended strting dse is 40–80 g/dy with  xiu dse f 320 g. Dses f 160 g nd bve re given s divided dses befreCMDT22_Ch27_p1212-p1255.indd  1221 29/06/21 8:53 PMCHAPTEr 271222 CMDT 2022T able 27–4. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Sulfonylueas Acetohexamide (Dymelor) (not available in United States)250 and 500 mg 0.25–1.5 g as single dose or in two divided doses 8–24 hours Chlorpropamide (Diabinese) 100 and 250 mg 0.1–0.5 g as single dose 24–72 hours Gliclazide (not available in United States) 80 mg 40–80 mg as single dose; 160–320 mg as divided dose 12 hours Glimepiride (Amaryl) 1, 2, and 4 mg Usual dose: 1–4 mg once daily Maximal dose: 8 mg once dailyUp to 24 hours Glipizide (Glucotrol) 5 and 10 mg Usual dose: 2.5–10 mg twice daily 30 minutes before meals Maximal dose: 20 mg twice daily6–12 hours (Glucotrol XL) 2.5, 5, and 10 mg Usual dose: 2.5–10 mg once daily Maximal dose: 20 mg once dailyUp to 24 hours Glyburide (Dia Beta, Micronase) 1.25, 2.5, and 5 mg 1.25–20 mg as single dose or in two divided doses Up to 24 hours (Glynase) 1.5, 3, and 6 mg 1.5–12 mg as single dose or in two divided doses Up to 24 hours Tolazamide (Tolinase) 100, 250, and 500 mg 0.1–1 g as single dose or in two divided doses Up to 24 hours Tolbutamide (Orinase) 250 and 500 mg 0.5–2 g in two or three divided doses 6–10 hours Meglitinide Analogs Mitiglinide (available in Japan) 5 and 10 mg 5 or 10 mg three times daily before meals 2 hours Repaglinide (Prandin) 0.5, 1, and 2 mg Usual dose: 0.5 to 4 mg three times daily 15 minutes before meals Maximal dose: 16 mg daily3 hoursd -Phenylalanine Deivative Nateglinide (Starlix) 60 and 120 mg 60 or 120 mg three times daily before meals 4 hours Biguanides Metformin (Glucophage) 500, 850, and 1000 mg 500–850 mg with meals two or three times daily; 850–1000 mg with breakfast and dinner4 hours Metformin, extended release (Glucophage XR)1500, 750, and 1000 mg 500–2000 mg once daily Up to 24 hours Thiazolidinediones Pioglitazone (Actos) 15, 30, and 45 mg 15–45 mg daily Up to 24 hours Rosiglitazone (Avandia) 2, 4, and 8 mg 4–8 mg daily (can be divided) Up to 24 hours Alpha-Glucosidase Inhibitos Acarbose (Precose) 25, 50, and 100 mg 25–100 mg three times daily just before meals 4 hours Miglitol (Glyset) 25, 50, and 100 mg 25–100 mg three times daily just before meals 4 hours Voglibose (not available in United States) 0.2 and 0.3 mg 0.2–0.3 mg three times daily just before meals 4 hours GLP-1 recepto Agonists Dulaglutide (Trulicity) 0.75-, 1.5-mg single- dose pen or pre- filled syringeUsual dose: 0.75 mg subcutaneously once weekly Maximal dose: 1.5 mg subcutaneously once weekly1 week Exenatide (Byetta) 1.2 mL and 2.4 mL prefilled pens deliv- ering 5 mcg and 10 mcg doses5 mcg subcutaneously twice daily within 1 hour of breakfast and dinner. Increase to 10 mcg subcuta- neously twice daily after about a month. AVOID if eGFR < 30 mL/min/1.73 m26 hours Exenatide, long-acting release (Byetta LAR, Bydureon)2 mg (powder) Suspend in provided diluent and inject subcutaneously.1 week (continued )CMDT22_Ch27_p1212-p1255.indd  1222 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1223 CMDT 2022T able 27–4. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Liraglutide (Victoza) Prefilled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mgInitial dose: 0.6 mg subcutaneously once daily. Increase to 1.2 mg after a week if no adverse reactions. Maximal dose: 1.8 mg subcutaneously once daily24 hours Lixisenatide (Adlyxin, Lyxumia) 3-mL prefilled pens delivering 10- or 20-mcg dosesInitial dose: 10 mcg daily. Increase to 20 mcg daily after 2 weeks.24 hours Semaglutide (Ozempic, Rybelsus) Prefilled pens deliver- ing 0.25 mg or 0.5 mg 1-, 3-,7-, and 14-mg tabletsInitial dose: 0.25 mg weekly for 1 month and increase to 0.5 mg weekly if no adverse reactions. Maximal dose: 1 mg weekly Initial dose: 3 mg for 1 month and then increase to 7 mg. Take fasting daily with water and wait 30 min to eat. Maximal dose: 14 mg1 week Daily DPP-4 Inhibitos Alogliptin (Nesina) 6.25, 12.5, and 25 mg 25 mg once daily if eGFR ≥ 60 mL/min/1.73 m2; 12.5 mg daily if eGFR 30–59 mL/min/1.73 m2; 6.25 mg daily if eGFR < 30 mL/min/1.73 m224 hours Linagliptin (Tradjenta) 5 mg 5 mg daily 24 hours Saxagliptin (Onglyza) 2.5 and 5 mg 2.5 mg or 5 mg once daily if eGFR > 50 mL/min/1.73 m2. 2.5 mg daily if eGFR ≤ 50 mL/min/1.73 m2or if also taking drugs that are strong CYP3A4/5 inhibitors such as ketoconazole24 hours Sitagliptin (Januvia) 25, 50, and 100 mg 100 mg once daily if eGFR > 50 mL/min/1.73 m2; 50 mg once daily if eGFR 30–50 mL/min/1.73 m2; 25 mg once daily if eGFR < 30 mL/min/1.73 m224 hours Vildagliptin (Galvus) (not available in United States)50 mg 50 mg once or twice daily. AVOID if eGFR ≤ 60 mL/min/1.73 m2or AST/ALT three times upper limit of normal24 hours SGLT2 Inhibitos Canagliflozin (Invokana) 100 and 300 mg Usual dose: 100 mg daily. 300 mg can be used if normal eGFR, resulting in lowering the HbA1can additional ~ 0.1–0.25%. AVOID if eGFR < 45 mL/min/1.73 m2.24 hours Dapagliflozin (Farxiga) 5 and 10 mg 10 mg daily 24 hours Empagliflozin (Jardiance) 10 and 25 mg Usual dose: 10 mg daily Maximal dose: 25 mg24 hours Ertugliflozin (Steglatro) 5 and 15 mg Usual dose: 5 mg daily Maximal dose: 15 mg24 hours Othes Bromocriptine (Cycloset) 0.8 mg 0.8 mg daily. Increase weekly by 1 tablet until maxi- mal tolerated dose of 1.6–4.8 mg daily.24 hours Colesevelam (Welchol) 625 mg 3 tablets twice daily 24 hours Pramlintide (Symlin) 5-mL vial containing 0.6 mg/mL; also available as pre- filled pens. Symlin pen 60 or Symlin pen 120For insulin-treated type 2 patients, start at 60-mcg dose subcutaneously three times daily (10 units on U100 insulin syringe). Increase to 120 mcg three times daily (20 units on U100 insulin syringe) if no nausea for 3–7 days. Give immediately before meal. For type 1 patients, start at 15 mcg three times daily (2.5 units on U100 insulin syringe) and increase by increments of 15 mcg to a maximum of 60 mcg three times daily, as tolerated. To avoid hypoglycemia, lower insulin dose by 50% on initiation of therapy.2 hours AST/ALT, aspartate aminotransferase/alanine aminotransferase; eGFR, estimated glomerular filtration rate.(continued)CMDT22_Ch27_p1212-p1255.indd  1223 29/06/21 8:53 PMCHAPTEr 271224 CMDT 2022brekfst  nd dinner. The editin is etblized by the liver; the etblites nd njugtes hve n hypglyei effet. An extended-relese preprtin is vilble. Glimepiride hs  lng durtin f effet with  hlf- life f 5 hurs llwing ne r twie dily dsing. Gliepiride hieves bld gluse lwering with the lw- est dse f ny sulfnylure pund. A single dily dse f 1 g/dy hs been shwn t be effetive, nd the xi- l reended dse is 8 g. It is pletely etb- lized by the liver t reltively intive etbli prduts. b. Meglitinide analogs— Repglinide is struturlly siilr t glyburide but lks the sulfni id-ure iety. It ts by binding t the sulfnylure reeptr nd lsing the densine triphsphte (ATP)-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine nd then underges plete etblis in the liver t intive biliry prduts, giving it  pls hlf-life f less thn 1 hur. The editin therefre uses  brief but rpid pulse f insulin. The strting dse is 0.5 g three ties  dy 15 inutes befre eh el. The dse n be titrted t  xiu dily dse f 16 g. Like the sulfnylures, repglinide n be used in bintin with etfrin. Hypglyei is the in side effet. Like the sulfnyl- ures, repglinide uses weight gin. Metblis is by ythre P450 3A4 isenzye, nd ther editins tht indue r inhibit this isenzye y inrese r inhibit (respetively) the etblis f repglinide. The editin y be useful in ptients with kidney ipir- ent r in lder dults. Mitiglinide is  benzylsuini id derivtive tht binds t the sulfnylure reeptr nd is siilr t rep- glinide in its linil effets. It is pprved fr use in Jpn. c. D-phenylalanine derivative— Nteglinide stiu- ltes insulin seretin by binding t the sulfnylure reep- tr nd lsing the ATP-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine, rehing pek pls levels within 1 hur. It is etblized in the liver nd hs  pls hlf-life f but 1.5 hurs. Like repglinide, it uses  brief rpid pulse f insulin, nd when given befre  el it redues the pstprndil rise in bld gluse. Fr st ptients, the reended strting nd intenne dse is 120 g three ties  dy befre els. Use 60 g in ptients wh hve ild elevtins in HbA1. Like the ther insulin seretggues, its in side effets re hyp- glyei nd weight gin. 2. Medications that primarily lower glucose levels by their actions on the liver, muscle, and adipose tissue— a. Metformin— Metfrin is the first-line therpy fr ptients with type 2 dibetes. It n be used lne r in njuntin with ther rl gents r insulin in the tret- ent f ptients with type 2 dibetes. It is ineffetive in ptients with type 1 dibetes. Metfrin’s therpeuti effets pririly derive fr the inresing hepti densine nphsphte-tivted pr- tein kinse tivity, whih redues hepti glunegenesis nd lipgenesis. Metfrin hs  hlf-life f 1.5–3 hurs nd is nt bund t pls prteins r etblized, being exreted unhnged by the kidneys.The urrent reendtin is t strt etfrin t dignsis. A side benefit f etfrin therpy is its ten- deny t iprve bth fsting nd pstprndil hypergly- ei nd hypertriglyeridei in bese ptients with dibetes withut the weight gin ssited with insulin r sulfnylure therpy. Ptients with hrni kidney disese shuld nt be given this editin beuse filure t exrete it wuld prdue high bld nd tissue levels f etfrin tht uld stiulte lti id verprdutin. In the United Sttes, etfrin use is nt reended t r bve  seru retinine level f 1.4 g/dL in wen nd 1.5 g/dL in en. In the United Kingd, the re- endtins re t review etfrin use when the seru retinine exeeds 130 l/L (1.5 g/dL) r the esti- ted glerulr filtrtin rte (eGFR) flls belw 45 L/ in/1.73 2. The editin shuld be stpped if the seru retinine exeeds 150 l/L (1.7 g/dL) r the eGFR is belw 30 L/in/1.73 2. Ptients with liver fil- ure r persns with exessive lhl intke shuld nt reeive this editin beuse f the risk f lti idsis. The xiu dsge f etfrin is 2550 g, lthugh little benefit is seen bve  ttl dse f 2000 g. It is iprtnt t begin with  lw dse nd inrese the dsge very grdully in divided dses—tken with els—t redue inr gstrintestinl upsets (nrexi, nuse, viting, bdinl disfrt, dirrhe), whih ur in up t 20% f ptients. A n shedule wuld be ne 500-g tblet three ties  dy with els r ne 850- r 1000-g tblet twie dily t brekfst nd dinner. Up t 2000 g f the extended-relese preprtin n be given ne  dy. Lwer dses shuld be used in ptients with eGFRs between 30 nd 45 L/in/1.73 2nd in the elderly wh re t higher risk fr ute kidney injury fr redued renl funtinl reserve. The gstrintestinl side effets re dse-relted, tend t ur t nset f therpy, nd ften re trnsient. Hw- ever, in 3–5% f ptients, therpy y hve t be disntin- ued beuse f persistent dirrhel disfrt. Ptients swithing fr iedite-relese etfrin t pr- ble dse f extended-relese etfrin y experiene fewer gstrintestinl side effets. Hypglyei des nt ur with therpeuti dses f etfrin, whih perits its desriptin s  “euglyei” r “ntihyperglyei” editin rther thn n rl hypglyei gent. Dertlgi r hetlgi txiity is rre. Metfrin interferes with the liu dependent bsrptin f vitin B12-intrinsi plex in the terinl ileu; vitin B12defiieny n ur fter ny yers f etfrin use. Peridi sreening with vitin B12levels shuld be nsidered, espeilly in ptients with peripherl neurpthy (whih y be errneusly ttributed t di- beti neurpthy) r if  ryti nei develps. Inresed intke f dietry liu y prevent the et- frin-indued B12lbrptin. Lti idsis hs been reprted s  side effet but is unn with etfrin in ntrst t phenfrin. Alst ll reprted ses hve invlved persns with ssited risk ftrs tht shuld hve ntrindited its use (kidney, liver, r rdirespirtry insuffiieny ndCMDT22_Ch27_p1212-p1255.indd  1224 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1225 CMDT 2022lhlis).  Aute kidney injury n ur rrely in er- tin ptients tking etfrin wh reeive rdintrst gents. Metfrin therpy shuld therefre be teprrily hlted n the dy f rdintrst dinistrtin nd restrted  dy r tw lter fter nfirtin tht kidney funtin hs nt deterirted. b. Thiazolidinediones— Tw editins f this lss, rsiglitzne nd piglitzne, re vilble fr linil use. These editins sensitize peripherl tissues t insulin. They bind the nuler reeptr perxise prlifertr- tivted reeptr g (PPAR-g) nd ffet the expressin f  nuber f genes. Like the bigunides, this lss f editins des nt use hypglyei. Bth rsiglitzne nd piglitzne re effetive s ntherpy nd in bintin with sulfnylures r etfrin r insulin, lwering HbA1by 1–2%. When used in bintin with insulin, they n result in  30–50% redutin in insulin dsge, nd se ptients n e ff insulin pletely. The rl dsge f rsigli- tzne is 4–8 g dily nd f piglitzne, 15–45 g dily; the editins d nt hve t be tken with fd. Rsigli- tzne is pririly etblized by the CYP 2C8 isen- zye nd piglitzne is etblized by CYP 2C8 nd CYP 3A4. The bintin f  thizlidinedine nd etfr- in hs the dvntge f nt using hypglyei. Ptients indequtely nged n sulfnylures n d well n  bintin f sulfnylure nd rsiglitzne r piglitzne. These editins hve se dditinl effets prt fr gluse lwering. Rsiglitzne therpy is ssited with inreses in ttl hlesterl, LDL hlesterl (15%), nd HDL hlesterl (10%). There is  redutin in free ftty ids f but 8–15%. The hnges in triglyerides re generlly nt different fr pleb. Piglitzne in lini- l trils lwered triglyerides (9%) nd inresed HDL hlesterl (15%) but did nt use  nsistent hnge in ttl hlesterl nd LDL hlesterl levels. A prspetive rndized prisn f the etbli effets f pigli- tzne nd rsiglitzne shwed siilr effets n HbA1 nd weight gin. Sll prspetive studies hve den- strted tht tretent with these editins leds t iprveents in the biheil nd histlgi fetures f nnlhli ftty liver disese. The thizlidinedines ls y liit vsulr sth usle prlifertin fter injury, nd there re reprts tht piglitzne n redue neintil prlifertin fter rnry stent pleent. In ne duble-blind, pleb-ntrlled study, rsiglitzne ws shwn t be ssited with  derese in the rti f urinry lbuin t retinine exretin. Safety concerns nd se trublese side effets liit the use f this lss f editin. Rsiglitzne use delined when  et-nlysis f 42 rndized linil trils suggested tht this editin inreses the risk f ngin petris r yrdil infrtin; the Eurpen Mediines Ageny suspended the use f rsiglitzne in Eurpe. In the United Sttes, the FDA estblished  restrited distributin prgr. A subsequent lrge pr- spetive linil tril (the RECORD study) filed tnfir the et-nlysis finding nd the restritins were lifted in the United Sttes. Ede urs in but 3–4% f ptients reeiving ntherpy with rsiglitzne r piglitzne. The ede urs re frequently (10–15%) in ptients reeiv- ing nitnt insulin therpy nd y result in hert filure. The editins re ntrindited in dibeti individuls with New Yrk Hert Assitin lss III nd IV rdi sttus. Thizlidinedines hve ls been reprted s being ssited with new nset r wrsening ulr ede. Apprently, this is  rre side effet, nd st f these ptients ls hd peripherl ede. The ulr ede reslved r iprved ne the editin ws disntinued. Trglitzne, the first editin in this lss, ws with- drwn fr linil use beuse f editin-ssited ftl liver filure. Althugh rsiglitzne nd piglitzne hve nt been reprted t use liver injury, the FDA re- ends tht they shuld nt be used in ptients with linil evidene f tive liver disese r pretretent elevtin f the lnine intrnsferse (ALT) level tht is 2.5 ties greter thn the upper liit f nrl. Liver biheil tests shuld be perfred n ll ptients prir t inititin f tretent nd peridilly therefter. An inrese in frture risk in wen (but nt en) hs been reprted with bth rsiglitzne nd pigli- tzne. The frture risk is in the rnge f 1.9 per 100 ptient-yers with the thizlidinedine s ppsed t 1.1 per 100 ptient-yers n prisn tretent. In t lest ne study f rsiglitzne, the frture risk ws inresed in preenpusl s well s pstenpusl wen. Other side effets inlude nei, whih urs in 4% f ptients treted with these editins; it y be due t  dilutinl effet f inresed pls vlue rther thn  redutin in red ell ss. Weight gin urs, espeilly when the editin is bined with  sulfnylure r insulin. Se f the weight gin is fluid retentin, but there is ls n inrese in ttl ft ss. Clinil studies hve reprted nfliting results regrding n ssitin f bldder ner with piglitzne use. A 10-yer bserv- tinl hrt study f ptients tking piglitzne filed t find n ssitin with bldder ner. A lrge ultippu- ltin pled nlysis (1.01 illin persns ver 5.9 illin persn-yers) ls filed t find n ssitin between uultive expsure f piglitzne r rsiglitzne nd inidene f bldder ner. Anther ppultin-bsed study, hwever, generting 689,616 persn-yers f fllw- up did find tht piglitzne but nt rsiglitzne ws ssited with n inresed risk f bldder ner. 3. Medications that affect absorption of glucose— Alph- glusidse inhibitrs petitively inhibit the lph- glusidse enzyes in the gut tht digest dietry strh nd surse. Tw f these editins—rbse nd iglitl—re vilble fr linil use in the United Sttes. Vglibse, nther lph-glusidse inhibitr is vilble in Jpn, Kre, nd Indi. Arbse nd iglitl re ptent inhibitrs f gluylse, lph-ylse, nd surse but hve less effet n isltse nd hrdly ny n trehlse nd ltse.CMDT22_Ch27_p1212-p1255.indd  1225 29/06/21 8:53 PMCHAPTEr 271226 CMDT 2022a.  Acarbose— The reended strting dse f r- bse is 50 g rlly twie dily, grdully inresing t 100 g three ties dily. Fr xil benefit n pstprn- dil hyperglyei, rbse shuld be given with the first uthful f fd ingested. In dibeti ptients, it redues pstprndil hyperglyei by 30–50%, nd its verll effet is t lwer the HbA1by 0.5–1%. The prinipl dverse effet, seen in 20–30% f ptients, is fltulene. This is used by undigested rbhydrte rehing the lwer bwel, where gses re prdued by bteril flr. In 3% f ses, trublese dirrhe urs. This gstrintestinl disfrt tends t disur- ge exessive rbhydrte nsuptin nd prtes iprved pline f type 2 ptients with their diet presriptins. When rbse is given lne, there is n risk f hypglyei. Hwever, if bined with insulin r sulfnylures, it ight inrese the risk f hypglyei fr these gents. A slight rise in hepti intrnsfer- ses hs been nted in linil trils with rbse (5% vs 2% in pleb ntrls, nd prtiulrly with dses greter thn 300 g/dy). The levels generlly return t nrl n stpping the editin. b. Miglitol— Miglitl is siilr t rbse in ters f its linil effets. It is indited fr use in diet- r sulfnyl- ure-treted ptients with type 2 dibetes. Therpy is initi- ted t the lwest effetive dsge f 25 g rlly three ties  dy. The usul intenne dse is 50 g three ties  dy, lthugh se ptients y benefit fr inresing the dse t 100 g three ties  dy. Gstrin- testinl side effets ur s with rbse. The editin is nt etblized nd is exreted unhnged by the kidney. Miglitl shuld nt be used in end-stge hrni kidney disese, when its lerne wuld be ipired. 4. Incretins— Orl gluse prvkes  threefld t furfld higher insulin respnse thn n equivlent dse f gluse given intrvenusly. This is beuse the rl gluse uses  relese f gut hrnes, priniplly glugn-like pep- tide 1 (GLP-1) nd gluse-dependent insulintrpi ply- peptide (GIP1), tht plify the gluse-indued insulin relese. This “inretin effet” f GLP-1 seretin (but nt GIP1 seretin) is redued in ptients with type 2 dibetes; when GLP-1 is infused in ptients with type 2 dibetes, it stiultes insulin seretin nd lwers gluse levels. GLP-1, unlike the sulfnylures, hs nly  dest insulin stiul- try effet t nrglyei nentrtins. This ens tht GLP-1 hs  lwer risk fr hypglyei thn the sulfnylures. In dditin t its insulin stiultry effet, GLP-1 ls hs  nuber f ther pnreti nd extrpnreti effets. It suppresses glugn seretin nd s y e- lirte the hyperglugnei tht is present in peple with dibetes nd iprve pstprndil hyperglyei. GLP-1 ts n the sth delying gstri eptying; the iprtne f this effet n gluse lwering is illustrted by the bservtin tht ntgnizing the deelertin f gstri eptying rkedly redues the gluse lwering effet f GLP-1. GLP-1 reeptrs re present in the entrl nervus syste nd y ply  rle in the nreti effet f the drugs. Type 2 dibeti ptients underging GLP-1infusin re less hungry; it is unler whether this is inly due t  deelertin f gstri eptying r whether there is  entrl nervus syste effet s well. a. GLP-1 receptor agonists— GLP-1’s hlf-life is nly 1–2 inutes. It is rpidly prtelyzed by dipeptidyl pepti- dse 4 (DPP-4) nd by ther enzyes, suh s endpepti- dse 24.11, nd is ls lered quikly by the kidney. The ntive peptide, therefre, nnt be used therpeutilly. Five GLP-1 reeptr gnists with lnger hlf-lives, exen- tide, lirglutide, dulglutide, lixisentide, nd seglutide, re vilble fr linil use. Exenatide (Exendin 4) is  GLP-1 reeptr gnist is- lted fr the sliv f the Gil nster ( venus lizrd) tht is re resistnt t DPP-4 tin nd lered by the kidney. Its hlf-life is 2.4 hurs, nd its gluse lwering effet is but 6 hurs. Exentide is dispensed s tw fixed-dse pens (5 g nd 10 g). It is injeted 60 inutes befre brekfst nd befre dinner. Ptients with type 2 dibetes shuld be presribed the 5 g pen fr the first nth nd, if tlerted, the dse n then be inresed t 10 g twie  dy. The editin is nt reended in ptients with eGFR less thn 30 L/in/1.73 2. In linil trils, dding exentide therpy t ptients with type 2 dibetes lredy tking etfrin r  sulfnylure, r bth, further lwered the HbA1vlue by 0.4% t 0.6% ver  30-week perid. These ptients ls experiened  weight lss f 3–6 punds. Exentide LAR is  ne-weekly preprtin tht is dispensed s  pwder (2 g). It is suspended in the prvided diluent just prir t injetin. In prtive linil trils, the lng- ting drug lwers the HbA1level  little re thn the twie dily drug. Lw-titer ntibdies ginst exentide develp in ver ne-third (38%) f ptients, but the linil effets re nt ttenuted. High-titer ntibdies develp in  subset f ptients (~6%), nd in but hlf f these ses, n ttenu- tin f glyei respnse hs been seen. Liraglutide is  sluble ftty id ylted GLP-1 n- lg. The hlf-life is pprxitely 12 hurs, llwing the editin t be injeted ne  dy. The dsing is initi- ted t 0.6 g dily, inresed fter 1 week t 1.2 g dily. Se ptients y benefit fr inresing the dse t 1.8 g. In linil trils lsting 26 nd 52 weeks, dding lirglutide t the therpeuti regien (etfrin, sulf- nylure, thizlidinedine) f ptients with type 2 dibetes further lwered the HbA1vlue. Depending n the dse nd design f the study, the HbA1deline ws in the rnge f 0.6% t 1.5%. The ptients hd sustined weight lss f 1–6 punds. Lirglutide t  dse f 3 g dily hs been pprved fr weight lss. In  pstrketing ultintinl study f 9340 ptients with type 2 dibetes with knwn rdivsulr disese, the dditin f lirglutide ws ssited with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.87, P= 0.01). Ptients tking lirglutide hd lwer HbA1levels, weight lss f 2.3 kg, lwer systli bld pres- sure, nd fewer episdes f severe hypglyei. Dulaglutide nsists f tw GLP-1 nlg leules vlently linked t n F frgent f hun IgG4. The GLP-1 leule hs in id substitutins tht resistCMDT22_Ch27_p1212-p1255.indd  1226 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1227 CMDT 2022DPP -4 tin. The hlf-life f dulglutide is but 5 dys. The usul dse is 0.75 g weekly by subutneus inje- tin. The xiu reended dse is 1.5 g weekly. Dulglutide ntherpy nd bintin therpy lwers HbA1by but 0.7% t 1.6%. Weight lss rnged fr 2 punds t 7 punds. Lixisenatide is  syntheti nlg f exendin 4 (deletin f  prline nd dditin f 6 lysines t the C-terinl regin) with  hlf-life f 3 hurs. It is dispensed s tw fixed-dse pens (10 g nd 20 g). The 10-g dse is injeted ne dily befre brekfst fr the first 2 weeks, nd if tlerted, the dse is then inresed t 20 g dily. Its linil effet is but the se s exentide with HbA1 lwering in the 0.4–0.6% rnge. Weight lss rnges fr 2 punds t 6 punds. Antibdies t lixisentide ur frequently (70%) nd ~2.4% with the highest ntibdy titers hve ttenuted glyei respnse. Semaglutide is  syntheti nlg f GLP-1 with  drug hlf-life f but 1 week. It hs n lph-inisbutyri id substitutin t psitin 8 tht kes the leule resistnt t DPP4 tin nd  C-18 ftty di-id hin tthed t lysine t psitin 26 tht binds t lbuin, whih unts fr the drug’s lng hlf-life. Seglutide is dispensed either subutneusly r rlly. There re tw pens fr subutneus injetin: ne pen delivers  0.25-g r 0.5-g dse nd the ther pen delivers  1-g dse. The reended dsing is 0.25 g weekly fr 4 weeks nd if tlerted the dse is then inresed t 0.5 g per week. The 1-g per week dse n prvide dditinl gluse lwering effet. Seglutide ntherpy nd bin- tin therpy lwers HbA1fr 1.5% t 1.8%. The ptient ust tke rl seglutide fsting with  glss f wter nd then wit hlf n hur befre eting, drinking, r tking ther ediines. The reended strting dse is 3 g dily fr the first nth, with the dse inresed t 7–14 g dily s tlerted nd s needed fr gluse ntrl. Side effects— The st frequent dverse retins f the GLP-1 reeptr gnists re nuse (11–40%), vit- ing (4–13%), nd dirrhe (9–17%). The retins re re frequent t the higher dses. In linil trils but 1–5% f prtiipnts withdrew fr the studies beuse f the gstrintestinl sypts. The GLP-1 reeptr gnists hve been ssited with inresed risk f pnretitis. The pnretitis ws severe (herrhgi r nertizing) in 6 instnes, nd 2 f these ptients died. In the lirglutide nd dulglutide linil trils, there were 13 nd 5 ses f pnretitis in the drug- treted grups versus 1 nd 1 se in the prtr grups, respetively. This trnsltes t but 1.4–2.2 vs 0.6–0.9 ses f pnretitis per 1000 ptient-yers. Patients taking GLP-1 receptor agonists should be advised to seek immediate medical care if they experience unexplained per- sistent severe abdominal pain . There hve been rre reprts f ute kidney injury in ptients tking exentide. Se f these ptients hd pre- existing kidney disese, nd thers hd ne r re risk ftrs fr kidney disese. A nuber f the ptients reprted nuse, viting, nd dirrhe, nd it is ps- sible tht these side effets used vlue depletin ndntributed t the develpent f the kidney injury. Lir- glutide, seglutide, nd dulglutide re etblized by prtelysis nd re preferred hies in ptients with kid- ney filure. GLP-1 reeptr gnists stiulte C-ell neplsi nd use edullry thyrid rin in rts. Hun C-ells express very few GLP-1 reeptrs, nd the relevne t hun therpy is unler. The editins, hwever, shuld nt be used in ptients with persnl r fily his- try f edullry thyrid rin r ultiple endrine neplsi (MEN) syndre type 2. b. DPP-4 inhibitors— An lternte pprh t the use f GLP-1 reeptr gnists is t inhibit the enzye DPP-4 nd prlng the tin f endgenusly relesed GLP-1 nd GIP . Fur rl DPP-4 inhibitrs, sitgliptin, sx- gliptin, lingliptin, nd lgliptin, re vilble in the United Sttes fr the tretent f type 2 dibetes. An ddi- tinl DPP-4 inhibitr, vildgliptin, is vilble in Eurpe. Other DPP-4 inhibitrs—geigliptin, ngliptin, teneligliptin, trelgliptin, rigliptin, evgliptin, nd gsgliptin—hve been pprved utside the United Sttes nd Eurpen Unin (Kre, Indi, Thilnd, Jpn, Russi, nd severl Suth Aerin untries). Sitagliptin, when used lne r in bintin with ther dibetes editins, lwers HbA1by pprxi- tely 0.5%. The usul dse f sitgliptin is 100 g ne dily, but the dse is redued t 50 g dily if the lu- lted retinine lerne is 30–50 L/in nd t 25 g fr lernes less thn 30 L/in. Sxgliptin, when dded t the therpeuti regien (etfrin, sulfnyl- ure, thizlidinedine) f ptients with type 2 dibetes, further lwered the HbA1vlue by but 0.7–0.9%. The dse is 2.5 g r 5 g rlly ne  dy. The 2.5-g dse shuld be used in ptients with eGFR less thn 50 L/in/ 1.73 2. Alogliptin lwers HbA1by but 0.5–0.6% when dded t etfrin, sulfnylure, r piglitzne. The usul dse is 25 g rlly dily. The 12.5-g dse is used in ptients with eGFR f 30–60 L/in/1.73 2; nd 6.25 g fr lerne less thn 30 L/in/1.73 2. Lin- gliptin lwers HbA1by but 0.4–0.6% when dded t etfrin, sulfnylure, r piglitzne. The dse is 5 g rlly dily, nd sine, it is pririly exreted unetblized vi the bile, n dse djustent is needed in ptients with kidney disese. Vildgliptin lwers HbA1by but 0.5–1% when dded t the ther- peuti regien f ptients with type 2 dibetes. The dse is 50 g ne r twie dily. Side effects— The in dverse effet f DPP-4 inhibi- trs ppers t be  predispsitin t nsphryngitis r upper respirtry trt infetin. Hypersensitivity re- tins, inluding nphylxis, ngiede, nd exflitive skin nditins (suh s Stevens-Jhnsn syndre), hve been reprted. There hve ls been reprts f pnretitis, but the frequeny f the event is unler. Cses f liver filure hve been reprted with the use f lgliptin, but it is unertin if lgliptin ws the use. The editin, hwever, shuld be disntinued in the event f liver fil- ure. Rre ses f hepti dysfuntin, inluding heptitis,CMDT22_Ch27_p1212-p1255.indd  1227 29/06/21 8:53 PMCHAPTEr 271228 CMDT 2022hve  been reprted with the use f vildgliptin; nd liver biheil testing is reended qurterly during the first yer f use nd peridilly therefter. Sxgliptin y inrese the risk f hert filure. In  pst-rketing study f 16,492 ptients with type 2 dibetes, hert filure urred in 3.5% in the sxgliptin grup nd 2.8% in the pleb grup (hzrd rti 1.27). Ptients with the highest risk f hert filure were thse wh hd  histry f hert filure r hd elevted levels f N-terinl f the prhr- ne B-type ntriureti peptide (NT-pBNP) r hd kidney ipirent. In  lrge pst-rketing study, lgliptin, like sxgliptin, ws ssited with  slightly inresed rte f hert filure. The FDA hs issued  wrning tht the DPP-4 inhibitrs n sinlly use jint pins tht reslve fter stpping the drug. 5. Sodiumglucose cotransporter 2 inhibitors— Gluse is freely filtered by the kidney gleruli nd is rebsrbed in the prxil tubules by the tin f sdiu-gluse -trnsprters (SGLT). Sdiu-gluse -trnsprter 2 (SGLT2) unts fr but 90% f gluse rebsrptin nd its inhibitin uses glysuri in peple with dibetes, lwering pls gluse levels. The rl SGLT2 inhibitrs ngliflzin, dpgliflzin, epgliflzin, nd ertugli- flzin re pprved fr linil use in the United Sttes. These gents redue the threshld fr glysuri fr  pls gluse threshld f but  180 g/dL t but 40 g/dL; nd lwer HbA1by 0.5–1% when used lne r in bintin with ther rl gents r insulin. The effi- y is higher t higher HbA1levels when re gluse is exreted s  result f SGLT2 inhibitin. The lss f l- ries results in dest weight lss f 2–5 kg. Cngliflzin is dsed t 100 g dily but up t 300 g dily n be used in ptients with nrl kidney funtin. The dse f dpgliflzin is 10 g dily but 5 g dily is the reended initil dse in ptients with hepti fil- ure. The usul dsge f epgliflzin is 10 g dily but  higher dse f 25 g dily n be used. The reended strting dse f ertugliflzin is 5 g, but the dse n be inresed t 15 g dily if dditinl gluse lwering is needed. Empagliflozin ws evluted in  ultintinl study f 7020 ptients with type 2 dibetes with knwn rdi- vsulr disese; the dditin f epgliflzin ws ssi- ted with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infr- tin, r nnftl strke (hzrd rti 0.86, P= 0.04). The ehniss regrding the benefit rein unler. Weight lss, lwer bld pressure, nd diuresis y hve plyed  rle sine there were fewer deths fr hert filure in the treted grup wheres the rtes f yrdil infrtin were unltered. A siilr ultintinl study ws per- fred with the dditin f ngliflzin. This ws  study f 10,142 ptients with type 2 dibetes with knwn r t inresed risk fr rdivsulr disese. The ngliflzin treted grup hd  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.86, P= 0.02). In  2019 hert filure study f 4744 ptients with NYHA lss II, III, r IV hert filure nd ejetin frtin f less40%, dpgliflzin redued the uultive inidene f wrsening hert filure r rdivsulr deth (hzrd rti 0.74, P< 0.001). Frty-tw perent f the ptients hd dibetes; the findings in ptients with nd withut dibetes were the se. Bth epgliflzin nd ngliflzin shw benefit in ters f prgressin f lbuinuri nd kidney injury, pssibly by lwering glerulr hyperfiltrtin. In  2019 ultintinl study f 4401 ptients with type 2 dibetes nd lbuinuri hrni kidney disese (eGFR 30–89 L/in/1.73 2with lbuin [g] t retinine [g] rti > 300 t 5000) nd tking n ACE inhibitr r ngitensin reeptr blker, ngliflzin redued the risk f end-stge kidney disese, the dubling f seru reti- nine, nd f renl deth. In  2020 ultintinl study f 4304 ptients with hrni kidney disese, dpgliflzin redued the risk f end-stge kidney disese r deth fr renl nd rdivsulr uses. A third f the ptients in the study did nt hve dibetes nd hd benefit. Side effects— As ight be expeted, the effiy f the SGLT2 inhibitrs is redued in hrni kidney disese. They n ls inrese retinine nd derese eGFR, espe- illy in ptients with kidney ipirent. Their use is generlly nt reended in ptients with eGFR less thn 45 L/in/1.73 2nd re ntrindited in ptients with eGFR less thn 30 L/in/1.73 2. The study f dpgliflzin in hrni kidney disese, hwever, nted tht the drug is sfe nd benefiil in ptients with eGFR s lw s 25 L/in/1.73 2. The in side effets re inresed inidene f genitl yti infetins nd urinry trt infetins ffeting ~8–9% f ptients. Cses f nertizing fsiitis f the perineu (Furnier gn- grene) hve been reprted. There hve ls been reprts f ses f pyelnephritis nd septiei requiring hspitl- iztin. The glysuri n use intrvsulr vlue ntrtin nd hyptensin. One ultintinl study with ngliflzin shwed n inresed risk f puttins, espeilly f the tes (hzrd rti 1.97). This finding hs nt been bserved in ther studies using this drug r with the ther SGLT2 inhibitrs. Cngliflzin hs been reprted t use  derese in bne inerl density t the lubr spine nd the hip. In  pled nlysis f eight linil trils (en durtin 68 weeks),  30% inrese in frtures ws bserved in ptients tking ngliflzin. It is likely tht the effet n the bnes is  lss effet nd nt restrited t n- gliflzin. All the SGLT2 inhibitrs use  dest inrese in LDL hlesterl levels (3–8%). Als, in linil trils, ptients tking dpgliflzin hd higher rtes f brest ner (nine ses vs nne in prtr rs) nd bld- der ner (10 ses vs 1 in pleb r). These ner rtes exeeded the expeted rtes in ge-thed referene dibetes ppultin. Cses f DKA hve been reprted with ff-lbel use f SGLT2 inhibitrs in ptients with type 1 dibetes. Type 1 ptients re tught t give less insulin if their gluse levels re nt elevted. SGLT2 inhibitrs lwer gluse levels by hnging the renl threshld nd nt by insulin tin. Type 1 ptients tking n SGLT2 inhibitr, beuse the gluse levels re nt elevted, y either withhld rCMDT22_Ch27_p1212-p1255.indd  1228 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1229 CMDT 2022redue  their insulin dses t suh  degree s t indue ketidsis. SGLT2 inhibitors should not be used in patients with type 1 diabetes and in those patients labeled as having type 2 diabetes but who are very insulin deficient and ketosis-prone. 6. Others— Prlintide is  syntheti nlg f islet y- lid plypeptide (IAPP r ylin). When given subutne- usly, it delys gstri eptying, suppresses glugn seretin, nd dereses ppetite. It is pprved fr use bth in type 1 dibetes nd in insulin-treted type 2 dibe- tes. In 6-nth linil studies with type 1 nd insulin- treted type 2 ptients, thse tking the editin hd n pprxitely 0.4% redutin in HbA1nd but 1.7 kg weight lss pred with pleb. The HbA1redutin ws sustined fr 2 yers but se f the weight ws regined. The editin is given by injetin ieditely befre the el. Hypglyei n ur, nd it is re- ended tht the shrt-ting r preixed insulin dses be redued by 50% when the editin is strted. Sine the editin slws gstri eptying, revery fr hyp- glyei n be  prble beuse f dely in bsrptin f fst-ting rbhydrtes. Nuse is the ther in side effet, ffeting 30–50% f persns, but tends t iprve with tie. In ptients with type 1 dibetes, the initil dse f prlintide is 15 g befre eh el nd titrted up by 15-g inreents t  intenne dse f 30 g r 60 g befre eh el. In ptients with type 2 dibetes, the strting dse is 60 g preels inresed t 120 g in 3 t 7 dys if n signifint nuse urs. Brriptine,  dpine 2 reeptr gnist, hs been shwn t destly lwer HbA1by 0.1–0.5% when pred t bseline nd 0.4–0.5% pred t pleb. Cn side effets re nuse, viting, dizziness, nd hedhe. Clesevel, the bile id sequestrnt, when dded t etfrin r sulfnylure r insulin, lwered HbA10.3– 0.4% when pred t bseline nd 0.5–0.6% pred t pleb. HbA1lwering, hwever, ws nt bserved in  single ntherpy linil tril pring lesevel t pleb. Clesevel use is ssited with ~20% inrese in triglyeride levels. Other dverse effets inlude nstiptin nd dyspepsi.With their modest glucose lowering and significant side effects, using bromocriptine or colesevelam to treat diabetes is not recommended. 7. Medication combinations— Severl editin bi- ntins re vilble in different dse sizes, inluding glyburide nd etfrin (Gluvne); glipizide nd et- frin (Metglip); repglinide nd etfrin (Prndi-Met); rsiglitzne nd etfrin (Avndet); piglitzne nd etfrin (ACTOplusMet); rsiglitzne nd gliepiride (Avndryl); piglitzne nd gliepiride (Duett); sitgliptin nd etfrin (Jnuet); sx- gliptin nd etfrin XR (Kbiglyze XR); lingliptin nd etfrin (Jentduet); lgliptin nd etfrin (Kzn); lgliptin nd piglitzne (Oseni); dp- gliflzin nd etfrin (Xigdu); ngliflzin nd et- frin (Invket); epgliflzin nd etfrin (Synjrdy); epgliflzin nd lingliptin (Glyxbi); epgliflzin, lingliptin, nd etfrin (Trijrdy); ertugliflzin nd etfrin (Segluret); ertugliflzin nd sitgliptin (Steglujn); insulin deglude nd lirglutide (Xultphy); nd insulin glrgine nd lixisentide (Sliqu). These editin bintins, hwever, liit the lini- in’s bility t ptilly djust dsge f the individul editins nd fr tht resn re nt reended.C.  InsulinInsulin is indi ted fr type 1 dibetes s well s fr type 2 dibeti ptients with insulinpeni whse hyperglyei des nt respnd t diet therpy either lne r bined with ther hypglyei editins. 1. Characteristics of available insulin preparations— Hun insulin is dispensed s either regulr (R) r NPH (N) frultins. Six nlgs f hun insulin—three rpidly ting (insulin lispr, insulin sprt, insulin gluli- sine) nd three lng-ting (insulin glrgine, insulin deteir, nd insulin deglude)—re vilble fr linil use. Insulin preprtins differ with respet t the tie f nset nd durtin f their bilgi tin (Tble 27–5). All urrently vilble insulins ntin less thn 10 pp f prinsulin nd re lbeled s “purified. ” These purified insulins preserve their pteny, s tht refrigertin Table 27–5. Summary of bioavailability characteristics of the insulins.Insulin  Pepaations1Onset of Action Peak Action Effective Duation Insulins lispro, aspart,2,3glulisine 5–15 minutes 1–1.5 hours 3–4 hours Human regular 30–60 minutes 2 hours 6–8 hours Human NPH 2–4 hours 6–7 hours 10–20 hours Insulin glargine 0.5–1 hour Flat ~24 hours Insulin detemir 0.5–1 hour Flat 17 hours Insulin degludec 0.5–1.5 hours Flat More than 42 hours Technosphere inhaled insulin 5–15 minutes 1 hour 3 hours1 Insulin administered subcutaneously unless otherwise noted.2 Insulin aspart formulated with niacinamide (FiAsp has an ~10-minute faster onset of action).3 Insulin lispro formulated with treprostinil and citrate (Lyumjev has an 11-minute faster onset of action).CMDT22_Ch27_p1212-p1255.indd  1229 29/06/21 8:53 PMCHAPTEr 271230 CMDT 2022is  reended but nt ruil. During trvel, reserve supplies f insulin n be redily trnsprted fr weeks withut lsing pteny if prteted fr extrees f het r ld. All the insulins in the United Sttes re vilble in  nentrtin f 100 units/L (U100) nd dispensed in 10-L vils r 0.3-L rtridges r prefilled dispsble pens. Severl insulins re vilble t higher nentr- tins: insulin glrgine, 300 units/L (U300); insulin deglude, 200 units/L (U200); insulin lispr, 200 units/L (U200); nd regulr insulin, 500 units/L (U500). 2. Insulin preparations— See Tble 27–6. The rpidly t- ing insulin nlgs nd the lng-ting insulins re designed fr subutneus dinistrtin, while regulr insulin nd insulin sprt n ls be given intrvenusly. a. Short-acting insulin preparations— (1) Regular insulin— Regulr insulin is  shrt-ting sluble rystlline zin insulin whse effet ppers within 30 inutes fter subutneus injetin nd lsts 5–7 hurs when usul quntities re dinistered. Intrvenus infu- sins f regulr insulin re prtiulrly useful in the tret- ent f DKA nd during the peripertive ngeent f ptients with dibetes wh require insulin. Fr rkedly insulin-resistnt persns wh wuld therwise require lrge vlues f insulin slutin,  U500 preprtin f hun regulr insulin is vilble bth in  vil fr nd  dispsble pen. A U500 insulin syringe shuld be used if the vil fr is dispensed. U500 regulr insulin is uh re expensive thn the U100 nentrtin nd is rrely needed.(2) Rapidly acting insulin analogs— Insulin lispr (Hulg, Adelg) is n insulin nlg where the pr- line t psitin B28 is reversed with the lysine t B29. Insulin sprt (Nvlg) is  single substitutin f prline by sprti id t psitin B28. In insulin glulisine (Apidr) the sprgine t psitin B3 is repled by lysine nd the lysine in psitin B29 by gluti id. These three n- lgs hve less f  tendeny t fr hexers, in ntrst t hun insulin. When injeted subutneusly, the n- lgs quikly dissite int ners nd re bsrbed very rpidly, rehing pek seru vlues in s sn s 1 hur—in ntrst t regulr hun insulin, whse hex- ers require nsiderbly re tie t dissite nd bee bsrbed. The in id hnges in these nlgs d nt interfere with their binding t the insulin reeptr, with the irulting hlf-life, r with their iungeniity, whih re ll identil with thse f hun regulr insulin. An insulin sprt frultin (FiAsp) tht ntins niin- ide (vitin B3) hs  re rpid initil bsrptin nd its nset f tin is but 10 inutes fster thn the stndrd insulin sprt frultin. Beuse f this re rpid nset f tin, the 1-hur (but nt 2-hur) pstprndil gluse exursins re lwer pred t the stndrd frultin. Siilrly, n insulin lispr frultin (Lyujev) ntin- ing trepstinil t indue ll vsdiltin nd itrte t inrese vsulr perebility hs 11 inutes fster nset f tin nd lwer 1- nd 2-hur pstprndil gluse exur- sins pred t the stndrd insulin lispr frultin. Clinil trils hve denstrted tht the ptil ties f preprndil subutneus injetin f prble dses f the rpidly ting insulin nlgs nd f regulr hun insulin re 20 inutes nd 60 inutes, respetively, befre the el. The quiker nset f tin with the rpidly t- ing insulin nlgs llws the ptient t injet insulin just befre eting rther thn wit fr 60 inutes s needed fr regulr insulin. Anther desirble feture f rpidly ting insulin nlgs is tht their durtin f tin reins t but 4 hurs fr st nly used dsges. This n- trsts with regulr insulin, whse durtin f tin is sig- nifintly prlnged when lrger dses re used. The rpidly ting nlgs re nly used in pups. In  duble-blind rssver study pring insu- lin lispr with regulr insulin in insulin pups, persns using insulin lispr hd lwer HbA1vlues nd iprved pstprndil gluse ntrl with the se frequeny f hypglyei. In the event f pup filure, hwever, users f the rpidly ting insulin nlgs will hve re rpid nset f hyperglyei nd ketsis. While insulin sprt hs been pprved fr intrvenus use (eg, in hyperglyei eergenies), there is n dvn- tge in using insulin sprt ver regulr insulin by this rute. A U200 nentrtin f insulin lispr is vilble in  dispsble prefilled pen. The nly dvntge f the U200 ver the U100 insulin lispr preprtin is tht it delivers the se dse in hlf the vlue. b. Long-acting insulin preparations— (1) NPH (neutral protamine Hagedorn or isophane) insulin— NPH is n interedite-ting insulin whse nset f tin is delyed t 2–4 hurs, nd its pekTable 27–6. Insulin preparations available in the United States.1rapidly  acting human insulin analogs Insulin lispro (Humalog, Lyumjev, Lilly; Admelog, Sanofi) Insulin aspart (Novolog, FiAsp, Novo Nordisk) Insulin glulisine (Apidra, Sanofi Aventis) Shot-acting egula insulin Regular insulin (Lilly, Novo Nordisk) Technosphere inhaled regular insulin (Afrezza) Intemediate-acting insulins NPH insulin (Lilly, Novo Nordisk) Pemixed insulins 70% NPH/30% regular (70/30 insulin—Lilly, Novo Nordisk) 70% NPL/25% insulin lispro (Humalog Mix 75/25—Lilly) 50% NPL/50% insulin lispro (Humalog Mix 50/50—Lilly) 70% insulin aspart protamine/30% insulin aspart (Novolog Mix 70/30—Novo Nordisk) 70% insulin degludec/30 insulin aspart (Ryzodeg, Novo Nordisk) Long-acting human insulin analogs Insulin glargine (Lantus (U100), Toujeo (U300), Sanofi Aventis; Basaglar (U100), Lilly) Insulin detemir (Levemir, Novo Nordisk) Insulin degludec (Tresiba, Novo Nordisk)1 All insulins available in the United States are recombinant human or human insulin analog origin. All the above insulins are dis- pensed at U100 concentration. There is an additional U500 prepa- ration of regular insulin; U300 preparation of insulin glargine; U200 preparation of insulin lispro; U200 preparation of insulin degludec. NPH, neutral protamine Hagedorn.CMDT22_Ch27_p1212-p1255.indd  1230 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1231 CMDT 2022respn se is generlly rehed in but 6–7 hurs. The nset f tin is delyed by bining 2 prts sluble rystlline zin insulin with 1 prt prtine zin insulin. This prdues equivlent unts f insulin nd prt- ine, s tht neither is present in n unplexed fr (“isphne”). Beuse its durtin f tin is ften less thn 24 hurs (with  rnge f 10–20 hurs), st ptients require t lest tw injetins dily t intin  sustined insulin effet. Osinl vils f NPH insulin hve tended t shw unusul luping f their ntents r “frsting” f the ntiner, with nsiderble lss f bitivity. This instbility is rre nd urs less frequently if NPH hun insulin is refrigerted when nt in use nd if bttles re disrded fter 1 nth f use. (2) Insulin glargine— In this insulin, the sprgine t psitin 21 f the insulin A hin is repled by glyine nd tw rginines re dded t the rbxyl terinl f the B hin. The rginines rise the iseletri pint f the l- eule lser t neutrl king it re sluble in n idi envirnent. In ntrst, hun insulin hs n iseletri pint f pH 5.4. Insulin glrgine is  ler insulin, whih, when injeted int the neutrl pH envirnent f the sub- utneus tissue, frs irpreipittes tht slwly relese the insulin int the irultin. This insulin lsts fr but 24 hurs withut ny prnuned peks nd is given ne  dy t prvide bsl verge. This insulin nnt be ixed with the ther hun insulins beuse f its idi pH. When this insulin ws given s  single injetin t bedtie t type 1 ptients in linil trils, fsting hyper- glyei ws better ntrlled with less nturnl hyp- glyei when pred t NPH insulin. A re nentrted fr f insulin glrgine (U300) is vilble s n insulin pen. In linil trils in type 1 ptients, U300 use did nt result in better ntrl r redue the rtes f hypglyei. Althugh liited linil dt suggest tht insulin glrgine is sfe in pregnny, it is nt pprved fr this use. (3) Insulin detemir— In this insulin nlg, the thre- nine t psitin B30 hs been reved nd  14-C ftty id hin (tetrdeni id) is tthed t the lysine t psitin 29 by yltin. Its prlnged tin is due t dihexeriztin nd binding f hexers nd diers t lbuin t the injetin site s well s binding f the ner vi its ftty id side hin t lbuin in the irultin. The ffinity f insulin deteir is furfld t fivefld lwer thn tht f hun sluble insulin nd therefre the U100 frultin f insulin deteir hs n insulin nentrtin f 2400 nl/L pred with 600 nl/L fr NPH. The durtin f tin fr insulin deteir is but 17 hurs t therpeutilly relevnt dses. It is reended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. It hs been pprved fr use during pregnny. (4) Insulin degludec— In this insulin nlg, the thre- nine t psitin B30 hs been reved, nd the lysine t psitin B29 is njugted t hexdeni id vi  g-L-glutyl sper. In the vil, in the presene f phenl nd zin, the insulin is in the fr f dihexers but when injeted subutneusly, it self ssites int lrge ultihexeri hins nsisting f thusnds fdihexers. The hins slwly disslve in the subutne- us tissue nd insulin ners re stedily relesed int the systei irultin. The hlf-life f insulin deglude is 25 hurs. Its nset f tin is in 30–90 inutes nd its durtin f tin is re thn 42 hurs. It is re- ended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. Insulin deglude is vil- ble in tw nentrtins, U100 nd U200, nd dispensed in prefilled dispsble pens. (5) Insulin icodec— This is n insulin nlg tht is suit- ble fr ne weekly injetin nd is in phse 3 linil trils. c. Mixed insulin preparations— Ptients with type 2 dibetes n seties hieve resnble gluse ntrl with just prebrekfst nd predinner injetins f ixtures f shrt ting nd NPH insulins. The regulr insulin r rpidly ting insulin nlg is withdrwn first, then the NPH insulin nd then injeted ieditely. Stble pre- ixed insulins (70% NPH nd 30% regulr) re vilble s  nveniene t ptients wh hve diffiulty ixing insu- lin beuse f visul prbles r ipirent f nul dexterity (Tble 27–6). Preixed preprtins f insulin lispr nd NPH insulins re unstble; stbility is hieved by repling the NPH insulin with NPL (neutrl prtine lispr). This insulin hs the se durtin f tin s NPH insulin. Preixed bintins f NPL nd insulin lispr (75% NPL/25% insulin lispr ixture [Hulg Mix 75/25] nd 50% NPL/50% insulin lispr ixture [Hulg Mix 50/50]) re vilble fr linil use. Sii- lrly,  70% insulin sprt prtine/30% insulin sprt (NvLg Mix 70/30) is vilble. The in dvntges f these ixtures re tht they n be given within 15 inutes f strting  el nd they re superir in ntrlling the pstprndil gluse rise fter  rbhydrte-rih el. These benefits hve nt trnslted int iprveents in HbA1levels when pred with the usul 70% NPH/30% regulr ixture. The lnger-ting insulin nlgs, insulin glrgine nd insulin deteir, nnt be ixed with either regulr insulin r the rpidly ting insulin nlgs. Insulin deglude, hwever, n be ixed nd is vilble s 70% insulin deglude/30% insulin sprt nd is injeted ne r twie  dy. 3. Methods of insulin administration— a. Insulin syringes and needles— Plsti dispsble syringes re vilble in 1-L, 0.5-L, nd 0.3-L sizes. Three lengths f needles re vilble: 6 , 8 , nd 12.7 . Lng needles re preferble in bese ptients t redue vribility f insulin bsrptin. The needles re f 28, 30, nd 31 guges. The 31-guge needles re lst pinless. “Dispsble” syringes y be reused until blunt- ing f the needle urs (usully fter three t five inje- tins). Sterility dequte t vid infetin with reuse ppers t be intined by repping syringes between uses. Clensing the needle with lhl y nt be desir- ble sine it n disslve the siline ting nd n inrese the pin f skin punturing. b. Sites of injection— Any prt f the bdy vered by lse skin n be used, suh s the bden, thighs, upperCMDT22_Ch27_p1212-p1255.indd  1231 29/06/21 8:53 PMCHAPTEr 271232 CMDT 2022rs,  flnks, nd upper buttks. Preprtin with l- hl is nt required prir t injetin s lng s the skin is len. Rttin f sites is reended t vid delyed bsrptin when fibrsis r liphypertrphy urs fr repeted use f  single site. Regulr insulin is bsrbed re rpidly when injeted in the deltid r bden pred t thighs nd buttks. Exerise n inrese bsrptin when the injetin site is djent t the exer- ise usle. Fr st ptients, the bden is the re- end regin fr injetin beuse it prvides dequte re in whih t rtte sites. The effet f nti regins ppers t be uh less prnuned with the nlg insulins. c. Insulin pen injector devices— Insulin pens (Nv Nrdisk, nd Owen Mufrd) eliinte the need fr r- rying insulin vils nd syringes. Srt pens (Cpnin Medil) tht re linked t ell phnes n be used t reind the user t tke their insulin befre els, lulte dses, nd keep trk f tiing f the dses. Crtridges f insulin lispr nd insulin sprt re vilble fr the reus- ble pens. Dispsble prefilled pens re ls vilble fr regulr insulin (U100 nd U500), insulin lispr, insulin sprt, insulin glulisine, insulin deteir, insulin glrgine, insulin deglude, NPH, 70% NPH/30% regulr, 75% NPL/25% insulin lispr, 50% NPL/50% insulin lispr, 70% insulin sprt prtine/30% insulin sprt, nd 70% insulin deglude/30% insulin sprt. Pen needles re vil- ble in 29, 31, nd 32 guges nd 4-, 5-, 6-, 8-, nd 12.7- lengths (Nvfine; BD). d. Insulin pumps— In the United Sttes, Medtrni Mini- Med, Insulet, nd Tnde ke bttery perted ntinu- us subutneus insulin infusin (CSII) pups. These pups re sll (but the size f  pger) nd esy t prgr. They ffer ny fetures, inluding the bility t set  nuber f different bsl rtes thrughut the 24 hurs nd t djust the tie ver whih blus dses re given. They ls re ble t detet pressure build-up if the theter is kinked. The theter nneting the insulin reservir t the subutneus nnul n be disn- neted, llwing the ptient t reve the pup teprr- ily (eg, fr bthing). Oinpd (Insulet Crprtin) is n insulin infusin syste in whih the insulin reservir nd infusin set re integrted int ne unit (pd), s there is n theter (eletrni pth pup). The pd, pled n the skin, delivers subutneus bsl nd blus insulin bsed n wirelessly trnsitted instrutins fr  per- snl digitl ssistnt. The gret dvntge f ntinuus subutneus insulin infusin (CSII) is tht it llws fr estblishent f  bsl prfile tilred t the ptient llwing fr better vernight nd between els gluse ntrl. The bility t djust the bsl insulin infusin kes it esier fr the ptient t nge glyei exur- sins tht ur with exerise. The pups hve sftwre tht n ssist the ptient t lulte bluses bsed n gluse reding nd rbhydrtes t be nsued. They keep trk f the tie elpsed sine the lst insulin blus; the ptient is reinded f this when he r she ttepts t give dditinl rretin blus befre the effet f the previus blus hs wrn ff (“insulin n brd” feture).This feture redues the risk f verrreting nd subse- quent hypglyei. CSII therpy is pprprite fr ptients with type 1 dibetes wh re tivted, ehnilly inlined, edu- ted but dibetes (diet, insulin tin, tretent f hypglyei nd hyperglyei), nd willing t nitr their bld gluse fur t six ties  dy. Knwn pli- tins f CSII inlude ketidsis, whih n ur when insulin delivery is interrupted, nd skin infetins. Anther disdvntge is its st nd the tie needed f the liniin nd stff t initite therpy. Alst ll ptients use rpid- ting insulin nlgs in their pups. V-g (Vlerits) is  ehnil pth pup designed speifilly fr peple with type 2 dibetes wh use  bsl/ blus insulin regien. The devie is preset t deliver ne f three fixed nd flt bsl rtes (20, 30, r 40 units) fr 24 hurs (t whih pint it ust be repled) nd there is  buttn tht delivers tw units per press t help ver els. e. Closed loop systems— Algriths hve been devised t use gluse dt fr the ntinuus gluse nitr- ing systes t uttilly deliver insulin by ntinuus subutneus insulin infusin pup. These lsed lp systes (rtifiil pnres) hve been shwn in linil studies t iprve nighttie gluse ntrl, destly lwer HbA1levels, nd redue the risk f nturnl hyp- glyei. The MiniMed 670 G nd the Tnde Cntrl- IQ, hve been pprved fr linil use. The MiniMed 670 G lsed lp syste uses gluse dt fr  sensr t uttilly djust bsl insulin dses every 5 inutes, trgeting  sensr gluse level f 120 g/dL (6.7 l/L). Insulin delivery is suspended when the sensr gluse level flls belw r is predited t fll belw trget level. The gluse trget n be djusted up t 150 g/dL (8.3 l/L) fr physil tivity. The Tnde Cntrl-IQ trgets  sen- sr gluse level f 112.5 g/dL (6.25 l/L). The ptient is still respnsible fr blusing insulin fr els nd snks. There re ls D-It-Yurself lsed lp sys- tes using free pen-sure sftwre. One suh syste, lled the “Lp, ” uses the Dex G6 sensr, the iPhne, nd the Onipd insulin pup. The “Lp” ntrller is dwnlded n t the iPhne, nd it uses the Dex G6 sensr gluse esureents (ls n the iPhne) t ut- tilly djust bsl insulin delivery n the Onipd pup. Inresing nubers f type 1 ptients use these D- It-Yurself systes, but they re nt pprved fr use by the FDA. Suessful use f these systes requires prfi- ieny t using bth the insulin pup nd ntinuus gluse nitr. The systes re expensive; the insulin pup, whih needs t be repled every 4 yers, sts but $6000 nd the pup supplies re $1500 per yer. The ntinuus gluse nitring syste sts pprxitely $4000 per yer. f. Inhaled insulin— Tehnsphere insulin (Afrezz) is  dry-pwder frultin f rebinnt hun regulr insulin tht n be inhled. It nsists f 2- t 2.5- rystls f the exipient furyl diketpiperzine tht pr- vide  lrge surfe re fr dsrptin f prteins like insulin. The tehnsphere insulin is rpidly bsrbed with pek insulin levels rehed in 12–15 inutes nd deliningCMDT22_Ch27_p1212-p1255.indd  1232 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1233 CMDT 2022t bseline  in 3 hurs; the edin tie t xiu effet with inhled insulin is pprxitely 1 hur nd delines t bseline by but 3 hurs. In ntrst, the edin tie t xiu effet with subutneus insulin lispr is but 2 hurs nd delines t bseline by 4 hurs. In lini- l trils, tehnsphere insulin bined with bsl insu- lin ws s effetive in gluse lwering s rpid-ting insulin nlgs bined with bsl insulin. It is fru- lted s  single-use, lr-ded rtridge delivering 4, 8, r 12 units ieditely befre the el. The nufturer prvides  dse nversin tble; ptients injeting up t 4 units f rpid-ting insulin nlg shuld use the 4-unit rtridge. Thse injeting 5 t 8 units shuld use the 8-unit rtridge. If the dse is 9–12 units f rpid-ting insulin preel then ne 4-unit rtridge nd ne 8-unit rtridge r ne 12-unit rtridge shuld be used. The inhler is but the size f  referee’s whistle. The st n dverse retin f the inhled insulin is  ugh, ffeting but 27% f ptients. A sll derese in pulnry funtin (fred expirtry vlue in 1 send [FEV1]) is seen in the first 3 nths f use, whih persists ver 2 yers f fllw-up. Inhled insulin is ntrindited in ptients wh ske nd in thse with hrni lung disese, suh s sth nd hrni bstru- tive pulnry disese. Spiretry shuld be perfred t identify ptentil lung disese prir t inititing therpy. During linil trils, there were tw ses f lung ner in ptients wh were tking inhled insulin nd nne in the prtr-treted ptients. All the ptients in wh lung ner develped hd  histry f prir igrette sking. Cses f lung ner were ls reprted in igrette sk- ers using  previusly vilble inhled insulin preprtin (Exuber). The inidene rte in the Exuber-treted grup ws 0.13 per 1000 ptient-yers, wheres it ws 0.03 per 1000 ptient-yers in the prtr-treted grup.D . Transplantation1. Pancreas transplan tation— All ptients with end-stge kidney disese nd type 1 dibetes wh re ndidtes fr  kidney trnsplnt shuld be nsidered ptentil ndi- dtes fr  pnres trnsplnt. Eligibility riteri inlude ge yunger thn 55 nd inil rdivsulr risk. Cntrinditins inlude nnrretble rnry rtery disese, extensive peripherl vsulr disese, nd signifi- nt besity (weight greter thn 100 kg). The pnres trnsplnt y ur t the se tie s kidney trnsplnt r fter kidney trnsplnt. Ptients underging siultne- us pnres nd kidney trnsplnttin hve n 83% hne f pnreti grft survivl t 1 yer nd 69% t 5 yers. Slitry pnreti trnsplnttin in the bsene f  need fr kidney trnsplnttin is nsidered nly in thse rre ptients wh d nt respnd t ll ther insulin therpeuti pprhes nd wh hve frequent severe hypglyei, r wh hve life-thretening plitins relted t their lk f etbli ntrl. Slitry pnres trnsplnt grft survivl is 78% t 1 yer nd 54% t 5 yers. 2. Islet transplantation— Ttl pnretety is urtive fr severe pin syndre ssited with hrni pnre- titis. The pnretety, hwever, results in surgildibetes. Hrvesting islets fr the reved pnres nd uttrnsplnting the int the liver (vi prtl vein) n prevent the develpent f dibetes r result in “ild” dibetes (prtil islet funtin) tht is esier t nge. Sine the islets re utlgus, n iunsuppressin is required. The nuber f islets trnsplnted is the in preditr f insulin independene. Peple with type 1 dibetes n bee insulin inde- pendent fter reeiving islets islted fr  dnr pn- res (llislet trnsplnt). The islets re infused int the prtl vein using  perutneus trnshepti pprh, nd they ldge in the liver relesing insulin in respnse t physilgi stiuli. Lng-ter iunsuppressin is neessry t prevent llgrft rejetin nd t suppress the utiune press tht led t the disese in the first ple. Insulin independene fr re thn 5 yers hs been denstrted in ptients wh gt nti-CD3 nti- bdy r nti-thyyte glbulin indutin iunsup- pressin nd lineurin inhibitrs, Tr inhibitrs, nd yphenlte fetil s intenne iunsuppres- sin. One jr liittin is the need fr re thn ne islet infusin t hieve insulin independene. This is beuse f signifint lss f islets during isltin nd the perid prir t engrftent. Widespred llislet trnsplnttin will depend n iprving insulin inde- pendene rtes with ne infusin nd ls denstrting tht the lng-ter utes re s gd s thse f pn- res trnsplnt lne.Kristensen  SL et l. Crdivsulr, rtlity, nd kidney ut- es with GLP-1 reeptr gnists in ptients with type 2 dibetes:  systeti review nd et-nlysis f rdivs- ulr ute trils. Lnet Dibetes Endrinl. 2019;7:776. [PMID: 31422062] Leelrthn L et l. Hybrid lsed-lp therpy: where re we in 2021? Dibetes Obes Metb. 2021;23:655. [PMID: 33269551] MGuire DK et l. Assitin f SGLT2 inhibitrs with rdi- vsulr nd kidney utes in ptients with type 2 dibe- tes:  et-nlysis. JAMA Crdil. 2021;6:148. [PMID: 33031522] »Steps in the Management of DiabetesA.  Distinguishing the Types of DiabetesAn tt ept shuld be de t hrterize the dibetes s type 1 r type 2 r ther speifi types suh s MODY, bsed n the linil fetures present nd n whether r nt ketnuri pnies the glysuri. Fetures tht suggest end-rgn insulin insensitivity t insulin, suh s viserl besity, nthsis nigrins, r bth, ust be identified. The fily histry shuld duent nt nly the inidene f dibetes in ther ebers f the fily but ls the ge t nset, ssitin with besity, the need fr insulin, nd whether there were plitins. Fr the sinl ptient, esureent f GAD65, IAA, ICA 512, nd zin trnsprter 8 ntibdies n help distinguish between type 1 nd type 2 dibetes (Tble 27–7). Mny ptients with newly dignsed type 1 dibetes still hve signifint endgenus insulin prdutin, nd C peptide levels d nt relibly distinguish between type 1 nd type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1233 29/06/21 8:53 PMCHAPTEr 271234 CMDT 2022B.  Patient Education (SelfManagement Training)Since  diabetes is a lifelong disorder, education of the patient and the family is probably the most important obligation of the clinician who provides care. The best persns t nge  disese tht is ffeted s rkedly by dily flututins in envirnentl stress, exerise, diet, nd infetins re the ptients theselves nd their fi- lies. The “tehing urriulu” shuld inlude expln- tins by the liniin r nurse f the nture f dibetes nd its ptentil ute nd hrni hzrds nd hw they n be regnized erly nd prevented r treted. Self- nitring f bld gluse shuld be ephsized, espe- illy in insulin-requiring dibeti ptients, nd instrutins ust be given n prper testing nd rerding f dt. Ptients tking insulin shuld hve n understnding f the tins f bsl nd blus insulins. They shuld be tught t deterine whether the bsl dse is pprprite nd hw t djust the rpidly ting insulin dse fr the rbhydrte ntent f  el. Ptients nd their filies nd friends shuld be tught t regnize signs nd syp- ts f hypglyei nd hw t tret lw gluse re- tins. Strenuus exerise n preipitte hypglyei, nd ptients ust therefre be tught t redue their insulin dsge in ntiiptin f strenuus tivity r t tke supple- entl rbhydrte. Injetin f insulin int  site frthest wy fr the usles st invlved in the exerise y help elirte exerise-indued hypglyei, sine insu- lin injeted in the prxiity f exerising usle y be re rpidly bilized. Exerise trining ls inreses the effetiveness f insulin, nd insulin dses shuld be djusted rdingly. Infetins n use insulin resistne, nd ptients shuld be instruted n hw t nge the hyper- glyei with suppleentl rpidly ting insulin. Advie n persnl hygiene, inluding detiled instru- tins n ft nd dentl re, shuld be prvided. All infe- tins (espeilly pygeni nes) prvke the relese f high levels f insulin ntgnists, suh s tehlines r glugn, nd thus bring but  rked inrese in insu- lin requireents. Ptients wh re tking rl gents y depenste nd teprrily require insulin. Ptients shuld be tld but unity genies, suh s Dibetes Assitin hpters, tht n serve s  ntinuing sure f instrutin.Finlly, vigrus effrts shuld be de t persude ptients with newly dignsed dibetes wh ske t give up the hbit, sine lrge vessel peripherl vsulr disese nd debilitting retinpthy re less n in nnsk- ing dibeti ptients.C.  MedicationsT retent ust be individulized n the bsis f the type f dibetes nd speifi needs f eh ptient. Hwever, ertin generl priniples f ngeent n be utlined fr hyperglyei sttes f different types. 1. Type 1 diabetes— A bintin f rpidly ting insu- lin nlgs nd lng-ting insulin nlgs llws fr re physilgi insulin repleent. Tble 27–8 illustrtes  regien with  rpidly ting insulin nlg nd lng- ting bsl insulin tht ight be pprprite fr  70-kg persn with type 1 dibetes eting els prviding stn- drd rbhydrte intke nd derte t lw ft ntent. Insulin glrgine r insulin deglude is usully given ne in the evening t prvide 24-hur verge. There re sinl ptients in wh insulin glrgine des nt lst fr 24 hurs, nd in suh ses, it needs t be given twie  dy. Insulin deteir usully hs t be given twie  dy t get dequte 24-hur bsl verge. Altern- tively, sll dses f NPH (~3–4 units) n be given with eh el t prvide dytie bsl verge with  lrger dse t night. CSII by prtble bttery-perted “pen lp” devies llw the setting f different bsl rtes thrughut the 24 hurs nd perit blus dse djustents by s little s 0.05-unit inreents. The 24-hur bsl dsge is usully bsed n ge nd bdy weight. An dlesent ight need s uh s 0.4 unit/kg/dy;  yung dult (less thn 25 yers),Table 27–7. Diagnostic sensitivity and specificity of autoimmune markers in patients with newly diag- nosed type 1 diabetes mellitus. Sensitivity Specificity Islet cell antibodies (ICA) 44–100% 96% Glutamic acid decarboxylase (GAD65)70–90% 99% Insulin (IAA) 40–70% 99% Tyrosine phosphatase (IA-2, ICA 512)50–70% 99% Zinc transporter 8 (ZnT8) 50–70% 99%T able 27–8. Examples of intensive insulin regimens using rapidly acting insulin analogs (insulin lispro, aspart, or glulisine) and long-acting insulin analogs (insulin detemir, or insulin glargine or degludec) in a 70-kg man with type 1 diabetes.1–3 Pe- beakfastPe- lunchPe- dinneAt Bedtime Rapidly acting insulin analog5 units 4 units 6 units Insulin detemir36–7 units  8–9 units OR Rapidly acting insulin analog5 units 4 units 6 units — Insulin glargine or degludec3—  15–16 units1 Assumes that patient is consuming approximately 75 g carbohy- drate at breakfast, 60 g at lunch, and 90 g at dinner.2 The dose of rapidly acting insulin can be raised by 1 or 2 units if extra carbohydrate (15–30 g) is ingested or if premeal blood glu- cose is > 170 mg/dL (9.4 mmol/L).3 Insulin glargine or insulin detemir must be given as a separate injection.CMDT22_Ch27_p1212-p1255.indd  1234 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1235 CMDT 20220.35 unit p er/kg/dy; nd n lder dult, 0.25 unit/kg/dy. Fr exple,  70-kg, 30-yer-ld persn y require  bsl rte f 0.7 unit per hur thrughut the 24 hurs with the exeptin f 3 am t 8 am, when 0.8 unit per hur ight be pprprite (given the “ dawn phenomenon ”— redued tissue sensitivity t insulin between 5 am nd 8 am). The el blus vries bsed n the tie f dy nd the persn’s ge. Adlesents nd yung dults usully require 1 unit fr but 10 g f rbhydrte. Older dults usully require but 1 unit fr 15 g f rbhydrte. The rretin ftr—hw uh insulin is needed t lwer gluse levels by 50 g/dL—n be lulted fr the insulin-t-rbhydrte rtis. Fr exple, if 1 unit is required fr 15 g f rbhydrte, then 1 unit will lwer gluse levels by 50 g/dL. If 1.5 units f insulin re required fr 15 g f rbhydrte (tht is, 1 unit fr 10 g rbhydrte), then 1.5 units f insulin will lwer gluse levels by 50 g/dL (tht is, 1 unit will lwer gluse level by 33 g/dL). Fr  70-kg 30-yer-ld persn, blus rtis f 1 unit fr 12–15 g f rbhydrte plus 1 unit fr 50 g/dL f bld gluse ver  trget vlue f 120 g/dL wuld be resnble strting pint. Further djustents t bsl nd blus dsges wuld depend n the results f bld gluse nitring. One f the re diffiult ther- peuti prbles in nging ptients with type 1 dibetes is deterining the prper djustent f insulin dse when the prebrekfst bld gluse level is high. Osinlly, the prebrekfst hyperglyei is due t the Somogyi effect, in whih nturnl hypglyei leds t  surge f unterregultry hrnes t prdue high bld glu- se levels by 7 am. Hwever,  re n use fr prebrekfst hyperglyei is the wning f irulting insulin levels by the rning. The dignsis f the use f prebrekfst hyperglye- i n be filitted by self-nitring f bld gluse t 3 am in dditin t the usul bedtie nd 7 am e- sureents r by nlyzing dt fr the ntinuus glu- se nitr. This is required fr nly  few nights, nd when  prtiulr pttern eerges fr nitring bld gluse levels vernight, pprprite therpeuti esures n be tken. The Sgyi effet n be treted by lwer- ing the bsl insulin dse t bedtie r by eting  snk t bedtie. When  wning insulin level is the use, then either inresing the evening bsl insulin dse r shifting it fr dinnertie t bedtie (r bth) n be effetive. The urrently vilble lsed lp systes enble ptients t hieve lse t nrl gluse levels in the rning with  lw risk f nturnl hypglyei nd iprve verll gluse ntrl. All ptients with type 1 dibetes wh re skilled t using insulin pups shuld use these systes. 2. Type 2 diabetes— Therpeuti reendtins re bsed n the reltive ntributins f bet ell insuffi- ieny nd insulin insensitivity in individul ptients. The pssibility tht the individul ptient hs  speifi eti- lgi use fr their dibetes shuld lwys be nsidered, espeilly when the ptient des nt hve  fily histry f type 2 dibetes r des nt hve ny evidene f entrl besity r insulin resistne. Suh ptients shuld be evlu- ted fr ther types f dibetes suh s LADA r MODY(Tble 27–1). Ptients with LADA shuld be presribed insulin when the disese is dignsed nd treted like ptients with type 1 dibetes. It is ls iprtnt t nte tht ny ptients with type 2 dibetes ellitus hve  prgressive lss f bet ell funtin nd will require ddi- tinl therpeuti interventins with tie. a. Weight reduction— One f the priry des f therpy in the bese ptient with type 2 dibetes is weight redutin. Nrliztin f glyei n be hieved by weight lss nd iprveent in tissue sensitivity t insu- lin. A bintin f lri restritin, inresed exer- ise, nd behvir difitin is required if  weight redutin prgr is t be suessful. Understnding the risks ssited with the dignsis f dibetes y ti- vte the ptient t lse weight. Fr seleted ptients, edil r surgil ptins fr weight lss shuld be nsidered. Orlistt, phenterine/ tpirte, lrserin, nltrexne/extended-relese bupr- pin, nd high-dse lirglutide (3 g dily) re weight lss editins pprved fr use in bintin with diet nd exerise (see Chpter 29). Britri surgery (Rux-en-Y, gstri bnding, gstri sleeve, bilipnreti diversin/dudenl swith) typilly results in substntil weight lss nd iprveent in glu- se levels. A et-nlysis exining the ipt f br- itri surgery n ptients with dibetes nd BMI f 40 kg/2r greter nted tht 82% f ptients hd reslu- tin f linil nd lbrtry nifesttins f dibetes in the first 2 yers fter surgery nd 62% reined free f dibetes re thn 2 yers fter surgery. The iprveent ws st rked in the predure tht used the gretest weight lss (bilipnreti diversin/dudenl swith). There ws, hwever,  high ttritin f ptients vilble fr fllw-up, nd there ws little infrtin but differ- ent ethni types. Weight regin des ur fter britri surgery, nd it n be expeted tht 20–25% f the lst weight will be regined ver 10 yers. The ipt f this weight gin n dibetes reurrene depends priniplly n the degree f bet ell dysfuntin. Nnbese ptients with type 2 dibetes frequently hve inresed viserl dipsity—the s-lled etblilly bese nrl weight ptient. There is less ephsis n weight lss, but exerise reins n iprtnt spet f tretent. b. Glucose-lowering agents— Figure 27–2 utlines the tretent pprh bsed n the nsensus lgrith prpsed by the Aerin Dibetes Assitin nd the Eurpen Assitin fr the Study f Dibetes. The ur- rent reendtin is t strt etfrin therpy t dignsis nd nt wit t see whether the ptient n hieve trget glyei ntrl with weight ngeent nd exerise. See disussin f the individul editins, bve. When dibetes is nt well ntrlled with initil ther- py (usully etfrin), then  send gent shuld be dded. Presene f rdivsulr r kidney disese, r bth, will deterine the hie f the send gent. Lir- glutide, seglutide, epgliflzin, ngliflzin, nd dpgliflzin hve iprved rdivsulr utes.CMDT22_Ch27_p1212-p1255.indd  1235 29/06/21 8:53 PMCHAPTEr 271236 CMDT 2022The  SGLT2 inhibitrs re espeilly benefiil in ptients with hert filure r dibeti nephrpthy, r bth. The need fr weight lss shuld led t the use f GLP1- reeptr gnists in the bese ptient with r withut r- nry rtery disese. SGLT2 inhibitrs ls prte dest weight lss nd shuld be presribed in the ptient with hert filure r dibeti nephrpthy. Sulfnylures hve been vilble fr ny yers nd their use in bintin with etfrin is well estblished. They d, hwever, hve the prpensity f using hypglyei nd weight gin. In ptients wh experiene hyperglyei fter  rbhy- drte-rih el (suh s dinner),  shrt-ting seret- ggue (repglinide r nteglinide) befre els y suffie t get the gluse levels int the trget rnge. Ptients with severe insulin resistne y be ndidtes fr pigli- tzne. Piglitzne y ls redue the risk fr reurrent strke in ptients wh hve  histry f strke r trnsient ishei ttk. If tw gents re indequte, then  third gent is dded, lthugh dt regrding effiy f suh bined therpy re liited. When the bintin f rl gents (nd injetble GLP-1 reeptr gnists) fils t hieve euglyei in ptients with type 2 dibetes, then insulin tretent shuld be instituted. Vrius insulin regiens y be effetive. One prpsed regien is t ntinue the rl bintin therpy nd then siply dd  bedtie dse f NPH r lng-ting insulin nlg (insulin glrgine, deteir, r deglude) t redue exessive nturnl hepti gluse utput nd iprve fsting gluse levels. If the ptient des nt hieve trget gluse levels during the dy, then dytie insulin tretent n be initited. A nvenient insulin regien under these irustnes is  split dse f 70/30 NPH/regulr ixture (r Hulg Mix 75/25 r NvLgMix 70/30) befre brekfst nd befre dinner. If this regien fils t hieve stisftry glye- i gls r is ssited with uneptble frequeny f hypglyei episdes, then  re intensive regien f ultiple insulin injetins n be instituted s in ptients with type 1 dibetes. Metfrin priniplly redues hepti gluse utput, nd it is resnble t ntinue with this editin when insulin therpy is instituted. Piglitzne, whih iprves peripherl insulin sensitiv- ity, n be used tgether with insulin but this bintin is ssited with re weight gin nd peripherl ede. The sulfnylures, the GLP-1 reeptr gnists, the DPP-4 inhibitrs, nd the SGLT2 inhibitrs ls hve been shwn t be f ntinued benefit. Weight-reduing interventins shuld ntinue even fter inititin f insulin therpy nd y llw fr siplifitin f the therpeuti regi- en in the future.D . Acceptable Levels of Glycemic ControlA  resnble i f therpy is t pprh nrl glye- i exursins withut prvking severe r frequent hyp- glyei. Tble 27–9 surizes bld gluse nd HbA1 gls fr different ptient grups. The UKPDS study dem- onstrated that blood pressure control was as significant or more significant than glycemic control in patients with type 2 diabetes regarding the prevention of microvascular as well as macrovascular complications.Weight loss + exercise + metformin Metformin + another agent (noninsulin or insulin) Metformin + two other agents (noninsulin or insulin) Factors in Therapeutic Decision (single agent or combination)Seven main classes of agents • Metformin • Sulfonylureas (includes nateglinide, repaglinide) • Pioglitazone • GLP-1 receptor agonists • DPP-4 inhibitors • SGLT2 inhibitors • InsulinsIf HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reache d after ~ 3 months Efficacy • DPP-4 inhibitors are of moderate efficacy • All other agents are of high efficacy Cost • All agents except metformin and sulfonylureas are expensive • Insulins are expensive if the additional cost of monitoring is taken into considerationCardiovascular and renal effects • Metformin, liraglutide, semaglutide, empagliflozin, and canagliflozin have know n cardiovascular benefits • SGLT2 inhibitors reduce the risk of ESKD, doubling of serum creatinine and renal death in patients with diabetic nephropathy Hypoglycemic risk • Sulfonylureas and insulins have increased risk of hypoglycemia Effect on weight • Metformin and DPP-4 inhibitors are weight neutral • GLP-1 receptor agonists and SGLT2 inhibitor s promote weight loss • Sulfonylureas, insulins, and pioglitazone ar e associated with weight gain Major side effects • Metformin: lactic acidosis • Pioglitazone: fluid retention, fracture risk, macular edema, possible bladder cancer • GLP-1 receptor agonists: nausea, vomiting and pancreatitis • DPP-4 inhibitors: possible pancreatitis • SGLT2 inhibitors: urinary tract infection; genital mycotic infections; dehydration; cannot use if eGFR < 30 mL/min/1.73 m2Metformin + insulin ± other noninsulin agent ▲Figure 27–2. Algorithm for the treatment of type 2 diabetes based on the 2018 recommendations of the consensus panel of the American Diabetes Association/ European Association for the Study of Diabetes.CMDT22_Ch27_p1212-p1255.indd  1236 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1237 CMDT 2022E.  Complications of Insulin Therapy1.  Hypoglycemia— Hypglyei retins re the st n plitins tht ur in ptients with dibetes wh re treted with insulin. The signs nd sypts f hypglyei y be divided int thse resulting fr stiultin f the utni nervus syste nd thse fr neurglypeni (insuffiient gluse fr nrl entrl nervus syste funtin). When the bld gluse flls t rund 54 g/dL (3 l/L), the ptient strts t experiene bth syptheti (thyrdi, plpittins, sweting, treulusness) nd prsyptheti (nuse, hunger) nervus syste sypts. If these utni sypts re ignred nd the gluse levels fll further (t rund 50 g/dL [2.8 l/L]), then neurglypeni sypts pper, inluding irritbility, nfusin, blurred visin, tiredness, hedhe, nd diffiulty speking. A fur- ther deline in gluse n led t lss f nsiusness r even  seizure. With repeted episdes f hypglyei, there is dpttin, nd utni sypts d nt ur until the bld gluse levels re uh lwer nd s the first sypts re ften due t neurglypeni. This nditin is referred t s “hypglyei unwreness. ” It hs been shwn tht hypglyei unwreness n be reversed by keeping gluse levels high fr  perid f severl weeks. Exept fr sweting, st f the syptheti sypts f hypglyei re blunted in ptients reeiv- ing bet-blking gents. Thugh nt bslutely ntrin- dited, these editins ust be used with utin in ptients with dibetes wh require insulin, nd bet-1- seletive blking gents re preferred. Hypglyei n ur in  ptient tking sulfnyl- ures, repglinide, nd nteglinide, prtiulrly if the ptient is elderly, hs kidney r liver disese, r is tking ertin ther editins tht lter etblis f the sul- fnylures (eg, phenylbutzne, sulfnides, r wrf- rin). It urs re frequently with the use f lng-tingsulfnylures thn with shrter-ting gents. Otherwise, hypglyei in insulin-treted ptients urs s  nse- quene f three ftrs: behvirl issues, ipired un- terregultry systes, nd plitins f dibetes. Behvirl issues inlude injeting t uh insulin fr the unt f rbhydrtes ingested. Drinking lhl in exess, espeilly n n epty sth, n ls use hypglyei. In ptients with type 1 dibetes, hypglye- i n ur during r even severl hurs fter exerise, nd s gluse levels need t be nitred nd fd nd insulin djusted. Se ptients d nt like their gluse levels t be high, nd they tret every high gluse level ggressively. These individuls wh “stk” their insulin— tht is, give nther dse f insulin befre the first injetin hs hd its full tin—n develp hypglyei. Cunterregultry issues resulting in hypglyei inlude ipired glugn respnse, sypth-drenl respnses, nd rtisl defiieny. Ptients with dibetes f greter thn 5 yers in durtin lse their glugn respnse t hypglyei. As  result, they re t  signifi- nt disdvntge in prteting theselves ginst flling gluse levels. One the glugn respnse is lst, their sypth-drenl respnses tke n dded iprtne. Unfrtuntely, ging, utni neurpthy, r hypgly- ei unwreness due t repeted lw gluse levels fur- ther blunts the sypth-drenl respnses. Osinlly, Addisn disese develps in persns with type 1 dibetes ellitus; when this hppens, insulin requireents fll sig- nifintly, nd unless insulin dse is redued, reurrent hypglyei will develp. Cplitins f dibetes tht inrese the risk fr hypglyei inlude utni neurpthy, gstrpre- sis, nd end-stge hrni kidney disese. The syptheti nervus syste is n iprtnt syste lerting the indi- vidul tht the gluse level is flling by using sypts f thyrdi, plpittins, sweting, nd treulusness.Table 27–9. Glycemic targets for different groups of adults with diabetes. Blood Glucose Tagets (mg/dL [mmol/L]) HbA1cTaget (% [mmol/mol]) Nonpregnant healthy adults Premeal glucose 90–130 (5–7.2) 1-hour peak < 180 (10) 2-hour peak < 150 (8.3)< 7 (53). Aim for < 6.5 (48) if it can be achieved without significant hypoglycemia or polypharmacy Pregnancy Premeal glucose ≤ 95 (5.3) 1-hour peak ≤ 140 (7.8) 2-hour peak ≤ 120 (6.7)6–6.5 (42–48). Aim for < 6 (42) if possible without significant hypoglycemia Older adults Healthy Frail with limited life expectancyPremeal 90–130 (5–7.2) Bedtime 90–150 (5–8.3) Premeal 100–180 (5.6–10) Bedtime 110–200 (6.1–11.1)< 7.5 (58) < 8.5 (69) History of severe hypoglycemia Premeal 90–150 (5–8.3) Bedtime 100–180 (5.6–10)< 8 (64) Hospitalized patient 140–180 (7.8–10) — Chronic kidney disease (CKD) Glycemic targets in CKD are the same as those without CKD. HbA1cand fructosamine values may not be accu- rate in end-stage kidney disease, and greater reliance should be placed on the home glucose measurementsCMDT22_Ch27_p1212-p1255.indd  1237 29/06/21 8:53 PMCHAPTEr 271238 CMDT 2022Fil ure f the sypth-drenl respnses inreses the risk f hypglyei. In dditin, in ptients with gstr- presis, if insulin is given befre  el, the pek f insulin tin y ur befre the fd is bsrbed using the gluse levels t fll. Finlly, in end-stge hrni kidney disese, hypglyei n ur presubly beuse f deresed insulin lerne s well s lss f renl ntri- butin t glunegenesis in the pstbsrptive stte. T prevent nd tret insulin-indued hypglyei, the dibeti ptient shuld rry gluse tblets r juie t ll ties. Fr st episdes, ingestin f 15 grs f rb- hydrte is suffiient t reverse the hypglyei. The ptient shuld be instruted t hek the bld gluse in 15 inutes nd tret gin if the gluse level is still lw. A prenterl (1 g) r nsl inhltin (3 g) glugn eergeny kit shuld be prvided t every ptient with dibetes wh is reeiving insulin therpy. Fily r friends shuld be instruted hw t injet it subutneusly r intrusulrly int the buttk, r, r thigh r din- ister  nsl dse in the event tht the ptient is unn- sius r refuses fd. The editin n sinlly use viting, nd the unnsius ptient shuld be turned n his r her side t prtet the irwy. Glugn bilizes glygen fr the liver, rising the bld gluse by but 36 g/dL (2 l/L) in but 15 inutes. After the ptient revers nsiusness, dditinl rl rb- hydrte shuld be given. Peple with dibetes reeiving hypglyei editin therpy shuld ls wer n identifitin MediAlert brelet r nekle r rry  rd in his r her wllet (1-800-ID-ALERT, www.edi- lert.rg). Medil persnnel treting severe hypglyei n give 50 L f 50% gluse slutin by rpid intrvenus infusin. If intrvenus ess is nt vilble, 1 g f glugn n be injeted intrusulrly r 3 g given by nsl spry. 2. Immunopathology of insulin therapy— At lest five leulr lsses f insulin ntibdies re prdued dur- ing the urse f insulin therpy in dibetes, inluding IgA, IgD, IgE, IgG, nd IgM. With the swith t hun nd purified prk insulin, the vrius iunpthlgi syn- dres suh s insulin llergy, iune insulin resistne, nd liptrphy hve bee quite rre sine the titers nd vidity f these indued ntibdies re generlly quite lw. a. Insulin allergy— Insulin llergy, r iedite-type hypersensitivity, is  rre nditin in whih ll r sys- tei urtiri is due t histine relese fr tissue st ells sensitized by dherene f nti-insulin IgE ntibdies. In severe ses, nphylxis results. When nly hun insulin hs been used fr the nset f insulin therpy, insulin llergy is exeedingly rre. Antihistines, rti- sterids, nd even desensitiztin y be required, espe- illy fr systei hypersensitivity. b. Immune insulin resistance— A lw titer f irult- ing IgG nti-insulin ntibdies tht neutrlize the tin f insulin t  sll extent develps in st insulin-treted ptients. With the ld nil insulins,  high titer f iru- lting ntibdies seties develped, resulting inextreely high insulin requireents—ften re thn 200 units dily. This is nw rrely seen with the swith t hun r highly purified prk insulins nd hs nt been reprted with the nlgs. c. Lipodystrophy— Atrphy f subutneus ftty tissue leding t disfiguring exvtins nd depressed res y rrely ur t the site f injetin. This plitin results fr n iune retin, nd it hs bee rrer with the develpent f hun nd highly purified insu- lin preprtins. Liphypertrphy, n the ther hnd, is  nsequene f the phrlgi effets f insulin being depsited in the se ltin repetedly. It n ur with purified insulins s well. Rttin f injetin sites will prevent liphypertrphy.Rdriguez-Gutierrez  R et l. Benefits nd hrs f intensive glyei ntrl in ptients with type 2 dibetes. BMJ. 2019;367:l5887. [PMID: 31690574] »Chronic Complications of DiabetesLte  linil nifesttins f dibetes ellitus inlude  nuber f pthlgi hnges tht invlve sll nd lrge bld vessels, rnil nd peripherl nerves, the skin, nd the lens f the eye. These lesins led t hypertensin, end- stge hrni kidney disese, blindness, utni nd peripherl neurpthy, puttins f the lwer extrei- ties, yrdil infrtin, nd erebrvsulr idents. These lte nifesttins rrelte with the durtin f the dibeti stte subsequent t the nset f puberty. In type 1 dibetes, end-stge hrni kidney disese develps in up t 40% f ptients, pred with less thn 20% f ptients with type 2 dibetes. Prlifertive retinpthy ultitely develps in bth types f dibetes but hs  slightly higher prevlene in type 1 ptients (25% fter 15 yers’ durtin). In ptients with type 1 dibetes, plitins fr end- stge hrni kidney disese re  jr use f deth, wheres ptients with type 2 dibetes re re likely t hve rvsulr diseses leding t yrdil infr- tin nd strke s the in uses f deth. Cigrette use dds signifintly t the risk f bth irvsulr nd rvsulr plitins in dibeti ptients.A.  Ocular Complications1.  Diabetic cataracts— Preture trts ur in di- beti ptients nd see t rrelte with bth the durtin f dibetes nd the severity f hrni hyperglyei. Nnenzyti glysyltin f lens prtein is twie s high in dibeti ptients s in ge-thed nndibeti persns nd y ntribute t the preture urrene f trts. 2. Diabetic retinopathy— The tw in tegries f di- beti retinpthy, nnprlifertive nd prlifertive, re disussed in Chpter 7. 3. Glaucoma— Glu urs in pprxitely 6% f persns with dibetes. It is respnsive t the usul therpy fr pen-ngle disese. Nevsulriztin f the iris in ptients with dibetes n predispse t lsed-ngleCMDT22_Ch27_p1212-p1255.indd  1238 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1239 CMDT 2022glu,  but this is reltively unn exept fter trt extrtin, when grwth f new vessels hs been knwn t prgress rpidly, invlving the ngle f the iris nd bstruting utflw.B.  Diabetic NephropathyDibeti  nephrpthy is initilly nifested by lbuin- uri; subsequently, s kidney funtin delines, ure nd retinine uulte in the bld (see Chpter 22). An lbuin-retinine rti in n erly rning spt urine lleted upn wkening is the preferred ethd t ssess lbuin exretin. In the erly rning spt urine,  rti f lbuin (g/L) t retinine (g/L) f less thn 30 g/g retinine is nrl, nd  rti f 30–300 g/g retinine suggests bnrl irlbuinuri. At lest tw erly rning spt urine lletins ver  3- t 6-nth perid shuld be bnrl befre  dignsis f irlbuinuri is justified. Shrt-ter hyperglyei, exerise, urinry trt infetins, hert filure, nd ute febrile illness n use trnsient lbuinuri nd s test- ing fr irlbuinuri shuld be pstpned until res- lutin f these prbles. Subsequent end-stge hrni kidney disese n be predited by persistent urinry lbuin exretin rtes exeeding 30 g/g retinine. Glyei ntrl s well s  prtein diet f ~0.8 g/kg/dy y redue bth the hyperfiltrtin nd the elevted irlbuinuri in ptients in the erly stges f dibetes nd thse with inipient dibeti nephrpthy. Antihypertensive therpy ls dereses irlbuinuri. Evidene fr se studies supprts  speifi rle fr ACE inhibitrs in redu- ing intrglerulr pressure in dditin t their lwering f systei hypertensin. An ACE inhibitr (ptpril, 50 g twie dily) in nrtensive dibeti ptients ipedes prgressin t prteinuri nd prevents the inrese in lbuin exretin rte. SGLT2 therpy shuld be instituted in ptients with type 2 dibetes wh hve prgressin f kidney disese despite tking ptil nti- hypertensive therpy, whih inludes n ACE inhibitr r ngitensin reeptr blker.C.  Diabetic NeuropathyDibeti  neurpthies re the st n plitins f dibetes, ffeting up t 50% f lder ptients with type 2 dibetes. 1. Peripheral neuropathy— a. Distal symmetric polyneuropathy— This is the st n fr f dibeti peripherl neurpthy where lss f funtin ppers in  stking-glve pttern nd is due t n xnl neurpthi press. Lnger nerves re espeilly vulnerble, hene the ipt n the ft. Bth tr nd sensry nerve ndutin is delyed in the peripherl nerves, nd nkle jerks y be bsent. Sensry invlveent usully urs first nd is gener- lly bilterl, syetri, nd ssited with dulled per- eptin f vibrtin, pin, nd teperture. The pin n rnge fr ild disfrt t severe inpitting syp- ts. The sensry defiit y eventully be f suffiientdegree t prevent ptients fr feeling pin. Ptients wh hve  sensry neurpthy shuld therefre be exined with  5.07 Sees-Weinstein filent nd thse wh nnt feel the filent ust be nsidered t risk fr unpereived neurpthi injury. The denervtin f the sll usles f the ft n result in lwing f the tes nd displeent f the sub- ettrsl ft pds nterirly. These hnges, tgether with the jint nd nnetive tissue hnges, lter the biehnis f the ft nd inrese plntr pressures. This bintin f deresed pin threshld, bnr- lly high ft pressures, nd repetitive stress (suh s fr wlking) n led t lluses nd ulertins in the high-pressure res suh s ver the ettrsl heds (Figure 27–3). Peripherl neurpthy, utni neu- rpthy, nd tru ls predispses t the develpent fCharcot arthropathy. An ute se f Chrt ft rthrpthy presents with pin nd swelling, nd if left untreted, leds t  “rker btt” defrity nd ulertin. The erly rdilgi hnges shw jint sub- luxtin nd perirtiulr frtures. As the press pr- gresses, there is frnk stelsti destrutin leding t dernged nd unstble jints prtiulrly in the idft. Nt surprisingly, the key issue fr the heling f neur- pthi ulers in  ft with gd vsulr supply is ehnil unlding. In dditin, ny infetin shuld be treted with debrideent nd pprprite ntibitis; heling durtin f 8–10 weeks is typil. Osinlly, when heling ppers refrtry, pltelet-derived grwth ftr (beplerin [Regrnex]) shuld be nsidered fr ll pplitin. One ulers re heled, therpeuti ftwer is key t preventing reurrenes. Cust lded shes re reserved fr ptients with signifint ft defrities. Other ptients with neurpthy y require dtive insles tht distribute the ld ver s wide n re s pssible. Ptients with ft defr- ities nd lss f their prtetive threshld shuld get regulr re fr  pditrist. Ptients shuld be edu- ted n pprprite ftwer nd thse with lss f their ▲Figure 27–3. Diabetic foot ulcer over head of first metatarsal (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch27_p1212-p1255.indd  1239 29/06/21 8:53 PMCHAPTEr 271240 CMDT 2022prtet ive threshld shuld be instruted t inspet their feet dily fr reddened res, blisters, brsins, r lertins. In se ptients, hypersensitivity t light tuh nd sinlly severe “burning” pin, prtiulrly t night, n bee physilly nd etinlly disbling. Nrtrip- tyline r desiprine in dses f 25–150 g/dy rlly y prvide drti relief fr pin fr dibeti neu- rpthy, ften within 48–72 hurs. Ptients ften ttribute the benefit t hving  full night’s sleep. Mild t derte rning drwsiness is  side effet tht generlly iprves with tie r n be lessened by giving the editin sev- erl hurs befre bedtie. This editin shuld nt be ntinued if iprveent hs nt urred fter 5 dys f therpy. Aitriptyline, 25–75 g rlly t bedtie, n ls be used but hs re ntihlinergi effets. Triyli ntidepressnts, in bintin with fluphenzine (3 g dily in three divided dses) hve been shwn in tw stud- ies t be effiius in pinful neurpthy, with benefits unrelted t relief f depressin. Gbpentin (900–1800 g rlly dily in three divided dses) hs ls been shwn t be effetive in the tretent f pinful neurpthy nd shuld be tried if the triyli editins prve ineffe- tive. Pregblin,  ngener f gbpentin, hs been shwn in n 8-week study t be re effetive thn pleb in treting pinful dibeti peripherl neurpthy. Hwever, this editin ws nt pred with n tive ntrl. Als, beuse f its buse ptentil, it hs been tegrized s  shedule V ntrlled substne. Dulxetine (60–120 g),  sertnin nd nrepinephrine reuptke inhibitr, is pprved fr the tretent f pinful dibeti neurpthy. Cpsiin,  tpil irritnt, is effetive in reduing ll nerve pin; it is dispensed s  re (Zstrix 0.025%, Zstrix-HP 0.075%) t be rubbed int the skin ver the pinful regin tw t fur ties dily. Glves shuld be used fr pplitin sine hnd ntintin uld result in disfrt if the re es in ntt with eyes r sensitive res suh s the genitli. Appli- tin f  5% lidine pth ver n re f xil pin hs been reprted t be f benefit. It is pprved fr tret- ent f pstherpeti neurlgi. Diabetic neuropathic cachexia is  syndre hr- terized by  syetri peripherl neurpthy ssited with prfund weight lss (up t 60% f ttl bdy weight) nd pinful dysesthesis ffeting the prxil lwer libs, the hnds, r the lwer trunk. Tretent is usully with insulin nd nlgesis. The prgnsis is generlly gd, nd ptients typilly rever their bseline weight with reslutin f the pinful sensry sypts within 1 yer. b. Isolated peripheral neuropathy— Invlveent f the distributin f nly ne nerve (“nneurpthy”) r f severl nerves (“nneurpthy ultiplex”) is hr- terized by sudden nset with subsequent revery f ll r st f the funtin. This neurpthlgy hs been ttrib- uted t vsulr ishei r truti dge. Crnil nd ferl nerves re nly invlved, nd tr bnrlities predinte. The ptient with rnil nerve invlveent usully hs diplpi nd single third, furth, r sixth nerve wekness n exintin but the pupil isspred. A full revery f funtin urs in 6–12 weeks. Dibeti ytrphy presents with nset f severe pin in the frnt f the thigh. Within  few dys r weeks f the nset f pin, wekness nd wsting f the qudrieps develps. As the wekness ppers, the pin tends t iprve. Mngeent inludes nlgesi nd iprved dibetes ntrl. The sypts iprve ver 6–18 nths. 2. Autonomic neuropathy— Neurpthy f the utni syste urs priniplly in ptients with dibetes f lng durtin. It ffets ny diverse viserl funtins inlud- ing bld pressure nd pulse, gstrintestinl tivity, bld- der funtin, nd eretile dysfuntin. Tretent is direted speifilly t eh bnrlity. Insulin neuritis r tretent-indued neurpthy f dibetes urs - sinlly in ptients with pr gluse ntrl nd whse gluse levels iprve rpidly in dys r  few weeks. Sypts inlude severe sensry neurpthi pins nd seties utni funtins. These sypts iprve ver  few nths. a. Gastrointestinal system— Invlveent f the gs- trintestinl syste y be nifested by nuse, vit- ing, pstprndil fullness, reflux r dysphgi, nstiptin r dirrhe (r bth), nd fel inntinene. Gstrpre- sis shuld be nsidered in type 1 dibeti ptients in wh unexpeted flututins nd vribility in their bld gluse levels develps fter els. Metlpride hs been f se help in treting dibeti gstrpresis. It is given in  dse f 10 g rlly three r fur ties  dy, 30 inutes befre els nd t bedtie. Drwsiness, rest- lessness, ftigue, nd lssitude re n dverse effets. Trdive dyskinesi nd extrpyridl effets n ur, espeilly when used fr lnger thn 3 nths, nd the FDA hs utined ginst the lng-ter use f etlpride. Erythryin ppers t bind t tilin reeptrs in the sth nd hs been fund t iprve gstri epty- ing ver the shrt ter in dses f 250 g three ties dily, but its effetiveness sees t diinish ver tie. In seleted ptients, injetins f btulinu txin int the pylrus n redue pylrus sphinter resistne nd enhne gstri eptying. Gstri eletril stiultin hs been reprted t iprve sypts nd qulity f life indies in ptients with gstrpresis refrtry t phr- lgi therpy. Dirrhe ssited with utni neurpthy hs sinlly respnded t brd-spetru ntibiti ther- py (suh s rifxiin, etrnidzle, xiillin/lvul- nte, iprflxin, r dxyyline), lthugh it ften underges spntneus reissin. Refrtry dibeti dirrhe is ften ssited with ipired sphinter n- trl nd fel inntinene. Therpy with lperide, 4–8 g dily, r diphenxylte with trpine, tw tblets up t fur ties  dy, y prvide relief. In re severe ses, tinture f pregri r deine (60-g tblets) y be required t redue the frequeny f dirrhe nd iprve the nsisteny f the stls. Clnidine hs been reprted t lessen dibeti dirrhe; hwever, its usefulness is liited by its tendeny t lwer bld pressure in these ptients wh lredy hve utni neurpthy, resultingCMDT22_Ch27_p1212-p1255.indd  1240 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1241 CMDT 2022in  rthstti hyptensin. Cnstiptin usully respnds t stiulnt lxtives suh s senn. b. Genitourinary system— Inplete eptying f the bldder n seties ur. Bethnehl in dses f 10–50 g rlly three ties  dy hs sinlly iprved eptying f the tni urinry bldder. Ctheter depressin f the distended bldder hs been reprted t iprve its funtin, nd nsiderble benefit hs been reprted fter surgil severing f the internl vesile sphinter. Eretile dysfuntin n result fr neurlgi, psy- hlgil, r vsulr uses, r  bintin f these uses. The phsphdiesterse type 5 (PDE5) inhibitrs sildenfil (Vigr), vrdenfil (Levitr), nd tdlfil (Cilis) hve been shwn in pleb-ntrlled linil tri- ls t iprve eretins in respnse t sexul stiultin. The reended dse f sildenfil fr st ptients is ne 50-g tblet tken pprxitely 1 hur befre sexul tivity. The pek effet is t 1.5–2 hurs, with se effet persisting fr 4 hurs. Ptients with dibetes ellitus using sildenfil reprted 50–60% iprveent in eretile fun- tin. The xiu reended dse is 100 g. The reended dse f bth vrdenfil nd tdlfil is 10 g. The dses y be inresed t 20 g r deresed t 5 g bsed n effiy nd side effets. Tdlfil hs been shwn t iprve eretile funtin fr up t 36 hurs fter dsing. Lw dses re vilble fr dily use. In linil trils, nly  few dverse effets hve been reprted—trnsient ild hedhe, flushing, dyspepsi, nd se ltered lr visin. Pripis n ur with these editins, nd ptients shuld be dvised t seek iedite edil ttentin if n eretin persists fr lnger thn 4 hurs. The PDE5 inhibi- trs ptentite the hyptensive effets f nitrtes nd their use is ntrindited in ptients wh re nurrently using rgni nitrtes in ny fr. Cutin is dvised fr en wh hve suffered  hert ttk, strke, r life-thretening rrhythi within the previus 6 nths; en wh hve resting hyptensin r hypertensin; nd en wh hve  histry f hert filure r hve unstble ngin. Rrely,  derese in visin r pernent visul lss hs been reprted fter PDE5 inhibitr use. Intrrprel injetin f vstive editins uses penile engrgeent nd eretin. Meditins st nly used inlude ppverine lne, ppverine with phentline, nd lprstdil (prstglndin E1). Alprst- dil injetins re reltively pinless, but reful instrutin is essentil t prevent ll tru, pripis, nd fibrsis. Intrurethrl pellets f lprstdil vid the prble f injetin f the editin. Externl vuu therpy (Ere-Aid Syste) is  nnsur- gil tretent nsisting f  sutin hber perted by  hnd pup tht retes  vuu rund the penis. This drws bld int the penis t prdue n eretin tht is intined by  speilly designed tensin ring inserted rund the bse f the penis nd whih n be kept in ple fr up t 20–30 inutes. While this ethd is generlly effetive, its uberse nture liits its ppel. Surgil iplnts f penile prstheses rein n ptin fr thse ptients in wh the nnsurgil pprhes re ineffetive.c. Orthostatic hypotension— Use f Jbst fitted stkings, tilting the hed f the bed, nd rising slwly fr the supine psitin n be helpful in treting syp- ts f rthstti hyptensin. When suh esures re indequte, then tretent with fludrrtisne 0.1–0.2 g rlly dily n be nsidered. This editin, hwever, n result in supine hypertensin nd hypklei. The lph-gnist iddrine (10 g rlly three ties  dy) n ls be used.D . Cardiovascular Complications1.  Heart disease— Mirngipthy urs in the hert f ptients with dibetes nd y explin the etilgy f n- gestive rdiypthies in thse wh d nt hve den- strble rnry rtery disese. Mre nly, hwever, hert disese in ptients with dibetes is due t rnry therslersis. Myrdil infrtin is three t five ties re n in dibeti ptients nd is the leding use f deth in ptients with type 2 dibetes. Crdivsulr disese risk is inresed in ptients with type 1 dibetes s well, lthugh the bslute risk is lwer thn in ptients with type 2 dibetes. Preenpusl wen wh nrlly hve lwer rtes f rnry rtery disese lse this prte- tin ne dibetes develps. The inresed risk in ptients with type 2 dibetes reflets the bintin f hypergly- ei, hyperlipidei, bnrlities f pltelet dhesive- ness, gultin ftrs, hypertensin, xidtive stress, nd infltin. Lrge interventin studies f risk ftr redutin in dibetes re lking, but it is resnble t ssue tht reduing these risk ftrs wuld hve  ben- efiil effet. Lwering LDL hlesterl redues first events in ptients withut knwn rnry disese nd sendry events in ptients with knwn rnry disese. These interventin studies inluded se ptients with dibetes, nd the benefits f LDL hlesterl lwering ws pprent in this grup. The Ntinl Chlesterl Edutin Pr- gr linil prtie guidelines hve designted dibetes s  rnry risk equivlent nd hve reended tht ptients with dibetes shuld hve n LDL hlesterl gl f less thn 100 g/dL (2.6 l/L). Lwering LDL h- lesterl t 70 g/dL (1.8 l/L) y hve dditinl benefit nd is  resnble trget fr st ptients with type 2 dibetes wh hve ultiple risk ftrs fr rdi- vsulr disese. Aspirin t  dse f 81–325 g dily is effetive in reduing rdivsulr rbidity nd rtlity in ptients wh hve  histry f yrdil infrtin r strke (sendry preventin). Fr priry preventin,  2018 rndized study f 15,480 persns with dibetes but n evident rdivsulr disese bserved tht 100 g f spirin redued the first vsulr event f yrdil infrtin, strke r trnsient ishei ttk r deth fr vsulr event (exluding intrrnil herrhge) (rte rti 0.88; 95% nfidene intervl 0.79 t 0.97). There were, hwever, re jr bleeding events, espe- illy gstrintestinl, in the spirin grup (rte rti 1.29; 95% nfidene intervl 1.09 t 1.52). Thus, fr priry preventin, the use f spirin shuld nly be nsidered fr ptients with high rdivsulr risk nd lw bleeding risk nd generlly nt fr dults lder thn 70 yers. BsedCMDT22_Ch27_p1212-p1255.indd  1241 29/06/21 8:53 PMCHAPTEr 271242 CMDT 2022n  the Erly Tretent Dibeti Retinpthy Study (ETDRS), there des nt pper t be  ntrinditin t spirin use t hieve rdivsulr benefit in dibeti ptients wh hve prlifertive retinpthy. Aspirin ls des nt see t ffet the severity f vitreus/preretinl herrhges r their reslutin. 2. Hypertension— The ADA reends lwering systli bld pressure t less thn 140  Hg nd distli pres- sure t less thn 90  Hg in ptients with dibetes. The systli trget f 130  Hg r less nd distli trget f 80  Hg r less re reended fr the yunger ptient if they n be hieved withut undue tretent burden. The Systli Bld Pressure Interventin Tril (SPRINT) reprted tht treting t  systli bld pressure f less thn 120  Hg redued rdivsulr events by 25% nd deth fr rdivsulr uses by 43% during 3.26 yers f fllw-up. Peple with dibetes, hwever, were exluded fr this study, nd it is unler if the results re pplible t this ppultin. Ptients with type 2 dibetes wh lredy hve rdivsulr disese r irlbuinuri shuld be nsidered fr tretent with n ACE inhibitr. Mre lini- l studies re needed t ddress the questin f whether ptients with type 2 dibetes wh d nt hve rdivsulr disese r irlbuinuri wuld speifilly benefit fr ACE inhibitr tretent. 3. Peripheral vascular disease— Atherslersis is rk- edly elerted in the lrger rteries. It is ften diffuse, with llized enhneent in ertin res f turbulent bld flw, suh s t the bifurtin f the rt r ther lrge vessels. Clinil nifesttins f peripherl vsulr disese inlude ishei f the lwer extreities, eretile dysfuntin, nd intestinl ngin. The inidene f gangrene of the feet in ptients with dibetes is 30 ties tht in ge-thed ntrls. The f- trs respnsible fr its develpent, in dditin t periph- erl vsulr disese, re sll vessel disese, peripherl neurpthy with lss f bth pin senstin nd neur- geni infltry respnses, nd sendry infetin. In tw-thirds f ptients with ishei gngrene, pedl pulses re nt plpble. In the reining ne-third wh hve plpble pulses, redued bld flw thrugh these vessels n be denstrted by plethysgrphi r Dppler ultrsund exintin. Preventin f ft injury is ipertive. Agents tht redue peripherl bld flw suh s tb shuld be vided. Cntrl f ther risk ftrs suh s hypertensin is essentil. Bet-blkers re rel- tively ntrindited beuse f presued negtive peripherl hedyni nsequenes but dt tht sup- prt this re lking. Chlesterl-lwering gents re use- ful s djuntive therpy when erly ishei signs re deteted nd when dyslipidei is present. Ptients shuld be dvised t seek iedite edil re if  dibeti ft uler develps. Iprveent in peripherl bld flw with endrterety nd bypss pertins is pssible in er- tin ptients.E.  Skin and Mucous Membrane ComplicationsChrni  pygeni infetins f the skin y ur, espe- illy in prly ntrlled dibeti ptients. Cndidlinfetin n prdue erythe nd ede f intertrigi- nus res belw the brests, in the xills, nd between the fingers. It uses vulvvginitis in wen with hrnilly unntrlled dibetes wh hve persistent glusuri nd is  frequent use f pruritus. While ntifungl res ntining inzle r ltrizle ffer iedite relief f vulvvginitis, reurrene is frequent unless glu- suri is redued. In se ptients with type 2 dibetes, pr glyei ntrl n use severe hypertriglyei, whih n pres- ent s eruptive utneus xnths nd pnretitis. The skin lesins pper s yellw rbillifr eruptins 2–5  in dieter with erythetus rele. They ur n extensr surfes (elbws, knees, buttks) nd dispper fter triglyeride levels re redued. Nerbisis lipidi dibetiru is usully lted ver the nterir surfes f the legs r the drsl surfes f the nkles. They re vl r irregulrly shped plques with derted brders nd  glistening yellw surfe nd ur in wen tw t fur ties re frequently thn in en. Pthlgilly, the lesins shw degenertin f llgen, grnultus infltin f subutneus tissues nd bld vessels, pillry bseent ebrne thikening nd blitertin f vessel luin. The nditin is ssited with type 1 dibetes, lthugh it n ur in ptients with type 2 dibetes, nd ls in ptients withut dibetes. First-line therpy inludes tpil nd subutne- us rtisterids. Iprving glyei ntrl y help the nditin. “Shin spts” re nt unn in dults with dibetes. They re brwnish, runded, pinless trphi lesins f the skin in the pretibil re.F . Bone and Joint ComplicationsLng-stnding  dibetes n use prgressive stiffness f the hnd sendry t ntrture nd tightening f skin ver the jints (dibeti heirrthrpthy), frzen shul- der (dhesive psulitis), rpl tunnel syndre, nd Dupuytren ntrtures. These plitins re believed t be due t glysyltin f llgen nd perhps ther prteins in nnetive tissue. There y ls be n infl- try pnent. Dt n bne inerl density nd frture risk in peple with dibetes re ntrditry. Ptients with type 2 dibetes d pper t be t inresed risk fr nnvertebrl frtures. Wen with type 1 dibetes hve n inresed risk f fr- ture when pred with wen withut dibetes. Other ftrs, suh s durtin f dibetes, nd dibetes pli- tins, suh s neurpthy nd kidney disese, likely ffet bth the bne inerl density nd frture risk. Diffuse idipthi skeletl hyperstsis (DISH) is hr- terized by ssifitin f the nterir lngitudinl lig- ents f the spine nd vrius extrspinl ligents. It uses stiffness nd deresed rnge f spinl tin. The peripherl jints st nly ffeted re the etr- pphlngel jints, elbws, nd shulders. Dibetes, be- sity, hypertensin, nd dyslipidei re risk ftrs fr this nditin. Hyperuriei nd ute nd tpheus gut re re n in type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1242 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1243 CMDT 2022Bursitis,  prtiulrly f the shulders nd hips, urs re frequently thn expeted in ptients with dibetes.ASCEND Study Cllbrtive Gr up et l. Effets f spirin fr priry preventin in persns with dibetes ellitus. N Engl J Med. 2018;379:1529. [PMID: 30146931] Grennn D. Dibeti ft ulers. JAMA. 2019;321:114. [PMID: 30620372] Hinhliffe RJ et l; Interntinl Wrking Grup n the Dibeti Ft (IWGDF). Guidelines n dignsis, prgnsis, nd n- geent f peripherl rtery disese in ptients with ft ulers nd dibetes (IWGDF 2019 updte). Dibetes Metb Res Rev. 2020;36:e3276. [PMID: 31958217] Selvrjh D et l. Dibeti peripherl neurpthy: dvnes in dignsis nd strtegies fr sreening nd erly interventin. Lnet Dibetes Endrinl. 2019;7:938. [PMID: 31624024] Shen JI et l. Evidene fr nd ginst ACC/AHA 2017 guideline fr trget systli bld pressure f < 130  Hg in persns with type 2 dibetes. Curr Crdil Rep. 2019;21:149. [PMID: 31760494] »Special SituationsA.  Diabetes Management in the HospitalH spitlized ptients re generlly nt eting s usul nd they re ften fsting fr predures, whih kes it hl- lenging t use utptient rl r insulin regiens. There y be n inrese in the dverse retins f dibetes edi- ines (eg, thizlidinedines n use fluid retentin nd wrsen hert filure); etfrin shuld nt be used in ptients with signifint hrni kidney r liver disese r thse getting ntrst fr rdigrphi studies; nd SGLT2 inhibitrs y be ssited with inresed risk f dibeti ketidsis. The dt n the use f ntinuus gluse nitrs, insulin pups, nd hybrid lsed lp systes in hspitlized ptients re insuffiient. Whether ptients sty n these systes in the hspitl will depend n their severity f illness nd ess t speilist re. In generl, deisins regrding insulin dsing shuld be de bsed n pillry bld gluse esureents nd nt n the dt fr n- tinuus gluse nitrs. Ptients shuld be trnsitined t  nventinl bsl blus subutneus insulin regien if they re unble t nge their pup nd/r ntinuus gluse nitr beuse f their illness r if they refuse t fllw the institutinl guidelines n using the pup r ntinuus nitr (eg, giving theselves insulin bluses nd nt infring the linil stff). The systes hve t be reved if the ptient is getting n MRI. On the general medical and surgical inpatient ser- vices, st ptients re treted with subutneus insulin regiens. Liited rss-setinl nd prspetive studies suggest tht the best gluse ntrl is hieved n  - bintin f bsl nd blus regien with 50% f dily insulin needs prvided by interedite- r lng-ting insulins. Stndrdized rder sets n redue errrs, nd they ften inlude lgriths fr regnitin nd tret- ent f hypglyei (see http://usfinptientdibetes. pbwrks. fr exples). Orl ediines, espeilly etfrin nd sulfnylures, n be resued s the ptient is being prepred fr hspitl dishrge. In the intensive care units (ICUs), gluse levels re ntrlled st frequently using insulin infusins(http://usfinptientdibetes.pbwrks.). Ptients reeiv- ing ttl prenterl nutritin n hve insulin dded t the bg. Stndrd ttl prenterl nutritin ntins 25% dex- trse s n infusin rte f 50 L/h delivers 12.5 g f dextrse per hur. Bsed n the evidene vilble, ICU ptients with dibe- tes nd new-nset hyperglyei with bld gluse levels bve 180 g/dL (10 l/L) shuld be treted with insu- lin, iing fr trget gluse levels between 140 g/dL (7.8 l/L) nd 180 g/dL (10 l/L). In the ICU set- ting, iing fr bld gluse levels lse t 100 g/dL (5.6 l/L) is nt benefiil nd y even be hrful. When ptients leve the ICU, trget gluse vlues between 100 g/dL (5.6 l/L) nd 180 g/dL (10 l/L) y be pprprite, lthugh this view is bsed n linil bser- vtins rther thn nlusive evidene. Preoperative and perioperative diabetic management strtegies re disussed in Chpter 3. The rbidity nd rtlity in hspitlized dibeti ptients re twie thse f nndibeti ptients. Thse with new-nset hyperglyei (ie, thse withut  predis- sin dignsis f dibetes) hve even higher rtlity— lst eightfld tht f nndibeti ptients in ne study. These bservtins hve led t the questin f whether tight glyei ntrl in the hspitl iprves utes.B.  Pregnancy and the Diabetic PatientSee Chpt er 19. Tight glyei ntrl with nrl HbA1 levels is very iprtnt during pregnny. Erly in preg- nny, pr ntrl inreses the risk f spntneus br- tin nd ngenitl lfrtins. Lte in pregnny, pr ntrl n result in plyhydrnis, preter lbr, stillbirth, nd fetl rsi with its ssited prb- les. Dibetes plitins n ipt bth ternl nd fetl helth. Dibeti retinpthy n first develp during pregnny r retinpthy tht is lredy present n wrsen. Dibeti wen with irlbuinuri n hve wrsening lbuinuri during pregnny nd re t higher risk fr preelpsi. Lw-dse (81 g) spirin n redue the risk f preelpsi nd shuld be presribed fter 12 weeks f gesttin. Ptients wh hve preexisting kidney filure (prepregnny retinine lerne less thn 80 L/in) re t high risk fr further deline in kidney funtin during the pregnny, nd this y nt reverse fter delivery. Dibeti gstrpresis n severely exer- bte the nuse nd viting f pregnny nd se ptients y require fluid nd nutritinl supprt. Althugh there is evidene tht glyburide is sfe during pregnny, the urrent prtie is t ntrl dibetes with insulin therpy. Every effrt shuld be de, utilizing ul- tiple injetins f insulin r  ntinuus infusin f insu- lin by pup, t intin ner-nrliztin f fsting nd preprndil bld gluse vlues while viding hypglyei. Regulr nd NPH insulin nd the insulin nlgs lispr, sprt, nd deteir re lbeled pregnny tegry B. Insu- lin glrgine, glulisine, nd deglude re lbeled tegry C beuse f lk f linil sfety dt. A sll study using insulin glrgine in 32 pregnnies did nt revel ny prbles.CMDT22_Ch27_p1212-p1255.indd  1243 29/06/21 8:53 PMCHAPTEr 271244 CMDT 2022U nless there re fetl r ternl plitins, dibeti wen shuld be ble t rry the pregnny t full-ter, delivering t 38 t 41 weeks. Indutin f lbr befre 39 weeks y be nsidered if there is nern but inresing fetl weight. See Chpter 19 fr further detils.Aerin  Dibetes Assitin. Mngeent f dibetes in pregnny: Standards of Medical Care in Diabetes—2020 . Dibetes Cre. 2020;43:S183. [PMID: 31862757]DI ABETIC COMAC  y be due t uses nt diretly relted t dibetes. Dibeti  requires differentitin (Tble 27–10): (1) Hypglyei  fr exessive insulin r rl hyp- glyei gents. (2) Hyperglyei  with either severe insulin defiieny (DKA) r ild t derte insu- lin defiieny (hyperglyei hyperslr stte). (3) Lti idsis, prtiulrly when ptients with dibetes hve severe infetins r rdivsulr llpse.DI ABETIC KETOACIDOSISE S S E N T I A L S  O F  D I A G N O S I S »Hyperglycemia > than 250 mg/dL (13.9 mmol/L). »Metabolic acidosis with blood pH < 7.3; serum bicarbonate < 15 mEq/L. »Serum positive for ketones. »General ConsiderationsDibeti  ketidsis (DKA) is  disrder pririly in ptients with type 1 dibetes but n ur in ptients with type 2 dibetes wh hve severe illness, suh s sepsis r tru. DKA y be the initil nifesttin f type 1dibetes r y result fr inresed insulin requireents in type 1 dibetes ptients during the urse f infetin, tru, yrdil infrtin, r surgery. It is  life-thret- ening edil eergeny. The Ntinl Dt Grup reprts n nnul inidene f five t eight episdes f DKA per 1000 dibeti persns. DKA is ne f the re n serius plitins f insulin pup therpy, urring in pprxitely 1 per 80 ptient-nths f tretent. Mny ptients wh nitr pillry bld gluse regulrly ignre urine ketne esureents, whih signls the pssibility f insulin lekge r pup filure befre serius illness develps. Pr pline, either fr psyhlgil resns r beuse f indequte edutin, is ne f the st n uses f reurrent DKA. »Clinical FindingsA.  Symptoms and SignsThe  pperne f DKA is usully preeded by  dy r re f plyuri nd plydipsi ssited with rked ftigue, nuse, nd viting. If untreted, entl stupr ensues tht n prgress t . Drwsiness is firly n, but frnk  nly urs in but 10% f ptients. On physil exintin, evidene f dehydrtin in  stuprus ptient with rpid deep brething nd  “fruity” breth dr f etne strngly suggests the dignsis. Hyptensin with thy- rdi indites prfund fluid nd eletrlyte depletin, nd ild hyptheri is usully present. Abdinl pin nd even tenderness y be present in the bsene f bdinl disese. Cnversely, hleystitis r pnretitis y ur with inil sypts nd signs.B.  Laboratory FindingsT ypilly, the ptient with dertely severe DKA hs  pls gluse f 350–900 g/dL (19.4–50 l/L), seru ketnes t  dilutin f 1:8 r greter rTable 27–10. Laboratory diagnosis of coma in diabetic patients. Uine Glucose Uine Ketones Plasma Glucose Seum Bicabonate Seum Ketones related to Diabetes Hypoglycemia 010 or + Low Normal 0 Diabetic ketoacidosis ++++ ++++ High Low ++++ Hyperglycemic hyperosmolar state coma++++ 0 or + High Normal or slightly low 0 Lactic acidosis 0 or + 0 or + Normal or low or high Low 0 or + Unelated to Diabetes Alcohol or other toxic drugs 0 or + 0 or + May be low Normal or low20 or + Cerebrovascular accident or head trauma+ or 0 0 Often high Normal 0 Uremia 0 or + 0 High or normal Low 0 or +1 Leftover urine in bladder might still contain glucose from earlier hyperglycemia.2 Alcohol can elevate plasma lactate as well as keto acids to reduce pH.CMDT22_Ch27_p1212-p1255.indd  1244 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1245 CMDT 2022bet-hydr xybutyrte re thn 4 nl/L, hyperklei (seru ptssiu level f 5–8 Eq/L), ild hypntrei (seru sdiu f pprxitely 130 Eq/L), hyperphs- phtei (seru phsphte level f 6–7 g/dL [1.9–2.3 l/L]), nd elevted bld ure nitrgen nd seru retinine levels (Tble 27–10). Aidsis y be severe (pH rnging fr 6.9 t 7.2 nd seru birbnte rnging fr 5 Eq/L t 15 Eq/L); Pco2is lw (15–20  Hg) relted t penstry hyperventiltin. Fluid depletin is rked, typilly but 100 L/kg. In euglyei ketidsis, the ptient n hve severe id- sis nd fluid depletin but the pls gluse levels re nly destly elevted, usully less thn 250 g/dy (13.9 l/L). This nditin is seen in ptients in wh dibeti ketidsis develps while reeiving tretent with SGLT2 inhibitrs. Ketidsis with lwer gluse levels ls urs in pregnny nd y reflet the expnded pls vlue nd the inresed glerulr filtrtin rte. The differene between venus nd rteril pH is 0.02 t 0.15 pH units nd venus nd rteril birbnte is 1.88 Eq/L. These sll differenes will nt ffet either the dignsis r the ngeent f DKA, nd there is n need t llet rteril bld fr esuring the id-bse sttus. The hyperklei urs despite ttl bdy ptssiu depletin beuse f the shift f ptssiu fr the intr- ellulr t extrellulr spes tht urs in systei i- dsis. The verge ttl bdy ptssiu defiit resulting fr sti diuresis, idsis, nd gstrintestinl lsses is but 3–5 Eq/kg. Siilrly, despite the elevted seru phsphte, ttl bdy phsphte is generlly depleted. Seru sdiu is generlly redued due t lss f sdiu ins (7–10 Eq/kg) by plyuri nd viting nd beuse severe hyperglyei shifts intrellulr wter int the interstitil prtent. Fr every 100 g/dL f pls gluse, seru sdiu dereses by 1.6 Eq/L (5.56 l/L). The derese in seru sdiu y be greter when ptients hve re severe hyperglyei (greter thn 400 g/dL, 22.2 l/L) nd  rretin ftr f 2.4 Eq/L y be used. Hypertriglyeridei shuld be nsidered if the rreted sdiu is very lw. Seru sllity n be diretly esured by stndrd tests f freezing pint depressin r n be estited by lulting the lrity f sdiu, hlride, nd gluse in the seru. A nvenient ethd f estiting effetive seru sllity is s fllws (nrl vlues re 280–300 Os/kg): mOsm/kg  2 [measured Na ]Glucose (mg/dL) 18=  ++These lulted esti tes re usully 10–20 Os/kg lwer thn vlues esured by stndrd ryspi teh- niques. Centrl nervus syste depressin r  urs when the effetive seru sllity exeeds 320–330 Os/L. C in  dibeti ptient with  lwer sllity shuld prpt  serh fr the use f  ther thn hypersllity (see Tble 27–10 nd Chpter 24).Ketidei represents the effet f insulin lk t ultiple enzye li. Insulin lk ssited with elevted levels f grwth hrne, tehlines, nd glugn ntributes t inreses in liplysis fr dipse tissue nd in hepti ketgenesis. In dditin, redued ketlysis by insulin-defiient peripherl tissues ntributes t the ket- idei. The nly true “ket” id present in dibeti ketidsis is eteti id whih, lng with its by- prdut etne, is esured by nitrprusside regents (Aetest nd Ketstix). The sensitivity fr etne, hw- ever, is pr, requiring ver 10 l/L, whih is seld rehed in the pls f ketidti ptients—lthugh this detetble nentrtin is redily hieved in urine. Thus, in the pls f ketti ptients, nly etette is esured by these regents. The re prevlent bet- hydrxybutyri id hs n ketne grup nd is therefre nt deteted by nventinl nitrprusside tests. This tkes n speil iprtne in the presene f irultry l- lpse during DKA, wherein n inrese in lti id n shift the redx stte t inrese bet-hydrxybutyri id t the expense f the redily detetble eteti id. Bed- side dignsti regents re then unrelible, suggesting n ketnei in ses where bet-hydrxybutyri id is  jr ftr in prduing the idsis. Cbined gluse nd ketne eters (Preisin Xtr, Nv Mx Plus) tht esure bld bet-hydrxybutyrte nentr- tin n pillry bld re vilble. Mny linil lbrtries ls ffer diret bld bet-hydrxybutyrte esureent. Nnspeifi elevtins f seru ylse nd lipse urs in but 16–25% f ses f DKA, nd n iging study y be neessry if the dignsis f ute pnreti- tis is being seriusly nsidered. Leukytsis s high s 25,000/L (25 × 109/L) with  left shift y ur with r withut ssited infetin. The presene f n elevted r even  nrl teperture n suggest the presene f n infetin sine ptients with DKA re generlly hyp- theri if uninfeted. »TreatmentP tients with mild DKA re lert nd hve pH levels between 7.25 nd 7.30 nd bet-hydrxybutyrte levels f 3–4 l/L; thse with moderate ketoacidosis re either lert r  little drwsy nd hve pH levels between 7.0 nd 7.24 nd bet-hydrxybutyrte levels f 4–8 l/L; nd thse with severe ketoacidosis re stuprse nd hve  pH < 7.0 nd bet-hydrxybutyrte levels f greter thn 8 l/L. Ptients with ild ketidsis n be treted in the eergeny deprtent, but thse with derte r severe ketidsis require dissin t the ICU r step- dwn unit. Therpeuti gls re t restre pls vlue nd tissue perfusin, redue bld gluse nd sllity twrd nrl, rret idsis, replenish eletrlyte lsses, nd identify nd tret preipitting ftrs. Gstri intubtin is reended in the tse ptient t prevent viting nd spirtin tht y ur s  result f gstri tny,  n plitin f DKA. An indwelling urinry theter y ls be neessry. In ptients with preexisting hert r kidney filure r thse in severe rdivsulr llpse,  entrl venus pressureCMDT22_Ch27_p1212-p1255.indd  1245 29/06/21 8:53 PMCHAPTEr 271246 CMDT 2022the ter shuld be inserted t evlute the degree f hypvlei nd t nitr subsequent fluid dinistrtin. A prehensive flw sheet tht inludes vitl signs, seril lbrtry dt, nd therpeuti interventins (eg, fluids, insulin) shuld be etiulusly intined by the liniin respnsible fr the ptient’s re. Pls gluse shuld be rerded hurly nd eletrlytes nd pH t lest every 2–3 hurs during the initil tretent perid. Bed- side gluse eters shuld be used t titrte the insulin therpy. The ptient shuld nt reeive sedtives r piids in rder t vid sking signs nd sypts f ipeding erebrl ede.A.  Fluid ReplacementIn  st ptients, the fluid defiit is 4–5 L. Initilly, 0.9% sline slutin is the slutin f hie t help reexpnd the ntrted vsulr vlue nd shuld be strted in the eergeny deprtent s sn s the dignsis is estblished. The sline shuld be infused rpidly t prvide 1 L/h ver the first 1–2 hurs. After the first 2 L f fluid hve been given, the intrvenus infusin shuld be t the rte f 300–400 L/h. Use 0.9% (“nrl”) sline unless the seru sdiu is greter thn 150 Eq/L, when 0.45% (“hlf nrl”) sline slutin shuld be used. The vlue sttus shuld be refully nitred linilly. Filure t give enugh vlue repleent (t lest 3–4 L in 8 hurs) t restre nrl perfusin is ne f the st serius therpeuti shrtings dversely influening stisf- try revery. Exessive fluid repleent (re thn 5 L in 8 hurs) y ntribute t ute respirtry distress syndre r erebrl ede. When bld gluse flls t pprxitely 250 g/dL (13.9 l/L), the fluids shuld be hnged t  5% gluse-ntining slutin t in- tin seru gluse in the rnge f 250–300 g/dL (13.9–16.7 l/L). This will prevent the develpent f hypglyei nd will ls redue the likelihd f ere- brl ede, whih uld result fr t rpid deline f bld gluse.B.  Insulin ReplacementIedi tely fter inititin f fluid repleent, regulr insulin n be given intrvenusly in  lding dse f 0.1 unit/kg s  blus t prie the tissue insulin reeptrs. Fllwing the initil blus, intrvenus dses f insulin s lw s 0.1 unit/kg/h re ntinuusly infused r given hurly s n intrusulr injetin; this is suffiient t reple the insulin defiit in st ptients. A prspetive rndized study shwed tht  blus dse is nt required if ptients re given hurly insulin infusin t 0.14 unit/kg. Repleent f insulin defiieny helps rret the id- sis by reduing the flux f ftty ids t the liver, reduing ketne prdutin by the liver, nd ls iprving revl f ketnes fr the bld. Insulin tretent redues the hypersllity by reduing the hyperglyei. It - plishes this by inresing revl f gluse thrugh peripherl utiliztin s well s by deresing prdutin f gluse by the liver. This ltter effet is plished by diret inhibitin f glunegenesis nd glygenlysis swell s by lwered in id flux fr usle t liver nd redued hyperglugnei. The insulin infusin shuld be “piggy-bked” int the fluid line s the rte f fluid repleent n be hnged withut ltering the insulin delivery rte. If the pls gluse level fils t fll t lest 10% in the first hur,  repet lding dse (0.1 r 0.14 unit/kg) is reended. Rrely,  ptient with iune insulin resistne is enun- tered, nd this requires dubling the insulin dse every 2–4 hurs if hyperglyei des nt iprve fter the first tw dses f insulin. The insulin dse shuld be djusted t lwer the gluse nentrtin by but 50–70 g/dL/h (2.8–3.9 l/L). If linil irustnes prevent use f n insulin infusin, then the insulin n be given intrus- ulrly. An initil 0.15 unit/kg f regulr insulin is given intrvenusly, nd t the se tie, the se size dse is given intrusulrly. Subsequently, regulr insulin is given intrusulrly hurly t  dse f 0.1 unit/kg until the bld gluse flls t rund 250 g/dL, when the insulin n be given subutneusly. Ptients wh nrlly tke insulin glrgine r insulin deteir n be given their usul intenne dses during the initil tretent f their DKA. The ntinutin f their subutneus bsl insulins ens tht lwer dses f intrvenus insulin will be needed, nd there will be  sther trnsitin fr intr- venus insulin infusin t the subutneus regien.C.  PotassiumT tl bdy ptssiu lss fr plyuri nd viting y be s high s 200 Eq. Hwever, beuse f shifts f pts- siu fr ells int the extrellulr spe s  nse- quene f idsis, seru ptssiu is usully nrl t slightly elevted prir t institutin f tretent. As the idsis is rreted, ptssiu flws bk int the ells, nd hypklei n develp if ptssiu repleent is nt instituted. If the ptient is nt urei nd hs n de- qute urinry utput, ptssiu hlride in dses f 10–30 Eq/h shuld be infused during the send nd third hurs fter beginning therpy s sn s the idsis strts t reslve. Repleent shuld be strted sner if the initil seru ptssiu is inpprpritely nrl r lw nd shuld be delyed if seru ptssiu fils t respnd t initil therpy nd reins bve 5 Eq/L, s in ses f hrni kidney disese. Osinlly,  ptient y present with  seru ptssiu level less thn 3.5 Eq/L, in whih se insulin therpy shuld be delyed until the ptssiu level is rreted t greter thn 3.5 Eq/L. An ECG n help nitr the ptient’s pts- siu sttus: High peked T wves re  sign f hyperkle- i, nd flttened T wves with U wves re  sign f hypklei. Fds high in ptssiu ntent shuld be presribed when the ptient hs revered suffiiently t tke fd rlly. Tt juie hs 14 Eq f ptssiu per 240 L, nd  ediu-sized bnn prvides but 10 Eq.D . Sodium BicarbonateThe  use f sdiu birbnte in the ngeent f DKA hs been questined sine linil benefit ws ntCMDT22_Ch27_p1212-p1255.indd  1246 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1247 CMDT 2022denstr ted in ne prspetive rndized tril nd beuse f the fllwing ptentilly hrful nsequenes: (1) develpent f hypklei fr rpid shift f pts- siu int ells if the idsis is verrreted; (2) tissue nxi fr redued dissitin f xygen fr he- glbin when idsis is rpidly reversed (leftwrd shift f the xygen dissitin urve); nd (3) erebrl idsis resulting fr lwering f erebrspinl fluid pH. It ust be ephsized, hwever, tht these nsidertins re less iprtnt when very severe idsis exists. Therefre, it is reended tht birbnte be dinistered in DKA if the rteril bld pH is 7.0 r less, with reful nitring t prevent verrretin. One r tw pules f sdiu birbnte (ne pule ntins 44 Eq/50 L) shuld be dded t 1 L f 0.45% sline with 20 Eq KCl r t 400 L f sterile wter with 20 Eq KCl nd infused ver 1 t 2 hurs. ( Note: Additin f sdiu birbnte t 0.9% sline wuld prdue  rkedly hypertni slutin tht uld ggrvte the hyperslr stte lredy pres- ent.) It n be repeted until the rteril pH rehes 7.1, but it should not be given if the pH is 7.1 or greater sine ddi- tinl birbnte wuld inrese the risk f rebund etbli lklsis s ketnes re etblized. Alklsis shifts ptssiu fr seru int ells, whih uld pre- ipitte  ftl rdi rrhythi.E.  PhosphatePh sphte repleent is seld required in treting DKA. Hwever, if severe hypphsphtei f less thn 1 g/dL (0.32 l/L) develps during insulin therpy,  sll unt f phsphte n be repled per hur s the pts- siu slt. Three rndized studies, thugh, in whih phsphte ws repled in ptients with DKA did nt shw ny pprent linil benefit fr phsphte dinistr- tin. Mrever, ttepts t use ptssiu phsphte s the sle ens f repling ptssiu hve led t  nuber f reprted ses f severe hyplei with tetny. T ini- ize the risk f induing tetny fr t-rpid repleent f phsphte, the verge defiit f 40–50 l f phs- phte shuld be repled intrvenusly t  rte no greater than 3–4 mmol/h in  60- t 70-kg persn. A stk slutin (Abbtt) prvides  ixture f 1.12 g KH2PO4nd 1.18 g K2HPO4in  5-L single-dse vil (this equls 22 l f ptssiu nd 15 l f phsphte). One-hlf f this vil (2.5 L) shuld be dded t 1 L f either 0.45% sline r 5% dextrse in wter. Tw liters f this slutin, infused t  rte f 400 L/h, will rret the phsphte defiit t the ptil rte f 3 l/h while prviding 4.4 Eq f ptssiu per hur. (Additinl ptssiu shuld be dinistered s ptssiu hlride t prvide  ttl f 10–30 Eq f pts- siu per hur, s nted bve.) If the seru phsphte reins belw 2.5 g/dL (0.8 l/L) fter this infusin,  repet 5-hur infusin n be given.F . Hyperchloremic Acidosis During TherapyBeuse  f the nsiderble lss f ket ids in the urine during the initil phse f therpy, substrte fr subsequent regenertin f birbnte is lst nd rretin f the ttl birbnte defiit is hpered. A prtin f thebirbnte defiit is repled with hlride ins infused in lrge unts s sline t rret the dehydrtin. In st ptients, s the ketidsis lers during insulin reple- ent,  hyperhlrei, lw-birbnte pttern eerges with  nrl nin gp. This is  reltively benign ndi- tin tht reverses itself ver the subsequent 12–24 hurs ne intrvenus sline is n lnger being dinistered. Using  blned eletrlyte slutin with  pH f 7.4 nd 98 Eq/L hlride suh s Pls-lyte insted f nrl sline (pH ~5.5; hlride 154 Eq/L) hs been reprted t prevent the hyperhlrei idsis.G.  Treatment of Associated InfectionAntibi tis re presribed s indited (Tble 30–5). Ch- leystitis nd pyelnephritis y be prtiulrly severe in these ptients.H.  Transition to Subcutaneous Insulin RegimenOn e the DKA is ntrlled nd the ptient is wke nd ble t et, subutneus insulin therpy n be initited. The ptient with type 1 dibetes y hve persistent signifi- nt tissue insulin resistne nd y require  ttl dily insulin dse f pprxitely 0.6 unit/kg. The unt f insulin required in the previus 8 hurs n ls be helpful in estiting the initil insulin dses. Hlf the ttl dily dse n be given s  lng-ting bsl insulin nd the ther hlf s shrt-ting insulin preels. The ptient shuld reeive subutneus bsl insulin nd rpid-ting insulin nlg with the first el nd the insulin infusin disntin- ued n hur lter. The verlp f the subutneus insulin tin nd insulin infusin is neessry t prevent relpse f the DKA. In ptients with preexisting dibetes, giving their bsl insulin by subutneus injetin t inititin f tret- ent siplifies the trnsitin fr intrvenus t subut- neus regien. The inresed insulin resistne is nly present fr  few dys, nd it is iprtnt t redue bth the bsl nd blus insulins t vid hypglyei. A ptient with new-nset type 1 dibetes usully still hs signifint bet ell funtin nd y nt need ny bsl insulin nd nly very lw dses f rpid-ting insulin befre els fter revery fr the ketidsis. Ptients with type 2 dibetes nd DKA due t severe illness y initilly require insulin therpy but n ften trnsitin bk t rl gents during utptient fllw-up. »Complications & PrognosisLw- dse insulin infusin nd fluid nd eletrlyte repleent bined with reful nitring f ptients’ linil nd lbrtry respnses t therpy hve drti- lly redued the rtlity rtes f DKA t less thn 5% in individuls under 40 yers f ge. Hwever, this pli- tin reins  signifint risk in the ged wh hve r- tlity rtes greter thn 20% nd in ptients in prfund  in wh tretent hs been delyed. Aute yr- dil infrtin nd infrtin f the bwel fllwing pr- lnged hyptensin wrsen the utlk. A serius prgnsti sign is end-stge hrni kidney disese, nd prir kidney dysfuntin wrsens the prgnsis nsider- bly beuse the kidney plys  key rle in penstingCMDT22_Ch27_p1212-p1255.indd  1247 29/06/21 8:53 PMCHAPTEr 271248 CMDT 2022f r ssive pH nd eletrlyte bnrlities. Syptti erebrl ede urs pririly in the peditri ppultin. Risk ftrs fr its develpent inlude severe bseline i- dsis, rpid rretin f hyperglyei, nd exess vlue dinistrtin in the first 4 hurs. Onset f hedhe r deterirtin in entl sttus during tretent shuld led t nsidertin f this plitin. Intrvenus nnitl t  dsge f 1–2 g/kg given ver 15 inutes is the insty f tretent. Exess rystllid infusin n preipitte pul- nry ede. Aute respirtry distress syndre is  rre plitin f tretent f DKA. After revery nd stbiliztin, ptients shuld be instruted n hw t regnize the erly sypts nd signs f ketidsis. Urine ketnes r pillry bld bet-hydrxybutyrte shuld be esured in ptients with signs f infetin r in insulin pup-treted ptients when pillry bld gluse reins unexpetedly nd persis- tently high. When hevy ketnuri nd glysuri persist n severl suessive exintins, suppleentl rpid- ting insulin shuld be dinistered nd liquid fds suh s lightly slted tt juie nd brth shuld be ingested t replenish fluids nd eletrlytes. The ptient shuld be instruted t ntt the liniin if ketnuri persists, nd espeilly if there is viting nd inbility t keep dwn fluids. Reurrent episdes f severe ketid- sis ften indite pr pline with the insulin regi- en, nd these ptients will require intensive unseling.F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Isl T et l. Guidelines nd ntrversies in the ngeent f dibeti ketidsis— ini-review. Wrld J Dibetes. 2018;9:226. [PMID: 30588284] Krsliglu Frenh E et l. Dibeti ketidsis nd hypers- lr hyperglyei syndre: review f ute depensted dibetes in dult ptients. BMJ. 2019;365:l114. [PMID: 31142480] Mdi A et l. Euglyei dibeti letidsis:  review. Curr Dibetes Rev. 2017;13:315. [PMID: 27097605]HYP ERGLYCEMIC HYPEROSMOLAR STATEE S S E N T I A L S  O F  D I A G N O S I S »Hyperglycemia > 600 mg/dL (33.3 mmol/L). »Serum osmolality > 310 mOsm/kg. »No acidosis; blood pH > 7.3. »Serum bicarbonate > 15 mEq/L. »Normal anion gap (< 14 mEq/L). »General ConsiderationsTh is send st n fr f hyperglyei  is hrterized by severe hyperglyei in the bsene f sig- nifint ketsis, with hypersllity nd dehydrtin. It urs in ptients with ild r ult dibetes, nd stptients re typilly iddle-ged t elderly. Aurte figures re nt vilble s t its true inidene, but fr dt n hspitl dishrges it is rrer thn DKA even in lder ge grups. Underlying hrni kidney disese r hert filure is n, nd the presene f either wrsens the prgnsis. A preipitting event suh s infetin, yrdil infrtin, strke, r reent pertin is ften present. Certin edi- tins suh s phenytin, dizxide, rtisterids, nd diuret- is hve been iplited in its pthgenesis, s hve predures ssited with gluse lding suh s peritnel dilysis. »PathogenesisA prtil  r reltive insulin defiieny y initite the syn- dre by reduing gluse utiliztin f usle, ft, nd liver while induing hyperglugnei nd inresing hepti gluse utput. With ssive glysuri, bligtry wter lss ensues. If  ptient is unble t intin dequte fluid intke beuse f n ssited ute r hrni illness r hs suffered exessive fluid lss, rked dehydrtin results. As the pls vlue ntrts, kidney funtin bees ipired, liiting the urinry gluse lsses nd exerbting the hyperglyei. Severe hypersllity develps tht uses entl nfusin nd finlly . It is nt ler why ketsis is virtully bsent under these ndi- tins f insulin insuffiieny, lthugh redued levels f grwth hrne y be  ftr, lng with prtl vein insulin nentrtins suffiient t restrin ketgenesis. »Clinical FindingsA.  Symptoms and SignsOnset  y be insidius ver  perid f dys r weeks, with wekness, plyuri, nd plydipsi. The lk f fe- tures f DKA (eg, viting, rpid deep brething, etne dr) y retrd regnitin f the syndre nd dely therpy until dehydrtin bees re prfund thn in ketidsis. Redued intke f fluid is nt n unn histril feture, due t either inpprprite lk f thirst, nuse, r inessibility f fluids t elderly, bedridden ptients. A histry f ingestin f lrge quntities f gluse-ntining fluids, suh s sft drinks r rnge juie, n sinlly be btined. Lethrgy nd nfu- sin develp s seru sllity exeeds 310 Os/kg, nd nvulsins nd  n ur if sllity exeeds 320–330 Os/kg. Physil exintin nfirs the presene f prfund dehydrtin in  lethrgi r - tse ptient withut Kussul respirtins.B.  Laboratory FindingsSevere h yperglyei is present, with bld gluse vlues rnging fr 800 g/dL t 2400 g/dL (44.4 l/L t 133.2 l/L) (Tble 27–10). In ild ses, where dehy- drtin is less severe, dilutinl hypntrei s well s urinry sdiu lsses y redue seru sdiu t 120–125 Eq/L, whih prtets t se extent ginst extree hypersllity. Hwever, s dehydrtin pr- gresses, seru sdiu n exeed 140 Eq/L, prduing seru sllity redings f 330–440 Os/kg. Ketsis nd idsis re usully bsent r ild. Prerenl zteiCMDT22_Ch27_p1212-p1255.indd  1248 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1249 CMDT 2022is  the rule, with seru ure nitrgen elevtins ver 100 g/dL (35.7 l/L) being typil. »TreatmentA.  Fluid ReplacementFluid  repleent is f prunt iprtne in treting the nnketti hyperglyei stte. Fluid defiit y be s uh s 6–10 L. If hypvlei is present s evidened by hyptensin nd liguri, fluid therpy shuld be initited with 0.9% sline. In ll ther ses, 0.45% sline ppers t be prefer- ble s the initil repleent slutin beuse the bdy flu- ids f these ptients re rkedly hyperslr. As uh s 4–6 L f fluid y be required in the first 8–10 hurs. Cre- ful nitring f the ptient is required fr prper sdiu nd wter repleent. An iprtnt end pint f fluid therpy is t restre urinry utput t 50 L/h r re. One bld gluse rehes 250 g/dL (13.9 l/L), fluid repleent shuld inlude 5% dextrse in either wter, 0.45% sline slutin, r 0.9% sline slutin. The rte f dextrse infusin shuld be djusted t intin glyei levels f 250–300 g/dL (13.9–16.7 l/L) in rder t redue the risk f erebrl ede.B.  InsulinLess  insulin y be required t redue the hyperglyei in nnketti ptients s pred t thse with dibeti ket- idti . In ft, fluid repleent lne n redue hyperglyei nsiderbly by rreting the hypvlei, whih then inreses bth glerulr filtrtin nd renl exretin f gluse. Insulin tretent shuld therefre be delyed unless the ptient hs signifint ketnei (bet- hydrxybutyrte re thn 1 l/L). Strt the insulin infusin rte t 0.05 unit/kg/h (blus is nt needed) nd titrte t lwer bld gluse levels by 50–70 g/dL per hur (2.8–3.9 l/L/h). One the ptient hs stbilized nd the bld gluse flls t rund 250 g/dL (13.9 l/L), insulin n be given subutneusly.C.  PotassiumW ith the bsene f idsis, there y be n initil hyper- klei unless ssited end-stge hrni kidney disese is present. This results in less severe ttl ptssiu deple- tin thn in DKA, nd less ptssiu repleent is there- fre needed. Hwever, beuse initil seru ptssiu is usully nt elevted nd beuse it delines rpidly s  result f insulin’s effet n driving ptssiu intrellulrly, it is reended tht ptssiu repleent be initited erlier thn in ketti ptients, ssuing tht n hrni kidney disese r liguri is present. Ptssiu hlride (10 Eq/L) n be dded t the initil bttle f fluids din- istered if the ptient’s seru ptssiu is nt elevted.D . PhosphateIf  severe hypphsphtei (seru phsphte less thn 1 g/dL [0.32 l/L]) develps during insulin therpy, phsphte repleent n be given s desribed fr ket- idti ptients (t 3 l/h).»Complications & PrognosisThe  severe dehydrtin nd lw utput stte y predis- pse the ptient t plitins suh s yrdil infrtin, strke, pulnry eblis, esenteri vein thrbsis, nd disseinted intrvsulr gultin. Fluid repleent reins the priry pprh t the preventin f these plitins. Lw-dse heprin pr- phylxis is resnble but benefits f rutine ntigul- tin rein dubtful. Rhbdylysis is  regnized plitin nd shuld be lked fr nd treted. The verll rtlity rte f hyperglyei hypers- lr stte  is re thn ten ties tht f DKA, hiefly beuse f its higher inidene in lder ptients, wh y hve prised rdivsulr systes r ssited jr illnesses nd whse dehydrtin is ften exessive beuse f delys in regnitin nd tretent. (When ptients re thed fr ge, the prgnses f these tw hyperglyei eergenies re resnbly pr- ble.) When prpt therpy is instituted, the rtlity rte n be redued fr nerly 50% t tht relted t the severity f existent disrders. After the ptient is stbilized, the pprprite fr f lng-ter ngeent f the dibetes ust be deter- ined. Insulin tretent shuld be ntinued fr  few weeks but ptients usully rever suffiient endgenus insulin seretin t ke  tril f diet r diet plus rl gents wrthwhile. When the episde urs in  ptient wh hs knwn dibetes, then edutin f the ptient nd regivers shuld be instituted. They shuld be tught hw t regnize situtins (nuse nd viting, infetin) tht predispse t reurrene f the hyperglyei, hyper- slr stte, s well s detiled infrtin n hw t prevent the eslting dehydrtin tht ulintes in hyperslr  (sll sips f sugr-free liquids, inrese in usul hypglyei therpy, r erly ntt with the liniin).F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Stt AR; Jint British Dibetes Sieties (JBDS) fr Inptient Cre; JBDS hyperslr hyperglyei guidelines grup. Mngeent f hyperslr hyperglyei stte in dults with dibetes. Dibet Med. 2015;32:714. [PMID: 25980647]LAC TIC ACIDOSISE S S E N T I A L S  O F  D I A G N O S I S »Severe metabolic acidosis with compensatory hyperventilation. »Blood pH < 7.30. »Serum bicarbonate < 15 mEq/L. »Anion gap > 15 mEq/L. »Absent serum ketones. »Serum lactate > 5 mmol/L.CMDT22_Ch27_p1212-p1255.indd  1249 29/06/21 8:53 PMCHAPTEr 271250 CMDT 2022 »General ConsiderationsL ti idsis is hrterized by uultin f exess lti id in the bld. Nrlly, the prinipl sures f this id re the erythrytes (whih lk enzyes fr erbi xidtin), skeletl usle, skin, nd brin. Cn- versin f lti id t gluse nd its xidtin prini- plly by the liver but ls by the kidneys represent the hief pthwys fr its revl. Hyperlttei nd i- dsis ur when ltte prdutin exeeds ltte n- suptin. Cuses inlude tissue hypxi (glbl r ll), disrders tht inrese epinephrine levels (severe sth with exess bet-drenergi gnist use, rdigeni r herrhgi shk, phehryt), nd drugs tht ipir xidtive phsphryltin (ntiretrvirl gents nd prpfl). Mst ses f etfrin-ssited lti idsis ur in ptients in wh there were ntrindi- tins t the use f etfrin, in prtiulr kidney filure. Metfrin levels re usully greter thn 5 g/L when etfrin is iplited s the use f lti id- sis. Other uses f lti idsis inlude severl inbrn errrs f etblis nd the MELAS syndre (it- hndril enephlpthy, lti idsis, nd strke-like episdes). D-lti idsis n ur in ptients with shrt bwel syndre when unbsrbed rbhydrtes re presented s substrte fr ferenttin by lni bteri. »Clinical FindingsA.  Symptoms and SignsThe  in linil feture f lti idsis is rked hyperventiltin. When lti idsis is sendry t tissue hypxi r vsulr llpse, the linil present- tin is vrible, being tht f the previling tstrphi illness. Hwever, in the idipthi, r spntneus, vri- ety, the nset is rpid (usully ver  few hurs), bld pressure is nrl, peripherl irultin is gd, nd there is n ynsis.B.  Laboratory FindingsPl s birbnte nd bld pH re quite lw, indit- ing the presene f severe etbli idsis. Ketnes re usully bsent fr pls nd urine r t lest nt prinent. The first lue y be  high nin gp (seru sdiu inus the su f hlride nd birbn- te nins [in Eq/L] shuld be n greter thn 15). A higher vlue indites the existene f n bnrl - prtent f nins. If this nnt be linilly explined by n exess f ket ids (dibetes), inrgni ids (urei), r nins fr editin verdsge (sliy- ltes, ethyl lhl, ethylene glyl), then lti id- sis is prbbly the rret dignsis. (See ls Chpter 21.) In the bsene f ztei, hyperphsphtei y be  lue t the presene f lti idsis fr resns tht re nt ler. The dignsis is nfired by  pls lti id nentrtin f 5 l/L r higher (vlues s high s 30 l/L hve been reprted). Nrl pls vl- ues verge 1 l/L, with  nrl ltte/pyruvterti f 10:1. This rti is gretly exeeded in lti idsis.1 »TreatmentAggressiv e tretent f the preipitting use f lti idsis is the in pnent f therpy, suh s ensur- ing dequte xygentin nd vsulr perfusin f tissues. Epiri ntibiti verge fr sepsis shuld be given fter ulture sples re btined in ny ptient in wh the use f the lti idsis is nt pprent (Tble 30–5). Alkliniztin with intrvenus sdiu birbnte t keep the pH bve 7.2 hs been reended by se in the eergeny tretent f lti idsis; s uh s 2000 Eq in 24 hurs hs been used. Hwever, there is n evidene tht the rtlity rte is fvrbly ffeted by dinistering birbnte, nd its use reins ntrver- sil. Hedilysis y be useful in ses where lrge sdiu lds re prly tlerted nd in ses ssited with etfrin txiity. »PrognosisThe  rtlity rte f spntneus lti idsis is high. The prgnsis in st ses is tht f the priry disrder tht prdued the lti idsis.DeFr nz R et l. Metfrin-ssited lti idsis: urrent perspetives n uses nd risk. Metblis. 2016;65:20. [PMID: 26773926] ºTHE HYPOGLYCEMIC STATESSpn tneus hypglyei in dults is f tw prinipl types: fsting nd pstprndil. Sypts begin t pls gluse levels in the rnge f 60 g/dL (3.3 l/L) nd ipirent f brin funtin t pprxitely 50 g/dL (2.8 l/L). Fsting hypglyei is ften subute r hrni nd usully presents with neurglypeni s its prinipl nifesttin; pstprndil hypglyei is rel- tively ute nd is ften herlded by sypts f neur- geni utni dishrge (sweting, plpittins, nxiety, treulusness). »Differential Diagnosis (Table 27–11)Fstin g hypglyei y ur in ertin endrine dis- rders, suh s hyppituitris, Addisn disese, r yx- ede; in disrders relted t liver lfuntin, suh s ute lhlis r liver filure; nd in instnes f end- stge hrni kidney disese, prtiulrly in ptients requiring dilysis. These nditins re usully bvius, with hypglyei being nly  sendry feture. When fsting hypglyei is  priry nifesttin develp- ing in dults withut pprent endrine disrders r inbrn etbli diseses fr hildhd, the prinipl1 In lleting sples, it is essentil t rpidly hill nd seprte the bld in rder t reve red ells, whse ntinued glylysis t r teperture is  n sure f errr in reprts f high pls ltte. Frzen pls reins stble fr subsequent ssy.CMDT22_Ch27_p1212-p1255.indd  1250 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1251 CMDT 2022dignsti pssibili ties inlude (1) hyperinsulinis, due t either pnreti B ell turs, itrgeni r surreptitius dinistrtin f insulin r sulfnylure; nd (2) hypgly- ei due t extrpnreti turs. Pstprndil (retive) hypglyei y ur fter gstrintestinl surgery nd is prtiulrly ssited with the duping syndre fter gstrety nd Rux-en-Y gstri bypss surgery. Oult dibetes very sinlly presents with pstprndil hypglyei. Rrely, it urs with islet ell hyperplsi—the s-lled nninsulin pnretgenus hypglyei syndre. Alhl-relted hypglyei is due t hepti gly- gen depletin bined with lhl-edited inhibitin f glunegenesis. It is st n in lnurished individuls with exessive lhl intke but n ur in nyne wh is unble t ingest fd fter n ute lhli episde fllwed by gstritis nd viting. Iunpthlgi hypglyei is n extreely rre nditin in whih nti-insulin ntibdies r ntibdies t insulin reeptrs develp spntneusly.HYP OGLYCEMIA DUE TO PANCREATIC B CELL TUMORSE S S E N T I A L S  O F  D I A G N O S I S »Hypoglycemic symptoms—often neuroglycopenic (confusion, blurred vision, anxiety, convulsions). »Immediate recovery upon administration of glucose. »Blood glucose < 45 mg/dL (2.5 mmol/L) with a serum insulin level of ≥ 6 microunits/mL. »General ConsiderationsFsting  hypglyei in n therwise helthy, well- nurished dult is rre nd is st nly due t nden f the islets f Lngerhns. Ninety perent f suh turs re single nd benign, but ultiple dens n ur s well s lignnt turs with funtinl etstses. Adens y be filil, nd ultiple de- ns hve been fund in njuntin with turs f the prthyrids nd pituitry (MEN type 1 [MEN 1]). Abut 30% f sprdi insulin turs hve  sti ut- tin in the YY1 gene (T372R) tht endes the trnsrip- tinl repressr YY1. Over 99% f insulins re lted within the pnres nd less thn 1% in etpi pnreti tissue. »Clinical FindingsA.  Symptoms and SignsThe st ip rtnt prerequisite t dignsing n insulin-  is siply t nsider it, prtiulrly in reltively helthy-ppering persns wh hve fsting hypglyei ssited with se degree f entrl nervus syste dysfuntin suh s nfusin r bnrl behvir. A dely in dignsis n result in unneessry tretent fr psyhtr epilepsy r psyhitri disrders nd y use irreversible brin dge. In lng-stnding ses, besity n result s  nsequene f vereting t relieve sypts. The s-lled Whipple trid is hrteristi f hyp- glyei regrdless f the use. It nsists f (1)  histry f hypglyei sypts, (2) n ssited lw pls gluse level (40–50 g/dL), nd (3) relief f sypts upn ingesting fst-ting rbhydrtes in pprxitely 15 inutes. The hypglyei sypts in insulin ften develp in the erly rning r fter issing  el. Osinlly, they ur fter exerise. Ptients typilly plin f neurglypeni syp- ts suh s blurred visin r diplpi, hedhe, feelings f dethent, slurred speeh, nd wekness. Persnlity nd entl hnges vry fr nxiety t psyhti behv- ir, nd neurlgi deterirtin n result in nvulsins r . Hypglyei unwreness is very n nd drenergi sypts f plpittins nd sweting y be blunted. With the redy vilbility f he bld gluse– nitring systes, ptients seties present with d- uented fingerstik bld gluse levels in 40s nd 50s t tie f sypts. Aess t sulfnylures r insulin shuld be explred—des  fily eber hve dibetes, r des the ptient r fily eber wrk in the edil field? Meditin-dispensing errrs shuld be exluded—hs the ptient’s presriptin editin hnged in shpe r lr? Ptients with insulin r ftitius hypglyei usully hve  nrl physil exintin.B.  Laboratory FindingsB  ell dens d nt redue seretin f insulin in the presene f hypglyei, nd the ritil dignsti test is t denstrte inpprpritely elevted seru insulin, prinsulin, nd C-peptide levels, t  tie when pls gluse level is belw 45 g/dL. The dignsti riteri fr insulin fter  72-hur fst re listed in Tble 27–12. Other uses f hyperinsulin- ei hypglyei inlude ftitius dinistrtin fTable 27–11. Common causes of hypoglycemia in adults.1F asting hypoglycemia Pancreatic B cell tumor Surreptitious administration of insulin or sulfonylureas Extrapancreatic tumors Postpandial hypoglycemia Gastric surgery Occult diabetes mellitus Alcohol-elated hypoglycemia Immunopathologic hypoglycemia Idiopathic anti-insulin antibodies (which release their bound insulin) Antibodies to insulin receptors (which act as agonists) Dug-induced hypoglycemia1 In the absence of clinically obvious endocrine, kidney, or liver disorders and exclusive of diabetes mellitus treated with hypogly- cemic agents.CMDT22_Ch27_p1212-p1255.indd  1251 29/06/21 8:53 PMCHAPTEr 271252 CMDT 2022insulin  r sulfnylures. Ftitius use f insulin will result in suppressin f endgenus insulin seretin nd lw C-peptide levels. In ptients wh hve injeted insulin, the insulin/C-peptide rti (pl/L) will be greter thn 1. An elevted irulting prinsulin level in the presene f fst- ing hypglyei is hrteristi f st B ell dens nd des nt ur in ftitius hyperinsulinis. Thus, C-peptide levels (by iunheiluinetri ssys [ICMA]) f greter thn 200 pl/L nd prin- sulin levels (by rdiiunssy [RIA]) f greter thn 5 pl/L re hrteristi f insulins. In ptients with insulin, pls bet-hydrxybutyrte levels re suppressed t 2.7 l/L r less. N single hrne esureent (insulin, prinsulin, C-peptide) is 100% sensitive nd speifi fr the dignsis f insulin, nd insulin ses hve been reprted with insulin lev- els belw 3 irunits/L (ICMA ssy) r prinsulin level belw 5 pl/L. These hrnl ssys re ls nt stndrdized, nd there n be signifint vritin in the test results. Therefre, the dignsis shuld be bsed n ultiple biheil preters. In ptients with epigstri distress,  histry f renl luli, r enstrul r eretile dysfuntin,  seru l- iu, gstrin, r prltin level y be useful in sreening fr MEN 1 ssited with insulin.C.  Diagnostic TestsIf  the histry is nsistent with episdi spntneus hyp- glyei, ptients shuld be given  he bld gluse nitr nd dvised t nitr bld gluse levels t the tie f sypts nd befre nsuptin f rbhy- drtes, if this n be dne sfely. Ptients with insulins frequently reprt fingerstik bld gluse levels between 40 g/dL (2.2 l/L) nd 50 g/dL (2.8 l/L) t the tie f sypts. The dignsis, hwever, nnt be de bsed n  fingerstik bld gluse. It is neessry t hve  lw lbrtry gluse nitntly with ele- vted pls insulin, prinsulin, nd C-peptide levels nd  negtive sulfnylure sreen. When ptients give  his- try f sypts fter nly  shrt perid f fd with- drwl r with exerise, then n utptient ssessent nbe ttepted. The ptient shuld be brught by  fily eber t the ffie fter n vernight fst nd bserved in the ffie. Ativity suh s wlking shuld be enur- ged nd fingerstik bld gluse esured repetedly during bservtin. If sypts ur r fingerstik bld gluse is belw 50 g/dL (2.8 l/L), then sples fr pls gluse, insulin, C-peptide, prinsulin, sulfnyl- ure sreen, seru ketnes, nd ntibdies t insulin shuld be sent. If utptient bservtin des nt result in sypts r hypglyei nd if the linil suspiin reins high, then the ptient shuld underg n inptient supervised 72-hur fst. A suggested prtl fr the supervised fst is shwn in Tble 27–13. In 30% f ptients with insulin, the bld gluse levels ften drp belw 45 g/dL (2.5 l/L) fter n vernight fst, but se ptients require up t 72 hurs t develp syptti hypglyei. Hwever, the ter “72-hur fst” is tully  isner in st ses sine the fst shuld be ieditely terinted s sn s sypts pper nd lbrtry nfirtin f hypgly- ei is vilble. In nrl le subjets, the bld glu- se des nt fll belw 55–60 g/dL (3.1–3.3 l/L) during  3-dy fst. In ntrst, in nrl preenpusl wen, the pls gluse n reh vlues s lw s 35 g/dL (1.9 l/L). In these ses, hwever, the wen re nt syptti, presubly wing t the develpent f suffiient ketnei t supply energy needs t the brin. Insulin ptients, n the ther hnd,Table 27–12. Diagnostic criteria for insulinoma after a 72-hour fast.Laboatoy  Test result Plasma glucose < 45 mg/dL (2.5 mmol/L) Plasma insulin (RIA) ≥ 6 microunits/mL (36 pmol/L) Plasma insulin (ICMA) ≥ 3 microunits/mL (18 pmol/L) Plasma C-peptide ≥ 200 pmol/L (0.2 nmol/L, 0.6 ng/mL) Plasma proinsulin ≥ 5 pmol/L Beta-hydroxybutyrate ≤ 2.7 mmol/L Sulfonylurea screen (including repaglinide and nateglinide)Negative ICMA, immunochemiluminometric assays; RIA, radioimmunoassay.T able 27–13. Suggested hospital protocol for super- vised fast in diagnosis of insulinoma.(1)  Place intravenous cannula and obtain baseline plasma glucose, insulin, proinsulin, beta-hydroxybutyrate, and C-peptide measurements at onset of fast. (2) Permit only calorie-free and caffeine-free fluids and encourage supervised activity (such as walking). (3) Obtain fingerstick glucose measurements every 4 hours until values < 60 mg/dL are obtained. Then increase the frequency of fingersticks to 1–2 hours, and when capillary glucose value is < 45 mg/dL send a venous blood sample to the laboratory for plasma glucose.1Check frequently for manifestations of neuroglycopenia. (4) At 48 hours into the fast, send a venous blood sample for plasma glucose, insulin, proinsulin, C-peptide, beta- hydroxybutyrate, and sulfonylurea measurement. (5) If symptoms of hypoglycemia occur oif a laboratory value of serum glucose is < 45 mg/dL, oif 72 hours have elapsed, conclude the fast with a final blood sample for plasma glucose,1insulin, proinsulin, C-peptide, beta-hydroxybutyrate, and sulfonylurea measurements. Then give oral fast-acting carbohydrate followed by a meal. If the patient is confused or unable to take oral agents, administer 50 mL of 50% dextrose intravenously over 3–5 minutes. Do not conclude a fast based simply on a capillary blood glucose measurement—wait for the laboratory glucose value—unless the patient is very symptomatic and it would be dangerous to wait.1 Glucose sample should be collected in sodium fluoride contain- ing tube on ice to prevent glycolysis and the plasma separated immediately upon receipt at the laboratory. Arrange for the labora- tory to run the glucose samples “stat.”CMDT22_Ch27_p1212-p1255.indd  1252 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1253 CMDT 2022bee  syptti when pls gluse drps t sub- nrl levels, sine inpprprite insulin seretin restrits ketne frtin. Mrever, the denstrtin f  nn- suppressed insulin level f 3 irunits/L r re using n ICMA ssy (greter thn 6 irunits/L using n RIA ssy) in the presene f hypglyei suggests the dignsis f insulin. If hypglyei des nt develp in  le ptient fter fsting fr up t 72 hurs—nd pr- tiulrly when this prlnged fst is terinted with  perid f derte exerise—insulin ust be nsid- ered n unlikely dignsis. An rl gluse tlerne test is f n vlue in the dig- nsis f insulin-sereting turs. HbA1levels y be lw but there is nsiderble verlp with nrl ptients nd n prtiulr vlue is dignsti.D . Preoperative Localization of B Cell TumorsAfter  the dignsis f insulin hs been unequivlly de by linil nd lbrtry findings, studies t llize the tur shuld be initited. Mst turs re in the pn- res, nd etpi ses re rre. Beuse f the sll size f these turs (verging 1.5  in dieter in ne lrge series), iging studies d nt neessrily identify ll f the. A pnreti dul phse helil CT sn with thin setin n identify 82–94% f the lesins. MRI sns with gdliniu n be helpful in deteting  tur in 85% f ses. One se reprt suggests tht diffusin-weighted MRI n be useful fr deteting nd llizing sll insulins, espeilly fr thse with n hypervsulr pttern. PET/CT sns using glliu-lbeled ststtin nlgs suh s DOTA- 1-NI3-tretide (DOTA-NOC), whih hve  higher ffinity fr ststtin reeptr subtypes 2, 3, nd 5, hve been reprted t be useful in llizing the turs. Insuli- ns express GLP-1 reeptrs, nd rdilbeled GLP-1 reeptr gnists suh s Lys(40)(Ahx-hydrzinnitin- ide [HYNIC]-[(99)T)NH(2)]-exendin-4 fr SPECT/ CT hve ls been reprted t visulize the turs. If the iging study is nrl, then n endspi ultrsund shuld be perfred. In experiened hnds, but 80–90% f turs n be deteted with this predure. Fine-needle spirtin f the identified lesin n be ttepted t n- fir the presene f  neurendrine tur. If the tur is nt identified r the iging result is equivl, then the ptient shuld underg seletive liu-stiulted ngi- grphy, whih hs been reprted t llize the tur t  prtiulr regin f the pnres pprxitely 90% f the tie. In this test, ngigrphy is bined with inje- tins f liu glunte int the gstrdudenl, spleni, nd superir esenteri rteries, nd insulin levels re esured in the hepti vein effluent. The predure is perfred fter n vernight fst. Cliu stiultes insulin relese fr insulins but nt nrl islets, nd s  step-up fr bseline in insulin levels (twfld r greter) reginlizes the sure f the hyperinsulinis t the hed f the pnres fr the gstrdudenl rtery, the uninte press fr the superir esenteri rtery, nd the bdy nd til f the pnres fr the spleni rtery liu infusins. These studies bined with reful intrper- tive ultrsngrphy nd plptin by  surgenexperiened in insulin surgery identifies up t 98% f turs. »TreatmentThe  tretent f hie fr insulin-sereting turs is surgil resetin. While witing fr surgery, ptients shuld be given rl dizxide. Divided dses f 300–400 g/dy usully suffie, lthugh n sinl ptient y require up t 800 g/dy. Side effets inlude ede due t sdiu retentin, gstri irrittin, nd ild hirsutis. Hydrhlrthizide, 25–50 g dily, n be used t untert the sdiu retentin nd ede s well ptentite dizxide’s hyperglyei effet. In ptients with  single benign pnreti B ell de- n, 90–95% hve  suessful ure t the first surgil ttept when intrpertive ultrsund is used by  skilled surgen. Dizxide shuld be dinistered n the dy f the surgery beuse it redues the risk f hypglyei during surgery. Typilly, it des nt sk the glyei rise inditive f surgil ure. Bld gluse shuld be nitred thrughut surgery, nd 5% r 10% dextrse infusin shuld be used t intin euglyei. In ses where the dignsis hs been estblished but n den is lted fter reful plptin nd use f intrpertive ultrsund, it is n lnger dvisble t blindly reset the bdy nd til f the pnres, sine  nnplpble tur issed by ultrsund is st likely ebedded within the fleshy hed f the pnres tht is left behind with subttl resetins. Mst surgens prefer t lse the inisin nd shedule  seletive rteril liu stiultin with hepti venus spling t lte the tur site prir t  repet pertin. Lprspy using ultrsund nd enu- letin hs been suessful with  single tur f the bdy r til f the pnres, but pen surgery reins neessry fr turs in the hed f the pnres. In ptients with inperble funtining islet ell ri- n with nd withut hepti etstsis nd in pprxi- tely 5–10% f MEN 1 ses when subttl revl f the pnres hs filed t prdue ure, the tretent pprh is the se s fr ther types f pnreti neu- rendrine turs (pNETs). Dizxide is the tretent f hie in preventing hypglyei. Frequent rbhy- drte feedings (every 2–3 hurs) n ls be helpful, lthugh weight gin n bee  prble. Ststtin nlgs, tretide r lnretide, shuld be nsidered if dizxide is ineffetive r if there is tur prgressin. Surgery r ebliztin (blnd, he- nd rdi-) r ther- l bltin (rdifrequeny, irwve, nd rybltin) n be used t redue tur burden nd ls prvide syp- tti relief. Chetherpy regiens tht n be nsid- ered inlude bintin f streptzin, 5-flururil, nd dxrubiin; peitbine nd xlipltin; nd peitbine nd tezlide (Tble 39–3). Trgeted therpies ginst ultiple steps in the PI3K/AKT/Tr pth- wy hve been shwn t be helpful. Everlius, n inhibi- tr f Tr, is pprved fr tretent f dvned pNETs. Sunitinib hs been shwn t slw grwth f pNETs. Tret- ent with rdiistpes (indiu-111 r yttriu-90 r lutetiu-177) linked t  ststtin nlg hs been reprted t shw benefit in  prprtin f ptients.CMDT22_Ch27_p1212-p1255.indd  1253 29/06/21 8:53 PMCHAPTEr 271254 CMDT 2022NO NISLET CELL TUMOR HYPOGLYCEMIAThese  rre uses f hypglyei inlude esenhyl turs suh s retrperitnel srs, heptellulr rins, drenrtil rins, nd isellneus epithelil-type turs. The turs re frequently lrge nd redily plpted r visulized n CT sns r MRI. In ny ses the hypglyei is due t the expres- sin nd relese f n inpletely pressed insulin-like grwth ftr 2 (IGF-2) by the tur. The dignsis is supprted by lbrtry duent- tin f seru insulin levels belw 5 irunit/L with pls gluse levels f 45 g/dL (2.5 l/L) r lwer. Vlues fr grwth hrne nd IGF-1 re ls deresed. Levels f IGF-2 y be inresed but ften re “nrl” in quntity, despite the presene f the iture, higher- leulr-weight fr f IGF-2, whih n be deteted nly by speil lbrtry tehniques. Nt ll the ptients with nnislet ell tur hypglye- i hve elevted pr-IGF-2. Etpi insulin prdutin hs been desribed in brnhil rin, vrin rin, nd sll ell rin f the ervix. Hypglyei due t IgF-1 relesed fr  etstti lrge ell rin f the lung hs ls been reprted. GLP-1–sereting turs (vr- in nd pNETs) n ls use hypglyei by stiulting insulin relese fr nrl pnreti islets. The prgnsis fr these turs is generlly pr, nd surgil revl shuld be ttepted when fesible. Dietry ngeent f the hypglyei is the insty f edil tretent, sine dizxide is usully ineffetive.PO STPRANDIAL HYPOGLYCEMIA 1. Hypoglycemia Following Gastic SugeyH ypglyei seties develps in ptients wh hve undergne gstri surgery (eg, gstrety, vgty, pylrplsty, gstrjejunsty, Nissn fundplitin, Billrth II predure, nd Rux-en-Y), espeilly when they nsue fds ntining high levels f redily bsrbble rbhydrtes. This lte duping syndre urs but 1–3 hurs fter  el nd is  result f rpid delivery f high nentrtin f rbhydrtes in the prxil sll bwel nd rpid bsrptin f gluse. The hyperinsulinei respnse t the high rbhydrte ld uses hypglyei. Exessive relese f gstrintestinl hrnes suh s GLP-1 likely ply  rle in the hyperin- sulinei respnse. The sypts inlude lightheded- ness, sweting, nfusin nd even lss f nsiusness fter eting  high rbhydrte el. T duent hyp- glyei, the ptient shuld nsue  el tht leds t sypts during everydy life. An rl gluse tlerne test is nt reended beuse ny nrl persns hve flse-psitive test results. There hve been se reprts f insulin nd nninsulin pnretge- nus hypglyei syndre in ptients with hypglye- i pst Rux-en-Y surgery. It is unler hw ften this urs. A reful histry y identify ptients wh hve  histry f hypglyei with exerise r issed els, nd these individuls y require  frl 72-hur fst t rule ut n insulin.Tretent fr sendry duping inludes dietry difitin, but this y be diffiult t sustin. Ptients n try re frequent els with sller prtins f less rpidly digested rbhydrtes. Alph-glusidse therpy y be  useful djunt t  lw rbhydrte diet. Otre- tide 50 g dinistered subutneusly tw r three ties  dy 30 inutes prir t eh el hs been reprted t iprve sypts due t lte duping syndre. Tret- ent with exendin 9-39,  GLP-1 reeptr gnist, y prevent pst gstri bypss hypglyei. SGLT2 inhibitrs y elirte the pstprndil gluse rise, the subse- quent insulin respnse, nd hypglyei. There is  reprt f  ptient with Rux-en-Y surgery wh hd plete reslutin f bth hyperglyei nd hypglyei when she ws given ngliflzin. Vrius surgil predures t dely gstri eptying hve been reprted t iprve sypts but lng-ter effiy studies re lking.2.  Functional Alimentay HypoglycemiaP tients hve sypts suggestive f inresed syp- theti tivity, inluding nxiety, wekness, trer, swet- ing r plpittins fter els. Physil exintin nd lbrtry tests re nrl. It is nt reended tht ptients with sypts suggestive f inresed syp- theti tivity underg either  prlnged rl gluse tl- erne test r  ixed el test. Insted, the ptients shuld be given he bld gluse nitrs (with eries) nd instruted t nitr fingerstik gluse levels t the tie f sypts. Only ptients wh hve sypts when their fingerstik bld gluse is lw (less thn 50 g/dL) nd wh hve reslutin f sypts when the gluse is rised by eting rpidly relesed rb- hydrte need dditinl evlutin. Ptients wh d nt hve evidene fr lw gluse levels t tie f sypts re generlly ressured by their findings. Cunseling nd supprt shuld be the instys in therpy, with dietry nipultin nly n djunt.3.  Occult DiabetesThis  nditin is hrterized by  dely in erly insulin relese fr pnreti B ells, resulting in initil exgger- tin f hyperglyei during  gluse tlerne test. In respnse t this hyperglyei, n exggerted insulin relese prdues  lte hypglyei 4–5 hurs fter inges- tin f gluse. These ptients re ften bese nd fre- quently hve  fily histry f dibetes ellitus. Ptients with this type f pstprndil hypglyei ften respnd t redued intke f refined sugrs with ultiple, sped, sll feedings high in dietry fiber. In the bese, tretent is direted t weight redutin t hieve idel weight. These ptients shuld be nsidered t hve predibetes r erly dibetes (type 1 r 2) nd dvised t hve peridi edil evlutins.4.  Autoimmune HypoglycemiaP tients with utiune hypglyei hve erly pstprn- dil hyperglyei fllwed by hypglyei 3–4 hurs lter. The hypglyei is ttributed t  dissitin f insulin- ntibdy iune plexes, relesing free insulin.CMDT22_Ch27_p1212-p1255.indd  1254 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1255 CMDT 2022The  disrder is ssited with ethizle tretent fr Grves disese, lthugh it n ls ur in ptients treted with vrius ther sulfhydryl-ntining edi- tins (ptpril, peniilline) s well s ther drugs suh s hydrlzine, isnizid, nd prinide. In dditin, it hs been reprted in ptients with utiune disrders suh s rheutid rthritis, systei lupus erythetsus, nd plyysitis s well s in pls ell yel nd ther pls ell dysrsis where prprteins r ntibdies rss-ret with insulin. There is ls n ssitin with the HLA lss II lleles (DRB1*0406, DQA1*0301, nd DQB1*0302). These lleles re 10 t 20 ties re n in Jpnese nd Kren ppultins, whih explins why the disrder hs been reprted stly in Jpnese ptients. High titers f insulin utntibdies, usully IgG lss, n be deteted. Insulin, prinsulin, nd C-peptide levels y be elevted, but the results y be errneus beuse f the interferene f the insulin ntibdies with the iu- nssys fr these peptides. In st ses, the hypglyei is trnsient nd usully reslves spntneusly within 3–6 nths f dignsis, prtiulrly when the ffending editins re stpped. The st nsistent therpeuti benefit in ngeent f this syndre hs been hieved by dietry tretent with sll, frequent lw-rbhydrte els. Prednisne (30–60 g rlly dily) hs been used t lwer the titer f insulin ntibdies.F ACTITIOUS HYPOGLYCEMIAF titius hypglyei y be diffiult t duent. A suspiin f self-indued hypglyei is supprted when the ptient is ssited with the helth prfessins r hs ess t dibeti editins tken by  dibeti eber f the fily. The trid f hypglyei, high iunretive insulin, nd suppressed pls C-peptide iunretivity is pthgnni f exgenus insulin dinistrtin. Insu- lin nd C-peptide re sereted in  1:1 lr rti. A lrge frtin f the endgenus insulin is lered by the liver, wheres C-peptide, whih is lered by the kidney, hs  lwer etbli lerne rte. Fr this resn, the lr rti f insulin nd C-peptide in  hypglyei ptient shuld be less thn 1.0 in ses f insulin nd is greter thn 1.0 in ses f exgenus insulin dinistrtin (see Hypglyei Due t Pnreti B Cell Turs, bve). When sulfnylures, repglinide, nd nteglinide re sus- peted s  use f ftitius hypglyei,  pls level f these editins t detet their presene y be required t distinguish lbrtry findings fr thse f insulin.HYP OGLYCEMIA DUE TO INSULIN RECEPTOR ANTIBODIESH ypglyei due t insulin reeptr utntibdies is n extreely rre syndre; st ses hve urred in wen ften with  histry f utiune disese. Alst ll f these ptients hve ls hd episdes f insulin- resistnt dibetes nd nthsis nigrins. Their hypglye- i y be either fsting r pstprndil nd is ften severend is ttributed t n gnisti tin f the ntibdy n the insulin reeptr. Blne between the ntgnisti nd g- nisti effets f the ntibdies deterines whether insulin- resistnt dibetes r hypglyei urs. Hypglyei ws fund t respnd t rtisterid therpy but nt t plspheresis r iunsuppressin.ME DICATION- & ETHANOL-INDUCED HYPOGLYCEMIAA  nuber f editins prt fr dibeti editins n sinlly use hypglyei. Cn ffenders inlude the flurquinlnes suh s gtiflxin nd lev- flxin, pentidine, quinine, ACE inhibitrs, sliyltes nd bet-drenergi blking gents. The flurquinlnes, prtiulrly gtiflxin, hve been ssited with bth hypglyei nd hyperglyei. It is thught tht the drug ts n the ATP sensitive ptssiu hnnels in the bet ell. Hypglyei is n erly event, nd hyperglyei urs severl dys int therpy. Intrvenus pentidine is yt- txi t bet ells nd uses ute hyperinsulinei nd hypglyei fllwed by insulinpeni nd hyperglyei. Fsting ptients tking nnrdiseletive bet-blkers n hve n exggerted hypglyei respnse t strvtin. The bet-blkde inhibits ftty ids nd glunegenesis substrte relese nd redues pls glugn respnse. Therpy with ACE inhibitrs inreses the risk f hypgly- ei in ptients wh re tking insulin r sulfnylures presubly beuse these drugs inrese sensitivity t iru- lting insulin by inresing bld flw t the usle. Se piids use hypglyei. Trdl use hs been ssi- ted with inresed risk f hspitliztin fr hypglyei. Methdne verdse hs ls been reprted t use hyp- glyei nd  rpid dse esltin f ethdne in ner ptients n lwer gluse levels. Ethnl-ssited hypglyei y be due t hepti lhl dehydrgense tivity depleting NAD. The resul- tnt hnge in the redx stte—inrese in NADH t NAD+rti—uses  prtil blk t severl pints in the glunegeni pthwy. With prlnged strvtin, gly- gen reserves bee depleted within 18–24 hurs nd hepti gluse utput bees ttlly dependent n glu- negenesis. Under these irustnes,  bld nen- trtin f ethnl s lw s 45 g/dL (9.8 l/L) n indue prfund hypglyei by blking glunegen- esis. Neurglypeni in  ptient whse breth sells f lhl y be istken fr lhli stupr. Preventin nsists f dequte fd intke during ethnl ingestin. Therpy nsists f gluse dinistrtin t replenish glygen stres until glunegenesis resues. When sugr-ntining sft drinks re used s ixers t dilute lhl in beverges (gin nd tni, ru nd l), there sees t be  greter insulin relese thn when the sft drink lne is ingested nd  tendeny fr re f  lte hypglyei verswing t ur 3–4 hurs lter. Preventin wuld nsist f viding sugr ixers while ingesting lhl nd ensuring suppleentry fd intke t prvide sustined bsrptin.CMDT22_Ch27_p1212-p1255.indd  1255 29/06/21 8:53 PM1256 CMDT 2022Lipid Disorders 28Michael J. Blaha, MD, MPHThe  “Lipid Hypothesis” of cardiovascular disease (CVD)— stating that cholesterol is causal in the development of atherosclerotic cardiovascular disease (ASCVD) and that lowering of cholesterol is associated with lower cardiovas- cular event rates—is widely accepted throughout the medi- cal community. For patients with known CVD (secondary prevention), studies have shown that cholesterol lowering leads to a consistent reduction in total mortality and in recurrent cardiovascular events in men and women; other studies have documented lowered mortality and events in middle-aged and older patients. Among patients without CVD (primary prevention), the data are generally consis- tent, with rates of cardiovascular events, heart disease mortality, and all-cause mortality differing among studies. Treatment guidelines have been designed to assist clini- cians in selecting patients for cholesterol-lowering therapy based predominantly on their overall risk of developing CVD as well as their baseline cholesterol levels. There are several genetic disorders that provide insight into the pathogenesis of lipid-related diseases. Familial hypercholesterolemia, rare in the homozygous state (about one per million), causes markedly high low-density lipoprotein (LDL) levels and early CVD. The most common genetic defects involve absent or defective LDL receptors, resulting in unregulated LDL metabolism, genetic muta- tions of apolipoprotein B, or gain of function in proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates breakdown of LDL receptors. Patients with two abnormal genes (homozygotes) have extremely high levels—up to eight times normal—and present with ath- erosclerotic disease in childhood. Patients with two abnor- mal genes (homozygotes) may require liver transplantation or plasmapheresis to correct their severe lipid abnormali- ties; early treatment with statins appears to confer lifetime benefits in such patients. Those with one defective gene (heterozygotes) have LDL concentrations up to two or three times normal; persons with this condition may develop CVD in their 30s or 40s. Another rare condition is caused by an abnormality of lipoprotein lipase, the enzyme that enables peripheral tissues to take up triglyceride from chylomicrons and very- low-density lipoprotein (VLDL) particles. Patients with this condition, one cause of familial chylomicronemiasyndrome, have marked hypertriglyceridemia with recur- rent pancreatitis and hepatosplenomegaly in childhood. Numerous other genetic abnormalities of lipid metabo- lism are named for the abnormality noted when serum is electrophoresed (eg, dysbetalipoproteinemia, character- ized by elevated levels of remnant lipoproteins) or from polygenic combinations of lipid abnormalities in families (eg, familial combined hyperlipidemia). »When to Refer• Known genetic lipid disorders. •Striking family history of hyperlipidemia or premature atherosclerosis. •Extremely high serum LDL cholesterol or triglycerides, or extremely low serum high-density lipoprotein (HDL) cholesterol.Chyzh yk V et al. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30:80. [PMID: 31003756] Hegele RA et al. Rare dyslipidaemias, from phenotype to geno- type to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020;8:50. [PMID: 31582260] Khera AV et al. What is familial hypercholesterolemia, and why does it matter? Circulation. 2020;141:1760. [PMID: 32479201] Mortensen MB et al. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary pre- vention cohort. Lancet. 2020;396:1644. [PMID: 33186534] Sniderman AD et al. Apolipoprotein B particles and cardiovas- cular disease: a narrative review. JAMA Cardiol. 2019;4:1287. [PMID: 31642874]LI PID FRACTIONS & THE RISK OF CORONARY HEART DISEASEIn  serum, cholesterol is carried primarily on three different lipoproteins—the VLDL, LDL, and HDL molecules. Total cholesterol equals the sum of these three components: =  + +Total cholesterol  HDL cholesterol  VLDL cholesterol LDL cholesterolCMDT22_Ch28_p1256-p1266.indd  1256 29/06/21 8:55 PM"
                ],
                [
                  "2",
                  "NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli  beverages, bright lights, lud nise, menstrua- tin, r use f ral ntraeptives. An unmmn variant is migraine with brainstem aura, in whih blindness r visual disturbanes thrughut bth visual fields are ampanied r fllwed by dysar- thria, dysequilibrium, tinnitus, and periral and distal paresthesias and are smetimes fllwed by transient lss r impairment f nsiusness r by a nfusinal state. This, in turn, is fllwed by a thrbbing (usually ipital) headahe, ften with nausea and vmiting. Inrecurrent painful ophthalmoplegic neuropathy (previusly phthalmplegi migraine), lateralized pain— ften abut the eye—is ampanied by nausea, vmiting, and diplpia due t transient external phthalmplegia. The phthalmplegia is due t third nerve palsy, smetimes with ampanying sixth nerve invlvement, and may ut- last the rbital pain by several days r even weeks. The phthalmi divisin f the fifth nerve has als been affeted in sme patients. The nditin is rare and a diagnsis f exlusin; mre mmn auses f a painful phthalmple- gia are internal artid artery aneurysms and diabetes. »TreatmentMan agement f migraine nsists f avidane f any pre- ipitating fatrs, tgether with prphylati r symptm- ati pharmalgi treatment if neessary.A.  Symptomatic TherapyDuring  aute attaks, rest in a quiet, darkened rm may be helpful until symptms subside. A simple analgesi (eg, aspirin, aetaminphen, ibuprfen, r naprxen) taken immediately ften prvides relief, but presriptin media- tin is smetimes neessary. To prevent medication overuse, use of simple analgesics should be limited to 15 days or less per month, and combination analgesics should be limited to no more than 10 days per month . 1. Ergotamines— Cafergt, a mbinatin f ergtamine tartrate (1 mg) and affeine (100 mg), is ften partiularly helpful; ne r tw tablets are taken at the nset f headahe r warning symptms, fllwed by ne tablet every 30 minutes, if neessary, up t six tablets per attak and n mre than 10 days per mnth. Cafergt given retally (ne- half t ne suppsitry ntaining 2 mg f ergtamine) r dihydrergtamine mesylate (0.5–1 mg intravenusly r 1–2 mg subutaneusly r intramusularly) may be useful when vmiting preludes use f ral mediatins. Ergta- mine-ntaining preparatins shuld be avided during pregnany, in patients with ardivasular disease r its risk fatrs, and in patients taking ptent CYP 3A4 inhibitrs. 2. Serotonin agonists— Triptans are 5-HT1b/1dreeptr agnists that inhibit release f vasative neurpeptides. Sumatriptan is a rapidly effetive agent fr abrting attaks when given subutaneusly by an autinjetin devie (4–6 mg ne subutaneusly, may repeat ne after 2 hurs if needed; maximum dse 12 mg/24 h). Nasal and ral preparatins are available but may be less effetive due t slwer absrptin. Zlmitriptan is available in ral and nasal frmulatins. The dse is 5 mg rally r in ne nstrilne; this may be repeated ne after 2 hurs. The maxi- mum dse fr bth frmulatins is 10 mg/24 h. Other triptans are available, inluding rizatriptan (5–10 mg rally at nset, may repeat every 2 hurs twie [maximum dse 30 mg/24 h]); naratriptan (1–2.5 mg rally at nset, may repeat ne after 4 hurs [maximum dse 5 mg/24 h]); almtriptan (6.25–12.5 mg rally at nset, may repeat dse ne after 2 hurs [maximum dse 25 mg/24 h]); frvatrip- tan (2.5 mg rally at nset, may repeat after 2 hurs ne [maximum dse 7.5 mg/24]); and eletriptan (20–40 mg rally at nset; may repeat after 2 hurs ne [maximum dse 80 mg/24 h]). Eletriptan is useful fr immediate therapy, and frvatriptan, whih has a lnger half-life, may be wrthwhile fr patients with prlnged attaks r attaks prvked by menstrual perids. Patients ften experiene greater benefit when the triptan is mbined with naprxen (500 mg rally). Triptans may ause nausea and vmiting. They shuld prbably be avided in wmen wh are pregnant, and in patients with hemiplegi r basilar migraine, a histry f strke r transient ishemi attak (TIA), r unntrlled hypertensin. In patients whse hypertensin is ntrlled, triptans are mmnly used safely, althugh autin is advised. Triptans are ntraindiated in patients with r- nary r peripheral vasular disease and Prinzmetal angina. Lasmiditan (50–200 mg taken ne at headahe nset; n mre than ne dse in 24 hurs) is a 5-HT1Freeptr agnist apprved fr use in the United States that laks the vasnstritive prperties f triptans and an be given safely t patients with ardivasular risk fatrs. Dizziness and smnlene are mmn side effets, and patients shuld nt drive within 8 hurs f administratin. 3. Calcitonin gene–related peptide antagonists— Rimegepant sulfate (75 mg rally disslved tablet taken ne at headahe nset; maximum dse 75 mg/24 h) and ubrgepant (50 r 100 mg rally at headahe nset, may repeat after 2 hurs ne [maximum dse 200 mg/24 h]) are bth alitnin gene–related peptide antagnists that ahieve pain freedm in 20% and pain relief in 60% f patients within 2 hurs. Hypersensitivity reatins may ur immediately r several days after administratin with rimegepant. 4. Other agents— Prhlrperazine is effetive and may be administered retally (25 mg suppsitry), intravenusly r intramusularly (5–10 mg), r rally (5–10 mg). Intrave- nus metlpramide (10–20 mg) is als partiularly use- ful in the emergeny department setting. Varius butalbital-ntaining mbinatin ral analgesis risk veruse and dependene and shuld nly be used as a last resrt. Opiid analgesis shuld be avoided beause f high rates f rebund headahe and the tendeny t develp mediatin veruse headahe. 5. Neuromodulation— Sham-ntrlled trials shw that single-pulse transranial magneti stimulatin abrts migraine with aura, and nninvasive vagus nerve stimula- tin, transutaneus trigeminal nerve stimulatin, and remte eletrial stimulatin applied t the upper arm abrt migraine with r withut aura. Transranial magneti stimulatin is ntraindiated in patients with epilepsy.CMDT22_Ch24_p0978-p1053.indd  979 29/06/21 8:50 PMChapTER 24980 CMDT 2022T able 24–1. Pharmacologic prophylaxis of migraine (listed in alphabetical order within classes).Mediction Usul adult Orl Dily Dose Selected Side Effects nd Comments antieiletic1T opiramate 100 mg (divided twice daily) Somnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glaucoma, renal calculi, weight loss, hypohidrosis, hyperthermia. Valproic acid2,3500–1000 mg (divided twice daily)Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxic- ity, thrombocytopenia, tremor, pancreatitis. Crdiovsculr Candesartan38–32 mg once daily Dizziness, cough, diarrhea, fatigue. Guanfacine 1 mg once daily Dry mouth, somnolence, dizziness, constipation, erectile dysfunction. Propranolol480–240 mg (divided twice to four times daily)Fatigue, dizziness, hypotension, bradycardia, depression, insomnia, nausea, vomiting, constipation. Verapamil5120–240 mg (divided three times daily)Headache, hypotension, flushing, edema, constipation. May aggravate atrioventricular nodal heart block and heart failure. antideressnt6Amitriptyline 710–150 mg at bedtime Sedation, dry mouth, constipation, weight gain, blurred vision, edema, hypotension, urinary retention. Venlafaxine 37.5–150 mg extended release once dailyNausea, somnolence, dry mouth, dizziness, diaphoresis, sexual dysfunction, anxiety, weight loss. Monoclonl ntibodies ginst clcitonin gene–relted etide Eptinezumab 100 mg intravenously every 3 monthsHypersensitivity reaction during infusion, nasopharyngitis. Erenumab 70–140 mg subcutaneously once monthlyInjection site reactions, constipation, muscle cramps, antibody development. Fremanezumab 225 mg subcutaneously once monthlyInjection site reactions, antibody development. Galcanezumab 120 mg subcutaneously daily × 2 doses, followed by 120 mg monthlyInjection site reactions, antibody development. Oter Acupuncture  More rapid pain relief and fewer side effects than pharmacologic treatment. Botulinum toxin A Intramuscular injection Injection site reaction, hypersensitivity, muscle weakness. Riboflavin 400 mg once daily Yellow-orange discoloration of urine. Transcutaneous supraor- bital neurostimulation20 minutes daily Transient paresthesia at site of stimulation.1 Gabapentin and possibly other antiepileptics have also been used successfully.2 Avoid during pregnancy.3 Not FDA-approved for this indication.4 Other beta-adrenergic antagonists such as atenolol, metoprolol, nadolol, and timolol are similarly effective.5 Other calcium channel antagonists (eg, nimodipine, nicardipine, and diltiazem) may also help.6 Depression is commonly comorbid with migraine disorder and may warrant separate treatment.7 Other tricyclic antidepressants (eg, nortriptyline and imipramine) may help similarly.B. Preventive TherapyPreven tive treatment may be neessary if migraine head- ahes ur more frequently than two or three times a month r signifiant disability is assiated with attaks. Avid- ane f triggers and maintenane f hmestasis with reg- ular sleep, meals, and hydratin shuld nt be negleted; a headahe diary may be useful t identify triggers. Sme mre mmn agents used fr prphylaxis are listed in Table 24–1. The mediatin hsen first will vary with theindividual patient, depending n fatrs suh as mrbid besity, depressin, anxiety, hypertensin, and patient preferene. Several mediatins may have t be tried in turn befre headahes are brught under ntrl. One a mediatin has been fund t help, it shuld be ntinued fr several mnths. If the patient remains headahe-free, the dse may be tapered and the mediatin eventually withdrawn. Transutaneus suprarbital neurstimulatin redued the number f migraine days per mnth in aCMDT22_Ch24_p0978-p1053.indd  980 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS981 CMDT 2022sham- ntrlled randmized trial and is apprved in the United States. In chronic migraine (at least 15 days per mnth with headahes lasting 4 hurs per day r lnger), aupunture is as effetive as prphylati pharmalgi treatment, and btulinum txin type A redues headahe frequeny. Certain neurstimulatin tehniques lk prmising as preventive treatment as well as having a rle in treatment f aute attaks. These inlude single-pulse transranial magneti stimulatin, vagus nerve stimula- trs, and implantable ipital nerve stimulatin, but riti- al appraisal is neessary.2.  Tension-Tye hedceThis is the mst mm n type f primary headahe disr- der. Patients frequently mplain f periranial tenderness, pr nentratin, and ther nnspeifi symptms, in additin t headahes that are ften vise-like r tight in quality but nt pulsatile. Headahes may be exaerbated by emtinal stress, fatigue, nise, r glare. The headahes are usually generalized, may be mst intense abut the nek r bak f the head, and are nt assiated with fal neur- lgi symptms. There is diagnsti verlap with migraine. The therapeuti apprah is similar t that in migraine, exept that triptans and ergtamines are notindiated. Triyli antidepressants, suh as amitriptyline, are sup- prted fr headahe prphylaxis by randmized trial evi- dene and ften are tried first. Treatment f mrbid anxiety r depressin is imprtant. Behaviral therapies that may be effetive inlude bifeedbak and relaxatin training.3.  Cluster hedceClus ter headahe affets predminantly middle-aged men. The pathphysilgy is unlear but may relate t ativatin f ells in the ipsilateral hypthalamus, triggering the tri- geminal autnmi vasular system. There is ften n fam- ily histry f headahe r migraine. Episdes f severe unilateral perirbital pain ur daily fr several weeks and are ften ampanied by ne r mre f the fllwing: ipsilateral nasal ngestin, rhinrrhea, larimatin, red- ness f the eye, and Hrner syndrme (ptsis, pupillary meisis, and faial anhidrsis r hyphidrsis). During attaks, patients are ften restless and agitated. Episdes typially ur at night, awaken the patient, and last between 15 minutes and 3 hurs. Spntaneus remissin then urs, and the patient remains well fr weeks r mnths befre anther but f lsely spaed attaks. Buts may last fr 4 t 8 weeks and may ur up t several times per year. During a but, many patients reprt alhl trig- gers an attak; thers reprt that stress, glare, r ingestin f speifi fds asinally preipitates attaks. In a- sinal patients, remissin des nt ur. This variant has been referred t as chronic cluster headache . In lngstand- ing ases, Hrner syndrme may persist between attaks. Cluster headahe is ne f the trigeminal autonomic cephalgias, whih inlude hemirania ntinua, parx- ysmal hemirania, and shrt-lasting neuralgifrm head- ahe attaks with njuntival injetin and tearing. Similar t luster headahe, the ther trigeminalautnmi ephalgias nsist f unilateral perirbital pain assiated with ipsilateral autnmi symptms; they are distinguished frm luster headahe by different attak duratin and frequeny and their exquisite respnsiveness t indmethain. Treatment f an individual attak with ral mediatins is generally unsatisfatry, but subutaneus (6 mg) r intranasal (20 mg/spray) sumatriptan r inhalatin f 100% xygen (12–15 L/min fr 15 minutes via a nn-rebreather mask) may be effetive. Zlmitriptan (5- and 10-mg nasal spray) is als effetive. Dihydrergtamine (0.5–1 mg intra- musularly r intravenusly) r visus lidaine (1 mg f 4–6% slutin intranasally) is smetimes effetive. Varius prphylati agents inlude ral mediatins suh as lithium arbnate (start at 300 mg daily, titrating arding t serum levels and treatment respnse up t a typial ttal daily dse f 900–1200 mg, divided three r fur times), verapamil (start at 240 mg daily, inrease by 80 mg every 2 weeks t 960 mg daily, with rutine ECG t mnitr the PR interval), tpiramate (100–400 mg daily), and ivamide (nt available in the United States). As there is ften a delay befre these mediatins are effetive, tran- sitinal therapy is ften used. Prednisne (60 mg daily fr 5 days fllwed by gradual withdrawal ver 7–10 days) is effetive in 70–80% f patients, and subipital rtiste- rid injetin abut the greater ipital nerve is effetive in 75%. Ergtamine tartrate an be given as retal suppsit- ries (0.5–1 mg at night r twie daily), by muth (2 mg daily), r by subutaneus injetin (0.25 mg three times daily fr 5 days per week). Eletrial stimulatin f the vagus nerve at headahe nset suessfully abrts pain in 30–50% f attaks, and twie daily prphylati stimulatin redues attak number in hrni luster headahe; this treatment is apprved in the United States. In Eurpe, sphe- npalatine ganglin stimulatin is apprved fr treatment f luster headahe based n effiay in ne randmized sham-ntrlled study. Limited evidene suggests that eletrial stimulatin f the ipital nerve by an implant- able devie may be helpful, espeially in hrni luster headahe.4.  posttrumtic hedceA variety  f nnspeifi symptms may fllw lsed head injury, regardless f whether nsiusness is lst (see Head Injury). Headahe is ften a nspiuus feature. It usually appears within a day r s fllwing injury, may wrsen ver the ensuing weeks, and then gradually sub- sides. It is usually a nstant dull ahe, with superimpsed thrbbing that may be lalized, lateralized, r generalized. Headahes are smetimes ampanied by nausea, vmit- ing, r sintillating stmas and ften respnd t simple analgesis; severe headahes may neessitate preventive treatment as utlined fr migraine.5.  primry Coug hedceSevere  head pain may be prdued by ughing (and by straining, sneezing, and laughing) but, frtunately, usually lasts fr nly a few minutes r less. Intraranial lesins, usually in the psterir fssa (eg, Arnld-ChiariCMDT22_Ch24_p0978-p1053.indd  981 29/06/21 8:50 PMChapTER 24982 CMDT 2022malfrma tin), are present in abut 10% f ases, and brain tumrs r ther spae-upying lesins may present in this way. Ardingly, CT scanning or MRI should be undertaken in all patients. The disrder is usually self-limited, althugh it may persist fr several years. Fr unknwn reasns, symptms smetimes lear mpletely after lumbar punture. Ind- methain (75–150 mg daily rally) may prvide relief. Similar ativity-triggered headahe syndrmes inlude primary exertinal headahe and primary headahe ass- iated with sexual ativity.6.  hedce Due to Gint Cell (Temorl or Crnil) arteritisThis tp i is disussed in Chapter 20.7.  hedce Due to Intrcrnil Mss LesionIn traranial mass lesins f all types may ause headahe wing t displaement f vasular strutures and ther pain-sensitive tissues. While pain and latin are nnspe- ifi, headahe may be wrse upn lying dwn, awaken the patient at night, r peak in the mrning after vernight reumbeny. The key feature prompting brain imaging is a new or worsening headache in middle or later life . Other features suggesting an intraranial lesin inlude signs r symptms f infetin r malignany suh as fever, night sweats, and weight lss; immunmprmise; r histry f malignany. Signs f fal r diffuse erebral dysfuntin r f inreased intraranial pressure (eg, papilledema) als neessitate investigatin.8.  Mediction Overuse (anlgesic Rebound) hedceIn  many patients with chronic daily headaches, media- tin veruse is respnsible. Patients have hrni pain r severe headahe unrespnsive t mediatin (typially defined as n effet after having been used regularly fr mre than 3 mnths). Ergtamines, triptans, mediatins ntaining butalbital, and piids ause mediatin ver- use headahe when taken n mre than 10 days per mnth; aetaminphen, aetylsaliyli aid, and nnsteridal anti- inflammatry drugs may als be ffenders if taken n mre than 15 days per mnth. Early initiatin f a migraine preventive therapy permits withdrawal f analgesis and eventual relief f headahe.9.  hedce Due to Oter Neurologic CusesCerebr vasular disease may be assiated with headahe, but the mehanism is unlear. Headahe may ur with internal artid artery lusin r artid dissetin and after artid endarteretmy. Aute severe headahe (“thunderclap” ) ampanies subarahnid hemrrhage, artid r vertebral artery dissetin, erebral venus thrmbsis, ishemi r hemrrhagi strke, reversible erebral vasnstritin syndrme, hypertensive risis, psterir reversible leukenephalpathy syndrme, pitu- itary applexy, spntaneus intraranial hyptensin, vas- ulitis, and meningeal infetins; ampanying falneurlgi signs, impairment f nsiusness, and signs f meningeal irritatin indiate the need fr further inves- tigatins. Headahes are als a feature f idipathi intra- ranial hypertensin (pseudtumr erebri). Dull r thrbbing headahe is a frequent sequela f lumbar punture and may last fr several days. It is aggra- vated by the eret psture and alleviated by reumbeny. The mehanism is unlear, but the headahe is mmnly attributed t leakage f erebrspinal fluid thrugh the dural punture site. Its inidene may be redued if an atraumati needle (instead f a beveled, utting needle) is used fr the lumbar punture. »When to Refer• Thunderlap nset. •Inreasing headahe unrespnsive t simple measures. •Histry f trauma, hypertensin, fever, visual hanges. •Presene f neurlgi signs r f salp tenderness. »When to AdmitSuspeted  subarahnid hemrrhage r ther strutural intraranial lesin.Ceriani  CEJ et al. Nvel mediatins fr the treatment f migraine. Headahe. 2019;59:1597. [PMID: 31559638] Vukvi-Cvetkvi V et al. Neurstimulatin fr the treatment f hrni migraine and luster headahe. Ata Neurl Sand. 2019;139:4. [PMID: 30291633]F ACIAL PAIN 1. Trigeminl NeurlgiE S S E N T I A L S  O F  D I A G N O S I S »Brief episodes of stabbing facial pain. »Pain is in the territory of the second and third divi- sion of the trigeminal nerve. »Pain exacerbated by touch. »General ConsiderationsT rigeminal neuralgia (“ti dulureux”) is mst mmn in middle and later life. It affets wmen mre frequently than men. Pain may be due t an anmalus artery r vein impinging n the trigeminal nerve. »Clinical FindingsM mentary episdes f sudden laninating faial pain mmnly arise near ne side f the muth and sht tward the ipsilateral ear, eye, r nstril. The pain may be triggered by suh fatrs as tuh, mvement, drafts, and eating. In rder t lessen the likelihd f triggering fur- ther attaks, many patients try t hld the fae still while talking. Spntaneus remissins fr several mnths rCMDT22_Ch24_p0978-p1053.indd  982 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS983 CMDT 2022lnger  may ur. As the disrder prgresses, hwever, the episdes f pain beme mre frequent, remissins beme shrter and less mmn, and a dull ahe may persist between the episdes f stabbing pain. Symptms remain nfined t the distributin f the trigeminal nerve (usu- ally the send r third divisin) n ne side nly. »Differential DiagnosisThe  harateristi features f the pain in trigeminal neural- gia usually distinguish it frm ther auses f faial pain. Neurlgi examinatin shws n abnrmality exept in a few patients in whm trigeminal neuralgia is symptmati f sme underlying lesin, suh as multiple slersis r a brainstem neplasm, in whih ase the finding will depend n the nature and site f the lesin. Multiple slersis mustbe suspeted in a patient yunger than 40 years in whm trigeminal neuralgia is the presenting symptm, even if there are n ther neurlgi signs. Bilateral symptms shuld als prmpt further investigatin. Brain MRI need nly be btained when a sendary ause is suspeted; it is usually nrmal in lassi trigeminal neuralgia. »TreatmentThe m ediatins mst helpful fr treatment are xarbaze- pine (althugh nt apprved by the FDA fr this india- tin) r arbamazepine, with mnitring by serial bld unts and liver bihemial tests. If these mediatins are ineffetive r annt be tlerated, phenytin shuld be tried. (Dses and side effets f these mediatins are shwn in Table 24–2.) Balfen (10–20 mg rally three r Table 24–2. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Generlized or Focl Seizures Brivaracetam2,350–100 mg 2 1–2 days CBC, liver biochemi- cal testsSomnolence, fatigue, ataxia, vertigo, psycho- sis, leukopenia, hypersensitivity (broncho- spasm and angioedema). Cannabidiol45–20 mg/kg 2 11–13 days Liver biochemical tests at baseline, 1, 3, and 6 monthsSomnolence, fatigue, anorexia, weight loss, anemia, diarrhea, rash, sleep disorder, infections. Elevation in liver enzymes may occur; reduce dose in hepatic impairment. Carbamazepine2400–1600 mg (immediate or extended release)2 3–4 days 4–8 mcg/mL CBC, liver biochemi- cal tests, BUN/CrNystagmus, dysarthria, diplopia, ataxia, drowsiness, nausea, blood dyscrasias, hepatotoxicity, hyponatremia, Stevens-Johnson syndrome.5My  excerbte myoclonic seizures. Cenobamate2,3200–400 mg 1 14 days Liver biochemical tests, potassiumMultiorgan hypersensitivity, QT shortening, somnolence, dizziness, cognitive dysfunc- tion, blurred vision. Clobazam610–40 mg 2 7–10 days  Lethargy and somnolence, ataxia, insomnia, dysarthria, aggression, constipation, fever, Stevens-Johnson syndrome. Clorazepate322.5–90 mg 2 10 days  Sedation, dizziness, confusion, ataxia, depres- sion, dependency/abuse. Eslicarbazepine2,3400–1200 mg 1 4 days Serum sodium and chloride; liver bio- chemical testsAs for carbamazepine. Ezogabine3300–1200 mg 3 2–3 days ECG to assess QT intervalDizziness, somnolence, confusion, vertigo, nausea, ataxia, psychiatric disturbances, prolonged QT interval, retinal abnormalities.7F elbamate2,3,6,81200–3600 mg 3 4–5 days CBC and reticulo- cytes, liver bio- chemical testsAnorexia, nausea, vomiting, headache, insom- nia, weight loss, dizziness, hepatotoxicity, fatal aplastic anemia. Reserved for refractory epilepsy. (continued )CMDT22_Ch24_p0978-p1053.indd  983 29/06/21 8:50 PMChapTER 24984 CMDT 2022T able 24–2. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Gabapentin3900–3600 mg 3 1 day  Sedation, fatigue, ataxia, nystagmus, weight loss. Lacosamide2,3100–400 mg 2 3 days ECG if known cardiac conduction problems or severe cardiac diseaseVertigo, diplopia, nausea, headache, fatigue, ataxia, tremor, anaphylactoid reactions, PR prolongation, cardiac dysrhythmia, suicidality. Lamotrigine3,6,9,10100–500 mg 2 4–5 days  Sedation, skin rash, visual disturbances, dyspepsia, ataxia. Levetiracetam3,9,111000–3000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Oxcarbazepine2,3900–1800 mg 2 2–3 days Serum sodium As for carbamazepine. Perampanel2,3,94–12 mg 1 3 weeks  Dizziness, somnolence, irritability, weight gain, falls, ataxia, dysarthria, blurred vision. Phenobarbital2,12100–200 mg 1 14–21 days 10–40 mcg/mL CBC, liver biochemi- cal tests, BUN/CrDrowsiness, nystagmus, ataxia, skin rashes, learning difficulties, hyperactivity. Phenytoin2,12200–400 mg 1 5–10 days 10–20 mcg/mL CBC, liver biochemi- cal tests, folateNystagmus, ataxia, dysarthria, sedation, con- fusion, gingival hyperplasia, hirsutism, megaloblastic anemia, blood dyscrasias, skin rashes, fever, systemic lupus erythema- tosus, lymphadenopathy, peripheral neu- ropathy, dyskinesias. My excerbte myoclonic seizures. Pregabalin3150–300 mg 2 2–4 days  Somnolence, dizziness, poor concentration, weight gain, thrombocytopenia, skin rashes, anaphylactoid reactions. Primidone2,12750–1500 mg 3 4–7 days 5–12 mcg/mL CBCSedation, nystagmus, ataxia, vertigo, nausea, skin rashes, megaloblastic anemia, irritability. Rufinamide6800–3200 mg 2 2 days  Somnolence, headache, dizziness, suicidality, Stevens-Johnson syndrome, leukopenia, shortened QT interval, nausea, vomiting. Tiagabine332–56 mg 2 2 days  Somnolence, anxiety, dizziness, poor concen- tration, tremor, diarrhea. Topiramate2,3,6,9,12200–400 mg 2 4 days Serum bicarbonate, BUN/Cr in elderly patientsSomnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glau- coma, renal calculi, weight loss, hypohidro- sis, hyperthermia. Valproic acid2,3,13,141500–2000 mg 2–3 2–4 days 50–100 mcg/mL CBC, liver biochemi- cal testsNausea, vomiting, diarrhea, drowsiness, alope- cia, weight gain, hepatotoxicity, thrombo- cytopenia, tremor, pancreatitis. Tertogenic; void in women of cildber- ing ge. Vigabatrin3,153000 mg 2 2 days  Somnolence, anorexia, nausea, vomiting, agi- tation, hostility, confusion, suicidality, neu- tropenia, Stevens-Johnson syndrome, permanent visual field loss.7Zoni samide3200–600 mg 1 14 days BUN/Cr, serum bicarbonateSomnolence, ataxia, anorexia, nausea, vomiting, rash, confusion, renal calculi. Do not use in patients with sulfonamide allergy. (continued )(continued )CMDT22_Ch24_p0978-p1053.indd  984 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS985 CMDT 2022T able 24–2. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections absence Seizures Clonaze- pam6,11,13,16,170.04–0.2 mg/kg 2 7–10 days 20–80 ng/mL CBC, liver biochemical testsDrowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Ethosuximide13500–1500 mg 2 5–10 days 40–100 mcg/mL CBC, liver biochemi- cal tests, urinalysisNausea, vomiting, anorexia, headache, lethargy, unsteadiness, blood dyscrasias, systemic lupus erythematosus, urticaria, pruritus. Valproic acid2,3,13,141500–2000 mg 2–3 2–4 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. Myoclonic Seizures Clonaze- pam6,11,13,16,170.04–0.2 mg/kg 2 7–10 days See above Drowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Levetiracetam3,9,111000–3000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Valproic acid2,3,13,141500–2000 mg 2–3 2–4 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. BUN, blood urea nitrogen; CBC, complete blood count; Cr, creatinine; ECG, electrocardiogram. Note that many factors influence o ptimal dose of these drugs including age, tolerance, and concomitant medication.1 Patients starting treatment with any antiepileptic drug should be monitored for new or worsening depression or suicidal thought s, especially during the first weeks of therapy. Baseline measurement of creatinine clearance is advisable in renally metabolized drugs.2 Approved as monotherapy for focal-onset seizures.3 Approved as adjunctive therapy for focal-onset seizures.4 Approved for treatment of seizures in Lennox-Gastaut and Dravet syndrome in patients 2 years and older.5 Carriers of the HLA-B*1502 allele are at higher risk for Stevens-Johnson syndrome. Patients of Asian ancestry should be tested for this allele prior to initiation of therapy.6 Approved as adjunctive therapy for Lennox-Gastaut syndrome.7 Regular ophthalmologic examination is recommended.8 Not to be used as a first-line drug; when used, blood counts should be performed regularly (every 2–4 weeks). Should be used on ly in selected patients because of risk of aplastic anemia and hepatic failure. It is advisable to obtain written informed consent be fore use.9 Approved as adjunctive therapy for primary generalized tonic-clonic seizures.10 Approved as monotherapy (after conversion from another drug) in focal-onset seizures.11 Approved as adjunctive therapy for myoclonic seizures.12 Approved as initial monotherapy for primary generalized tonic-clonic seizures.13 Approved as monotherapy and adjunctive therapy for absence seizures.14 Approved as adjunctive therapy for patients with multiple seizure types including absence seizures.15 Approved as monotherapy for infantile spasms.16 Approved as monotherapy for Lennox-Gastaut syndrome.17 Approved as monotherapy for myoclonic seizures.f ur times daily), tpiramate (50 mg rally twie daily), r lamtrigine (400 mg rally daily) may als be helpful, either alne r in mbinatin with ne f these ther agents. Gabapentin may als relieve pain, espeially in patients wh d nt respnd t nventinal medial therapy and thse with multiple slersis. Depending n respnse and tler- ane, up t 3600 mg daily rally is given in divided dses. Fr neuralgia refratry t medial treatment, several surgial treatment ptins are available that prvide initial pain relief in at least 80% f patients. Mirvasularsurgial dempressin with separatin f the anmalus vessel (usually nt visible n CT sans, MRI, r arteri- grams) frm the nerve rt prdues lng-term relief f symptms in rughly 75% f patients. Three less invasive tehniques are based n destrutin f nieptive tri- geminal nerve fibers, whih auses sensry lss in additin t symptm relief in half f patients: (1) radifrequeny rhiztmy prdues lng-term pain relief in 60% f patients, (2) perutaneus balln mpressin f the tri- geminal ganglin in 67%, and (3) steretati radisurgery(continued )CMDT22_Ch24_p0978-p1053.indd  985 29/06/21 8:50 PMChapTER 24986 CMDT 2022t  the trigeminal nerve rt in 45%. In elderly patients with a limited life expetany, radifrequeny rhiztmy and steretati radisurgery are smetimes preferred beause bth an be perfrmed withut general anesthesia and have few mpliatins. Surgial explratin is inapprpri- ate in patients with trigeminal neuralgia due t multiple slersis, but the less invasive tehniques are smetimes helpful.2.  atyicl Fcil pinFaial  pain withut the typial features f trigeminal neu- ralgia is generally a nstant, ften burning pain that may have a restrited distributin at its nset but sn spreads t the rest f the fae n the affeted side and smetimes invlves the ther side, the nek, r the bak f the head as well. The disrder is espeially mmn in middle-aged wmen, many f them depressed, but it is nt lear whether depressin is the ause f r a reatin t the pain. Simple analgesis shuld be given a trial, as shuld triyli antidepressants, arbamazepine, xarbazepine, and phenytin; the respnse is ften disappinting. Opiid analgesis pse a danger f additin. Attempts at surgial treatment are nt indiated.3.  Glossoryngel NeurlgiGlsspharyngeal  neuralgia is an unmmn disrder in whih pain similar in quality t that in trigeminal neural- gia urs in the thrat, abut the tnsillar fssa, and smetimes deep in the ear and at the bak f the tngue. The pain may be preipitated by swallwing, hewing, talk- ing, r yawning and is smetimes ampanied by syn- pe. In mst instanes, n underlying strutural abnrmality is present; multiple slersis is smetimes respnsible. Oxarbazepine and arbamazepine are the treatments f hie and shuld be tried befre any surgi- al predures are nsidered. Mirvasular dempres- sin is ften effetive and is generally preferred ver destrutive surgial predures suh as partial rhiztmy in medially refratry ases.4.  posteretic NeurlgiP stherpeti neuralgia develps in abut 15% f patients wh have herpes zster (shingles). This mpliatin seems espeially likely t ur in elderly r immunm- prmised persns, when the rash is severe, and when the first divisin f the trigeminal nerve is affeted. It als relates t the duratin f the rash befre treatment is insti- tuted. A histry f shingles and the presene f utaneus sarring resulting frm shingles aid in the diagnsis. Severe pain with shingles rrelates with the intensity f psther- peti symptms. Aylvir (800 mg five times daily) r valaylvir (1000 mg three times daily), when given within 72 hurs f rash nset, redues the inidene f pstherpeti neuralgia by almst half; systemi rtisterids d nothelp prevent pstherpeti neuralgia (see Chapter 6). Management f the established mpliatin is with simple analgesis. If they fail t help, a trial f a triyli antidepressant (eg, amitrip- tyline r nrtriptyline, up t 100–150 mg daily rally) isften effetive. Other patients respnd t gabapentin (up t 3600 mg daily rally) r pregabalin (up t 600 mg/daily rally). Subutaneus injetin f btulinum txin A int the affeted regin prdued sustained pain relief in 87% f patients in a small plaeb-ntrlled trial. Tpial applia- tin f apsaiin ream may be helpful, as may tpial lidaine (5%). The administratin f recombinant zoster vaccine t patients ver the age f 50 years is imprtant in reduing the likelihd f herpes zster r reduing the severity f pstherpeti neuralgia shuld a reativatin ur.5.  Fcil pin Due to Oter CusesFa ial pain may be aused by temprmandibular jint dysfuntin in patients with mallusin, abnrmal bite, r faulty dentures. There may be tenderness f the mastia- try musles, and smetimes pain begins at the nset f hewing. This pattern differs frm that f jaw (mastiatry) laudiatin, a symptm f giant ell arteritis, in whih pain develps prgressively with mastiatin. Treatment f the underlying jint dysfuntin relieves symptms. A relatinship f faial pain t hewing r temperature hanges may suggest a dental disturbane. The ause is smetimes nt bvius, and diagnsis requires areful dental examinatin and radigraphs. Sinusitis and ear infetins ausing faial pain are usually regnized by a histry f respiratry trat infetin, fever, and, in sme instanes, nasal r aural disharge. There may be lalized tenderness. Radilgi evidene f sinus infetin r mas- tiditis is nfirmatry. Glauma is an imprtant ular ause f faial pain, usually lalized t the perirbital regin. On asin, pain in the jaw may be the prinipal mani- festatin f angina petris. Preipitatin by exertin and radiatin t mre typial areas suggests a ardia rigin. »When to Refer• Wrsening pain unrespnsive t simple measures. •Cntinuing pain f unertain ause. •Fr nsideratin f surgial treatment (trigeminal r glsspharyngeal neuralgia).Bendtsen  L et al. Advanes in diagnsis, lassifiatin, path- physilgy, and management f trigeminal neuralgia. Lanet Neurl. 2020;19:784. [PMID: 32822636]EP ILEPSYE S S E N T I A L S  O F  D I A G N O S I S »Recurrent unprovoked seizures. »Characteristic electroencephalographic changes accompany seizures. »Mental status abnormalities or focal neurologic symptoms may persist for hours postictally.CMDT22_Ch24_p0978-p1053.indd  986 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS987 CMDT 2022 »General ConsiderationsThe term “ epilepsy” dentes any disrder haraterized by recurrent unprovoked seizures. A seizure is a transient dis- turbane f erebral funtin due t an abnrmal parxys- mal neurnal disharge in the brain. Epilepsy is relatively mmn, affeting apprximately 0.5% f the ppulatin in the United States. Patients with reurrent seizures prvked by a readily reversible ause, suh as withdrawal frm alhl r drugs, hypglyemia, hyperglyemia, r uremia, are nt nsid- ered t have epilepsy. »Classification of EpilepsyA rding t the Internatinal League Against Epilepsy lassifiatin system, reurrent seizures shuld be lassi- fied first by seizure type, send by epilepsy type, and third, if pssible, by epilepsy syndrme. The etilgy f reurrent seizures shuld be sught at eah stage f lassi- fiatin (see Etilgy f Epilepsy).A.  Seizure TypesThe  Internatinal League Against Epilepsy distinguishes seizures affeting nly part f the brain (fal seizures) frm thse that are generalized. 1. Focal onset seizures— The initial linial and eletren- ephalgraphi manifestatins f fal (partial) seizures indiate that nly a restrited part f ne erebral hemi- sphere has been ativated. The ital manifestatins depend n the area f the brain invlved. Fal seizures are lassi- fied by mtr r nnmtr nset as well as by whether awareness is impaired. a. Motor versus nonmotor onset— Seizures with mtr nset may be clonic, tonic, atonic, myoclonic, r hyperkinetic, r may manifest as automatisms repilep- tic spasms . The mst mmnly bserved fal mtr seizures nsist f lni jerking r autmatisms. Nnm- tr seizures may be manifested by sensry symptms (eg, paresthesias r tingling, gustatry, lfatry, visual r audi- try sensatins), behavir arrest, gnitive symptms (eg, speeh arrest, déjà vu, jamais vu), emtinal symptms (eg, fear), r autnmi symptms r signs (eg, abnrmal epi- gastri sensatins, sweating, flushing, pupillary dilatin). Fal sensry and mtr seizures may spread (r “marh”) t different parts f the limb r bdy depending n their rtial representatin and were previusly alled “simple partial” seizures. b. Aware versus impaired awareness— Awareness is defined as knwledge f self and envirnment and f events urring during a seizure. Impaired awareness may be preeded, ampanied, r fllwed by the varius mtr and nnmtr symptms mentined abve. Suh seizures were previusly alled “mplex partial” seizures. c. Focal to bilateral tonic-clonic— Fal seizures smetimes invlve lss f awareness and evlve t bilateral tni-lni seizures, in a press previusly alled “se- ndary generalizatin. ”2. Generalized onset seizures— Generalized seizures are thught t riginate in r rapidly spread t invlve bilateral rtial netwrks. In sme ases, the distintin between fal and generalized nset an nly be made by eletren- ephalgram (EEG). Generalized seizures are lassified int thse with mtr r nnmtr features. Awareness is typially lst with generalized seizures but may be retained partially in the briefest absene attaks and sme my- lni seizures. a. Nonmotor (absence) seizures— These are harater- ized by impairment f nsiusness, smetimes with mild lni, tni, mylni, r atni mpnents (ie, redu- tin r lss f pstural tne), autnmi mpnents (eg, enuresis), r ampanying autmatisms. Onset and termi- natin f attaks are abrupt. If attaks ur during nver- satin, the patient may miss a few wrds r may break ff in midsentene fr a few sends. The impairment f external awareness is s brief that the patient is unaware f it. Absence (“petit mal”) seizures almst always begin in hildhd and frequently ease by the age f 20 years r are then replaed by ther frms f generalized seizure. Ele- trenephalgraphially, suh attaks are assiated with bursts f bilaterally synhrnus and symmetri 3-Hz spike-wave ativity. A nrmal bakgrund in the eletren- ephalgram and nrmal r abve-nrmal intelligene imply a gd prgnsis fr the ultimate essatin f these seizures. Atypical absence seizures may demnstrate mre marked hanges in tne, r attaks may have a mre gradual nset and terminatin than in typial absene seizures. They mmnly ur in patients with multiple seizure types, may be ampanied by develpmental delay r mental retardatin, and are assiated with slwer spike- wave disharges than thse in typial absene attaks. b. Motor seizures— Types f generalized mtr seizures inlude tonic-clonic, clonic, tonic, myoclonic, myoclonic- tonic-clonic, myoclonic-atonic, atonic, and epileptic spasms. During tni-lni seizures there is sudden lss f nsiusness, the patient bemes rigid and falls t the grund, and respiratin is arrested. This tni phase, whih usually lasts fr under 1 minute, is fllwed by a lni phase in whih there is jerking f the bdy musulature that may last fr 2 r 3 minutes and is then fllwed by a stage f flaid ma. During the seizure, the tngue r lips may be bitten, urinary r feal inntinene may ur, and the patient may be injured. Immediately after the sei- zure, the patient may rever nsiusness, drift int sleep, have a further nvulsin withut revery f n- siusness between the attaks (status epilepticus), r after revering nsiusness have a further nvulsin (serial seizures). In ther ases, patients may behave in an abnrmal fashin in the immediate pstital perid, with- ut subsequent awareness r memry f events (postepi- leptic automatism) . Headahe, disrientatin, nfusin, drwsiness, nausea, sreness f the musles, r sme m- binatin f these symptms mmnly urs pstitally. Mylni seizures nsist f single r multiple mylni jerks. Atni seizures nsist f very brief (less than 2 sends) lss f musle tne and ften result in falls (epileptic drop attacks) .Epileptic spasms are sudden flexin rCMDT22_Ch24_p0978-p1053.indd  987 29/06/21 8:50 PMChapTER 24988 CMDT 2022extensin  f trunal musles; these seizures usually mani- fest during infany. 3. Unknown onset seizures— In sme irumstanes, sei- zures annt be lassified beause f inmplete infrmatin r beause they d nt fit int any ategry. Generally, with additinal infrmatin frm the histry r frm vide-EEG telemetry, the seizure nset an be rretly lassified.B.  Epilepsy TypesThe  Internatinal League Against Epilepsy lassifies epi- lepsy by the seizure type. Thus, epilepsy may be focal , generalized, rcombined generalized and focal. The EEG may be helpful in failitating lassifiatin.C.  Epilepsy SyndromesEp ilepsy syndrmes are defined by nstellatins f seizure types, EEG findings, and imaging features, and ften als depend n age at nset and mrbidities. Nt every patient with epilepsy an be given a syndrmi diagnsis. Several well-knwn epilepsy syndrmes exist but are beynd the spe f this hapter. »Etiology of EpilepsyIn  parallel t lassifying the seizure type, epilepsy type, and epilepsy syndrme (if appliable), the ause f the patient’s seizures shuld be sught. The Internatinal League Against Epilepsy lists six brad etilgi ategries; sme- times a patient’s seizures have mre than ne etilgy.A.  Structural Etiology1.  Pediatric age groups— Cngenital abnrmalities and perinatal injuries may result in seizures presenting in infany r hildhd. 2. Mesial temporal sclerosis— Hippampal slersis is a regnized ause f fal and sendarily generalized sei- zures f unertain etilgy. 3. Trauma— Trauma is an imprtant ause f seizures at any age, but espeially in yung adults. Psttraumati epi- lepsy is mre likely t develp if the dura mater was pene- trated and generally bemes manifest within 2 years fllwing the injury. Seizures develping in the first week after head injury d nt neessarily imply that future attaks will ur. There is noevidene that prphylati antinvulsant mediatin treatment redues the inidene f psttraumati epilepsy. 4. Tumors and other spaceoccupying lesions— Ne- plasms may lead t seizures at any age, but they are an espeially imprtant ause f seizures in middle and later life, when the inidene f neplasti disease inreases. Seizures are mmnly the initial symptms f the tumr and ften are fal in harater. They are mst likely t ur with strutural lesins invlving the frntal, parietal, r tempral regins. Tumors must be excluded by imaging studies (MRI preferred over CT) in all patients with onset of seizures after 20 years of age, focal seizures or signs, or a progressive seizure disorder.5. Vascular diseases— Strke and ther vasular diseases beme inreasingly frequent auses f seizures with advaning age and are the mst mmn ause f seizures with nset at age 60 years r lder. 6. Degenerative disorders— Alzheimer disease and ther degenerative disrders are a ause f seizures in later life.B.  Genetic EtiologyThis ategry enmpasses a  brad range f disrders, fr whih the age at nset ranges frm the nenatal perid t adlesene r even later in life. Mngeni disrders tend t exhibit an autsmal dminant pattern f inheritane, and where the mutatin is knwn, the respnsible gene ften endes a neurnal in hannel. A geneti etilgy may als underpin ertain epilepsies with a metabli r strutural basis.C.  Infectious EtiologyInfetius diseases must be nsider ed in all age grups as ptentially reversible auses f seizures. Seizures may ur with an aute infetive r inflammatry illness, suh as baterial meningitis r herpes enephalitis, r in patients with mre lngstanding r hrni disrders, suh as neu- rsyphilis r erebral ystiersis. In patients with AIDS, seizures may result frm entral nervus system txplas- msis, ryptal meningitis, sendary viral enephali- tis, r ther infetive mpliatins. Seizures are a mmn sequela f supratentrial brain absess, develping mst frequently in the first year after treatment.D . Metabolic EtiologyInbrn  errrs f metablism and ther inherited ndi- tins may ause epilepsy as ne f their manifestatins (eg, pyridxine defiieny, mithndrial disease); these disr- ders typially present during hildhd.E.  Immune EtiologyA utimmune diseases suh as systemi lupus erythemat- sus and autimmune limbi enephalitis may ause epi- lepsy; ften the epilepsy an be ured with immuntherapy and lifelng antiepilepti mediatin treatment is nt neessary.F . Unknown EtiologyIn  many ases, the ause f epilepsy annt be determined. »Clinical FindingsA.  Symptoms and SignsN nspeifi hanges suh as headahe, md alteratins, lethargy, and mylni jerking alert sme patients t an impending seizure hurs befre it urs. These prodro- mal symptoms are distint frm the aura; the aura that may preede a generalized seizure by a few sends r minutes is itself a part f the seizure indiating fal nset frm a restrited part f the brain.CMDT22_Ch24_p0978-p1053.indd  988 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS989 CMDT 2022In  mst patients, seizures ur unpreditably at any time and withut any relatinship t psture r nging ativities. Oasinally, hwever, they ur at a partiu- lar time (eg, during sleep) r in relatin t external pre- ipitants suh as lak f sleep, missed meals, emtinal stress, menstruatin, alhl ingestin (r alhl with- drawal), r use f ertain rereatinal drugs. Fever and nnspeifi infetins may als preipitate seizures in patients with epilepsy. In a few patients, seizures are pr- vked by speifi stimuli suh as flashing lights r a flik- ering televisin set (photosensitive epilepsy), musi, r reading. Clinial examinatin between seizures shws n abnr- mality in patients with idipathi epilepsy, but in the immediate pstital perid, extensr plantar respnses may be seen. The presene f lateralized r fal signs pstitally suggests that seizures may have a fal rigin. In patients with symptmati epilepsy, the findings n exami- natin will reflet the underlying ause.B.  ImagingMRI  is indiated fr patients with fal neurlgi symp- tms r signs, fal seizures, r eletrenephalgraphi findings f a fal disturbane. It shuld als be perfrmed in patients with linial evidene f a prgressive disrder and in thse with new nset f seizures after the age f 20 years beause f the pssibility f an underlying ne- plasm. CT is generally less sensitive than MRI in deteting small strutural brain abnrmalities but may be used when MRI is ntraindiated r unavailable.C.  Laboratory StudiesInit ial investigatins after a first seizure shuld inlude mplete bld unt, serum gluse, eletrlytes, re- atinine, alium, magnesium, and liver bihemial tests t exlude varius auses f prvked seizures and t prvide a baseline fr subsequent mnitring f lng-term effets f treatment. Rutine labratry investigatins are notusually neessary after reurrent seizures in patients with knwn epilepsy. A lumbar punture may be neessary when any sign f infetin is present r in the evaluatin f new-nset seizures in the aute setting.D . ElectroencephalographyEletrenephalgraph y may supprt the linial diagnsis f epilepsy (by demnstrating parxysmal abnrmalities ntaining spikes r sharp waves), prvide a guide t prg- nsis, and help lassify the seizure disrder. Classifiatin f the disrder is imprtant fr determining the mst apprpriate antinvulsant mediatin with whih t start treatment. Fr example, absene and fal seizures with impaired awareness may be diffiult t distinguish lini- ally, but the eletrenephalgraphi findings and treat- ment f hie differ in these tw nditins. Finally, by lalizing the epileptgeni sure, the eletrenephal- graphi findings are imprtant in evaluating andidates fr surgial treatment.»Differential DiagnosisThe  distintin between the varius disrders likely t be nfused with generalized seizures is usually made n the basis f the histry. The imprtane f btaining an eye- witness aunt f the attaks annt be veremphasized.A.  Differential Diagnosis of Focal Seizures1.  TIAs— These are distinguished frm seizures by their lnger duratin, lak f spread, and negative (eg, weakness r numbness) rather than psitive (eg, nvulsive jerking r paresthesias) symptms. Level f nsiusness, whih is unaltered, des nt distinguish them. 2. Migraine aura— Migraine aura may prdue psitive r negative symptms, tends t spread slwly frm ne part f the bdy t anther (ver minutes rather than sends), and is usually lnger in duratin (minutes t hurs). It is usually, but nt always, fllwed by a typial migraine headahe. 3. Panic attacks— These may be hard t distinguish frm fal seizures unless there is evidene f an anxiety disr- der between attaks and the attaks have a lear relatin- ship t external irumstanes. 4. Rage attacks— These are situatinal and lead t gal- direted aggressive behavir.B.  Differential Diagnosis of Generalized Seizures1.  Syncope— Synpal episdes usually ur in relatin t pstural hange, emtinal stress, instrumentatin, pain, r straining. They are typially preeded by pallr, sweating, nausea, and malaise and lead t lss f nsiusness ampanied by flaidity; revery urs rapidly with reumbeny, and there is n pstital headahe r nfu- sin. In sme instanes, hwever, mtr ampaniments and urinary inntinene may simulate a seizure. 2. Cardiac disease— Cerebral hypperfusin due t a dis- turbane f ardia rhythm shuld be suspeted in patients with knwn ardia r vasular disease r in elderly patients wh present with episdi lss f nsiusness. Prdrmal symptms are typially absent. Cardia rhythm mnitring may be neessary t establish the diagnsis; external event rerders r implantable lp rerders may be valuable if the disturbanes f nsiusness are rare. A relatinship f attaks t physial ativity and the finding f a systli murmur are suggestive f arti stensis. 3. Brainstem ischemia— Lss f nsiusness is preeded r ampanied by ther brainstem signs. Basilar artery migraine and vertebrbasilar vasular disease are disussed elsewhere in this hapter. 4. Psychogenic nonepileptic seizure PNES— Simulating an epilepti seizure, a PNES may ur due t a nversin disrder r malingering. Many patients als have epilepti seizures r a family histry f epilepsy. A histry f hild- hd physial r sexual abuse is mmn. Althugh a PNES tends t ur at times f emtinal stress, this may als be the ase with epilepti seizures.CMDT22_Ch24_p0978-p1053.indd  989 29/06/21 8:50 PMChapTER 24990 CMDT 2022Clini ally, the attaks superfiially resemble tni-lni seizures, but there may be bvius preparatin befre a PNES. Mrever, there is usually n tni phase; instead, there may be an asynhrnus thrashing f the limbs and the attak rarely leads t injury. Eyes are ften fribly lsed during PNES, unlike epilepti seizures, in whih they are typially pen. Cnsiusness may be nrmal r “lst, ” but in the latter ntext the urrene f gal-direted behavir r f shuting, swearing, et, indiates that it is feigned. Pstitally, there are n hanges in behavir r neurlgi findings. Often, linial bservatin is insuffiient t disriminate epilepti frm nnepilepti seizures and video electroen- cephalographic monitoring is required. Elevatin f serum prlatin level t at least twie the upper limit f nrmal an be seen between 10 and 20 minutes after a seizure r syn- pal event but nt after a PNES. Hwever, prlatin measure- ment has limited linial utility beause levels are nrmal after an epilepti seizure in rughly half f patients and a baseline prlatin must be drawn 6 hurs after the attak. »TreatmentA.  General MeasuresF r patients with epilepsy, mediatin is presribed with the gal f preventing further attaks and is usually ntinued until there have been n seizures fr at least 2 years. Patients shuld be advised t avid situatins that uld be danger- us r life-threatening if further seizures shuld ur. Legislatin may require liniians t reprt t the state authrities any patients with seizures r ther episdi dis- turbanes f nsiusness; driving cessation for 6 months r as legislated is apprpriate fllwing an unprvked seizure. 1. Choice of medication— Mediatin seletin depends n seizure type (Table 24–2). The dse f the seleted anti- nvulsant is gradually inreased until seizures are n- trlled r side effets prevent further inreases. If seizures ntinue despite treatment at the maximal tlerated dse, a send mediatin is added and the dse inreased depending n tlerane; the first mediatin is then gradu- ally withdrawn. In mst patients with seizures f a single type, satisfatry ntrl an be ahieved with a single antinvulsant. Treatment with tw mediatins may fur- ther redue seizure frequeny r severity but usually nly at the st f greater txiity. Treatment with mre than tw mediatins is almst always unhelpful unless the patient is having seizures f different types. Other fatrs t nsider in seleting an antinvulsant inlude likely side effets, teratgeniity, interatins with ther media- tins and ral ntraeptives, and rute f metablism. All antiepileptis are ptentially teratgeni, althugh the teratgeniity f the newer antiseizure mediatins is less lear. Nevertheless, antiepilepti mediatin must be given t pregnant wmen with epilepsy t prevent seizures, whih an pse serius risk t the fetus frm trauma, hypxia, r ther fatrs. 2. Monitoring— Individual differenes in drug metablism ause a given dse f a mediatin t prdue differentbld nentratins in different patients, and this will affet the therapeuti respnse. In general, the dose of an antiepileptic agent is increased, depending on tolerance, to achieve the desired clinical response regardless of the serum drug level. When a dse is reahed that either ntrls sei- zures r is the maximum tlerated, then a steady-state trugh drug level may be btained fr future referene; reheking this level may be apprpriate during pregnany, if a breakthrugh seizure urs, a dse hange urs, r anther (ptentially interating) mediatin is added t the regimen. A labratry’s therapeuti range fr a mediatin is nly a guide; many patients ahieve gd seizure ntrl with n adverse effet at serum levels that exeed the stipu- lated range, and in these ases n dse adjustment is needed. The mst mmn ause f a lwer nentratin f mediatin than expeted fr the presribed dse is sub- ptimal patient adherene. Adherene an be imprved by limiting t a minimum the number f daily dses. Reur- rent seizures r status epileptius may result if mediatins are taken erratially, and in sme irumstanes nnadher- ent patients may be better ff withut any mediatin. All antinvulsants have side effets, and many require base- line and regular labratry mnitring (Table 24–2). 3. Discontinuance of medication— Only when adult patients have been seizure-free fr 2 years shuld with- drawal f mediatin be nsidered. Unfrtunately, there is n way f prediting whih patients an be managed su- essfully withut treatment, althugh seizure reurrene is mre likely in (1) patients with a lnger duratin f epi- lepsy prir t remissin, (2) thse with a shrter duratin f remissin, (3) thse wh initially did nt respnd t therapy, (4) thse with seizures having fal features r f multiple types, (5) thse with nset during adulthd, and (6) thse with ntinuing eletrenephalgraphi abnr- malities. Dse redutin shuld be gradual (ver weeks r mnths), and mediatins shuld be withdrawn ne at a time. If seizures reur, treatment is reinstituted with the previusly effetive regimen. 4. Surgical treatment— Patients with seizures refratry t tw r mre mediatins may be andidates fr perative treatment. Surgial resetin is mst effiaius when there is a single well-defined seizure fus, partiularly in the tempral lbe. Amng well-hsen patients, up t 70% remain seizure-free after extended fllw-up. Additinal surgial tehniques fr medially refratry epilepsy apprved in the United States inlude laser interstitial ther- mal therapy, deep brain stimulatin, respnsive rtial stimulatin, and vagus nerve stimulatin.B.  Special Circumstances1.  Solitary seizures— In patients wh have had nly ne seizure r a flurry f seizures ver a brief perid f several hurs, investigatin as utlined earlier shuld exlude an underlying ause requiring speifi treatment. An eletr- enephalgram shuld be btained, preferably within 24 hurs after the seizure. Prphylati antinvulsant treat- ment is generally nt required unless further attaks ur r investigatins reveal underlying pathlgy. The risk f seizure reurrene varies in different series between abutCMDT22_Ch24_p0978-p1053.indd  990 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS991 CMDT 202230%  and 70%, with higher risk f reurrene in patients with strutural brain lesins r abnrmalities n eletren- ephalgram. Epilepsy shuld notbe diagnsed n the basis f a slitary seizure. If seizures ur in the ntext f transient, nnreurrent systemi disrders suh as hypna- tremia r hypglyemia, the diagnsis f epilepsy is ina- urate, and lng-term prphylati antinvulsant treatment is unneessary. 2. Alcohol withdrawal seizures— The harateristi al- hl withdrawal seizure pattern is ne r mre generalized tni-lni seizures that may ur within 48 hurs r s f withdrawal frm alhl after a perid f high r pr- lnged intake. If the seizures have nsistently fal fea- tures, the pssibility f an assiated strutural abnrmality, ften traumati in rigin, must be nsidered. Treatment with antinvulsants is generally nt required fr alhl withdrawal seizures, sine they are self-limited. Benzdiaz- epines are effetive and safe fr preventing further seizures. Status epileptius may mpliate alhl withdrawal and is managed alng nventinal lines. Further attaks will nt ur if the patient abstains frm alhl. 3. Tonicclonic status epilepticus— Pr adherene t the antinvulsant regimen is the mst mmn ause; hw- ever, any disrder that an ause a single seizure may be respnsible. The mrtality rate may be as high as 20%, and amng survivrs the inidene f neurlgi and gnitive sequelae is high. The prgnsis relates t the underlying ause as well as the length f time between nset f status epileptius and the start f effetive treatment. Status epilepticus is a medical emergency. Initial management inludes maintenane f the airway and 50% dextrse (25–50 mL) intravenusly in ase hypglyemia is respnsible. If seizures ntinue, an intravenus blus f lrazepam, 4 mg, is given at a rate f 2 mg/min and repeated ne after 10 minutes if neessary; alternatively, 10 mg f midazlam is given intramusularly, and again after 10 minutes if neessary. Diazepam an als be given retally as a gel (0.2 mg/kg). These measures are usually effetive in halting seizures fr a brief perid. Respiratry depressin and hyptensin may mpliate the treatment and are treated as in ther irumstanes, inluding intuba- tin and mehanial ventilatin and admissin t an inten- sive are unit. Regardless f the respnse t lrazepam r midazlam, fsphenytin r phenytin shuld be administered intrave- nusly. Fsphenytin (18–20 mg phenytin equivalents [PE]/kg) is rapidly and mpletely nverted t phenytin fllwing intravenus administratin and is preferred beause it is less likely t ause reatins at the infusin site, an be given with all mmn intravenus slutins, and may be administered at a faster rate (150 mg PE/min). When fsphenytin is nt available, phenytin (18–20 mg/kg) is given intravenusly at a rate f 50 mg/min. Phenytin is best injeted diretly but an als be given in saline; it pre- ipitates, hwever, if injeted int gluse-ntaining slu- tins. Beause arrhythmias may develp during rapid administratin f fsphenytin r phenytin, eletrar- digraphi mnitring is prudent. Hyptensin may ur, espeially if diazepam has als been given. Alternatively radditinally, intravenus valprate (lading dse 20–40 mg/ kg ver 15 min, maximum dse 3000 mg) r levetiraetam (lading dse 60 mg/kg ver 15 min, maximum dse 4500 mg) is used fr status epileptius. Althugh neither is apprved by the FDA fr this indiatin, bth were equiva- lent t fsphenytin in a randmized trial. Due t the teratgeniity f valprate, it shuld be avided in wmen wh may be pregnant. If seizures ntinue, phenbarbital is then given in a lading dse f 10–20 mg/kg intravenusly by slw r intermittent injetin (50 mg/min). Respiratry depressin and hyptensin are espeially mmn with this therapy. If these measures fail, general anesthesia with ventila- try assistane may be required; sme experts rem- mend preeding diretly t general anesthesia if nvulsins d nt ease after the initial 18–20 PE/kg fsphenytin lad. Intravenus midazlam may prvide ntrl f refratry status epileptius; the suggested lading dse is 0.2 mg/kg, fllwed by 0.05–0.2 mg/kg/h. Prpfl (1–2 mg/kg as an intravenus blus, fllwed by infusin at 2–15 mg/kg/h depending n respnse) may als be used, as may pentbarbital (5–15 mg/kg intrave- nusly, fllwed by 0.5–4 mg/kg/h). After status epileptius is ntrlled, an ral mediatin prgram fr the lng-term management f seizures is started, and investigatins int the ause f the disrder are pursued. 4. Nonconvulsive status epilepticus— In sme ases, sta- tus epileptius presents nt with nvulsins, but with a flutuating abnrmal mental status, nfusin, impaired respnsiveness, and autmatism. Eletrenephalgraphy establishes the diagnsis. The treatment apprah utlined abve applies t any type f status epileptius, althugh intravenus anesthesia is usually nt neessary. The prg- nsis is a refletin f the underlying ause rather than f ntinuing seizures. »When to Refer• Behaviral episdes f unertain nature. •Seizures are diffiult t ntrl with mntherapy. •There is a prgressive neurlgi disrder. »When to Admit• Status epileptius. •Frequent seizures requiring rapid mediatin titratin and eletrenephalgraphi mnitring. •Fr inpatient mnitring when PNES is suspeted.Ahmad  S et al. Surgial treatments f epilepsy. Semin Neurl. 2020;40:696. [PMID: 33176368] Kanner AM et al. Pratie guideline update summary: effiay and tlerability f the new antiepilepti drugs I: treatment f new-nset epilepsy. Epilepsy Curr. 2018;18:260. [PMID: 30254527] Kapur J et al; NETT and PECARN Investigatrs. Randmized trial f three antinvulsant mediatins fr status epilepti- us. N Engl J Med. 2019;381:2103. [PMID: 31774955]CMDT22_Ch24_p0978-p1053.indd  991 29/06/21 8:50 PMChapTER 24992 CMDT 2022DYSAUTO NOMIAE S S E N T I A L S  O F  D I A G N O S I S »Postural hypotension or abnormal heart rate regulation. »Abnormalities of sweating, intestinal motility, sex- ual function, or sphincter control. »Syncope may occur. »Symptoms occur in isolation or any combination. »General ConsiderationsDysautn mia may ur as a result f pathlgial pr- esses in the entral r peripheral nervus system. It is manifested by a variety f symptms related t abnrmali- ties f bld pressure regulatin, thermregulatry sweat- ing, gastrintestinal funtin, sphinter ntrl, sexual funtin, respiratin, and ular funtin. The differential diagnsis depends n the time urse f autnmi dys- funtin and whether dysautnmia is an islated symp- tm r assiated with entral r peripheral neurlgi symptms and signs.A.  Causes in the Central Nervous SystemDisease at  ertain sites, regardless f its nature, may lead t dysautnmi symptms. Postural hypotension, whih is usually the mst trublesme and disabling symptm, may result frm spinal rd transetin and ther myelpathies (eg, due t tumr r syringmyelia) abve the T6 level r frm brainstem lesins suh as syringbulbia and psterir fssa tumrs. Sphincter or sexual disturbances may result frm rd lesins at any level. Certain primary degenera- tive disrders are respnsible fr dysautnmia urring in islatin (pure autonomic failure) r in assiatin with mre widespread abnrmalities (multisystem atro- phy) that may inlude parkinsnism, pyramidal symp- tms, and erebellar defiits. Pstural hyptensin is als a prminent symptm f idipathi Parkinsn disease and dementia with Lewy bdies.B.  Causes in the Peripheral Nervous SystemA  pure autnmi neurpathy may ur autely r sub- autely after a viral infetin r as a paraneplasti disr- der related usually t small ell lung aner, partiularly in assiatin with ertain antibdies, suh as anti-Hu r thse direted at neurnal nitini ganglini aetylh- line reeptrs. Dysautnmia is ften nspiuus in patients with Guillain-Barré syndrme, manifesting with marked hyptensin r hypertensin r ardia arrhyth- mias that may have a fatal utme. It may als ur with diabeti, uremi, amylidti, and varius ther metabli r txi neurpathies; in assiatin with leprsy r Cha- gas disease; and as a feature f ertain hereditary neurpa- thies with autsmal dminant r reessive inheritane r an X-linked pattern. Autnmi symptms are prminentin the rises f hepati prphyria. Small fiber neurpathies may underlie sme ases f postural orthostatic tachycar- dia syndrome (POTS) due t impaired ntratility in denervated venules and resulting prelad failure (see belw). Patients with btulism r the Lambert-Eatn myastheni syndrme may have nstipatin, urinary retentin, and a sia syndrme as a result f impaired hlinergi funtin. »Clinical FindingsA.  Symptoms and SignsDysautn mi symptms inlude synpe, pstural hyp- tensin, parxysmal hypertensin, persistent tahyardia withut ther ause, faial flushing, hyphidrsis r hyper- hidrsis, vmiting, nstipatin, diarrhea, dysphagia, abdminal distentin, disturbanes f mituritin r defe- atin, eretile dysfuntin, apnei episdes, and delining night visin. In synpe, prdrmal malaise, nausea, head- ahe, diaphresis, pallr, visual disturbane, lss f ps- tural tne, and a sense f weakness and impending lss f nsiusness are fllwed by atual lss f nsiusness. It is usually ampanied by hyptensin and bradyardia and may ur in respnse t emtinal stress, pstural hyptensin, vigrus exerise in a ht envirnment, bstruted venus return t the heart, aute pain r its antiipatin, fluid lss, and a variety f ther irum- stanes. Althugh the patient is usually flaid, sme mtr ativity is nt unmmn, and urinary (and rarely feal) inntinene may als ur, thereby simulating a seizure. Revery is rapid ne the patient bemes reum- bent, but headahe, nausea, and fatigue mmnly persist.B.  Evaluation of the PatientThe e xtent and severity f autnmi dysfuntin shuld be determined, and the presene f assiated neurlgi symptms and signs asertained. Bedside testing f aut- nmi funtin inludes examinatin f pupillary rea- tivity, examinatin f the skin fr areas f exessive r redued sweating and f the hands and feet fr lr r temperature hanges, as well as assessment f bld pres- sure and heart rate in the supine psitin and 2 minutes after standing. With dysautnmia, postural hypotension is not accompanied by a compensatory rise in heart rate. Speialized tests inlude the ardivasular respnse t the Valsalva maneuver and deep respiratin, tilt-table testing, the thermregulatry sweat test, the quantitative sudmtr axn reflex test, and the quantitative diret and indiret axn reflex test. Tests f gastrintestinal mtility and urdynamis may be helpful when symptms f dysmtility, inntinene, r urinary retentin are present. The neurlgi examinatin shuld fus n deteting signs f parkinsnism, erebellar dysfuntin, disrders f neurmusular transmissin, and peripheral neurpathy. All patients shuld be tested fr vitamin B12defiieny and diabetes. Patients with aute r subaute islated dysaut- nmia shuld underg testing fr ganglini aetylhline reeptr, anti-Hu, vltage-gated ptassium hannel m- plex, and vltage-gated alium hannel antibdies. Fr thse with evidene f peripheral neurpathy, nerveCMDT22_Ch24_p0978-p1053.indd  992 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS993 CMDT 2022ndu tin studies; eletrmygraphy; and testing fr HIV , amylidsis, Sjögren syndrme, and Fabry disease are indiated. If there is evidene f entral pathlgy, imag- ing studies will exlude a treatable strutural ause. If the neurlgi examinatin is nrmal, reversible, nnneur- lgi auses f symptms must be nsidered. Islated pstural hyptensin and synpe may relate t a redued ardia utput, parxysmal ardia dysrhythmias, vlume depletin, varius mediatins, and endrine and meta- bli disrders suh as Addisn disease, hypthyridism r hyperthyridism, phehrmytma, and arinid syndrme. »TreatmentThe  mst disabling symptms are usually pstural hypten- sin and synpe. Abrupt pstural hange, prlnged reumbeny, heavy meals, and ther preipitants shuld be avided. Mediatins assiated with pstural hyptensin shuld be disntinued r redued in dse. Treatment may inlude wearing waist-high elasti hsiery, salt supplementa- tin, sleeping in a semieret psitin (whih minimizes the natriuresis and diuresis that ur during reumbeny), ingestin f 500 mL water 30 minutes befre arising, and fludrrtisne (0.1–0.5 mg rally daily). Vasnstritr agents may be helpful and inlude middrine (2.5–10 mg rally three times daily), drxidpa (100–600 mg rally three times daily), and ephedrine (15–30 mg rally three times daily). Other agents that have been used asinally r experimentally are dihydrergtamine, yhimbine, pyr- idstigmine, and lnidine; refratry ases may respnd t erythrpietin (epetin alfa) r desmpressin. Patients must be mnitred fr reumbent hypertensin. Pstprandial hyptensin is helped by affeine. There is n satisfatry treatment fr disturbanes f sweating, but an air-nditined envirnment is helpful in aviding extreme swings in bdy temperature. »When to Refer• When the diagnsis is unertain. •When symptms persist despite nventinal treatment.Shiba  CA et al. Management f rthstati hyptensin, pst- prandial hyptensin, and supine hypertensin. Semin Neurl. 2020;40:515. [PMID: 33058087]PO STURAL ORTHOSTATIC TACHYCARDIA SYNDROME »Clinical FindingsIn PO TS, rthstati symptms (tremulusness, lighthead- edness, palpitatins, visual disturbanes, weakness, fatigue, anxiety, hyperventilatin, nausea) develp with a signifiant tahyardia (an inrease f 30 beats/min r mre r a heart rate f 120 beats/min r mre) within 10 minutes f stand- ing, in the absene f pstural hyptensin r an autnmi neurpathy. POTS is mre mmn in wmen than menand in patients between 20 and 50 years f age. Other medi- al prblems ausing a tahyardia must be exluded. Its pathphysilgy is unertain but may invlve ar- dia denditining; impaired peripheral vasnstri- tin due t peripheral sympatheti denervatin, leading t venus pling in the legs n standing and a mpen- satry tahyardia (“ neuropathic POTS ”); r an exagger- ated sympatheti respnse t standing, with markedly elevated levels f plasma nrepinephrine ausing the tahyardia (“ hyperadrenergic POTS ”). Other pssible mehanisms inlude hypvlemia, pssibly frm impaired funtin f the renin-angitensin system (“volume dysregulation POTS ”) and exessive mast ell ativatin leading t inapprpriate release f histamine during physial ativity. Psyhlgial mehanisms have als been invked. POTS may be assiated with jint hypermbility syndrme and mitral valve prlapse, and it may fllw pregnany, surgery, trauma, hemtherapy, vainatins, r viral infetins. »TreatmentMana gement may invlve vlume repletin, a high salt diet and pius fluids, pstural and psyhphysilgi train- ing, and a graduated exerise prgram. Mediatin treat- ment may inlude a beta-blking agent (eg, prpranll 10–40 mg three times daily), phenbarbital (15 mg in the mrning, 60 mg at night) r lnidine (0.2 mg twie daily) fr patients with hyperadrenergi POTS; and mid- drine (2.5–10 mg three times daily) r fludrrtisne (0.1–0.2 mg daily) if the bld pressure is lw. The lng- term prgnsis is unlear but apprximately 50% f patients rever within 3 years.TR ANSIENT ISCHEMIC ATTACKSE S S E N T I A L S  O F  D I A G N O S I S »Focal neurologic deficit of acute onset. »Clinical deficit resolves completely within 24 hours. »Risk factors for vascular disease often present. »General ConsiderationsT ransient ishemi attaks (TIAs) are haraterized by focal ischemic cerebral neurologic deficits that last frless than 24 hours (usually less than 1–2 hurs). Abut 30% f patients with strke have a histry f TIAs and 5–10% f patients with TIAs will have a strke within 90 days. The natural his- try f attaks is variable. Sme patients will have a majr strke after nly a few attaks, whereas thers may have frequent attaks fr weeks r mnths withut having a strke. The risk f strke is high in the first 3 mnths after an attak, partiularly in the first mnth and espeially within the first 48 hurs. The strke risk is greater in patients lder than 60 years, in patients with diabetes, r after TIAs that last lnger than 10 minutes and with symptms r signsCMDT22_Ch24_p0978-p1053.indd  993 29/06/21 8:50 PMChapTER 24994 CMDT 2022f  weakness, speeh impairment, r gait disturbane. In general, artid ishemi attaks are mre liable than verte- brbasilar ishemi attaks t be fllwed by strke. Urgent interventin in TIA patients redues rates f subsequent strke, and the condition should be treated with a similar sense of urgency as unstable angina. »EtiologyAn  imprtant ause f transient erebral ishemia is emblizatin. In many patients with these attaks, a sure is readily apparent in the heart r a majr extraranial artery t the head, and embli smetimes are visible in the retinal arteries. An embli phenmenn explains why separate attaks may affet different parts f the territry supplied by the same majr vessel. Cardia auses f embli ishemi attaks inlude atrial fibrillatin, heart failure, infetive and nnbaterial thrmbti endardi- tis, atrial myxma, and mural thrmbi mpliating my- ardial infartin. Atrial septal defets and patent framen vale may permit venus thrmbembli t reah the brain ( paradoxical emboli ). An ulerated plaque n a majr artery t the brain may serve as a sure f embli. In the anterir irulatin, atherslerti hanges ur mst mmnly in the regin f the artid bifuratin extraranially; these hanges may ause a bruit. Ather- slersis als affets the vertebrbasilar system and the majr intraranial vessels inluding the middle and ante- rir erebral arteries. Less mmn abnrmalities f bld vessels that may ause TIAs inlude fibrmusular dysplasia, whih affets partiularly the ervial internal artid artery; athersle- rsis f the arti arh; inflammatry arterial disrders suh as giant ell arteritis, plyarteritis, and granulma- tus angiitis; and meningvasular syphilis. Critial sten- sis f a majr extraranial r intraranial artery may ause TIA, espeially in the setting f hyptensin. Hematlgi auses f TIA inlude plyythemia, sikle ell disease, hypervissity syndrmes, and the antiphsphlipid antibdy syndrme. Severe anemia may als lead t transient fal neurlgi defiits in patients with preexisting erebral arterial disease. The subclavian steal syndrome may lead t transient vertebrbasilar ishemia. Symptms develp when there is lalized stensis r lusin f ne sublavian artery prximal t the sure f the vertebral artery, s that bld is “stlen” frm the vertebral artery t supply the arm. A bruit in the supralaviular fssa, unequal radial pulses, and a differene f 20 mm Hg r mre between the systli bld pressures in the arms shuld suggest the diagnsis in patients with vertebrbasilar TIAs. »Clinical FindingsA.  Symptoms and SignsThe  symptms f TIAs vary markedly amng patients; hw- ever, the symptms in a given individual tend t be nstant in type. Onset is abrupt and withut warning, and revery usually urs rapidly, ften within a few minutes. The spe- ifi symptms depend n the arterial distributin affeted,as utlined in the subsequent setin n strke. Of nte, TIA rarely auses f lss f nsiusness r aute nfusin but is ften errneusly blamed fr suh symptms.B.  ImagingCT  r MRI san is indiated within 24 hurs f symptm nset, in part t exlude the pssibility f a small erebral hemrrhage r a erebral tumr masquerading as a TIA. MRI with diffusin-weighted sequenes is partiularly sen- sitive fr revealing aute r subaute infartin, whih is seen in up t ne-third f ases despite reslutin f linial symptms and indiates a high risk f subsequent strke. Nninvasive imaging f the ervial vasulature shuld als be perfrmed; artid duplex ultrasngraphy is useful fr deteting signifiant stensis f the internal artid artery, and MR r CT angigraphy permits brader visualizatin f ervial and intraranial vasulature.C.  Laboratory and Other StudiesClinial  and labratry evaluatin must inlude assessment fr hypertensin, heart disease, hematlgi disrders, dia- betes mellitus, hyperlipidemia, and peripheral vasular dis- ease. It shuld inlude mplete bld unt, fasting bld gluse and serum hlesterl determinatins, and may inlude serlgi tests fr syphilis and HIV infetin. An ECG shuld be btained. Ehardigraphy with agitated saline ntrast is perfrmed if a ardiembli sure is likely, and bld ultures are btained if endarditis is suspeted. Ambulatry ECG mnitring is indiated t detet parxysmal atrial fibrillatin and, if the ause f the TIA remains elusive, extended monitoring may detet parx- ysmal atrial fibrillatin in up t 20% f patients. »Differential DiagnosisFal  seizures usually ause abnrmal mtr r sensry phenmena suh as lni limb mvements, paresthesias, r tingling, rather than weakness r lss f feeling. Symp- tms generally spread (“marh”) up the limb and may lead t a generalized tni-lni seizure. Classi migraine is easily regnized by the visual pre- mnitry symptms, fllwed by nausea, headahe, and phtphbia, but less typial ases may be hard t distin- guish. Patients with migraine are typially yunger, m- mnly have a histry f episdes sine adlesene, and reprt that ther family members have a similar disrder. Fal neurlgi defiits may ur during perids f hypglyemia in diabeti patients reeiving insulin r ral hypglyemi agent therapy. »TreatmentA.  Medical MeasuresMedial  treatment is aimed at preventing further attaks and strke. Treat diabetes mellitus, hematlgi disrders, and hypertensin, preferably with an angitensin-nverting enzyme inhibitr r angitensin reeptr blker. ACMDT22_Ch24_p0978-p1053.indd  994 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS995 CMDT 2022stati n shuld be started regardless f the urrent lw- density lipprtein level (LDL), althugh this pratie is nly supprted by randmized trial data in patients with an LDL greater than 100 mg/dL. Cigarette smking shuld be stpped, and ardia sures f emblizatin shuld be treated apprpriately. Weight redutin and regular physial ativity shuld be enuraged when apprpriate. An antiplatelet r antiagulant shuld be started as sn as imaging has established the absene f hemrrhage. 1. Hospitalization— Hspitalizatin shuld be nsid- ered fr patients seen within a week f the attak, when they are at inreased risk fr early reurrene. One m- mnly used methd t assess reurrene risk is the ABCD2score; pints are assigned fr eah f the fllw- ing riteria: age 60 years r lder (1 pint), bld pressure 140/90 mm Hg r higher (1 pint), linial symptms f fal weakness (2 pints) r speeh impairment withut weakness (1 pint), duratin f 60 minutes r lnger (2 pints) r 10–59 minutes (1 pint), r diabetes mellitus (1 pint). An ABCD2sre f 4 r mre pints has been suggested as a threshld fr hspital admissin. The ABCD2I(with an additinal 3 pints fr any abnrmal diffusin-weighted MRI finding r any infart [new r ld] n nnntrast CT) has been prpsed as a better preditr f subsequent strke risk. Admissin is als advisable fr patients with resend attaks, symptm- ati artid stensis, r a knwn ardia sure f embli r hyperagulable state; suh hspitalizatin failitates early interventin fr any reurrene and rapid institu- tin f sendary preventin measures. 2. Anticoagulation— The hief indiatin fr antiagula- tin after TIA is atrial fibrillatin. Patients with metal heart valves, left ventriular thrmbus, and the antiphs- phlipid antibdy syndrme shuld als reeive anti- agulatin therapy. Treatment is with warfarin (target INR 2.0–3.0); bridging warfarin with heparin is nt neessary, but sme experts advate treatment with aspirin until the INR bemes therapeuti. Fr lng-term antiagulatin in the setting f atrial fibrillatin, apixaban (2.5–5 mg rally twie daily), dabigatran (150 mg rally twie daily), edxa- ban (60 mg rally daily), and rivarxaban (20 mg rally daily) are ptins. Cmbinatin antiplatelet-antiagula- tin therapy is nly indiated in patients with mehanial heart valves r thse with a separate indiatin fr anti- platelet therapy suh as a ardia stent. In patients with ardimypathy and an ejetin fratin under 35% withut atrial fibrillatin, warfarin (target INR 2.0–3.0) redues ishemi strke risk mpared t aspirin but results in a rughly equivalent inrease in the risk f majr hemrrhage; treatment in this ppulatin shuld there- fre be individualized. 3. Antiplatelet therapy— All patients in whm antiag- ulatin is nt indiated shuld be treated with shrt-term dual antiplatelet therapy and lng-term mntherapy t redue the frequeny f TIAs and the inidene f strke. Treatment shuld be initiated within 12 hurs after the TIA r minr strke (defined by a Natinal Institutes fHealth Strke Sale f 3 r less) with an ral lading dse f lpidgrel (300–600 mg) fllwed by 75 mg/day rally plus aspirin (50–325 mg daily rally) fr 21 days, fllwed by mntherapy with aspirin (81 mg daily rally), aspirin mbined with extended-release dipyridamle (200 mg twie daily rally), r lpidgrel (75 mg daily rally). Cilstazl (100 mg twie daily) had similar effiay as aspirin at lng-term strke preventin in an Asian ppu- latin with less risk f hemrrhage. Cmbining lpid- grel with aspirin beynd 90 days inreases the risk f hemrrhagi mpliatins and is notremmended.B. Surgic al or Endovascular Measures1. Car otid revascularization— When arterigraphy reveals a surgially aessible high-grade stensis (70–99% in lumi- nal diameter) n the side apprpriate t artid ishemi attaks, perative treatment ( carotid endarterectomy ) r endovascular intervention redues the risk f ipsilateral artid strke, espeially when TIAs are f reent nset (less than 1 mnth) and when the periperative mrbidity and mrtality risk is estimated t be less than 6%. Endvasular therapy arries a slightly higher predural strke risk than endarteretmy in patients lder than 70 years and is gener- ally reserved fr yunger patients whse nek anatmy is unfavrable fr surgery. Patients with symptmati artid stensis f 50–69% derive mderate benefit frm interven- tin, but surgery is nt indiated fr mild stensis (less than 50%). 2. Closure of patent foramen ovale— Carefully seleted patients with patent framen vale (PFO) and right-t- left shunt benefit frm PFO lsure and antiplatelet therapy. Patients shuld be nsidered fr PFO lsure if they are between 18 and 60 years ld; have had a rypt- geni strke r TIA; and d nt have unntrlled diabe- tes, hypertensin, r a speifi indiatin fr lng-term antiagulatin. A ryptgeni strke des nt have an identified mehanism, suh as large artery atherslersis (greater than r equal t 30–50% stensis f the intrara- nial r ervial arteries r a plaque greater than r equal t 4mm thik in the arti arh), knwn ardiembli sure (eg, atrial fibrillatin), small vessel arterilsler- sis (eg, launar strke smaller than 1.5 m in diameter), hyperagulable state, r dissetin. Patients with mder- ate t large interatrial shunts r assiated atrial septal aneurysms appear t benefit mst frm PFO lsure. See als Chapter 10. »When to ReferAll  patients shuld be referred fr urgent investigatin andtreatment to prevent stroke. »When to AdmitIf s een within a week f a TIA, patients shuld be nsid- ered fr admissin when they have an ABCD2sre f 4 pints r mre, when utpatient evaluatin is impratial, r when there are multiple attaks, artid stensis f greater than 70%, r ther nern fr early reurrene r strke.CMDT22_Ch24_p0978-p1053.indd  995 29/06/21 8:50 PMChapTER 24996 CMDT 2022Pa n Y et al. Outmes assiated with lpidgrel-aspirin use in minr strke r transient ishemi attak: a pled analysis f Clpidgrel in High-Risk Patients With Aute Nn-Disabling Cerebrvasular Events (CHANCE) and Platelet-Oriented Inhibitin in New TIA and Minr Ishemi Strke (POINT) trials. JAMA Neurl. 2019;76:1466. [PMID: 31424481]ST ROKEE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of neurologic deficit of cerebrovas- cular origin. »Patient often has hypertension, diabetes mellitus, tobacco use, atrial fibrillation, or atherosclerosis. »Distinctive neurologic signs reflect the region of the brain involved. »General ConsiderationsIn  the United States, strke is the sixth leading ause f death and a leading ause f disability. Risk fatrs fr strke inlude hypertensin, diabetes mellitus, hyperlipid- emia, igarette smking, ardia disease, HIV infetin, trigeminal herpes zster, rereatinal drug abuse, heavy alhl nsumptin, and a family histry f strke. Strkes are subdivided pathlgially int infarcts and hemorrhages. The distintin may be diffiult linially; CT sanning is essential t larify the pathlgi basis (Table 24–3).1.  Lcunr InfrctionLa unar infarts are small lesins (usually less than 1.5 m in diameter) that ur in the distributin f shrt penetrating arteriles in the basal ganglia, pns, erebel- lum, internal apsule, thalamus, and, less mmnly, the deep erebral white matter (Table 24–3). Launar infarts are assiated with prly ntrlled hypertensin r diabetes and have been fund in several linial syn- drmes, inluding ntralateral pure mtr hemiparesis r pure hemisensry defiit, ipsilateral ataxia with hemi- paresis, and dysarthria with lumsiness f the hand. The neurlgi defiit may prgress ver 24–36 hurs befre stabilizing. Early mrtality and risk f strke reurrene is higher fr patients with nnlaunar than launar infarts. The prgnsis fr revery frm the defiit prdued by a lau- nar infart is usually gd, with partial r mplete reslu- tin urring ver the fllwing 4–6 weeks in many instanes. Treatment is as desribed fr TIA and erebral infartin.2.  Cerebrl InfrctionThrm bti r embli lusin f a majr vessel leads t erebral infartin. Causes are idential t the disrders predispsing t TIAs. The resulting defiit depends n the partiular vessel invlved and the extent f any llateralirulatin. Cerebral ishemia leads t release f exitatry and ther neurpeptides that may augment alium flux int neurns, thereby leading t ell death and inreasing the neurlgi defiit. »Clinical FindingsA.  Symptoms and SignsOnset  is usually abrupt, and there may then be very little prgressin exept that due t brain swelling. Clinial evaluatin shuld always inlude examinatin f the heart fr murmurs and rhythm irregularities. Ausultating ver the artid r sublavian vessels may reveal a bruit but is nt sensitive enugh t substitute fr vasular imaging. 1. Obstruction of carotid circulation— Olusin f the anterior cerebral artery distal t its juntin with the ante- rir mmuniating artery auses weakness and rtial sensry lss in the ntralateral leg and smetimes mild weakness f the arm, espeially prximally. There may be a ntralateral grasp reflex, paratni rigidity, abulia (lak f initiative), r frank nfusin. Urinary inntinene is nt unmmn, partiularly if behaviral disturbanes are nspiuus. Bilateral anterir erebral infartin is espe- ially likely t ause marked behaviral hanges and memry disturbanes. Unilateral anterir erebral artery lusin prximal t the juntin with the anterir m- muniating artery is generally well tlerated beause f the llateral supply frm the ther side. Middle cerebral artery lusin leads t ntralateral hemiplegia, hemisensry lss, and hmnymus hemian- pia (ie, bilaterally symmetri lss f visin in half f the visual fields), with the eyes deviated t the side f the lesin. If the dminant hemisphere is invlved, glbal aphasia is als present. It may be impssible t distinguish this linially frm lusin f the internal artid artery. With lusin f either f these arteries, there may als be nsiderable swelling f the hemisphere during the first 72 hurs. Fr example, an infart invlving ne erebral hemisphere may lead t suh swelling that the funtin f the ther hemisphere r the rstral brainstem is disturbed and ma results. Olusins f different branhes f the middle erebral artery ause mre limited findings. Fr example, invlvement f the superir divisin in the dmi- nant hemisphere leads t a predminantly expressive (Broca ) aphasia and t ntralateral paralysis and lss f sensatins in the arm, the fae and, t a lesser extent, the leg. Inferir branh lusin in the dminant hemisphere prdues a reeptive ( Wernicke ) aphasia and a hmny- mus visual field defet. With invlvement f the nn- dminant hemisphere, speeh and mprehensin are preserved, but there may be a left hemispatial neglet syn- drme r nstrutinal and visuspatial defiits. Olusin f the ophthalmic or central retinal artery leads t sudden painless visual lss with retinal pallr and a maular herry red spt n fundspi examinatin. Sudden, transient visin lss in ne eye ( amaurosis fugax ) is a TIA in this arterial territry. Patients with a cilioretinal artery (apprximately 25%) may have maular sparing due t llateral bld supply.CMDT22_Ch24_p0978-p1053.indd  996 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS997 CMDT 20222. Obstruction of  vertebrobasilar circulation— Olusin f the posterior cerebral artery may lead t a thalami syndrme in whih ntralateral hemisensry disturbane urs, fllwed by the develpment f spntaneus pain and hyperpathia. There is ften a maular-sparing hm- nymus hemianpia and smetimes a mild, usually tem- prary, hemiparesis. Depending n the site f the lesinand the llateral irulatin, the severity f these defiits varies and ther defiits may als ur, inluding invlun- tary mvements and alexia. Olusin f the main artery beynd the rigin f its penetrating branhes may lead slely t a maular-sparing hemianpia. Vertebral artery occlusion belw the rigin f the anterir spinal and psterir inferir erebellar arteriesTable 24–3. Features of the major stroke subtypes.Stro ke Tye nd Subtye Clinicl Fetures Dignosis Tretment Iscemic Stroke Lacunar infarct Small (< 1.5 cm) lesions in the basal ganglia, pons, cerebel- lum, or internal capsule; less often in deep cerebral white matter; prognosis generally good; clinical features depend on location, but may worsen over first 24–36 hours.MRI with diffusion-weighted sequences usually defines the area of infarction; CT is insensitive acutely but can be used to exclude hemorrhage.Antiplatelet; control risk factors (hypertension, tobacco use, hyper- cholesterolemia, and diabetes mellitus). Carotid circulation obstructionSee text—signs vary depending on occluded vessel.Noncontrast CT to exclude hemorrhage but findings may be normal during first 6–24 hours of an ischemic stroke; diffusion-weighted MRI is gold stan- dard for identifying acute stroke; elec- trocardiography, carotid duplex studies, echocardiography, blood glucose, com- plete blood count, and tests for hyper- lipidemia are indicated; ambulatory ECG monitoring, including extended monitoring in selected instances; CTA, MRA, or conventional angiography in selected cases; tests for hypercoagula- ble states in selected cases.0–3 hours in United States: intrave- nous thrombolytics (approved in Europe for up to 4.5 hours). 0–6 hours: endovascular mechanical embolectomy. 6–24 hours: endovascular mechanical embolectomy in select cases. Secondary prevention: antiplatelet agent is first-line therapy; anticoag- ulation without heparin bridge for cardioembolic strokes due to atrial fibrillation and other select cases when no contraindications exist; control risk factors as above. Vertebrobasilar occlusionSee text—signs vary based on location of occluded vessel.As for carotid circulation obstruction. As for carotid circulation obstruction. hemorrgic Stroke Spontaneous intracerebral hemorrhageCommonly associated with hypertension; also with bleed- ing disorders, amyloid angiopathy. Hypertensive hemorrhage is located commonly in the basal ganglia, pons, thalamus, cere- bellum, and less commonly the cerebral white matter.Noncontrast CT is superior to MRI for detecting bleeds of < 48 hours dura- tion; laboratory tests to identify bleeding disorder: angiography may be indicated to exclude aneurysm or AVM in younger patients without hypertension. Do notperform lumbar puncture.Lower systolic blood pressure to 140 mm Hg; cerebellar bleeds or hematomas with gross mass effect may require urgent surgical evacuation. AVM: surgical resection indicated to prevent further bleeding; other modalities to treat nonoperable AVMs available at specialized centers. Subarachnoid hemorrhagePresent with sudden onset of worst headache of life, may lead rapidly to loss of con- sciousness; signs of meningeal irritation often present; etiol- ogy usually aneurysm or AVM, but 20% have no source identified.CT to confirm diagnosis, but may be normal in rare instances; if CT negative and suspicion high, perform lumbar puncture to look for red blood cells or xanthochromia; angiography to determine source of bleed in candidates for treatment.Lower systolic blood pressure to < 140 mm Hg immediately. Aneurysm: prevent further bleeding by clipping aneurysm or coil embo- lization; nimodipine helps prevent vasospasm; once aneurysm has been obliterated intravenous fluids and induced hypertension to pre- vent vasospasm; angioplasty may also reverse symptomatic vasospasm. AVM: as above. AVMs, arteriovenous malformations; CTA, computed tomography angiography; MRA, magnetic resonance angiography.CMDT22_Ch24_p0978-p1053.indd  997 29/06/21 8:50 PMChapTER 24998 CMDT 2022may  be linially silent beause the irulatin is main- tained by the ther vertebral artery. If the remaining verte- bral artery is ngenitally small r severely atherslerti, hwever, a defiit similar t that f basilar artery lusin is seen unless there is gd llateral irulatin frm the anterir irulatin thrugh the irle f Willis. An bstrutin f the posterior inferior cerebellar artery r an bstrutin f the vertebral artery just befre it branhes t this vessel leads t the lateral medullary syndrome, haraterized by vertig and nystagmus (vestibular nuleus), ipsilateral spinthalami sensry lss invlving the fae (trigeminal nuleus and trat), dysphagia (nuleus ambiguus), limb ataxia (inferir erebellar pedunle), and Hrner syndrme (desending sympatheti fibers), m- bined with ntralateral spinthalami sensry lss invlv- ing the limbs. Olusin f both vertebral arteries r the basilar artery leads t ma with pinpint pupils, flaid quadri- plegia and sensry lss, and variable ranial nerve abnr- malities. With partial basilar artery lusin, there may be diplpia, visual lss, vertig, dysarthria, ataxia, weakness r sensry disturbanes in sme r all f the limbs, and disrete ranial nerve palsies. In patients with hemiplegia f pntine rigin, the eyes are ften deviated t the para- lyzed side, whereas in patients with a hemispheri lesin, the eyes mmnly deviate frm the hemiplegi side. When the small paramedian arteries arising frm the basi- lar artery are luded, ntralateral hemiplegia and sen- sry defiit ur in assiatin with an ipsilateral ranial nerve palsy at the level f the lesin. Olusin f any f the majr cerebellar arteries pr- dues vertig, nausea, vmiting, nystagmus, and ipsilateral limb ataxia. Cntralateral spinthalami sensry lss in the limbs may als be present. Deafness due t hlear infar- tin may fllw lusin f the anterir inferir erebellar artery, whih may als ause ipsilateral faial spintha- lami sensry lss and weakness. Massive erebellar infar- tin may lead t bstrutive hydrephalus, ma, tnsillar herniatin, and death.B.  ImagingA  CT san f the head (withut ntrast) shuld be per- frmed immediately , befre the administratin f aspirin r ther antithrmbti agents, t exlude erebral hemr- rhage (Table 24–3). CT is relatively insensitive t aute ishemi strke within the first 6–12 hurs, and subse- quent MRI with diffusin-weighted sequenes helps define the distributin and extent f infartin as well as exlude tumr r ther differential nsideratins. CT angigraphy f the head and nek shuld be perfrmed t identify large vessel lusins amenable t endvasular therapy in patients presenting within 6 hurs f strke nset and shuld be nsidered in thse presenting between 6 and 24 hurs, tgether with CT perfusin studies. Regardless f timing f presentatin, imaging f the ervial vasulature is indiated as part f a searh t identify the sure f the strke. In patients with a PFO and therwise ryptgeni strke, the intraranial vasulature must be imaged t rule ut large vessel atherslersis befre PFO lsure an be nsidered.C. Laboratory and Other StudiesIn vestigatins shuld inlude a mplete bld unt, bld gluse determinatin, and fasting lipid panel. Ser- lgi tests fr syphilis and HIV infetin may be inluded depending n the irumstanes. Sreening fr antiphs- phlipid antibdies (lupus antiagulants, antiardilipin, and anti-beta2-glyprtein antibdies); the fatr V Leiden mutatin; abnrmalities f prtein C, prtein S, r antithrmbin; r a prthrmbin gene mutatin is indiated nly if a hyperagulable disrder is suspeted (eg, a yung patient withut apparent risk fatrs fr strke) r needs t be ruled ut if PFO lsure is under nsideratin. While elevated serum hmysteine is a risk fatr fr strke, lwering hmysteine levels with vitamin supplementa- tin has nt been shwn t derease strke risk, and there- fre, rutinely heking hmysteine is notremmended. Eletrardigraphy r ntinuus ardia mnitring fr at least 24 hurs will help exlude a reent myardial infartin r a ardia arrhythmia that might be a sure f emblizatin. While atrial fibrillatin will be disvered in apprximately 10% f patients with ishemi strke during their hspitalizatin, it is estimated that an arrhythmia will be fund in an additinal 10% with prlnged ambulatry ECG mnitring after disharge; this testing is indiated in ases where atrial fibrillatin is suspeted (eg, nnlaunar strke and left atrial enlargement n ehardigraphy r lak f intraranial r artid atherslersis) but has nt been demnstrated. Ehardigraphy (with agitated saline ntrast) shuld be perfrmed in ases f nnlau- nar strke t exlude valvular disease, right-t-left shunt- ing, and ardia thrmbus. Bld ultures shuld be perfrmed if endarditis is suspeted but are nt required rutinely. Examinatin f the erebrspinal fluid is nt always neessary but may be helpful if erebral vasulitis r anther inflammatry r infetius ause f strke is sus- peted, but it shuld be delayed until after CT r MRI t exlude any risk fr herniatin due t mass effet. »TreatmentMana gement is divided int aute and hrni phases: the first is aimed at minimizing disability and the send at preventing reurrent strke. A mbinatin f thrmbly- sis and endvasular therapies is available t patients wh present within 24 hurs f strke nset, determined by when the patient was last nrmal. Intravenous thrombolytic therapy with rembinant tissue plasmingen ativatr (rtPA; 0.9 mg/kg t a maxi- mum f 90 mg, with 10% given as a blus ver 1 minute and the remainder ver 1 hur) imprves the hane f revery withut signifiant disability at 90 days frm 26% t 39% if given within 3 hurs frm strke nset; it is still effetive up t 4.5 hurs frm strke nset. Treatment shuld be initiated as sn as pssible; utme is diretly related t the time frm strke nset t treatment. Intrave- nus thrmblysis is apprved in Eurpe fr use up t 4.5 hurs frm strke nset but nly fr up t 3 hurs in the United States, althugh ff-label use during the 3- t 4.5-hur windw is standard. In patients with systli pressure greater than 185 mm Hg r diastli pressure greater thanCMDT22_Ch24_p0978-p1053.indd  998 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS999 CMDT 2022110  mm Hg, the bld pressure shuld be lwered t less than 185/110 mm Hg with intravenus labetall r niar- dipine t enable rtPA administratin. Due t the risk f hemrrhage, rtPA shuld nt be used beynd 4.5 hurs, r in ther situatins where it is medially ntraindiated, althugh sme evidene suggests patients with ishemi but nt infarted tissue identified by autmated perfusin imaging r MRI may be treated up t 9 hurs after nset r upn awakening with strke symptms. Several randmized trials have demnstrated an inreased likelihd f ahieving funtinal independene after endovascular mechanical embolectomy by stent retrievers as an adjunt t intravenus rtPA. Patients with large vessel lusin (abut 20% f patients with aute ishemi strke) in whm treatment an be initiated within 6 hurs f strke nset are eligible fr embletmy, as are patients wh present between 6 hurs and 24 hurs and als have a large ishemi penumbra identified by perfu- sin CT, perfusin MRI, r diffusin-weighted MRI. Early management f a mpleted strke therwise requires general supprtive measures. Management in a stroke care unit has been shwn t imprve utmes, likely due t early rehabilitatin and preventin f medial mpliatins. During the aute stage, there may be marked brain swelling and edema, with symptms and signs f inreasing intraranial pressure, an inreasing neurlgi defiit, r herniatin syndrme. Elevated intraranial pres- sure is managed by head elevatin and smti agents suh as mannitl. Maintenane f an adequate erebral perfusin pressure helps prevent further ishemia. Early dempres- sive hemiranietmy (within 48 hurs f strke nset) fr malignant middle erebral artery infartins redues mr- tality and imprves funtinal utme. Attempts t lwer the bld pressure f hypertensive patients during the aute phase (ie, within 72 hurs) f a strke shuld generally be avoided unless the purpse is t enable the safe administra- tin f rtPA, as there is lss f erebral autregulatin, and lwering the bld pressure may further mprmise ishemi areas. Hwever, if the systli pressure exeeds 220 mm Hg, it an be lwered using intravenus labetall r niardipine with ntinuus mnitring t 170–200 mm Hg, and then after 72 hurs, it an be redued further t less than 140/90 mm Hg. Bld pressure augmentatin is usu- ally nt neessary in patients with relative hyptensin but maintenane f intravenus hydratin is imprtant. Prphylati and medial measures are disussed in the setin n TIAs and shuld guide management. One hemrrhage has been exluded by CT, aspirin (325 mg rally daily) is started immediately unless the patient reeived thrmblysis, in whih ase aspirin is initiated after a fllw-up CT has ruled ut thrmblyti-assiated hemrrhage at 24 hurs. Dual antiplatelet therapy shuld be used fr 21 days in patients with minr strke (Natinal Institutes f Health Strke Sale f 3 r less). Anticoagulant mediatins are started when indiated, as disussed in the setin n TIAs. There is generally noadvantage in delay, and the mmn fear f ausing hemrrhage int a previ- usly infarted area is misplaed, sine there is a far greater risk f further emblism t the erebral irulatin if treat- ment is withheld.Physical therapy has an imprtant rle in the manage- ment f patients with impaired mtr funtin. Passive mvements at an early stage will help prevent ntratures. As peratin inreases and sme revery begins, ative mvements will imprve strength and rdinatin. In all ases, early mbilizatin and ative rehabilitatin are impr- tant. Occupational therapy may imprve mrale and mtr skills, while speech therapy may help expressive aphasia r dysarthria. Beause f the risk fr dysphagia fllwing strke, aess t fd and drink is typially restrited until an appr- priate swallwing evaluatin; the head f the bed shuld be kept elevated t prevent aspiratin. Urinary atheters shuld notbe plaed and, if plaed, remved within 24–48 hurs. »PrognosisThe  prgnsis fr survival after erebral infartin is better than after erebral r subarahnid hemrrhage. Patients reeiving treatment with rtPA are at least 30% mre likely t have minimal r n disability at 3 mnths than thse nt treated by this means. Thse treated with mehanial embletmy are als at least 30% mre likely t ahieve funtinal independene. Lss f nsiusness after a erebral infart implies a prer prgnsis than therwise. The extent f the infart gverns the ptential fr rehabili- tatin. Patients wh have had a erebral infart are at risk fr additinal strkes and fr myardial infarts. The prphylati measures disussed earlier redue this risk. Antiplatelet therapy redues the reurrene rate by 30% amng patients withut a ardia ause fr the strke wh are nt andidates fr artid endarteretmy. Neverthe- less, the umulative risk f reurrene f nnardiembli strke is still 3–7% annually. Management is fused n palliative are when meaningful revery frm massive strkes is unlikely (see Chapter 5). »When to ReferAll patients sh uld be referred. »When to AdmitAll  patients shuld be hspitalized, preferably in a strke are unit.Albers  GW et al; DEFUSE 3 Investigatrs. Thrmbetmy fr strke at 6 t 16 hurs with seletin by perfusin imaging. N Engl J Med. 2018;378:708. [PMID: 29364767] Ngueira RG et al; DAWN Trial Investigatrs. Thrmbetmy 6 t 24 hurs after strke with a mismath between defiit and infart. N Engl J Med. 2018;378:11. [PMID: 29129157] Pwers WJ et al. Guidelines fr the early management f patients with aute ishemi strke: 2019 update t the 2018 guide- lines fr the early management f aute ishemi strke: a guideline fr healthare prfessinals frm the Amerian Heart Assiatin/Amerian Strke Assiatin. Strke. 2019;50:e344. [PMID: 31662037]3.  Intrcerebrl hemorrgeSpn taneus, nntraumati intraerebral hemrrhage in patients with n angigraphi evidene f an assiated vasular anmaly (eg, aneurysm r angima) is usually dueCMDT22_Ch24_p0978-p1053.indd  999 29/06/21 8:50 PMChapTER 241000 CMDT 2022t  hypertensin. The pathlgi basis fr hemrrhage is prbably the presene f miraneurysms that develp n perfrating vessels in hypertensive patients. Hypertensive intraerebral hemrrhage urs mst frequently in the basal ganglia, pns, thalamus, and erebellum, and less mmnly in the erebral white matter. Hemrrhage may extend int the ventriular system r subarahnid spae, and signs f meningeal irritatin are then fund. In lder adults, erebral amylid angipathy is anther imprtant and frequent ause f hemrrhage, whih is usually lbar in distributin, smetimes reurrent, and assiated with a better immediate prgnsis than hypertensive hemr- rhage. Arterivenus malfrmatins are an imprtant ause f intraerebral hemrrhage in yunger patients. Other auses f nntraumati intraerebral hemr- rhage inlude hematlgi and bleeding disrders (eg, leukemia, thrmbytpenia, hemphilia, r disseminated intravasular agulatin), antiagulant therapy, liver disease, high alhl intake, aine and methamphet- amine abuse, herpes simplex enephalitis, vasulitis, my- amya disease, reversible erebral vasnstritin syndrme, and primary r sendary brain tumrs. There is als an assiatin with advaning age and male sex. Bleeding is primarily int the subarahnid spae when it urs frm an intraranial aneurysm, but it may be partly intraparenhymal as well. Hemrrhage an als ur int arterial and venus erebral infarts. »Clinical FindingsA.  Symptoms and SignsW ith hemrrhage int the erebral hemisphere, nsius- ness is initially lst r impaired in abut ne-half f patients. Vmiting urs very frequently at the nset f bleeding, and headahe is smetimes present. Fal symp- tms and signs then develp, depending n the site f the hemrrhage. With hypertensive hemrrhage, there is gen- erally a rapidly evlving neurlgi defiit with hemiplegia r hemiparesis. A hemisensry disturbane is als present with mre deeply plaed lesins. With lesins f the puta- men, lss f njugate lateral gaze may be nspiuus. With thalami hemrrhage, there may be a lss f upward gaze, dwnward r skew deviatin f the eyes, lateral gaze palsies, and pupillary inequalities. Cerebellar hemrrhage may present with sudden nset f nausea and vmiting, dysequilibrium, ataxia f gait, limbs, r trunk; headahe; and lss f nsiusness that may terminate fatally within 48 hurs. Pntine hemrrhage auses sme mbinatin f lateral njugate gaze palsies t the side f the lesin; small reative pupils; ntralateral hemiplegia; peripheral faial weakness; and peridi respi- ratin. These signs may be bilateral with larger pntine hemrrhage, and the patient may beme lked in, with quadriplegia and preserved nsiusness.B.  ImagingCT  sanning (withut ntrast) is imprtant nt nly in nfirming that hemrrhage has urred but als in determining the size and site f the hematma. MRI isequally sensitive when magneti suseptibility weighted sequenes (eg, gradient eh) are used. If the patient’s n- ditin permits further interventin, CT angigraphy, MR angigraphy, r erebral angigraphy may be undertaken t determine whether an aneurysm r arterivenus mal- frmatin is present. In patients under age 55 with lbar hemrrhage and n histry f hypertensin, a ntrast- enhaned MRI may indiate a nnhypertensive ause, suh as an underlying neplasm.C.  Laboratory and Other StudiesA  mplete bld unt, platelet unt, prthrmbin and partial thrmbplastin times, liver bihemial tests, and kidney funtin tests may reveal a predispsing ause fr the hemrrhage. Lumbar puncture is contraindicated beause it may preipitate a herniatin syndrme in patients with a large hematma, and CT sanning is supe- rir in deteting intraerebral hemrrhage. »TreatmentPa tients shuld be admitted t an intensive are unit fr bservatin and supprtive are. The systli bld pres- sure shuld be lwered t 140 mm Hg with intravenus labetall r niardipine, althugh randmized trials target- ing systli bld pressures f less than 140 mm Hg and less than 180 mm Hg have nt shwn a differene in ut- mes. Thrmbytpenia shuld be treated with platelet transfusin; the speifi threshld fr treatment and the gal platelet unt after transfusin vary with patient har- ateristis and prvider experiene. Cagulpathies shuld be reversed using fresh frzen plasma, prthrmbin m- plex nentrates, vitamin K, r speifi reversal agents (eg, prtamine fr heparin; idaruizumab fr dabigatran; and andexanet alfa fr apixaban, betrixaban, edxaban, and rivarxaban). Hemstati therapy with rembinant ativated fatr VII in patients withut underlying agu- lpathy has nt imprved survival r funtinal utme. Intraranial pressure may require mnitring and smti therapy. Ventriular drainage may be required in patients with intraventriular hemrrhage and aute hydrephalus. Dempressin may be helpful when a superfiial hema- tma in erebral white matter is exerting a mass effet and ausing inipient herniatin. In patients with erebellar hemrrhage wh are deterirating neurlgially r wh have brainstem mpressin r hydrephalus, prmpt surgial evauatin f the hematma is apprpriate beause spntaneus unpreditable deteriratin may therwise lead t a fatal utme and beause perative treatment may lead t mplete reslutin f the linial defiit. The treatment f underlying strutural lesins r bleeding dis- rders depends n their nature. There is n speifi treatment fr erebral amylid angipathy. »When to ReferAll patients sh uld be referred. »When to AdmitAll patients sh uld be hspitalized.CMDT22_Ch24_p0978-p1053.indd  1000 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1001 CMDT 2022Hst ettler IC et al. Intraerebral hemrrhage: an update n diag- nsis and treatment. Expert Rev Neurther. 2019;19:679. [PMID: 31188036]4.  Sontneous Subrcnoid hemorrgeE S S E N T I A L S  O F  D I A G N O S I S »Sudden (“thunderclap”) severe headache. »Signs of meningeal irritation usually present. »Obtundation is common. »Focal deficits frequently absent. »General ConsiderationsBetween  5% and 10% f strkes are due t subarahnid hemrrhage. Trauma is the mst mmn ause f sub- arahnid hemrrhage, the prgnsis f whih depends n the severity f the head injury. Spntaneus (nntrau- mati) subarahnid hemrrhage frequently results frm the rupture f an arterial saccular (“berry”) aneurysm r frm an arteriovenous malformation. »Clinical FindingsA.  Symptoms and SignsSubarahn id hemrrhage has a harateristi linial pi- ture. Its nset is with sudden (“ thunderclap ”) headahe f a severity never experiened previusly by the patient. This may be fllwed by nausea and vmiting and by a lss r impairment f nsiusness that an either be transient r prgress inexrably t deepening ma and death. If n- siusness is regained, the patient is ften nfused and irritable and may shw ther symptms f an altered men- tal status. Neurlgi examinatin generally reveals nuhal rigidity and ther signs f meningeal irritatin, exept in deeply matse patients. Mst aneurysms are asymptmati until they rupture, but they may ause a fal neurlgi defiit by mpress- ing adjaent strutures. Oasinal patients with aneurysms have headahes, smetimes ampanied by nausea and nek stiffness, a few hurs r days befre massive subarah- nid hemrrhage urs. This has been attributed t “warn- ing leaks” f a small amunt f bld frm the aneurysm. A higher risk f subarahnid hemrrhage is assiated with lder age, female sex, nn-White ethniity, hyperten- sin, tba smking, high alhl nsumptin (exeed- ing 150 g per week), previus symptms, psterir irulatin aneurysms, and larger aneurysms. Fal neur- lgi signs are usually absent but, when present, may relate either t a fal intraerebral hematma (frm arterive- nus malfrmatins) r t ishemia in the territry f the vessel with a ruptured aneurysm.B.  ImagingA  CT san (preferably with CT angigraphy) shuld be perfrmed immediately t nfirm that hemrrhage hasurred and t searh fr lues regarding its sure. It is preferable t MRI beause it is faster and mre sensitive in deteting hemrrhage in the first 24 hurs. CT findings smetimes are nrmal in patients with suspeted hemr- rhage, and the erebrspinal fluid must then be examined fr the presene f bld r xanthhrmia befre the ps- sibility f subarahnid hemrrhage is disunted. Cerebral arterigraphy is undertaken t determine the sure f bleeding. In general, bilateral artid and verte- bral arterigraphy are neessary beause aneurysms are ften multiple, while arterivenus malfrmatins may be supplied frm several sures. The predure allws an interventinal radilgist t treat an underlying aneurysm r arterivenus malfrmatin by varius tehniques. If arterigrams shw n abnrmality, the examinatin shuld be repeated after 2 weeks beause vasspasm r thrmbus may have prevented detetin f an aneurysm r ther vasular anmaly during the initial study. CT r MR angi- graphy may als be revealing but is less sensitive than nventinal arterigraphy.C.  Laboratory and Other StudiesThe  erebrspinal fluid demnstrates an elevated red bld ell unt. Subarahnid hemrrhage an be differentiated frm a traumati lumbar punture by the lak f learing f red bld ells frm the first and furth tube f erebrspi- nal fluid r by the presene f xanthhrmia, whih urs due t lysis f red bld ells and takes at least 2 hurs t develp. The abslute red bld ell unt is als helpful: in the absene f xanthhrmia, a red bld ell unt f less than 2000 × 106/L is very unlikely t be due t subarahnid hemrrhage. Eletrardigraphi evidene f arrhythmias r myardial ishemia has been well desribed and prbably relates t exessive sympatheti ativity. Peripheral leukytsis and transient glysuria are als mmn findings. »TreatmentAll p atients shuld be hspitalized and seen by a neurl- gist. The measures utlined belw in the setin n stupr and ma are applied t matse patients. Cnsius patients are nfined t bed, advised against any exertin r straining, treated symptmatially fr headahe and anxiety, and given laxatives r stl sfteners. The systli bld pressure shuld be lwered t 140 mm Hg until the aneurysm is treated definitively. Seizure prphylaxis is nt neessary unless a nvulsin has urred (see Table 24–2). Patients are generally hspitalized fr at least 14 days t mnitr, prevent, and treat vasspasm. The majr aim f treatment is t prevent further hem- rrhage. The risk f further hemrrhage frm a ruptured aneurysm is greatest within a few days f the first hemr- rhage; apprximately 20% f patients will have further bleeding within 2 weeks and 40% within 6 mnths. Defini- tive treatment, ideally within 2 days f the hemrrhage, requires surgial lipping f the aneurysm r endvasular treatment by il emblizatin; the latter is smetimes feasible even fr inperable aneurysms and has a lwer mrbidity than surgery.CMDT22_Ch24_p0978-p1053.indd  1001 29/06/21 8:50 PMChapTER 241002 CMDT 2022 »ComplicationsSpntaneu s subarahnid hemrrhage may result in severe mpliatins, s mnitring is neessary, usually in an intensive are unit. Hemiplegia r ther fal defiit smetimes may fllw aneurysmal bleeding after a delay f 2–14 days due t fal arterial spasm. The etilgy f vaso- spasm is unertain and likely multifatrial, and it sme- times leads t signifiant erebral ishemia r infartin and may further aggravate any existing inrease in intra- ranial pressure. Transranial Dppler ultrasund may be used t sreen nninvasively fr vasspasm, but nven- tinal arterigraphy is required t dument and treat vasspasm when the linial suspiin is high. Nimdipine has been shwn t redue the inidene f ishemi defiits frm arterial spasm; a dse f 60 mg every 4 hurs rally fr 21 days is given prphylatially t all patients. After surgial bliteratin f all aneurysms, symptmati vas- spasm may als be treated by intravasular vlume expan- sin and indued hypertensin; transluminal balln angiplasty f invlved intraranial vessels is als helpful. Acute hydrocephalus, whih smetimes urs due t erebrspinal fluid utflw disruptin by the subarahnid bld, shuld be suspeted if the patient deterirates lini- ally; a repeat CT san shuld be btained. Aute hydr- ephalus frequently auses intraranial hypertensin severe enugh t require temprary, and less mmnly pr- lnged r permanent, intraventriular erebrspinal fluid shunting. Cerebral salt-wasting is anther mpliatin f subarahnid hemrrhage that may develp abruptly dur- ing the first several days f hspitalizatin. The resulting hypnatremia and erebral edema may exaerbate intra- ranial hypertensin and may require arefully titrated treatment with ral sdium hlride r intravenus hyper- smti sdium slutin. Daily measurement f the serum sdium level allws fr the early detetin f this mplia- tin. Hypopituitarism may ur as a late mpliatin f subarahnid hemrrhage.Etmina n N et al. Neurvasular disease, diagnsis, and therapy: subarahnid hemrrhage and erebral vasspasm. Handb Clin Neurl. 2021;176:135. [PMID: 33272393] Lindgren A et al. Endvasular iling versus neursurgial lip- ping fr peple with aneurysmal subarahnid hemrrhage. Chrane Database Syst Rev. 2018;8:CD003085. [PMID: 30110521]5.  Intrcrnil aneurysmE S S E N T I A L S  O F  D I A G N O S I S »Subarachnoid hemorrhage or focal deficit. »Abnormal imaging studies. »General ConsiderationsSaular  aneurysms (“berry” aneurysms) tend t ur at arterial bifuratins, are frequently multiple (20% f ases), and are usually asymptmati. They are assiated withplyysti kidney disease, myamya disease, familial aldsternism type 1, and artatin f the arta. Risk fatrs fr aneurysm frmatin inlude igarette smking, hypertensin, and female sex. Mst aneurysms are lated n the anterir part f the irle f Willis—partiularly n the anterir r psterir mmuniating arteries, at the bifuratin f the middle erebral artery, and at the bifur- atin f the internal artid artery. Myti aneurysms resulting frm septi emblism ur in mre distal vessels and ften at the rtial surfae. The mst signifiant m- pliatin f intraranial aneurysms is a subarahnid hem- rrhage, whih is disussed in the preeding setin. »Clinical FindingsA.  Symptoms and SignsAneurysms  may ause a fal neurlgi defiit by m- pressing adjaent strutures. Hwever, mst are asymp- tmati r prdue nly nnspeifi symptms until they rupture, at whih time subarahnid hemrrhage results. Its manifestatins, mpliatins, and management were utlined in the preeding setin.B.  ImagingDefinitive evaluatin is  by digital subtratin angigraphy (bilateral artid and vertebral studies), whih generally indiates the size and site f the lesin, smetimes reveals multiple aneurysms, and may shw arterial spasm if rup- ture has urred. Visualizatin by CT r MR angigraphy is nt usually adequate if perative treatment is under nsideratin beause lesins may be multiple and small lesins are smetimes missed, but these mdalities an be used t sreen patients wh have tw r mre first-degree relatives with intraranial aneurysms. »TreatmentThe m ajr aim f treatment is t prevent hemorrhage. Man- agement f ruptured aneurysms was desribed in the setin n subarahnid hemrrhage. Symptmati but unruptured aneurysms merit prmpt treatment, either surgially r by endvasular tehniques. The deisin t treat r mnitr asymptmati aneurysms disvered inidentally is mpli- ated and depends n aneurysm size, latin, risk fatrs fr rupture, and treatment-related mrbidity; risk sres t guide deisin-making are available. »When to ReferAll patients sh uld be referred. »When to Admit• All patients with a subarahnid hemrrhage. •All patients fr detailed imaging. •All patients underging surgial r endvasular treatment.Hak enberg KAM et al. Neurvasular disease, diagnsis, and therapy: brain aneurysms. Handb Clin Neurl. 2021;176:121. [PMID: 33272392]CMDT22_Ch24_p0978-p1053.indd  1002 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1003 CMDT 20226.  arteriovenous MlformtionsE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of subarachnoid and intracerebral hemorrhage. »Distinctive neurologic signs reflect the region of the brain involved. »Signs of meningeal irritation in patients present- ing with subarachnoid hemorrhage. »Seizures or focal deficits may occur. »General ConsiderationsArteriven us malfrmatins are ngenital vasular mal- frmatins that result frm a lalized maldevelpment f part f the primitive vasular plexus and nsist f abnr- mal arterivenus mmuniatins withut intervening apillaries. They vary in size, ranging frm massive lesins that are fed by multiple vessels and invlve a large part f the brain t lesins s small that they are hard t identify at arterigraphy, surgery, r autpsy. In apprximately 10% f ases, there is an assiated arterial aneurysm, while 1–2% f patients presenting with aneurysms have assi- ated arterivenus malfrmatins. Clinial presentatin may relate t hemrrhage frm the malfrmatin r an assiated aneurysm r may relate t erebral ishemia due t diversin f bld by the anmalus arterivenus shunt r due t venus stagnatin. Reginal maldevelp- ment f the brain, mpressin r distrtin f adjaent erebral tissue by enlarged anmalus vessels, and prgres- sive glisis due t mehanial and ishemi fatrs may als be ntributry. »Clinical FindingsMs t erebral arterivenus malfrmatins are supratent- rial, usually lying in the territry f the middle erebral artery. Up t 70% bleed at sme pint in their natural his- try, mst mmnly befre the patient reahes the age f 40 years. Arterivenus malfrmatins that have bled ne are mre likely t bleed again, at an apprximate rate f 4.5% annually. A higher risk f bleeding is als bserved if there is an assiated aneurysm, deep venus drainage, r deep brain latin; size f the malfrmatin and sex are nt assiated with risk f hemrrhage.A.  Symptoms and SignsInitial  symptms nsist f hemrrhage in 30–60% f ases, reurrent seizures in 20–40%, headahe in 5–25%, and misellaneus mplaints (inluding fal defiits) in 10–15%. Hemrrhage is mmnly intraerebral as well as int the subarahnid spae and is fatal in abut 10% f ases. Seizures are mre likely with frntal r parietal arte- rivenus malfrmatins. Headahes are espeially likely when the external artid arteries are invlved in the mal- frmatin. These smetimes simulate migraine, but mremmnly are nnspeifi in harater, with nthing abut them t suggest an underlying strutural lesin. Brainstem and erebellar arterivenus malfrmatins may ause bstrutive hydrephalus. In patients presenting with subarahnid hemrrhage, examinatin may reveal an abnrmal mental status and signs f meningeal irritatin. Additinal findings may help lalize the lesin and smetimes indiate that intraranial pressure is inreased. A ranial bruit always suggests the pssibility f a erebral arterivenus malfrmatin, but bruits may als be fund with aneurysms, meningimas, aquired arterivenus fistulas, and arterivenus malfr- matins invlving the salp, alvarium, r rbit. Bruits are best heard ver the ipsilateral eye r mastid regin and are f sme help in lateralizatin but f n help in lalizatin. Absene f a bruit does not exclude the pssibility f arte- rivenus malfrmatin.B.  ImagingIn patien ts with suspeted hemrrhage, CT sanning indi- ates whether subarahnid r intraerebral bleeding has reently urred, helps lalize its sure, and may reveal the arterivenus malfrmatin. When intraranial hem- rrhage is nfirmed but the sure f hemrrhage is nt evident n the CT san, arterigraphy is neessary t exlude aneurysm r arterivenus malfrmatin. MR and CT angigraphy are nt sensitive enugh fr this purpse. Even if the findings n CT san suggest arterivenus mal- frmatin, arterigraphy is required t establish the nature f the lesin with ertainty and t determine its anatmi features s that treatment an be planned. The examinatin must generally inlude bilateral paifiatin f the inter- nal and external artid arteries and the vertebral arteries. In patients presenting withut hemrrhage, CT san r MRI usually reveals the underlying abnrmality, and MRI frequently als shws evidene f ld r reent hemr- rhage that may have been asymptmati. The nature and detailed anatmy f any fal lesin identified by these means are delineated by angigraphy, espeially if pera- tive treatment is under nsideratin. »TreatmentSurgial  treatment t prevent further hemrrhage is justi- fied in patients with arterivenus malfrmatins that have bled, prvided that the lesin is aessible and the patient has a reasnable life expetany. Surgial treatment is als apprpriate if intraranial pressure is inreased and t prevent further prgressin f a fal neurlgi defiit. In patients presenting slely with seizures, antinvulsant treatment is usually suffiient (Table 24–2), and perative treatment is unneessary unless seizures annt be n- trlled medially. Definitive perative treatment nsists f exisin f the arterivenus malfrmatin if it is surgially aessible. Steretati radisurgery is used t treat inperable ere- bral arterivenus malfrmatins. Arterivenus malfr- matins that are inperable beause f their latin are smetimes treated slely by emblizatin; althugh the risk f hemrrhage is nt redued, neurlgi defiits mayCMDT22_Ch24_p0978-p1053.indd  1003 29/06/21 8:50 PMChapTER 241004 CMDT 2022be  stabilized r even reversed by this predure. Embliza- tin is mre mmnly perfrmed as an adjunt t surgery r radisurgery; it is als used t treat aneurysms assi- ated with the arterivenus malfrmatins. »When to ReferAll patients sh uld be referred. »When to Admit• All patients with a subarahnid r erebral hemrrhage. •All patients fr detailed imaging. •All patients underging surgial r endvasular treatment.Ru tledge C et al. Brain arterivenus malfrmatins. Handb Clin Neurl. 2021;176:171. [PMID: 33272394]7.  Intrcrnil Venous TrombosisIn traranial venus thrmbsis may ur in assiatin with intraranial r maxillfaial infetins, hyperagu- lable states, plyythemia, sikle ell disease, yanti ngenital heart disease, and in pregnany r during the puerperium. Geneti fatrs are als imprtant. The disr- der is haraterized by headahe, fal r generalized n- vulsins, drwsiness, nfusin, inreased intraranial pressure, and fal neurlgi defiits—and smetimes by evidene f meningeal irritatin. The diagnsis is n- firmed by CT r MR vengraphy r angigraphy. Treatment inludes antinvulsants if seizures have urred (Table 24–2) and—if neessary—measures t redue intraranial pressure. Antiagulatin with dse- adjusted intravenus heparin r weight-adjusted subuta- neus lw-mleular-weight heparin, fllwed by ral warfarin antiagulatin fr 6 mnths redues mrbidity and mrtality f venus sinus thrmbsis. Dabigatran shwed similar effiay t warfarin in ne randmized trial and may be an aeptable alternative. Cnmitant intra- ranial hemrrhage related t the venus thrmbsis des nt ntraindiate heparin therapy. In ases refratry t heparin, endvasular tehniques inluding atheter- direted thrmblyti therapy (urkinase) and thrmbe- tmy are smetimes helpful but may inrease the risk fr majr hemrrhage. »When to ReferAll patients sh uld be referred. »When to AdmitAll patients sh uld be hspitalized.Ferr  JM et al; RE-SPECT CVT Study Grup. Safety and effiay f dabigatran etexilate vs dse-adjusted warfarin in patients with erebral venus thrmbsis: a randmized linial trial. JAMA Neurl. 2019;76:1457. [PMID: 31479105]8. Sinl Cord Vsculr DisesesE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of back or limb pain and neurologic deficit in limbs. »Motor, sensory, or reflex changes in limbs depend- ing on level of lesion. »Imaging studies distinguish between infarct and hematoma. »Infarction of the Spinal CordInf artin f the spinal rd is rare. It typially urs in the territry f the anterior spinal artery beause this vessel, whih supplies the anterir tw-thirds f the rd, is itself supplied by nly a limited number f feeders. Infartin usu- ally results frm interrupted flw in ne r mre f these feeders, eg, with arti dissetin, arti aneurysm, artgra- phy, plyarteritis, severe hyptensin, r after surgial repair f the thrai r abdminal arta. The paired psterir spinal arteries, by ntrast, are supplied by numerus arteries at different levels f the rd. Spinal rd hypperfusin may lead t a entral rd syndrme with distal weakness f lwer mtr neurn type and lss f pain and temperature appre- iatin, with preserved psterir lumn funtin. Sine the anterir spinal artery reeives numerus feeders in the ervial regin, infarts almst always ur audally. Clinial presentatin is haraterized by aute nset f flaid, areflexive paraplegia that evlves after a few days r weeks int a spasti paraplegia with extensr plantar respnses. There is an ampanying dissiated sensry lss, with impairment f appreiatin f pain and temperature but pres- ervatin f sensatins f vibratin and jint psitin. The risk f spinal rd infartin in the setting f abdminal arti surgery and thrai endvasular repair may be redued by intraperative erebrspinal fluid drainage thrugh a atheter plaed in the lumbar subarah- nid spae t redue intraspinal pressure. If signs f infar- tin are nted after surgery, bld pressure augmentatin fr 24–48 hurs in additin t lumbar drainage has been nted anedtally t imprve utmes. Treatment is th- erwise symptmati. »Epidural or Subdural HemorrhageEp idural r subdural hemrrhage may lead t sudden severe bak pain fllwed by an aute mpressive myelp- athy neessitating urgent spinal MRI r myelgraphy and surgial evauatin. It may ur in patients with bleeding disrders r thse wh are taking antiagulants, sme- times fllwing trauma r lumbar punture. Epidural hemrrhage may als be related t a vasular malfrmatin r tumr depsit. »Spinal Dural Arteriovenous FistulaeSpi nal dural arterivenus fistulae are ngenital lesins that present with spinal subarahnid hemrrhage rCMDT22_Ch24_p0978-p1053.indd  1004 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1005 CMDT 2022my elradiulpathy. Sine mst f these malfrmatins are lated in the thralumbar regin, they lead t mtr and sensry disturbanes in the legs and t sphinter disrders. Pain in the legs r bak is ften severe. Examinatin reveals an upper, lwer, r mixed mtr defiit in the legs; sensry defiits are als present and are usually extensive, althugh asinally they are nfined t a radiular distributin. Cervial spinal dural arterivenus fistulae lead als t symptms and signs in the arms. Spinal MRI may nt detet the spinal dural arterivenus fistula, althugh mst ases shw either T2 hyperintensity in the rd r perimedullary flw vids. Myelgraphy (perfrmed with the patient prne and supine) may detet serpiginus filling defets due t enlarged vessels. Seletive spinal arterigraphy is required t nfirm the diagnsis and plan treatment. Mst lesins are extramedullary, are psterir t the rd (lying either intradurally r extradurally), and an easily be treated by ligatin f feeding vessels and exisin f the fistulus anmaly r by emblizatin predures. Delay in treatment may lead t inreased and irreversible disability r t death frm reurrent subarahnid hemrrhage. »When to ReferAll patients sh uld be referred. »When to AdmitAll patients sh uld be hspitalized.Gyal A et  al. Outmes fllwing surgial versus endvasular treatment f spinal dural arterivenus fistula: a systemati review and meta-analysis. J Neurl Neursurg Psyhiatry. 2019;90:1139. [PMID: 31142659]IN TRACRANIAL & SPINAL MASS LESIONS 1. primry Intrcrnil TumorsE S S E N T I A L S  O F  D I A G N O S I S »Generalized or focal disturbance of cerebral func- tion, or both. »Increased intracranial pressure in some patients. »Neuroradiologic evidence of space-occupying lesion. »General ConsiderationsRughl y ne-third f all primary intraranial neplasms (Table 24–4) are meningimas, ne-quarter are glimas, and the remainder are pituitary adenmas (see Chapter 26), neurfibrmas, and ther tumrs. Certain tumrs, espe- ially neurfibrmas, hemangiblastmas, and retinblas- tmas, may have a familial basis, and ngenital fatrs bear n the develpment f ranipharyngimas. Tumrs may ur at any age, but ertain glimas shw partiular age prediletins.»Clinical FindingsA.  Symptoms and SignsIn traranial tumrs typially present with headahe, sei- zures, r fal neurlgi defiits. New headahes r symp- tms f elevated intraranial pressure, suh as headahes awaking a patient frm sleep r wrsening with Valsalva maneuver, ugh, r reumbeny, are suggestive f brain tumr. Intraranial tumrs may als lead t a generalized disturbane f erebral funtin with persnality hanges, intelletual deline, emtinal lability, nausea, and malaise. 1. Frontal lobe lesions— Tumrs f the frntal lbe ften lead t prgressive intelletual deline, slwing f mental ativity, persnality hanges, and ntralateral grasp reflexes. They may lead t expressive aphasia if the pste- rir part f the left inferir frntal gyrus is invlved. Ans- mia may als ur as a nsequene f pressure n the lfatry nerve. Preentral lesins may ause fal mtr seizures r ntralateral pyramidal defiits. 2. Temporal lobe lesions— Tumrs f the uninate regin may be manifested by seizures with lfatry r gustatry halluinatins, mtr phenmena suh as liking r smaking f the lips, and sme impairment f external awareness withut atual lss f nsiusness. Tempral lbe lesins als lead t depersnalizatin, emtinal hanges, behaviral disturbanes, sensatins f déjà vu r jamais vu, mirpsia r marpsia (bjets appear smaller r larger than they are), visual field defets (rssed upper quadrantanpia), and auditry illusins r halluinatins. Left-sided lesins may lead t dysnmia and reeptive aphasia, while right-sided invlvement smetimes disturbs the pereptin f musial ntes and meldies. 3. Parietal lobe lesions— Tumrs in this latin hara- teristially ause ntralateral disturbanes f sensatin and may ause sensry seizures, sensry lss r inatten- tin, r sme mbinatin f these symptms. The sensry lss is rtial in type and invlves pstural sensibility and tatile disriminatin, s that the appreiatin f shape, size, weight, and texture is impaired. Objets plaed in the hand may nt be regnized (asteregnsis). Extensive parietal lbe lesins may prdue ntralateral hyper- pathia and spntaneus pain (thalami syndrme). Invlvement f the pti radiatin leads t a ntralateral hmnymus field defet that smetimes nsists slely f lwer quadrantanpia. Lesins f the left angular gyrus ause Gerstmann syndrome (a mbinatin f alexia, agraphia, aalulia, right-left nfusin, and finger agn- sia), whereas invlvement f the left submarginal gyrus auses ideatinal apraxia. Ansgnsia (the denial, neglet, r rejetin f a paralyzed limb) is seen in patients with lesins f the nndminant (right) hemisphere. Cnstru- tinal apraxia and dressing apraxia may als ur with right-sided lesins. 4. Occipital lobe lesions— Tumrs f the ipital lbe harateristially prdue ntralateral hmnymus hemianpia r a partial field defet. With left-sided r bilateral lesins, there may be visual agnsia bth fr bjets and fr lrs, while irritative lesins n either sideCMDT22_Ch24_p0978-p1053.indd  1005 29/06/21 8:50 PMChapTER 241006 CMDT 2022T able 24–4. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Tumors of Meninges Meningioma Originates from the dura mater or arachnoid; compresses rather than invades adjacent neural structures. Increasingly common with advancing age. Tumor size varies greatly. Symptoms vary with tumor site—eg, unilateral proptosis (sphenoidal ridge); anosmia and optic nerve compression (olfactory groove). Tumor is usually benign and readily detected by CT scanning; may lead to calcification and bone erosion visible on plain radiographs of skull.Treatment is surgical. Tumor may recur if removal is incomplete. Tumors of Neuroeitelil Origin Glioblastoma multiformePresents commonly with nonspecific complaints and increased intracranial pressure. As it grows, focal deficits develop. O6-methylguanine-DNA methyltransferase pro- moter methylation positivity (seen in 40% of cases) and iso- citrate dehydrogenase 1/2 mutations (seen in 10% of cases) carry better prognosis.Course is rapidly progressive, with poor prognosis (< 20% survival at 2 years). Total surgical removal is usually not possible. Radiation therapy and temozolamide may prolong survival. Tumor treatment fields added to temozolamide after completion of radiation therapy prolong survival. Astrocytoma Presentation similar to glioblastoma multiforme but course more protracted, often over several years. Cerebellar astro- cytoma may have a more benign course. Isocitrate dehy- drogenase 1/2 mutations (seen in a majority of cases) carry better prognosis in grade II and III tumors.Prognosis is variable. By the time of diagnosis, total excision is usually impossible; tumor may be radio- sensitive and temozolamide is also helpful in grade II and III tumors. In cerebellar astrocytoma, total surgical removal is often possible. Ependymoma Glioma arising from the ependyma of a ventricle, especially the fourth ventricle; leads to early signs of increased intra- cranial pressure. Arises also from central canal of cord.Tumor is best treated surgically if possible. Radiation therapy may be used for residual tumor. Oligodendroglioma Slow-growing. Usually arises in cerebral hemisphere in adults. Calcification may be visible on skull radiograph. Co-deletion of 1p/19q and isocitrate dehydrogenase 1/2 mutation required for diagnosis.Treatment is surgical and usually successful. Radiation and chemotherapy (temozolamide or procarbazine, lomustine, and vincristine) are used in grade II and III tumors. Brainstem glioma Presents during childhood with cranial nerve palsies and then with long tract signs in the limbs. Signs of increased intra- cranial pressure occur late.Tumor is inoperable; treatment is by irradiation and shunt for increased intracranial pressure. Neuronal and mixed neuronal-glial tumorsSlow-growing; usually arise in cerebral hemispheres; often associated with seizures. Some are benign (eg, dysembryo- blastic neuroepithelial tumors) and some have malignant potential (eg, ganglioglioma).Resection is not always necessary for benign tumors unless seizures are medically refractory, but is indi- cated for those with malignant potential. Medulloblastoma Seen most frequently in children. Generally arises from roof of fourth ventricle and leads to increased intracranial pressure accompanied by brainstem and cerebellar signs. May seed subarachnoid space. Wingless activated tumors carry best prognosis (> 90% 5-year survival).Treatment consists of surgery combined with radia- tion therapy and chemotherapy; 5-year survival exceeds 70%. Wingless activated tumors may require less aggressive treatment. Pineal tumor Presents with increased intracranial pressure, sometimes asso- ciated with impaired upward gaze (Parinaud syndrome) and other deficits indicative of midbrain lesion.Ventricular decompression by shunting is followed by surgical approach to tumor; irradiation is indicated if tumor is malignant. Prognosis depends on histo- pathologic findings and extent of tumor. Tumors of te Sellr Region Pituitary adenoma Functioning adenomas present with symptoms of hormone secretion; nonfunctioning adenomas present with symp- toms of local mass effect (eg, bitemporal hemianopsia, hypopituitarism) or are found incidentally.Prolactin-secreting adenomas are treated with bro- mocriptine or cabergoline. Others are surgically resected. Pituitary hormone replacement may be required. Craniopharyngioma Originates from remnants of Rathke pouch above the sella, depressing the optic chiasm. May present at any age but usually in childhood, with endocrine dysfunction and bitemporal visual field defects.Treatment is surgical, but total removal may not be possible. Radiation may be used for residual tumor. (continued )CMDT22_Ch24_p0978-p1053.indd  1006 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1007 CMDT 2022an ause unfrmed visual halluinatin s. Bilateral ipi- tal lbe invlvement auses rtial blindness in whih there is preservatin f pupillary respnses t light and lak f awareness f the defet by the patient. There may als be lss f lr pereptin, prspagnsia (inability t identify a familiar fae), simultagnsia (inability t inte- grate and interpret a mpsite sene as ppsed t its individual elements), and Balint syndrme (failure t turn the eyes t a partiular pint in spae, despite preservatin f spntaneus and reflex eye mvements). The denial f blindness r a field defet nstitutes Antn syndrme. 5. Brainstem and cerebellar lesions— Brainstem lesins lead t ranial nerve palsies, ataxia, inrdinatin, nystag- mus, and pyramidal and sensry defiits in the limbs n ne r bth sides. Intrinsi brainstem tumrs, suh as gli- mas, tend t prdue an inrease in intraranial pressure nly late in their urse. Cerebellar tumrs prdue marked ataxia f the trunk if the vermis erebelli is invlved and ipsilateral appendiular defiits (ataxia, in- rdinatin, and hyptnia f the limbs) if the erebellar hemispheres are affeted. 6. Herniation syndromes— If the pressure is inreased in a partiular ranial mpartment, brain tissue may herniate int a mpartment with lwer pressure. The mst familiar syndrme is herniatin f the tempral lbe unus thrugh the tentrial hiatus, whih auses mpressin f the third ranial nerve, midbrain, and psterir erebral artery. The earliest sign f this is ipsilateral pupillary dilatin, fllwed by stupr, ma, deerebrate psturing, and respiratry arrest. Anther imprtant herniatin syndrme nsists fdisplaement f the erebellar tnsils thrugh the framen magnum, whih auses medullary mpressin leading t apnea, irulatry llapse, and death. 7. False localizing signs— Tumrs may lead t neurlgi signs ther than by diret mpressin r infiltratin, thereby leading t errrs f linial lalizatin. These false lalizing signs inlude third r sixth nerve palsy and bilat- eral extensr plantar respnses prdued by herniatin syndrmes, and an extensr plantar respnse urring ipsilateral t a hemispheri tumr as a result f mpressin f the ppsite erebral pedunle against the tentrium.B.  ImagingMRI  with gadlinium enhanement is the preferred methd t detet the lesin and t define its latin, shape, and size; the extent t whih nrmal anatmy is distrted; and the degree f any assiated erebral edema r mass effet. CT sanning with radintrast enhanement uld be perfrmed; hwever, it is less helpful than MRI fr small lesins r tumrs in the psterir fssa. The harateristi appearane f meningimas n MRI r CT sanning is virtually diagnsti, ie, a lesin in a typial site (parasagittal and sylvian regins, lfatry grve, sphenidal ridge, tuberulum sellae) that appears as a hmgeneus area f inreased density in nnntrast sans and enhanes uni- frmly with ntrast. Additinal MRI sequenes that may be helpful in differentiating glimas frm ther intraranial pathlgy inlude perfusin imaging, magneti resnane spetrspy, and diffusin-weighted imaging, althugh nne are speifi enugh t bviate the need fr tissueTable 24–4. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Germ cell tumors (germinomas and nongerminoma- tous germ cell tumors)Two most common locations are pineal and suprasellar regions. The pineal region presentation is as described in pineal tumors, above. Suprasellar tumors present with hypothalamic and pituitary dysfunction such as diabetes insipidus, delayed or precocious puberty, or growth hor- mone deficiency.Germinomas are treated with radiation; prognosis is good for localized tumors. Chemotherapy is added for nongerminomatous germ cell tumors. Tumors of Crnil nd Sinl Nerves Acoustic neurinoma (also referred to as acoustic neuroma)Ipsilateral hearing loss is most common initial symptom. Sub- sequent symptoms may include tinnitus, headache, vertigo, facial weakness or numbness, and long tract signs. (May be familial and bilateral when related to neurofibromatosis.) Most sensitive screening tests are MRI and brainstem audi- tory evoked potential.Treatment is excision by translabyrinthine surgery, craniectomy, or a combined approach. Outcome is usually good. Lymoms Primary cerebral lymphomaAssociated with AIDS and other immunodeficient states. Pre- sentation may be with focal deficits or with disturbances of cognition and consciousness. May be indistinguishable from cerebral toxoplasmosis.Treatment is high-dose methotrexate and corticoste- roids followed by radiation therapy. Prognosis depends on CD4 count at diagnosis. Unclssified Cerebellar hemangioblas- tomaPresents with dysequilibrium, ataxia of trunk or limbs, and signs of increased intracranial pressure. Sometimes familial. May be associated with retinal and spinal vascular lesions, polycythemia, and renal cell carcinoma.Treatment is surgical. Radiation is used for residual tumor.(continued)CMDT22_Ch24_p0978-p1053.indd  1007 29/06/21 8:50 PMChapTER 241008 CMDT 2022samp ling. Arterigraphy is largely reserved fr presurgial emblizatin f highly vasular tumrs. In patients with nrmal hrmne levels and an intrasellar mass, angigra- phy is smetimes neessary t distinguish with nfidene between a pituitary adenma and an arterial aneurysm.C.  Laboratory and Other StudiesWhen  glial neplasms are suspeted, bipsy is neessary fr definitive histlgi diagnsis and mleular analysis. The Wrld Health Organizatin lassifies glial tumrs by bth histlgy and geneti harateristis. Lumbar pun- ture is rarely neessary; the findings are seldm diagnsti, and the predure arries the risk f ausing a herniatin syndrme. Suspeted intraranial germ ell tumrs are an exeptin. If lumbar punture an be perfrmed safely, ytlgy and determinatin f alpha-fetprtein and beta- human hrini gnadtrpin shuld be perfrmed in erebrspinal fluid; tumr markers shuld be examined in serum as well. »TreatmentT reatment depends n the type and site f the tumr (Table 24–4) and the nditin f the patient. Sme benign tumrs, espeially meningimas disvered inidentally during brain imaging fr anther purpse, may be mni- tred with serial annual imaging. Fr symptmati tumrs, mplete surgial remval may be pssible if the tumr is extra-axial (eg, meningima, austi neurma) r is nt in a ritial r inaessible regin f the brain (eg, erebel- lar hemangiblastma). Surgery als permits the diagnsis t be verified and may be benefiial in reduing intrara- nial pressure and relieving symptms even if the neplasm annt be mpletely remved. Clinial defiits are sme- times due in part t bstrutive hydrephalus, in whih ase simple surgial shunting predures ften prdue dramati benefit. In patients with malignant glimas, sur- vival rrelates t the extent f initial resetin. Radiatin therapy inreases median survival rates regardless f any preeding surgery, and its mbinatin with hemtherapy prvides additinal benefit. India- tins fr irradiatin in the treatment f patients with ther primary intraranial neplasms depend n tumr type and aessibility and the feasibility f mplete surgial remval. Lng-term neurgnitive defiits may mpliate radia- tin therapy. Temzlmide is a mmnly used ral and intravenus hemtherapeuti fr glimas. In patients with gliblastma with methylated methylguanine-DNA meth- yltransferase (MGMT) prmter, mbinatin therapy with lmustine and temzlmide imprved median survival frm 31 t 48 mnths in a randmized ntrlled trial. The additin f lw-intensity, 200 kHz frequeny alternating eletri fields (tumr treatment fields) delivered extrarani- ally at least 18 hurs daily, imprves prgressin-free sur- vival by 2.7 mnths and median survival by 4.9 mnths mpared t temzlmide alne in gliblastma. Bevai- zumab is apprved in the United States but nt in Eurpe fr use in reurrent high-grade glima. Cmbinatin therapy with prarbazine, lmustine, and vinristine imprves median survival when given with radiatin tpatients with isitrate dehydrgenase–mutant astry- tma and isitrate dehydrgenase–mutant, p1/19q - deleted ligdendrglima. Crtisterids help redue erebral edema and are usu- ally started befre surgery. Herniatin is treated with intra- venus dexamethasne (10–20 mg as a blus, fllwed by 4 mg every 6 hurs) and intravenus mannitl (20% slutin given in a dse f 1.5 g/kg ver abut 30 minutes). Antinvulsants are als mmnly administered in standard dses (see Table 24–2), but are nt indiated fr prphylaxis in patients wh have n histry f seizures. Fr thse patients with diffiult t treat symptms r thse needing help with advane are planning, speialty pallia- tive are nsultatin is apprpriate (see Chapter 5). »When to ReferAll patients sh uld be referred. »When to Admit• All patients with inreased intraranial pressure. •All patients requiring bipsy, surgial treatment, r shunting predures.Bell  EH et al. Cmprehensive genmi analysis in NRG nl- gy/RTOG 9802: a phase III trial f radiatin versus radiatin plus prarbazine, lmustine (CCNU), and vinristine in high-risk lw-grade glima. J Clin Onl. 2020;38:3407. [PMID: 32706640] Desjardins A et al. Reurrent gliblastma treated with rembi- nant plivirus. N Engl J Med. 2018;379:150. [PMID: 29943666] Herrlinger U et al; Neurnlgy Wrking Grup f the German Caner Siety. Lmustine-temzlmide mbinatin therapy versus standard temzlmide therapy in patients with newly diagnsed gliblastma with methylated MGMT prmter (CeTeG/NOA-09): a randmised, pen-label, phase 3 trial. Lanet. 2019;393:678. [PMID: 30782343]2.  Metsttic Intrcrnil TumorsA.  Cerebral MetastasesMetasta ti brain tumrs present in the same way as ther erebral neplasms, ie, with inreased intraranial pres- sure, with fal r diffuse disturbane f erebral funtin, r with bth f these manifestatins. Indeed, in patients with a single erebral lesin, the metastati nature f the lesin may beme evident nly n histpathlgi exami- natin. In ther patients, there is evidene f widespread metastati disease, r an islated erebral metastasis devel- ps during treatment f the primary neplasm. The most common source of intracranial metastasis is carcinoma of the lung; ther primary sites are the breast, kidney, skin (melanma), and gastrintestinal trat. Mst erebral metastases are lated supratentrially. Labratry and radilgi studies used t evaluate patients with metastases are thse desribed fr primary neplasms. They inlude MRI and CT sanning perfrmed bth with and withut ntrast. Lumbar punture is neessary nly in patients with suspeted arinmatus meningitis. In patients with verified erebral metastasis frm an unknwnCMDT22_Ch24_p0978-p1053.indd  1008 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1009 CMDT 2022primary , investigatin is guided by symptms and signs. In wmen, mammgraphy is indiated; in men under 50, germ ell rigin is sught. Treatment f brain metastases is rapidly evlving and a multidisiplinary apprah between neursurgery, radia- tin nlgy, and nlgy is neessary. In patients with nly a single, surgially aessible erebral metastasis wh are therwise well (ie, a high level f funtining and little r n evidene f extraranial disease), it may be pssible t remve the lesin and then treat with irradiatin; the latter may als be seleted as the sle treatment. Systemi immuntherapy may als be an aeptable initial ptin in selet ases. In patients with multiple metastases r wide- spread systemi disease, steretati radisurgery, whle- brain raditherapy, r bth may help in sme instanes; systemi hemtherapy r immuntherapy may be ptins in thers, but in many, treatment is palliative nly.Fuen tes R et al. Surgery versus steretati raditherapy fr peple with single r slitary brain metastasis. Chrane Database Syst Rev. 2018;8:CD012086. [PMID: 30125049] Tsa MN et al. Whle brain raditherapy fr the treatment f newly diagnsed multiple brain metastases. Chrane Data- base Syst Rev. 2018;1:CD003869. [PMID: 29365347]B.  Leptomeningeal Metastases Carcinomatous MeningitisThe  neoplasms metastasizing most commonly to the lepto- meninges are carcinoma of the breast and lung, lymphomas, and leukemia (see Chapter 39). Leptmeningeal metastases lead t multifal neurlgi defiits, whih may be assi- ated with infiltratin f ranial and spinal nerve rts, diret invasin f the brain r spinal rd, bstrutive r mmuniating hydrephalus, r sme mbinatin f these fatrs. The diagnsis is nfirmed by examinatin f the ere- brspinal fluid. Findings may inlude elevated erebr- spinal fluid pressure, pleytsis, inreased prtein nentratin, and dereased gluse nentratin. Cyt- lgi studies may indiate that malignant ells are present; if nt, lumbar punture shuld be repeated at least twie t btain further samples fr analysis. CT sans shwing ntrast enhanement in the basal isterns r shwing hydrephalus withut any evidene f a mass lesin supprt the diagnsis. Gadlinium-enhaned MRI is mre sensitive and frequently shws enhaning fi in the leptmeninges. Myelgraphy may shw depsits n multiple nerve rts. Treatment is by irradiatin t symptmati areas, m- bined with intratheal hemtherapy in selet patients. The lng-term prgnsis is pr—nly abut 10% f patients survive fr 1 year—and palliative are is therefre impr- tant (see Chapter 5).3.  Intrcrnil Mss Lesions in ptients wit aIDSPrimary  cerebral lymphoma is a mmn mpliatin in patients with AIDS. This leads t disturbanes in gni- tin r nsiusness, fal mtr r sensry defiits,aphasia, seizures, and ranial neurpathies. Similar linial disturbanes may result frm cerebral toxoplasmosis , whih is als a mmn mpliatin in patients with AIDS (see Chapters 31 and 35). Neither CT nr MRI find- ings distinguish these tw disrders and serlgi tests fr txplasmsis are unreliable in AIDS patients. Toxoplasma gondii DNA deteted by plymerase hain reatin in the spinal fluid is speifi but nt sensitive fr txplasmsis, and the finding f Epstein-Barr virus DNA suggests lym- phma but is nt speifi enugh t initiate treatment. Ardingly, fr neurlgially stable patients, a trial f treatment fr txplasmsis with pyrimethamine and sul- fadiazine is remmended fr 3 weeks; the imaging studies are then repeated, and if any lesin has imprved, the regi- men is ntinued indefinitely. If any lesin des nt imprve, erebral bipsy is neessary (see als Chapter 31). Primary erebral lymphma in patients with AIDS is treated with rtisterids, high-dse methtrexate, and antiretrviral therapy. Rituximab may be used in sme patients. Whle-brain irradiatin may nt be neessary. Cryptococcal meningitis is a mmn pprtunisti infetin in patients with AIDS. Clinially, it may resemble erebral txplasmsis r lymphma, but ranial CT sans are usually nrmal (see Chapter 36).4.  primry & Metsttic Sinl TumorsA pprximately 10% f spinal tumrs are intramedullary. Ependymma is the mst mmn type f intramedullary tumr; the remainder are ther types f glima. Extramed- ullary tumrs may be extradural r intradural in latin. Amng the primary extramedullary tumrs, neurfibr- mas and meningimas are relatively mmn, benign, and may be intradural r extradural. Carinmatus metasta- ses, lymphmatus r leukemi depsits, and myelma are usually extradural; in the ase f metastases, the prstate, breast, lung, and kidney are mmn primary sites. Tumrs may lead t spinal rd dysfuntin by diret mpressin, by ishemia sendary t arterial r venus bstrutin and, in the ase f intramedullary lesins, by invasive infiltratin. »Clinical FindingsA.  Symptoms and SignsSymp tms usually develp insidiusly. Pain is ften n- spiuus with extradural lesins; is harateristially aggravated by ughing r straining; may be radiular, lalized t the bak, r felt diffusely in an extremity; and may be ampanied by mtr defiits, paresthesias, r numbness, espeially in the legs. Bladder, bwel, and sexual dysfuntin may ur. When sphinter disturbanes ur, they are usually partiularly disabling. Pain, hw- ever, ften preedes speifi neurlgi symptms frm epidural metastases. Examinatin may reveal lalized spinal tenderness. A segmental lwer mtr neurn defiit r dermatmal sen- sry hanges (r bth) are smetimes fund at the level f the lesin, while an upper mtr neurn defiit and sen- sry disturbane are fund belw it.CMDT22_Ch24_p0978-p1053.indd  1009 29/06/21 8:50 PMChapTER 241010 CMDT 2022B.  ImagingMRI  with ntrast r CT myelgraphy is used t identify and lalize the lesin. The mbinatin f knwn tumr elsewhere in the bdy, bak pain, and either abnrmal plain films f the spine r neurlgi signs f rd m- pressin is an indiatin t perfrm this n an urgent basis.C.  Laboratory FindingsThe  erebrspinal fluid is ften xanthhrmi and n- tains a greatly inreased prtein nentratin with nrmal ell ntent and gluse nentratin. »TreatmentIn tramedullary tumrs are treated by dempressin and surgial exisin (when feasible) and by irradiatin. The prgnsis depends n the ause and severity f rd m- pressin befre it is relieved. Treatment f epidural spinal metastases nsists f surgial dempressin, radiatin, r bth. Dexametha- sne is als given in a high dsage (eg, 10–96 mg ne intravenusly, fllwed by 4–25 mg fur times daily fr 3 days rally r intravenusly, fllwed by rapid tapering f the dsage, depending n initial dse and respnse) t redue rd swelling and relieve pain. Radiatin alne is ften all that is required in patients with radisensitive tumrs. Surgial dempressin is reserved fr patients with tumrs that are unrespnsive t irradiatin r wh have previusly been irradiated, fr thse with spinal instability, and fr patients in whm there is sme uner- tainty abut the diagnsis. The lng-term utlk is pr, but treatment may at least delay the nset f majr disability.Lawtn  AJ et al. Assessment and management f patients with metastati spinal rd mpressin: a multidisiplinary review. J Clin Onl. 2019;37:61. [PMID: 30395488]5.  Brin abscessE S S E N T I A L S  O F  D I A G N O S I S »Signs of expanding intracranial mass. »Signs of primary infection or congenital heart dis- ease are sometimes present. »Fever may be absent. »General ConsiderationsBrain  absess presents as an intraranial spae-upying lesin and arises as a sequela f disease f the ear r nse, may be a mpliatin f infetin elsewhere in the bdy, r may result frm infetin intrdued intraranially by trauma r surgial predures. The mst mmn infe- tive rganisms are strepti, staphyli, and anaer- bes; mixed infetins als ur.»Clinical FindingsA.  Symptoms and SignsHeadahe,  drwsiness, inattentin, nfusin, and seizures are early symptms, fllwed by signs f inreasing intra- ranial pressure and then a fal neurlgi defiit. There may be little r n systemi evidene f infetin.B.  Imaging and Other InvestigationsA  CT san f the head harateristially shws an area f ntrast enhanement surrunding a lw-density re. Similar abnrmalities may be fund in patients with meta- stati neplasms. MRI findings ften permit earlier reg- nitin f fal erebritis r an absess. Steretati needle aspiratin may enable a speifi etilgi rganism t be identified. Examinatin f the erebrspinal fluid des nt help in diagnsis and may preipitate a herniatin syn- drme. Peripheral leukytsis is smetimes present. »TreatmentT reatment nsists f intravenus antibitis mbined with surgial drainage (aspiratin r exisin), if neessary, t redue the mass effet r smetimes t establish the diagnsis. Absesses smaller than 2 m an ften be ured medially. Brad-spetrum antibitis, seleted based n risk fatrs and likely rganisms, are used if the infeting rganism is unknwn (see Chapter 33). An initial empiri multi-antibiti regimen typially inludes eftriaxne (2 g intravenusly every 12 hurs), metrnidazle (15 mg/kg intravenus lading dse, fllwed by 7.5 mg/kg intrave- nusly every 6 hurs), and vanmyin (1 g intravenusly every 12 hurs). The regimen is altered ne ulture and sensitivity data are available. Antimirbial treatment is usually ntinued parenterally fr 6–8 weeks and is fl- lwed by ral treatment fr ertain infetins, suh as nardisis, atinmysis, fungal infetins, and tuberu- lsis. The patient shuld be mnitred by serial CT sans r MRI every 2 weeks and at deteriratin. Dexametha- sne (4–25 mg fur times daily intravenusly r rally, depending n severity, fllwed by tapering f dse, depending n respnse) may redue any assiated edema, but intravenus mannitl is smetimes required.Chw  F. Brain and spinal epidural absess. Cntinuum (Min- neap Minn). 2018;24:1327. [PMID: 30273242]NO NMETASTATIC NEUROLOGIC COMPLICATIONS OF MALIGNANT DISEASEA  variety f nnmetastati neurlgi mpliatins f malignant disease an be regnized. Metabolic encepha- lopathy due t eletrlyte abnrmalities, infetins, drug verdse, r the failure f sme vital rgan may be refleted by drwsiness, lethargy, restlessness, insmnia, agitatin, nfusin, stupr, r ma. The mental hanges are usually assiated with tremr, asterixis, and multifal mylnus. The eletrenephalgram is generally diffusely slwed. Labratry studies are neessary t detet the ause f the enephalpathy, whih must then be treated apprpriately.CMDT22_Ch24_p0978-p1053.indd  1010 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1011 CMDT 2022Im mune suppression resulting frm either the malig- nant disease r its treatment (eg, by hemtherapy) predis- pses patients t brain absess, prgressive multifal leukenephalpathy, meningitis, herpes zster infetin, and ther pprtunisti infetius diseases. Mrever, an vert r ult erebrspinal fluid fistula, as urs with sme tumrs, may als inrease the risk f infetin. MRI r CT sanning aids in the early regnitin f a brain absess, but metastati brain tumrs may have a similar appearane. Examinatin f the erebrspinal fluid is essential in the evaluatin f patients with meningitis and enephalitis but is f n help in the diagnsis f brain absess. Cerebrovascular disorders that ause neurlgi m- pliatins in patients with systemi aner inlude nnbate- rial thrmbti endarditis and septi emblizatin. Cerebral, subarahnid, r subdural hemrrhages may ur in patients with myelgenus leukemia and may be fund in assiatin with metastati tumrs, espeially melanma. Spinal subdural hemrrhage smetimes urs after lumbar punture in patients with marked thrmbytpenia. Disseminated intravascular coagulation urs mst mmnly in patients with aute prmyelyti leukemia r with sme adenarinmas and is haraterized by a flutuating enephalpathy, ften with assiated seizures, that frequently prgresses t ma r death. There may be few ampanying neurlgi signs. Venous sinus throm- bosis, whih usually presents with nvulsins and head- ahes, may als ur in patients with leukemia r lymphma. Examinatin mmnly reveals papilledema and fal r diffuse neurlgi signs. Antinvulsants, antiagulants, and mediatins t lwer the intraranial pressure may be f value. Autoimmune paraneoplastic disorders ur when the immune system reats against neurnal antigens expressed by tumr ells. The linial manifestatins depend n the autantibdy. Symptms may preede thse due t the neplasm itself. Several distint syndrmes are mmn, eah assiated with speifi antibdies and tumrs (Table 24–5). Identifiatin f an antibdy is nt always pssible in a suspeted autimmune paraneplasti nditin, and a searh fr an underlying neplasm shuld be undertaken. Treatment f the neplasm ffers the best hpe fr stabilizatin r imprvement f the neurlgi symptms, whih ften are nt mpletely reversible. Spe- ifi treatment f the antibdy-mediated symptms by intravenus immunglbulin (IVIG) administratin, plas- mapheresis, rtisterids, r ther immunsuppressive regimens is frequently attempted despite limited evidene f effiay. Many f the disrders listed in Table 24–5 an ur either as paraneplasti phenmena r in islatin; when they ur in the absene f a tumr, the respnse t immuntherapy is typially mre favrable. Autimmune disrders may als be triggered as a result f aner immuntherapy; enephalitis, meningitis, trans- verse myelitis, aute and hrni inflammatry demyelin- ating plyneurpathy, autnmi neurpathy, myasthenia gravis, and mysitis have all been desribed.Rsenfeld MR et al. P araneplasti neurlgi syndrmes. Neu- rl Clin. 2018;36:675. [PMID: 30072076]IDIOPATHIC INTRACRANIAL HYPERTENSION (Pseudotumor Cerebri)E S S E N T I A L S  O F  D I A G N O S I S »Headache, worse on straining. »Visual obscurations or diplopia may occur. »Examination reveals papilledema. »Abducens palsy is commonly present. »General ConsiderationsThere are man y auses f this disrder. Thrmbsis f the transverse venus sinus as a mpliatin f titis media r hrni mastiditis is ne ause, and sagittal sinus thrm- bsis may lead t a linially similar piture. Other auses inlude hrni pulmnary disease, systemi lupus erythe- matsus, uremia, endrine disturbanes suh as hyp- parathyridism, hypthyridism, r Addisn disease, vitamin A txiity, and the use f tetrayline r ral n- traeptives. Cases have als fllwed withdrawal f rti- sterids after lng-term use. In mst instanes, hwever, n speifi ause an be fund, and the disrder remits spntaneusly after several mnths. This idipathi variety urs mst mmnly amng verweight wmen aged 20–44. In all ases, sreening fr a spae-upying lesin f the brain is imprtant. »Clinical FindingsA.  Symptoms and SignsSymp tms nsist f headahe, diplpia, and ther visual disturbanes due t papilledema and abduens nerve dys- funtin. Pulse-synhrnus tinnitus may als ur. Examinatin reveals papilledema and sme enlargement f the blind spts, but patients therwise lk well.B.  ImagingIn vestigatins reveal n evidene f a spae-upying lesin. CT r MRI shws small r nrmal ventriles and an empty sella turia. MR vengraphy is imprtant in sreen- ing fr thrmbsis f the intraranial venus sinuses. In sme ases, stensis f ne r mre f the venus sinuses will be bserved.C.  Laboratory FindingsLum bar punture is neessary t nfirm the presene f intraranial hypertensin, but the erebrspinal fluid is nrmal. Labratry studies help exlude sme f the ther auses mentined earlier. »TreatmentU ntreated intraranial hypertensin smetimes leads t sendary pti atrphy and permanent visual lss. Aet- azlamide (250–500 mg rally three times daily, inreasing slwly t a maintenane dse f up t 4000 mg daily,CMDT22_Ch24_p0978-p1053.indd  1011 29/06/21 8:50 PMChapTER 241012 CMDT 2022T able 245. Autoimmune paraneoplastic disorders and their associated antibodies and tumors (listed in alphabetical order).Syndrome Clinicl Fetures associted antibodies Tyicl associted Tumors Anti-NMDA receptor– associated encephalitisParanoia, delusions, behavioral disturbance, seizure, orofacial dyskinesias, athetosis, dysau- tonomia, hypoventilationNMDA receptor1Ovarian teratoma, lung, breast, ovary, testicle Autoimmune necrotizing myopathyWeakness SRP ,1HMGCR1Lung, breast, gastrointestinal, bladder Autonomic neuropathy Postural hypotension, gastroparesisHu, ganglionic AChR1 Cerebellar degeneration Ataxia, dysarthria, nystagmus GAD65,1KLHL11, mGluR1,1NIF,1Ri, Tr, VGCC,1YoLung, breast, thymus, ovary, testicle, Hodgkin lymphoma Dermatomyositis Weakness, heliotrope skin rash TIF-1 gamma Lung, breast, ovary, gastrointes- tinal, lymphoma Lambert-Eaton myasthenic syndromeFatiguable weakness, ptosis, dip- lopia, dry mouth, constipationVGCC1Lung Limbic encephalitis/ encephalomyelitisShort-term memory loss, halluci- nations, seizures, behavioral disturbance, encephalopathyAMPA receptor,1Caspr2,1CV2/CRMP5, DPPX,1GABAAreceptor,1GABAB receptor,1GAD65,1GFAP ,1Hu, LGI1,1 Ma2, mGluR5,1NIF,1thyroglobulin1/ thyroperoxidase1Lung, breast, thymus, ovary, testicle, Hodgkin lymphoma Myasthenia gravis Fatiguable weakness, ptosis, diplopiaAChR,1LRP4,1MuSK1Thymus Myelitis Paraparesis, bowel and bladder dysfunction; sensory levelAmphiphysin,1aquaporin 4,1CRMP-5, GFAP ,1Hu, MOG,1YoLung, breast, lymphoma, leukemia, thyroid, renal Opsoclonus/myoclonus Erratic, conjugate saccadic eye movements and limb myoclonusRi Lung, breast, ovary, testicle, neuroblastoma (children) Retinopathy Vision loss Anti-recoverin, anti-retinal bipolar cell Small cell lung, melanoma Sensorimotor neuropathy Numbness with or without weak- ness; may be mild and chronic or acute and severeHu, MAG Sensory neuronopathy Pain, numbness, sensory ataxia, hearing lossHu Small cell lung Stiff person syndrome Co-contraction of antagonist and agonist musclesAmphiphysin,1GAD65,1GlyR1Small cell lung, breast, thymus, lymphoma1 Can occur in absence of tumor. AChR, acetylcholine receptor; AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; Caspr2, contactin associated prot ein-like 2; CRMP , collapsin response-mediator protein; DPPX, dipeptidyl-peptidase-like protein-6; GABA, gamma-aminobutyric acid; GAD, gl utamic acid decarboxylase; GFAP , glial fibrillary acidic protein; GlyR, glycine receptor; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; KLHL11, kelch-like protein 11; LGI1, leucine rich glioma inactivated; LRP4, low-density lipoprotein receptor-related protein 4; mGluR, metabotropic glutamate receptor; MAG, myelin-associated glycoprotein; MOG, myelin oligodendrocyte glycoprotein; MuSK, Muscle- specific tyrosine kinase; NIF, neuronal intermediate filament; NMDA, N-methyl-D-aspartate; SRP , signal recognition particle; TI F-1, human transcription intermediary factor-1; VGCC, voltage-gated calcium channel.divided tw  t fur times daily) redues frmatin f ere- brspinal fluid. Like aetazlamide, the antiepilepti medi- atin tpiramate (Table 24–2) is a arbni anhydrase inhibitr and was shwn t be similarly effetive in an pen label study; tpiramate has the added benefit f aus- ing weight lss. Fursemide (20–40 mg daily) may be help- ful as adjunt therapy. Crtisterids (eg, prednisne 60–80 mg daily) are smetimes presribed, but side effets and the risk f relapse n withdrawal have disuragedtheir use. Obese patients shuld be advised t lse weight. Repeated lumbar punture t lwer the intraranial pres- sure by remval f erebrspinal fluid is effetive as a temprizing measure, but pharmalgi apprahes t treatment prvide better lng-term relief. Treatment is mnitred by heking visual auity and visual fields, fun- duspi appearane, and pressure f the erebrspinal fluid. The disrder may wrsen after a perid f stability, indiating the need fr lng-term fllw-up.CMDT22_Ch24_p0978-p1053.indd  1012 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1013 CMDT 2022If  medial treatment fails t ntrl the intraranial pressure, surgial plaement f a lumbperitneal r ven- triulperitneal shunt r pti nerve sheath fenestratin shuld be undertaken t preserve visin. Venus sinus stenting is an inreasingly aepted therapeuti ptin fr dural venus sinus stensis. In additin t the abve measures, any speifi ause f intraranial hypertensin requires apprpriate treatment. Thus, hrmne therapy shuld be initiated if there is an underlying endrine disturbane. Disntinuing the use f tetrayline, ral ntraeptives, r vitamin A will allw fr reslutin f intraranial hypertensin due t these agents. If rtisterid withdrawal is respnsible, the mediatin shuld be reintrdued and then tapered mre gradually. »When to ReferAll patients sh uld be referred. »When to AdmitAll  patients with wrsening visin requiring shunt plae- ment r pti nerve sheath fenestratin shuld be hspitalized.Kalyvas  A et al. A systemati review f surgial treatments f idipathi intraranial hypertensin (IIH). Neursurg Rev. 2021;44:773. [PMID: 32335853] Madriz Peralta G et al. An update f idipathi intraranial hypertensin. Curr Opin Ophthalml. 2018;29:495. [PMID: 30169466]SE LECTED NEUROCUTANEOUS DISEASESBeause  the nervus system develps frm the epithelial layer f the embry, a number f ngenital diseases inlude bth neurlgi and utaneus manifestatins. Amng these disrders, three are disussed belw, and vn Hippel-Lindau disease is disussed in Chapter 26.1.  Tuberous SclerosisT uberus slersis may ur spradially r n a familial basis with autsmal dminant inheritane. Neurlgi presentatin is with seizures and prgressive psyhmtr retardatin beginning in early hildhd. The utaneus abnrmality adenma sebaeum bemes manifest usually between 5 and 10 years f age and typially nsists f red- dened ndules n the fae (heeks, naslabial flds, sides f the nse, and hin) and smetimes n the frehead and nek. Other typial utaneus lesins inlude subungual fibrmas, shagreen pathes (leathery plaques f subepider- mal fibrsis, situated usually n the trunk), and leaf-shaped hyppigmented spts. Assiated abnrmalities inlude retinal lesins and tumrs, benign rhabdmymas f the heart, lung ysts, benign tumrs in the visera, and bne ysts. The disease is slwly prgressive and leads t inreasing mental deteriratin. Antinvulsants are indiated t ntrl seizures. Everlimus, a mammalian target frapamyin (mTOR) inhibitr, is apprved in the United States and Eurpe fr medially refratry epilepsy and subepen- dymal giant ell astrytmas due t tuberus slersis.2.  NeurofibromtosisNeur fibrmatsis may ur either spradially r n a familial basis with autsmal dminant inheritane. Tw distint frms are regnized: Type 1 (Recklinghausen disease) is haraterized by multiple hyperpigmented ma- ules, Lish ndules, and neurfibrmas, and results frm mutatins in the NF1 gene n hrmsme 17. Type 2 is haraterized by bilateral eighth nerve tumrs, ften ampanied by ther intraranial r intraspinal tumrs, and is assiated with mutatins in the NF2 (merlin) gene n hrmsme 22. Neurlgi presentatin is usually with symptms and signs f tumr. Multiple neurfibrmas harateristially are present and may invlve spinal r ranial nerves, espe- ially the eighth nerve. Examinatin f the superfiial utaneus nerves usually reveals palpable mbile ndules. In sme ases, there is marked vergrwth f subutaneus tissues (plexifrm neurmas), smetimes with an underly- ing bny abnrmality. Assiated utaneus lesins inlude axillary frekling and pathes f utaneus pigmentatin (café au lait spots ). Malignant degeneratin f neurfibr- mas asinally urs and may lead t peripheral sar- mas. Meningimas, glimas (espeially pti nerve glimas), bne ysts, phehrmytmas, slisis, and bstrutive hydrephalus may als ur. Selumetinib (25 mg/m2rally twie daily), a mitgen-ativated prtein kinase inhibitr, auses plexifrm neurfibrmas t shrink by at least 20% in tw-thirds f patients and is apprved by the FDA fr treatment f inperable plexifrm neurfibr- mas in hildren 2 years f age and lder. Studies in adults are nging.3.  Sturge-Weber SyndromeSturg e-Weber syndrme nsists f a ngenital, usually unilateral, utaneus apillary angima invlving the upper fae, leptmeningeal angimatsis, and, in many patients, hridal angima. It has n sex prediletin and usually urs spradially. The utaneus angima sme- times has a mre extensive distributin ver the head and nek and is ften quite disfiguring, espeially if there is assiated vergrwth f nnetive tissue. Fal r gener- alized seizures are the usual neurlgi presentatin and may mmene at any age. There may be ntralateral hmnymus hemianpia, hemiparesis and hemisensry disturbane, ipsilateral glauma, and mental subnrmal- ity. Skull radigraphs taken after the first 2 years f life usually reveal gyrifrm (“tramline”) intraranial alifia- tin, espeially in the pariet-ipital regin, due t min- eral depsitin in the rtex beneath the intraranial angima. Treatment is aimed at ntrlling seizures pharma- lgially (Table 24–2), but surgial treatment may be ne- essary. Ophthalmlgi advie shuld be sught nerning the management f hridal angima and f inreased intraular pressure.CMDT22_Ch24_p0978-p1053.indd  1013 29/06/21 8:50 PMChapTER 241014 CMDT 2022MO VEMENT DISORDERS 1. Essentil (Fmilil) TremorE S S E N T I A L S  O F  D I A G N O S I S »Postural tremor of hands, head, or voice. »Family history common. »May improve temporarily with alcohol. »No abnormal findings other than tremor. »General ConsiderationsThe  ause f essential tremr is unertain, but it is sme- times inherited in an autsmal dminant manner. »Clinical FindingsT remr may begin at any age and is enhaned by emtinal stress. The tremr usually invlves ne r bth hands, the head, r the hands and head, while the legs tend t be spared. The tremr is nt present at rest, but emerges with atin. Examinatin reveals n ther abnrmalities. Inges- tin f a small quantity f alhl mmnly prvides remarkable but shrt-lived relief by an unknwn mehanism. The tremr typially bemes mre nspiuus with time. Oasinally, it interferes with manual skills and leads t impairment f handwriting. Speeh may als be affeted if the laryngeal musles are invlved. »TreatmentT reatment is ften unneessary. When it is required beause f disability, prpranll (60–240 mg daily rally) may be helpful. Lng-term therapy is typial; hwever, intermittent therapy is smetimes useful in patients whse tremr bemes exaerbated in speifi preditable situa- tins. Primidne may be helpful when prpranll is inef- fetive, but patients with essential tremr are ften very sensitive t it. Therefre, the starting dse is 50 mg daily rally, and the daily dse is inreased by 50 mg every 2 weeks depending n the patient’s respnse; a mainte- nane dse f 125 mg three times daily rally is mmnly effetive. Oasinal patients d nt respnd t these mea- sures but are helped by alprazlam (up t 3 mg daily rally in divided dses), tpiramate (titrated up t a dse f 400 mg daily rally in divided dses ver abut 8 weeks), r gabapentin (1800 mg daily rally in divided dses). Btulinum txin A may redue tremr, but adverse effets inlude dse-dependent weakness f the injeted musles. Disabling tremr unrespnsive t medial treatment may be helped by high-frequeny thalami stimulatin (“deep brain stimulatin”) n ne r bth sides, arding t the laterality f symptms. Fused transranial ultra- sund thalamtmy using MRI guidane is als effetive, as is steretati radisurgery fr unilateral upper extrem- ity tremr.»When to Refer• When refratry t first-line treatment with prpran- ll r primidne. •When additinal neurlgi signs are present (ie, parkinsnism). »When to AdmitPa tients requiring surgial treatment (deep brain stimula- tr plaement) shuld be hspitalized.Ha ubenberger D et al. Essential tremr. N Engl J Med. 2018;378: 1802. [PMID: 29742376]2.  prkinson DiseseE S S E N T I A L S  O F  D I A G N O S I S »Any combination of tremor, rigidity, bradykinesia, and progressive postural instability (“parkinsonism”). »Cognitive impairment is sometimes prominent. »General ConsiderationsPar kinsnism is a relatively mmn disrder that urs in all ethni grups, with an apprximately equal sex distri- butin. The mst mmn variety, idipathi Parkinsn disease, begins mst ften between 45 and 65 years f age and is a prgressive disease. »EtiologyPar kinsnism may rarely ur n a familial basis, and the parkinsnian phentype may result frm mutatins f several different genes. Pstenephaliti parkinsnism is beming inreasingly rare. Expsure t ertain txins (eg, manganese dust, arbn disulfide) and severe arbn mn- xide pisning may lead t parkinsnism. Reversible parkinsnism may develp in patients reeiving neurlep- ti mediatins (see Chapter 25), reserpine, r metl- pramide. Only rarely is hemiparkinsnism the presenting feature f a prgressive spae-upying lesin. In idipathi Parkinsn disease, dpamine depletin due t degeneratin f the dpaminergi nigrstriatal sys- tem leads t an imbalane f dpamine and aetylhline, whih are neurtransmitters nrmally present in the r- pus striatum. Treatment f the mtr disturbane is direted at redressing this imbalane by blking the effet f aetylhline with antihlinergi mediatins r by the administratin f levdpa, the preursr f dpamine. Prir use f ibuprfen is assiated with a decreased risk f develping Parkinsn disease; age, family histry, male sex, nging herbiide/pestiide expsure, and signifiant prir head trauma are risk fatrs. »Clinical FindingsT remor, rigidity, bradykinesia, and postural instability are the ardinal mtr features f parkinsnism and mayCMDT22_Ch24_p0978-p1053.indd  1014 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1015 CMDT 2022be  present in any mbinatin. Nnmtr manifestatins inlude affetive disrders (depressin, anxiety, and apa- thy), psyhsis, gnitive hanges, fatigue, sleep disrders, ansmia, autnmi disturbanes, sensry mplaints r pain, and sebrrhei dermatitis. Dementia r mild gni- tive impairment will eventually develp in many patients. The tremr f abut fur t six yles per send is most conspicuous at rest , is enhaned by emtinal stress, and is ften less severe during vluntary ativity. Althugh it may ultimately be present in all limbs, the tremr is mmnly nfined t ne limb r t the limbs n ne side fr mnths r years befre it bemes mre generalized. In sme patients, tremr is absent. Rigidity (an inrease in resistane t passive mvement) is respnsible fr the harateristially flexed psture seen in many patients, but the mst disabling symptms f par- kinsnism are due t bradykinesia, manifested as a slwness f vluntary mvement and a redutin in autmati mve- ments suh as swinging f the arms while walking. Curi- usly, hwever, effetive vluntary ativity may briefly be regained during an emergeny (eg, the patient is able t leap aside t avid an nming mtr vehile). Clinial diagnsis f the well-develped syndrme is usually simple. The patient has a relatively immbile fae with widened palpebral fissures, infrequent blinking, and a fixity f faial expressin. Sebrrhea f the salp and fae is mmn. There is ften mild blepharlnus, and a tremr may be present abut the muth and lips. Repetitive tap- ping (abut twie per send) ver the bridge f the nse prdues a sustained blink respnse ( Myerson sign ). Other findings may inlude saliva drling frm the muth, per- haps due t impairment f swallwing; sft and prly mdulated vie; a variable rest tremr and rigidity in sme r all f the limbs; slwness f vluntary mvements; impairment f fine r rapidly alternating mvements; and mirgraphia. There is typially n musle weakness (pr- vided that suffiient time is allwed fr pwer t be devel- ped) and n alteratin in the tendn reflexes r plantar respnses. It is diffiult fr the patient t arise frm a sitting psitin and begin walking. The gait itself is haraterized by small shuffling steps and a lss f the nrmal autmati arm swing; there may be unsteadiness n turning, diffiulty in stpping, and a tendeny t fall. »Differential DiagnosisDiagn sti prblems may ur in mild ases, espeially if tremr is minimal r absent. Fr example, mild hypkinesia r slight tremr is mmnly attributed t ld age. Depres- sin, with its assiated expressinless fae, prly mdu- lated vie, and redutin in vluntary ativity, an be diffiult t distinguish frm mild parkinsnism, espeially sine the tw disrders may exist. The family histry, the harater f the tremr, and lak f ther neurlgi signs shuld distinguish essential tremr frm parkinsnism. Wilsn disease an be distinguished by its early age at nset, the presene f ther abnrmal mvements, Kayser- Fleisher rings, and hrni hepatitis, and by inreased nentratins f pper in the tissues. Huntingtn disease presenting with rigidity and bradykinesia may be mistakenfr parkinsnism unless the family histry and ampany- ing dementia are regnized. In multisystem atrphy (pre- viusly alled the Shy-Drager syndrme), autnmi insuffiieny (leading t pstural hyptensin, anhidrsis, disturbanes f sphinter ntrl, eretile dysfuntin, et) may be ampanied by parkinsnism, pyramidal defiits, lwer mtr neurn signs, r erebellar dysfuntin. In prgressive supranulear palsy, bradykinesia and rigidity are ampanied by a supranulear disrder f eye mve- ments, pseudbulbar palsy, pseud-emtinal lability (pseudbulbar affet), and axial dystnia. Creutzfeldt-Jakb disease may be ampanied by features f parkinsnism, but prgressin is rapid, dementia is usual, mylni jerk- ing is mmn, ataxia and pyramidal signs may be n- spiuus, and the MRI and eletrenephalgraphi findings are usually harateristi. In rtibasal degener- atin, asymmetri parkinsnism is ampanied by n- spiuus signs f rtial dysfuntin (eg, apraxia, sensry inattentin, dementia, aphasia). Diffuse Lewy bdy disease is haraterized by prminent visual halluinatins and gnitive impairment that begin befre r within 1 year f nset f the mtr features f parkinsnism. »TreatmentT reatment is symptmati. There is great interest in devel- ping disease-mdifying therapies, but trials f several putative neurprtetive agents have shwn n benefit. Tri- als f varius gene therapies have shwn limited r n benefit.A.  Medical MeasuresMe diatin is nt required early in the urse f Parkinsn disease, but the nature f the disrder and the availability f medial treatment fr use when neessary shuld be dis- ussed with the patient. 1. Amantadine— Patients with mild symptms but n dis- ability may be helped by amantadine (100 mg rally tw t three times daily [immediate release] r ne daily [extended release]). This mediatin imprves all f the linial features f parkinsnism, but its mde f atin is unlear. Side effets are unmmn but may inlude rest- lessness, nfusin, depressin, skin rashes, edema, nausea, nstipatin, anrexia, pstural hyptensin, and distur- banes f ardia rhythm. It als amelirates dyskinesias resulting frm lng-term levdpa therapy. 2. Levodopa— Levdpa, whih is nverted in the bdy t dpamine, imprves all f the majr features f parkinsn- ism, inluding bradykinesia, but does not stop progression f the disrder. The mst mmn early side effets f levdpa are nausea, vmiting, and hyptensin, but ar- dia arrhythmias may als ur. Dyskinesias, restlessness, nfusin, and ther behaviral hanges tend t ur smewhat later and beme mre mmn with time. Levodopa-induced dyskinesias may take any neivable frm, inluding hrea, athetsis, dystnia, tremr, tis, and mylnus. An even later mpliatin is the wearing off effect r the on-off phenomenon, in whih abrupt but transient flutuatins in the severity f parkinsnism urCMDT22_Ch24_p0978-p1053.indd  1015 29/06/21 8:50 PMChapTER 241016 CMDT 2022un preditably but frequently during the day. The “off” period of marked bradykinesia has been shwn t relate in sme instanes t falling plasma levels f levdpa. During the “ on”phase , dyskinesias are ften nspiuus but mbility is inreased. Hwever, suh respnse flutuatins may relate t advaning disease rather than t levdpa therapy itself. Carbidpa, whih inhibits the enzyme respnsible fr the breakdwn f levdpa t dpamine, des nt rss the bld-brain barrier. When levdpa is given in mbina- tin with arbidpa, the extraerebral breakdwn f levdpa is diminished. This redues the amunt f levdpa required daily fr benefiial effets, and it lwers the inidene f nausea, vmiting, hyptensin, and ardia irregularities. Suh a mbinatin des nt prevent the develpment f respnse flutuatins and the inidene f ther side effets (dyskinesias r psyhiatri mpliatins) may atually be inreased. Sinemet, a mmerially available preparatin that n- tains arbidpa and levdpa in a fixed rati (1:10 r 1:4), is generally used. Treatment is started with a small dse— eg, ne tablet f Sinemet 25/100 (ntaining 25 mg f ar- bidpa and 100 mg f levdpa) three times daily—and gradually inreased depending n the respnse. Sinemet CR is a ntrlled-release frmulatin (ntaining 25 r 50 mg f arbidpa and 100 r 200 mg f levdpa). It is mainly useful when taken at bedtime t lessen mtr dis- ability upn awakening. A frmulatin f arbidpa/ levdpa (Rytary) ntaining bth immediate- and delayed- release beads prvides a smther respnse in patients with flutuatins. The mmerially available mbinatin f levdpa with bth arbidpa and entaapne (Stalev) may als be helpful in this ntext and is disussed in the fllwing setin n COMT inhibitrs. Respnse flutua- tins are als redued by keeping the daily intake f protein at the remmended minimum and taking the main prtein meal as the last meal f the day. A ntinuus infusin f a arbidpa-levdpa enteral suspensin thrugh a peruta- neus gastrjejunstmy tube by a prtable infusin pump redues “ff” time in patients with advaned Parkinsn disease. Levdpa an als be taken by inhalatin (Inbrija) as a resue mediatin fr patients develping severe akine- sia (ff perids). Benefit urs abut 10 minutes after inhalatin. Side effets inlude ugh, upper respiratry trat infetin, nausea, and dislred sputum. The dyskinesias and behaviral side effets f levdpa are dse-related, but redutin in dse may eliminate any therapeuti benefit. Levdpa-indued dyskinesias may als respnd t amantadine. Levdpa therapy is ntraindiated in patients with psyhti illness r narrw-angle glauma. It shuld nt be given t patients taking mnamine xidase A inhibitrs r within 2 weeks f their withdrawal, beause hypertensive rises may result. Sudden disntinuatin f levdpa an preipitate neurlepti malignant syndrme and shuld be avided. 3. Dopamine agonists— Dpamine agnists, suh as pramipexle and rpinirle, at diretly n dpamine reeptrs, and their use in parkinsnism is assiated with a lwer inidene f the respnse flutuatins anddyskinesias that ur with lng-term levdpa therapy. They are effetive in bth early and advaned stages f Par- kinsn disease. They are ften given either befre the intr- dutin f levdpa r with a lw dse f Sinemet 25/100 (arbidpa 25 mg and levdpa 100 mg, ne tablet three times daily) when dpaminergi therapy is first intrdued; the dse f Sinemet is kept nstant, while the dse f the agnist is gradually inreased. Pramipexle is started at a dsage f 0.125 mg three times daily rally, and the dse is built up gradually t between 0.5 and 1.5 mg three times daily. Rpinirle is begun at 0.25 mg three times daily rally and gradually inreased; mst patients require between 2 and 8 mg three times daily fr benefit. Extended-release, ne-daily frmu- latins f pramipexle and rpinirle have similar effiay and tlerability as the immediate release versins. Rtig- tine is a dpamine agnist absrbed transdermally frm a skin path; it is started at 2 mg ne daily and inreased weekly by 2 mg daily until ahieving an ptimal respnse, up t a maximum f 8 mg daily. Adverse effets f these varius agnists inlude fatigue, smnlene, nausea, peripheral edema, dyskinesias, nfusin, and pstural hyptensin. Less mmnly, an irresistible urge t sleep may ur, smetimes in inapprpriate and hazardus ir- umstanes. Impulse ntrl disrders invlving gambling, shpping, r sexual ativity als ur. Lal skin reatins may ur with the rtigtine path. The dopamine ago- nist withdrawal syndrome develps asinally in patients in whm a dpamine agnist is tapered. It nsists f a mbinatin f distressing physial and psyhlgial symptms that are refratry t levdpa and ther dpa- minergi mediatins and may persist fr mnths r lnger. There is n effetive treatment. The dpamine agnist shuld be reintrdued and tapered mre gradually if pssible. 4. Selective monoamine oxidase inhibitors— Rasagiline, a seletive mnamine xidase B inhibitr, has a lear symp- tmati benefit in sme patients at a daily ral dse f 1 mg, taken in the mrning; it may als be used fr adjuntive therapy in patients with respnse flutuatins t levdpa. Selegiline (5 mg rally with breakfast and lunh) and safin- amide (50 mg rally daily, inreased t 100 mg daily after 14 days) are als apprved as adjuntive treatments. By inhibiting the metabli breakdwn f dpamine, these mediatins may imprve flutuatins r delining respnse t levdpa. Studies have suggested (but failed t shw nlusively) that rasagiline may slw the prgressin f Parkinsn dis- ease, and it appears t delay the need fr ther symptmati therapies. Fr these reasns, rasagiline is ften started early, partiularly fr patients wh are yung r have mild dis- ease. Hwever, the FDA has rejeted an expansin f rasa- giline’s indiatin t inlude disease mdifiatin. 5. COMT inhibitors— Catehlamine- O-methyltransferase (COMT) inhibitrs redue the metablism f levdpa t 3-O-methyldpa and thereby alter the plasma pharmaki- netis f levdpa, leading t mre sustained plasma levels and mre nstant dpaminergi stimulatin f the brain. Treatment with entaapne r tlapne results in reduedCMDT22_Ch24_p0978-p1053.indd  1016 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1017 CMDT 2022res pnse flutuatins, with a greater perid f respnsive- ness t administered levdpa. Tlapne is given in a dsage f 100 mg r 200 mg three times daily rally, and entaapne is given as 200 mg with eah dse f Sinemet. Opiapne, a lng-ating, peripherally seletive COMT inhibitr, is taken ne daily (50 mg) at bedtime at least 1 hur befre and after eating. The dse f Sinemet taken nurrently may have t be redued by up t ne-third t avid side effets. Diarrhea is smetimes trublesme. Beause rare ases f fulminant hepati failure have fl- lwed its use, tlapne shuld be avided in patients with preexisting liver disease. Serial liver bihemial tests shuld be perfrmed at 2-week intervals fr the first year and at lnger intervals thereafter in patients reeiving the mediatin—as remmended by the manufaturer. Seri- us hepattxiity has nt been reprted with entaapne r piapne. Stalev is the mmerial preparatin f levdpa m- bined with bth arbidpa and entaapne. It is best used in patients already stabilized n equivalent dses f arbi- dpa/levdpa and entaapne. It is pried at r belw the prie f the individual ingredients (ie, arbidpa/levdpa and entaapne) and has the added nveniene f requir- ing fewer tablets t be taken daily. It is available in three strengths: Stalev 50 (12.5 mg f arbidpa, 50 mg f levdpa, and 200 mg f entaapne), Stalev 100 (25 mg f arbidpa, 100 mg f levdpa, and 200 mg f entaa- pne), and Stalev 150 (37.5 mg f arbidpa, 150 mg f levdpa, and 200 mg f entaapne). 6. Istradefylline— This adensine A2Areeptr antagnist (20–40 mg rally ne daily) is given t patients taking levdpa r a dpamine agnist t redue ff time; ttal ff time is typially redued by less than 1 hur per day. 7. Anticholinergic medications— Antihlinergis are mre helpful in alleviating tremr and rigidity than brady- kinesia. Trihexyphenidyl and benztrpine are mmnly used frmulatins. Treatment is started with a small dse and gradually inreased until benefit urs r side effets limit further inrements. If treatment is ineffetive, the mediatin is gradually withdrawn and anther prepara- tin then tried. Hwever, these mediatins are ften prly tlerated, espeially in lder adults. Side effets limit the rutine use f these mediatins, and inlude dryness f the muth, nausea, nstipatin, palpitatins, ardia arrhythmias, urinary retentin, n- fusin, agitatin, restlessness, drwsiness, mydriasis, inreased intraular pressure, and defetive ammda- tin. Antihlinergi mediatins are ntraindiated in patients with prstati hyperplasia, narrw-angle glau- ma, r bstrutive gastrintestinal disease and are ften tlerated prly by the elderly. They are best avided whenever gnitive impairment r a predispsitin t delirium exists. 8. Antipsychotics— Cnfusin and psyhti symptms may ur as a side effet f dpaminergi therapy r as a part f the underlying illness. Pimavanserin (34 mg ne daily), a sertnin(2A) agnist, is apprved by the FDA speifially fr treating the psyhsis f Parkinsn disease. This may als respnd t the atypial antipsyhti agentslzapine and quetiapine, whih have few extrapyramidal side effets and d nt blk the effets f dpaminergi mediatin. Clzapine may rarely ause marrw suppres- sin, and weekly bld unts are therefre neessary fr patients taking it. The patient is started n 6.25 mg at bedtime and the dsage inreased t 25–100 mg/day as needed. In lw dses, it may als imprve iatrgeni dyskinesias. Typical antipsychotic agents and the second- generation antipsychotic agents risperidone and olanzapine may cause worsening of motor symptoms and should be avoided .B.  General MeasuresPhysial  therapy r speeh therapy helps many patients. Cgnitive impairment and psyhiatri symptms may be helped by a hlinesterase inhibitr, suh as rivastigmine (3–12 mg rally daily r 4.6 r 9.5 mg/24 hurs transder- mally daily). The quality f life an ften be imprved by the prvisin f simple aids t daily living, eg, rails r ban- isters plaed strategially abut the hme, speial table utlery with large handles, nnslip rubber table mats, and devies t amplify the vie.C.  Stimulation and Ablative TreatmentsHigh-frequeny  stimulatin f the subthalami nulei r glbus pallidus internus may benefit many f the mtr features f the disease but des nt affet its natural histry. Eletrial stimulatin f the brain has the advantage ver ablative thalamtmy and pallidtmy predures f being reversible and f ausing minimal r n damage t the brain, and is therefre the preferred surgial apprah t treatment. It is reserved fr patients withut gnitive impairment r psyhiatri disrder wh have a gd respnse t levdpa, but in whm dyskinesias r respnse flutuatins are prblemati. It frequently takes 3–6 mnths after surgery t adjust stimulatr prgramming and t ahieve ptimal results. Side effets inlude depressin, apathy, impulsivity, exeutive dysfuntin, and dereased verbal flueny in a subset f patients. Fused ultrasund thalamtmy r steretati radisurgery may help patients with medially refratry tremr-predminant parkinsnism wh are relutant t underg surgery.D . Gene TherapyIn jetins f aden-assiated viruses ending varius human genes have been made int the subthalami nuleus r putamen in varius linial trials. These apprahes may be useful in the future but remain experimental. »When to ReferAll patients sh uld be referred. »When to AdmitPa tients requiring surgial treatment shuld be admitted.Mith ell KT et al. Surgial treatment f Parkinsn disease. Neu- rl Clin. 2020;38:293. [PMID: 32279711]CMDT22_Ch24_p0978-p1053.indd  1017 29/06/21 8:50 PMChapTER 241018 CMDT 2022Rugha ni A et al. Cngress f Neurlgial Surgens systemati review and evidene-based guideline n subthalami nuleus and glbus pallidus internus deep brain stimulatin fr the treatment f patients with Parkinsn’s disease: exeutive sum- mary. Neursurgery. 2018;82:753. [PMID: 29538685]3.  huntington DiseseE S S E N T I A L S  O F  D I A G N O S I S »Gradual onset and progression of chorea and dementia or behavioral change. »Family history of the disorder. »Responsible gene identified on chromosome 4. »General ConsiderationsHunt ingtn disease is haraterized by chorea and dementia. It is inherited in an autsmal dminant manner and urs thrughut the wrld, in all ethni grups, with a prevalene rate f abut 5 per 100,000. There is an expanded and unstable CAG trinuletide repeat in the huntingtin gene at 4p16.3; lnger repeat lengths rre- spnd t an earlier age f nset and faster disease prgressin. »Clinical FindingsA.  Symptoms and SignsClinial  nset is usually between 30 and 50 years f age. The disease is prgressive and usually leads t a fatal ut- me within 15–20 years. The initial symptms may n- sist f either abnrmal mvements r intelletual hanges, but ultimately bth ur. The earliest mental hanges are ften behaviral, with irritability, mdiness, antisial behavir, r a psyhiatri disturbane, but a mre bvius dementia subsequently develps. The dyskinesia may ini- tially be n mre than an apparent fidgetiness r restless- ness, but eventually hreifrm mvements and sme dystni psturing ur. A parkinsnian syndrme with prgressive rigidity and akinesia (rather than hrea) smetimes urs in assiatin with dementia, espeially in ases with hildhd nset. The diagnsis is established with a widely available geneti test, althugh suh testing shuld be pursued under the guidane f a liensed geneti unselr.B.  ImagingCT  sanning r MRI usually demnstrates erebral atrphy and atrphy f the audate nuleus in established ases. Psitrn emissin tmgraphy (PET) has shwn redued striatal metabli rate. »Differential DiagnosisChre a develping with n family histry f hreathetsis shuld nt be attributed t Huntingtn disease, at least nt until ther auses f hrea have been exluded liniallyand by apprpriate labratry studies. Nngeneti auses f hrea inlude strke, systemi lupus erythematsus and antiphsphlipid antibdy syndrme, paraneplasti syn- drmes, infetin with HIV , and varius mediatins. In yunger patients, self-limiting Sydenham hrea develps after grup A streptal infetins n rare asins. If a patient presents slely with prgressive intelletual fail- ure, it may nt be pssible t distinguish Huntingtn dis- ease frm ther auses f dementia unless there is a harateristi family histry r a dyskinesia develps. Huntington disease–like (HDL) disorders resemble Huntingtn disease but are aused by ther geneti muta- tins. A linially similar autsmal dminant disrder (dentatorubral-pallidoluysian atrophy), manifested by hrea, dementia, ataxia, and mylni epilepsy, is unmmn exept in persns f Japanese anestry. Treat- ment is as fr Huntingtn disease. »TreatmentThere  is n ure fr Huntingtn disease; prgressin an- nt be halted; and treatment is purely symptmati, althugh studies f antisense lignuletides inhibiting prdutin f mutant huntingtin prtein are nging. The reprted bihemial hanges suggest a relative undera- tivity f neurns ntaining GABA and aetylhline r a relative verativity f dpaminergi neurns. Tetrabena- zine, a mediatin that interferes with the vesiular strage f bigeni amines, is widely used t treat the dyskinesia. The starting dse is 12.5 mg twie r three times daily rally, inreasing by 12.5 mg every 5 days depending n respnse and tlerane; the usual maintenane dse is 25 mg three times daily. Side effets inlude depressin, pstural hyptensin, drwsiness, and parkinsnian fea- tures; tetrabenazine shuld nt be given within 14 days f taking mnamine xidase inhibitrs and is nt indiated fr the treatment f levdpa-indued dyskinesias. Reser- pine is similar in depleting entral mnamines but has mre peripheral effets and a wrse side-effet prfile, making its use prblemati in Huntingtn disease; if utilized, the dse is built up gradually t between 2 mg and 5 mg rally daily, depending n the respnse. Deutetrabenazine is als effetive in reduing hrea in Huntingtn disease and may have fewer side effets than tetrabenazine but diret mparisns are laking. The starting dse is 6 mg ne daily rally, inreased t 6 mg twie daily after 1 week and by 6-mg inrements weekly thereafter, t a maximum f 24 mg twie daily. Treatment with mediatins blking dpamine reeptrs, suh as phenthiazines r halperidl, may ntrl the dyskinesia and any behaviral distur- banes. Halperidl treatment is usually begun with a dse f 1 mg ne r twie daily rally, whih is then inreased every 3 r 4 days depending n the respnse; alternatively, atypial antipsyhti agents suh as quetiapine (inreasing frm 25 mg daily rally up t 100 mg twie daily rally as tlerated) may be tried. Amantadine in a dse f 200 mg t 400 mg daily rally is smetimes helpful fr hrea. Deep brain stimulatin has been used suessfully t treat hrea in a small number f patients. Behaviral disturbanes may respnd t lzapine. Attempts t mpensate fr the rela- tive GABA defiieny by enhaning entral GABA ativityCMDT22_Ch24_p0978-p1053.indd  1018 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1019 CMDT 2022r t mpensat e fr the relative hlinergi underativity by giving hline hlride have nt been therapeutially helpful. Offspring shuld be ffered geneti unseling. Geneti testing permits presymptmati detetin and definitive diagnsis f the disease. »When to ReferAll patients sh uld be referred.T abrizi SJ et al; Phase 1–2a IONIS-HTTRx Study Site Teams. Targeting huntingtin expressin in patients with Huntingtn’s disease. N Engl J Med. 2019;380:2307. [PMID: 31059641]4.  Idiotic Torsion DystoniE S S E N T I A L S  O F  D I A G N O S I S »Dystonic movements and postures. »Normal birth and developmental history. No other neurologic signs. »Investigations (including CT scan or MRI) reveal no cause of dystonia. »General ConsiderationsIdi pathi trsin dystnia may ur spradially r n a hereditary basis, with autsmal dminant, autsmal reessive, and X-linked reessive mdes f transmissin. Symptms may begin in hildhd r later and persist thrughut life. »Clinical FindingsThe  disrder is haraterized by the nset f abnrmal mvements and pstures in a patient with a nrmal birth and develpmental histry, n relevant past medial ill- ness, and n ther neurlgi signs. Investigatins (inlud- ing CT san) reveal n ause fr the abnrmal mvements. Dystni mvements f the head and nek may take the frm f trtillis, blepharspasm, faial grimaing, r fred pening r lsing f the muth. The limbs may als adpt abnrmal but harateristi pstures. The age at nset influenes bth the linial findings and the prgn- sis. With nset in hildhd, there is usually a family his- try f the disrder, symptms mmnly mmene in the legs, and prgressin is likely until there is severe dis- ability frm generalized dystnia. In ntrast, when nset is later, a psitive family histry is unlikely, initial symp- tms are ften in the arms r axial strutures, and severe disability des nt usually ur, althugh generalized dystnia may ultimately develp in sme patients. If all ases are nsidered tgether, abut ne-third f patients eventually beme s severely disabled that they are n- fined t hair r bed, while anther ne-third are affeted nly mildly.»Differential DiagnosisPe rinatal anxia, birth trauma, and kerniterus are m- mn auses f dystnia, but abnrmal mvements usually then develp befre the age f 5, the early develpment f the patient is usually abnrmal, and a histry f seizures is nt unusual. Mrever, examinatin may reveal signs f mental retardatin r pyramidal defiit in additin t the mvement disrder. Dystni psturing may als ur in Wilsn disease, Huntingtn disease, r parkinsnism; as a sequela f enephalitis lethargia r previus neurlepti mediatin therapy; and in ertain ther disrders. In these ases, diagnsis is based n the histry and ampa- nying linial manifestatins. »TreatmentIdi pathi trsin dystnia usually respnds prly t mediatins. A distint variety f dminantly inherited dys- tnia is remarkably respnsive t levdpa; therefre, a levdpa trial is warranted in all patients. Failing this, diaze- pam, balfen, arbamazepine, amantadine, r antihliner- gi mediatin suh as trihexyphenidyl r benztrpine (in high dsage) is asinally helpful; if nt, a trial f treatment with tetrabenazine, phenthiazines, r halperidl may be wrthwhile. In eah ase, the dse has t be individualized, depending n respnse and tlerane. Hwever, the dses f these latter mediatins that are required fr benefit lead usually t mild parkinsnism. Pallidal deep brain stimulatin is helpful fr disabling generalized dystnia and has a lwer mrbidity than steretati thalamtmy, whih is sme- times helpful in patients with predminantly unilateral limb dystnia. Ptential adverse events f deep brain stimulatin inlude erebral infetin r hemrrhage, brken leads, affetive hanges, and dysarthria. »When to ReferAll patients sh uld be referred. »When to AdmitPa tients requiring surgial treatment shuld be admitted.R drigues FB et al. Deep brain stimulatin fr dystnia. Chrane Database Syst Rev. 2019;1:CD012405. [PMID: 30629283]5.  Focl Torsion DystoniA  number f the dystni manifestatins that ur in idipathi trsin dystnia may als ur as islated phe- nmena. They are best regarded as fal dystnias that either ur as frmes frustes f idipathi trsin dyst- nia in patients with a psitive family histry r represent a fal manifestatin f the adult-nset frm f that disrder when there is n family histry. Medial treatment is gen- erally unsatisfatry. A trial f the mediatins used in idipathi trsin dystnia is wrthwhile, hwever, sine a few patients d shw sme respnse. In additin, with restrited dystnias suh as blepharspasm r trtillis, lal injetin f btulinum A txin int the verativeCMDT22_Ch24_p0978-p1053.indd  1019 29/06/21 8:50 PMChapTER 241020 CMDT 2022musles  may prdue wrthwhile benefit fr several weeks r mnths and an be repeated as needed. Bth blepharospasm and oromandibular dystonia may ur as an islated fal dystnia. The frmer is har- aterized by spntaneus invluntary fred lsure f the eyelids fr a variable interval. Ormandibular dystnia is manifested by invluntary ntratin f the musles abut the muth ausing, fr example, invluntary pen- ing r lsing f the muth, rving r prtruding tngue mvements, and retratin f the platysma. Cervical dys- tonia (spasmdi trtillis), usually with nset between 25 and 50 years f age, is haraterized by a tendeny fr the nek t twist t ne side. This initially urs episdi- ally, but eventually the nek is held t the side. Sme patients have a sensry trik (“geste antagniste”) that lessens the dystni psture, eg, tuhing the side f the fae. Spntaneus reslutin may ur in the first year r s. The disrder is therwise usually lifelng. Lal inje- tin f btulinum A txin prvides benefit in mst ases. Deep brain stimulatin f the glbus pallidus interna is an ptin if medial treatment and btulinum txin injetin are unsuessful. Writer’s cramp is haraterized by dystni psturing f the hand and frearm when the hand is used fr writing and smetimes when it is used fr ther tasks, eg, playing the pian r using a srewdriver r eating utensils. Media- tin treatment is usually unrewarding, and patients are ften best advised t learn t use the ther hand fr ativi- ties requiring manual dexterity. Injetins f btulinum A txin are helpful in sme instanes.Rdrigues FB  et al. Btulinum txin type A therapy fr ervial dystnia. Chrane Database Syst Rev. 2020;11:CD003633. [PMID: 33180963]6.  MyoclonusOasi nal mylni jerks may ur in anyne, espeially when drifting int sleep. General or multifocal myoclonus is mmn in patients with idipathi epilepsy and is espe- ially prminent in ertain hereditary disrders harater- ized by seizures and prgressive intelletual deline, suh as the lipid strage diseases. It is als a feature f subaute slersing panenephalitis and Creutzfeldt-Jakb disease. Generalized mylni jerking may ampany uremi and ther metabli enephalpathies, result frm therapy with levdpa r triyli antidepressants, ur in alhl r drug withdrawal states, r fllw anxi brain damage. It als urs n a hereditary r spradi basis as an islated phenmenn in therwise healthy subjets. Segmental myoclonus is a rare manifestatin f a fal spinal rd lesin. It may als be the linial expressin f epilepsia partialis continua , a disrder in whih a repeti- tive fal epilepti disharge arises in the ntralateral sensrimtr rtex, smetimes frm an underlying stru- tural lesin. An eletrenephalgram is ften helpful in larifying the epilepti nature f the disrder, and CT r MRI san may reveal the ausal lesin. Mylnus may respnd t ertain antinvulsant mediatins, espeially valpri aid r levetiraetam, r tne f the benzdiazepines, partiularly lnazepam (see Table 24–2). It may als respnd t piraetam (up t 16.8 g daily; nt available in the United States). Mylnus fl- lwing anxi brain damage is ften respnsive t xitrip- tan (5-hydrxytryptphan), the preursr f sertnin, and smetimes t lnazepam. Oxitriptan is given in gradually inreasing dses up t 1–1.5 mg daily. In patients with segmental mylnus, a lalized lesin shuld be searhed fr and treated apprpriately.7.  Wilson DiseseIn th is metabli disrder, abnrmal mvement and ps- ture may ur with r withut existing signs f liver invlvement. Psyhiatri and neurpsyhlgial mani- festatins are mmn. Wilsn disease is disussed in Chapter 16.8.  Drug-Induced abnorml MovementsPhent hiazines, butyrphennes, and metlpramide may prdue a wide variety f abnrmal mvements, inluding parkinsnism, akathisia (ie, mtr restlessness), aute dystnia, hrea, and tardive dyskinesias r dystnia; several f these are als prdued by aripiprazle. These mpliatins are disussed in Chapter 25. Chrea may als develp in patients reeiving levdpa, brmriptine, antihlinergi mediatins, phenytin, arbamazepine, lithium, amphetamines, r ral ntraeptives, and it reslves with withdrawal f the ffending substane. Simi- larly, dystnia may be prdued by levdpa, brmrip- tine, lithium, r arbamazepine; and parkinsnism by reserpine and tetrabenazine. Pstural tremr may ur with a variety f mediatins, inluding epinephrine, is- prterenl, amidarne, thephylline, affeine, lithium, thyrid hrmne, triyli antidepressants, and valpri aid.9.  Restless Legs SyndromeThis  mmn disrder, affeting 1–5% f peple, may ur as a primary (idipathi) disrder r in relatin t Parkinsn disease, pregnany, irn defiieny anemia, r peripheral neurpathy (espeially uremi r diabeti). It may have a hereditary basis, and several geneti li have been assiated with the disrder. Restlessness and urius sensry disturbanes lead t an irresistible urge t mve the limbs, espeially during perids f relaxatin; mve- ment f the limbs prvides relief. The urge urs exlu- sively in the evening and at night r is wrse at night than during the day. Mst patients als have periodic limb movements of sleep and ne-third have peridi limb mvements during relaxed wakefulness; bth nsist f brief invluntary flexin at the ankle, knee, and hip. Dis- turbed nturnal sleep and exessive daytime smnlene may result. Ferritin levels shuld always be measured; treatment with ral irn sulfate in patients with ferritin levels less than r equal t 75 mg/L (13.4 mml/L) shuld be attempted prir t initiatin f ther pharma- therapies. Therapy is with nnergt dpamine agnists, suh as pramipexle (0.125–0.5 mg rally ne daily),CMDT22_Ch24_p0978-p1053.indd  1020 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1021 CMDT 2022rp inirle (0.25–4 mg rally ne daily 2 t 3 hurs befre bedtime), r rtigtine (1–3 mg/24 h transdermal path ne daily), r with gabapentin enaarbil (300–1200 mg rally eah evening). Gabapentin (starting with 300 mg rally daily, inreasing t apprximately 1800 mg daily depending n respnse and tlerane) and pregabalin (150–300 mg rally divided twie t three times daily) are related mediatins that imprve symptms. Levdpa is helpful but may lead t an augmentatin f symptms, s its use is generally reserved fr thse wh d nt respnd t ther measures. Extended-release xydne-nalxne (2.5–5 mg t 5–10 mg rally twie daily) is useful in patients with severe symptms r thse wh are refratry t first-line therapies.Win kelmann J et al. Treatment f restless legs syndrme: evidene-based review and impliatins fr linial pratie. Mv Disrd. 2018;33:1077. [PMID: 29756335]10.  Gilles De L Tourette SyndromeE S S E N T I A L S  O F  D I A G N O S I S »Multiple motor and phonic tics. »Symptoms begin before age 18 years. »Tics occur frequently for at least 1 year. »Tics vary in number, frequency, and nature over time. »Clinical FindingsSimple  tis ur transiently in up t 25% f hildren, remit within weeks t mnths, and d nt require treat- ment. Turette syndrme is a mre mplex disrder. Motor tics are the initial manifestatin in 80% f ases and mst mmnly invlve the fae, whereas in the remaining 20%, the initial symptms are phonic tics; ulti- mately a mbinatin f different mtr and phni tis develp in all patients. Tis are preeded by an urge that is relieved upn perfrmane f the mvement r valiza- tin; they an be temprarily suppressed but eventually the urge bemes verwhelming. These are nted first in hildhd, generally between the ages f 2 and 15. Mtr tis ur espeially abut the fae, head, and shulders (eg, sniffing, blinking, frwning, shulder shrugging, head thrusting, et). Phni tis mmnly nsist f grunts, barks, hisses, thrat-learing, ughs, et, but smetimes als f verbal utteranes inluding prlalia (bsene speeh). There may als be ehlalia (repetitin f the speeh f thers), ehpraxia (imitatin f thers’ mve- ments), and palilalia (repetitin f wrds r phrases). Sme tis may be self-mutilating in nature, suh as nail- biting, hair-pulling, r biting f the lips r tngue. The disrder is hrni, but the urse may be puntuated by relapses and remissins. Obsessive-mpulsive disrder (OCD) and attentin defiit hyperativity disrder (ADHD) are mmnly assiated and may be mre dis-abling than the tis themselves. A family histry is sme- times btained. Examinatin usually reveals n abnrmalities ther than the tis. In additin t OCD, psyhiatri disturbanes may ur beause f the assiated smeti and sial embarrassment. The diagnsis f the disrder is ften delayed fr years, the tis being interpreted as psyhiatri illness r sme ther frm f abnrmal mvement. Patients are thus ften subjeted t unneessary treatment befre the disrder is regnized. The ti-like harater f the abnrmal mvements and the absene f ther neurlgi signs shuld differentiate this disrder frm ther mve- ment disrders presenting in hildhd. Wilsn disease, hwever, an simulate the nditin and shuld be exluded. »TreatmentT reatment is symptmati and may need t be ntinued indefinitely. Habit reversal training r ther frms f behaviral therapy an be effetive alne r in mbinatin with pharmatherapy. Alpha-adrenergi agnists, suh as lnidine (start 0.05 mg rally at bedtime, titrating t 0.3–0.4 mg rally daily, divided three t fur times per day) r guanfaine (start 0.5 mg rally at bedtime, titrating t a maximum f 3–4 mg rally daily, divided twie daily), are first-line therapies beause f a favrable side-effet prfile mpared with typial antipsyhtis, whih are the nly FDA-apprved therapies fr the disrder. They als have the advantage f imprving the symptms f nmitant ADHD. Many speialists favr the use f tetrabenazine. The atypial antipsyhti risperidne (1–6 mg daily rally) is mre effetive than plaeb in ntrlling tis and mre effetive than pimzide in imprving symptms f mrbid OCD and may be tried befre the typial anti- psyhti agents. When a typial antipsyhti is required in ases f severe tis, halperidl is generally regarded as the mediatin f hie. It is started in a lw dse (0.25 mg daily rally) that is gradually inreased (by 0.25 mg every 4 r 5 days) until there is maximum benefit with a minimum f side effets r until side effets limit further inrements. A ttal daily ral dse f between 2 mg and 8 mg is usually ptimal, but higher dses are sme- times neessary. Fluphenazine (1–15 mg rally daily) and pimzide (1–10 mg rally daily) are alternatives. Typial antipsyhtis an ause signifiant weight gain and arry a risk f tardive dyskinesias and ther lng-term, ptentially irreversible mtr side effets. Small ran- dmized trials r bservatinal studies have reprted benefit frm tpiramate, nitine, tetrahydrannabinl, balfen, and lnazepam. A number f ther media- tins, inluding deutetrabenazine, valbenazine, and e- pipam, are being studied fr the treatment f tis. Injetin f btulinum txin type A at the site f the mst distressing tis is smetimes wrthwhile and has fewer side effets than systemi antipsyhti therapy. Bilateral high-frequeny deep brain stimulatin at varius sites has been helpful in sme, therwise intratable, ases. »When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1021 29/06/21 8:50 PMChapTER 241022 CMDT 2022 »When to AdmitPatients  underging surgial (deep brain stimulatin) treatment shuld be admitted.M artinez-Ramirez D et al. Effiay and safety f deep brain stimu- latin in Turette syndrme: the Internatinal Turette Syn- drme Deep Brain Stimulatin Publi Database and Registry. JAMA Neurl. 2018;75:353. [PMID: 29340590] Pringsheim T et al. Pratie guideline remmendatins summary: treatment f tis in peple with Turette syndrme and hrni ti disrders. Neurlgy. 2019;92:896. [PMID: 31061208]DE MENTIAE S S E N T I A L S  O F  D I A G N O S I S »Progressive intellectual decline. »Not due to delirium or psychiatric disease. »Age is the main risk factor, followed by family his- tory and vascular disease risk factors.»General ConsiderationsDementia  is a prgressive deline in intelletual funtin that is severe enugh t mprmise sial r upatinal funtining. Mild cognitive impairment desribes a deline that has notresulted in a hange in the level f funtin. Althugh a few patients identify a preipitating event, mst experiene an insidius nset and gradual prgressin f symptms. Dementia typially begins after age 60, and the preva- lene dubles apprximately every 5 years thereafter; in persns aged 85 and lder, arund half have dementia. The prevalene f Alzheimer dementia is predited t be 15 millin by 2060 in the United States. In mst ases, the ause f dementia is aquired, either as a spradi primary neurdegenerative disease r as the result f anther disr- der, suh as strke (Table 24–6). Other risk fatrs fr dementia inlude family histry, diabetes mellitus, iga- rette smking, hypertensin, besity, a histry f signifi- ant head injury, and hearing lss. Vitamin D defiieny and hrni sleep deprivatin may als inrease the risk f dementia. Dementia is mre prevalent amng wmen, but this may be aunted fr by their lnger life expetany. Table 24–6. Common causes of age-related dementia (listed by prevalence).Disorder ptology Clinicl Fetures Alzheimer disease Plaques containing beta-amyloid pep- tide, and neurofibrillary tangles con- taining tau protein, occur throughout the neocortex.• Most common age-related neurodegenerative disease; incidence doubles every 5 years after age 60. • Short-term memory impairment is early and prominent in most cases. • Variable deficits of executive function, visuospatial function, and language. Vascular dementia Multifocal ischemic change. • Stepwise or progressive accumulation of cognitive deficits in association with repeated strokes. • Symptoms depend on localization of strokes. Dementia with Lewy bodiesHistologically indistinguishable from Parkinson disease: alpha-synuclein- containing Lewy bodies occur in the brainstem, midbrain, olfactory bulb, and neocortex. Alzheimer pathology may coexist.• Cognitive dysfunction, with prominent visuospatial and executive deficits. • Psychiatric disturbance, with anxiety, visual hallucinations, and fluctuating delirium. • Parkinsonian motor deficits with or after other features. • Cholinesterase inhibitors lessen delirium; poor tolerance of neuroleptics and dopaminergics. Frontotemporal dementia (FTD)Neuropathology is variable and defined by the protein found in intraneuronal aggregates. Tau protein, TAR DNA- binding protein 43 (TDP-43), or fused-in-sarcoma (FUS) protein account for most cases.• Peak incidence in the sixth decade; approximately equal to Alzheimer disease as a cause of dementia in patients under 60 years old. • Familial cases result from mutations in genes for tau, progranulin, or others. Beviorl vrint FTD • Deficits in empathy, social comportment, insight, abstract thought, and executive function. • Behavior is disinhibited, impulsive, and ritualistic, with prominent apathy and increased interest in sex or sweet/fatty foods. • Relative preservation of memory. • Focal right frontal atrophy. • Association with amyotrophic lateral sclerosis. Semntic vrint rimry rogressive si • Deficits in word-finding, single-word comprehension, object and category knowledge, and face recognition. • Behaviors may be similar to behavioral variant FTD. • Focal, asymmetric temporal pole atrophy. Nonfluent/grmmtic vrint rimry rogressive si • Speech is effortful with dysarthria, phonemic errors, sound distortions, and poor grammar. • Focal extrapyramidal signs and apraxia of the right arm and leg are common; overlaps with corticobasal degeneration. • Focal left frontal atrophy.CMDT22_Ch24_p0978-p1053.indd  1022 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1023 CMDT 2022Ph ysial ativity seems t be prtetive; eduatin, nging intelletual stimulatin, and sial engagement may als be prtetive, perhaps by prmting cognitive reserve, an imprved apaity t mpensate fr insidius neurdegeneratin. Dementia is distint frm delirium and psyhiatri dis- ease. Delirium is an aute nfusinal state that ften urs in respnse t an identifiable trigger, suh as drug r alhl intxiatin r withdrawal (eg, Wernike enepha- lpathy, desribed belw), mediatin side effets (espe- ially mediatins with antihlinergi prperties, antihistamines, benzdiazepines, sleeping aids, piids, neurleptis, rtisterids, and ther sedative r psyh- trpi agents), infetin (nsider ult urinary trat infetin r pneumnia in elderly patients), metabli dis- turbane (inluding an eletrlyte abnrmality; hypglye- mia r hyperglyemia; r a nutritinal, endrine, renal, r hepati disrder), sleep deprivatin, r ther neurlgi disease (seizure, inluding a pstital state, r strke). Delirium typially invlves fluctuating levels f arusal, inluding drwsiness r agitatin, and it imprves after remval r treatment f the preipitating fatr. Patients with dementia are espeially suseptible t episdes f delirium, but regnitin f dementia is nt pssible until delirium lifts. Fr this reasn, dementia is typially diag- nsed in utpatients wh are therwise medially stable, rather than in autely ill patients in the hspital. Psyhiatri disease smetimes leads t mplaints f impaired gnitin ( pseudodementia ). Impaired attentin is usually t blame, and in sme patients with depressin r anxiety, pr fus and nentratin may even be a pri- mary mplaint. The symptms shuld imprve with appr- priate psyhiatri treatment. Md disrders are mmnly seen in patients with neurdegenerative disease and in sme ases are an early symptm. There is sme evidene that a persistent, untreated md disrder may predispse t the develpment f an age-related dementia, and psyhiatri symptms an learly exaerbate gnitive impairment in patients wh already have dementia; therefre, suspiin f dementia shuld nt distrat frm apprpriate sreening fr and treatment f depressin r anxiety. »Clinical FindingsA.  Symptoms and SignsSym ptms and signs f the mmn auses f dementia are detailed in Table 24–6. Cliniians shuld be aware that a patient’s insight int a gnitive hange may be vague r absent, and llateral histry is essential t a prper evalua- tin. As patients age, primary are liniians shuld inquire peridially abut the presene f any gnitive symptms. Symptms depend n the area f the brain affeted. Short-term memory loss , invlving the repeating f ques- tins r stries and a diminished ability t reall the details f reent nversatins r events, frequently results frm pathlgi hanges in the hippampus. Word-finding dif- ficulty ften invlves diffiulty realling the names f pe- ple, plaes, r bjets, with lw-frequeny wrds affeted first, eventually resulting in speeh laden with prnuns and irumlutins. This prblem is thught t arise frmpathlgy at the temprparietal juntin f the left hemi- sphere. Prblems with artiulatin, flueny, mprehensin, r wrd meaning are anatmially distint and less m- mn. Visuospatial dysfunction may result in pr naviga- tin and getting lst in familiar plaes, impaired regnitin f previusly familiar faes and buildings, r truble dis- erning an bjet against a bakgrund. The right parietal lbe is ne f the brain areas impliated in suh symptms. Executive dysfunction may manifest by easy distratibility, impulsivity, mental inflexibility, nrete thught, slwed pressing speed, pr planning and rganizatin, r impaired judgment. Lalizatin may vary and uld inlude the frntal lbes r subrtial areas like the basal ganglia r erebral white matter. Apathy r indifferene, separate frm depressin, is mmn and may have a simi- lar anatmy as exeutive dysfuntin. Apraxia , r the lss f learned mtr behavirs, may result frm dysfuntin f the frntal r parietal lbes, espeially the left parietal lbe. The time f symptm nset must be established, but subtle, early symptms are ften apparent nly in retr- spet. Anther event, suh as an illness r hspitalizatin, may lead t new regnitin f existing symptms. Symp- tms ften aumulate ver time, and the nature of the earliest symptom is most helpful in forming the differential diagnosis. The histry shuld establish risk fatrs fr dementia, inluding family histry, ther hrni illnesses, and vasular disease risk fatrs. Finally, it is imprtant t dument the patient’s urrent apaity t perfrm basic and instrumental activities of daily living (see Chapter 4) and t nte the extent f deline frm the premrbid level f funtin. Indeed, it is this funtinal assessment that defines the presene and severity f dementia. The physial examinatin is imprtant t identify any ult medial illness. In additin, eye mvement abnr- malities, parkinsnism, r ther mtr abnrmalities may help identify an underlying neurlgi nditin. The wrkup shuld priritize the exlusin f nditins that are reversible r require separate therapy. Sreening fr depressin is neessary, alng with imaging and labratry wrkup, as indiated belw.B.  Neuropsychological AssessmentBrief q uantifiatin f gnitive impairment is indiated in a patient mplaining f gnitive symptms r if aregiv- ers raise similar nerns. The Folstein Mini Mental State Exam (MMSE), Montreal Cognitive Assessment (MoCA), Mini-Cg, and ther similar tests are brief, bjetive, and widely used but have imprtant limitatins: they are insen- sitive t mild gnitive impairment, they may be biased negatively by the presene f language r attentin prb- lems, and they d nt rrelate with funtinal apaity. A neurpsyhiatri evaluatin by a trained neurpsy- hlgist r psyhmetriian may be apprpriate. The gal f suh testing is t enhane lalizatin by defining the gnitive dmains that are impaired as well as t quantify the degree f impairment. There is n standard battery f tests, but a variety f metris is mmnly used t assess the symptm types highlighted abve. Assessments are mst aurate when a patient is well rested, mfrtable, and therwise medially stable.CMDT22_Ch24_p0978-p1053.indd  1023 29/06/21 8:50 PMChapTER 241024 CMDT 2022C.  ImagingBra in imaging with MRI r CT withut ntrast is indiated in any patient with a new, prgressive gnitive mplaint. The gal is t exlude ult erebrvasular disease, tumr, r ther identifiable strutural abnrmality, rather than t prvide psitive evidene f a neurdegenerative disease. Glbal r fal brain atrphy may be wrse than expeted fr age and uld suggest a partiular neurde- generative press, but suh findings are rarely speifi. PET with flurdexygluse (FDG) des nt nfirm r exlude any speifi ause f dementia but may be useful as an element f the wrkup in speifi linial irum- stanes, suh as disriminating between Alzheimer disease and frnttempral dementia in a patient with sme symp- tms f eah. PET imaging with a radilabeled ligand fr beta-amylid, ne f the pathlgi prteins in Alzheimer disease, is highly sensitive t amylid pathlgy and may prvide psitive evidene fr Alzheimer disease in a patient with gnitive deline. Hwever, after age 60 r 70, amylid plaques an aumulate in the absene f gnitive impair- ment; thus, the speifiity f a psitive amylid san dimin- ishes with age. Single-phtn emissin mputed tmgraphy ffers similar infrmatin as FDG-PET but is less sensitive. PET imaging with radilabeled ligands fr tau, a pathgeni prtein in Alzheimer disease, prgressive supranulear palsy, and sme frms f frnttempral dementia, als may help refine premrtem diagnsti auray.D . Laboratory FindingsSerum  levels f vitamin B12, free T4, and thyrid-stimulat- ing hrmne shuld be measured fr any patient with gnitive symptms. A serum rapid plasma reagin (RPR) and testing fr HIV shuld be nsidered. Other testing shuld be driven by linial suspiin, and ften inludes a mplete bld unt, serum eletrlytes, gluse, and lipid prfile. Althugh the presene f ne r tw ApE epsiln-4 alleles indiates an inreased risk f Alzheimer disease and ApE gentyping is linially available, it is f limited clinical utility. Finding an ApE epsiln-4 allele in a yung patient with dementia might raise the index f suspiin fr Alzheimer disease, but btaining a gentype in an elderly patient is unlikely t be helpful, and ding s in an asymptmati patient as a marker f risk fr Alzheimer disease is inapprpriate until a preventive therapy bemes available. Spinal fluid prtein measurements are als avail- able and may supprt the diagnsis f Alzheimer disease in the apprpriate linial ntext; levels f beta-amylid derease and tau prtein inrease in Alzheimer disease, but this testing shares sme f the same nerns as amylid PET imaging. »Differential DiagnosisIn  elderly patients with gradually prgressive gnitive symptms and n ther mplaint r sign, a neurde- generative disease is likely (Table 24–6). Deline begin- ning befre age 60, rapid prgressin, flutuating urse, unintended weight lss, systemi mplaints, r therunexplained symptms r signs raise suspiin fr a pr- ess ther than a neurdegenerative disease. In this ase, the differential is brad and inludes infetin r inflam- matry disease (nsider a lumbar punture t sreen fr ells r antibdies in the spinal fluid), neplasm r a para- neplasti nditin, endrine r metabli disease, drugs r txins, r ther nditins. Nrmal pressure hydrephalus is a diffiult diagnsis t establish. Symp- tms inlude gait apraxia (smetimes desribed as a “mag- neti” gait, as if the feet are stuk t the flr), urinary inntinene, and dementia. CT sanning r MRI f the brain reveals ventriles that are enlarged in bvius dispr- prtin t sulal widening and verall brain atrphy. »TreatmentA.  Nonpharmacologic ApproachesAe robic exercise (30 minutes several days per week) may redue the rate f funtinal deline and derease the demented patient’s aregiving needs and may redue the risk f dementia in nrmal individuals. Maintaining as ative a rle in the family and mmunity as pratially pssible is likely t be f benefit, emphasizing ativities at whih the patient feels nfident. Patients with neurde- generative diseases have a limited apaity t regain lst skills; fr instane, memry drills in a patient with Alzheimer disease are mre likely t lead t frustratin than benefit and studies shw that mputerized gnitive training des not imprve gnitin r funtin in demented patients. Vitamin E (1000 internatinal units twie daily) appears t redue the rate f funtinal deline in patients with Alzheimer disease, but des nt affet gnitin r prevent the develpment f Alzheimer disease in patients with mild gnitive impairment.B.  Cognitive SymptomsCh olinesterase inhibitors are first-line therapy fr Alzheimer disease and dementia with Lewy bdies (Table 24–6). They prvide mdest, symptmati treat- ment fr gnitive dysfuntin and may prlng the apaity fr independene but d notprevent disease prgressin. Cmmnly used mediatins inlude dnepezil (start at 5 mg rally daily fr 4 weeks, then inrease t 10 mg daily; a 23 mg daily dse is apprved fr mderate t severe Alzheimer disease, althugh its very mdest additinal effiay ver the 10 mg dse is vershad- wed by an inreased risk f side effets); rivastigmine (start at 1.5 mg rally twie daily, then inreasing every 2 weeks by 1.5 mg twie daily t a gal f 3–6 mg twie daily; r 4.6, 9.5, r 13.3 mg/24 h transdermally daily); and galantamine (start at 4 mg rally twie daily, then inreasing every 4 weeks by 4 mg twie daily t a gal f 8–12 mg twie daily; a ne-daily extended-release frmulatin is als available). Chlinesterase inhibitrs are notgiven fr frn- ttempral dementia beause they may wrsen behaviral symptms. Nausea and diarrhea are mmn side effets; synpe and ardia dysrhythmia are unmmn but mre serius. An ECG is ften btained befre and after starting therapy, partiularly in a patient with ardia disease r a histry f synpe.CMDT22_Ch24_p0978-p1053.indd  1024 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1025 CMDT 2022Mema ntine (start at 5 mg rally daily, then inrease by 5 mg per week up t a target f 10 mg twie daily) is apprved fr the treatment f mderate t severe Alzheimer disease. In frnttempral dementia, memantine is ineffe- tive and may wrsen gnitin. There is sme evidene that memantine may imprve gnitin and behavir amng patients with dementia with Lewy bdies. Disease-mdifying mediatins are nt yet available fr Alzheimer disease.C.  Mood and Behavioral DisturbancesSeletive  sertnin reuptake inhibitrs are generally safe and well tlerated in elderly, gnitively impaired patients, and they may be effiaius fr the treatment f depres- sin, anxiety, r agitatin. There is evidene t supprt the use f italpram (10–30 mg rally daily ) for agitation; side effets inlude QT prlngatin and wrsened gnitin at the highest dse. Parxetine shuld be avided beause it has antihlinergi effets; avid all triyli antidepres- sants fr the same reasn. Other antidepressant agents, suh as buprpin r venlafaxine, may be tried. Insmnia is mmn, and trazdne (25–50 mg rally at bedtime as needed) an be safe and effetive. Over-the- unter antihistamine hypntis must be avided, alng with benzdiazepines, beause f their tendeny t wrsen gnitin and preipitate delirium. Other presriptin hypntis suh as zlpidem may result in similar adverse reatins. Fr agitatin, impulsivity, and ther behavirs that interfere with safe aregiving, auses f delirium (detailed abve) shuld first be nsidered. When n reversible trigger is identified, treatment shuld be apprahed in a staged manner. Behaviral interventins, suh as rerien- tatin and distratin frm anxiety-prvking stimuli, are first-line. Ensure that the patient is kept ative during the day with bth physial exerise and mentally stimulating ativities, and that there is adequate sleep at night. Reas- sess the level f aregiving, and nsider inreasing the time spent diretly with an attendant. Next, ensure that apprpriate pharmalgi treatment f gnitin and md is ptimized. Finally, as a last resrt, when ther measures prve insuffiient and the patient’s behavirs raise safety nerns, nsider pharmalgi therapy. Citalpram r lw dses f an atypial antipsyhti mediatin suh as quetiapine (start 25 mg rally daily as needed, inreasing t tw t three times daily as needed) an be tried; even thugh atypial agents ause extrapyra- midal side effets less frequently than typial antipsyht- is, they shuld be used with partiular autin in a patient at risk fr falls, espeially if parkinsnian signs are already present. Regularly sheduled dsing f antipsy- htis is nt remmended, and if implemented shuld be reassessed n a frequent basis (eg, weekly), with attempts t taper ff as tlerated. There is an FDA blak bx warning against the use f all antipsyhti media- tins in elderly demented patients beause f an increased risk of death; the reasn fr the inreased mrtality is unlear. The mbinatin f dextrmethrphan and quini- dine (up t 30/10 mg rally twie daily) has shwn prmise in early linial trials.»Special CircumstancesA.  Rapidly Progressive DementiaWhen  dementia develps quikly, with bvius deline ver a few weeks t a few mnths, the syndrme may be lassified as a rapidly progressive dementia. The differen- tial diagnsis fr typial dementias is still relevant, but additinal etilgies must be nsidered, inluding prin disease; infetins; txins; neplasms; and autimmune and inflammatry diseases, inluding rtisterid- respnsive (Hashimt) enephalpathy and antibdy- mediated paraneplasti and nnparaneplasti enephalitis (Table 24–5). Wrkup shuld begin with brain MRI with ntrast and diffusin-weighted imaging, ru- tine labratry studies (serum vitamin B12, free T4, and thyrid-stimulating hrmne levels), serum RPR, HIV antibdy, Lyme serlgy, rheumatlgi tests (erythryte sedimentatin rate, C-reative prtein, and antinulear antibdy), anti-thyrglbulin and anti-thyrperxidase antibdy levels, paraneplasti and nnparaneplasti autimmune antibdies (Table 24–5), and erebrspinal fluid studies (ell unt and differential; prtein and glu- se levels; prtein eletrphresis fr liglnal bands; IgG index [spinal-fluid-t-serum-gamma-glbulin level] rati; and VDRL). Depending n the linial ntext, it may be neessary t exlude Wilsn disease (24-hur urine pper level); heavy metal intxiatin (urine heavy metal panel); and infetius enephalitis due t atypial bateria, viruses, fungi, and mybateria. Creutzfeldt-Jakob disease is a relatively mmn ause f rapidly prgressive dementia (see Chapter 32). Family histry is imprtant sine mutatins in PRNP , the gene fr the prin prtein, aunt fr arund 15% f ases. Diffu- sin-weighted MRI is the mst helpful diagnsti tl, lassially revealing rtial ribbning (a gyral pattern f hyperintensity) as well as restrited diffusin in the audate and anterir putamen. An eletrenephalgram ften shws peridi mplexes. Real time quaking indued nversin (RT-QuIC), in whih patient erebrspinal fluid is mixed with rembinant prin prtein and aggre- gatin f prin prtein is deteted, is a sensitive and spe- ifi diagnsti test. Refleting the high rate f neurnal death, erebrspinal fluid levels f the intraneurnal pr- teins tau, 14-3-3, and neurn-speifi enlase are ften elevated, althugh this finding is neither sensitive nr speifi.B.  Driving and DementiaI t is remmended that anypatient with mild dementia or worse should discontinue driving. Mst states have laws regulating driving amng gnitively impaired individuals, and many require the liniian t reprt the patient’s diag- nsis t the publi health department r department f mtr vehiles. There is n evidene that driving lasses help patients with neurdegenerative diseases. »When to ReferAll  patients with new, unexplained gnitive deline shuld be referred.CMDT22_Ch24_p0978-p1053.indd  1025 29/06/21 8:50 PMChapTER 241026 CMDT 2022 »When to AdmitAdmi ssin t the hspital shuld nly ur when essen- tial in patients with dementia due t inreased risk f develping hspital-aquired delirium.Arvanitakis  Z et al. Diagnsis and management f dementia: review. JAMA. 2019;322:1589. [PMID: 31638686] Law CK et al. Physial exerise attenuates gnitive deline and redues behaviral prblems in peple with mild gnitive impairment and dementia: a systemati review. J Physither. 2020;66:9. [PMID: 31843427]WE RNICKE ENCEPHALOPATHY & KORSAKOFF SYNDROMEW ernicke encephalopathy is haraterized by nfusin, ataxia, and nystagmus leading t phthalmplegia (lateral retus musle weakness, njugate gaze palsies); peripheral neurpathy may als be present. It is due to thiamine defi- ciency and in the United States urs mst mmnly in patients with alhlism. It may als ur in patients with AIDS r hyperemesis gravidarum, and after bariatri sur- gery. In suspeted ases, thiamine (100 mg) is given intra- venusly immediately and then intramusularly n a daily basis until a satisfatry diet an be ensured after whih the same dse is given rally. Sme guidelines remmend initial dses f 200–500 mg intravenusly three times daily fr the first 5–7 days f treatment. Intravenus gluse given before thiamine may preipitate the syndrme r wrsen the symptms. The diagnsis is nfirmed by the respnse in 1 r 2 days t treatment, whih must nt be delayed while awaiting labratry nfirmatin f thia- mine defiieny frm a bld sample btained prir t thiamine administratin. Korsakoff syndrome urs in mre severe ases; it inludes antergrade and retrgrade amnesia and smetimes nfabulatin, and may nt be regnized until after the initial delirium has lifted.ST UPOR & COMAE S S E N T I A L S  O F  D I A G N O S I S »Level of consciousness is depressed. »Stuporous patients respond only to repeated vig- orous stimuli. »Comatose patients are unarousable and unresponsive. »General ConsiderationsThe pa tient wh is stuporous is unrespnsive exept when subjeted t repeated vigrus stimuli, while the comatose patient is unarusable and unable t respnd t external events r inner needs, althugh reflex mvements and psturing may be present. Cma is a majr mpliatin f serius entral nervus system disrders. It an result frm seizures,hypthermia, metabli disturbanes, r strutural lesins ausing bilateral erebral hemispheri dysfuntin r a disturbane f the brainstem retiular ativating system. A mass lesin invlving ne erebral hemisphere may ause ma by mpressin f the brainstem. »Assessment & Emergency MeasuresThe  diagnsti wrkup f the matse patient must pr- eed nmitantly with management. Supprtive therapy fr respiratin r bld pressure is initiated; in hypther- mia, all vital signs may be absent and all suh patients shuld be rewarmed befre the prgnsis is assessed. The patient an be psitined n ne side with the nek partly extended, dentures remved, and seretins leared by sutin; if neessary, the pateny f the airways is main- tained with an rpharyngeal airway. Bld is drawn fr serum gluse, eletrlyte, and alium levels; arterial bld gases; liver bihemial and kidney funtin tests; and txilgi studies as indiated. Thiamine (100 mg), fllwed by dextrse 50% (25 g), and nalxne (0.4–1.2 mg) are given intravenusly withut delay. Further details are then btained frm attendants f the patient’s medial histry, the irumstanes surrunding the nset f ma, and the time urse f subsequent events. Abrupt nset f ma suggests subarahnid hemrrhage, brainstem strke, r intraerebral hemrrhage, whereas a slwer nset and prgressin ur with ther strutural r mass lesins. Urgent nnntrast CT sanning f the head is apprpriate if it an be btained diretly frm the emer- geny department, in rder t identify intraranial hemr- rhage, brain herniatin, r ther strutural lesin that may require immediate neursurgial interventin. A metabli ause is likely with a preeding intxiated state r agitated delirium. On examinatin, attentin is paid t the behav- iral respnse t painful stimuli, the pupils and their respnse t light, the respnse t tuhing the rnea with a wisp f sterile gauze, psitin f the eyes and their mve- ment in respnse t passive mvement f the head and ie-water alri stimulatin, and the respiratry pattern.A.  Response to Painful StimuliPurp seful limb withdrawal frm painful stimuli implies that sensry pathways frm and mtr pathways t the stimulated limb are funtinally intat. Unilateral absene f respnses despite appliatin f stimuli t bth sides f the bdy in turn implies a rtispinal lesin; bilateral absene f respnsiveness suggests brainstem invlvement, bilateral pyramidal trat lesins, r psyhgeni unrespnsiveness. Dertiate (flexr) psturing may ur with lesins f the internal apsule and rstral erebral pedunle and deere- brate (extensr) psturing with dysfuntin r destrutin f the midbrain and rstral pns. Deerebrate psturing urs in the arms ampanied by flaidity r slight flexr respnses in the legs in patients with extensive brainstem damage extending dwn t the pns at the trigeminal level.B.  Ocular Findings1.  Pupils— Hypthalami disease presses may lead t unilateral Hrner syndrme, while bilateral dienephaliCMDT22_Ch24_p0978-p1053.indd  1026 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1027 CMDT 2022inv lvement r destrutive pntine lesins may lead t small but reative pupils. Ipsilateral pupillary dilatin with n diret r nsensual respnse t light urs with m- pressin f the third ranial nerve, eg, with unal hernia- tin. The pupils are slightly smaller than nrmal but respnsive t light in many metabli enephalpathies; hwever, they may be fixed and dilated fllwing verds- age with atrpine r splamine, and pinpint (but respnsive) with piids. 2. Corneal reflex— Tuhing the rnea with a wisp f sterile gauze r ttn shuld eliit a blink reflex. The affer- ent limb f the ar is mediated by the fifth ranial nerve; the efferent limb by the seventh nerve. A unilateral absent rneal reflex implies damage t the ipsilateral pns r a trigeminal defiit. Bilateral lss an be seen with large pn- tine lesins r in deep pharmalgi ma. 3. Eye movements— Cnjugate deviatin f the eyes t the side suggests the presene f an ipsilateral hemispheri lesin, a ntralateral pntine lesin, r nging seizures frm the ntralateral hemisphere. A mesenephali lesin leads t dwnward njugate deviatin. Dysnjugate u- lar deviatin in ma implies a strutural brainstem lesin unless there was preexisting strabismus. The ulmtr respnses t passive head turning and t alri stimulatin relate t eah ther and prvide m- plementary infrmatin. In respnse t brisk rtatin f the head frm side t side and t flexin and extensin f the head, nrmally nsius patients with pen eyes d nt exhibit ntraversive njugate eye deviatin ( oculocephalic reflex ) unless there is vluntary visual fixatin r bilateral frntal pathlgy. With rtial depressin in lightly ma- tse patients, a brisk ulephali reflex is seen. With brain- stem lesins, this ulephali reflex bemes impaired r lst, depending n the site f the lesin. Theoculovestibular reflex is tested by alri stimula- tin using irrigatin with ie water. In nrmal patients, jerk nystagmus is eliited fr abut 2 r 3 minutes, with the slw mpnent tward the irrigated ear. In unnsius patients with an intat brainstem, the fast mpnent f the nystagmus disappears, s that the eyes tnially deviate tward the irrigated side fr 2–3 minutes befre returning t their riginal psitin. With impairment f brainstem funtin, the respnse bemes abnrmal and finally dis- appears. In metabli ma, ulephali and ulves- tibular reflex respnses are preserved, at least initially.C.  Respiratory PatternsDiseases ausing ma may lead t resp iratry abnrmali- ties. Cheyne-Stokes respiration (in whih episdes f deep breathing alternate with perids f apnea) may ur with bihemispheri r dienephali disease r in metabli disrders. Central neurogenic hyperventilation urs with lesins f the brainstem tegmentum; apneustic breathing (in whih there are prminent end-inspiratry pauses) suggests damage at the pntine level (eg, due t basilar artery lusin); and ataxic breathing (a m- pletely irregular pattern f breathing with deep and shallw breaths urring randmly) is assiated with lesins f the lwer pntine tegmentum and medulla.1. Stuor & Com Due to Structurl LesionsSupra tentorial mass lesions tend t affet brain funtin in a systemati way. There may initially be signs f hemi- spheri dysfuntin, suh as hemiparesis. As ma devel- ps and deepens, erebral funtin bemes prgressively disturbed, prduing a preditable prgressin f neur- lgi signs that suggest rstraudal deteriratin. Thus, as a supratentrial mass lesin begins t impair the dienephaln, the patient bemes drwsy, then stu- prus, and finally matse. There may be Cheyne-Stkes respiratin; small but reative pupils r an ipsilateral third nerve palsy due t unal herniatin; nrmal ulephali respnses with side-t-side head mvements but sme- times an impairment f reflex upward gaze with brisk flexin f the head; tni ipsilateral deviatin f the eyes in respnse t vestibular stimulatin with ld water; and initially a psitive respnse t pain but subsequently nly dertiate psturing. With further prgressin, midbrain failure urs. Mtr dysfuntin prgresses frm derti- ate t bilateral deerebrate psturing in respnse t pain- ful stimuli; Cheyne-Stkes respiratin is gradually replaed by sustained entral hyperventilatin; the pupils beme middle-sized and fixed; and the ulephali and ul- vestibular reflex respnses beme impaired, abnrmal, r lst. As the pns and then the medulla fail, the pupils remain unrespnsive; ulvestibular respnses are unb- tainable; respiratin is rapid and shallw; and painful stimuli may lead nly t flexr respnses in the legs. Finally, respiratin bemes irregular and stps, the pupils ften then dilating widely. In ntrast, a subtentorial (ie, brainstem) lesion may lead t an early, smetimes abrupt disturbane f n- siusness withut any rderly rstraudal prgressin f neurlgi signs. Cmpressive lesins f the brainstem, espeially erebellar hemrrhage, may be linially indis- tinguishable frm intraparenhymal presses. A strutural lesin is suspeted if the findings suggest fality. In suh irumstanes, a CT san shuld be per- frmed befre, r instead f, a lumbar punture in rder t avid any risk f erebral herniatin. Further management is f the ausal lesin and is nsidered separately under the individual disrders.2.  Stuor & Com Due to Metbolic DisturbncesPa tients with a metabli ause f ma generally have signs f pathy, diffuse, and symmetri neurlgi invlve- ment that annt be explained by lss f funtin at any single level r in a sequential manner, althugh fal r lateralized defiits may ur in hypglyemia. Pupillary reativity is usually preserved. Cmatse patients with meningitis, enephalitis, r subarahnid hemrrhage may als exhibit little in the way f fal neurlgi signs, hw- ever, and linial evidene f meningeal irritatin is sme- times very subtle in matse patients. Examinatin f the erebrspinal fluid in suh patients is essential t establish the rret diagnsis. In patients with ma due t erebral ishemia and hypxia, the absene f pupillary light reflexes 24 hursCMDT22_Ch24_p0978-p1053.indd  1027 29/06/21 8:50 PMChapTER 241028 CMDT 2022after retu rn f spntaneus irulatin indiates that there is little hane f regaining independene; absent rneal reflexes r absent r extensr mtr respnses at 72 hurs als indiate a grim prgnsis. Physial findings are less reliable preditrs f utme amng thse treated with therapeuti hypthermia, althugh absent rneal r pupillary light reflexes at 72 hurs likely indiate a pr prgnsis, as d bilaterally absent rtial smatsensry evked ptentials in respnse t median nerve stimulatin after the patient has returned t nrmthermia. Treatment f metabli enephalpathy is f the under- lying disturbane and is nsidered in ther hapters. If the ause f the enephalpathy is bsure, all mediatins exept essential nes may have t be withdrawn in ase they are respnsible fr the altered mental status.3.  Brin DetBrain  death urs when there is mplete and irreversible essatin f all brain funtin; althugh the rgans an be maintained with mehanial ventilatin fr the purpses f dnatin, in mst untries the diagnsis f brain death is equivalent to a declaration of death. T diagnse brain death, the ause f ma must be established, be mpati- ble with a knwn ause f brain death, and be irreversible. Reversible ma simulating brain death may be seen with hypthermia (temperature lwer than 32°C) and verds- age with entral nervus system depressant drugs. These nditins must be exluded by warming the patient and allwing enugh time fr all sedating mediatins t be metablized (ie, at least five half-lives) r by measuring serum levels. Severe bld pressure, eletrlyte, aid-base, and endrine derangements annt be present. Finally, a neurlgi examinatin must demnstrate that the patient is matse (ie, n eye pening and n respnse t entral r peripheral pain); has lst all brain- stem reflex respnses, inluding the pupillary, rneal, ulvestibular, ulephali, rpharyngeal, and ugh reflexes; and has n respiratry drive. The respnse t pain shuld be absent r nly nsist f spinal reflex mve- ments; deerebrate r dertiate psturing is nt nsis- tent with brain death. Absene f respiratry drive is demnstrated with an apnea test (absene f spntaneus respiratry ativity at a PAco2f at least 60 mm Hg r after a rise f 20 mm Hg frm baseline). Certain anillary tests may assist the determinatin f brain death if an apnea test annt be perfrmed but are nt essential. These inlude an iseletri eletrenepha- lgram, when the rerding is made arding t the re- mmendatins f the Amerian Clinial Neurphysilgy Siety, and demnstratin f an absent erebral irula- tin by intravenus radiistpe erebral angigraphy r by fur-vessel ntrast erebral angigraphy.4.  persistent Vegettive SttePa tients with severe bilateral hemispheri disease may shw sme imprvement frm an initially matse state, s that, after a variable interval, they appear t be awake but lie mtinless and withut evidene f awareness r higher mental ativity. This is alled a “persistent”vegetative state ne it has lasted ver 4 weeks and has als been variusly referred t as akineti mutism, apalli state, r ma vigil. Patients in a vegetative state frm a medial ause (eg, anxi brain injury) fr mre than 3 mnths and frm a traumati brain injury fr mre than 12 mnths are said t be in a “chronic” vegetative state, frm whih a few patients may regain nsiusness but remain severely disabled.5.  Minimlly Conscious StteIn this  state, patients exhibit innsistent evidene f n- siusness. There is sme degree f funtinal revery f behavirs suggesting self- r envirnmental-awareness, suh as basi verbalizatin r ntext-apprpriate gestures, emtinal respnses (eg, smiling) t emtinal but nt neutral stimuli, r purpsive respnses t envirnmental stimuli (eg, a finger mvement r eye blink apparently t mmand). Further imprvement is manifest by the rest- ratin f mmuniatin with the patient. The minimally nsius state may be temprary r permanent. Little infrmatin is available abut its natural histry r lng- term utlk, whih reflets the underlying ause. The likelihd f useful funtinal revery diminishes with time; after 12 mnths, patients are likely t remain severely disabled and withut a reliable means f mmuniatin. Prgnstiatin is diffiult. Amantadine (100–200 mg rally daily) may hasten revery when given t patients in a vegetative r minimally nsius state 4–16 weeks after traumati brain injury.6.  Locked-In Syndrome (De-Efferented Stte)Aute  destrutive lesins (eg, infartin, hemrrhage, demyelinatin, enephalitis) invlving the ventral pns and sparing the tegmentum may lead t a mute, quadripa- reti but nsius state in whih the patient is apable f blinking and vluntary eye mvement in the vertial plane, with preserved pupillary respnses t light. Suh a patient an mistakenly be regarded as matse. Cliniians shuld regnize that “lked-in” individuals are fully aware f their surrundings. The prgnsis is usually pr, but revery has asinally been reprted in sme ases, inluding resumptin f independent daily life. A similar nditin may ur with severe Guillain-Barré syndrme and has a better prgnsis.Giain  JT et al. Pratie guideline update remmendatins summary: disrders f nsiusness: reprt f the Guideline Develpment, Disseminatin, and Implementatin Subm- mittee f the Amerian Aademy f Neurlgy; the Amerian Cngress f Rehabilitatin Mediine; and the Natinal Institute n Disability, Independent Living, and Rehabili- tatin Researh. Neurlgy. 2018;91:450. [PMID: 30089618]HE AD INJURYT rauma is the mst mmn ause f death in yung pe- ple, and head injury aunts fr almst half f these trauma-related deaths. Head injury severity ranges frm concussion tsevere traumatic brain injury (TBI). Cn- ussin is bradly defined as an alteratin in mental statusCMDT22_Ch24_p0978-p1053.indd  1028 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1029 CMDT 2022aused  by trauma with r withut lss f nsiusness. The term nussin is ften used synnymusly with mild TBI. Grades f TBI are traditinally defined by the Glasgw Cma Sale (GCS) measured 30 minutes after injury (Table 24–7).Head trauma may ause erebral injury thrugh a vari- ety f mehanisms (Table 24–8). Central t management is determinatin f whih patients need head imaging and bservatin. Of partiular nern is identifiatin f patients with epidural and subdural hematma, wh may present with nrmal neurlgi findings shrtly after injury ( lucid interval ) but rapidly deterirate thereafter, and in whm surgial interventin is life-saving. »Clinical FindingsA.  Symptoms and SignsCmmn  symptms f nussin that develp autely inlude headahe, nausea, vmiting, nfusin, disrienta- tin, dizziness, and imbalane. A perid f amnesia enmpassing the traumati event and a variable perid f time leading up t the trauma is typial. Lss f nsius- ness may ur. Additinal symptms f phtphbia, phnphbia, diffiulty nentrating, irritability, and sleep and md disturbanes may develp ver the fllw- ing hurs t days. Examinatin is usually nrmal, althugh rientatin and attentin, shrt-term memry, and rea- tin time may be impaired. Persistent r prgressive deline in the level f nsiusness after the initial injury, r fal neurlgi findings, suggests the need fr urgent imaging and neursurgial nsultatin. Patients shuld als be examined fr signs f salp la- eratins, faial and skull frature, and nek injury. The linial signs f basilar skull frature inlude bruising Table 24–8. Acute cerebral sequelae of head injury (listed in alphabetical order).Sequele Clinicl Fetures ptology Acute epidural hemorrhageHeadache, confusion, somnolence, seizures, and focal defi- cits occur several hours after injury (lucid interval) and lead to coma, respiratory depression, and death unless treated by surgical evacuation.Tear in meningeal artery, vein, or dural sinus, leading to hematoma visible on CT scan. Acute subdural hemorrhageSimilar to epidural hemorrhage, but interval before onset of symptoms is longer. Neurosurgical consultation for consideration of evacuation.Hematoma from tear in veins from cortex to superior sagittal sinus or from cerebral laceration, visible on CT scan. Cerebral contusion or lacerationLoss of consciousness longer than with concussion. Focal neurologic deficits are often present. May lead to death or severe residual neurologic deficit.Bruising on side of impact (coup injury) or contralaterally (contrecoup injury). Vasogenic edema, multiple petechial hemorrhages, and mass effect. May have subarachnoid bleeding. Hernia- tion may occur in severe cases. Cerebral laceration specifically involves tearing of the cerebral tissue and pia-arachnoid overlying a contusion. Cerebral hemorrhageGenerally develops immediately after injury. Clinically resembles hypertensive hemorrhage. Surgery to relieve mass effect is sometimes necessary.Hematoma, visible on CT scan. Concussion A transient, trauma-induced alteration in mental status that may or may not involve loss of consciousness. Symptoms and signs include headache, nausea, disori- entation, irritability, amnesia, clumsiness, visual distur- bances, and focal neurologic deficit.Unknown; likely mild diffuse axonal injury and excito- toxic neuronal injury. Cerebral contusion may occur. Diffuse axonal injury Persistent loss of consciousness, coma, or persistent vege- tative state resulting from severe rotational shearing forces or deceleration.Imaging may be normal or may show tiny, scattered white matter hemorrhages. Histology reveals torn axons.Table 24–7. Glasgow Coma Scale.1point sEye OeningVerbl ResonseMotor Resonse 1 None None None 2 To pain Vocal but not verbalExtension 3 To voice Verbal but not conversationalFlexion 4 Spontaneous Conversational but disorientedWithdraws from pain 5 Spontaneous Oriented Localizes pain 6 Spontaneous Oriented Obeys commands1 GCS score indicating severity of traumatic brain injury (TBI): mild, 13–15; moderate , 9–12; severe , ≤ 8. Reproduced, with permission, from Aminoff MJ et al. Clinical Neurology , 9th ed, McGraw-Hill Education, 2015; Data from Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet . 1974;304:81–4.CMDT22_Ch24_p0978-p1053.indd  1029 29/06/21 8:50 PMChapTER 241030 CMDT 2022abut the  rbit ( raccoon sign ), bld in the external audi- try meatus ( Battle sign ), and leakage f erebrspinal fluid (whih an be identified by its gluse r beta- 2-transferrin ntent) frm the ear r nse. Cranial nerve palsies (invlving espeially the first, send, third, furth, fifth, seventh, and eighth nerves in any mbinatin) may als ur. The head and nek shuld be immbilized until imaging an be perfrmed.B.  Imaging and Other InvestigationsCurren t remmendatins are that head CT be perfrmed in patients with nussin and any f the fllwing: GCS sre less than 15, fal neurlgi defiit, seizure, agu- lpathy, aged 65 r lder, skull frature, persistent headahe r vmiting, retrgrade amnesia exeeding 30 minutes, intxiatin, r sft tissue injury f the head r nek. Otherwise, patients an be sent hme as lng as a respnsible aregiver an hek the patient at hurly inter- vals fr the next 24 hurs. Patients requiring imaging shuld be admitted unless the head CT is nrmal, the GCS sre is 15, there have been n seizures, there is n predis- psitin t bleeding, and they an be mnitred by a are- giver at hme. Beause injury t the spine may have ampanied head trauma, ervial spine radigraphs (three views) r CT shuld always be btained in matse patients and in patients with severe nek pain r a defiit pssibly related t rd mpressin. »TreatmentHead  injury an ften be prevented by helmets, seatbelts, and ther prtetive equipment. After intraranial bleeding has been exluded linially r by head CT, treatment f mild TBI is aimed at prmt- ing reslutin f pstnussive symptms and preventing recurrent injury, whih inreases the risk f hrni neu- rbehaviral impairment and delays revery. Rarely, a reurrent nussin while a patient is still symptmati frm a first nussin may lead t fatal erebral edema (second impact syndrome ). These bservatins frm the basis f the remmendatin that patients at risk fr reur- rent nussin (eg, athletes) be held ut f the risky ativ- ity until their nussive symptms have fully reslved. In patients hspitalized with mderate r severe TBI, management ften requires a multidisiplinary apprah due t multiple nmitant injuries. Elevated intraranial pressure an result frm diffuse axnal injury r a hema- tma requiring surgial evauatin, r frm a variety f medial auses. Dempressive ranietmy may redue therwise refratry intraranial hypertensin but des nt imprve neurlgi utme. Hypthermia is assi- ated with wrsened funtinal utmes. Beause bridging veins between the brain and venus sinuses beme mre vulnerable t shear injury as the brain atrphies, a subdural hematoma may develp days r weeks fllwing head injury in elderly patients r even ur spntaneusly. Clinial presentatin an be subtle, ften with mental hanges suh as slwness, drwsiness, headahe, nfusin, r memry disturbane. Falneurlgi defiits suh as hemiparesis r hemisensry disturbane are less mmn. Surgial interventin is indi- ated if the hematma is 10 mm r mre in thikness r there is a midline shift f 5 mm r mre; if there is a deline in GCS sre f 2 r mre frm injury t hspital admis- sin; r if ne r bth pupils are fixed and dilated. Salp laeratins and depressed skull fratures shuld be treated surgially as apprpriate. Simple skull fratures require n speifi treatment. If there is any leakage f erebrspinal fluid, nservative treatment, with elevatin f the head, restritin f fluids, and administratin f aetazlamide (250 mg rally fur times daily), is ften helpful; if the leak ntinues fr mre than a few days, lumbar subarahnid drainage may be neessary. Antibit- is are given if infetin urs, based n ulture and sen- sitivity studies; vainatin against pneumus is remmended (see Table 30–7). Only very asinal patients require intraranial repair f the dural defet beause f persistene f the leak r reurrent meningitis. »PrognosisMdera te and severe TBI may result in permanent gni- tive and mtr impairment depending n the severity and latin f the initial injury. Initial GCS and head CT find- ings have prgnsti value. Amng patients with a GCS sre f 8 r less at presentatin, mrtality apprahes 30% and nly ne-third f survivrs regain funtinal indepen- dene. Cgnitive impairment tends t affet frntal and tempral lbe funtin, ausing defiits in attentin, mem- ry, judgment, and exeutive funtin. Behaviral dysregu- latin, depressin, and disinhibitin an impair sial funtining. Ansmia, presumably due t shearing f fibers frm the nasal epithelium, is mmn. Epilepsy an develp after TBI, espeially with mre severe injury. Amng patients with severe TBI (typially lss f nsiusness fr at least 12–24 hurs, intraranial hematma, depressed skull frature, r erebral ntu- sin), phenytin r levetiraetam is typially given fr 7 days t redue the inidene f early psttraumati sei- zures; this is dne exlusively t minimize aute mplia- tins resulting frm suh seizures and des nt prevent the develpment f psttraumati epilepsy. Amng patients with mild TBI, symptms f nus- sin reslve in mst patients by 1 mnth and in the vast majrity by 3 mnths. Prlnged pstnussive symp- tms are unmmn, persisting at 1 year in 10–15% f patients. Risk fatrs fr prlnged pstnussive symp- tms inlude ative litigatin regarding the injury; repeated nussins; and GCS sre f 13 r less at presentatin. Headahes ften have migrainus features and may respnd t triyli antidepressants r beta-blkers (see Table 24–1). Opiids shuld be avided t minimize the risk f mediatin veruse headahe. Md symptms may respnd t antidepressants, anxilytis, and gnitive behaviral therapy. There appears t be an assiatin between head trauma and the later develpment f neurdegenerative disease, suh as Alzheimer disease, Parkinsn disease, r amytrphi lateral slersis (ALS). Nrmal pressure hydrephalus may als ur. Repetitive, mild headCMDT22_Ch24_p0978-p1053.indd  1030 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1031 CMDT 2022inju ry, suh as that whih urs in athletes r military persnnel, an lead t chronic traumatic encephalopathy, a distint pathlgi entity assiated with md and gnitive hanges and haraterized by the abnrmal aggregatin f tau r ther prteins either fally r glbally in the erebral rtex. Whether hrni trau- mati enephalpathy is a stati respnse t reurrent head injury r a prgressive neurdegenerative disease is nt knwn, but the severity f neurpathlgy appears t rrelate t lifetime expsure t repetitive head injury. »When to Refer• Patients with fal neurlgi defiits, altered n- siusness, r skull frature. •Patients with late mpliatins f head injury, eg, psttraumati seizure disrder r nrmal pressure hydrephalus. »When to Admit• Patients with nussin and GCS sre less than 15, predispsitin t bleeding, seizure, r n respnsible aregiver at hme. •Patients with abnrmal head CT.Ma riani M et al. Clinial presentatin f hrni traumati enephalpathy. Semin Neurl. 2020;40:370. [PMID: 32740900] Mish MR et al. Sprts mediine update: nussin. Emerg Med Clin Nrth Am. 2020;38:207. [PMID: 31757251]MU LTIPLE SCLEROSISE S S E N T I A L S  O F  D I A G N O S I S »Episodic neurologic symptoms. »Patient usually < 55 years of age at onset. »Single pathologic lesion cannot explain clinical findings. »Multiple foci best visualized by MRI. »General ConsiderationsThis  mmn neurlgi disrder, whih prbably has an autimmune basis, has its greatest inidene in yung adults. Epidemilgi studies indiate that multiple slersis is muh mre mmn in persns f western Eurpean lineage wh live in temperate znes. N ppulatin with a high risk fr multiple slersis exists between latitudes 40° N and 40° S. A geneti susepti- bility t the disease is present. Pathlgially, fal— ften perivenular—areas f demyelinatin with reative glisis are fund sattered in the white matter f the brain and spinal rd and in the pti nerves. Axnal damage als urs.»Clinical FindingsA.  Symptoms and SignsThe  mmn initial presentatin is weakness, numbness, tingling, r unsteadiness in a limb; spasti paraparesis; retrbulbar pti neuritis; diplpia; dysequilibrium; r a sphinter disturbane suh as urinary urgeny r hesi- tany. Symptms may disappear after a few days r weeks, althugh examinatin ften reveals a residual defiit. Several frms f the disease are regnized. In mst patients, there is an interval f mnths r years after the initial episde befre new symptms develp r the riginal nes reur (relapsing-remitting disease) . Eventually, hw- ever, relapses and usually inmplete remissins lead t inreasing disability, with weakness, spastiity, and ataxia f the limbs, impaired visin, and urinary inntinene. The findings n examinatin at this stage mmnly inlude pti atrphy; nystagmus; dysarthria; and pyramidal, sen- sry, r erebellar defiits in sme r all f the limbs. In sme f these patients, the linial urse hanges s that a steady deteriratin urs, unrelated t aute relapses (secondary progressive disease) . Less mmnly, symp- tms are steadily prgressive frm their nset, and disability develps at a relatively early stage (primary progressive disease) . The diagnsis annt be made with nfidene unless the ttal linial piture indiates invlvement f different parts of the central nervous system at different times. Fatigue is mmn in all frms f the disease. A number f fatrs (eg, infetin) may preipitate r trigger exaerbatins. Relapses are redued in pregnany but are mre likely during the 2 r 3 mnths fllwing pregnany, pssibly beause f the inreased demands and stresses that ur in the pstpartum perid.B.  ImagingMRI  f the brain and ervial rd has a majr rle in exluding ther auses f neurlgi dysfuntin and in demnstrating the presene f multiple lesins. In T1-weighted images, hypintense “blak hles” prbably represent areas f permanent axnal damage. Gadlinium- enhaned T1-weighted images may highlight areas f ative inflammatin with breakdwn f the bld-brain barrier, whih helps identify newer lesins. T2-weighted images prvide infrmatin abut disease burden r ttal number f lesins, whih typially appear as areas f high signal intensity. CT sans are less helpful than MRI. In patients with myelpathy alne and n linial r labratry evidene f mre widespread disease, MRI r myelgraphy is neessary t exlude a ngenital r aquired surgially treatable lesin. In patients with mixed pyramidal and erebellar defiits in the limbs, the framen magnum regin must be visualized t exlude the pssibil- ity f Arnld-Chiari malfrmatin, in whih parts f the erebellum and lwer brainstem are displaed int the ervial anal.C.  Laboratory and Other StudiesA  definitive diagnsis an never be based slely n the labratry findings. If there is linial evidene f nly aCMDT22_Ch24_p0978-p1053.indd  1031 29/06/21 8:50 PMChapTER 241032 CMDT 2022single  lesin in the entral nervus system, multiple sler- sis annt prperly be diagnsed unless it an be shwn that ther regins are affeted sublinially. Visual, brain- stem auditry, and smatsensry evked ptentials are helpful in this regard, but ther disrders may als be haraterized by multifal eletrphysilgi abnrmali- ties refleting disease f entral white matter. Certain infetins (eg, HIV , Lyme disease, syphilis), nnetive tissue diseases (eg, systemi lupus erythematsus, Sjögren syndrme), saridsis, metabli disrders (eg, vitamin B12 defiieny), and lymphma may therefre require exlusin. There may be mild lymphytsis r a slightly inreased prtein nentratin in the erebrspinal fluid, espeially sn after an aute relapse. Elevated IgG in erebrspinal fluid and disrete bands f IgG (liglnal bands) are present in many patients. The presene f suh bands is nt speifi, hwever, sine they have been fund in a variety f inflammatry neurlgi disrders and asinally in patients with vasular r neplasti disrders f the ner- vus system. Vitamin D defiieny may be assiated with an inreased risk f develping multiple slersis; randmized trials have nt shwn vitamin D supplementatin redues attak rate r prgressin in relapsing remitting disease.D . DiagnosisMultiple slersi s shuld nt be diagnsed unless there is evidene that tw r mre different regins f the entral white matter ( dissemination in space ) have been affeted at different times ( dissemination in time ); the mst widely used diagnsti algrithm is the 2017 revisin t the MDnald riteria. The diagnsis may be made in a patient with tw r mre typial attaks and bjetive evidene n linial examinatin f tw lesins (eg, pti disk atrphy and pyramidal weakness), r bjetive evi- dene f ne lesin with lear-ut histrial evidene the ther attak was typial f multiple slersis and in a dis- tint neuranatmi latin, and when n alternative explanatin fr the patient’s presentatin has been fund. T fulfill the riterin f disseminatin in spae in a patient with tw linial attaks but bjetive linial evi- dene f nly ne lesin, MRI shuld demnstrate at least ne lesin in at least tw f fur typial sites (periventriu- lar, rtial r juxtartial, infratentrial, r spinal); alternatively, an additinal attak lalized t a different site suffies. The riterin f disseminatin in time in a patient with nly ne attak an be fulfilled by the simul- taneus presene f gadlinium-enhaning and nnen- haning lesins at any time (inluding at initial examinatin); the presene f liglnal bands unique t the erebrspinal fluid; a new lesin n fllw-up MRI; r a send attak. Lesins in the pti nerve n MRI in patients with pti neuritis annt be used t fulfill the MDnald riteria fr disseminatin in spae r time. Pri- mary prgressive disease requires at least a year f prgres- sin, plus tw f three f the fllwing: at least ne typial brain lesin, at least tw spinal lesins, r liglnal banding in the erebrspinal fluid.In patients with a single linial event wh d nt sat- isfy riteria fr multiple slersis, a diagnsis f a clinically isolated syndrome (CIS) is made. Suh patients are at risk fr develping multiple slersis and are smetimes ffered beta-interfern r glatiramer aetate therapy, whih may delay prgressin t linially definite disease. Fllw-up MRI shuld be nsidered 6–12 mnths later t assess fr the presene f any new lesin. »TreatmentA t least partial revery frm aute exaerbatins an rea- snably be expeted, but further relapses may ur with- ut warning. Sme disability is likely t result eventually, but abut half f all patients are withut signifiant dis- ability even 10 years after nset f symptms. Current treatments are hiefly aimed at preventing relapses, thereby reduing disability. Recovery from acute relapses may be hastened by treat- ment with corticosteroids, but the extent of recovery is unchanged. Intravenus therapy is ften given first— typially methylprednislne 1 g daily fr 3 days—fllwed by ral prednisne at 60–80 mg daily fr 1 week with a taper ver the ensuing 2–3 weeks, but randmized trials shw similar effiay whether the initial high dse is given rally r intravenusly. Lng-term treatment with rti- sterids prvides n benefit and des nt prevent further relapses. Transient exaerbatin f symptms relating t interurrent infetin r heat requires n added treatment. In patients with relapsing disease, numerus media- tins have well-established effiay at reducing the frequency of attacks (Table 24–9). The initial agent is h- sen after nsidering mediatin tlerane and risks, patient preferene, and disease severity. Glatiramer aetate, an interfern, r dimethyl fumarate is ften used initially due t favrable side effet prfiles and availability, althugh the effiay f early treatment with higher inten- sity therapy is being explred. In general, the mediatins mst effetive in reduing relapses have strnger immun- mdulatry effets and mre, albeit rare, serius adverse effets. Presriptin f these agents shuld be managed by a speialist. Orelizumab is the nly mediatin effetive in slwing disability prgressin in primary prgressive multiple sle- rsis and is apprved fr this indiatin by the FDA. Fr patients with ative sendary prgressive disease, ladrib- ine, relizumab, fatumumab, zanimd, and sipnimd an be used. Plasmapheresis is smetimes helpful in patients with severe relapses unrespnsive t rtisterids. Symptmati therapy fr spastiity, neurgeni bladder, r fatigue may be required. Fatigue is espeially mmn in multiple slersis, and mdafinil (200 mg rally every mrning) is an effetive and FDA-apprved therapy fr this indiatin. Dalfampridine (an extended-release fr- mulatin f 4-aminpyridine administered as 10 mg rally twie daily) is effiaius at imprving timed gait in mul- tiple slersis. Depressin and even suiidality an ur in multiple slersis and may wrsen with interfern beta-1a therapy; sreening and nventinal treatment f suh symptms are apprpriate.CMDT22_Ch24_p0978-p1053.indd  1032 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1033 CMDT 2022 »When to ReferAll  patients, but espeially thse with prgressive disease despite standard therapy, shuld be referred. »When to Admit• Patients requiring plasma exhange fr severe relapses unrespnsive t rtisterids. •During severe relapses. •Patients unable t manage at hme.Fr eedman MS et al. Treatment ptimizatin in multiple slersis: Canadian MS wrking grup remmendatins. Can J Neurl Si. 2020;47:437. [PMID: 32654681] Rae-Grant A et al. Pratie guideline remmendatins summary: disease-mdifying therapies fr adults with multiple slersis: reprt f the Guideline Develpment, Disseminatin, and Implementatin Submmittee f the Amerian Aademy f Neurlgy. Neurlgy. 2018;90:777. [PMID: 29686116]NEUROMYELITIS OPTICAThis  disrder is haraterized by pti neuritis and aute myelitis with MRI hanges that extend ver at least three segments f the spinal rd. An islated myelitis r pti neuritis may als ur. Previusly knwn as Devi disease and ne regarded as a variant f multiple slersis, neur- myelitis ptia is assiated with a speifi antibdy marker (NMO-IgG) targeting the water hannel aquaprin-4 in 80% f ases, and with antibdies t myelin ligdendr- yte glyprtein (MOG-IgG) in apprximately 33% f NMO-IgG sernegative patients. MRI f the brain typially des nt shw widespread white matter invlvement, but suh hanges d nt exlude the diagnsis. Treatment is by lng-term immunsuppressin. Three mediatins are apprved by the FDA fr treatment f neurmyelitis ptia based n plaeb-ntrlled trials demnstrating a redued annual relapse rate r time t first relapse. Eulizumab is a mplement inhibitr, inebilizumab is a humanizedTable 24–9. Treatment of multiple sclerosis (in alphabetical order within categories).1Mediction Dose acute Eisode, Including Relse2Dexamethasone 160 mg orally daily for 3–5 days Methylprednisolone 1 g intravenously or orally daily for 3–5 days Plasmapheresis Disese-Modifying Tery (FDa roved) Alemtuzumab (Lemtrada)3,412 mg intravenously daily for 5 days; 3-day course given 1 year later Cladribine (Mavenclad)3,5,61.75 mg/kg orally divided between weeks 1 and 5, repeated once in 1 year Dimethyl fumarate (Tecfidera)3,5240 mg orally twice daily Fingolimod (Gilenya)3,4,50.5 mg orally daily Glatiramer acetate (Copaxone, Mylan, Glatopa)520 mg subcutaneously daily or 40 mg subcutaneously three times weekly Interferon β-1a (Rebif)544 mcg subcutaneously three times per week Interferon β-1a (Avonex)530 mcg intramuscularly once per week Interferon β-1b (Betaseron, Extavia)50.25 mg subcutaneously on alternate days Mitoxantrone312 mg/m2intravenously every 3 months; maximum lifetime dose, 140 mg/m2Natalizumab  (Tysabri)3,4300 mg intravenously monthly Ocrelizumab (Ocrevus)3,4,5,6,7300 mg intravenously on day 1 and day 15, followed by 600 mg every 6 months Ofatumumab (Kesimpta)3,4,5,620 mg subcutaneously weeks 0, 1, 2, 4, and monthly thereafter Ozanimod (Zeposia)3,4,5,60.23 mg orally daily on days 1–4, 0.46 mg daily on days 5–7, and 0.92 mg daily thereafter Pegylated interferon β-1a (Plegridy)5125 mg subcutaneously once every 2 weeks Siponimod (Mayzent)3,4,5,60.25 mg orally daily, titrated over 5 or 6 days to 1 or 2 mg orally daily, depending on CYP2C9 genotype Teriflunomide (Aubagio)514 mg or 7 mg orally daily1 Several of these agents require special monitoring or pretreatment; some should be avoided during pregnancy. Readers should ref er to the manufacturer’s guidelines.2 For corticosteroid-refractory relapses, plasmapheresis may be used.3 Relapse prevention for disease activity despite use of first-line treatment.4 High disease activity (typically with multiple gadolinium-enhancing lesions on MRI).5 Relapse prevention, first-line treatment.6 Active secondary progressive disease.7 Primary progressive disease.CMDT22_Ch24_p0978-p1053.indd  1033 29/06/21 8:50 PMChapTER 241034 CMDT 2022an ti-CD19 antibdy that depletes B ells, and satralizumab is an interleukin-6 reeptr antagnist. Use f eulizumab requires prir immunizatin against meningus. Off- label therapy is with rituximab (tw 1-g intravenus infusins spaed by 2 weeks, r fur weekly infusins f 375 mg/m2; re-dsing may ur every 6 mnths r when CD19/20-psitive r CD27-psitive lymphytes beme detetable), myphenlate mfetil (500–1500 mg rally twie daily, titrated until the abslute lymphyte unt falls belw 1500/mL [1.5 × 109/L]), r azathiprine (2.5–3 mg/kg rally). Aute relapses are treated with rti- sterids at dses similar t thse utlined fr multiple slersis and with plasma exhange fr severe relapses unrespnsive t rtisterids.Cree  BAC et al; N-MOmentum Study Investigatrs. Inebili- zumab fr the treatment f neurmyelitis ptia spetrum disrder (N-MOmentum): a duble-blind, randmized plaeb-ntrlled phase 2/3 trial. Lanet. 2019;394:1352. [PMID: 31495497] Pittk SJ et al. Eulizumab in aquaprin-4-psitive neurmyeli- tis ptia spetrum disrder. N Engl J Med. 2019;381:614. [PMID: 31050279]VI TAMIN E DEFICIENCYV itamin E defiieny may prdue a disrder smewhat similar t Friedreih ataxia. There is spinerebellar degen- eratin invlving partiularly the psterir lumns f the spinal rd and leading t limb ataxia, sensry lss, absent tendn reflexes, slurring f speeh, and, in sme ases, pigmentary retinal degeneratin. The disrder may ur as a nsequene f malabsrptin r n a hereditary basis (eg, abetalipprteinemia).SP ASTICITYThe  term “spastiity” is mmnly used fr an upper mtr neurn defiit, but it prperly refers t a velity- dependent inrease in resistane t passive mvement that affets different musles t a different extent, is nt uni- frm in degree thrughut the range f a partiular mve- ment, and is mmnly assiated with ther features f pyramidal defiit. It is ften a majr mpliatin f strke, erebral r spinal injury, stati perinatal enephalpathy, and multiple slersis. Spastiity may be exaerbated by pressure injuries, urinary r ther infetins, and niep- tive stimuli. Physial therapy with apprpriate strething prgrams is imprtant during rehabilitatin after the develpment f an upper mtr neurn lesin and in subsequent manage- ment f the patient. The aim is t prevent jint and musle contractures and perhaps t mdulate spastiity. Mediatin management is imprtant als, but treat- ment may inrease funtinal disability when inreased extensr tne is prviding additinal supprt fr patients with weak legs. Pharmalgi treatment with balfen (5–10 mg twie daily rally titrated t 80 mg daily), tizani- dine (2–8 mg three time daily rally), diazepam (2–10 mg three times daily rally), r dantrlene (25 mg ne daily rally, titrated every 3 days as tlerated t a maximum f100 mg fur times daily) is ften helpful. Dantrlene is best avided in patients with pr respiratry funtin r severe myardial disease. Cannabinids are als effetive in reduing spastiity, but are assiated with side effets, inluding dizziness, drwsiness, and fatigue. Intramusular injetin f btulinum txin is used t relax targeted musles. In patients with severe spastiity that is unrespnsive t ther therapies and is assiated with marked disability, intratheal injetin f phenl r alhl may be helpful. Surgial ptins inlude implantatin f an intratheal balfen pump, rhiztmy, r neuretmy. Severe ntra- tures may be treated by surgial tendn release.MYE LOPATHIES IN AIDSA  variety f myelpathies may ur in patients with AIDS. These are disussed in Chapter 31.MYE LOPATHY OF HUMAN T-CELL LEUKEMIA VIRUS INFECTIONH uman T-ell leukemia virus (HTLV-1), a human retrvi- rus, is transmitted by breastfeeding, sexual ntat, bld transfusin, and ntaminated needles. Mst patients are asymptmati, but after a variable latent perid (whih may be as lng as several years), a myelpathy develps in sme instanes. The MRI, eletrphysilgi, and erebr- spinal fluid findings are similar t thse f multiple sler- sis, but HTLV-1 antibdies are present in serum and spinal fluid. There is n speifi treatment, but intravenus r ral rtisterids may help in the initial inflammatry phase f the disease. Prphylati measures are imprtant. Needles r syringes shuld nt be shared; infeted patients shuld nt breastfeed their infants r dnate bld, semen, r ther tissue. Infeted patients shuld use ndms t prevent sexual transmissin.SU BACUTE COMBINED DEGENERATION OF THE SPINAL CORDSubaute  mbined degeneratin f the spinal rd is due tvitamin B12deficiency , suh as urs in perniius anemia. It is haraterized by myelpathy with spastiity, weakness, prprieptive lss, and numbness due t degeneratin f the rtispinal trats and psterir l- umns. Plyneurpathy, mental hanges, r pti neurpa- thy als develp in sme patients. Megalblasti anemia may als ur, but this des notparallel the neurlgi disrder, and the frmer may be bsured if fli aid supplements have been taken. Treatment is with vitamin B12. Fr perniius anemia, a nvenient therapeuti regi- men is 1000 mg yanbalamin intramusularly daily fr 1 week, then weekly fr 1 mnth, and then mnthly fr the remainder f the patient’s life. Oral yanbalamin replaement is nt advised fr perniius anemia when neurlgi symptms are present. A similar syndrme is aused by rereatinal abuse f inhaled nitrus xide due t its interferene with vitamin B12metablism. Cpper defiieny, aused by malabsrptin r exess zin inges- tin, may als be respnsible.CMDT22_Ch24_p0978-p1053.indd  1034 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1035 CMDT 2022SP INAL TRAUMAE S S E N T I A L S  O F  D I A G N O S I S »History of preceding trauma. »Development of acute neurologic deficit. »Signs of myelopathy on examination. »General ConsiderationsWhile  spinal rd damage may result frm whiplash injury, severe injury usually relates t frature-dislatin ausing mpressin r angular defrmity f the rd either ervi- ally r in the lwer thrai and upper lumbar regins. Extreme hyptensin fllwing injury may als lead t rd infartin. »Clinical FindingsT tal rd transetin results in immediate flaid paraly- sis and lss f sensatin belw the level f the lesin. Reflex ativity is lst fr a variable perid, and there is urinary and feal retentin. As reflex funtin returns ver the fl- lwing days and weeks, spasti paraplegia r quadriplegia develps, with hyperreflexia and extensr plantar respnses, but a flaid atrphi (lwer mtr neurn) paralysis may be fund depending n the segments f the rd that are affeted. The bladder and bwels als regain sme reflex funtin, permitting urine and fees t be expelled at intervals. As spastiity inreases, flexr r extensr spasms (r bth) f the legs beme trublesme, espeially if the patient develps bed sres r a urinary trat infetin. Paraplegia with the legs in flexin r exten- sin may eventually result. With lesser degrees f injury, patients may be left with mild limb weakness, distal sensry disturbane, r bth. Sphinter funtin may als be impaired, urinary urgeny and urge inntinene being espeially mmn. Mre partiularly, a unilateral rd lesin leads t an ipsilateral mtr disturbane with ampanying impairment f pr- prieptin and ntralateral lss f pain and temperature appreiatin belw the lesin ( Brown-Séquard syndrome ). A entral rd syndrme may lead t a lwer mtr neurn defiit at the level f the lesin and lss f pain and tem- perature appreiatin belw it, with sparing f psterir lumn funtins. With mre extensive invlvement, ps- terir lumn sensatin may als be impaired and pyrami- dal weakness develps. A radiular defiit may ur at the level f the injury—r, if the auda equina is invlved, there may be evidene f disturbed funtin in several lumbsa- ral rts. »TreatmentT reatment f the injury nsists f immbilizatin and—if there is rd mpressin—early dempressive lamine- tmy and fusin (within 24 hurs). Early treatment with high dses f rtisterids (eg, methylprednislne,30 mg/kg by intravenus blus, fllwed by 5.4 mg/kg/h fr 23 hurs) may imprve neurlgi revery if m- mened within 8 hurs after injury, althugh the evidene is limited and sme neursurgial guidelines d nt re- mmend their use. Anatmi realignment f the spinal rd by tratin and ther rthpedi predures is imprtant. Subsequent are f the residual neurlgi defiit—paraplegia r quadriplegia—requires treatment f spastiity and are f the skin, bladder, and bwels. »When to ReferAll  patients with fal neurlgi defiits shuld be referred. »When to Admit• Patients with neurlgi defiits. •Patients with spinal rd injury, mpressin, r aute epidural r subdural hematma. •Patients with vertebral frature-dislatin likely t mpress the rd.Ong B  et al. Management f the patient with hrni spinal rd injury. Med Clin Nrth Am. 2020;104:263. [PMID: 32035568]SYR INGOMYELIADestruti n r degeneratin f gray and white matter adja- ent t the entral anal f the ervial spinal rd leads t avitatin and aumulatin f fluid within the spinal rd. The preise pathgenesis is unlear, but many ases are assiated with Arnold-Chiari malformation , in whih there is displaement f the erebellar tnsils, medulla, and furth ventrile int the spinal anal, smetimes with ampanying meningmyelele. In suh irumstanes, the rd avity nnets with and may merely represent a dilated entral anal. In ther ases, the ause f avitatin is less lear. There is a harateristi linial piture, with segmental atrphy, areflexia, and lss f pain and tempera- ture appreiatin in a “ape” distributin, wing t the destrutin f fibers rssing in frnt f the entral anal in the mid-ervial spinal rd. Thrai kyphslisis is usually present. With prgressin, invlvement f the lng mtr and sensry trats urs as well, s that a pyrami- dal and sensry defiit develps in the legs. Upward exten- sin f the avitatin (syringbulbia) leads t dysfuntin f the lwer brainstem and thus t bulbar palsy, nystagmus, and sensry impairment ver ne r bth sides f the fae. Syringmyelia, ie, rd avitatin, may als ur in assiatin with an intramedullary tumr r fllwing severe rd injury, and the avity then des nt mmuni- ate with the entral anal. In patients with Arnld-Chiari malfrmatin, CT sans reveal a small psterir fssa and enlargement f the fra- men magnum, alng with ther assiated skeletal abnr- malities at the base f the skull and upper ervial spine. MRI reveals the syrinx as well as the harateristi findings f the Arnld-Chiari malfrmatin, inluding the audal displaement f the furth ventrile and herniatin f theCMDT22_Ch24_p0978-p1053.indd  1035 29/06/21 8:50 PMChapTER 241036 CMDT 2022erebellar  tnsils thrugh the framen magnum. Fal rd enlargement is fund at myelgraphy r by MRI in patients with avitatin related t past injury r intramed- ullary neplasms. Treatment f Arnld-Chiari malfrmatin with assi- ated syringmyelia is by subipital ranietmy and upper ervial laminetmy, with the aim f dempress- ing the malfrmatin at the framen magnum. The rd avity shuld be drained and, if neessary, an utlet fr the furth ventrile an be made. In avitatin assiated with intramedullary tumr, treatment is surgial, but radiatin therapy may be neessary if mplete remval is nt ps- sible. Psttraumati syringmyelia is als treated surgi- ally if it leads t inreasing neurlgi defiits r t intlerable pain.DE GENERATIVE MOTOR NEURON DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Weakness. »No sensory loss or sphincter disturbance. »Progressive course. »No identifiable underlying cause other than genetic basis in familial cases. »General ConsiderationsThis gr up f degenerative disrders is haraterized lini- ally by weakness and variable wasting f affeted musles, withut ampanying sensry hanges. Mtr neurn disease in adults generally mmenes between 30 and 60 years f age. There is degeneratin f the anterir hrn ells in the spinal rd, the mtr nulei f the lwer ranial nerves, and the rtispinal and r- tibulbar pathways. The disrder is usually spradi, but familial ases may ur and several geneti mutatins r li have been identified. Cigarette smking may be ne risk fatr. »ClassificationFive varieties ha ve been distinguished n linial grunds.A.  Progressive Bulbar PalsyBulbar  invlvement predminates wing t disease pr- esses affeting primarily the mtr nulei f the ranial nerves.B.  Pseudobulbar PalsyBulbar  invlvement predminates in this variety als, but it is due t bilateral rtibulbar disease and thus reflets upper mtr neurn dysfuntin. There may be a “pseud- bulbar affet, ” with unntrllable episdes f laughing r rying t stimuli that wuld nt nrmally have eliited suh marked reatins.C. Progressive Spinal Muscular AtrophyThis  is haraterized primarily by a lwer mtr neurn defiit in the limbs due t degeneratin f the anterir hrn ells in the spinal rd.D . Primary Lateral SclerosisThere is a p urely upper mtr neurn defiit in the limbs.E.  Amyotrophic Lateral Sclerosis ALSA mixed u pper and lwer mtr neurn defiit is fund in the limbs. This disrder is smetimes assiated with g- nitive deline (in a pattern nsistent with frnttempral dementia), a pseudbulbar affet, r parkinsnism. Apprximately 10% f ALS ases are familial and have been assiated with mutatins at several different geneti li, inluding a hexanuletide repeat n hrmsme 9 that als assiates with frnttempral dementia. »Differential DiagnosisTh e spinal musular atrphies (SMAs) are inherited syndrmes aused mst ften by mutatins f the sur- vival mtr neurn 1 ( SMN1 ) gene n hrmsme 5. Different mutatins result in mre r less severe disrup- tins f the prtein, resulting in an age f nset that ranges frm infany (SMA type I), t early (type II) r late hildhd (type III), t adulthd (type IV). X-linked spinal and bulbar musular atrphy (Kennedy syndrme) is assiated with an expanded trinuletide repeat sequene n the andrgen reeptr gene and ar- ries a mre benign prgnsis than ther frms f mtr neurn disease. There are reprts f juvenile SMA due t hexsa- minidase defiieny. Pure mtr syndrmes resembling mtr neurn disease may als ur in assiatin with mnlnal gammpathy r multifal mtr neurpa- thies with ndutin blk. A mtr neurnpathy may als develp in Hdgkin disease and has a relatively benign prgnsis. Infetive anterir hrn ell diseases (pli virus r West Nile virus infetin) an generally be distinguished by the aute nset and mnphasi urse f the illness, as disussed in Chapter 32. Aute flaid myelitis fllwing infetin with entervirus may ur, espeially in hildren, withut sensry invlve- ment and resembles plimyelitis. There is n speifi treatment. »Clinical FindingsA.  Symptoms and SignsDiffiu lty in swallwing, hewing, ughing, breathing, and talking (dysarthria) urs with bulbar invlvement. In prgressive bulbar palsy, there is drping f the palate; a depressed gag reflex; pling f saliva in the pharynx; a weak ugh; and a wasted, fasiulating tngue. In pseud- bulbar palsy, the tngue is ntrated and spasti and an- nt be mved rapidly frm side t side. Limb invlvement is haraterized by mtr disturbanes (weakness, stiff- ness, wasting, fasiulatins) refleting lwer r upperCMDT22_Ch24_p0978-p1053.indd  1036 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1037 CMDT 2022mt r neurn dysfuntin; there are n bjetive hanges n sensry examinatin, althugh there may be vague sen- sry mplaints. The sphinters are generally spared. Cg- nitive hanges r pseudbulbar affet may be present. The disrder is prgressive, and ALS is usually fatal within 3–5 years; death usually results frm pulmnary infetins. Patients with bulbar invlvement generally have the pr- est prgnsis, while patients with primary lateral slersis ften have a lnger survival despite prfund quadriparesis and spastiity.B.  Laboratory and Other StudiesEletrmygraphy  may shw signs f aute and hrni partial denervatin with reinnervatin. In patients with suspeted ALS, the diagnsis shuld nt be made with nfidene unless suh hanges are fund in at least three spinal regins (ervial, thrai, lumbsaral) r tw spinal regins and the bulbar musulature. Mtr ndu- tin velity is usually nrmal but may be slightly redued, and sensry ndutin studies are als nrmal. Bipsy f a wasted musle shws the histlgi hanges f denerva- tin but is nt neessary fr diagnsis. The serum reatine kinase may be slightly elevated but never reahes the extremely high values seen in sme f the musular dys- trphies. The erebrspinal fluid is nrmal. T diagnse SMA, mleular geneti testing fr pathgeni variants f SMN1 is available. There are abnrmal findings n retal bipsy and redued hexsaminidase A in serum and leuk- ytes in patients with juvenile SMA due t hexsaminidase defiieny. »TreatmentRiluzle,  50 mg rally twie daily, whih redues the pre- synapti release f glutamate, inreased shrt-term sur- vival in ALS in randmized trials. Edaravne, a free radial savenger, slws disease prgressin in patients with mild disease. It is administered in mnthly yles as a 60 mg intravenus infusin n days 1–14 in the first mnth and days 1–10 in the subsequent mnths. Nninvasive ventilatin at least 4 hurs per day in patients with a maximal inspiratry pressure less than 60 m H2O may prlng survival in ALS. Symptmati and supprtive measures t treat spastiity (disussed earlier), drling, and dysphagia, prevent ntratures, and pre- serve mbility are imprtant. Drling is treated with ver- the-unter dengestants, antihlinergi mediatins (suh as trihexyphenidyl, amitriptyline, r atrpine), btu- linum txin injetins int the salivary glands, r use f a prtable sutin mahine. Physial and upatinal ther- apy are helpful thrughut the disease urse. Cmbina- tin dextrmethrphan/quinidine (20 mg/10 mg, ne tablet rally ne r twie daily) may relieve symptms f pseudbulbar affet. A semiliquid diet r gastrstmy tube feeding may be needed if dysphagia is severe; it is advisable t perfrm the predure befre the fred vital apaity falls belw 50% f predited t minimize the risk f m- pliatins. Trahestmy is smetimes perfrmed if respi- ratry musles are severely affeted; hwever, in the terminal stages f these disrders, realisti expetatinsand advane are planning shuld be disussed. Infrma- tin n palliative are is prvided in Chapter 5. Treatment f spinal musular atrphy takes advantage f the fat that the SMN prtein is als ended by a se- nd gene, SMN2, that usually des nt translate funtinal prtein due t aberrant spliing. Nusinersen is an antisense lignuletide that mdulates premessenger RNA spli- ing f the SMN2 gene and results in inreased prdutin f the full-length prtein; it has shwn effetiveness in bth infants and hildren with SMA. It is apprved fr use in all ages and is administered intratheally (12 mg every 14 days fr three dses, then ne after a 30-day interval, then ne every 4 mnths). Risdiplam (5 mg rally daily fr patients 2 years f age and lder weighing mre than 20 kg) is a small mleule SMN2 spliing mdifier that als results in prdutin f the full-length prtein and is apprved fr use in infants and adults. Gene therapy with intravenus delivery f an intat SMN1 gene using a viral vetr (nasemngene abeparvve) imprves ventilatr-free survival mpared t histrial ntrls and is apprved by the FDA fr use in hildren under 2 years f age with bi- alleli mutatins in SMN1 . »When to ReferAll patien ts (t exlude ther treatable auses f symptms and signs) shuld be referred. »When to AdmitPa tients may need t be admitted fr initiatin r titratin f nninvasive ventilatin, r fr perids f inreased requirement f nninvasive ventilatr supprt during pul- mnary infetins.Me ruri E et al; CHERISH Study Grup. Nusinersen versus sham ntrl in later-nset spinal musular atrphy. N Engl J Med. 2018;378:625. [PMID: 29443664] Nrris SP et al. Amytrphi lateral slersis: update n linial management. Curr Opin Neurl. 2020;33:641. [PMID: 32868602] ºpERIphERaL NEUROpaThIESPe ripheral neurpathies an be ategrized n the basis f the struture primarily affeted. The predminant path- lgi feature may be axonal degeneration (axonal or neuronal neuropathies ) r paranodal or segmental demyelination. The distintin may be pssible n the basis f neurphysilgi findings. Mtr and sensry ndutin velity an be measured in aessible seg- ments f peripheral nerves. In axnal neurpathies, n- dutin velity is nrmal r redued nly mildly and needle eletrmygraphy prvides evidene f denerva- tin in affeted musles. In demyelinating neurpathies, ndutin may be slwed nsiderably in affeted fibers, and in mre severe ases, ndutin is blked m- pletely, withut ampanying eletrmygraphi signs f denervatin.CMDT22_Ch24_p0978-p1053.indd  1037 29/06/21 8:50 PMChapTER 241038 CMDT 2022PO LYNEUROPATHIES & MONONEURITIS MULTIPLEXE S S E N T I A L S  O F  D I A G N O S I S »Weakness, sensory disturbances, or both in the extremities. »Pain is common. »Depressed or absent tendon reflexes. »May be family history of neuropathy. »May be history of systemic illness or toxic exposure. »General ConsiderationsDiffuse  polyneuropathies lead t a symmetri sensry, mtr, r mixed defiit, ften mst marked distally. They inlude the hereditary, metabli, and txi disrders; idi- pathi inflammatry plyneurpathy ( Guillain-Barré syn- drome ); and the peripheral neurpathies that may ur as a nnmetastati mpliatin f malignant diseases. Invlvement f mtr fibers leads t flaid weakness that is mst marked distally; dysfuntin f sensry fibers auses impaired sensry pereptin. Tendn reflexes are depressed r absent. Paresthesias, pain, and musle tender- ness may als ur. Multiple mnneurpathies ( mono- neuropathy multiplex ) suggest a pathy multifal disease press suh as vasulpathy (eg, diabetes, arteritis), an infiltrative press (eg, leprsy, saridsis), radiatin dam- age, r an immunlgi disrder (eg, brahial plexpathy). »Clinical FindingsThe  ause f plyneurpathy r mnneuritis multiplex is suggested by the histry, mde f nset, and predminant linial manifestatins. Labratry wrkup inludes a m- plete bld unt, serum prtein eletrphresis with reflex t immunfixatin r immuntyping, determinatin f plasma urea and eletrlytes, liver bihemial tests, thy- rid funtin tests, vitamin B12level, tests fr rheumatid fatr and antinulear antibdy, HBsAg determinatin, a serlgi test fr syphilis, fasting bld gluse level and hemglbin A1, urinary heavy metal levels, erebrspinal fluid examinatin, and hest radigraphy. These tests shuld be rdered seletively, as guided by symptms and signs. Measurement f nerve ndutin velity an n- firm the peripheral nerve rigin f symptms and prvides a means f fllwing linial hanges, as well as indiate the likely disease press (ie, axnal r demyelinating neurpa- thy). Cutaneus nerve bipsy may help establish a preise diagnsis (eg, plyarteritis, amylidsis). In abut half f ases, n speifi ause an be established; f these, slightly less than half are subsequently fund t be familial. »TreatmentT reatment is f the underlying ause, when feasible, and is disussed belw under the individual disrders. Physial therapy helps prevent ntratures, and splints anmaintain a weak extremity in a psitin f useful funtin. Anestheti extremities must be prteted frm injury. T guard against burns, patients shuld hek the temperature f water and ht surfaes with a prtin f skin having nrmal sensatin, measure water temperature with a ther- mmeter, and use ld water fr washing r lwer the temperature setting f their ht-water heaters. Shes shuld be examined frequently during the day fr grit r freign bjets in rder t prevent pressure lesins. Patients with plyneurpathies r mnneuritis multi- plex are subjet t additinal nerve injury at pressure pints and shuld therefre avid suh behavir as leaning n elbws r sitting with rssed legs fr lengthy perids. Neurpathi, burning pain may respnd t simple anal- gesis, suh as aspirin r nnsteridal anti-inflammatry agents, and t gabapentin (300 mg rally three times daily, titrated up t a maximum f 1200 mg rally three times daily as neessary) r pregabalin (50–100 mg rally three times daily). Dulxetine (60 mg rally ne r twie daily), venlafaxine (start 37.5 mg rally twie daily, and titrate up t 75 mg rally tw t three times daily), r triyli antide- pressants (eg, amitriptyline 10–150 mg rally at bedtime daily) may be helpful, espeially in painful diabeti neu- rpathy. Medial annabis may prvide sme relief, but lng-term safety data are laking. The use f a frame r radle t redue ntat with bedlthes may be helpful. Many patients experiene episdi stabbing pains, whih may respnd t gabapentin, pregabalin, arbamazepine (start 100 mg rally twie daily, and titrate up t 400 mg rally twie daily), r triyli antidepressants. Opiids may be neessary fr severe hyperpathia r pain indued by minimal stimuli, but their use generally shuld be avided. Symptms f autnmi dysfuntin are asinally trublesme. Treatment f pstural hyptensin is dis- ussed earlier in this hapter. Eretile dysfuntin an be treated with phsphdiesterase inhibitrs; a flaid neur- pathi bladder may respnd t parasympathmimeti mediatins suh as bethanehl hlride, 10–50 mg three r fur times daily.Ada ms D et al. Patisiran, an RNAi therapeuti, fr hereditary transthyretin amylidsis. N Engl J Med. 2018;379:11. [PMID: 29972753] Bensn MD et al. Intersen treatment fr patients with heredi- tary transthyretin amylidsis. N Engl J Med. 2018;379:22. [PMID: 29972757]1.  Inerited NeurotiesA.  CharcotMarieTooth Disease HMSN Type I, IIThere  are several distint varieties f Chart-Marie-Tth disease, usually with an autsmal dminant mde f inheritane, but asinal ases ur n a spradi, reessive, r X-linked basis. Clinial presentatin may be with ft defrmities r gait disturbanes in hildhd r early adult life. Slw prgressin leads t the typial fea- tures f plyneurpathy, with distal weakness and wasting that begin in the legs, a variable amunt f distal sensry lss, and depressed r absent tendn reflexes. Tremr is a nspiuus feature in sme instanes. Hereditary motorCMDT22_Ch24_p0978-p1053.indd  1038 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1039 CMDT 2022and  sensory neuropathy (HMSN) type I is haraterized by demyelinatin n eletrdiagnsti studies and is usu- ally aused by mutatins in the peripheral myelin prtein 22 r myelin prtein zer gene. In HMSN type II , eletr- diagnsti studies shw axnal lss rather than demyelin- atin; ne-third f ases are due t mutatins in the gene mitfusin 2. A similar disrder may ur in patients with prgres- sive distal spinal musular atrphies, but there is n sen- sry lss; eletrphysilgi investigatin reveals that mtr ndutin velity is nrmal r nly slightly redued, and nerve atin ptentials are nrmal.B.  DejerineSottas Disease HMSN Type IIIThe  disrder may ur n a spradi, autsmal dmi- nant r, less mmnly, autsmal reessive basis. Onset in infany r hildhd leads t a prgressive mtr and sensry plyneurpathy with weakness, ataxia, sensry lss, and depressed r absent tendn reflexes. The periph- eral nerves may be palpably enlarged and are haraterized pathlgially by segmental demyelinatin, Shwann ell hyperplasia, and thin myelin sheaths. Eletrphysilgi- ally, there is a slwing f ndutin, and sensry atin ptentials may be unrerdable.C.  Friedreich AtaxiaThis disrder , the nly knwn autosomal recessive trinu- cleotide repeat disease, is aused by expansin f a ply- GAA lus in the gene fr frataxin n hrmsme 9, leading t symptms in hildhd r early adult life. The gait bemes ataxi, the hands beme lumsy, and ther signs f erebellar dysfuntin develp ampanied by weakness f the legs and extensr plantar respnses. Invlvement f peripheral sensry fibers leads t sensry disturbanes in the limbs and depressed tendn reflexes. There is bilateral pes avus. Pathlgially, there is a marked lss f ells in the psterir rt ganglia and degeneratin f peripheral sensry fibers. In the entral nervus system, hanges are nspiuus in the psterir and lateral lumns f the rd. Eletrphysilgially, ndutin velity in mtr fibers is nrmal r nly mildly redued, but sensry atin ptentials are small r absent. Cardia disease is the mst mmn ause f death. In the differential diagnsis fr Friedreih ataxia are ther spinerebellar ataxias, a grwing grup f at least 30 inherited disrders, eah invlving a different identified gene. These hetergeneus disrders, whih frequently (but nt exlusively) exhibit an autsmal dminant inher- itane pattern and ply-CAG expansin f the affeted gene, typially ause erebellar ataxia and varying mbi- natins f ther symptms (suh as peripheral neurpathy, phthalmparesis, dysarthria, and pyramidal and extrapy- ramidal signs).D . Refsum Disease HMSN Type IVThis  autsmal reessive disrder is due t a disturbane in phytani aid metablism. Pigmentary retinal degen- eratin is ampanied by prgressive sensrimtr ply- neurpathy and erebellar signs. Auditry dysfuntin,ardimypathy, and utaneus manifestatins may als ur. Mtr and sensry ndutin velities are redued, ften markedly, and there may be eletrmy- graphi evidene f denervatin in affeted musles. Dietary restritin f phytani aid and its preursrs may be helpful therapeutially. Plasmapheresis t redue stred phytani aid may help at the initiatin f treatment.E.  PorphyriaPe ripheral nerve invlvement may ur during aute attaks in bth variegate porphyria andacute intermit- tent porphyria. Mtr symptms usually ur first, and weakness is ften mst marked prximally and in the upper limbs rather than the lwer. Sensry symptms and signs may be prximal r distal in distributin. Autnmi invlvement is smetimes prnuned. The eletrphysi- lgi findings are in keeping with the results f neur- pathlgi studies suggesting that the neurpathy is axnal in type (see Chapter 40).F . Familial Amyloid PolyneuropathySensr y and autnmi symptms are espeially nspiu- us, whereas distal wasting and weakness ur later. The plyneurpathy is axnal and likely results frm amylid depsitin within the peripheral nerves due t mutatins in the genes ending transthyretin, aplipprtein A1, r gelslin. Transthyretin amyloidosis is the mst mmn; is assiated with ardimypathy, nephrpathy, lept- meningeal invlvement, and vitreus paity; and is treat- able with liver transplantatin, the small interfering ribnulei aid patisiran (0.3 mg/kg up t 30 mg intrave- nusly ne every 3 weeks), r the antisense lignule- tide intersen (284 mg subutaneusly weekly). Tafamidis helps transthyretin amylid ardimypathy and may slw the prgressin f the neurpathy.2.  Neuroties associted wit Systemic & Metbolic DisordersA.  Diabetes MellitusIn  this disrder, invlvement f the peripheral nervus system may lead t symmetri sensry r mixed plyneu- rpathy, asymmetri mtr radiulneurpathy r plexpa- thy (diabeti amytrphy), thraabdminal radiulpathy, autnmi neurpathy, r islated lesins f individual nerves. These may ur singly r in any mbinatin and are disussed in Chapter 27.B.  UremiaU remia may lead t a symmetri sensrimtr plyneu- rpathy that tends t affet the lwer limbs mre than the upper limbs and is mre marked distally than prxi- mally (see Chapter 22). The diagnsis an be nfirmed eletrphysilgially beause mtr and sensry n- dutin velity is mderately redued. The neurpathy imprves bth linially and eletrphysilgially with kidney transplantatin and t a lesser extent with hrni dialysis.CMDT22_Ch24_p0978-p1053.indd  1039 29/06/21 8:50 PMChapTER 241040 CMDT 2022C.  Alcoholism and Nutritional DeficiencyMan y patients with alhl use disrder have an axnal distal sensrimtr plyneurpathy that is frequently ampanied by painful ramps, musle tenderness, and painful paresthesias and is ften mre marked in the legs than in the arms. Symptms f autnmi dysfuntin may als be nspiuus. Mtr and sensry ndutin velity may be slightly redued, even in sublinial ases, but grss slwing f ndutin is unmmn. Treatment is similar t diabeti plyneurpathy but als inludes abstinene frm alhl. A similar distal sensrimtr plyneurpathy is a well-regnized feature f beriberi (thiamine defiieny). In vitamin B12defiieny, distal sen- sry plyneurpathy may develp but is usually vershad- wed by entral nervus system manifestatins (eg, myelpathy, pti neurpathy, r intelletual hanges).D . ParaproteinemiasA symmetri s ensrimtr plyneurpathy that is gradual in nset, prgressive in urse, and ften ampanied by pain and dysesthesias in the limbs may ur in patients (espeially men) with plasma cell myeloma (frmerly multiple myelma). The neurpathy is f the axnal type in lassi lyti myelma, but segmental demyelinatin (pri- mary r sendary) and axnal lss may ur in slerti myelma and lead t predminantly mtr linial mani- festatins. Bth demyelinating and axnal neurpathies are als bserved in patients with paraprteinemias withut myelma. A small fratin will develp myelma if serially fllwed. The demyelinating neurpathy in these patients may be due t the mnlnal prteins reating t a m- pnent f the nerve myelin. The neurpathy f lassi plasma ell myelma is prly respnsive t therapy. The plyneurpathy f benign monoclonal gammopathy may respnd t immunsuppressant mediatins and plasmapheresis. Plyneurpathy may als ur in assiatin with mnlnal gammpathy f unknwn signifiane, ma- rglbulinemia, and ryglbulinemia and smetimes respnds t plasmapheresis. Many patients with an IgM M-prtein will have antibdies t myelin-assiated gly- prtein (MAG); these patients may respnd t treatment with rituximab. Entrapment neurpathy, suh as arpal tunnel syndrme, is mre mmn than plyneurpathy in patients with (nnhereditary) generalized amylidsis.3.  Neuroties associted wit Infectious & Inflmmtory DisesesA.  LeprosyLeprsy is an imprtan t ause f peripheral neurpathy in ertain parts f the wrld. Sensry disturbanes are mainly due t invlvement f intrautaneus nerves. In tuberu- lid leprsy, they develp at the same time and in the same distributin as the nerve; trunks lying beneath the lesin are als invlved. In leprmatus leprsy, there is mre extensive sensry lss, and this develps earlier and t a greater extent in the lest regins f the bdy, suh as the drsal surfaes f the hands and feet, where the bailliprliferate mst atively. Mtr defiits result frm invlve- ment f superfiial nerves where their temperature is lw- est, eg, the ulnar nerve in the regin prximal t the lerann grve, the median nerve as it emerges frm beneath the frearm flexr musle t run tward the arpal tunnel, the perneal nerve at the head f the fibula, and the psterir tibial nerve in the lwer part f the leg; pathy faial musular weakness may als ur wing t invlve- ment f the superfiial branhes f the seventh ranial nerve. Mtr disturbanes in leprsy are suggestive f multiple mnneurpathy, whereas sensry hanges resemble thse f distal plyneurpathy. Examinatin, hwever, relates the distributin f sensry defiits t the temperature f the tissues; in the legs, fr example, sparing frequently urs between the tes and in the ppliteal fssae, where the temperature is higher. Treatment is with antileprti agents (see Chapter 33).B.  AIDSA  variety f neurpathies ur in HIV-infeted patients (see Chapter 31).C.  Lyme BorreliosisThe  neurlgi manifestatins f Lyme disease inlude meningitis, meningenephalitis, plyradiulneurpathy, mnneurpathy multiplex, and ranial neurpathy. Ser- lgi tests establish the underlying disrder. Lyme disease and its treatment are disussed in depth in Chapter 34.D . SarcoidosisCranial  nerve palsies (espeially faial palsy), multiple mnneurpathy and, less mmnly, symmetri plyneu- rpathy may all ur, the latter smetimes preferentially affeting either mtr r sensry fibers. Imprvement may ur with use f rtisterids.E.  PolyarteritisIn vlvement f the vasa nervrum by the vasuliti press may result in infartin f the nerve. Clinially, ne enunters an asymmetri sensrimtr plyneurpathy (mnneuritis multiplex) that pursues a waxing and waning urse. Crtisterids and yttxi agents— espeially ylphsphamide—may be f benefit in severe ases (Chapter 20).F . Rheumatoid ArthritisCmpr essive r entrapment neurpathies, ishemi neu- rpathies, mild distal sensry plyneurpathy, and severe prgressive sensrimtr plyneurpathy an ur in rheumatid arthritis.4.  Neuroty associted wit Criticl IllnessPa tients in intensive are units with sepsis and multirgan failure smetimes develp plyneurpathies. This may be manifested initially by unexpeted diffiulty in weaningCMDT22_Ch24_p0978-p1053.indd  1040 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1041 CMDT 2022patients  frm a mehanial ventilatr and in mre advaned ases by wasting and weakness f the extremities and lss f tendn reflexes. Sensry abnrmalities are relatively innspiuus. The neurpathy is axnal in type. Its path- genesis is bsure, and treatment is supprtive. The prg- nsis is gd prvided patients rever frm the underlying ritial illness. A mypathy may als ur (disussed belw).5.  Toxic NeurotiesAxnal  plyneurpathy may fllw expsure t industrial agents r pestiides suh as arylamide, rganphsph- rus mpunds, hexaarbn slvents, methyl brmide, and arbn disulfide; metals suh as arseni, thallium, merury, and lead; and mediatins suh as phenytin, amidarne, perhexiline, isniazid, nitrfurantin, vin- ristine, and pyridxine in high dses. Detailed upa- tinal, envirnmental, and medial histries and regnitin f lusters f ases are imprtant in suggesting the diagnsis. Treatment is by preventing further expsure t the ausal agent. Isniazid neurpathy is prevented by pyridxine supplementatin. Diphtheriti neurpathy results frm a neurtxin released by the ausative rganism and is mmn in many areas. Palatal weakness may develp 2–4 weeks after infe- tin f the thrat, and infetin f the skin may similarly be fllwed by fal weakness f neighbring musles. Disturbanes f ammdatin may ur abut 4–5 weeks after infetin and distal sensrimtr demye- linating plyneurpathy after 1–3 mnths.6.  Neuroties associted wit Mlignnt DisesesA  variety f neurpathies have been assiated with nn- metastati mpliatins f malignany and were dis- ussed earlier.7.  acute Idiotic polyneuroty (Guillin-Brré Syndrome)E S S E N T I A L S  O F  D I A G N O S I S »Acute or subacute progressive polyradiculoneuro- pathy. »Weakness is more severe than sensory disturbances. »Acute dysautonomia may be life-threatening. »General ConsiderationsThis aute  r subaute plyradiulneurpathy smetimes fllws infetive illness, inulatins, r surgial pre- dures. There is an assiatin with preeding Campylo- bacter jejuni enteritis. The disrder prbably has an immunlgi basis, but the preise mehanism is unlear.»Clinical FindingsA.  Symptoms and SignsThe  main mplaint is f weakness that varies widely in severity in different patients and ften has a prximal emphasis and symmetri distributin. It usually begins in the legs, spreading t a variable extent but frequently invlving the arms and ften ne r bth sides f the fae. The musles f respiratin r deglutitin may als be affeted. Sensry symptms are usually less nspiuus than mtr nes, but distal paresthesias and dysesthesias are mmn, and neurpathi r radiular pain is present in many patients. Autnmi disturbanes are als m- mn, may be severe, and are smetimes life-threatening; they inlude tahyardia, ardia irregularities, hypten- sin r hypertensin, faial flushing, abnrmalities f sweating, pulmnary dysfuntin, and impaired sphinter ntrl. The axnal subtypes f the syndrme ( acute motor axonal neuropathy [AMAN] andacute motor and sensory axonal neuropathy [AMSAN] ) are aused by antibdies t ganglisides n the axn membrane. The Miller Fisher syndrome, anther subtype, is haraterized by the linial triad f phthalmplegia, ataxia, and are- flexia, and is assiated with anti-GQ1b antibdies.B.  Laboratory FindingsThe  erebrspinal fluid harateristially ntains a high prtein nentratin with a nrmal ell unt, but these hanges may take up t 2 weeks t develp; white bld ell unts greater than 50 ells/mL (0.05 × 109/L) shuld prmpt nsideratin f alternative diagnses. Eletr- physilgi studies may reveal marked abnrmalities, whih d nt neessarily parallel the linial disrder in their tempral urse. »Differential DiagnosisWhen  the diagnsis is made, the histry and apprpriate labratry studies shuld exlude the pssibility f pr- phyri, diphtheriti, r txi (heavy metal, hexaarbn, rganphsphate) neurpathies, and f HIV infetin. The tempral urse exludes ther peripheral neurpathies. Plimyelitis, btulism, and tik paralysis must als be nsidered as they ause weakness f aute nset. The presene f pyramidal signs, a markedly asymmetri mtr defiit, a sharp sensry level, r early sphinter invlve- ment shuld suggest a fal rd lesin. »TreatmentT reatment with prednisne is ineffetive and may prlng revery time. Plasmapheresis is f value; it is best per- frmed within the first few days f illness and is partiularly useful fr linially severe r rapidly prgressive ases r thse with ventilatry impairment. IVIG (400 mg/kg/day fr 5 days) is equally helpful. Patients shuld be admitted t intensive are units if their fred vital apaity is delining, and intubatin is nsidered if the fred vital apaity reahes 15 mL/kg, the maximum inspiratryCMDT22_Ch24_p0978-p1053.indd  1041 29/06/21 8:50 PMChapTER 241042 CMDT 2022pres sure reahes –30 mm Hg, r dyspnea bemes evident. Delining xygen saturatin is a late indiatr f neur- musular respiratry failure. Respiratry tilet and hest physial therapy help prevent ateletasis. Marked hypten- sin may respnd t vlume replaement r pressr agents. Thrmbprphylaxis is imprtant. »PrognosisMs t patients eventually make a gd revery, but this may take many mnths, and abut 20% f patients are left with persisting disability. Apprximately 3% f patients with aute idipathi plyneurpathy have ne r mre linially similar relapses, smetimes several years after the initial illness. »When to ReferAll patients sh uld be referred. »When to AdmitAll  patients shuld be hspitalized until their nditin is stable and there is n respiratry mprmise.Malek  E et al. Guillain-Barré syndrme. Semin Neurl. 2019;39:589. [PMID: 31639842]8.  Cronic Inflmmtory polyneurotyChrni  inflammatry demyelinating plyneurpathy, an aquired immunlgially mediated disrder, is linially similar t Guillain-Barré syndrme exept that it has a relapsing r steadily prgressive urse ver mnths r years and that autnmi dysfuntin is generally less mmn. It may present as an exlusively mtr disrder r with a mixed sensrimtr disturbane. In the relapsing frm, partial revery may ur after sme relapses, but in ther instanes there is n revery between exaerba- tins. Althugh remissin may ur spntaneusly with time, the disrder frequently fllws a prgressive dwn- hill urse leading t severe funtinal disability. Eletrdiagnsti studies shw marked slwing f mtr and sensry ndutin, and fal ndutin blk. Signs f partial denervatin may als be present wing t sendary axnal degeneratin. Nerve bipsy may shw hrni perivasular inflammatry infiltrates in the endneurium and epineurium, withut ampanying evidene f vasulitis. Hwever, a nrmal nerve bipsy result r the presene f nnspeifi abnrmalities des nt exlude the diagnsis. Crtisterids may arrest r reverse the dwnhill urse. Treatment is usually begun with prednisne, 60–80 mg rally daily, ntinued fr 2–3 mnths r until a definite respnse has urred. If n respnse has urred despite 3 mnths f treatment, a higher dse may be tried. In respnsive ases, the dse is gradually tapered, but mst patients beme rtisterid-dependent, ften requiring prednisne, 20 mg daily n alternate days, n a lng-term basis. IVIG an be used in plae f, r in additin t rti- sterids, and is best used as the initial treatment in puremtr syndrmes (2 g/kg ver 2–5 days fllwed by 1 g/kg every 3 weeks); a weekly regimen f 0.2–0.4 g/kg f a 20% subutaneus immunglbulin slutin is an effetive alternative but has nt been mpared diretly t rti- sterids r IVIG. When bth IVIG and rtisterids are ineffetive, plasma exhange may be wrthwhile. Cnsis- tent with the ntin that the nditin is antibdy medi- ated, rituximab has shwn prmise. Immunsuppressant r immunmdulatry mediatins (suh as azathiprine) may be added when the respnse t ther measures is unsatisfatry r t enable maintenane dses f rti- sterids t be lwered. Symptmati treatment is als imprtant.Bunshten  C et al. Prgress in diagnsis and treatment f hrni inflammatry demyelinating plyneurpathy. Lanet Neurl. 2019;18:784. [PMID: 31076244]MO NONEUROPATHIESE S S E N T I A L S  O F  D I A G N O S I S »Focal motor or sensory deficit. »Deficit is in territory of an individual peripheral nerve. An individual nerve may be injured alng its urse r may be mpressed, angulated, r strethed by neighbring ana- tmi strutures, espeially at a pint where it passes thrugh a narrw spae ( entrapment neuropathy ). The relative ntributins f mehanial fatrs and ishemia t the lal damage are nt lear. With invlvement f a sen- sry r mixed nerve, pain is mmnly felt distal t the lesin. Symptms never develp with sme entrapment neurpathies, reslve rapidly and spntaneusly in thers, and beme prgressively mre disabling and distressing in yet ther ases. The preise neurlgi defiit depends n the nerve invlved. Perussin f the nerve at the site f the lesin may lead t paresthesias in its distal distributin. Entrapment neurpathy may be the sle manifestatin f sublinial plyneurpathy, and this must be brne in mind and exluded by nerve ndutin studies. Suh studies are als indispensable fr the lalizatin f the fal lesin. In patients with aute mpressin neurpathy suh as may ur in intxiated individuals ( Saturday night palsy ), n treatment is neessary. Cmplete revery gen- erally urs, usually within 2 mnths, presumably beause the underlying pathlgy is demyelinatin. Hwever, ax- nal degeneratin an ur in severe ases, and revery then takes lnger and may never be mplete. In hrni mpressive r entrapment neurpathies, avidane f aggravating fatrs and rretin f any under- lying systemi nditins are imprtant. Lal infiltratin f the regin abut the nerve with rtisterids may be f value; in additin, surgial dempressin may help ifCMDT22_Ch24_p0978-p1053.indd  1042 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1043 CMDT 2022there  is a prgressively inreasing neurlgi defiit r if eletrdiagnsti studies shw evidene f partial denerva- tin in weak musles. Peripheral nerve tumrs are unmmn, exept in neu- rfibrmatsis type 1, but als give rise t mnneurpathy. This may be distinguishable frm entrapment neurpathy nly by nting the presene f a mass alng the urse f the nerve and by demnstrating the preise site f the lesin with apprpriate eletrphysilgi studies. Treatment f symptmati lesins is by surgial remval if pssible.1.  Crl Tunnel SyndromeSee Chapter 41. 2.  prontor Teres or anterior Interosseous SyndromeThe  median nerve gives ff its mtr branh, the anterir intersseus nerve, belw the elbw as it desends between the tw heads f the prnatr teres musle. A lesin f either nerve may ur in this regin, smetimes after trauma r wing t mpressin frm, fr example, a fibrus band. With anterir intersseus nerve invlvement, there is n sensry lss, and weakness is nfined t the prnatr qua- dratus, flexr plliis lngus, and the flexr digitrum pr- fundus t the send and third digits. Weakness is mre widespread and sensry hanges ur in an apprpriate distributin when the median nerve itself is affeted. The prgnsis is variable. If imprvement des nt ur spn- taneusly, dempressive surgery may be helpful.3.  Ulnr Nerve LesionsUlnar nerve lesi ns are likely t ur in the elbw regin as the nerve runs behind the medial epindyle and desends int the ubital tunnel. In the ndylar grve, the ulnar nerve is expsed t pressure r trauma. Mre- ver, any inrease in the arrying angle f the elbw, whether ngenital, degenerative, r traumati, may ause exessive strething f the nerve when the elbw is flexed. Ulnar nerve lesins may als result frm thikening r distrtin f the anatmi strutures frming the ubital tunnel, and the resulting symptms may als be aggravated by flexin f the elbw, beause the tunnel is then nar- rwed by tightening f its rf r inward bulging f its flr. A severe lesin at either site auses sensry hanges in the fifth and medial half f the furth digits and alng the medial brder f the hand. There is weakness f the ulnar-innervated musles in the frearm and hand. With a ubital tunnel lesin, hwever, there may be relative spar- ing f the flexr arpi ulnaris musle. Eletrphysilgi evaluatin using nerve stimulatin tehniques allws mre preise lalizatin f the lesin. Initial treatment nsists f aviding pressure n the medial elbw (eg, avid resting the elbws n arm rests; pad the elbw during sleep) and preventing prlnged elbw flexin, espeially at night. Splints are available t keep the elbw frm flexing beynd 45 t 90 degrees. If nservative measures are unsuessful in relieving symp- tms and preventing further prgressin, surgial treat- ment may be neessary. This nsists f nerve transpsitinif the lesin is in the ndylar grve, r a release pre- dure if it is in the ubital tunnel. Ulnar nerve lesins may als develp at the wrist r in the palm f the hand, usually wing t repetitive trauma r t mpressin frm ganglia r benign tumrs. They an be subdivided depending n their presumed site. Cm- pressive lesins are treated surgially. If repetitive mehani- al trauma is respnsible, this is avided by upatinal adjustment r jb retraining.4.  Rdil Nerve LesionsThe  radial nerve is partiularly liable t mpressin r injury in the axilla (eg, by ruthes r by pressure when the arm hangs ver the bak f a hair). This leads t weakness r paralysis f all the musles supplied by the nerve, inluding the trieps. Sensry hanges may als ur but are ften surprisingly innspiuus, being marked nly in a small area n the bak f the hand between the thumb and index finger. Injuries t the radial nerve in the spiral grve ur harateristially during deep sleep, as in intxiated individuals, and there is then sparing f the trieps musle, whih is supplied mre prximally. The nerve may als be injured at r abve the elbw; its purely mtr psterir intersseus branh, supplying the exten- srs f the wrist and fingers, may be invlved immediately belw the elbw, but then there is sparing f the extensr arpi radialis lngus, s that the wrist an still be extended. The superfiial radial nerve may be mpressed by hand- uffs r a tight wath strap.5.  Femorl NeurotyThe  linial features f femral nerve palsy nsist f weak- ness and wasting f the quadrieps musle, with sensry impairment ver the antermedian aspet f the thigh and smetimes als f the leg t the medial mallelus, and a depressed r absent knee jerk. Islated femral neurpathy may ur in patients with diabetes r frm mpressin by retrperitneal neplasms r hematmas (eg, expanding arti aneurysm). Femral neurpathy may als result frm pressure frm the inguinal ligament when the thighs are markedly flexed and abduted, as in the lithtmy psitin.6.  Merlgi presteticThe  lateral femral utaneus nerve, a sensry nerve arising frm the L2 and L3 rts, may be mpressed r strethed in bese r diabeti patients and during pregnany. The nerve usually runs under the uter prtin f the inguinal ligament t reah the thigh, but the ligament smetimes splits t enlse it. Hyperextensin f the hip r inreased lumbar lrdsis—suh as urs during pregnany—leads t nerve mpressin by the psterir fasile f the liga- ment. Hwever, entrapment f the nerve at any pint alng its urse may ause similar symptms, and several ther anatmi variatins predispse the nerve t damage when it is strethed. Pain, paresthesia, r numbness urs abut the uter aspet f the thigh, usually unilaterally, and is smetimes relieved by sitting. The pain stps at the knee, unlike the pain frm lwer lumbar siatia that radiates t the ft. Examinatin shws n abnrmalities exept inCMDT22_Ch24_p0978-p1053.indd  1043 29/06/21 8:50 PMChapTER 241044 CMDT 2022severe  ases when utaneus sensatin is impaired in the affeted area. Symptms are usually mild and mmnly settle spntaneusly. Hydrrtisne injetins medial t the antersuperir ilia spine ften relieve symptms tem- prarily, while nerve dempressin by transpsitin may prvide mre lasting relief.7.  Scitic & Common peronel (Fibulr) Nerve plsiesMisplaed  deep intramusular injetins are prbably still the mst mmn ause f siati nerve palsy. Trauma t the buttk, hip, r thigh may als be respnsible. The resulting linial defiit depends n whether the whle nerve has been affeted r nly ertain fibers. In general, the perneal (fibular) fibers f the siati nerve are mre suseptible t damage than thse destined fr the tibial nerve. A siati nerve lesin may therefre be diffiult t distinguish frm perneal (fibular) neurpathy unless there is eletrmygraphi evidene f invlvement f the shrt head f the bieps femris musle. The mmn perneal (fibular) nerve itself may be mpressed r injured in the regin f the head and nek f the fibula, eg, by sitting with rssed legs r wearing high bts. There is weakness f drsiflexin and eversin f the ft, am- panied by numbness r blunted sensatin f the anterlat- eral aspet f the alf and drsum f the ft.8.  Trsl Tunnel SyndromeThe  tibial nerve, the ther branh f the siati, supplies several musles in the lwer extremity, gives rigin t the sural nerve, and then ntinues as the psterir tibial nerve t supply the plantar flexrs f the ft and tes. It passes thrugh the tarsal tunnel behind and belw the medial mal- lelus, giving ff alaneal branhes and the medial and lat- eral plantar nerves that supply small musles f the ft and the skin n the plantar aspet f the ft and tes. Cmpres- sin f the psterir tibial nerve r its branhes between the bny flr and ligamentus rf f the tarsal tunnel leads t pain, paresthesias, and numbness ver the bttm f the ft, espeially at night, with sparing f the heel. Musle weakness may be hard t regnize linially. Cmpressive lesins f the individual plantar nerves may als ur mre distally, with linial features similar t thse f the tarsal tunnel syndrme. Treatment is surgial dempressin. »When to Refer• If there is unertainty abut the diagnsis. •Symptms r signs are prgressing despite treatment.BE LL PALSYE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of lower motor neuron facial palsy. »Hyperacusis or impaired taste may occur. »No other neurologic abnormalities.»General ConsiderationsBell pa lsy is an idiopathic facial paresis of lower motor neu- ron type that has been attributed t an inflammatry rea- tin invlving the faial nerve near the stylmastid framen r in the bny faial anal. In sme instanes, this may be due t reativatin f herpes simplex r variella zster virus infetin in the geniulate ganglin. The disr- der is mre mmn in pregnant wmen and in persns with diabetes mellitus. »Clinical FindingsThe  faial paresis (Figure 24–1) generally mes n abruptly, but it may wrsen ver the fllwing day r s. Pain abut the ear preedes r ampanies the weakness in many ases but usually lasts fr nly a few days. The fae itself feels stiff and pulled t ne side. There may be ipsilat- eral restritin f eye lsure and diffiulty with eating and fine faial mvements. A disturbane f taste is mmn, wing t invlvement f hrda tympani fibers, and hyper- ausis due t invlvement f fibers t the stapedius urs asinally. In ases due t herpes zster infetin, vesi- les may be bserved in the external ear anal. »Differential DiagnosisLwer  mtr neurn faial palsy an be differentiated frm strke by linial examinatin. A strke r ther entral lesin will nt ause hyperausis r disturbane f taste, ▲Figure 24–1. Facial palsy caused by an infection with Borrelia burgdorferi (Lyme disease). (Public Health Image Library, CDC.)CMDT22_Ch24_p0978-p1053.indd  1044 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1045 CMDT 2022generally  spares the frehead, and is ampanied by ther fal defiits. An islated faial palsy may ur in patients with HIV serpsitivity, saridsis, Lyme disease (Figure 24–1; als see Chapter 34), r any press ausing an inflammatry reatin in the subarahnid spae, suh as meningitis. Whenever faial palsies ur bilaterally, r a faial palsy urs in njuntin with ther neurlgi defiits, MRI brain imaging shuld be undertaken and ther investigatins nsidered. »TreatmentA pprximately 60% f ases f Bell palsy rever m- pletely withut treatment, presumably beause the lesin is s mild that it leads merely t ndutin blk. Treat- ment with rtisterids (prednisne 60 mg rally daily fr 5 days fllwed by a 5-day taper, r prednislne 25 mg rally twie daily fr 10 days) inreases the hane f a mplete revery at 9–12 mnths by 12–15%. Treat- ment with aylvir r valaylvir is nly indiated when there is evidene f herpeti vesiles in the external ear anal. It is helpful t prtet the eye with lubriating drps (r lubriating intment at night) and a path if eye lsure is nt pssible. There is n evidene that surgial predures t dempress the faial nerve are f benefit. Physial therapy may imprve faial funtin.Gagyr  I et al. Antiviral treatment f Bell’s palsy (idipathi faial paralysis). Chrane Database Syst Rev. 2019;9:CD001869. [PMID: 31486071]DI SCOGENIC NECK PAINE S S E N T I A L S  O F  D I A G N O S I S »Neck pain, sometimes radiating to arms. »Restricted neck movements. »Motor, sensory, or reflex changes in arms with root involvement. »Neurologic deficit in legs, gait disorder, or sphinc- ter disturbance with cord involvement. »General ConsiderationsA variety  f ngenital abnrmalities may invlve the er- vial spine and lead t nek pain; these inlude hemiverte- brae, fused vertebrae, basilar impressin, and instability f the atlantaxial jint. Traumati, degenerative, infetive, and neplasti disrders may als lead t pain in the nek. When rheumatid arthritis invlves the spine, it tends t affet espeially the ervial regin, leading t pain, stiff- ness, and redued mbility; displaement f vertebrae r atlantaxial subluxatin may lead t rd mpressin that an be life-threatening if nt treated by fixatin. Furtherdetails are given in Chapter 41 and disussin here is restrited t disk disease.1.  acute Cervicl Disk protrusionAut e ervial disk prtrusin leads t pain in the nek and radiular pain in the arm, exaerbated by head mvement. With lateral herniatin f the disk, mtr, sensry, r reflex hanges may be fund in a radiular (usually C6 r C7) distributin n the affeted side (Figure 24–2); with mre entrally direted herniatins, the spinal rd may als be invlved, leading t spasti paraparesis and sensry distur- banes in the legs, smetimes ampanied by impaired sphinter funtin. The diagnsis is nfirmed by MRI r CT myelgraphy. In mild ases, the prgnsis is gd and mplete revery urs in a majrity f patients with nservative therapy. Evidene des nt supprt any spe- ifi interventin, and sme mbinatin f bed rest, ativ- ity restritin, immbilizatin f the nek in a llar fr several weeks, and physial therapy is generally presribed. If these measures are unsuessful r the patient has a sig- nifiant neurlgi defiit, surgial remval f the prtrud- ing disk may be neessary.2.  Cervicl SondylosisCer vial spndylsis results frm hrni ervial disk degeneratin, with herniatin f disk material, sendary alifiatin, and assiated stephyti utgrwths. One r mre f the ervial nerve rts may be mpressed, strethed, r angulated; and myelpathy may als develp as a result f mpressin, vasular insuffiieny, r reur- rent minr trauma t the rd. Patients present with nek pain and restrited head mvement, ipital headahes, radiular pain and ther sensry disturbanes in the arms, weakness f the arms r legs, r sme mbinatin f these symptms. Examinatin generally reveals that lateral flex- in and rtatin f the nek are limited. A segmental pat- tern f weakness r dermatmal sensry lss (r bth) may be fund unilaterally r bilaterally in the upper limbs, and tendn reflexes mediated by the affeted rt r rts are depressed. The C5 and C6 nerve rts are mst mmnly invlved, and examinatin frequently then reveals weak- ness f musles supplied by these rts (eg, deltids, supra- spinatus and infraspinatus, bieps, brahiradialis), pain r sensry lss abut the shulder and uter brder f the arm and frearm, and depressed bieps and brahiradialis reflexes. Spasti paraparesis may als be present if there is an assiated myelpathy, smetimes ampanied by uri- nary urgeny, inntinene, r psterir lumn r spin- thalami sensry defiits in the legs. Plain radigraphs f the ervial spine shw stephyte frmatin, narrwing f disk spaes, and enrahment n the intervertebral framina, but suh hanges are mmn in middle-aged persns and may be unrelated t the pre- senting mplaint. CT r MRI helps nfirm the diagnsis and exlude ther strutural auses f the myelpathy. Restritin f nek mvements by a ervial llar may relieve pain. Lal injetin f anesthetis r rtisterids, fr instane by a pain management speialist, may be fCMDT22_Ch24_p0978-p1053.indd  1045 29/06/21 8:50 PMChapTER 241046 CMDT 2022 ▲Figure 24–2. Cutaneous innervation. The segmental or radicular (root) distribution is shown on the left side of the body and the peripheral nerve distribution on the right side. Segmental maps show differences depending on how they were constructed (single root stimulation or section; local anesthetic injection into single dorsal root ganglia). (Adapted, with permission, from Aminoff MJ, Greenberg DA, Simon RP . Clinical Neurology, 9th ed. McGraw-Hill Education, 2015.)= Iliohypogastric = Ilioinguinal = Genitofemoral Dorsal nerve of penis Perineal nerve of penisPeripheral nerve Nerve root Trigeminal (Cranial nerve V) Anterior cutaneous nerve of neck Supraclavicular nerves Axillary nerve Medial cutaneous nerve of arm Lateral cutaneous nerve of arm (branch of radial nerve) Medial cutaneous nerve of forearm Lateral cutaneous nerve of forearm Radial Median Ulnar Lateral femoral cutaneous Obturator Anterior femoral cutaneous Lateral cutaneous nerve of calf Saphenous Superficial peroneal Sural Lateral and medial plantar Deep peronealOphthalmic branch (V1) Maxillary branch (V2) Mandibular branch (V3)* *† †X XLateral thoracic rami Post.Mid.Ant.Anterior thoracic ramiC3 C4 C5 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1L1 L2 L3 L4 L5 S1T2 T1 C8C6C6 C7CMDT22_Ch24_p0978-p1053.indd  1046 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1047 CMDT 2022P eripheral nerve Posterior rami of cervical nerves Supraclavicular Axillary Medial cutaneous nerve of forearmLateral cutaneous nerve of forearm Lateral femoral cutaneous Obturator Anterior femoral cutaneous Posterior femoral cutaneous Lateral cutaneous nerve of calf SaphenousSuperficial peroneal Calcaneal Lateral plantar Medial plantarGreat occipital Lesser occipital Great auricular Posterior cutaneous nerve of forearmMedial cutaneous nerve of armLateral cutaneous nerve of arm Posterior cutaneous nerve of arm MedianPosterior lumbar rami Posterior sacral rami = IliohypogastricXX Nerve root Radial Ulnar SuralT2 T2 T1T3C2 C3 C4 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1 L2 C8C6 C7 S1L5 L5S3 L 3S4 S5 L4S2P osterior thoracic ramiLateral thoracic ramiC5 C6benefit . Operative treatment may be neessary t prevent further prgressin if there is a signifiant neurlgi defi- it; bwel r bladder symptms; r if rt pain is severe, persistent, and unrespnsive t nservative measures. »When to Refer• Pain unrespnsive t simple measures. •Patients with neurlgi defiits. •Patients in whm surgial treatment is under nsideratin.»When to Admit• Patients with prgressive r signifiant neurlgi defiit. •Patients with sphinter invlvement (frm rd mpressin). •Patients requiring surgial treatment.Stin AM et  al. Myelpathies due t strutural ervial and th- rai disease. Cntinuum (Minneap Minn). 2018;24:567. [PMID: 29613900]▲Figure 24–2. (Continued )CMDT22_Ch24_p0978-p1053.indd  1047 29/06/21 8:50 PMChapTER 241048 CMDT 2022BR aChIaL & LUMBaR pLEXUS LESIONS 1. Brcil plexus NeurotyBrahial  plexus neurpathy may be idipathi, smetimes urring in relatinship t a number f different nnspe- ifi illnesses r fatrs. In ther instanes, brahial plexus lesins fllw trauma r result frm ngenital anmalies, neplasti invlvement, r injury by varius physial agents. In rare instanes, the disrder urs n a familial basis. Idipathi brahial plexus neurpathy ( neuralgic amyotrophy ) harateristially begins with severe pain abut the shulder, fllwed within a few days by weak- ness, reflex hanges, and sensry disturbanes invlving espeially the C5 and C6 segments but affeting any nerve in the brahial plexus. Symptms and signs are usually unilateral but may be bilateral. Wasting f affeted musles is smetimes prfund. The disrder relates t disturbed funtin f ervial rts r part f the brahial plexus, but its preise ause is unknwn. Revery urs ver the ensuing mnths but may be inmplete. Treatment is purely symptmati, althugh emerging evidene suggests that mirsurgial neurlysis f hurglass-like nstri- tins n affeted nerves identified by magneti resnane neurgraphy r high-reslutin ultrasund imprves ut- me in patients wh have nt revered after several mnths f nservative management.2.  Cervicl Rib SyndromeC mpressin f the C8 and T1 rts r the lwer trunk f the brahial plexus by a ervial rib r band arising frm the seventh ervial vertebra leads t weakness and wasting f intrinsi hand musles, espeially thse in the thenar emi- nene, ampanied by pain and numbness in the medial tw fingers and the ulnar brder f the hand and frearm. Ele- trmygraphy, nerve ndutin studies, and smatsensry evked ptential studies may help nfirm the diagnsis. MRI may be espeially helpful in revealing the underlying mpressive struture. Plain radigraphs r CT sanning smetimes shws the ervial rib r a large transverse press f the seventh ervial vertebra, but nrmal findings d nt exlude the pssibility f a ervial band. Treatment f the disrder is by surgial exisin f the rib r band.3.  Lumboscrl plexus LesionsA  lumbsaral plexus lesin may develp in assiatin with diseases suh as diabetes, aner, r bleeding disr- ders r in relatin t injury. It asinally urs as an islated phenmenn similar t idipathi brahial plexpathy (nndiabeti lumbsaral radiulplexus neu- rpathy), and pain and weakness then tend t be mre nspiuus than sensry symptms. The distributin f symptms and signs depends n the level and pattern f neurlgi invlvement.Gstettner  C et al. Neuralgi amytrphy: a paradigm shift in diagnsis and treatment. J Neurl Neursurg Psyhiatry. 2020;91:879. [PMID: 32487526]DISORDERS OF NEUROMUSCULaR TRaNSMISSION 1. Mysteni GrvisE S S E N T I A L S  O F  D I A G N O S I S »Fluctuating weakness of commonly used volun- tary muscles, producing symptoms such as diplo- pia, ptosis, and difficulty in swallowing. »Activity increases weakness of affected muscles. »Short-acting anticholinesterases transiently improve the weakness. »General ConsiderationsM yasthenia gravis urs at all ages, sometimes in association with a thymic tumor or thyrotoxicosis , as well as in rheu- matid arthritis and lupus erythematsus. It is mst m- mn in yung wmen with HLA-DR3; if thymma is assiated, lder men are mre mmnly affeted. Onset is usually insidius, but the disrder is smetimes unmasked by a inidental infetin that leads t exa- erbatin f symptms. Exaerbatins may als ur befre the menstrual perid and during r shrtly after pregnany. Symptms are due t a variable degree f blk f neurmusular transmissin aused by autanti- bdies binding t aetylhline reeptrs; these are fund in mst patients with the disease and have a primary rle in reduing the number f funtining aetylhline reep- trs. Additinally, ellular immune ativity against the reeptr is fund. »Clinical FindingsA.  Symptoms and SignsPa tients present with ptsis, diplpia, diffiulty in hewing r swallwing, respiratry diffiulties, limb weakness, r sme mbinatin f these prblems. Weakness may remain lalized t a few musle grups r may beme generalized. The external ular musles and ertain ther ranial musles, inluding the mastiatry, faial, and pha- ryngeal musles, are espeially likely t be affeted, and the respiratry and limb musles may als be invlved. Symp- tms ften flutuate in intensity during the day, and this diurnal variatin is superimpsed n a tendeny t lnger- term spntaneus relapses and remissins that may last fr weeks. Nevertheless, the disrder fllws a slwly prgres- sive urse and may have a fatal utme wing t respira- try mpliatins suh as aspiratin pneumnia. Clinial examinatin nfirms the weakness and fatiga- bility f affeted musles. In mst ases, the extraular musles are invlved, and this leads t ular palsies and ptsis, whih are mmnly asymmetri. Pupillary respnses are nrmal. The bulbar and limb musles are ften weak, but the pattern f invlvement is variable. Sus- tained ativity f affeted musles inreases the weakness,CMDT22_Ch24_p0978-p1053.indd  1048 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1049 CMDT 2022whih impr ves after a brief rest. Sensatin is nrmal, and there are usually n reflex hanges. Life-threatening exaerbatins f myasthenia (s-alled myasthenic crisis ) may lead t respiratry weakness requiring immediate admissin t the intensive are unit, where respiratry funtin an be mnitred and ventila- tr supprt is readily available.B.  Laboratory and Other StudiesAssay  f serum fr elevated levels f irulating aetylh- line reeptr antibdies is useful beause it has a sensitiv- ity f 80–90% fr the diagnsis f myasthenia gravis. Certain patients withut antibdies t aetylhline reeptrs have serum antibdies t musle-speifi tyr- sine kinase (MuSK), whih shuld therefre be deter- mined; these patients are mre likely t have faial, respiratry, and prximal musle weakness than thse with antibdies t aetylhline reeptrs. Other antibd- ies assiated with myasthenia gravis inlude lw-density lipprtein reeptr-related prtein 4 (LRP4) and agrin, but tests fr these antibdies are nt widely mmerially available. Eletrphysilgi demnstratin f a derementing musle respnse t repetitive 2- r 3-Hz stimulatin f mtr nerves indiates a disturbane f neurmusular transmissin. Suh an abnrmality may even be deteted in linially strng musles with ertain prvative pre- dures. Needle eletrmygraphy f affeted musles shws a marked variatin in nfiguratin and size f individual mtr unit ptentials, and single-fiber eletrmygraphy reveals an inreased jitter, r variability, in the time interval between tw musle fiber atin ptentials frm the same mtr unit.C.  ImagingA  CT san f the hest with and withut ntrast shuld be btained t demnstrate a existing thymma. »TreatmentAntih linesterase mediatins prvide symptmati ben- efit withut influening the urse f the disease. Nestig- mine, pyridstigmine, r bth an be used, the dse being determined n an individual basis. The usual dse f ne- stigmine is 7.5–30 mg (average, 15 mg) rally taken fur times daily; f pyridstigmine, 30–180 mg (average, 60 mg) rally fur times daily. Overmediatin may temprarily inrease weakness. A wide range f mediatins (eg, ami- nglysides) may exaerbate myasthenia gravis and shuld be avided. Thymetmy shuld be perfrmed when a thymma is present. A multienter randmized trial demnstrated the benefit f thymetmy even in the absene f a radilgi- ally identifiable thymma, with imprved strength, lwer immunsuppressin requirements, and fewer hspitaliza- tins in the surgially treated grup. Thus, thymectomy should be considered in all patients younger than age 65 unless weakness is restricted to the extraocular muscles. If the disease is f reent nset and nly slwly prgressive,peratin is smetimes delayed fr a year r s, in the hpe that spntaneus remissin will ur. Treatment with rtisterids is indiated fr patients wh have respnded prly t antihlinester- ase mediatins. Sme patients experiene transient exaerbatin f weakness and even develp respiratry failure within the first 1–2 weeks if rtisterids are initiated at high dses (eg, prednisne 1 mg/kg/day). Therefre, in stable patients, rtisterids are intr- dued gradually in the utpatient setting. Prednisne an be started at 20 mg rally daily and inreased by 10 mg inrements weekly t a target f 1 mg/kg/day (maximum daily dse 100 mg). Fr patients hspitalized with severe myasthenia and treated with IVIG r plasma- pheresis, the higher dse an be given initially beause the mre rapid nset f atin f the frmer tw thera- pies mitigates the initial dip in strength due t rti- sterids. Crtisterids an be presribed as alternate-day r daily treatment, with alternate-day therapy ptentially mitigating side effets. One the patient has stabilized at the initial high dse, rtiste- rids an gradually be tapered t a relatively lw main- tenane level (eg, 10 mg prednisne rally daily) as imprvement urs; ttal withdrawal is diffiult, hw- ever. Treatment with azathiprine may be effetive in allwing a lwer dse f rtisterids. The usual dse is 2–3 mg/kg rally daily after a lwer initial dse. Other immunsuppressive agents that are used in myasthenia gravis t redue the rtisterid dse inlude myphe- nlate mfetil, rituximab, ylsprine, methtrexate, and tarlimus. Eulizumab, a mplement inhibitr, is apprved by the FDA fr aetylhline reeptr antibdy psitive myasthenia in patients wh have disease refra- try t at least tw alternate immunsuppressive thera- pies. It is administered intravenusly (900 mg weekly fr fur dses, fllwed by 1200 mg at week 5, then 1200 mg every 2 weeks). Patients must be vainated against menin- gus prir t reeiving eulizumab. In patients with majr disability, plasmapheresis r IVIG therapy may be benefiial and have similar effiay. It is als useful fr stabilizing patients befre thymetmy and fr managing aute risis. »When to ReferAll patients sh uld be referred. »When to Admit• Patients with aute exaerbatin r respiratry invlvement. •Patients requiring plasmapheresis. •Fr thymetmy.Fa rmakidis C et al. Treatment f myasthenia gravis. Neurl Clin. 2018;36:311. [PMID: 29655452] Muppidi S et al; Regain Study Grup. Lng-term safety and effiay f eulizumab in generalized myasthenia gravis. Musle Nerve. 2019;60:14. [PMID: 30767274]CMDT22_Ch24_p0978-p1053.indd  1049 29/06/21 8:50 PMChapTER 241050 CMDT 20222.  Mystenic Syndrome (Lmbert-Eton Mystenic Syndrome)E S S E N T I A L S  O F  D I A G N O S I S »Variable weakness, typically improving with activity. »Dysautonomic symptoms may also be present. »A history of malignant disease may be obtained. »Clinical FindingsM yastheni syndrme may be associated with small cell carcinoma, smetimes develping befre the tumr is diag- nsed, and asinally urs with ertain autimmune diseases. There is defetive release f aetylhline in respnse t a nerve impulse, aused by P/Q-type vltage- gated alium hannel antibdies, and this leads t weak- ness, espeially f the prximal musles f the limbs. Unlike myasthenia gravis, hwever, pwer steadily increases with sustained ntratin. The diagnsis an be n- firmed eletrphysilgially, beause the musle respnse t stimulatin f its mtr nerve inreases remarkably after exerise r if the nerve is stimulated repetitively at high rates (50 Hz), even in musles that are nt linially weak. »TreatmentT reatment with IVIG, plasmapheresis, and immunsup- pressive mediatin therapy (prednisne and azathiprine) may lead t linial and eletrphysilgi imprvement, in additin t therapy aimed at tumr when present. Pred- nisne is usually initiated in a daily dse f 60–80 mg rally and azathiprine in a daily dse f 2 mg/kg rally. Symp- tmati therapy inludes the use f ptassium hannel antagnists; f these, amifampridine is a 3,4-diaminpyri- dine (15–80 mg/day rally in three divided dses) and is apprved in the United States and Eurpe. Guanidine hydrhlride (25–50 mg/kg/day rally in divided dses) is an alternative and is asinally helpful in seriusly dis- abled patients, but adverse effets f the mediatin inlude marrw suppressin. The respnse t treatment with antihlinesterase mediatins suh as pyridstig- mine r nestigmine is usually disappinting.3.  BotulismThe txin f  Clostridium botulinum prevents the release f aetylhline at neurmusular juntins and autnmi synapses. Btulism urs mst mmnly fllwing the ingestin f ntaminated hme-anned fd; utbreaks have als urred amng drug abusers due t wund infetin after injetin f ntaminated herin. The diagnsis shuld be suggested by the develpment f sud- den, flutuating, severe weakness with preserved sensa- tin in a previusly healthy persn. Symptms begin within 72 hurs fllwing ingestin f the txin and may prgress fr several days. Typially, there is diplpia, ptsis,faial weakness, dysphagia, and nasal speeh, fllwed by respiratry diffiulty and finally by weakness that appears last in the limbs. Blurring f visin (with unreative dilated pupils) is harateristi, and there may be dryness f the muth, nstipatin (paralyti ileus), and pstural hyp- tensin. The tendn reflexes are nt affeted unless the invlved musles are very weak. If the diagnsis is sus- peted, the lal health authrity shuld be ntified and a sample f serum and ntaminated fd (if available) sent t be assayed fr txin. Supprt fr the diagnsis may be btained by eletrphysilgi studies; with repetitive stimulatin f mtr nerves at fast rates, the musle respnse inreases in size prgressively. Patients shuld be hspitalized in ase respiratry assis- tane bemes neessary. Treatment is with heptavalent antitxin, in patients withut knwn allergy t hrse serum. Ptassium hannel antagnists may prvide symp- tmati relief as they d in Lambert-Eatn myastheni syndrme. Antihlinesterase mediatins are f n value. Respiratry assistane and ther supprtive measures shuld be prvided as neessary. Further details are pr- vided in Chapter 33.4.  Disorders associted wit Use of aminoglycosidesAminglyside  antibitis, eg, gentamiin, may prdue a linial disturbane similar t btulism by preventing the release f aetylhline frm nerve endings, but symptms subside rapidly as the respnsible mediatin is eliminated frm the bdy. These antibitis are partiularly dangerus in patients with preexisting disturbanes f neurmusular transmissin and are therefre best avided in patients with myasthenia gravis.MYOp aThIC DISORDERSE S S E N T I A L S  O F  D I A G N O S I S »Muscle weakness without sensory loss, often in a characteristic distribution. »Serum creatine kinase elevated in most cases. »Age at onset, time course, and inheritance pattern may suggest underlying disorder. »General ConsiderationsMy pathies an be inherited r aquired. Aquired mypa- thies ften present autely r subautely while inherited mypathies are typially insidius in nset. Patients typi- ally mplain f weakness affeting prximal musles, suh as diffiulty limbing stairs, arising frm a hair, r reahing verhead, r f head drp. Sensry symptms are absent. A detailed family histry is required. Examinatin shws weakness f prximal musles. In sme ases, there is a mre speifi pattern f weaknessCMDT22_Ch24_p0978-p1053.indd  1050 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1051 CMDT 2022(eg,  quadrieps and finger flexr weakness in inlusin bdy mysitis). Extraular musle invlvement is rarely seen, exept in ertain mithndrial disrders, ulpha- ryngeal musular dystrphy, and hyperthyridism; when present, it shuld suggest the pssibility f a neurmusular juntin disrder. Reflexes are nrmal r diminished in prprtin t the degree f weakness. Sensatin is nrmal. Initial testing shuld inlude serum reatine kinase determinatin. Cnsider testing thyrid-stimulating hr- mne, rtisl, vitamin D, and alium. Antibdies speifi t ertain inflammatry mypathies and nnetive tissue disease an be heked when these nditins are suspeted (see Chapter 20). Eletrmygraphy will reveal small mtr units and early reruitment; it is helpful in nfirming the lalizatin f weakness t the musle and suggesting a suitable site fr bipsy, as des MRI. The eletrmy- graphi findings may be nrmal in rtisterid and mithndrial mypathies. Musle bipsy establishes the diagnsis when inflammatry, mithndrial, metabli, r ertain inherited mypathies are suspeted. In ases where the family histry r pattern f weakness suggests aspeifi geneti disrder, geneti testing an be pursued diretly and bipsy may nt be needed. Seleted mmn and treatable mypathies are disussed belw.1.  Musculr DystroiesThese  inherited mypathi disrders are subdivided by mde f inheritane, age at nset, and linial features, as shwn in Table 24–10. In the Duchenne type, pseudhy- pertrphy f musles frequently urs at sme stage; intel- letual disability is mmn; and there may be skeletal defrmities, musle ntratures, and ardia invlvement. A geneti defet n the shrt arm f the X hrmsme has been identified in Duhenne dystrphy. The affeted gene des fr the prtein dystrphin, whih is markedly redued r absent frm the musle f patients with the disease. Dystrphin levels are generally nrmal in the Becker variety, but the prtein is qualitatively altered. The diagnsis is usually made with geneti testing; musle bipsy is needed asinally. Duhenne musular dystr- phy an be regnized early in pregnany in abut 95% f Table 24–10. Selected muscular dystrophies (listed in order of anatomic location and physiologic underpinning).1Disorder Ineritnceage t Onset (yers) Distribution prognosis Genetic assocition Duchenne type X-linked recessive 1–5 Pelvic, then shoulder girdle; later, limb and respiratory muscles.Rapid progression. Death within about 15 years after onset.Xp21; Dystrophin (loss of functional expression). Becker X-linked recessive 5–25 Pelvic, then shoulder girdle.Slow progression. May have normal life span.Xp21; Dystrophin (reduced functional expression). Limb-girdle (Erb) Autosomal recessive, dominant, or sporadic10–30 Pelvic or shoulder girdle initially, with later spread to the other.Variable severity and rate of progression. Possi- ble severe disability in middle life.Multiple. Facioscapulo- humeralAutosomal dominantAny age Face and shoulder girdle initially; later, pelvic girdle and legs.Slow progression. Minor disability. Usually normal life span.4q35.2; Double homeobox protein 4. 18p11.32; Structural maintenance of chromosome’s flexible hinge domain- containing protein 1. Emery-Dreifuss X-linked recessive or autosomal dominant5–10 Humeroperoneal or scapuloperoneal.Variable. Multiple. Distal Autosomal domi- nant or recessive40–60 Onset distally in extremities; proximal involvement later.Slow progression. Multiple. Oculopharyngeal Autosomal dominantAny age Ptosis, external ophthal- moplegia, and dysphagia.Slow progression. 14q11.2–q13; Poly (A)-binding protein-2. Myotonic dystrophyAutosomal dominantAny age (usually 20–40)Face, neck, distal limbs. Slow progression. 19q13.32; Myotonin- protein kinase. 3q21.3; Cellular nucleic acid-binding protein.1 Not all possible genetic loci are shown.CMDT22_Ch24_p0978-p1053.indd  1051 29/06/21 8:50 PMChapTER 241052 CMDT 2022wmen  by geneti studies; in late pregnany, DNA prbes an be used n fetal tissue btained fr this purpse by amnientesis. The genes ausing sme f the ther mus- ular dystrphies are listed in Table 24–10. Three antisense lignuletides are apprved by the FDA fr treatment f Duhenne musular dystrphy. Eteplirsen appears t benefit thse patients with a dystr- phin mutatin amenable t exn 51 skipping; gldirsen and viltlarsen benefit thse with a mutatin amenable t exn 53 skipping. Patients treated with these antisense lignuletides had mre funtinal dystrphin n mus- le bipsy than ntrls and a slwer rate f disease pr- gressin than mathed histrial ntrls. Prednisne (0.75 mg/kg rally daily r 10 mg/kg rally given weekly ver 2 days) r deflazart (0.9 mg/kg rally daily) imprves musle strength and funtin in bys with Duhenne dystrphy, but side effets need t be mni- tred. Althugh bth rtisterid preparatins ause similar side effets, weight gain at 1 year is less with deflazart. Prlnged bed rest must be avided, as inativ- ity ften leads t wrsening f the underlying musle dis- ease. Physial therapy and rthpedi predures may help unterat defrmities r ntratures.2.  Myotonic DystroyMy tni dystrphy, a slwly prgressive, dminantly inherited disrder, usually manifests itself in the third r furth deade but asinally appears early in hildhd. Tw types, with a different geneti basis, have been reg- nized. Mytnia leads t mplaints f musle stiffness and is evidened by the marked delay that urs befre affeted musles an relax after a ntratin. This an ften be demnstrated linially by delayed relaxatin f the hand after sustained grip r by perussin f the belly f a musle. In additin, there is weakness and wasting f the faial, sternleidmastid, and distal limb musles. Assiated linial features inlude atarats, frntal bald- ness, testiular atrphy, diabetes mellitus, ardia abnr- malities, and intelletual hanges. Eletrmygraphi sampling f affeted musles reveals mytni disharges in additin t hanges suggestive f mypathy. It is diffiult t determine whether mediatin therapy fr mytnia is safe r effetive. When mytnia is dis- abling, treatment with a sdium hannel blker—suh as phenytin (100 mg rally three times daily), prainamide (0.5–1 g rally fur times daily), r mexiletine (150–200 mg rally three times daily)—may be helpful, but the assiated side effets, partiularly fr antiarrhythmi mediatins, are ften limiting. Neither the weakness nr the urse f the disrder is influened by treatment. Cardia funtin shuld be mnitred, and paemaker plaement may be nsidered if there is evidene f heart blk.3.  Myotoni CongenitM ytnia ngenita is mmnly inherited as a dminant trait. Generalized mytnia withut weakness is usually present frm birth, but symptms may nt appear until early hildhd. Patients mplain f musle stiffness that is enhaned by ld and inativity and relieved by exerise.Musle hypertrphy, at times prnuned, is als a feature. A reessive frm with later nset is assiated with slight weakness and atrphy f distal musles. Treatment with prainamide, tainide, mexiletine, r phenytin may help the mytnia, as in mytni dystrphy.4.  Mitocondril MyotiesThe  mithndrial mypathies are a linially diverse grup f disrders that n pathlgi examinatin f skel- etal musle with the mdified Gmri stain shw hara- teristi “ragged red fibers” ntaining aumulatins f abnrmal mithndria. Patients may present with pr- gressive external phthalmplegia r with limb weakness that is exaerbated r indued by ativity. Other patients present with entral neurlgi dysfuntin, eg, my- lni epilepsy ( myoclonic epilepsy, ragged red fiber syndrome, or MERRF ), r the mbinatin f mypathy, enephalpathy, lati aidsis, and strke-like episdes (MELAS ). Migraine is a mmn symptm. Systemi fea- tures inlude but are nt limited t diabetes mellitus, hear- ing lss, retinpathy, ardimypathy, gastri dysmtility, and shrt stature. The serum reatine kinase is usually nr- mal. Mithndrial mypathies result frm separate abnr- malities f mithndrial DNA. Treatment is symptmati and palliative, but varius experimental apprahes are being explred.5.  acid Mltse Deficiency (pome Disese)This  is a glygen strage disease due t mutatins in the gene ending aid alpha-1,4-glusidase. Age at presenta- tin ranges frm infany t the late fifties and depends n the degree f residual enzyme ativity. The juvenile and adult-nset frms present with slwly prgressive prximal weakness that inludes respiratry failure. Cardimypathy is less mmn in the adult frm. Serum reatine kinase is mildly elevated. Musle bipsy shws glygen ntaining lyssmal vaules, but the diagnsis is suggested by deteting redued aid-1,4-alpha-glusidase ativity n a dried bld spt, and nfirmed by geneti testing. Treat- ment with rembinant alpha-glusidase (20 mg/kg intra- venusly every 2 weeks) stabilizes disease prgressin and results in imprvement in respiratry funtin.6.  Dermtomyositis, anti-Syntetse Syndromes, Immune-Medited Necrotizing Myoties, & polymyositisSee Chapter 20. 7.  Inclusion Body MyositisThis  disrder, f unknwn ause, begins insidiusly, usu- ally after middle age, with prgressive prximal weakness f first the lwer and then the upper extremities, and affeting faial and pharyngeal musles. Weakness ften begins in the quadrieps femris in the lwer limbs and the frearm flexrs in the upper limbs. Distal weakness is usu- ally mild. Serum reatine kinase levels may be nrmal r inreased. The diagnsis is nfirmed by musle bipsy.CMDT22_Ch24_p0978-p1053.indd  1052 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1053 CMDT 2022Antiytsli  5’-nuletidase 1A antibdies are deteted in ne-third f ases and may be assiated with a mre severe phentype. Crtisterid and immunsuppressive therapy is smetimes ffered but is usually ineffetive, and IVIG therapy is nt remmended.8.  Endocrine MyotiesM ypathy is bserved with hypthyridism, hyperthyrid- ism, Cushing syndrme and disease, Addisn disease, vitamin D defiieny, and bth hyperparathyridism and hypparathyridism (the latter mediated by alium derangements). In hypthyridism, there may be assi- ated entrapment neurpathies, and examinatin may shw delayed relaxatin f tendn reflexes, musle enlargement, r myedema. Hyperthyridism an ause bth distal and prximal weakness and rarely a bulbar mypathy. Serum reatine kinase is nrmal exept in hypthyrid mypathy, whih an als be painful. Treatment is f the underlying endrinpathy.9.  Criticl Illness MyotyM ypathy may ur in assiatin with ritial illness, typially in patients wh reeived neurmusular blking agents and rtisterids. It is frequently disvered when patients unexpetedly require prlnged ventilatry sup- prt. There an be an assiated sensrimtr plyneu- rpathy. Serum reatine kinase may be elevated initially but has frequently returned t nrmal r is belw nrmal by the time the nditin is suspeted. Treatment is supprtive.10.  Toxic MyotiesM ypathy an ur in patients taking aminapri aid, amidarne, hlrquine, lhiine, rtisterids, yl- sprine, daptmyin, emetine, fibrates, gemitabine, nule- side reverse transriptase inhibitrs, r statin mediatins. Mypathy als urs with hrni alhlism, whereas aute reversible musle nersis may ur shrtly after aute alhl, aine, r methamphetamine intxiatin, and with prpfl infusin. Inflammatry mypathy may ur in patients taking peniillamine and an be indued by pr- grammed death-1 inhibitrs; mytnia may be indued by lfibrate, and preexisting mytnia may be exaerbated r unmasked by deplarizing musle relaxants (eg, suxameth- nium), beta-blkers (eg, prpranll), fenterl and, pssi- bly, ertain diuretis. Valpri aid an preipitate r wrsen mypathy in patients with mithndrial disrders r arni- tine palmityltransferase II defiieny. »When to ReferAll  patients shuld be referred t establish the diagnsis and underlying ause.»When to Admit• Fr respiratry assistane. •Fr rhabdmylysis.MD nald CM et al; CINRG Investigatrs. Lng-term effets f glurtiids n funtin, quality f life, and survival in patients with Duhenne musular dystrphy: a prspetive hrt study. Lanet. 2018;391:451. [PMID: 29174484] Pasnr M et al. Apprah t musle and neurmusular jun- tin disrders. Cntinuum (Minneap Minn). 2019;25:1536. [PMID: 31794459]pE RIODIC paRaLYSIS SYNDROMESPe ridi paralysis may have a familial (dminant inheri- tane) basis. The syndrmes t be desribed are channelo- pathies that manifest as abnrmal, ften ptassium-sensitive, musle-membrane exitability and lead linially t epi- sdes f flaid weakness r paralysis, smetimes in ass- iatin with abnrmalities f the plasma ptassium level. Strength is initially nrmal between attaks, but prgres- sive mypathi weakness may develp in up t ne-third f patients as they age. Hypokalemic periodic paralysis is haraterized by attaks that tend t ur n awakening, after exerise, r after a heavy meal and may last fr several days. Patients shuld avid exessive exertin. A lw- arbhydrate and lw-salt diet may help prevent attaks. An nging attak may be abrted by ptassium hlride given rally r by intravenus drip, prvided the ECG an be mnitred and kidney funtin is satisfatry. In yung Asian men, it is mmnly assiated with hyperthyrid- ism; treatment f the endrine disrder prevents reur- renes. A nnseletive beta-adrenergi blker may prevent attaks until the endrine abnrmality has been treated. Inhyperkalemic periodic paralysis, attaks als tend t ur after exerise but usually last fr less than 1 hur. They may be terminated by intravenus alium glunate (1–2 g) r by intravenus diuretis (fursemide, 20–40 mg), gluse, r gluse and insulin. Normokalemic periodic paralysis is similar linially t the hyperkalemi variety, but the plasma ptassium level remains nrmal during attaks. Several randmized trials supprt the use f dihlrphenamide (50–100 mg rally twie daily) fr pre- ventin f attaks in bth hyperkalemi and hypkalemi peridi paralysis; aetazlamide (250–750 mg rally daily) is als effetive. Chlrthiazide may als be used t prevent attaks in hyperkalemi peridi paralysis. »When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1053 29/06/21 8:50 PM1054 CMDT 2022The fifth e dition of the American Psychiatric Association’s Diagnostic and Statistical Manual (DSM-5) is the common language that clinicians use for psychiatric conditions. It utilizes specific criteria with which to objectively assess symptoms for use in clinical diagnosis and communication. ºCOMMON PSYCHIATRIC DISORDERS ADJUSTMENT DISORDERSE S S E N T I A L S  O F  D I A G N O S I S »Anxiety or depression in reaction to an identifi- able stress, though out of proportion to the sever- ity of the stressor. »Symptoms are not at the severity of a major depressive episode or with the chronicity of gen- eralized anxiety disorder (GAD). »General ConsiderationsAn individual experiences stress when adaptive ca pacity is overwhelmed by events. The event may be an insignificant one when objectively considered, and even favorable changes (eg, promotion and transfer) requiring adaptive behavior can produce stress. For everyone, stress is subjec- tively defined, and the response to stress is a function of each person’s personality and physiologic endowment. Opinion differs about what events are most apt to pro- duce stress reactions. The causes of stress are different at different ages—eg, in young adulthood, the sources of stress are found in the marriage or parent-child relation- ship, the employment relationship, and the struggle to achieve financial stability; in the middle years, the focus shifts to changing spousal relationships, problems with aging parents, and problems associated with having young adult offspring who themselves are encountering stressful situations; in old age, the principal concerns are apt to be retirement, loss of physical and mental capacity, major personal losses, and thoughts of death.»Clinical FindingsAn  individual may react to stress by becoming anxious or depressed, by developing a physical symptom, by running away, drinking alcohol, overeating, starting an affair, or in limitless other ways. Common subjective responses are anxiety, sadness, fear, rage, guilt, and shame. Acute and reactivated stress may be manifested by restlessness, irrita- bility, fatigue, increased startle reaction, and a feeling of tension. Inability to concentrate, sleep disturbances (insomnia, bad dreams), and somatic preoccupations sometimes lead to self-medication, most commonly with alcohol or other central nervous system depressants. Emo- tional and behavioral distressing symptomatology in response to stress is called adjustment disorder , with the major symptom specified (eg, “adjustment disorder with depressed mood, anxiety, mixed depression and anxiety, disturbance of conduct, mixed disturbance of emotions and conduct, or unspecified. ”). Even with an identifiable stressor, if the patient meets syndromal criteria for another disorder such as major depression, then the convention would be to diagnose a major depression and not an adjustment disorder with depressed mood . »Differential DiagnosisAd justment disorders are distinguished from anxiety dis- orders, mood disorders, bereavement, other stress disor- ders such as posttraumatic stress disorder (PTSD), and personality disorders exacerbated by stress and from somatic disorders with psychic overlay. Unlike many other psychiatric disorders, such as bipolar disorder or schizo- phrenia, adjustment disorders are wholly situational and usually resolve when the stressor resolves or the individual effectively adapts to the situation. Adjustment disorders may have symptoms that overlap with other disorders, such as anxiety symptoms, but they occur in reaction to an iden- tifiable life stressor such as a difficult work situation or romantic breakup. An adjustment disorder that persists and worsens can potentially evolve into another psychiatric disorder such as major depression or GAD. However, that is not the case for most patients. Patients with adjustment disorders have marked distress after a stressor and signifi- cant impairment in social or occupational functioning but25Kristin S. Raj, MD Nolan Williams, MD Charles DeBattista, DMH, MDPsychiatric DisordersCMDT22_Ch25_p1054-p1109.indd  1054 29/06/21 8:51 PM",
                  "NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli  beverages, bright lights, lud nise, menstrua- tin, r use f ral ntraeptives. An unmmn variant is migraine with brainstem aura, in whih blindness r visual disturbanes thrughut bth visual fields are ampanied r fllwed by dysar- thria, dysequilibrium, tinnitus, and periral and distal paresthesias and are smetimes fllwed by transient lss r impairment f nsiusness r by a nfusinal state. This, in turn, is fllwed by a thrbbing (usually ipital) headahe, ften with nausea and vmiting. Inrecurrent painful ophthalmoplegic neuropathy (previusly phthalmplegi migraine), lateralized pain— ften abut the eye—is ampanied by nausea, vmiting, and diplpia due t transient external phthalmplegia. The phthalmplegia is due t third nerve palsy, smetimes with ampanying sixth nerve invlvement, and may ut- last the rbital pain by several days r even weeks. The phthalmi divisin f the fifth nerve has als been affeted in sme patients. The nditin is rare and a diagnsis f exlusin; mre mmn auses f a painful phthalmple- gia are internal artid artery aneurysms and diabetes. »TreatmentMan agement f migraine nsists f avidane f any pre- ipitating fatrs, tgether with prphylati r symptm- ati pharmalgi treatment if neessary.A.  Symptomatic TherapyDuring  aute attaks, rest in a quiet, darkened rm may be helpful until symptms subside. A simple analgesi (eg, aspirin, aetaminphen, ibuprfen, r naprxen) taken immediately ften prvides relief, but presriptin media- tin is smetimes neessary. To prevent medication overuse, use of simple analgesics should be limited to 15 days or less per month, and combination analgesics should be limited to no more than 10 days per month . 1. Ergotamines— Cafergt, a mbinatin f ergtamine tartrate (1 mg) and affeine (100 mg), is ften partiularly helpful; ne r tw tablets are taken at the nset f headahe r warning symptms, fllwed by ne tablet every 30 minutes, if neessary, up t six tablets per attak and n mre than 10 days per mnth. Cafergt given retally (ne- half t ne suppsitry ntaining 2 mg f ergtamine) r dihydrergtamine mesylate (0.5–1 mg intravenusly r 1–2 mg subutaneusly r intramusularly) may be useful when vmiting preludes use f ral mediatins. Ergta- mine-ntaining preparatins shuld be avided during pregnany, in patients with ardivasular disease r its risk fatrs, and in patients taking ptent CYP 3A4 inhibitrs. 2. Serotonin agonists— Triptans are 5-HT1b/1dreeptr agnists that inhibit release f vasative neurpeptides. Sumatriptan is a rapidly effetive agent fr abrting attaks when given subutaneusly by an autinjetin devie (4–6 mg ne subutaneusly, may repeat ne after 2 hurs if needed; maximum dse 12 mg/24 h). Nasal and ral preparatins are available but may be less effetive due t slwer absrptin. Zlmitriptan is available in ral and nasal frmulatins. The dse is 5 mg rally r in ne nstrilne; this may be repeated ne after 2 hurs. The maxi- mum dse fr bth frmulatins is 10 mg/24 h. Other triptans are available, inluding rizatriptan (5–10 mg rally at nset, may repeat every 2 hurs twie [maximum dse 30 mg/24 h]); naratriptan (1–2.5 mg rally at nset, may repeat ne after 4 hurs [maximum dse 5 mg/24 h]); almtriptan (6.25–12.5 mg rally at nset, may repeat dse ne after 2 hurs [maximum dse 25 mg/24 h]); frvatrip- tan (2.5 mg rally at nset, may repeat after 2 hurs ne [maximum dse 7.5 mg/24]); and eletriptan (20–40 mg rally at nset; may repeat after 2 hurs ne [maximum dse 80 mg/24 h]). Eletriptan is useful fr immediate therapy, and frvatriptan, whih has a lnger half-life, may be wrthwhile fr patients with prlnged attaks r attaks prvked by menstrual perids. Patients ften experiene greater benefit when the triptan is mbined with naprxen (500 mg rally). Triptans may ause nausea and vmiting. They shuld prbably be avided in wmen wh are pregnant, and in patients with hemiplegi r basilar migraine, a histry f strke r transient ishemi attak (TIA), r unntrlled hypertensin. In patients whse hypertensin is ntrlled, triptans are mmnly used safely, althugh autin is advised. Triptans are ntraindiated in patients with r- nary r peripheral vasular disease and Prinzmetal angina. Lasmiditan (50–200 mg taken ne at headahe nset; n mre than ne dse in 24 hurs) is a 5-HT1Freeptr agnist apprved fr use in the United States that laks the vasnstritive prperties f triptans and an be given safely t patients with ardivasular risk fatrs. Dizziness and smnlene are mmn side effets, and patients shuld nt drive within 8 hurs f administratin. 3. Calcitonin gene–related peptide antagonists— Rimegepant sulfate (75 mg rally disslved tablet taken ne at headahe nset; maximum dse 75 mg/24 h) and ubrgepant (50 r 100 mg rally at headahe nset, may repeat after 2 hurs ne [maximum dse 200 mg/24 h]) are bth alitnin gene–related peptide antagnists that ahieve pain freedm in 20% and pain relief in 60% f patients within 2 hurs. Hypersensitivity reatins may ur immediately r several days after administratin with rimegepant. 4. Other agents— Prhlrperazine is effetive and may be administered retally (25 mg suppsitry), intravenusly r intramusularly (5–10 mg), r rally (5–10 mg). Intrave- nus metlpramide (10–20 mg) is als partiularly use- ful in the emergeny department setting. Varius butalbital-ntaining mbinatin ral analgesis risk veruse and dependene and shuld nly be used as a last resrt. Opiid analgesis shuld be avoided beause f high rates f rebund headahe and the tendeny t develp mediatin veruse headahe. 5. Neuromodulation— Sham-ntrlled trials shw that single-pulse transranial magneti stimulatin abrts migraine with aura, and nninvasive vagus nerve stimula- tin, transutaneus trigeminal nerve stimulatin, and remte eletrial stimulatin applied t the upper arm abrt migraine with r withut aura. Transranial magneti stimulatin is ntraindiated in patients with epilepsy.CMDT22_Ch24_p0978-p1053.indd  979 29/06/21 8:50 PMChapTER 24980 CMDT 2022T able 24–1. Pharmacologic prophylaxis of migraine (listed in alphabetical order within classes).Mediction Usul adult Orl Dily Dose Selected Side Effects nd Comments antieiletic1T opiramate 100 mg (divided twice daily) Somnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glaucoma, renal calculi, weight loss, hypohidrosis, hyperthermia. Valproic acid2,3500–1000 mg (divided twice daily)Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxic- ity, thrombocytopenia, tremor, pancreatitis. Crdiovsculr Candesartan38–32 mg once daily Dizziness, cough, diarrhea, fatigue. Guanfacine 1 mg once daily Dry mouth, somnolence, dizziness, constipation, erectile dysfunction. Propranolol480–240 mg (divided twice to four times daily)Fatigue, dizziness, hypotension, bradycardia, depression, insomnia, nausea, vomiting, constipation. Verapamil5120–240 mg (divided three times daily)Headache, hypotension, flushing, edema, constipation. May aggravate atrioventricular nodal heart block and heart failure. antideressnt6Amitriptyline 710–150 mg at bedtime Sedation, dry mouth, constipation, weight gain, blurred vision, edema, hypotension, urinary retention. Venlafaxine 37.5–150 mg extended release once dailyNausea, somnolence, dry mouth, dizziness, diaphoresis, sexual dysfunction, anxiety, weight loss. Monoclonl ntibodies ginst clcitonin gene–relted etide Eptinezumab 100 mg intravenously every 3 monthsHypersensitivity reaction during infusion, nasopharyngitis. Erenumab 70–140 mg subcutaneously once monthlyInjection site reactions, constipation, muscle cramps, antibody development. Fremanezumab 225 mg subcutaneously once monthlyInjection site reactions, antibody development. Galcanezumab 120 mg subcutaneously daily × 2 doses, followed by 120 mg monthlyInjection site reactions, antibody development. Oter Acupuncture  More rapid pain relief and fewer side effects than pharmacologic treatment. Botulinum toxin A Intramuscular injection Injection site reaction, hypersensitivity, muscle weakness. Riboflavin 400 mg once daily Yellow-orange discoloration of urine. Transcutaneous supraor- bital neurostimulation20 minutes daily Transient paresthesia at site of stimulation.1 Gabapentin and possibly other antiepileptics have also been used successfully.2 Avoid during pregnancy.3 Not FDA-approved for this indication.4 Other beta-adrenergic antagonists such as atenolol, metoprolol, nadolol, and timolol are similarly effective.5 Other calcium channel antagonists (eg, nimodipine, nicardipine, and diltiazem) may also help.6 Depression is commonly comorbid with migraine disorder and may warrant separate treatment.7 Other tricyclic antidepressants (eg, nortriptyline and imipramine) may help similarly.B. Preventive TherapyPreven tive treatment may be neessary if migraine head- ahes ur more frequently than two or three times a month r signifiant disability is assiated with attaks. Avid- ane f triggers and maintenane f hmestasis with reg- ular sleep, meals, and hydratin shuld nt be negleted; a headahe diary may be useful t identify triggers. Sme mre mmn agents used fr prphylaxis are listed in Table 24–1. The mediatin hsen first will vary with theindividual patient, depending n fatrs suh as mrbid besity, depressin, anxiety, hypertensin, and patient preferene. Several mediatins may have t be tried in turn befre headahes are brught under ntrl. One a mediatin has been fund t help, it shuld be ntinued fr several mnths. If the patient remains headahe-free, the dse may be tapered and the mediatin eventually withdrawn. Transutaneus suprarbital neurstimulatin redued the number f migraine days per mnth in aCMDT22_Ch24_p0978-p1053.indd  980 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS981 CMDT 2022sham- ntrlled randmized trial and is apprved in the United States. In chronic migraine (at least 15 days per mnth with headahes lasting 4 hurs per day r lnger), aupunture is as effetive as prphylati pharmalgi treatment, and btulinum txin type A redues headahe frequeny. Certain neurstimulatin tehniques lk prmising as preventive treatment as well as having a rle in treatment f aute attaks. These inlude single-pulse transranial magneti stimulatin, vagus nerve stimula- trs, and implantable ipital nerve stimulatin, but riti- al appraisal is neessary.2.  Tension-Tye hedceThis is the mst mm n type f primary headahe disr- der. Patients frequently mplain f periranial tenderness, pr nentratin, and ther nnspeifi symptms, in additin t headahes that are ften vise-like r tight in quality but nt pulsatile. Headahes may be exaerbated by emtinal stress, fatigue, nise, r glare. The headahes are usually generalized, may be mst intense abut the nek r bak f the head, and are nt assiated with fal neur- lgi symptms. There is diagnsti verlap with migraine. The therapeuti apprah is similar t that in migraine, exept that triptans and ergtamines are notindiated. Triyli antidepressants, suh as amitriptyline, are sup- prted fr headahe prphylaxis by randmized trial evi- dene and ften are tried first. Treatment f mrbid anxiety r depressin is imprtant. Behaviral therapies that may be effetive inlude bifeedbak and relaxatin training.3.  Cluster hedceClus ter headahe affets predminantly middle-aged men. The pathphysilgy is unlear but may relate t ativatin f ells in the ipsilateral hypthalamus, triggering the tri- geminal autnmi vasular system. There is ften n fam- ily histry f headahe r migraine. Episdes f severe unilateral perirbital pain ur daily fr several weeks and are ften ampanied by ne r mre f the fllwing: ipsilateral nasal ngestin, rhinrrhea, larimatin, red- ness f the eye, and Hrner syndrme (ptsis, pupillary meisis, and faial anhidrsis r hyphidrsis). During attaks, patients are ften restless and agitated. Episdes typially ur at night, awaken the patient, and last between 15 minutes and 3 hurs. Spntaneus remissin then urs, and the patient remains well fr weeks r mnths befre anther but f lsely spaed attaks. Buts may last fr 4 t 8 weeks and may ur up t several times per year. During a but, many patients reprt alhl trig- gers an attak; thers reprt that stress, glare, r ingestin f speifi fds asinally preipitates attaks. In a- sinal patients, remissin des nt ur. This variant has been referred t as chronic cluster headache . In lngstand- ing ases, Hrner syndrme may persist between attaks. Cluster headahe is ne f the trigeminal autonomic cephalgias, whih inlude hemirania ntinua, parx- ysmal hemirania, and shrt-lasting neuralgifrm head- ahe attaks with njuntival injetin and tearing. Similar t luster headahe, the ther trigeminalautnmi ephalgias nsist f unilateral perirbital pain assiated with ipsilateral autnmi symptms; they are distinguished frm luster headahe by different attak duratin and frequeny and their exquisite respnsiveness t indmethain. Treatment f an individual attak with ral mediatins is generally unsatisfatry, but subutaneus (6 mg) r intranasal (20 mg/spray) sumatriptan r inhalatin f 100% xygen (12–15 L/min fr 15 minutes via a nn-rebreather mask) may be effetive. Zlmitriptan (5- and 10-mg nasal spray) is als effetive. Dihydrergtamine (0.5–1 mg intra- musularly r intravenusly) r visus lidaine (1 mg f 4–6% slutin intranasally) is smetimes effetive. Varius prphylati agents inlude ral mediatins suh as lithium arbnate (start at 300 mg daily, titrating arding t serum levels and treatment respnse up t a typial ttal daily dse f 900–1200 mg, divided three r fur times), verapamil (start at 240 mg daily, inrease by 80 mg every 2 weeks t 960 mg daily, with rutine ECG t mnitr the PR interval), tpiramate (100–400 mg daily), and ivamide (nt available in the United States). As there is ften a delay befre these mediatins are effetive, tran- sitinal therapy is ften used. Prednisne (60 mg daily fr 5 days fllwed by gradual withdrawal ver 7–10 days) is effetive in 70–80% f patients, and subipital rtiste- rid injetin abut the greater ipital nerve is effetive in 75%. Ergtamine tartrate an be given as retal suppsit- ries (0.5–1 mg at night r twie daily), by muth (2 mg daily), r by subutaneus injetin (0.25 mg three times daily fr 5 days per week). Eletrial stimulatin f the vagus nerve at headahe nset suessfully abrts pain in 30–50% f attaks, and twie daily prphylati stimulatin redues attak number in hrni luster headahe; this treatment is apprved in the United States. In Eurpe, sphe- npalatine ganglin stimulatin is apprved fr treatment f luster headahe based n effiay in ne randmized sham-ntrlled study. Limited evidene suggests that eletrial stimulatin f the ipital nerve by an implant- able devie may be helpful, espeially in hrni luster headahe.4.  posttrumtic hedceA variety  f nnspeifi symptms may fllw lsed head injury, regardless f whether nsiusness is lst (see Head Injury). Headahe is ften a nspiuus feature. It usually appears within a day r s fllwing injury, may wrsen ver the ensuing weeks, and then gradually sub- sides. It is usually a nstant dull ahe, with superimpsed thrbbing that may be lalized, lateralized, r generalized. Headahes are smetimes ampanied by nausea, vmit- ing, r sintillating stmas and ften respnd t simple analgesis; severe headahes may neessitate preventive treatment as utlined fr migraine.5.  primry Coug hedceSevere  head pain may be prdued by ughing (and by straining, sneezing, and laughing) but, frtunately, usually lasts fr nly a few minutes r less. Intraranial lesins, usually in the psterir fssa (eg, Arnld-ChiariCMDT22_Ch24_p0978-p1053.indd  981 29/06/21 8:50 PMChapTER 24982 CMDT 2022malfrma tin), are present in abut 10% f ases, and brain tumrs r ther spae-upying lesins may present in this way. Ardingly, CT scanning or MRI should be undertaken in all patients. The disrder is usually self-limited, althugh it may persist fr several years. Fr unknwn reasns, symptms smetimes lear mpletely after lumbar punture. Ind- methain (75–150 mg daily rally) may prvide relief. Similar ativity-triggered headahe syndrmes inlude primary exertinal headahe and primary headahe ass- iated with sexual ativity.6.  hedce Due to Gint Cell (Temorl or Crnil) arteritisThis tp i is disussed in Chapter 20.7.  hedce Due to Intrcrnil Mss LesionIn traranial mass lesins f all types may ause headahe wing t displaement f vasular strutures and ther pain-sensitive tissues. While pain and latin are nnspe- ifi, headahe may be wrse upn lying dwn, awaken the patient at night, r peak in the mrning after vernight reumbeny. The key feature prompting brain imaging is a new or worsening headache in middle or later life . Other features suggesting an intraranial lesin inlude signs r symptms f infetin r malignany suh as fever, night sweats, and weight lss; immunmprmise; r histry f malignany. Signs f fal r diffuse erebral dysfuntin r f inreased intraranial pressure (eg, papilledema) als neessitate investigatin.8.  Mediction Overuse (anlgesic Rebound) hedceIn  many patients with chronic daily headaches, media- tin veruse is respnsible. Patients have hrni pain r severe headahe unrespnsive t mediatin (typially defined as n effet after having been used regularly fr mre than 3 mnths). Ergtamines, triptans, mediatins ntaining butalbital, and piids ause mediatin ver- use headahe when taken n mre than 10 days per mnth; aetaminphen, aetylsaliyli aid, and nnsteridal anti- inflammatry drugs may als be ffenders if taken n mre than 15 days per mnth. Early initiatin f a migraine preventive therapy permits withdrawal f analgesis and eventual relief f headahe.9.  hedce Due to Oter Neurologic CusesCerebr vasular disease may be assiated with headahe, but the mehanism is unlear. Headahe may ur with internal artid artery lusin r artid dissetin and after artid endarteretmy. Aute severe headahe (“thunderclap” ) ampanies subarahnid hemrrhage, artid r vertebral artery dissetin, erebral venus thrmbsis, ishemi r hemrrhagi strke, reversible erebral vasnstritin syndrme, hypertensive risis, psterir reversible leukenephalpathy syndrme, pitu- itary applexy, spntaneus intraranial hyptensin, vas- ulitis, and meningeal infetins; ampanying falneurlgi signs, impairment f nsiusness, and signs f meningeal irritatin indiate the need fr further inves- tigatins. Headahes are als a feature f idipathi intra- ranial hypertensin (pseudtumr erebri). Dull r thrbbing headahe is a frequent sequela f lumbar punture and may last fr several days. It is aggra- vated by the eret psture and alleviated by reumbeny. The mehanism is unlear, but the headahe is mmnly attributed t leakage f erebrspinal fluid thrugh the dural punture site. Its inidene may be redued if an atraumati needle (instead f a beveled, utting needle) is used fr the lumbar punture. »When to Refer• Thunderlap nset. •Inreasing headahe unrespnsive t simple measures. •Histry f trauma, hypertensin, fever, visual hanges. •Presene f neurlgi signs r f salp tenderness. »When to AdmitSuspeted  subarahnid hemrrhage r ther strutural intraranial lesin.Ceriani  CEJ et al. Nvel mediatins fr the treatment f migraine. Headahe. 2019;59:1597. [PMID: 31559638] Vukvi-Cvetkvi V et al. Neurstimulatin fr the treatment f hrni migraine and luster headahe. Ata Neurl Sand. 2019;139:4. [PMID: 30291633]F ACIAL PAIN 1. Trigeminl NeurlgiE S S E N T I A L S  O F  D I A G N O S I S »Brief episodes of stabbing facial pain. »Pain is in the territory of the second and third divi- sion of the trigeminal nerve. »Pain exacerbated by touch. »General ConsiderationsT rigeminal neuralgia (“ti dulureux”) is mst mmn in middle and later life. It affets wmen mre frequently than men. Pain may be due t an anmalus artery r vein impinging n the trigeminal nerve. »Clinical FindingsM mentary episdes f sudden laninating faial pain mmnly arise near ne side f the muth and sht tward the ipsilateral ear, eye, r nstril. The pain may be triggered by suh fatrs as tuh, mvement, drafts, and eating. In rder t lessen the likelihd f triggering fur- ther attaks, many patients try t hld the fae still while talking. Spntaneus remissins fr several mnths rCMDT22_Ch24_p0978-p1053.indd  982 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS983 CMDT 2022lnger  may ur. As the disrder prgresses, hwever, the episdes f pain beme mre frequent, remissins beme shrter and less mmn, and a dull ahe may persist between the episdes f stabbing pain. Symptms remain nfined t the distributin f the trigeminal nerve (usu- ally the send r third divisin) n ne side nly. »Differential DiagnosisThe  harateristi features f the pain in trigeminal neural- gia usually distinguish it frm ther auses f faial pain. Neurlgi examinatin shws n abnrmality exept in a few patients in whm trigeminal neuralgia is symptmati f sme underlying lesin, suh as multiple slersis r a brainstem neplasm, in whih ase the finding will depend n the nature and site f the lesin. Multiple slersis mustbe suspeted in a patient yunger than 40 years in whm trigeminal neuralgia is the presenting symptm, even if there are n ther neurlgi signs. Bilateral symptms shuld als prmpt further investigatin. Brain MRI need nly be btained when a sendary ause is suspeted; it is usually nrmal in lassi trigeminal neuralgia. »TreatmentThe m ediatins mst helpful fr treatment are xarbaze- pine (althugh nt apprved by the FDA fr this india- tin) r arbamazepine, with mnitring by serial bld unts and liver bihemial tests. If these mediatins are ineffetive r annt be tlerated, phenytin shuld be tried. (Dses and side effets f these mediatins are shwn in Table 24–2.) Balfen (10–20 mg rally three r Table 24–2. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Generlized or Focl Seizures Brivaracetam2,350–100 mg 2 1–2 days CBC, liver biochemi- cal testsSomnolence, fatigue, ataxia, vertigo, psycho- sis, leukopenia, hypersensitivity (broncho- spasm and angioedema). Cannabidiol45–20 mg/kg 2 11–13 days Liver biochemical tests at baseline, 1, 3, and 6 monthsSomnolence, fatigue, anorexia, weight loss, anemia, diarrhea, rash, sleep disorder, infections. Elevation in liver enzymes may occur; reduce dose in hepatic impairment. Carbamazepine2400–1600 mg (immediate or extended release)2 3–4 days 4–8 mcg/mL CBC, liver biochemi- cal tests, BUN/CrNystagmus, dysarthria, diplopia, ataxia, drowsiness, nausea, blood dyscrasias, hepatotoxicity, hyponatremia, Stevens-Johnson syndrome.5My  excerbte myoclonic seizures. Cenobamate2,3200–400 mg 1 14 days Liver biochemical tests, potassiumMultiorgan hypersensitivity, QT shortening, somnolence, dizziness, cognitive dysfunc- tion, blurred vision. Clobazam610–40 mg 2 7–10 days  Lethargy and somnolence, ataxia, insomnia, dysarthria, aggression, constipation, fever, Stevens-Johnson syndrome. Clorazepate322.5–90 mg 2 10 days  Sedation, dizziness, confusion, ataxia, depres- sion, dependency/abuse. Eslicarbazepine2,3400–1200 mg 1 4 days Serum sodium and chloride; liver bio- chemical testsAs for carbamazepine. Ezogabine3300–1200 mg 3 2–3 days ECG to assess QT intervalDizziness, somnolence, confusion, vertigo, nausea, ataxia, psychiatric disturbances, prolonged QT interval, retinal abnormalities.7F elbamate2,3,6,81200–3600 mg 3 4–5 days CBC and reticulo- cytes, liver bio- chemical testsAnorexia, nausea, vomiting, headache, insom- nia, weight loss, dizziness, hepatotoxicity, fatal aplastic anemia. Reserved for refractory epilepsy. (continued )CMDT22_Ch24_p0978-p1053.indd  983 29/06/21 8:50 PMChapTER 24984 CMDT 2022T able 24–2. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Gabapentin3900–3600 mg 3 1 day  Sedation, fatigue, ataxia, nystagmus, weight loss. Lacosamide2,3100–400 mg 2 3 days ECG if known cardiac conduction problems or severe cardiac diseaseVertigo, diplopia, nausea, headache, fatigue, ataxia, tremor, anaphylactoid reactions, PR prolongation, cardiac dysrhythmia, suicidality. Lamotrigine3,6,9,10100–500 mg 2 4–5 days  Sedation, skin rash, visual disturbances, dyspepsia, ataxia. Levetiracetam3,9,111000–3000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Oxcarbazepine2,3900–1800 mg 2 2–3 days Serum sodium As for carbamazepine. Perampanel2,3,94–12 mg 1 3 weeks  Dizziness, somnolence, irritability, weight gain, falls, ataxia, dysarthria, blurred vision. Phenobarbital2,12100–200 mg 1 14–21 days 10–40 mcg/mL CBC, liver biochemi- cal tests, BUN/CrDrowsiness, nystagmus, ataxia, skin rashes, learning difficulties, hyperactivity. Phenytoin2,12200–400 mg 1 5–10 days 10–20 mcg/mL CBC, liver biochemi- cal tests, folateNystagmus, ataxia, dysarthria, sedation, con- fusion, gingival hyperplasia, hirsutism, megaloblastic anemia, blood dyscrasias, skin rashes, fever, systemic lupus erythema- tosus, lymphadenopathy, peripheral neu- ropathy, dyskinesias. My excerbte myoclonic seizures. Pregabalin3150–300 mg 2 2–4 days  Somnolence, dizziness, poor concentration, weight gain, thrombocytopenia, skin rashes, anaphylactoid reactions. Primidone2,12750–1500 mg 3 4–7 days 5–12 mcg/mL CBCSedation, nystagmus, ataxia, vertigo, nausea, skin rashes, megaloblastic anemia, irritability. Rufinamide6800–3200 mg 2 2 days  Somnolence, headache, dizziness, suicidality, Stevens-Johnson syndrome, leukopenia, shortened QT interval, nausea, vomiting. Tiagabine332–56 mg 2 2 days  Somnolence, anxiety, dizziness, poor concen- tration, tremor, diarrhea. Topiramate2,3,6,9,12200–400 mg 2 4 days Serum bicarbonate, BUN/Cr in elderly patientsSomnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glau- coma, renal calculi, weight loss, hypohidro- sis, hyperthermia. Valproic acid2,3,13,141500–2000 mg 2–3 2–4 days 50–100 mcg/mL CBC, liver biochemi- cal testsNausea, vomiting, diarrhea, drowsiness, alope- cia, weight gain, hepatotoxicity, thrombo- cytopenia, tremor, pancreatitis. Tertogenic; void in women of cildber- ing ge. Vigabatrin3,153000 mg 2 2 days  Somnolence, anorexia, nausea, vomiting, agi- tation, hostility, confusion, suicidality, neu- tropenia, Stevens-Johnson syndrome, permanent visual field loss.7Zoni samide3200–600 mg 1 14 days BUN/Cr, serum bicarbonateSomnolence, ataxia, anorexia, nausea, vomiting, rash, confusion, renal calculi. Do not use in patients with sulfonamide allergy. (continued )(continued )CMDT22_Ch24_p0978-p1053.indd  984 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS985 CMDT 2022T able 24–2. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections absence Seizures Clonaze- pam6,11,13,16,170.04–0.2 mg/kg 2 7–10 days 20–80 ng/mL CBC, liver biochemical testsDrowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Ethosuximide13500–1500 mg 2 5–10 days 40–100 mcg/mL CBC, liver biochemi- cal tests, urinalysisNausea, vomiting, anorexia, headache, lethargy, unsteadiness, blood dyscrasias, systemic lupus erythematosus, urticaria, pruritus. Valproic acid2,3,13,141500–2000 mg 2–3 2–4 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. Myoclonic Seizures Clonaze- pam6,11,13,16,170.04–0.2 mg/kg 2 7–10 days See above Drowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Levetiracetam3,9,111000–3000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Valproic acid2,3,13,141500–2000 mg 2–3 2–4 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. BUN, blood urea nitrogen; CBC, complete blood count; Cr, creatinine; ECG, electrocardiogram. Note that many factors influence o ptimal dose of these drugs including age, tolerance, and concomitant medication.1 Patients starting treatment with any antiepileptic drug should be monitored for new or worsening depression or suicidal thought s, especially during the first weeks of therapy. Baseline measurement of creatinine clearance is advisable in renally metabolized drugs.2 Approved as monotherapy for focal-onset seizures.3 Approved as adjunctive therapy for focal-onset seizures.4 Approved for treatment of seizures in Lennox-Gastaut and Dravet syndrome in patients 2 years and older.5 Carriers of the HLA-B*1502 allele are at higher risk for Stevens-Johnson syndrome. Patients of Asian ancestry should be tested for this allele prior to initiation of therapy.6 Approved as adjunctive therapy for Lennox-Gastaut syndrome.7 Regular ophthalmologic examination is recommended.8 Not to be used as a first-line drug; when used, blood counts should be performed regularly (every 2–4 weeks). Should be used on ly in selected patients because of risk of aplastic anemia and hepatic failure. It is advisable to obtain written informed consent be fore use.9 Approved as adjunctive therapy for primary generalized tonic-clonic seizures.10 Approved as monotherapy (after conversion from another drug) in focal-onset seizures.11 Approved as adjunctive therapy for myoclonic seizures.12 Approved as initial monotherapy for primary generalized tonic-clonic seizures.13 Approved as monotherapy and adjunctive therapy for absence seizures.14 Approved as adjunctive therapy for patients with multiple seizure types including absence seizures.15 Approved as monotherapy for infantile spasms.16 Approved as monotherapy for Lennox-Gastaut syndrome.17 Approved as monotherapy for myoclonic seizures.f ur times daily), tpiramate (50 mg rally twie daily), r lamtrigine (400 mg rally daily) may als be helpful, either alne r in mbinatin with ne f these ther agents. Gabapentin may als relieve pain, espeially in patients wh d nt respnd t nventinal medial therapy and thse with multiple slersis. Depending n respnse and tler- ane, up t 3600 mg daily rally is given in divided dses. Fr neuralgia refratry t medial treatment, several surgial treatment ptins are available that prvide initial pain relief in at least 80% f patients. Mirvasularsurgial dempressin with separatin f the anmalus vessel (usually nt visible n CT sans, MRI, r arteri- grams) frm the nerve rt prdues lng-term relief f symptms in rughly 75% f patients. Three less invasive tehniques are based n destrutin f nieptive tri- geminal nerve fibers, whih auses sensry lss in additin t symptm relief in half f patients: (1) radifrequeny rhiztmy prdues lng-term pain relief in 60% f patients, (2) perutaneus balln mpressin f the tri- geminal ganglin in 67%, and (3) steretati radisurgery(continued )CMDT22_Ch24_p0978-p1053.indd  985 29/06/21 8:50 PMChapTER 24986 CMDT 2022t  the trigeminal nerve rt in 45%. In elderly patients with a limited life expetany, radifrequeny rhiztmy and steretati radisurgery are smetimes preferred beause bth an be perfrmed withut general anesthesia and have few mpliatins. Surgial explratin is inapprpri- ate in patients with trigeminal neuralgia due t multiple slersis, but the less invasive tehniques are smetimes helpful.2.  atyicl Fcil pinFaial  pain withut the typial features f trigeminal neu- ralgia is generally a nstant, ften burning pain that may have a restrited distributin at its nset but sn spreads t the rest f the fae n the affeted side and smetimes invlves the ther side, the nek, r the bak f the head as well. The disrder is espeially mmn in middle-aged wmen, many f them depressed, but it is nt lear whether depressin is the ause f r a reatin t the pain. Simple analgesis shuld be given a trial, as shuld triyli antidepressants, arbamazepine, xarbazepine, and phenytin; the respnse is ften disappinting. Opiid analgesis pse a danger f additin. Attempts at surgial treatment are nt indiated.3.  Glossoryngel NeurlgiGlsspharyngeal  neuralgia is an unmmn disrder in whih pain similar in quality t that in trigeminal neural- gia urs in the thrat, abut the tnsillar fssa, and smetimes deep in the ear and at the bak f the tngue. The pain may be preipitated by swallwing, hewing, talk- ing, r yawning and is smetimes ampanied by syn- pe. In mst instanes, n underlying strutural abnrmality is present; multiple slersis is smetimes respnsible. Oxarbazepine and arbamazepine are the treatments f hie and shuld be tried befre any surgi- al predures are nsidered. Mirvasular dempres- sin is ften effetive and is generally preferred ver destrutive surgial predures suh as partial rhiztmy in medially refratry ases.4.  posteretic NeurlgiP stherpeti neuralgia develps in abut 15% f patients wh have herpes zster (shingles). This mpliatin seems espeially likely t ur in elderly r immunm- prmised persns, when the rash is severe, and when the first divisin f the trigeminal nerve is affeted. It als relates t the duratin f the rash befre treatment is insti- tuted. A histry f shingles and the presene f utaneus sarring resulting frm shingles aid in the diagnsis. Severe pain with shingles rrelates with the intensity f psther- peti symptms. Aylvir (800 mg five times daily) r valaylvir (1000 mg three times daily), when given within 72 hurs f rash nset, redues the inidene f pstherpeti neuralgia by almst half; systemi rtisterids d nothelp prevent pstherpeti neuralgia (see Chapter 6). Management f the established mpliatin is with simple analgesis. If they fail t help, a trial f a triyli antidepressant (eg, amitrip- tyline r nrtriptyline, up t 100–150 mg daily rally) isften effetive. Other patients respnd t gabapentin (up t 3600 mg daily rally) r pregabalin (up t 600 mg/daily rally). Subutaneus injetin f btulinum txin A int the affeted regin prdued sustained pain relief in 87% f patients in a small plaeb-ntrlled trial. Tpial applia- tin f apsaiin ream may be helpful, as may tpial lidaine (5%). The administratin f recombinant zoster vaccine t patients ver the age f 50 years is imprtant in reduing the likelihd f herpes zster r reduing the severity f pstherpeti neuralgia shuld a reativatin ur.5.  Fcil pin Due to Oter CusesFa ial pain may be aused by temprmandibular jint dysfuntin in patients with mallusin, abnrmal bite, r faulty dentures. There may be tenderness f the mastia- try musles, and smetimes pain begins at the nset f hewing. This pattern differs frm that f jaw (mastiatry) laudiatin, a symptm f giant ell arteritis, in whih pain develps prgressively with mastiatin. Treatment f the underlying jint dysfuntin relieves symptms. A relatinship f faial pain t hewing r temperature hanges may suggest a dental disturbane. The ause is smetimes nt bvius, and diagnsis requires areful dental examinatin and radigraphs. Sinusitis and ear infetins ausing faial pain are usually regnized by a histry f respiratry trat infetin, fever, and, in sme instanes, nasal r aural disharge. There may be lalized tenderness. Radilgi evidene f sinus infetin r mas- tiditis is nfirmatry. Glauma is an imprtant ular ause f faial pain, usually lalized t the perirbital regin. On asin, pain in the jaw may be the prinipal mani- festatin f angina petris. Preipitatin by exertin and radiatin t mre typial areas suggests a ardia rigin. »When to Refer• Wrsening pain unrespnsive t simple measures. •Cntinuing pain f unertain ause. •Fr nsideratin f surgial treatment (trigeminal r glsspharyngeal neuralgia).Bendtsen  L et al. Advanes in diagnsis, lassifiatin, path- physilgy, and management f trigeminal neuralgia. Lanet Neurl. 2020;19:784. [PMID: 32822636]EP ILEPSYE S S E N T I A L S  O F  D I A G N O S I S »Recurrent unprovoked seizures. »Characteristic electroencephalographic changes accompany seizures. »Mental status abnormalities or focal neurologic symptoms may persist for hours postictally.CMDT22_Ch24_p0978-p1053.indd  986 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS987 CMDT 2022 »General ConsiderationsThe term “ epilepsy” dentes any disrder haraterized by recurrent unprovoked seizures. A seizure is a transient dis- turbane f erebral funtin due t an abnrmal parxys- mal neurnal disharge in the brain. Epilepsy is relatively mmn, affeting apprximately 0.5% f the ppulatin in the United States. Patients with reurrent seizures prvked by a readily reversible ause, suh as withdrawal frm alhl r drugs, hypglyemia, hyperglyemia, r uremia, are nt nsid- ered t have epilepsy. »Classification of EpilepsyA rding t the Internatinal League Against Epilepsy lassifiatin system, reurrent seizures shuld be lassi- fied first by seizure type, send by epilepsy type, and third, if pssible, by epilepsy syndrme. The etilgy f reurrent seizures shuld be sught at eah stage f lassi- fiatin (see Etilgy f Epilepsy).A.  Seizure TypesThe  Internatinal League Against Epilepsy distinguishes seizures affeting nly part f the brain (fal seizures) frm thse that are generalized. 1. Focal onset seizures— The initial linial and eletren- ephalgraphi manifestatins f fal (partial) seizures indiate that nly a restrited part f ne erebral hemi- sphere has been ativated. The ital manifestatins depend n the area f the brain invlved. Fal seizures are lassi- fied by mtr r nnmtr nset as well as by whether awareness is impaired. a. Motor versus nonmotor onset— Seizures with mtr nset may be clonic, tonic, atonic, myoclonic, r hyperkinetic, r may manifest as automatisms repilep- tic spasms . The mst mmnly bserved fal mtr seizures nsist f lni jerking r autmatisms. Nnm- tr seizures may be manifested by sensry symptms (eg, paresthesias r tingling, gustatry, lfatry, visual r audi- try sensatins), behavir arrest, gnitive symptms (eg, speeh arrest, déjà vu, jamais vu), emtinal symptms (eg, fear), r autnmi symptms r signs (eg, abnrmal epi- gastri sensatins, sweating, flushing, pupillary dilatin). Fal sensry and mtr seizures may spread (r “marh”) t different parts f the limb r bdy depending n their rtial representatin and were previusly alled “simple partial” seizures. b. Aware versus impaired awareness— Awareness is defined as knwledge f self and envirnment and f events urring during a seizure. Impaired awareness may be preeded, ampanied, r fllwed by the varius mtr and nnmtr symptms mentined abve. Suh seizures were previusly alled “mplex partial” seizures. c. Focal to bilateral tonic-clonic— Fal seizures smetimes invlve lss f awareness and evlve t bilateral tni-lni seizures, in a press previusly alled “se- ndary generalizatin. ”2. Generalized onset seizures— Generalized seizures are thught t riginate in r rapidly spread t invlve bilateral rtial netwrks. In sme ases, the distintin between fal and generalized nset an nly be made by eletren- ephalgram (EEG). Generalized seizures are lassified int thse with mtr r nnmtr features. Awareness is typially lst with generalized seizures but may be retained partially in the briefest absene attaks and sme my- lni seizures. a. Nonmotor (absence) seizures— These are harater- ized by impairment f nsiusness, smetimes with mild lni, tni, mylni, r atni mpnents (ie, redu- tin r lss f pstural tne), autnmi mpnents (eg, enuresis), r ampanying autmatisms. Onset and termi- natin f attaks are abrupt. If attaks ur during nver- satin, the patient may miss a few wrds r may break ff in midsentene fr a few sends. The impairment f external awareness is s brief that the patient is unaware f it. Absence (“petit mal”) seizures almst always begin in hildhd and frequently ease by the age f 20 years r are then replaed by ther frms f generalized seizure. Ele- trenephalgraphially, suh attaks are assiated with bursts f bilaterally synhrnus and symmetri 3-Hz spike-wave ativity. A nrmal bakgrund in the eletren- ephalgram and nrmal r abve-nrmal intelligene imply a gd prgnsis fr the ultimate essatin f these seizures. Atypical absence seizures may demnstrate mre marked hanges in tne, r attaks may have a mre gradual nset and terminatin than in typial absene seizures. They mmnly ur in patients with multiple seizure types, may be ampanied by develpmental delay r mental retardatin, and are assiated with slwer spike- wave disharges than thse in typial absene attaks. b. Motor seizures— Types f generalized mtr seizures inlude tonic-clonic, clonic, tonic, myoclonic, myoclonic- tonic-clonic, myoclonic-atonic, atonic, and epileptic spasms. During tni-lni seizures there is sudden lss f nsiusness, the patient bemes rigid and falls t the grund, and respiratin is arrested. This tni phase, whih usually lasts fr under 1 minute, is fllwed by a lni phase in whih there is jerking f the bdy musulature that may last fr 2 r 3 minutes and is then fllwed by a stage f flaid ma. During the seizure, the tngue r lips may be bitten, urinary r feal inntinene may ur, and the patient may be injured. Immediately after the sei- zure, the patient may rever nsiusness, drift int sleep, have a further nvulsin withut revery f n- siusness between the attaks (status epilepticus), r after revering nsiusness have a further nvulsin (serial seizures). In ther ases, patients may behave in an abnrmal fashin in the immediate pstital perid, with- ut subsequent awareness r memry f events (postepi- leptic automatism) . Headahe, disrientatin, nfusin, drwsiness, nausea, sreness f the musles, r sme m- binatin f these symptms mmnly urs pstitally. Mylni seizures nsist f single r multiple mylni jerks. Atni seizures nsist f very brief (less than 2 sends) lss f musle tne and ften result in falls (epileptic drop attacks) .Epileptic spasms are sudden flexin rCMDT22_Ch24_p0978-p1053.indd  987 29/06/21 8:50 PMChapTER 24988 CMDT 2022extensin  f trunal musles; these seizures usually mani- fest during infany. 3. Unknown onset seizures— In sme irumstanes, sei- zures annt be lassified beause f inmplete infrmatin r beause they d nt fit int any ategry. Generally, with additinal infrmatin frm the histry r frm vide-EEG telemetry, the seizure nset an be rretly lassified.B.  Epilepsy TypesThe  Internatinal League Against Epilepsy lassifies epi- lepsy by the seizure type. Thus, epilepsy may be focal , generalized, rcombined generalized and focal. The EEG may be helpful in failitating lassifiatin.C.  Epilepsy SyndromesEp ilepsy syndrmes are defined by nstellatins f seizure types, EEG findings, and imaging features, and ften als depend n age at nset and mrbidities. Nt every patient with epilepsy an be given a syndrmi diagnsis. Several well-knwn epilepsy syndrmes exist but are beynd the spe f this hapter. »Etiology of EpilepsyIn  parallel t lassifying the seizure type, epilepsy type, and epilepsy syndrme (if appliable), the ause f the patient’s seizures shuld be sught. The Internatinal League Against Epilepsy lists six brad etilgi ategries; sme- times a patient’s seizures have mre than ne etilgy.A.  Structural Etiology1.  Pediatric age groups— Cngenital abnrmalities and perinatal injuries may result in seizures presenting in infany r hildhd. 2. Mesial temporal sclerosis— Hippampal slersis is a regnized ause f fal and sendarily generalized sei- zures f unertain etilgy. 3. Trauma— Trauma is an imprtant ause f seizures at any age, but espeially in yung adults. Psttraumati epi- lepsy is mre likely t develp if the dura mater was pene- trated and generally bemes manifest within 2 years fllwing the injury. Seizures develping in the first week after head injury d nt neessarily imply that future attaks will ur. There is noevidene that prphylati antinvulsant mediatin treatment redues the inidene f psttraumati epilepsy. 4. Tumors and other spaceoccupying lesions— Ne- plasms may lead t seizures at any age, but they are an espeially imprtant ause f seizures in middle and later life, when the inidene f neplasti disease inreases. Seizures are mmnly the initial symptms f the tumr and ften are fal in harater. They are mst likely t ur with strutural lesins invlving the frntal, parietal, r tempral regins. Tumors must be excluded by imaging studies (MRI preferred over CT) in all patients with onset of seizures after 20 years of age, focal seizures or signs, or a progressive seizure disorder.5. Vascular diseases— Strke and ther vasular diseases beme inreasingly frequent auses f seizures with advaning age and are the mst mmn ause f seizures with nset at age 60 years r lder. 6. Degenerative disorders— Alzheimer disease and ther degenerative disrders are a ause f seizures in later life.B.  Genetic EtiologyThis ategry enmpasses a  brad range f disrders, fr whih the age at nset ranges frm the nenatal perid t adlesene r even later in life. Mngeni disrders tend t exhibit an autsmal dminant pattern f inheritane, and where the mutatin is knwn, the respnsible gene ften endes a neurnal in hannel. A geneti etilgy may als underpin ertain epilepsies with a metabli r strutural basis.C.  Infectious EtiologyInfetius diseases must be nsider ed in all age grups as ptentially reversible auses f seizures. Seizures may ur with an aute infetive r inflammatry illness, suh as baterial meningitis r herpes enephalitis, r in patients with mre lngstanding r hrni disrders, suh as neu- rsyphilis r erebral ystiersis. In patients with AIDS, seizures may result frm entral nervus system txplas- msis, ryptal meningitis, sendary viral enephali- tis, r ther infetive mpliatins. Seizures are a mmn sequela f supratentrial brain absess, develping mst frequently in the first year after treatment.D . Metabolic EtiologyInbrn  errrs f metablism and ther inherited ndi- tins may ause epilepsy as ne f their manifestatins (eg, pyridxine defiieny, mithndrial disease); these disr- ders typially present during hildhd.E.  Immune EtiologyA utimmune diseases suh as systemi lupus erythemat- sus and autimmune limbi enephalitis may ause epi- lepsy; ften the epilepsy an be ured with immuntherapy and lifelng antiepilepti mediatin treatment is nt neessary.F . Unknown EtiologyIn  many ases, the ause f epilepsy annt be determined. »Clinical FindingsA.  Symptoms and SignsN nspeifi hanges suh as headahe, md alteratins, lethargy, and mylni jerking alert sme patients t an impending seizure hurs befre it urs. These prodro- mal symptoms are distint frm the aura; the aura that may preede a generalized seizure by a few sends r minutes is itself a part f the seizure indiating fal nset frm a restrited part f the brain.CMDT22_Ch24_p0978-p1053.indd  988 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS989 CMDT 2022In  mst patients, seizures ur unpreditably at any time and withut any relatinship t psture r nging ativities. Oasinally, hwever, they ur at a partiu- lar time (eg, during sleep) r in relatin t external pre- ipitants suh as lak f sleep, missed meals, emtinal stress, menstruatin, alhl ingestin (r alhl with- drawal), r use f ertain rereatinal drugs. Fever and nnspeifi infetins may als preipitate seizures in patients with epilepsy. In a few patients, seizures are pr- vked by speifi stimuli suh as flashing lights r a flik- ering televisin set (photosensitive epilepsy), musi, r reading. Clinial examinatin between seizures shws n abnr- mality in patients with idipathi epilepsy, but in the immediate pstital perid, extensr plantar respnses may be seen. The presene f lateralized r fal signs pstitally suggests that seizures may have a fal rigin. In patients with symptmati epilepsy, the findings n exami- natin will reflet the underlying ause.B.  ImagingMRI  is indiated fr patients with fal neurlgi symp- tms r signs, fal seizures, r eletrenephalgraphi findings f a fal disturbane. It shuld als be perfrmed in patients with linial evidene f a prgressive disrder and in thse with new nset f seizures after the age f 20 years beause f the pssibility f an underlying ne- plasm. CT is generally less sensitive than MRI in deteting small strutural brain abnrmalities but may be used when MRI is ntraindiated r unavailable.C.  Laboratory StudiesInit ial investigatins after a first seizure shuld inlude mplete bld unt, serum gluse, eletrlytes, re- atinine, alium, magnesium, and liver bihemial tests t exlude varius auses f prvked seizures and t prvide a baseline fr subsequent mnitring f lng-term effets f treatment. Rutine labratry investigatins are notusually neessary after reurrent seizures in patients with knwn epilepsy. A lumbar punture may be neessary when any sign f infetin is present r in the evaluatin f new-nset seizures in the aute setting.D . ElectroencephalographyEletrenephalgraph y may supprt the linial diagnsis f epilepsy (by demnstrating parxysmal abnrmalities ntaining spikes r sharp waves), prvide a guide t prg- nsis, and help lassify the seizure disrder. Classifiatin f the disrder is imprtant fr determining the mst apprpriate antinvulsant mediatin with whih t start treatment. Fr example, absene and fal seizures with impaired awareness may be diffiult t distinguish lini- ally, but the eletrenephalgraphi findings and treat- ment f hie differ in these tw nditins. Finally, by lalizing the epileptgeni sure, the eletrenephal- graphi findings are imprtant in evaluating andidates fr surgial treatment.»Differential DiagnosisThe  distintin between the varius disrders likely t be nfused with generalized seizures is usually made n the basis f the histry. The imprtane f btaining an eye- witness aunt f the attaks annt be veremphasized.A.  Differential Diagnosis of Focal Seizures1.  TIAs— These are distinguished frm seizures by their lnger duratin, lak f spread, and negative (eg, weakness r numbness) rather than psitive (eg, nvulsive jerking r paresthesias) symptms. Level f nsiusness, whih is unaltered, des nt distinguish them. 2. Migraine aura— Migraine aura may prdue psitive r negative symptms, tends t spread slwly frm ne part f the bdy t anther (ver minutes rather than sends), and is usually lnger in duratin (minutes t hurs). It is usually, but nt always, fllwed by a typial migraine headahe. 3. Panic attacks— These may be hard t distinguish frm fal seizures unless there is evidene f an anxiety disr- der between attaks and the attaks have a lear relatin- ship t external irumstanes. 4. Rage attacks— These are situatinal and lead t gal- direted aggressive behavir.B.  Differential Diagnosis of Generalized Seizures1.  Syncope— Synpal episdes usually ur in relatin t pstural hange, emtinal stress, instrumentatin, pain, r straining. They are typially preeded by pallr, sweating, nausea, and malaise and lead t lss f nsiusness ampanied by flaidity; revery urs rapidly with reumbeny, and there is n pstital headahe r nfu- sin. In sme instanes, hwever, mtr ampaniments and urinary inntinene may simulate a seizure. 2. Cardiac disease— Cerebral hypperfusin due t a dis- turbane f ardia rhythm shuld be suspeted in patients with knwn ardia r vasular disease r in elderly patients wh present with episdi lss f nsiusness. Prdrmal symptms are typially absent. Cardia rhythm mnitring may be neessary t establish the diagnsis; external event rerders r implantable lp rerders may be valuable if the disturbanes f nsiusness are rare. A relatinship f attaks t physial ativity and the finding f a systli murmur are suggestive f arti stensis. 3. Brainstem ischemia— Lss f nsiusness is preeded r ampanied by ther brainstem signs. Basilar artery migraine and vertebrbasilar vasular disease are disussed elsewhere in this hapter. 4. Psychogenic nonepileptic seizure PNES— Simulating an epilepti seizure, a PNES may ur due t a nversin disrder r malingering. Many patients als have epilepti seizures r a family histry f epilepsy. A histry f hild- hd physial r sexual abuse is mmn. Althugh a PNES tends t ur at times f emtinal stress, this may als be the ase with epilepti seizures.CMDT22_Ch24_p0978-p1053.indd  989 29/06/21 8:50 PMChapTER 24990 CMDT 2022Clini ally, the attaks superfiially resemble tni-lni seizures, but there may be bvius preparatin befre a PNES. Mrever, there is usually n tni phase; instead, there may be an asynhrnus thrashing f the limbs and the attak rarely leads t injury. Eyes are ften fribly lsed during PNES, unlike epilepti seizures, in whih they are typially pen. Cnsiusness may be nrmal r “lst, ” but in the latter ntext the urrene f gal-direted behavir r f shuting, swearing, et, indiates that it is feigned. Pstitally, there are n hanges in behavir r neurlgi findings. Often, linial bservatin is insuffiient t disriminate epilepti frm nnepilepti seizures and video electroen- cephalographic monitoring is required. Elevatin f serum prlatin level t at least twie the upper limit f nrmal an be seen between 10 and 20 minutes after a seizure r syn- pal event but nt after a PNES. Hwever, prlatin measure- ment has limited linial utility beause levels are nrmal after an epilepti seizure in rughly half f patients and a baseline prlatin must be drawn 6 hurs after the attak. »TreatmentA.  General MeasuresF r patients with epilepsy, mediatin is presribed with the gal f preventing further attaks and is usually ntinued until there have been n seizures fr at least 2 years. Patients shuld be advised t avid situatins that uld be danger- us r life-threatening if further seizures shuld ur. Legislatin may require liniians t reprt t the state authrities any patients with seizures r ther episdi dis- turbanes f nsiusness; driving cessation for 6 months r as legislated is apprpriate fllwing an unprvked seizure. 1. Choice of medication— Mediatin seletin depends n seizure type (Table 24–2). The dse f the seleted anti- nvulsant is gradually inreased until seizures are n- trlled r side effets prevent further inreases. If seizures ntinue despite treatment at the maximal tlerated dse, a send mediatin is added and the dse inreased depending n tlerane; the first mediatin is then gradu- ally withdrawn. In mst patients with seizures f a single type, satisfatry ntrl an be ahieved with a single antinvulsant. Treatment with tw mediatins may fur- ther redue seizure frequeny r severity but usually nly at the st f greater txiity. Treatment with mre than tw mediatins is almst always unhelpful unless the patient is having seizures f different types. Other fatrs t nsider in seleting an antinvulsant inlude likely side effets, teratgeniity, interatins with ther media- tins and ral ntraeptives, and rute f metablism. All antiepileptis are ptentially teratgeni, althugh the teratgeniity f the newer antiseizure mediatins is less lear. Nevertheless, antiepilepti mediatin must be given t pregnant wmen with epilepsy t prevent seizures, whih an pse serius risk t the fetus frm trauma, hypxia, r ther fatrs. 2. Monitoring— Individual differenes in drug metablism ause a given dse f a mediatin t prdue differentbld nentratins in different patients, and this will affet the therapeuti respnse. In general, the dose of an antiepileptic agent is increased, depending on tolerance, to achieve the desired clinical response regardless of the serum drug level. When a dse is reahed that either ntrls sei- zures r is the maximum tlerated, then a steady-state trugh drug level may be btained fr future referene; reheking this level may be apprpriate during pregnany, if a breakthrugh seizure urs, a dse hange urs, r anther (ptentially interating) mediatin is added t the regimen. A labratry’s therapeuti range fr a mediatin is nly a guide; many patients ahieve gd seizure ntrl with n adverse effet at serum levels that exeed the stipu- lated range, and in these ases n dse adjustment is needed. The mst mmn ause f a lwer nentratin f mediatin than expeted fr the presribed dse is sub- ptimal patient adherene. Adherene an be imprved by limiting t a minimum the number f daily dses. Reur- rent seizures r status epileptius may result if mediatins are taken erratially, and in sme irumstanes nnadher- ent patients may be better ff withut any mediatin. All antinvulsants have side effets, and many require base- line and regular labratry mnitring (Table 24–2). 3. Discontinuance of medication— Only when adult patients have been seizure-free fr 2 years shuld with- drawal f mediatin be nsidered. Unfrtunately, there is n way f prediting whih patients an be managed su- essfully withut treatment, althugh seizure reurrene is mre likely in (1) patients with a lnger duratin f epi- lepsy prir t remissin, (2) thse with a shrter duratin f remissin, (3) thse wh initially did nt respnd t therapy, (4) thse with seizures having fal features r f multiple types, (5) thse with nset during adulthd, and (6) thse with ntinuing eletrenephalgraphi abnr- malities. Dse redutin shuld be gradual (ver weeks r mnths), and mediatins shuld be withdrawn ne at a time. If seizures reur, treatment is reinstituted with the previusly effetive regimen. 4. Surgical treatment— Patients with seizures refratry t tw r mre mediatins may be andidates fr perative treatment. Surgial resetin is mst effiaius when there is a single well-defined seizure fus, partiularly in the tempral lbe. Amng well-hsen patients, up t 70% remain seizure-free after extended fllw-up. Additinal surgial tehniques fr medially refratry epilepsy apprved in the United States inlude laser interstitial ther- mal therapy, deep brain stimulatin, respnsive rtial stimulatin, and vagus nerve stimulatin.B.  Special Circumstances1.  Solitary seizures— In patients wh have had nly ne seizure r a flurry f seizures ver a brief perid f several hurs, investigatin as utlined earlier shuld exlude an underlying ause requiring speifi treatment. An eletr- enephalgram shuld be btained, preferably within 24 hurs after the seizure. Prphylati antinvulsant treat- ment is generally nt required unless further attaks ur r investigatins reveal underlying pathlgy. The risk f seizure reurrene varies in different series between abutCMDT22_Ch24_p0978-p1053.indd  990 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS991 CMDT 202230%  and 70%, with higher risk f reurrene in patients with strutural brain lesins r abnrmalities n eletren- ephalgram. Epilepsy shuld notbe diagnsed n the basis f a slitary seizure. If seizures ur in the ntext f transient, nnreurrent systemi disrders suh as hypna- tremia r hypglyemia, the diagnsis f epilepsy is ina- urate, and lng-term prphylati antinvulsant treatment is unneessary. 2. Alcohol withdrawal seizures— The harateristi al- hl withdrawal seizure pattern is ne r mre generalized tni-lni seizures that may ur within 48 hurs r s f withdrawal frm alhl after a perid f high r pr- lnged intake. If the seizures have nsistently fal fea- tures, the pssibility f an assiated strutural abnrmality, ften traumati in rigin, must be nsidered. Treatment with antinvulsants is generally nt required fr alhl withdrawal seizures, sine they are self-limited. Benzdiaz- epines are effetive and safe fr preventing further seizures. Status epileptius may mpliate alhl withdrawal and is managed alng nventinal lines. Further attaks will nt ur if the patient abstains frm alhl. 3. Tonicclonic status epilepticus— Pr adherene t the antinvulsant regimen is the mst mmn ause; hw- ever, any disrder that an ause a single seizure may be respnsible. The mrtality rate may be as high as 20%, and amng survivrs the inidene f neurlgi and gnitive sequelae is high. The prgnsis relates t the underlying ause as well as the length f time between nset f status epileptius and the start f effetive treatment. Status epilepticus is a medical emergency. Initial management inludes maintenane f the airway and 50% dextrse (25–50 mL) intravenusly in ase hypglyemia is respnsible. If seizures ntinue, an intravenus blus f lrazepam, 4 mg, is given at a rate f 2 mg/min and repeated ne after 10 minutes if neessary; alternatively, 10 mg f midazlam is given intramusularly, and again after 10 minutes if neessary. Diazepam an als be given retally as a gel (0.2 mg/kg). These measures are usually effetive in halting seizures fr a brief perid. Respiratry depressin and hyptensin may mpliate the treatment and are treated as in ther irumstanes, inluding intuba- tin and mehanial ventilatin and admissin t an inten- sive are unit. Regardless f the respnse t lrazepam r midazlam, fsphenytin r phenytin shuld be administered intrave- nusly. Fsphenytin (18–20 mg phenytin equivalents [PE]/kg) is rapidly and mpletely nverted t phenytin fllwing intravenus administratin and is preferred beause it is less likely t ause reatins at the infusin site, an be given with all mmn intravenus slutins, and may be administered at a faster rate (150 mg PE/min). When fsphenytin is nt available, phenytin (18–20 mg/kg) is given intravenusly at a rate f 50 mg/min. Phenytin is best injeted diretly but an als be given in saline; it pre- ipitates, hwever, if injeted int gluse-ntaining slu- tins. Beause arrhythmias may develp during rapid administratin f fsphenytin r phenytin, eletrar- digraphi mnitring is prudent. Hyptensin may ur, espeially if diazepam has als been given. Alternatively radditinally, intravenus valprate (lading dse 20–40 mg/ kg ver 15 min, maximum dse 3000 mg) r levetiraetam (lading dse 60 mg/kg ver 15 min, maximum dse 4500 mg) is used fr status epileptius. Althugh neither is apprved by the FDA fr this indiatin, bth were equiva- lent t fsphenytin in a randmized trial. Due t the teratgeniity f valprate, it shuld be avided in wmen wh may be pregnant. If seizures ntinue, phenbarbital is then given in a lading dse f 10–20 mg/kg intravenusly by slw r intermittent injetin (50 mg/min). Respiratry depressin and hyptensin are espeially mmn with this therapy. If these measures fail, general anesthesia with ventila- try assistane may be required; sme experts rem- mend preeding diretly t general anesthesia if nvulsins d nt ease after the initial 18–20 PE/kg fsphenytin lad. Intravenus midazlam may prvide ntrl f refratry status epileptius; the suggested lading dse is 0.2 mg/kg, fllwed by 0.05–0.2 mg/kg/h. Prpfl (1–2 mg/kg as an intravenus blus, fllwed by infusin at 2–15 mg/kg/h depending n respnse) may als be used, as may pentbarbital (5–15 mg/kg intrave- nusly, fllwed by 0.5–4 mg/kg/h). After status epileptius is ntrlled, an ral mediatin prgram fr the lng-term management f seizures is started, and investigatins int the ause f the disrder are pursued. 4. Nonconvulsive status epilepticus— In sme ases, sta- tus epileptius presents nt with nvulsins, but with a flutuating abnrmal mental status, nfusin, impaired respnsiveness, and autmatism. Eletrenephalgraphy establishes the diagnsis. The treatment apprah utlined abve applies t any type f status epileptius, althugh intravenus anesthesia is usually nt neessary. The prg- nsis is a refletin f the underlying ause rather than f ntinuing seizures. »When to Refer• Behaviral episdes f unertain nature. •Seizures are diffiult t ntrl with mntherapy. •There is a prgressive neurlgi disrder. »When to Admit• Status epileptius. •Frequent seizures requiring rapid mediatin titratin and eletrenephalgraphi mnitring. •Fr inpatient mnitring when PNES is suspeted.Ahmad  S et al. Surgial treatments f epilepsy. Semin Neurl. 2020;40:696. [PMID: 33176368] Kanner AM et al. Pratie guideline update summary: effiay and tlerability f the new antiepilepti drugs I: treatment f new-nset epilepsy. Epilepsy Curr. 2018;18:260. [PMID: 30254527] Kapur J et al; NETT and PECARN Investigatrs. Randmized trial f three antinvulsant mediatins fr status epilepti- us. N Engl J Med. 2019;381:2103. [PMID: 31774955]CMDT22_Ch24_p0978-p1053.indd  991 29/06/21 8:50 PMChapTER 24992 CMDT 2022DYSAUTO NOMIAE S S E N T I A L S  O F  D I A G N O S I S »Postural hypotension or abnormal heart rate regulation. »Abnormalities of sweating, intestinal motility, sex- ual function, or sphincter control. »Syncope may occur. »Symptoms occur in isolation or any combination. »General ConsiderationsDysautn mia may ur as a result f pathlgial pr- esses in the entral r peripheral nervus system. It is manifested by a variety f symptms related t abnrmali- ties f bld pressure regulatin, thermregulatry sweat- ing, gastrintestinal funtin, sphinter ntrl, sexual funtin, respiratin, and ular funtin. The differential diagnsis depends n the time urse f autnmi dys- funtin and whether dysautnmia is an islated symp- tm r assiated with entral r peripheral neurlgi symptms and signs.A.  Causes in the Central Nervous SystemDisease at  ertain sites, regardless f its nature, may lead t dysautnmi symptms. Postural hypotension, whih is usually the mst trublesme and disabling symptm, may result frm spinal rd transetin and ther myelpathies (eg, due t tumr r syringmyelia) abve the T6 level r frm brainstem lesins suh as syringbulbia and psterir fssa tumrs. Sphincter or sexual disturbances may result frm rd lesins at any level. Certain primary degenera- tive disrders are respnsible fr dysautnmia urring in islatin (pure autonomic failure) r in assiatin with mre widespread abnrmalities (multisystem atro- phy) that may inlude parkinsnism, pyramidal symp- tms, and erebellar defiits. Pstural hyptensin is als a prminent symptm f idipathi Parkinsn disease and dementia with Lewy bdies.B.  Causes in the Peripheral Nervous SystemA  pure autnmi neurpathy may ur autely r sub- autely after a viral infetin r as a paraneplasti disr- der related usually t small ell lung aner, partiularly in assiatin with ertain antibdies, suh as anti-Hu r thse direted at neurnal nitini ganglini aetylh- line reeptrs. Dysautnmia is ften nspiuus in patients with Guillain-Barré syndrme, manifesting with marked hyptensin r hypertensin r ardia arrhyth- mias that may have a fatal utme. It may als ur with diabeti, uremi, amylidti, and varius ther metabli r txi neurpathies; in assiatin with leprsy r Cha- gas disease; and as a feature f ertain hereditary neurpa- thies with autsmal dminant r reessive inheritane r an X-linked pattern. Autnmi symptms are prminentin the rises f hepati prphyria. Small fiber neurpathies may underlie sme ases f postural orthostatic tachycar- dia syndrome (POTS) due t impaired ntratility in denervated venules and resulting prelad failure (see belw). Patients with btulism r the Lambert-Eatn myastheni syndrme may have nstipatin, urinary retentin, and a sia syndrme as a result f impaired hlinergi funtin. »Clinical FindingsA.  Symptoms and SignsDysautn mi symptms inlude synpe, pstural hyp- tensin, parxysmal hypertensin, persistent tahyardia withut ther ause, faial flushing, hyphidrsis r hyper- hidrsis, vmiting, nstipatin, diarrhea, dysphagia, abdminal distentin, disturbanes f mituritin r defe- atin, eretile dysfuntin, apnei episdes, and delining night visin. In synpe, prdrmal malaise, nausea, head- ahe, diaphresis, pallr, visual disturbane, lss f ps- tural tne, and a sense f weakness and impending lss f nsiusness are fllwed by atual lss f nsiusness. It is usually ampanied by hyptensin and bradyardia and may ur in respnse t emtinal stress, pstural hyptensin, vigrus exerise in a ht envirnment, bstruted venus return t the heart, aute pain r its antiipatin, fluid lss, and a variety f ther irum- stanes. Althugh the patient is usually flaid, sme mtr ativity is nt unmmn, and urinary (and rarely feal) inntinene may als ur, thereby simulating a seizure. Revery is rapid ne the patient bemes reum- bent, but headahe, nausea, and fatigue mmnly persist.B.  Evaluation of the PatientThe e xtent and severity f autnmi dysfuntin shuld be determined, and the presene f assiated neurlgi symptms and signs asertained. Bedside testing f aut- nmi funtin inludes examinatin f pupillary rea- tivity, examinatin f the skin fr areas f exessive r redued sweating and f the hands and feet fr lr r temperature hanges, as well as assessment f bld pres- sure and heart rate in the supine psitin and 2 minutes after standing. With dysautnmia, postural hypotension is not accompanied by a compensatory rise in heart rate. Speialized tests inlude the ardivasular respnse t the Valsalva maneuver and deep respiratin, tilt-table testing, the thermregulatry sweat test, the quantitative sudmtr axn reflex test, and the quantitative diret and indiret axn reflex test. Tests f gastrintestinal mtility and urdynamis may be helpful when symptms f dysmtility, inntinene, r urinary retentin are present. The neurlgi examinatin shuld fus n deteting signs f parkinsnism, erebellar dysfuntin, disrders f neurmusular transmissin, and peripheral neurpathy. All patients shuld be tested fr vitamin B12defiieny and diabetes. Patients with aute r subaute islated dysaut- nmia shuld underg testing fr ganglini aetylhline reeptr, anti-Hu, vltage-gated ptassium hannel m- plex, and vltage-gated alium hannel antibdies. Fr thse with evidene f peripheral neurpathy, nerveCMDT22_Ch24_p0978-p1053.indd  992 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS993 CMDT 2022ndu tin studies; eletrmygraphy; and testing fr HIV , amylidsis, Sjögren syndrme, and Fabry disease are indiated. If there is evidene f entral pathlgy, imag- ing studies will exlude a treatable strutural ause. If the neurlgi examinatin is nrmal, reversible, nnneur- lgi auses f symptms must be nsidered. Islated pstural hyptensin and synpe may relate t a redued ardia utput, parxysmal ardia dysrhythmias, vlume depletin, varius mediatins, and endrine and meta- bli disrders suh as Addisn disease, hypthyridism r hyperthyridism, phehrmytma, and arinid syndrme. »TreatmentThe  mst disabling symptms are usually pstural hypten- sin and synpe. Abrupt pstural hange, prlnged reumbeny, heavy meals, and ther preipitants shuld be avided. Mediatins assiated with pstural hyptensin shuld be disntinued r redued in dse. Treatment may inlude wearing waist-high elasti hsiery, salt supplementa- tin, sleeping in a semieret psitin (whih minimizes the natriuresis and diuresis that ur during reumbeny), ingestin f 500 mL water 30 minutes befre arising, and fludrrtisne (0.1–0.5 mg rally daily). Vasnstritr agents may be helpful and inlude middrine (2.5–10 mg rally three times daily), drxidpa (100–600 mg rally three times daily), and ephedrine (15–30 mg rally three times daily). Other agents that have been used asinally r experimentally are dihydrergtamine, yhimbine, pyr- idstigmine, and lnidine; refratry ases may respnd t erythrpietin (epetin alfa) r desmpressin. Patients must be mnitred fr reumbent hypertensin. Pstprandial hyptensin is helped by affeine. There is n satisfatry treatment fr disturbanes f sweating, but an air-nditined envirnment is helpful in aviding extreme swings in bdy temperature. »When to Refer• When the diagnsis is unertain. •When symptms persist despite nventinal treatment.Shiba  CA et al. Management f rthstati hyptensin, pst- prandial hyptensin, and supine hypertensin. Semin Neurl. 2020;40:515. [PMID: 33058087]PO STURAL ORTHOSTATIC TACHYCARDIA SYNDROME »Clinical FindingsIn PO TS, rthstati symptms (tremulusness, lighthead- edness, palpitatins, visual disturbanes, weakness, fatigue, anxiety, hyperventilatin, nausea) develp with a signifiant tahyardia (an inrease f 30 beats/min r mre r a heart rate f 120 beats/min r mre) within 10 minutes f stand- ing, in the absene f pstural hyptensin r an autnmi neurpathy. POTS is mre mmn in wmen than menand in patients between 20 and 50 years f age. Other medi- al prblems ausing a tahyardia must be exluded. Its pathphysilgy is unertain but may invlve ar- dia denditining; impaired peripheral vasnstri- tin due t peripheral sympatheti denervatin, leading t venus pling in the legs n standing and a mpen- satry tahyardia (“ neuropathic POTS ”); r an exagger- ated sympatheti respnse t standing, with markedly elevated levels f plasma nrepinephrine ausing the tahyardia (“ hyperadrenergic POTS ”). Other pssible mehanisms inlude hypvlemia, pssibly frm impaired funtin f the renin-angitensin system (“volume dysregulation POTS ”) and exessive mast ell ativatin leading t inapprpriate release f histamine during physial ativity. Psyhlgial mehanisms have als been invked. POTS may be assiated with jint hypermbility syndrme and mitral valve prlapse, and it may fllw pregnany, surgery, trauma, hemtherapy, vainatins, r viral infetins. »TreatmentMana gement may invlve vlume repletin, a high salt diet and pius fluids, pstural and psyhphysilgi train- ing, and a graduated exerise prgram. Mediatin treat- ment may inlude a beta-blking agent (eg, prpranll 10–40 mg three times daily), phenbarbital (15 mg in the mrning, 60 mg at night) r lnidine (0.2 mg twie daily) fr patients with hyperadrenergi POTS; and mid- drine (2.5–10 mg three times daily) r fludrrtisne (0.1–0.2 mg daily) if the bld pressure is lw. The lng- term prgnsis is unlear but apprximately 50% f patients rever within 3 years.TR ANSIENT ISCHEMIC ATTACKSE S S E N T I A L S  O F  D I A G N O S I S »Focal neurologic deficit of acute onset. »Clinical deficit resolves completely within 24 hours. »Risk factors for vascular disease often present. »General ConsiderationsT ransient ishemi attaks (TIAs) are haraterized by focal ischemic cerebral neurologic deficits that last frless than 24 hours (usually less than 1–2 hurs). Abut 30% f patients with strke have a histry f TIAs and 5–10% f patients with TIAs will have a strke within 90 days. The natural his- try f attaks is variable. Sme patients will have a majr strke after nly a few attaks, whereas thers may have frequent attaks fr weeks r mnths withut having a strke. The risk f strke is high in the first 3 mnths after an attak, partiularly in the first mnth and espeially within the first 48 hurs. The strke risk is greater in patients lder than 60 years, in patients with diabetes, r after TIAs that last lnger than 10 minutes and with symptms r signsCMDT22_Ch24_p0978-p1053.indd  993 29/06/21 8:50 PMChapTER 24994 CMDT 2022f  weakness, speeh impairment, r gait disturbane. In general, artid ishemi attaks are mre liable than verte- brbasilar ishemi attaks t be fllwed by strke. Urgent interventin in TIA patients redues rates f subsequent strke, and the condition should be treated with a similar sense of urgency as unstable angina. »EtiologyAn  imprtant ause f transient erebral ishemia is emblizatin. In many patients with these attaks, a sure is readily apparent in the heart r a majr extraranial artery t the head, and embli smetimes are visible in the retinal arteries. An embli phenmenn explains why separate attaks may affet different parts f the territry supplied by the same majr vessel. Cardia auses f embli ishemi attaks inlude atrial fibrillatin, heart failure, infetive and nnbaterial thrmbti endardi- tis, atrial myxma, and mural thrmbi mpliating my- ardial infartin. Atrial septal defets and patent framen vale may permit venus thrmbembli t reah the brain ( paradoxical emboli ). An ulerated plaque n a majr artery t the brain may serve as a sure f embli. In the anterir irulatin, atherslerti hanges ur mst mmnly in the regin f the artid bifuratin extraranially; these hanges may ause a bruit. Ather- slersis als affets the vertebrbasilar system and the majr intraranial vessels inluding the middle and ante- rir erebral arteries. Less mmn abnrmalities f bld vessels that may ause TIAs inlude fibrmusular dysplasia, whih affets partiularly the ervial internal artid artery; athersle- rsis f the arti arh; inflammatry arterial disrders suh as giant ell arteritis, plyarteritis, and granulma- tus angiitis; and meningvasular syphilis. Critial sten- sis f a majr extraranial r intraranial artery may ause TIA, espeially in the setting f hyptensin. Hematlgi auses f TIA inlude plyythemia, sikle ell disease, hypervissity syndrmes, and the antiphsphlipid antibdy syndrme. Severe anemia may als lead t transient fal neurlgi defiits in patients with preexisting erebral arterial disease. The subclavian steal syndrome may lead t transient vertebrbasilar ishemia. Symptms develp when there is lalized stensis r lusin f ne sublavian artery prximal t the sure f the vertebral artery, s that bld is “stlen” frm the vertebral artery t supply the arm. A bruit in the supralaviular fssa, unequal radial pulses, and a differene f 20 mm Hg r mre between the systli bld pressures in the arms shuld suggest the diagnsis in patients with vertebrbasilar TIAs. »Clinical FindingsA.  Symptoms and SignsThe  symptms f TIAs vary markedly amng patients; hw- ever, the symptms in a given individual tend t be nstant in type. Onset is abrupt and withut warning, and revery usually urs rapidly, ften within a few minutes. The spe- ifi symptms depend n the arterial distributin affeted,as utlined in the subsequent setin n strke. Of nte, TIA rarely auses f lss f nsiusness r aute nfusin but is ften errneusly blamed fr suh symptms.B.  ImagingCT  r MRI san is indiated within 24 hurs f symptm nset, in part t exlude the pssibility f a small erebral hemrrhage r a erebral tumr masquerading as a TIA. MRI with diffusin-weighted sequenes is partiularly sen- sitive fr revealing aute r subaute infartin, whih is seen in up t ne-third f ases despite reslutin f linial symptms and indiates a high risk f subsequent strke. Nninvasive imaging f the ervial vasulature shuld als be perfrmed; artid duplex ultrasngraphy is useful fr deteting signifiant stensis f the internal artid artery, and MR r CT angigraphy permits brader visualizatin f ervial and intraranial vasulature.C.  Laboratory and Other StudiesClinial  and labratry evaluatin must inlude assessment fr hypertensin, heart disease, hematlgi disrders, dia- betes mellitus, hyperlipidemia, and peripheral vasular dis- ease. It shuld inlude mplete bld unt, fasting bld gluse and serum hlesterl determinatins, and may inlude serlgi tests fr syphilis and HIV infetin. An ECG shuld be btained. Ehardigraphy with agitated saline ntrast is perfrmed if a ardiembli sure is likely, and bld ultures are btained if endarditis is suspeted. Ambulatry ECG mnitring is indiated t detet parxysmal atrial fibrillatin and, if the ause f the TIA remains elusive, extended monitoring may detet parx- ysmal atrial fibrillatin in up t 20% f patients. »Differential DiagnosisFal  seizures usually ause abnrmal mtr r sensry phenmena suh as lni limb mvements, paresthesias, r tingling, rather than weakness r lss f feeling. Symp- tms generally spread (“marh”) up the limb and may lead t a generalized tni-lni seizure. Classi migraine is easily regnized by the visual pre- mnitry symptms, fllwed by nausea, headahe, and phtphbia, but less typial ases may be hard t distin- guish. Patients with migraine are typially yunger, m- mnly have a histry f episdes sine adlesene, and reprt that ther family members have a similar disrder. Fal neurlgi defiits may ur during perids f hypglyemia in diabeti patients reeiving insulin r ral hypglyemi agent therapy. »TreatmentA.  Medical MeasuresMedial  treatment is aimed at preventing further attaks and strke. Treat diabetes mellitus, hematlgi disrders, and hypertensin, preferably with an angitensin-nverting enzyme inhibitr r angitensin reeptr blker. ACMDT22_Ch24_p0978-p1053.indd  994 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS995 CMDT 2022stati n shuld be started regardless f the urrent lw- density lipprtein level (LDL), althugh this pratie is nly supprted by randmized trial data in patients with an LDL greater than 100 mg/dL. Cigarette smking shuld be stpped, and ardia sures f emblizatin shuld be treated apprpriately. Weight redutin and regular physial ativity shuld be enuraged when apprpriate. An antiplatelet r antiagulant shuld be started as sn as imaging has established the absene f hemrrhage. 1. Hospitalization— Hspitalizatin shuld be nsid- ered fr patients seen within a week f the attak, when they are at inreased risk fr early reurrene. One m- mnly used methd t assess reurrene risk is the ABCD2score; pints are assigned fr eah f the fllw- ing riteria: age 60 years r lder (1 pint), bld pressure 140/90 mm Hg r higher (1 pint), linial symptms f fal weakness (2 pints) r speeh impairment withut weakness (1 pint), duratin f 60 minutes r lnger (2 pints) r 10–59 minutes (1 pint), r diabetes mellitus (1 pint). An ABCD2sre f 4 r mre pints has been suggested as a threshld fr hspital admissin. The ABCD2I(with an additinal 3 pints fr any abnrmal diffusin-weighted MRI finding r any infart [new r ld] n nnntrast CT) has been prpsed as a better preditr f subsequent strke risk. Admissin is als advisable fr patients with resend attaks, symptm- ati artid stensis, r a knwn ardia sure f embli r hyperagulable state; suh hspitalizatin failitates early interventin fr any reurrene and rapid institu- tin f sendary preventin measures. 2. Anticoagulation— The hief indiatin fr antiagula- tin after TIA is atrial fibrillatin. Patients with metal heart valves, left ventriular thrmbus, and the antiphs- phlipid antibdy syndrme shuld als reeive anti- agulatin therapy. Treatment is with warfarin (target INR 2.0–3.0); bridging warfarin with heparin is nt neessary, but sme experts advate treatment with aspirin until the INR bemes therapeuti. Fr lng-term antiagulatin in the setting f atrial fibrillatin, apixaban (2.5–5 mg rally twie daily), dabigatran (150 mg rally twie daily), edxa- ban (60 mg rally daily), and rivarxaban (20 mg rally daily) are ptins. Cmbinatin antiplatelet-antiagula- tin therapy is nly indiated in patients with mehanial heart valves r thse with a separate indiatin fr anti- platelet therapy suh as a ardia stent. In patients with ardimypathy and an ejetin fratin under 35% withut atrial fibrillatin, warfarin (target INR 2.0–3.0) redues ishemi strke risk mpared t aspirin but results in a rughly equivalent inrease in the risk f majr hemrrhage; treatment in this ppulatin shuld there- fre be individualized. 3. Antiplatelet therapy— All patients in whm antiag- ulatin is nt indiated shuld be treated with shrt-term dual antiplatelet therapy and lng-term mntherapy t redue the frequeny f TIAs and the inidene f strke. Treatment shuld be initiated within 12 hurs after the TIA r minr strke (defined by a Natinal Institutes fHealth Strke Sale f 3 r less) with an ral lading dse f lpidgrel (300–600 mg) fllwed by 75 mg/day rally plus aspirin (50–325 mg daily rally) fr 21 days, fllwed by mntherapy with aspirin (81 mg daily rally), aspirin mbined with extended-release dipyridamle (200 mg twie daily rally), r lpidgrel (75 mg daily rally). Cilstazl (100 mg twie daily) had similar effiay as aspirin at lng-term strke preventin in an Asian ppu- latin with less risk f hemrrhage. Cmbining lpid- grel with aspirin beynd 90 days inreases the risk f hemrrhagi mpliatins and is notremmended.B. Surgic al or Endovascular Measures1. Car otid revascularization— When arterigraphy reveals a surgially aessible high-grade stensis (70–99% in lumi- nal diameter) n the side apprpriate t artid ishemi attaks, perative treatment ( carotid endarterectomy ) r endovascular intervention redues the risk f ipsilateral artid strke, espeially when TIAs are f reent nset (less than 1 mnth) and when the periperative mrbidity and mrtality risk is estimated t be less than 6%. Endvasular therapy arries a slightly higher predural strke risk than endarteretmy in patients lder than 70 years and is gener- ally reserved fr yunger patients whse nek anatmy is unfavrable fr surgery. Patients with symptmati artid stensis f 50–69% derive mderate benefit frm interven- tin, but surgery is nt indiated fr mild stensis (less than 50%). 2. Closure of patent foramen ovale— Carefully seleted patients with patent framen vale (PFO) and right-t- left shunt benefit frm PFO lsure and antiplatelet therapy. Patients shuld be nsidered fr PFO lsure if they are between 18 and 60 years ld; have had a rypt- geni strke r TIA; and d nt have unntrlled diabe- tes, hypertensin, r a speifi indiatin fr lng-term antiagulatin. A ryptgeni strke des nt have an identified mehanism, suh as large artery atherslersis (greater than r equal t 30–50% stensis f the intrara- nial r ervial arteries r a plaque greater than r equal t 4mm thik in the arti arh), knwn ardiembli sure (eg, atrial fibrillatin), small vessel arterilsler- sis (eg, launar strke smaller than 1.5 m in diameter), hyperagulable state, r dissetin. Patients with mder- ate t large interatrial shunts r assiated atrial septal aneurysms appear t benefit mst frm PFO lsure. See als Chapter 10. »When to ReferAll  patients shuld be referred fr urgent investigatin andtreatment to prevent stroke. »When to AdmitIf s een within a week f a TIA, patients shuld be nsid- ered fr admissin when they have an ABCD2sre f 4 pints r mre, when utpatient evaluatin is impratial, r when there are multiple attaks, artid stensis f greater than 70%, r ther nern fr early reurrene r strke.CMDT22_Ch24_p0978-p1053.indd  995 29/06/21 8:50 PMChapTER 24996 CMDT 2022Pa n Y et al. Outmes assiated with lpidgrel-aspirin use in minr strke r transient ishemi attak: a pled analysis f Clpidgrel in High-Risk Patients With Aute Nn-Disabling Cerebrvasular Events (CHANCE) and Platelet-Oriented Inhibitin in New TIA and Minr Ishemi Strke (POINT) trials. JAMA Neurl. 2019;76:1466. [PMID: 31424481]ST ROKEE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of neurologic deficit of cerebrovas- cular origin. »Patient often has hypertension, diabetes mellitus, tobacco use, atrial fibrillation, or atherosclerosis. »Distinctive neurologic signs reflect the region of the brain involved. »General ConsiderationsIn  the United States, strke is the sixth leading ause f death and a leading ause f disability. Risk fatrs fr strke inlude hypertensin, diabetes mellitus, hyperlipid- emia, igarette smking, ardia disease, HIV infetin, trigeminal herpes zster, rereatinal drug abuse, heavy alhl nsumptin, and a family histry f strke. Strkes are subdivided pathlgially int infarcts and hemorrhages. The distintin may be diffiult linially; CT sanning is essential t larify the pathlgi basis (Table 24–3).1.  Lcunr InfrctionLa unar infarts are small lesins (usually less than 1.5 m in diameter) that ur in the distributin f shrt penetrating arteriles in the basal ganglia, pns, erebel- lum, internal apsule, thalamus, and, less mmnly, the deep erebral white matter (Table 24–3). Launar infarts are assiated with prly ntrlled hypertensin r diabetes and have been fund in several linial syn- drmes, inluding ntralateral pure mtr hemiparesis r pure hemisensry defiit, ipsilateral ataxia with hemi- paresis, and dysarthria with lumsiness f the hand. The neurlgi defiit may prgress ver 24–36 hurs befre stabilizing. Early mrtality and risk f strke reurrene is higher fr patients with nnlaunar than launar infarts. The prgnsis fr revery frm the defiit prdued by a lau- nar infart is usually gd, with partial r mplete reslu- tin urring ver the fllwing 4–6 weeks in many instanes. Treatment is as desribed fr TIA and erebral infartin.2.  Cerebrl InfrctionThrm bti r embli lusin f a majr vessel leads t erebral infartin. Causes are idential t the disrders predispsing t TIAs. The resulting defiit depends n the partiular vessel invlved and the extent f any llateralirulatin. Cerebral ishemia leads t release f exitatry and ther neurpeptides that may augment alium flux int neurns, thereby leading t ell death and inreasing the neurlgi defiit. »Clinical FindingsA.  Symptoms and SignsOnset  is usually abrupt, and there may then be very little prgressin exept that due t brain swelling. Clinial evaluatin shuld always inlude examinatin f the heart fr murmurs and rhythm irregularities. Ausultating ver the artid r sublavian vessels may reveal a bruit but is nt sensitive enugh t substitute fr vasular imaging. 1. Obstruction of carotid circulation— Olusin f the anterior cerebral artery distal t its juntin with the ante- rir mmuniating artery auses weakness and rtial sensry lss in the ntralateral leg and smetimes mild weakness f the arm, espeially prximally. There may be a ntralateral grasp reflex, paratni rigidity, abulia (lak f initiative), r frank nfusin. Urinary inntinene is nt unmmn, partiularly if behaviral disturbanes are nspiuus. Bilateral anterir erebral infartin is espe- ially likely t ause marked behaviral hanges and memry disturbanes. Unilateral anterir erebral artery lusin prximal t the juntin with the anterir m- muniating artery is generally well tlerated beause f the llateral supply frm the ther side. Middle cerebral artery lusin leads t ntralateral hemiplegia, hemisensry lss, and hmnymus hemian- pia (ie, bilaterally symmetri lss f visin in half f the visual fields), with the eyes deviated t the side f the lesin. If the dminant hemisphere is invlved, glbal aphasia is als present. It may be impssible t distinguish this linially frm lusin f the internal artid artery. With lusin f either f these arteries, there may als be nsiderable swelling f the hemisphere during the first 72 hurs. Fr example, an infart invlving ne erebral hemisphere may lead t suh swelling that the funtin f the ther hemisphere r the rstral brainstem is disturbed and ma results. Olusins f different branhes f the middle erebral artery ause mre limited findings. Fr example, invlvement f the superir divisin in the dmi- nant hemisphere leads t a predminantly expressive (Broca ) aphasia and t ntralateral paralysis and lss f sensatins in the arm, the fae and, t a lesser extent, the leg. Inferir branh lusin in the dminant hemisphere prdues a reeptive ( Wernicke ) aphasia and a hmny- mus visual field defet. With invlvement f the nn- dminant hemisphere, speeh and mprehensin are preserved, but there may be a left hemispatial neglet syn- drme r nstrutinal and visuspatial defiits. Olusin f the ophthalmic or central retinal artery leads t sudden painless visual lss with retinal pallr and a maular herry red spt n fundspi examinatin. Sudden, transient visin lss in ne eye ( amaurosis fugax ) is a TIA in this arterial territry. Patients with a cilioretinal artery (apprximately 25%) may have maular sparing due t llateral bld supply.CMDT22_Ch24_p0978-p1053.indd  996 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS997 CMDT 20222. Obstruction of  vertebrobasilar circulation— Olusin f the posterior cerebral artery may lead t a thalami syndrme in whih ntralateral hemisensry disturbane urs, fllwed by the develpment f spntaneus pain and hyperpathia. There is ften a maular-sparing hm- nymus hemianpia and smetimes a mild, usually tem- prary, hemiparesis. Depending n the site f the lesinand the llateral irulatin, the severity f these defiits varies and ther defiits may als ur, inluding invlun- tary mvements and alexia. Olusin f the main artery beynd the rigin f its penetrating branhes may lead slely t a maular-sparing hemianpia. Vertebral artery occlusion belw the rigin f the anterir spinal and psterir inferir erebellar arteriesTable 24–3. Features of the major stroke subtypes.Stro ke Tye nd Subtye Clinicl Fetures Dignosis Tretment Iscemic Stroke Lacunar infarct Small (< 1.5 cm) lesions in the basal ganglia, pons, cerebel- lum, or internal capsule; less often in deep cerebral white matter; prognosis generally good; clinical features depend on location, but may worsen over first 24–36 hours.MRI with diffusion-weighted sequences usually defines the area of infarction; CT is insensitive acutely but can be used to exclude hemorrhage.Antiplatelet; control risk factors (hypertension, tobacco use, hyper- cholesterolemia, and diabetes mellitus). Carotid circulation obstructionSee text—signs vary depending on occluded vessel.Noncontrast CT to exclude hemorrhage but findings may be normal during first 6–24 hours of an ischemic stroke; diffusion-weighted MRI is gold stan- dard for identifying acute stroke; elec- trocardiography, carotid duplex studies, echocardiography, blood glucose, com- plete blood count, and tests for hyper- lipidemia are indicated; ambulatory ECG monitoring, including extended monitoring in selected instances; CTA, MRA, or conventional angiography in selected cases; tests for hypercoagula- ble states in selected cases.0–3 hours in United States: intrave- nous thrombolytics (approved in Europe for up to 4.5 hours). 0–6 hours: endovascular mechanical embolectomy. 6–24 hours: endovascular mechanical embolectomy in select cases. Secondary prevention: antiplatelet agent is first-line therapy; anticoag- ulation without heparin bridge for cardioembolic strokes due to atrial fibrillation and other select cases when no contraindications exist; control risk factors as above. Vertebrobasilar occlusionSee text—signs vary based on location of occluded vessel.As for carotid circulation obstruction. As for carotid circulation obstruction. hemorrgic Stroke Spontaneous intracerebral hemorrhageCommonly associated with hypertension; also with bleed- ing disorders, amyloid angiopathy. Hypertensive hemorrhage is located commonly in the basal ganglia, pons, thalamus, cere- bellum, and less commonly the cerebral white matter.Noncontrast CT is superior to MRI for detecting bleeds of < 48 hours dura- tion; laboratory tests to identify bleeding disorder: angiography may be indicated to exclude aneurysm or AVM in younger patients without hypertension. Do notperform lumbar puncture.Lower systolic blood pressure to 140 mm Hg; cerebellar bleeds or hematomas with gross mass effect may require urgent surgical evacuation. AVM: surgical resection indicated to prevent further bleeding; other modalities to treat nonoperable AVMs available at specialized centers. Subarachnoid hemorrhagePresent with sudden onset of worst headache of life, may lead rapidly to loss of con- sciousness; signs of meningeal irritation often present; etiol- ogy usually aneurysm or AVM, but 20% have no source identified.CT to confirm diagnosis, but may be normal in rare instances; if CT negative and suspicion high, perform lumbar puncture to look for red blood cells or xanthochromia; angiography to determine source of bleed in candidates for treatment.Lower systolic blood pressure to < 140 mm Hg immediately. Aneurysm: prevent further bleeding by clipping aneurysm or coil embo- lization; nimodipine helps prevent vasospasm; once aneurysm has been obliterated intravenous fluids and induced hypertension to pre- vent vasospasm; angioplasty may also reverse symptomatic vasospasm. AVM: as above. AVMs, arteriovenous malformations; CTA, computed tomography angiography; MRA, magnetic resonance angiography.CMDT22_Ch24_p0978-p1053.indd  997 29/06/21 8:50 PMChapTER 24998 CMDT 2022may  be linially silent beause the irulatin is main- tained by the ther vertebral artery. If the remaining verte- bral artery is ngenitally small r severely atherslerti, hwever, a defiit similar t that f basilar artery lusin is seen unless there is gd llateral irulatin frm the anterir irulatin thrugh the irle f Willis. An bstrutin f the posterior inferior cerebellar artery r an bstrutin f the vertebral artery just befre it branhes t this vessel leads t the lateral medullary syndrome, haraterized by vertig and nystagmus (vestibular nuleus), ipsilateral spinthalami sensry lss invlving the fae (trigeminal nuleus and trat), dysphagia (nuleus ambiguus), limb ataxia (inferir erebellar pedunle), and Hrner syndrme (desending sympatheti fibers), m- bined with ntralateral spinthalami sensry lss invlv- ing the limbs. Olusin f both vertebral arteries r the basilar artery leads t ma with pinpint pupils, flaid quadri- plegia and sensry lss, and variable ranial nerve abnr- malities. With partial basilar artery lusin, there may be diplpia, visual lss, vertig, dysarthria, ataxia, weakness r sensry disturbanes in sme r all f the limbs, and disrete ranial nerve palsies. In patients with hemiplegia f pntine rigin, the eyes are ften deviated t the para- lyzed side, whereas in patients with a hemispheri lesin, the eyes mmnly deviate frm the hemiplegi side. When the small paramedian arteries arising frm the basi- lar artery are luded, ntralateral hemiplegia and sen- sry defiit ur in assiatin with an ipsilateral ranial nerve palsy at the level f the lesin. Olusin f any f the majr cerebellar arteries pr- dues vertig, nausea, vmiting, nystagmus, and ipsilateral limb ataxia. Cntralateral spinthalami sensry lss in the limbs may als be present. Deafness due t hlear infar- tin may fllw lusin f the anterir inferir erebellar artery, whih may als ause ipsilateral faial spintha- lami sensry lss and weakness. Massive erebellar infar- tin may lead t bstrutive hydrephalus, ma, tnsillar herniatin, and death.B.  ImagingA  CT san f the head (withut ntrast) shuld be per- frmed immediately , befre the administratin f aspirin r ther antithrmbti agents, t exlude erebral hemr- rhage (Table 24–3). CT is relatively insensitive t aute ishemi strke within the first 6–12 hurs, and subse- quent MRI with diffusin-weighted sequenes helps define the distributin and extent f infartin as well as exlude tumr r ther differential nsideratins. CT angigraphy f the head and nek shuld be perfrmed t identify large vessel lusins amenable t endvasular therapy in patients presenting within 6 hurs f strke nset and shuld be nsidered in thse presenting between 6 and 24 hurs, tgether with CT perfusin studies. Regardless f timing f presentatin, imaging f the ervial vasulature is indiated as part f a searh t identify the sure f the strke. In patients with a PFO and therwise ryptgeni strke, the intraranial vasulature must be imaged t rule ut large vessel atherslersis befre PFO lsure an be nsidered.C. Laboratory and Other StudiesIn vestigatins shuld inlude a mplete bld unt, bld gluse determinatin, and fasting lipid panel. Ser- lgi tests fr syphilis and HIV infetin may be inluded depending n the irumstanes. Sreening fr antiphs- phlipid antibdies (lupus antiagulants, antiardilipin, and anti-beta2-glyprtein antibdies); the fatr V Leiden mutatin; abnrmalities f prtein C, prtein S, r antithrmbin; r a prthrmbin gene mutatin is indiated nly if a hyperagulable disrder is suspeted (eg, a yung patient withut apparent risk fatrs fr strke) r needs t be ruled ut if PFO lsure is under nsideratin. While elevated serum hmysteine is a risk fatr fr strke, lwering hmysteine levels with vitamin supplementa- tin has nt been shwn t derease strke risk, and there- fre, rutinely heking hmysteine is notremmended. Eletrardigraphy r ntinuus ardia mnitring fr at least 24 hurs will help exlude a reent myardial infartin r a ardia arrhythmia that might be a sure f emblizatin. While atrial fibrillatin will be disvered in apprximately 10% f patients with ishemi strke during their hspitalizatin, it is estimated that an arrhythmia will be fund in an additinal 10% with prlnged ambulatry ECG mnitring after disharge; this testing is indiated in ases where atrial fibrillatin is suspeted (eg, nnlaunar strke and left atrial enlargement n ehardigraphy r lak f intraranial r artid atherslersis) but has nt been demnstrated. Ehardigraphy (with agitated saline ntrast) shuld be perfrmed in ases f nnlau- nar strke t exlude valvular disease, right-t-left shunt- ing, and ardia thrmbus. Bld ultures shuld be perfrmed if endarditis is suspeted but are nt required rutinely. Examinatin f the erebrspinal fluid is nt always neessary but may be helpful if erebral vasulitis r anther inflammatry r infetius ause f strke is sus- peted, but it shuld be delayed until after CT r MRI t exlude any risk fr herniatin due t mass effet. »TreatmentMana gement is divided int aute and hrni phases: the first is aimed at minimizing disability and the send at preventing reurrent strke. A mbinatin f thrmbly- sis and endvasular therapies is available t patients wh present within 24 hurs f strke nset, determined by when the patient was last nrmal. Intravenous thrombolytic therapy with rembinant tissue plasmingen ativatr (rtPA; 0.9 mg/kg t a maxi- mum f 90 mg, with 10% given as a blus ver 1 minute and the remainder ver 1 hur) imprves the hane f revery withut signifiant disability at 90 days frm 26% t 39% if given within 3 hurs frm strke nset; it is still effetive up t 4.5 hurs frm strke nset. Treatment shuld be initiated as sn as pssible; utme is diretly related t the time frm strke nset t treatment. Intrave- nus thrmblysis is apprved in Eurpe fr use up t 4.5 hurs frm strke nset but nly fr up t 3 hurs in the United States, althugh ff-label use during the 3- t 4.5-hur windw is standard. In patients with systli pressure greater than 185 mm Hg r diastli pressure greater thanCMDT22_Ch24_p0978-p1053.indd  998 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS999 CMDT 2022110  mm Hg, the bld pressure shuld be lwered t less than 185/110 mm Hg with intravenus labetall r niar- dipine t enable rtPA administratin. Due t the risk f hemrrhage, rtPA shuld nt be used beynd 4.5 hurs, r in ther situatins where it is medially ntraindiated, althugh sme evidene suggests patients with ishemi but nt infarted tissue identified by autmated perfusin imaging r MRI may be treated up t 9 hurs after nset r upn awakening with strke symptms. Several randmized trials have demnstrated an inreased likelihd f ahieving funtinal independene after endovascular mechanical embolectomy by stent retrievers as an adjunt t intravenus rtPA. Patients with large vessel lusin (abut 20% f patients with aute ishemi strke) in whm treatment an be initiated within 6 hurs f strke nset are eligible fr embletmy, as are patients wh present between 6 hurs and 24 hurs and als have a large ishemi penumbra identified by perfu- sin CT, perfusin MRI, r diffusin-weighted MRI. Early management f a mpleted strke therwise requires general supprtive measures. Management in a stroke care unit has been shwn t imprve utmes, likely due t early rehabilitatin and preventin f medial mpliatins. During the aute stage, there may be marked brain swelling and edema, with symptms and signs f inreasing intraranial pressure, an inreasing neurlgi defiit, r herniatin syndrme. Elevated intraranial pres- sure is managed by head elevatin and smti agents suh as mannitl. Maintenane f an adequate erebral perfusin pressure helps prevent further ishemia. Early dempres- sive hemiranietmy (within 48 hurs f strke nset) fr malignant middle erebral artery infartins redues mr- tality and imprves funtinal utme. Attempts t lwer the bld pressure f hypertensive patients during the aute phase (ie, within 72 hurs) f a strke shuld generally be avoided unless the purpse is t enable the safe administra- tin f rtPA, as there is lss f erebral autregulatin, and lwering the bld pressure may further mprmise ishemi areas. Hwever, if the systli pressure exeeds 220 mm Hg, it an be lwered using intravenus labetall r niardipine with ntinuus mnitring t 170–200 mm Hg, and then after 72 hurs, it an be redued further t less than 140/90 mm Hg. Bld pressure augmentatin is usu- ally nt neessary in patients with relative hyptensin but maintenane f intravenus hydratin is imprtant. Prphylati and medial measures are disussed in the setin n TIAs and shuld guide management. One hemrrhage has been exluded by CT, aspirin (325 mg rally daily) is started immediately unless the patient reeived thrmblysis, in whih ase aspirin is initiated after a fllw-up CT has ruled ut thrmblyti-assiated hemrrhage at 24 hurs. Dual antiplatelet therapy shuld be used fr 21 days in patients with minr strke (Natinal Institutes f Health Strke Sale f 3 r less). Anticoagulant mediatins are started when indiated, as disussed in the setin n TIAs. There is generally noadvantage in delay, and the mmn fear f ausing hemrrhage int a previ- usly infarted area is misplaed, sine there is a far greater risk f further emblism t the erebral irulatin if treat- ment is withheld.Physical therapy has an imprtant rle in the manage- ment f patients with impaired mtr funtin. Passive mvements at an early stage will help prevent ntratures. As peratin inreases and sme revery begins, ative mvements will imprve strength and rdinatin. In all ases, early mbilizatin and ative rehabilitatin are impr- tant. Occupational therapy may imprve mrale and mtr skills, while speech therapy may help expressive aphasia r dysarthria. Beause f the risk fr dysphagia fllwing strke, aess t fd and drink is typially restrited until an appr- priate swallwing evaluatin; the head f the bed shuld be kept elevated t prevent aspiratin. Urinary atheters shuld notbe plaed and, if plaed, remved within 24–48 hurs. »PrognosisThe  prgnsis fr survival after erebral infartin is better than after erebral r subarahnid hemrrhage. Patients reeiving treatment with rtPA are at least 30% mre likely t have minimal r n disability at 3 mnths than thse nt treated by this means. Thse treated with mehanial embletmy are als at least 30% mre likely t ahieve funtinal independene. Lss f nsiusness after a erebral infart implies a prer prgnsis than therwise. The extent f the infart gverns the ptential fr rehabili- tatin. Patients wh have had a erebral infart are at risk fr additinal strkes and fr myardial infarts. The prphylati measures disussed earlier redue this risk. Antiplatelet therapy redues the reurrene rate by 30% amng patients withut a ardia ause fr the strke wh are nt andidates fr artid endarteretmy. Neverthe- less, the umulative risk f reurrene f nnardiembli strke is still 3–7% annually. Management is fused n palliative are when meaningful revery frm massive strkes is unlikely (see Chapter 5). »When to ReferAll patients sh uld be referred. »When to AdmitAll  patients shuld be hspitalized, preferably in a strke are unit.Albers  GW et al; DEFUSE 3 Investigatrs. Thrmbetmy fr strke at 6 t 16 hurs with seletin by perfusin imaging. N Engl J Med. 2018;378:708. [PMID: 29364767] Ngueira RG et al; DAWN Trial Investigatrs. Thrmbetmy 6 t 24 hurs after strke with a mismath between defiit and infart. N Engl J Med. 2018;378:11. [PMID: 29129157] Pwers WJ et al. Guidelines fr the early management f patients with aute ishemi strke: 2019 update t the 2018 guide- lines fr the early management f aute ishemi strke: a guideline fr healthare prfessinals frm the Amerian Heart Assiatin/Amerian Strke Assiatin. Strke. 2019;50:e344. [PMID: 31662037]3.  Intrcerebrl hemorrgeSpn taneus, nntraumati intraerebral hemrrhage in patients with n angigraphi evidene f an assiated vasular anmaly (eg, aneurysm r angima) is usually dueCMDT22_Ch24_p0978-p1053.indd  999 29/06/21 8:50 PMChapTER 241000 CMDT 2022t  hypertensin. The pathlgi basis fr hemrrhage is prbably the presene f miraneurysms that develp n perfrating vessels in hypertensive patients. Hypertensive intraerebral hemrrhage urs mst frequently in the basal ganglia, pns, thalamus, and erebellum, and less mmnly in the erebral white matter. Hemrrhage may extend int the ventriular system r subarahnid spae, and signs f meningeal irritatin are then fund. In lder adults, erebral amylid angipathy is anther imprtant and frequent ause f hemrrhage, whih is usually lbar in distributin, smetimes reurrent, and assiated with a better immediate prgnsis than hypertensive hemr- rhage. Arterivenus malfrmatins are an imprtant ause f intraerebral hemrrhage in yunger patients. Other auses f nntraumati intraerebral hemr- rhage inlude hematlgi and bleeding disrders (eg, leukemia, thrmbytpenia, hemphilia, r disseminated intravasular agulatin), antiagulant therapy, liver disease, high alhl intake, aine and methamphet- amine abuse, herpes simplex enephalitis, vasulitis, my- amya disease, reversible erebral vasnstritin syndrme, and primary r sendary brain tumrs. There is als an assiatin with advaning age and male sex. Bleeding is primarily int the subarahnid spae when it urs frm an intraranial aneurysm, but it may be partly intraparenhymal as well. Hemrrhage an als ur int arterial and venus erebral infarts. »Clinical FindingsA.  Symptoms and SignsW ith hemrrhage int the erebral hemisphere, nsius- ness is initially lst r impaired in abut ne-half f patients. Vmiting urs very frequently at the nset f bleeding, and headahe is smetimes present. Fal symp- tms and signs then develp, depending n the site f the hemrrhage. With hypertensive hemrrhage, there is gen- erally a rapidly evlving neurlgi defiit with hemiplegia r hemiparesis. A hemisensry disturbane is als present with mre deeply plaed lesins. With lesins f the puta- men, lss f njugate lateral gaze may be nspiuus. With thalami hemrrhage, there may be a lss f upward gaze, dwnward r skew deviatin f the eyes, lateral gaze palsies, and pupillary inequalities. Cerebellar hemrrhage may present with sudden nset f nausea and vmiting, dysequilibrium, ataxia f gait, limbs, r trunk; headahe; and lss f nsiusness that may terminate fatally within 48 hurs. Pntine hemrrhage auses sme mbinatin f lateral njugate gaze palsies t the side f the lesin; small reative pupils; ntralateral hemiplegia; peripheral faial weakness; and peridi respi- ratin. These signs may be bilateral with larger pntine hemrrhage, and the patient may beme lked in, with quadriplegia and preserved nsiusness.B.  ImagingCT  sanning (withut ntrast) is imprtant nt nly in nfirming that hemrrhage has urred but als in determining the size and site f the hematma. MRI isequally sensitive when magneti suseptibility weighted sequenes (eg, gradient eh) are used. If the patient’s n- ditin permits further interventin, CT angigraphy, MR angigraphy, r erebral angigraphy may be undertaken t determine whether an aneurysm r arterivenus mal- frmatin is present. In patients under age 55 with lbar hemrrhage and n histry f hypertensin, a ntrast- enhaned MRI may indiate a nnhypertensive ause, suh as an underlying neplasm.C.  Laboratory and Other StudiesA  mplete bld unt, platelet unt, prthrmbin and partial thrmbplastin times, liver bihemial tests, and kidney funtin tests may reveal a predispsing ause fr the hemrrhage. Lumbar puncture is contraindicated beause it may preipitate a herniatin syndrme in patients with a large hematma, and CT sanning is supe- rir in deteting intraerebral hemrrhage. »TreatmentPa tients shuld be admitted t an intensive are unit fr bservatin and supprtive are. The systli bld pres- sure shuld be lwered t 140 mm Hg with intravenus labetall r niardipine, althugh randmized trials target- ing systli bld pressures f less than 140 mm Hg and less than 180 mm Hg have nt shwn a differene in ut- mes. Thrmbytpenia shuld be treated with platelet transfusin; the speifi threshld fr treatment and the gal platelet unt after transfusin vary with patient har- ateristis and prvider experiene. Cagulpathies shuld be reversed using fresh frzen plasma, prthrmbin m- plex nentrates, vitamin K, r speifi reversal agents (eg, prtamine fr heparin; idaruizumab fr dabigatran; and andexanet alfa fr apixaban, betrixaban, edxaban, and rivarxaban). Hemstati therapy with rembinant ativated fatr VII in patients withut underlying agu- lpathy has nt imprved survival r funtinal utme. Intraranial pressure may require mnitring and smti therapy. Ventriular drainage may be required in patients with intraventriular hemrrhage and aute hydrephalus. Dempressin may be helpful when a superfiial hema- tma in erebral white matter is exerting a mass effet and ausing inipient herniatin. In patients with erebellar hemrrhage wh are deterirating neurlgially r wh have brainstem mpressin r hydrephalus, prmpt surgial evauatin f the hematma is apprpriate beause spntaneus unpreditable deteriratin may therwise lead t a fatal utme and beause perative treatment may lead t mplete reslutin f the linial defiit. The treatment f underlying strutural lesins r bleeding dis- rders depends n their nature. There is n speifi treatment fr erebral amylid angipathy. »When to ReferAll patients sh uld be referred. »When to AdmitAll patients sh uld be hspitalized.CMDT22_Ch24_p0978-p1053.indd  1000 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1001 CMDT 2022Hst ettler IC et al. Intraerebral hemrrhage: an update n diag- nsis and treatment. Expert Rev Neurther. 2019;19:679. [PMID: 31188036]4.  Sontneous Subrcnoid hemorrgeE S S E N T I A L S  O F  D I A G N O S I S »Sudden (“thunderclap”) severe headache. »Signs of meningeal irritation usually present. »Obtundation is common. »Focal deficits frequently absent. »General ConsiderationsBetween  5% and 10% f strkes are due t subarahnid hemrrhage. Trauma is the mst mmn ause f sub- arahnid hemrrhage, the prgnsis f whih depends n the severity f the head injury. Spntaneus (nntrau- mati) subarahnid hemrrhage frequently results frm the rupture f an arterial saccular (“berry”) aneurysm r frm an arteriovenous malformation. »Clinical FindingsA.  Symptoms and SignsSubarahn id hemrrhage has a harateristi linial pi- ture. Its nset is with sudden (“ thunderclap ”) headahe f a severity never experiened previusly by the patient. This may be fllwed by nausea and vmiting and by a lss r impairment f nsiusness that an either be transient r prgress inexrably t deepening ma and death. If n- siusness is regained, the patient is ften nfused and irritable and may shw ther symptms f an altered men- tal status. Neurlgi examinatin generally reveals nuhal rigidity and ther signs f meningeal irritatin, exept in deeply matse patients. Mst aneurysms are asymptmati until they rupture, but they may ause a fal neurlgi defiit by mpress- ing adjaent strutures. Oasinal patients with aneurysms have headahes, smetimes ampanied by nausea and nek stiffness, a few hurs r days befre massive subarah- nid hemrrhage urs. This has been attributed t “warn- ing leaks” f a small amunt f bld frm the aneurysm. A higher risk f subarahnid hemrrhage is assiated with lder age, female sex, nn-White ethniity, hyperten- sin, tba smking, high alhl nsumptin (exeed- ing 150 g per week), previus symptms, psterir irulatin aneurysms, and larger aneurysms. Fal neur- lgi signs are usually absent but, when present, may relate either t a fal intraerebral hematma (frm arterive- nus malfrmatins) r t ishemia in the territry f the vessel with a ruptured aneurysm.B.  ImagingA  CT san (preferably with CT angigraphy) shuld be perfrmed immediately t nfirm that hemrrhage hasurred and t searh fr lues regarding its sure. It is preferable t MRI beause it is faster and mre sensitive in deteting hemrrhage in the first 24 hurs. CT findings smetimes are nrmal in patients with suspeted hemr- rhage, and the erebrspinal fluid must then be examined fr the presene f bld r xanthhrmia befre the ps- sibility f subarahnid hemrrhage is disunted. Cerebral arterigraphy is undertaken t determine the sure f bleeding. In general, bilateral artid and verte- bral arterigraphy are neessary beause aneurysms are ften multiple, while arterivenus malfrmatins may be supplied frm several sures. The predure allws an interventinal radilgist t treat an underlying aneurysm r arterivenus malfrmatin by varius tehniques. If arterigrams shw n abnrmality, the examinatin shuld be repeated after 2 weeks beause vasspasm r thrmbus may have prevented detetin f an aneurysm r ther vasular anmaly during the initial study. CT r MR angi- graphy may als be revealing but is less sensitive than nventinal arterigraphy.C.  Laboratory and Other StudiesThe  erebrspinal fluid demnstrates an elevated red bld ell unt. Subarahnid hemrrhage an be differentiated frm a traumati lumbar punture by the lak f learing f red bld ells frm the first and furth tube f erebrspi- nal fluid r by the presene f xanthhrmia, whih urs due t lysis f red bld ells and takes at least 2 hurs t develp. The abslute red bld ell unt is als helpful: in the absene f xanthhrmia, a red bld ell unt f less than 2000 × 106/L is very unlikely t be due t subarahnid hemrrhage. Eletrardigraphi evidene f arrhythmias r myardial ishemia has been well desribed and prbably relates t exessive sympatheti ativity. Peripheral leukytsis and transient glysuria are als mmn findings. »TreatmentAll p atients shuld be hspitalized and seen by a neurl- gist. The measures utlined belw in the setin n stupr and ma are applied t matse patients. Cnsius patients are nfined t bed, advised against any exertin r straining, treated symptmatially fr headahe and anxiety, and given laxatives r stl sfteners. The systli bld pressure shuld be lwered t 140 mm Hg until the aneurysm is treated definitively. Seizure prphylaxis is nt neessary unless a nvulsin has urred (see Table 24–2). Patients are generally hspitalized fr at least 14 days t mnitr, prevent, and treat vasspasm. The majr aim f treatment is t prevent further hem- rrhage. The risk f further hemrrhage frm a ruptured aneurysm is greatest within a few days f the first hemr- rhage; apprximately 20% f patients will have further bleeding within 2 weeks and 40% within 6 mnths. Defini- tive treatment, ideally within 2 days f the hemrrhage, requires surgial lipping f the aneurysm r endvasular treatment by il emblizatin; the latter is smetimes feasible even fr inperable aneurysms and has a lwer mrbidity than surgery.CMDT22_Ch24_p0978-p1053.indd  1001 29/06/21 8:50 PMChapTER 241002 CMDT 2022 »ComplicationsSpntaneu s subarahnid hemrrhage may result in severe mpliatins, s mnitring is neessary, usually in an intensive are unit. Hemiplegia r ther fal defiit smetimes may fllw aneurysmal bleeding after a delay f 2–14 days due t fal arterial spasm. The etilgy f vaso- spasm is unertain and likely multifatrial, and it sme- times leads t signifiant erebral ishemia r infartin and may further aggravate any existing inrease in intra- ranial pressure. Transranial Dppler ultrasund may be used t sreen nninvasively fr vasspasm, but nven- tinal arterigraphy is required t dument and treat vasspasm when the linial suspiin is high. Nimdipine has been shwn t redue the inidene f ishemi defiits frm arterial spasm; a dse f 60 mg every 4 hurs rally fr 21 days is given prphylatially t all patients. After surgial bliteratin f all aneurysms, symptmati vas- spasm may als be treated by intravasular vlume expan- sin and indued hypertensin; transluminal balln angiplasty f invlved intraranial vessels is als helpful. Acute hydrocephalus, whih smetimes urs due t erebrspinal fluid utflw disruptin by the subarahnid bld, shuld be suspeted if the patient deterirates lini- ally; a repeat CT san shuld be btained. Aute hydr- ephalus frequently auses intraranial hypertensin severe enugh t require temprary, and less mmnly pr- lnged r permanent, intraventriular erebrspinal fluid shunting. Cerebral salt-wasting is anther mpliatin f subarahnid hemrrhage that may develp abruptly dur- ing the first several days f hspitalizatin. The resulting hypnatremia and erebral edema may exaerbate intra- ranial hypertensin and may require arefully titrated treatment with ral sdium hlride r intravenus hyper- smti sdium slutin. Daily measurement f the serum sdium level allws fr the early detetin f this mplia- tin. Hypopituitarism may ur as a late mpliatin f subarahnid hemrrhage.Etmina n N et al. Neurvasular disease, diagnsis, and therapy: subarahnid hemrrhage and erebral vasspasm. Handb Clin Neurl. 2021;176:135. [PMID: 33272393] Lindgren A et al. Endvasular iling versus neursurgial lip- ping fr peple with aneurysmal subarahnid hemrrhage. Chrane Database Syst Rev. 2018;8:CD003085. [PMID: 30110521]5.  Intrcrnil aneurysmE S S E N T I A L S  O F  D I A G N O S I S »Subarachnoid hemorrhage or focal deficit. »Abnormal imaging studies. »General ConsiderationsSaular  aneurysms (“berry” aneurysms) tend t ur at arterial bifuratins, are frequently multiple (20% f ases), and are usually asymptmati. They are assiated withplyysti kidney disease, myamya disease, familial aldsternism type 1, and artatin f the arta. Risk fatrs fr aneurysm frmatin inlude igarette smking, hypertensin, and female sex. Mst aneurysms are lated n the anterir part f the irle f Willis—partiularly n the anterir r psterir mmuniating arteries, at the bifuratin f the middle erebral artery, and at the bifur- atin f the internal artid artery. Myti aneurysms resulting frm septi emblism ur in mre distal vessels and ften at the rtial surfae. The mst signifiant m- pliatin f intraranial aneurysms is a subarahnid hem- rrhage, whih is disussed in the preeding setin. »Clinical FindingsA.  Symptoms and SignsAneurysms  may ause a fal neurlgi defiit by m- pressing adjaent strutures. Hwever, mst are asymp- tmati r prdue nly nnspeifi symptms until they rupture, at whih time subarahnid hemrrhage results. Its manifestatins, mpliatins, and management were utlined in the preeding setin.B.  ImagingDefinitive evaluatin is  by digital subtratin angigraphy (bilateral artid and vertebral studies), whih generally indiates the size and site f the lesin, smetimes reveals multiple aneurysms, and may shw arterial spasm if rup- ture has urred. Visualizatin by CT r MR angigraphy is nt usually adequate if perative treatment is under nsideratin beause lesins may be multiple and small lesins are smetimes missed, but these mdalities an be used t sreen patients wh have tw r mre first-degree relatives with intraranial aneurysms. »TreatmentThe m ajr aim f treatment is t prevent hemorrhage. Man- agement f ruptured aneurysms was desribed in the setin n subarahnid hemrrhage. Symptmati but unruptured aneurysms merit prmpt treatment, either surgially r by endvasular tehniques. The deisin t treat r mnitr asymptmati aneurysms disvered inidentally is mpli- ated and depends n aneurysm size, latin, risk fatrs fr rupture, and treatment-related mrbidity; risk sres t guide deisin-making are available. »When to ReferAll patients sh uld be referred. »When to Admit• All patients with a subarahnid hemrrhage. •All patients fr detailed imaging. •All patients underging surgial r endvasular treatment.Hak enberg KAM et al. Neurvasular disease, diagnsis, and therapy: brain aneurysms. Handb Clin Neurl. 2021;176:121. [PMID: 33272392]CMDT22_Ch24_p0978-p1053.indd  1002 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1003 CMDT 20226.  arteriovenous MlformtionsE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of subarachnoid and intracerebral hemorrhage. »Distinctive neurologic signs reflect the region of the brain involved. »Signs of meningeal irritation in patients present- ing with subarachnoid hemorrhage. »Seizures or focal deficits may occur. »General ConsiderationsArteriven us malfrmatins are ngenital vasular mal- frmatins that result frm a lalized maldevelpment f part f the primitive vasular plexus and nsist f abnr- mal arterivenus mmuniatins withut intervening apillaries. They vary in size, ranging frm massive lesins that are fed by multiple vessels and invlve a large part f the brain t lesins s small that they are hard t identify at arterigraphy, surgery, r autpsy. In apprximately 10% f ases, there is an assiated arterial aneurysm, while 1–2% f patients presenting with aneurysms have assi- ated arterivenus malfrmatins. Clinial presentatin may relate t hemrrhage frm the malfrmatin r an assiated aneurysm r may relate t erebral ishemia due t diversin f bld by the anmalus arterivenus shunt r due t venus stagnatin. Reginal maldevelp- ment f the brain, mpressin r distrtin f adjaent erebral tissue by enlarged anmalus vessels, and prgres- sive glisis due t mehanial and ishemi fatrs may als be ntributry. »Clinical FindingsMs t erebral arterivenus malfrmatins are supratent- rial, usually lying in the territry f the middle erebral artery. Up t 70% bleed at sme pint in their natural his- try, mst mmnly befre the patient reahes the age f 40 years. Arterivenus malfrmatins that have bled ne are mre likely t bleed again, at an apprximate rate f 4.5% annually. A higher risk f bleeding is als bserved if there is an assiated aneurysm, deep venus drainage, r deep brain latin; size f the malfrmatin and sex are nt assiated with risk f hemrrhage.A.  Symptoms and SignsInitial  symptms nsist f hemrrhage in 30–60% f ases, reurrent seizures in 20–40%, headahe in 5–25%, and misellaneus mplaints (inluding fal defiits) in 10–15%. Hemrrhage is mmnly intraerebral as well as int the subarahnid spae and is fatal in abut 10% f ases. Seizures are mre likely with frntal r parietal arte- rivenus malfrmatins. Headahes are espeially likely when the external artid arteries are invlved in the mal- frmatin. These smetimes simulate migraine, but mremmnly are nnspeifi in harater, with nthing abut them t suggest an underlying strutural lesin. Brainstem and erebellar arterivenus malfrmatins may ause bstrutive hydrephalus. In patients presenting with subarahnid hemrrhage, examinatin may reveal an abnrmal mental status and signs f meningeal irritatin. Additinal findings may help lalize the lesin and smetimes indiate that intraranial pressure is inreased. A ranial bruit always suggests the pssibility f a erebral arterivenus malfrmatin, but bruits may als be fund with aneurysms, meningimas, aquired arterivenus fistulas, and arterivenus malfr- matins invlving the salp, alvarium, r rbit. Bruits are best heard ver the ipsilateral eye r mastid regin and are f sme help in lateralizatin but f n help in lalizatin. Absene f a bruit does not exclude the pssibility f arte- rivenus malfrmatin.B.  ImagingIn patien ts with suspeted hemrrhage, CT sanning indi- ates whether subarahnid r intraerebral bleeding has reently urred, helps lalize its sure, and may reveal the arterivenus malfrmatin. When intraranial hem- rrhage is nfirmed but the sure f hemrrhage is nt evident n the CT san, arterigraphy is neessary t exlude aneurysm r arterivenus malfrmatin. MR and CT angigraphy are nt sensitive enugh fr this purpse. Even if the findings n CT san suggest arterivenus mal- frmatin, arterigraphy is required t establish the nature f the lesin with ertainty and t determine its anatmi features s that treatment an be planned. The examinatin must generally inlude bilateral paifiatin f the inter- nal and external artid arteries and the vertebral arteries. In patients presenting withut hemrrhage, CT san r MRI usually reveals the underlying abnrmality, and MRI frequently als shws evidene f ld r reent hemr- rhage that may have been asymptmati. The nature and detailed anatmy f any fal lesin identified by these means are delineated by angigraphy, espeially if pera- tive treatment is under nsideratin. »TreatmentSurgial  treatment t prevent further hemrrhage is justi- fied in patients with arterivenus malfrmatins that have bled, prvided that the lesin is aessible and the patient has a reasnable life expetany. Surgial treatment is als apprpriate if intraranial pressure is inreased and t prevent further prgressin f a fal neurlgi defiit. In patients presenting slely with seizures, antinvulsant treatment is usually suffiient (Table 24–2), and perative treatment is unneessary unless seizures annt be n- trlled medially. Definitive perative treatment nsists f exisin f the arterivenus malfrmatin if it is surgially aessible. Steretati radisurgery is used t treat inperable ere- bral arterivenus malfrmatins. Arterivenus malfr- matins that are inperable beause f their latin are smetimes treated slely by emblizatin; althugh the risk f hemrrhage is nt redued, neurlgi defiits mayCMDT22_Ch24_p0978-p1053.indd  1003 29/06/21 8:50 PMChapTER 241004 CMDT 2022be  stabilized r even reversed by this predure. Embliza- tin is mre mmnly perfrmed as an adjunt t surgery r radisurgery; it is als used t treat aneurysms assi- ated with the arterivenus malfrmatins. »When to ReferAll patients sh uld be referred. »When to Admit• All patients with a subarahnid r erebral hemrrhage. •All patients fr detailed imaging. •All patients underging surgial r endvasular treatment.Ru tledge C et al. Brain arterivenus malfrmatins. Handb Clin Neurl. 2021;176:171. [PMID: 33272394]7.  Intrcrnil Venous TrombosisIn traranial venus thrmbsis may ur in assiatin with intraranial r maxillfaial infetins, hyperagu- lable states, plyythemia, sikle ell disease, yanti ngenital heart disease, and in pregnany r during the puerperium. Geneti fatrs are als imprtant. The disr- der is haraterized by headahe, fal r generalized n- vulsins, drwsiness, nfusin, inreased intraranial pressure, and fal neurlgi defiits—and smetimes by evidene f meningeal irritatin. The diagnsis is n- firmed by CT r MR vengraphy r angigraphy. Treatment inludes antinvulsants if seizures have urred (Table 24–2) and—if neessary—measures t redue intraranial pressure. Antiagulatin with dse- adjusted intravenus heparin r weight-adjusted subuta- neus lw-mleular-weight heparin, fllwed by ral warfarin antiagulatin fr 6 mnths redues mrbidity and mrtality f venus sinus thrmbsis. Dabigatran shwed similar effiay t warfarin in ne randmized trial and may be an aeptable alternative. Cnmitant intra- ranial hemrrhage related t the venus thrmbsis des nt ntraindiate heparin therapy. In ases refratry t heparin, endvasular tehniques inluding atheter- direted thrmblyti therapy (urkinase) and thrmbe- tmy are smetimes helpful but may inrease the risk fr majr hemrrhage. »When to ReferAll patients sh uld be referred. »When to AdmitAll patients sh uld be hspitalized.Ferr  JM et al; RE-SPECT CVT Study Grup. Safety and effiay f dabigatran etexilate vs dse-adjusted warfarin in patients with erebral venus thrmbsis: a randmized linial trial. JAMA Neurl. 2019;76:1457. [PMID: 31479105]8. Sinl Cord Vsculr DisesesE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of back or limb pain and neurologic deficit in limbs. »Motor, sensory, or reflex changes in limbs depend- ing on level of lesion. »Imaging studies distinguish between infarct and hematoma. »Infarction of the Spinal CordInf artin f the spinal rd is rare. It typially urs in the territry f the anterior spinal artery beause this vessel, whih supplies the anterir tw-thirds f the rd, is itself supplied by nly a limited number f feeders. Infartin usu- ally results frm interrupted flw in ne r mre f these feeders, eg, with arti dissetin, arti aneurysm, artgra- phy, plyarteritis, severe hyptensin, r after surgial repair f the thrai r abdminal arta. The paired psterir spinal arteries, by ntrast, are supplied by numerus arteries at different levels f the rd. Spinal rd hypperfusin may lead t a entral rd syndrme with distal weakness f lwer mtr neurn type and lss f pain and temperature appre- iatin, with preserved psterir lumn funtin. Sine the anterir spinal artery reeives numerus feeders in the ervial regin, infarts almst always ur audally. Clinial presentatin is haraterized by aute nset f flaid, areflexive paraplegia that evlves after a few days r weeks int a spasti paraplegia with extensr plantar respnses. There is an ampanying dissiated sensry lss, with impairment f appreiatin f pain and temperature but pres- ervatin f sensatins f vibratin and jint psitin. The risk f spinal rd infartin in the setting f abdminal arti surgery and thrai endvasular repair may be redued by intraperative erebrspinal fluid drainage thrugh a atheter plaed in the lumbar subarah- nid spae t redue intraspinal pressure. If signs f infar- tin are nted after surgery, bld pressure augmentatin fr 24–48 hurs in additin t lumbar drainage has been nted anedtally t imprve utmes. Treatment is th- erwise symptmati. »Epidural or Subdural HemorrhageEp idural r subdural hemrrhage may lead t sudden severe bak pain fllwed by an aute mpressive myelp- athy neessitating urgent spinal MRI r myelgraphy and surgial evauatin. It may ur in patients with bleeding disrders r thse wh are taking antiagulants, sme- times fllwing trauma r lumbar punture. Epidural hemrrhage may als be related t a vasular malfrmatin r tumr depsit. »Spinal Dural Arteriovenous FistulaeSpi nal dural arterivenus fistulae are ngenital lesins that present with spinal subarahnid hemrrhage rCMDT22_Ch24_p0978-p1053.indd  1004 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1005 CMDT 2022my elradiulpathy. Sine mst f these malfrmatins are lated in the thralumbar regin, they lead t mtr and sensry disturbanes in the legs and t sphinter disrders. Pain in the legs r bak is ften severe. Examinatin reveals an upper, lwer, r mixed mtr defiit in the legs; sensry defiits are als present and are usually extensive, althugh asinally they are nfined t a radiular distributin. Cervial spinal dural arterivenus fistulae lead als t symptms and signs in the arms. Spinal MRI may nt detet the spinal dural arterivenus fistula, althugh mst ases shw either T2 hyperintensity in the rd r perimedullary flw vids. Myelgraphy (perfrmed with the patient prne and supine) may detet serpiginus filling defets due t enlarged vessels. Seletive spinal arterigraphy is required t nfirm the diagnsis and plan treatment. Mst lesins are extramedullary, are psterir t the rd (lying either intradurally r extradurally), and an easily be treated by ligatin f feeding vessels and exisin f the fistulus anmaly r by emblizatin predures. Delay in treatment may lead t inreased and irreversible disability r t death frm reurrent subarahnid hemrrhage. »When to ReferAll patients sh uld be referred. »When to AdmitAll patients sh uld be hspitalized.Gyal A et  al. Outmes fllwing surgial versus endvasular treatment f spinal dural arterivenus fistula: a systemati review and meta-analysis. J Neurl Neursurg Psyhiatry. 2019;90:1139. [PMID: 31142659]IN TRACRANIAL & SPINAL MASS LESIONS 1. primry Intrcrnil TumorsE S S E N T I A L S  O F  D I A G N O S I S »Generalized or focal disturbance of cerebral func- tion, or both. »Increased intracranial pressure in some patients. »Neuroradiologic evidence of space-occupying lesion. »General ConsiderationsRughl y ne-third f all primary intraranial neplasms (Table 24–4) are meningimas, ne-quarter are glimas, and the remainder are pituitary adenmas (see Chapter 26), neurfibrmas, and ther tumrs. Certain tumrs, espe- ially neurfibrmas, hemangiblastmas, and retinblas- tmas, may have a familial basis, and ngenital fatrs bear n the develpment f ranipharyngimas. Tumrs may ur at any age, but ertain glimas shw partiular age prediletins.»Clinical FindingsA.  Symptoms and SignsIn traranial tumrs typially present with headahe, sei- zures, r fal neurlgi defiits. New headahes r symp- tms f elevated intraranial pressure, suh as headahes awaking a patient frm sleep r wrsening with Valsalva maneuver, ugh, r reumbeny, are suggestive f brain tumr. Intraranial tumrs may als lead t a generalized disturbane f erebral funtin with persnality hanges, intelletual deline, emtinal lability, nausea, and malaise. 1. Frontal lobe lesions— Tumrs f the frntal lbe ften lead t prgressive intelletual deline, slwing f mental ativity, persnality hanges, and ntralateral grasp reflexes. They may lead t expressive aphasia if the pste- rir part f the left inferir frntal gyrus is invlved. Ans- mia may als ur as a nsequene f pressure n the lfatry nerve. Preentral lesins may ause fal mtr seizures r ntralateral pyramidal defiits. 2. Temporal lobe lesions— Tumrs f the uninate regin may be manifested by seizures with lfatry r gustatry halluinatins, mtr phenmena suh as liking r smaking f the lips, and sme impairment f external awareness withut atual lss f nsiusness. Tempral lbe lesins als lead t depersnalizatin, emtinal hanges, behaviral disturbanes, sensatins f déjà vu r jamais vu, mirpsia r marpsia (bjets appear smaller r larger than they are), visual field defets (rssed upper quadrantanpia), and auditry illusins r halluinatins. Left-sided lesins may lead t dysnmia and reeptive aphasia, while right-sided invlvement smetimes disturbs the pereptin f musial ntes and meldies. 3. Parietal lobe lesions— Tumrs in this latin hara- teristially ause ntralateral disturbanes f sensatin and may ause sensry seizures, sensry lss r inatten- tin, r sme mbinatin f these symptms. The sensry lss is rtial in type and invlves pstural sensibility and tatile disriminatin, s that the appreiatin f shape, size, weight, and texture is impaired. Objets plaed in the hand may nt be regnized (asteregnsis). Extensive parietal lbe lesins may prdue ntralateral hyper- pathia and spntaneus pain (thalami syndrme). Invlvement f the pti radiatin leads t a ntralateral hmnymus field defet that smetimes nsists slely f lwer quadrantanpia. Lesins f the left angular gyrus ause Gerstmann syndrome (a mbinatin f alexia, agraphia, aalulia, right-left nfusin, and finger agn- sia), whereas invlvement f the left submarginal gyrus auses ideatinal apraxia. Ansgnsia (the denial, neglet, r rejetin f a paralyzed limb) is seen in patients with lesins f the nndminant (right) hemisphere. Cnstru- tinal apraxia and dressing apraxia may als ur with right-sided lesins. 4. Occipital lobe lesions— Tumrs f the ipital lbe harateristially prdue ntralateral hmnymus hemianpia r a partial field defet. With left-sided r bilateral lesins, there may be visual agnsia bth fr bjets and fr lrs, while irritative lesins n either sideCMDT22_Ch24_p0978-p1053.indd  1005 29/06/21 8:50 PMChapTER 241006 CMDT 2022T able 24–4. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Tumors of Meninges Meningioma Originates from the dura mater or arachnoid; compresses rather than invades adjacent neural structures. Increasingly common with advancing age. Tumor size varies greatly. Symptoms vary with tumor site—eg, unilateral proptosis (sphenoidal ridge); anosmia and optic nerve compression (olfactory groove). Tumor is usually benign and readily detected by CT scanning; may lead to calcification and bone erosion visible on plain radiographs of skull.Treatment is surgical. Tumor may recur if removal is incomplete. Tumors of Neuroeitelil Origin Glioblastoma multiformePresents commonly with nonspecific complaints and increased intracranial pressure. As it grows, focal deficits develop. O6-methylguanine-DNA methyltransferase pro- moter methylation positivity (seen in 40% of cases) and iso- citrate dehydrogenase 1/2 mutations (seen in 10% of cases) carry better prognosis.Course is rapidly progressive, with poor prognosis (< 20% survival at 2 years). Total surgical removal is usually not possible. Radiation therapy and temozolamide may prolong survival. Tumor treatment fields added to temozolamide after completion of radiation therapy prolong survival. Astrocytoma Presentation similar to glioblastoma multiforme but course more protracted, often over several years. Cerebellar astro- cytoma may have a more benign course. Isocitrate dehy- drogenase 1/2 mutations (seen in a majority of cases) carry better prognosis in grade II and III tumors.Prognosis is variable. By the time of diagnosis, total excision is usually impossible; tumor may be radio- sensitive and temozolamide is also helpful in grade II and III tumors. In cerebellar astrocytoma, total surgical removal is often possible. Ependymoma Glioma arising from the ependyma of a ventricle, especially the fourth ventricle; leads to early signs of increased intra- cranial pressure. Arises also from central canal of cord.Tumor is best treated surgically if possible. Radiation therapy may be used for residual tumor. Oligodendroglioma Slow-growing. Usually arises in cerebral hemisphere in adults. Calcification may be visible on skull radiograph. Co-deletion of 1p/19q and isocitrate dehydrogenase 1/2 mutation required for diagnosis.Treatment is surgical and usually successful. Radiation and chemotherapy (temozolamide or procarbazine, lomustine, and vincristine) are used in grade II and III tumors. Brainstem glioma Presents during childhood with cranial nerve palsies and then with long tract signs in the limbs. Signs of increased intra- cranial pressure occur late.Tumor is inoperable; treatment is by irradiation and shunt for increased intracranial pressure. Neuronal and mixed neuronal-glial tumorsSlow-growing; usually arise in cerebral hemispheres; often associated with seizures. Some are benign (eg, dysembryo- blastic neuroepithelial tumors) and some have malignant potential (eg, ganglioglioma).Resection is not always necessary for benign tumors unless seizures are medically refractory, but is indi- cated for those with malignant potential. Medulloblastoma Seen most frequently in children. Generally arises from roof of fourth ventricle and leads to increased intracranial pressure accompanied by brainstem and cerebellar signs. May seed subarachnoid space. Wingless activated tumors carry best prognosis (> 90% 5-year survival).Treatment consists of surgery combined with radia- tion therapy and chemotherapy; 5-year survival exceeds 70%. Wingless activated tumors may require less aggressive treatment. Pineal tumor Presents with increased intracranial pressure, sometimes asso- ciated with impaired upward gaze (Parinaud syndrome) and other deficits indicative of midbrain lesion.Ventricular decompression by shunting is followed by surgical approach to tumor; irradiation is indicated if tumor is malignant. Prognosis depends on histo- pathologic findings and extent of tumor. Tumors of te Sellr Region Pituitary adenoma Functioning adenomas present with symptoms of hormone secretion; nonfunctioning adenomas present with symp- toms of local mass effect (eg, bitemporal hemianopsia, hypopituitarism) or are found incidentally.Prolactin-secreting adenomas are treated with bro- mocriptine or cabergoline. Others are surgically resected. Pituitary hormone replacement may be required. Craniopharyngioma Originates from remnants of Rathke pouch above the sella, depressing the optic chiasm. May present at any age but usually in childhood, with endocrine dysfunction and bitemporal visual field defects.Treatment is surgical, but total removal may not be possible. Radiation may be used for residual tumor. (continued )CMDT22_Ch24_p0978-p1053.indd  1006 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1007 CMDT 2022an ause unfrmed visual halluinatin s. Bilateral ipi- tal lbe invlvement auses rtial blindness in whih there is preservatin f pupillary respnses t light and lak f awareness f the defet by the patient. There may als be lss f lr pereptin, prspagnsia (inability t identify a familiar fae), simultagnsia (inability t inte- grate and interpret a mpsite sene as ppsed t its individual elements), and Balint syndrme (failure t turn the eyes t a partiular pint in spae, despite preservatin f spntaneus and reflex eye mvements). The denial f blindness r a field defet nstitutes Antn syndrme. 5. Brainstem and cerebellar lesions— Brainstem lesins lead t ranial nerve palsies, ataxia, inrdinatin, nystag- mus, and pyramidal and sensry defiits in the limbs n ne r bth sides. Intrinsi brainstem tumrs, suh as gli- mas, tend t prdue an inrease in intraranial pressure nly late in their urse. Cerebellar tumrs prdue marked ataxia f the trunk if the vermis erebelli is invlved and ipsilateral appendiular defiits (ataxia, in- rdinatin, and hyptnia f the limbs) if the erebellar hemispheres are affeted. 6. Herniation syndromes— If the pressure is inreased in a partiular ranial mpartment, brain tissue may herniate int a mpartment with lwer pressure. The mst familiar syndrme is herniatin f the tempral lbe unus thrugh the tentrial hiatus, whih auses mpressin f the third ranial nerve, midbrain, and psterir erebral artery. The earliest sign f this is ipsilateral pupillary dilatin, fllwed by stupr, ma, deerebrate psturing, and respiratry arrest. Anther imprtant herniatin syndrme nsists fdisplaement f the erebellar tnsils thrugh the framen magnum, whih auses medullary mpressin leading t apnea, irulatry llapse, and death. 7. False localizing signs— Tumrs may lead t neurlgi signs ther than by diret mpressin r infiltratin, thereby leading t errrs f linial lalizatin. These false lalizing signs inlude third r sixth nerve palsy and bilat- eral extensr plantar respnses prdued by herniatin syndrmes, and an extensr plantar respnse urring ipsilateral t a hemispheri tumr as a result f mpressin f the ppsite erebral pedunle against the tentrium.B.  ImagingMRI  with gadlinium enhanement is the preferred methd t detet the lesin and t define its latin, shape, and size; the extent t whih nrmal anatmy is distrted; and the degree f any assiated erebral edema r mass effet. CT sanning with radintrast enhanement uld be perfrmed; hwever, it is less helpful than MRI fr small lesins r tumrs in the psterir fssa. The harateristi appearane f meningimas n MRI r CT sanning is virtually diagnsti, ie, a lesin in a typial site (parasagittal and sylvian regins, lfatry grve, sphenidal ridge, tuberulum sellae) that appears as a hmgeneus area f inreased density in nnntrast sans and enhanes uni- frmly with ntrast. Additinal MRI sequenes that may be helpful in differentiating glimas frm ther intraranial pathlgy inlude perfusin imaging, magneti resnane spetrspy, and diffusin-weighted imaging, althugh nne are speifi enugh t bviate the need fr tissueTable 24–4. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Germ cell tumors (germinomas and nongerminoma- tous germ cell tumors)Two most common locations are pineal and suprasellar regions. The pineal region presentation is as described in pineal tumors, above. Suprasellar tumors present with hypothalamic and pituitary dysfunction such as diabetes insipidus, delayed or precocious puberty, or growth hor- mone deficiency.Germinomas are treated with radiation; prognosis is good for localized tumors. Chemotherapy is added for nongerminomatous germ cell tumors. Tumors of Crnil nd Sinl Nerves Acoustic neurinoma (also referred to as acoustic neuroma)Ipsilateral hearing loss is most common initial symptom. Sub- sequent symptoms may include tinnitus, headache, vertigo, facial weakness or numbness, and long tract signs. (May be familial and bilateral when related to neurofibromatosis.) Most sensitive screening tests are MRI and brainstem audi- tory evoked potential.Treatment is excision by translabyrinthine surgery, craniectomy, or a combined approach. Outcome is usually good. Lymoms Primary cerebral lymphomaAssociated with AIDS and other immunodeficient states. Pre- sentation may be with focal deficits or with disturbances of cognition and consciousness. May be indistinguishable from cerebral toxoplasmosis.Treatment is high-dose methotrexate and corticoste- roids followed by radiation therapy. Prognosis depends on CD4 count at diagnosis. Unclssified Cerebellar hemangioblas- tomaPresents with dysequilibrium, ataxia of trunk or limbs, and signs of increased intracranial pressure. Sometimes familial. May be associated with retinal and spinal vascular lesions, polycythemia, and renal cell carcinoma.Treatment is surgical. Radiation is used for residual tumor.(continued)CMDT22_Ch24_p0978-p1053.indd  1007 29/06/21 8:50 PMChapTER 241008 CMDT 2022samp ling. Arterigraphy is largely reserved fr presurgial emblizatin f highly vasular tumrs. In patients with nrmal hrmne levels and an intrasellar mass, angigra- phy is smetimes neessary t distinguish with nfidene between a pituitary adenma and an arterial aneurysm.C.  Laboratory and Other StudiesWhen  glial neplasms are suspeted, bipsy is neessary fr definitive histlgi diagnsis and mleular analysis. The Wrld Health Organizatin lassifies glial tumrs by bth histlgy and geneti harateristis. Lumbar pun- ture is rarely neessary; the findings are seldm diagnsti, and the predure arries the risk f ausing a herniatin syndrme. Suspeted intraranial germ ell tumrs are an exeptin. If lumbar punture an be perfrmed safely, ytlgy and determinatin f alpha-fetprtein and beta- human hrini gnadtrpin shuld be perfrmed in erebrspinal fluid; tumr markers shuld be examined in serum as well. »TreatmentT reatment depends n the type and site f the tumr (Table 24–4) and the nditin f the patient. Sme benign tumrs, espeially meningimas disvered inidentally during brain imaging fr anther purpse, may be mni- tred with serial annual imaging. Fr symptmati tumrs, mplete surgial remval may be pssible if the tumr is extra-axial (eg, meningima, austi neurma) r is nt in a ritial r inaessible regin f the brain (eg, erebel- lar hemangiblastma). Surgery als permits the diagnsis t be verified and may be benefiial in reduing intrara- nial pressure and relieving symptms even if the neplasm annt be mpletely remved. Clinial defiits are sme- times due in part t bstrutive hydrephalus, in whih ase simple surgial shunting predures ften prdue dramati benefit. In patients with malignant glimas, sur- vival rrelates t the extent f initial resetin. Radiatin therapy inreases median survival rates regardless f any preeding surgery, and its mbinatin with hemtherapy prvides additinal benefit. India- tins fr irradiatin in the treatment f patients with ther primary intraranial neplasms depend n tumr type and aessibility and the feasibility f mplete surgial remval. Lng-term neurgnitive defiits may mpliate radia- tin therapy. Temzlmide is a mmnly used ral and intravenus hemtherapeuti fr glimas. In patients with gliblastma with methylated methylguanine-DNA meth- yltransferase (MGMT) prmter, mbinatin therapy with lmustine and temzlmide imprved median survival frm 31 t 48 mnths in a randmized ntrlled trial. The additin f lw-intensity, 200 kHz frequeny alternating eletri fields (tumr treatment fields) delivered extrarani- ally at least 18 hurs daily, imprves prgressin-free sur- vival by 2.7 mnths and median survival by 4.9 mnths mpared t temzlmide alne in gliblastma. Bevai- zumab is apprved in the United States but nt in Eurpe fr use in reurrent high-grade glima. Cmbinatin therapy with prarbazine, lmustine, and vinristine imprves median survival when given with radiatin tpatients with isitrate dehydrgenase–mutant astry- tma and isitrate dehydrgenase–mutant, p1/19q - deleted ligdendrglima. Crtisterids help redue erebral edema and are usu- ally started befre surgery. Herniatin is treated with intra- venus dexamethasne (10–20 mg as a blus, fllwed by 4 mg every 6 hurs) and intravenus mannitl (20% slutin given in a dse f 1.5 g/kg ver abut 30 minutes). Antinvulsants are als mmnly administered in standard dses (see Table 24–2), but are nt indiated fr prphylaxis in patients wh have n histry f seizures. Fr thse patients with diffiult t treat symptms r thse needing help with advane are planning, speialty pallia- tive are nsultatin is apprpriate (see Chapter 5). »When to ReferAll patients sh uld be referred. »When to Admit• All patients with inreased intraranial pressure. •All patients requiring bipsy, surgial treatment, r shunting predures.Bell  EH et al. Cmprehensive genmi analysis in NRG nl- gy/RTOG 9802: a phase III trial f radiatin versus radiatin plus prarbazine, lmustine (CCNU), and vinristine in high-risk lw-grade glima. J Clin Onl. 2020;38:3407. [PMID: 32706640] Desjardins A et al. Reurrent gliblastma treated with rembi- nant plivirus. N Engl J Med. 2018;379:150. [PMID: 29943666] Herrlinger U et al; Neurnlgy Wrking Grup f the German Caner Siety. Lmustine-temzlmide mbinatin therapy versus standard temzlmide therapy in patients with newly diagnsed gliblastma with methylated MGMT prmter (CeTeG/NOA-09): a randmised, pen-label, phase 3 trial. Lanet. 2019;393:678. [PMID: 30782343]2.  Metsttic Intrcrnil TumorsA.  Cerebral MetastasesMetasta ti brain tumrs present in the same way as ther erebral neplasms, ie, with inreased intraranial pres- sure, with fal r diffuse disturbane f erebral funtin, r with bth f these manifestatins. Indeed, in patients with a single erebral lesin, the metastati nature f the lesin may beme evident nly n histpathlgi exami- natin. In ther patients, there is evidene f widespread metastati disease, r an islated erebral metastasis devel- ps during treatment f the primary neplasm. The most common source of intracranial metastasis is carcinoma of the lung; ther primary sites are the breast, kidney, skin (melanma), and gastrintestinal trat. Mst erebral metastases are lated supratentrially. Labratry and radilgi studies used t evaluate patients with metastases are thse desribed fr primary neplasms. They inlude MRI and CT sanning perfrmed bth with and withut ntrast. Lumbar punture is neessary nly in patients with suspeted arinmatus meningitis. In patients with verified erebral metastasis frm an unknwnCMDT22_Ch24_p0978-p1053.indd  1008 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1009 CMDT 2022primary , investigatin is guided by symptms and signs. In wmen, mammgraphy is indiated; in men under 50, germ ell rigin is sught. Treatment f brain metastases is rapidly evlving and a multidisiplinary apprah between neursurgery, radia- tin nlgy, and nlgy is neessary. In patients with nly a single, surgially aessible erebral metastasis wh are therwise well (ie, a high level f funtining and little r n evidene f extraranial disease), it may be pssible t remve the lesin and then treat with irradiatin; the latter may als be seleted as the sle treatment. Systemi immuntherapy may als be an aeptable initial ptin in selet ases. In patients with multiple metastases r wide- spread systemi disease, steretati radisurgery, whle- brain raditherapy, r bth may help in sme instanes; systemi hemtherapy r immuntherapy may be ptins in thers, but in many, treatment is palliative nly.Fuen tes R et al. Surgery versus steretati raditherapy fr peple with single r slitary brain metastasis. Chrane Database Syst Rev. 2018;8:CD012086. [PMID: 30125049] Tsa MN et al. Whle brain raditherapy fr the treatment f newly diagnsed multiple brain metastases. Chrane Data- base Syst Rev. 2018;1:CD003869. [PMID: 29365347]B.  Leptomeningeal Metastases Carcinomatous MeningitisThe  neoplasms metastasizing most commonly to the lepto- meninges are carcinoma of the breast and lung, lymphomas, and leukemia (see Chapter 39). Leptmeningeal metastases lead t multifal neurlgi defiits, whih may be assi- ated with infiltratin f ranial and spinal nerve rts, diret invasin f the brain r spinal rd, bstrutive r mmuniating hydrephalus, r sme mbinatin f these fatrs. The diagnsis is nfirmed by examinatin f the ere- brspinal fluid. Findings may inlude elevated erebr- spinal fluid pressure, pleytsis, inreased prtein nentratin, and dereased gluse nentratin. Cyt- lgi studies may indiate that malignant ells are present; if nt, lumbar punture shuld be repeated at least twie t btain further samples fr analysis. CT sans shwing ntrast enhanement in the basal isterns r shwing hydrephalus withut any evidene f a mass lesin supprt the diagnsis. Gadlinium-enhaned MRI is mre sensitive and frequently shws enhaning fi in the leptmeninges. Myelgraphy may shw depsits n multiple nerve rts. Treatment is by irradiatin t symptmati areas, m- bined with intratheal hemtherapy in selet patients. The lng-term prgnsis is pr—nly abut 10% f patients survive fr 1 year—and palliative are is therefre impr- tant (see Chapter 5).3.  Intrcrnil Mss Lesions in ptients wit aIDSPrimary  cerebral lymphoma is a mmn mpliatin in patients with AIDS. This leads t disturbanes in gni- tin r nsiusness, fal mtr r sensry defiits,aphasia, seizures, and ranial neurpathies. Similar linial disturbanes may result frm cerebral toxoplasmosis , whih is als a mmn mpliatin in patients with AIDS (see Chapters 31 and 35). Neither CT nr MRI find- ings distinguish these tw disrders and serlgi tests fr txplasmsis are unreliable in AIDS patients. Toxoplasma gondii DNA deteted by plymerase hain reatin in the spinal fluid is speifi but nt sensitive fr txplasmsis, and the finding f Epstein-Barr virus DNA suggests lym- phma but is nt speifi enugh t initiate treatment. Ardingly, fr neurlgially stable patients, a trial f treatment fr txplasmsis with pyrimethamine and sul- fadiazine is remmended fr 3 weeks; the imaging studies are then repeated, and if any lesin has imprved, the regi- men is ntinued indefinitely. If any lesin des nt imprve, erebral bipsy is neessary (see als Chapter 31). Primary erebral lymphma in patients with AIDS is treated with rtisterids, high-dse methtrexate, and antiretrviral therapy. Rituximab may be used in sme patients. Whle-brain irradiatin may nt be neessary. Cryptococcal meningitis is a mmn pprtunisti infetin in patients with AIDS. Clinially, it may resemble erebral txplasmsis r lymphma, but ranial CT sans are usually nrmal (see Chapter 36).4.  primry & Metsttic Sinl TumorsA pprximately 10% f spinal tumrs are intramedullary. Ependymma is the mst mmn type f intramedullary tumr; the remainder are ther types f glima. Extramed- ullary tumrs may be extradural r intradural in latin. Amng the primary extramedullary tumrs, neurfibr- mas and meningimas are relatively mmn, benign, and may be intradural r extradural. Carinmatus metasta- ses, lymphmatus r leukemi depsits, and myelma are usually extradural; in the ase f metastases, the prstate, breast, lung, and kidney are mmn primary sites. Tumrs may lead t spinal rd dysfuntin by diret mpressin, by ishemia sendary t arterial r venus bstrutin and, in the ase f intramedullary lesins, by invasive infiltratin. »Clinical FindingsA.  Symptoms and SignsSymp tms usually develp insidiusly. Pain is ften n- spiuus with extradural lesins; is harateristially aggravated by ughing r straining; may be radiular, lalized t the bak, r felt diffusely in an extremity; and may be ampanied by mtr defiits, paresthesias, r numbness, espeially in the legs. Bladder, bwel, and sexual dysfuntin may ur. When sphinter disturbanes ur, they are usually partiularly disabling. Pain, hw- ever, ften preedes speifi neurlgi symptms frm epidural metastases. Examinatin may reveal lalized spinal tenderness. A segmental lwer mtr neurn defiit r dermatmal sen- sry hanges (r bth) are smetimes fund at the level f the lesin, while an upper mtr neurn defiit and sen- sry disturbane are fund belw it.CMDT22_Ch24_p0978-p1053.indd  1009 29/06/21 8:50 PMChapTER 241010 CMDT 2022B.  ImagingMRI  with ntrast r CT myelgraphy is used t identify and lalize the lesin. The mbinatin f knwn tumr elsewhere in the bdy, bak pain, and either abnrmal plain films f the spine r neurlgi signs f rd m- pressin is an indiatin t perfrm this n an urgent basis.C.  Laboratory FindingsThe  erebrspinal fluid is ften xanthhrmi and n- tains a greatly inreased prtein nentratin with nrmal ell ntent and gluse nentratin. »TreatmentIn tramedullary tumrs are treated by dempressin and surgial exisin (when feasible) and by irradiatin. The prgnsis depends n the ause and severity f rd m- pressin befre it is relieved. Treatment f epidural spinal metastases nsists f surgial dempressin, radiatin, r bth. Dexametha- sne is als given in a high dsage (eg, 10–96 mg ne intravenusly, fllwed by 4–25 mg fur times daily fr 3 days rally r intravenusly, fllwed by rapid tapering f the dsage, depending n initial dse and respnse) t redue rd swelling and relieve pain. Radiatin alne is ften all that is required in patients with radisensitive tumrs. Surgial dempressin is reserved fr patients with tumrs that are unrespnsive t irradiatin r wh have previusly been irradiated, fr thse with spinal instability, and fr patients in whm there is sme uner- tainty abut the diagnsis. The lng-term utlk is pr, but treatment may at least delay the nset f majr disability.Lawtn  AJ et al. Assessment and management f patients with metastati spinal rd mpressin: a multidisiplinary review. J Clin Onl. 2019;37:61. [PMID: 30395488]5.  Brin abscessE S S E N T I A L S  O F  D I A G N O S I S »Signs of expanding intracranial mass. »Signs of primary infection or congenital heart dis- ease are sometimes present. »Fever may be absent. »General ConsiderationsBrain  absess presents as an intraranial spae-upying lesin and arises as a sequela f disease f the ear r nse, may be a mpliatin f infetin elsewhere in the bdy, r may result frm infetin intrdued intraranially by trauma r surgial predures. The mst mmn infe- tive rganisms are strepti, staphyli, and anaer- bes; mixed infetins als ur.»Clinical FindingsA.  Symptoms and SignsHeadahe,  drwsiness, inattentin, nfusin, and seizures are early symptms, fllwed by signs f inreasing intra- ranial pressure and then a fal neurlgi defiit. There may be little r n systemi evidene f infetin.B.  Imaging and Other InvestigationsA  CT san f the head harateristially shws an area f ntrast enhanement surrunding a lw-density re. Similar abnrmalities may be fund in patients with meta- stati neplasms. MRI findings ften permit earlier reg- nitin f fal erebritis r an absess. Steretati needle aspiratin may enable a speifi etilgi rganism t be identified. Examinatin f the erebrspinal fluid des nt help in diagnsis and may preipitate a herniatin syn- drme. Peripheral leukytsis is smetimes present. »TreatmentT reatment nsists f intravenus antibitis mbined with surgial drainage (aspiratin r exisin), if neessary, t redue the mass effet r smetimes t establish the diagnsis. Absesses smaller than 2 m an ften be ured medially. Brad-spetrum antibitis, seleted based n risk fatrs and likely rganisms, are used if the infeting rganism is unknwn (see Chapter 33). An initial empiri multi-antibiti regimen typially inludes eftriaxne (2 g intravenusly every 12 hurs), metrnidazle (15 mg/kg intravenus lading dse, fllwed by 7.5 mg/kg intrave- nusly every 6 hurs), and vanmyin (1 g intravenusly every 12 hurs). The regimen is altered ne ulture and sensitivity data are available. Antimirbial treatment is usually ntinued parenterally fr 6–8 weeks and is fl- lwed by ral treatment fr ertain infetins, suh as nardisis, atinmysis, fungal infetins, and tuberu- lsis. The patient shuld be mnitred by serial CT sans r MRI every 2 weeks and at deteriratin. Dexametha- sne (4–25 mg fur times daily intravenusly r rally, depending n severity, fllwed by tapering f dse, depending n respnse) may redue any assiated edema, but intravenus mannitl is smetimes required.Chw  F. Brain and spinal epidural absess. Cntinuum (Min- neap Minn). 2018;24:1327. [PMID: 30273242]NO NMETASTATIC NEUROLOGIC COMPLICATIONS OF MALIGNANT DISEASEA  variety f nnmetastati neurlgi mpliatins f malignant disease an be regnized. Metabolic encepha- lopathy due t eletrlyte abnrmalities, infetins, drug verdse, r the failure f sme vital rgan may be refleted by drwsiness, lethargy, restlessness, insmnia, agitatin, nfusin, stupr, r ma. The mental hanges are usually assiated with tremr, asterixis, and multifal mylnus. The eletrenephalgram is generally diffusely slwed. Labratry studies are neessary t detet the ause f the enephalpathy, whih must then be treated apprpriately.CMDT22_Ch24_p0978-p1053.indd  1010 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1011 CMDT 2022Im mune suppression resulting frm either the malig- nant disease r its treatment (eg, by hemtherapy) predis- pses patients t brain absess, prgressive multifal leukenephalpathy, meningitis, herpes zster infetin, and ther pprtunisti infetius diseases. Mrever, an vert r ult erebrspinal fluid fistula, as urs with sme tumrs, may als inrease the risk f infetin. MRI r CT sanning aids in the early regnitin f a brain absess, but metastati brain tumrs may have a similar appearane. Examinatin f the erebrspinal fluid is essential in the evaluatin f patients with meningitis and enephalitis but is f n help in the diagnsis f brain absess. Cerebrovascular disorders that ause neurlgi m- pliatins in patients with systemi aner inlude nnbate- rial thrmbti endarditis and septi emblizatin. Cerebral, subarahnid, r subdural hemrrhages may ur in patients with myelgenus leukemia and may be fund in assiatin with metastati tumrs, espeially melanma. Spinal subdural hemrrhage smetimes urs after lumbar punture in patients with marked thrmbytpenia. Disseminated intravascular coagulation urs mst mmnly in patients with aute prmyelyti leukemia r with sme adenarinmas and is haraterized by a flutuating enephalpathy, ften with assiated seizures, that frequently prgresses t ma r death. There may be few ampanying neurlgi signs. Venous sinus throm- bosis, whih usually presents with nvulsins and head- ahes, may als ur in patients with leukemia r lymphma. Examinatin mmnly reveals papilledema and fal r diffuse neurlgi signs. Antinvulsants, antiagulants, and mediatins t lwer the intraranial pressure may be f value. Autoimmune paraneoplastic disorders ur when the immune system reats against neurnal antigens expressed by tumr ells. The linial manifestatins depend n the autantibdy. Symptms may preede thse due t the neplasm itself. Several distint syndrmes are mmn, eah assiated with speifi antibdies and tumrs (Table 24–5). Identifiatin f an antibdy is nt always pssible in a suspeted autimmune paraneplasti nditin, and a searh fr an underlying neplasm shuld be undertaken. Treatment f the neplasm ffers the best hpe fr stabilizatin r imprvement f the neurlgi symptms, whih ften are nt mpletely reversible. Spe- ifi treatment f the antibdy-mediated symptms by intravenus immunglbulin (IVIG) administratin, plas- mapheresis, rtisterids, r ther immunsuppressive regimens is frequently attempted despite limited evidene f effiay. Many f the disrders listed in Table 24–5 an ur either as paraneplasti phenmena r in islatin; when they ur in the absene f a tumr, the respnse t immuntherapy is typially mre favrable. Autimmune disrders may als be triggered as a result f aner immuntherapy; enephalitis, meningitis, trans- verse myelitis, aute and hrni inflammatry demyelin- ating plyneurpathy, autnmi neurpathy, myasthenia gravis, and mysitis have all been desribed.Rsenfeld MR et al. P araneplasti neurlgi syndrmes. Neu- rl Clin. 2018;36:675. [PMID: 30072076]IDIOPATHIC INTRACRANIAL HYPERTENSION (Pseudotumor Cerebri)E S S E N T I A L S  O F  D I A G N O S I S »Headache, worse on straining. »Visual obscurations or diplopia may occur. »Examination reveals papilledema. »Abducens palsy is commonly present. »General ConsiderationsThere are man y auses f this disrder. Thrmbsis f the transverse venus sinus as a mpliatin f titis media r hrni mastiditis is ne ause, and sagittal sinus thrm- bsis may lead t a linially similar piture. Other auses inlude hrni pulmnary disease, systemi lupus erythe- matsus, uremia, endrine disturbanes suh as hyp- parathyridism, hypthyridism, r Addisn disease, vitamin A txiity, and the use f tetrayline r ral n- traeptives. Cases have als fllwed withdrawal f rti- sterids after lng-term use. In mst instanes, hwever, n speifi ause an be fund, and the disrder remits spntaneusly after several mnths. This idipathi variety urs mst mmnly amng verweight wmen aged 20–44. In all ases, sreening fr a spae-upying lesin f the brain is imprtant. »Clinical FindingsA.  Symptoms and SignsSymp tms nsist f headahe, diplpia, and ther visual disturbanes due t papilledema and abduens nerve dys- funtin. Pulse-synhrnus tinnitus may als ur. Examinatin reveals papilledema and sme enlargement f the blind spts, but patients therwise lk well.B.  ImagingIn vestigatins reveal n evidene f a spae-upying lesin. CT r MRI shws small r nrmal ventriles and an empty sella turia. MR vengraphy is imprtant in sreen- ing fr thrmbsis f the intraranial venus sinuses. In sme ases, stensis f ne r mre f the venus sinuses will be bserved.C.  Laboratory FindingsLum bar punture is neessary t nfirm the presene f intraranial hypertensin, but the erebrspinal fluid is nrmal. Labratry studies help exlude sme f the ther auses mentined earlier. »TreatmentU ntreated intraranial hypertensin smetimes leads t sendary pti atrphy and permanent visual lss. Aet- azlamide (250–500 mg rally three times daily, inreasing slwly t a maintenane dse f up t 4000 mg daily,CMDT22_Ch24_p0978-p1053.indd  1011 29/06/21 8:50 PMChapTER 241012 CMDT 2022T able 245. Autoimmune paraneoplastic disorders and their associated antibodies and tumors (listed in alphabetical order).Syndrome Clinicl Fetures associted antibodies Tyicl associted Tumors Anti-NMDA receptor– associated encephalitisParanoia, delusions, behavioral disturbance, seizure, orofacial dyskinesias, athetosis, dysau- tonomia, hypoventilationNMDA receptor1Ovarian teratoma, lung, breast, ovary, testicle Autoimmune necrotizing myopathyWeakness SRP ,1HMGCR1Lung, breast, gastrointestinal, bladder Autonomic neuropathy Postural hypotension, gastroparesisHu, ganglionic AChR1 Cerebellar degeneration Ataxia, dysarthria, nystagmus GAD65,1KLHL11, mGluR1,1NIF,1Ri, Tr, VGCC,1YoLung, breast, thymus, ovary, testicle, Hodgkin lymphoma Dermatomyositis Weakness, heliotrope skin rash TIF-1 gamma Lung, breast, ovary, gastrointes- tinal, lymphoma Lambert-Eaton myasthenic syndromeFatiguable weakness, ptosis, dip- lopia, dry mouth, constipationVGCC1Lung Limbic encephalitis/ encephalomyelitisShort-term memory loss, halluci- nations, seizures, behavioral disturbance, encephalopathyAMPA receptor,1Caspr2,1CV2/CRMP5, DPPX,1GABAAreceptor,1GABAB receptor,1GAD65,1GFAP ,1Hu, LGI1,1 Ma2, mGluR5,1NIF,1thyroglobulin1/ thyroperoxidase1Lung, breast, thymus, ovary, testicle, Hodgkin lymphoma Myasthenia gravis Fatiguable weakness, ptosis, diplopiaAChR,1LRP4,1MuSK1Thymus Myelitis Paraparesis, bowel and bladder dysfunction; sensory levelAmphiphysin,1aquaporin 4,1CRMP-5, GFAP ,1Hu, MOG,1YoLung, breast, lymphoma, leukemia, thyroid, renal Opsoclonus/myoclonus Erratic, conjugate saccadic eye movements and limb myoclonusRi Lung, breast, ovary, testicle, neuroblastoma (children) Retinopathy Vision loss Anti-recoverin, anti-retinal bipolar cell Small cell lung, melanoma Sensorimotor neuropathy Numbness with or without weak- ness; may be mild and chronic or acute and severeHu, MAG Sensory neuronopathy Pain, numbness, sensory ataxia, hearing lossHu Small cell lung Stiff person syndrome Co-contraction of antagonist and agonist musclesAmphiphysin,1GAD65,1GlyR1Small cell lung, breast, thymus, lymphoma1 Can occur in absence of tumor. AChR, acetylcholine receptor; AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; Caspr2, contactin associated prot ein-like 2; CRMP , collapsin response-mediator protein; DPPX, dipeptidyl-peptidase-like protein-6; GABA, gamma-aminobutyric acid; GAD, gl utamic acid decarboxylase; GFAP , glial fibrillary acidic protein; GlyR, glycine receptor; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; KLHL11, kelch-like protein 11; LGI1, leucine rich glioma inactivated; LRP4, low-density lipoprotein receptor-related protein 4; mGluR, metabotropic glutamate receptor; MAG, myelin-associated glycoprotein; MOG, myelin oligodendrocyte glycoprotein; MuSK, Muscle- specific tyrosine kinase; NIF, neuronal intermediate filament; NMDA, N-methyl-D-aspartate; SRP , signal recognition particle; TI F-1, human transcription intermediary factor-1; VGCC, voltage-gated calcium channel.divided tw  t fur times daily) redues frmatin f ere- brspinal fluid. Like aetazlamide, the antiepilepti medi- atin tpiramate (Table 24–2) is a arbni anhydrase inhibitr and was shwn t be similarly effetive in an pen label study; tpiramate has the added benefit f aus- ing weight lss. Fursemide (20–40 mg daily) may be help- ful as adjunt therapy. Crtisterids (eg, prednisne 60–80 mg daily) are smetimes presribed, but side effets and the risk f relapse n withdrawal have disuragedtheir use. Obese patients shuld be advised t lse weight. Repeated lumbar punture t lwer the intraranial pres- sure by remval f erebrspinal fluid is effetive as a temprizing measure, but pharmalgi apprahes t treatment prvide better lng-term relief. Treatment is mnitred by heking visual auity and visual fields, fun- duspi appearane, and pressure f the erebrspinal fluid. The disrder may wrsen after a perid f stability, indiating the need fr lng-term fllw-up.CMDT22_Ch24_p0978-p1053.indd  1012 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1013 CMDT 2022If  medial treatment fails t ntrl the intraranial pressure, surgial plaement f a lumbperitneal r ven- triulperitneal shunt r pti nerve sheath fenestratin shuld be undertaken t preserve visin. Venus sinus stenting is an inreasingly aepted therapeuti ptin fr dural venus sinus stensis. In additin t the abve measures, any speifi ause f intraranial hypertensin requires apprpriate treatment. Thus, hrmne therapy shuld be initiated if there is an underlying endrine disturbane. Disntinuing the use f tetrayline, ral ntraeptives, r vitamin A will allw fr reslutin f intraranial hypertensin due t these agents. If rtisterid withdrawal is respnsible, the mediatin shuld be reintrdued and then tapered mre gradually. »When to ReferAll patients sh uld be referred. »When to AdmitAll  patients with wrsening visin requiring shunt plae- ment r pti nerve sheath fenestratin shuld be hspitalized.Kalyvas  A et al. A systemati review f surgial treatments f idipathi intraranial hypertensin (IIH). Neursurg Rev. 2021;44:773. [PMID: 32335853] Madriz Peralta G et al. An update f idipathi intraranial hypertensin. Curr Opin Ophthalml. 2018;29:495. [PMID: 30169466]SE LECTED NEUROCUTANEOUS DISEASESBeause  the nervus system develps frm the epithelial layer f the embry, a number f ngenital diseases inlude bth neurlgi and utaneus manifestatins. Amng these disrders, three are disussed belw, and vn Hippel-Lindau disease is disussed in Chapter 26.1.  Tuberous SclerosisT uberus slersis may ur spradially r n a familial basis with autsmal dminant inheritane. Neurlgi presentatin is with seizures and prgressive psyhmtr retardatin beginning in early hildhd. The utaneus abnrmality adenma sebaeum bemes manifest usually between 5 and 10 years f age and typially nsists f red- dened ndules n the fae (heeks, naslabial flds, sides f the nse, and hin) and smetimes n the frehead and nek. Other typial utaneus lesins inlude subungual fibrmas, shagreen pathes (leathery plaques f subepider- mal fibrsis, situated usually n the trunk), and leaf-shaped hyppigmented spts. Assiated abnrmalities inlude retinal lesins and tumrs, benign rhabdmymas f the heart, lung ysts, benign tumrs in the visera, and bne ysts. The disease is slwly prgressive and leads t inreasing mental deteriratin. Antinvulsants are indiated t ntrl seizures. Everlimus, a mammalian target frapamyin (mTOR) inhibitr, is apprved in the United States and Eurpe fr medially refratry epilepsy and subepen- dymal giant ell astrytmas due t tuberus slersis.2.  NeurofibromtosisNeur fibrmatsis may ur either spradially r n a familial basis with autsmal dminant inheritane. Tw distint frms are regnized: Type 1 (Recklinghausen disease) is haraterized by multiple hyperpigmented ma- ules, Lish ndules, and neurfibrmas, and results frm mutatins in the NF1 gene n hrmsme 17. Type 2 is haraterized by bilateral eighth nerve tumrs, ften ampanied by ther intraranial r intraspinal tumrs, and is assiated with mutatins in the NF2 (merlin) gene n hrmsme 22. Neurlgi presentatin is usually with symptms and signs f tumr. Multiple neurfibrmas harateristially are present and may invlve spinal r ranial nerves, espe- ially the eighth nerve. Examinatin f the superfiial utaneus nerves usually reveals palpable mbile ndules. In sme ases, there is marked vergrwth f subutaneus tissues (plexifrm neurmas), smetimes with an underly- ing bny abnrmality. Assiated utaneus lesins inlude axillary frekling and pathes f utaneus pigmentatin (café au lait spots ). Malignant degeneratin f neurfibr- mas asinally urs and may lead t peripheral sar- mas. Meningimas, glimas (espeially pti nerve glimas), bne ysts, phehrmytmas, slisis, and bstrutive hydrephalus may als ur. Selumetinib (25 mg/m2rally twie daily), a mitgen-ativated prtein kinase inhibitr, auses plexifrm neurfibrmas t shrink by at least 20% in tw-thirds f patients and is apprved by the FDA fr treatment f inperable plexifrm neurfibr- mas in hildren 2 years f age and lder. Studies in adults are nging.3.  Sturge-Weber SyndromeSturg e-Weber syndrme nsists f a ngenital, usually unilateral, utaneus apillary angima invlving the upper fae, leptmeningeal angimatsis, and, in many patients, hridal angima. It has n sex prediletin and usually urs spradially. The utaneus angima sme- times has a mre extensive distributin ver the head and nek and is ften quite disfiguring, espeially if there is assiated vergrwth f nnetive tissue. Fal r gener- alized seizures are the usual neurlgi presentatin and may mmene at any age. There may be ntralateral hmnymus hemianpia, hemiparesis and hemisensry disturbane, ipsilateral glauma, and mental subnrmal- ity. Skull radigraphs taken after the first 2 years f life usually reveal gyrifrm (“tramline”) intraranial alifia- tin, espeially in the pariet-ipital regin, due t min- eral depsitin in the rtex beneath the intraranial angima. Treatment is aimed at ntrlling seizures pharma- lgially (Table 24–2), but surgial treatment may be ne- essary. Ophthalmlgi advie shuld be sught nerning the management f hridal angima and f inreased intraular pressure.CMDT22_Ch24_p0978-p1053.indd  1013 29/06/21 8:50 PMChapTER 241014 CMDT 2022MO VEMENT DISORDERS 1. Essentil (Fmilil) TremorE S S E N T I A L S  O F  D I A G N O S I S »Postural tremor of hands, head, or voice. »Family history common. »May improve temporarily with alcohol. »No abnormal findings other than tremor. »General ConsiderationsThe  ause f essential tremr is unertain, but it is sme- times inherited in an autsmal dminant manner. »Clinical FindingsT remr may begin at any age and is enhaned by emtinal stress. The tremr usually invlves ne r bth hands, the head, r the hands and head, while the legs tend t be spared. The tremr is nt present at rest, but emerges with atin. Examinatin reveals n ther abnrmalities. Inges- tin f a small quantity f alhl mmnly prvides remarkable but shrt-lived relief by an unknwn mehanism. The tremr typially bemes mre nspiuus with time. Oasinally, it interferes with manual skills and leads t impairment f handwriting. Speeh may als be affeted if the laryngeal musles are invlved. »TreatmentT reatment is ften unneessary. When it is required beause f disability, prpranll (60–240 mg daily rally) may be helpful. Lng-term therapy is typial; hwever, intermittent therapy is smetimes useful in patients whse tremr bemes exaerbated in speifi preditable situa- tins. Primidne may be helpful when prpranll is inef- fetive, but patients with essential tremr are ften very sensitive t it. Therefre, the starting dse is 50 mg daily rally, and the daily dse is inreased by 50 mg every 2 weeks depending n the patient’s respnse; a mainte- nane dse f 125 mg three times daily rally is mmnly effetive. Oasinal patients d nt respnd t these mea- sures but are helped by alprazlam (up t 3 mg daily rally in divided dses), tpiramate (titrated up t a dse f 400 mg daily rally in divided dses ver abut 8 weeks), r gabapentin (1800 mg daily rally in divided dses). Btulinum txin A may redue tremr, but adverse effets inlude dse-dependent weakness f the injeted musles. Disabling tremr unrespnsive t medial treatment may be helped by high-frequeny thalami stimulatin (“deep brain stimulatin”) n ne r bth sides, arding t the laterality f symptms. Fused transranial ultra- sund thalamtmy using MRI guidane is als effetive, as is steretati radisurgery fr unilateral upper extrem- ity tremr.»When to Refer• When refratry t first-line treatment with prpran- ll r primidne. •When additinal neurlgi signs are present (ie, parkinsnism). »When to AdmitPa tients requiring surgial treatment (deep brain stimula- tr plaement) shuld be hspitalized.Ha ubenberger D et al. Essential tremr. N Engl J Med. 2018;378: 1802. [PMID: 29742376]2.  prkinson DiseseE S S E N T I A L S  O F  D I A G N O S I S »Any combination of tremor, rigidity, bradykinesia, and progressive postural instability (“parkinsonism”). »Cognitive impairment is sometimes prominent. »General ConsiderationsPar kinsnism is a relatively mmn disrder that urs in all ethni grups, with an apprximately equal sex distri- butin. The mst mmn variety, idipathi Parkinsn disease, begins mst ften between 45 and 65 years f age and is a prgressive disease. »EtiologyPar kinsnism may rarely ur n a familial basis, and the parkinsnian phentype may result frm mutatins f several different genes. Pstenephaliti parkinsnism is beming inreasingly rare. Expsure t ertain txins (eg, manganese dust, arbn disulfide) and severe arbn mn- xide pisning may lead t parkinsnism. Reversible parkinsnism may develp in patients reeiving neurlep- ti mediatins (see Chapter 25), reserpine, r metl- pramide. Only rarely is hemiparkinsnism the presenting feature f a prgressive spae-upying lesin. In idipathi Parkinsn disease, dpamine depletin due t degeneratin f the dpaminergi nigrstriatal sys- tem leads t an imbalane f dpamine and aetylhline, whih are neurtransmitters nrmally present in the r- pus striatum. Treatment f the mtr disturbane is direted at redressing this imbalane by blking the effet f aetylhline with antihlinergi mediatins r by the administratin f levdpa, the preursr f dpamine. Prir use f ibuprfen is assiated with a decreased risk f develping Parkinsn disease; age, family histry, male sex, nging herbiide/pestiide expsure, and signifiant prir head trauma are risk fatrs. »Clinical FindingsT remor, rigidity, bradykinesia, and postural instability are the ardinal mtr features f parkinsnism and mayCMDT22_Ch24_p0978-p1053.indd  1014 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1015 CMDT 2022be  present in any mbinatin. Nnmtr manifestatins inlude affetive disrders (depressin, anxiety, and apa- thy), psyhsis, gnitive hanges, fatigue, sleep disrders, ansmia, autnmi disturbanes, sensry mplaints r pain, and sebrrhei dermatitis. Dementia r mild gni- tive impairment will eventually develp in many patients. The tremr f abut fur t six yles per send is most conspicuous at rest , is enhaned by emtinal stress, and is ften less severe during vluntary ativity. Althugh it may ultimately be present in all limbs, the tremr is mmnly nfined t ne limb r t the limbs n ne side fr mnths r years befre it bemes mre generalized. In sme patients, tremr is absent. Rigidity (an inrease in resistane t passive mvement) is respnsible fr the harateristially flexed psture seen in many patients, but the mst disabling symptms f par- kinsnism are due t bradykinesia, manifested as a slwness f vluntary mvement and a redutin in autmati mve- ments suh as swinging f the arms while walking. Curi- usly, hwever, effetive vluntary ativity may briefly be regained during an emergeny (eg, the patient is able t leap aside t avid an nming mtr vehile). Clinial diagnsis f the well-develped syndrme is usually simple. The patient has a relatively immbile fae with widened palpebral fissures, infrequent blinking, and a fixity f faial expressin. Sebrrhea f the salp and fae is mmn. There is ften mild blepharlnus, and a tremr may be present abut the muth and lips. Repetitive tap- ping (abut twie per send) ver the bridge f the nse prdues a sustained blink respnse ( Myerson sign ). Other findings may inlude saliva drling frm the muth, per- haps due t impairment f swallwing; sft and prly mdulated vie; a variable rest tremr and rigidity in sme r all f the limbs; slwness f vluntary mvements; impairment f fine r rapidly alternating mvements; and mirgraphia. There is typially n musle weakness (pr- vided that suffiient time is allwed fr pwer t be devel- ped) and n alteratin in the tendn reflexes r plantar respnses. It is diffiult fr the patient t arise frm a sitting psitin and begin walking. The gait itself is haraterized by small shuffling steps and a lss f the nrmal autmati arm swing; there may be unsteadiness n turning, diffiulty in stpping, and a tendeny t fall. »Differential DiagnosisDiagn sti prblems may ur in mild ases, espeially if tremr is minimal r absent. Fr example, mild hypkinesia r slight tremr is mmnly attributed t ld age. Depres- sin, with its assiated expressinless fae, prly mdu- lated vie, and redutin in vluntary ativity, an be diffiult t distinguish frm mild parkinsnism, espeially sine the tw disrders may exist. The family histry, the harater f the tremr, and lak f ther neurlgi signs shuld distinguish essential tremr frm parkinsnism. Wilsn disease an be distinguished by its early age at nset, the presene f ther abnrmal mvements, Kayser- Fleisher rings, and hrni hepatitis, and by inreased nentratins f pper in the tissues. Huntingtn disease presenting with rigidity and bradykinesia may be mistakenfr parkinsnism unless the family histry and ampany- ing dementia are regnized. In multisystem atrphy (pre- viusly alled the Shy-Drager syndrme), autnmi insuffiieny (leading t pstural hyptensin, anhidrsis, disturbanes f sphinter ntrl, eretile dysfuntin, et) may be ampanied by parkinsnism, pyramidal defiits, lwer mtr neurn signs, r erebellar dysfuntin. In prgressive supranulear palsy, bradykinesia and rigidity are ampanied by a supranulear disrder f eye mve- ments, pseudbulbar palsy, pseud-emtinal lability (pseudbulbar affet), and axial dystnia. Creutzfeldt-Jakb disease may be ampanied by features f parkinsnism, but prgressin is rapid, dementia is usual, mylni jerk- ing is mmn, ataxia and pyramidal signs may be n- spiuus, and the MRI and eletrenephalgraphi findings are usually harateristi. In rtibasal degener- atin, asymmetri parkinsnism is ampanied by n- spiuus signs f rtial dysfuntin (eg, apraxia, sensry inattentin, dementia, aphasia). Diffuse Lewy bdy disease is haraterized by prminent visual halluinatins and gnitive impairment that begin befre r within 1 year f nset f the mtr features f parkinsnism. »TreatmentT reatment is symptmati. There is great interest in devel- ping disease-mdifying therapies, but trials f several putative neurprtetive agents have shwn n benefit. Tri- als f varius gene therapies have shwn limited r n benefit.A.  Medical MeasuresMe diatin is nt required early in the urse f Parkinsn disease, but the nature f the disrder and the availability f medial treatment fr use when neessary shuld be dis- ussed with the patient. 1. Amantadine— Patients with mild symptms but n dis- ability may be helped by amantadine (100 mg rally tw t three times daily [immediate release] r ne daily [extended release]). This mediatin imprves all f the linial features f parkinsnism, but its mde f atin is unlear. Side effets are unmmn but may inlude rest- lessness, nfusin, depressin, skin rashes, edema, nausea, nstipatin, anrexia, pstural hyptensin, and distur- banes f ardia rhythm. It als amelirates dyskinesias resulting frm lng-term levdpa therapy. 2. Levodopa— Levdpa, whih is nverted in the bdy t dpamine, imprves all f the majr features f parkinsn- ism, inluding bradykinesia, but does not stop progression f the disrder. The mst mmn early side effets f levdpa are nausea, vmiting, and hyptensin, but ar- dia arrhythmias may als ur. Dyskinesias, restlessness, nfusin, and ther behaviral hanges tend t ur smewhat later and beme mre mmn with time. Levodopa-induced dyskinesias may take any neivable frm, inluding hrea, athetsis, dystnia, tremr, tis, and mylnus. An even later mpliatin is the wearing off effect r the on-off phenomenon, in whih abrupt but transient flutuatins in the severity f parkinsnism urCMDT22_Ch24_p0978-p1053.indd  1015 29/06/21 8:50 PMChapTER 241016 CMDT 2022un preditably but frequently during the day. The “off” period of marked bradykinesia has been shwn t relate in sme instanes t falling plasma levels f levdpa. During the “ on”phase , dyskinesias are ften nspiuus but mbility is inreased. Hwever, suh respnse flutuatins may relate t advaning disease rather than t levdpa therapy itself. Carbidpa, whih inhibits the enzyme respnsible fr the breakdwn f levdpa t dpamine, des nt rss the bld-brain barrier. When levdpa is given in mbina- tin with arbidpa, the extraerebral breakdwn f levdpa is diminished. This redues the amunt f levdpa required daily fr benefiial effets, and it lwers the inidene f nausea, vmiting, hyptensin, and ardia irregularities. Suh a mbinatin des nt prevent the develpment f respnse flutuatins and the inidene f ther side effets (dyskinesias r psyhiatri mpliatins) may atually be inreased. Sinemet, a mmerially available preparatin that n- tains arbidpa and levdpa in a fixed rati (1:10 r 1:4), is generally used. Treatment is started with a small dse— eg, ne tablet f Sinemet 25/100 (ntaining 25 mg f ar- bidpa and 100 mg f levdpa) three times daily—and gradually inreased depending n the respnse. Sinemet CR is a ntrlled-release frmulatin (ntaining 25 r 50 mg f arbidpa and 100 r 200 mg f levdpa). It is mainly useful when taken at bedtime t lessen mtr dis- ability upn awakening. A frmulatin f arbidpa/ levdpa (Rytary) ntaining bth immediate- and delayed- release beads prvides a smther respnse in patients with flutuatins. The mmerially available mbinatin f levdpa with bth arbidpa and entaapne (Stalev) may als be helpful in this ntext and is disussed in the fllwing setin n COMT inhibitrs. Respnse flutua- tins are als redued by keeping the daily intake f protein at the remmended minimum and taking the main prtein meal as the last meal f the day. A ntinuus infusin f a arbidpa-levdpa enteral suspensin thrugh a peruta- neus gastrjejunstmy tube by a prtable infusin pump redues “ff” time in patients with advaned Parkinsn disease. Levdpa an als be taken by inhalatin (Inbrija) as a resue mediatin fr patients develping severe akine- sia (ff perids). Benefit urs abut 10 minutes after inhalatin. Side effets inlude ugh, upper respiratry trat infetin, nausea, and dislred sputum. The dyskinesias and behaviral side effets f levdpa are dse-related, but redutin in dse may eliminate any therapeuti benefit. Levdpa-indued dyskinesias may als respnd t amantadine. Levdpa therapy is ntraindiated in patients with psyhti illness r narrw-angle glauma. It shuld nt be given t patients taking mnamine xidase A inhibitrs r within 2 weeks f their withdrawal, beause hypertensive rises may result. Sudden disntinuatin f levdpa an preipitate neurlepti malignant syndrme and shuld be avided. 3. Dopamine agonists— Dpamine agnists, suh as pramipexle and rpinirle, at diretly n dpamine reeptrs, and their use in parkinsnism is assiated with a lwer inidene f the respnse flutuatins anddyskinesias that ur with lng-term levdpa therapy. They are effetive in bth early and advaned stages f Par- kinsn disease. They are ften given either befre the intr- dutin f levdpa r with a lw dse f Sinemet 25/100 (arbidpa 25 mg and levdpa 100 mg, ne tablet three times daily) when dpaminergi therapy is first intrdued; the dse f Sinemet is kept nstant, while the dse f the agnist is gradually inreased. Pramipexle is started at a dsage f 0.125 mg three times daily rally, and the dse is built up gradually t between 0.5 and 1.5 mg three times daily. Rpinirle is begun at 0.25 mg three times daily rally and gradually inreased; mst patients require between 2 and 8 mg three times daily fr benefit. Extended-release, ne-daily frmu- latins f pramipexle and rpinirle have similar effiay and tlerability as the immediate release versins. Rtig- tine is a dpamine agnist absrbed transdermally frm a skin path; it is started at 2 mg ne daily and inreased weekly by 2 mg daily until ahieving an ptimal respnse, up t a maximum f 8 mg daily. Adverse effets f these varius agnists inlude fatigue, smnlene, nausea, peripheral edema, dyskinesias, nfusin, and pstural hyptensin. Less mmnly, an irresistible urge t sleep may ur, smetimes in inapprpriate and hazardus ir- umstanes. Impulse ntrl disrders invlving gambling, shpping, r sexual ativity als ur. Lal skin reatins may ur with the rtigtine path. The dopamine ago- nist withdrawal syndrome develps asinally in patients in whm a dpamine agnist is tapered. It nsists f a mbinatin f distressing physial and psyhlgial symptms that are refratry t levdpa and ther dpa- minergi mediatins and may persist fr mnths r lnger. There is n effetive treatment. The dpamine agnist shuld be reintrdued and tapered mre gradually if pssible. 4. Selective monoamine oxidase inhibitors— Rasagiline, a seletive mnamine xidase B inhibitr, has a lear symp- tmati benefit in sme patients at a daily ral dse f 1 mg, taken in the mrning; it may als be used fr adjuntive therapy in patients with respnse flutuatins t levdpa. Selegiline (5 mg rally with breakfast and lunh) and safin- amide (50 mg rally daily, inreased t 100 mg daily after 14 days) are als apprved as adjuntive treatments. By inhibiting the metabli breakdwn f dpamine, these mediatins may imprve flutuatins r delining respnse t levdpa. Studies have suggested (but failed t shw nlusively) that rasagiline may slw the prgressin f Parkinsn dis- ease, and it appears t delay the need fr ther symptmati therapies. Fr these reasns, rasagiline is ften started early, partiularly fr patients wh are yung r have mild dis- ease. Hwever, the FDA has rejeted an expansin f rasa- giline’s indiatin t inlude disease mdifiatin. 5. COMT inhibitors— Catehlamine- O-methyltransferase (COMT) inhibitrs redue the metablism f levdpa t 3-O-methyldpa and thereby alter the plasma pharmaki- netis f levdpa, leading t mre sustained plasma levels and mre nstant dpaminergi stimulatin f the brain. Treatment with entaapne r tlapne results in reduedCMDT22_Ch24_p0978-p1053.indd  1016 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1017 CMDT 2022res pnse flutuatins, with a greater perid f respnsive- ness t administered levdpa. Tlapne is given in a dsage f 100 mg r 200 mg three times daily rally, and entaapne is given as 200 mg with eah dse f Sinemet. Opiapne, a lng-ating, peripherally seletive COMT inhibitr, is taken ne daily (50 mg) at bedtime at least 1 hur befre and after eating. The dse f Sinemet taken nurrently may have t be redued by up t ne-third t avid side effets. Diarrhea is smetimes trublesme. Beause rare ases f fulminant hepati failure have fl- lwed its use, tlapne shuld be avided in patients with preexisting liver disease. Serial liver bihemial tests shuld be perfrmed at 2-week intervals fr the first year and at lnger intervals thereafter in patients reeiving the mediatin—as remmended by the manufaturer. Seri- us hepattxiity has nt been reprted with entaapne r piapne. Stalev is the mmerial preparatin f levdpa m- bined with bth arbidpa and entaapne. It is best used in patients already stabilized n equivalent dses f arbi- dpa/levdpa and entaapne. It is pried at r belw the prie f the individual ingredients (ie, arbidpa/levdpa and entaapne) and has the added nveniene f requir- ing fewer tablets t be taken daily. It is available in three strengths: Stalev 50 (12.5 mg f arbidpa, 50 mg f levdpa, and 200 mg f entaapne), Stalev 100 (25 mg f arbidpa, 100 mg f levdpa, and 200 mg f entaa- pne), and Stalev 150 (37.5 mg f arbidpa, 150 mg f levdpa, and 200 mg f entaapne). 6. Istradefylline— This adensine A2Areeptr antagnist (20–40 mg rally ne daily) is given t patients taking levdpa r a dpamine agnist t redue ff time; ttal ff time is typially redued by less than 1 hur per day. 7. Anticholinergic medications— Antihlinergis are mre helpful in alleviating tremr and rigidity than brady- kinesia. Trihexyphenidyl and benztrpine are mmnly used frmulatins. Treatment is started with a small dse and gradually inreased until benefit urs r side effets limit further inrements. If treatment is ineffetive, the mediatin is gradually withdrawn and anther prepara- tin then tried. Hwever, these mediatins are ften prly tlerated, espeially in lder adults. Side effets limit the rutine use f these mediatins, and inlude dryness f the muth, nausea, nstipatin, palpitatins, ardia arrhythmias, urinary retentin, n- fusin, agitatin, restlessness, drwsiness, mydriasis, inreased intraular pressure, and defetive ammda- tin. Antihlinergi mediatins are ntraindiated in patients with prstati hyperplasia, narrw-angle glau- ma, r bstrutive gastrintestinal disease and are ften tlerated prly by the elderly. They are best avided whenever gnitive impairment r a predispsitin t delirium exists. 8. Antipsychotics— Cnfusin and psyhti symptms may ur as a side effet f dpaminergi therapy r as a part f the underlying illness. Pimavanserin (34 mg ne daily), a sertnin(2A) agnist, is apprved by the FDA speifially fr treating the psyhsis f Parkinsn disease. This may als respnd t the atypial antipsyhti agentslzapine and quetiapine, whih have few extrapyramidal side effets and d nt blk the effets f dpaminergi mediatin. Clzapine may rarely ause marrw suppres- sin, and weekly bld unts are therefre neessary fr patients taking it. The patient is started n 6.25 mg at bedtime and the dsage inreased t 25–100 mg/day as needed. In lw dses, it may als imprve iatrgeni dyskinesias. Typical antipsychotic agents and the second- generation antipsychotic agents risperidone and olanzapine may cause worsening of motor symptoms and should be avoided .B.  General MeasuresPhysial  therapy r speeh therapy helps many patients. Cgnitive impairment and psyhiatri symptms may be helped by a hlinesterase inhibitr, suh as rivastigmine (3–12 mg rally daily r 4.6 r 9.5 mg/24 hurs transder- mally daily). The quality f life an ften be imprved by the prvisin f simple aids t daily living, eg, rails r ban- isters plaed strategially abut the hme, speial table utlery with large handles, nnslip rubber table mats, and devies t amplify the vie.C.  Stimulation and Ablative TreatmentsHigh-frequeny  stimulatin f the subthalami nulei r glbus pallidus internus may benefit many f the mtr features f the disease but des nt affet its natural histry. Eletrial stimulatin f the brain has the advantage ver ablative thalamtmy and pallidtmy predures f being reversible and f ausing minimal r n damage t the brain, and is therefre the preferred surgial apprah t treatment. It is reserved fr patients withut gnitive impairment r psyhiatri disrder wh have a gd respnse t levdpa, but in whm dyskinesias r respnse flutuatins are prblemati. It frequently takes 3–6 mnths after surgery t adjust stimulatr prgramming and t ahieve ptimal results. Side effets inlude depressin, apathy, impulsivity, exeutive dysfuntin, and dereased verbal flueny in a subset f patients. Fused ultrasund thalamtmy r steretati radisurgery may help patients with medially refratry tremr-predminant parkinsnism wh are relutant t underg surgery.D . Gene TherapyIn jetins f aden-assiated viruses ending varius human genes have been made int the subthalami nuleus r putamen in varius linial trials. These apprahes may be useful in the future but remain experimental. »When to ReferAll patients sh uld be referred. »When to AdmitPa tients requiring surgial treatment shuld be admitted.Mith ell KT et al. Surgial treatment f Parkinsn disease. Neu- rl Clin. 2020;38:293. [PMID: 32279711]CMDT22_Ch24_p0978-p1053.indd  1017 29/06/21 8:50 PMChapTER 241018 CMDT 2022Rugha ni A et al. Cngress f Neurlgial Surgens systemati review and evidene-based guideline n subthalami nuleus and glbus pallidus internus deep brain stimulatin fr the treatment f patients with Parkinsn’s disease: exeutive sum- mary. Neursurgery. 2018;82:753. [PMID: 29538685]3.  huntington DiseseE S S E N T I A L S  O F  D I A G N O S I S »Gradual onset and progression of chorea and dementia or behavioral change. »Family history of the disorder. »Responsible gene identified on chromosome 4. »General ConsiderationsHunt ingtn disease is haraterized by chorea and dementia. It is inherited in an autsmal dminant manner and urs thrughut the wrld, in all ethni grups, with a prevalene rate f abut 5 per 100,000. There is an expanded and unstable CAG trinuletide repeat in the huntingtin gene at 4p16.3; lnger repeat lengths rre- spnd t an earlier age f nset and faster disease prgressin. »Clinical FindingsA.  Symptoms and SignsClinial  nset is usually between 30 and 50 years f age. The disease is prgressive and usually leads t a fatal ut- me within 15–20 years. The initial symptms may n- sist f either abnrmal mvements r intelletual hanges, but ultimately bth ur. The earliest mental hanges are ften behaviral, with irritability, mdiness, antisial behavir, r a psyhiatri disturbane, but a mre bvius dementia subsequently develps. The dyskinesia may ini- tially be n mre than an apparent fidgetiness r restless- ness, but eventually hreifrm mvements and sme dystni psturing ur. A parkinsnian syndrme with prgressive rigidity and akinesia (rather than hrea) smetimes urs in assiatin with dementia, espeially in ases with hildhd nset. The diagnsis is established with a widely available geneti test, althugh suh testing shuld be pursued under the guidane f a liensed geneti unselr.B.  ImagingCT  sanning r MRI usually demnstrates erebral atrphy and atrphy f the audate nuleus in established ases. Psitrn emissin tmgraphy (PET) has shwn redued striatal metabli rate. »Differential DiagnosisChre a develping with n family histry f hreathetsis shuld nt be attributed t Huntingtn disease, at least nt until ther auses f hrea have been exluded liniallyand by apprpriate labratry studies. Nngeneti auses f hrea inlude strke, systemi lupus erythematsus and antiphsphlipid antibdy syndrme, paraneplasti syn- drmes, infetin with HIV , and varius mediatins. In yunger patients, self-limiting Sydenham hrea develps after grup A streptal infetins n rare asins. If a patient presents slely with prgressive intelletual fail- ure, it may nt be pssible t distinguish Huntingtn dis- ease frm ther auses f dementia unless there is a harateristi family histry r a dyskinesia develps. Huntington disease–like (HDL) disorders resemble Huntingtn disease but are aused by ther geneti muta- tins. A linially similar autsmal dminant disrder (dentatorubral-pallidoluysian atrophy), manifested by hrea, dementia, ataxia, and mylni epilepsy, is unmmn exept in persns f Japanese anestry. Treat- ment is as fr Huntingtn disease. »TreatmentThere  is n ure fr Huntingtn disease; prgressin an- nt be halted; and treatment is purely symptmati, althugh studies f antisense lignuletides inhibiting prdutin f mutant huntingtin prtein are nging. The reprted bihemial hanges suggest a relative undera- tivity f neurns ntaining GABA and aetylhline r a relative verativity f dpaminergi neurns. Tetrabena- zine, a mediatin that interferes with the vesiular strage f bigeni amines, is widely used t treat the dyskinesia. The starting dse is 12.5 mg twie r three times daily rally, inreasing by 12.5 mg every 5 days depending n respnse and tlerane; the usual maintenane dse is 25 mg three times daily. Side effets inlude depressin, pstural hyptensin, drwsiness, and parkinsnian fea- tures; tetrabenazine shuld nt be given within 14 days f taking mnamine xidase inhibitrs and is nt indiated fr the treatment f levdpa-indued dyskinesias. Reser- pine is similar in depleting entral mnamines but has mre peripheral effets and a wrse side-effet prfile, making its use prblemati in Huntingtn disease; if utilized, the dse is built up gradually t between 2 mg and 5 mg rally daily, depending n the respnse. Deutetrabenazine is als effetive in reduing hrea in Huntingtn disease and may have fewer side effets than tetrabenazine but diret mparisns are laking. The starting dse is 6 mg ne daily rally, inreased t 6 mg twie daily after 1 week and by 6-mg inrements weekly thereafter, t a maximum f 24 mg twie daily. Treatment with mediatins blking dpamine reeptrs, suh as phenthiazines r halperidl, may ntrl the dyskinesia and any behaviral distur- banes. Halperidl treatment is usually begun with a dse f 1 mg ne r twie daily rally, whih is then inreased every 3 r 4 days depending n the respnse; alternatively, atypial antipsyhti agents suh as quetiapine (inreasing frm 25 mg daily rally up t 100 mg twie daily rally as tlerated) may be tried. Amantadine in a dse f 200 mg t 400 mg daily rally is smetimes helpful fr hrea. Deep brain stimulatin has been used suessfully t treat hrea in a small number f patients. Behaviral disturbanes may respnd t lzapine. Attempts t mpensate fr the rela- tive GABA defiieny by enhaning entral GABA ativityCMDT22_Ch24_p0978-p1053.indd  1018 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1019 CMDT 2022r t mpensat e fr the relative hlinergi underativity by giving hline hlride have nt been therapeutially helpful. Offspring shuld be ffered geneti unseling. Geneti testing permits presymptmati detetin and definitive diagnsis f the disease. »When to ReferAll patients sh uld be referred.T abrizi SJ et al; Phase 1–2a IONIS-HTTRx Study Site Teams. Targeting huntingtin expressin in patients with Huntingtn’s disease. N Engl J Med. 2019;380:2307. [PMID: 31059641]4.  Idiotic Torsion DystoniE S S E N T I A L S  O F  D I A G N O S I S »Dystonic movements and postures. »Normal birth and developmental history. No other neurologic signs. »Investigations (including CT scan or MRI) reveal no cause of dystonia. »General ConsiderationsIdi pathi trsin dystnia may ur spradially r n a hereditary basis, with autsmal dminant, autsmal reessive, and X-linked reessive mdes f transmissin. Symptms may begin in hildhd r later and persist thrughut life. »Clinical FindingsThe  disrder is haraterized by the nset f abnrmal mvements and pstures in a patient with a nrmal birth and develpmental histry, n relevant past medial ill- ness, and n ther neurlgi signs. Investigatins (inlud- ing CT san) reveal n ause fr the abnrmal mvements. Dystni mvements f the head and nek may take the frm f trtillis, blepharspasm, faial grimaing, r fred pening r lsing f the muth. The limbs may als adpt abnrmal but harateristi pstures. The age at nset influenes bth the linial findings and the prgn- sis. With nset in hildhd, there is usually a family his- try f the disrder, symptms mmnly mmene in the legs, and prgressin is likely until there is severe dis- ability frm generalized dystnia. In ntrast, when nset is later, a psitive family histry is unlikely, initial symp- tms are ften in the arms r axial strutures, and severe disability des nt usually ur, althugh generalized dystnia may ultimately develp in sme patients. If all ases are nsidered tgether, abut ne-third f patients eventually beme s severely disabled that they are n- fined t hair r bed, while anther ne-third are affeted nly mildly.»Differential DiagnosisPe rinatal anxia, birth trauma, and kerniterus are m- mn auses f dystnia, but abnrmal mvements usually then develp befre the age f 5, the early develpment f the patient is usually abnrmal, and a histry f seizures is nt unusual. Mrever, examinatin may reveal signs f mental retardatin r pyramidal defiit in additin t the mvement disrder. Dystni psturing may als ur in Wilsn disease, Huntingtn disease, r parkinsnism; as a sequela f enephalitis lethargia r previus neurlepti mediatin therapy; and in ertain ther disrders. In these ases, diagnsis is based n the histry and ampa- nying linial manifestatins. »TreatmentIdi pathi trsin dystnia usually respnds prly t mediatins. A distint variety f dminantly inherited dys- tnia is remarkably respnsive t levdpa; therefre, a levdpa trial is warranted in all patients. Failing this, diaze- pam, balfen, arbamazepine, amantadine, r antihliner- gi mediatin suh as trihexyphenidyl r benztrpine (in high dsage) is asinally helpful; if nt, a trial f treatment with tetrabenazine, phenthiazines, r halperidl may be wrthwhile. In eah ase, the dse has t be individualized, depending n respnse and tlerane. Hwever, the dses f these latter mediatins that are required fr benefit lead usually t mild parkinsnism. Pallidal deep brain stimulatin is helpful fr disabling generalized dystnia and has a lwer mrbidity than steretati thalamtmy, whih is sme- times helpful in patients with predminantly unilateral limb dystnia. Ptential adverse events f deep brain stimulatin inlude erebral infetin r hemrrhage, brken leads, affetive hanges, and dysarthria. »When to ReferAll patients sh uld be referred. »When to AdmitPa tients requiring surgial treatment shuld be admitted.R drigues FB et al. Deep brain stimulatin fr dystnia. Chrane Database Syst Rev. 2019;1:CD012405. [PMID: 30629283]5.  Focl Torsion DystoniA  number f the dystni manifestatins that ur in idipathi trsin dystnia may als ur as islated phe- nmena. They are best regarded as fal dystnias that either ur as frmes frustes f idipathi trsin dyst- nia in patients with a psitive family histry r represent a fal manifestatin f the adult-nset frm f that disrder when there is n family histry. Medial treatment is gen- erally unsatisfatry. A trial f the mediatins used in idipathi trsin dystnia is wrthwhile, hwever, sine a few patients d shw sme respnse. In additin, with restrited dystnias suh as blepharspasm r trtillis, lal injetin f btulinum A txin int the verativeCMDT22_Ch24_p0978-p1053.indd  1019 29/06/21 8:50 PMChapTER 241020 CMDT 2022musles  may prdue wrthwhile benefit fr several weeks r mnths and an be repeated as needed. Bth blepharospasm and oromandibular dystonia may ur as an islated fal dystnia. The frmer is har- aterized by spntaneus invluntary fred lsure f the eyelids fr a variable interval. Ormandibular dystnia is manifested by invluntary ntratin f the musles abut the muth ausing, fr example, invluntary pen- ing r lsing f the muth, rving r prtruding tngue mvements, and retratin f the platysma. Cervical dys- tonia (spasmdi trtillis), usually with nset between 25 and 50 years f age, is haraterized by a tendeny fr the nek t twist t ne side. This initially urs episdi- ally, but eventually the nek is held t the side. Sme patients have a sensry trik (“geste antagniste”) that lessens the dystni psture, eg, tuhing the side f the fae. Spntaneus reslutin may ur in the first year r s. The disrder is therwise usually lifelng. Lal inje- tin f btulinum A txin prvides benefit in mst ases. Deep brain stimulatin f the glbus pallidus interna is an ptin if medial treatment and btulinum txin injetin are unsuessful. Writer’s cramp is haraterized by dystni psturing f the hand and frearm when the hand is used fr writing and smetimes when it is used fr ther tasks, eg, playing the pian r using a srewdriver r eating utensils. Media- tin treatment is usually unrewarding, and patients are ften best advised t learn t use the ther hand fr ativi- ties requiring manual dexterity. Injetins f btulinum A txin are helpful in sme instanes.Rdrigues FB  et al. Btulinum txin type A therapy fr ervial dystnia. Chrane Database Syst Rev. 2020;11:CD003633. [PMID: 33180963]6.  MyoclonusOasi nal mylni jerks may ur in anyne, espeially when drifting int sleep. General or multifocal myoclonus is mmn in patients with idipathi epilepsy and is espe- ially prminent in ertain hereditary disrders harater- ized by seizures and prgressive intelletual deline, suh as the lipid strage diseases. It is als a feature f subaute slersing panenephalitis and Creutzfeldt-Jakb disease. Generalized mylni jerking may ampany uremi and ther metabli enephalpathies, result frm therapy with levdpa r triyli antidepressants, ur in alhl r drug withdrawal states, r fllw anxi brain damage. It als urs n a hereditary r spradi basis as an islated phenmenn in therwise healthy subjets. Segmental myoclonus is a rare manifestatin f a fal spinal rd lesin. It may als be the linial expressin f epilepsia partialis continua , a disrder in whih a repeti- tive fal epilepti disharge arises in the ntralateral sensrimtr rtex, smetimes frm an underlying stru- tural lesin. An eletrenephalgram is ften helpful in larifying the epilepti nature f the disrder, and CT r MRI san may reveal the ausal lesin. Mylnus may respnd t ertain antinvulsant mediatins, espeially valpri aid r levetiraetam, r tne f the benzdiazepines, partiularly lnazepam (see Table 24–2). It may als respnd t piraetam (up t 16.8 g daily; nt available in the United States). Mylnus fl- lwing anxi brain damage is ften respnsive t xitrip- tan (5-hydrxytryptphan), the preursr f sertnin, and smetimes t lnazepam. Oxitriptan is given in gradually inreasing dses up t 1–1.5 mg daily. In patients with segmental mylnus, a lalized lesin shuld be searhed fr and treated apprpriately.7.  Wilson DiseseIn th is metabli disrder, abnrmal mvement and ps- ture may ur with r withut existing signs f liver invlvement. Psyhiatri and neurpsyhlgial mani- festatins are mmn. Wilsn disease is disussed in Chapter 16.8.  Drug-Induced abnorml MovementsPhent hiazines, butyrphennes, and metlpramide may prdue a wide variety f abnrmal mvements, inluding parkinsnism, akathisia (ie, mtr restlessness), aute dystnia, hrea, and tardive dyskinesias r dystnia; several f these are als prdued by aripiprazle. These mpliatins are disussed in Chapter 25. Chrea may als develp in patients reeiving levdpa, brmriptine, antihlinergi mediatins, phenytin, arbamazepine, lithium, amphetamines, r ral ntraeptives, and it reslves with withdrawal f the ffending substane. Simi- larly, dystnia may be prdued by levdpa, brmrip- tine, lithium, r arbamazepine; and parkinsnism by reserpine and tetrabenazine. Pstural tremr may ur with a variety f mediatins, inluding epinephrine, is- prterenl, amidarne, thephylline, affeine, lithium, thyrid hrmne, triyli antidepressants, and valpri aid.9.  Restless Legs SyndromeThis  mmn disrder, affeting 1–5% f peple, may ur as a primary (idipathi) disrder r in relatin t Parkinsn disease, pregnany, irn defiieny anemia, r peripheral neurpathy (espeially uremi r diabeti). It may have a hereditary basis, and several geneti li have been assiated with the disrder. Restlessness and urius sensry disturbanes lead t an irresistible urge t mve the limbs, espeially during perids f relaxatin; mve- ment f the limbs prvides relief. The urge urs exlu- sively in the evening and at night r is wrse at night than during the day. Mst patients als have periodic limb movements of sleep and ne-third have peridi limb mvements during relaxed wakefulness; bth nsist f brief invluntary flexin at the ankle, knee, and hip. Dis- turbed nturnal sleep and exessive daytime smnlene may result. Ferritin levels shuld always be measured; treatment with ral irn sulfate in patients with ferritin levels less than r equal t 75 mg/L (13.4 mml/L) shuld be attempted prir t initiatin f ther pharma- therapies. Therapy is with nnergt dpamine agnists, suh as pramipexle (0.125–0.5 mg rally ne daily),CMDT22_Ch24_p0978-p1053.indd  1020 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1021 CMDT 2022rp inirle (0.25–4 mg rally ne daily 2 t 3 hurs befre bedtime), r rtigtine (1–3 mg/24 h transdermal path ne daily), r with gabapentin enaarbil (300–1200 mg rally eah evening). Gabapentin (starting with 300 mg rally daily, inreasing t apprximately 1800 mg daily depending n respnse and tlerane) and pregabalin (150–300 mg rally divided twie t three times daily) are related mediatins that imprve symptms. Levdpa is helpful but may lead t an augmentatin f symptms, s its use is generally reserved fr thse wh d nt respnd t ther measures. Extended-release xydne-nalxne (2.5–5 mg t 5–10 mg rally twie daily) is useful in patients with severe symptms r thse wh are refratry t first-line therapies.Win kelmann J et al. Treatment f restless legs syndrme: evidene-based review and impliatins fr linial pratie. Mv Disrd. 2018;33:1077. [PMID: 29756335]10.  Gilles De L Tourette SyndromeE S S E N T I A L S  O F  D I A G N O S I S »Multiple motor and phonic tics. »Symptoms begin before age 18 years. »Tics occur frequently for at least 1 year. »Tics vary in number, frequency, and nature over time. »Clinical FindingsSimple  tis ur transiently in up t 25% f hildren, remit within weeks t mnths, and d nt require treat- ment. Turette syndrme is a mre mplex disrder. Motor tics are the initial manifestatin in 80% f ases and mst mmnly invlve the fae, whereas in the remaining 20%, the initial symptms are phonic tics; ulti- mately a mbinatin f different mtr and phni tis develp in all patients. Tis are preeded by an urge that is relieved upn perfrmane f the mvement r valiza- tin; they an be temprarily suppressed but eventually the urge bemes verwhelming. These are nted first in hildhd, generally between the ages f 2 and 15. Mtr tis ur espeially abut the fae, head, and shulders (eg, sniffing, blinking, frwning, shulder shrugging, head thrusting, et). Phni tis mmnly nsist f grunts, barks, hisses, thrat-learing, ughs, et, but smetimes als f verbal utteranes inluding prlalia (bsene speeh). There may als be ehlalia (repetitin f the speeh f thers), ehpraxia (imitatin f thers’ mve- ments), and palilalia (repetitin f wrds r phrases). Sme tis may be self-mutilating in nature, suh as nail- biting, hair-pulling, r biting f the lips r tngue. The disrder is hrni, but the urse may be puntuated by relapses and remissins. Obsessive-mpulsive disrder (OCD) and attentin defiit hyperativity disrder (ADHD) are mmnly assiated and may be mre dis-abling than the tis themselves. A family histry is sme- times btained. Examinatin usually reveals n abnrmalities ther than the tis. In additin t OCD, psyhiatri disturbanes may ur beause f the assiated smeti and sial embarrassment. The diagnsis f the disrder is ften delayed fr years, the tis being interpreted as psyhiatri illness r sme ther frm f abnrmal mvement. Patients are thus ften subjeted t unneessary treatment befre the disrder is regnized. The ti-like harater f the abnrmal mvements and the absene f ther neurlgi signs shuld differentiate this disrder frm ther mve- ment disrders presenting in hildhd. Wilsn disease, hwever, an simulate the nditin and shuld be exluded. »TreatmentT reatment is symptmati and may need t be ntinued indefinitely. Habit reversal training r ther frms f behaviral therapy an be effetive alne r in mbinatin with pharmatherapy. Alpha-adrenergi agnists, suh as lnidine (start 0.05 mg rally at bedtime, titrating t 0.3–0.4 mg rally daily, divided three t fur times per day) r guanfaine (start 0.5 mg rally at bedtime, titrating t a maximum f 3–4 mg rally daily, divided twie daily), are first-line therapies beause f a favrable side-effet prfile mpared with typial antipsyhtis, whih are the nly FDA-apprved therapies fr the disrder. They als have the advantage f imprving the symptms f nmitant ADHD. Many speialists favr the use f tetrabenazine. The atypial antipsyhti risperidne (1–6 mg daily rally) is mre effetive than plaeb in ntrlling tis and mre effetive than pimzide in imprving symptms f mrbid OCD and may be tried befre the typial anti- psyhti agents. When a typial antipsyhti is required in ases f severe tis, halperidl is generally regarded as the mediatin f hie. It is started in a lw dse (0.25 mg daily rally) that is gradually inreased (by 0.25 mg every 4 r 5 days) until there is maximum benefit with a minimum f side effets r until side effets limit further inrements. A ttal daily ral dse f between 2 mg and 8 mg is usually ptimal, but higher dses are sme- times neessary. Fluphenazine (1–15 mg rally daily) and pimzide (1–10 mg rally daily) are alternatives. Typial antipsyhtis an ause signifiant weight gain and arry a risk f tardive dyskinesias and ther lng-term, ptentially irreversible mtr side effets. Small ran- dmized trials r bservatinal studies have reprted benefit frm tpiramate, nitine, tetrahydrannabinl, balfen, and lnazepam. A number f ther media- tins, inluding deutetrabenazine, valbenazine, and e- pipam, are being studied fr the treatment f tis. Injetin f btulinum txin type A at the site f the mst distressing tis is smetimes wrthwhile and has fewer side effets than systemi antipsyhti therapy. Bilateral high-frequeny deep brain stimulatin at varius sites has been helpful in sme, therwise intratable, ases. »When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1021 29/06/21 8:50 PMChapTER 241022 CMDT 2022 »When to AdmitPatients  underging surgial (deep brain stimulatin) treatment shuld be admitted.M artinez-Ramirez D et al. Effiay and safety f deep brain stimu- latin in Turette syndrme: the Internatinal Turette Syn- drme Deep Brain Stimulatin Publi Database and Registry. JAMA Neurl. 2018;75:353. [PMID: 29340590] Pringsheim T et al. Pratie guideline remmendatins summary: treatment f tis in peple with Turette syndrme and hrni ti disrders. Neurlgy. 2019;92:896. [PMID: 31061208]DE MENTIAE S S E N T I A L S  O F  D I A G N O S I S »Progressive intellectual decline. »Not due to delirium or psychiatric disease. »Age is the main risk factor, followed by family his- tory and vascular disease risk factors.»General ConsiderationsDementia  is a prgressive deline in intelletual funtin that is severe enugh t mprmise sial r upatinal funtining. Mild cognitive impairment desribes a deline that has notresulted in a hange in the level f funtin. Althugh a few patients identify a preipitating event, mst experiene an insidius nset and gradual prgressin f symptms. Dementia typially begins after age 60, and the preva- lene dubles apprximately every 5 years thereafter; in persns aged 85 and lder, arund half have dementia. The prevalene f Alzheimer dementia is predited t be 15 millin by 2060 in the United States. In mst ases, the ause f dementia is aquired, either as a spradi primary neurdegenerative disease r as the result f anther disr- der, suh as strke (Table 24–6). Other risk fatrs fr dementia inlude family histry, diabetes mellitus, iga- rette smking, hypertensin, besity, a histry f signifi- ant head injury, and hearing lss. Vitamin D defiieny and hrni sleep deprivatin may als inrease the risk f dementia. Dementia is mre prevalent amng wmen, but this may be aunted fr by their lnger life expetany. Table 24–6. Common causes of age-related dementia (listed by prevalence).Disorder ptology Clinicl Fetures Alzheimer disease Plaques containing beta-amyloid pep- tide, and neurofibrillary tangles con- taining tau protein, occur throughout the neocortex.• Most common age-related neurodegenerative disease; incidence doubles every 5 years after age 60. • Short-term memory impairment is early and prominent in most cases. • Variable deficits of executive function, visuospatial function, and language. Vascular dementia Multifocal ischemic change. • Stepwise or progressive accumulation of cognitive deficits in association with repeated strokes. • Symptoms depend on localization of strokes. Dementia with Lewy bodiesHistologically indistinguishable from Parkinson disease: alpha-synuclein- containing Lewy bodies occur in the brainstem, midbrain, olfactory bulb, and neocortex. Alzheimer pathology may coexist.• Cognitive dysfunction, with prominent visuospatial and executive deficits. • Psychiatric disturbance, with anxiety, visual hallucinations, and fluctuating delirium. • Parkinsonian motor deficits with or after other features. • Cholinesterase inhibitors lessen delirium; poor tolerance of neuroleptics and dopaminergics. Frontotemporal dementia (FTD)Neuropathology is variable and defined by the protein found in intraneuronal aggregates. Tau protein, TAR DNA- binding protein 43 (TDP-43), or fused-in-sarcoma (FUS) protein account for most cases.• Peak incidence in the sixth decade; approximately equal to Alzheimer disease as a cause of dementia in patients under 60 years old. • Familial cases result from mutations in genes for tau, progranulin, or others. Beviorl vrint FTD • Deficits in empathy, social comportment, insight, abstract thought, and executive function. • Behavior is disinhibited, impulsive, and ritualistic, with prominent apathy and increased interest in sex or sweet/fatty foods. • Relative preservation of memory. • Focal right frontal atrophy. • Association with amyotrophic lateral sclerosis. Semntic vrint rimry rogressive si • Deficits in word-finding, single-word comprehension, object and category knowledge, and face recognition. • Behaviors may be similar to behavioral variant FTD. • Focal, asymmetric temporal pole atrophy. Nonfluent/grmmtic vrint rimry rogressive si • Speech is effortful with dysarthria, phonemic errors, sound distortions, and poor grammar. • Focal extrapyramidal signs and apraxia of the right arm and leg are common; overlaps with corticobasal degeneration. • Focal left frontal atrophy.CMDT22_Ch24_p0978-p1053.indd  1022 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1023 CMDT 2022Ph ysial ativity seems t be prtetive; eduatin, nging intelletual stimulatin, and sial engagement may als be prtetive, perhaps by prmting cognitive reserve, an imprved apaity t mpensate fr insidius neurdegeneratin. Dementia is distint frm delirium and psyhiatri dis- ease. Delirium is an aute nfusinal state that ften urs in respnse t an identifiable trigger, suh as drug r alhl intxiatin r withdrawal (eg, Wernike enepha- lpathy, desribed belw), mediatin side effets (espe- ially mediatins with antihlinergi prperties, antihistamines, benzdiazepines, sleeping aids, piids, neurleptis, rtisterids, and ther sedative r psyh- trpi agents), infetin (nsider ult urinary trat infetin r pneumnia in elderly patients), metabli dis- turbane (inluding an eletrlyte abnrmality; hypglye- mia r hyperglyemia; r a nutritinal, endrine, renal, r hepati disrder), sleep deprivatin, r ther neurlgi disease (seizure, inluding a pstital state, r strke). Delirium typially invlves fluctuating levels f arusal, inluding drwsiness r agitatin, and it imprves after remval r treatment f the preipitating fatr. Patients with dementia are espeially suseptible t episdes f delirium, but regnitin f dementia is nt pssible until delirium lifts. Fr this reasn, dementia is typially diag- nsed in utpatients wh are therwise medially stable, rather than in autely ill patients in the hspital. Psyhiatri disease smetimes leads t mplaints f impaired gnitin ( pseudodementia ). Impaired attentin is usually t blame, and in sme patients with depressin r anxiety, pr fus and nentratin may even be a pri- mary mplaint. The symptms shuld imprve with appr- priate psyhiatri treatment. Md disrders are mmnly seen in patients with neurdegenerative disease and in sme ases are an early symptm. There is sme evidene that a persistent, untreated md disrder may predispse t the develpment f an age-related dementia, and psyhiatri symptms an learly exaerbate gnitive impairment in patients wh already have dementia; therefre, suspiin f dementia shuld nt distrat frm apprpriate sreening fr and treatment f depressin r anxiety. »Clinical FindingsA.  Symptoms and SignsSym ptms and signs f the mmn auses f dementia are detailed in Table 24–6. Cliniians shuld be aware that a patient’s insight int a gnitive hange may be vague r absent, and llateral histry is essential t a prper evalua- tin. As patients age, primary are liniians shuld inquire peridially abut the presene f any gnitive symptms. Symptms depend n the area f the brain affeted. Short-term memory loss , invlving the repeating f ques- tins r stries and a diminished ability t reall the details f reent nversatins r events, frequently results frm pathlgi hanges in the hippampus. Word-finding dif- ficulty ften invlves diffiulty realling the names f pe- ple, plaes, r bjets, with lw-frequeny wrds affeted first, eventually resulting in speeh laden with prnuns and irumlutins. This prblem is thught t arise frmpathlgy at the temprparietal juntin f the left hemi- sphere. Prblems with artiulatin, flueny, mprehensin, r wrd meaning are anatmially distint and less m- mn. Visuospatial dysfunction may result in pr naviga- tin and getting lst in familiar plaes, impaired regnitin f previusly familiar faes and buildings, r truble dis- erning an bjet against a bakgrund. The right parietal lbe is ne f the brain areas impliated in suh symptms. Executive dysfunction may manifest by easy distratibility, impulsivity, mental inflexibility, nrete thught, slwed pressing speed, pr planning and rganizatin, r impaired judgment. Lalizatin may vary and uld inlude the frntal lbes r subrtial areas like the basal ganglia r erebral white matter. Apathy r indifferene, separate frm depressin, is mmn and may have a simi- lar anatmy as exeutive dysfuntin. Apraxia , r the lss f learned mtr behavirs, may result frm dysfuntin f the frntal r parietal lbes, espeially the left parietal lbe. The time f symptm nset must be established, but subtle, early symptms are ften apparent nly in retr- spet. Anther event, suh as an illness r hspitalizatin, may lead t new regnitin f existing symptms. Symp- tms ften aumulate ver time, and the nature of the earliest symptom is most helpful in forming the differential diagnosis. The histry shuld establish risk fatrs fr dementia, inluding family histry, ther hrni illnesses, and vasular disease risk fatrs. Finally, it is imprtant t dument the patient’s urrent apaity t perfrm basic and instrumental activities of daily living (see Chapter 4) and t nte the extent f deline frm the premrbid level f funtin. Indeed, it is this funtinal assessment that defines the presene and severity f dementia. The physial examinatin is imprtant t identify any ult medial illness. In additin, eye mvement abnr- malities, parkinsnism, r ther mtr abnrmalities may help identify an underlying neurlgi nditin. The wrkup shuld priritize the exlusin f nditins that are reversible r require separate therapy. Sreening fr depressin is neessary, alng with imaging and labratry wrkup, as indiated belw.B.  Neuropsychological AssessmentBrief q uantifiatin f gnitive impairment is indiated in a patient mplaining f gnitive symptms r if aregiv- ers raise similar nerns. The Folstein Mini Mental State Exam (MMSE), Montreal Cognitive Assessment (MoCA), Mini-Cg, and ther similar tests are brief, bjetive, and widely used but have imprtant limitatins: they are insen- sitive t mild gnitive impairment, they may be biased negatively by the presene f language r attentin prb- lems, and they d nt rrelate with funtinal apaity. A neurpsyhiatri evaluatin by a trained neurpsy- hlgist r psyhmetriian may be apprpriate. The gal f suh testing is t enhane lalizatin by defining the gnitive dmains that are impaired as well as t quantify the degree f impairment. There is n standard battery f tests, but a variety f metris is mmnly used t assess the symptm types highlighted abve. Assessments are mst aurate when a patient is well rested, mfrtable, and therwise medially stable.CMDT22_Ch24_p0978-p1053.indd  1023 29/06/21 8:50 PMChapTER 241024 CMDT 2022C.  ImagingBra in imaging with MRI r CT withut ntrast is indiated in any patient with a new, prgressive gnitive mplaint. The gal is t exlude ult erebrvasular disease, tumr, r ther identifiable strutural abnrmality, rather than t prvide psitive evidene f a neurdegenerative disease. Glbal r fal brain atrphy may be wrse than expeted fr age and uld suggest a partiular neurde- generative press, but suh findings are rarely speifi. PET with flurdexygluse (FDG) des nt nfirm r exlude any speifi ause f dementia but may be useful as an element f the wrkup in speifi linial irum- stanes, suh as disriminating between Alzheimer disease and frnttempral dementia in a patient with sme symp- tms f eah. PET imaging with a radilabeled ligand fr beta-amylid, ne f the pathlgi prteins in Alzheimer disease, is highly sensitive t amylid pathlgy and may prvide psitive evidene fr Alzheimer disease in a patient with gnitive deline. Hwever, after age 60 r 70, amylid plaques an aumulate in the absene f gnitive impair- ment; thus, the speifiity f a psitive amylid san dimin- ishes with age. Single-phtn emissin mputed tmgraphy ffers similar infrmatin as FDG-PET but is less sensitive. PET imaging with radilabeled ligands fr tau, a pathgeni prtein in Alzheimer disease, prgressive supranulear palsy, and sme frms f frnttempral dementia, als may help refine premrtem diagnsti auray.D . Laboratory FindingsSerum  levels f vitamin B12, free T4, and thyrid-stimulat- ing hrmne shuld be measured fr any patient with gnitive symptms. A serum rapid plasma reagin (RPR) and testing fr HIV shuld be nsidered. Other testing shuld be driven by linial suspiin, and ften inludes a mplete bld unt, serum eletrlytes, gluse, and lipid prfile. Althugh the presene f ne r tw ApE epsiln-4 alleles indiates an inreased risk f Alzheimer disease and ApE gentyping is linially available, it is f limited clinical utility. Finding an ApE epsiln-4 allele in a yung patient with dementia might raise the index f suspiin fr Alzheimer disease, but btaining a gentype in an elderly patient is unlikely t be helpful, and ding s in an asymptmati patient as a marker f risk fr Alzheimer disease is inapprpriate until a preventive therapy bemes available. Spinal fluid prtein measurements are als avail- able and may supprt the diagnsis f Alzheimer disease in the apprpriate linial ntext; levels f beta-amylid derease and tau prtein inrease in Alzheimer disease, but this testing shares sme f the same nerns as amylid PET imaging. »Differential DiagnosisIn  elderly patients with gradually prgressive gnitive symptms and n ther mplaint r sign, a neurde- generative disease is likely (Table 24–6). Deline begin- ning befre age 60, rapid prgressin, flutuating urse, unintended weight lss, systemi mplaints, r therunexplained symptms r signs raise suspiin fr a pr- ess ther than a neurdegenerative disease. In this ase, the differential is brad and inludes infetin r inflam- matry disease (nsider a lumbar punture t sreen fr ells r antibdies in the spinal fluid), neplasm r a para- neplasti nditin, endrine r metabli disease, drugs r txins, r ther nditins. Nrmal pressure hydrephalus is a diffiult diagnsis t establish. Symp- tms inlude gait apraxia (smetimes desribed as a “mag- neti” gait, as if the feet are stuk t the flr), urinary inntinene, and dementia. CT sanning r MRI f the brain reveals ventriles that are enlarged in bvius dispr- prtin t sulal widening and verall brain atrphy. »TreatmentA.  Nonpharmacologic ApproachesAe robic exercise (30 minutes several days per week) may redue the rate f funtinal deline and derease the demented patient’s aregiving needs and may redue the risk f dementia in nrmal individuals. Maintaining as ative a rle in the family and mmunity as pratially pssible is likely t be f benefit, emphasizing ativities at whih the patient feels nfident. Patients with neurde- generative diseases have a limited apaity t regain lst skills; fr instane, memry drills in a patient with Alzheimer disease are mre likely t lead t frustratin than benefit and studies shw that mputerized gnitive training des not imprve gnitin r funtin in demented patients. Vitamin E (1000 internatinal units twie daily) appears t redue the rate f funtinal deline in patients with Alzheimer disease, but des nt affet gnitin r prevent the develpment f Alzheimer disease in patients with mild gnitive impairment.B.  Cognitive SymptomsCh olinesterase inhibitors are first-line therapy fr Alzheimer disease and dementia with Lewy bdies (Table 24–6). They prvide mdest, symptmati treat- ment fr gnitive dysfuntin and may prlng the apaity fr independene but d notprevent disease prgressin. Cmmnly used mediatins inlude dnepezil (start at 5 mg rally daily fr 4 weeks, then inrease t 10 mg daily; a 23 mg daily dse is apprved fr mderate t severe Alzheimer disease, althugh its very mdest additinal effiay ver the 10 mg dse is vershad- wed by an inreased risk f side effets); rivastigmine (start at 1.5 mg rally twie daily, then inreasing every 2 weeks by 1.5 mg twie daily t a gal f 3–6 mg twie daily; r 4.6, 9.5, r 13.3 mg/24 h transdermally daily); and galantamine (start at 4 mg rally twie daily, then inreasing every 4 weeks by 4 mg twie daily t a gal f 8–12 mg twie daily; a ne-daily extended-release frmulatin is als available). Chlinesterase inhibitrs are notgiven fr frn- ttempral dementia beause they may wrsen behaviral symptms. Nausea and diarrhea are mmn side effets; synpe and ardia dysrhythmia are unmmn but mre serius. An ECG is ften btained befre and after starting therapy, partiularly in a patient with ardia disease r a histry f synpe.CMDT22_Ch24_p0978-p1053.indd  1024 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1025 CMDT 2022Mema ntine (start at 5 mg rally daily, then inrease by 5 mg per week up t a target f 10 mg twie daily) is apprved fr the treatment f mderate t severe Alzheimer disease. In frnttempral dementia, memantine is ineffe- tive and may wrsen gnitin. There is sme evidene that memantine may imprve gnitin and behavir amng patients with dementia with Lewy bdies. Disease-mdifying mediatins are nt yet available fr Alzheimer disease.C.  Mood and Behavioral DisturbancesSeletive  sertnin reuptake inhibitrs are generally safe and well tlerated in elderly, gnitively impaired patients, and they may be effiaius fr the treatment f depres- sin, anxiety, r agitatin. There is evidene t supprt the use f italpram (10–30 mg rally daily ) for agitation; side effets inlude QT prlngatin and wrsened gnitin at the highest dse. Parxetine shuld be avided beause it has antihlinergi effets; avid all triyli antidepres- sants fr the same reasn. Other antidepressant agents, suh as buprpin r venlafaxine, may be tried. Insmnia is mmn, and trazdne (25–50 mg rally at bedtime as needed) an be safe and effetive. Over-the- unter antihistamine hypntis must be avided, alng with benzdiazepines, beause f their tendeny t wrsen gnitin and preipitate delirium. Other presriptin hypntis suh as zlpidem may result in similar adverse reatins. Fr agitatin, impulsivity, and ther behavirs that interfere with safe aregiving, auses f delirium (detailed abve) shuld first be nsidered. When n reversible trigger is identified, treatment shuld be apprahed in a staged manner. Behaviral interventins, suh as rerien- tatin and distratin frm anxiety-prvking stimuli, are first-line. Ensure that the patient is kept ative during the day with bth physial exerise and mentally stimulating ativities, and that there is adequate sleep at night. Reas- sess the level f aregiving, and nsider inreasing the time spent diretly with an attendant. Next, ensure that apprpriate pharmalgi treatment f gnitin and md is ptimized. Finally, as a last resrt, when ther measures prve insuffiient and the patient’s behavirs raise safety nerns, nsider pharmalgi therapy. Citalpram r lw dses f an atypial antipsyhti mediatin suh as quetiapine (start 25 mg rally daily as needed, inreasing t tw t three times daily as needed) an be tried; even thugh atypial agents ause extrapyra- midal side effets less frequently than typial antipsyht- is, they shuld be used with partiular autin in a patient at risk fr falls, espeially if parkinsnian signs are already present. Regularly sheduled dsing f antipsy- htis is nt remmended, and if implemented shuld be reassessed n a frequent basis (eg, weekly), with attempts t taper ff as tlerated. There is an FDA blak bx warning against the use f all antipsyhti media- tins in elderly demented patients beause f an increased risk of death; the reasn fr the inreased mrtality is unlear. The mbinatin f dextrmethrphan and quini- dine (up t 30/10 mg rally twie daily) has shwn prmise in early linial trials.»Special CircumstancesA.  Rapidly Progressive DementiaWhen  dementia develps quikly, with bvius deline ver a few weeks t a few mnths, the syndrme may be lassified as a rapidly progressive dementia. The differen- tial diagnsis fr typial dementias is still relevant, but additinal etilgies must be nsidered, inluding prin disease; infetins; txins; neplasms; and autimmune and inflammatry diseases, inluding rtisterid- respnsive (Hashimt) enephalpathy and antibdy- mediated paraneplasti and nnparaneplasti enephalitis (Table 24–5). Wrkup shuld begin with brain MRI with ntrast and diffusin-weighted imaging, ru- tine labratry studies (serum vitamin B12, free T4, and thyrid-stimulating hrmne levels), serum RPR, HIV antibdy, Lyme serlgy, rheumatlgi tests (erythryte sedimentatin rate, C-reative prtein, and antinulear antibdy), anti-thyrglbulin and anti-thyrperxidase antibdy levels, paraneplasti and nnparaneplasti autimmune antibdies (Table 24–5), and erebrspinal fluid studies (ell unt and differential; prtein and glu- se levels; prtein eletrphresis fr liglnal bands; IgG index [spinal-fluid-t-serum-gamma-glbulin level] rati; and VDRL). Depending n the linial ntext, it may be neessary t exlude Wilsn disease (24-hur urine pper level); heavy metal intxiatin (urine heavy metal panel); and infetius enephalitis due t atypial bateria, viruses, fungi, and mybateria. Creutzfeldt-Jakob disease is a relatively mmn ause f rapidly prgressive dementia (see Chapter 32). Family histry is imprtant sine mutatins in PRNP , the gene fr the prin prtein, aunt fr arund 15% f ases. Diffu- sin-weighted MRI is the mst helpful diagnsti tl, lassially revealing rtial ribbning (a gyral pattern f hyperintensity) as well as restrited diffusin in the audate and anterir putamen. An eletrenephalgram ften shws peridi mplexes. Real time quaking indued nversin (RT-QuIC), in whih patient erebrspinal fluid is mixed with rembinant prin prtein and aggre- gatin f prin prtein is deteted, is a sensitive and spe- ifi diagnsti test. Refleting the high rate f neurnal death, erebrspinal fluid levels f the intraneurnal pr- teins tau, 14-3-3, and neurn-speifi enlase are ften elevated, althugh this finding is neither sensitive nr speifi.B.  Driving and DementiaI t is remmended that anypatient with mild dementia or worse should discontinue driving. Mst states have laws regulating driving amng gnitively impaired individuals, and many require the liniian t reprt the patient’s diag- nsis t the publi health department r department f mtr vehiles. There is n evidene that driving lasses help patients with neurdegenerative diseases. »When to ReferAll  patients with new, unexplained gnitive deline shuld be referred.CMDT22_Ch24_p0978-p1053.indd  1025 29/06/21 8:50 PMChapTER 241026 CMDT 2022 »When to AdmitAdmi ssin t the hspital shuld nly ur when essen- tial in patients with dementia due t inreased risk f develping hspital-aquired delirium.Arvanitakis  Z et al. Diagnsis and management f dementia: review. JAMA. 2019;322:1589. [PMID: 31638686] Law CK et al. Physial exerise attenuates gnitive deline and redues behaviral prblems in peple with mild gnitive impairment and dementia: a systemati review. J Physither. 2020;66:9. [PMID: 31843427]WE RNICKE ENCEPHALOPATHY & KORSAKOFF SYNDROMEW ernicke encephalopathy is haraterized by nfusin, ataxia, and nystagmus leading t phthalmplegia (lateral retus musle weakness, njugate gaze palsies); peripheral neurpathy may als be present. It is due to thiamine defi- ciency and in the United States urs mst mmnly in patients with alhlism. It may als ur in patients with AIDS r hyperemesis gravidarum, and after bariatri sur- gery. In suspeted ases, thiamine (100 mg) is given intra- venusly immediately and then intramusularly n a daily basis until a satisfatry diet an be ensured after whih the same dse is given rally. Sme guidelines remmend initial dses f 200–500 mg intravenusly three times daily fr the first 5–7 days f treatment. Intravenus gluse given before thiamine may preipitate the syndrme r wrsen the symptms. The diagnsis is nfirmed by the respnse in 1 r 2 days t treatment, whih must nt be delayed while awaiting labratry nfirmatin f thia- mine defiieny frm a bld sample btained prir t thiamine administratin. Korsakoff syndrome urs in mre severe ases; it inludes antergrade and retrgrade amnesia and smetimes nfabulatin, and may nt be regnized until after the initial delirium has lifted.ST UPOR & COMAE S S E N T I A L S  O F  D I A G N O S I S »Level of consciousness is depressed. »Stuporous patients respond only to repeated vig- orous stimuli. »Comatose patients are unarousable and unresponsive. »General ConsiderationsThe pa tient wh is stuporous is unrespnsive exept when subjeted t repeated vigrus stimuli, while the comatose patient is unarusable and unable t respnd t external events r inner needs, althugh reflex mvements and psturing may be present. Cma is a majr mpliatin f serius entral nervus system disrders. It an result frm seizures,hypthermia, metabli disturbanes, r strutural lesins ausing bilateral erebral hemispheri dysfuntin r a disturbane f the brainstem retiular ativating system. A mass lesin invlving ne erebral hemisphere may ause ma by mpressin f the brainstem. »Assessment & Emergency MeasuresThe  diagnsti wrkup f the matse patient must pr- eed nmitantly with management. Supprtive therapy fr respiratin r bld pressure is initiated; in hypther- mia, all vital signs may be absent and all suh patients shuld be rewarmed befre the prgnsis is assessed. The patient an be psitined n ne side with the nek partly extended, dentures remved, and seretins leared by sutin; if neessary, the pateny f the airways is main- tained with an rpharyngeal airway. Bld is drawn fr serum gluse, eletrlyte, and alium levels; arterial bld gases; liver bihemial and kidney funtin tests; and txilgi studies as indiated. Thiamine (100 mg), fllwed by dextrse 50% (25 g), and nalxne (0.4–1.2 mg) are given intravenusly withut delay. Further details are then btained frm attendants f the patient’s medial histry, the irumstanes surrunding the nset f ma, and the time urse f subsequent events. Abrupt nset f ma suggests subarahnid hemrrhage, brainstem strke, r intraerebral hemrrhage, whereas a slwer nset and prgressin ur with ther strutural r mass lesins. Urgent nnntrast CT sanning f the head is apprpriate if it an be btained diretly frm the emer- geny department, in rder t identify intraranial hemr- rhage, brain herniatin, r ther strutural lesin that may require immediate neursurgial interventin. A metabli ause is likely with a preeding intxiated state r agitated delirium. On examinatin, attentin is paid t the behav- iral respnse t painful stimuli, the pupils and their respnse t light, the respnse t tuhing the rnea with a wisp f sterile gauze, psitin f the eyes and their mve- ment in respnse t passive mvement f the head and ie-water alri stimulatin, and the respiratry pattern.A.  Response to Painful StimuliPurp seful limb withdrawal frm painful stimuli implies that sensry pathways frm and mtr pathways t the stimulated limb are funtinally intat. Unilateral absene f respnses despite appliatin f stimuli t bth sides f the bdy in turn implies a rtispinal lesin; bilateral absene f respnsiveness suggests brainstem invlvement, bilateral pyramidal trat lesins, r psyhgeni unrespnsiveness. Dertiate (flexr) psturing may ur with lesins f the internal apsule and rstral erebral pedunle and deere- brate (extensr) psturing with dysfuntin r destrutin f the midbrain and rstral pns. Deerebrate psturing urs in the arms ampanied by flaidity r slight flexr respnses in the legs in patients with extensive brainstem damage extending dwn t the pns at the trigeminal level.B.  Ocular Findings1.  Pupils— Hypthalami disease presses may lead t unilateral Hrner syndrme, while bilateral dienephaliCMDT22_Ch24_p0978-p1053.indd  1026 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1027 CMDT 2022inv lvement r destrutive pntine lesins may lead t small but reative pupils. Ipsilateral pupillary dilatin with n diret r nsensual respnse t light urs with m- pressin f the third ranial nerve, eg, with unal hernia- tin. The pupils are slightly smaller than nrmal but respnsive t light in many metabli enephalpathies; hwever, they may be fixed and dilated fllwing verds- age with atrpine r splamine, and pinpint (but respnsive) with piids. 2. Corneal reflex— Tuhing the rnea with a wisp f sterile gauze r ttn shuld eliit a blink reflex. The affer- ent limb f the ar is mediated by the fifth ranial nerve; the efferent limb by the seventh nerve. A unilateral absent rneal reflex implies damage t the ipsilateral pns r a trigeminal defiit. Bilateral lss an be seen with large pn- tine lesins r in deep pharmalgi ma. 3. Eye movements— Cnjugate deviatin f the eyes t the side suggests the presene f an ipsilateral hemispheri lesin, a ntralateral pntine lesin, r nging seizures frm the ntralateral hemisphere. A mesenephali lesin leads t dwnward njugate deviatin. Dysnjugate u- lar deviatin in ma implies a strutural brainstem lesin unless there was preexisting strabismus. The ulmtr respnses t passive head turning and t alri stimulatin relate t eah ther and prvide m- plementary infrmatin. In respnse t brisk rtatin f the head frm side t side and t flexin and extensin f the head, nrmally nsius patients with pen eyes d nt exhibit ntraversive njugate eye deviatin ( oculocephalic reflex ) unless there is vluntary visual fixatin r bilateral frntal pathlgy. With rtial depressin in lightly ma- tse patients, a brisk ulephali reflex is seen. With brain- stem lesins, this ulephali reflex bemes impaired r lst, depending n the site f the lesin. Theoculovestibular reflex is tested by alri stimula- tin using irrigatin with ie water. In nrmal patients, jerk nystagmus is eliited fr abut 2 r 3 minutes, with the slw mpnent tward the irrigated ear. In unnsius patients with an intat brainstem, the fast mpnent f the nystagmus disappears, s that the eyes tnially deviate tward the irrigated side fr 2–3 minutes befre returning t their riginal psitin. With impairment f brainstem funtin, the respnse bemes abnrmal and finally dis- appears. In metabli ma, ulephali and ulves- tibular reflex respnses are preserved, at least initially.C.  Respiratory PatternsDiseases ausing ma may lead t resp iratry abnrmali- ties. Cheyne-Stokes respiration (in whih episdes f deep breathing alternate with perids f apnea) may ur with bihemispheri r dienephali disease r in metabli disrders. Central neurogenic hyperventilation urs with lesins f the brainstem tegmentum; apneustic breathing (in whih there are prminent end-inspiratry pauses) suggests damage at the pntine level (eg, due t basilar artery lusin); and ataxic breathing (a m- pletely irregular pattern f breathing with deep and shallw breaths urring randmly) is assiated with lesins f the lwer pntine tegmentum and medulla.1. Stuor & Com Due to Structurl LesionsSupra tentorial mass lesions tend t affet brain funtin in a systemati way. There may initially be signs f hemi- spheri dysfuntin, suh as hemiparesis. As ma devel- ps and deepens, erebral funtin bemes prgressively disturbed, prduing a preditable prgressin f neur- lgi signs that suggest rstraudal deteriratin. Thus, as a supratentrial mass lesin begins t impair the dienephaln, the patient bemes drwsy, then stu- prus, and finally matse. There may be Cheyne-Stkes respiratin; small but reative pupils r an ipsilateral third nerve palsy due t unal herniatin; nrmal ulephali respnses with side-t-side head mvements but sme- times an impairment f reflex upward gaze with brisk flexin f the head; tni ipsilateral deviatin f the eyes in respnse t vestibular stimulatin with ld water; and initially a psitive respnse t pain but subsequently nly dertiate psturing. With further prgressin, midbrain failure urs. Mtr dysfuntin prgresses frm derti- ate t bilateral deerebrate psturing in respnse t pain- ful stimuli; Cheyne-Stkes respiratin is gradually replaed by sustained entral hyperventilatin; the pupils beme middle-sized and fixed; and the ulephali and ul- vestibular reflex respnses beme impaired, abnrmal, r lst. As the pns and then the medulla fail, the pupils remain unrespnsive; ulvestibular respnses are unb- tainable; respiratin is rapid and shallw; and painful stimuli may lead nly t flexr respnses in the legs. Finally, respiratin bemes irregular and stps, the pupils ften then dilating widely. In ntrast, a subtentorial (ie, brainstem) lesion may lead t an early, smetimes abrupt disturbane f n- siusness withut any rderly rstraudal prgressin f neurlgi signs. Cmpressive lesins f the brainstem, espeially erebellar hemrrhage, may be linially indis- tinguishable frm intraparenhymal presses. A strutural lesin is suspeted if the findings suggest fality. In suh irumstanes, a CT san shuld be per- frmed befre, r instead f, a lumbar punture in rder t avid any risk f erebral herniatin. Further management is f the ausal lesin and is nsidered separately under the individual disrders.2.  Stuor & Com Due to Metbolic DisturbncesPa tients with a metabli ause f ma generally have signs f pathy, diffuse, and symmetri neurlgi invlve- ment that annt be explained by lss f funtin at any single level r in a sequential manner, althugh fal r lateralized defiits may ur in hypglyemia. Pupillary reativity is usually preserved. Cmatse patients with meningitis, enephalitis, r subarahnid hemrrhage may als exhibit little in the way f fal neurlgi signs, hw- ever, and linial evidene f meningeal irritatin is sme- times very subtle in matse patients. Examinatin f the erebrspinal fluid in suh patients is essential t establish the rret diagnsis. In patients with ma due t erebral ishemia and hypxia, the absene f pupillary light reflexes 24 hursCMDT22_Ch24_p0978-p1053.indd  1027 29/06/21 8:50 PMChapTER 241028 CMDT 2022after retu rn f spntaneus irulatin indiates that there is little hane f regaining independene; absent rneal reflexes r absent r extensr mtr respnses at 72 hurs als indiate a grim prgnsis. Physial findings are less reliable preditrs f utme amng thse treated with therapeuti hypthermia, althugh absent rneal r pupillary light reflexes at 72 hurs likely indiate a pr prgnsis, as d bilaterally absent rtial smatsensry evked ptentials in respnse t median nerve stimulatin after the patient has returned t nrmthermia. Treatment f metabli enephalpathy is f the under- lying disturbane and is nsidered in ther hapters. If the ause f the enephalpathy is bsure, all mediatins exept essential nes may have t be withdrawn in ase they are respnsible fr the altered mental status.3.  Brin DetBrain  death urs when there is mplete and irreversible essatin f all brain funtin; althugh the rgans an be maintained with mehanial ventilatin fr the purpses f dnatin, in mst untries the diagnsis f brain death is equivalent to a declaration of death. T diagnse brain death, the ause f ma must be established, be mpati- ble with a knwn ause f brain death, and be irreversible. Reversible ma simulating brain death may be seen with hypthermia (temperature lwer than 32°C) and verds- age with entral nervus system depressant drugs. These nditins must be exluded by warming the patient and allwing enugh time fr all sedating mediatins t be metablized (ie, at least five half-lives) r by measuring serum levels. Severe bld pressure, eletrlyte, aid-base, and endrine derangements annt be present. Finally, a neurlgi examinatin must demnstrate that the patient is matse (ie, n eye pening and n respnse t entral r peripheral pain); has lst all brain- stem reflex respnses, inluding the pupillary, rneal, ulvestibular, ulephali, rpharyngeal, and ugh reflexes; and has n respiratry drive. The respnse t pain shuld be absent r nly nsist f spinal reflex mve- ments; deerebrate r dertiate psturing is nt nsis- tent with brain death. Absene f respiratry drive is demnstrated with an apnea test (absene f spntaneus respiratry ativity at a PAco2f at least 60 mm Hg r after a rise f 20 mm Hg frm baseline). Certain anillary tests may assist the determinatin f brain death if an apnea test annt be perfrmed but are nt essential. These inlude an iseletri eletrenepha- lgram, when the rerding is made arding t the re- mmendatins f the Amerian Clinial Neurphysilgy Siety, and demnstratin f an absent erebral irula- tin by intravenus radiistpe erebral angigraphy r by fur-vessel ntrast erebral angigraphy.4.  persistent Vegettive SttePa tients with severe bilateral hemispheri disease may shw sme imprvement frm an initially matse state, s that, after a variable interval, they appear t be awake but lie mtinless and withut evidene f awareness r higher mental ativity. This is alled a “persistent”vegetative state ne it has lasted ver 4 weeks and has als been variusly referred t as akineti mutism, apalli state, r ma vigil. Patients in a vegetative state frm a medial ause (eg, anxi brain injury) fr mre than 3 mnths and frm a traumati brain injury fr mre than 12 mnths are said t be in a “chronic” vegetative state, frm whih a few patients may regain nsiusness but remain severely disabled.5.  Minimlly Conscious StteIn this  state, patients exhibit innsistent evidene f n- siusness. There is sme degree f funtinal revery f behavirs suggesting self- r envirnmental-awareness, suh as basi verbalizatin r ntext-apprpriate gestures, emtinal respnses (eg, smiling) t emtinal but nt neutral stimuli, r purpsive respnses t envirnmental stimuli (eg, a finger mvement r eye blink apparently t mmand). Further imprvement is manifest by the rest- ratin f mmuniatin with the patient. The minimally nsius state may be temprary r permanent. Little infrmatin is available abut its natural histry r lng- term utlk, whih reflets the underlying ause. The likelihd f useful funtinal revery diminishes with time; after 12 mnths, patients are likely t remain severely disabled and withut a reliable means f mmuniatin. Prgnstiatin is diffiult. Amantadine (100–200 mg rally daily) may hasten revery when given t patients in a vegetative r minimally nsius state 4–16 weeks after traumati brain injury.6.  Locked-In Syndrome (De-Efferented Stte)Aute  destrutive lesins (eg, infartin, hemrrhage, demyelinatin, enephalitis) invlving the ventral pns and sparing the tegmentum may lead t a mute, quadripa- reti but nsius state in whih the patient is apable f blinking and vluntary eye mvement in the vertial plane, with preserved pupillary respnses t light. Suh a patient an mistakenly be regarded as matse. Cliniians shuld regnize that “lked-in” individuals are fully aware f their surrundings. The prgnsis is usually pr, but revery has asinally been reprted in sme ases, inluding resumptin f independent daily life. A similar nditin may ur with severe Guillain-Barré syndrme and has a better prgnsis.Giain  JT et al. Pratie guideline update remmendatins summary: disrders f nsiusness: reprt f the Guideline Develpment, Disseminatin, and Implementatin Subm- mittee f the Amerian Aademy f Neurlgy; the Amerian Cngress f Rehabilitatin Mediine; and the Natinal Institute n Disability, Independent Living, and Rehabili- tatin Researh. Neurlgy. 2018;91:450. [PMID: 30089618]HE AD INJURYT rauma is the mst mmn ause f death in yung pe- ple, and head injury aunts fr almst half f these trauma-related deaths. Head injury severity ranges frm concussion tsevere traumatic brain injury (TBI). Cn- ussin is bradly defined as an alteratin in mental statusCMDT22_Ch24_p0978-p1053.indd  1028 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1029 CMDT 2022aused  by trauma with r withut lss f nsiusness. The term nussin is ften used synnymusly with mild TBI. Grades f TBI are traditinally defined by the Glasgw Cma Sale (GCS) measured 30 minutes after injury (Table 24–7).Head trauma may ause erebral injury thrugh a vari- ety f mehanisms (Table 24–8). Central t management is determinatin f whih patients need head imaging and bservatin. Of partiular nern is identifiatin f patients with epidural and subdural hematma, wh may present with nrmal neurlgi findings shrtly after injury ( lucid interval ) but rapidly deterirate thereafter, and in whm surgial interventin is life-saving. »Clinical FindingsA.  Symptoms and SignsCmmn  symptms f nussin that develp autely inlude headahe, nausea, vmiting, nfusin, disrienta- tin, dizziness, and imbalane. A perid f amnesia enmpassing the traumati event and a variable perid f time leading up t the trauma is typial. Lss f nsius- ness may ur. Additinal symptms f phtphbia, phnphbia, diffiulty nentrating, irritability, and sleep and md disturbanes may develp ver the fllw- ing hurs t days. Examinatin is usually nrmal, althugh rientatin and attentin, shrt-term memry, and rea- tin time may be impaired. Persistent r prgressive deline in the level f nsiusness after the initial injury, r fal neurlgi findings, suggests the need fr urgent imaging and neursurgial nsultatin. Patients shuld als be examined fr signs f salp la- eratins, faial and skull frature, and nek injury. The linial signs f basilar skull frature inlude bruising Table 24–8. Acute cerebral sequelae of head injury (listed in alphabetical order).Sequele Clinicl Fetures ptology Acute epidural hemorrhageHeadache, confusion, somnolence, seizures, and focal defi- cits occur several hours after injury (lucid interval) and lead to coma, respiratory depression, and death unless treated by surgical evacuation.Tear in meningeal artery, vein, or dural sinus, leading to hematoma visible on CT scan. Acute subdural hemorrhageSimilar to epidural hemorrhage, but interval before onset of symptoms is longer. Neurosurgical consultation for consideration of evacuation.Hematoma from tear in veins from cortex to superior sagittal sinus or from cerebral laceration, visible on CT scan. Cerebral contusion or lacerationLoss of consciousness longer than with concussion. Focal neurologic deficits are often present. May lead to death or severe residual neurologic deficit.Bruising on side of impact (coup injury) or contralaterally (contrecoup injury). Vasogenic edema, multiple petechial hemorrhages, and mass effect. May have subarachnoid bleeding. Hernia- tion may occur in severe cases. Cerebral laceration specifically involves tearing of the cerebral tissue and pia-arachnoid overlying a contusion. Cerebral hemorrhageGenerally develops immediately after injury. Clinically resembles hypertensive hemorrhage. Surgery to relieve mass effect is sometimes necessary.Hematoma, visible on CT scan. Concussion A transient, trauma-induced alteration in mental status that may or may not involve loss of consciousness. Symptoms and signs include headache, nausea, disori- entation, irritability, amnesia, clumsiness, visual distur- bances, and focal neurologic deficit.Unknown; likely mild diffuse axonal injury and excito- toxic neuronal injury. Cerebral contusion may occur. Diffuse axonal injury Persistent loss of consciousness, coma, or persistent vege- tative state resulting from severe rotational shearing forces or deceleration.Imaging may be normal or may show tiny, scattered white matter hemorrhages. Histology reveals torn axons.Table 24–7. Glasgow Coma Scale.1point sEye OeningVerbl ResonseMotor Resonse 1 None None None 2 To pain Vocal but not verbalExtension 3 To voice Verbal but not conversationalFlexion 4 Spontaneous Conversational but disorientedWithdraws from pain 5 Spontaneous Oriented Localizes pain 6 Spontaneous Oriented Obeys commands1 GCS score indicating severity of traumatic brain injury (TBI): mild, 13–15; moderate , 9–12; severe , ≤ 8. Reproduced, with permission, from Aminoff MJ et al. Clinical Neurology , 9th ed, McGraw-Hill Education, 2015; Data from Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet . 1974;304:81–4.CMDT22_Ch24_p0978-p1053.indd  1029 29/06/21 8:50 PMChapTER 241030 CMDT 2022abut the  rbit ( raccoon sign ), bld in the external audi- try meatus ( Battle sign ), and leakage f erebrspinal fluid (whih an be identified by its gluse r beta- 2-transferrin ntent) frm the ear r nse. Cranial nerve palsies (invlving espeially the first, send, third, furth, fifth, seventh, and eighth nerves in any mbinatin) may als ur. The head and nek shuld be immbilized until imaging an be perfrmed.B.  Imaging and Other InvestigationsCurren t remmendatins are that head CT be perfrmed in patients with nussin and any f the fllwing: GCS sre less than 15, fal neurlgi defiit, seizure, agu- lpathy, aged 65 r lder, skull frature, persistent headahe r vmiting, retrgrade amnesia exeeding 30 minutes, intxiatin, r sft tissue injury f the head r nek. Otherwise, patients an be sent hme as lng as a respnsible aregiver an hek the patient at hurly inter- vals fr the next 24 hurs. Patients requiring imaging shuld be admitted unless the head CT is nrmal, the GCS sre is 15, there have been n seizures, there is n predis- psitin t bleeding, and they an be mnitred by a are- giver at hme. Beause injury t the spine may have ampanied head trauma, ervial spine radigraphs (three views) r CT shuld always be btained in matse patients and in patients with severe nek pain r a defiit pssibly related t rd mpressin. »TreatmentHead  injury an ften be prevented by helmets, seatbelts, and ther prtetive equipment. After intraranial bleeding has been exluded linially r by head CT, treatment f mild TBI is aimed at prmt- ing reslutin f pstnussive symptms and preventing recurrent injury, whih inreases the risk f hrni neu- rbehaviral impairment and delays revery. Rarely, a reurrent nussin while a patient is still symptmati frm a first nussin may lead t fatal erebral edema (second impact syndrome ). These bservatins frm the basis f the remmendatin that patients at risk fr reur- rent nussin (eg, athletes) be held ut f the risky ativ- ity until their nussive symptms have fully reslved. In patients hspitalized with mderate r severe TBI, management ften requires a multidisiplinary apprah due t multiple nmitant injuries. Elevated intraranial pressure an result frm diffuse axnal injury r a hema- tma requiring surgial evauatin, r frm a variety f medial auses. Dempressive ranietmy may redue therwise refratry intraranial hypertensin but des nt imprve neurlgi utme. Hypthermia is assi- ated with wrsened funtinal utmes. Beause bridging veins between the brain and venus sinuses beme mre vulnerable t shear injury as the brain atrphies, a subdural hematoma may develp days r weeks fllwing head injury in elderly patients r even ur spntaneusly. Clinial presentatin an be subtle, ften with mental hanges suh as slwness, drwsiness, headahe, nfusin, r memry disturbane. Falneurlgi defiits suh as hemiparesis r hemisensry disturbane are less mmn. Surgial interventin is indi- ated if the hematma is 10 mm r mre in thikness r there is a midline shift f 5 mm r mre; if there is a deline in GCS sre f 2 r mre frm injury t hspital admis- sin; r if ne r bth pupils are fixed and dilated. Salp laeratins and depressed skull fratures shuld be treated surgially as apprpriate. Simple skull fratures require n speifi treatment. If there is any leakage f erebrspinal fluid, nservative treatment, with elevatin f the head, restritin f fluids, and administratin f aetazlamide (250 mg rally fur times daily), is ften helpful; if the leak ntinues fr mre than a few days, lumbar subarahnid drainage may be neessary. Antibit- is are given if infetin urs, based n ulture and sen- sitivity studies; vainatin against pneumus is remmended (see Table 30–7). Only very asinal patients require intraranial repair f the dural defet beause f persistene f the leak r reurrent meningitis. »PrognosisMdera te and severe TBI may result in permanent gni- tive and mtr impairment depending n the severity and latin f the initial injury. Initial GCS and head CT find- ings have prgnsti value. Amng patients with a GCS sre f 8 r less at presentatin, mrtality apprahes 30% and nly ne-third f survivrs regain funtinal indepen- dene. Cgnitive impairment tends t affet frntal and tempral lbe funtin, ausing defiits in attentin, mem- ry, judgment, and exeutive funtin. Behaviral dysregu- latin, depressin, and disinhibitin an impair sial funtining. Ansmia, presumably due t shearing f fibers frm the nasal epithelium, is mmn. Epilepsy an develp after TBI, espeially with mre severe injury. Amng patients with severe TBI (typially lss f nsiusness fr at least 12–24 hurs, intraranial hematma, depressed skull frature, r erebral ntu- sin), phenytin r levetiraetam is typially given fr 7 days t redue the inidene f early psttraumati sei- zures; this is dne exlusively t minimize aute mplia- tins resulting frm suh seizures and des nt prevent the develpment f psttraumati epilepsy. Amng patients with mild TBI, symptms f nus- sin reslve in mst patients by 1 mnth and in the vast majrity by 3 mnths. Prlnged pstnussive symp- tms are unmmn, persisting at 1 year in 10–15% f patients. Risk fatrs fr prlnged pstnussive symp- tms inlude ative litigatin regarding the injury; repeated nussins; and GCS sre f 13 r less at presentatin. Headahes ften have migrainus features and may respnd t triyli antidepressants r beta-blkers (see Table 24–1). Opiids shuld be avided t minimize the risk f mediatin veruse headahe. Md symptms may respnd t antidepressants, anxilytis, and gnitive behaviral therapy. There appears t be an assiatin between head trauma and the later develpment f neurdegenerative disease, suh as Alzheimer disease, Parkinsn disease, r amytrphi lateral slersis (ALS). Nrmal pressure hydrephalus may als ur. Repetitive, mild headCMDT22_Ch24_p0978-p1053.indd  1030 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1031 CMDT 2022inju ry, suh as that whih urs in athletes r military persnnel, an lead t chronic traumatic encephalopathy, a distint pathlgi entity assiated with md and gnitive hanges and haraterized by the abnrmal aggregatin f tau r ther prteins either fally r glbally in the erebral rtex. Whether hrni trau- mati enephalpathy is a stati respnse t reurrent head injury r a prgressive neurdegenerative disease is nt knwn, but the severity f neurpathlgy appears t rrelate t lifetime expsure t repetitive head injury. »When to Refer• Patients with fal neurlgi defiits, altered n- siusness, r skull frature. •Patients with late mpliatins f head injury, eg, psttraumati seizure disrder r nrmal pressure hydrephalus. »When to Admit• Patients with nussin and GCS sre less than 15, predispsitin t bleeding, seizure, r n respnsible aregiver at hme. •Patients with abnrmal head CT.Ma riani M et al. Clinial presentatin f hrni traumati enephalpathy. Semin Neurl. 2020;40:370. [PMID: 32740900] Mish MR et al. Sprts mediine update: nussin. Emerg Med Clin Nrth Am. 2020;38:207. [PMID: 31757251]MU LTIPLE SCLEROSISE S S E N T I A L S  O F  D I A G N O S I S »Episodic neurologic symptoms. »Patient usually < 55 years of age at onset. »Single pathologic lesion cannot explain clinical findings. »Multiple foci best visualized by MRI. »General ConsiderationsThis  mmn neurlgi disrder, whih prbably has an autimmune basis, has its greatest inidene in yung adults. Epidemilgi studies indiate that multiple slersis is muh mre mmn in persns f western Eurpean lineage wh live in temperate znes. N ppulatin with a high risk fr multiple slersis exists between latitudes 40° N and 40° S. A geneti susepti- bility t the disease is present. Pathlgially, fal— ften perivenular—areas f demyelinatin with reative glisis are fund sattered in the white matter f the brain and spinal rd and in the pti nerves. Axnal damage als urs.»Clinical FindingsA.  Symptoms and SignsThe  mmn initial presentatin is weakness, numbness, tingling, r unsteadiness in a limb; spasti paraparesis; retrbulbar pti neuritis; diplpia; dysequilibrium; r a sphinter disturbane suh as urinary urgeny r hesi- tany. Symptms may disappear after a few days r weeks, althugh examinatin ften reveals a residual defiit. Several frms f the disease are regnized. In mst patients, there is an interval f mnths r years after the initial episde befre new symptms develp r the riginal nes reur (relapsing-remitting disease) . Eventually, hw- ever, relapses and usually inmplete remissins lead t inreasing disability, with weakness, spastiity, and ataxia f the limbs, impaired visin, and urinary inntinene. The findings n examinatin at this stage mmnly inlude pti atrphy; nystagmus; dysarthria; and pyramidal, sen- sry, r erebellar defiits in sme r all f the limbs. In sme f these patients, the linial urse hanges s that a steady deteriratin urs, unrelated t aute relapses (secondary progressive disease) . Less mmnly, symp- tms are steadily prgressive frm their nset, and disability develps at a relatively early stage (primary progressive disease) . The diagnsis annt be made with nfidene unless the ttal linial piture indiates invlvement f different parts of the central nervous system at different times. Fatigue is mmn in all frms f the disease. A number f fatrs (eg, infetin) may preipitate r trigger exaerbatins. Relapses are redued in pregnany but are mre likely during the 2 r 3 mnths fllwing pregnany, pssibly beause f the inreased demands and stresses that ur in the pstpartum perid.B.  ImagingMRI  f the brain and ervial rd has a majr rle in exluding ther auses f neurlgi dysfuntin and in demnstrating the presene f multiple lesins. In T1-weighted images, hypintense “blak hles” prbably represent areas f permanent axnal damage. Gadlinium- enhaned T1-weighted images may highlight areas f ative inflammatin with breakdwn f the bld-brain barrier, whih helps identify newer lesins. T2-weighted images prvide infrmatin abut disease burden r ttal number f lesins, whih typially appear as areas f high signal intensity. CT sans are less helpful than MRI. In patients with myelpathy alne and n linial r labratry evidene f mre widespread disease, MRI r myelgraphy is neessary t exlude a ngenital r aquired surgially treatable lesin. In patients with mixed pyramidal and erebellar defiits in the limbs, the framen magnum regin must be visualized t exlude the pssibil- ity f Arnld-Chiari malfrmatin, in whih parts f the erebellum and lwer brainstem are displaed int the ervial anal.C.  Laboratory and Other StudiesA  definitive diagnsis an never be based slely n the labratry findings. If there is linial evidene f nly aCMDT22_Ch24_p0978-p1053.indd  1031 29/06/21 8:50 PMChapTER 241032 CMDT 2022single  lesin in the entral nervus system, multiple sler- sis annt prperly be diagnsed unless it an be shwn that ther regins are affeted sublinially. Visual, brain- stem auditry, and smatsensry evked ptentials are helpful in this regard, but ther disrders may als be haraterized by multifal eletrphysilgi abnrmali- ties refleting disease f entral white matter. Certain infetins (eg, HIV , Lyme disease, syphilis), nnetive tissue diseases (eg, systemi lupus erythematsus, Sjögren syndrme), saridsis, metabli disrders (eg, vitamin B12 defiieny), and lymphma may therefre require exlusin. There may be mild lymphytsis r a slightly inreased prtein nentratin in the erebrspinal fluid, espeially sn after an aute relapse. Elevated IgG in erebrspinal fluid and disrete bands f IgG (liglnal bands) are present in many patients. The presene f suh bands is nt speifi, hwever, sine they have been fund in a variety f inflammatry neurlgi disrders and asinally in patients with vasular r neplasti disrders f the ner- vus system. Vitamin D defiieny may be assiated with an inreased risk f develping multiple slersis; randmized trials have nt shwn vitamin D supplementatin redues attak rate r prgressin in relapsing remitting disease.D . DiagnosisMultiple slersi s shuld nt be diagnsed unless there is evidene that tw r mre different regins f the entral white matter ( dissemination in space ) have been affeted at different times ( dissemination in time ); the mst widely used diagnsti algrithm is the 2017 revisin t the MDnald riteria. The diagnsis may be made in a patient with tw r mre typial attaks and bjetive evidene n linial examinatin f tw lesins (eg, pti disk atrphy and pyramidal weakness), r bjetive evi- dene f ne lesin with lear-ut histrial evidene the ther attak was typial f multiple slersis and in a dis- tint neuranatmi latin, and when n alternative explanatin fr the patient’s presentatin has been fund. T fulfill the riterin f disseminatin in spae in a patient with tw linial attaks but bjetive linial evi- dene f nly ne lesin, MRI shuld demnstrate at least ne lesin in at least tw f fur typial sites (periventriu- lar, rtial r juxtartial, infratentrial, r spinal); alternatively, an additinal attak lalized t a different site suffies. The riterin f disseminatin in time in a patient with nly ne attak an be fulfilled by the simul- taneus presene f gadlinium-enhaning and nnen- haning lesins at any time (inluding at initial examinatin); the presene f liglnal bands unique t the erebrspinal fluid; a new lesin n fllw-up MRI; r a send attak. Lesins in the pti nerve n MRI in patients with pti neuritis annt be used t fulfill the MDnald riteria fr disseminatin in spae r time. Pri- mary prgressive disease requires at least a year f prgres- sin, plus tw f three f the fllwing: at least ne typial brain lesin, at least tw spinal lesins, r liglnal banding in the erebrspinal fluid.In patients with a single linial event wh d nt sat- isfy riteria fr multiple slersis, a diagnsis f a clinically isolated syndrome (CIS) is made. Suh patients are at risk fr develping multiple slersis and are smetimes ffered beta-interfern r glatiramer aetate therapy, whih may delay prgressin t linially definite disease. Fllw-up MRI shuld be nsidered 6–12 mnths later t assess fr the presene f any new lesin. »TreatmentA t least partial revery frm aute exaerbatins an rea- snably be expeted, but further relapses may ur with- ut warning. Sme disability is likely t result eventually, but abut half f all patients are withut signifiant dis- ability even 10 years after nset f symptms. Current treatments are hiefly aimed at preventing relapses, thereby reduing disability. Recovery from acute relapses may be hastened by treat- ment with corticosteroids, but the extent of recovery is unchanged. Intravenus therapy is ften given first— typially methylprednislne 1 g daily fr 3 days—fllwed by ral prednisne at 60–80 mg daily fr 1 week with a taper ver the ensuing 2–3 weeks, but randmized trials shw similar effiay whether the initial high dse is given rally r intravenusly. Lng-term treatment with rti- sterids prvides n benefit and des nt prevent further relapses. Transient exaerbatin f symptms relating t interurrent infetin r heat requires n added treatment. In patients with relapsing disease, numerus media- tins have well-established effiay at reducing the frequency of attacks (Table 24–9). The initial agent is h- sen after nsidering mediatin tlerane and risks, patient preferene, and disease severity. Glatiramer aetate, an interfern, r dimethyl fumarate is ften used initially due t favrable side effet prfiles and availability, althugh the effiay f early treatment with higher inten- sity therapy is being explred. In general, the mediatins mst effetive in reduing relapses have strnger immun- mdulatry effets and mre, albeit rare, serius adverse effets. Presriptin f these agents shuld be managed by a speialist. Orelizumab is the nly mediatin effetive in slwing disability prgressin in primary prgressive multiple sle- rsis and is apprved fr this indiatin by the FDA. Fr patients with ative sendary prgressive disease, ladrib- ine, relizumab, fatumumab, zanimd, and sipnimd an be used. Plasmapheresis is smetimes helpful in patients with severe relapses unrespnsive t rtisterids. Symptmati therapy fr spastiity, neurgeni bladder, r fatigue may be required. Fatigue is espeially mmn in multiple slersis, and mdafinil (200 mg rally every mrning) is an effetive and FDA-apprved therapy fr this indiatin. Dalfampridine (an extended-release fr- mulatin f 4-aminpyridine administered as 10 mg rally twie daily) is effiaius at imprving timed gait in mul- tiple slersis. Depressin and even suiidality an ur in multiple slersis and may wrsen with interfern beta-1a therapy; sreening and nventinal treatment f suh symptms are apprpriate.CMDT22_Ch24_p0978-p1053.indd  1032 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1033 CMDT 2022 »When to ReferAll  patients, but espeially thse with prgressive disease despite standard therapy, shuld be referred. »When to Admit• Patients requiring plasma exhange fr severe relapses unrespnsive t rtisterids. •During severe relapses. •Patients unable t manage at hme.Fr eedman MS et al. Treatment ptimizatin in multiple slersis: Canadian MS wrking grup remmendatins. Can J Neurl Si. 2020;47:437. [PMID: 32654681] Rae-Grant A et al. Pratie guideline remmendatins summary: disease-mdifying therapies fr adults with multiple slersis: reprt f the Guideline Develpment, Disseminatin, and Implementatin Submmittee f the Amerian Aademy f Neurlgy. Neurlgy. 2018;90:777. [PMID: 29686116]NEUROMYELITIS OPTICAThis  disrder is haraterized by pti neuritis and aute myelitis with MRI hanges that extend ver at least three segments f the spinal rd. An islated myelitis r pti neuritis may als ur. Previusly knwn as Devi disease and ne regarded as a variant f multiple slersis, neur- myelitis ptia is assiated with a speifi antibdy marker (NMO-IgG) targeting the water hannel aquaprin-4 in 80% f ases, and with antibdies t myelin ligdendr- yte glyprtein (MOG-IgG) in apprximately 33% f NMO-IgG sernegative patients. MRI f the brain typially des nt shw widespread white matter invlvement, but suh hanges d nt exlude the diagnsis. Treatment is by lng-term immunsuppressin. Three mediatins are apprved by the FDA fr treatment f neurmyelitis ptia based n plaeb-ntrlled trials demnstrating a redued annual relapse rate r time t first relapse. Eulizumab is a mplement inhibitr, inebilizumab is a humanizedTable 24–9. Treatment of multiple sclerosis (in alphabetical order within categories).1Mediction Dose acute Eisode, Including Relse2Dexamethasone 160 mg orally daily for 3–5 days Methylprednisolone 1 g intravenously or orally daily for 3–5 days Plasmapheresis Disese-Modifying Tery (FDa roved) Alemtuzumab (Lemtrada)3,412 mg intravenously daily for 5 days; 3-day course given 1 year later Cladribine (Mavenclad)3,5,61.75 mg/kg orally divided between weeks 1 and 5, repeated once in 1 year Dimethyl fumarate (Tecfidera)3,5240 mg orally twice daily Fingolimod (Gilenya)3,4,50.5 mg orally daily Glatiramer acetate (Copaxone, Mylan, Glatopa)520 mg subcutaneously daily or 40 mg subcutaneously three times weekly Interferon β-1a (Rebif)544 mcg subcutaneously three times per week Interferon β-1a (Avonex)530 mcg intramuscularly once per week Interferon β-1b (Betaseron, Extavia)50.25 mg subcutaneously on alternate days Mitoxantrone312 mg/m2intravenously every 3 months; maximum lifetime dose, 140 mg/m2Natalizumab  (Tysabri)3,4300 mg intravenously monthly Ocrelizumab (Ocrevus)3,4,5,6,7300 mg intravenously on day 1 and day 15, followed by 600 mg every 6 months Ofatumumab (Kesimpta)3,4,5,620 mg subcutaneously weeks 0, 1, 2, 4, and monthly thereafter Ozanimod (Zeposia)3,4,5,60.23 mg orally daily on days 1–4, 0.46 mg daily on days 5–7, and 0.92 mg daily thereafter Pegylated interferon β-1a (Plegridy)5125 mg subcutaneously once every 2 weeks Siponimod (Mayzent)3,4,5,60.25 mg orally daily, titrated over 5 or 6 days to 1 or 2 mg orally daily, depending on CYP2C9 genotype Teriflunomide (Aubagio)514 mg or 7 mg orally daily1 Several of these agents require special monitoring or pretreatment; some should be avoided during pregnancy. Readers should ref er to the manufacturer’s guidelines.2 For corticosteroid-refractory relapses, plasmapheresis may be used.3 Relapse prevention for disease activity despite use of first-line treatment.4 High disease activity (typically with multiple gadolinium-enhancing lesions on MRI).5 Relapse prevention, first-line treatment.6 Active secondary progressive disease.7 Primary progressive disease.CMDT22_Ch24_p0978-p1053.indd  1033 29/06/21 8:50 PMChapTER 241034 CMDT 2022an ti-CD19 antibdy that depletes B ells, and satralizumab is an interleukin-6 reeptr antagnist. Use f eulizumab requires prir immunizatin against meningus. Off- label therapy is with rituximab (tw 1-g intravenus infusins spaed by 2 weeks, r fur weekly infusins f 375 mg/m2; re-dsing may ur every 6 mnths r when CD19/20-psitive r CD27-psitive lymphytes beme detetable), myphenlate mfetil (500–1500 mg rally twie daily, titrated until the abslute lymphyte unt falls belw 1500/mL [1.5 × 109/L]), r azathiprine (2.5–3 mg/kg rally). Aute relapses are treated with rti- sterids at dses similar t thse utlined fr multiple slersis and with plasma exhange fr severe relapses unrespnsive t rtisterids.Cree  BAC et al; N-MOmentum Study Investigatrs. Inebili- zumab fr the treatment f neurmyelitis ptia spetrum disrder (N-MOmentum): a duble-blind, randmized plaeb-ntrlled phase 2/3 trial. Lanet. 2019;394:1352. [PMID: 31495497] Pittk SJ et al. Eulizumab in aquaprin-4-psitive neurmyeli- tis ptia spetrum disrder. N Engl J Med. 2019;381:614. [PMID: 31050279]VI TAMIN E DEFICIENCYV itamin E defiieny may prdue a disrder smewhat similar t Friedreih ataxia. There is spinerebellar degen- eratin invlving partiularly the psterir lumns f the spinal rd and leading t limb ataxia, sensry lss, absent tendn reflexes, slurring f speeh, and, in sme ases, pigmentary retinal degeneratin. The disrder may ur as a nsequene f malabsrptin r n a hereditary basis (eg, abetalipprteinemia).SP ASTICITYThe  term “spastiity” is mmnly used fr an upper mtr neurn defiit, but it prperly refers t a velity- dependent inrease in resistane t passive mvement that affets different musles t a different extent, is nt uni- frm in degree thrughut the range f a partiular mve- ment, and is mmnly assiated with ther features f pyramidal defiit. It is ften a majr mpliatin f strke, erebral r spinal injury, stati perinatal enephalpathy, and multiple slersis. Spastiity may be exaerbated by pressure injuries, urinary r ther infetins, and niep- tive stimuli. Physial therapy with apprpriate strething prgrams is imprtant during rehabilitatin after the develpment f an upper mtr neurn lesin and in subsequent manage- ment f the patient. The aim is t prevent jint and musle contractures and perhaps t mdulate spastiity. Mediatin management is imprtant als, but treat- ment may inrease funtinal disability when inreased extensr tne is prviding additinal supprt fr patients with weak legs. Pharmalgi treatment with balfen (5–10 mg twie daily rally titrated t 80 mg daily), tizani- dine (2–8 mg three time daily rally), diazepam (2–10 mg three times daily rally), r dantrlene (25 mg ne daily rally, titrated every 3 days as tlerated t a maximum f100 mg fur times daily) is ften helpful. Dantrlene is best avided in patients with pr respiratry funtin r severe myardial disease. Cannabinids are als effetive in reduing spastiity, but are assiated with side effets, inluding dizziness, drwsiness, and fatigue. Intramusular injetin f btulinum txin is used t relax targeted musles. In patients with severe spastiity that is unrespnsive t ther therapies and is assiated with marked disability, intratheal injetin f phenl r alhl may be helpful. Surgial ptins inlude implantatin f an intratheal balfen pump, rhiztmy, r neuretmy. Severe ntra- tures may be treated by surgial tendn release.MYE LOPATHIES IN AIDSA  variety f myelpathies may ur in patients with AIDS. These are disussed in Chapter 31.MYE LOPATHY OF HUMAN T-CELL LEUKEMIA VIRUS INFECTIONH uman T-ell leukemia virus (HTLV-1), a human retrvi- rus, is transmitted by breastfeeding, sexual ntat, bld transfusin, and ntaminated needles. Mst patients are asymptmati, but after a variable latent perid (whih may be as lng as several years), a myelpathy develps in sme instanes. The MRI, eletrphysilgi, and erebr- spinal fluid findings are similar t thse f multiple sler- sis, but HTLV-1 antibdies are present in serum and spinal fluid. There is n speifi treatment, but intravenus r ral rtisterids may help in the initial inflammatry phase f the disease. Prphylati measures are imprtant. Needles r syringes shuld nt be shared; infeted patients shuld nt breastfeed their infants r dnate bld, semen, r ther tissue. Infeted patients shuld use ndms t prevent sexual transmissin.SU BACUTE COMBINED DEGENERATION OF THE SPINAL CORDSubaute  mbined degeneratin f the spinal rd is due tvitamin B12deficiency , suh as urs in perniius anemia. It is haraterized by myelpathy with spastiity, weakness, prprieptive lss, and numbness due t degeneratin f the rtispinal trats and psterir l- umns. Plyneurpathy, mental hanges, r pti neurpa- thy als develp in sme patients. Megalblasti anemia may als ur, but this des notparallel the neurlgi disrder, and the frmer may be bsured if fli aid supplements have been taken. Treatment is with vitamin B12. Fr perniius anemia, a nvenient therapeuti regi- men is 1000 mg yanbalamin intramusularly daily fr 1 week, then weekly fr 1 mnth, and then mnthly fr the remainder f the patient’s life. Oral yanbalamin replaement is nt advised fr perniius anemia when neurlgi symptms are present. A similar syndrme is aused by rereatinal abuse f inhaled nitrus xide due t its interferene with vitamin B12metablism. Cpper defiieny, aused by malabsrptin r exess zin inges- tin, may als be respnsible.CMDT22_Ch24_p0978-p1053.indd  1034 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1035 CMDT 2022SP INAL TRAUMAE S S E N T I A L S  O F  D I A G N O S I S »History of preceding trauma. »Development of acute neurologic deficit. »Signs of myelopathy on examination. »General ConsiderationsWhile  spinal rd damage may result frm whiplash injury, severe injury usually relates t frature-dislatin ausing mpressin r angular defrmity f the rd either ervi- ally r in the lwer thrai and upper lumbar regins. Extreme hyptensin fllwing injury may als lead t rd infartin. »Clinical FindingsT tal rd transetin results in immediate flaid paraly- sis and lss f sensatin belw the level f the lesin. Reflex ativity is lst fr a variable perid, and there is urinary and feal retentin. As reflex funtin returns ver the fl- lwing days and weeks, spasti paraplegia r quadriplegia develps, with hyperreflexia and extensr plantar respnses, but a flaid atrphi (lwer mtr neurn) paralysis may be fund depending n the segments f the rd that are affeted. The bladder and bwels als regain sme reflex funtin, permitting urine and fees t be expelled at intervals. As spastiity inreases, flexr r extensr spasms (r bth) f the legs beme trublesme, espeially if the patient develps bed sres r a urinary trat infetin. Paraplegia with the legs in flexin r exten- sin may eventually result. With lesser degrees f injury, patients may be left with mild limb weakness, distal sensry disturbane, r bth. Sphinter funtin may als be impaired, urinary urgeny and urge inntinene being espeially mmn. Mre partiularly, a unilateral rd lesin leads t an ipsilateral mtr disturbane with ampanying impairment f pr- prieptin and ntralateral lss f pain and temperature appreiatin belw the lesin ( Brown-Séquard syndrome ). A entral rd syndrme may lead t a lwer mtr neurn defiit at the level f the lesin and lss f pain and tem- perature appreiatin belw it, with sparing f psterir lumn funtins. With mre extensive invlvement, ps- terir lumn sensatin may als be impaired and pyrami- dal weakness develps. A radiular defiit may ur at the level f the injury—r, if the auda equina is invlved, there may be evidene f disturbed funtin in several lumbsa- ral rts. »TreatmentT reatment f the injury nsists f immbilizatin and—if there is rd mpressin—early dempressive lamine- tmy and fusin (within 24 hurs). Early treatment with high dses f rtisterids (eg, methylprednislne,30 mg/kg by intravenus blus, fllwed by 5.4 mg/kg/h fr 23 hurs) may imprve neurlgi revery if m- mened within 8 hurs after injury, althugh the evidene is limited and sme neursurgial guidelines d nt re- mmend their use. Anatmi realignment f the spinal rd by tratin and ther rthpedi predures is imprtant. Subsequent are f the residual neurlgi defiit—paraplegia r quadriplegia—requires treatment f spastiity and are f the skin, bladder, and bwels. »When to ReferAll  patients with fal neurlgi defiits shuld be referred. »When to Admit• Patients with neurlgi defiits. •Patients with spinal rd injury, mpressin, r aute epidural r subdural hematma. •Patients with vertebral frature-dislatin likely t mpress the rd.Ong B  et al. Management f the patient with hrni spinal rd injury. Med Clin Nrth Am. 2020;104:263. [PMID: 32035568]SYR INGOMYELIADestruti n r degeneratin f gray and white matter adja- ent t the entral anal f the ervial spinal rd leads t avitatin and aumulatin f fluid within the spinal rd. The preise pathgenesis is unlear, but many ases are assiated with Arnold-Chiari malformation , in whih there is displaement f the erebellar tnsils, medulla, and furth ventrile int the spinal anal, smetimes with ampanying meningmyelele. In suh irumstanes, the rd avity nnets with and may merely represent a dilated entral anal. In ther ases, the ause f avitatin is less lear. There is a harateristi linial piture, with segmental atrphy, areflexia, and lss f pain and tempera- ture appreiatin in a “ape” distributin, wing t the destrutin f fibers rssing in frnt f the entral anal in the mid-ervial spinal rd. Thrai kyphslisis is usually present. With prgressin, invlvement f the lng mtr and sensry trats urs as well, s that a pyrami- dal and sensry defiit develps in the legs. Upward exten- sin f the avitatin (syringbulbia) leads t dysfuntin f the lwer brainstem and thus t bulbar palsy, nystagmus, and sensry impairment ver ne r bth sides f the fae. Syringmyelia, ie, rd avitatin, may als ur in assiatin with an intramedullary tumr r fllwing severe rd injury, and the avity then des nt mmuni- ate with the entral anal. In patients with Arnld-Chiari malfrmatin, CT sans reveal a small psterir fssa and enlargement f the fra- men magnum, alng with ther assiated skeletal abnr- malities at the base f the skull and upper ervial spine. MRI reveals the syrinx as well as the harateristi findings f the Arnld-Chiari malfrmatin, inluding the audal displaement f the furth ventrile and herniatin f theCMDT22_Ch24_p0978-p1053.indd  1035 29/06/21 8:50 PMChapTER 241036 CMDT 2022erebellar  tnsils thrugh the framen magnum. Fal rd enlargement is fund at myelgraphy r by MRI in patients with avitatin related t past injury r intramed- ullary neplasms. Treatment f Arnld-Chiari malfrmatin with assi- ated syringmyelia is by subipital ranietmy and upper ervial laminetmy, with the aim f dempress- ing the malfrmatin at the framen magnum. The rd avity shuld be drained and, if neessary, an utlet fr the furth ventrile an be made. In avitatin assiated with intramedullary tumr, treatment is surgial, but radiatin therapy may be neessary if mplete remval is nt ps- sible. Psttraumati syringmyelia is als treated surgi- ally if it leads t inreasing neurlgi defiits r t intlerable pain.DE GENERATIVE MOTOR NEURON DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Weakness. »No sensory loss or sphincter disturbance. »Progressive course. »No identifiable underlying cause other than genetic basis in familial cases. »General ConsiderationsThis gr up f degenerative disrders is haraterized lini- ally by weakness and variable wasting f affeted musles, withut ampanying sensry hanges. Mtr neurn disease in adults generally mmenes between 30 and 60 years f age. There is degeneratin f the anterir hrn ells in the spinal rd, the mtr nulei f the lwer ranial nerves, and the rtispinal and r- tibulbar pathways. The disrder is usually spradi, but familial ases may ur and several geneti mutatins r li have been identified. Cigarette smking may be ne risk fatr. »ClassificationFive varieties ha ve been distinguished n linial grunds.A.  Progressive Bulbar PalsyBulbar  invlvement predminates wing t disease pr- esses affeting primarily the mtr nulei f the ranial nerves.B.  Pseudobulbar PalsyBulbar  invlvement predminates in this variety als, but it is due t bilateral rtibulbar disease and thus reflets upper mtr neurn dysfuntin. There may be a “pseud- bulbar affet, ” with unntrllable episdes f laughing r rying t stimuli that wuld nt nrmally have eliited suh marked reatins.C. Progressive Spinal Muscular AtrophyThis  is haraterized primarily by a lwer mtr neurn defiit in the limbs due t degeneratin f the anterir hrn ells in the spinal rd.D . Primary Lateral SclerosisThere is a p urely upper mtr neurn defiit in the limbs.E.  Amyotrophic Lateral Sclerosis ALSA mixed u pper and lwer mtr neurn defiit is fund in the limbs. This disrder is smetimes assiated with g- nitive deline (in a pattern nsistent with frnttempral dementia), a pseudbulbar affet, r parkinsnism. Apprximately 10% f ALS ases are familial and have been assiated with mutatins at several different geneti li, inluding a hexanuletide repeat n hrmsme 9 that als assiates with frnttempral dementia. »Differential DiagnosisTh e spinal musular atrphies (SMAs) are inherited syndrmes aused mst ften by mutatins f the sur- vival mtr neurn 1 ( SMN1 ) gene n hrmsme 5. Different mutatins result in mre r less severe disrup- tins f the prtein, resulting in an age f nset that ranges frm infany (SMA type I), t early (type II) r late hildhd (type III), t adulthd (type IV). X-linked spinal and bulbar musular atrphy (Kennedy syndrme) is assiated with an expanded trinuletide repeat sequene n the andrgen reeptr gene and ar- ries a mre benign prgnsis than ther frms f mtr neurn disease. There are reprts f juvenile SMA due t hexsa- minidase defiieny. Pure mtr syndrmes resembling mtr neurn disease may als ur in assiatin with mnlnal gammpathy r multifal mtr neurpa- thies with ndutin blk. A mtr neurnpathy may als develp in Hdgkin disease and has a relatively benign prgnsis. Infetive anterir hrn ell diseases (pli virus r West Nile virus infetin) an generally be distinguished by the aute nset and mnphasi urse f the illness, as disussed in Chapter 32. Aute flaid myelitis fllwing infetin with entervirus may ur, espeially in hildren, withut sensry invlve- ment and resembles plimyelitis. There is n speifi treatment. »Clinical FindingsA.  Symptoms and SignsDiffiu lty in swallwing, hewing, ughing, breathing, and talking (dysarthria) urs with bulbar invlvement. In prgressive bulbar palsy, there is drping f the palate; a depressed gag reflex; pling f saliva in the pharynx; a weak ugh; and a wasted, fasiulating tngue. In pseud- bulbar palsy, the tngue is ntrated and spasti and an- nt be mved rapidly frm side t side. Limb invlvement is haraterized by mtr disturbanes (weakness, stiff- ness, wasting, fasiulatins) refleting lwer r upperCMDT22_Ch24_p0978-p1053.indd  1036 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1037 CMDT 2022mt r neurn dysfuntin; there are n bjetive hanges n sensry examinatin, althugh there may be vague sen- sry mplaints. The sphinters are generally spared. Cg- nitive hanges r pseudbulbar affet may be present. The disrder is prgressive, and ALS is usually fatal within 3–5 years; death usually results frm pulmnary infetins. Patients with bulbar invlvement generally have the pr- est prgnsis, while patients with primary lateral slersis ften have a lnger survival despite prfund quadriparesis and spastiity.B.  Laboratory and Other StudiesEletrmygraphy  may shw signs f aute and hrni partial denervatin with reinnervatin. In patients with suspeted ALS, the diagnsis shuld nt be made with nfidene unless suh hanges are fund in at least three spinal regins (ervial, thrai, lumbsaral) r tw spinal regins and the bulbar musulature. Mtr ndu- tin velity is usually nrmal but may be slightly redued, and sensry ndutin studies are als nrmal. Bipsy f a wasted musle shws the histlgi hanges f denerva- tin but is nt neessary fr diagnsis. The serum reatine kinase may be slightly elevated but never reahes the extremely high values seen in sme f the musular dys- trphies. The erebrspinal fluid is nrmal. T diagnse SMA, mleular geneti testing fr pathgeni variants f SMN1 is available. There are abnrmal findings n retal bipsy and redued hexsaminidase A in serum and leuk- ytes in patients with juvenile SMA due t hexsaminidase defiieny. »TreatmentRiluzle,  50 mg rally twie daily, whih redues the pre- synapti release f glutamate, inreased shrt-term sur- vival in ALS in randmized trials. Edaravne, a free radial savenger, slws disease prgressin in patients with mild disease. It is administered in mnthly yles as a 60 mg intravenus infusin n days 1–14 in the first mnth and days 1–10 in the subsequent mnths. Nninvasive ventilatin at least 4 hurs per day in patients with a maximal inspiratry pressure less than 60 m H2O may prlng survival in ALS. Symptmati and supprtive measures t treat spastiity (disussed earlier), drling, and dysphagia, prevent ntratures, and pre- serve mbility are imprtant. Drling is treated with ver- the-unter dengestants, antihlinergi mediatins (suh as trihexyphenidyl, amitriptyline, r atrpine), btu- linum txin injetins int the salivary glands, r use f a prtable sutin mahine. Physial and upatinal ther- apy are helpful thrughut the disease urse. Cmbina- tin dextrmethrphan/quinidine (20 mg/10 mg, ne tablet rally ne r twie daily) may relieve symptms f pseudbulbar affet. A semiliquid diet r gastrstmy tube feeding may be needed if dysphagia is severe; it is advisable t perfrm the predure befre the fred vital apaity falls belw 50% f predited t minimize the risk f m- pliatins. Trahestmy is smetimes perfrmed if respi- ratry musles are severely affeted; hwever, in the terminal stages f these disrders, realisti expetatinsand advane are planning shuld be disussed. Infrma- tin n palliative are is prvided in Chapter 5. Treatment f spinal musular atrphy takes advantage f the fat that the SMN prtein is als ended by a se- nd gene, SMN2, that usually des nt translate funtinal prtein due t aberrant spliing. Nusinersen is an antisense lignuletide that mdulates premessenger RNA spli- ing f the SMN2 gene and results in inreased prdutin f the full-length prtein; it has shwn effetiveness in bth infants and hildren with SMA. It is apprved fr use in all ages and is administered intratheally (12 mg every 14 days fr three dses, then ne after a 30-day interval, then ne every 4 mnths). Risdiplam (5 mg rally daily fr patients 2 years f age and lder weighing mre than 20 kg) is a small mleule SMN2 spliing mdifier that als results in prdutin f the full-length prtein and is apprved fr use in infants and adults. Gene therapy with intravenus delivery f an intat SMN1 gene using a viral vetr (nasemngene abeparvve) imprves ventilatr-free survival mpared t histrial ntrls and is apprved by the FDA fr use in hildren under 2 years f age with bi- alleli mutatins in SMN1 . »When to ReferAll patien ts (t exlude ther treatable auses f symptms and signs) shuld be referred. »When to AdmitPa tients may need t be admitted fr initiatin r titratin f nninvasive ventilatin, r fr perids f inreased requirement f nninvasive ventilatr supprt during pul- mnary infetins.Me ruri E et al; CHERISH Study Grup. Nusinersen versus sham ntrl in later-nset spinal musular atrphy. N Engl J Med. 2018;378:625. [PMID: 29443664] Nrris SP et al. Amytrphi lateral slersis: update n linial management. Curr Opin Neurl. 2020;33:641. [PMID: 32868602] ºpERIphERaL NEUROpaThIESPe ripheral neurpathies an be ategrized n the basis f the struture primarily affeted. The predminant path- lgi feature may be axonal degeneration (axonal or neuronal neuropathies ) r paranodal or segmental demyelination. The distintin may be pssible n the basis f neurphysilgi findings. Mtr and sensry ndutin velity an be measured in aessible seg- ments f peripheral nerves. In axnal neurpathies, n- dutin velity is nrmal r redued nly mildly and needle eletrmygraphy prvides evidene f denerva- tin in affeted musles. In demyelinating neurpathies, ndutin may be slwed nsiderably in affeted fibers, and in mre severe ases, ndutin is blked m- pletely, withut ampanying eletrmygraphi signs f denervatin.CMDT22_Ch24_p0978-p1053.indd  1037 29/06/21 8:50 PMChapTER 241038 CMDT 2022PO LYNEUROPATHIES & MONONEURITIS MULTIPLEXE S S E N T I A L S  O F  D I A G N O S I S »Weakness, sensory disturbances, or both in the extremities. »Pain is common. »Depressed or absent tendon reflexes. »May be family history of neuropathy. »May be history of systemic illness or toxic exposure. »General ConsiderationsDiffuse  polyneuropathies lead t a symmetri sensry, mtr, r mixed defiit, ften mst marked distally. They inlude the hereditary, metabli, and txi disrders; idi- pathi inflammatry plyneurpathy ( Guillain-Barré syn- drome ); and the peripheral neurpathies that may ur as a nnmetastati mpliatin f malignant diseases. Invlvement f mtr fibers leads t flaid weakness that is mst marked distally; dysfuntin f sensry fibers auses impaired sensry pereptin. Tendn reflexes are depressed r absent. Paresthesias, pain, and musle tender- ness may als ur. Multiple mnneurpathies ( mono- neuropathy multiplex ) suggest a pathy multifal disease press suh as vasulpathy (eg, diabetes, arteritis), an infiltrative press (eg, leprsy, saridsis), radiatin dam- age, r an immunlgi disrder (eg, brahial plexpathy). »Clinical FindingsThe  ause f plyneurpathy r mnneuritis multiplex is suggested by the histry, mde f nset, and predminant linial manifestatins. Labratry wrkup inludes a m- plete bld unt, serum prtein eletrphresis with reflex t immunfixatin r immuntyping, determinatin f plasma urea and eletrlytes, liver bihemial tests, thy- rid funtin tests, vitamin B12level, tests fr rheumatid fatr and antinulear antibdy, HBsAg determinatin, a serlgi test fr syphilis, fasting bld gluse level and hemglbin A1, urinary heavy metal levels, erebrspinal fluid examinatin, and hest radigraphy. These tests shuld be rdered seletively, as guided by symptms and signs. Measurement f nerve ndutin velity an n- firm the peripheral nerve rigin f symptms and prvides a means f fllwing linial hanges, as well as indiate the likely disease press (ie, axnal r demyelinating neurpa- thy). Cutaneus nerve bipsy may help establish a preise diagnsis (eg, plyarteritis, amylidsis). In abut half f ases, n speifi ause an be established; f these, slightly less than half are subsequently fund t be familial. »TreatmentT reatment is f the underlying ause, when feasible, and is disussed belw under the individual disrders. Physial therapy helps prevent ntratures, and splints anmaintain a weak extremity in a psitin f useful funtin. Anestheti extremities must be prteted frm injury. T guard against burns, patients shuld hek the temperature f water and ht surfaes with a prtin f skin having nrmal sensatin, measure water temperature with a ther- mmeter, and use ld water fr washing r lwer the temperature setting f their ht-water heaters. Shes shuld be examined frequently during the day fr grit r freign bjets in rder t prevent pressure lesins. Patients with plyneurpathies r mnneuritis multi- plex are subjet t additinal nerve injury at pressure pints and shuld therefre avid suh behavir as leaning n elbws r sitting with rssed legs fr lengthy perids. Neurpathi, burning pain may respnd t simple anal- gesis, suh as aspirin r nnsteridal anti-inflammatry agents, and t gabapentin (300 mg rally three times daily, titrated up t a maximum f 1200 mg rally three times daily as neessary) r pregabalin (50–100 mg rally three times daily). Dulxetine (60 mg rally ne r twie daily), venlafaxine (start 37.5 mg rally twie daily, and titrate up t 75 mg rally tw t three times daily), r triyli antide- pressants (eg, amitriptyline 10–150 mg rally at bedtime daily) may be helpful, espeially in painful diabeti neu- rpathy. Medial annabis may prvide sme relief, but lng-term safety data are laking. The use f a frame r radle t redue ntat with bedlthes may be helpful. Many patients experiene episdi stabbing pains, whih may respnd t gabapentin, pregabalin, arbamazepine (start 100 mg rally twie daily, and titrate up t 400 mg rally twie daily), r triyli antidepressants. Opiids may be neessary fr severe hyperpathia r pain indued by minimal stimuli, but their use generally shuld be avided. Symptms f autnmi dysfuntin are asinally trublesme. Treatment f pstural hyptensin is dis- ussed earlier in this hapter. Eretile dysfuntin an be treated with phsphdiesterase inhibitrs; a flaid neur- pathi bladder may respnd t parasympathmimeti mediatins suh as bethanehl hlride, 10–50 mg three r fur times daily.Ada ms D et al. Patisiran, an RNAi therapeuti, fr hereditary transthyretin amylidsis. N Engl J Med. 2018;379:11. [PMID: 29972753] Bensn MD et al. Intersen treatment fr patients with heredi- tary transthyretin amylidsis. N Engl J Med. 2018;379:22. [PMID: 29972757]1.  Inerited NeurotiesA.  CharcotMarieTooth Disease HMSN Type I, IIThere  are several distint varieties f Chart-Marie-Tth disease, usually with an autsmal dminant mde f inheritane, but asinal ases ur n a spradi, reessive, r X-linked basis. Clinial presentatin may be with ft defrmities r gait disturbanes in hildhd r early adult life. Slw prgressin leads t the typial fea- tures f plyneurpathy, with distal weakness and wasting that begin in the legs, a variable amunt f distal sensry lss, and depressed r absent tendn reflexes. Tremr is a nspiuus feature in sme instanes. Hereditary motorCMDT22_Ch24_p0978-p1053.indd  1038 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1039 CMDT 2022and  sensory neuropathy (HMSN) type I is haraterized by demyelinatin n eletrdiagnsti studies and is usu- ally aused by mutatins in the peripheral myelin prtein 22 r myelin prtein zer gene. In HMSN type II , eletr- diagnsti studies shw axnal lss rather than demyelin- atin; ne-third f ases are due t mutatins in the gene mitfusin 2. A similar disrder may ur in patients with prgres- sive distal spinal musular atrphies, but there is n sen- sry lss; eletrphysilgi investigatin reveals that mtr ndutin velity is nrmal r nly slightly redued, and nerve atin ptentials are nrmal.B.  DejerineSottas Disease HMSN Type IIIThe  disrder may ur n a spradi, autsmal dmi- nant r, less mmnly, autsmal reessive basis. Onset in infany r hildhd leads t a prgressive mtr and sensry plyneurpathy with weakness, ataxia, sensry lss, and depressed r absent tendn reflexes. The periph- eral nerves may be palpably enlarged and are haraterized pathlgially by segmental demyelinatin, Shwann ell hyperplasia, and thin myelin sheaths. Eletrphysilgi- ally, there is a slwing f ndutin, and sensry atin ptentials may be unrerdable.C.  Friedreich AtaxiaThis disrder , the nly knwn autosomal recessive trinu- cleotide repeat disease, is aused by expansin f a ply- GAA lus in the gene fr frataxin n hrmsme 9, leading t symptms in hildhd r early adult life. The gait bemes ataxi, the hands beme lumsy, and ther signs f erebellar dysfuntin develp ampanied by weakness f the legs and extensr plantar respnses. Invlvement f peripheral sensry fibers leads t sensry disturbanes in the limbs and depressed tendn reflexes. There is bilateral pes avus. Pathlgially, there is a marked lss f ells in the psterir rt ganglia and degeneratin f peripheral sensry fibers. In the entral nervus system, hanges are nspiuus in the psterir and lateral lumns f the rd. Eletrphysilgially, ndutin velity in mtr fibers is nrmal r nly mildly redued, but sensry atin ptentials are small r absent. Cardia disease is the mst mmn ause f death. In the differential diagnsis fr Friedreih ataxia are ther spinerebellar ataxias, a grwing grup f at least 30 inherited disrders, eah invlving a different identified gene. These hetergeneus disrders, whih frequently (but nt exlusively) exhibit an autsmal dminant inher- itane pattern and ply-CAG expansin f the affeted gene, typially ause erebellar ataxia and varying mbi- natins f ther symptms (suh as peripheral neurpathy, phthalmparesis, dysarthria, and pyramidal and extrapy- ramidal signs).D . Refsum Disease HMSN Type IVThis  autsmal reessive disrder is due t a disturbane in phytani aid metablism. Pigmentary retinal degen- eratin is ampanied by prgressive sensrimtr ply- neurpathy and erebellar signs. Auditry dysfuntin,ardimypathy, and utaneus manifestatins may als ur. Mtr and sensry ndutin velities are redued, ften markedly, and there may be eletrmy- graphi evidene f denervatin in affeted musles. Dietary restritin f phytani aid and its preursrs may be helpful therapeutially. Plasmapheresis t redue stred phytani aid may help at the initiatin f treatment.E.  PorphyriaPe ripheral nerve invlvement may ur during aute attaks in bth variegate porphyria andacute intermit- tent porphyria. Mtr symptms usually ur first, and weakness is ften mst marked prximally and in the upper limbs rather than the lwer. Sensry symptms and signs may be prximal r distal in distributin. Autnmi invlvement is smetimes prnuned. The eletrphysi- lgi findings are in keeping with the results f neur- pathlgi studies suggesting that the neurpathy is axnal in type (see Chapter 40).F . Familial Amyloid PolyneuropathySensr y and autnmi symptms are espeially nspiu- us, whereas distal wasting and weakness ur later. The plyneurpathy is axnal and likely results frm amylid depsitin within the peripheral nerves due t mutatins in the genes ending transthyretin, aplipprtein A1, r gelslin. Transthyretin amyloidosis is the mst mmn; is assiated with ardimypathy, nephrpathy, lept- meningeal invlvement, and vitreus paity; and is treat- able with liver transplantatin, the small interfering ribnulei aid patisiran (0.3 mg/kg up t 30 mg intrave- nusly ne every 3 weeks), r the antisense lignule- tide intersen (284 mg subutaneusly weekly). Tafamidis helps transthyretin amylid ardimypathy and may slw the prgressin f the neurpathy.2.  Neuroties associted wit Systemic & Metbolic DisordersA.  Diabetes MellitusIn  this disrder, invlvement f the peripheral nervus system may lead t symmetri sensry r mixed plyneu- rpathy, asymmetri mtr radiulneurpathy r plexpa- thy (diabeti amytrphy), thraabdminal radiulpathy, autnmi neurpathy, r islated lesins f individual nerves. These may ur singly r in any mbinatin and are disussed in Chapter 27.B.  UremiaU remia may lead t a symmetri sensrimtr plyneu- rpathy that tends t affet the lwer limbs mre than the upper limbs and is mre marked distally than prxi- mally (see Chapter 22). The diagnsis an be nfirmed eletrphysilgially beause mtr and sensry n- dutin velity is mderately redued. The neurpathy imprves bth linially and eletrphysilgially with kidney transplantatin and t a lesser extent with hrni dialysis.CMDT22_Ch24_p0978-p1053.indd  1039 29/06/21 8:50 PMChapTER 241040 CMDT 2022C.  Alcoholism and Nutritional DeficiencyMan y patients with alhl use disrder have an axnal distal sensrimtr plyneurpathy that is frequently ampanied by painful ramps, musle tenderness, and painful paresthesias and is ften mre marked in the legs than in the arms. Symptms f autnmi dysfuntin may als be nspiuus. Mtr and sensry ndutin velity may be slightly redued, even in sublinial ases, but grss slwing f ndutin is unmmn. Treatment is similar t diabeti plyneurpathy but als inludes abstinene frm alhl. A similar distal sensrimtr plyneurpathy is a well-regnized feature f beriberi (thiamine defiieny). In vitamin B12defiieny, distal sen- sry plyneurpathy may develp but is usually vershad- wed by entral nervus system manifestatins (eg, myelpathy, pti neurpathy, r intelletual hanges).D . ParaproteinemiasA symmetri s ensrimtr plyneurpathy that is gradual in nset, prgressive in urse, and ften ampanied by pain and dysesthesias in the limbs may ur in patients (espeially men) with plasma cell myeloma (frmerly multiple myelma). The neurpathy is f the axnal type in lassi lyti myelma, but segmental demyelinatin (pri- mary r sendary) and axnal lss may ur in slerti myelma and lead t predminantly mtr linial mani- festatins. Bth demyelinating and axnal neurpathies are als bserved in patients with paraprteinemias withut myelma. A small fratin will develp myelma if serially fllwed. The demyelinating neurpathy in these patients may be due t the mnlnal prteins reating t a m- pnent f the nerve myelin. The neurpathy f lassi plasma ell myelma is prly respnsive t therapy. The plyneurpathy f benign monoclonal gammopathy may respnd t immunsuppressant mediatins and plasmapheresis. Plyneurpathy may als ur in assiatin with mnlnal gammpathy f unknwn signifiane, ma- rglbulinemia, and ryglbulinemia and smetimes respnds t plasmapheresis. Many patients with an IgM M-prtein will have antibdies t myelin-assiated gly- prtein (MAG); these patients may respnd t treatment with rituximab. Entrapment neurpathy, suh as arpal tunnel syndrme, is mre mmn than plyneurpathy in patients with (nnhereditary) generalized amylidsis.3.  Neuroties associted wit Infectious & Inflmmtory DisesesA.  LeprosyLeprsy is an imprtan t ause f peripheral neurpathy in ertain parts f the wrld. Sensry disturbanes are mainly due t invlvement f intrautaneus nerves. In tuberu- lid leprsy, they develp at the same time and in the same distributin as the nerve; trunks lying beneath the lesin are als invlved. In leprmatus leprsy, there is mre extensive sensry lss, and this develps earlier and t a greater extent in the lest regins f the bdy, suh as the drsal surfaes f the hands and feet, where the bailliprliferate mst atively. Mtr defiits result frm invlve- ment f superfiial nerves where their temperature is lw- est, eg, the ulnar nerve in the regin prximal t the lerann grve, the median nerve as it emerges frm beneath the frearm flexr musle t run tward the arpal tunnel, the perneal nerve at the head f the fibula, and the psterir tibial nerve in the lwer part f the leg; pathy faial musular weakness may als ur wing t invlve- ment f the superfiial branhes f the seventh ranial nerve. Mtr disturbanes in leprsy are suggestive f multiple mnneurpathy, whereas sensry hanges resemble thse f distal plyneurpathy. Examinatin, hwever, relates the distributin f sensry defiits t the temperature f the tissues; in the legs, fr example, sparing frequently urs between the tes and in the ppliteal fssae, where the temperature is higher. Treatment is with antileprti agents (see Chapter 33).B.  AIDSA  variety f neurpathies ur in HIV-infeted patients (see Chapter 31).C.  Lyme BorreliosisThe  neurlgi manifestatins f Lyme disease inlude meningitis, meningenephalitis, plyradiulneurpathy, mnneurpathy multiplex, and ranial neurpathy. Ser- lgi tests establish the underlying disrder. Lyme disease and its treatment are disussed in depth in Chapter 34.D . SarcoidosisCranial  nerve palsies (espeially faial palsy), multiple mnneurpathy and, less mmnly, symmetri plyneu- rpathy may all ur, the latter smetimes preferentially affeting either mtr r sensry fibers. Imprvement may ur with use f rtisterids.E.  PolyarteritisIn vlvement f the vasa nervrum by the vasuliti press may result in infartin f the nerve. Clinially, ne enunters an asymmetri sensrimtr plyneurpathy (mnneuritis multiplex) that pursues a waxing and waning urse. Crtisterids and yttxi agents— espeially ylphsphamide—may be f benefit in severe ases (Chapter 20).F . Rheumatoid ArthritisCmpr essive r entrapment neurpathies, ishemi neu- rpathies, mild distal sensry plyneurpathy, and severe prgressive sensrimtr plyneurpathy an ur in rheumatid arthritis.4.  Neuroty associted wit Criticl IllnessPa tients in intensive are units with sepsis and multirgan failure smetimes develp plyneurpathies. This may be manifested initially by unexpeted diffiulty in weaningCMDT22_Ch24_p0978-p1053.indd  1040 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1041 CMDT 2022patients  frm a mehanial ventilatr and in mre advaned ases by wasting and weakness f the extremities and lss f tendn reflexes. Sensry abnrmalities are relatively innspiuus. The neurpathy is axnal in type. Its path- genesis is bsure, and treatment is supprtive. The prg- nsis is gd prvided patients rever frm the underlying ritial illness. A mypathy may als ur (disussed belw).5.  Toxic NeurotiesAxnal  plyneurpathy may fllw expsure t industrial agents r pestiides suh as arylamide, rganphsph- rus mpunds, hexaarbn slvents, methyl brmide, and arbn disulfide; metals suh as arseni, thallium, merury, and lead; and mediatins suh as phenytin, amidarne, perhexiline, isniazid, nitrfurantin, vin- ristine, and pyridxine in high dses. Detailed upa- tinal, envirnmental, and medial histries and regnitin f lusters f ases are imprtant in suggesting the diagnsis. Treatment is by preventing further expsure t the ausal agent. Isniazid neurpathy is prevented by pyridxine supplementatin. Diphtheriti neurpathy results frm a neurtxin released by the ausative rganism and is mmn in many areas. Palatal weakness may develp 2–4 weeks after infe- tin f the thrat, and infetin f the skin may similarly be fllwed by fal weakness f neighbring musles. Disturbanes f ammdatin may ur abut 4–5 weeks after infetin and distal sensrimtr demye- linating plyneurpathy after 1–3 mnths.6.  Neuroties associted wit Mlignnt DisesesA  variety f neurpathies have been assiated with nn- metastati mpliatins f malignany and were dis- ussed earlier.7.  acute Idiotic polyneuroty (Guillin-Brré Syndrome)E S S E N T I A L S  O F  D I A G N O S I S »Acute or subacute progressive polyradiculoneuro- pathy. »Weakness is more severe than sensory disturbances. »Acute dysautonomia may be life-threatening. »General ConsiderationsThis aute  r subaute plyradiulneurpathy smetimes fllws infetive illness, inulatins, r surgial pre- dures. There is an assiatin with preeding Campylo- bacter jejuni enteritis. The disrder prbably has an immunlgi basis, but the preise mehanism is unlear.»Clinical FindingsA.  Symptoms and SignsThe  main mplaint is f weakness that varies widely in severity in different patients and ften has a prximal emphasis and symmetri distributin. It usually begins in the legs, spreading t a variable extent but frequently invlving the arms and ften ne r bth sides f the fae. The musles f respiratin r deglutitin may als be affeted. Sensry symptms are usually less nspiuus than mtr nes, but distal paresthesias and dysesthesias are mmn, and neurpathi r radiular pain is present in many patients. Autnmi disturbanes are als m- mn, may be severe, and are smetimes life-threatening; they inlude tahyardia, ardia irregularities, hypten- sin r hypertensin, faial flushing, abnrmalities f sweating, pulmnary dysfuntin, and impaired sphinter ntrl. The axnal subtypes f the syndrme ( acute motor axonal neuropathy [AMAN] andacute motor and sensory axonal neuropathy [AMSAN] ) are aused by antibdies t ganglisides n the axn membrane. The Miller Fisher syndrome, anther subtype, is haraterized by the linial triad f phthalmplegia, ataxia, and are- flexia, and is assiated with anti-GQ1b antibdies.B.  Laboratory FindingsThe  erebrspinal fluid harateristially ntains a high prtein nentratin with a nrmal ell unt, but these hanges may take up t 2 weeks t develp; white bld ell unts greater than 50 ells/mL (0.05 × 109/L) shuld prmpt nsideratin f alternative diagnses. Eletr- physilgi studies may reveal marked abnrmalities, whih d nt neessarily parallel the linial disrder in their tempral urse. »Differential DiagnosisWhen  the diagnsis is made, the histry and apprpriate labratry studies shuld exlude the pssibility f pr- phyri, diphtheriti, r txi (heavy metal, hexaarbn, rganphsphate) neurpathies, and f HIV infetin. The tempral urse exludes ther peripheral neurpathies. Plimyelitis, btulism, and tik paralysis must als be nsidered as they ause weakness f aute nset. The presene f pyramidal signs, a markedly asymmetri mtr defiit, a sharp sensry level, r early sphinter invlve- ment shuld suggest a fal rd lesin. »TreatmentT reatment with prednisne is ineffetive and may prlng revery time. Plasmapheresis is f value; it is best per- frmed within the first few days f illness and is partiularly useful fr linially severe r rapidly prgressive ases r thse with ventilatry impairment. IVIG (400 mg/kg/day fr 5 days) is equally helpful. Patients shuld be admitted t intensive are units if their fred vital apaity is delining, and intubatin is nsidered if the fred vital apaity reahes 15 mL/kg, the maximum inspiratryCMDT22_Ch24_p0978-p1053.indd  1041 29/06/21 8:50 PMChapTER 241042 CMDT 2022pres sure reahes –30 mm Hg, r dyspnea bemes evident. Delining xygen saturatin is a late indiatr f neur- musular respiratry failure. Respiratry tilet and hest physial therapy help prevent ateletasis. Marked hypten- sin may respnd t vlume replaement r pressr agents. Thrmbprphylaxis is imprtant. »PrognosisMs t patients eventually make a gd revery, but this may take many mnths, and abut 20% f patients are left with persisting disability. Apprximately 3% f patients with aute idipathi plyneurpathy have ne r mre linially similar relapses, smetimes several years after the initial illness. »When to ReferAll patients sh uld be referred. »When to AdmitAll  patients shuld be hspitalized until their nditin is stable and there is n respiratry mprmise.Malek  E et al. Guillain-Barré syndrme. Semin Neurl. 2019;39:589. [PMID: 31639842]8.  Cronic Inflmmtory polyneurotyChrni  inflammatry demyelinating plyneurpathy, an aquired immunlgially mediated disrder, is linially similar t Guillain-Barré syndrme exept that it has a relapsing r steadily prgressive urse ver mnths r years and that autnmi dysfuntin is generally less mmn. It may present as an exlusively mtr disrder r with a mixed sensrimtr disturbane. In the relapsing frm, partial revery may ur after sme relapses, but in ther instanes there is n revery between exaerba- tins. Althugh remissin may ur spntaneusly with time, the disrder frequently fllws a prgressive dwn- hill urse leading t severe funtinal disability. Eletrdiagnsti studies shw marked slwing f mtr and sensry ndutin, and fal ndutin blk. Signs f partial denervatin may als be present wing t sendary axnal degeneratin. Nerve bipsy may shw hrni perivasular inflammatry infiltrates in the endneurium and epineurium, withut ampanying evidene f vasulitis. Hwever, a nrmal nerve bipsy result r the presene f nnspeifi abnrmalities des nt exlude the diagnsis. Crtisterids may arrest r reverse the dwnhill urse. Treatment is usually begun with prednisne, 60–80 mg rally daily, ntinued fr 2–3 mnths r until a definite respnse has urred. If n respnse has urred despite 3 mnths f treatment, a higher dse may be tried. In respnsive ases, the dse is gradually tapered, but mst patients beme rtisterid-dependent, ften requiring prednisne, 20 mg daily n alternate days, n a lng-term basis. IVIG an be used in plae f, r in additin t rti- sterids, and is best used as the initial treatment in puremtr syndrmes (2 g/kg ver 2–5 days fllwed by 1 g/kg every 3 weeks); a weekly regimen f 0.2–0.4 g/kg f a 20% subutaneus immunglbulin slutin is an effetive alternative but has nt been mpared diretly t rti- sterids r IVIG. When bth IVIG and rtisterids are ineffetive, plasma exhange may be wrthwhile. Cnsis- tent with the ntin that the nditin is antibdy medi- ated, rituximab has shwn prmise. Immunsuppressant r immunmdulatry mediatins (suh as azathiprine) may be added when the respnse t ther measures is unsatisfatry r t enable maintenane dses f rti- sterids t be lwered. Symptmati treatment is als imprtant.Bunshten  C et al. Prgress in diagnsis and treatment f hrni inflammatry demyelinating plyneurpathy. Lanet Neurl. 2019;18:784. [PMID: 31076244]MO NONEUROPATHIESE S S E N T I A L S  O F  D I A G N O S I S »Focal motor or sensory deficit. »Deficit is in territory of an individual peripheral nerve. An individual nerve may be injured alng its urse r may be mpressed, angulated, r strethed by neighbring ana- tmi strutures, espeially at a pint where it passes thrugh a narrw spae ( entrapment neuropathy ). The relative ntributins f mehanial fatrs and ishemia t the lal damage are nt lear. With invlvement f a sen- sry r mixed nerve, pain is mmnly felt distal t the lesin. Symptms never develp with sme entrapment neurpathies, reslve rapidly and spntaneusly in thers, and beme prgressively mre disabling and distressing in yet ther ases. The preise neurlgi defiit depends n the nerve invlved. Perussin f the nerve at the site f the lesin may lead t paresthesias in its distal distributin. Entrapment neurpathy may be the sle manifestatin f sublinial plyneurpathy, and this must be brne in mind and exluded by nerve ndutin studies. Suh studies are als indispensable fr the lalizatin f the fal lesin. In patients with aute mpressin neurpathy suh as may ur in intxiated individuals ( Saturday night palsy ), n treatment is neessary. Cmplete revery gen- erally urs, usually within 2 mnths, presumably beause the underlying pathlgy is demyelinatin. Hwever, ax- nal degeneratin an ur in severe ases, and revery then takes lnger and may never be mplete. In hrni mpressive r entrapment neurpathies, avidane f aggravating fatrs and rretin f any under- lying systemi nditins are imprtant. Lal infiltratin f the regin abut the nerve with rtisterids may be f value; in additin, surgial dempressin may help ifCMDT22_Ch24_p0978-p1053.indd  1042 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1043 CMDT 2022there  is a prgressively inreasing neurlgi defiit r if eletrdiagnsti studies shw evidene f partial denerva- tin in weak musles. Peripheral nerve tumrs are unmmn, exept in neu- rfibrmatsis type 1, but als give rise t mnneurpathy. This may be distinguishable frm entrapment neurpathy nly by nting the presene f a mass alng the urse f the nerve and by demnstrating the preise site f the lesin with apprpriate eletrphysilgi studies. Treatment f symptmati lesins is by surgial remval if pssible.1.  Crl Tunnel SyndromeSee Chapter 41. 2.  prontor Teres or anterior Interosseous SyndromeThe  median nerve gives ff its mtr branh, the anterir intersseus nerve, belw the elbw as it desends between the tw heads f the prnatr teres musle. A lesin f either nerve may ur in this regin, smetimes after trauma r wing t mpressin frm, fr example, a fibrus band. With anterir intersseus nerve invlvement, there is n sensry lss, and weakness is nfined t the prnatr qua- dratus, flexr plliis lngus, and the flexr digitrum pr- fundus t the send and third digits. Weakness is mre widespread and sensry hanges ur in an apprpriate distributin when the median nerve itself is affeted. The prgnsis is variable. If imprvement des nt ur spn- taneusly, dempressive surgery may be helpful.3.  Ulnr Nerve LesionsUlnar nerve lesi ns are likely t ur in the elbw regin as the nerve runs behind the medial epindyle and desends int the ubital tunnel. In the ndylar grve, the ulnar nerve is expsed t pressure r trauma. Mre- ver, any inrease in the arrying angle f the elbw, whether ngenital, degenerative, r traumati, may ause exessive strething f the nerve when the elbw is flexed. Ulnar nerve lesins may als result frm thikening r distrtin f the anatmi strutures frming the ubital tunnel, and the resulting symptms may als be aggravated by flexin f the elbw, beause the tunnel is then nar- rwed by tightening f its rf r inward bulging f its flr. A severe lesin at either site auses sensry hanges in the fifth and medial half f the furth digits and alng the medial brder f the hand. There is weakness f the ulnar-innervated musles in the frearm and hand. With a ubital tunnel lesin, hwever, there may be relative spar- ing f the flexr arpi ulnaris musle. Eletrphysilgi evaluatin using nerve stimulatin tehniques allws mre preise lalizatin f the lesin. Initial treatment nsists f aviding pressure n the medial elbw (eg, avid resting the elbws n arm rests; pad the elbw during sleep) and preventing prlnged elbw flexin, espeially at night. Splints are available t keep the elbw frm flexing beynd 45 t 90 degrees. If nservative measures are unsuessful in relieving symp- tms and preventing further prgressin, surgial treat- ment may be neessary. This nsists f nerve transpsitinif the lesin is in the ndylar grve, r a release pre- dure if it is in the ubital tunnel. Ulnar nerve lesins may als develp at the wrist r in the palm f the hand, usually wing t repetitive trauma r t mpressin frm ganglia r benign tumrs. They an be subdivided depending n their presumed site. Cm- pressive lesins are treated surgially. If repetitive mehani- al trauma is respnsible, this is avided by upatinal adjustment r jb retraining.4.  Rdil Nerve LesionsThe  radial nerve is partiularly liable t mpressin r injury in the axilla (eg, by ruthes r by pressure when the arm hangs ver the bak f a hair). This leads t weakness r paralysis f all the musles supplied by the nerve, inluding the trieps. Sensry hanges may als ur but are ften surprisingly innspiuus, being marked nly in a small area n the bak f the hand between the thumb and index finger. Injuries t the radial nerve in the spiral grve ur harateristially during deep sleep, as in intxiated individuals, and there is then sparing f the trieps musle, whih is supplied mre prximally. The nerve may als be injured at r abve the elbw; its purely mtr psterir intersseus branh, supplying the exten- srs f the wrist and fingers, may be invlved immediately belw the elbw, but then there is sparing f the extensr arpi radialis lngus, s that the wrist an still be extended. The superfiial radial nerve may be mpressed by hand- uffs r a tight wath strap.5.  Femorl NeurotyThe  linial features f femral nerve palsy nsist f weak- ness and wasting f the quadrieps musle, with sensry impairment ver the antermedian aspet f the thigh and smetimes als f the leg t the medial mallelus, and a depressed r absent knee jerk. Islated femral neurpathy may ur in patients with diabetes r frm mpressin by retrperitneal neplasms r hematmas (eg, expanding arti aneurysm). Femral neurpathy may als result frm pressure frm the inguinal ligament when the thighs are markedly flexed and abduted, as in the lithtmy psitin.6.  Merlgi presteticThe  lateral femral utaneus nerve, a sensry nerve arising frm the L2 and L3 rts, may be mpressed r strethed in bese r diabeti patients and during pregnany. The nerve usually runs under the uter prtin f the inguinal ligament t reah the thigh, but the ligament smetimes splits t enlse it. Hyperextensin f the hip r inreased lumbar lrdsis—suh as urs during pregnany—leads t nerve mpressin by the psterir fasile f the liga- ment. Hwever, entrapment f the nerve at any pint alng its urse may ause similar symptms, and several ther anatmi variatins predispse the nerve t damage when it is strethed. Pain, paresthesia, r numbness urs abut the uter aspet f the thigh, usually unilaterally, and is smetimes relieved by sitting. The pain stps at the knee, unlike the pain frm lwer lumbar siatia that radiates t the ft. Examinatin shws n abnrmalities exept inCMDT22_Ch24_p0978-p1053.indd  1043 29/06/21 8:50 PMChapTER 241044 CMDT 2022severe  ases when utaneus sensatin is impaired in the affeted area. Symptms are usually mild and mmnly settle spntaneusly. Hydrrtisne injetins medial t the antersuperir ilia spine ften relieve symptms tem- prarily, while nerve dempressin by transpsitin may prvide mre lasting relief.7.  Scitic & Common peronel (Fibulr) Nerve plsiesMisplaed  deep intramusular injetins are prbably still the mst mmn ause f siati nerve palsy. Trauma t the buttk, hip, r thigh may als be respnsible. The resulting linial defiit depends n whether the whle nerve has been affeted r nly ertain fibers. In general, the perneal (fibular) fibers f the siati nerve are mre suseptible t damage than thse destined fr the tibial nerve. A siati nerve lesin may therefre be diffiult t distinguish frm perneal (fibular) neurpathy unless there is eletrmygraphi evidene f invlvement f the shrt head f the bieps femris musle. The mmn perneal (fibular) nerve itself may be mpressed r injured in the regin f the head and nek f the fibula, eg, by sitting with rssed legs r wearing high bts. There is weakness f drsiflexin and eversin f the ft, am- panied by numbness r blunted sensatin f the anterlat- eral aspet f the alf and drsum f the ft.8.  Trsl Tunnel SyndromeThe  tibial nerve, the ther branh f the siati, supplies several musles in the lwer extremity, gives rigin t the sural nerve, and then ntinues as the psterir tibial nerve t supply the plantar flexrs f the ft and tes. It passes thrugh the tarsal tunnel behind and belw the medial mal- lelus, giving ff alaneal branhes and the medial and lat- eral plantar nerves that supply small musles f the ft and the skin n the plantar aspet f the ft and tes. Cmpres- sin f the psterir tibial nerve r its branhes between the bny flr and ligamentus rf f the tarsal tunnel leads t pain, paresthesias, and numbness ver the bttm f the ft, espeially at night, with sparing f the heel. Musle weakness may be hard t regnize linially. Cmpressive lesins f the individual plantar nerves may als ur mre distally, with linial features similar t thse f the tarsal tunnel syndrme. Treatment is surgial dempressin. »When to Refer• If there is unertainty abut the diagnsis. •Symptms r signs are prgressing despite treatment.BE LL PALSYE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of lower motor neuron facial palsy. »Hyperacusis or impaired taste may occur. »No other neurologic abnormalities.»General ConsiderationsBell pa lsy is an idiopathic facial paresis of lower motor neu- ron type that has been attributed t an inflammatry rea- tin invlving the faial nerve near the stylmastid framen r in the bny faial anal. In sme instanes, this may be due t reativatin f herpes simplex r variella zster virus infetin in the geniulate ganglin. The disr- der is mre mmn in pregnant wmen and in persns with diabetes mellitus. »Clinical FindingsThe  faial paresis (Figure 24–1) generally mes n abruptly, but it may wrsen ver the fllwing day r s. Pain abut the ear preedes r ampanies the weakness in many ases but usually lasts fr nly a few days. The fae itself feels stiff and pulled t ne side. There may be ipsilat- eral restritin f eye lsure and diffiulty with eating and fine faial mvements. A disturbane f taste is mmn, wing t invlvement f hrda tympani fibers, and hyper- ausis due t invlvement f fibers t the stapedius urs asinally. In ases due t herpes zster infetin, vesi- les may be bserved in the external ear anal. »Differential DiagnosisLwer  mtr neurn faial palsy an be differentiated frm strke by linial examinatin. A strke r ther entral lesin will nt ause hyperausis r disturbane f taste, ▲Figure 24–1. Facial palsy caused by an infection with Borrelia burgdorferi (Lyme disease). (Public Health Image Library, CDC.)CMDT22_Ch24_p0978-p1053.indd  1044 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1045 CMDT 2022generally  spares the frehead, and is ampanied by ther fal defiits. An islated faial palsy may ur in patients with HIV serpsitivity, saridsis, Lyme disease (Figure 24–1; als see Chapter 34), r any press ausing an inflammatry reatin in the subarahnid spae, suh as meningitis. Whenever faial palsies ur bilaterally, r a faial palsy urs in njuntin with ther neurlgi defiits, MRI brain imaging shuld be undertaken and ther investigatins nsidered. »TreatmentA pprximately 60% f ases f Bell palsy rever m- pletely withut treatment, presumably beause the lesin is s mild that it leads merely t ndutin blk. Treat- ment with rtisterids (prednisne 60 mg rally daily fr 5 days fllwed by a 5-day taper, r prednislne 25 mg rally twie daily fr 10 days) inreases the hane f a mplete revery at 9–12 mnths by 12–15%. Treat- ment with aylvir r valaylvir is nly indiated when there is evidene f herpeti vesiles in the external ear anal. It is helpful t prtet the eye with lubriating drps (r lubriating intment at night) and a path if eye lsure is nt pssible. There is n evidene that surgial predures t dempress the faial nerve are f benefit. Physial therapy may imprve faial funtin.Gagyr  I et al. Antiviral treatment f Bell’s palsy (idipathi faial paralysis). Chrane Database Syst Rev. 2019;9:CD001869. [PMID: 31486071]DI SCOGENIC NECK PAINE S S E N T I A L S  O F  D I A G N O S I S »Neck pain, sometimes radiating to arms. »Restricted neck movements. »Motor, sensory, or reflex changes in arms with root involvement. »Neurologic deficit in legs, gait disorder, or sphinc- ter disturbance with cord involvement. »General ConsiderationsA variety  f ngenital abnrmalities may invlve the er- vial spine and lead t nek pain; these inlude hemiverte- brae, fused vertebrae, basilar impressin, and instability f the atlantaxial jint. Traumati, degenerative, infetive, and neplasti disrders may als lead t pain in the nek. When rheumatid arthritis invlves the spine, it tends t affet espeially the ervial regin, leading t pain, stiff- ness, and redued mbility; displaement f vertebrae r atlantaxial subluxatin may lead t rd mpressin that an be life-threatening if nt treated by fixatin. Furtherdetails are given in Chapter 41 and disussin here is restrited t disk disease.1.  acute Cervicl Disk protrusionAut e ervial disk prtrusin leads t pain in the nek and radiular pain in the arm, exaerbated by head mvement. With lateral herniatin f the disk, mtr, sensry, r reflex hanges may be fund in a radiular (usually C6 r C7) distributin n the affeted side (Figure 24–2); with mre entrally direted herniatins, the spinal rd may als be invlved, leading t spasti paraparesis and sensry distur- banes in the legs, smetimes ampanied by impaired sphinter funtin. The diagnsis is nfirmed by MRI r CT myelgraphy. In mild ases, the prgnsis is gd and mplete revery urs in a majrity f patients with nservative therapy. Evidene des nt supprt any spe- ifi interventin, and sme mbinatin f bed rest, ativ- ity restritin, immbilizatin f the nek in a llar fr several weeks, and physial therapy is generally presribed. If these measures are unsuessful r the patient has a sig- nifiant neurlgi defiit, surgial remval f the prtrud- ing disk may be neessary.2.  Cervicl SondylosisCer vial spndylsis results frm hrni ervial disk degeneratin, with herniatin f disk material, sendary alifiatin, and assiated stephyti utgrwths. One r mre f the ervial nerve rts may be mpressed, strethed, r angulated; and myelpathy may als develp as a result f mpressin, vasular insuffiieny, r reur- rent minr trauma t the rd. Patients present with nek pain and restrited head mvement, ipital headahes, radiular pain and ther sensry disturbanes in the arms, weakness f the arms r legs, r sme mbinatin f these symptms. Examinatin generally reveals that lateral flex- in and rtatin f the nek are limited. A segmental pat- tern f weakness r dermatmal sensry lss (r bth) may be fund unilaterally r bilaterally in the upper limbs, and tendn reflexes mediated by the affeted rt r rts are depressed. The C5 and C6 nerve rts are mst mmnly invlved, and examinatin frequently then reveals weak- ness f musles supplied by these rts (eg, deltids, supra- spinatus and infraspinatus, bieps, brahiradialis), pain r sensry lss abut the shulder and uter brder f the arm and frearm, and depressed bieps and brahiradialis reflexes. Spasti paraparesis may als be present if there is an assiated myelpathy, smetimes ampanied by uri- nary urgeny, inntinene, r psterir lumn r spin- thalami sensry defiits in the legs. Plain radigraphs f the ervial spine shw stephyte frmatin, narrwing f disk spaes, and enrahment n the intervertebral framina, but suh hanges are mmn in middle-aged persns and may be unrelated t the pre- senting mplaint. CT r MRI helps nfirm the diagnsis and exlude ther strutural auses f the myelpathy. Restritin f nek mvements by a ervial llar may relieve pain. Lal injetin f anesthetis r rtisterids, fr instane by a pain management speialist, may be fCMDT22_Ch24_p0978-p1053.indd  1045 29/06/21 8:50 PMChapTER 241046 CMDT 2022 ▲Figure 24–2. Cutaneous innervation. The segmental or radicular (root) distribution is shown on the left side of the body and the peripheral nerve distribution on the right side. Segmental maps show differences depending on how they were constructed (single root stimulation or section; local anesthetic injection into single dorsal root ganglia). (Adapted, with permission, from Aminoff MJ, Greenberg DA, Simon RP . Clinical Neurology, 9th ed. McGraw-Hill Education, 2015.)= Iliohypogastric = Ilioinguinal = Genitofemoral Dorsal nerve of penis Perineal nerve of penisPeripheral nerve Nerve root Trigeminal (Cranial nerve V) Anterior cutaneous nerve of neck Supraclavicular nerves Axillary nerve Medial cutaneous nerve of arm Lateral cutaneous nerve of arm (branch of radial nerve) Medial cutaneous nerve of forearm Lateral cutaneous nerve of forearm Radial Median Ulnar Lateral femoral cutaneous Obturator Anterior femoral cutaneous Lateral cutaneous nerve of calf Saphenous Superficial peroneal Sural Lateral and medial plantar Deep peronealOphthalmic branch (V1) Maxillary branch (V2) Mandibular branch (V3)* *† †X XLateral thoracic rami Post.Mid.Ant.Anterior thoracic ramiC3 C4 C5 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1L1 L2 L3 L4 L5 S1T2 T1 C8C6C6 C7CMDT22_Ch24_p0978-p1053.indd  1046 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1047 CMDT 2022P eripheral nerve Posterior rami of cervical nerves Supraclavicular Axillary Medial cutaneous nerve of forearmLateral cutaneous nerve of forearm Lateral femoral cutaneous Obturator Anterior femoral cutaneous Posterior femoral cutaneous Lateral cutaneous nerve of calf SaphenousSuperficial peroneal Calcaneal Lateral plantar Medial plantarGreat occipital Lesser occipital Great auricular Posterior cutaneous nerve of forearmMedial cutaneous nerve of armLateral cutaneous nerve of arm Posterior cutaneous nerve of arm MedianPosterior lumbar rami Posterior sacral rami = IliohypogastricXX Nerve root Radial Ulnar SuralT2 T2 T1T3C2 C3 C4 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1 L2 C8C6 C7 S1L5 L5S3 L 3S4 S5 L4S2P osterior thoracic ramiLateral thoracic ramiC5 C6benefit . Operative treatment may be neessary t prevent further prgressin if there is a signifiant neurlgi defi- it; bwel r bladder symptms; r if rt pain is severe, persistent, and unrespnsive t nservative measures. »When to Refer• Pain unrespnsive t simple measures. •Patients with neurlgi defiits. •Patients in whm surgial treatment is under nsideratin.»When to Admit• Patients with prgressive r signifiant neurlgi defiit. •Patients with sphinter invlvement (frm rd mpressin). •Patients requiring surgial treatment.Stin AM et  al. Myelpathies due t strutural ervial and th- rai disease. Cntinuum (Minneap Minn). 2018;24:567. [PMID: 29613900]▲Figure 24–2. (Continued )CMDT22_Ch24_p0978-p1053.indd  1047 29/06/21 8:50 PMChapTER 241048 CMDT 2022BR aChIaL & LUMBaR pLEXUS LESIONS 1. Brcil plexus NeurotyBrahial  plexus neurpathy may be idipathi, smetimes urring in relatinship t a number f different nnspe- ifi illnesses r fatrs. In ther instanes, brahial plexus lesins fllw trauma r result frm ngenital anmalies, neplasti invlvement, r injury by varius physial agents. In rare instanes, the disrder urs n a familial basis. Idipathi brahial plexus neurpathy ( neuralgic amyotrophy ) harateristially begins with severe pain abut the shulder, fllwed within a few days by weak- ness, reflex hanges, and sensry disturbanes invlving espeially the C5 and C6 segments but affeting any nerve in the brahial plexus. Symptms and signs are usually unilateral but may be bilateral. Wasting f affeted musles is smetimes prfund. The disrder relates t disturbed funtin f ervial rts r part f the brahial plexus, but its preise ause is unknwn. Revery urs ver the ensuing mnths but may be inmplete. Treatment is purely symptmati, althugh emerging evidene suggests that mirsurgial neurlysis f hurglass-like nstri- tins n affeted nerves identified by magneti resnane neurgraphy r high-reslutin ultrasund imprves ut- me in patients wh have nt revered after several mnths f nservative management.2.  Cervicl Rib SyndromeC mpressin f the C8 and T1 rts r the lwer trunk f the brahial plexus by a ervial rib r band arising frm the seventh ervial vertebra leads t weakness and wasting f intrinsi hand musles, espeially thse in the thenar emi- nene, ampanied by pain and numbness in the medial tw fingers and the ulnar brder f the hand and frearm. Ele- trmygraphy, nerve ndutin studies, and smatsensry evked ptential studies may help nfirm the diagnsis. MRI may be espeially helpful in revealing the underlying mpressive struture. Plain radigraphs r CT sanning smetimes shws the ervial rib r a large transverse press f the seventh ervial vertebra, but nrmal findings d nt exlude the pssibility f a ervial band. Treatment f the disrder is by surgial exisin f the rib r band.3.  Lumboscrl plexus LesionsA  lumbsaral plexus lesin may develp in assiatin with diseases suh as diabetes, aner, r bleeding disr- ders r in relatin t injury. It asinally urs as an islated phenmenn similar t idipathi brahial plexpathy (nndiabeti lumbsaral radiulplexus neu- rpathy), and pain and weakness then tend t be mre nspiuus than sensry symptms. The distributin f symptms and signs depends n the level and pattern f neurlgi invlvement.Gstettner  C et al. Neuralgi amytrphy: a paradigm shift in diagnsis and treatment. J Neurl Neursurg Psyhiatry. 2020;91:879. [PMID: 32487526]DISORDERS OF NEUROMUSCULaR TRaNSMISSION 1. Mysteni GrvisE S S E N T I A L S  O F  D I A G N O S I S »Fluctuating weakness of commonly used volun- tary muscles, producing symptoms such as diplo- pia, ptosis, and difficulty in swallowing. »Activity increases weakness of affected muscles. »Short-acting anticholinesterases transiently improve the weakness. »General ConsiderationsM yasthenia gravis urs at all ages, sometimes in association with a thymic tumor or thyrotoxicosis , as well as in rheu- matid arthritis and lupus erythematsus. It is mst m- mn in yung wmen with HLA-DR3; if thymma is assiated, lder men are mre mmnly affeted. Onset is usually insidius, but the disrder is smetimes unmasked by a inidental infetin that leads t exa- erbatin f symptms. Exaerbatins may als ur befre the menstrual perid and during r shrtly after pregnany. Symptms are due t a variable degree f blk f neurmusular transmissin aused by autanti- bdies binding t aetylhline reeptrs; these are fund in mst patients with the disease and have a primary rle in reduing the number f funtining aetylhline reep- trs. Additinally, ellular immune ativity against the reeptr is fund. »Clinical FindingsA.  Symptoms and SignsPa tients present with ptsis, diplpia, diffiulty in hewing r swallwing, respiratry diffiulties, limb weakness, r sme mbinatin f these prblems. Weakness may remain lalized t a few musle grups r may beme generalized. The external ular musles and ertain ther ranial musles, inluding the mastiatry, faial, and pha- ryngeal musles, are espeially likely t be affeted, and the respiratry and limb musles may als be invlved. Symp- tms ften flutuate in intensity during the day, and this diurnal variatin is superimpsed n a tendeny t lnger- term spntaneus relapses and remissins that may last fr weeks. Nevertheless, the disrder fllws a slwly prgres- sive urse and may have a fatal utme wing t respira- try mpliatins suh as aspiratin pneumnia. Clinial examinatin nfirms the weakness and fatiga- bility f affeted musles. In mst ases, the extraular musles are invlved, and this leads t ular palsies and ptsis, whih are mmnly asymmetri. Pupillary respnses are nrmal. The bulbar and limb musles are ften weak, but the pattern f invlvement is variable. Sus- tained ativity f affeted musles inreases the weakness,CMDT22_Ch24_p0978-p1053.indd  1048 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1049 CMDT 2022whih impr ves after a brief rest. Sensatin is nrmal, and there are usually n reflex hanges. Life-threatening exaerbatins f myasthenia (s-alled myasthenic crisis ) may lead t respiratry weakness requiring immediate admissin t the intensive are unit, where respiratry funtin an be mnitred and ventila- tr supprt is readily available.B.  Laboratory and Other StudiesAssay  f serum fr elevated levels f irulating aetylh- line reeptr antibdies is useful beause it has a sensitiv- ity f 80–90% fr the diagnsis f myasthenia gravis. Certain patients withut antibdies t aetylhline reeptrs have serum antibdies t musle-speifi tyr- sine kinase (MuSK), whih shuld therefre be deter- mined; these patients are mre likely t have faial, respiratry, and prximal musle weakness than thse with antibdies t aetylhline reeptrs. Other antibd- ies assiated with myasthenia gravis inlude lw-density lipprtein reeptr-related prtein 4 (LRP4) and agrin, but tests fr these antibdies are nt widely mmerially available. Eletrphysilgi demnstratin f a derementing musle respnse t repetitive 2- r 3-Hz stimulatin f mtr nerves indiates a disturbane f neurmusular transmissin. Suh an abnrmality may even be deteted in linially strng musles with ertain prvative pre- dures. Needle eletrmygraphy f affeted musles shws a marked variatin in nfiguratin and size f individual mtr unit ptentials, and single-fiber eletrmygraphy reveals an inreased jitter, r variability, in the time interval between tw musle fiber atin ptentials frm the same mtr unit.C.  ImagingA  CT san f the hest with and withut ntrast shuld be btained t demnstrate a existing thymma. »TreatmentAntih linesterase mediatins prvide symptmati ben- efit withut influening the urse f the disease. Nestig- mine, pyridstigmine, r bth an be used, the dse being determined n an individual basis. The usual dse f ne- stigmine is 7.5–30 mg (average, 15 mg) rally taken fur times daily; f pyridstigmine, 30–180 mg (average, 60 mg) rally fur times daily. Overmediatin may temprarily inrease weakness. A wide range f mediatins (eg, ami- nglysides) may exaerbate myasthenia gravis and shuld be avided. Thymetmy shuld be perfrmed when a thymma is present. A multienter randmized trial demnstrated the benefit f thymetmy even in the absene f a radilgi- ally identifiable thymma, with imprved strength, lwer immunsuppressin requirements, and fewer hspitaliza- tins in the surgially treated grup. Thus, thymectomy should be considered in all patients younger than age 65 unless weakness is restricted to the extraocular muscles. If the disease is f reent nset and nly slwly prgressive,peratin is smetimes delayed fr a year r s, in the hpe that spntaneus remissin will ur. Treatment with rtisterids is indiated fr patients wh have respnded prly t antihlinester- ase mediatins. Sme patients experiene transient exaerbatin f weakness and even develp respiratry failure within the first 1–2 weeks if rtisterids are initiated at high dses (eg, prednisne 1 mg/kg/day). Therefre, in stable patients, rtisterids are intr- dued gradually in the utpatient setting. Prednisne an be started at 20 mg rally daily and inreased by 10 mg inrements weekly t a target f 1 mg/kg/day (maximum daily dse 100 mg). Fr patients hspitalized with severe myasthenia and treated with IVIG r plasma- pheresis, the higher dse an be given initially beause the mre rapid nset f atin f the frmer tw thera- pies mitigates the initial dip in strength due t rti- sterids. Crtisterids an be presribed as alternate-day r daily treatment, with alternate-day therapy ptentially mitigating side effets. One the patient has stabilized at the initial high dse, rtiste- rids an gradually be tapered t a relatively lw main- tenane level (eg, 10 mg prednisne rally daily) as imprvement urs; ttal withdrawal is diffiult, hw- ever. Treatment with azathiprine may be effetive in allwing a lwer dse f rtisterids. The usual dse is 2–3 mg/kg rally daily after a lwer initial dse. Other immunsuppressive agents that are used in myasthenia gravis t redue the rtisterid dse inlude myphe- nlate mfetil, rituximab, ylsprine, methtrexate, and tarlimus. Eulizumab, a mplement inhibitr, is apprved by the FDA fr aetylhline reeptr antibdy psitive myasthenia in patients wh have disease refra- try t at least tw alternate immunsuppressive thera- pies. It is administered intravenusly (900 mg weekly fr fur dses, fllwed by 1200 mg at week 5, then 1200 mg every 2 weeks). Patients must be vainated against menin- gus prir t reeiving eulizumab. In patients with majr disability, plasmapheresis r IVIG therapy may be benefiial and have similar effiay. It is als useful fr stabilizing patients befre thymetmy and fr managing aute risis. »When to ReferAll patients sh uld be referred. »When to Admit• Patients with aute exaerbatin r respiratry invlvement. •Patients requiring plasmapheresis. •Fr thymetmy.Fa rmakidis C et al. Treatment f myasthenia gravis. Neurl Clin. 2018;36:311. [PMID: 29655452] Muppidi S et al; Regain Study Grup. Lng-term safety and effiay f eulizumab in generalized myasthenia gravis. Musle Nerve. 2019;60:14. [PMID: 30767274]CMDT22_Ch24_p0978-p1053.indd  1049 29/06/21 8:50 PMChapTER 241050 CMDT 20222.  Mystenic Syndrome (Lmbert-Eton Mystenic Syndrome)E S S E N T I A L S  O F  D I A G N O S I S »Variable weakness, typically improving with activity. »Dysautonomic symptoms may also be present. »A history of malignant disease may be obtained. »Clinical FindingsM yastheni syndrme may be associated with small cell carcinoma, smetimes develping befre the tumr is diag- nsed, and asinally urs with ertain autimmune diseases. There is defetive release f aetylhline in respnse t a nerve impulse, aused by P/Q-type vltage- gated alium hannel antibdies, and this leads t weak- ness, espeially f the prximal musles f the limbs. Unlike myasthenia gravis, hwever, pwer steadily increases with sustained ntratin. The diagnsis an be n- firmed eletrphysilgially, beause the musle respnse t stimulatin f its mtr nerve inreases remarkably after exerise r if the nerve is stimulated repetitively at high rates (50 Hz), even in musles that are nt linially weak. »TreatmentT reatment with IVIG, plasmapheresis, and immunsup- pressive mediatin therapy (prednisne and azathiprine) may lead t linial and eletrphysilgi imprvement, in additin t therapy aimed at tumr when present. Pred- nisne is usually initiated in a daily dse f 60–80 mg rally and azathiprine in a daily dse f 2 mg/kg rally. Symp- tmati therapy inludes the use f ptassium hannel antagnists; f these, amifampridine is a 3,4-diaminpyri- dine (15–80 mg/day rally in three divided dses) and is apprved in the United States and Eurpe. Guanidine hydrhlride (25–50 mg/kg/day rally in divided dses) is an alternative and is asinally helpful in seriusly dis- abled patients, but adverse effets f the mediatin inlude marrw suppressin. The respnse t treatment with antihlinesterase mediatins suh as pyridstig- mine r nestigmine is usually disappinting.3.  BotulismThe txin f  Clostridium botulinum prevents the release f aetylhline at neurmusular juntins and autnmi synapses. Btulism urs mst mmnly fllwing the ingestin f ntaminated hme-anned fd; utbreaks have als urred amng drug abusers due t wund infetin after injetin f ntaminated herin. The diagnsis shuld be suggested by the develpment f sud- den, flutuating, severe weakness with preserved sensa- tin in a previusly healthy persn. Symptms begin within 72 hurs fllwing ingestin f the txin and may prgress fr several days. Typially, there is diplpia, ptsis,faial weakness, dysphagia, and nasal speeh, fllwed by respiratry diffiulty and finally by weakness that appears last in the limbs. Blurring f visin (with unreative dilated pupils) is harateristi, and there may be dryness f the muth, nstipatin (paralyti ileus), and pstural hyp- tensin. The tendn reflexes are nt affeted unless the invlved musles are very weak. If the diagnsis is sus- peted, the lal health authrity shuld be ntified and a sample f serum and ntaminated fd (if available) sent t be assayed fr txin. Supprt fr the diagnsis may be btained by eletrphysilgi studies; with repetitive stimulatin f mtr nerves at fast rates, the musle respnse inreases in size prgressively. Patients shuld be hspitalized in ase respiratry assis- tane bemes neessary. Treatment is with heptavalent antitxin, in patients withut knwn allergy t hrse serum. Ptassium hannel antagnists may prvide symp- tmati relief as they d in Lambert-Eatn myastheni syndrme. Antihlinesterase mediatins are f n value. Respiratry assistane and ther supprtive measures shuld be prvided as neessary. Further details are pr- vided in Chapter 33.4.  Disorders associted wit Use of aminoglycosidesAminglyside  antibitis, eg, gentamiin, may prdue a linial disturbane similar t btulism by preventing the release f aetylhline frm nerve endings, but symptms subside rapidly as the respnsible mediatin is eliminated frm the bdy. These antibitis are partiularly dangerus in patients with preexisting disturbanes f neurmusular transmissin and are therefre best avided in patients with myasthenia gravis.MYOp aThIC DISORDERSE S S E N T I A L S  O F  D I A G N O S I S »Muscle weakness without sensory loss, often in a characteristic distribution. »Serum creatine kinase elevated in most cases. »Age at onset, time course, and inheritance pattern may suggest underlying disorder. »General ConsiderationsMy pathies an be inherited r aquired. Aquired mypa- thies ften present autely r subautely while inherited mypathies are typially insidius in nset. Patients typi- ally mplain f weakness affeting prximal musles, suh as diffiulty limbing stairs, arising frm a hair, r reahing verhead, r f head drp. Sensry symptms are absent. A detailed family histry is required. Examinatin shws weakness f prximal musles. In sme ases, there is a mre speifi pattern f weaknessCMDT22_Ch24_p0978-p1053.indd  1050 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1051 CMDT 2022(eg,  quadrieps and finger flexr weakness in inlusin bdy mysitis). Extraular musle invlvement is rarely seen, exept in ertain mithndrial disrders, ulpha- ryngeal musular dystrphy, and hyperthyridism; when present, it shuld suggest the pssibility f a neurmusular juntin disrder. Reflexes are nrmal r diminished in prprtin t the degree f weakness. Sensatin is nrmal. Initial testing shuld inlude serum reatine kinase determinatin. Cnsider testing thyrid-stimulating hr- mne, rtisl, vitamin D, and alium. Antibdies speifi t ertain inflammatry mypathies and nnetive tissue disease an be heked when these nditins are suspeted (see Chapter 20). Eletrmygraphy will reveal small mtr units and early reruitment; it is helpful in nfirming the lalizatin f weakness t the musle and suggesting a suitable site fr bipsy, as des MRI. The eletrmy- graphi findings may be nrmal in rtisterid and mithndrial mypathies. Musle bipsy establishes the diagnsis when inflammatry, mithndrial, metabli, r ertain inherited mypathies are suspeted. In ases where the family histry r pattern f weakness suggests aspeifi geneti disrder, geneti testing an be pursued diretly and bipsy may nt be needed. Seleted mmn and treatable mypathies are disussed belw.1.  Musculr DystroiesThese  inherited mypathi disrders are subdivided by mde f inheritane, age at nset, and linial features, as shwn in Table 24–10. In the Duchenne type, pseudhy- pertrphy f musles frequently urs at sme stage; intel- letual disability is mmn; and there may be skeletal defrmities, musle ntratures, and ardia invlvement. A geneti defet n the shrt arm f the X hrmsme has been identified in Duhenne dystrphy. The affeted gene des fr the prtein dystrphin, whih is markedly redued r absent frm the musle f patients with the disease. Dystrphin levels are generally nrmal in the Becker variety, but the prtein is qualitatively altered. The diagnsis is usually made with geneti testing; musle bipsy is needed asinally. Duhenne musular dystr- phy an be regnized early in pregnany in abut 95% f Table 24–10. Selected muscular dystrophies (listed in order of anatomic location and physiologic underpinning).1Disorder Ineritnceage t Onset (yers) Distribution prognosis Genetic assocition Duchenne type X-linked recessive 1–5 Pelvic, then shoulder girdle; later, limb and respiratory muscles.Rapid progression. Death within about 15 years after onset.Xp21; Dystrophin (loss of functional expression). Becker X-linked recessive 5–25 Pelvic, then shoulder girdle.Slow progression. May have normal life span.Xp21; Dystrophin (reduced functional expression). Limb-girdle (Erb) Autosomal recessive, dominant, or sporadic10–30 Pelvic or shoulder girdle initially, with later spread to the other.Variable severity and rate of progression. Possi- ble severe disability in middle life.Multiple. Facioscapulo- humeralAutosomal dominantAny age Face and shoulder girdle initially; later, pelvic girdle and legs.Slow progression. Minor disability. Usually normal life span.4q35.2; Double homeobox protein 4. 18p11.32; Structural maintenance of chromosome’s flexible hinge domain- containing protein 1. Emery-Dreifuss X-linked recessive or autosomal dominant5–10 Humeroperoneal or scapuloperoneal.Variable. Multiple. Distal Autosomal domi- nant or recessive40–60 Onset distally in extremities; proximal involvement later.Slow progression. Multiple. Oculopharyngeal Autosomal dominantAny age Ptosis, external ophthal- moplegia, and dysphagia.Slow progression. 14q11.2–q13; Poly (A)-binding protein-2. Myotonic dystrophyAutosomal dominantAny age (usually 20–40)Face, neck, distal limbs. Slow progression. 19q13.32; Myotonin- protein kinase. 3q21.3; Cellular nucleic acid-binding protein.1 Not all possible genetic loci are shown.CMDT22_Ch24_p0978-p1053.indd  1051 29/06/21 8:50 PMChapTER 241052 CMDT 2022wmen  by geneti studies; in late pregnany, DNA prbes an be used n fetal tissue btained fr this purpse by amnientesis. The genes ausing sme f the ther mus- ular dystrphies are listed in Table 24–10. Three antisense lignuletides are apprved by the FDA fr treatment f Duhenne musular dystrphy. Eteplirsen appears t benefit thse patients with a dystr- phin mutatin amenable t exn 51 skipping; gldirsen and viltlarsen benefit thse with a mutatin amenable t exn 53 skipping. Patients treated with these antisense lignuletides had mre funtinal dystrphin n mus- le bipsy than ntrls and a slwer rate f disease pr- gressin than mathed histrial ntrls. Prednisne (0.75 mg/kg rally daily r 10 mg/kg rally given weekly ver 2 days) r deflazart (0.9 mg/kg rally daily) imprves musle strength and funtin in bys with Duhenne dystrphy, but side effets need t be mni- tred. Althugh bth rtisterid preparatins ause similar side effets, weight gain at 1 year is less with deflazart. Prlnged bed rest must be avided, as inativ- ity ften leads t wrsening f the underlying musle dis- ease. Physial therapy and rthpedi predures may help unterat defrmities r ntratures.2.  Myotonic DystroyMy tni dystrphy, a slwly prgressive, dminantly inherited disrder, usually manifests itself in the third r furth deade but asinally appears early in hildhd. Tw types, with a different geneti basis, have been reg- nized. Mytnia leads t mplaints f musle stiffness and is evidened by the marked delay that urs befre affeted musles an relax after a ntratin. This an ften be demnstrated linially by delayed relaxatin f the hand after sustained grip r by perussin f the belly f a musle. In additin, there is weakness and wasting f the faial, sternleidmastid, and distal limb musles. Assiated linial features inlude atarats, frntal bald- ness, testiular atrphy, diabetes mellitus, ardia abnr- malities, and intelletual hanges. Eletrmygraphi sampling f affeted musles reveals mytni disharges in additin t hanges suggestive f mypathy. It is diffiult t determine whether mediatin therapy fr mytnia is safe r effetive. When mytnia is dis- abling, treatment with a sdium hannel blker—suh as phenytin (100 mg rally three times daily), prainamide (0.5–1 g rally fur times daily), r mexiletine (150–200 mg rally three times daily)—may be helpful, but the assiated side effets, partiularly fr antiarrhythmi mediatins, are ften limiting. Neither the weakness nr the urse f the disrder is influened by treatment. Cardia funtin shuld be mnitred, and paemaker plaement may be nsidered if there is evidene f heart blk.3.  Myotoni CongenitM ytnia ngenita is mmnly inherited as a dminant trait. Generalized mytnia withut weakness is usually present frm birth, but symptms may nt appear until early hildhd. Patients mplain f musle stiffness that is enhaned by ld and inativity and relieved by exerise.Musle hypertrphy, at times prnuned, is als a feature. A reessive frm with later nset is assiated with slight weakness and atrphy f distal musles. Treatment with prainamide, tainide, mexiletine, r phenytin may help the mytnia, as in mytni dystrphy.4.  Mitocondril MyotiesThe  mithndrial mypathies are a linially diverse grup f disrders that n pathlgi examinatin f skel- etal musle with the mdified Gmri stain shw hara- teristi “ragged red fibers” ntaining aumulatins f abnrmal mithndria. Patients may present with pr- gressive external phthalmplegia r with limb weakness that is exaerbated r indued by ativity. Other patients present with entral neurlgi dysfuntin, eg, my- lni epilepsy ( myoclonic epilepsy, ragged red fiber syndrome, or MERRF ), r the mbinatin f mypathy, enephalpathy, lati aidsis, and strke-like episdes (MELAS ). Migraine is a mmn symptm. Systemi fea- tures inlude but are nt limited t diabetes mellitus, hear- ing lss, retinpathy, ardimypathy, gastri dysmtility, and shrt stature. The serum reatine kinase is usually nr- mal. Mithndrial mypathies result frm separate abnr- malities f mithndrial DNA. Treatment is symptmati and palliative, but varius experimental apprahes are being explred.5.  acid Mltse Deficiency (pome Disese)This  is a glygen strage disease due t mutatins in the gene ending aid alpha-1,4-glusidase. Age at presenta- tin ranges frm infany t the late fifties and depends n the degree f residual enzyme ativity. The juvenile and adult-nset frms present with slwly prgressive prximal weakness that inludes respiratry failure. Cardimypathy is less mmn in the adult frm. Serum reatine kinase is mildly elevated. Musle bipsy shws glygen ntaining lyssmal vaules, but the diagnsis is suggested by deteting redued aid-1,4-alpha-glusidase ativity n a dried bld spt, and nfirmed by geneti testing. Treat- ment with rembinant alpha-glusidase (20 mg/kg intra- venusly every 2 weeks) stabilizes disease prgressin and results in imprvement in respiratry funtin.6.  Dermtomyositis, anti-Syntetse Syndromes, Immune-Medited Necrotizing Myoties, & polymyositisSee Chapter 20. 7.  Inclusion Body MyositisThis  disrder, f unknwn ause, begins insidiusly, usu- ally after middle age, with prgressive prximal weakness f first the lwer and then the upper extremities, and affeting faial and pharyngeal musles. Weakness ften begins in the quadrieps femris in the lwer limbs and the frearm flexrs in the upper limbs. Distal weakness is usu- ally mild. Serum reatine kinase levels may be nrmal r inreased. The diagnsis is nfirmed by musle bipsy.CMDT22_Ch24_p0978-p1053.indd  1052 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1053 CMDT 2022Antiytsli  5’-nuletidase 1A antibdies are deteted in ne-third f ases and may be assiated with a mre severe phentype. Crtisterid and immunsuppressive therapy is smetimes ffered but is usually ineffetive, and IVIG therapy is nt remmended.8.  Endocrine MyotiesM ypathy is bserved with hypthyridism, hyperthyrid- ism, Cushing syndrme and disease, Addisn disease, vitamin D defiieny, and bth hyperparathyridism and hypparathyridism (the latter mediated by alium derangements). In hypthyridism, there may be assi- ated entrapment neurpathies, and examinatin may shw delayed relaxatin f tendn reflexes, musle enlargement, r myedema. Hyperthyridism an ause bth distal and prximal weakness and rarely a bulbar mypathy. Serum reatine kinase is nrmal exept in hypthyrid mypathy, whih an als be painful. Treatment is f the underlying endrinpathy.9.  Criticl Illness MyotyM ypathy may ur in assiatin with ritial illness, typially in patients wh reeived neurmusular blking agents and rtisterids. It is frequently disvered when patients unexpetedly require prlnged ventilatry sup- prt. There an be an assiated sensrimtr plyneu- rpathy. Serum reatine kinase may be elevated initially but has frequently returned t nrmal r is belw nrmal by the time the nditin is suspeted. Treatment is supprtive.10.  Toxic MyotiesM ypathy an ur in patients taking aminapri aid, amidarne, hlrquine, lhiine, rtisterids, yl- sprine, daptmyin, emetine, fibrates, gemitabine, nule- side reverse transriptase inhibitrs, r statin mediatins. Mypathy als urs with hrni alhlism, whereas aute reversible musle nersis may ur shrtly after aute alhl, aine, r methamphetamine intxiatin, and with prpfl infusin. Inflammatry mypathy may ur in patients taking peniillamine and an be indued by pr- grammed death-1 inhibitrs; mytnia may be indued by lfibrate, and preexisting mytnia may be exaerbated r unmasked by deplarizing musle relaxants (eg, suxameth- nium), beta-blkers (eg, prpranll), fenterl and, pssi- bly, ertain diuretis. Valpri aid an preipitate r wrsen mypathy in patients with mithndrial disrders r arni- tine palmityltransferase II defiieny. »When to ReferAll  patients shuld be referred t establish the diagnsis and underlying ause.»When to Admit• Fr respiratry assistane. •Fr rhabdmylysis.MD nald CM et al; CINRG Investigatrs. Lng-term effets f glurtiids n funtin, quality f life, and survival in patients with Duhenne musular dystrphy: a prspetive hrt study. Lanet. 2018;391:451. [PMID: 29174484] Pasnr M et al. Apprah t musle and neurmusular jun- tin disrders. Cntinuum (Minneap Minn). 2019;25:1536. [PMID: 31794459]pE RIODIC paRaLYSIS SYNDROMESPe ridi paralysis may have a familial (dminant inheri- tane) basis. The syndrmes t be desribed are channelo- pathies that manifest as abnrmal, ften ptassium-sensitive, musle-membrane exitability and lead linially t epi- sdes f flaid weakness r paralysis, smetimes in ass- iatin with abnrmalities f the plasma ptassium level. Strength is initially nrmal between attaks, but prgres- sive mypathi weakness may develp in up t ne-third f patients as they age. Hypokalemic periodic paralysis is haraterized by attaks that tend t ur n awakening, after exerise, r after a heavy meal and may last fr several days. Patients shuld avid exessive exertin. A lw- arbhydrate and lw-salt diet may help prevent attaks. An nging attak may be abrted by ptassium hlride given rally r by intravenus drip, prvided the ECG an be mnitred and kidney funtin is satisfatry. In yung Asian men, it is mmnly assiated with hyperthyrid- ism; treatment f the endrine disrder prevents reur- renes. A nnseletive beta-adrenergi blker may prevent attaks until the endrine abnrmality has been treated. Inhyperkalemic periodic paralysis, attaks als tend t ur after exerise but usually last fr less than 1 hur. They may be terminated by intravenus alium glunate (1–2 g) r by intravenus diuretis (fursemide, 20–40 mg), gluse, r gluse and insulin. Normokalemic periodic paralysis is similar linially t the hyperkalemi variety, but the plasma ptassium level remains nrmal during attaks. Several randmized trials supprt the use f dihlrphenamide (50–100 mg rally twie daily) fr pre- ventin f attaks in bth hyperkalemi and hypkalemi peridi paralysis; aetazlamide (250–750 mg rally daily) is als effetive. Chlrthiazide may als be used t prevent attaks in hyperkalemi peridi paralysis. »When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1053 29/06/21 8:50 PM1054 CMDT 2022The fifth e dition of the American Psychiatric Association’s Diagnostic and Statistical Manual (DSM-5) is the common language that clinicians use for psychiatric conditions. It utilizes specific criteria with which to objectively assess symptoms for use in clinical diagnosis and communication. ºCOMMON PSYCHIATRIC DISORDERS ADJUSTMENT DISORDERSE S S E N T I A L S  O F  D I A G N O S I S »Anxiety or depression in reaction to an identifi- able stress, though out of proportion to the sever- ity of the stressor. »Symptoms are not at the severity of a major depressive episode or with the chronicity of gen- eralized anxiety disorder (GAD). »General ConsiderationsAn individual experiences stress when adaptive ca pacity is overwhelmed by events. The event may be an insignificant one when objectively considered, and even favorable changes (eg, promotion and transfer) requiring adaptive behavior can produce stress. For everyone, stress is subjec- tively defined, and the response to stress is a function of each person’s personality and physiologic endowment. Opinion differs about what events are most apt to pro- duce stress reactions. The causes of stress are different at different ages—eg, in young adulthood, the sources of stress are found in the marriage or parent-child relation- ship, the employment relationship, and the struggle to achieve financial stability; in the middle years, the focus shifts to changing spousal relationships, problems with aging parents, and problems associated with having young adult offspring who themselves are encountering stressful situations; in old age, the principal concerns are apt to be retirement, loss of physical and mental capacity, major personal losses, and thoughts of death.»Clinical FindingsAn  individual may react to stress by becoming anxious or depressed, by developing a physical symptom, by running away, drinking alcohol, overeating, starting an affair, or in limitless other ways. Common subjective responses are anxiety, sadness, fear, rage, guilt, and shame. Acute and reactivated stress may be manifested by restlessness, irrita- bility, fatigue, increased startle reaction, and a feeling of tension. Inability to concentrate, sleep disturbances (insomnia, bad dreams), and somatic preoccupations sometimes lead to self-medication, most commonly with alcohol or other central nervous system depressants. Emo- tional and behavioral distressing symptomatology in response to stress is called adjustment disorder , with the major symptom specified (eg, “adjustment disorder with depressed mood, anxiety, mixed depression and anxiety, disturbance of conduct, mixed disturbance of emotions and conduct, or unspecified. ”). Even with an identifiable stressor, if the patient meets syndromal criteria for another disorder such as major depression, then the convention would be to diagnose a major depression and not an adjustment disorder with depressed mood . »Differential DiagnosisAd justment disorders are distinguished from anxiety dis- orders, mood disorders, bereavement, other stress disor- ders such as posttraumatic stress disorder (PTSD), and personality disorders exacerbated by stress and from somatic disorders with psychic overlay. Unlike many other psychiatric disorders, such as bipolar disorder or schizo- phrenia, adjustment disorders are wholly situational and usually resolve when the stressor resolves or the individual effectively adapts to the situation. Adjustment disorders may have symptoms that overlap with other disorders, such as anxiety symptoms, but they occur in reaction to an iden- tifiable life stressor such as a difficult work situation or romantic breakup. An adjustment disorder that persists and worsens can potentially evolve into another psychiatric disorder such as major depression or GAD. However, that is not the case for most patients. Patients with adjustment disorders have marked distress after a stressor and signifi- cant impairment in social or occupational functioning but25Kristin S. Raj, MD Nolan Williams, MD Charles DeBattista, DMH, MDPsychiatric DisordersCMDT22_Ch25_p1054-p1109.indd  1054 29/06/21 8:51 PM"
                ],
                [
                  "3",
                  "KIDNEY DISEASE913 CMDT 2022Thr  ar svral rasons protinuria may dvlop: (1) Functional proteinuria is a bnign procss stmming from strssors such as acut illnss, xrcis, and “ortho- static protinuria. ” Th lattr condition, gnrally found in popl undr 30 yars of ag, usually causs protin xcr- tion lss than 1 g/day. Th orthostatic natur of th protin- uria is confirmd by masuring an 8-hour ovrnight supin urinary protin xcrtion, which should b lss than 50 mg. (2)Overload proteinuria occurs whn th rabsorptiv capacity of tubuls is ovrwhlmd, which can rsult from xcss production of low-molcular-wight plasma pro- tins (g, Bnc Jons protins associatd with plasma cll myloma). In th cas of plasma cll myloma, protin lctrophorsis from srum or urin will xhibit a discrt, monoclonal protin spik. Othr xampls of ovrload protinuria includ myoglobinuria in rhabdomyolysis and hmoglobinuria in hmolysis. (3) Glomerular proteinuria rsults from ffacmnt of pithlial cll foot procsss and altrd glomrular prmability with an incrasd filtra- tion fraction of normal plasma protins, as in diabtic nphropathy. Protin lctrophorsis will xhibit a larg albumin spik indicativ of th incrasd prmability of albumin across th damagd GBM. (4) Tubular protein- uria occurs as a rsult of faulty rabsorption of normally filtrd protins in th proximal tubul, such as bta- 2-microglobulin. Causs may includ ATN, toxic injury (lad, aminoglycosids, and crtain antirtrovirals), drug- inducd intrstitial nphritis, and hrditary mtabolic disordrs (Wilson disas and Fanconi syndrom). Evaluation of protinuria by urin dipstick dos not actually masur protin but instad dtcts th ngativ lctrochmical charg that charactrizs albumin. As a rsult, positivly chargd Bnc Jons protins ar missd with dipstick analysis. Bnc Jons protins can b dtctd by th addition of sulfosalicylic acid to th urin spcimn or, mor commonly, dirctly masuring urin protin. It should b notd that, bcaus urin dipstick simply dtcts ngativ lctrochmical charg, alkalin urin (pH > 7.0) can caus fals-positiv rsults. Whil urin dipstick is commonly usd to scrn for pro- tinuria, quantitativ invstigation rquirs dirct valuationof urin protin xcrtion. This can b stimatd with a random urin sampl or masurd from a timd urin collction (typically 24 hours). Collction of a random urin sampl is far simplr, and th ratio of urin protin- to-cratinin concntration ([Uprotin]/[Ucratinin]) corrlats with a 24-hour urin protin collction (lss than 0.2 is normal and corrsponds to xcrtion of lss than 200 mg/ 24 hours). In a 24-hour collction, protinuria abov 150 mg is abnormal and abov 3 g is classifid as nphrotic- rang. On bnfit of a random protin-to-cratinin ratio is th minimization of rror from ovrcollction or undrcol- lction of urin in th 24-hour spcimn. A kidny biopsy may b indicatd to dtrmin th caus of abnormal pro- tinuria, particularly if accompanid by abnormal GFR or hmaturia. Th clinical squla of protinuria ar dis- cussd in th sction on Nphrotic Spctrum Glomrular Disass.B.  HematuriaH maturia is considrd clinically significant if thr ar mor than thr rd blood clls pr high-powr fild on at last two occasions. It is usually dtctd incidntally on urin dipstick or following an pisod of macroscopic hma- turia. Th diagnosis must b confirmd via microscopic xamination, as fals-positiv dipstick tsts can b causd by myoglobin, oxidizing agnts, bts and rhubarb, hydrochlo- ric acid, and bactria. Transint hmaturia is common but is lss oftn clinically significant in patints youngr than 40 yars du to lowr concrn for malignancy. Hmaturia may b du to rnal or xtrarnal causs. Extrarnal causs ar addrssd in Chaptr 23. Rnal causs account for approximatly 10% of cass and ar clas- sifid as ithr glomrular or xtraglomrular. Glomrular causs includ glomrulonphritis (g, immunoglobulin A [IgA] nphropathy), thin basmnt mmbran disas and othr hrditary disordrs (g, Alport syndrom), and sys- tmic nphritic syndroms (g, lupus nphritis). Extraglo- mrular sourcs includ cysts; calculi; intrstitial nphritis; and, most worrisom, gnitourinary noplasms from th kidny, prostat, or bladdr (s Chaptr 39). »Glomerular Filtration RateTh  GFR provids a usful masur of kidny function at th lvl of th glomrulus and can ithr b masurd dirctly using biomarkrs (most commonly cratinin) or stimatd using validatd formula. Th GFR masurs th amount of plasma ultrafiltrd across th glomrular capil- laris pr unit tim and rflcts th kidnys’ ability to filtr fluids and substancs, including mdications; it is oftn usd to dtrmin drug dosing. Daily GFR in normal indi- viduals is variabl, with a rang of 150–250 L/24 h or 100–120 mL/min/1.73 m2of body surfac ara. Patints with kidny disas can hav dcrasd GFR from any procss that causs loss of functional glomruli. Howvr, thy can also hav normal or incrasd GFR, ithr from glomrular hyprfiltration or disas at a diffrnt sgmnt of th nphron, intrstitium, or vascular supply. GFR can b masurd by dtrmining th rnal clar- anc of plasma substancs that ar not bound to plasmaTable 22–1. Significance of specific urinary casts.T ye Significance Hyaline casts Not indicative of kidney disease Concentrated urine, febrile disease, diuretic therapy, after strenuous exercise Red cell casts Glomerulonephritis White cell casts Indicative of infection or inflammation Pyelonephritis, interstitial nephritis Renal tubular cell castsAcute tubular necrosis, interstitial nephritis Granular (muddy brown) castsNonspecific; can indicate acute tubular necrosis Broad waxy casts Indicative of stasis in enlarged collecting tubules Chronic kidney diseaseCMDT22_Ch22_p0912-p0951.indd  913 02/07/21 2:33 PMChApTEr 22914 CMDT 2022pro tins, ar frly filtrabl across th glomrulus, and ar nithr scrtd nor rabsorbd along th rnal tubuls. Th rnal claranc of a substanc is dfind as:= ×CU  V Pwhr  C is th claranc, U and P ar th rspctiv urin and plasma concntrations of th substanc (mg/dL), and V.is volum of urin pr unit tim (typically mL/min). In clinical practic, th claranc of ndognous cratinin (trmd creatinine clearance ) is th primary way to ma- sur GFR. Th cratinin claranc (Ccr) is approximatly 100 mL/min in halthy young womn and 120 mL/min in halthy young mn. Th cratinin claranc dclins by an avrag of 0.8 mL/min/yr aftr ag 40 yars as part of th aging procss. Cratinin is a product of muscl mtabolism producd at a rlativly constant rat and clard by rnal xcrtion. It is frly filtrd by th glomrulus and not rabsorbd by th rnal tubuls. Howvr, cratinin is not a prfct indicator of GFR for th following rasons: (1) a small amount is normally liminatd by tubular scrtion, and it progrssivly incrass as GFR dclins (thus ovrs- timating GFR); (2) with svr kidny failur, gut microor- ganisms dgrad cratinin; (3) ditary mat intak and muscl mass affct plasma cratinin lvls; (4) mdications such as aspirin, dolutgravir, probncid, and trimthoprim rduc tubular scrtion of cratinin, incrasing th plasma cratinin concntration and falsly suggsting kidny dys- function; and (5) th masurmnt assums a stabl plasma cratinin concntration ovr a 24-hour priod, so whn valus ar changing during th dvlopmnt of and rcov- ry from AKI, cratinin claranc is inaccurat. On way to masur cratinin claranc is to prform a timd urin collction and dtrmin th plasma cratinin lvl midway through th collction. An incomplt or pro- longd urin collction is a common sourc of rror. Th compltnss of th collction can b stimatd by compar- ing th amount of cratinin xcrtd in th collction to that xpctd ovr a 24-hour priod, which should b constant: Ucr× V.= 15 − 20 mg/kg for healthy young women Ucr× V.= 20 − 25 mg/kg for healthy young men Givn th tdious natur of timd urin collctions for masuring GFR, GFR is mor commonly stimatd (dnotd GFR) using formula that hav bn validatd using patint charactristics (such as ag, wight, rac, and sx) and plasma cratinin lvls. Th Kidny Disas Improv- ing Global Outcoms workgroup rcommnds GFR for- mula as th primary mthod for dtrmining GFR. Th prfrrd GFR formula is th 2009 CKD-Epidmiology (EPI) Collaboration cratinin quation (https://www. kidny.org/contnt/ckd-pi-cratinin-quation-2009). An altrnativ cratinin-basd GFR stimating quation is accptabl if it improvs accuracy ovr th CKD-EPI qua- tion. Svral wb-basd calculators will calculat th GFR (g, http://touchcalc.com/calculators/pi). Th Cockcroft- Gault formula is commonly usd to dtrmin drug dos- ing, but it is no longr rcommndd sinc it was dvlopdbfor th standardization of cratinin assays currntly in us.Cystatin C is anothr ndognous markr of GFR that is filtrd frly at th glomrulus, producd at a rlativly constant rat, and lss dpndnt on muscl mass. It is rabsorbd and partially mtabolizd in th rnal tubular pithlial clls. Adding th masurmnt of cystatin C to srum cratinin can improv th accuracy of th GFR. A larg mta-analysis showd that cystatin C alon or in combination with srum cratinin is a strongr prdictor of important clinical vnts, such as nd-stag kidny dis- as (ESKD) or dath, than srum cratinin alon. How- vr, bcaus cystatin C is not univrsally availabl or standardizd across assays, it rmains a complmntary biomarkr for stimating GFR. BUN is anothr indx usd in assssing kidny func- tion. It is synthsizd mainly in th livr and is th nd product of protin catabolism. Ura is frly filtrd by th glomrulus, but about 30–70% is rabsorbd in th rnal tubuls. As such, it undrstimats GFR. Rnal ura rab- sorption incrass (in conjunction with incrasd sodium rabsorption) in hypovolmic patints (who, thrfor, hav an incrasd BUN). A normal BUN:cratinin ratio is approximatly 10:1, although this varis btwn individu- als. With volum dpltion, th ratio can incras to 20:1 or highr. Othr causs of incrasd BUN includ incrasd catabolism (gastrointstinal [GI] blding, cll lysis, and corticostroid usag), incrasd ditary protin, and dcrasd rnal prfusion prompting incrasd sodium (and thrfor BUN) rabsorption (g, hart failur, rnal artry stnosis) (Tabl 22–2). Rducd BUN lvls ar sn in livr disas and in th syndrom of inappropriat antidiurtic hormon (SIADH). In summary, cratinin and ura clarancs ovrsti- mat and undrstimat GFR, rspctivly. Bcaus ach of ths stimats bcom mor inaccurat as kidny disas advancs, a mor accurat masur of GFR as patints approach ESKD is th avrag of th cratinin and ura clarancs.KI DNEY BIOPSYIndica tions for prcutanous ndl biopsy includ (1) unxplaind AKI or CKD; (2) unxplaind protinuria or hmaturia, or both; (3) prviously idntifid and tratd Table 22–2. Conditions affecting BUN independently of GFR.Inceased  BUN Reduced effective circulating blood volume (prerenal azotemia) Catabolic states (gastrointestinal bleeding, corticosteroid use) High-protein diets Tetracycline Deceased BUN Liver disease Malnutrition Sickle cell anemia SIADH BUN, blood urea nitrogen; GFR, glomerular filtration rate; SIADH, syndrome of inappropriate antidiuretic hormone.CMDT22_Ch22_p0912-p0951.indd  914 02/07/21 2:33 PMKIDNEY DISEASE915 CMDT 2022lsions to guid futur thrapy; (4) sy stmic disass asso- ciatd with kidny dysfunction, such as systmic lupus rythmatosus (SLE), anti-GBM disas, and granuloma- tosis with polyangiitis; and (5) kidny transplant dysfunc- tion, to valuat for transplant rjction or othr abnormalitis. Kidny biopsis should only b prformd if th rsults will influnc th tratmnt plan or facilitat discussion about prognosis. Rlativ contraindications includ a solitary or ctopic kidny (xcption for trans- plant allografts), horssho kidny, ESKD, congnital anomalis, and multipl cysts. Absolut contraindications includ an uncorrctd blding disordr; svr uncon- trolld hyprtnsion; rnal infction or noplasm; hydro- nphrosis; or uncooprativ patints, including thos who ar unabl to li flat for th procdur. Prcutanous kidny biopsis ar gnrally saf. Th major risk is blding, which may occur up to 72 hours post biopsy. Mor than half of patints will hav at last a small hmatoma; approximatly 1–5% of patints will xprinc significant blding rquiring a blood transfusion. Antico- agulation should b hld for 5–7 days post biopsy if possibl. Th risks of nphrctomy and mortality ar about 0.06– 0.08%. Whn a prcutanous ndl biopsy is tchnically not fasibl and kidny tissu is dmd clinically ssntial, a closd biopsy via intrvntional radiologic tchniqus or opn biopsy undr gnral ansthsia can b prformd.Böknkamp  A. Protinuria—tak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Cavanaugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Lvy AS t al. Masurd and stimatd glomrular filtration rat: currnt status and futur dirctions. Nat Rv Nphrol. 2020;16:51. [PMID: 31527790] ºACUTE KIDNEY INJUrYE S S E N T I A L S  O F  D I A G N O S I S »Rapid increase in serum creatinine. »Oliguria may be present. »Symptoms and signs depend on cause. »General ConsiderationsAKI is dfi nd as an absolut incras in srum cratinin by 0.3 mg/dL or mor within 48 hours or a rlativ incras of at last 1.5 tims baslin that is known or prsumd to hav occurrd within 7 days. AKI is charactrizd as oligu- ric if urin production is lss than roughly 400–500 mL/day. Clinically, AKI is charactrizd by an inability to maintain acid-bas, fluid, and lctrolyt balanc and to xcrt nitrognous wasts. Stage 1 is a 1.5- to 1.9-fold incras in srum cratinin or a dclin in urinary output to lss than 0.5 mL/kg/h ovr 6–12 hours; stage 2 is a 2.0- to 2.9-fold incras in srum cratinin or dclin in urinary output to lss than 0.5 mL/kg/h ovr 12 hours or longr; stage 3 is a3.0-fold or gratr incras in srum cratinin, an incras in srum cratinin to gratr than or qual to 4 mg/dL, a dclin in urinary output to lss than 0.3 mL/ kg/h for 24 hours or longr, anuria for 12 hours or longr, or initiation of rnal rplacmnt thrapy. In th absnc of functioning kidnys, srum cratinin concntration will typically incras by 1–1.5 mg/dL daily, although with crtain conditions, such as rhabdomyolysis, srum crati- nin can incras mor rapidly. On avrag, 5% of hospital admissions and 30% of intnsiv car unit (ICU) admis- sions includ a diagnosis of AKI, and AKI dvlops in 25% of hospitalizd patints. Th rats of AKI in th hospital stting hav incrasd stadily sinc th 1980s and continu to ris. »Clinical FindingsA.  Symptoms and SignsAlthough  many patints will not xprinc any symptoms or xhibit any signs of AKI, th buildup of wast products can caus nonspcific symptoms and signs collctivly trmd uremia : nausa, vomiting, malais, and altrd snsorium. Mor commonly, patints xprinc symp- toms and signs of th undrlying disas causing thir AKI (g, lupus). Hyprtnsion can occur, and fluid homostasis is oftn impaird. Hypovolmia can caus stats of low blood flow to th kidnys, somtims trmd prerenal azotemia, whras hyprvolmia can rsult from intrinsic or postrnal disas. Pricardial ffusions can occur with urmia and may rsult in cardiac tamponad; a pricardial friction rub can b prsnt, signaling pricarditis. With hyprkalmia, vntricular tachycardia and othr tachyar- rhythmias can occur. Th lung xamination may rval rals in th prsnc of hyprvolmia. AKI can caus non- spcific diffus abdominal pain and ilus. Platlt dysfunc- tion with blding and clotting disordrs can occur. Th nurologic xamination somtims rvals ncphalo- pathic changs with astrixis and confusion; uncommonly sizurs may nsu.B.  Laboratory FindingsBy  dfinition, lvatd srum cratinin (and oftn BUN) lvls ar prsnt, though ths lvations do not distin- guish AKI from CKD. Mtabolic acidosis (du to dcrasd claranc of organic and inorganic acids) is oftn notd. Hyprkalmia can occur from impaird rnal potassium xcrtion or from shifting of potassium from clls into th blood as a rsult of mtabolic acidosis. With hyprkalmia, ECG can rval pakd T wavs, PR prolongation, and QRS widning. A long QT sgmnt can occur with hypo- calcmia. Hyprphosphatmia occurs whn phosphorus cannot b scrtd by damagd tubuls ithr with or with- out incrasd cll catabolism. Anmia can occur as a rsult of dcrasd rythropoitin production ovr wks, and platlt dysfunction is typical. »Classification & EtiologyAKI  is commonly dividd into thr catgoris: prrnal causs (kidny hypoprfusion), intrinsic kidny disas,CMDT22_Ch22_p0912-p0951.indd  915 02/07/21 2:33 PMChApTEr 22916 CMDT 2022and  postrnal causs (obstruction to urinary outflow). Idntifying th caus is th first stp toward tratmnt (Tabl 22–3).A.  Prerenal CausesPrr nal causs ar th most common tiology of AKI, accounting for 40–80% of cass. Prrnal azotmia is a physiologic rspons to rnal hypoprfusion. If rvrsd quickly with rstoration of rnal blood flow (g, fluid rsuscitation), rnal parnchymal damag oftn dos not occur. If hypoprfusion prsists, prrnal azotmia can lad to intrinsic kidny injury. Dcrasd rnal prfusion can occur in svral ways, such as a dcras in intravascular volum, a chang in vascular rsistanc, or low cardiac output. Causs of vol- um dpltion includ hmorrhag (g, from trauma), GI losss, xcssiv diursis, and xtravascular fluid squstra- tion (g, pancratitis, burns, and pritonitis). Changs in systmic vascular rsistanc can occur with spsis, anaphylaxis, ansthsia, and aftrload-rducing drugs. Blockad of th rnin-angiotnsin-aldostron sys- tm, such as with angiotnsin-convrting nzym (ACE) inhibitors, limits ffrnt rnal artriolar constriction out of proportion to affrnt artriolar constriction and thrby dcrass GFR. Nonstroidal anti-inflammatory drugs (NSAIDs) minimiz affrnt artriolar vasodilation by inhibiting prostaglandin-mdiatd signals. NSAIDs may hav particularly dltrious ffcts on rnal prfusion in cirrhosis and hart failur whn prostaglandins ar rcruitd to incras rnal blood flow. Epinphrin, nor- pinphrin, high-dos dopamin, ansthtic agnts, and calcinurin inhibitors also can caus rnal vasoconstric- tion. Rnal artry stnosis causs incrasd rsistanc and dcrasd rnal prfusion.Low cardiac output is a stat of low ffctiv rnal art- rial blood flow. This occurs in stats of hart failur (including cardiognic shock), pulmonary mbolism, and pricardial tamponad. Arrhythmias and valvular disor- drs can also rduc cardiac output. In th intnsiv car stting, positiv prssur vntilation will dcras vnous rturn and, in ffct, cardiac output. Whn GFR falls acutly, it is important to dtrmin whthr AKI is du to prrnal or intrinsic causs. Th his- tory, physical xamination, and laboratory data may b hlpful in distinguishing btwn ths causs. In prrnal AKI, th BUN:cratinin ratio oftn xcds 20:1 du to incrasd ura rabsorption. In oliguric patints, anothr usful indx is th fractional xcrtion of sodium (FeNa). With dcrasd GFR, th kidny rabsorbs salt and watr avidly if thr is no intrinsic tubular dysfunction. Thus, oliguric patints with prrnal AKI should hav a low frac- tional xcrtion of sodium (lss than 1%). Oliguric patints with intrinsic kidny dysfunction typically hav a high FeNa (gratr than 1–2%), indicating loss of tubular clls’ ability to rabsorb sodium. Th FeNais calculatd as follows: FeNa = claranc of Na+/GFR = claranc of Na+/Ccr:F Urine  / Serum Urine  / Serum100%E NaNa  Na cr  cr=  ×Th  quation was cratd and validatd to assss th diffrnc btwn oliguric ATN and prrnal AKI; its util- ity in nonoliguric patints is limitd. Furthr, bcaus diurtics act by incrasing sodium xcrtion, a high FeNa within 12–24 hours aftr diurtic administration cannot b maningfully intrprtd. In contrast, a low FeNadespite rciving diurtics offrs strong vidnc of prrnal stats in oliguric patints. Givn th limitations of FeNaTable 22–3. Classification and differential diagnosis of acute kidney injury. peenal Azotemiapostenal AzotemiaIntinsic renal Disease Acute Tubula Necosis Acute GlomeuloneitisAcute Intestitial Neitis Etiology Poor renal perfusionObstruction of the urinary tractIschemia, nephrotoxinsImmune complex-mediated, pauci-immune, anti-GBM related, monoclonal immunoglobulin–mediated, C3 glomerulopathyAllergic reaction; drug reaction; infection; autoimmune disease Serum BUN:Cr ratio > 20:1 > 20:1 < 20:1 > 20:1 < 20:1 UNa(mEq/L) < 20 Variable > 20 < 20 Variable FENa(%) < 1 Variable > 1 (when oliguric) < 1 Variable Urine osmolality (mOsm/kg)> 500 < 400 250–300 Variable Variable Urinary sediment Benign or hyaline castsNormal or red cells, white cells, or crystalsGranular (muddy brown) casts, renal tubular cell castsRed cells, dysmorphic red cells, and red cell castsWhite cells, white cell casts, with or without eosinophils BUN:Cr, blood urea nitrogen:creatinine ratio; FENa, fractional excretion of sodium; GBM, glomerular basement membrane; UNa, urinary concentration of sodium.CMDT22_Ch22_p0912-p0951.indd  916 02/07/21 2:33 PMKIDNEY DISEASE917 CMDT 2022calculations,  urin microscopy is a much mor valuabl tool for dtrmining caus of AKI. Patints with prrnal azotmia typically hav bland urin sdimnts, though som hav hyalin casts. In contrast, patints with ATN oftn hav rnal tubular pithlial clls or muddy brown casts visibl. Tratmnt of prrnal AKI dpnds on th undrlying caus, but achivmnt of uvolmia, attntion to srum lctrolyts, and avoidanc of nphrotoxic drugs ar bnch- marks of thrapy. This involvs carful assssmnt of vol- um status, cardiac function, dit, and drug usag.B.  Postrenal CausesP ostrnal causs of AKI ar th last common, accounting for approximatly 5–10% of cass, but ar important to dtct bcaus of thir rvrsibility. Postrnal azotmia occurs whn urinary flow from both kidnys, or a singl functioning kidny, is obstructd. Obstruction lads to lvatd intraluminal prssur and rsultant kidny parn- chymal damag, with markd ffcts on rnal blood flow and tubular function. Postrnal causs of AKI includ urthral obstruction, bladdr dysfunction or obstruction, and obstruction of both urtrs or rnal plviss. In mn, bnign prostatic hyprplasia is th most common caus. Patints taking anticholinrgic drugs ar at risk for urinary rtntion. Obstruction can also b causd by bladdr, prostat, and crvical cancrs; rtropritonal fibrosis; and nurognic bladdr (g, from diabts mllitus). Lss common causs includ blood clots, bilatral urtral stons, urthral stons or stricturs, and bilatral papillary ncrosis. Patints may b anuric or polyuric and may xprinc lowr abdominal or back pain. Polyuria can occur in th stting of partial obstruction with rsultant tubular dys- function and an inability to appropriatly rabsorb salt and watr loads. Obstruction can b constant or intrmittnt and partial or complt. On xamination, th patint may hav an nlargd prostat, distndd bladdr, or mass dtctd on abdominal xamination. Laboratory xamination may initially rval high urin osmolality, low urin sodium, high BUN:cratinin ratio, and low FeNa(as tubular function may not b compromisd initially). Ths indics ar similar to a prrnal stat bcaus xtnsiv intrinsic rnal damag has not yt occurrd. Aftr svral days, howvr, th urin sodium incrass as th kidnys fail and ar unabl to concntrat th urin; this inability to concntrat th urin is calld isosthnuria. Th urin sdimnt is gnrally bland, though hmaturia may b sn if th obstruction is du to stons, blood clots, or papillary ncrosis. Patints with AKI du to suspctd postrnal causs should undrgo bladdr cathtrization and ultrasonogra- phy to assss for hydrourtr, hydronphrosis, or larg bladdr volum. Aftr rvrsal of th undrlying procss, som patints xprinc significant urinary output (calld postobstructiv diursis). In such sttings, car should b takn to avoid volum dpltion or lctrolyt drang- mnts. Prompt tratmnt of obstruction within days by cathtrs, stnts, or othr surgical procdurs can rsult in partial or complt rvrsal of AKI.C. Intrinsic Acute Kidney InjuryIn trinsic rnal disordrs account for up to 50% of all cass of AKI. Intrinsic dysfunction is considrd aftr prrnal and postrnal causs hav bn xcludd. Th potntial sits of injury ar th tubuls, intrstitium, vasculatur, and glomruli. Intrinsic AKI is discussd in gratr dtail in th following sctions. »When to Refer• If a patint has signs of AKI that hav not rvrsd ovr 1–2 wks, or if th dgr of AKI is concrning (g, doubling of cratinin) and without an immdiatly rvrsibl caus such as obstruction. •If a patint has signs of urinary tract obstruction, th patint should b rfrrd to a urologist. »When to AdmitTh  patint should b admittd if thr is suddn loss of kidny function rsulting in abnormalitis that cannot b handld xpditiously in an outpatint stting (g, hyprka- lmia, volum ovrload, urmia) or an acut intrvntion is ndd, such as mrgnt urologic procdurs or dialysis.Ost rmann t al. Rcommndations on acut kidny injury bio- markrs from th Acut Disas Quality Initiativ Consnsus Confrnc: a consnsus statmnt. JAMA Ntw Opn. 2020;3:2019209. [PMID: 33021646] Ronco C t al. Acut kidny injury. Lanct. 2019;394:1949. [PMID: 31777389] Srisawat N t al. Th rol of biomarkrs in acut kidny injury. Crit Car Clin. 2020;36:125. [PMID: 31733675]ACU TE TUBULAR NECROSISE S S E N T I A L S  O F  D I A G N O S I S »AKI. »Ischemic or toxic insult or underlying sepsis. »Urine sediment with granular (muddy brown) casts and renal tubular epithelial cells is pathog- nomonic but not essential. »General ConsiderationsAKI  du to tubular damag is trmd acute tubular necro- sis (ATN) and accounts for approximatly 85% of intrinsic AKI. Th two major causs of ATN ar ischmia and nph- rotoxin xposur. Ischmic ATN is charactrizd not only by inadquat GFR but also by rnal blood flow that is inadquat to maintain parnchymal cllular prfusion. Rnal tubular damag can b causd by low ffctiv art- rial blood flow to th kidnys in th stting of prolongd hypotnsion or hypoxmia, such as volum dpltion or shock. Undrlying spsis is an indpndnt risk factor for ATN, vn in th absnc of hmodynamic compromis.CMDT22_Ch22_p0912-p0951.indd  917 02/07/21 2:33 PMChApTEr 22918 CMDT 2022Pro longd priods of rnal hypoprfusion can occur with major surgical procdurs, which ar xacrbatd by vaso- dilating ansthtic agnts.A.  Exogenous NephrotoxinsExognous  nphrotoxins mor commonly caus damag than ndognous nphrotoxins. Aminoglycosides caus som dgr of ATN in up to 25% of hospitalizd patints rciving thraputic lvls of th drugs. Nonoliguric kidny injury typically occurs aftr 5–10 days of xposur. Prdisposing factors includ undr- lying kidny damag, volum dpltion, and advancd ag. Monitoring drug lvls is important, and troughs ar par- ticularly hlpful in prdicting rnal toxicity. Amphotericin B is typically nphrotoxic aftr a dos of 2–3 g. This causs a typ 1 (distal) rnal tubular acidosis with svr vasoconstriction and tubular damag, which can lad to hypokalmia and nphrognic diabts insipi- dus. Vancomycin , intravnous acyclovir , and svral cephalosporins hav also bn known to caus or b asso- ciatd with ATN. Radiographic contrast media may b dirctly nphro- toxic. Contrast nphropathy is th third lading caus of incidnt AKI in hospitalizd patints and is thought to rsult from th synrgistic combination of dirct rnal tubular pithlial cll toxicity and rnal mdullary ischmia. Th combination of prxisting diabts mllitus and CKD is associatd with th gratst risk (15–50%) of contrast nphropathy. Othr risk factors includ advancd ag; vol- um dpltion; hart failur; plasma cll myloma; rpatd doss of contrast; and rcnt xposur to othr nphrotoxic agnts, including NSAIDs and ACE inhibitors. Lowr volums of contrast with low osmolality ar rcommndd in high-risk patints. Toxicity usually occurs within 24–48 hours aftr th radiocontrast study. Nonionic con- trast mdia may b lss toxic, but this has not bn wll provn. Prvntion of contrast nphropathy is th goal whn using ths agnts. Th mainstay of prophylaxis is 1–3 mL/kg or 500–1000 mL of intravnous 0.9% (normal) salin ovr 6 hours both bfor and aftr th contrast administration—cautiously in patints with prxisting cardiac dysfunction; oral intak of fluids is an accptabl altrnativ for outpatint studis. Isotonic intravnous vol- um rpltion is suprior to hypotonic intravnous solutions, and both ar suprior to oral solutions in small studis. Othr nphrotoxic agnts should b avoidd during th day bfor and aftr dy administration. Altrnativ prophylactic strat- gis involving N-actylcystin, sodium bicarbonat, manni- tol, and furosmid do not show bnfit ovr 0.9% (normal) salin administration. In fact, furosmid may lad to incrasd rats of kidny dysfunction in this stting. Calcineurin inhibitor toxicity (from tacrolimus or cyclosporin) is usually dos dpndnt. It causs distal tubular dysfunction (a typ 4 rnal tubular acidosis) and svr vasoconstriction. Rgular blood lvl monitoring is important to prvnt both acut and chronic nphrotoxic- ity. Kidny function usually improvs aftr rducing th dos or stopping th drug. Othr xognous nphrotoxins includ antinoplastics, such as cisplatin and organic solvnts, and havy mtalssuch as mrcury, cadmium, and arsnic. Hrbal mdicins ar also incrasingly rcognizd as potntially nphrotoxic.B.  Endogenous NephrotoxinsEndo gnous nphrotoxins includ pigmnt-containing products (myoglobin and hmoglobin), uric acid, and paraprotins. Pigmnt-containing products can caus dirct tubular toxicity, rsulting in ATN. Th most common typ of pig- mnt nphropathy is rhabdomyolysis, causd by rlas of myoglobin from muscl. Massiv intravascular hmolysis is sn in transfusion ractions and in crtain hmolytic anmias, and causs rlas of hmoglobin. Rvrsal of th undrlying disordr and hydration ar th mainstays of tratmnt. Hyperuricemia can occur in th stting of rapid cll turnovr and lysis. Chmothrapy for grm cll and hmatologic malignancis (lukmia and lymphoma) is th primary caus; spontanous tumor lysis syndrom can also occur, though is lss common. AKI occurs with intra- tubular prcipitation of uric acid crystals; srum uric acid lvls oftn xcd 15–20 mg/dL and urin uric acid lvls ar typically gratr than 600 mg/24 h. A urin uric acid to urin cratinin ratio gratr than 1.0 idntifis individuals at risk for AKI. Allopurinol or rasburicas can b usd prophylactically, and rasburicas with or without dialysis is oftn usd for tratmnt in stablishd cass. Paraproteins sn in conjunction with plasma cll myloma can caus dirct tubular toxicity and tubular obstruction. Othr rnal complications from plasma cll myloma includ hyprcalcmia and rnal tubular dys- function, including proximal rnal tubular acidosis (s Plasma Cll Myloma blow). »Clinical FindingsA.  Symptoms and SignsS Acut Kidny I njury.B.  Laboratory FindingsHyprka lmia and hyprphosphatmia ar commonly prsnt. Th BUN:cratinin ratio is usually lss than 20:1 bcaus tubular function is not intact, as dscribd in th gnral sction on AKI (Tabl 22–3). Urinary output can b oliguric or nonoliguric, with oliguria portnding a wors prognosis. Urin sodium concntration and FeNaar typically lvatd, indicativ of tubular dysfunction. Urin microscopy may show vidnc of acut tubular damag; th prsnc of two or mor granular casts or rnal tubular pithlial clls is strongly prdictiv of ATN but has a low ngativ prdictiv valu (s Tabl 22–1). Although not usually prformd in cass of ATN, kidny biopsy is som- tims hlpful in cass of diagnostic uncrtainty. »TreatmentT ratmnt of ATN is aimd at hastning rcovry and avoiding complications. Prvntiv masurs should b takn to avoid volum ovrload and hyprkalmia. A pro- spctiv randomizd controlld trial did not show a bnfitCMDT22_Ch22_p0912-p0951.indd  918 02/07/21 2:33 PMKIDNEY DISEASE919 CMDT 2022of  loop diurtics on ithr rcovry from AKI or dath. Widsprad us of diurtics in critically ill patints with AKI should b usd only whn othrwis clinically indi- catd (g, in stats of volum ovrload), although unrspon- sivnss to high-dos diurtics has bn shown to prdict futur nd for acut dialysis in this population (trmd “furosmid strss tst”). A 2012 randomizd controlld trial did not show a bnfit on mortality from plasma ultra- filtration compard to intravnous diurtics in patints with dcompnsatd hart failur. Thus, ultrafiltration should gnrally b rsrvd for ICU patints with AKI in nd of volum rmoval who ar nonrsponsiv to diurtics, with th rcognition that this has not ultimatly improvd sur- vival in this patint population. Nutritional support should mt daily nds whil prvnting xcssiv catabolism. Ditary protin rstriction of 0.6 g/kg/day hlps prvnt mtabolic acidosis. Hypocalcmia and hyprphosphatmia can b improvd with ditary modification and phosphat- binding agnts takn with mals; xampls includ alumi- num hydroxid (500 mg orally) ovr th short trm, and calcium carbonat (500–1500 mg orally), calcium actat (667 mg, two or thr tablts), svlamr carbonat (800– 1600 mg orally), and lanthanum carbonat (1000 mg orally) ovr longr priods. Hypocalcmia should not b tratd in patints with rhabdomyolysis unlss thy ar symptomatic. Hyprmagnsmia can occur bcaus of rducd magn- sium xcrtion by th rnal tubuls, so magnsium-containing antacids and laxativs should b avoidd in ths patints. Dosags of all mdications must b adjustd for drugs liminatd by th kidny. Indications for dialysis in AKI from ATN or othr intrinsic disordrs includ lif-thratning lctrolyt dis- turbancs (such as hyprkalmia), volum ovrload unr- sponsiv to diursis, rfractory acidosis, and urmic complications (g, ncphalopathy, pricarditis, and si- zurs). In gravly ill patints, lss svr but worsning abnormalitis may also b indications for dialytic support. Unfortunatly, thr is no vidnc that mor intnsiv or arlir initiation of rnal rplacmnt thrapy for patints with AKI confrs any survival bnfit. »Course & PrognosisTh  clinical cours of ATN is oftn dividd into thr phass: initial injury, maintnanc, and rcovry. Th maintnanc phas is xprssd as ithr oliguric (urinary output lss than 500 mL/day) or nonoliguric. Nonoliguric ATN is associatd with bttr outcoms than oliguric ATN; convrsion from oliguric to nonoliguric stats with th us of diurtics dos not altr prognosis. Whil dopamin has somtims bn usd for this purpos, numrous studis hav shown that its us in this stting is not bnficial. Avrag duration of th maintnanc phas is 1–3 wks, but som cass may last svral months. Cllular rpair and rmoval of tubular dbris occur during this priod. Th rcovry phas can b hraldd by diursis, du to inability of rcovring rnal tubuls to rabsorb salt and watr appro- priatly, and a solut diursis from lvatd BUN lvls. As GFR bgins to ris, BUN and srum cratinin fall. Th mortality rat associatd with AKI is 20–50% in hospitalizd sttings, and up to 70% for thos in th ICUrquiring dialysis with additional comorbid illnsss. Incrasd mortality is associatd with advancd ag, svr undrlying disas, and multisystm organ failur. Lading causs of dath ar infctions, fluid and lctrolyt distur- bancs, and worsning of undrlying disas. »When to Refer• Whn uncrtainty xists as to th caus of or tratmnt for AKI. •For fluid, lctrolyt, and acid-bas abnormalitis that ar rcalcitrant to intrvntions. •Nphrology rfrral improvs outcoms in AKI. »When to AdmitA  patint with symptoms or signs of AKI that rquir immdiat intrvntion, such as administration of intrav- nous fluids or dialytic thrapy, or that rquir a tam approach that cannot b coordinatd as an outpatint.Griffin  BR t al. Critical car nphrology: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:435. [PMID: 31982214] Prapornratana S t al. Acut kidny injury from spsis: currnt concpts, pidmiology, pathophysiology, prvntion and tratmnt. Kidny Int. 2019;96:1083. [PMID: 31443997] STARRT-AKI Invstigators; Canadian Critical Car Trials Group; Australian and Nw Zaland Intnsiv Car Socity Clinical Trials Group; Unitd Kingdom Critical Car Rsarch Group; Canadian Nphrology Trials Ntwork; Irish Critical Car Trials Group, Bagshaw SM t al. Timing of initiation of rnal-rplacmnt thrapy in acut kidny injury. N Engl J Md. 2020;383:240. [PMID: 32668114]RH ABDOMYOLYSISE S S E N T I A L S  O F  D I A G N O S I S »Associated with crush injuries to muscle, immobil- ity, drug toxicities, and hypothermia. »Characterized by serum elevations in muscle enzymes, including creatine kinase, and marked electrolyte abnormalities. »Release of myoglobin leads to direct renal toxicity. »General ConsiderationsRhabdomyolysis  is a syndrom of acut skltal muscl ncrosis, lading to myoglobinuria and markdly lvatd cratin kinas lvls. Acut tubular ncrosis is a com- mon complication of rhabdomyolysis and is du to th filtration of xcssiv quantitis of myoglobin, which can b xacrbatd by volum dpltion. Distal tubular obstruction from pigmntd casts and intrarnal vaso- constriction can also occur. Rhabdomyolysis can rsult from crush injuris, prolongd immobility, sizurs, sub- stanc abus (g, cocain), and mdications (spcially statins). Th prsnc of kidny or livr dysfunction, dia- bts mllitus, and hypothyroidism incras th risk ofCMDT22_Ch22_p0912-p0951.indd  919 02/07/21 2:33 PMChApTEr 22920 CMDT 2022rh abdomyolysis in patints taking statins. Concurrnt us of drugs that inhibit cytochrom P450 (including protas inhibitors, rythromycin or clarithromycin, itraconazol, diltiazm, and vrapamil) with statins (xcpt pravastatin or rosuvastatin) as wll as concurrnt us of niacin and fibrat- containing thrapy can incras th risk of dvlopmnt of rhabdomyolysis. »Clinical FindingsA.  Symptoms and SignsPa tints with rhabdomyolysis may hav myalgias or wak- nss or both, though it is not uncommon for thm to b asymptomatic. Urin may appar dark.B.  Laboratory FindingsRhabdomy olysis of clinical importanc commonly occurs with a srum cratin kinas gratr than 20,000–50,000 intrnational units/L; on study showd that 58% of patints with AKI from rhabdomyolysis had cratin kinas lvls gratr than 16,000 intrnational units/L, whil only 11% of patints without kidny injury had cr- atin kinas valus gratr than 16,000 intrnational units/L. Oftn, thr ar lvatd srum lvls of aspartat aminotransfras (AST), alanin aminotransfras (ALT), and lactat dhydrognas (LD) (du to rlas of ths nzyms from skltal muscl). Th massiv acut lva- tions of muscl nzyms pak quickly and usually rsolv within days onc th inciting injury has bn rmovd. Th classic laboratory finding in rhabdomyolysis is a urin dipstick tst that is positiv for “blood” but without rd blood clls on microscopy. This fals-positiv rsult is du to dtction of myoglobin. Additionally, clinically maningful rhabdomyolysis causs injurd muscl clls to rlas intracllular componnts, lading to lctrolyt drangmnts (including hyprkalmia, hyprphosphat- mia, hypruricmia, and hypocalcmia). »TreatmentTh  mainstay of tratmnt is aggrssiv volum rpltion with 0.9% normal salin (i, mor than 4 L/day) and rmoval of offnding mdications if thought to hav causd th disordr. Adjunctiv tratmnts with mannitol and alkalization of th urin hav not bn provn to chang outcoms in human trials. As patints rcovr, calcium can mov back from tissus to plasma, so arly xognous cal- cium administration for hypocalcmia is not rcommndd unlss th patint is symptomatic or th lvl bcoms xcdingly low in an unconscious patint; calcium rpl- tion can caus prcipitation of calcium phosphat givn th frquntly concurrnt hyprphosphatmia. Myopathic complications of statins usually rsolv within svral wks of discontinuing th drug. »When to ReferClinically  maningful rhabdomyolysis rquirs immdiat attntion and inpatint managmnt, so affctd patints should not b rfrrd to outpatint nphrology clinics unlss to follow up aftr a hospital admission.»When to AdmitPa tints whos srum cratin kinas lvls ar gratr than 15,000–20,000 intrnational units/L or patints with AKI or lctrolyt drangmnts should b admittd for fluid rpltion and srial monitoring of cratin kinas and lctrolyts.Long  B t al. An vidnc-basd narrativ rviw of th mr- gncy dpartmnt valuation and managmnt of rhabdomy- olysis. Am J Emrg Md. 2019;37:518. [PMID: 30630682]IN TERSTITIAL NEPHRITISE S S E N T I A L S  O F  D I A G N O S I S »Fever. »Transient maculopapular rash. »Acute or chronic in nature. »Pyuria, white blood cell casts, and hematuria. »General ConsiderationsAcut  intrstitial nphritis accounts for 10–15% of cass of intrinsic rnal failur. An intrstitial inflammatory rspons with dma and possibl tubular cll damag is th typical pathologic finding. Although drugs account for ovr 70% of cass, acut intrstitial nphritis also occurs in infctious disass, autoimmun disordrs, or as idiopathic conditions. Th most common drugs implicatd ar pnicillins and cphalosporins, immun chckpoint inhibitors, sulfon- amids and sulfonamid-containing diurtics, NSAIDs, proton pump inhibitors, rifampin, and allopurinol. Infc- tious causs includ strptococcal infctions, lptospirosis, cytomgalovirus, histoplasmosis, and Rocky Mountain spottd fvr. SLE, Sjögrn syndrom, sarcoidosis, and cryoglobulinmia can also caus intrstitial nphritis, though thy ar mor classically associatd with glomrulonphritis. »Clinical FindingsClinical  faturs includ fvr (mor than 80% of cass), rash (25–50%), arthralgias, and priphral blood osino- philia (80%). Th classic triad of fvr, rash, and arthralgias is prsnt in only 10–15% of cass. Th urin oftn contains whit clls (95%), rd clls, and whit cll casts. Protinuria is oftn prsnt, particularly in NSAID-inducd intrstitial nphritis, but is usually modst (lss than 2 g/24 h). Eosin- ophiluria is nithr vry snsitiv nor spcific for intrstitial nphritis; valuation for osinophiluria is not advisd. Although th clinical history and laboratory data oftn giv clus to th diagnosis, kidny biopsy is somtims ndd. »Treatment & PrognosisAcut  intrstitial nphritis oftn carris a good prognosis, with rcovry occurring ovr wks to months. UrgntCMDT22_Ch22_p0912-p0951.indd  920 02/07/21 2:33 PMKIDNEY DISEASE921 CMDT 2022dialytic  thrapy may b ncssary in up to on-third of all rfrrd patints bfor rsolution, but patints rarly prog- rss to ESKD. Thos with prolongd oliguria and advancd ag hav a wors prognosis. Tratmnt consists of support- iv masurs and rmoval of th inciting agnt. If kidny injury prsists, a short cours of corticostroids can b considrd, although th data to support thir us ar not substantial, and thir fficacy may dpnd on th lapsd tim btwn onst of AKI and thir initiation. Short-trm, high-dos mthylprdnisolon (0.5–1 g/day intravnously for 1–4 days) or prdnison (60 mg/day orally for 1–2 wks) followd by a prdnison tapr can b usd in mor svr cass of drug-inducd intrstitial nphritis.Mo ldina DG t al. Tratmnt of drug-inducd acut tubuloint- rstitial nphritis: th sarch for bttr vidnc. Clin J Am Soc Nphrol. 2018;13:1785. [PMID: 30397028] Shingarv R t al. Kidny complications of immun chckpoint inhibitors: a rviw. Am J Kidny Dis. 2019;74:529. [PMID: 31303350]GLOM ERULONEPHRITISE S S E N T I A L S  O F  D I A G N O S I S »Hematuria, subnephrotic proteinuria. »Red cell casts pathognomonic but not required for diagnosis. »Dependent edema and hypertension. »AKI. »General ConsiderationsAcu t glomrulonphritis is a rlativly uncommon caus of AKI, accounting for about 5% of cass. Pathologically, inflammatory glomrular lsions ar sn. Ths includ msangioprolifrativ, focal and diffus ndocapillary prolif- rativ, and crscntic lsions. Th largr th prcntag of glomruli involvd and th mor svr th lsion, th mor likly it is that th patint will hav a poor clinical outcom. Glomrulonphritids ar classifid into fiv pathophysi- ologic procsss, which can b charactrizd by srologic analysis. Markrs includ anti-GBM antibodis, antinu- trophil cytoplasmic antibodis (ANCAs), and othr immun markrs of disas. Immune complex deposition occurs whn thr is modrat ovrproduction of antign compard to antibody production. Complxs formd with markd antign xcss tnd to rmain in th circulation. Antibody xcss with larg antign–antibody aggrgats usually rsults in phago- cytosis and claranc of th prcipitats by th mononuclar phagocytic systm in th livr and spln. Causs includ IgA nphropathy, infction-rlatd glomrulonphritis, lupus nphritis, and cryoglobulinmic glomrulonphritis (oftn associatd with hpatitis C virus [HCV]). Anti-GBM–associated acute glomerulonephritis is ithr confind to th kidny or associatd with pulmonary hmorrhag. Th lattr is trmd “Goodpastur syndrom. ”Injury is rlatd to autoantibodis against typ IV collagn in th GBM. Pauci-immune acute glomerulonephritis is a form of small-vssl vasculitis associatd with ANCAs, causing kid- ny disass without dirct immun complx dposition or antibody binding. Tissu injury is blivd to b du to cll- mdiatd immun procsss. An xampl is granulomatosis with polyangiitis, a systmic ncrotizing vasculitis of small artris and vins associatd with intravascular and xtra- vascular granuloma formation. In addition to glomrulon- phritis, ths patints can hav uppr airway, pulmonary, and skin manifstations. Cytoplasmic ANCA (c-ANCA) is th common staining pattrn. Microscopic polyangiitis is anothr pauci-immun vasculitis causing acut glomrulo- nphritis, which is mor commonly associatd with pri- nuclar staining (p-ANCA). ANCA-associatd and anti-GBM–associatd acut glomrulonphritids can volv to crscntic glomrulonphritis and oftn hav poor outcoms unlss tratmnt is startd arly. Monoclonal immunoglobulin–mediated glomerulo- nephritis is charactrizd by th dposition of a monoclo- nal immunoglobulin in glomruli or tubular basmnt mmbran or both. It is dtctd on immunofluorscnt or immunohistochmical staining of kidny biopsis as mono- typic immunoglobulin dposits. Srum protin lctropho- rsis and srum fr light chains ar usful diagnostic tsts to prform whn monoclonal immunoglobulin–mdiatd glomrulonphritis is suspctd or confirmd. Whil many cass will occur in th stting of a monoclonal gammopa- thy, this is not always th cas. C3 glomerulopathy rsults from prdominant C3 dposition in th glomruli with or without minimal dposition of immunoglobulins. It is also idntifid by immunofluorscnc or immunohistochmistry. Th pathognsis of C3 glomrulonphropathy stms from abnormalitis in rgulation of th altrnativ pathway of complmnt. Whil chcking srum C3 lvls may b hlp- ful, normal lvls do not rul out C3 glomrulopathy. Other vascular causes of glomrulonphritis includ hyprtnsiv mrgncis and th thrombotic microangi- opathis such as hmolytic-urmic syndrom and throm- botic thrombocytopnic purpura (s Chaptr 14). »Clinical FindingsA.  Symptoms and SignsPa tints with acut glomrulonphritis ar oftn hyprtn- siv and dmatous with an abnormal urinary sdimnt. Th dma is found first in body parts with low tissu tn- sion, such as th priorbital and scrotal rgions.B.  Laboratory FindingsSrum  cratinin can ris ovr days to months, dpnding on th rapidity of th undrlying procss. Th BUN:cratinin ratio is not a rliabl markr of kidny function and is mor rflctiv of th patint’s undrlying volum status. Dipstick and microscopic valuation rval vidnc of hmaturia and typically subnphrotic protin- uria; thr may b cllular lmnts such as dysmorphic rd clls, rd cll casts, and whit clls. Rd cll casts arCMDT22_Ch22_p0912-p0951.indd  921 02/07/21 2:33 PMChApTEr 22922 CMDT 2022spcific  for glomrulonphritis, and a dtaild sarch on urin microscopy is warrantd. Additional tsts includ srum complmnt lvls (C3, C4) that may b low in immun complx glomrulonphri- tis (xcpt for IgA nphropathy) or C3 glomrulopathy and normal in pauci-immun, anti-GBM–rlatd, and mono- clonal immunoglobulin–mdiatd glomrulonphritids. Othr tsts includ ASO titrs, anti-GBM antibody lvls, ANCAs, antinuclar antibody titrs, cryoglobulins, hpati- tis srologis, srum protin lctrophorsis and srum fr light chains, blood culturs, and rnal ultrasound. With fw xcptions, a kidny biopsy is ultimatly ncssary to con- firm th diagnosis, irrspctiv of laboratory data. »TreatmentDpnding  on th natur and svrity of disas, tratmnt might includ high-dos corticostroids, rituximab, and cytotoxic agnts (such as cyclophosphamid). Plasma xchang can b usd in Goodpastur syndrom as a tm- porizing masur until chmothrapy can tak ffct. Tratmnt and prognosis for spcific disass ar discussd mor fully blow.Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Sthi S t al. Standardizd classification and rporting of glomrulonphritis. Nphrol Dial Transplant. 2019;34:193. [PMID: 30124958]COVI D-19 & THE KIDNEYE S S E N T I A L S  O F  D I A G N O S I S »Broad array of clinical presentation and kidney pathology. »Clinical Findings & TreatmentNar ly half of patints hospitalizd with COVID-19 prs- nt with or dvlop AKI, which is associatd with poorr prognosis. Many causs of AKI ar dscribd in patints with COVID-19, but th most common is ATN rlatd to a high inflammatory stat (trmd “cytokin storm”). Urinalysis may rval hmaturia, rflcting ndothlial injury and fibrin thrombi that ar commonly obsrvd on biopsy. Anothr mrging ntity is COVID-19–associatd collapsing glomrulopathy, which is a typ of focal sgmntal glomrulosclrosis (s sction on “Nphrotic Spctrum Glomrular Disass” blow). Patints with collapsing glo- mrulopathy prsnt with nphrotic syndrom and ar typi- cally of African ancstry, highlighting a suspctd gntic prdisposition. Tratmnt of COVID-19–rlatd AKI is largly supportiv; th rol of corticostroids in COVID-19– associatd collapsing glomrulopathy is undr invstigation.Cha n L t al; Mount Sinai COVID Informatics Cntr (MSCIC). AKI in hospitalizd patints with COVID-19. J Am Soc Nphrol. 2021;32:151. [PMID: 32883700]Nasr SH t al. COVID-19-associatd collapsing glomrulopathy: an mrging ntity. Kidny Int Rp. 2020;5:759. [PMID: 32368701] Ronco C t al. Managmnt of acut kidny injury in patints with COVID-19. Lanct Rspir Md. 2020;8:738. [PMID: 32416769] Shtty AA t al. COVID-19-associatd glomrular disas. J Am Soc Nphrol. 2021;32:33. [PMID: 33214201]C ARDIORENAL SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S »Cadiac dysfunction: acute or chronic heart failure, ischemic injury, or arrhythmias. »Kidney disease: acute or chronic, depending on the type of cardiorenal syndrome. »General ConsiderationsCardior nal syndrom is a pathophysiologic disordr of th hart and kidnys whrin th acut or chronic dtrio- ration of on organ rsults in th acut or chronic dtrio- ration of th othr. This syndrom is classifid into fiv typs as a mattr of convntion. Achiving uvolmia is th ovrarching thraputic goal rgardlss of typ (s Hart Failur sction in Chaptr 10). Typ 1 consists of AKI stmming from acut cardiac disas. Typ 2 is CKD du to chronic cardiac disas. Typ 3 is acut cardiac disas as a rsult of AKI. Typ 4 is chronic cardiac dcompnsation from CKD. Typ 5 con- sists of hart and kidny dysfunction du to othr acut or chronic systmic disordrs (such as spsis). Although novl agnts ar bing xamind for futur thrapis, th main- stay of tratmnt is to addrss th primary undrlying hart or kidny dysfunction.K umar U t al. Cardiornal syndrom: pathophysiology. Cardiol Clin. 2019;37:251. [PMID: 31279419] Raina R t al. An updat on th pathophysiology and tratmnt of cardiornal syndrom. Cardiol Rs. 2020;11:76. [PMID: 32256914] ºChrONIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Decline in the GFR over months to years. »Persistent proteinuria or abnormal renal morphol- ogy may be present. »Hypertension in most cases. »Symptoms and signs of uremia when nearing end- stage disease. »Bilateral small or echogenic kidneys on ultrasound in advanced disease.CMDT22_Ch22_p0912-p0951.indd  922 02/07/21 2:33 PMKIDNEY DISEASE923 CMDT 2022 »General ConsiderationsCKD affcts at last 10% of Amricans. Ma ny ar unawar of th condition bcaus thy rmain asymptomatic until th disas is nar nd stag. Th National Kidny Founda- tion’s staging systm hlps clinicians formulat practic plans (Tabl 22–4). Ovr 70% of cass of lat-stag CKD (stag 5 CKD and ESKD) in th Unitd Stats ar du to diabts mllitus or hyprtnsion/vascular disas. Glo- mrulonphritis, cystic disass, chronic tubulointrstitial disass, and othr urologic disass account for th rmaindr (Tabl 22–5). Gntic polymorphisms of th APOL-1 gn hav bn shown to b associatd with an incrasd risk of th dvlopmnt of CKD in prsons of African ancstry. CKD usually lads to a progrssiv dclin in kidny function vn if th inciting caus can b idntifid and tratd or rmovd. Dstruction of nphrons lads to compnsatory hyprtrophy and supranormal GFR of th rmaining nphrons in ordr to maintain ovrall homo- stasis. As a rsult, th srum cratinin may rmain rla- tivly normal vn in th fac of significant loss of rnal mass and is, thrfor, an insnsitiv markr for arly rnal damag and scarring. In addition, compnsatory hyprfiltration lads to ovrwork injury in th rmaining nphrons, which in turn causs progrssiv glomrular sclrosis and intrstitial fibrosis. Angiotnsin rcptor blockrs (ARBs) and ACE inhibitors can hlp rduc hyprfiltration injury and may slow th progrssion of protinuric CKD. Whil CKD is an indpndnt risk factor for cardiovas- cular disas (CVD), protinuric CKD confrs th highst risk. Most patints with stag 3 CKD di of undrlying CVD prior to progrssion to ESKD.»Clinical FindingsA.  Symptoms and SignsStags  1–4 CKD ar asymptomatic. Symptoms dvlop slowly with th progrssiv dclin in GFR, ar nonsp- cific, and do not manifst until kidny disas is far advancd (GFR lss than 5–10 mL/min/1.73 m2). At this point, th accumulation of mtabolic wast products, or urmic toxins, rsults in th uremic syndrome . Gnral symptoms of urmia may includ fatigu, anorxia, nausa, and a mtallic tast in th mouth. Nurologic symptoms such as mmory impairmnt, insomnia, rstlss lgs, and twitching may b du to urmia. Gnralizd pruritus (without rash) may occur, as may dcrasd libido and mnstrual irrgularitis. Pricarditis, a rar complication of CKD, may prsnt with pluritic chst pain. Mdications that ar clard by th kidnys will accumulat as kidny function worsns and toxicity may nsu; an important xampl is insulin and an incrasing risk of significant hypoglycmia if doss ar not appropriatly rducd. Th most common physical finding in CKD is hypr- tnsion; this is du in part to impaird sodium xcrtion. It is oftn prsnt in arly stags of CKD and tnds to worsn with CKD progrssion. In latr stags of CKD, sodium rtntion may lad to clinically apparnt volum ovrload. Urmic signs ar sn with a profound dcras in GFR (lss than 5–10 mL/min/1.73 m2) and may includ a gnr- ally sallow and ill apparanc, halitosis (urmic ftor), and th urmic ncphalopathic signs of dcrasd mntal sta- tus, astrixis, myoclonus, and possibly sizurs. Symptoms and signs of urmia warrant immdiat hos- pital admission and nphrology consultation for initiation of dialysis. Th urmic syndrom is amlioratd with dialytic thrapy.Table 22–4. Stages of chronic kidney disease: a clinical action plan.1,2Stage 3Descition GFr (mL/min/1.73 m2) Action 1 Kidney damage with normal or ↑↑GFR ≥ 90 Diagnosis and treatment of underlying etiology if possible. Treatment of comorbid conditions. Estimate progression, work to slow progression. Cardiovascular disease risk reduction.2 Kidney damage with mildly ↓GFR 60–89 3a Mildly-moderately ↓GFR 45–59 As above, and evaluating and treating complications. 3b Moderately-severely ↓GFR 30–44 4 Severely ↓GFR 15–29 Preparation for end-stage kidney disease. 5 End-stage kidney disease < 15 (or dialysis) Dialysis, transplant, or palliative care.1 Based on National Kidney Foundation, KDOQI, and KDIGO Chronic Kidney Disease Guidelines.2 Chronic kidney disease is defined as either kidney damage or GFR < 60 mL/min/1.73 m2for 3 or more months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.3 At all stages, persistent albuminuria confers added risk for chronic kidney disease progression and cardiovascular disease in t he following gradations: < 30 mg/day = lowest added risk, 30–300 mg/day = mildly increased risk, > 300–1000 mg/day = moderately increased ri sk, > 1000 mg/day = severely increased risk. GFR, glomerular filtration rate. Modified and reproduced, with permission, from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013 Jan;3(1) (Suppl):1–15 0. Copyright © 2013 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.CMDT22_Ch22_p0912-p0951.indd  923 02/07/21 2:33 PMChApTEr 22924 CMDT 2022T able 22–5. Causes of chronic kidney disease.Glomeula  Diseases pimay glomeula diseases Focal segmental glomerulosclerosis Membranoproliferative glomerulonephritis IgA nephropathy Membranous nephropathy Alport syndrome (hereditary nephritis) Seconday glomeula diseases Diabetic nephropathy Renal amyloidosis Postinfectious glomerulonephritis HIV-associated nephropathy Collagen-vascular diseases (eg, SLE) HCV-associated membranoproliferative glomerulonephritis Tubulointestitial Neitis Drug hypersensitivity Heavy metals Analgesic nephropathy Reflux/chronic pyelonephritis Sickle cell nephropathy Idiopathic Cystic Diseases Polycystic kidney disease Medullary cystic disease Obstuctive Neoaties Prostatic disease Nephrolithiasis Retroperitoneal fibrosis/tumor Congenital/reflux Vascula Diseases Hypertensive nephrosclerosis Renal artery stenosis HCV, hepatitis C virus; SLE, systemic lupus erythematosus.Table 22–6. Reversible causes of kidney injury.revesible  Factos Diagnostic Clues Obstruction Post-void residual, bladder cath- eterization, renal ultrasound Extracellular fluid volume depletion or significant hypotension relative to baselineBlood pressure and pulse, including orthostatic pulse Hypercalcemia Serum electrolytes, calcium, phosphate Nephrotoxic agents Drug history Severe/urgent hypertension Blood pressure, chest radiograph Heart failure exacerbation Physical examination, chest radiograph• • •1 2 31 .0 0.9 0.7 0.5 0.3 0.1 1 2 3 4 5 6 7 8 9 1 01/ScrTime  (years)1 Value of serum creatinine level = 1 .0 mg/dL2 Value of serum creatinine level = 2.0 mg/dL3 Value of serum creatinine level = 5.0 mg/dL ▲Figure 22–1. Decline in kidney function (expressed as the reciprocal of serum creatinine as shown here, or as estimated glomerular filtration rate [eGFR]) plotted against time to ESKD. The solid line indicates the linear decline in kidney function over time. The dotted line indicates the approximate time to ESKD.In any patint with kidny disas, it is important to idntify and corrct all possibly rvrsibl insults or xac- rbating factors (Tabl 22–6). Urinary obstruction, hypo- volmia, hypotnsion, nphrotoxins (such as NSAIDs, aminoglycosids, or proton pump inhibitors), svr or mrgnt hyprtnsion, and hart failur xacrbation should b xcludd.B.  Laboratory FindingsCKD is u sually dfind by an abnormal GFR prsisting for at last 3 months. Prsistnt protinuria or abnormalitis on rnal imaging (g, polycystic kidnys or a singl kidny) ar also diagnostic of CKD, vn whn GFR is normal. If multipl masurmnts of GFR ovr tim ar availabl, th rat of progrssion should b assssd (Figur 22–1). If th slop of th lin acutly dclins, potntially rvrsibl rnal insults should b xcludd. Anmia, hyprphospha- tmia, hypocalcmia, hyprkalmia, and mtabolic acido- sis ar common complications of advancd CKD. Th urinary sdimnt may show broad waxy casts as a rsult ofdilatd, hyprtrophic nphrons. If protinuria is prsnt, it should b quantifid as dscribd abov. This can hlp nar- row th diffrntial diagnosis of th tiology of th CKD (Tabl 22–5); for xampl, glomrular disass tnd to prsnt with protin xcrtion of mor than 1 g/day. Addi- tionally, highr urinary protin xcrtion is associatd with mor rapid progrssion of CKD and incrasd risk of car- diovascular mortality.CMDT22_Ch22_p0912-p0951.indd  924 02/07/21 2:33 PMKIDNEY DISEASE925 CMDT 2022C.  ImagingTh  finding of small, chognic kidnys bilatrally (lss than 9–10 cm) by ultrasonography suggsts th chronic scarring of advancd CKD. Larg kidnys can b sn with adult polycystic kidny disas, diabtic nphropathy, HIV-associatd nphropathy, plasma cll myloma, amy- loidosis, and obstructiv uropathy. »ComplicationsTh  complications of CKD tnd to occur at rlativly pr- dictabl stags of disas as notd in Figur 22–2.A.  Cardiovascular ComplicationsPa tints with CKD xprinc gratr morbidity and mor- tality from CVD in comparison to th gnral population. Roughly 80% of patints with CKD di bfor raching ESKD, primarily of CVD. Of thos undrgoing dialysis, 45% will di of a cardiovascular caus. Th mchanisms for nhancd cardiovascular mortality in CKD ar complx and includ abnormal phosphorus and calcium homosta- sis, incrasd burdn of oxidativ strss, incrasd vascular ractivity, lft vntricular hyprtrophy, and coxistnt con- ditions such as hyprtnsion and diabts mllitus. 1. Hypertension— Hyprtnsion is th most common complication of CKD; it tnds to b progrssiv and salt- snsitiv. Hyprrninmic stats and xognous rythro- poitin administration can xacrbat hyprtnsion. As with othr patint populations, control of hyprtn- sion should focus on both pharmacologic and nonpharma- cologic thrapy (g, dit, xrcis, wight loss, tratmnt of obstructiv slp apna). CKD rsults in disturbd sodium homostasis such that th ability of th kidny to adjust to variations in sodium and watr intak bcoms limitd as GFR dclins. A low salt dit (2 g/day) is oftn ssntial to control blood prssur and hlp avoid ovrt volum ovr- load. Diurtics ar narly always ndd to hlp control hyprtnsion (s Tabl 11–8); thiazids work wll in arly CKD, but loop diurtics may b mor ffctiv in thoswith a GFR lss than 30 mL/min/1.73 m2. Howvr, vol- um contraction as a rsult of vry low sodium intak (spcially with intrcurrnt illnss) or ovr-diursis in th prsnc of impaird sodium homostasis can rsult in AKI. Initial drug thrapy for protinuric patints should includ ACE inhibitors or ARBs (s Tabl 11–6); howvr, thr is no vidnc of supriority of ths drugs ovr othr drug classs for nonprotinuric CKD. Whn an ACE inhibitor or an ARB is initiatd or uptitratd, patints must hav srum cratinin and potassium chckd within 7–14 days. A ris in srum cratinin gratr than 30% from baslin mandats dos rduction or cssation of th drug. Hyprkalmia may also warrant drug cssation, xcpt in th rliabl patint who can follow a low-potas- sium dit and adhr to a potassium-binding rsin; such patints should b monitord closly. An ACE inhibitor and ARB should not b usd in combination. CKD is a common caus of rfractory hyprtnsion for which agnts from multipl classs ar oftn ndd. Currnt guidlins diffr with rspct to blood prssur goals in CKD; thos from th Joint National Commission suggst a goal of lss than 140/90 mm Hg, whil th Amrican Hart Associa- tion advocats for lss than 130/80 mm Hg. As patints with CKD ar at risk for rnal hypoprfusion and AKI with ovrtratmnt of hyprtnsion, it is prudnt to individual- iz th approach to blood prssur control to ach patint. 2. Coronary artery disease— Patints with CKD ar at highr risk for dath from CVD than th gnral popula- tion. Traditional modifiabl risk factors for CVD, such as hyprtnsion, tobacco us, and hyprlipidmia, should b aggrssivly tratd. Urmic vascular calcification involv- ing disordrd phosphorus homostasis and othr mdia- tors may also b a cardiovascular risk factor in ths patints. 3. Heart failure— CKD complications rsult in incrasd cardiac workload du to hyprtnsion, volum ovrload, and anmia. Patints may also hav acclratd rats of athrosclrosis and vascular calcification rsulting in vssl stiffnss. All of ths factors contribut to lft vntricular↑PTHGlomerular filtration  rate (mL/min/1.73 m2)↑PhosphorusHTN Anemia Acidosis, hyperkalemia Uremic syndromeCKD stage5 4 3 20 20 40 60 80 100 ▲Figure 22–2. Complications of chronic kidney disease (CKD) by stage and glomerular filtration rate (GFR). Compli- cations arising from CKD tend to occur at the stages depicted, although there is considerable variability noted in clin- ical practice. HTN, hypertension; PTH, parathyroid hormone. (Adapted, with permission, from William Bennett, MD.)CMDT22_Ch22_p0912-p0951.indd  925 02/07/21 2:33 PMChApTEr 22926 CMDT 2022hyprtrop hy and hart failur with prsrvd jction frac- tion, which is common in CKD. Ovr tim, hart failur with dcrasd jction fraction may dvlop. Diurtic thrapy, in addition to fluid and salt rstriction, is usually ncssary; diurtic dos scalation may b ndd as kid- ny function dclins. ACE inhibitors and ARBs can b usd for patints with advancd CKD with clos monitor- ing of blood prssur as wll as for hyprkalmia and wors- ning kidny function; minralocorticoid rcptor antagonists may b usd with similar prcautions but should b discontinud whn GFR is lss than 30 mL/ min/1.73 m2. SGLT2 inhibitors hav bn shown to improv outcoms for both hart failur and CKD. 4. Atrial fibrillation— Patints with advancd CKD and ESKD suffr disproportionat rats of atrial fibrillation, which approach 20% in patints rciving dialysis. Whil thos with up to CKD stag 4 should b tratd as th gn- ral population, anticoagulation for prvntion of throm- bombolic vnts bcoms challnging in thos with ESKD du to compting risks of blding and clotting as wll as a lack of data supporting its routin us. 5. Pericarditis— Pricarditis rarly dvlops in urmic patints; typical findings includ pluritic chst pain and a friction rub. Cardiac tamponad can occur; thrfor, ur- mic pricarditis is a mandatory indication for hospitaliza- tion and initiation of hmodialysis.Bangalor  S t al. Managmnt of coronary disas in patints with advancd kidny disas. N Engl J Md. 2020;382:1608. [PMID: 32227756] Fay KS t al. Rsistant hyprtnsion in popl with CKD: a rviw. Am J Kidny Dis. 2021;77:110. [PMID: 32712185] Gurrot D t al. Blood prssur targts in chronic kidny disas: an updat on th vidnc. Curr Opin Nphrol Hyprtns. 2020;29:327. [PMID: 32167996] Packr M t al; EMPEROR-Rducd Trial Invstigators. Cardio- vascular and rnal outcoms with mpagliflozin in hart failur. N Engl J Md. 2020;383:1413. [PMID: 32865377] Palmr BF. Potassium bindrs for hyprkalmia in chronic kidny disas—dit, rnin-angiotnsin-aldostron systm inhibitor thrapy, and hmodialysis. Mayo Clin Proc. 2020;95: 339. [PMID: 31668450]B.  Metabolic Bone DiseaseTh mtabolic b on disas of CKD rfrs to th complx disturbancs of calcium and phosphorus mtabolism, parathyroid hormon (PTH), activ vitamin D, and fibro- blast growth factor-23 (FGF-23) homostasis (s Chaptr 21 and Figur 22–3). A typical pattrn sn as arly as CKD stag 3 is hyprphosphatmia, hypocalcmia, and hypovitaminosis D, rsulting in scondary hyprparathy- roidism. Ths abnormalitis can contribut to vascular calcification and may b rsponsibl in part for th acclr- atd CVD and xcss mortality sn in th CKD popula- tion. Epidmiologic studis show an association btwn lvatd phosphorus lvls and incrasd risk of cardiovas- cular mortality in arly CKD through ESKD. As yt, thr ar no intrvntion trials suggsting th bst cours of tratmnt in ths patints; control of minral and PTH lvls pr currnt guidlins is discussd blow.Bon disas, or rnal ostodystrophy, in advancd CKD is common and thr ar svral typs of lsions. Rnal ostodystrophy can b diagnosd only by bon biopsy, which is rarly don. Th most common bon dis- as, ostitis fibrosa cystica, is a rsult of scondary hypr- parathyroidism and th ostoclast-stimulating ffcts of PTH. This is a high-turnovr disas with bon rsorption and subpriostal lsions; it can rsult in bon pain and proximal muscl waknss. Adynamic bon disas, or low-bon turnovr, is bcoming mor common; it may rsult iatrognically from supprssion of PTH or via spon- tanously low PTH production. Ostomalacia is charactr- izd by lack of bon minralization. In th past, ostomalacia was associatd with aluminum toxicity—ithr as a rsult of chronic ingstion of prscribd aluminum-containing phosphorus bindrs or from high lvls of aluminum in impur dialysat watr. Currntly, ostomalacia is mor likly to rsult from hypovitaminosis D; thr is also tho- rtical risk of ostomalacia associatd with us of bisphos- phonats in advancd CKD. All of th abov ntitis incras th risk of fracturs. Tratmnt may involv corrction of calcium, phosphorus, and 25-OH vitamin D lvls toward normal valus, and mitigation of hyprparathyroidism. Undrstanding th intrplay btwn ths abnormalitis can hlp targt thrapy (Figur 22–3). Dclining GFR lads to phosphorus rtntion. This rsults in hypocalcmia as phosphorus complxs with calcium, dposits in soft tissus, and stim- ulats PTH. Loss of rnal mass and low 25-OH vitamin D lvls oftn sn in CKD patints rsult in low 1,25(OH) vitamin D production by th kidny. Bcaus 1,25(OH) vitamin D is a supprssor of PTH production, hypovita- minosis D also lads to scondary hyprparathyroidism. Th first stp in tratmnt of mtabolic bon disas is control of hyprphosphatmia. This involvs ditary phos- phorus rstriction initially (s sction on ditary manag- mnt), followd by th administration of oral phosphorus bindrs if targts ar not achivd. Oral phosphorus bind- rs block absorption of ditary phosphorus in th gut and ar givn thric daily with mals. Ths should b titratd to a nar-normal srum phosphorus lvl. Calcium- containing bindrs (calcium carbonat, 650 mg/tablt, or calcium actat, 667 mg/capsul, usd at doss of on to thr↓GFR↓25(OH) Vitamin D ↑PTH↓ Calcium↑Phosphorus ↓1,25(OH) Vitamin D ▲Figure 22–3. Mineral abnormalities of CKD. Decline in glomerular filtration rate (GFR) and loss of renal mass lead directly to increased serum phosphorus and hypo- vitaminosis D. Both of these abnormalities result in hypocalcemia and hyperparathyroidism. Many CKD patients also have nutritional 25(OH) vitamin D defi- ciency. PTH, parathyroid hormone.CMDT22_Ch22_p0912-p0951.indd  926 02/07/21 2:33 PMKIDNEY DISEASE927 CMDT 2022pills  pr mal) ar rlativly inxpnsiv but may contribut to positiv calcium balanc and vascular calcification; ovrt hyprcalcmia may also occur. Currnt guidlins suggst limiting thir us in favor of th non-calcium–containing bindrs svlamr carbonat (800–3200 mg/mal) and lanthanum carbonat (500–1000 mg/mal). Nwr, iron- basd phosphorus bindrs includ frric citrat and sucro- frric oxyhydroxid and may b considrd whn othr bindrs ar not tolratd ithr du to hyprcalcmia or constipation. Thy should b avoidd in patints with iron ovrload. Aluminum hydroxid is a highly ffctiv phos- phorus bindr but can caus ostomalacia and nurologic complications whn usd long-trm; it can b usd in th acut stting for svr hyprphosphatmia or for short priods (g, 3 wks) in CKD patints. Onc srum phosphorus lvls ar controlld, activ vitamin D (1,25[OH] vitamin D, or calcitriol) or othr vita- min D analogs ar usd to trat scondary hyprparathy- roidism in advancd CKD and ESKD. Srum 25-OH vitamin D lvls should b masurd and brought to nor- mal (s Chaptr 26) prior to considring administration of activ vitamin D. Activ vitamin D (calcitriol) incrass srum calcium and phosphorus lvls; both nd to b monitord closly during calcitriol thrapy, and its dos should b dcrasd if hyprcalcmia or hyprphosphat- mia occurs. Typical calcitriol dosing is 0.25 or 0.5 mcg orally daily or vry othr day. Cinacalct targts th cal- cium-snsing rcptors of th parathyroid gland and sup- prsss PTH production. Cinacalct, 30–90 mg orally onc a day, can b usd if lvatd srum phosphorus or calcium lvls prohibit th us of vitamin D analogs; it can caus srious hypocalcmia, and patints should b closly moni- tord for this complication. Optimal PTH lvls in CKD ar not known, but bcaus skltal rsistanc to PTH dvlops with urmia, rlativly high lvls ar targtd in advancd CKD to avoid adynamic bon disas. Exprt guidlins suggst goal PTH lvls nar or just abov th uppr limit of normal for modrat CKD, and at last twofold and up to ninfold th uppr limit of normal for ESKD.Ev npol P t al. Europan Consnsus Statmnt on th diag- nosis and managmnt of ostoporosis in chronic kidny disas stags G4-G5D. Nphrol Dial Transplant. 2021;36:42. [PMID: 33098421] Scialla JJ t al. Stat-of-th-art managmnt of hyprphosphat- mia in patints with CKD: an NKF-KDOQI controvrsis prspctiv. Am J Kidny Dis. 2021;77:132. [PMID: 32771650]C.  Hematologic Complications1.  Anemia— Th anmia of CKD, primarily du to dcrasd rythropoitin production, oftn bcoms clini- cally significant during stag 3 CKD. CKD is also associ- atd with high lvls of hpcidin, which blocks GI iron absorption and mobilization of iron from body stors; this rsults in a functional iron dficincy—th so-calld “an- mia of chronic disas. ” Th approach to a patint with CKD and anmia bgins with nsuring that th bon mar- row can rspond to rythropoitin. Thus, thyroid function tsts, srum vitamin B12lvls, and iron stors (frritin and iron saturation) should b chckd. Iron stors ar targtdto highr goals du to a functional blockad of iron utiliza- tion in this population. In CKD, a srum frritin blow 100–200 ng/mL or iron saturation lss than 20% is suggs- tiv of iron dficincy. Iron stors may b rpltd with oral or parntral iron; iron thrapy should probably b withhld if th srum frritin is gratr than 500–800 ng/mL, vn if th iron saturation is lss than 20%. Oral thrapy with fr- rous sulfat, gluconat, or fumarat, 325 mg onc daily, is th initial thrapy in pr-ESKD CKD; highr doss will rsult in incrasing hpcidin lvls. For thos who do not rspond du to poor GI absorption or lack of tolranc, intravnous iron (g, iron sucros or iron gluconat) may b ncssary. Erythropoisis-stimulating agnts (ESAs, g, rcombi- nant rythropoitin [potin alfa or bta] and darbpo- tin) ar usd to trat th anmia of CKD if othr tratabl causs ar xcludd. Thr is likly no bnfit of starting an ESA bfor hmoglobin (Hgb) valus ar lss than 9 g/dL. Th starting dos of potin alfa is 50–100 units/kg onc or twic a wk, and darbpotin is startd at 0.45 mcg/kg and administrd vry 2–4 wks; potin bta at a starting dos of 60–100 mcg is givn vry 2–4 wks. Ths agnts can b givn intravnously (g, to th hmodialysis patint) or subcutanously (to both th prdialysis or dialysis patint); subcutanous dosing of potin alfa is roughly 30% mor ffctiv than intravnous dosing. ESAs should b titratd to an Hgb of 10–11 g/dL for optimal safty; studis show that targting a highr Hgb incrass th risk of strok and possibly othr cardiovascular vnts. Whn titrating doss, Hgb lvls should ris no mor than 1 g/dL vry 3–4 wks. Hyprtnsion is a common complication of tratmnt with ESAs. 2. Coagulopathy— Th blding diathsis that may occur in stag 4–5 CKD is mainly du to platlt dysfunction, but svr anmia may also contribut. Tratmnt is rquird only in patints who ar symptom- atic. Raising th Hgb to 9–10 g/dL in anmic patints can rduc risk of blding via improvd clot formation. Dsmo- prssin (25 mcg intravnously vry 8–12 hours for two doss) is a short-livd but ffctiv tratmnt for platlt dysfunction and it is oftn usd in prparation for surgry or kidny biopsy; hyponatrmia is a potntial advrs ffct of this tratmnt. Dialysis improvs th blding tim.Locatlli  F t al. Ar all rythropoisis-stimulating agnts cratd qual? Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 32206785]D . HyperkalemiaPo tassium balanc gnrally rmains intact in CKD until stags 4–5. Howvr, hyprkalmia may occur at arlir stags whn crtain conditions ar prsnt, such as typ 4 rnal tubular acidosis (sn in patints with diabts ml- litus), high potassium dits, or mdications that dcras rnal potassium scrtion (amilorid, triamtrn, spi- ronolacton, plrnon, NSAIDs, ACE inhibitors, ARBs) or block cllular potassium uptak (bta-blockrs). Othr causs includ acidmic stats and any typ of cllular dstruction causing rlas of intracllular contnts, such as hmolysis and rhabdomyolysis.CMDT22_Ch22_p0912-p0951.indd  927 02/07/21 2:33 PMChApTEr 22928 CMDT 2022T ratmnt of acut hyprkalmia is discussd in Chaptr 21 (s Tabl 21–5). Cardiac monitoring is indi- catd for any ECG changs sn with hyprkalmia or a srum potassium lvl gratr than 6.0–6.5 mEq/L or mmol/L. Chronic hyprkalmia is bst tratd with ditary potassium rstriction (2 g/day) and minimization or limi- nation of any mdications that may impair rnal potassium xcrtion, as notd abov. Loop diurtics may b adminis- trd for thir kaliurtic ffct as long as th patint is not volum-dpltd, and oral potassium-binding rsins may b considrd.Palmr  BF t al. Clinical managmnt of hyprkalmia. Mayo Clin Proc. 2021;96:744. [PMID: 33160639]E.  AcidBase DisordersDamagd kidnys  ar unabl to xcrt th 1 mEq/kg/day of acid gnratd by mtabolism of ditary animal protins in th typical Wstrn dit. Th rsultant mtabolic acido- sis is primarily du to dcrasd GFR; proximal or distal tubular dfcts may contribut to or worsn th acidosis. Excss hydrogn ions ar buffrd by bon; th consqunt laching of calcium and phosphorus from th bon con- tributs to th mtabolic bon disas dscribd abov. Chronic acidosis can also rsult in muscl protin catabo- lism as wll as growth rtardation in childrn with CKD and may acclrat progrssion of CKD. Rduction of ditary animal protin and incrasd fruit and vgtabl intak, and th administration of oral sodium bicarbonat (in doss of 0.5–1.0 mEq/kg/day dividd twic daily and titratd as ndd) ar stratgis to bring srum bicarbon- at lvls toward normal. Citrat salts incras th absorp- tion of ditary aluminum and should b avoidd in CKD.Na vanthan SD t al. Effcts of tratmnt of mtabolic acidosis in CKD: a systmatic rviw and mta-analysis. Clin J Am Soc Nphrol. 2019;14:1011. [PMID: 31196951]F . Neurologic ComplicationsUrmic  ncphalopathy, rsulting from th aggrgation of urmic toxins, dos not occur until GFR falls blow 5–10 mL/min/1.73 m2. Symptoms bgin with difficulty in concntrating and can progrss to lthargy, confusion, si- zur, and coma. Physical findings may includ altrd mntal status, waknss, and astrixis. Ths findings improv with dialysis. Othr nurologic complications that can manifst with advancd CKD includ priphral nuropathis (stocking- glov or isolatd mononuropathis), rctil dysfunction, autonomic dysfunction, and rstlss lg syndrom. Ths may not improv with dialysis thrapy.G.  Endocrine DisordersDcrasd  libido and rctil dysfunction ar common in advancd CKD. Mn hav dcrasd tstostron lvls; womn ar oftn anovulatory. Womn with srum crati- nin lss than 1.4 mg/dL ar not at incrasd risk for poor outcoms in prgnancy; howvr, thos with srumcratinin gratr than 1.4 mg/dL may xprinc fastr progrssion of CKD with prgnancy. Ftal survival is not compromisd, howvr, unlss CKD is advancd. »TreatmentA.  Slowing ProgressionT ratmnt of th undrlying caus of CKD is vital. Control of diabts should b aggrssiv in arly CKD; howvr, risk of hypoglycmia incrass in advancd CKD, and gly- cmic targts may nd to b rlaxd to avoid this dangr- ous complication. Blood prssur control is vital to slow progrssion of all forms of CKD; agnts that block th rnin-angiotnsin-aldostron systm ar particularly important in protinuric patints. Obs patints should b ncouragd to los wight. Managmnt of traditional car- diovascular risk factors is vital. Risks for AKI should b minimizd or avoidd, including long-trm us of NSAIDs. Tratmnt of mtabolic acidosis may b hlpful. Th ffi- cacy of SGLT2 inhibition for slowing progrssion of CKD in thos with and without diabts or significant protin- uria has bn dmonstratd in svral rcnt trials.Han nan M t al. Risk factors for CKD progrssion: ovrviw of findings from th CRIC study. Clin J Am Soc Nphrol. 2021;16:648. [PMID: 33177074] Hrspink HJL t al; DAPA-CKD Trial Committs and Invsti- gators. Dapagliflozin in patints with chronic kidny disas. N Engl J Md. 2020;383:1436. [PMID: 32970396] Klly JT t al. Modifiabl lifstyl factors for primary prvntion of CKD: a systmatic rviw and mta-analysis. J Am Soc Nphrol. 2021;32:239. [PMID: 32868398]B.  Dietary ManagementPa tints with CKD should b valuatd by a rnal nutri- tionist. Patint-spcific rcommndations should b mad concrning protin, salt, watr, potassium, and phosphorus intak to hlp manag CKD progrssion and complications. 1. Protein restriction— Thr is incrasing intrst in plant-basd dits for th tratmnt of CKD. Rducd intak of animal protin to 0.6–0.8 g/kg/day may slow CKD progrssion. Howvr, significant protin rstriction is not advisabl in thos with cachxia or low srum albu- min in th absnc of th nphrotic syndrom. 2. Salt and water restriction— In advancd CKD, th kid- ny is unabl to adapt to larg changs in sodium intak. Intak of gratr than 3–4 g/day can lad to hyprtnsion and hyprvolmia, whras intak of lss than 1 g/day can lad to volum dpltion and hypotnsion. A goal of 2 g/day of sodium is rasonabl for most patints. Daily fluid rstriction to 2 L may b ndd if volum ovrload is prsnt. 3. Potassium restriction— Rstriction is ndd onc th GFR has falln blow 10–20 mL/min/1.73 m2, or arlir if th patint is hyprkalmic. Patints should rciv dtaild lists dscribing potassium contnt of foods and should limit thir intak to lss than 50–60 mEq/day (2 g/day). An aggrssiv bowl rgimn should b institutd for patints with hyprkalmia (mor than two bowl movmntsCMDT22_Ch22_p0912-p0951.indd  928 02/07/21 2:33 PMKIDNEY DISEASE929 CMDT 2022daily),  sinc a highr prcntag of potassium is xcrtd through th GI tract as GFR dclins. Potassium-binding rsins may b usd (s sction on Hyprkalmia). 4. Phosphorus restriction— Guidlins suggst lowring lvatd srum phosphorus lvls toward normal in all stags of CKD. Ditary phosphat rstriction to 800–1000 mg/day is th first stp. Procssd foods and cola bvrags ar oftn prsrvd with highly bioavailabl phosphorus and should b avoidd. Foods rich in phos- phorus such as ggs, dairy products, nuts, bans, and mat may also nd to b limitd, although car must b takn to avoid protin malnutrition. Whn GFR is lss than 20–30 mL/min/1.73 m2, ditary rstriction is rarly suffi- cint to rach targt lvls, and phosphorus bindrs ar usually rquird (s sction on Mtabolic Bon Disas).Ikizlr T A t al. KDOQI clinical practic guidlin for nutrition in CKD: 2020 updat. Am J Kidny Dis. 2020;76:S1. [PMID: 32829751] Joshi S t al. Plant-basd dits for kidny disas: a guid for clinicians. Am J Kidny Dis. 2021;77:287. [PMID: 33075387]C.  Medication ManagementMan y drugs ar xcrtd by th kidny; dosags should b adjustd for GFR. Dcrasd rnal limination of insulin in advancd CKD confrs risk for hypoglycmia in tratd diabtic patints. Doss of oral hypoglycmics and insulin may nd rduction. Th risk of lactic acidosis with mt- formin is du to both dos and GFR; it should b discon- tinud whn GFR is lss than 30 mL/min/1.73 m2. Magnsium-containing mdications, such as laxativs or antacids, and phosphorus-containing mdicins (g, cathartics) should b avoidd. Activ morphin mtabo- lits can accumulat in advancd CKD; this problm is not ncountrd with othr opioid agnts. Drugs with potn- tial nphrotoxicity (NSAIDs, intravnous contrast, as wll as othrs notd in th Acut Kidny Injury sction) should b avoidd. Proton pump inhibitors should b usd only whn mdically ncssary.Shaddock  R t al. Rnal rprcussions of mdications. Prim Car. 2020;47:691. [PMID: 33121637]D . Treatment of ESKDWhn  GFR dclins to 5–10 mL/min/1.73 m2, rnal rplac- mnt thrapy (hmodialysis, pritonal dialysis, or kidny transplantation) is rquird to sustain lif. Patint ducation is important in undrstanding which mod of thrapy is most suitabl, as is timly prparation for tratmnt. Rfr- ral to a nphrologist has bn shown to improv mortality and thrfor should tak plac in lat stag 3 CKD or whn th GFR is dclining rapidly. Prparation for ESKD trat- mnt rquirs a tam approach with th involvmnt of diticians, social workrs, primary car clinicians, and nphrologists. For vry ldrly patints, or thos with mul- tipl dbilitating or lif-limiting comorbiditis, dialysis thrapy may not maningfully prolong lif, and th option of palliativ car should b discussd with th patint andfamily. Convrsly, for patints who ar othrwis rlativly halthy, valuation for possibl kidny transplantation should b considrd prior to initiation of dialysis. 1. Dialysis— Dialysis initiation should b considrd whn GFR is nar 10 mL/min/1.73 m2and urmic symptoms ar prsnt. Othr indications for dialysis, which may occur whn GFR is 10–15 mL/min/1.73 m2, ar fluid ovrload unrsponsiv to diursis and rfractory hyprkalmia. a. Hemodialysis— Vascular accss for hmodialysis can b accomplishd by an artriovnous fistula (th prfrrd mthod) or prosthtic graft; cration of dialysis accss should b considrd wll bfor dialysis initiation. An indwlling cathtr is usd whn thr is no usabl vascu- lar accss. Bcaus cathtrs confr a high risk of blood- stram infction, thy should b considrd a tmporary masur. Nativ fistulas typically last longr than pros- thtic grafts but rquir a longr tim aftr surgical construction for maturation (6–8 wks for a fistula vrsus 2 wks for a graft). Infction, thrombosis, and anurysm formation ar complications sn mor oftn in grafts than fistulas. Staphylococcus spcis ar th most common caus of soft tissu infctions and bactrmia. Tratmnt at a hmodialysis cntr typically occurs thr tims a wk. Sssions last 3–5 hours, dpnding on patint siz and typ of dialysis accss. Hom hmodialysis is oftn prformd mor frquntly (3–6 days pr wk for shortr sssions) and rquirs a traind hlpr. Rsults of trials comparing quotidian modalitis (nocturnal and fr- qunt hom hmodialysis) to convntional in-cntr dialy- sis hav not thus far shown significant mortality diffrncs, but thr may b improvmnts in blood prssur control, minral mtabolism, and quality of lif. b. Peritoneal dialysis— With pritonal dialysis, th pritonal mmbran is th “dialyzr. ” Thr ar diffrnt kinds of pritonal dialysis: continu- ous ambulatory pritonal dialysis (CAPD), in which th patint xchangs th dialysat four to six tims a day manually; and continuous cyclic pritonal dialysis (CCPD), which utilizs a cyclr machin to automatically prform xchangs at night. Th most common complication of pritonal dialysis is pritonitis. Pritonitis may prsnt with nausa and vom- iting, abdominal pain, diarrha or constipation, and fvr. Th normally clar dialysat bcoms cloudy; and a diagnostic pritonal fluid cll count gratr than 100 whit blood clls/mcL (0.1 × 109/L) with a diffrn- tial of gratr than 50% polymorphonuclar nutrophils is prsnt. Staphylococcus aureus is th most common infcting organism, but strptococci and gram-ngativ spcis may also b causativ. Empiric intrapritonal administration of ithr vancomycin or a first-gnration cphalosporin (cfazolin) plus a third-gnration cph- alosporin (cftazidim) should b institutd with th first signs of pritonitis and subsquntly tailord basd on cultur rsults. 2. Kidney transplantation— Many patints with ESKD ar othrwis halthy nough to b suitabl for transplan- tation, although standard critria for rcipint slctionCMDT22_Ch22_p0912-p0951.indd  929 02/07/21 2:33 PMChApTEr 22930 CMDT 2022ar  lacking btwn transplant cntrs. Two-thirds of kidny allografts com from dcasd donors, with th rmaindr from living rlatd or unrlatd donors. Ovr 100,000 patints ar on th waiting list for a dcasd donor transplant in th Unitd Stats; th avrag wait is 3–7 yars, dpnding on gographic location and rcipint blood typ. 3. Medical management of ESKD— As notd abov, som patints ar not candidats for kidny transplanta- tion and may not bnfit from dialysis. Vry ldrly prsons may di soon aftr dialysis initiation; thos who do not may nonthlss rapidly los functional status in th first yar of tratmnt. Th dcision to initiat dialy- sis in patints with limitd lif xpctancy should b wighd against possibl dtrioration in quality of lif. For patints with ESKD who lct not to undrgo dialysis or who withdraw from dialysis, progrssiv urmia with gradual supprssion of snsorium rsults in a painlss dath within days to months. Involvmnt of a palliativ car tam is ssntial.Fost r JG t al. Car of th rnal transplant patint. Prim Car. 2020;47:703. [PMID: 33121638] Zarantonllo D t al. Novl consrvativ managmnt of chronic kidny disas via dialysis-fr intrvntions. Curr Opin Nphrol Hyprtns. 2021;30:97. [PMID: 33186220] »Prognosis in ESKDCompard  with kidny transplant rcipints and ag- matchd controls, mortality is highr for patints undrgo- ing dialysis. Thr is likly littl diffrnc in survival for wll-matchd pritonal vrsus hmodialysis patints. Survival rats on dialysis dpnd on th undrlying disas procss. Fiv-yar Kaplan-Mir survival rats vary from 37% for patints with diabts to 54% for patints with glomrulonphritis. Ovrall 5-yar survival is cur- rntly stimatd at 40%. Patints undrgoing dialysis hav an avrag lif xpctancy of 3–5 yars, but survival for as long as 25 yars may b achivd dpnding on comorbidi- tis. Th most common caus of dath is cardiac disas (mor than 50%). Othr causs includ infction, crbro- vascular disas, and malignancy. »When to Refer• A patint with stag 3–5 CKD should b rfrrd to a nphrologist for managmnt in conjunction with th primary car providr. •A patint with othr forms of CKD such as thos with protinuria gratr than 1 g/day or polycystic kidny disas should b rfrrd to a nphrologist at arlir stags. »When to Admit• Admission should b considrd for dcompnsation of problms rlatd to CKD, such as worsning of acid- bas status, lctrolyt abnormalitis, and volum ovr- load, that cannot b appropriatly tratd in th outpatint stting.•Admission is appropriat whn a patint nds to start dialysis and is not stabl for its outpatint initiation.Charls  C t al. Chronic kidny disas. Prim Car. 2020;47:585. [PMID: 33121630] Li PK t al. Kidny halth for vryon vrywhr—from pr- vntion to dtction and quitabl accss to car. Clin Nphrol. 2020;93:111. [PMID: 32017699] Shlipak MG t al. Th cas for arly idntification and intrvn- tion of chronic kidny disas: conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvr- sis Confrnc. Kidny Int. 2021;99:34. [PMID: 33127436] Stnvinkl P t al. A plantary halth prspctiv for kidny disas. Kidny Int. 2020;98:261. [PMID: 32709283]RE NAL ARTERY STENOSISE S S E N T I A L S  O F  D I A G N O S I S »Produced by atherosclerotic occlusive disease (80–90% of patients) or fibromuscular dysplasia (10–15%). »Hypertension. »AKI in patients starting ACE inhibitor therapy if stenosis is bilateral. »General ConsiderationsA pproximatly 5% of Amricans with hyprtnsion suffr from rnal artry stnosis. Athrosclrotic ischmic rnal disas accounts for most cass of rnal artry stnosis. It typically occurs among prsons ovr 45 yars of ag with additional risk factors such as CKD, diabts mllitus, and tobacco us. Fibromuscular dysplasia is a lss common caus of rnal artry stnosis that most commonly occurs in young womn. »Clinical FindingsA.  Symptoms and SignsPa tints with athrosclrotic ischmic rnal disas may hav rfractory hyprtnsion, nw-onst hyprtnsion (in an oldr patint), pulmonary dma with poorly controlld blood prssur, and AKI upon starting an ACE inhibitor or ARB. Physical xamination may rval an audibl abdomi- nal bruit on th affctd sid. Unxplaind hyprtnsion in a woman youngr than 40 yars should rais suspicion for fibromuscular dysplasia.B.  Laboratory FindingsBUN and s rum cratinin may b lvatd if thr is sig- nificant rnal ischmia. Patints with bilatral rnal artry stnosis may hav hypokalmia, a finding that rflcts activation of th rnin-angiotnsin-aldostron systm in rspons to rducd blood flow (a “prrnal” stat).CMDT22_Ch22_p0912-p0951.indd  930 02/07/21 2:33 PMKIDNEY DISEASE931 CMDT 2022C.  ImagingA bdominal ultrasound can rval ithr asymmtric kid- ny siz if on rnal artry is affctd mor than th othr or small hyprchoic kidnys if both ar affctd. Scrning with Dopplr ultrasonography, CT angiogra- phy, or magntic rsonanc angiography (MRA) is rcom- mndd if a corrctiv procdur would b prformd whn a positiv tst rsult is found. Doppler ultrasonogra- phyis highly snsitiv and spcific (85% and 92%, rspc- tivly) and rlativly inxpnsiv but is xtrmly oprator and patint dpndnt. CT angiography consists of intravnous contrast injc- tion with digital subtraction artriography. Th snsitivi- tis from various studis rang from 77% to 98%, with spcificitis of 90–94%. MRA is an xcllnt but xpnsiv way to scrn for rnal artry stnosis, particularly in thos with athroscl- rotic disas. Snsitivity is 77–100% and spcificity rangs from 71% to 96%. Th imaging agnt for MRA (gadolin- ium) has bn associatd with nphrognic systmic fibro- sis, which is discussd lswhr undr Nphrognic Systmic Fibrosis. Renal angiography is th gold standard for diagnosis, but it is mor invasiv than th thr scrning tsts dis- cussd abov. Thus, it is prformd aftr a positiv scrn- ing tst. Lsions ar most commonly found in th proximal third or ostial rgion of th rnal artry. Th risk of athro- mbolic phnomna aftr angiography rangs from 5% to 10%. Fibromuscular dysplasia has a charactristic “bads- on-a-string” apparanc on angiography. »TreatmentT ratmnt of athrosclrotic ischmic rnal disas is con- trovrsial. Options includ mdical managmnt, angio- plasty with or without stnting, and surgical bypass. Two larg randomizd trials showd that vascular intrvntion is no bttr than optimal mdical managmnt in patints with rnal artry stnosis, xcpt in slctd circumstancs (g, patints with rcurrnt pisods of flash pulmonary dma). Angioplasty might rduc th numbr of antihy- prtnsiv mdications but dos not significantly chang th progrssion of kidny dysfunction. Stnting producs significantly bttr rsults than angioplasty. Howvr, blood prssur and srum cratinin ar similar at 6 months with mdical managmnt as with ithr angioplasty and stnts. Tratmnt of fibromuscular dysplasia with prcutan- ous transluminal angioplasty is oftn curativ, which is in stark contrast to tratmnts for athrosclrotic disas.Gornik  HL t al. First intrnational consnsus on th diagnosis and managmnt of fibromuscular dysplasia. Vasc Md. 2019;24:164. [PMID: 30648921] Mannmuddhu SS t al. Rnovascular hyprtnsion. Prim Car. 2020;47:631. [PMID: 33121633] Princ M t al. Rnal rvascularization in rsistant hyprtnsion. Prog Cardiovasc Dis. 2020;63:58. [PMID: 31821813]ºGLOMErULAr DISEASESGlomrular  disass can b challnging to undrstand clinically bcaus th glomrulus is a histologically com- plx structur (consisting of th pithlial clls [podo- cyts], basmnt mmbran, capillary ndothlium, and msangium). Th following ar xampls of injuris that can affct any or all of th constitunts of th glomrulus: (1) ovrwork injury, as in CKD; (2) an inflammatory pro- css, such as SLE; (3) a podocyt protin mutation, as in hrditary focal sgmntal glomrulosclrosis (FSGS); or (4) a dposition disas, as in diabts or amyloidosis. Whn a glomrular disas is suspctd, a kidny biopsy may b ndd to clarify th tiology. »ClassificationGlomr ular disass can b classifid in on of two clini- cal spctra—th nphritic spctrum or th nphrotic spctrum (Figur 22–4). At th “last svr” nd of th nephritic spectrum , th findings of asymptomatic glo- mrular hmaturia (i, dysmorphic rd blood clls with or without som protinuria [lss than 1 g/day]) ar charactristic. Th nphritic syndrome , comprising glo- mrular hmaturia, subnphrotic protinuria (lss than 3 g/day), dma, and lvatd cratinin, falls in th mid- portion of th spctrum. Th rapidly progrssiv glo- mrulonphritids (RPGNs), with systmic symptoms, ar at th “most svr” and clinically urgnt nd of th spctrum. Th nephrotic spectrum is comprisd of dis- ass that prsnt primarily with protinuria of at last 0.5–1 g/day and a bland urin sdimnt (no clls or cl- lular casts). At th mor svr nd of th nphrotic spctrum is th nphrotic syndrome , consisting of nphrotic-rang protinuria (gratr than 3 g/day), hypoalbuminmia, dma, hyprlipidmia, and urinary oval fat bodis. Diffrntiating btwn a clinical prsn- tation within th nphritic spctrum vrsus th nphrotic spctrum is important bcaus it hlps narrow th diffr- ntial diagnosis of th undrlying glomrular disas (Tabls 22–7 and 22–8). Glomrular disass can also b classifid according to whthr thy caus rnal abnormalitis alon (primary rnal disas) or whthr th rnal abnormalitis rsult from a systmic disas (scondary rnal disas). Furthr valuation prior to kidny biopsy may includ srologic tsting for systmic disass that can rsult in glomrular damag (Figur 22–5).Cavana ugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Flog J t al. Managmnt and tratmnt of glomrular disass (part 1): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:268. [PMID: 30665568] Rovin BH t al. Managmnt and tratmnt of glomrular dis- ass (part 2): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:281. [PMID: 30665569]CMDT22_Ch22_p0912-p0951.indd  931 02/07/21 2:33 PMChApTEr 22932 CMDT 2022NE PHRITIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Asymtomatic glomeula ematuia –Hematuria with dysmorphic RBCs –Proteinuria < 1 g/day »Neitic syndome in more severe cases – Glomerular hematuria (and RBC casts if glomerular bleeding is heavy) –Proteinuria of 1–3 g/day –Hypertension –Edema –Rising creatinine over days to months »raidly ogessive glomeuloneiti sin most severe cases –AKI with rising creatinine over days to months –Glomerular hematuria (and RBC casts) –Proteinuria of 1–3 g/day –Systemic symptoms –Hypertension and edema uncommon»General Considerations“ Glomrulonphritis” is a trm givn to thos disass that prsnt in th nphritic spctrum and usually signifis an inflammatory procss causing rnal dysfunction. It can b acut, dvloping ovr days to wks, with or without rso- lution, or may b chronic and indolnt with progrssiv scarring. As notd abov, disass that caus a nphritic spctrum prsntation may prsnt with glomrular hma- turia and protinuria, with nphritic syndrom, or with RPGN (Figur 22–4). Th prsntation dpnds on th svrity of th undrlying inflammation and th pattrn of injury causd by th disas procss. »Clinical FindingsA.  Symptoms and SignsNp hritic syndrom usually lads to an acut dcras in GFR and rsultant sodium rtntion. This is manifstd by hyprtnsion and dma, which is first sn in rgions of low tissu prssur such as th priorbital and scrotal aras. Havy glomrular blding from inflammation may rsult in gross hmaturia (smoky or cola-colord urin).B.  Laboratory Findings1. Serologic testing—  Srologic tsts basd on th history and physical xamination hlp narrow th diffrntialAsymptomatic glomerular hematuriaNephritic syndromeNephritic Spectrum Nephrotic SpectrumMicroscop ic or macroscopic hematuria with or without proteinuria (< 1 g/day)Acute kidney injury with proteinuria of 1–3 g/day, hematuria, RBC casts, edema, and hypertensionAcute kidney injury with proteinuria of 1–3 g/day, hematuria, RBC casts, and systemic symptomsProteinuria of 300 mg/day–10 g/day and bland urineProteinuria of > 3 g/day plus hypoalbuminemia, edema, hyperlipidemia, and possible oval fat bodies in urineAsymptomatic proteinuriaNephrotic syndrome Chronic glomerular disease Chronic kidney disease with or without hematuria, proteinuria, hypertension, late-stage glomerulonephritis, burned-out diseaseRapidly progressive glomerulonephritis ▲Figure 22–4. Glomerular diseases present within one of the clinical spectra shown; the exact presentation is determined by the severity of the underlying disease and the pattern of injury. Nephritic diseases are characterized by the presence of an active urine sediment with glomerular hematuria and often with proteinuria. Nephrotic spec- trum diseases are proteinuric with bland urine sediments (no cells or cellular casts). All glomerular diseases may progress to a chronic, scarred state. (Adapted, with permission, from Megan Troxell, MD, PhD.)CMDT22_Ch22_p0912-p0951.indd  932 02/07/21 2:33 PMKIDNEY DISEASE933 CMDT 2022diagnosis. Ths  tsts may includ C3 and C4 complmnt lvls, antinuclar antibodis, cryoglobulins, hpatitis srologis, srum and urin protin lctrophorss, srum fr light chains, ANCAs, anti-GBM antibodis, and anti- strptolysin O (ASO) titrs (Figur 22–5). 2. Urinalysis— Th urin dipstick is positiv for protin and blood. Urinary microscopy rvals rd blood clls that ar misshapn or dysmorphic from travrsing a damagd glo- mrular filtration barrir. Rd blood cll casts ar sn with havy glomrular blding and tubular stasis. Whn quan- tifid, protinuria is usually subnphrotic rang (lss than 3 g/day). 3. Biopsy— Dfinitiv diagnosis of th undrlying glomr- ular disas cannot b mad without a kidny biopsy. Candidats for biopsy ar patints for whom tst rsults would influnc managmnt; xcptions includ thoswith advancd undrlying CKD, thos who cannot adhr to mdical thrapy, thos for whom immunosupprssiv thrapy is not appropriat, or thos for whom th prsnta- tion is “classic” for a particular disas (g, post-strptococcal glomrulonphritis, childhood minimal chang disas, and diabtic nphropathy). Th major risk of biopsy is blding. Contraindications includ a blding diathsis, thrombocytopnia, and uncontrolld hyprtnsion. »TreatmentGn ral masurs includ tratmnt of hyprtnsion and fluid ovrload, if prsnt. Antiprotinuric thrapy with an ACE inhibitor or ARB should b considrd for thos without AKI. For thos with profound AKI, dialysis may b ndd. Th inflammatory glomrular injury may rquir immuno- supprssiv agnts (s spcific disass discussd blow).Table 22–7. Classification and findings in glomerulonephritis: nephritic spectrum presentations. Tyical pesentation Association/Notes Seology Postinfectious glomerulonephritisChildren: abrupt onset of nephritic syndrome and acute kidney injury but can present anywhere in nephritic spectrumStreptococci, other bacterial infec- tions (eg, staphylococci, endocardi- tis, shunt infections)Rising ASO titers, low comple- ment levels IgA nephropathy (Berger disease) and Henoch- Schönlein purpura, sys- temic IgA vasculitisClassically: gross hematuria with respiratory tract infection, but can present anywhere in nephritic spectrum; Henoch-Schönlein pur- pura with vasculitic rash and gas- trointestinal hemorrhageAbnormal IgA glycosylation in both primary (familial predisposition) and secondary disease (associated with cirrhosis, HIV, celiac disease) Henoch-Schönlein purpura in chil- dren after an inciting infectionNo serologic tests helpful; com- plement levels are normal Pauci-immune (granulo- matosis with polyangi- itis, eosinophilic granulomatosis with polyangiitis, polyarteri- tis, idiopathic crescen- tic glomerulonephritis)Classically: crescentic or RPGN, but can present anywhere in nephritic spectrum; may have respiratory tract/sinus symptoms in granulo- matosis with polyangiitisSee Figure 22–5 ANCAs: MPO or PR3 titers high; complement levels normal Anti-GBM glomerulone- phritis; Goodpasture syndromeClassically: crescentic or RPGN, but can present anywhere in nephritic spectrum; pulmonary hemorrhage in Goodpasture syndromeMay develop as a result of respiratory irritant exposure (chemicals or tobacco use)Anti-GBM antibody titers high; complement levels normal Cryoglobulin-associated glomerulonephritisOften acute nephritic syndrome; often with systemic vasculitis including rash and arthritisMost commonly associated with chronic hepatitis C; may occur with other chronic infections or some connective tissue diseasesCryoglobulins positive; rheuma- toid factor may be elevated; complement levels low MPGN Classically: acute nephritic syndrome, but can also have nephrotic syn- drome featuresMost patients are < 30 years old Immune complex MPGN most common C3 glomerulonephritisLow complement levels, may have findings of underlying infection or paraproteinemia Hepatitis C infection Anywhere in nephritic spectrum Can cause MPGN pattern of injury or cryoglobulinemic glomerulone- phritis; membranous nephropathy pattern of injury uncommonLow complement levels; posi- tive hepatitis C serology; rheumatoid factor may be elevated Systemic lupus erythematosusAnywhere in nephritic spectrum, depending on pattern/severity of injuryTreatment depends on clinical course and International Society of Nephrology and Renal Pathology Society classification on biopsyHigh ANA and anti-double- stranded DNA titers; low complement levels ANA, antinuclear antibodies; ANCAs: antineutrophil cytoplasmic antibodies; GBM, glomerular basement membrane; MPGN, membranop- roliferative glomerulonephritis; MPO, myeloperoxidase; PR3, proteinase 3; RPGN, rapidly progressive glomerulonephritis.CMDT22_Ch22_p0912-p0951.indd  933 02/07/21 2:33 PMChApTEr 22934 CMDT 2022 »When to ReferAny  patint in whom a glomrulonphritis is suspctd should b rfrrd to a nphrologist. »When to AdmitAny  suspicion of acut nphritic syndrom or RPGN warrants considration of immdiat hospitalization.Lamba  P t al. Nphritic syndrom. Prim Car. 2020;47:615. [PMID: 33121632] Popplaars F t al. Complmnt-mdiatd kidny disass. Mol Immunol. 2020;128:175. [PMID: 33137606]1.  Infection-related & postinfectious GlomeuloneitisE S S E N T I A L S  O F  D I A G N O S I S »Proteinuria. »Glomerular hematuria. »Symptoms 1–3 weeks after some infections (often pharyngitis or impetigo) or during course of other infections (eg, pneumonia or endocarditis).»General ConsiderationsP ostinfctious glomrulonphritis is most oftn du to infction with nphritognic group A bta-hmolytic strptococcal infctions (pharyngitis or imptigo). It can occur sporadically or in clustrs and during pidmics, with onst up to 1–3 wks aftr infction (avrag 7–10 days). Othr infctions hav bn associatd with glomrulo- nphritis including bactrmia (spcially S aureus ), bac- trial pnumonias, dp-satd abscsss, gram-ngativ infctions, infctiv ndocarditis, and shunt infctions; viral, fungal, and parasitic causs of glomrulonphritis includ hpatitis B or C, HIV , cytomgalovirus infction, infctious mononuclosis, coccidioidomycosis, malaria, mycobactria, syphilis, and toxoplasmosis. Ths ntitis rsult in glomrular injury during activ infction, and ar bttr trmd “infction-rlatd glomrulonphritis” rathr than “postinfctious glomrulonphritis. ” »Clinical FindingsA.  Symptoms and SignsDisas  prsntation varis across th nphritic spctrum from asymptomatic glomrular hmaturia (spcially in pidmic cass) with minimal chang in kidny function, to nphritic syndrom with hyprtnsion, dma, andTable 22–8. Classification and findings in glomerulonephritis: nephrotic spectrum presentations.Disease Tyical pesentation Association/Notes Minimal change disease (nil disease; lipoid nephrosis)Child with sudden onset of full nephrotic syndromeChildren: associated with allergy or viral infection Adults: associated with Hodgkin disease, NSAIDs Membranous nephropathy Anywhere in nephrotic spectrum, but nephrotic syndrome not uncommon; particular predispo- sition to hypercoagulable statePrimary (idiopathic) may be associated with antibodies to PLA2R Secondary may be associated with non-Hodgkin lymphoma, carci- noma (gastrointestinal, renal, bronchogenic, thyroid), gold therapy, penicillamine, SLE, chronic hepatitis B or C infection Focal and segmental glomerulosclerosisAnywhere in nephrotic spectrum; children with congenital disease have nephrotic syndromeChildren: congenital disease with podocyte gene mutation, or in spec- trum of disease with minimal change disease Adults: associated with heroin abuse, HIV infection, reflux nephropa- thy, obesity, pamidronate, podocyte protein mutations, APOL1 mutations Amyloidosis Anywhere in nephrotic spectrum AL: plasma cell dyscrasia with Ig light chain overproduction and depo- sition; check SPEP and UPEP AA: serum amyloid protein A overproduction and deposition in response to chronic inflammatory disease (rheumatoid arthritis, inflammatory bowel disease, chronic infection) Diabetic nephropathy High GFR (hyperfiltration) →micro- albuminuria →frank proteinuria →decline in GFRDiabetes diagnosis precedes diagnosis of nephropathy by years HIV-associated nephropathy Heavy proteinuria, often nephrotic syndrome, progresses to ESKD relatively quicklyUsually seen in antiviral treatment-naïve patients (rare in antiretroviral therapy era), predilection for those of African descent ( APOL1 mutations) Membranoproliferative glomerulonephropathyClassically presents with acute nephritic syndrome, some may also exhibit nephrotic featuresImmune complex–MPGN are idiopathic or secondary to infections, paraproteinemia, or systemic autoimmune disease; C3 glomerulopa- thies are due to alternative complement pathway dysregulation ESKD, end-stage kidney disease; GFR, glomerular filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs; PLA2R, phospholipase A2 receptor; SLE, systemic lupus erythematosus; SPEP/UPEP , serum and urine protein electrophoresis.CMDT22_Ch22_p0912-p0951.indd  934 02/07/21 2:33 PMKIDNEY DISEASE935 CMDT 2022+ + +Glomerulonephritis (GN) Serologic analysis Anti-glomerular basement membrane (GBM) antibodies Anti-GBM GNAntineutrophil cytoplasmic antibodies (ANCA) No lung hemorrhage Anti-GBM GNLung hemorrhage Goodpasture syndromeImmune complex disease markers Immune complex GNIgA IgA nephropathyAntipathogen antibodies Postinfectious or peri- infectious GNCryoglobulins Cryoglobulinemic GNAntinuclear antibodies Lupus GNComplement activation MPGN ANCA GNSystemic necrotizing vasculitis Microscopic polyangiitisRespiratory necrotizing granulomas Granulomatosis with polyangiitisAsthma and eosinophiliaNo extra- renal disease ANCA- associated crescentic GNEosinophilic granulomatosis with polyangiitis ▲Figure 22–5. Serologic analysis of patients with glomerulonephritis. MPGN, membranoproliferative glomerulonephritis. (Modified, with permission, from Greenberg A et al.Primer on Kidney Diseases . Academic Press, 1994; and Jennette JC, Falk RJ. Diagnosis and management of glomerulonephritis and vasculitis presenting as a cute renal failure. Med Clin North Am. 1990;74(4):893–908. © Elsevier.)CMDT22_Ch22_p0912-p0951.indd  935 02/07/21 2:33 PMChApTEr 22936 CMDT 2022prh aps gross glomrular hmaturia (smoky-colord urin); th most svr cass may rsult in oliguric AKI rquiring dialysis.B.  Laboratory FindingsSrum  complmnt lvls ar low; in postinfctious glo- mrulonphritis du to group A strptococcal infction, anti-strptolysin O (ASO) titrs can b high unlss th immun rspons has bn bluntd with prvious antibiotic tratmnt. Glomrular hmaturia and protinuria ar prs- nt. In childrn with a rcnt strptococcal infction and nphritic faturs, a diagnosis may b mad mpirically without a biopsy. Whn prformd, kidny biopsy shows a diffus prolifrativ pattrn of injury on light microscopy. Immunofluorscnc dmonstrats granular dposition of IgG and C3 in th msangium and along th capillary bas- mnt mmbran. Elctron microscopy shows larg, dns subpithlial dposits or “humps. ” Kidny biopsy findings in infction-rlatd glomrulonphritis ar varid and may show ovrlap with immun-complx mmbranoprolifra- tiv glomrulonphritis or C3 glomrulonphritis. »TreatmentAny  activ infction should b idntifid and tratd appropriatly; othrwis, tratmnt for postinfctious glo- mrulonphritis is supportiv. Antihyprtnsivs, salt rstriction, and diurtics should b usd if ndd. Corti- costroids hav not bn shown to improv outcoms. Prognosis dpnds on th svrity of th glomrular injury and ag of th patint. Childrn ar mor likly to fully rcovr; adults ar mor pron to th dvlopmnt of svr disas (RPGN with crscnt formation) and CKD.Mo hammad D t al. Postinfctious glomrulonphritis. Pdiatr Ann. 2020;49:273. [PMID: 32520369] Satoskar AA t al. Epidmiology, pathognsis, tratmnt and outcoms of infction-associatd glomrulonphritis. Nat Rv Nphrol. 2020;16:32. [PMID: 31399725]2.  IgA NeoatyE S S E N T I A L S  O F  D I A G N O S I S »Proteinuria: minimal to nephrotic range. »Glomerular hematuria: microscopic is common; macroscopic (gross) after infection. »Positive IgA staining on kidney biopsy. »General ConsiderationsIgA  nphropathy (Brgr disas) is a primary rnal dis- as of IgA dposition in th glomrular msangium. Th inciting caus is unknown. IgA nphropathy can b a pri- mary (rnal-limitd) disas or scondary to hpatic cir- rhosis, cliac disas, and infctions such as HIV and cytomgalovirus. Suscptibility to IgA nphropathy is inhritabl.IgA nphropathy is th most common primary glo- mrular disas worldwid, particularly in Asia. It is most oftn sn in childrn and young adults, with mals affctd two to thr tims mor commonly than fmals. »Clinical FindingsTh  classical prsntation of IgA nphropathy is an pisod of gross hmaturia associatd with a mucosal viral infc- tion, oftn of th uppr rspiratory tract. Th urin bcoms rd or smoky-colord 1–2 days aftr illnss onst—a so-calld synpharyngitic prsntation in contra- distinction to th latnt priod sn in postinfctious glo- mrulonphritis. Howvr, IgA nphropathy can prsnt anywhr along th nphritic spctrum from asymptom- atic microscopic hmaturia with minimal protinuria and prsrvd GFR to RPGN (Figur 22–4). Rarly, nphrotic syndrom can b prsnt. Thr ar no srologic tsts that aid in this diagnosis; srum complmnts ar normal. Th typical pattrn of injury sn on kidny biopsy is a focal glomrulonphritis with msangial prolifration; immunofluorscnc dm- onstrats diffus msangial IgA and C3 dposits. »TreatmentTh  disas cours of primary IgA nphropathy varis widly among patints; tratmnt approach nds to b tailord to risk for progrssion. Patints with low risk for progrssion (no hyprtnsion, normal GFR, minimal pro- tinuria) can b monitord annually. Patints at highr risk (protinuria gratr than 1.0 g/day, dcrasd GFR, or hyprtnsion or any combination of ths thr condi- tions) should b tratd with an ACE inhibitor or ARB. Thrapy should b titratd to rduc protinuria to lss than 1 g/day and to control blood prssur in th rang of 125/75 mm Hg to 130/80 mm Hg. Prior trials suggstd that corticostroids rducd protinuria whn adminis- trd to patints with GFR gratr than 50 mL/min/1.73 m2 and prsistnt protinuria gratr than 1 g/day. Howvr, mor rcnt data faild to dmonstrat slowing of GFR loss with corticostroid thrapy compard with us of ACE inhibitor or ARB alon; nthusiasm for glucocorticoid thrapy thrfor has wand. For th rar patint with IgA nphropathy and a rapidly progrssiv clinical cours with crscnt formation on biopsy, cyclophosphamid and cor- ticostroid thrapy should b considrd (s sction on ANCA-associatd vasculitis blow). Kidny transplanta- tion is an xcllnt option for patints with ESKD, but rcurrnt disas has bn documntd in 30% of patints 5–10 yars posttransplant. »PrognosisA pproximatly on-third of patints xprinc spontan- ous clinical rmission. Progrssion to ESKD occurs in 20–40% of patints. Th most unfavorabl prognostic indi- cator is protinuria gratr than 1 g/day; othr includ hyprtnsion, tubulointrstitial fibrosis, glomrulosclro- sis, or glomrular crscnts on biopsy, and abnormal GFR on prsntation.CMDT22_Ch22_p0912-p0951.indd  936 02/07/21 2:33 PMKIDNEY DISEASE937 CMDT 2022Ca mbir A t al. Nw thraputic prspctivs for IgA nphropathy in childrn. Pdiatr Nphrol. 2021;36:497. [PMID: 32040630] Raun T t al. Aftr tn yars of follow-up, no diffrnc btwn supportiv car plus immunosupprssion and supportiv car alon in IgA nphropathy. Kidny Int. 2020;98:1044. [PMID: 32450154] Trimarchi H t al. IgA nphropathy: “Stat of th art”: a rport from th 15th Intrnational Symposium on IgA Nphropathy clbrating th 50th annivrsary of its first dscription. Kidny Int. 2019;95:750. [PMID: 30904065]3.  henoc-Scönlein puuaH noch-Schönlin purpura is a systmic small-vssl lu- kocytoclastic vasculitis associatd with IgA subclass 1 dpo- sition in vssl walls. It is most common in childrn and is oftn associatd with an inciting infction, such as group A strptococcus or othr xposur. Thr is a mal prdomi- nanc. It classically prsnts with palpabl purpura in th lowr xtrmitis and buttock ara; arthralgias; abdominal symptoms, such as nausa, colic, and mlna; and AKI with nphritic urin sdimnt. Th rnal lsions can b idntical to thos found in IgA nphropathy, and th undrlying pathophysiology appars to b similar. Most patints with microscopic hmaturia and minimal protinuria rcovr fully ovr svral wks. Progrssiv CKD and possibly ESKD ar mor likly to dvlop in adults and in thos with both nphritic and nphrotic syndroms. Although svral tratmnt rgimns of various immunosupprssiv agnts hav bn clinically tstd, non ar provn to altr th cours of svr nphritis. Rituximab tratmnt and plasma xchang hav bn succssful for svr disas according to svral cas rports, but clinical trials ar lacking. Rapidly progrssiv disas with crscnt formation on biopsy may b tratd as in ANCA-associatd vasculitis (s sction blow). Furthr dtails about Hnoch-Schönlin purpura ar providd in Chaptr 20.Mari tati F t al. Adult-onst IgA vasculitis (Hnoch-Schönlin): updat on thrapy. Prss Md. 2020;49:104035. [PMID: 32645417]4.  pauci-Immune Glomeuloneitis (ANCA-Associated)Pa uci-immun ncrotizing glomrulonphritis is causd by th following systmic ANCA-associatd small-vssl vasculitids: granulomatosis with polyangiitis, microscopic polyangiitis, and osinophilic granulomatosis with polyan- giitis (formrly Churg-Strauss disas; s Chaptr 20). ANCA-associatd glomrulonphritis can also prsnt as a primary rnal lsion without systmic involvmnt; this is trmd “idiopathic crscntic glomrulonphritis. ” Th pathognsis of ths ntitis appars to involv cytokin- primd nutrophils prsnting cytoplasmic antigns on thir surfacs (protinas 3 and myloproxidas). Circu- lating ANCAs thn bind to ths antigns and activat a nutrophil rspiratory burst with consqunt vascular damag; primd nutrophils also appar to activat th altrnativ complmnt pathway. Putativ nvironmntal xposurs that may incit th initial rspons includ S aureusand silica. Immunofluorscnc of kidny biopsy spcimns dmonstrats lack of immunoglobulin or complmnt dposition, hnc th trm “pauci-immun. ” Rnal involv- mnt classically prsnts as an RPGN, but mor indolnt prsntations can b sn. »Clinical FindingsA.  Symptoms and SignsSymp toms of a systmic inflammatory disas, including fvr, malais, and wight loss, may b prsnt and usually prcd initial prsntation by svral months. In addition to hmaturia and protinuria from glomrular inflamma- tion, som patints xhibit purpura from drmal capillary involvmnt and mononuritis multiplx from nrv artrio- lar involvmnt. Ninty prcnt of patints with granulomato- sis with polyangiitis hav uppr (spcially sinus) or lowr rspiratory tract symptoms with nodular lsions that can cavi- tat and bld. Hmoptysis is a concrning sign and usually warrants hospitalization and aggrssiv immunosupprssion.B.  Laboratory FindingsSrologically , ANCA subtyp analysis is don to dtrmin whthr antiprotinas-3 antibodis (PR3-ANCA) or anti- myloproxidas antibodis (MPO-ANCA) ar prsnt. Most patints with granulomatosis with polyangiitis ar PR3 positiv; th rmaindr ar MPO positiv or, mor rarly, do not dmonstrat circulating ANCA. Microscopic angiitis is gnrally associatd with MPO ANCA. Rnal biopsy dmonstrats ncrotizing lsions and crscnts on light microscopy; immunofluorscnc is ngativ for immun complx dposition. »TreatmentT ratmnt should b institutd arly if aggrssiv disas is prsnt. Induction thrapy of high-dos corticostroids (mthylprdnisolon, 1–2 g/day intravnously for 3 days, followd by prdnison, 1 mg/kg orally for 1 month, with a slow tapr ovr th nxt 6 months) and cytotoxic agnts (cyclophosphamid, 0.5–1 g/m2intravnously pr month or 1.5–2 mg/kg orally for 3–6 months) is followd by long-trm azathioprin or mycophnolat moftil. Rituximab has bn shown to b noninfrior to cyclophosphamid for induction and is also usd in rfractory or rlapsing cass and as an altrnativ to azathioprin for maintnanc of rmission. Plasma xchang is likly hlpful in conjunction with induc- tion thrapy for cass complicatd by pulmonary hmor- rhag. Trials using th complmnt inhibitor avacopan in plac of glucocorticoids in cyclophosphamid- or rituximab- basd rgimns ar ongoing and appar promising. »PrognosisW ithout tratmnt, prognosis is xtrmly poor. With aggrssiv tratmnt, complt rmission can b achivd in 75% of patints. Prognosis dpnds on th xtnt of rnal involvmnt bfor tratmnt is startd and may b wors in thos with PR3-associatd disas. ANCA titrs may b monitord to follow tratmnt fficacy; rising titrs may hrald rlaps.CMDT22_Ch22_p0912-p0951.indd  937 02/07/21 2:33 PMChApTEr 22938 CMDT 2022Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Smith RM t al. Rituximab as thrapy to induc rmission aftr rlaps in ANCA-associatd vasculitis. Ann Rhum Dis. 2020;79:1243. [PMID: 32581088] Walsh M t al. Plasma xchang and glucocorticoids in svr ANCA-associatd vasculitis. N Engl J Md. 2020;382:622. [PMID: 32053298]5.  Anti-Glomeula Basement Membane Glomeuloneitis & Goodastue SyndomeA utoantibodis to pitops of th GBM caus a glomrulo- nphritis (anti-GBM disas); concomitant immun attack on alvolar basmnt mmbrans rsults in pulmonary hmorrhag as wll (Goodpastur syndrom) (Figur 22–5). Anti-GBM–associatd glomrulonphritis accounts for 10–20% of patints with acut RPGN. Th incidnc paks in th third dcad of lif during which tim mals ar prdominantly affctd and lung involvmnt is mor common, and again in th sixth and svnth dcads with lss gndr spcificity and pulmonary involvmnt. Good- pastur syndrom has bn associatd with pulmonary infction, tobacco us, and xposur to hydrocarbon sol- vnts or almtuzumab; HLA-DR2 and -B7 antigns may prdispos as wll. »Clinical FindingsA.  Symptoms and SignsTh on st of disas may b prcdd by an uppr rspira- tory tract infction; hmoptysis, dyspna, and possibl rspiratory failur may nsu. Othr findings ar consistnt with an RPGN, although rar cass may prsnt with much mildr forms of th nphritic spctrum of disas (g, glo- mrular hmaturia and protinuria with minimal kidny dysfunction).B.  Laboratory FindingsChst radiographs may dmonstrat  pulmonary infiltrats if pulmonary hmorrhag is prsnt. Srum complmnt lvls ar normal. Circulating anti-GBM antibodis ar prsnt in ovr 90% of patints. A small prcntag of patints hav lvatd ANCA titrs; ths patints should b tratd with plasma xchang as for anti-GBM disas. Kidny biopsy typically shows crscnt formation with light microscopy, with linar IgG staining along th GBM with immunofluorscnc. »TreatmentPa tints with pulmonary hmorrhag and strong clinical suspicion of Goodpastur syndrom should b tratd mrgntly—possibly prior to confirming th diagnosis with srology and kidny biopsy. Tratmnt is a combina- tion of plasma xchang thrapy daily for up to 2 wks to rmov circulating antibodis, and administration of corti- costroids and cyclophosphamid to prvnt formation of nw antibodis and control th inflammatory rspons. Rituximab has bn usd in a small numbr of patintswith rfractory disas. Patints with oliguric AKI or who rquir dialysis upon prsntation hav a poor prognosis. Anti-GBM antibody titrs should dcras as th clinical cours improvs.Sglm ark M t al. Anti-glomrular basmnt mmbran disas: an updat on subgroups, pathognsis and thrapis. Nphrol Dial Transplant. 2019;34(11):1826. [PMID: 30371823] Umatsu-Uchida M t al. Rituximab in tratmnt of anti-GBM antibody glomrulonphritis: a cas rport and litratur rviw. Mdicin (Baltimor). 2019;98:17801. [PMID: 31689860]6.  Membanoolifeative Glomeuloneitis & C3 GlomeuloatiesMPGN is a  rlativly rar pattrn of glomrular injury that can prsnt anywhr along th nphritic spctrum from asymptomatic glomrular hmaturia to acut nphritic syndrom with bouts of gross hmaturia to RPGN; nphrotic syndrom can also b sn. MPGN is classifid pathologically and mchanistically into immun complx– and C3-rlatd disas. Etiologis of immun complx– mdiatd MPGN includ chronic infction (most commonly HCV , but also bactrial and parasitic infc- tions), a paraprotinmia, or an undrlying autoimmun disas (such as lupus); it can also b idiopathic (spcially in childrn and young adults). In ths cass, th pathogn- sis is likly a chronic antignmia lading to classical complmnt pathway activation with immun complx dposition; howvr, som cass may rsult from altrna- tiv complmnt pathway dysrgulation. C3 glomrulopa- this ar causd by svral inhritd or acquird abnormalitis in th altrnativ complmnt pathway. Both typs rsult in low circulating C3 complmnt; C4 is low in immun complx disas. Light microscopy of both typs shows varying dgrs of msangial hyprcllularity, ndo- capillary prolifration and capillary wall rmodling rsulting in doubl contours of th GBM (“tram track” apparanc). Immunofluorscnc and lctron micros- copy provid distinguishing information. Immun complx–mdiatd MPGN rvals C3 and IgG or IgM staining (or both) on immunofluorscnc; lctron microscopy dmonstrats msangial and subpithlial dposits. C3 glomrulonphritis is distinguishd by lack of immunoglobulin staining on immunofluorscnc, but can appar similar to immun complx disas with rspct to light and lctron microscopy. An additional but rar typ of C3 glomrular injury is “dns dposit disas” basd on thick ribbon-lik dposits sn on lctron microscopy. Togthr, dns dposit disas and C3 glomrulonphritis ar trmd “C3 glomrulopathis. ” Tratmnt of immun complx MPGN should b dirctd at any idntifiabl undrlying caus; idiopathic immun complx disas tratmnt is controvrsial and controlld trial data ar lacking. For thos with mild dis- as, ACE inhibitors and ARBs should b usd. For svr disas, a combination of oral cyclophosphamid or myco- phnolat moftil plus corticostroids could b considrd; rituximab is also somtims usd. Thos with RPGN and crscnts on biopsy may b tratd th sam as thos withCMDT22_Ch22_p0912-p0951.indd  938 02/07/21 2:33 PMKIDNEY DISEASE939 CMDT 2022ANCA -associatd disas providd scondary causs hav bn ruld out. Dspit thrapy, most will progrss to ESKD. Tratmnt for th C3 glomrulopathis is in volu- tion as novl thrapis to targt th dysrgulatd altrnativ complmnt cascad ar bing xplord; small, uncon- trolld sris suggst a possibl bnfit of culizumab in som patints; othrs may rspond to mycophnolat moftil. Lss favorabl prognostic findings includ dns dposit disas, arly dclin in GFR, hyprtnsion, and prsistnt nphrotic syndrom. All typs of MPGN rcur with high frquncy aftr kidny transplantation; howvr, dns dposit disas rcurs mor commonly. Plasma xchang, with or without culizumab, has bn usd with mixd rsults to trat posttransplant rcurrnc of MPGN.Fakhouri  F t al. Practical managmnt of C3 glomrulopathy and Ig-mdiatd MPGN: facts and uncrtaintis. Kidny Int. 2020;98:1135. [PMID: 32622830]7.  Cyoglobulin-Associated GlomeuloneitisEssnt ial (mixd) cryoglobulinmia is a vasculitis causd by cold-prcipitabl immunoglobulins (cryoglobulins). Th most common undrlying tiology is HCV infction; in ths cass, thr is clonal xpansion of B lymphocyts, which produc IgM rhumatoid factor. Rhumatoid fac- tor, HCV antign, and polyclonal anti-HCV IgG form complxs that dposit in vssls and incit inflamma- tion. Othr ovrt or occult infctions (g, viral, bactrial, and fungal) as wll as som autoimmun disass and lymphoprolifrativ disordrs can caus cryoglobulin- mic vasculitis. Patints xhibit purpuric and ncrotizing skin lsions in dpndnt aras, arthralgias, fvr, and hpatosplnomg- aly. Srum complmnt lvls ar low and rhumatoid fac- tor is oftn lvatd. Kidny biopsy may show svral diffrnt pattrns of injury; thr may b crscnt forma- tion, glomrular capillary thrombi, or MPGN (s abov). Tratmnt consists of aggrssivly targting th causativ infction. Puls corticostroids, plasma xchang, ritux- imab, and cytotoxic agnts hav bn usd whn thr is littl risk of xacrbating th undrlying infction or whn no infction is prsnt. S also Hpatitis C Virus–Associatd Kidny Disas.Ko lopp-Sarda MN t al. Cryoglobulinmic vasculitis: patho- physiological mchanisms and diagnosis. Curr Opin Rhu- matol. 2021;33:1. [PMID: 33186245]8.  heatitis C Vius–Associated Kidney DiseaseKidny dis as can occur in th stting of HCV infction. Th thr pattrns of kidny injury associatd with HCV ar scondary MPGN (most common), cryoglobulinmic glomrulonphritis, and mmbranous nphropathy. Th clinical prsntation is dictatd by th undrlying pattrn of injury. Many patints hav lvatd srum transami- nass and an lvatd rhumatoid factor. Hypocompl- mntmia is vry common, with C4 typically mor rducd than C3; complmnt lvls and rhumatoid factor tnd to b normal if thr is a mmbranous pattrn of injury.»TreatmentV iral supprssion or radication is th cornrston of trat- mnt of HCV–associatd kidny disas (s Chaptr 16). Us of most dirct-acting antiviral agnts appars to b saf in thos with rducd GFR, with th xcption of sofosbu- vir. Thrapy with rituximab and possibly corticostroids and plasmaphrsis should b initiatd in patints with svr vasculitis prior to th initiation of antiviral thrapy.Comarm ond C t al. Tratmnt of chronic hpatitis C–associatd cryoglobulinmia vasculitis at th ra of dirct-acting antivi- rals. Thrap Adv Gastrontrol. 2020;13:1756284820942617. [PMID: 32782479] Roth D t al. KDOQI US commntary on th 2018 KDIGO clini- cal practic guidlin for th prvntion, diagnosis, valua- tion, and tratmnt of hpatitis C. Am J Kidny Dis. 2020;75: 665. [PMID: 32279907]9.  Systemic Luus EytematosusRnal invol vmnt occurs in 35–90% of patints who hav SLE, with highr stimats ncompassing subclinical dis- as. Rats of lupus nphritis ar highst in non-Whits. Th pathognsis may b dysrgulatd cllular apoptosis rsulting in autoantibodis against nuclosoms; antibody/ nuclosom complxs thn bind to componnts of th glomrulus to form immun complx glomrular disas. S Chaptr 20 for furthr discussion of SLE. Th trm “lupus nphritis” ncompasss many possibl pattrns of rnal injury—most cass prsnt within th nphritic spctrum (class I–IV). Nonglomrular syn- droms includ tubulointrstitial nphritis and vasculitis. All patints with SLE should hav routin urinalyss to monitor for th apparanc of hmaturia or protinuria. If urinary abnormalitis ar dtctd, kidny biopsy is oftn prformd. Th Intrnational Socity of Nphrology and Rnal Pathology Socity classification of rnal glomrular lsions is class I, minimal msangial nphritis; class II, msangial prolifrativ nphritis; class III, focal (lss than 50% of glomruli affctd with capillary involvmnt) pro- lifrativ nphritis; class IV , diffus (gratr than 50% of glomruli affctd with capillary involvmnt) prolifrativ nphritis; class V , mmbranous nphropathy; and class VI, advancd sclrosis without rsidual disas activity. Classs III and IV , th most svr forms of lupus nphritis, ar furthr classifid as activ or chronic, and global or sg- mntal, which confrs additional prognostic valu. »TreatmentIndivid uals with class I and class II lesions gnrally rquir no tratmnt; corticostroids or calcinurin inhibi- tors should b considrd for thos with class II lsions with nphrotic-rang protinuria. Transformation of ths typs to a mor activ lsion may occur and is usually accompanid by an incras in lupus srologic activity (g, rising titrs of anti–doubl-strandd DNA antibodis and falling C3 and C4 lvls) and incrasing protinuria or fall- ing GFR. Rpat biopsy in such patints is rcommndd. Hydroxychloroquin should b considrd for all patints with lupus nphritis, rgardlss of histological class.CMDT22_Ch22_p0912-p0951.indd  939 02/07/21 2:33 PMChApTEr 22940 CMDT 2022Pa tints with xtnsiv class III lesions and all class IV lesions should rciv aggrssiv immunosupprssiv thrapy. Poor prognostic indicators in patints with class III or IV lsions includ lvatd srum cratinin, lowr complmnt lvls, mal sx, prsnc of antiphospholipid antibodis, nphrotic-rang protinuria, African dscnt (possibly in association with APOL1 risk allls), and poor rspons to thrapy. Immunosupprssiv thrapy for class V lupus nphritis is indicatd if suprimposd prolifrativ lsions xist. Class VI lsions should not b tratd. Tratmnt of class III or IV lupus nphritis consists of induction thrapy, followd by maintnanc thrapy. Induction thrapy includs corticostroids (g, mthyl- prdnisolon 1 g intravnously daily for 3 days followd by prdnison, 1 mg/kg orally daily with subsqunt tapr ovr 6–12 months) in combination with ithr cyclophos- phamid or mycophnolat moftil. Data suggst that Blacks and Hispanics rspond mor favorably to mycoph- nolat moftil than cyclophosphamid; in addition, myco- phnolat moftil has a mor favorabl sid-ffct profil than cyclophosphamid and should b favord whn prs- rvation of frtility is a considration. Mycophnolat moftil induction is typically givn at 2–3 g orally daily, thn taprd to 1–2 g/day for maintnanc. Cyclophospha- mid induction rgimns vary but usually involv monthly intravnous puls doss (500–1000 mg/m2) for 6 months. Induction is followd by daily oral mycophnolat moftil or azathioprin maintnanc thrapy; mycophnolat moftil may b suprior to azathioprin maintnanc and causs fw advrs ffcts. Maintnanc with calcinurin inhibitors may also b considrd, but th rlaps rat is high upon discontinuation of ths agnts. With standard thrapy, rmission rats with induction vary from 80% for partial rmission to 50–60% for full rmission; it may tak mor than 6 months to s ths ffcts. Rlaps is com- mon and rats of disas flar ar highr in thos who do not xprinc complt rmission; similarly, progrssion to ESKD is mor common in thos who rlaps mor fr- quntly, or in whom no rmission has bn achivd. Th us of add-on B-cll-targtd thrapy with rituximab or blimumab for class III, IV , and/or V disas may b con- sidrd. Pur class V disas is tratd with mycophnolat moftil with or without rituximab. Th lvls of various disas activity markrs (doubl- strandd DNA antibodis, srum C3, C4, CH50lvls) and th urinary protin lvls and sdimnt activity can b us- ful in monitoring rspons to tratmnt; howvr, rpat rnal biopsy yilds mor rliabl information rgarding disas activity and may b usd to guid maintnanc thrapy withdrawal. Patints with SLE who undrgo dialy- sis hav a favorabl prospct for long-trm survival; intr- stingly, systmic lupus symptoms may bcom quiscnt with th dvlopmnt of ESKD. Patints with SLE undr- going kidny transplants can hav rcurrnt rnal disas, although rats ar rlativly low.Fan ouriakis A t al. 2019 updat of th Joint Europan Lagu Against Rhumatism and Europan Dialysis and Transplant Association (EULAR/ERA-EDTA) rcommndations for th managmnt of lupus nphritis. Ann Rhum Dis. 2020;79:713. [PMID: 32220834]Furi R t al. Two-yar, randomizd, controlld trial of blimumab in lupus nphritis. N Engl J Md. 2020;383:1117. [PMID: 32937045] Parikh SV t al. Updat on lupus nphritis: Cor Curriculum 2020. Am J Kidny Dis. 2020;76:265. [PMID: 32220510]NE PHROTIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Proteinuria with bland urine sediment (few if any cells or cellular casts). »Nephrotic syndrome (if present) manifestations: – Nephrotic-range proteinuria (urine protein excretion > 3 g per 24 hours). –Hypoalbuminemia (albumin < 3 g/dL). –Peripheral edema. –Hyperlipidemia. –Oval fat bodies may be seen in the urine. »General ConsiderationsIn Amrican  adults, th most common caus of nphrotic spctrum glomrular disas is diabts mllitus. Othr causs includ minimal chang disas, FSGS, mmbra- nous nphropathy, and amyloidosis. Any of ths ntitis can prsnt on th lss svr nd of th nphrotic spc- trum with a bland urinalysis and protinuria or on th most svr nd of th full nphrotic syndrom. Srum cratinin may b abnormal at th tim of prsntation, dpnding on th svrity and chronicity of th disas. »Clinical FindingsA.  Symptoms and SignsPa tints with subnphrotic rang protinuria do not mani- fst symptoms of kidny disas. In thos with th nphrotic syndrom, priphral dma is prsnt—most likly du both to sodium rtntion and hypoalbuminmia- inducd low plasma oncotic prssur. Edma may dvlop solly in dpndnt rgions, such as th lowr xtrmitis, or it may bcom gnralizd and includ priorbital dma. Dyspna du to pulmonary dma, plural ffu- sions, and diaphragmatic compromis du to ascits can occur.B.  Laboratory Findings1. Urinalysis—  Protinuria occurs as a rsult of podocyto- pathy and variabl altrations of th GBM. Th urin dip- stick is a good scrning tst for albuminuria; if positiv, urinary protin xcrtion should b quantifid (s arlir Protinuria sction). A spot urin protin to urin crati- nin ratio givs a rasonabl approximation of grams of protin xcrtd pr day; a 24-hour urin sampl for pro- tin xcrtion is rarly ndd.CMDT22_Ch22_p0912-p0951.indd  940 02/07/21 2:33 PMKIDNEY DISEASE941 CMDT 2022Microscop ically, th urinary sdimnt has rlativly fw cllular lmnts or casts. Howvr, if markd hyprlipid- mia is prsnt, urinary oval fat bodis may b sn. Thy appar as “grap clustrs” undr light microscopy and “Malts crosss” undr polarizd light. 2. Blood chemistries— Th nphrotic syndrom rsults in hypoalbuminmia (lss than 3 g/dL [30 g/L]). Hyprlipid- mia, du both falling oncotic prssur triggring incrasd hpatic production of lipids and to dcrasd claranc of vry low-dnsity lipoprotins causing hyprtriglycrid- mia, occurs in ovr 50% of patints with arly nphrotic syndrom, and bcoms mor frqunt and worsns in dgr as th svrity of th nphrotic syndrom incrass. An lvatd rythrocyt sdimntation rat may b sn as a rsult of incrasd lvls of fibrinogn. Havy urinary xcrtion of binding protins may rsult in dficincis of vitamin D, zinc, and coppr. Laboratory tsting to hlp lucidat th undrlying caus of th glomrular disas includs complmnt lvls, srum and urin protin lctrophorsis, srum fr light chains, antinuclar antibodis, PLA2R antibody titrs, HbA1c, and srologic tsting for hpatitis B and C, HIV , and syphilis. 3. Kidney biopsy— Kidny biopsy is oftn prformd in adults with nw-onst idiopathic nphrotic syndrom if a primary rnal disas that may rquir immunosupprssiv thrapy is suspctd. Chronically and significantly dcrasd GFR indicats irrvrsibl kidny disas mitigating th usfulnss of kidny biopsy. In th stting of long-standing diabts mllitus typ 1 or 2, protinuric rnal disas is rarly biopsid unlss atypical faturs (such as significant glomrular hmaturia or cllular casts) ar also prsnt, or if thr is othr rason to suspct an additional rnal lsion. »TreatmentA.  Protein LossIn  thos with subnphrotic protinuria, ditary protin rstriction may b hlpful in slowing progrssion of kidny disas (s CKD sction). In both diabtic and nondiabtic patints, anti-protin- uric thrapy should also slow progrssion of kidny dis- as. ACE inhibitors and ARBs rduc urin protin xcrtion by dcrasing glomrular capillary prssur and also hav antifibrotic ffcts. Thy can b usd in patints with rducd GFR as long as significant hyprkalmia (potassium gratr than 5.2–5.5 mEq/L or mmol/L) dos not occur and srum cratinin riss lss than 30% aftr drug initiation or dos titration; patints should b moni- tord closly to avoid AKI and hyprkalmia. Combination thrapy of an ARB and an ACE inhibitor incrass risk for AKI and hyprkalmia and is not rcommndd.B.  EdemaDitary  salt rstriction is ssntial for managing dma; most patints also rquir diurtic thrapy. A combination of loop and thiazid diurtics may b ndd for rfractory fluid rtntion. Both thiazid and loop diurtics ar highly protin bound; thrfor, with hypoalbuminmia and dcrasd GFR, diurtic dlivry to th kidny is rducd and largr doss oftn ar rquird.C. HyperlipidemiaH yprcholstrolmia and hyprtriglycridmia occur as notd abov. Ditary modification and xrcis should b advocatd; howvr, ffctiv lipid-lowring usually also rquirs pharmacologic tratmnt (s Chaptr 28). Thr is significant risk of rhabdomyolysis in patints with CKD who tak gmfibrozil in combination with statins; combin- ing fnofibrat or niacin with a statin is prfrrd.D . Hypercoagulable StatePa tints with nphrotic syndrom hav urinary losss of antithrombin, protin C, and protin S and incrasd plat- lt activation. Patints with srum albumin lss than 2 g/dL (20 g/L) hav considrabl risk for thrombophilia and may dvlop rnal vin thrombosis, pulmonary mbolus, and othr vnous thrombomboli; this is particularly likly with mmbranous nphropathy. Anticoagulation thrapy with warfarin is warrantd for at last 3–6 months in patints with vidnc of thrombosis in any location and may b rquird indfinitly for rnal vin thrombosis, pulmonary mbolus, rcurrnt thrombomboli or whn ongoing nphrotic syndrom poss a risk of thrombosis rcurrnc. »When to ReferAny  patint with th nphrotic syndrom should b rfrrd immdiatly to a nphrologist for volum and blood prssur managmnt, assssmnt for kidny biopsy, and tratmnt of th undrlying disas. Protinuria of mor than 1 g/24 hours without th nphrotic syndrom also mrits nphrology rfrral, though with lss urgncy. »When to AdmitPa tints with dma rfractory to outpatint thrapy or rapidly worsning kidny function that may rquir inpa- tint intrvntions should b admittd.Böknkamp  A. Protinuria—tak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Politano SA t al. Nphrotic syndrom. Prim Car. 2020;47:597. [PMID: 33121631] Wang CS t al. Nphrotic syndrom. Pdiatr Clin North Am. 2019;66:73. [PMID: 30454752] ºNEphrOTIC SpECTrUM DISEASE IN prIMArY rENAL DISOrDErS MINIMAL CHANGE DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Nephrotic-range proteinuria. »Kidney biopsy shows no changes on light microscopy. »Characteristic foot-process effacement on electron microscopy.CMDT22_Ch22_p0912-p0951.indd  941 02/07/21 2:33 PMChApTEr 22942 CMDT 2022 »General ConsiderationsMinimal cha ng disas is th most common caus of pro- tinuric rnal disas in childrn, accounting for about 80% of cass. It oftn rmits upon tratmnt with a cours of corticostroids. Indd, childrn with nphrotic syn- drom ar oftn tratd for minimal chang disas mpir- ically without a biopsy diagnosis. Minimal chang disas is lss common in adults, accounting for 20–25% of cass of primary nphrotic syndrom in thos ovr ag 40 yars. This ntity can b idiopathic but also occurs following viral uppr rspiratory infctions (spcially in childrn), in association with noplasms such as Hodgkin disas, with drugs (lithium), and with hyprsnsitivity ractions (sp- cially to NSAIDs and b stings). »Clinical FindingsA.  Symptoms and SignsPa tints prsnt with nphrotic syndrom, which confrs suscptibility to infction, tndncy toward thrombom- bolic vnts, svr hyprlipidmia, and possibly protin malnutrition. Minimal chang disas can caus AKI du to rnal tubular damag and intrstitial dma.B.  Laboratory and Histologic FindingsTh r is no hlpful srologic tsting. Biopsy should b consid- rd for childrn with nphrotic syndrom who xhibit unusual faturs (such as signs of othr systmic illnss), or who ar stroid-rsistant or rlaps upon withdrawal of corti- costroid thrapy; th lattr two conditions may indicat an undrlying focal and sgmntal glomrulosclrosis rathr than minimal chang disas. Whn kidny biopsy is pr- formd, glomruli appar normal on light microscopy and immunofluorscnc. On lctron microscopy, thr is a charactristic ffacmnt of podocyt foot procsss. Msan- gial cll prolifration may b sn in a subgroup of patints; this finding is associatd with mor hmaturia and hyprtn- sion and poor rspons to standard corticostroid tratmnt. »TreatmentT ratmnt is with prdnison, 60 mg/m2/day orally; rmis- sion in stroid-rsponsiv minimal chang disas gnr- ally occurs within 4–8 wks. Adults oftn rquir longr courss of thrapy than childrn, rquiring up to 16 wks to achiv a rspons. Tratmnt should b continud for svral wks aftr complt rmission of protinuria, and dosing taprs should b individualizd. A significant num- br of patints will rlaps and rquir rpatd corticost- roid tratmnt. Patints with frqunt rlapss or corticostroid rsistanc may rquir cyclophosphamid, a calcinurin inhibitor (tacrolimus, cyclosporin), or ritux- imab to induc subsqunt rmissions. Progrssion to ESKD is rar. Complications most oftn aris from pro- longd corticostroid us.M djral-Thomas NR t al. Randomizd, controlld trial of tacro- limus and prdnisolon monothrapy for adults with de novo minimal chang disas: a multicntr, randomizd, controlld trial. Clin J Am Soc Nphrol. 2020;15:209. [PMID: 31953303]FOCAL SEGMENTAL GLOMERULOSCLEROSIS »General ConsiderationsThis r lativly common rnal pattrn of injury rsults from damag to podocyts; such damag may b a primary/ rnal-limitd disordr or may b scondary to anothr undrlying disas stat. Primary causs fall into thr cat- goris: (1) hritabl abnormalitis in any on of svral podocyt protins, or to undrlying typ 4 collagn muta- tions; (2) polymorphisms in th APOL1 gn in thos of African ancstry; or (3) incrasd lvls of a circulating prmability factor. Scondary causs includ rnal ovr- work injury, obsity, hyprtnsion, chronic urinary rflux, HIV or SARS-CoV-2 infction, or analgsic or bisphospho- nat xposur. Gntic tsting in primary cass is bcoming mor common, spcially in th pdiatric population. »Clinical FindingsIn  FSGS causd by a primary kidny disas, 80% of chil- drn and 50% of adults hav ovrt nphrotic syndrom; howvr, whn it dvlops du to a scondary caus, frank nphrotic syndrom is uncommon. Dcrasd GFR is prs- nt in 25–50% of thos with FSGS at tim of diagnosis. Diagnosis rquirs kidny biopsy; thr is no hlpful srologic tst. Light microscopy shows sclrosis of sg- mnts of som, but not all, glomruli. On immunofluors- cnc, IgM and C3 ar sn in th sclrotic lsions, although it is prsumd that ths immun componnts ar simply trappd in th sclrotic glomruli and not pathog- ntic. As in minimal chang disas, lctron microscopy shows fusion of pithlial foot procsss. »TreatmentT ratmnt for all forms of FSGS includs diurtics for dma, ACE inhibitors or ARBs to control protinuria and hyprtnsion, and statins or niacin for hyprlipidmia. Immunosupprssion thrapy (oral prdnison, 1 mg/kg/ day for 4–16 wks followd by a slow tapr) is rsrvd for nphrotic primary FSGS cass prsumd to b du to a circulating prmability factor; in thos with stroid- rsistanc or intolranc, calcinurin inhibitors and myco- phnolat moftil can b considrd. Kidny transplantation in this subgroup of FSGS patints is complicatd by a rla- tivly high rlaps rat and risk of graft loss. Thos with APOL1 -associatd and nonhrditary primary rnal dis- as may not bnfit from immunosupprssion, although robust clinical trials ar lacking. Patints with scondary FSGS do not bnfit from immunosupprssiv thrapy; tratmnt should b dirctd at th inciting caus.Ahn  W t al. Approach to diagnosis and managmnt of primary glomrular disass du to podocytopathis in adults: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:955. [PMID: 32331832] Andrs HJ t al. SGLT2 inhibition rquirs rconsidration of fundamntal paradigms in chronic kidny disas, ‘diabtic nphropathy’ , IgA nphropathy and podocytopathis with FSGS lsions. Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 33313878]CMDT22_Ch22_p0912-p0951.indd  942 02/07/21 2:33 PMKIDNEY DISEASE943 CMDT 2022Shabaka  A t al. Focal sgmntal glomrulosclrosis: stat-of- th-art and clinical prspctiv. Nphron. 2020;144:413. [PMID: 32721952]ME MBRANOUS NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S »Varying degrees of proteinuria. »Most common cause of primary adult nephrotic syndrome. »Significant risk for hypercoagulable state if nephrotic syndrome present. »“Spike and dome” pattern on kidney biopsy from subepithelial deposits. »Secondary causes include hepatitis B virus and carcinomas. »General ConsiderationsMm branous nphropathy is th most common caus of primary nphrotic syndrom in adults, most oftn prsnting in th fifth and sixth dcads. Primary mmbranous nphropathy is an autoimmun disas with ractivity against svral possibl podocyt antigns. Scondary disas is associatd with infctions, such as hpatitis B and C, ndo- carditis, and syphilis; undrlying carcinomas (som of ths cass may also involv autoimmunity to THSD7A); autoim- mun disas, such as SLE, mixd connctiv tissu disas, and thyroiditis; and crtain drugs, such as NSAIDs and cap- topril. Th cours of primary disas is highly variabl, with spontanous rmission in approximatly 30% of patints and progrssion to ESKD ovr 3–10 yars in 50%. Poorr out- com is associatd with concomitant tubulointrstitial fibro- sis, mal sx, lvatd srum cratinin on prsntation, hyprtnsion, and protinuria gratr than 10 g/day. Patints with mmbranous nphropathy and nphrotic syndrom hav a highr risk of hyprcoagulabl stat with thrombosis than nphrosis from othr tiologis, including a particular prdisposition to rnal vin thrombosis. »Clinical FindingsA.  Symptoms and SignsPa tints may b asymptomatic or may hav dma or frothy urin. Symptomatic vnous thrombosis may b an initial sign. Thr may b symptoms or signs of an undrlying infction or noplasm (spcially lung, stomach, brast, and colon cancrs) in scondary mmbranous nphropathy.B.  Laboratory FindingsH ypoalbuminmia and hyprlipidmia ar charactristic laboratory findings in th nphrotic syndrom. Evaluation for scondary causs including srologic tsting for SLE, syphilis, and viral hpatitids, and ag- and risk-appropri- at cancr scrning should b prformd. Elvatd titr ofcirculating PLA2R antibodis is now considrd diagnostic for primary mmbranous nphropathy and may liminat th nd for kidny biopsy. Kidny biopsy findings in mmbranous nphropathy includ incrasd capillary wall thicknss without inflammatory changs or cllular prolif- ration; whn staind with silvr mthnamin, a “spik and dom” pattrn rsults from projctions of xcss GBM btwn th subpithlial immun complx dposits. Immunofluorscnc shows IgG and C3 staining along capillary loops. Elctron microscopy shows a discontinu- ous pattrn of dns dposits along th subpithlial sur- fac of th basmnt mmbran. »TreatmentScondary  causs must b considrd prior to considr- ation of tratmnt. Primary disas tratmnt dpnds on th risk of rnal disas progrssion. Roughly 30% of patints prsnt with subnphrotic protinuria (lss than 3 g/day) and most hav a good prognosis with consrvativ managmnt, including antiprotinuric thrapy with ACE inhibitor or ARB if blood prssur is gratr than 125/75 mm Hg. Spontanous rmission may dvlop vn in thos with havy protinuria (about 30% of cass). Thus, us of immunosupprssiv agnts should b limitd to thos at highst risk for progrssion and with salvagabl rnal function. Patints with nphrotic syndrom dspit 6 months of consrvativ managmnt and srum crati- nin lss than 3.0 mg/dL (265 mcmol/L) may lct thrapy with rituximab or with corticostroids and cyclophospha- mid for 6 months. Calcinurin inhibitors with or without corticostroids may b considrd as wll. Rduction in protinuria may tak up to 6 months, spcially with rituximab-basd rgimns. Patints with primary mmbra- nous nphropathy ar xcllnt candidats for transplant.Frvnza FC  t al; MENTOR Invstigators. Rituximab or cyclo- sporin in th tratmnt of mmbranous nphropathy. N Engl J Md. 2019;381:36. [PMID: 31269364] Safar-Bouri L t al. Mmbranous nphropathy: diagnosis, trat- mnt, and monitoring in th post-PLA2R ra. Pdiatr Nphrol. 2021;36:19. [PMID: 31811540] Trujillo H t al. Nw ways of undrstanding mmbranous nphropathy. Nphron. 2020;144:261. [PMID: 32229730] ºNEphrOTIC SpECTrUM DISEASE FrOM SYSTEMIC DISOrDErS DIABETIC NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S »Evidence of diabetes mellitus, typically over 10 years. »Albuminuria usually precedes decline in GFR. »Other end-organ damage, such as retinopathy, is common.CMDT22_Ch22_p0912-p0951.indd  943 02/07/21 2:33 PMChApTEr 22944 CMDT 2022 »General ConsiderationsDiabtic nphropa thy is th most common caus of ESKD in th Unitd Stats. Th incidnc is approximatly 30% in both typ 1 and typ 2 diabts mllitus. ESKD is much mor likly to dvlop in prsons with typ 1 diabts ml- litus, in part du to fwr comorbiditis and daths bfor ESKD nsus. With th currnt pidmic of obsity and typ 2 diabts mllitus, rats of diabtic nphropathy will con- tinu to incras. Patints at highr risk includ mals, African Amricans, Nativ Amricans, and thos with a family history of kidny disas. Mortality rats ar highr for diabt- ics with kidny disas compard to thos without CKD. »Clinical FindingsDiabtic  nphropathy dvlops about 10 yars aftr th onst of diabts mllitus. It may b prsnt at th tim typ 2 diabts mllitus is diagnosd. Th first stag of clas- sic diabtic nphropathy is hyprfiltration with an incras in GFR, followd by th dvlopmnt of microalbuminuria (30–300 mg/day). With progrssion, albuminuria incrass to gratr than 300 mg/day and can b dtctd on a urin dipstick as ovrt protinuria; th GFR subsquntly dclins ovr tim. Yarly scrning for microalbuminuria is rcommndd for all diabtic patints to dtct disas at its arlist stag; howvr, diabtic nphropathy can, lss commonly prsnt as nonprotinuric CKD. Th most common lsion in diabtic nphropathy is diffus glomrulosclrosis, but nodular glomrulosclrosis (Kimmlstil-Wilson noduls) is pathognomonic. Th kidnys ar usually nlargd. Kidny biopsy is not rquird in most patints unlss atypical findings ar prsnt, such as suddn onst of protinuria, nphritic spctrum faturs (s abov), massiv protinuria (gratr than 10 g/day), urinary cllular casts, or rapid dclin in GFR. Patints with diabts ar pron to othr rnal disass. Ths includ papillary ncrosis, chronic intrstitial nphri- tis, and typ 4 (hyporninmic hypoaldostronmic) rnal tubular acidosis. Patints ar mor suscptibl to AKI from many insults, including intravnous contrast matrial and concomitant us of an ACE inhibitor or ARB with NSAID. »TreatmentW ith th onst of microalbuminuria, aggrssiv tratmnt is ncssary. Strict glycmic control should b mphasizd arly in diabtic nphropathy, with rcognition of risk of hypoglycmia as CKD bcoms advancd (s CKD sc- tion). Rcommndd blood prssur goals should b tai- lord to th individual patint: basd on th ACCORD trial, thos with microalbuminuria (30–300 mg/day) and prsrvd GFR and thos with significant CVD likly driv littl bnfit from blood prssur lowring much blow 140/90 mm Hg, although th 2017 guidlins from th Amrican Hart Association advocat tratmnt to 130/80 mm Hg or lss. Thos with ovrt protinuria (sp- cially mor than 1 g/day) bnfit from a goal of lss than 130/80 mm Hg. ACE inhibitors and ARBs in thos with microalbuminuria lowr th rat of progrssion to ovrt protinuria and slow progrssion to ESKD by rducing intraglomrular prssur and via antifibrotic ffcts; thsagnts ar not absolutly indicatd in diabtic patints without albuminuria. Diabtic patints, spcially with advancd CKD, ar at rlativly high risk for AKI and hyprkalmia with inhibition of th rnin-angiotnsin sys- tm, so monitoring for hyprkalmia or a dclin in GFR mor than 30% within ~2 wks of th initiation or uptitra- tion of this thrapy is prudnt, with dos rduction or dis- continuation of thrapy if ths complications ar ncountrd. Combination ARB and ACE inhibitor therapy is not recommended due to lack of efficacy and increased adverse events of hyperkalemia and AKI. In addition to thir cardioprotctiv ffcts, th SGLT inhibitors, includ- ing canagliflozin, mpagliflozin, and dapagliflozin, slow progrssion of diabtic nphropathy; thir us is limitd to thos with typ 2 diabts mllitus with GFR gratr than 30 mL/min/1.73 m2. Us of ths agnts may rquir rduction in diurtic dosing in thos patints rquiring natriursis. Tratmnt of othr cardiovascular risk factors and obsity is crucial. Many with diabts hav multipl comorbid conditions; thrfor, in patints with ESKD who progrss to dialysis, mortality ovr th first 5 yars is high. Patints who ar rlativly halthy, howvr, bnfit from rnal transplantation.Bakris  G. Stmming th progrssion of diabtic kidny disas: th rol of th primary car clinician. J Fam Prac. 2020;69:S81. [PMID: 33104113] D Bor IH t al. Excutiv summary of th 2020 KDIGO Diab- ts Managmnt in CKD Guidlin: vidnc-basd advancs in monitoring and tratmnt. Kidny Int. 2020;98:839. [PMID: 32653403] Li J t al. Dcision algorithm for prscribing SGLT2 inhibitors and GLP-1 rcptor agonists for diabtic kidny disas. Clin J Am Soc Nphrol. 2020;15:1678. [PMID: 32518100] Tuttl KR t al. SLGT2 inhibition for CKD and cardiovascular disas in typ 2 diabts: rport of a scintific workshop sponsord by th National Kidny Foundation. Am J Kidny Dis. 2021;77:94. [PMID: 33121838]HI V-ASSOCIATED NEPHROPATHYHI V-associatd nphropathy usually prsnts with nphrotic syndrom and dclining GFR in patints with activ HIV infction. Most who prsnt with HIV-associatd nphropathy ar of African dscnt with APOL1 risk allls (s sction on Focal Sgmntal Glomrulosclrosis). HIV- associatd nphropathy is usually associatd with low CD4 counts and AIDS, but it can also b th initial prsntation of HIV disas. Prsons living with HIV ar at risk for othr kidny disass, such as toxicity from antirtroviral mdica- tions (g, tnofovir disoproxil fumarat), vascular disas, and diabts, or an immun complx–mdiatd glomrular disas (HIV-immun complx disas). Classic HIV-associatd nphropathy is charactrizd by an FSGS pattrn of injury with glomrular collaps; svr tubulointrstitial damag may also b prsnt. HIV-associatd nphropathy is lss common in th ra of HIV scrning and mor ffctiv antirtroviral thrapy. Small, uncontrolld studis hav shown that antirtroviral thrapy slows progrssion of disas. ACE inhibitors or ARBs can b usd to control blood prssur and protin- uria. Kidny biopsy is ncssary for diagnosis and to rulCMDT22_Ch22_p0912-p0951.indd  944 02/07/21 2:33 PMKIDNEY DISEASE945 CMDT 2022out  othr causs of kidny dysfunction. Patints who prog- rss to ESKD and ar othrwis halthy ar good candi- dats for kidny transplantation.H amzah L t al. Optimizing antirtroviral rgimns in chronic kid- ny disas. Curr Opin Infct Dis. 2019;32:1. [PMID: 30461453] Naickr S. HIV/AIDS and chronic kidny disas. Clin Nphrol. 2020;93:87. [PMID: 31397267]RE NAL AMYLOIDOSISAm yloidosis is a rlativly rar caus of nphrotic syndrom. It is causd by tissu dposition of an ovrproducd and abnormally foldd protin (amyloid). Svral diffrnt pro- tins can form amyloid fibrils with rnal dposition. Primary amyloidosis, or AL amyloidosis, is th most common form and is du to a plasma cll dyscrasia causing ovrproduction and dposition of monoclonal Ig light chains (s Chaptr 13). Scondary amyloidosis, or AA amyloidosis, can rarly occur in chronic inflammatory disas such as rhumatoid arthri- tis, inflammatory bowl disas, or chronic infction; in ths cass, thr is dposition of an acut phas ractant, srum amyloid A protin. Othr lss common forms of amy- loidosis may also b ncountrd. Protinuria, dcrasd GFR, and nphrotic syndrom ar prsnting symptoms and signs of rnal involvmnt in amyloidosis; vidnc of othr organ involvmnt, such as th hart, is common. Srum and urin protin lctropho- rsis should b don as scrning tsts; if a monoclonal spik is found on ithr, srum fr light chains should b quantifid and th kappa:lambda ratio assssd. Amyloid- affctd kidnys ar oftn largr than 10 cm. Pathologi- cally, glomruli ar filld with amorphous dposits that show grn birfringnc with Congo rd staining. AL amyloidosis progrsss to ESKD in an avrag of 2–3 yars. Fiv-yar ovrall survival is lss than 20%, with wors prognosis in thos with advancd cardiac involv- mnt. Standard tratmnt is a combination of mlphalan, corticostroids, and th protosom inhibitor bortzomib; addition of daratumumab shows promis. Mlphalan and autologous stm cll transplantation ar associatd with a high (45%) mortality rat but can induc rmission in 80% of survivors; howvr, fw patints ar ligibl for this tratmnt. In AA amyloidosis, rmission can occur if th undrlying disas is succssfully tratd. Rnal transplan- tation is an option.H ogan JJ t al. Dysprotinmia and th kidny: Cor Curriculum 2019. Am J Kidny Dis. 2019;74:822. [PMID: 31331759] Mn P t al. Monoclonal gammopathis of rnal significanc: rnal biopsy and byond. Cancrs (Basl). 2020;12:1741. [PMID: 32629844] Palladini G t al. Managmnt of AL amyloidosis in 2020. Hma- tology Am Soc Hmatol Educ Program. 2020;2020:363. [PMID: 33275753] ºTUBULOINTErSTITIAL DISEASEST ubulointrstitial disas may b acut or chronic. Acut disas is most commonly associatd with mdications, infctious agnts, and systmic rhumatologic disordrs.Intrstitial dma, infiltration with polymorphonuclar nutrophils, and accompanying ATN can b sn. (S Acut Kidny Injury, abov, and Tabl 22–9.) Chronic dis- as is associatd with insults from an acut factor or pro- grssiv insults without any obvious acut caus. Intrstitial fibrosis and tubular atrophy ar prsnt, with a mononu- clar cll prdominanc. Th chronic disordrs ar dscribd blow.CH RONIC TUBULOINTERSTITIAL DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Kidney size is small and contracted. »Decreased urinary concentrating ability. »Hyperchloremic metabolic acidosis. »Reduced GFR.Table 22–9. Causes of acute tubulointerstitial nephritis (abbreviated list).Dug  reactions Antibiotics Beta-lactam antibiotics: methicillin, penicillin, ampicillin, cephalosporins Ciprofloxacin Erythromycin Sulfonamides (trimethoprim-sulfamethoxazole, loop and thiazide diuretics) Tetracycline Vancomycin Ethambutol Rifampin Nonsteoidal anti-inflammatoy dugs Diuetics Thiazides Furosemide Ote Allopurinol Cimetidine Phenytoin Proton pump inhibitors Systemic Infections Bacteia Streptococcus Corynebacterium diphtheriae Legionella Viuses Epstein-Barr Ote Mycoplasma Rickettsia rickettsii Leptospira icterohaemorrhagiae Toxoplasma Idioatic Tubulointerstitial nephritis-uveitisCMDT22_Ch22_p0912-p0951.indd  945 02/07/21 2:33 PMChApTEr 22946 CMDT 2022 »General ConsiderationsTh  most common caus of chronic tubulointrstitial disas isobstructive uropathy , which may rsult from prolongd or rcurrnt obstruction. Th major causs ar prostat dis- as in mn; urtral calculus in a singl functioning kidny; bilatral urtral calculi; carcinoma of th crvix, colon, or bladdr; and rtropritonal tumors or fibrosis. Rflux nphropathy from vesicoureteral reflux is pri- marily a disordr of childhood and occurs whn urin passs rtrograd from th bladdr to th kidnys during voiding. It is th scond most common caus of chronic tubulointrstitial disas. It occurs as a rsult of an incom- ptnt vsicourtral sphinctr. Urin can xtravasat into th intrstitium, triggring an inflammatory rspons that lads to fibrosis ovr tim. Th inflammatory rspons is du to ithr bactria or normal urinary componnts. Analgesic nephropathy is most commonly sn in patints who ingst larg quantitis of pain mdication. Th drugs of concrn ar phnactin, paractamol, aspirin, and othr NSAIDs; actaminophn is a possibl but lss crtain culprit. Ingstion of at last 1 g/day for 3 yars of ths analgsics is considrd ncssary for kidny dys- function to dvlop, and most patints grossly undrsti- mat thir analgsic us. This disordr occurs most frquntly in individuals who ar using analgsics for chronic hadachs, muscular pains, and arthritis; fmal sx, oldr ag, and malnutrition ar risk factors for analg- sic nphropathy. Tubulointrstitial inflammation and pap- illary ncrosis ar sn on pathologic xamination. Papillary tip and innr mdullary concntrations of som analgsics ar tnfold highr than in th rnal cortx. Phnactin was onc a common caus of this disordr but is now rarly availabl. Aspirin and othr NSAIDs can caus damag through intrmdiat mtabolits, which can lad to cll ncrosis. Ths drugs also dcras mdul- lary blood flow (via inhibition of prostaglandin synthsis) and dcras glutathion lvls, which ar ncssary for dtoxification. Environmntal xposur to heavy metals —such as lad, cadmium, mrcury, and bismuth—occurs infr- quntly now in th Unitd Stats but can caus tubuloint- rstitial disas. Individuals at risk for lad-inducd tubulointrstitial disas ar thos with occupational xpo- sur (g, wldrs who work with lad-basd paint) and drinkrs of alcohol distilld in automobil radiators (“moonshin” whisky usrs). Lad is filtrd by th glom- rulus and is transportd across th proximal convolutd tubul, whr it accumulats and causs cll damag. Fibrosd artriols and cortical scarring also lad to dam- agd kidnys. A form of chronic tubulointrstitial disas dispropor- tionatly affcting mal agricultural workrs in Cntral Amrica is an important caus of ESKD. Whil th xact pathophysiology is still unknown, th trm Mesoamerican nephropathy is applid to rflct th gographic rgion in which this disas occurs. Affctd individuals tnd to b 30–50 yars of ag without diabts, hyprtnsion, or othr causs of kidny disas who work undr hot conditions, particularly in sugar can or cotton filds, and ar thus suscptibl to dhydration.»Clinical FindingsA.  General FindingsPo lyuria is common bcaus tubular damag lads to nphrognic diabts insipidus, possibly from vasoprssin insnsitivity. Volum dpltion can also occur as a rsult of a salt-wasting dfct in som individuals. Patints can bcom hyprkalmic both bcaus th GFR is lowr and th distal tubuls bcom aldostron rsistant. Rnal tubular acidosis is common and dvlops through thr possibl mchanisms: (1) rducd ammonia production in th proximal tubuls, (2) inability to rab- sorb bicarbonat in th proximal tubuls, and (3) inability to scrt protons in th distal tubuls, which is ndd for urinary acidification. A typ 1 or typ 4 rnal tubular acidosis is mor commonly obsrvd in tubulointrstitial disas, xcpt in th cas of havy mtal xposur whr dirct proximal tubular damag lads to a proximal (typ 2) rnal tubular acidosis. In contrast to acut intrstitial nphritis, th urinalysis in chronic tubulointrstitial disas is oftn nonspcific; a fw clls or broad waxy casts may b sn, but urinalysis oftn is bland. Protinuria is typically lss than 2 g/day, owing to inability of th proximal tubul to rabsorb frly filtrabl protins.B.  Specific Findings1. Obstructive uropathy—  In partial obstruction, patints can xhibit polyuria (from tubular damag) or oliguria (du to dcrasd GFR). Azotmia and hyprtnsion (du to incrasd rnin-angiotnsin production) ar usually prsnt. Abdominal, rctal, and gnitourinary xamina- tions may b hlpful in dtcting a distndd bladdr or larg prostat. Urinalysis may show hmaturia, pyuria, and bactriuria but is oftn bland. Abdominal ultrasound may dtct mass lsions, hydrourtr, and hydronphrosis but may ovrlook 5% of cass. CT scanning or MRI can b considrd if suspicion rmains dspit a normal ultrasound. 2. Vesicoureteral reflux— Vsicourtral rflux is typically diagnosd in young childrn with a history of rcurrnt urinary tract infctions but can also dvlop aftr kidny transplantation. Rnal ultrasound or IVP can show rnal scarring and hydronphrosis. Although most damag occurs bfor ag 5 yars, progrssiv dtrioration to ESKD occurs. 3. Analgesics— Patints can xhibit hmaturia, mild pro- tinuria, polyuria (from tubular damag), anmia (from GI blding or rythropoitin dficincy), and stril pyuria. Sloughd papilla can b found in th urin whn papillary ncrosis occurs and can lad to obstruction. Although clas- sically diagnosd by IVP , papillary ncrosis is mor com- monly dtctd by CT imaging. 4. Heavy metals— Proximal tubular damag from lad xposur can caus dcrasd scrtion of uric acid, rsult- ing in hypruricmia and saturnin gout. Patints com- monly ar hyprtnsiv. Diagnosis is stablishd with a calcium disodium dtat (EDTA) chlation tst pr- formd on a timd urin collction. Urin xcrtion ofCMDT22_Ch22_p0912-p0951.indd  946 02/07/21 2:33 PMKIDNEY DISEASE947 CMDT 2022gratr  than 600 mg of lad following 1 g of EDTA indi- cats xcssiv lad xposur. Th proximal tubular dys- function from cadmium can caus hyprcalciuria and nphrolithiasis. 5. Mesoamerican nephropathy— In addition to low-grad protinuria, hypruricmia and hypokalmia ar consis- tntly (but not univrsally) idntifid among affctd indi- viduals. Although not pathognomonic, aras of glomrular ischmia (dspit vry mild vascular disas) that accom- pany chronic tubulointrstitial injury on kidny biopsy ar highly suggstiv of Msoamrican nphropathy. 6. Balkan nephropathy— Patints commonly dvlop pro- tinuria, glycosuria, acidosis, and suffr urinary concn- trating dfcts. Notably, urothlial carcinomas ar prsnt in approximatly 50% of affctd individuals at tim of diagnosis. »TreatmentT ratmnt dpnds first on idntifying th disordr rsponsibl for kidny dysfunction. Th dgr of intrsti- tial fibrosis on biopsy rflcts irrvrsibl damag, which is dirctly associatd with th liklihood of ESKD progrs- sion. Tratmnt is dirctd at mdical managmnt of risk factors for disas progrssion, such as hyprtnsion and protinuria. Tubular dysfunction may rquir bicarbonat supplmntation to trat mtabolic acidosis or phosphorus and potassium rstriction. If hydronphrosis is prsnt, th obstruction should b promptly rlivd. Prolongd obstruction lads to furthr tubular damag—particularly in th distal nphron— which may bcom irrvrsibl. Although surgical corrc- tion of rflux may b indicatd in slct circumstancs, this will unlikly prvnt dtrioration toward ESKD if fibrosis is xtnsiv. Patints in whom lad nphropathy is suspctd should continu chlation thrapy with EDTA if thr is minimalvidnc of irrvrsibl rnal damag, and continud xpo- sur should b avoidd. Tratmnt of analgsic nphropathy rquirs with- drawal of all analgsics. Stabilization of or improvmnt in kidny function may occur if significant intrstitial fibrosis is not prsnt. Ensuring volum rpltion during xposur to analgsics may also hav som bnficial ffcts. Patints with Msoamrican nphropathy should b counsld to rmain adquatly hydratd and, if possibl, minimiz hat xposur. NSAIDs should b avoidd du to thir hmodynamic ffcts (rducd rnal blood flow and glomrular filtration), which may xacrbat rnal injury in stats of volum dpltion and hot climats. »When to Refer• Patints with stag 3–5 CKD should b rfrrd to a nphrologist whn tubulointrstitial disass ar sus- pctd. Othr slct cass of stag 1–2 CKD should also b rfrrd, for xampl if rnal tubular acidosis is prsnt. •Patints with urologic abnormalitis should b rfrrd to a urologist.Cor ra-Rottr R t al. Msoamrican nphropathy. Smin Nphrol. 2019;39:263. [PMID: 31054625] ºCYSTIC DISEASES OF ThE KIDNEYRnal cysts  ar pithlium-lind cavitis filld with fluid or smisolid matrial that dvlop primarily from rnal tubu- lar lmnts. On or mor simpl cysts ar found in 50% of individuals ovr th ag of 50 yars. Thy ar rarly symp- tomatic and hav littl clinical significanc. In contrast, gnralizd cystic disass ar associatd with cysts scat- trd throughout th cortx and mdulla of both kidnys and can progrss to ESKD (Tabl 22–10). Table 22–10. Clinical features of renal cystic disease. Simle renal CystsAcquied renal CystsAutosomal Domi- nant polycystic Kidney DiseaseMedullay Songe KidneyMedullay Cystic Kidney Prevalence Common Dialysis patients 1:1000 1:5000 Rare Inheritance None None Autosomal dominant None Autosomal dominant Age at onset … … 20–40 years 40–60 years Adulthood Kidney size Normal Small Large Normal Small Cyst location Cortex and medulla Cortex and medulla Cortex and medulla Collecting ducts Corticomedullary junction Hematuria Occasional Occasional Common Rare Rare Hypertension None Variable Common None None Associated complicationsNone Adenocarcinoma in cystsHepatic cysts, urinary tract infections, renal calculi, cere- bral aneurysmsRenal calculi, urinary tract infectionsPolyuria, salt wasting Kidney failure Never Always Frequently Never AlwaysCMDT22_Ch22_p0912-p0951.indd  947 02/07/21 2:33 PMChApTEr 22948 CMDT 2022SI MPLE OR SOLITARY CYSTSSimpl  cysts account for 65–70% of all rnal masss. Thy ar gnrally found at th outr cortx and contain fluid that is consistnt with an ultrafiltrat of plasma. Most ar found incidntally on ultrasonographic xamination. Simpl cysts ar typically asymptomatic but can bcom infctd. Th major objctiv with simpl cysts is to diffrnti- at thm from malignancy, abscss, or polycystic kidny disas. Cystic disas can dvlop in dialysis patints and has th potntial to progrss to malignancy. Ultrasound and CT scanning ar rcommndd to valuat ths masss. Simpl cysts must mt thr sonographic critria to b considrd bnign: (1) cho fr, (2) sharply dmar- catd with smooth walls, and (3) an nhancd back wall (indicating good transmission through th cyst). Com- plx cysts can hav thick walls, calcifications, solid com- ponnts, and mixd chognicity. On CT scan, simpl cysts should hav smooth thin walls that ar sharply dmarcatd and should not nhanc with contrast mdia. Rnal cll carcinoma will nhanc but typically is of lowr dnsity than halthy parnchyma. Artriography can also b usd to valuat a mass proprativly. Rnal cll car- cinoma is hyprvascular in 80%, hypovascular in 15%, and avascular in 5% of cass. If a cyst has qustionabl imaging charactristics or is of uncrtain significanc, priodic rvaluation is rcom- mndd. Urologic consultation and surgical xploration may b considrd. Bnign cysts do not rquir any sp- cific follow-up, though changs in clinical prsntation should prompt rpat imaging.Smith AD t  al. Approach to rnal cystic masss and th rol of radiology. Radiol Clin North Am. 2020;58:897. [PMID: 32792122]AUTOS OMAL DOMINANT POLYCYSTIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Multiple cysts in both kidneys; number of cysts depends on patient age. »Combination of hypertension and large palpable kidneys suggestive of disease. »Autosomal dominant chromosomal abnormalities present in some patients. »General ConsiderationsA utosomal dominant polycystic kidny disas is th most common monognic kidny disas, affcting 12.5 million individuals worldwid. ESKD dvlops by ag 60 in up to 50% of patints. Th disas has variabl pntranc but accounts for 5–10% of all ESKD cass globally. At last two gns account for this disordr: PKD1 on th short arm of chromosom 16 (85–90% of patints) and PKD2on chromosom 4 (10–15%). Patints with th PKD2 mutation hav slowr progrssion of disas and longr lif xpctancy than thos with PKD1 . Othr sporadic cass without ths mutations ar also rcognizd. »Clinical FindingsA bdominal or flank pain and hmaturia (ithr microscopic or gross) ar prsnt in most patints. A history of urinary tract infctions and nphrolithiasis is common. A family history of autosomal dominant polycystic kidny disas is prsnt in 75% of cass, and mor than 50% of patints hav hyprtnsion that may prcd clinical manifstations. Patints hav larg kidnys that may b palpabl on abdomi- nal xamination. Th combination of hyprtnsion and an abdominal mass should rais suspicion for th disas. Forty to 50 prcnt hav concurrnt hpatic cysts; pancratic and splnic cysts may occur. Dspit dvlopmnt of CKD, hmoglobin is oftn normal as a rsult of cystic rythropoi- tin production. Urinalysis may show hmaturia and subn- phrotic protinuria. In patints with an stablishd family history of autosomal dominant polycystic kidny disas, ultrasonography confirms th diagnosis—two or mor cysts in patints undr ag 30 yars (snsitivity of 88.5%), two or mor cysts in ach kidny in patints agd 30–59 yars (sn- sitivity of 100%), and four or mor cysts in ach kidny in patints agd 60 yars or oldr ar diagnostic for autosomal dominant polycystic kidny disas. Importantly, ths cri- tria do notapply to individuals without a known family history; patints without a known family history of polycys- tic kidny disas rquir additional diagnostic valuation including CT scanning, which rvals innumrabl cysts in cass of polycystic kidny disas (Figur 22–6); th prs- nc of multipl hpatic cysts can aid in stablishing th diagnosis. In som cass, gntic tsting for PKD1 andPKD2 mutations may b rquird. ▲Figure 22–6. Polycystic kidney disease. CT scan showing bilateral polycystic kidneys in a 43-year-old woman who presented with newly diagnosed hyper- tension and microscopic hematuria. (Used, with permis- sion, from Michael Freckleton, MD, in Usatine RP , Smith MA, Mayeaux EJ Jr, Chumley H. The Color Atlas of Family Medicine , 2nd ed. McGraw-Hill, 2013.)CMDT22_Ch22_p0912-p0951.indd  948 02/07/21 2:33 PMKIDNEY DISEASE949 CMDT 2022 »Complications & TreatmentA.  PainA bdominal or flank pain is causd by infction, blding into cysts, and nphrolithiasis. Bd rst and analgsics ar rcom- mndd. Cyst dcomprssion can hlp with chronic pain.B.  HematuriaGross  hmaturia is most commonly du to cystic ruptur into th rnal plvis, but it can also b causd by a kidny ston or urinary tract infction. Hmaturia typically rsolvs within 7 days with bd rst and hydration.C.  Renal InfectionAn  infctd rnal cyst should b suspctd in patints who hav flank pain, fvr, and lukocytosis. Importantly, urinaly- sis may b normal if th cyst dos not communicat dirctly with th urinary tract. CT scans can b hlpful bcaus an infctd cyst may hav incrasd wall thicknss. Bactrial cyst infctions ar difficult to trat. Antibiotics with cystic pntration ar th agnts of choic (g, fluoroquinolons [ciprofloxacin, 500 mg vry 12 hours, or lvofloxacin, 500 mg onc daily if GFR normal], or trimthoprim- sulfamthoxazol doubl-strngth tablt twic daily).D . NephrolithiasisU p to 20% of patints hav kidny stons, primarily cal- cium oxalat. Hydration (2–3 L/day) is rcommndd in ordr to prvnt prcipitation of stons.E.  HypertensionA t th tim of prsntation, 50% of patints hav hyprtn- sion, and it will dvlop in most patints during th cours of th disas. Cyst-inducd ischmia appars to caus activation of th rnin-angiotnsin systm, and cyst dcomprssion can lowr blood prssur tmporarily. Hyprtnsion should b tratd with an ACE inhibitor or an ARB as th prfrrd drug if tolratd. Intnsiv blood prssur control (goal lss than or qual to 110/75 mm Hg) is rcommndd in adults youngr than 50 yars of ag with GFR gratr than 60 mL/min/1.73m2; for all othr affctd individuals, goal blood prssur is lss than or qual to 130/85 mm Hg.F . Cerebral AneurysmsAbo ut 10–15% of patints hav artrial anurysms in th circl of Willis. Scrning artriography is not rcom- mndd unlss th patint has a family history of anu- rysms, is mployd in a high-risk profssion (g, airlin pilot), or is undrgoing lctiv surgry with a high risk of dvloping modrat to svr prioprativ hyprtnsion.G.  Other ComplicationsV ascular problms includ mitral valv prolaps in up to 25% of patints, aortic anurysms, and aortic valv abnor- malitis. Colonic divrticula ar mor common in patints with polycystic kidnys.»PrognosisKidny  siz, rportd as total kidny volum, is th bst prdictor of kidny function dclin in patints with auto- somal dominant polycystic kidny disas, and it can b masurd via CT or MRI using th Mayo Classification systm (www.mayo.du/rsarch/documnts/pkd-cntr- adkpkd-classification/doc-20094754). Thos at high risk according to this classification systm may bnfit from tratmnts that dlay cyst growth. Vasoprssin rcptor antagonists dcras th rat of chang in total kidny vol- um and GFR dclin, and on such mdication (tolvap- tan) is FDA approvd for th tratmnt of autosomal dominant polycystic kidny disas. Libral ingstion of watr will hav th sam physiologic ffct on vasoprssin, and patints should b ncouragd to drink at last 2 L of watr daily. Othr agnts such as octrotid, sirolimus, and tyrosin kinas inhibitors dcras th rat of cyst growth but not th dclin in kidny function and ar thus not routinly usd. Avoidanc of caffin may prvnt cyst formation du to ffcts on G-coupld protins.Cornc-L  Gall E t al. Autosomal dominant polycystic kidny disas. Lanct. 2019;393:919. [PMID: 30819518] Nobakht N t al. Advancs in autosomal dominant polycystic kidny disas: a clinical rviw. Kidny Md. 2020;2:196. [PMID: 32734239]ME DULLARY SPONGE KIDNEYMd ullary spong kidny is blivd to affct lss than 1% of th gnral population. Although prsnt at birth, it is not usually diagnosd until th fourth or fifth dcad. It is thought to occur du to disruption of th urtric bud- mtanphric msnchym intrfac, oftn rsulting from autosomal dominant mutations in gns rsponsibl for urognital dvlopmnt. Kidnys hav a markd irrgular nlargmnt of th mdullary and intrpapillary collcting ducts. This is associatd with mdullary cysts that ar dif- fus, giving a “Swiss chs” apparanc in ths rgions. »Clinical FindingsNp hrolithiasis is th most common clinical prsntation for mdullary spong kidny. Othr prsntations may includ hmaturia (ithr gross or microscopic) or rcur- rnt urinary tract infctions. Common abnormalitis ar a dcrasd urinary concntrating ability and nphrocalci- nosis; lss common is incomplt typ 1 distal rnal tubular acidosis. Th diagnosis is stablishd clinically through laboratory data and imaging charactristics. As th pr- frrd imaging tst, CT shows cystic dilatation of th distal collcting tubuls with a striatd apparanc, and calcifica- tions in th rnal collcting systm. Similar findings on ultrasound may also support th diagnosis. »TreatmentT ratmnt for mdullary spong kidny is supportiv and aimd at undrlying abnormalitis such as nphrolithiasis and acidosis. Adquat fluid intak (2 L/day) hlps rduc risk of ston formation. If hyprcalciuria is prsnt,CMDT22_Ch22_p0912-p0951.indd  949 02/07/21 2:33 PMChApTEr 22950 CMDT 2022thiazid diurtics ar  rcommndd bcaus thy dcras calcium xcrtion. Alkali thrapy is rcommndd if rnal tubular acidosis is prsnt. »PrognosisRnal function is wll maintaind unlss thr ar  compli- cations from rcurrnt urinary tract infctions and nphrolithiasis.Pisani I t  al. Ultrasound to addrss mdullary spong kidny: a rtrospctiv study. BMC Nphrol. 2020;21:430. [PMID: 33046028] ºMULTISYSTEM DISEASES WITh VArIABLE KIDNEY INVOLVEMENT PLASMA CELL MYELOMAPlasma  cll myloma is a malignancy of plasma clls (s Chaptr 13) that can caus a varity of rnal disordrs. Injury is du to th toxic ffcts of monoclonal immuno- globulins or light chain componnts producd by plasma clls. “Myloma kidny” (formally calld cast nphropathy) is th most common kidny disas in plasma cll myloma and occurs whn light chains (Bnc Jons protin) in th urin caus rnal toxicity and tubular obstruction by pr- cipitating in th distal tubuls. Plasma cll myloma may also caus Fanconi syndrom, a typ 2 proximal rnal tubular acidosis charactrizd by hypophosphatmia and inappropriat glycosuria. Protinuria in “myloma kidny” is xclusivly tubular; hnc, urin dipstick findings ar minimal sinc glomrular protinuria is not prsnt. Hyprcalcmia and hypruricmia ar frquntly sn. Glomrular amyloidosis with nphrotic syndrom can dvlop in patints with plasma cll myloma; in ths patints, urin dipstick is positiv du to glomrular pi- thlial cll foot procss ffacmnt and albumin “spilling” into th Bowman capsul; hmaturia may or may not b prsnt. Othr conditions rsulting in kidny dysfunction includ plasma cll infiltration of th rnal parnchyma and hyprviscosity syndrom compromising rnal blood flow. Th prsnc of myloma-rlatd kidny disas dos not itslf prclud us of contrast dy for imaging studis; standard prcautions for th us of intravnous contrast and gadolinium in patints with rducd GFR apply to patints with myloma-rlatd kidny disas. Thrapy for AKI (s Acut Kidny Injury, abov) attributd to plasma cll myloma includs corrction of hyprcalcmia; vol- um rpltion; and chmothrapy for th undrlying malignancy, typically with bortzomib-basd agnts. Plas- maphrsis has bn proposd to rduc th burdn of circulating monoclonal protins, but rsults hav bn quivocal and its us is controvrsial.Małyszko  J t al. KDIGO Controvrsis Confrnc on onco- nphrology: kidny disas in hmatological malignancis and th burdn of cancr aftr kidny transplantation. Kidny Int. 2020;98:1407. [PMID: 33276867]SICKLE CELL DISEASEKidny  dysfunction associatd with sickl cll disas is most commonly du to sickling of rd blood clls in th rnal mdulla bcaus of low oxygn tnsion and hyprto- nicity. Congstion and stasis lad to hmorrhag, intrsti- tial inflammation, and papillary infarcts with rsultant ncrosis. Clinically, hmaturia is common, and protinuria can b prsnt as wll, portnding a poorr prognosis. Damag to rnal capillaris also lads to diminishd con- cntrating ability. Isosthnuria (urin osmolality qual to that of srum) is routin, and patints can asily bcom dhydratd. Ths abnormalitis ar also ncountrd in patints with sickl cll trait. Sickl cll glomrulopathy is lss common but inxorably progrsss to ESKD. Its pri- mary clinical manifstation is protinuria. Optimal trat- mnt rquirs adquat hydration and control of th sickl cll disas.Lim  RI t al. Amrican Socity of Hmatology 2019 guidlins for sickl cll disas: cardiopulmonary and kidny disas. Blood Adv. 2019;3:3867. [PMID: 31794601] Olaniran KO t al. Kidny function dclin among black patints with sickl cll trait and sickl cll disas: an obsr- vational cohort study. J Am Soc Nphrol. 2020;31:393. [PMID: 31810990]TU BERCULOSISRnal  tubrculosis usually rsults from hmatognous sprad and is an undrdiagnosd ntity. Up to 20% of patints with xtrapulmonary tubrculosis hav urognital involvmnt, of which th kidny is most commonly affctd. Its classic manifstation is th prsnc of micro- scopic pyuria without bactrial growth on urin cultur— or “stril pyuria. ” Mor oftn, othr bactria ar also prsnt, and microscopic hmaturia may coxist. Urin culturs wr onc th gold standard for diagnosis, but th advnt of urin nuclic acid tsting for tubrculosis has incrasd snsitivity. Charactristic findings on imaging includ papillary ncrosis and cavitation of th rnal parnchyma. Urtral stricturs or calcifications may also b prsnt. Kidny biopsy is not usually ndd to confirm th diagnosis but rvals granulomatous inflammation and tubulointrstitial nphritis. Prompt initiation of anti- tubrculosis tratmnt is indicatd, without which pro- grssion to ESKD occurs du to chronic inflammation and obstruction.K ulchavnya E t al. Challngs in urognital tubrculosis. World J Urol. 2020;38:89. [PMID: 30997530]GO UT & THE KIDNEYTh  kidny is th primary organ for xcrtion of uric acid. Patints with proximal tubular dysfunction hav dcrasd xcrtion of uric acid and ar mor pron to gouty arthritis attacks. Dpnding on th pH and uric acid concntration, dposition can occur in th tubuls, th intrstitium, or th urinary tract. Th mor alkalin pH of th intrstitium causs urat salt dposition,CMDT22_Ch22_p0912-p0951.indd  950 02/07/21 2:33 PMKIDNEY DISEASE951 CMDT 2022wh ras th acidic nvironmnt of th tubuls and uri- nary tract causs uric acid crystal dposition at high concntrations. Thr disordrs ar commonly sn: (1) uric acid nph- rolithiasis, (2) acut uric acid nphropathy, and (3) chronic urat nphropathy. Kidny dysfunction with uric acid nphrolithiasis stms from obstructiv physiology. Acut uric acid nphropathy prsnts with dirct tubulointrsti- tial toxicity from uric acid crystals and distal tubul obstruction causd by prcipitation of uric acid crystals. Chronic urat nphropathy is causd by dposition of urat crystals in th alkalin mdium of th intrstitium; this can lad to fibrosis and atrophy. Tratmnt btwn gouty attacks involvs avoidanc of food and drugs causing hypruricmia (s Chaptr 20), aggrssiv hydration, and urat-lowring thrapy (such as with allopurinol and fbuxostat). Th thr disordrs mn- tiond abov ar sn in both “ovrproducrs” and “undrx- crtors” of uric acid. Th lattr situation may sm countrintuitiv; howvr, ths patints hav acidic urin, which nabls prcipitation of rlativly insolubl uric acid crystals. For thos with uric acid nphrolithiasis, fluid intak should xcd 3 L/day, and us of a urinary alkalinizing agnt can b considrd. Patints with hypruricmia who do not hav a history of gout or uric acid nphrolithiasis hav not bn shown to bnfit from urat-lowring thrapy.Badv SV  t al; CKD-FIX Study Invstigators. Effcts of allopu- rinol on th progrssion of chronic kidny disas. N Engl J Md. 2020;382:2504. [PMID: 32579811]NE PHROGENIC SYSTEMIC FIBROSISNp hrognic systmic fibrosis is a multisystm disordr sn only in patints with CKD (primarily with an GFR lss than 15 mL/min/1.73 m2, but rarly 15–29 mL/ min/1.73 m2), AKI, and aftr kidny transplantation. His- topathologically, thr is an incras in drmal spindl cllspositiv for CD34 and procollagn I. Collagn bundls with mucin and lastic fibrs ar also notd. Nphrognic systmic fibrosis was first rcognizd in hmodialysis patints in 1997 and has bn strongly linkd to us of contrast agnts containing gadolinium. Incidnc following gadolinium injction is approximatly 1–4% in th highst risk (ESKD) population and lowr in patints with lss svr kidny dysfunction. Th incidnc has dcrasd ovr tim du to limiting us of gadolinium in patints with CKD and AKI and modifid gadolinium prparations. Thr is an FDA warning rgarding avoidanc of this agnt for patints with an GFR lss than 30 mL/min/1.73 m2. »Clinical FindingsNp hrognic systmic fibrosis affcts svral organ sys- tms, including th skin, muscls, lungs, and cardiovascu- lar systm. Th most common manifstation is a dbilitating fibrosing skin disordr that can rang from skin-colord to rythmatous papuls, which coalsc to brawny patchs. Th skin can b thick and woody in aras and is painful out of proportion to findings on xamination. »TreatmentCas  rports and sris dscrib bnfit of corticostroids, photophrsis, plasmaphrsis, and sodium thiosulfat, but thir tru fficacy is unknown. CT is prfrrd to MR imaging with gadolinium whn similar diagnostic infor- mation can b gland. If gadolinium absolutly must b usd in patints on dialysis, practic guidlins rcom- mnd using no mor than th standard dos and hmodi- alysis immdiatly aftr xposur.Ma thur M t al. Gadolinium dposition and nphrognic systmic fibrosis: a radiologist’s primr. Radiographics. 2020;40:153. [PMID: 31809230] Rudnick MR t al. Risks and options with gadolinium-basd con- trast agnts in patints with CKD: a rviw. Am J Kidny Dis. 2021;77:517. [PMID: 32861792]CMDT22_Ch22_p0912-p0951.indd  951 02/07/21 2:33 PM952 CMDT 2022 Mathew Sorensen, MD, MS, FACS Thomas J. Walsh, MD, MS Maahum A. Haider, MD, MPHUrologic Disorders23HE MATURIAE S S E N T I A L S  O F  D I A G N O S I S »Gross hematuria requires evaluation: the upper urinary tract should be imaged, and the lower tract evaluated by cystoscopy. »In microscopic hematuria, the workup should be risk stratified. »General ConsiderationsAn upper tract source (kidneys and ureters) can be identified in 10% of patients with gross or microscopic hematuria. For upper tract sources, stone disease accounts for 40%, medical kidney disease (medullary sponge kidney, glomerulonephri- tis, papillary necrosis) for 20%, renal cell carcinoma for 10%, and urothelial cell carcinoma of the ureter or renal pelvis for 5%. Medication ingestion and associated medical problems may provide diagnostic clues. Analgesic use (papillary necro- sis), cyclophosphamide (chemical cystitis), antibiotics (inter- stitial nephritis), diabetes mellitus, sickle cell trait or disease (papillary necrosis), a history of stone disease, or malignancy should all be investigated. The lower tract source of gross hematuria (in the absence of infection) is most commonly from bleeding prostatic varices or urothelial carcinoma of the bladder. Microscopic hematuria in the male is most com- monly from benign prostatic hyperplasia (13%), kidney stones (6%), or urethral stricture (1.4%). The presence of hematuria in patients receiving antiplatelet or anticoagulation therapy cannot be presumed to be due to the medication; a complete evaluation is warranted consisting of upper tract imaging, cystoscopy, and urine cytology (see Chapter 39 for Bladder Cancer, Cancers of the Ureter & Renal Pelvis, Renal Cell Carcinoma, and Other Primary T umors of the Kidney). »Clinical FindingsA.  Symptoms and SignsIf  gross hematuria occurs, a description of the timing (initial, terminal, total) may provide a clue to the localization ofdisease. Associated symptoms (ie, renal colic, irritative void- ing symptoms, or constitutional symptoms) should be inves- tigated. The history should be focused on risk factors for urothelial cancer (age, male sex, smoking history, history of gross hematuria, irritative lower urinary tract voiding symp- toms, history of cyclophosphamide or ifosfamide chemo- therapy, family history of urothelial carcinoma or Lynch syndrome, occupational exposure to benzene chemicals or aromatic amines, history of chronic indwelling foreign body in the urinary tract) and on nonmalignant causes. The physical examination should look for signs of systemic disease (fever, rash, lymphadenopathy, abdominal or pelvic masses) as well as signs of medical kidney disease (hyperten- sion, volume overload). The urologic evaluation may dem- onstrate an enlarged prostate, flank mass, or urethral disease. The evaluation of patients with hematuria and their risk stratification should not be influenced by whether they are taking any antiplatelet or anticoagulant agents.B.  Laboratory FindingsIn itial laboratory investigations include a urinalysis and urine culture. Microhematuria is defined as three or more red blood cells per high-power field on a microscopic evaluation of the urine. The degree of microscopic hematuria is impor- tant in risk stratification according to the 2020 American Urological Association hematuria guidelines (Figure 23–1). A positive dipstick reading for heme merits microscopic examination to confirm or refute the diagnosis of hematuria but is not enough to warrant workup on its own. If urinaly- sis and culture is suggestive of a urinary tract infection, follow-up urinalysis after treatment of the infection is important to ensure resolution of the hematuria. An esti- mate of kidney function should be obtained since renal insufficiency may influence the methods of further evalua- tion and management (eg, ability to obtain contrast imag- ing) of patients with hematuria. Urine cytology and other urinary-based markers are not routinely recommended in the evaluation of asymptomatic microscopic hematuria.C.  Risk StratificationFo llowing initial evaluation, clinicians should categorize patients with microscopic hematuria as low, intermediate, or high risk for a urothelial malignancy (Figure 23–1).CMDT22_Ch23_p0952-p0977.indd  952 29/06/21 8:49 PM",
                  "KIDNEY DISEASE913 CMDT 2022Thr  ar svral rasons protinuria may dvlop: (1) Functional proteinuria is a bnign procss stmming from strssors such as acut illnss, xrcis, and “ortho- static protinuria. ” Th lattr condition, gnrally found in popl undr 30 yars of ag, usually causs protin xcr- tion lss than 1 g/day. Th orthostatic natur of th protin- uria is confirmd by masuring an 8-hour ovrnight supin urinary protin xcrtion, which should b lss than 50 mg. (2)Overload proteinuria occurs whn th rabsorptiv capacity of tubuls is ovrwhlmd, which can rsult from xcss production of low-molcular-wight plasma pro- tins (g, Bnc Jons protins associatd with plasma cll myloma). In th cas of plasma cll myloma, protin lctrophorsis from srum or urin will xhibit a discrt, monoclonal protin spik. Othr xampls of ovrload protinuria includ myoglobinuria in rhabdomyolysis and hmoglobinuria in hmolysis. (3) Glomerular proteinuria rsults from ffacmnt of pithlial cll foot procsss and altrd glomrular prmability with an incrasd filtra- tion fraction of normal plasma protins, as in diabtic nphropathy. Protin lctrophorsis will xhibit a larg albumin spik indicativ of th incrasd prmability of albumin across th damagd GBM. (4) Tubular protein- uria occurs as a rsult of faulty rabsorption of normally filtrd protins in th proximal tubul, such as bta- 2-microglobulin. Causs may includ ATN, toxic injury (lad, aminoglycosids, and crtain antirtrovirals), drug- inducd intrstitial nphritis, and hrditary mtabolic disordrs (Wilson disas and Fanconi syndrom). Evaluation of protinuria by urin dipstick dos not actually masur protin but instad dtcts th ngativ lctrochmical charg that charactrizs albumin. As a rsult, positivly chargd Bnc Jons protins ar missd with dipstick analysis. Bnc Jons protins can b dtctd by th addition of sulfosalicylic acid to th urin spcimn or, mor commonly, dirctly masuring urin protin. It should b notd that, bcaus urin dipstick simply dtcts ngativ lctrochmical charg, alkalin urin (pH > 7.0) can caus fals-positiv rsults. Whil urin dipstick is commonly usd to scrn for pro- tinuria, quantitativ invstigation rquirs dirct valuationof urin protin xcrtion. This can b stimatd with a random urin sampl or masurd from a timd urin collction (typically 24 hours). Collction of a random urin sampl is far simplr, and th ratio of urin protin- to-cratinin concntration ([Uprotin]/[Ucratinin]) corrlats with a 24-hour urin protin collction (lss than 0.2 is normal and corrsponds to xcrtion of lss than 200 mg/ 24 hours). In a 24-hour collction, protinuria abov 150 mg is abnormal and abov 3 g is classifid as nphrotic- rang. On bnfit of a random protin-to-cratinin ratio is th minimization of rror from ovrcollction or undrcol- lction of urin in th 24-hour spcimn. A kidny biopsy may b indicatd to dtrmin th caus of abnormal pro- tinuria, particularly if accompanid by abnormal GFR or hmaturia. Th clinical squla of protinuria ar dis- cussd in th sction on Nphrotic Spctrum Glomrular Disass.B.  HematuriaH maturia is considrd clinically significant if thr ar mor than thr rd blood clls pr high-powr fild on at last two occasions. It is usually dtctd incidntally on urin dipstick or following an pisod of macroscopic hma- turia. Th diagnosis must b confirmd via microscopic xamination, as fals-positiv dipstick tsts can b causd by myoglobin, oxidizing agnts, bts and rhubarb, hydrochlo- ric acid, and bactria. Transint hmaturia is common but is lss oftn clinically significant in patints youngr than 40 yars du to lowr concrn for malignancy. Hmaturia may b du to rnal or xtrarnal causs. Extrarnal causs ar addrssd in Chaptr 23. Rnal causs account for approximatly 10% of cass and ar clas- sifid as ithr glomrular or xtraglomrular. Glomrular causs includ glomrulonphritis (g, immunoglobulin A [IgA] nphropathy), thin basmnt mmbran disas and othr hrditary disordrs (g, Alport syndrom), and sys- tmic nphritic syndroms (g, lupus nphritis). Extraglo- mrular sourcs includ cysts; calculi; intrstitial nphritis; and, most worrisom, gnitourinary noplasms from th kidny, prostat, or bladdr (s Chaptr 39). »Glomerular Filtration RateTh  GFR provids a usful masur of kidny function at th lvl of th glomrulus and can ithr b masurd dirctly using biomarkrs (most commonly cratinin) or stimatd using validatd formula. Th GFR masurs th amount of plasma ultrafiltrd across th glomrular capil- laris pr unit tim and rflcts th kidnys’ ability to filtr fluids and substancs, including mdications; it is oftn usd to dtrmin drug dosing. Daily GFR in normal indi- viduals is variabl, with a rang of 150–250 L/24 h or 100–120 mL/min/1.73 m2of body surfac ara. Patints with kidny disas can hav dcrasd GFR from any procss that causs loss of functional glomruli. Howvr, thy can also hav normal or incrasd GFR, ithr from glomrular hyprfiltration or disas at a diffrnt sgmnt of th nphron, intrstitium, or vascular supply. GFR can b masurd by dtrmining th rnal clar- anc of plasma substancs that ar not bound to plasmaTable 22–1. Significance of specific urinary casts.T ye Significance Hyaline casts Not indicative of kidney disease Concentrated urine, febrile disease, diuretic therapy, after strenuous exercise Red cell casts Glomerulonephritis White cell casts Indicative of infection or inflammation Pyelonephritis, interstitial nephritis Renal tubular cell castsAcute tubular necrosis, interstitial nephritis Granular (muddy brown) castsNonspecific; can indicate acute tubular necrosis Broad waxy casts Indicative of stasis in enlarged collecting tubules Chronic kidney diseaseCMDT22_Ch22_p0912-p0951.indd  913 02/07/21 2:33 PMChApTEr 22914 CMDT 2022pro tins, ar frly filtrabl across th glomrulus, and ar nithr scrtd nor rabsorbd along th rnal tubuls. Th rnal claranc of a substanc is dfind as:= ×CU  V Pwhr  C is th claranc, U and P ar th rspctiv urin and plasma concntrations of th substanc (mg/dL), and V.is volum of urin pr unit tim (typically mL/min). In clinical practic, th claranc of ndognous cratinin (trmd creatinine clearance ) is th primary way to ma- sur GFR. Th cratinin claranc (Ccr) is approximatly 100 mL/min in halthy young womn and 120 mL/min in halthy young mn. Th cratinin claranc dclins by an avrag of 0.8 mL/min/yr aftr ag 40 yars as part of th aging procss. Cratinin is a product of muscl mtabolism producd at a rlativly constant rat and clard by rnal xcrtion. It is frly filtrd by th glomrulus and not rabsorbd by th rnal tubuls. Howvr, cratinin is not a prfct indicator of GFR for th following rasons: (1) a small amount is normally liminatd by tubular scrtion, and it progrssivly incrass as GFR dclins (thus ovrs- timating GFR); (2) with svr kidny failur, gut microor- ganisms dgrad cratinin; (3) ditary mat intak and muscl mass affct plasma cratinin lvls; (4) mdications such as aspirin, dolutgravir, probncid, and trimthoprim rduc tubular scrtion of cratinin, incrasing th plasma cratinin concntration and falsly suggsting kidny dys- function; and (5) th masurmnt assums a stabl plasma cratinin concntration ovr a 24-hour priod, so whn valus ar changing during th dvlopmnt of and rcov- ry from AKI, cratinin claranc is inaccurat. On way to masur cratinin claranc is to prform a timd urin collction and dtrmin th plasma cratinin lvl midway through th collction. An incomplt or pro- longd urin collction is a common sourc of rror. Th compltnss of th collction can b stimatd by compar- ing th amount of cratinin xcrtd in th collction to that xpctd ovr a 24-hour priod, which should b constant: Ucr× V.= 15 − 20 mg/kg for healthy young women Ucr× V.= 20 − 25 mg/kg for healthy young men Givn th tdious natur of timd urin collctions for masuring GFR, GFR is mor commonly stimatd (dnotd GFR) using formula that hav bn validatd using patint charactristics (such as ag, wight, rac, and sx) and plasma cratinin lvls. Th Kidny Disas Improv- ing Global Outcoms workgroup rcommnds GFR for- mula as th primary mthod for dtrmining GFR. Th prfrrd GFR formula is th 2009 CKD-Epidmiology (EPI) Collaboration cratinin quation (https://www. kidny.org/contnt/ckd-pi-cratinin-quation-2009). An altrnativ cratinin-basd GFR stimating quation is accptabl if it improvs accuracy ovr th CKD-EPI qua- tion. Svral wb-basd calculators will calculat th GFR (g, http://touchcalc.com/calculators/pi). Th Cockcroft- Gault formula is commonly usd to dtrmin drug dos- ing, but it is no longr rcommndd sinc it was dvlopdbfor th standardization of cratinin assays currntly in us.Cystatin C is anothr ndognous markr of GFR that is filtrd frly at th glomrulus, producd at a rlativly constant rat, and lss dpndnt on muscl mass. It is rabsorbd and partially mtabolizd in th rnal tubular pithlial clls. Adding th masurmnt of cystatin C to srum cratinin can improv th accuracy of th GFR. A larg mta-analysis showd that cystatin C alon or in combination with srum cratinin is a strongr prdictor of important clinical vnts, such as nd-stag kidny dis- as (ESKD) or dath, than srum cratinin alon. How- vr, bcaus cystatin C is not univrsally availabl or standardizd across assays, it rmains a complmntary biomarkr for stimating GFR. BUN is anothr indx usd in assssing kidny func- tion. It is synthsizd mainly in th livr and is th nd product of protin catabolism. Ura is frly filtrd by th glomrulus, but about 30–70% is rabsorbd in th rnal tubuls. As such, it undrstimats GFR. Rnal ura rab- sorption incrass (in conjunction with incrasd sodium rabsorption) in hypovolmic patints (who, thrfor, hav an incrasd BUN). A normal BUN:cratinin ratio is approximatly 10:1, although this varis btwn individu- als. With volum dpltion, th ratio can incras to 20:1 or highr. Othr causs of incrasd BUN includ incrasd catabolism (gastrointstinal [GI] blding, cll lysis, and corticostroid usag), incrasd ditary protin, and dcrasd rnal prfusion prompting incrasd sodium (and thrfor BUN) rabsorption (g, hart failur, rnal artry stnosis) (Tabl 22–2). Rducd BUN lvls ar sn in livr disas and in th syndrom of inappropriat antidiurtic hormon (SIADH). In summary, cratinin and ura clarancs ovrsti- mat and undrstimat GFR, rspctivly. Bcaus ach of ths stimats bcom mor inaccurat as kidny disas advancs, a mor accurat masur of GFR as patints approach ESKD is th avrag of th cratinin and ura clarancs.KI DNEY BIOPSYIndica tions for prcutanous ndl biopsy includ (1) unxplaind AKI or CKD; (2) unxplaind protinuria or hmaturia, or both; (3) prviously idntifid and tratd Table 22–2. Conditions affecting BUN independently of GFR.Inceased  BUN Reduced effective circulating blood volume (prerenal azotemia) Catabolic states (gastrointestinal bleeding, corticosteroid use) High-protein diets Tetracycline Deceased BUN Liver disease Malnutrition Sickle cell anemia SIADH BUN, blood urea nitrogen; GFR, glomerular filtration rate; SIADH, syndrome of inappropriate antidiuretic hormone.CMDT22_Ch22_p0912-p0951.indd  914 02/07/21 2:33 PMKIDNEY DISEASE915 CMDT 2022lsions to guid futur thrapy; (4) sy stmic disass asso- ciatd with kidny dysfunction, such as systmic lupus rythmatosus (SLE), anti-GBM disas, and granuloma- tosis with polyangiitis; and (5) kidny transplant dysfunc- tion, to valuat for transplant rjction or othr abnormalitis. Kidny biopsis should only b prformd if th rsults will influnc th tratmnt plan or facilitat discussion about prognosis. Rlativ contraindications includ a solitary or ctopic kidny (xcption for trans- plant allografts), horssho kidny, ESKD, congnital anomalis, and multipl cysts. Absolut contraindications includ an uncorrctd blding disordr; svr uncon- trolld hyprtnsion; rnal infction or noplasm; hydro- nphrosis; or uncooprativ patints, including thos who ar unabl to li flat for th procdur. Prcutanous kidny biopsis ar gnrally saf. Th major risk is blding, which may occur up to 72 hours post biopsy. Mor than half of patints will hav at last a small hmatoma; approximatly 1–5% of patints will xprinc significant blding rquiring a blood transfusion. Antico- agulation should b hld for 5–7 days post biopsy if possibl. Th risks of nphrctomy and mortality ar about 0.06– 0.08%. Whn a prcutanous ndl biopsy is tchnically not fasibl and kidny tissu is dmd clinically ssntial, a closd biopsy via intrvntional radiologic tchniqus or opn biopsy undr gnral ansthsia can b prformd.Böknkamp  A. Protinuria—tak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Cavanaugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Lvy AS t al. Masurd and stimatd glomrular filtration rat: currnt status and futur dirctions. Nat Rv Nphrol. 2020;16:51. [PMID: 31527790] ºACUTE KIDNEY INJUrYE S S E N T I A L S  O F  D I A G N O S I S »Rapid increase in serum creatinine. »Oliguria may be present. »Symptoms and signs depend on cause. »General ConsiderationsAKI is dfi nd as an absolut incras in srum cratinin by 0.3 mg/dL or mor within 48 hours or a rlativ incras of at last 1.5 tims baslin that is known or prsumd to hav occurrd within 7 days. AKI is charactrizd as oligu- ric if urin production is lss than roughly 400–500 mL/day. Clinically, AKI is charactrizd by an inability to maintain acid-bas, fluid, and lctrolyt balanc and to xcrt nitrognous wasts. Stage 1 is a 1.5- to 1.9-fold incras in srum cratinin or a dclin in urinary output to lss than 0.5 mL/kg/h ovr 6–12 hours; stage 2 is a 2.0- to 2.9-fold incras in srum cratinin or dclin in urinary output to lss than 0.5 mL/kg/h ovr 12 hours or longr; stage 3 is a3.0-fold or gratr incras in srum cratinin, an incras in srum cratinin to gratr than or qual to 4 mg/dL, a dclin in urinary output to lss than 0.3 mL/ kg/h for 24 hours or longr, anuria for 12 hours or longr, or initiation of rnal rplacmnt thrapy. In th absnc of functioning kidnys, srum cratinin concntration will typically incras by 1–1.5 mg/dL daily, although with crtain conditions, such as rhabdomyolysis, srum crati- nin can incras mor rapidly. On avrag, 5% of hospital admissions and 30% of intnsiv car unit (ICU) admis- sions includ a diagnosis of AKI, and AKI dvlops in 25% of hospitalizd patints. Th rats of AKI in th hospital stting hav incrasd stadily sinc th 1980s and continu to ris. »Clinical FindingsA.  Symptoms and SignsAlthough  many patints will not xprinc any symptoms or xhibit any signs of AKI, th buildup of wast products can caus nonspcific symptoms and signs collctivly trmd uremia : nausa, vomiting, malais, and altrd snsorium. Mor commonly, patints xprinc symp- toms and signs of th undrlying disas causing thir AKI (g, lupus). Hyprtnsion can occur, and fluid homostasis is oftn impaird. Hypovolmia can caus stats of low blood flow to th kidnys, somtims trmd prerenal azotemia, whras hyprvolmia can rsult from intrinsic or postrnal disas. Pricardial ffusions can occur with urmia and may rsult in cardiac tamponad; a pricardial friction rub can b prsnt, signaling pricarditis. With hyprkalmia, vntricular tachycardia and othr tachyar- rhythmias can occur. Th lung xamination may rval rals in th prsnc of hyprvolmia. AKI can caus non- spcific diffus abdominal pain and ilus. Platlt dysfunc- tion with blding and clotting disordrs can occur. Th nurologic xamination somtims rvals ncphalo- pathic changs with astrixis and confusion; uncommonly sizurs may nsu.B.  Laboratory FindingsBy  dfinition, lvatd srum cratinin (and oftn BUN) lvls ar prsnt, though ths lvations do not distin- guish AKI from CKD. Mtabolic acidosis (du to dcrasd claranc of organic and inorganic acids) is oftn notd. Hyprkalmia can occur from impaird rnal potassium xcrtion or from shifting of potassium from clls into th blood as a rsult of mtabolic acidosis. With hyprkalmia, ECG can rval pakd T wavs, PR prolongation, and QRS widning. A long QT sgmnt can occur with hypo- calcmia. Hyprphosphatmia occurs whn phosphorus cannot b scrtd by damagd tubuls ithr with or with- out incrasd cll catabolism. Anmia can occur as a rsult of dcrasd rythropoitin production ovr wks, and platlt dysfunction is typical. »Classification & EtiologyAKI  is commonly dividd into thr catgoris: prrnal causs (kidny hypoprfusion), intrinsic kidny disas,CMDT22_Ch22_p0912-p0951.indd  915 02/07/21 2:33 PMChApTEr 22916 CMDT 2022and  postrnal causs (obstruction to urinary outflow). Idntifying th caus is th first stp toward tratmnt (Tabl 22–3).A.  Prerenal CausesPrr nal causs ar th most common tiology of AKI, accounting for 40–80% of cass. Prrnal azotmia is a physiologic rspons to rnal hypoprfusion. If rvrsd quickly with rstoration of rnal blood flow (g, fluid rsuscitation), rnal parnchymal damag oftn dos not occur. If hypoprfusion prsists, prrnal azotmia can lad to intrinsic kidny injury. Dcrasd rnal prfusion can occur in svral ways, such as a dcras in intravascular volum, a chang in vascular rsistanc, or low cardiac output. Causs of vol- um dpltion includ hmorrhag (g, from trauma), GI losss, xcssiv diursis, and xtravascular fluid squstra- tion (g, pancratitis, burns, and pritonitis). Changs in systmic vascular rsistanc can occur with spsis, anaphylaxis, ansthsia, and aftrload-rducing drugs. Blockad of th rnin-angiotnsin-aldostron sys- tm, such as with angiotnsin-convrting nzym (ACE) inhibitors, limits ffrnt rnal artriolar constriction out of proportion to affrnt artriolar constriction and thrby dcrass GFR. Nonstroidal anti-inflammatory drugs (NSAIDs) minimiz affrnt artriolar vasodilation by inhibiting prostaglandin-mdiatd signals. NSAIDs may hav particularly dltrious ffcts on rnal prfusion in cirrhosis and hart failur whn prostaglandins ar rcruitd to incras rnal blood flow. Epinphrin, nor- pinphrin, high-dos dopamin, ansthtic agnts, and calcinurin inhibitors also can caus rnal vasoconstric- tion. Rnal artry stnosis causs incrasd rsistanc and dcrasd rnal prfusion.Low cardiac output is a stat of low ffctiv rnal art- rial blood flow. This occurs in stats of hart failur (including cardiognic shock), pulmonary mbolism, and pricardial tamponad. Arrhythmias and valvular disor- drs can also rduc cardiac output. In th intnsiv car stting, positiv prssur vntilation will dcras vnous rturn and, in ffct, cardiac output. Whn GFR falls acutly, it is important to dtrmin whthr AKI is du to prrnal or intrinsic causs. Th his- tory, physical xamination, and laboratory data may b hlpful in distinguishing btwn ths causs. In prrnal AKI, th BUN:cratinin ratio oftn xcds 20:1 du to incrasd ura rabsorption. In oliguric patints, anothr usful indx is th fractional xcrtion of sodium (FeNa). With dcrasd GFR, th kidny rabsorbs salt and watr avidly if thr is no intrinsic tubular dysfunction. Thus, oliguric patints with prrnal AKI should hav a low frac- tional xcrtion of sodium (lss than 1%). Oliguric patints with intrinsic kidny dysfunction typically hav a high FeNa (gratr than 1–2%), indicating loss of tubular clls’ ability to rabsorb sodium. Th FeNais calculatd as follows: FeNa = claranc of Na+/GFR = claranc of Na+/Ccr:F Urine  / Serum Urine  / Serum100%E NaNa  Na cr  cr=  ×Th  quation was cratd and validatd to assss th diffrnc btwn oliguric ATN and prrnal AKI; its util- ity in nonoliguric patints is limitd. Furthr, bcaus diurtics act by incrasing sodium xcrtion, a high FeNa within 12–24 hours aftr diurtic administration cannot b maningfully intrprtd. In contrast, a low FeNadespite rciving diurtics offrs strong vidnc of prrnal stats in oliguric patints. Givn th limitations of FeNaTable 22–3. Classification and differential diagnosis of acute kidney injury. peenal Azotemiapostenal AzotemiaIntinsic renal Disease Acute Tubula Necosis Acute GlomeuloneitisAcute Intestitial Neitis Etiology Poor renal perfusionObstruction of the urinary tractIschemia, nephrotoxinsImmune complex-mediated, pauci-immune, anti-GBM related, monoclonal immunoglobulin–mediated, C3 glomerulopathyAllergic reaction; drug reaction; infection; autoimmune disease Serum BUN:Cr ratio > 20:1 > 20:1 < 20:1 > 20:1 < 20:1 UNa(mEq/L) < 20 Variable > 20 < 20 Variable FENa(%) < 1 Variable > 1 (when oliguric) < 1 Variable Urine osmolality (mOsm/kg)> 500 < 400 250–300 Variable Variable Urinary sediment Benign or hyaline castsNormal or red cells, white cells, or crystalsGranular (muddy brown) casts, renal tubular cell castsRed cells, dysmorphic red cells, and red cell castsWhite cells, white cell casts, with or without eosinophils BUN:Cr, blood urea nitrogen:creatinine ratio; FENa, fractional excretion of sodium; GBM, glomerular basement membrane; UNa, urinary concentration of sodium.CMDT22_Ch22_p0912-p0951.indd  916 02/07/21 2:33 PMKIDNEY DISEASE917 CMDT 2022calculations,  urin microscopy is a much mor valuabl tool for dtrmining caus of AKI. Patints with prrnal azotmia typically hav bland urin sdimnts, though som hav hyalin casts. In contrast, patints with ATN oftn hav rnal tubular pithlial clls or muddy brown casts visibl. Tratmnt of prrnal AKI dpnds on th undrlying caus, but achivmnt of uvolmia, attntion to srum lctrolyts, and avoidanc of nphrotoxic drugs ar bnch- marks of thrapy. This involvs carful assssmnt of vol- um status, cardiac function, dit, and drug usag.B.  Postrenal CausesP ostrnal causs of AKI ar th last common, accounting for approximatly 5–10% of cass, but ar important to dtct bcaus of thir rvrsibility. Postrnal azotmia occurs whn urinary flow from both kidnys, or a singl functioning kidny, is obstructd. Obstruction lads to lvatd intraluminal prssur and rsultant kidny parn- chymal damag, with markd ffcts on rnal blood flow and tubular function. Postrnal causs of AKI includ urthral obstruction, bladdr dysfunction or obstruction, and obstruction of both urtrs or rnal plviss. In mn, bnign prostatic hyprplasia is th most common caus. Patints taking anticholinrgic drugs ar at risk for urinary rtntion. Obstruction can also b causd by bladdr, prostat, and crvical cancrs; rtropritonal fibrosis; and nurognic bladdr (g, from diabts mllitus). Lss common causs includ blood clots, bilatral urtral stons, urthral stons or stricturs, and bilatral papillary ncrosis. Patints may b anuric or polyuric and may xprinc lowr abdominal or back pain. Polyuria can occur in th stting of partial obstruction with rsultant tubular dys- function and an inability to appropriatly rabsorb salt and watr loads. Obstruction can b constant or intrmittnt and partial or complt. On xamination, th patint may hav an nlargd prostat, distndd bladdr, or mass dtctd on abdominal xamination. Laboratory xamination may initially rval high urin osmolality, low urin sodium, high BUN:cratinin ratio, and low FeNa(as tubular function may not b compromisd initially). Ths indics ar similar to a prrnal stat bcaus xtnsiv intrinsic rnal damag has not yt occurrd. Aftr svral days, howvr, th urin sodium incrass as th kidnys fail and ar unabl to concntrat th urin; this inability to concntrat th urin is calld isosthnuria. Th urin sdimnt is gnrally bland, though hmaturia may b sn if th obstruction is du to stons, blood clots, or papillary ncrosis. Patints with AKI du to suspctd postrnal causs should undrgo bladdr cathtrization and ultrasonogra- phy to assss for hydrourtr, hydronphrosis, or larg bladdr volum. Aftr rvrsal of th undrlying procss, som patints xprinc significant urinary output (calld postobstructiv diursis). In such sttings, car should b takn to avoid volum dpltion or lctrolyt drang- mnts. Prompt tratmnt of obstruction within days by cathtrs, stnts, or othr surgical procdurs can rsult in partial or complt rvrsal of AKI.C. Intrinsic Acute Kidney InjuryIn trinsic rnal disordrs account for up to 50% of all cass of AKI. Intrinsic dysfunction is considrd aftr prrnal and postrnal causs hav bn xcludd. Th potntial sits of injury ar th tubuls, intrstitium, vasculatur, and glomruli. Intrinsic AKI is discussd in gratr dtail in th following sctions. »When to Refer• If a patint has signs of AKI that hav not rvrsd ovr 1–2 wks, or if th dgr of AKI is concrning (g, doubling of cratinin) and without an immdiatly rvrsibl caus such as obstruction. •If a patint has signs of urinary tract obstruction, th patint should b rfrrd to a urologist. »When to AdmitTh  patint should b admittd if thr is suddn loss of kidny function rsulting in abnormalitis that cannot b handld xpditiously in an outpatint stting (g, hyprka- lmia, volum ovrload, urmia) or an acut intrvntion is ndd, such as mrgnt urologic procdurs or dialysis.Ost rmann t al. Rcommndations on acut kidny injury bio- markrs from th Acut Disas Quality Initiativ Consnsus Confrnc: a consnsus statmnt. JAMA Ntw Opn. 2020;3:2019209. [PMID: 33021646] Ronco C t al. Acut kidny injury. Lanct. 2019;394:1949. [PMID: 31777389] Srisawat N t al. Th rol of biomarkrs in acut kidny injury. Crit Car Clin. 2020;36:125. [PMID: 31733675]ACU TE TUBULAR NECROSISE S S E N T I A L S  O F  D I A G N O S I S »AKI. »Ischemic or toxic insult or underlying sepsis. »Urine sediment with granular (muddy brown) casts and renal tubular epithelial cells is pathog- nomonic but not essential. »General ConsiderationsAKI  du to tubular damag is trmd acute tubular necro- sis (ATN) and accounts for approximatly 85% of intrinsic AKI. Th two major causs of ATN ar ischmia and nph- rotoxin xposur. Ischmic ATN is charactrizd not only by inadquat GFR but also by rnal blood flow that is inadquat to maintain parnchymal cllular prfusion. Rnal tubular damag can b causd by low ffctiv art- rial blood flow to th kidnys in th stting of prolongd hypotnsion or hypoxmia, such as volum dpltion or shock. Undrlying spsis is an indpndnt risk factor for ATN, vn in th absnc of hmodynamic compromis.CMDT22_Ch22_p0912-p0951.indd  917 02/07/21 2:33 PMChApTEr 22918 CMDT 2022Pro longd priods of rnal hypoprfusion can occur with major surgical procdurs, which ar xacrbatd by vaso- dilating ansthtic agnts.A.  Exogenous NephrotoxinsExognous  nphrotoxins mor commonly caus damag than ndognous nphrotoxins. Aminoglycosides caus som dgr of ATN in up to 25% of hospitalizd patints rciving thraputic lvls of th drugs. Nonoliguric kidny injury typically occurs aftr 5–10 days of xposur. Prdisposing factors includ undr- lying kidny damag, volum dpltion, and advancd ag. Monitoring drug lvls is important, and troughs ar par- ticularly hlpful in prdicting rnal toxicity. Amphotericin B is typically nphrotoxic aftr a dos of 2–3 g. This causs a typ 1 (distal) rnal tubular acidosis with svr vasoconstriction and tubular damag, which can lad to hypokalmia and nphrognic diabts insipi- dus. Vancomycin , intravnous acyclovir , and svral cephalosporins hav also bn known to caus or b asso- ciatd with ATN. Radiographic contrast media may b dirctly nphro- toxic. Contrast nphropathy is th third lading caus of incidnt AKI in hospitalizd patints and is thought to rsult from th synrgistic combination of dirct rnal tubular pithlial cll toxicity and rnal mdullary ischmia. Th combination of prxisting diabts mllitus and CKD is associatd with th gratst risk (15–50%) of contrast nphropathy. Othr risk factors includ advancd ag; vol- um dpltion; hart failur; plasma cll myloma; rpatd doss of contrast; and rcnt xposur to othr nphrotoxic agnts, including NSAIDs and ACE inhibitors. Lowr volums of contrast with low osmolality ar rcommndd in high-risk patints. Toxicity usually occurs within 24–48 hours aftr th radiocontrast study. Nonionic con- trast mdia may b lss toxic, but this has not bn wll provn. Prvntion of contrast nphropathy is th goal whn using ths agnts. Th mainstay of prophylaxis is 1–3 mL/kg or 500–1000 mL of intravnous 0.9% (normal) salin ovr 6 hours both bfor and aftr th contrast administration—cautiously in patints with prxisting cardiac dysfunction; oral intak of fluids is an accptabl altrnativ for outpatint studis. Isotonic intravnous vol- um rpltion is suprior to hypotonic intravnous solutions, and both ar suprior to oral solutions in small studis. Othr nphrotoxic agnts should b avoidd during th day bfor and aftr dy administration. Altrnativ prophylactic strat- gis involving N-actylcystin, sodium bicarbonat, manni- tol, and furosmid do not show bnfit ovr 0.9% (normal) salin administration. In fact, furosmid may lad to incrasd rats of kidny dysfunction in this stting. Calcineurin inhibitor toxicity (from tacrolimus or cyclosporin) is usually dos dpndnt. It causs distal tubular dysfunction (a typ 4 rnal tubular acidosis) and svr vasoconstriction. Rgular blood lvl monitoring is important to prvnt both acut and chronic nphrotoxic- ity. Kidny function usually improvs aftr rducing th dos or stopping th drug. Othr xognous nphrotoxins includ antinoplastics, such as cisplatin and organic solvnts, and havy mtalssuch as mrcury, cadmium, and arsnic. Hrbal mdicins ar also incrasingly rcognizd as potntially nphrotoxic.B.  Endogenous NephrotoxinsEndo gnous nphrotoxins includ pigmnt-containing products (myoglobin and hmoglobin), uric acid, and paraprotins. Pigmnt-containing products can caus dirct tubular toxicity, rsulting in ATN. Th most common typ of pig- mnt nphropathy is rhabdomyolysis, causd by rlas of myoglobin from muscl. Massiv intravascular hmolysis is sn in transfusion ractions and in crtain hmolytic anmias, and causs rlas of hmoglobin. Rvrsal of th undrlying disordr and hydration ar th mainstays of tratmnt. Hyperuricemia can occur in th stting of rapid cll turnovr and lysis. Chmothrapy for grm cll and hmatologic malignancis (lukmia and lymphoma) is th primary caus; spontanous tumor lysis syndrom can also occur, though is lss common. AKI occurs with intra- tubular prcipitation of uric acid crystals; srum uric acid lvls oftn xcd 15–20 mg/dL and urin uric acid lvls ar typically gratr than 600 mg/24 h. A urin uric acid to urin cratinin ratio gratr than 1.0 idntifis individuals at risk for AKI. Allopurinol or rasburicas can b usd prophylactically, and rasburicas with or without dialysis is oftn usd for tratmnt in stablishd cass. Paraproteins sn in conjunction with plasma cll myloma can caus dirct tubular toxicity and tubular obstruction. Othr rnal complications from plasma cll myloma includ hyprcalcmia and rnal tubular dys- function, including proximal rnal tubular acidosis (s Plasma Cll Myloma blow). »Clinical FindingsA.  Symptoms and SignsS Acut Kidny I njury.B.  Laboratory FindingsHyprka lmia and hyprphosphatmia ar commonly prsnt. Th BUN:cratinin ratio is usually lss than 20:1 bcaus tubular function is not intact, as dscribd in th gnral sction on AKI (Tabl 22–3). Urinary output can b oliguric or nonoliguric, with oliguria portnding a wors prognosis. Urin sodium concntration and FeNaar typically lvatd, indicativ of tubular dysfunction. Urin microscopy may show vidnc of acut tubular damag; th prsnc of two or mor granular casts or rnal tubular pithlial clls is strongly prdictiv of ATN but has a low ngativ prdictiv valu (s Tabl 22–1). Although not usually prformd in cass of ATN, kidny biopsy is som- tims hlpful in cass of diagnostic uncrtainty. »TreatmentT ratmnt of ATN is aimd at hastning rcovry and avoiding complications. Prvntiv masurs should b takn to avoid volum ovrload and hyprkalmia. A pro- spctiv randomizd controlld trial did not show a bnfitCMDT22_Ch22_p0912-p0951.indd  918 02/07/21 2:33 PMKIDNEY DISEASE919 CMDT 2022of  loop diurtics on ithr rcovry from AKI or dath. Widsprad us of diurtics in critically ill patints with AKI should b usd only whn othrwis clinically indi- catd (g, in stats of volum ovrload), although unrspon- sivnss to high-dos diurtics has bn shown to prdict futur nd for acut dialysis in this population (trmd “furosmid strss tst”). A 2012 randomizd controlld trial did not show a bnfit on mortality from plasma ultra- filtration compard to intravnous diurtics in patints with dcompnsatd hart failur. Thus, ultrafiltration should gnrally b rsrvd for ICU patints with AKI in nd of volum rmoval who ar nonrsponsiv to diurtics, with th rcognition that this has not ultimatly improvd sur- vival in this patint population. Nutritional support should mt daily nds whil prvnting xcssiv catabolism. Ditary protin rstriction of 0.6 g/kg/day hlps prvnt mtabolic acidosis. Hypocalcmia and hyprphosphatmia can b improvd with ditary modification and phosphat- binding agnts takn with mals; xampls includ alumi- num hydroxid (500 mg orally) ovr th short trm, and calcium carbonat (500–1500 mg orally), calcium actat (667 mg, two or thr tablts), svlamr carbonat (800– 1600 mg orally), and lanthanum carbonat (1000 mg orally) ovr longr priods. Hypocalcmia should not b tratd in patints with rhabdomyolysis unlss thy ar symptomatic. Hyprmagnsmia can occur bcaus of rducd magn- sium xcrtion by th rnal tubuls, so magnsium-containing antacids and laxativs should b avoidd in ths patints. Dosags of all mdications must b adjustd for drugs liminatd by th kidny. Indications for dialysis in AKI from ATN or othr intrinsic disordrs includ lif-thratning lctrolyt dis- turbancs (such as hyprkalmia), volum ovrload unr- sponsiv to diursis, rfractory acidosis, and urmic complications (g, ncphalopathy, pricarditis, and si- zurs). In gravly ill patints, lss svr but worsning abnormalitis may also b indications for dialytic support. Unfortunatly, thr is no vidnc that mor intnsiv or arlir initiation of rnal rplacmnt thrapy for patints with AKI confrs any survival bnfit. »Course & PrognosisTh  clinical cours of ATN is oftn dividd into thr phass: initial injury, maintnanc, and rcovry. Th maintnanc phas is xprssd as ithr oliguric (urinary output lss than 500 mL/day) or nonoliguric. Nonoliguric ATN is associatd with bttr outcoms than oliguric ATN; convrsion from oliguric to nonoliguric stats with th us of diurtics dos not altr prognosis. Whil dopamin has somtims bn usd for this purpos, numrous studis hav shown that its us in this stting is not bnficial. Avrag duration of th maintnanc phas is 1–3 wks, but som cass may last svral months. Cllular rpair and rmoval of tubular dbris occur during this priod. Th rcovry phas can b hraldd by diursis, du to inability of rcovring rnal tubuls to rabsorb salt and watr appro- priatly, and a solut diursis from lvatd BUN lvls. As GFR bgins to ris, BUN and srum cratinin fall. Th mortality rat associatd with AKI is 20–50% in hospitalizd sttings, and up to 70% for thos in th ICUrquiring dialysis with additional comorbid illnsss. Incrasd mortality is associatd with advancd ag, svr undrlying disas, and multisystm organ failur. Lading causs of dath ar infctions, fluid and lctrolyt distur- bancs, and worsning of undrlying disas. »When to Refer• Whn uncrtainty xists as to th caus of or tratmnt for AKI. •For fluid, lctrolyt, and acid-bas abnormalitis that ar rcalcitrant to intrvntions. •Nphrology rfrral improvs outcoms in AKI. »When to AdmitA  patint with symptoms or signs of AKI that rquir immdiat intrvntion, such as administration of intrav- nous fluids or dialytic thrapy, or that rquir a tam approach that cannot b coordinatd as an outpatint.Griffin  BR t al. Critical car nphrology: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:435. [PMID: 31982214] Prapornratana S t al. Acut kidny injury from spsis: currnt concpts, pidmiology, pathophysiology, prvntion and tratmnt. Kidny Int. 2019;96:1083. [PMID: 31443997] STARRT-AKI Invstigators; Canadian Critical Car Trials Group; Australian and Nw Zaland Intnsiv Car Socity Clinical Trials Group; Unitd Kingdom Critical Car Rsarch Group; Canadian Nphrology Trials Ntwork; Irish Critical Car Trials Group, Bagshaw SM t al. Timing of initiation of rnal-rplacmnt thrapy in acut kidny injury. N Engl J Md. 2020;383:240. [PMID: 32668114]RH ABDOMYOLYSISE S S E N T I A L S  O F  D I A G N O S I S »Associated with crush injuries to muscle, immobil- ity, drug toxicities, and hypothermia. »Characterized by serum elevations in muscle enzymes, including creatine kinase, and marked electrolyte abnormalities. »Release of myoglobin leads to direct renal toxicity. »General ConsiderationsRhabdomyolysis  is a syndrom of acut skltal muscl ncrosis, lading to myoglobinuria and markdly lvatd cratin kinas lvls. Acut tubular ncrosis is a com- mon complication of rhabdomyolysis and is du to th filtration of xcssiv quantitis of myoglobin, which can b xacrbatd by volum dpltion. Distal tubular obstruction from pigmntd casts and intrarnal vaso- constriction can also occur. Rhabdomyolysis can rsult from crush injuris, prolongd immobility, sizurs, sub- stanc abus (g, cocain), and mdications (spcially statins). Th prsnc of kidny or livr dysfunction, dia- bts mllitus, and hypothyroidism incras th risk ofCMDT22_Ch22_p0912-p0951.indd  919 02/07/21 2:33 PMChApTEr 22920 CMDT 2022rh abdomyolysis in patints taking statins. Concurrnt us of drugs that inhibit cytochrom P450 (including protas inhibitors, rythromycin or clarithromycin, itraconazol, diltiazm, and vrapamil) with statins (xcpt pravastatin or rosuvastatin) as wll as concurrnt us of niacin and fibrat- containing thrapy can incras th risk of dvlopmnt of rhabdomyolysis. »Clinical FindingsA.  Symptoms and SignsPa tints with rhabdomyolysis may hav myalgias or wak- nss or both, though it is not uncommon for thm to b asymptomatic. Urin may appar dark.B.  Laboratory FindingsRhabdomy olysis of clinical importanc commonly occurs with a srum cratin kinas gratr than 20,000–50,000 intrnational units/L; on study showd that 58% of patints with AKI from rhabdomyolysis had cratin kinas lvls gratr than 16,000 intrnational units/L, whil only 11% of patints without kidny injury had cr- atin kinas valus gratr than 16,000 intrnational units/L. Oftn, thr ar lvatd srum lvls of aspartat aminotransfras (AST), alanin aminotransfras (ALT), and lactat dhydrognas (LD) (du to rlas of ths nzyms from skltal muscl). Th massiv acut lva- tions of muscl nzyms pak quickly and usually rsolv within days onc th inciting injury has bn rmovd. Th classic laboratory finding in rhabdomyolysis is a urin dipstick tst that is positiv for “blood” but without rd blood clls on microscopy. This fals-positiv rsult is du to dtction of myoglobin. Additionally, clinically maningful rhabdomyolysis causs injurd muscl clls to rlas intracllular componnts, lading to lctrolyt drangmnts (including hyprkalmia, hyprphosphat- mia, hypruricmia, and hypocalcmia). »TreatmentTh  mainstay of tratmnt is aggrssiv volum rpltion with 0.9% normal salin (i, mor than 4 L/day) and rmoval of offnding mdications if thought to hav causd th disordr. Adjunctiv tratmnts with mannitol and alkalization of th urin hav not bn provn to chang outcoms in human trials. As patints rcovr, calcium can mov back from tissus to plasma, so arly xognous cal- cium administration for hypocalcmia is not rcommndd unlss th patint is symptomatic or th lvl bcoms xcdingly low in an unconscious patint; calcium rpl- tion can caus prcipitation of calcium phosphat givn th frquntly concurrnt hyprphosphatmia. Myopathic complications of statins usually rsolv within svral wks of discontinuing th drug. »When to ReferClinically  maningful rhabdomyolysis rquirs immdiat attntion and inpatint managmnt, so affctd patints should not b rfrrd to outpatint nphrology clinics unlss to follow up aftr a hospital admission.»When to AdmitPa tints whos srum cratin kinas lvls ar gratr than 15,000–20,000 intrnational units/L or patints with AKI or lctrolyt drangmnts should b admittd for fluid rpltion and srial monitoring of cratin kinas and lctrolyts.Long  B t al. An vidnc-basd narrativ rviw of th mr- gncy dpartmnt valuation and managmnt of rhabdomy- olysis. Am J Emrg Md. 2019;37:518. [PMID: 30630682]IN TERSTITIAL NEPHRITISE S S E N T I A L S  O F  D I A G N O S I S »Fever. »Transient maculopapular rash. »Acute or chronic in nature. »Pyuria, white blood cell casts, and hematuria. »General ConsiderationsAcut  intrstitial nphritis accounts for 10–15% of cass of intrinsic rnal failur. An intrstitial inflammatory rspons with dma and possibl tubular cll damag is th typical pathologic finding. Although drugs account for ovr 70% of cass, acut intrstitial nphritis also occurs in infctious disass, autoimmun disordrs, or as idiopathic conditions. Th most common drugs implicatd ar pnicillins and cphalosporins, immun chckpoint inhibitors, sulfon- amids and sulfonamid-containing diurtics, NSAIDs, proton pump inhibitors, rifampin, and allopurinol. Infc- tious causs includ strptococcal infctions, lptospirosis, cytomgalovirus, histoplasmosis, and Rocky Mountain spottd fvr. SLE, Sjögrn syndrom, sarcoidosis, and cryoglobulinmia can also caus intrstitial nphritis, though thy ar mor classically associatd with glomrulonphritis. »Clinical FindingsClinical  faturs includ fvr (mor than 80% of cass), rash (25–50%), arthralgias, and priphral blood osino- philia (80%). Th classic triad of fvr, rash, and arthralgias is prsnt in only 10–15% of cass. Th urin oftn contains whit clls (95%), rd clls, and whit cll casts. Protinuria is oftn prsnt, particularly in NSAID-inducd intrstitial nphritis, but is usually modst (lss than 2 g/24 h). Eosin- ophiluria is nithr vry snsitiv nor spcific for intrstitial nphritis; valuation for osinophiluria is not advisd. Although th clinical history and laboratory data oftn giv clus to th diagnosis, kidny biopsy is somtims ndd. »Treatment & PrognosisAcut  intrstitial nphritis oftn carris a good prognosis, with rcovry occurring ovr wks to months. UrgntCMDT22_Ch22_p0912-p0951.indd  920 02/07/21 2:33 PMKIDNEY DISEASE921 CMDT 2022dialytic  thrapy may b ncssary in up to on-third of all rfrrd patints bfor rsolution, but patints rarly prog- rss to ESKD. Thos with prolongd oliguria and advancd ag hav a wors prognosis. Tratmnt consists of support- iv masurs and rmoval of th inciting agnt. If kidny injury prsists, a short cours of corticostroids can b considrd, although th data to support thir us ar not substantial, and thir fficacy may dpnd on th lapsd tim btwn onst of AKI and thir initiation. Short-trm, high-dos mthylprdnisolon (0.5–1 g/day intravnously for 1–4 days) or prdnison (60 mg/day orally for 1–2 wks) followd by a prdnison tapr can b usd in mor svr cass of drug-inducd intrstitial nphritis.Mo ldina DG t al. Tratmnt of drug-inducd acut tubuloint- rstitial nphritis: th sarch for bttr vidnc. Clin J Am Soc Nphrol. 2018;13:1785. [PMID: 30397028] Shingarv R t al. Kidny complications of immun chckpoint inhibitors: a rviw. Am J Kidny Dis. 2019;74:529. [PMID: 31303350]GLOM ERULONEPHRITISE S S E N T I A L S  O F  D I A G N O S I S »Hematuria, subnephrotic proteinuria. »Red cell casts pathognomonic but not required for diagnosis. »Dependent edema and hypertension. »AKI. »General ConsiderationsAcu t glomrulonphritis is a rlativly uncommon caus of AKI, accounting for about 5% of cass. Pathologically, inflammatory glomrular lsions ar sn. Ths includ msangioprolifrativ, focal and diffus ndocapillary prolif- rativ, and crscntic lsions. Th largr th prcntag of glomruli involvd and th mor svr th lsion, th mor likly it is that th patint will hav a poor clinical outcom. Glomrulonphritids ar classifid into fiv pathophysi- ologic procsss, which can b charactrizd by srologic analysis. Markrs includ anti-GBM antibodis, antinu- trophil cytoplasmic antibodis (ANCAs), and othr immun markrs of disas. Immune complex deposition occurs whn thr is modrat ovrproduction of antign compard to antibody production. Complxs formd with markd antign xcss tnd to rmain in th circulation. Antibody xcss with larg antign–antibody aggrgats usually rsults in phago- cytosis and claranc of th prcipitats by th mononuclar phagocytic systm in th livr and spln. Causs includ IgA nphropathy, infction-rlatd glomrulonphritis, lupus nphritis, and cryoglobulinmic glomrulonphritis (oftn associatd with hpatitis C virus [HCV]). Anti-GBM–associated acute glomerulonephritis is ithr confind to th kidny or associatd with pulmonary hmorrhag. Th lattr is trmd “Goodpastur syndrom. ”Injury is rlatd to autoantibodis against typ IV collagn in th GBM. Pauci-immune acute glomerulonephritis is a form of small-vssl vasculitis associatd with ANCAs, causing kid- ny disass without dirct immun complx dposition or antibody binding. Tissu injury is blivd to b du to cll- mdiatd immun procsss. An xampl is granulomatosis with polyangiitis, a systmic ncrotizing vasculitis of small artris and vins associatd with intravascular and xtra- vascular granuloma formation. In addition to glomrulon- phritis, ths patints can hav uppr airway, pulmonary, and skin manifstations. Cytoplasmic ANCA (c-ANCA) is th common staining pattrn. Microscopic polyangiitis is anothr pauci-immun vasculitis causing acut glomrulo- nphritis, which is mor commonly associatd with pri- nuclar staining (p-ANCA). ANCA-associatd and anti-GBM–associatd acut glomrulonphritids can volv to crscntic glomrulonphritis and oftn hav poor outcoms unlss tratmnt is startd arly. Monoclonal immunoglobulin–mediated glomerulo- nephritis is charactrizd by th dposition of a monoclo- nal immunoglobulin in glomruli or tubular basmnt mmbran or both. It is dtctd on immunofluorscnt or immunohistochmical staining of kidny biopsis as mono- typic immunoglobulin dposits. Srum protin lctropho- rsis and srum fr light chains ar usful diagnostic tsts to prform whn monoclonal immunoglobulin–mdiatd glomrulonphritis is suspctd or confirmd. Whil many cass will occur in th stting of a monoclonal gammopa- thy, this is not always th cas. C3 glomerulopathy rsults from prdominant C3 dposition in th glomruli with or without minimal dposition of immunoglobulins. It is also idntifid by immunofluorscnc or immunohistochmistry. Th pathognsis of C3 glomrulonphropathy stms from abnormalitis in rgulation of th altrnativ pathway of complmnt. Whil chcking srum C3 lvls may b hlp- ful, normal lvls do not rul out C3 glomrulopathy. Other vascular causes of glomrulonphritis includ hyprtnsiv mrgncis and th thrombotic microangi- opathis such as hmolytic-urmic syndrom and throm- botic thrombocytopnic purpura (s Chaptr 14). »Clinical FindingsA.  Symptoms and SignsPa tints with acut glomrulonphritis ar oftn hyprtn- siv and dmatous with an abnormal urinary sdimnt. Th dma is found first in body parts with low tissu tn- sion, such as th priorbital and scrotal rgions.B.  Laboratory FindingsSrum  cratinin can ris ovr days to months, dpnding on th rapidity of th undrlying procss. Th BUN:cratinin ratio is not a rliabl markr of kidny function and is mor rflctiv of th patint’s undrlying volum status. Dipstick and microscopic valuation rval vidnc of hmaturia and typically subnphrotic protin- uria; thr may b cllular lmnts such as dysmorphic rd clls, rd cll casts, and whit clls. Rd cll casts arCMDT22_Ch22_p0912-p0951.indd  921 02/07/21 2:33 PMChApTEr 22922 CMDT 2022spcific  for glomrulonphritis, and a dtaild sarch on urin microscopy is warrantd. Additional tsts includ srum complmnt lvls (C3, C4) that may b low in immun complx glomrulonphri- tis (xcpt for IgA nphropathy) or C3 glomrulopathy and normal in pauci-immun, anti-GBM–rlatd, and mono- clonal immunoglobulin–mdiatd glomrulonphritids. Othr tsts includ ASO titrs, anti-GBM antibody lvls, ANCAs, antinuclar antibody titrs, cryoglobulins, hpati- tis srologis, srum protin lctrophorsis and srum fr light chains, blood culturs, and rnal ultrasound. With fw xcptions, a kidny biopsy is ultimatly ncssary to con- firm th diagnosis, irrspctiv of laboratory data. »TreatmentDpnding  on th natur and svrity of disas, tratmnt might includ high-dos corticostroids, rituximab, and cytotoxic agnts (such as cyclophosphamid). Plasma xchang can b usd in Goodpastur syndrom as a tm- porizing masur until chmothrapy can tak ffct. Tratmnt and prognosis for spcific disass ar discussd mor fully blow.Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Sthi S t al. Standardizd classification and rporting of glomrulonphritis. Nphrol Dial Transplant. 2019;34:193. [PMID: 30124958]COVI D-19 & THE KIDNEYE S S E N T I A L S  O F  D I A G N O S I S »Broad array of clinical presentation and kidney pathology. »Clinical Findings & TreatmentNar ly half of patints hospitalizd with COVID-19 prs- nt with or dvlop AKI, which is associatd with poorr prognosis. Many causs of AKI ar dscribd in patints with COVID-19, but th most common is ATN rlatd to a high inflammatory stat (trmd “cytokin storm”). Urinalysis may rval hmaturia, rflcting ndothlial injury and fibrin thrombi that ar commonly obsrvd on biopsy. Anothr mrging ntity is COVID-19–associatd collapsing glomrulopathy, which is a typ of focal sgmntal glomrulosclrosis (s sction on “Nphrotic Spctrum Glomrular Disass” blow). Patints with collapsing glo- mrulopathy prsnt with nphrotic syndrom and ar typi- cally of African ancstry, highlighting a suspctd gntic prdisposition. Tratmnt of COVID-19–rlatd AKI is largly supportiv; th rol of corticostroids in COVID-19– associatd collapsing glomrulopathy is undr invstigation.Cha n L t al; Mount Sinai COVID Informatics Cntr (MSCIC). AKI in hospitalizd patints with COVID-19. J Am Soc Nphrol. 2021;32:151. [PMID: 32883700]Nasr SH t al. COVID-19-associatd collapsing glomrulopathy: an mrging ntity. Kidny Int Rp. 2020;5:759. [PMID: 32368701] Ronco C t al. Managmnt of acut kidny injury in patints with COVID-19. Lanct Rspir Md. 2020;8:738. [PMID: 32416769] Shtty AA t al. COVID-19-associatd glomrular disas. J Am Soc Nphrol. 2021;32:33. [PMID: 33214201]C ARDIORENAL SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S »Cadiac dysfunction: acute or chronic heart failure, ischemic injury, or arrhythmias. »Kidney disease: acute or chronic, depending on the type of cardiorenal syndrome. »General ConsiderationsCardior nal syndrom is a pathophysiologic disordr of th hart and kidnys whrin th acut or chronic dtrio- ration of on organ rsults in th acut or chronic dtrio- ration of th othr. This syndrom is classifid into fiv typs as a mattr of convntion. Achiving uvolmia is th ovrarching thraputic goal rgardlss of typ (s Hart Failur sction in Chaptr 10). Typ 1 consists of AKI stmming from acut cardiac disas. Typ 2 is CKD du to chronic cardiac disas. Typ 3 is acut cardiac disas as a rsult of AKI. Typ 4 is chronic cardiac dcompnsation from CKD. Typ 5 con- sists of hart and kidny dysfunction du to othr acut or chronic systmic disordrs (such as spsis). Although novl agnts ar bing xamind for futur thrapis, th main- stay of tratmnt is to addrss th primary undrlying hart or kidny dysfunction.K umar U t al. Cardiornal syndrom: pathophysiology. Cardiol Clin. 2019;37:251. [PMID: 31279419] Raina R t al. An updat on th pathophysiology and tratmnt of cardiornal syndrom. Cardiol Rs. 2020;11:76. [PMID: 32256914] ºChrONIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Decline in the GFR over months to years. »Persistent proteinuria or abnormal renal morphol- ogy may be present. »Hypertension in most cases. »Symptoms and signs of uremia when nearing end- stage disease. »Bilateral small or echogenic kidneys on ultrasound in advanced disease.CMDT22_Ch22_p0912-p0951.indd  922 02/07/21 2:33 PMKIDNEY DISEASE923 CMDT 2022 »General ConsiderationsCKD affcts at last 10% of Amricans. Ma ny ar unawar of th condition bcaus thy rmain asymptomatic until th disas is nar nd stag. Th National Kidny Founda- tion’s staging systm hlps clinicians formulat practic plans (Tabl 22–4). Ovr 70% of cass of lat-stag CKD (stag 5 CKD and ESKD) in th Unitd Stats ar du to diabts mllitus or hyprtnsion/vascular disas. Glo- mrulonphritis, cystic disass, chronic tubulointrstitial disass, and othr urologic disass account for th rmaindr (Tabl 22–5). Gntic polymorphisms of th APOL-1 gn hav bn shown to b associatd with an incrasd risk of th dvlopmnt of CKD in prsons of African ancstry. CKD usually lads to a progrssiv dclin in kidny function vn if th inciting caus can b idntifid and tratd or rmovd. Dstruction of nphrons lads to compnsatory hyprtrophy and supranormal GFR of th rmaining nphrons in ordr to maintain ovrall homo- stasis. As a rsult, th srum cratinin may rmain rla- tivly normal vn in th fac of significant loss of rnal mass and is, thrfor, an insnsitiv markr for arly rnal damag and scarring. In addition, compnsatory hyprfiltration lads to ovrwork injury in th rmaining nphrons, which in turn causs progrssiv glomrular sclrosis and intrstitial fibrosis. Angiotnsin rcptor blockrs (ARBs) and ACE inhibitors can hlp rduc hyprfiltration injury and may slow th progrssion of protinuric CKD. Whil CKD is an indpndnt risk factor for cardiovas- cular disas (CVD), protinuric CKD confrs th highst risk. Most patints with stag 3 CKD di of undrlying CVD prior to progrssion to ESKD.»Clinical FindingsA.  Symptoms and SignsStags  1–4 CKD ar asymptomatic. Symptoms dvlop slowly with th progrssiv dclin in GFR, ar nonsp- cific, and do not manifst until kidny disas is far advancd (GFR lss than 5–10 mL/min/1.73 m2). At this point, th accumulation of mtabolic wast products, or urmic toxins, rsults in th uremic syndrome . Gnral symptoms of urmia may includ fatigu, anorxia, nausa, and a mtallic tast in th mouth. Nurologic symptoms such as mmory impairmnt, insomnia, rstlss lgs, and twitching may b du to urmia. Gnralizd pruritus (without rash) may occur, as may dcrasd libido and mnstrual irrgularitis. Pricarditis, a rar complication of CKD, may prsnt with pluritic chst pain. Mdications that ar clard by th kidnys will accumulat as kidny function worsns and toxicity may nsu; an important xampl is insulin and an incrasing risk of significant hypoglycmia if doss ar not appropriatly rducd. Th most common physical finding in CKD is hypr- tnsion; this is du in part to impaird sodium xcrtion. It is oftn prsnt in arly stags of CKD and tnds to worsn with CKD progrssion. In latr stags of CKD, sodium rtntion may lad to clinically apparnt volum ovrload. Urmic signs ar sn with a profound dcras in GFR (lss than 5–10 mL/min/1.73 m2) and may includ a gnr- ally sallow and ill apparanc, halitosis (urmic ftor), and th urmic ncphalopathic signs of dcrasd mntal sta- tus, astrixis, myoclonus, and possibly sizurs. Symptoms and signs of urmia warrant immdiat hos- pital admission and nphrology consultation for initiation of dialysis. Th urmic syndrom is amlioratd with dialytic thrapy.Table 22–4. Stages of chronic kidney disease: a clinical action plan.1,2Stage 3Descition GFr (mL/min/1.73 m2) Action 1 Kidney damage with normal or ↑↑GFR ≥ 90 Diagnosis and treatment of underlying etiology if possible. Treatment of comorbid conditions. Estimate progression, work to slow progression. Cardiovascular disease risk reduction.2 Kidney damage with mildly ↓GFR 60–89 3a Mildly-moderately ↓GFR 45–59 As above, and evaluating and treating complications. 3b Moderately-severely ↓GFR 30–44 4 Severely ↓GFR 15–29 Preparation for end-stage kidney disease. 5 End-stage kidney disease < 15 (or dialysis) Dialysis, transplant, or palliative care.1 Based on National Kidney Foundation, KDOQI, and KDIGO Chronic Kidney Disease Guidelines.2 Chronic kidney disease is defined as either kidney damage or GFR < 60 mL/min/1.73 m2for 3 or more months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.3 At all stages, persistent albuminuria confers added risk for chronic kidney disease progression and cardiovascular disease in t he following gradations: < 30 mg/day = lowest added risk, 30–300 mg/day = mildly increased risk, > 300–1000 mg/day = moderately increased ri sk, > 1000 mg/day = severely increased risk. GFR, glomerular filtration rate. Modified and reproduced, with permission, from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013 Jan;3(1) (Suppl):1–15 0. Copyright © 2013 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.CMDT22_Ch22_p0912-p0951.indd  923 02/07/21 2:33 PMChApTEr 22924 CMDT 2022T able 22–5. Causes of chronic kidney disease.Glomeula  Diseases pimay glomeula diseases Focal segmental glomerulosclerosis Membranoproliferative glomerulonephritis IgA nephropathy Membranous nephropathy Alport syndrome (hereditary nephritis) Seconday glomeula diseases Diabetic nephropathy Renal amyloidosis Postinfectious glomerulonephritis HIV-associated nephropathy Collagen-vascular diseases (eg, SLE) HCV-associated membranoproliferative glomerulonephritis Tubulointestitial Neitis Drug hypersensitivity Heavy metals Analgesic nephropathy Reflux/chronic pyelonephritis Sickle cell nephropathy Idiopathic Cystic Diseases Polycystic kidney disease Medullary cystic disease Obstuctive Neoaties Prostatic disease Nephrolithiasis Retroperitoneal fibrosis/tumor Congenital/reflux Vascula Diseases Hypertensive nephrosclerosis Renal artery stenosis HCV, hepatitis C virus; SLE, systemic lupus erythematosus.Table 22–6. Reversible causes of kidney injury.revesible  Factos Diagnostic Clues Obstruction Post-void residual, bladder cath- eterization, renal ultrasound Extracellular fluid volume depletion or significant hypotension relative to baselineBlood pressure and pulse, including orthostatic pulse Hypercalcemia Serum electrolytes, calcium, phosphate Nephrotoxic agents Drug history Severe/urgent hypertension Blood pressure, chest radiograph Heart failure exacerbation Physical examination, chest radiograph• • •1 2 31 .0 0.9 0.7 0.5 0.3 0.1 1 2 3 4 5 6 7 8 9 1 01/ScrTime  (years)1 Value of serum creatinine level = 1 .0 mg/dL2 Value of serum creatinine level = 2.0 mg/dL3 Value of serum creatinine level = 5.0 mg/dL ▲Figure 22–1. Decline in kidney function (expressed as the reciprocal of serum creatinine as shown here, or as estimated glomerular filtration rate [eGFR]) plotted against time to ESKD. The solid line indicates the linear decline in kidney function over time. The dotted line indicates the approximate time to ESKD.In any patint with kidny disas, it is important to idntify and corrct all possibly rvrsibl insults or xac- rbating factors (Tabl 22–6). Urinary obstruction, hypo- volmia, hypotnsion, nphrotoxins (such as NSAIDs, aminoglycosids, or proton pump inhibitors), svr or mrgnt hyprtnsion, and hart failur xacrbation should b xcludd.B.  Laboratory FindingsCKD is u sually dfind by an abnormal GFR prsisting for at last 3 months. Prsistnt protinuria or abnormalitis on rnal imaging (g, polycystic kidnys or a singl kidny) ar also diagnostic of CKD, vn whn GFR is normal. If multipl masurmnts of GFR ovr tim ar availabl, th rat of progrssion should b assssd (Figur 22–1). If th slop of th lin acutly dclins, potntially rvrsibl rnal insults should b xcludd. Anmia, hyprphospha- tmia, hypocalcmia, hyprkalmia, and mtabolic acido- sis ar common complications of advancd CKD. Th urinary sdimnt may show broad waxy casts as a rsult ofdilatd, hyprtrophic nphrons. If protinuria is prsnt, it should b quantifid as dscribd abov. This can hlp nar- row th diffrntial diagnosis of th tiology of th CKD (Tabl 22–5); for xampl, glomrular disass tnd to prsnt with protin xcrtion of mor than 1 g/day. Addi- tionally, highr urinary protin xcrtion is associatd with mor rapid progrssion of CKD and incrasd risk of car- diovascular mortality.CMDT22_Ch22_p0912-p0951.indd  924 02/07/21 2:33 PMKIDNEY DISEASE925 CMDT 2022C.  ImagingTh  finding of small, chognic kidnys bilatrally (lss than 9–10 cm) by ultrasonography suggsts th chronic scarring of advancd CKD. Larg kidnys can b sn with adult polycystic kidny disas, diabtic nphropathy, HIV-associatd nphropathy, plasma cll myloma, amy- loidosis, and obstructiv uropathy. »ComplicationsTh  complications of CKD tnd to occur at rlativly pr- dictabl stags of disas as notd in Figur 22–2.A.  Cardiovascular ComplicationsPa tints with CKD xprinc gratr morbidity and mor- tality from CVD in comparison to th gnral population. Roughly 80% of patints with CKD di bfor raching ESKD, primarily of CVD. Of thos undrgoing dialysis, 45% will di of a cardiovascular caus. Th mchanisms for nhancd cardiovascular mortality in CKD ar complx and includ abnormal phosphorus and calcium homosta- sis, incrasd burdn of oxidativ strss, incrasd vascular ractivity, lft vntricular hyprtrophy, and coxistnt con- ditions such as hyprtnsion and diabts mllitus. 1. Hypertension— Hyprtnsion is th most common complication of CKD; it tnds to b progrssiv and salt- snsitiv. Hyprrninmic stats and xognous rythro- poitin administration can xacrbat hyprtnsion. As with othr patint populations, control of hyprtn- sion should focus on both pharmacologic and nonpharma- cologic thrapy (g, dit, xrcis, wight loss, tratmnt of obstructiv slp apna). CKD rsults in disturbd sodium homostasis such that th ability of th kidny to adjust to variations in sodium and watr intak bcoms limitd as GFR dclins. A low salt dit (2 g/day) is oftn ssntial to control blood prssur and hlp avoid ovrt volum ovr- load. Diurtics ar narly always ndd to hlp control hyprtnsion (s Tabl 11–8); thiazids work wll in arly CKD, but loop diurtics may b mor ffctiv in thoswith a GFR lss than 30 mL/min/1.73 m2. Howvr, vol- um contraction as a rsult of vry low sodium intak (spcially with intrcurrnt illnss) or ovr-diursis in th prsnc of impaird sodium homostasis can rsult in AKI. Initial drug thrapy for protinuric patints should includ ACE inhibitors or ARBs (s Tabl 11–6); howvr, thr is no vidnc of supriority of ths drugs ovr othr drug classs for nonprotinuric CKD. Whn an ACE inhibitor or an ARB is initiatd or uptitratd, patints must hav srum cratinin and potassium chckd within 7–14 days. A ris in srum cratinin gratr than 30% from baslin mandats dos rduction or cssation of th drug. Hyprkalmia may also warrant drug cssation, xcpt in th rliabl patint who can follow a low-potas- sium dit and adhr to a potassium-binding rsin; such patints should b monitord closly. An ACE inhibitor and ARB should not b usd in combination. CKD is a common caus of rfractory hyprtnsion for which agnts from multipl classs ar oftn ndd. Currnt guidlins diffr with rspct to blood prssur goals in CKD; thos from th Joint National Commission suggst a goal of lss than 140/90 mm Hg, whil th Amrican Hart Associa- tion advocats for lss than 130/80 mm Hg. As patints with CKD ar at risk for rnal hypoprfusion and AKI with ovrtratmnt of hyprtnsion, it is prudnt to individual- iz th approach to blood prssur control to ach patint. 2. Coronary artery disease— Patints with CKD ar at highr risk for dath from CVD than th gnral popula- tion. Traditional modifiabl risk factors for CVD, such as hyprtnsion, tobacco us, and hyprlipidmia, should b aggrssivly tratd. Urmic vascular calcification involv- ing disordrd phosphorus homostasis and othr mdia- tors may also b a cardiovascular risk factor in ths patints. 3. Heart failure— CKD complications rsult in incrasd cardiac workload du to hyprtnsion, volum ovrload, and anmia. Patints may also hav acclratd rats of athrosclrosis and vascular calcification rsulting in vssl stiffnss. All of ths factors contribut to lft vntricular↑PTHGlomerular filtration  rate (mL/min/1.73 m2)↑PhosphorusHTN Anemia Acidosis, hyperkalemia Uremic syndromeCKD stage5 4 3 20 20 40 60 80 100 ▲Figure 22–2. Complications of chronic kidney disease (CKD) by stage and glomerular filtration rate (GFR). Compli- cations arising from CKD tend to occur at the stages depicted, although there is considerable variability noted in clin- ical practice. HTN, hypertension; PTH, parathyroid hormone. (Adapted, with permission, from William Bennett, MD.)CMDT22_Ch22_p0912-p0951.indd  925 02/07/21 2:33 PMChApTEr 22926 CMDT 2022hyprtrop hy and hart failur with prsrvd jction frac- tion, which is common in CKD. Ovr tim, hart failur with dcrasd jction fraction may dvlop. Diurtic thrapy, in addition to fluid and salt rstriction, is usually ncssary; diurtic dos scalation may b ndd as kid- ny function dclins. ACE inhibitors and ARBs can b usd for patints with advancd CKD with clos monitor- ing of blood prssur as wll as for hyprkalmia and wors- ning kidny function; minralocorticoid rcptor antagonists may b usd with similar prcautions but should b discontinud whn GFR is lss than 30 mL/ min/1.73 m2. SGLT2 inhibitors hav bn shown to improv outcoms for both hart failur and CKD. 4. Atrial fibrillation— Patints with advancd CKD and ESKD suffr disproportionat rats of atrial fibrillation, which approach 20% in patints rciving dialysis. Whil thos with up to CKD stag 4 should b tratd as th gn- ral population, anticoagulation for prvntion of throm- bombolic vnts bcoms challnging in thos with ESKD du to compting risks of blding and clotting as wll as a lack of data supporting its routin us. 5. Pericarditis— Pricarditis rarly dvlops in urmic patints; typical findings includ pluritic chst pain and a friction rub. Cardiac tamponad can occur; thrfor, ur- mic pricarditis is a mandatory indication for hospitaliza- tion and initiation of hmodialysis.Bangalor  S t al. Managmnt of coronary disas in patints with advancd kidny disas. N Engl J Md. 2020;382:1608. [PMID: 32227756] Fay KS t al. Rsistant hyprtnsion in popl with CKD: a rviw. Am J Kidny Dis. 2021;77:110. [PMID: 32712185] Gurrot D t al. Blood prssur targts in chronic kidny disas: an updat on th vidnc. Curr Opin Nphrol Hyprtns. 2020;29:327. [PMID: 32167996] Packr M t al; EMPEROR-Rducd Trial Invstigators. Cardio- vascular and rnal outcoms with mpagliflozin in hart failur. N Engl J Md. 2020;383:1413. [PMID: 32865377] Palmr BF. Potassium bindrs for hyprkalmia in chronic kidny disas—dit, rnin-angiotnsin-aldostron systm inhibitor thrapy, and hmodialysis. Mayo Clin Proc. 2020;95: 339. [PMID: 31668450]B.  Metabolic Bone DiseaseTh mtabolic b on disas of CKD rfrs to th complx disturbancs of calcium and phosphorus mtabolism, parathyroid hormon (PTH), activ vitamin D, and fibro- blast growth factor-23 (FGF-23) homostasis (s Chaptr 21 and Figur 22–3). A typical pattrn sn as arly as CKD stag 3 is hyprphosphatmia, hypocalcmia, and hypovitaminosis D, rsulting in scondary hyprparathy- roidism. Ths abnormalitis can contribut to vascular calcification and may b rsponsibl in part for th acclr- atd CVD and xcss mortality sn in th CKD popula- tion. Epidmiologic studis show an association btwn lvatd phosphorus lvls and incrasd risk of cardiovas- cular mortality in arly CKD through ESKD. As yt, thr ar no intrvntion trials suggsting th bst cours of tratmnt in ths patints; control of minral and PTH lvls pr currnt guidlins is discussd blow.Bon disas, or rnal ostodystrophy, in advancd CKD is common and thr ar svral typs of lsions. Rnal ostodystrophy can b diagnosd only by bon biopsy, which is rarly don. Th most common bon dis- as, ostitis fibrosa cystica, is a rsult of scondary hypr- parathyroidism and th ostoclast-stimulating ffcts of PTH. This is a high-turnovr disas with bon rsorption and subpriostal lsions; it can rsult in bon pain and proximal muscl waknss. Adynamic bon disas, or low-bon turnovr, is bcoming mor common; it may rsult iatrognically from supprssion of PTH or via spon- tanously low PTH production. Ostomalacia is charactr- izd by lack of bon minralization. In th past, ostomalacia was associatd with aluminum toxicity—ithr as a rsult of chronic ingstion of prscribd aluminum-containing phosphorus bindrs or from high lvls of aluminum in impur dialysat watr. Currntly, ostomalacia is mor likly to rsult from hypovitaminosis D; thr is also tho- rtical risk of ostomalacia associatd with us of bisphos- phonats in advancd CKD. All of th abov ntitis incras th risk of fracturs. Tratmnt may involv corrction of calcium, phosphorus, and 25-OH vitamin D lvls toward normal valus, and mitigation of hyprparathyroidism. Undrstanding th intrplay btwn ths abnormalitis can hlp targt thrapy (Figur 22–3). Dclining GFR lads to phosphorus rtntion. This rsults in hypocalcmia as phosphorus complxs with calcium, dposits in soft tissus, and stim- ulats PTH. Loss of rnal mass and low 25-OH vitamin D lvls oftn sn in CKD patints rsult in low 1,25(OH) vitamin D production by th kidny. Bcaus 1,25(OH) vitamin D is a supprssor of PTH production, hypovita- minosis D also lads to scondary hyprparathyroidism. Th first stp in tratmnt of mtabolic bon disas is control of hyprphosphatmia. This involvs ditary phos- phorus rstriction initially (s sction on ditary manag- mnt), followd by th administration of oral phosphorus bindrs if targts ar not achivd. Oral phosphorus bind- rs block absorption of ditary phosphorus in th gut and ar givn thric daily with mals. Ths should b titratd to a nar-normal srum phosphorus lvl. Calcium- containing bindrs (calcium carbonat, 650 mg/tablt, or calcium actat, 667 mg/capsul, usd at doss of on to thr↓GFR↓25(OH) Vitamin D ↑PTH↓ Calcium↑Phosphorus ↓1,25(OH) Vitamin D ▲Figure 22–3. Mineral abnormalities of CKD. Decline in glomerular filtration rate (GFR) and loss of renal mass lead directly to increased serum phosphorus and hypo- vitaminosis D. Both of these abnormalities result in hypocalcemia and hyperparathyroidism. Many CKD patients also have nutritional 25(OH) vitamin D defi- ciency. PTH, parathyroid hormone.CMDT22_Ch22_p0912-p0951.indd  926 02/07/21 2:33 PMKIDNEY DISEASE927 CMDT 2022pills  pr mal) ar rlativly inxpnsiv but may contribut to positiv calcium balanc and vascular calcification; ovrt hyprcalcmia may also occur. Currnt guidlins suggst limiting thir us in favor of th non-calcium–containing bindrs svlamr carbonat (800–3200 mg/mal) and lanthanum carbonat (500–1000 mg/mal). Nwr, iron- basd phosphorus bindrs includ frric citrat and sucro- frric oxyhydroxid and may b considrd whn othr bindrs ar not tolratd ithr du to hyprcalcmia or constipation. Thy should b avoidd in patints with iron ovrload. Aluminum hydroxid is a highly ffctiv phos- phorus bindr but can caus ostomalacia and nurologic complications whn usd long-trm; it can b usd in th acut stting for svr hyprphosphatmia or for short priods (g, 3 wks) in CKD patints. Onc srum phosphorus lvls ar controlld, activ vitamin D (1,25[OH] vitamin D, or calcitriol) or othr vita- min D analogs ar usd to trat scondary hyprparathy- roidism in advancd CKD and ESKD. Srum 25-OH vitamin D lvls should b masurd and brought to nor- mal (s Chaptr 26) prior to considring administration of activ vitamin D. Activ vitamin D (calcitriol) incrass srum calcium and phosphorus lvls; both nd to b monitord closly during calcitriol thrapy, and its dos should b dcrasd if hyprcalcmia or hyprphosphat- mia occurs. Typical calcitriol dosing is 0.25 or 0.5 mcg orally daily or vry othr day. Cinacalct targts th cal- cium-snsing rcptors of th parathyroid gland and sup- prsss PTH production. Cinacalct, 30–90 mg orally onc a day, can b usd if lvatd srum phosphorus or calcium lvls prohibit th us of vitamin D analogs; it can caus srious hypocalcmia, and patints should b closly moni- tord for this complication. Optimal PTH lvls in CKD ar not known, but bcaus skltal rsistanc to PTH dvlops with urmia, rlativly high lvls ar targtd in advancd CKD to avoid adynamic bon disas. Exprt guidlins suggst goal PTH lvls nar or just abov th uppr limit of normal for modrat CKD, and at last twofold and up to ninfold th uppr limit of normal for ESKD.Ev npol P t al. Europan Consnsus Statmnt on th diag- nosis and managmnt of ostoporosis in chronic kidny disas stags G4-G5D. Nphrol Dial Transplant. 2021;36:42. [PMID: 33098421] Scialla JJ t al. Stat-of-th-art managmnt of hyprphosphat- mia in patints with CKD: an NKF-KDOQI controvrsis prspctiv. Am J Kidny Dis. 2021;77:132. [PMID: 32771650]C.  Hematologic Complications1.  Anemia— Th anmia of CKD, primarily du to dcrasd rythropoitin production, oftn bcoms clini- cally significant during stag 3 CKD. CKD is also associ- atd with high lvls of hpcidin, which blocks GI iron absorption and mobilization of iron from body stors; this rsults in a functional iron dficincy—th so-calld “an- mia of chronic disas. ” Th approach to a patint with CKD and anmia bgins with nsuring that th bon mar- row can rspond to rythropoitin. Thus, thyroid function tsts, srum vitamin B12lvls, and iron stors (frritin and iron saturation) should b chckd. Iron stors ar targtdto highr goals du to a functional blockad of iron utiliza- tion in this population. In CKD, a srum frritin blow 100–200 ng/mL or iron saturation lss than 20% is suggs- tiv of iron dficincy. Iron stors may b rpltd with oral or parntral iron; iron thrapy should probably b withhld if th srum frritin is gratr than 500–800 ng/mL, vn if th iron saturation is lss than 20%. Oral thrapy with fr- rous sulfat, gluconat, or fumarat, 325 mg onc daily, is th initial thrapy in pr-ESKD CKD; highr doss will rsult in incrasing hpcidin lvls. For thos who do not rspond du to poor GI absorption or lack of tolranc, intravnous iron (g, iron sucros or iron gluconat) may b ncssary. Erythropoisis-stimulating agnts (ESAs, g, rcombi- nant rythropoitin [potin alfa or bta] and darbpo- tin) ar usd to trat th anmia of CKD if othr tratabl causs ar xcludd. Thr is likly no bnfit of starting an ESA bfor hmoglobin (Hgb) valus ar lss than 9 g/dL. Th starting dos of potin alfa is 50–100 units/kg onc or twic a wk, and darbpotin is startd at 0.45 mcg/kg and administrd vry 2–4 wks; potin bta at a starting dos of 60–100 mcg is givn vry 2–4 wks. Ths agnts can b givn intravnously (g, to th hmodialysis patint) or subcutanously (to both th prdialysis or dialysis patint); subcutanous dosing of potin alfa is roughly 30% mor ffctiv than intravnous dosing. ESAs should b titratd to an Hgb of 10–11 g/dL for optimal safty; studis show that targting a highr Hgb incrass th risk of strok and possibly othr cardiovascular vnts. Whn titrating doss, Hgb lvls should ris no mor than 1 g/dL vry 3–4 wks. Hyprtnsion is a common complication of tratmnt with ESAs. 2. Coagulopathy— Th blding diathsis that may occur in stag 4–5 CKD is mainly du to platlt dysfunction, but svr anmia may also contribut. Tratmnt is rquird only in patints who ar symptom- atic. Raising th Hgb to 9–10 g/dL in anmic patints can rduc risk of blding via improvd clot formation. Dsmo- prssin (25 mcg intravnously vry 8–12 hours for two doss) is a short-livd but ffctiv tratmnt for platlt dysfunction and it is oftn usd in prparation for surgry or kidny biopsy; hyponatrmia is a potntial advrs ffct of this tratmnt. Dialysis improvs th blding tim.Locatlli  F t al. Ar all rythropoisis-stimulating agnts cratd qual? Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 32206785]D . HyperkalemiaPo tassium balanc gnrally rmains intact in CKD until stags 4–5. Howvr, hyprkalmia may occur at arlir stags whn crtain conditions ar prsnt, such as typ 4 rnal tubular acidosis (sn in patints with diabts ml- litus), high potassium dits, or mdications that dcras rnal potassium scrtion (amilorid, triamtrn, spi- ronolacton, plrnon, NSAIDs, ACE inhibitors, ARBs) or block cllular potassium uptak (bta-blockrs). Othr causs includ acidmic stats and any typ of cllular dstruction causing rlas of intracllular contnts, such as hmolysis and rhabdomyolysis.CMDT22_Ch22_p0912-p0951.indd  927 02/07/21 2:33 PMChApTEr 22928 CMDT 2022T ratmnt of acut hyprkalmia is discussd in Chaptr 21 (s Tabl 21–5). Cardiac monitoring is indi- catd for any ECG changs sn with hyprkalmia or a srum potassium lvl gratr than 6.0–6.5 mEq/L or mmol/L. Chronic hyprkalmia is bst tratd with ditary potassium rstriction (2 g/day) and minimization or limi- nation of any mdications that may impair rnal potassium xcrtion, as notd abov. Loop diurtics may b adminis- trd for thir kaliurtic ffct as long as th patint is not volum-dpltd, and oral potassium-binding rsins may b considrd.Palmr  BF t al. Clinical managmnt of hyprkalmia. Mayo Clin Proc. 2021;96:744. [PMID: 33160639]E.  AcidBase DisordersDamagd kidnys  ar unabl to xcrt th 1 mEq/kg/day of acid gnratd by mtabolism of ditary animal protins in th typical Wstrn dit. Th rsultant mtabolic acido- sis is primarily du to dcrasd GFR; proximal or distal tubular dfcts may contribut to or worsn th acidosis. Excss hydrogn ions ar buffrd by bon; th consqunt laching of calcium and phosphorus from th bon con- tributs to th mtabolic bon disas dscribd abov. Chronic acidosis can also rsult in muscl protin catabo- lism as wll as growth rtardation in childrn with CKD and may acclrat progrssion of CKD. Rduction of ditary animal protin and incrasd fruit and vgtabl intak, and th administration of oral sodium bicarbonat (in doss of 0.5–1.0 mEq/kg/day dividd twic daily and titratd as ndd) ar stratgis to bring srum bicarbon- at lvls toward normal. Citrat salts incras th absorp- tion of ditary aluminum and should b avoidd in CKD.Na vanthan SD t al. Effcts of tratmnt of mtabolic acidosis in CKD: a systmatic rviw and mta-analysis. Clin J Am Soc Nphrol. 2019;14:1011. [PMID: 31196951]F . Neurologic ComplicationsUrmic  ncphalopathy, rsulting from th aggrgation of urmic toxins, dos not occur until GFR falls blow 5–10 mL/min/1.73 m2. Symptoms bgin with difficulty in concntrating and can progrss to lthargy, confusion, si- zur, and coma. Physical findings may includ altrd mntal status, waknss, and astrixis. Ths findings improv with dialysis. Othr nurologic complications that can manifst with advancd CKD includ priphral nuropathis (stocking- glov or isolatd mononuropathis), rctil dysfunction, autonomic dysfunction, and rstlss lg syndrom. Ths may not improv with dialysis thrapy.G.  Endocrine DisordersDcrasd  libido and rctil dysfunction ar common in advancd CKD. Mn hav dcrasd tstostron lvls; womn ar oftn anovulatory. Womn with srum crati- nin lss than 1.4 mg/dL ar not at incrasd risk for poor outcoms in prgnancy; howvr, thos with srumcratinin gratr than 1.4 mg/dL may xprinc fastr progrssion of CKD with prgnancy. Ftal survival is not compromisd, howvr, unlss CKD is advancd. »TreatmentA.  Slowing ProgressionT ratmnt of th undrlying caus of CKD is vital. Control of diabts should b aggrssiv in arly CKD; howvr, risk of hypoglycmia incrass in advancd CKD, and gly- cmic targts may nd to b rlaxd to avoid this dangr- ous complication. Blood prssur control is vital to slow progrssion of all forms of CKD; agnts that block th rnin-angiotnsin-aldostron systm ar particularly important in protinuric patints. Obs patints should b ncouragd to los wight. Managmnt of traditional car- diovascular risk factors is vital. Risks for AKI should b minimizd or avoidd, including long-trm us of NSAIDs. Tratmnt of mtabolic acidosis may b hlpful. Th ffi- cacy of SGLT2 inhibition for slowing progrssion of CKD in thos with and without diabts or significant protin- uria has bn dmonstratd in svral rcnt trials.Han nan M t al. Risk factors for CKD progrssion: ovrviw of findings from th CRIC study. Clin J Am Soc Nphrol. 2021;16:648. [PMID: 33177074] Hrspink HJL t al; DAPA-CKD Trial Committs and Invsti- gators. Dapagliflozin in patints with chronic kidny disas. N Engl J Md. 2020;383:1436. [PMID: 32970396] Klly JT t al. Modifiabl lifstyl factors for primary prvntion of CKD: a systmatic rviw and mta-analysis. J Am Soc Nphrol. 2021;32:239. [PMID: 32868398]B.  Dietary ManagementPa tints with CKD should b valuatd by a rnal nutri- tionist. Patint-spcific rcommndations should b mad concrning protin, salt, watr, potassium, and phosphorus intak to hlp manag CKD progrssion and complications. 1. Protein restriction— Thr is incrasing intrst in plant-basd dits for th tratmnt of CKD. Rducd intak of animal protin to 0.6–0.8 g/kg/day may slow CKD progrssion. Howvr, significant protin rstriction is not advisabl in thos with cachxia or low srum albu- min in th absnc of th nphrotic syndrom. 2. Salt and water restriction— In advancd CKD, th kid- ny is unabl to adapt to larg changs in sodium intak. Intak of gratr than 3–4 g/day can lad to hyprtnsion and hyprvolmia, whras intak of lss than 1 g/day can lad to volum dpltion and hypotnsion. A goal of 2 g/day of sodium is rasonabl for most patints. Daily fluid rstriction to 2 L may b ndd if volum ovrload is prsnt. 3. Potassium restriction— Rstriction is ndd onc th GFR has falln blow 10–20 mL/min/1.73 m2, or arlir if th patint is hyprkalmic. Patints should rciv dtaild lists dscribing potassium contnt of foods and should limit thir intak to lss than 50–60 mEq/day (2 g/day). An aggrssiv bowl rgimn should b institutd for patints with hyprkalmia (mor than two bowl movmntsCMDT22_Ch22_p0912-p0951.indd  928 02/07/21 2:33 PMKIDNEY DISEASE929 CMDT 2022daily),  sinc a highr prcntag of potassium is xcrtd through th GI tract as GFR dclins. Potassium-binding rsins may b usd (s sction on Hyprkalmia). 4. Phosphorus restriction— Guidlins suggst lowring lvatd srum phosphorus lvls toward normal in all stags of CKD. Ditary phosphat rstriction to 800–1000 mg/day is th first stp. Procssd foods and cola bvrags ar oftn prsrvd with highly bioavailabl phosphorus and should b avoidd. Foods rich in phos- phorus such as ggs, dairy products, nuts, bans, and mat may also nd to b limitd, although car must b takn to avoid protin malnutrition. Whn GFR is lss than 20–30 mL/min/1.73 m2, ditary rstriction is rarly suffi- cint to rach targt lvls, and phosphorus bindrs ar usually rquird (s sction on Mtabolic Bon Disas).Ikizlr T A t al. KDOQI clinical practic guidlin for nutrition in CKD: 2020 updat. Am J Kidny Dis. 2020;76:S1. [PMID: 32829751] Joshi S t al. Plant-basd dits for kidny disas: a guid for clinicians. Am J Kidny Dis. 2021;77:287. [PMID: 33075387]C.  Medication ManagementMan y drugs ar xcrtd by th kidny; dosags should b adjustd for GFR. Dcrasd rnal limination of insulin in advancd CKD confrs risk for hypoglycmia in tratd diabtic patints. Doss of oral hypoglycmics and insulin may nd rduction. Th risk of lactic acidosis with mt- formin is du to both dos and GFR; it should b discon- tinud whn GFR is lss than 30 mL/min/1.73 m2. Magnsium-containing mdications, such as laxativs or antacids, and phosphorus-containing mdicins (g, cathartics) should b avoidd. Activ morphin mtabo- lits can accumulat in advancd CKD; this problm is not ncountrd with othr opioid agnts. Drugs with potn- tial nphrotoxicity (NSAIDs, intravnous contrast, as wll as othrs notd in th Acut Kidny Injury sction) should b avoidd. Proton pump inhibitors should b usd only whn mdically ncssary.Shaddock  R t al. Rnal rprcussions of mdications. Prim Car. 2020;47:691. [PMID: 33121637]D . Treatment of ESKDWhn  GFR dclins to 5–10 mL/min/1.73 m2, rnal rplac- mnt thrapy (hmodialysis, pritonal dialysis, or kidny transplantation) is rquird to sustain lif. Patint ducation is important in undrstanding which mod of thrapy is most suitabl, as is timly prparation for tratmnt. Rfr- ral to a nphrologist has bn shown to improv mortality and thrfor should tak plac in lat stag 3 CKD or whn th GFR is dclining rapidly. Prparation for ESKD trat- mnt rquirs a tam approach with th involvmnt of diticians, social workrs, primary car clinicians, and nphrologists. For vry ldrly patints, or thos with mul- tipl dbilitating or lif-limiting comorbiditis, dialysis thrapy may not maningfully prolong lif, and th option of palliativ car should b discussd with th patint andfamily. Convrsly, for patints who ar othrwis rlativly halthy, valuation for possibl kidny transplantation should b considrd prior to initiation of dialysis. 1. Dialysis— Dialysis initiation should b considrd whn GFR is nar 10 mL/min/1.73 m2and urmic symptoms ar prsnt. Othr indications for dialysis, which may occur whn GFR is 10–15 mL/min/1.73 m2, ar fluid ovrload unrsponsiv to diursis and rfractory hyprkalmia. a. Hemodialysis— Vascular accss for hmodialysis can b accomplishd by an artriovnous fistula (th prfrrd mthod) or prosthtic graft; cration of dialysis accss should b considrd wll bfor dialysis initiation. An indwlling cathtr is usd whn thr is no usabl vascu- lar accss. Bcaus cathtrs confr a high risk of blood- stram infction, thy should b considrd a tmporary masur. Nativ fistulas typically last longr than pros- thtic grafts but rquir a longr tim aftr surgical construction for maturation (6–8 wks for a fistula vrsus 2 wks for a graft). Infction, thrombosis, and anurysm formation ar complications sn mor oftn in grafts than fistulas. Staphylococcus spcis ar th most common caus of soft tissu infctions and bactrmia. Tratmnt at a hmodialysis cntr typically occurs thr tims a wk. Sssions last 3–5 hours, dpnding on patint siz and typ of dialysis accss. Hom hmodialysis is oftn prformd mor frquntly (3–6 days pr wk for shortr sssions) and rquirs a traind hlpr. Rsults of trials comparing quotidian modalitis (nocturnal and fr- qunt hom hmodialysis) to convntional in-cntr dialy- sis hav not thus far shown significant mortality diffrncs, but thr may b improvmnts in blood prssur control, minral mtabolism, and quality of lif. b. Peritoneal dialysis— With pritonal dialysis, th pritonal mmbran is th “dialyzr. ” Thr ar diffrnt kinds of pritonal dialysis: continu- ous ambulatory pritonal dialysis (CAPD), in which th patint xchangs th dialysat four to six tims a day manually; and continuous cyclic pritonal dialysis (CCPD), which utilizs a cyclr machin to automatically prform xchangs at night. Th most common complication of pritonal dialysis is pritonitis. Pritonitis may prsnt with nausa and vom- iting, abdominal pain, diarrha or constipation, and fvr. Th normally clar dialysat bcoms cloudy; and a diagnostic pritonal fluid cll count gratr than 100 whit blood clls/mcL (0.1 × 109/L) with a diffrn- tial of gratr than 50% polymorphonuclar nutrophils is prsnt. Staphylococcus aureus is th most common infcting organism, but strptococci and gram-ngativ spcis may also b causativ. Empiric intrapritonal administration of ithr vancomycin or a first-gnration cphalosporin (cfazolin) plus a third-gnration cph- alosporin (cftazidim) should b institutd with th first signs of pritonitis and subsquntly tailord basd on cultur rsults. 2. Kidney transplantation— Many patints with ESKD ar othrwis halthy nough to b suitabl for transplan- tation, although standard critria for rcipint slctionCMDT22_Ch22_p0912-p0951.indd  929 02/07/21 2:33 PMChApTEr 22930 CMDT 2022ar  lacking btwn transplant cntrs. Two-thirds of kidny allografts com from dcasd donors, with th rmaindr from living rlatd or unrlatd donors. Ovr 100,000 patints ar on th waiting list for a dcasd donor transplant in th Unitd Stats; th avrag wait is 3–7 yars, dpnding on gographic location and rcipint blood typ. 3. Medical management of ESKD— As notd abov, som patints ar not candidats for kidny transplanta- tion and may not bnfit from dialysis. Vry ldrly prsons may di soon aftr dialysis initiation; thos who do not may nonthlss rapidly los functional status in th first yar of tratmnt. Th dcision to initiat dialy- sis in patints with limitd lif xpctancy should b wighd against possibl dtrioration in quality of lif. For patints with ESKD who lct not to undrgo dialysis or who withdraw from dialysis, progrssiv urmia with gradual supprssion of snsorium rsults in a painlss dath within days to months. Involvmnt of a palliativ car tam is ssntial.Fost r JG t al. Car of th rnal transplant patint. Prim Car. 2020;47:703. [PMID: 33121638] Zarantonllo D t al. Novl consrvativ managmnt of chronic kidny disas via dialysis-fr intrvntions. Curr Opin Nphrol Hyprtns. 2021;30:97. [PMID: 33186220] »Prognosis in ESKDCompard  with kidny transplant rcipints and ag- matchd controls, mortality is highr for patints undrgo- ing dialysis. Thr is likly littl diffrnc in survival for wll-matchd pritonal vrsus hmodialysis patints. Survival rats on dialysis dpnd on th undrlying disas procss. Fiv-yar Kaplan-Mir survival rats vary from 37% for patints with diabts to 54% for patints with glomrulonphritis. Ovrall 5-yar survival is cur- rntly stimatd at 40%. Patints undrgoing dialysis hav an avrag lif xpctancy of 3–5 yars, but survival for as long as 25 yars may b achivd dpnding on comorbidi- tis. Th most common caus of dath is cardiac disas (mor than 50%). Othr causs includ infction, crbro- vascular disas, and malignancy. »When to Refer• A patint with stag 3–5 CKD should b rfrrd to a nphrologist for managmnt in conjunction with th primary car providr. •A patint with othr forms of CKD such as thos with protinuria gratr than 1 g/day or polycystic kidny disas should b rfrrd to a nphrologist at arlir stags. »When to Admit• Admission should b considrd for dcompnsation of problms rlatd to CKD, such as worsning of acid- bas status, lctrolyt abnormalitis, and volum ovr- load, that cannot b appropriatly tratd in th outpatint stting.•Admission is appropriat whn a patint nds to start dialysis and is not stabl for its outpatint initiation.Charls  C t al. Chronic kidny disas. Prim Car. 2020;47:585. [PMID: 33121630] Li PK t al. Kidny halth for vryon vrywhr—from pr- vntion to dtction and quitabl accss to car. Clin Nphrol. 2020;93:111. [PMID: 32017699] Shlipak MG t al. Th cas for arly idntification and intrvn- tion of chronic kidny disas: conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvr- sis Confrnc. Kidny Int. 2021;99:34. [PMID: 33127436] Stnvinkl P t al. A plantary halth prspctiv for kidny disas. Kidny Int. 2020;98:261. [PMID: 32709283]RE NAL ARTERY STENOSISE S S E N T I A L S  O F  D I A G N O S I S »Produced by atherosclerotic occlusive disease (80–90% of patients) or fibromuscular dysplasia (10–15%). »Hypertension. »AKI in patients starting ACE inhibitor therapy if stenosis is bilateral. »General ConsiderationsA pproximatly 5% of Amricans with hyprtnsion suffr from rnal artry stnosis. Athrosclrotic ischmic rnal disas accounts for most cass of rnal artry stnosis. It typically occurs among prsons ovr 45 yars of ag with additional risk factors such as CKD, diabts mllitus, and tobacco us. Fibromuscular dysplasia is a lss common caus of rnal artry stnosis that most commonly occurs in young womn. »Clinical FindingsA.  Symptoms and SignsPa tints with athrosclrotic ischmic rnal disas may hav rfractory hyprtnsion, nw-onst hyprtnsion (in an oldr patint), pulmonary dma with poorly controlld blood prssur, and AKI upon starting an ACE inhibitor or ARB. Physical xamination may rval an audibl abdomi- nal bruit on th affctd sid. Unxplaind hyprtnsion in a woman youngr than 40 yars should rais suspicion for fibromuscular dysplasia.B.  Laboratory FindingsBUN and s rum cratinin may b lvatd if thr is sig- nificant rnal ischmia. Patints with bilatral rnal artry stnosis may hav hypokalmia, a finding that rflcts activation of th rnin-angiotnsin-aldostron systm in rspons to rducd blood flow (a “prrnal” stat).CMDT22_Ch22_p0912-p0951.indd  930 02/07/21 2:33 PMKIDNEY DISEASE931 CMDT 2022C.  ImagingA bdominal ultrasound can rval ithr asymmtric kid- ny siz if on rnal artry is affctd mor than th othr or small hyprchoic kidnys if both ar affctd. Scrning with Dopplr ultrasonography, CT angiogra- phy, or magntic rsonanc angiography (MRA) is rcom- mndd if a corrctiv procdur would b prformd whn a positiv tst rsult is found. Doppler ultrasonogra- phyis highly snsitiv and spcific (85% and 92%, rspc- tivly) and rlativly inxpnsiv but is xtrmly oprator and patint dpndnt. CT angiography consists of intravnous contrast injc- tion with digital subtraction artriography. Th snsitivi- tis from various studis rang from 77% to 98%, with spcificitis of 90–94%. MRA is an xcllnt but xpnsiv way to scrn for rnal artry stnosis, particularly in thos with athroscl- rotic disas. Snsitivity is 77–100% and spcificity rangs from 71% to 96%. Th imaging agnt for MRA (gadolin- ium) has bn associatd with nphrognic systmic fibro- sis, which is discussd lswhr undr Nphrognic Systmic Fibrosis. Renal angiography is th gold standard for diagnosis, but it is mor invasiv than th thr scrning tsts dis- cussd abov. Thus, it is prformd aftr a positiv scrn- ing tst. Lsions ar most commonly found in th proximal third or ostial rgion of th rnal artry. Th risk of athro- mbolic phnomna aftr angiography rangs from 5% to 10%. Fibromuscular dysplasia has a charactristic “bads- on-a-string” apparanc on angiography. »TreatmentT ratmnt of athrosclrotic ischmic rnal disas is con- trovrsial. Options includ mdical managmnt, angio- plasty with or without stnting, and surgical bypass. Two larg randomizd trials showd that vascular intrvntion is no bttr than optimal mdical managmnt in patints with rnal artry stnosis, xcpt in slctd circumstancs (g, patints with rcurrnt pisods of flash pulmonary dma). Angioplasty might rduc th numbr of antihy- prtnsiv mdications but dos not significantly chang th progrssion of kidny dysfunction. Stnting producs significantly bttr rsults than angioplasty. Howvr, blood prssur and srum cratinin ar similar at 6 months with mdical managmnt as with ithr angioplasty and stnts. Tratmnt of fibromuscular dysplasia with prcutan- ous transluminal angioplasty is oftn curativ, which is in stark contrast to tratmnts for athrosclrotic disas.Gornik  HL t al. First intrnational consnsus on th diagnosis and managmnt of fibromuscular dysplasia. Vasc Md. 2019;24:164. [PMID: 30648921] Mannmuddhu SS t al. Rnovascular hyprtnsion. Prim Car. 2020;47:631. [PMID: 33121633] Princ M t al. Rnal rvascularization in rsistant hyprtnsion. Prog Cardiovasc Dis. 2020;63:58. [PMID: 31821813]ºGLOMErULAr DISEASESGlomrular  disass can b challnging to undrstand clinically bcaus th glomrulus is a histologically com- plx structur (consisting of th pithlial clls [podo- cyts], basmnt mmbran, capillary ndothlium, and msangium). Th following ar xampls of injuris that can affct any or all of th constitunts of th glomrulus: (1) ovrwork injury, as in CKD; (2) an inflammatory pro- css, such as SLE; (3) a podocyt protin mutation, as in hrditary focal sgmntal glomrulosclrosis (FSGS); or (4) a dposition disas, as in diabts or amyloidosis. Whn a glomrular disas is suspctd, a kidny biopsy may b ndd to clarify th tiology. »ClassificationGlomr ular disass can b classifid in on of two clini- cal spctra—th nphritic spctrum or th nphrotic spctrum (Figur 22–4). At th “last svr” nd of th nephritic spectrum , th findings of asymptomatic glo- mrular hmaturia (i, dysmorphic rd blood clls with or without som protinuria [lss than 1 g/day]) ar charactristic. Th nphritic syndrome , comprising glo- mrular hmaturia, subnphrotic protinuria (lss than 3 g/day), dma, and lvatd cratinin, falls in th mid- portion of th spctrum. Th rapidly progrssiv glo- mrulonphritids (RPGNs), with systmic symptoms, ar at th “most svr” and clinically urgnt nd of th spctrum. Th nephrotic spectrum is comprisd of dis- ass that prsnt primarily with protinuria of at last 0.5–1 g/day and a bland urin sdimnt (no clls or cl- lular casts). At th mor svr nd of th nphrotic spctrum is th nphrotic syndrome , consisting of nphrotic-rang protinuria (gratr than 3 g/day), hypoalbuminmia, dma, hyprlipidmia, and urinary oval fat bodis. Diffrntiating btwn a clinical prsn- tation within th nphritic spctrum vrsus th nphrotic spctrum is important bcaus it hlps narrow th diffr- ntial diagnosis of th undrlying glomrular disas (Tabls 22–7 and 22–8). Glomrular disass can also b classifid according to whthr thy caus rnal abnormalitis alon (primary rnal disas) or whthr th rnal abnormalitis rsult from a systmic disas (scondary rnal disas). Furthr valuation prior to kidny biopsy may includ srologic tsting for systmic disass that can rsult in glomrular damag (Figur 22–5).Cavana ugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Flog J t al. Managmnt and tratmnt of glomrular disass (part 1): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:268. [PMID: 30665568] Rovin BH t al. Managmnt and tratmnt of glomrular dis- ass (part 2): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:281. [PMID: 30665569]CMDT22_Ch22_p0912-p0951.indd  931 02/07/21 2:33 PMChApTEr 22932 CMDT 2022NE PHRITIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Asymtomatic glomeula ematuia –Hematuria with dysmorphic RBCs –Proteinuria < 1 g/day »Neitic syndome in more severe cases – Glomerular hematuria (and RBC casts if glomerular bleeding is heavy) –Proteinuria of 1–3 g/day –Hypertension –Edema –Rising creatinine over days to months »raidly ogessive glomeuloneiti sin most severe cases –AKI with rising creatinine over days to months –Glomerular hematuria (and RBC casts) –Proteinuria of 1–3 g/day –Systemic symptoms –Hypertension and edema uncommon»General Considerations“ Glomrulonphritis” is a trm givn to thos disass that prsnt in th nphritic spctrum and usually signifis an inflammatory procss causing rnal dysfunction. It can b acut, dvloping ovr days to wks, with or without rso- lution, or may b chronic and indolnt with progrssiv scarring. As notd abov, disass that caus a nphritic spctrum prsntation may prsnt with glomrular hma- turia and protinuria, with nphritic syndrom, or with RPGN (Figur 22–4). Th prsntation dpnds on th svrity of th undrlying inflammation and th pattrn of injury causd by th disas procss. »Clinical FindingsA.  Symptoms and SignsNp hritic syndrom usually lads to an acut dcras in GFR and rsultant sodium rtntion. This is manifstd by hyprtnsion and dma, which is first sn in rgions of low tissu prssur such as th priorbital and scrotal aras. Havy glomrular blding from inflammation may rsult in gross hmaturia (smoky or cola-colord urin).B.  Laboratory Findings1. Serologic testing—  Srologic tsts basd on th history and physical xamination hlp narrow th diffrntialAsymptomatic glomerular hematuriaNephritic syndromeNephritic Spectrum Nephrotic SpectrumMicroscop ic or macroscopic hematuria with or without proteinuria (< 1 g/day)Acute kidney injury with proteinuria of 1–3 g/day, hematuria, RBC casts, edema, and hypertensionAcute kidney injury with proteinuria of 1–3 g/day, hematuria, RBC casts, and systemic symptomsProteinuria of 300 mg/day–10 g/day and bland urineProteinuria of > 3 g/day plus hypoalbuminemia, edema, hyperlipidemia, and possible oval fat bodies in urineAsymptomatic proteinuriaNephrotic syndrome Chronic glomerular disease Chronic kidney disease with or without hematuria, proteinuria, hypertension, late-stage glomerulonephritis, burned-out diseaseRapidly progressive glomerulonephritis ▲Figure 22–4. Glomerular diseases present within one of the clinical spectra shown; the exact presentation is determined by the severity of the underlying disease and the pattern of injury. Nephritic diseases are characterized by the presence of an active urine sediment with glomerular hematuria and often with proteinuria. Nephrotic spec- trum diseases are proteinuric with bland urine sediments (no cells or cellular casts). All glomerular diseases may progress to a chronic, scarred state. (Adapted, with permission, from Megan Troxell, MD, PhD.)CMDT22_Ch22_p0912-p0951.indd  932 02/07/21 2:33 PMKIDNEY DISEASE933 CMDT 2022diagnosis. Ths  tsts may includ C3 and C4 complmnt lvls, antinuclar antibodis, cryoglobulins, hpatitis srologis, srum and urin protin lctrophorss, srum fr light chains, ANCAs, anti-GBM antibodis, and anti- strptolysin O (ASO) titrs (Figur 22–5). 2. Urinalysis— Th urin dipstick is positiv for protin and blood. Urinary microscopy rvals rd blood clls that ar misshapn or dysmorphic from travrsing a damagd glo- mrular filtration barrir. Rd blood cll casts ar sn with havy glomrular blding and tubular stasis. Whn quan- tifid, protinuria is usually subnphrotic rang (lss than 3 g/day). 3. Biopsy— Dfinitiv diagnosis of th undrlying glomr- ular disas cannot b mad without a kidny biopsy. Candidats for biopsy ar patints for whom tst rsults would influnc managmnt; xcptions includ thoswith advancd undrlying CKD, thos who cannot adhr to mdical thrapy, thos for whom immunosupprssiv thrapy is not appropriat, or thos for whom th prsnta- tion is “classic” for a particular disas (g, post-strptococcal glomrulonphritis, childhood minimal chang disas, and diabtic nphropathy). Th major risk of biopsy is blding. Contraindications includ a blding diathsis, thrombocytopnia, and uncontrolld hyprtnsion. »TreatmentGn ral masurs includ tratmnt of hyprtnsion and fluid ovrload, if prsnt. Antiprotinuric thrapy with an ACE inhibitor or ARB should b considrd for thos without AKI. For thos with profound AKI, dialysis may b ndd. Th inflammatory glomrular injury may rquir immuno- supprssiv agnts (s spcific disass discussd blow).Table 22–7. Classification and findings in glomerulonephritis: nephritic spectrum presentations. Tyical pesentation Association/Notes Seology Postinfectious glomerulonephritisChildren: abrupt onset of nephritic syndrome and acute kidney injury but can present anywhere in nephritic spectrumStreptococci, other bacterial infec- tions (eg, staphylococci, endocardi- tis, shunt infections)Rising ASO titers, low comple- ment levels IgA nephropathy (Berger disease) and Henoch- Schönlein purpura, sys- temic IgA vasculitisClassically: gross hematuria with respiratory tract infection, but can present anywhere in nephritic spectrum; Henoch-Schönlein pur- pura with vasculitic rash and gas- trointestinal hemorrhageAbnormal IgA glycosylation in both primary (familial predisposition) and secondary disease (associated with cirrhosis, HIV, celiac disease) Henoch-Schönlein purpura in chil- dren after an inciting infectionNo serologic tests helpful; com- plement levels are normal Pauci-immune (granulo- matosis with polyangi- itis, eosinophilic granulomatosis with polyangiitis, polyarteri- tis, idiopathic crescen- tic glomerulonephritis)Classically: crescentic or RPGN, but can present anywhere in nephritic spectrum; may have respiratory tract/sinus symptoms in granulo- matosis with polyangiitisSee Figure 22–5 ANCAs: MPO or PR3 titers high; complement levels normal Anti-GBM glomerulone- phritis; Goodpasture syndromeClassically: crescentic or RPGN, but can present anywhere in nephritic spectrum; pulmonary hemorrhage in Goodpasture syndromeMay develop as a result of respiratory irritant exposure (chemicals or tobacco use)Anti-GBM antibody titers high; complement levels normal Cryoglobulin-associated glomerulonephritisOften acute nephritic syndrome; often with systemic vasculitis including rash and arthritisMost commonly associated with chronic hepatitis C; may occur with other chronic infections or some connective tissue diseasesCryoglobulins positive; rheuma- toid factor may be elevated; complement levels low MPGN Classically: acute nephritic syndrome, but can also have nephrotic syn- drome featuresMost patients are < 30 years old Immune complex MPGN most common C3 glomerulonephritisLow complement levels, may have findings of underlying infection or paraproteinemia Hepatitis C infection Anywhere in nephritic spectrum Can cause MPGN pattern of injury or cryoglobulinemic glomerulone- phritis; membranous nephropathy pattern of injury uncommonLow complement levels; posi- tive hepatitis C serology; rheumatoid factor may be elevated Systemic lupus erythematosusAnywhere in nephritic spectrum, depending on pattern/severity of injuryTreatment depends on clinical course and International Society of Nephrology and Renal Pathology Society classification on biopsyHigh ANA and anti-double- stranded DNA titers; low complement levels ANA, antinuclear antibodies; ANCAs: antineutrophil cytoplasmic antibodies; GBM, glomerular basement membrane; MPGN, membranop- roliferative glomerulonephritis; MPO, myeloperoxidase; PR3, proteinase 3; RPGN, rapidly progressive glomerulonephritis.CMDT22_Ch22_p0912-p0951.indd  933 02/07/21 2:33 PMChApTEr 22934 CMDT 2022 »When to ReferAny  patint in whom a glomrulonphritis is suspctd should b rfrrd to a nphrologist. »When to AdmitAny  suspicion of acut nphritic syndrom or RPGN warrants considration of immdiat hospitalization.Lamba  P t al. Nphritic syndrom. Prim Car. 2020;47:615. [PMID: 33121632] Popplaars F t al. Complmnt-mdiatd kidny disass. Mol Immunol. 2020;128:175. [PMID: 33137606]1.  Infection-related & postinfectious GlomeuloneitisE S S E N T I A L S  O F  D I A G N O S I S »Proteinuria. »Glomerular hematuria. »Symptoms 1–3 weeks after some infections (often pharyngitis or impetigo) or during course of other infections (eg, pneumonia or endocarditis).»General ConsiderationsP ostinfctious glomrulonphritis is most oftn du to infction with nphritognic group A bta-hmolytic strptococcal infctions (pharyngitis or imptigo). It can occur sporadically or in clustrs and during pidmics, with onst up to 1–3 wks aftr infction (avrag 7–10 days). Othr infctions hav bn associatd with glomrulo- nphritis including bactrmia (spcially S aureus ), bac- trial pnumonias, dp-satd abscsss, gram-ngativ infctions, infctiv ndocarditis, and shunt infctions; viral, fungal, and parasitic causs of glomrulonphritis includ hpatitis B or C, HIV , cytomgalovirus infction, infctious mononuclosis, coccidioidomycosis, malaria, mycobactria, syphilis, and toxoplasmosis. Ths ntitis rsult in glomrular injury during activ infction, and ar bttr trmd “infction-rlatd glomrulonphritis” rathr than “postinfctious glomrulonphritis. ” »Clinical FindingsA.  Symptoms and SignsDisas  prsntation varis across th nphritic spctrum from asymptomatic glomrular hmaturia (spcially in pidmic cass) with minimal chang in kidny function, to nphritic syndrom with hyprtnsion, dma, andTable 22–8. Classification and findings in glomerulonephritis: nephrotic spectrum presentations.Disease Tyical pesentation Association/Notes Minimal change disease (nil disease; lipoid nephrosis)Child with sudden onset of full nephrotic syndromeChildren: associated with allergy or viral infection Adults: associated with Hodgkin disease, NSAIDs Membranous nephropathy Anywhere in nephrotic spectrum, but nephrotic syndrome not uncommon; particular predispo- sition to hypercoagulable statePrimary (idiopathic) may be associated with antibodies to PLA2R Secondary may be associated with non-Hodgkin lymphoma, carci- noma (gastrointestinal, renal, bronchogenic, thyroid), gold therapy, penicillamine, SLE, chronic hepatitis B or C infection Focal and segmental glomerulosclerosisAnywhere in nephrotic spectrum; children with congenital disease have nephrotic syndromeChildren: congenital disease with podocyte gene mutation, or in spec- trum of disease with minimal change disease Adults: associated with heroin abuse, HIV infection, reflux nephropa- thy, obesity, pamidronate, podocyte protein mutations, APOL1 mutations Amyloidosis Anywhere in nephrotic spectrum AL: plasma cell dyscrasia with Ig light chain overproduction and depo- sition; check SPEP and UPEP AA: serum amyloid protein A overproduction and deposition in response to chronic inflammatory disease (rheumatoid arthritis, inflammatory bowel disease, chronic infection) Diabetic nephropathy High GFR (hyperfiltration) →micro- albuminuria →frank proteinuria →decline in GFRDiabetes diagnosis precedes diagnosis of nephropathy by years HIV-associated nephropathy Heavy proteinuria, often nephrotic syndrome, progresses to ESKD relatively quicklyUsually seen in antiviral treatment-naïve patients (rare in antiretroviral therapy era), predilection for those of African descent ( APOL1 mutations) Membranoproliferative glomerulonephropathyClassically presents with acute nephritic syndrome, some may also exhibit nephrotic featuresImmune complex–MPGN are idiopathic or secondary to infections, paraproteinemia, or systemic autoimmune disease; C3 glomerulopa- thies are due to alternative complement pathway dysregulation ESKD, end-stage kidney disease; GFR, glomerular filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs; PLA2R, phospholipase A2 receptor; SLE, systemic lupus erythematosus; SPEP/UPEP , serum and urine protein electrophoresis.CMDT22_Ch22_p0912-p0951.indd  934 02/07/21 2:33 PMKIDNEY DISEASE935 CMDT 2022+ + +Glomerulonephritis (GN) Serologic analysis Anti-glomerular basement membrane (GBM) antibodies Anti-GBM GNAntineutrophil cytoplasmic antibodies (ANCA) No lung hemorrhage Anti-GBM GNLung hemorrhage Goodpasture syndromeImmune complex disease markers Immune complex GNIgA IgA nephropathyAntipathogen antibodies Postinfectious or peri- infectious GNCryoglobulins Cryoglobulinemic GNAntinuclear antibodies Lupus GNComplement activation MPGN ANCA GNSystemic necrotizing vasculitis Microscopic polyangiitisRespiratory necrotizing granulomas Granulomatosis with polyangiitisAsthma and eosinophiliaNo extra- renal disease ANCA- associated crescentic GNEosinophilic granulomatosis with polyangiitis ▲Figure 22–5. Serologic analysis of patients with glomerulonephritis. MPGN, membranoproliferative glomerulonephritis. (Modified, with permission, from Greenberg A et al.Primer on Kidney Diseases . Academic Press, 1994; and Jennette JC, Falk RJ. Diagnosis and management of glomerulonephritis and vasculitis presenting as a cute renal failure. Med Clin North Am. 1990;74(4):893–908. © Elsevier.)CMDT22_Ch22_p0912-p0951.indd  935 02/07/21 2:33 PMChApTEr 22936 CMDT 2022prh aps gross glomrular hmaturia (smoky-colord urin); th most svr cass may rsult in oliguric AKI rquiring dialysis.B.  Laboratory FindingsSrum  complmnt lvls ar low; in postinfctious glo- mrulonphritis du to group A strptococcal infction, anti-strptolysin O (ASO) titrs can b high unlss th immun rspons has bn bluntd with prvious antibiotic tratmnt. Glomrular hmaturia and protinuria ar prs- nt. In childrn with a rcnt strptococcal infction and nphritic faturs, a diagnosis may b mad mpirically without a biopsy. Whn prformd, kidny biopsy shows a diffus prolifrativ pattrn of injury on light microscopy. Immunofluorscnc dmonstrats granular dposition of IgG and C3 in th msangium and along th capillary bas- mnt mmbran. Elctron microscopy shows larg, dns subpithlial dposits or “humps. ” Kidny biopsy findings in infction-rlatd glomrulonphritis ar varid and may show ovrlap with immun-complx mmbranoprolifra- tiv glomrulonphritis or C3 glomrulonphritis. »TreatmentAny  activ infction should b idntifid and tratd appropriatly; othrwis, tratmnt for postinfctious glo- mrulonphritis is supportiv. Antihyprtnsivs, salt rstriction, and diurtics should b usd if ndd. Corti- costroids hav not bn shown to improv outcoms. Prognosis dpnds on th svrity of th glomrular injury and ag of th patint. Childrn ar mor likly to fully rcovr; adults ar mor pron to th dvlopmnt of svr disas (RPGN with crscnt formation) and CKD.Mo hammad D t al. Postinfctious glomrulonphritis. Pdiatr Ann. 2020;49:273. [PMID: 32520369] Satoskar AA t al. Epidmiology, pathognsis, tratmnt and outcoms of infction-associatd glomrulonphritis. Nat Rv Nphrol. 2020;16:32. [PMID: 31399725]2.  IgA NeoatyE S S E N T I A L S  O F  D I A G N O S I S »Proteinuria: minimal to nephrotic range. »Glomerular hematuria: microscopic is common; macroscopic (gross) after infection. »Positive IgA staining on kidney biopsy. »General ConsiderationsIgA  nphropathy (Brgr disas) is a primary rnal dis- as of IgA dposition in th glomrular msangium. Th inciting caus is unknown. IgA nphropathy can b a pri- mary (rnal-limitd) disas or scondary to hpatic cir- rhosis, cliac disas, and infctions such as HIV and cytomgalovirus. Suscptibility to IgA nphropathy is inhritabl.IgA nphropathy is th most common primary glo- mrular disas worldwid, particularly in Asia. It is most oftn sn in childrn and young adults, with mals affctd two to thr tims mor commonly than fmals. »Clinical FindingsTh  classical prsntation of IgA nphropathy is an pisod of gross hmaturia associatd with a mucosal viral infc- tion, oftn of th uppr rspiratory tract. Th urin bcoms rd or smoky-colord 1–2 days aftr illnss onst—a so-calld synpharyngitic prsntation in contra- distinction to th latnt priod sn in postinfctious glo- mrulonphritis. Howvr, IgA nphropathy can prsnt anywhr along th nphritic spctrum from asymptom- atic microscopic hmaturia with minimal protinuria and prsrvd GFR to RPGN (Figur 22–4). Rarly, nphrotic syndrom can b prsnt. Thr ar no srologic tsts that aid in this diagnosis; srum complmnts ar normal. Th typical pattrn of injury sn on kidny biopsy is a focal glomrulonphritis with msangial prolifration; immunofluorscnc dm- onstrats diffus msangial IgA and C3 dposits. »TreatmentTh  disas cours of primary IgA nphropathy varis widly among patints; tratmnt approach nds to b tailord to risk for progrssion. Patints with low risk for progrssion (no hyprtnsion, normal GFR, minimal pro- tinuria) can b monitord annually. Patints at highr risk (protinuria gratr than 1.0 g/day, dcrasd GFR, or hyprtnsion or any combination of ths thr condi- tions) should b tratd with an ACE inhibitor or ARB. Thrapy should b titratd to rduc protinuria to lss than 1 g/day and to control blood prssur in th rang of 125/75 mm Hg to 130/80 mm Hg. Prior trials suggstd that corticostroids rducd protinuria whn adminis- trd to patints with GFR gratr than 50 mL/min/1.73 m2 and prsistnt protinuria gratr than 1 g/day. Howvr, mor rcnt data faild to dmonstrat slowing of GFR loss with corticostroid thrapy compard with us of ACE inhibitor or ARB alon; nthusiasm for glucocorticoid thrapy thrfor has wand. For th rar patint with IgA nphropathy and a rapidly progrssiv clinical cours with crscnt formation on biopsy, cyclophosphamid and cor- ticostroid thrapy should b considrd (s sction on ANCA-associatd vasculitis blow). Kidny transplanta- tion is an xcllnt option for patints with ESKD, but rcurrnt disas has bn documntd in 30% of patints 5–10 yars posttransplant. »PrognosisA pproximatly on-third of patints xprinc spontan- ous clinical rmission. Progrssion to ESKD occurs in 20–40% of patints. Th most unfavorabl prognostic indi- cator is protinuria gratr than 1 g/day; othr includ hyprtnsion, tubulointrstitial fibrosis, glomrulosclro- sis, or glomrular crscnts on biopsy, and abnormal GFR on prsntation.CMDT22_Ch22_p0912-p0951.indd  936 02/07/21 2:33 PMKIDNEY DISEASE937 CMDT 2022Ca mbir A t al. Nw thraputic prspctivs for IgA nphropathy in childrn. Pdiatr Nphrol. 2021;36:497. [PMID: 32040630] Raun T t al. Aftr tn yars of follow-up, no diffrnc btwn supportiv car plus immunosupprssion and supportiv car alon in IgA nphropathy. Kidny Int. 2020;98:1044. [PMID: 32450154] Trimarchi H t al. IgA nphropathy: “Stat of th art”: a rport from th 15th Intrnational Symposium on IgA Nphropathy clbrating th 50th annivrsary of its first dscription. Kidny Int. 2019;95:750. [PMID: 30904065]3.  henoc-Scönlein puuaH noch-Schönlin purpura is a systmic small-vssl lu- kocytoclastic vasculitis associatd with IgA subclass 1 dpo- sition in vssl walls. It is most common in childrn and is oftn associatd with an inciting infction, such as group A strptococcus or othr xposur. Thr is a mal prdomi- nanc. It classically prsnts with palpabl purpura in th lowr xtrmitis and buttock ara; arthralgias; abdominal symptoms, such as nausa, colic, and mlna; and AKI with nphritic urin sdimnt. Th rnal lsions can b idntical to thos found in IgA nphropathy, and th undrlying pathophysiology appars to b similar. Most patints with microscopic hmaturia and minimal protinuria rcovr fully ovr svral wks. Progrssiv CKD and possibly ESKD ar mor likly to dvlop in adults and in thos with both nphritic and nphrotic syndroms. Although svral tratmnt rgimns of various immunosupprssiv agnts hav bn clinically tstd, non ar provn to altr th cours of svr nphritis. Rituximab tratmnt and plasma xchang hav bn succssful for svr disas according to svral cas rports, but clinical trials ar lacking. Rapidly progrssiv disas with crscnt formation on biopsy may b tratd as in ANCA-associatd vasculitis (s sction blow). Furthr dtails about Hnoch-Schönlin purpura ar providd in Chaptr 20.Mari tati F t al. Adult-onst IgA vasculitis (Hnoch-Schönlin): updat on thrapy. Prss Md. 2020;49:104035. [PMID: 32645417]4.  pauci-Immune Glomeuloneitis (ANCA-Associated)Pa uci-immun ncrotizing glomrulonphritis is causd by th following systmic ANCA-associatd small-vssl vasculitids: granulomatosis with polyangiitis, microscopic polyangiitis, and osinophilic granulomatosis with polyan- giitis (formrly Churg-Strauss disas; s Chaptr 20). ANCA-associatd glomrulonphritis can also prsnt as a primary rnal lsion without systmic involvmnt; this is trmd “idiopathic crscntic glomrulonphritis. ” Th pathognsis of ths ntitis appars to involv cytokin- primd nutrophils prsnting cytoplasmic antigns on thir surfacs (protinas 3 and myloproxidas). Circu- lating ANCAs thn bind to ths antigns and activat a nutrophil rspiratory burst with consqunt vascular damag; primd nutrophils also appar to activat th altrnativ complmnt pathway. Putativ nvironmntal xposurs that may incit th initial rspons includ S aureusand silica. Immunofluorscnc of kidny biopsy spcimns dmonstrats lack of immunoglobulin or complmnt dposition, hnc th trm “pauci-immun. ” Rnal involv- mnt classically prsnts as an RPGN, but mor indolnt prsntations can b sn. »Clinical FindingsA.  Symptoms and SignsSymp toms of a systmic inflammatory disas, including fvr, malais, and wight loss, may b prsnt and usually prcd initial prsntation by svral months. In addition to hmaturia and protinuria from glomrular inflamma- tion, som patints xhibit purpura from drmal capillary involvmnt and mononuritis multiplx from nrv artrio- lar involvmnt. Ninty prcnt of patints with granulomato- sis with polyangiitis hav uppr (spcially sinus) or lowr rspiratory tract symptoms with nodular lsions that can cavi- tat and bld. Hmoptysis is a concrning sign and usually warrants hospitalization and aggrssiv immunosupprssion.B.  Laboratory FindingsSrologically , ANCA subtyp analysis is don to dtrmin whthr antiprotinas-3 antibodis (PR3-ANCA) or anti- myloproxidas antibodis (MPO-ANCA) ar prsnt. Most patints with granulomatosis with polyangiitis ar PR3 positiv; th rmaindr ar MPO positiv or, mor rarly, do not dmonstrat circulating ANCA. Microscopic angiitis is gnrally associatd with MPO ANCA. Rnal biopsy dmonstrats ncrotizing lsions and crscnts on light microscopy; immunofluorscnc is ngativ for immun complx dposition. »TreatmentT ratmnt should b institutd arly if aggrssiv disas is prsnt. Induction thrapy of high-dos corticostroids (mthylprdnisolon, 1–2 g/day intravnously for 3 days, followd by prdnison, 1 mg/kg orally for 1 month, with a slow tapr ovr th nxt 6 months) and cytotoxic agnts (cyclophosphamid, 0.5–1 g/m2intravnously pr month or 1.5–2 mg/kg orally for 3–6 months) is followd by long-trm azathioprin or mycophnolat moftil. Rituximab has bn shown to b noninfrior to cyclophosphamid for induction and is also usd in rfractory or rlapsing cass and as an altrnativ to azathioprin for maintnanc of rmission. Plasma xchang is likly hlpful in conjunction with induc- tion thrapy for cass complicatd by pulmonary hmor- rhag. Trials using th complmnt inhibitor avacopan in plac of glucocorticoids in cyclophosphamid- or rituximab- basd rgimns ar ongoing and appar promising. »PrognosisW ithout tratmnt, prognosis is xtrmly poor. With aggrssiv tratmnt, complt rmission can b achivd in 75% of patints. Prognosis dpnds on th xtnt of rnal involvmnt bfor tratmnt is startd and may b wors in thos with PR3-associatd disas. ANCA titrs may b monitord to follow tratmnt fficacy; rising titrs may hrald rlaps.CMDT22_Ch22_p0912-p0951.indd  937 02/07/21 2:33 PMChApTEr 22938 CMDT 2022Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Smith RM t al. Rituximab as thrapy to induc rmission aftr rlaps in ANCA-associatd vasculitis. Ann Rhum Dis. 2020;79:1243. [PMID: 32581088] Walsh M t al. Plasma xchang and glucocorticoids in svr ANCA-associatd vasculitis. N Engl J Md. 2020;382:622. [PMID: 32053298]5.  Anti-Glomeula Basement Membane Glomeuloneitis & Goodastue SyndomeA utoantibodis to pitops of th GBM caus a glomrulo- nphritis (anti-GBM disas); concomitant immun attack on alvolar basmnt mmbrans rsults in pulmonary hmorrhag as wll (Goodpastur syndrom) (Figur 22–5). Anti-GBM–associatd glomrulonphritis accounts for 10–20% of patints with acut RPGN. Th incidnc paks in th third dcad of lif during which tim mals ar prdominantly affctd and lung involvmnt is mor common, and again in th sixth and svnth dcads with lss gndr spcificity and pulmonary involvmnt. Good- pastur syndrom has bn associatd with pulmonary infction, tobacco us, and xposur to hydrocarbon sol- vnts or almtuzumab; HLA-DR2 and -B7 antigns may prdispos as wll. »Clinical FindingsA.  Symptoms and SignsTh on st of disas may b prcdd by an uppr rspira- tory tract infction; hmoptysis, dyspna, and possibl rspiratory failur may nsu. Othr findings ar consistnt with an RPGN, although rar cass may prsnt with much mildr forms of th nphritic spctrum of disas (g, glo- mrular hmaturia and protinuria with minimal kidny dysfunction).B.  Laboratory FindingsChst radiographs may dmonstrat  pulmonary infiltrats if pulmonary hmorrhag is prsnt. Srum complmnt lvls ar normal. Circulating anti-GBM antibodis ar prsnt in ovr 90% of patints. A small prcntag of patints hav lvatd ANCA titrs; ths patints should b tratd with plasma xchang as for anti-GBM disas. Kidny biopsy typically shows crscnt formation with light microscopy, with linar IgG staining along th GBM with immunofluorscnc. »TreatmentPa tints with pulmonary hmorrhag and strong clinical suspicion of Goodpastur syndrom should b tratd mrgntly—possibly prior to confirming th diagnosis with srology and kidny biopsy. Tratmnt is a combina- tion of plasma xchang thrapy daily for up to 2 wks to rmov circulating antibodis, and administration of corti- costroids and cyclophosphamid to prvnt formation of nw antibodis and control th inflammatory rspons. Rituximab has bn usd in a small numbr of patintswith rfractory disas. Patints with oliguric AKI or who rquir dialysis upon prsntation hav a poor prognosis. Anti-GBM antibody titrs should dcras as th clinical cours improvs.Sglm ark M t al. Anti-glomrular basmnt mmbran disas: an updat on subgroups, pathognsis and thrapis. Nphrol Dial Transplant. 2019;34(11):1826. [PMID: 30371823] Umatsu-Uchida M t al. Rituximab in tratmnt of anti-GBM antibody glomrulonphritis: a cas rport and litratur rviw. Mdicin (Baltimor). 2019;98:17801. [PMID: 31689860]6.  Membanoolifeative Glomeuloneitis & C3 GlomeuloatiesMPGN is a  rlativly rar pattrn of glomrular injury that can prsnt anywhr along th nphritic spctrum from asymptomatic glomrular hmaturia to acut nphritic syndrom with bouts of gross hmaturia to RPGN; nphrotic syndrom can also b sn. MPGN is classifid pathologically and mchanistically into immun complx– and C3-rlatd disas. Etiologis of immun complx– mdiatd MPGN includ chronic infction (most commonly HCV , but also bactrial and parasitic infc- tions), a paraprotinmia, or an undrlying autoimmun disas (such as lupus); it can also b idiopathic (spcially in childrn and young adults). In ths cass, th pathogn- sis is likly a chronic antignmia lading to classical complmnt pathway activation with immun complx dposition; howvr, som cass may rsult from altrna- tiv complmnt pathway dysrgulation. C3 glomrulopa- this ar causd by svral inhritd or acquird abnormalitis in th altrnativ complmnt pathway. Both typs rsult in low circulating C3 complmnt; C4 is low in immun complx disas. Light microscopy of both typs shows varying dgrs of msangial hyprcllularity, ndo- capillary prolifration and capillary wall rmodling rsulting in doubl contours of th GBM (“tram track” apparanc). Immunofluorscnc and lctron micros- copy provid distinguishing information. Immun complx–mdiatd MPGN rvals C3 and IgG or IgM staining (or both) on immunofluorscnc; lctron microscopy dmonstrats msangial and subpithlial dposits. C3 glomrulonphritis is distinguishd by lack of immunoglobulin staining on immunofluorscnc, but can appar similar to immun complx disas with rspct to light and lctron microscopy. An additional but rar typ of C3 glomrular injury is “dns dposit disas” basd on thick ribbon-lik dposits sn on lctron microscopy. Togthr, dns dposit disas and C3 glomrulonphritis ar trmd “C3 glomrulopathis. ” Tratmnt of immun complx MPGN should b dirctd at any idntifiabl undrlying caus; idiopathic immun complx disas tratmnt is controvrsial and controlld trial data ar lacking. For thos with mild dis- as, ACE inhibitors and ARBs should b usd. For svr disas, a combination of oral cyclophosphamid or myco- phnolat moftil plus corticostroids could b considrd; rituximab is also somtims usd. Thos with RPGN and crscnts on biopsy may b tratd th sam as thos withCMDT22_Ch22_p0912-p0951.indd  938 02/07/21 2:33 PMKIDNEY DISEASE939 CMDT 2022ANCA -associatd disas providd scondary causs hav bn ruld out. Dspit thrapy, most will progrss to ESKD. Tratmnt for th C3 glomrulopathis is in volu- tion as novl thrapis to targt th dysrgulatd altrnativ complmnt cascad ar bing xplord; small, uncon- trolld sris suggst a possibl bnfit of culizumab in som patints; othrs may rspond to mycophnolat moftil. Lss favorabl prognostic findings includ dns dposit disas, arly dclin in GFR, hyprtnsion, and prsistnt nphrotic syndrom. All typs of MPGN rcur with high frquncy aftr kidny transplantation; howvr, dns dposit disas rcurs mor commonly. Plasma xchang, with or without culizumab, has bn usd with mixd rsults to trat posttransplant rcurrnc of MPGN.Fakhouri  F t al. Practical managmnt of C3 glomrulopathy and Ig-mdiatd MPGN: facts and uncrtaintis. Kidny Int. 2020;98:1135. [PMID: 32622830]7.  Cyoglobulin-Associated GlomeuloneitisEssnt ial (mixd) cryoglobulinmia is a vasculitis causd by cold-prcipitabl immunoglobulins (cryoglobulins). Th most common undrlying tiology is HCV infction; in ths cass, thr is clonal xpansion of B lymphocyts, which produc IgM rhumatoid factor. Rhumatoid fac- tor, HCV antign, and polyclonal anti-HCV IgG form complxs that dposit in vssls and incit inflamma- tion. Othr ovrt or occult infctions (g, viral, bactrial, and fungal) as wll as som autoimmun disass and lymphoprolifrativ disordrs can caus cryoglobulin- mic vasculitis. Patints xhibit purpuric and ncrotizing skin lsions in dpndnt aras, arthralgias, fvr, and hpatosplnomg- aly. Srum complmnt lvls ar low and rhumatoid fac- tor is oftn lvatd. Kidny biopsy may show svral diffrnt pattrns of injury; thr may b crscnt forma- tion, glomrular capillary thrombi, or MPGN (s abov). Tratmnt consists of aggrssivly targting th causativ infction. Puls corticostroids, plasma xchang, ritux- imab, and cytotoxic agnts hav bn usd whn thr is littl risk of xacrbating th undrlying infction or whn no infction is prsnt. S also Hpatitis C Virus–Associatd Kidny Disas.Ko lopp-Sarda MN t al. Cryoglobulinmic vasculitis: patho- physiological mchanisms and diagnosis. Curr Opin Rhu- matol. 2021;33:1. [PMID: 33186245]8.  heatitis C Vius–Associated Kidney DiseaseKidny dis as can occur in th stting of HCV infction. Th thr pattrns of kidny injury associatd with HCV ar scondary MPGN (most common), cryoglobulinmic glomrulonphritis, and mmbranous nphropathy. Th clinical prsntation is dictatd by th undrlying pattrn of injury. Many patints hav lvatd srum transami- nass and an lvatd rhumatoid factor. Hypocompl- mntmia is vry common, with C4 typically mor rducd than C3; complmnt lvls and rhumatoid factor tnd to b normal if thr is a mmbranous pattrn of injury.»TreatmentV iral supprssion or radication is th cornrston of trat- mnt of HCV–associatd kidny disas (s Chaptr 16). Us of most dirct-acting antiviral agnts appars to b saf in thos with rducd GFR, with th xcption of sofosbu- vir. Thrapy with rituximab and possibly corticostroids and plasmaphrsis should b initiatd in patints with svr vasculitis prior to th initiation of antiviral thrapy.Comarm ond C t al. Tratmnt of chronic hpatitis C–associatd cryoglobulinmia vasculitis at th ra of dirct-acting antivi- rals. Thrap Adv Gastrontrol. 2020;13:1756284820942617. [PMID: 32782479] Roth D t al. KDOQI US commntary on th 2018 KDIGO clini- cal practic guidlin for th prvntion, diagnosis, valua- tion, and tratmnt of hpatitis C. Am J Kidny Dis. 2020;75: 665. [PMID: 32279907]9.  Systemic Luus EytematosusRnal invol vmnt occurs in 35–90% of patints who hav SLE, with highr stimats ncompassing subclinical dis- as. Rats of lupus nphritis ar highst in non-Whits. Th pathognsis may b dysrgulatd cllular apoptosis rsulting in autoantibodis against nuclosoms; antibody/ nuclosom complxs thn bind to componnts of th glomrulus to form immun complx glomrular disas. S Chaptr 20 for furthr discussion of SLE. Th trm “lupus nphritis” ncompasss many possibl pattrns of rnal injury—most cass prsnt within th nphritic spctrum (class I–IV). Nonglomrular syn- droms includ tubulointrstitial nphritis and vasculitis. All patints with SLE should hav routin urinalyss to monitor for th apparanc of hmaturia or protinuria. If urinary abnormalitis ar dtctd, kidny biopsy is oftn prformd. Th Intrnational Socity of Nphrology and Rnal Pathology Socity classification of rnal glomrular lsions is class I, minimal msangial nphritis; class II, msangial prolifrativ nphritis; class III, focal (lss than 50% of glomruli affctd with capillary involvmnt) pro- lifrativ nphritis; class IV , diffus (gratr than 50% of glomruli affctd with capillary involvmnt) prolifrativ nphritis; class V , mmbranous nphropathy; and class VI, advancd sclrosis without rsidual disas activity. Classs III and IV , th most svr forms of lupus nphritis, ar furthr classifid as activ or chronic, and global or sg- mntal, which confrs additional prognostic valu. »TreatmentIndivid uals with class I and class II lesions gnrally rquir no tratmnt; corticostroids or calcinurin inhibi- tors should b considrd for thos with class II lsions with nphrotic-rang protinuria. Transformation of ths typs to a mor activ lsion may occur and is usually accompanid by an incras in lupus srologic activity (g, rising titrs of anti–doubl-strandd DNA antibodis and falling C3 and C4 lvls) and incrasing protinuria or fall- ing GFR. Rpat biopsy in such patints is rcommndd. Hydroxychloroquin should b considrd for all patints with lupus nphritis, rgardlss of histological class.CMDT22_Ch22_p0912-p0951.indd  939 02/07/21 2:33 PMChApTEr 22940 CMDT 2022Pa tints with xtnsiv class III lesions and all class IV lesions should rciv aggrssiv immunosupprssiv thrapy. Poor prognostic indicators in patints with class III or IV lsions includ lvatd srum cratinin, lowr complmnt lvls, mal sx, prsnc of antiphospholipid antibodis, nphrotic-rang protinuria, African dscnt (possibly in association with APOL1 risk allls), and poor rspons to thrapy. Immunosupprssiv thrapy for class V lupus nphritis is indicatd if suprimposd prolifrativ lsions xist. Class VI lsions should not b tratd. Tratmnt of class III or IV lupus nphritis consists of induction thrapy, followd by maintnanc thrapy. Induction thrapy includs corticostroids (g, mthyl- prdnisolon 1 g intravnously daily for 3 days followd by prdnison, 1 mg/kg orally daily with subsqunt tapr ovr 6–12 months) in combination with ithr cyclophos- phamid or mycophnolat moftil. Data suggst that Blacks and Hispanics rspond mor favorably to mycoph- nolat moftil than cyclophosphamid; in addition, myco- phnolat moftil has a mor favorabl sid-ffct profil than cyclophosphamid and should b favord whn prs- rvation of frtility is a considration. Mycophnolat moftil induction is typically givn at 2–3 g orally daily, thn taprd to 1–2 g/day for maintnanc. Cyclophospha- mid induction rgimns vary but usually involv monthly intravnous puls doss (500–1000 mg/m2) for 6 months. Induction is followd by daily oral mycophnolat moftil or azathioprin maintnanc thrapy; mycophnolat moftil may b suprior to azathioprin maintnanc and causs fw advrs ffcts. Maintnanc with calcinurin inhibitors may also b considrd, but th rlaps rat is high upon discontinuation of ths agnts. With standard thrapy, rmission rats with induction vary from 80% for partial rmission to 50–60% for full rmission; it may tak mor than 6 months to s ths ffcts. Rlaps is com- mon and rats of disas flar ar highr in thos who do not xprinc complt rmission; similarly, progrssion to ESKD is mor common in thos who rlaps mor fr- quntly, or in whom no rmission has bn achivd. Th us of add-on B-cll-targtd thrapy with rituximab or blimumab for class III, IV , and/or V disas may b con- sidrd. Pur class V disas is tratd with mycophnolat moftil with or without rituximab. Th lvls of various disas activity markrs (doubl- strandd DNA antibodis, srum C3, C4, CH50lvls) and th urinary protin lvls and sdimnt activity can b us- ful in monitoring rspons to tratmnt; howvr, rpat rnal biopsy yilds mor rliabl information rgarding disas activity and may b usd to guid maintnanc thrapy withdrawal. Patints with SLE who undrgo dialy- sis hav a favorabl prospct for long-trm survival; intr- stingly, systmic lupus symptoms may bcom quiscnt with th dvlopmnt of ESKD. Patints with SLE undr- going kidny transplants can hav rcurrnt rnal disas, although rats ar rlativly low.Fan ouriakis A t al. 2019 updat of th Joint Europan Lagu Against Rhumatism and Europan Dialysis and Transplant Association (EULAR/ERA-EDTA) rcommndations for th managmnt of lupus nphritis. Ann Rhum Dis. 2020;79:713. [PMID: 32220834]Furi R t al. Two-yar, randomizd, controlld trial of blimumab in lupus nphritis. N Engl J Md. 2020;383:1117. [PMID: 32937045] Parikh SV t al. Updat on lupus nphritis: Cor Curriculum 2020. Am J Kidny Dis. 2020;76:265. [PMID: 32220510]NE PHROTIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Proteinuria with bland urine sediment (few if any cells or cellular casts). »Nephrotic syndrome (if present) manifestations: – Nephrotic-range proteinuria (urine protein excretion > 3 g per 24 hours). –Hypoalbuminemia (albumin < 3 g/dL). –Peripheral edema. –Hyperlipidemia. –Oval fat bodies may be seen in the urine. »General ConsiderationsIn Amrican  adults, th most common caus of nphrotic spctrum glomrular disas is diabts mllitus. Othr causs includ minimal chang disas, FSGS, mmbra- nous nphropathy, and amyloidosis. Any of ths ntitis can prsnt on th lss svr nd of th nphrotic spc- trum with a bland urinalysis and protinuria or on th most svr nd of th full nphrotic syndrom. Srum cratinin may b abnormal at th tim of prsntation, dpnding on th svrity and chronicity of th disas. »Clinical FindingsA.  Symptoms and SignsPa tints with subnphrotic rang protinuria do not mani- fst symptoms of kidny disas. In thos with th nphrotic syndrom, priphral dma is prsnt—most likly du both to sodium rtntion and hypoalbuminmia- inducd low plasma oncotic prssur. Edma may dvlop solly in dpndnt rgions, such as th lowr xtrmitis, or it may bcom gnralizd and includ priorbital dma. Dyspna du to pulmonary dma, plural ffu- sions, and diaphragmatic compromis du to ascits can occur.B.  Laboratory Findings1. Urinalysis—  Protinuria occurs as a rsult of podocyto- pathy and variabl altrations of th GBM. Th urin dip- stick is a good scrning tst for albuminuria; if positiv, urinary protin xcrtion should b quantifid (s arlir Protinuria sction). A spot urin protin to urin crati- nin ratio givs a rasonabl approximation of grams of protin xcrtd pr day; a 24-hour urin sampl for pro- tin xcrtion is rarly ndd.CMDT22_Ch22_p0912-p0951.indd  940 02/07/21 2:33 PMKIDNEY DISEASE941 CMDT 2022Microscop ically, th urinary sdimnt has rlativly fw cllular lmnts or casts. Howvr, if markd hyprlipid- mia is prsnt, urinary oval fat bodis may b sn. Thy appar as “grap clustrs” undr light microscopy and “Malts crosss” undr polarizd light. 2. Blood chemistries— Th nphrotic syndrom rsults in hypoalbuminmia (lss than 3 g/dL [30 g/L]). Hyprlipid- mia, du both falling oncotic prssur triggring incrasd hpatic production of lipids and to dcrasd claranc of vry low-dnsity lipoprotins causing hyprtriglycrid- mia, occurs in ovr 50% of patints with arly nphrotic syndrom, and bcoms mor frqunt and worsns in dgr as th svrity of th nphrotic syndrom incrass. An lvatd rythrocyt sdimntation rat may b sn as a rsult of incrasd lvls of fibrinogn. Havy urinary xcrtion of binding protins may rsult in dficincis of vitamin D, zinc, and coppr. Laboratory tsting to hlp lucidat th undrlying caus of th glomrular disas includs complmnt lvls, srum and urin protin lctrophorsis, srum fr light chains, antinuclar antibodis, PLA2R antibody titrs, HbA1c, and srologic tsting for hpatitis B and C, HIV , and syphilis. 3. Kidney biopsy— Kidny biopsy is oftn prformd in adults with nw-onst idiopathic nphrotic syndrom if a primary rnal disas that may rquir immunosupprssiv thrapy is suspctd. Chronically and significantly dcrasd GFR indicats irrvrsibl kidny disas mitigating th usfulnss of kidny biopsy. In th stting of long-standing diabts mllitus typ 1 or 2, protinuric rnal disas is rarly biopsid unlss atypical faturs (such as significant glomrular hmaturia or cllular casts) ar also prsnt, or if thr is othr rason to suspct an additional rnal lsion. »TreatmentA.  Protein LossIn  thos with subnphrotic protinuria, ditary protin rstriction may b hlpful in slowing progrssion of kidny disas (s CKD sction). In both diabtic and nondiabtic patints, anti-protin- uric thrapy should also slow progrssion of kidny dis- as. ACE inhibitors and ARBs rduc urin protin xcrtion by dcrasing glomrular capillary prssur and also hav antifibrotic ffcts. Thy can b usd in patints with rducd GFR as long as significant hyprkalmia (potassium gratr than 5.2–5.5 mEq/L or mmol/L) dos not occur and srum cratinin riss lss than 30% aftr drug initiation or dos titration; patints should b moni- tord closly to avoid AKI and hyprkalmia. Combination thrapy of an ARB and an ACE inhibitor incrass risk for AKI and hyprkalmia and is not rcommndd.B.  EdemaDitary  salt rstriction is ssntial for managing dma; most patints also rquir diurtic thrapy. A combination of loop and thiazid diurtics may b ndd for rfractory fluid rtntion. Both thiazid and loop diurtics ar highly protin bound; thrfor, with hypoalbuminmia and dcrasd GFR, diurtic dlivry to th kidny is rducd and largr doss oftn ar rquird.C. HyperlipidemiaH yprcholstrolmia and hyprtriglycridmia occur as notd abov. Ditary modification and xrcis should b advocatd; howvr, ffctiv lipid-lowring usually also rquirs pharmacologic tratmnt (s Chaptr 28). Thr is significant risk of rhabdomyolysis in patints with CKD who tak gmfibrozil in combination with statins; combin- ing fnofibrat or niacin with a statin is prfrrd.D . Hypercoagulable StatePa tints with nphrotic syndrom hav urinary losss of antithrombin, protin C, and protin S and incrasd plat- lt activation. Patints with srum albumin lss than 2 g/dL (20 g/L) hav considrabl risk for thrombophilia and may dvlop rnal vin thrombosis, pulmonary mbolus, and othr vnous thrombomboli; this is particularly likly with mmbranous nphropathy. Anticoagulation thrapy with warfarin is warrantd for at last 3–6 months in patints with vidnc of thrombosis in any location and may b rquird indfinitly for rnal vin thrombosis, pulmonary mbolus, rcurrnt thrombomboli or whn ongoing nphrotic syndrom poss a risk of thrombosis rcurrnc. »When to ReferAny  patint with th nphrotic syndrom should b rfrrd immdiatly to a nphrologist for volum and blood prssur managmnt, assssmnt for kidny biopsy, and tratmnt of th undrlying disas. Protinuria of mor than 1 g/24 hours without th nphrotic syndrom also mrits nphrology rfrral, though with lss urgncy. »When to AdmitPa tints with dma rfractory to outpatint thrapy or rapidly worsning kidny function that may rquir inpa- tint intrvntions should b admittd.Böknkamp  A. Protinuria—tak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Politano SA t al. Nphrotic syndrom. Prim Car. 2020;47:597. [PMID: 33121631] Wang CS t al. Nphrotic syndrom. Pdiatr Clin North Am. 2019;66:73. [PMID: 30454752] ºNEphrOTIC SpECTrUM DISEASE IN prIMArY rENAL DISOrDErS MINIMAL CHANGE DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Nephrotic-range proteinuria. »Kidney biopsy shows no changes on light microscopy. »Characteristic foot-process effacement on electron microscopy.CMDT22_Ch22_p0912-p0951.indd  941 02/07/21 2:33 PMChApTEr 22942 CMDT 2022 »General ConsiderationsMinimal cha ng disas is th most common caus of pro- tinuric rnal disas in childrn, accounting for about 80% of cass. It oftn rmits upon tratmnt with a cours of corticostroids. Indd, childrn with nphrotic syn- drom ar oftn tratd for minimal chang disas mpir- ically without a biopsy diagnosis. Minimal chang disas is lss common in adults, accounting for 20–25% of cass of primary nphrotic syndrom in thos ovr ag 40 yars. This ntity can b idiopathic but also occurs following viral uppr rspiratory infctions (spcially in childrn), in association with noplasms such as Hodgkin disas, with drugs (lithium), and with hyprsnsitivity ractions (sp- cially to NSAIDs and b stings). »Clinical FindingsA.  Symptoms and SignsPa tints prsnt with nphrotic syndrom, which confrs suscptibility to infction, tndncy toward thrombom- bolic vnts, svr hyprlipidmia, and possibly protin malnutrition. Minimal chang disas can caus AKI du to rnal tubular damag and intrstitial dma.B.  Laboratory and Histologic FindingsTh r is no hlpful srologic tsting. Biopsy should b consid- rd for childrn with nphrotic syndrom who xhibit unusual faturs (such as signs of othr systmic illnss), or who ar stroid-rsistant or rlaps upon withdrawal of corti- costroid thrapy; th lattr two conditions may indicat an undrlying focal and sgmntal glomrulosclrosis rathr than minimal chang disas. Whn kidny biopsy is pr- formd, glomruli appar normal on light microscopy and immunofluorscnc. On lctron microscopy, thr is a charactristic ffacmnt of podocyt foot procsss. Msan- gial cll prolifration may b sn in a subgroup of patints; this finding is associatd with mor hmaturia and hyprtn- sion and poor rspons to standard corticostroid tratmnt. »TreatmentT ratmnt is with prdnison, 60 mg/m2/day orally; rmis- sion in stroid-rsponsiv minimal chang disas gnr- ally occurs within 4–8 wks. Adults oftn rquir longr courss of thrapy than childrn, rquiring up to 16 wks to achiv a rspons. Tratmnt should b continud for svral wks aftr complt rmission of protinuria, and dosing taprs should b individualizd. A significant num- br of patints will rlaps and rquir rpatd corticost- roid tratmnt. Patints with frqunt rlapss or corticostroid rsistanc may rquir cyclophosphamid, a calcinurin inhibitor (tacrolimus, cyclosporin), or ritux- imab to induc subsqunt rmissions. Progrssion to ESKD is rar. Complications most oftn aris from pro- longd corticostroid us.M djral-Thomas NR t al. Randomizd, controlld trial of tacro- limus and prdnisolon monothrapy for adults with de novo minimal chang disas: a multicntr, randomizd, controlld trial. Clin J Am Soc Nphrol. 2020;15:209. [PMID: 31953303]FOCAL SEGMENTAL GLOMERULOSCLEROSIS »General ConsiderationsThis r lativly common rnal pattrn of injury rsults from damag to podocyts; such damag may b a primary/ rnal-limitd disordr or may b scondary to anothr undrlying disas stat. Primary causs fall into thr cat- goris: (1) hritabl abnormalitis in any on of svral podocyt protins, or to undrlying typ 4 collagn muta- tions; (2) polymorphisms in th APOL1 gn in thos of African ancstry; or (3) incrasd lvls of a circulating prmability factor. Scondary causs includ rnal ovr- work injury, obsity, hyprtnsion, chronic urinary rflux, HIV or SARS-CoV-2 infction, or analgsic or bisphospho- nat xposur. Gntic tsting in primary cass is bcoming mor common, spcially in th pdiatric population. »Clinical FindingsIn  FSGS causd by a primary kidny disas, 80% of chil- drn and 50% of adults hav ovrt nphrotic syndrom; howvr, whn it dvlops du to a scondary caus, frank nphrotic syndrom is uncommon. Dcrasd GFR is prs- nt in 25–50% of thos with FSGS at tim of diagnosis. Diagnosis rquirs kidny biopsy; thr is no hlpful srologic tst. Light microscopy shows sclrosis of sg- mnts of som, but not all, glomruli. On immunofluors- cnc, IgM and C3 ar sn in th sclrotic lsions, although it is prsumd that ths immun componnts ar simply trappd in th sclrotic glomruli and not pathog- ntic. As in minimal chang disas, lctron microscopy shows fusion of pithlial foot procsss. »TreatmentT ratmnt for all forms of FSGS includs diurtics for dma, ACE inhibitors or ARBs to control protinuria and hyprtnsion, and statins or niacin for hyprlipidmia. Immunosupprssion thrapy (oral prdnison, 1 mg/kg/ day for 4–16 wks followd by a slow tapr) is rsrvd for nphrotic primary FSGS cass prsumd to b du to a circulating prmability factor; in thos with stroid- rsistanc or intolranc, calcinurin inhibitors and myco- phnolat moftil can b considrd. Kidny transplantation in this subgroup of FSGS patints is complicatd by a rla- tivly high rlaps rat and risk of graft loss. Thos with APOL1 -associatd and nonhrditary primary rnal dis- as may not bnfit from immunosupprssion, although robust clinical trials ar lacking. Patints with scondary FSGS do not bnfit from immunosupprssiv thrapy; tratmnt should b dirctd at th inciting caus.Ahn  W t al. Approach to diagnosis and managmnt of primary glomrular disass du to podocytopathis in adults: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:955. [PMID: 32331832] Andrs HJ t al. SGLT2 inhibition rquirs rconsidration of fundamntal paradigms in chronic kidny disas, ‘diabtic nphropathy’ , IgA nphropathy and podocytopathis with FSGS lsions. Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 33313878]CMDT22_Ch22_p0912-p0951.indd  942 02/07/21 2:33 PMKIDNEY DISEASE943 CMDT 2022Shabaka  A t al. Focal sgmntal glomrulosclrosis: stat-of- th-art and clinical prspctiv. Nphron. 2020;144:413. [PMID: 32721952]ME MBRANOUS NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S »Varying degrees of proteinuria. »Most common cause of primary adult nephrotic syndrome. »Significant risk for hypercoagulable state if nephrotic syndrome present. »“Spike and dome” pattern on kidney biopsy from subepithelial deposits. »Secondary causes include hepatitis B virus and carcinomas. »General ConsiderationsMm branous nphropathy is th most common caus of primary nphrotic syndrom in adults, most oftn prsnting in th fifth and sixth dcads. Primary mmbranous nphropathy is an autoimmun disas with ractivity against svral possibl podocyt antigns. Scondary disas is associatd with infctions, such as hpatitis B and C, ndo- carditis, and syphilis; undrlying carcinomas (som of ths cass may also involv autoimmunity to THSD7A); autoim- mun disas, such as SLE, mixd connctiv tissu disas, and thyroiditis; and crtain drugs, such as NSAIDs and cap- topril. Th cours of primary disas is highly variabl, with spontanous rmission in approximatly 30% of patints and progrssion to ESKD ovr 3–10 yars in 50%. Poorr out- com is associatd with concomitant tubulointrstitial fibro- sis, mal sx, lvatd srum cratinin on prsntation, hyprtnsion, and protinuria gratr than 10 g/day. Patints with mmbranous nphropathy and nphrotic syndrom hav a highr risk of hyprcoagulabl stat with thrombosis than nphrosis from othr tiologis, including a particular prdisposition to rnal vin thrombosis. »Clinical FindingsA.  Symptoms and SignsPa tints may b asymptomatic or may hav dma or frothy urin. Symptomatic vnous thrombosis may b an initial sign. Thr may b symptoms or signs of an undrlying infction or noplasm (spcially lung, stomach, brast, and colon cancrs) in scondary mmbranous nphropathy.B.  Laboratory FindingsH ypoalbuminmia and hyprlipidmia ar charactristic laboratory findings in th nphrotic syndrom. Evaluation for scondary causs including srologic tsting for SLE, syphilis, and viral hpatitids, and ag- and risk-appropri- at cancr scrning should b prformd. Elvatd titr ofcirculating PLA2R antibodis is now considrd diagnostic for primary mmbranous nphropathy and may liminat th nd for kidny biopsy. Kidny biopsy findings in mmbranous nphropathy includ incrasd capillary wall thicknss without inflammatory changs or cllular prolif- ration; whn staind with silvr mthnamin, a “spik and dom” pattrn rsults from projctions of xcss GBM btwn th subpithlial immun complx dposits. Immunofluorscnc shows IgG and C3 staining along capillary loops. Elctron microscopy shows a discontinu- ous pattrn of dns dposits along th subpithlial sur- fac of th basmnt mmbran. »TreatmentScondary  causs must b considrd prior to considr- ation of tratmnt. Primary disas tratmnt dpnds on th risk of rnal disas progrssion. Roughly 30% of patints prsnt with subnphrotic protinuria (lss than 3 g/day) and most hav a good prognosis with consrvativ managmnt, including antiprotinuric thrapy with ACE inhibitor or ARB if blood prssur is gratr than 125/75 mm Hg. Spontanous rmission may dvlop vn in thos with havy protinuria (about 30% of cass). Thus, us of immunosupprssiv agnts should b limitd to thos at highst risk for progrssion and with salvagabl rnal function. Patints with nphrotic syndrom dspit 6 months of consrvativ managmnt and srum crati- nin lss than 3.0 mg/dL (265 mcmol/L) may lct thrapy with rituximab or with corticostroids and cyclophospha- mid for 6 months. Calcinurin inhibitors with or without corticostroids may b considrd as wll. Rduction in protinuria may tak up to 6 months, spcially with rituximab-basd rgimns. Patints with primary mmbra- nous nphropathy ar xcllnt candidats for transplant.Frvnza FC  t al; MENTOR Invstigators. Rituximab or cyclo- sporin in th tratmnt of mmbranous nphropathy. N Engl J Md. 2019;381:36. [PMID: 31269364] Safar-Bouri L t al. Mmbranous nphropathy: diagnosis, trat- mnt, and monitoring in th post-PLA2R ra. Pdiatr Nphrol. 2021;36:19. [PMID: 31811540] Trujillo H t al. Nw ways of undrstanding mmbranous nphropathy. Nphron. 2020;144:261. [PMID: 32229730] ºNEphrOTIC SpECTrUM DISEASE FrOM SYSTEMIC DISOrDErS DIABETIC NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S »Evidence of diabetes mellitus, typically over 10 years. »Albuminuria usually precedes decline in GFR. »Other end-organ damage, such as retinopathy, is common.CMDT22_Ch22_p0912-p0951.indd  943 02/07/21 2:33 PMChApTEr 22944 CMDT 2022 »General ConsiderationsDiabtic nphropa thy is th most common caus of ESKD in th Unitd Stats. Th incidnc is approximatly 30% in both typ 1 and typ 2 diabts mllitus. ESKD is much mor likly to dvlop in prsons with typ 1 diabts ml- litus, in part du to fwr comorbiditis and daths bfor ESKD nsus. With th currnt pidmic of obsity and typ 2 diabts mllitus, rats of diabtic nphropathy will con- tinu to incras. Patints at highr risk includ mals, African Amricans, Nativ Amricans, and thos with a family history of kidny disas. Mortality rats ar highr for diabt- ics with kidny disas compard to thos without CKD. »Clinical FindingsDiabtic  nphropathy dvlops about 10 yars aftr th onst of diabts mllitus. It may b prsnt at th tim typ 2 diabts mllitus is diagnosd. Th first stag of clas- sic diabtic nphropathy is hyprfiltration with an incras in GFR, followd by th dvlopmnt of microalbuminuria (30–300 mg/day). With progrssion, albuminuria incrass to gratr than 300 mg/day and can b dtctd on a urin dipstick as ovrt protinuria; th GFR subsquntly dclins ovr tim. Yarly scrning for microalbuminuria is rcommndd for all diabtic patints to dtct disas at its arlist stag; howvr, diabtic nphropathy can, lss commonly prsnt as nonprotinuric CKD. Th most common lsion in diabtic nphropathy is diffus glomrulosclrosis, but nodular glomrulosclrosis (Kimmlstil-Wilson noduls) is pathognomonic. Th kidnys ar usually nlargd. Kidny biopsy is not rquird in most patints unlss atypical findings ar prsnt, such as suddn onst of protinuria, nphritic spctrum faturs (s abov), massiv protinuria (gratr than 10 g/day), urinary cllular casts, or rapid dclin in GFR. Patints with diabts ar pron to othr rnal disass. Ths includ papillary ncrosis, chronic intrstitial nphri- tis, and typ 4 (hyporninmic hypoaldostronmic) rnal tubular acidosis. Patints ar mor suscptibl to AKI from many insults, including intravnous contrast matrial and concomitant us of an ACE inhibitor or ARB with NSAID. »TreatmentW ith th onst of microalbuminuria, aggrssiv tratmnt is ncssary. Strict glycmic control should b mphasizd arly in diabtic nphropathy, with rcognition of risk of hypoglycmia as CKD bcoms advancd (s CKD sc- tion). Rcommndd blood prssur goals should b tai- lord to th individual patint: basd on th ACCORD trial, thos with microalbuminuria (30–300 mg/day) and prsrvd GFR and thos with significant CVD likly driv littl bnfit from blood prssur lowring much blow 140/90 mm Hg, although th 2017 guidlins from th Amrican Hart Association advocat tratmnt to 130/80 mm Hg or lss. Thos with ovrt protinuria (sp- cially mor than 1 g/day) bnfit from a goal of lss than 130/80 mm Hg. ACE inhibitors and ARBs in thos with microalbuminuria lowr th rat of progrssion to ovrt protinuria and slow progrssion to ESKD by rducing intraglomrular prssur and via antifibrotic ffcts; thsagnts ar not absolutly indicatd in diabtic patints without albuminuria. Diabtic patints, spcially with advancd CKD, ar at rlativly high risk for AKI and hyprkalmia with inhibition of th rnin-angiotnsin sys- tm, so monitoring for hyprkalmia or a dclin in GFR mor than 30% within ~2 wks of th initiation or uptitra- tion of this thrapy is prudnt, with dos rduction or dis- continuation of thrapy if ths complications ar ncountrd. Combination ARB and ACE inhibitor therapy is not recommended due to lack of efficacy and increased adverse events of hyperkalemia and AKI. In addition to thir cardioprotctiv ffcts, th SGLT inhibitors, includ- ing canagliflozin, mpagliflozin, and dapagliflozin, slow progrssion of diabtic nphropathy; thir us is limitd to thos with typ 2 diabts mllitus with GFR gratr than 30 mL/min/1.73 m2. Us of ths agnts may rquir rduction in diurtic dosing in thos patints rquiring natriursis. Tratmnt of othr cardiovascular risk factors and obsity is crucial. Many with diabts hav multipl comorbid conditions; thrfor, in patints with ESKD who progrss to dialysis, mortality ovr th first 5 yars is high. Patints who ar rlativly halthy, howvr, bnfit from rnal transplantation.Bakris  G. Stmming th progrssion of diabtic kidny disas: th rol of th primary car clinician. J Fam Prac. 2020;69:S81. [PMID: 33104113] D Bor IH t al. Excutiv summary of th 2020 KDIGO Diab- ts Managmnt in CKD Guidlin: vidnc-basd advancs in monitoring and tratmnt. Kidny Int. 2020;98:839. [PMID: 32653403] Li J t al. Dcision algorithm for prscribing SGLT2 inhibitors and GLP-1 rcptor agonists for diabtic kidny disas. Clin J Am Soc Nphrol. 2020;15:1678. [PMID: 32518100] Tuttl KR t al. SLGT2 inhibition for CKD and cardiovascular disas in typ 2 diabts: rport of a scintific workshop sponsord by th National Kidny Foundation. Am J Kidny Dis. 2021;77:94. [PMID: 33121838]HI V-ASSOCIATED NEPHROPATHYHI V-associatd nphropathy usually prsnts with nphrotic syndrom and dclining GFR in patints with activ HIV infction. Most who prsnt with HIV-associatd nphropathy ar of African dscnt with APOL1 risk allls (s sction on Focal Sgmntal Glomrulosclrosis). HIV- associatd nphropathy is usually associatd with low CD4 counts and AIDS, but it can also b th initial prsntation of HIV disas. Prsons living with HIV ar at risk for othr kidny disass, such as toxicity from antirtroviral mdica- tions (g, tnofovir disoproxil fumarat), vascular disas, and diabts, or an immun complx–mdiatd glomrular disas (HIV-immun complx disas). Classic HIV-associatd nphropathy is charactrizd by an FSGS pattrn of injury with glomrular collaps; svr tubulointrstitial damag may also b prsnt. HIV-associatd nphropathy is lss common in th ra of HIV scrning and mor ffctiv antirtroviral thrapy. Small, uncontrolld studis hav shown that antirtroviral thrapy slows progrssion of disas. ACE inhibitors or ARBs can b usd to control blood prssur and protin- uria. Kidny biopsy is ncssary for diagnosis and to rulCMDT22_Ch22_p0912-p0951.indd  944 02/07/21 2:33 PMKIDNEY DISEASE945 CMDT 2022out  othr causs of kidny dysfunction. Patints who prog- rss to ESKD and ar othrwis halthy ar good candi- dats for kidny transplantation.H amzah L t al. Optimizing antirtroviral rgimns in chronic kid- ny disas. Curr Opin Infct Dis. 2019;32:1. [PMID: 30461453] Naickr S. HIV/AIDS and chronic kidny disas. Clin Nphrol. 2020;93:87. [PMID: 31397267]RE NAL AMYLOIDOSISAm yloidosis is a rlativly rar caus of nphrotic syndrom. It is causd by tissu dposition of an ovrproducd and abnormally foldd protin (amyloid). Svral diffrnt pro- tins can form amyloid fibrils with rnal dposition. Primary amyloidosis, or AL amyloidosis, is th most common form and is du to a plasma cll dyscrasia causing ovrproduction and dposition of monoclonal Ig light chains (s Chaptr 13). Scondary amyloidosis, or AA amyloidosis, can rarly occur in chronic inflammatory disas such as rhumatoid arthri- tis, inflammatory bowl disas, or chronic infction; in ths cass, thr is dposition of an acut phas ractant, srum amyloid A protin. Othr lss common forms of amy- loidosis may also b ncountrd. Protinuria, dcrasd GFR, and nphrotic syndrom ar prsnting symptoms and signs of rnal involvmnt in amyloidosis; vidnc of othr organ involvmnt, such as th hart, is common. Srum and urin protin lctropho- rsis should b don as scrning tsts; if a monoclonal spik is found on ithr, srum fr light chains should b quantifid and th kappa:lambda ratio assssd. Amyloid- affctd kidnys ar oftn largr than 10 cm. Pathologi- cally, glomruli ar filld with amorphous dposits that show grn birfringnc with Congo rd staining. AL amyloidosis progrsss to ESKD in an avrag of 2–3 yars. Fiv-yar ovrall survival is lss than 20%, with wors prognosis in thos with advancd cardiac involv- mnt. Standard tratmnt is a combination of mlphalan, corticostroids, and th protosom inhibitor bortzomib; addition of daratumumab shows promis. Mlphalan and autologous stm cll transplantation ar associatd with a high (45%) mortality rat but can induc rmission in 80% of survivors; howvr, fw patints ar ligibl for this tratmnt. In AA amyloidosis, rmission can occur if th undrlying disas is succssfully tratd. Rnal transplan- tation is an option.H ogan JJ t al. Dysprotinmia and th kidny: Cor Curriculum 2019. Am J Kidny Dis. 2019;74:822. [PMID: 31331759] Mn P t al. Monoclonal gammopathis of rnal significanc: rnal biopsy and byond. Cancrs (Basl). 2020;12:1741. [PMID: 32629844] Palladini G t al. Managmnt of AL amyloidosis in 2020. Hma- tology Am Soc Hmatol Educ Program. 2020;2020:363. [PMID: 33275753] ºTUBULOINTErSTITIAL DISEASEST ubulointrstitial disas may b acut or chronic. Acut disas is most commonly associatd with mdications, infctious agnts, and systmic rhumatologic disordrs.Intrstitial dma, infiltration with polymorphonuclar nutrophils, and accompanying ATN can b sn. (S Acut Kidny Injury, abov, and Tabl 22–9.) Chronic dis- as is associatd with insults from an acut factor or pro- grssiv insults without any obvious acut caus. Intrstitial fibrosis and tubular atrophy ar prsnt, with a mononu- clar cll prdominanc. Th chronic disordrs ar dscribd blow.CH RONIC TUBULOINTERSTITIAL DISEASESE S S E N T I A L S  O F  D I A G N O S I S »Kidney size is small and contracted. »Decreased urinary concentrating ability. »Hyperchloremic metabolic acidosis. »Reduced GFR.Table 22–9. Causes of acute tubulointerstitial nephritis (abbreviated list).Dug  reactions Antibiotics Beta-lactam antibiotics: methicillin, penicillin, ampicillin, cephalosporins Ciprofloxacin Erythromycin Sulfonamides (trimethoprim-sulfamethoxazole, loop and thiazide diuretics) Tetracycline Vancomycin Ethambutol Rifampin Nonsteoidal anti-inflammatoy dugs Diuetics Thiazides Furosemide Ote Allopurinol Cimetidine Phenytoin Proton pump inhibitors Systemic Infections Bacteia Streptococcus Corynebacterium diphtheriae Legionella Viuses Epstein-Barr Ote Mycoplasma Rickettsia rickettsii Leptospira icterohaemorrhagiae Toxoplasma Idioatic Tubulointerstitial nephritis-uveitisCMDT22_Ch22_p0912-p0951.indd  945 02/07/21 2:33 PMChApTEr 22946 CMDT 2022 »General ConsiderationsTh  most common caus of chronic tubulointrstitial disas isobstructive uropathy , which may rsult from prolongd or rcurrnt obstruction. Th major causs ar prostat dis- as in mn; urtral calculus in a singl functioning kidny; bilatral urtral calculi; carcinoma of th crvix, colon, or bladdr; and rtropritonal tumors or fibrosis. Rflux nphropathy from vesicoureteral reflux is pri- marily a disordr of childhood and occurs whn urin passs rtrograd from th bladdr to th kidnys during voiding. It is th scond most common caus of chronic tubulointrstitial disas. It occurs as a rsult of an incom- ptnt vsicourtral sphinctr. Urin can xtravasat into th intrstitium, triggring an inflammatory rspons that lads to fibrosis ovr tim. Th inflammatory rspons is du to ithr bactria or normal urinary componnts. Analgesic nephropathy is most commonly sn in patints who ingst larg quantitis of pain mdication. Th drugs of concrn ar phnactin, paractamol, aspirin, and othr NSAIDs; actaminophn is a possibl but lss crtain culprit. Ingstion of at last 1 g/day for 3 yars of ths analgsics is considrd ncssary for kidny dys- function to dvlop, and most patints grossly undrsti- mat thir analgsic us. This disordr occurs most frquntly in individuals who ar using analgsics for chronic hadachs, muscular pains, and arthritis; fmal sx, oldr ag, and malnutrition ar risk factors for analg- sic nphropathy. Tubulointrstitial inflammation and pap- illary ncrosis ar sn on pathologic xamination. Papillary tip and innr mdullary concntrations of som analgsics ar tnfold highr than in th rnal cortx. Phnactin was onc a common caus of this disordr but is now rarly availabl. Aspirin and othr NSAIDs can caus damag through intrmdiat mtabolits, which can lad to cll ncrosis. Ths drugs also dcras mdul- lary blood flow (via inhibition of prostaglandin synthsis) and dcras glutathion lvls, which ar ncssary for dtoxification. Environmntal xposur to heavy metals —such as lad, cadmium, mrcury, and bismuth—occurs infr- quntly now in th Unitd Stats but can caus tubuloint- rstitial disas. Individuals at risk for lad-inducd tubulointrstitial disas ar thos with occupational xpo- sur (g, wldrs who work with lad-basd paint) and drinkrs of alcohol distilld in automobil radiators (“moonshin” whisky usrs). Lad is filtrd by th glom- rulus and is transportd across th proximal convolutd tubul, whr it accumulats and causs cll damag. Fibrosd artriols and cortical scarring also lad to dam- agd kidnys. A form of chronic tubulointrstitial disas dispropor- tionatly affcting mal agricultural workrs in Cntral Amrica is an important caus of ESKD. Whil th xact pathophysiology is still unknown, th trm Mesoamerican nephropathy is applid to rflct th gographic rgion in which this disas occurs. Affctd individuals tnd to b 30–50 yars of ag without diabts, hyprtnsion, or othr causs of kidny disas who work undr hot conditions, particularly in sugar can or cotton filds, and ar thus suscptibl to dhydration.»Clinical FindingsA.  General FindingsPo lyuria is common bcaus tubular damag lads to nphrognic diabts insipidus, possibly from vasoprssin insnsitivity. Volum dpltion can also occur as a rsult of a salt-wasting dfct in som individuals. Patints can bcom hyprkalmic both bcaus th GFR is lowr and th distal tubuls bcom aldostron rsistant. Rnal tubular acidosis is common and dvlops through thr possibl mchanisms: (1) rducd ammonia production in th proximal tubuls, (2) inability to rab- sorb bicarbonat in th proximal tubuls, and (3) inability to scrt protons in th distal tubuls, which is ndd for urinary acidification. A typ 1 or typ 4 rnal tubular acidosis is mor commonly obsrvd in tubulointrstitial disas, xcpt in th cas of havy mtal xposur whr dirct proximal tubular damag lads to a proximal (typ 2) rnal tubular acidosis. In contrast to acut intrstitial nphritis, th urinalysis in chronic tubulointrstitial disas is oftn nonspcific; a fw clls or broad waxy casts may b sn, but urinalysis oftn is bland. Protinuria is typically lss than 2 g/day, owing to inability of th proximal tubul to rabsorb frly filtrabl protins.B.  Specific Findings1. Obstructive uropathy—  In partial obstruction, patints can xhibit polyuria (from tubular damag) or oliguria (du to dcrasd GFR). Azotmia and hyprtnsion (du to incrasd rnin-angiotnsin production) ar usually prsnt. Abdominal, rctal, and gnitourinary xamina- tions may b hlpful in dtcting a distndd bladdr or larg prostat. Urinalysis may show hmaturia, pyuria, and bactriuria but is oftn bland. Abdominal ultrasound may dtct mass lsions, hydrourtr, and hydronphrosis but may ovrlook 5% of cass. CT scanning or MRI can b considrd if suspicion rmains dspit a normal ultrasound. 2. Vesicoureteral reflux— Vsicourtral rflux is typically diagnosd in young childrn with a history of rcurrnt urinary tract infctions but can also dvlop aftr kidny transplantation. Rnal ultrasound or IVP can show rnal scarring and hydronphrosis. Although most damag occurs bfor ag 5 yars, progrssiv dtrioration to ESKD occurs. 3. Analgesics— Patints can xhibit hmaturia, mild pro- tinuria, polyuria (from tubular damag), anmia (from GI blding or rythropoitin dficincy), and stril pyuria. Sloughd papilla can b found in th urin whn papillary ncrosis occurs and can lad to obstruction. Although clas- sically diagnosd by IVP , papillary ncrosis is mor com- monly dtctd by CT imaging. 4. Heavy metals— Proximal tubular damag from lad xposur can caus dcrasd scrtion of uric acid, rsult- ing in hypruricmia and saturnin gout. Patints com- monly ar hyprtnsiv. Diagnosis is stablishd with a calcium disodium dtat (EDTA) chlation tst pr- formd on a timd urin collction. Urin xcrtion ofCMDT22_Ch22_p0912-p0951.indd  946 02/07/21 2:33 PMKIDNEY DISEASE947 CMDT 2022gratr  than 600 mg of lad following 1 g of EDTA indi- cats xcssiv lad xposur. Th proximal tubular dys- function from cadmium can caus hyprcalciuria and nphrolithiasis. 5. Mesoamerican nephropathy— In addition to low-grad protinuria, hypruricmia and hypokalmia ar consis- tntly (but not univrsally) idntifid among affctd indi- viduals. Although not pathognomonic, aras of glomrular ischmia (dspit vry mild vascular disas) that accom- pany chronic tubulointrstitial injury on kidny biopsy ar highly suggstiv of Msoamrican nphropathy. 6. Balkan nephropathy— Patints commonly dvlop pro- tinuria, glycosuria, acidosis, and suffr urinary concn- trating dfcts. Notably, urothlial carcinomas ar prsnt in approximatly 50% of affctd individuals at tim of diagnosis. »TreatmentT ratmnt dpnds first on idntifying th disordr rsponsibl for kidny dysfunction. Th dgr of intrsti- tial fibrosis on biopsy rflcts irrvrsibl damag, which is dirctly associatd with th liklihood of ESKD progrs- sion. Tratmnt is dirctd at mdical managmnt of risk factors for disas progrssion, such as hyprtnsion and protinuria. Tubular dysfunction may rquir bicarbonat supplmntation to trat mtabolic acidosis or phosphorus and potassium rstriction. If hydronphrosis is prsnt, th obstruction should b promptly rlivd. Prolongd obstruction lads to furthr tubular damag—particularly in th distal nphron— which may bcom irrvrsibl. Although surgical corrc- tion of rflux may b indicatd in slct circumstancs, this will unlikly prvnt dtrioration toward ESKD if fibrosis is xtnsiv. Patints in whom lad nphropathy is suspctd should continu chlation thrapy with EDTA if thr is minimalvidnc of irrvrsibl rnal damag, and continud xpo- sur should b avoidd. Tratmnt of analgsic nphropathy rquirs with- drawal of all analgsics. Stabilization of or improvmnt in kidny function may occur if significant intrstitial fibrosis is not prsnt. Ensuring volum rpltion during xposur to analgsics may also hav som bnficial ffcts. Patints with Msoamrican nphropathy should b counsld to rmain adquatly hydratd and, if possibl, minimiz hat xposur. NSAIDs should b avoidd du to thir hmodynamic ffcts (rducd rnal blood flow and glomrular filtration), which may xacrbat rnal injury in stats of volum dpltion and hot climats. »When to Refer• Patints with stag 3–5 CKD should b rfrrd to a nphrologist whn tubulointrstitial disass ar sus- pctd. Othr slct cass of stag 1–2 CKD should also b rfrrd, for xampl if rnal tubular acidosis is prsnt. •Patints with urologic abnormalitis should b rfrrd to a urologist.Cor ra-Rottr R t al. Msoamrican nphropathy. Smin Nphrol. 2019;39:263. [PMID: 31054625] ºCYSTIC DISEASES OF ThE KIDNEYRnal cysts  ar pithlium-lind cavitis filld with fluid or smisolid matrial that dvlop primarily from rnal tubu- lar lmnts. On or mor simpl cysts ar found in 50% of individuals ovr th ag of 50 yars. Thy ar rarly symp- tomatic and hav littl clinical significanc. In contrast, gnralizd cystic disass ar associatd with cysts scat- trd throughout th cortx and mdulla of both kidnys and can progrss to ESKD (Tabl 22–10). Table 22–10. Clinical features of renal cystic disease. Simle renal CystsAcquied renal CystsAutosomal Domi- nant polycystic Kidney DiseaseMedullay Songe KidneyMedullay Cystic Kidney Prevalence Common Dialysis patients 1:1000 1:5000 Rare Inheritance None None Autosomal dominant None Autosomal dominant Age at onset … … 20–40 years 40–60 years Adulthood Kidney size Normal Small Large Normal Small Cyst location Cortex and medulla Cortex and medulla Cortex and medulla Collecting ducts Corticomedullary junction Hematuria Occasional Occasional Common Rare Rare Hypertension None Variable Common None None Associated complicationsNone Adenocarcinoma in cystsHepatic cysts, urinary tract infections, renal calculi, cere- bral aneurysmsRenal calculi, urinary tract infectionsPolyuria, salt wasting Kidney failure Never Always Frequently Never AlwaysCMDT22_Ch22_p0912-p0951.indd  947 02/07/21 2:33 PMChApTEr 22948 CMDT 2022SI MPLE OR SOLITARY CYSTSSimpl  cysts account for 65–70% of all rnal masss. Thy ar gnrally found at th outr cortx and contain fluid that is consistnt with an ultrafiltrat of plasma. Most ar found incidntally on ultrasonographic xamination. Simpl cysts ar typically asymptomatic but can bcom infctd. Th major objctiv with simpl cysts is to diffrnti- at thm from malignancy, abscss, or polycystic kidny disas. Cystic disas can dvlop in dialysis patints and has th potntial to progrss to malignancy. Ultrasound and CT scanning ar rcommndd to valuat ths masss. Simpl cysts must mt thr sonographic critria to b considrd bnign: (1) cho fr, (2) sharply dmar- catd with smooth walls, and (3) an nhancd back wall (indicating good transmission through th cyst). Com- plx cysts can hav thick walls, calcifications, solid com- ponnts, and mixd chognicity. On CT scan, simpl cysts should hav smooth thin walls that ar sharply dmarcatd and should not nhanc with contrast mdia. Rnal cll carcinoma will nhanc but typically is of lowr dnsity than halthy parnchyma. Artriography can also b usd to valuat a mass proprativly. Rnal cll car- cinoma is hyprvascular in 80%, hypovascular in 15%, and avascular in 5% of cass. If a cyst has qustionabl imaging charactristics or is of uncrtain significanc, priodic rvaluation is rcom- mndd. Urologic consultation and surgical xploration may b considrd. Bnign cysts do not rquir any sp- cific follow-up, though changs in clinical prsntation should prompt rpat imaging.Smith AD t  al. Approach to rnal cystic masss and th rol of radiology. Radiol Clin North Am. 2020;58:897. [PMID: 32792122]AUTOS OMAL DOMINANT POLYCYSTIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Multiple cysts in both kidneys; number of cysts depends on patient age. »Combination of hypertension and large palpable kidneys suggestive of disease. »Autosomal dominant chromosomal abnormalities present in some patients. »General ConsiderationsA utosomal dominant polycystic kidny disas is th most common monognic kidny disas, affcting 12.5 million individuals worldwid. ESKD dvlops by ag 60 in up to 50% of patints. Th disas has variabl pntranc but accounts for 5–10% of all ESKD cass globally. At last two gns account for this disordr: PKD1 on th short arm of chromosom 16 (85–90% of patints) and PKD2on chromosom 4 (10–15%). Patints with th PKD2 mutation hav slowr progrssion of disas and longr lif xpctancy than thos with PKD1 . Othr sporadic cass without ths mutations ar also rcognizd. »Clinical FindingsA bdominal or flank pain and hmaturia (ithr microscopic or gross) ar prsnt in most patints. A history of urinary tract infctions and nphrolithiasis is common. A family history of autosomal dominant polycystic kidny disas is prsnt in 75% of cass, and mor than 50% of patints hav hyprtnsion that may prcd clinical manifstations. Patints hav larg kidnys that may b palpabl on abdomi- nal xamination. Th combination of hyprtnsion and an abdominal mass should rais suspicion for th disas. Forty to 50 prcnt hav concurrnt hpatic cysts; pancratic and splnic cysts may occur. Dspit dvlopmnt of CKD, hmoglobin is oftn normal as a rsult of cystic rythropoi- tin production. Urinalysis may show hmaturia and subn- phrotic protinuria. In patints with an stablishd family history of autosomal dominant polycystic kidny disas, ultrasonography confirms th diagnosis—two or mor cysts in patints undr ag 30 yars (snsitivity of 88.5%), two or mor cysts in ach kidny in patints agd 30–59 yars (sn- sitivity of 100%), and four or mor cysts in ach kidny in patints agd 60 yars or oldr ar diagnostic for autosomal dominant polycystic kidny disas. Importantly, ths cri- tria do notapply to individuals without a known family history; patints without a known family history of polycys- tic kidny disas rquir additional diagnostic valuation including CT scanning, which rvals innumrabl cysts in cass of polycystic kidny disas (Figur 22–6); th prs- nc of multipl hpatic cysts can aid in stablishing th diagnosis. In som cass, gntic tsting for PKD1 andPKD2 mutations may b rquird. ▲Figure 22–6. Polycystic kidney disease. CT scan showing bilateral polycystic kidneys in a 43-year-old woman who presented with newly diagnosed hyper- tension and microscopic hematuria. (Used, with permis- sion, from Michael Freckleton, MD, in Usatine RP , Smith MA, Mayeaux EJ Jr, Chumley H. The Color Atlas of Family Medicine , 2nd ed. McGraw-Hill, 2013.)CMDT22_Ch22_p0912-p0951.indd  948 02/07/21 2:33 PMKIDNEY DISEASE949 CMDT 2022 »Complications & TreatmentA.  PainA bdominal or flank pain is causd by infction, blding into cysts, and nphrolithiasis. Bd rst and analgsics ar rcom- mndd. Cyst dcomprssion can hlp with chronic pain.B.  HematuriaGross  hmaturia is most commonly du to cystic ruptur into th rnal plvis, but it can also b causd by a kidny ston or urinary tract infction. Hmaturia typically rsolvs within 7 days with bd rst and hydration.C.  Renal InfectionAn  infctd rnal cyst should b suspctd in patints who hav flank pain, fvr, and lukocytosis. Importantly, urinaly- sis may b normal if th cyst dos not communicat dirctly with th urinary tract. CT scans can b hlpful bcaus an infctd cyst may hav incrasd wall thicknss. Bactrial cyst infctions ar difficult to trat. Antibiotics with cystic pntration ar th agnts of choic (g, fluoroquinolons [ciprofloxacin, 500 mg vry 12 hours, or lvofloxacin, 500 mg onc daily if GFR normal], or trimthoprim- sulfamthoxazol doubl-strngth tablt twic daily).D . NephrolithiasisU p to 20% of patints hav kidny stons, primarily cal- cium oxalat. Hydration (2–3 L/day) is rcommndd in ordr to prvnt prcipitation of stons.E.  HypertensionA t th tim of prsntation, 50% of patints hav hyprtn- sion, and it will dvlop in most patints during th cours of th disas. Cyst-inducd ischmia appars to caus activation of th rnin-angiotnsin systm, and cyst dcomprssion can lowr blood prssur tmporarily. Hyprtnsion should b tratd with an ACE inhibitor or an ARB as th prfrrd drug if tolratd. Intnsiv blood prssur control (goal lss than or qual to 110/75 mm Hg) is rcommndd in adults youngr than 50 yars of ag with GFR gratr than 60 mL/min/1.73m2; for all othr affctd individuals, goal blood prssur is lss than or qual to 130/85 mm Hg.F . Cerebral AneurysmsAbo ut 10–15% of patints hav artrial anurysms in th circl of Willis. Scrning artriography is not rcom- mndd unlss th patint has a family history of anu- rysms, is mployd in a high-risk profssion (g, airlin pilot), or is undrgoing lctiv surgry with a high risk of dvloping modrat to svr prioprativ hyprtnsion.G.  Other ComplicationsV ascular problms includ mitral valv prolaps in up to 25% of patints, aortic anurysms, and aortic valv abnor- malitis. Colonic divrticula ar mor common in patints with polycystic kidnys.»PrognosisKidny  siz, rportd as total kidny volum, is th bst prdictor of kidny function dclin in patints with auto- somal dominant polycystic kidny disas, and it can b masurd via CT or MRI using th Mayo Classification systm (www.mayo.du/rsarch/documnts/pkd-cntr- adkpkd-classification/doc-20094754). Thos at high risk according to this classification systm may bnfit from tratmnts that dlay cyst growth. Vasoprssin rcptor antagonists dcras th rat of chang in total kidny vol- um and GFR dclin, and on such mdication (tolvap- tan) is FDA approvd for th tratmnt of autosomal dominant polycystic kidny disas. Libral ingstion of watr will hav th sam physiologic ffct on vasoprssin, and patints should b ncouragd to drink at last 2 L of watr daily. Othr agnts such as octrotid, sirolimus, and tyrosin kinas inhibitors dcras th rat of cyst growth but not th dclin in kidny function and ar thus not routinly usd. Avoidanc of caffin may prvnt cyst formation du to ffcts on G-coupld protins.Cornc-L  Gall E t al. Autosomal dominant polycystic kidny disas. Lanct. 2019;393:919. [PMID: 30819518] Nobakht N t al. Advancs in autosomal dominant polycystic kidny disas: a clinical rviw. Kidny Md. 2020;2:196. [PMID: 32734239]ME DULLARY SPONGE KIDNEYMd ullary spong kidny is blivd to affct lss than 1% of th gnral population. Although prsnt at birth, it is not usually diagnosd until th fourth or fifth dcad. It is thought to occur du to disruption of th urtric bud- mtanphric msnchym intrfac, oftn rsulting from autosomal dominant mutations in gns rsponsibl for urognital dvlopmnt. Kidnys hav a markd irrgular nlargmnt of th mdullary and intrpapillary collcting ducts. This is associatd with mdullary cysts that ar dif- fus, giving a “Swiss chs” apparanc in ths rgions. »Clinical FindingsNp hrolithiasis is th most common clinical prsntation for mdullary spong kidny. Othr prsntations may includ hmaturia (ithr gross or microscopic) or rcur- rnt urinary tract infctions. Common abnormalitis ar a dcrasd urinary concntrating ability and nphrocalci- nosis; lss common is incomplt typ 1 distal rnal tubular acidosis. Th diagnosis is stablishd clinically through laboratory data and imaging charactristics. As th pr- frrd imaging tst, CT shows cystic dilatation of th distal collcting tubuls with a striatd apparanc, and calcifica- tions in th rnal collcting systm. Similar findings on ultrasound may also support th diagnosis. »TreatmentT ratmnt for mdullary spong kidny is supportiv and aimd at undrlying abnormalitis such as nphrolithiasis and acidosis. Adquat fluid intak (2 L/day) hlps rduc risk of ston formation. If hyprcalciuria is prsnt,CMDT22_Ch22_p0912-p0951.indd  949 02/07/21 2:33 PMChApTEr 22950 CMDT 2022thiazid diurtics ar  rcommndd bcaus thy dcras calcium xcrtion. Alkali thrapy is rcommndd if rnal tubular acidosis is prsnt. »PrognosisRnal function is wll maintaind unlss thr ar  compli- cations from rcurrnt urinary tract infctions and nphrolithiasis.Pisani I t  al. Ultrasound to addrss mdullary spong kidny: a rtrospctiv study. BMC Nphrol. 2020;21:430. [PMID: 33046028] ºMULTISYSTEM DISEASES WITh VArIABLE KIDNEY INVOLVEMENT PLASMA CELL MYELOMAPlasma  cll myloma is a malignancy of plasma clls (s Chaptr 13) that can caus a varity of rnal disordrs. Injury is du to th toxic ffcts of monoclonal immuno- globulins or light chain componnts producd by plasma clls. “Myloma kidny” (formally calld cast nphropathy) is th most common kidny disas in plasma cll myloma and occurs whn light chains (Bnc Jons protin) in th urin caus rnal toxicity and tubular obstruction by pr- cipitating in th distal tubuls. Plasma cll myloma may also caus Fanconi syndrom, a typ 2 proximal rnal tubular acidosis charactrizd by hypophosphatmia and inappropriat glycosuria. Protinuria in “myloma kidny” is xclusivly tubular; hnc, urin dipstick findings ar minimal sinc glomrular protinuria is not prsnt. Hyprcalcmia and hypruricmia ar frquntly sn. Glomrular amyloidosis with nphrotic syndrom can dvlop in patints with plasma cll myloma; in ths patints, urin dipstick is positiv du to glomrular pi- thlial cll foot procss ffacmnt and albumin “spilling” into th Bowman capsul; hmaturia may or may not b prsnt. Othr conditions rsulting in kidny dysfunction includ plasma cll infiltration of th rnal parnchyma and hyprviscosity syndrom compromising rnal blood flow. Th prsnc of myloma-rlatd kidny disas dos not itslf prclud us of contrast dy for imaging studis; standard prcautions for th us of intravnous contrast and gadolinium in patints with rducd GFR apply to patints with myloma-rlatd kidny disas. Thrapy for AKI (s Acut Kidny Injury, abov) attributd to plasma cll myloma includs corrction of hyprcalcmia; vol- um rpltion; and chmothrapy for th undrlying malignancy, typically with bortzomib-basd agnts. Plas- maphrsis has bn proposd to rduc th burdn of circulating monoclonal protins, but rsults hav bn quivocal and its us is controvrsial.Małyszko  J t al. KDIGO Controvrsis Confrnc on onco- nphrology: kidny disas in hmatological malignancis and th burdn of cancr aftr kidny transplantation. Kidny Int. 2020;98:1407. [PMID: 33276867]SICKLE CELL DISEASEKidny  dysfunction associatd with sickl cll disas is most commonly du to sickling of rd blood clls in th rnal mdulla bcaus of low oxygn tnsion and hyprto- nicity. Congstion and stasis lad to hmorrhag, intrsti- tial inflammation, and papillary infarcts with rsultant ncrosis. Clinically, hmaturia is common, and protinuria can b prsnt as wll, portnding a poorr prognosis. Damag to rnal capillaris also lads to diminishd con- cntrating ability. Isosthnuria (urin osmolality qual to that of srum) is routin, and patints can asily bcom dhydratd. Ths abnormalitis ar also ncountrd in patints with sickl cll trait. Sickl cll glomrulopathy is lss common but inxorably progrsss to ESKD. Its pri- mary clinical manifstation is protinuria. Optimal trat- mnt rquirs adquat hydration and control of th sickl cll disas.Lim  RI t al. Amrican Socity of Hmatology 2019 guidlins for sickl cll disas: cardiopulmonary and kidny disas. Blood Adv. 2019;3:3867. [PMID: 31794601] Olaniran KO t al. Kidny function dclin among black patints with sickl cll trait and sickl cll disas: an obsr- vational cohort study. J Am Soc Nphrol. 2020;31:393. [PMID: 31810990]TU BERCULOSISRnal  tubrculosis usually rsults from hmatognous sprad and is an undrdiagnosd ntity. Up to 20% of patints with xtrapulmonary tubrculosis hav urognital involvmnt, of which th kidny is most commonly affctd. Its classic manifstation is th prsnc of micro- scopic pyuria without bactrial growth on urin cultur— or “stril pyuria. ” Mor oftn, othr bactria ar also prsnt, and microscopic hmaturia may coxist. Urin culturs wr onc th gold standard for diagnosis, but th advnt of urin nuclic acid tsting for tubrculosis has incrasd snsitivity. Charactristic findings on imaging includ papillary ncrosis and cavitation of th rnal parnchyma. Urtral stricturs or calcifications may also b prsnt. Kidny biopsy is not usually ndd to confirm th diagnosis but rvals granulomatous inflammation and tubulointrstitial nphritis. Prompt initiation of anti- tubrculosis tratmnt is indicatd, without which pro- grssion to ESKD occurs du to chronic inflammation and obstruction.K ulchavnya E t al. Challngs in urognital tubrculosis. World J Urol. 2020;38:89. [PMID: 30997530]GO UT & THE KIDNEYTh  kidny is th primary organ for xcrtion of uric acid. Patints with proximal tubular dysfunction hav dcrasd xcrtion of uric acid and ar mor pron to gouty arthritis attacks. Dpnding on th pH and uric acid concntration, dposition can occur in th tubuls, th intrstitium, or th urinary tract. Th mor alkalin pH of th intrstitium causs urat salt dposition,CMDT22_Ch22_p0912-p0951.indd  950 02/07/21 2:33 PMKIDNEY DISEASE951 CMDT 2022wh ras th acidic nvironmnt of th tubuls and uri- nary tract causs uric acid crystal dposition at high concntrations. Thr disordrs ar commonly sn: (1) uric acid nph- rolithiasis, (2) acut uric acid nphropathy, and (3) chronic urat nphropathy. Kidny dysfunction with uric acid nphrolithiasis stms from obstructiv physiology. Acut uric acid nphropathy prsnts with dirct tubulointrsti- tial toxicity from uric acid crystals and distal tubul obstruction causd by prcipitation of uric acid crystals. Chronic urat nphropathy is causd by dposition of urat crystals in th alkalin mdium of th intrstitium; this can lad to fibrosis and atrophy. Tratmnt btwn gouty attacks involvs avoidanc of food and drugs causing hypruricmia (s Chaptr 20), aggrssiv hydration, and urat-lowring thrapy (such as with allopurinol and fbuxostat). Th thr disordrs mn- tiond abov ar sn in both “ovrproducrs” and “undrx- crtors” of uric acid. Th lattr situation may sm countrintuitiv; howvr, ths patints hav acidic urin, which nabls prcipitation of rlativly insolubl uric acid crystals. For thos with uric acid nphrolithiasis, fluid intak should xcd 3 L/day, and us of a urinary alkalinizing agnt can b considrd. Patints with hypruricmia who do not hav a history of gout or uric acid nphrolithiasis hav not bn shown to bnfit from urat-lowring thrapy.Badv SV  t al; CKD-FIX Study Invstigators. Effcts of allopu- rinol on th progrssion of chronic kidny disas. N Engl J Md. 2020;382:2504. [PMID: 32579811]NE PHROGENIC SYSTEMIC FIBROSISNp hrognic systmic fibrosis is a multisystm disordr sn only in patints with CKD (primarily with an GFR lss than 15 mL/min/1.73 m2, but rarly 15–29 mL/ min/1.73 m2), AKI, and aftr kidny transplantation. His- topathologically, thr is an incras in drmal spindl cllspositiv for CD34 and procollagn I. Collagn bundls with mucin and lastic fibrs ar also notd. Nphrognic systmic fibrosis was first rcognizd in hmodialysis patints in 1997 and has bn strongly linkd to us of contrast agnts containing gadolinium. Incidnc following gadolinium injction is approximatly 1–4% in th highst risk (ESKD) population and lowr in patints with lss svr kidny dysfunction. Th incidnc has dcrasd ovr tim du to limiting us of gadolinium in patints with CKD and AKI and modifid gadolinium prparations. Thr is an FDA warning rgarding avoidanc of this agnt for patints with an GFR lss than 30 mL/min/1.73 m2. »Clinical FindingsNp hrognic systmic fibrosis affcts svral organ sys- tms, including th skin, muscls, lungs, and cardiovascu- lar systm. Th most common manifstation is a dbilitating fibrosing skin disordr that can rang from skin-colord to rythmatous papuls, which coalsc to brawny patchs. Th skin can b thick and woody in aras and is painful out of proportion to findings on xamination. »TreatmentCas  rports and sris dscrib bnfit of corticostroids, photophrsis, plasmaphrsis, and sodium thiosulfat, but thir tru fficacy is unknown. CT is prfrrd to MR imaging with gadolinium whn similar diagnostic infor- mation can b gland. If gadolinium absolutly must b usd in patints on dialysis, practic guidlins rcom- mnd using no mor than th standard dos and hmodi- alysis immdiatly aftr xposur.Ma thur M t al. Gadolinium dposition and nphrognic systmic fibrosis: a radiologist’s primr. Radiographics. 2020;40:153. [PMID: 31809230] Rudnick MR t al. Risks and options with gadolinium-basd con- trast agnts in patints with CKD: a rviw. Am J Kidny Dis. 2021;77:517. [PMID: 32861792]CMDT22_Ch22_p0912-p0951.indd  951 02/07/21 2:33 PM952 CMDT 2022 Mathew Sorensen, MD, MS, FACS Thomas J. Walsh, MD, MS Maahum A. Haider, MD, MPHUrologic Disorders23HE MATURIAE S S E N T I A L S  O F  D I A G N O S I S »Gross hematuria requires evaluation: the upper urinary tract should be imaged, and the lower tract evaluated by cystoscopy. »In microscopic hematuria, the workup should be risk stratified. »General ConsiderationsAn upper tract source (kidneys and ureters) can be identified in 10% of patients with gross or microscopic hematuria. For upper tract sources, stone disease accounts for 40%, medical kidney disease (medullary sponge kidney, glomerulonephri- tis, papillary necrosis) for 20%, renal cell carcinoma for 10%, and urothelial cell carcinoma of the ureter or renal pelvis for 5%. Medication ingestion and associated medical problems may provide diagnostic clues. Analgesic use (papillary necro- sis), cyclophosphamide (chemical cystitis), antibiotics (inter- stitial nephritis), diabetes mellitus, sickle cell trait or disease (papillary necrosis), a history of stone disease, or malignancy should all be investigated. The lower tract source of gross hematuria (in the absence of infection) is most commonly from bleeding prostatic varices or urothelial carcinoma of the bladder. Microscopic hematuria in the male is most com- monly from benign prostatic hyperplasia (13%), kidney stones (6%), or urethral stricture (1.4%). The presence of hematuria in patients receiving antiplatelet or anticoagulation therapy cannot be presumed to be due to the medication; a complete evaluation is warranted consisting of upper tract imaging, cystoscopy, and urine cytology (see Chapter 39 for Bladder Cancer, Cancers of the Ureter & Renal Pelvis, Renal Cell Carcinoma, and Other Primary T umors of the Kidney). »Clinical FindingsA.  Symptoms and SignsIf  gross hematuria occurs, a description of the timing (initial, terminal, total) may provide a clue to the localization ofdisease. Associated symptoms (ie, renal colic, irritative void- ing symptoms, or constitutional symptoms) should be inves- tigated. The history should be focused on risk factors for urothelial cancer (age, male sex, smoking history, history of gross hematuria, irritative lower urinary tract voiding symp- toms, history of cyclophosphamide or ifosfamide chemo- therapy, family history of urothelial carcinoma or Lynch syndrome, occupational exposure to benzene chemicals or aromatic amines, history of chronic indwelling foreign body in the urinary tract) and on nonmalignant causes. The physical examination should look for signs of systemic disease (fever, rash, lymphadenopathy, abdominal or pelvic masses) as well as signs of medical kidney disease (hyperten- sion, volume overload). The urologic evaluation may dem- onstrate an enlarged prostate, flank mass, or urethral disease. The evaluation of patients with hematuria and their risk stratification should not be influenced by whether they are taking any antiplatelet or anticoagulant agents.B.  Laboratory FindingsIn itial laboratory investigations include a urinalysis and urine culture. Microhematuria is defined as three or more red blood cells per high-power field on a microscopic evaluation of the urine. The degree of microscopic hematuria is impor- tant in risk stratification according to the 2020 American Urological Association hematuria guidelines (Figure 23–1). A positive dipstick reading for heme merits microscopic examination to confirm or refute the diagnosis of hematuria but is not enough to warrant workup on its own. If urinaly- sis and culture is suggestive of a urinary tract infection, follow-up urinalysis after treatment of the infection is important to ensure resolution of the hematuria. An esti- mate of kidney function should be obtained since renal insufficiency may influence the methods of further evalua- tion and management (eg, ability to obtain contrast imag- ing) of patients with hematuria. Urine cytology and other urinary-based markers are not routinely recommended in the evaluation of asymptomatic microscopic hematuria.C.  Risk StratificationFo llowing initial evaluation, clinicians should categorize patients with microscopic hematuria as low, intermediate, or high risk for a urothelial malignancy (Figure 23–1).CMDT22_Ch23_p0952-p0977.indd  952 29/06/21 8:49 PM"
                ],
                [
                  "4",
                  "Chapter 11444 CMDT 2022Elev ated BP reading (office, home or pharmacy) No hypertension6White coat  hypertension6HypertensionDedicated office visit1Mean of fice BP ≥ 180/110 mm Hg No Diabetes Diabetes31 .AOBP2≥ 135/85 mm Hg (preferred) 2.Non-AOBP2≥ 140/90 mm Hg (if AOBP unavailable)AOBP or non-AOBP2≥ 1 30/80 mm HgOR Out-of-office measurement41 .ABPM (preferred) Daytime mean ≥ 135/85 mm Hg 24-hour mean ≥ 130/80 mm Hg 2.Home BP series5 Mean ≥ 135/85 mm HgORYes YesNo NoYesNo1. If AOBP is used, use the mean calculated and displayed by the device. If non-AOBP is used, take at least three readings, discard the first and calculate the mean of the remaining measurements. A history and physical examination should be performed and diagnostic tests ordered. 2.AOBP is performed with the patient unattended in a private area. Non-AOBP is performed using an electronic upper arm device with the provider in the room. 3. Diagnostic thresholds for AOBP, ABPM, and home BP in patients with diabetes have yet to be established (and may be lower than 130/80 mm Hg). 4. Serial office measurements over 3–5 visits can be used if ABPM or home measurement not available. 5. Home BP series: Two readings taken each morning and evening for 7 days (28 total). Discard first day readings and average the last 6 days. 6. Annual BP measurement is recommended to detect progression to hypertension.Notes: ▲Figure 11–1. According to these recommendations, if AOBP measurements are not available, blood pressures recorded manually in the office may be substituted if taken as the mean of the last two readings of three consecu- tive readings. Note that the blood pressure threshold for diagnosing hypertension is higher if recorded manually in these guidelines. If home blood pressure monitoring is unavailable, office measurements recorded over three to five separate visits can be substituted. ABPM, ambulatory blood pressure measurement; AOBP , automated office blood pressure; BP , blood pressure. (Reproduced, with permission, from Leung AA et al; Hypertension Canada. Hyper- tension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. Copyright © 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.) Table 11–1. Corresponding blood pressure values across a range of blood pressure measurement methods.Mnul  Msumn in Clinic1hom Blood pssu Msumnambuloy Blood pssu Msumn (Dyim)ambuloy Blood pssu Msumn (Nigim)ambuloy Blood pssu Msumn (24-hou) 120/80 mm Hg 120/80 mm Hg 120/80 mm Hg 100/65 mm Hg 115/75 mm Hg 130/80 mm Hg 130/80 mm Hg 130/80 mm Hg 110/65 mm Hg 125/75 mm Hg 140/90 mm Hg 135/85 mm Hg 135/85 mm Hg 120/70 mm Hg 130/80 mm Hg 160/100 mm Hg 145/90 mm Hg 145/90 mm Hg 140/85 mm Hg 145/90 mm Hg1 Clinic manual blood pressures are critically dependent on technique. The use of automated devices in an unattended setting typi cally result in systolic blood pressures 9–13 mm Hg lower than clinic manual pressures. Data abstracted from Greenland P et al. The New 2017 ACC/AHA Guidelines “up the pressure” on diagnosis and treatment of hyperten sion. JAMA. 2017;318:2083.CMDT22_Ch11_p0443-p0474.indd  444 29/06/21 8:37 PMSYSteMIC hYperteNSION445 CMDT 2022I t is important to recognize that the diagnosis of hyper- tension does not automatically entail drug treatment; this decision depends on the clinical setting and evaluation of cardiovascular risk, as discussed below.Greenland  P et al. The New 2017 ACC/AHA Guidelines “up the pressure” on diagnosis and treatment of hypertension. JAMA. 2017;318:2083. [PMID: 29159417] Jin J. JAMA patient page. Checking blood pressure at home. JAMA. 2017;318:310. [PMID: 28719694] Leung AA et al; Hypertension Canada. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. [PMID: 28449828] Melville S et al. Out-of-office blood pressure monitoring in 2018. JAMA. 2018;320:1805. [PMID: 30398589] Myers MG. Automated office blood pressure—incorporating SPRINT into clinical practice. Am J Hypertens. 2017;30:8. [PMID: 27551025]AP PROACH TO HYPERTENSION »Etiology & ClassificationA.  Primary Essential Hypertension“Essential  hypertension” is the term applied to the 95% of hypertensive patients in which elevated blood pressure results from complex interactions between multiple genetic and environmental factors. Blood pressure elevation above 140/90 mm Hg occurs in 10–15% of White adults and 20–30% of Black adults in the United States. The onset is usually between ages 25 and 50 years; it is uncommon before age 20 years. The best understood pathways under- lying hypertension include overactivation of the sympa- thetic nervous and renin-angiotensin-aldosterone systems (RAAS), blunting of the pressure-natriuresis relationship, variation in cardiovascular and renal development, and elevated intracellular sodium and calcium levels. Exacerbating factors include obesity, sleep apnea, increased salt intake, excessive alcohol use, cigarette smok- ing, polycythemia, nonsteroidal anti-inflammatory drug (NSAID) therapy, and low potassium intake. Obesity is associated with an increase in intravascular volume, ele- vated cardiac output, activation of the renin-angiotensin system, and, probably, increased sympathetic outflow. Life- style-driven weight reduction lowers blood pressure mod- estly, but the dramatic weight reduction following bariatric surgery results in improved blood pressure in most patients, and actual remission of hypertension in 20–40% of cases. In patients with sleep apnea, treatment with continuous posi- tive airway pressure (CPAP) has been associated with improvements in blood pressure. Increased salt intake probably elevates blood pressure in some individuals so dietary salt restriction is recommended in patients with hypertension. Excessive use of alcohol also raises blood pressure, perhaps by increasing plasma catecholamines. Hypertension can be difficult to control in patients who consume more than 40 g of ethanol (two drinks) daily or drink in “binges. ” Cigarette smoking raises blood pressure by increasing plasma norepinephrine. Although the long- term effect of smoking on blood pressure is less clear, the synergistic effects of smoking and high blood pressure oncardiovascular risk are well documented. The relationship of exercise to hypertension is variable. Aerobic exercise low- ers blood pressure in previously sedentary individuals, but increasingly strenuous exercise in already active subjects has less effect. The relationship between stress and hyper- tension is not established. Polycythemia, whether primary, drug-induced, or due to diminished plasma volume, increases blood viscosity and may raise blood pressure. NSAIDs produce increases in blood pressure averaging 5 mm Hg and are best avoided in patients with borderline or elevated blood pressures. Low potassium intake is associ- ated with higher blood pressure in some patients; an intake of 90 mmol/day is recommended. The complex of abnormalities termed the “metabolic syndrome” (upper body obesity, insulin resistance, and hypertriglyceridemia) is associated with both the develop- ment of hypertension and an increased risk of adverse cardiovascular outcomes. Affected patients usually also have low high-density lipoprotein (HDL) cholesterol levels and elevated catecholamines and inflammatory markers such as C-reactive protein.B.  Secondary HypertensionA pproximately 5% of patients have hypertension second- ary to identifiable specific causes (Table 11–2). Secondary hypertension should be suspected in patients in whom hypertension develops at an early age or after the age of 50 years, and in those previously well controlled who become refractory to treatment. Hypertension resistant to maximum doses of three medications is another clue, although multiple medications are usually required to con- trol hypertension in persons with diabetes. 1. Genetic causes— Hypertension can be caused by muta- tions in single genes, inherited on a Mendelian basis. Although rare, these conditions provide important insight into blood pressure regulation and possibly the genetic basis of essential hypertension. Glucocorticoid remediable aldosteronism is an autosomal dominant cause of early- onset hypertension with normal or high aldosterone and low renin levels. The syndrome of hypertension exacer- bated in pregnancy is inherited as an autosomal dominant trait. In these patients, a mutation in the mineralocorticoid receptor makes it abnormally responsive to progesterone and, paradoxically, to spironolactone. 2. Kidney disease— Renal parenchymal disease is the most common cause of secondary hypertension, which results from increased intravascular volume and increased activity of the RAAS. Increased sympathetic nerve activity may also contribute. 3. Renal vascular hypertension— Renal artery stenosis is present in 1–2% of hypertensive patients. The most com- mon cause is atherosclerosis, but fibromuscular dysplasia should be suspected in women under 50 years of age. Excessive renin release occurs due to reduction in renal perfusion pressure, while attenuation of pressure natriure- sis contributes to hypertension in patients with a single kidney or bilateral lesions. Activation of the renal sympa- thetic nerves may also be important.CMDT22_Ch11_p0443-p0474.indd  445 29/06/21 8:37 PMChapter 11446 CMDT 2022Renal vascula r hypertension should be suspected in the following circumstances: (1) the documented onset is before age 20 or after age 50 years, (2) the hypertension is resistant to three or more drugs, (3) there are epigastric or renal artery bruits, (4) there is atherosclerotic disease of the aorta or peripheral arteries (15–25% of patients with symp- tomatic lower limb atherosclerotic vascular disease have renal artery stenosis), (5) there is an abrupt increase (more than 25%) in the level of serum creatinine after administra- tion of angiotensin-converting enzyme (ACE) inhibitors, or (6) episodes of pulmonary edema are associated with abrupt surges in blood pressure. (See Renal Artery Stenosis, Chapter 22.) 4. Primary hyperaldosteronism— Hyperaldosteronism should be considered in people with resistant hypertension, blood pressures consistently greater than 150/100 mm Hg, hypokalemia (although this is often absent), or adrenal incidentaloma, and in those with a family history of hyper- aldosteronism. Mild hypernatremia and metabolic alkalo- sis may also occur. Hypersecretion of aldosterone is estimated to be present in 5–10% of hypertensive patientsand, besides noncompliance, is the most common cause of resistant hypertension. The initial screening step is the simultaneous measurement of aldosterone and renin in blood in a morning sample collected after 30 minutes qui- etly seated. Hyperaldosteronism is suggested when the plasma aldosterone concentration is elevated (normal: 1–16 ng/dL) in association with suppression of plasma renin activity (normal: 1–2.5 ng/mL/h). However, the plasma aldosterone/renin ratio (normal less than 30) is not highly specific as a screening test. This is because renin levels may approach zero, which leads to exponential increases in the plasma aldosterone/renin ratio even when aldosterone levels are normal. Hence, an elevated plasma aldosterone/renin ratio should probably not be taken as evidence of hyperaldosteronism unless the aldosterone level is actually elevated. During the workup for hyperaldosteronism, an initial plasma aldosterone/renin ratio can be measured while the patient continues taking usual medications. If under these circumstances the ratio proves normal or equivocal, medica- tions that alter renin and aldosterone levels, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, beta-blockers, and clonidine, should be discontinued for 2 weeks before repeating the plasma aldosterone/renin ratio; spironolactone and eplerenone should be held for 4 weeks. Slow-release verapamil and alpha-receptor blockers can be used to control blood pressure during this drug washout period. Patients with a plasma aldosterone level greater than 16 ng/dL and an aldosterone/renin ratio of 30 or more might require further evaluation for primary hyperaldosteronism. The lesion responsible for hyperaldosteronism is an adrenal adenoma or bilateral adrenal hyperplasia. 5. Cushing syndrome— Hypertension occurs in about 80% of patients with spontaneous Cushing syndrome. Excess glucocorticoid may act through salt and water retention (via mineralocorticoid effects), increased angiotensinogen lev- els, or permissive effects in the regulation of vascular tone. Diagnosis and treatment of Cushing syndrome are dis- cussed in Chapter 26. 6. Pheochromocytoma— Pheochromocytomas are uncom- mon; they are probably found in less than 0.1% of all patients with hypertension and in approximately two indi- viduals per million population. Chronic vasoconstriction of the arterial and venous beds leads to a reduction in plasma volume and predisposes to postural hypotension. Glucose intolerance develops in some patients. Hypertensive crisis in pheochromocytoma may be precipitated by a variety of drugs, including tricyclic antidepressants, antidopaminer- gic agents, metoclopramide, and naloxone. The diagnosis and treatment of pheochromocytoma are discussed in Chapter 26. 7. Coarctation of the aorta— This uncommon cause of hypertension is discussed in Chapter 10. Evidence of radial-femoral delay should be sought in all younger patients with hypertension. 8. Hypertension associated with pregnancy— Hypertension occurring de novo or worsening during pregnancy, includ- ing preeclampsia and eclampsia, is one of the most commonTable 11–2. Causes of secondary hypertension.endocin Conn syndrome (hyperaldosteronism) Licorice Cushing syndrome (hypercortisolism) Thyroid disease Pheochromocytoma Acromegaly Mutations in steroid gene regulatory domains Hypercalcemia rnl Parenchymal kidney disease Polycystic kidney disease Systemic sclerosis (scleroderma) Page kidney Mutations in genes encoding ion transport proteins Vscul Renal artery stenosis Coarctation auonomic Stress Neurogenic Mdicions Nonsteroidal anti-inflammatory drugs Corticosteroids Calcineurin inhibitors Stimulants Decongestants Angiogenesis inhibitors Tyrosine kinase inhibitors Estrogen Erythropoietin Alcohol, cocaine Gemcitabine Atypical antipsychotics Monoamine oxidase inhibitors O Obstructive sleep apnea PregnancyCMDT22_Ch11_p0443-p0474.indd  446 29/06/21 8:37 PMSYSteMIC hYperteNSION447 CMDT 2022cau ses of maternal and fetal morbidity and mortality (see Chapter 19). Autoantibodies with the potential to activate the angiotensin II type 1 receptor have been caus- ally implicated in preeclampsia, in resistant hypertension, and in progressive systemic sclerosis. 9. Estrogen use— A small increase in blood pressure occurs in most women taking oral contraceptives. A more significant increase of 8/6 mm Hg systolic/diastolic is noted in about 5% of women, mostly in obese individuals older than age 35 who have been treated for more than 5 years. This is caused by increased hepatic synthesis of angiotensinogen. The lower dose of postmenopausal estro- gen does not generally cause hypertension but rather main- tains endothelium-mediated vasodilation. 10. Other causes of secondary hypertension— Hypertension has been associated with hypercalcemia, acromegaly, hyper- thyroidism, hypothyroidism, baroreceptor denervation, com- pression of the rostral ventrolateral medulla, and increased intracranial pressure. Certain medications may cause or exac- erbate hypertension—most importantly cyclosporine, tacroli- mus, angiogenesis inhibitors, and erythrocyte-stimulating agents (such as erythropoietin). Decongestants, NSAIDs, cocaine, and alcohol should also be considered. Over-the- counter products should not be overlooked, eg, a dietary sup- plement marketed to enhance libido was found to contain yohimbine, an alpha-2–antagonist, which can produce severe rebound hypertension in patients taking clonidine. »When to ReferReferra l to a hypertension specialist should be considered in cases of severe, resistant or early-/late-onset hypertension or when secondary hypertension is suggested by screening.Byrd  JB et al. Primary aldosteronism. Circulation. 2018;138:823. [PMID: 30359120] Herrmann SM et al. Renovascular hypertension. Endocrinol Metab Clin North Am. 2019;48:765. [PMID: 31655775] »Complications of Untreated HypertensionM ost of the adverse outcomes in hypertension are associated with thrombosis rather than bleeding, possibly because increased vascular shear stress converts the normally antico- agulant endothelium to a prothrombotic state. The excess morbidity and mortality related to hypertension approxi- mately doubles for each 6 mm Hg increase in diastolic blood pressure. However, target-organ damage varies markedly between individuals with similar levels of office hyperten- sion; home and ambulatory pressures are superior to office readings in the prediction of end-organ damage (Table 11–1).A.  Hypertensive Cardiovascular DiseaseCardiac  complications are the major causes of morbidity and mortality in primary (essential) hypertension. For any level of blood pressure, left ventricular hypertrophy is asso- ciated with incremental cardiovascular risk in association with heart failure (through systolic or diastolic dysfunc- tion), ventricular arrhythmias, myocardial ischemia, and sudden death.The occurrence of heart failure is reduced by 50% with antihypertensive therapy. Hypertensive left ventricular hypertrophy regresses with therapy and is most closely related to the degree of systolic blood pressure reduction. Diuretics have produced equal or greater reductions of left ventricular mass when compared with other drug classes. Conventional beta-blockers are less effective in reducing left ventricular hypertrophy but play a specific role in patients with established coronary artery disease or impaired left ventricular function.B.  Hypertensive Cerebrovascular Disease and DementiaH ypertension is the major predisposing cause of hemor- rhagic and ischemic stroke. Cerebrovascular complications are more closely correlated with systolic than diastolic blood pressure. The incidence of these complications is markedly reduced by antihypertensive therapy. Preceding hypertension is associated with a higher incidence of sub- sequent dementia of both vascular and Alzheimer types. Home and ambulatory blood pressure may be a better predictor of cognitive decline than office readings in older people. Effective blood pressure control reduces the risk of cognitive dysfunction developing later in life.C.  Hypertensive Kidney DiseaseCh ronic hypertension is associated with injury to vascular, glomerular, and tubulointerstitial compartments within the kidney, accounting for about 25% of end-stage kidney disease. Nephrosclerosis is particularly prevalent in Blacks, in whom susceptibility is linked to APOL1 mutations and hypertension results from kidney disease rather than causing it.D . Aortic DissectionH ypertension is a contributing factor in many patients with dissection of the aorta. Its diagnosis and treatment are discussed in Chapter 12.E.  Atherosclerotic ComplicationsMost  Americans with hypertension die of complications of atherosclerosis, but antihypertensive therapy seems to have a lesser impact on atherosclerotic complications compared with heart failure, stroke, and kidney disease. Prevention of cardiovascular outcomes related to atherosclerosis proba- bly requires control of multiple risk factors, of which hypertension is only one.Seccia TM  et al. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35:205. [PMID: 27782909] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] »Clinical FindingsThe  clinical and laboratory findings are mainly referable to involvement of the target organs: heart, brain, kidneys, eyes, and peripheral arteries.CMDT22_Ch11_p0443-p0474.indd  447 29/06/21 8:37 PMChapter 11448 CMDT 2022A.  SymptomsMild  to moderate primary (essential) hypertension is largely asymptomatic for many years. The most frequent symptom, headache, is also nonspecific. Accelerated hyper- tension is associated with somnolence, confusion, visual disturbances, and nausea and vomiting (hypertensive encephalopathy). Hypertension in patients with pheochromocytomas that secrete predominantly norepinephrine is usually sustained but may be episodic. The typical attack lasts from minutes to hours and is associated with headache, anxiety, palpitation, profuse perspiration, pallor, tremor, and nausea and vomit- ing. Blood pressure is markedly elevated, and angina or acute pulmonary edema may occur. In primary aldosteron- ism, patients may have muscular weakness, polyuria, and nocturia due to hypokalemia; hypertensive emergency is rare. Chronic hypertension often leads to left ventricular hypertrophy and diastolic dysfunction, which can present with exertional and paroxysmal nocturnal dyspnea. Cerebral involvement causes stroke due to thrombosis or hemorrhage from microaneurysms of small penetrating intracranial arteries. Hypertensive encephalopathy is probably caused by acute capillary congestion and exudation with cerebral edema and may present as posterior reversible encephalopa- thy syndrome, comprising headache, visual disturbances, altered mental state, and seizures. These symptoms usually improve rapidly with control of hypertension.B.  SignsLike  symptoms, physical findings depend on the cause of hypertension, its duration and severity, and the degree of effect on target organs. 1. Blood pressure— Blood pressure is taken in both arms and, if lower extremity pulses are diminished or delayed, in the legs to exclude coarctation of the aorta. If blood pres- sure differs between right and left arms, the higher reading should be recorded as the actual blood pressure and subcla- vian stenosis suspected in the other arm. An orthostatic drop of at least 20/10 mm Hg is often present in pheochro- mocytoma. Older patients may have falsely elevated read- ings by sphygmomanometry because of noncompressible vessels. This may be suspected in the presence of Osler sign—a palpable brachial or radial artery when the cuff is inflated above systolic pressure. Occasionally, it may be necessary to make direct measurements of intra-arterial pressure, especially in patients with apparent severe hyper- tension who do not tolerate therapy. 2. Retinas— Narrowing of arterial diameter to less than 50% of venous diameter, copper or silver wire appearance, exudates, hemorrhages, and hypertensive retinopathy are associated with a worse prognosis. The typical changes of severe hypertensive retinopathy are shown in Figure 11–2 (see Chapter 7). 3. Heart— A left ventricular heave indicates severe hyper- trophy. Aortic regurgitation may be auscultated in up to 5% of patients, and hemodynamically insignificant aortic regurgitation can be detected by Doppler echocardiogra- phy in 10–20%. A presystolic (S4) gallop due to decreasedcompliance of the left ventricle is quite common in patients in sinus rhythm. 4. Pulses— Radial-femoral delay suggests coarctation of the aorta; loss of peripheral pulses occurs due to atherosclero- sis, less commonly aortic dissection, and rarely Takayasu arteritis, all of which can involve the renal arteries.C.  Laboratory FindingsRecommended  testing includes hemoglobin; serum elec- trolytes and serum creatinine; fasting blood sugar level (hypertension is a risk factor for the development of diabe- tes, and hyperglycemia can be a presenting feature of pheo- chromocytoma); plasma lipids (necessary to calculate cardiovascular risk and as a modifiable risk factor); serum uric acid (hyperuricemia is a relative contraindication to diuretic therapy); and urinalysis.D . Electrocardiography and Chest RadiographsElectrocardiographic  criteria are highly specific but not very sensitive for left ventricular hypertrophy. The “strain” pattern of ST–T wave changes is a sign of more advanced disease and is associated with a poor prognosis. A chest radiograph is not necessary in the workup for uncompli- cated hypertension.E.  EchocardiographyThe primary  role of echocardiography should be to evalu- ate patients with clinical symptoms or signs of cardiac disease.F . Diagnostic StudiesAddi tional diagnostic studies are indicated only if the clini- cal presentation or routine tests suggest secondary or com- plicated hypertension. These may include 24-hour urine free cortisol, urine or plasma metanephrines, and plasma ▲Figure 11–2. Severe, chronic hypertensive retinopa- thy with hard exudates, increased vessel light reflexes, and sausage-shaped veins. (Used, with permission, from Richard E. Wyszynski, MD, in Knoop KJ, Stack LB, Storrow AB, Thurman RJ. The Atlas of Emergency Medicine , 4th ed. McGraw-Hill, 2016.)CMDT22_Ch11_p0443-p0474.indd  448 29/06/21 8:37 PMSYSteMIC hYperteNSION449 CMDT 2022aldostero ne and renin concentrations to screen for endo- crine causes of hypertension. Renal ultrasound will detect structural changes (such as polycystic kidneys, asymmetry, and hydronephrosis); echogenicity and reduced cortical volume are reliable indicators of advanced chronic kidney disease. Evaluation for renal artery stenosis should be undertaken in concert with subspecialist consultation.G.  SummarySince  most hypertension is essential or primary, few studies are necessary beyond those listed above. If conventional therapy is unsuccessful or if secondary hypertension is suspected, further studies and perhaps referral to a hyper- tension specialist are indicated. »Nonpharmacologic TherapyLife style modification is recommended in all patients with elevated blood pressure. A diet rich in fruits, vegeta- bles, and low-fat dairy foods and low in saturated and total fats (DASH diet) has been shown to lower blood pressure. Increased dietary fiber lowers blood pressure. For every 7 g of dietary fiber ingested, cardiovascular risk could be lowered by 9%. The effect of diet on blood pres- sure may be mediated by shifts in the microbial species in the gut, the intestinal microbiota. Hand squeezing exer- cises three times a week can lower systolic blood pressure by 6 mm Hg. The protocol comprises four repeats of 2 minutes at 30% of maximum force (using a handheld dynamometer) with 1- to 3-minute rest intervals between squeezes. The acute increase in systolic blood pressure during vigorous exercise, known as the exercise pressor response, is around 50 mm Hg in normal individuals. In hypertensive persons, the exercise pressor response is elevated to about 75 mm Hg above resting systolic blood pressure. This exaggerated response is not reduced by antihypertensive medications, even in those with other- wise controlled hypertension, and is exacerbated by increased dietary sodium intake. Additional lifestyle changes, listed in Table 11–3, can prevent or mitigate hypertension or its cardiovascular consequences.Fu J et  al. Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension. J Am Heart Assoc. 2020;9:e016804. [PMID: 32975166] Smart NA et al. An evidence-based analysis of managing hyper- tension with isometric resistance exercise—are the guidelines current? Hypertens Res. 2020;43:249. [PMID: 31758166] »Who Should Be Treated With Medications?T reatment should be offered to all persons in whom blood pressure reduction, irrespective of initial blood pressure levels, will reduce cardiovascular risk with an acceptably low rate of medication-associated adverse effects. The American College of Cardiology and the American Heart Association (ACC/ AHA), Hypertension Canada (HC), and the European Soci- ety of Hypertension and European Society of Cardiology(ESH/ESC) have developed independent guidelines for the evaluation and management of hypertension. There is broad agreement that drug treatment is necessary in those with office-based blood pressures exceeding 160/100 mm Hg, irrespective of cardiac risk. Similarly, the American, Canadian, and European guidelines agree that treatment thresholds should be lower in the presence of elevated car- diovascular risk. American guidelines stand apart in recom- mending initiation of antihypertensive pharmacotherapy in those with blood pressure of 140–159/90–99 mm Hg, even if cardiovascular risk is not elevated. By contrast, the Cana- dian guidelines suggest lifestyle modifications in this low- cardiovascular-risk group, while the European guidelines recommend initiation of pharmacotherapy only if elevated pressure in this low-risk population persists after lifestyle modification. There is no outcomes evidence that mortal- ity or risk of cardiovascular events can be reduced by treat- ing mild hypertension (140/90–160/100 mm Hg) in low-risk individuals. Table 11–4 compares these three sets of guidelines. Since evaluation of total cardiovascular risk (Table 11–5) is important in deciding who to treat with antihypertensive medications, risk calculators are essential clinical tools. The ACC has an online toolkit relevant to primary prevention (https://tools.acc.org/ascvd-risk- estimator-plus/#!/calculate/estimate/), and an associated app called ASCVD Risk Estimator Plus (downloadable at https://www.acc.org/ASCVDApp). »Goals of TreatmentT raditionally, the most widely accepted goal for blood pres- sure management has been less than 140/90 mm Hg. How- ever, observational studies suggest that there does not seem to be a blood pressure level below which decrements in cardiovascular risk taper off, and a number of randomized controlled trials have suggested that treatment to bloodTable 11–3. The impact of lifestyle modifications.Modific- ion Invnionrsuling Dcs in Blood pssu Weight loss Target BMI 18.5–24.9 5–20 mm Hg/ 10-kg loss DASH diet Fruit, vegetables, low fat dairy8–14 mm Hg Sodium intake< 100 mmol/day (< 6 g salt)2–8 mm Hg Alcohol intakeMale ≤ 2 drinks/day Female ≤ 1 drink/day4 mm Hg Exercise Aerobic 30 min/day Dynamic 90-150 min/week Isometric (hand grip 4 rep- etitions 3 times/week)5–10 mm Hg Mindfulness Meditation and breathing control5 mm Hg BMI, body mass index; DASH, Dietary Approaches to Stop Hypertension.CMDT22_Ch11_p0443-p0474.indd  449 29/06/21 8:37 PMChapter 11450 CMDT 2022pres sure targets considerably below 140 mm Hg may ben- efit certain patient groups. The SPRINT study suggests that outcomes improve in nondiabetic patients with considerably elevated cardiovascu- lar risk when treatment lowers systolic pressure to less than 120 mm Hg compared to less than 140 mm Hg. On the other hand, in the HOPE3 study of largely nondiabetic patients at somewhat lower risk than those in SPRINT, reducing blood pressure by an average of 6/3 mm Hg systolic/diastolic from a baseline of 138/82 mm Hg provided no significant out- comes benefits. Therefore, it appears that blood pressure targets should be lower in people at greater estimated cardio- vascular risk. In response to the SPRINT study, the 2018 Hypertension Canada guidelines urge prescribers to consider a blood pressure goal of less than 120/80 mm Hg in patients considered at elevated risk for cardiovascular events. The 2017 ACC/AHA guidelines take a different approach by defining a 130/80 mm Hg goal as “reasonable” in nonelevated risk patients, strengthening this to “recommended” in ele- vated risk hypertensive patients. The 2018 ESH/ESC guide- lines specify a target of less than 140 mm Hg systolic for all, and less than 130 mm Hg for most if tolerated. There is a trend toward recommending similar treatment targets in the elderly; this topic is discussed in greater detail below. Some experts note that manual office measurements of around 130/80 mm Hg are likely to approximate the lower blood pressure targets specified in the SPRINT study, which used automated office blood pressure measuring devices that have been demonstrated to read as much as 16/7 mm Hg lowerTable 11–4. Comparison of blood pressure treatment thresholds from the 2017 ACC/AHA guidelines, the 2018 Hypertension Canada guidelines, and the 2018 ESH/ESC guidelines.Guidlins 1Cdiovscul risktsold fo pmcoy (mm hg) tg (mm hg) ACC/AHA Not increased > 140/90 < 130/80 (reasonable) Hypertension Canada Not increased > 160/100 < 140/90 (< 130/80 for diabetes) ESH/ESC Not increased > 140/902All < 140/90, most < 130/80, not < 120 ACC/AHA Increased < 130/80 < 130/80 (recommended) Hypertension Canada Increased > 140 systolic3< 120 systolic ESH/ESC Increased > 130/803120–130/< 80 ACC/AHA > 65 yr Risk due to advanced age > 130/80 < 130 systolic Hypertension Canada4Increased Not specified4Not specified4ESH/ESC  > 65 yr Not increased > 140/905130–140/> 806 1In all three sets of guidelines, blood pressure values are based upon nonautomated office blood pressure readings.2 Consider drug treatment if lifestyle changes fail to control blood pressure.3 Consider drug treatment if very high risk, eg, established cardiovascular disease, especially coronary disease. Note: The > 130/80 mm Hg threshold for treatment of high-risk patients in the Canadian guidelines refers to automated blood pressure readings, which are lower than nonautomated readings.4 Recommendations for persons > 75 years are not explicitly stated in the Hypertension Canada guidelines. They removed separate g oals for the elderly but consider age > 75 years to be a risk signifier triggering an approach that many would view as overly aggres sive in the extremely old.5 The European guidelines indicate a slightly more conservative treatment threshold of > 160/90 mm Hg for those > 80 years.6 This target range is also suggested in the European guidelines for patients > 80 years. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; ESH, European Societ y of Hypertension.T able 11–5. Cardiovascular risk factors.Mjo  isk fcos Hypertension1 Cigarette smoking Obesity (BMI ≥ 30)1 Physical inactivity Dyslipidemia1 Diabetes mellitus1 Microalbuminuria or estimated GFR < 60 mL/min/1.73 m2 Age (> 55 years for men, > 65 years for women) Family history of premature cardiovascular disease (< 55 years for men, < 65 years for women) tg-ogn dmg Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart failure Brain Stroke or transient ischemic attack Chronic kidney disease Peripheral arterial disease Retinopathy1 Components of the metabolic syndrome. BMI, body mass index; GFR, glomerular filtration rate. Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560–72.CMDT22_Ch11_p0443-p0474.indd  450 29/06/21 8:37 PMSYSteMIC hYperteNSION451 CMDT 2022th an manual office readings. The 2018 Canadian guidelines acknowledge this disparity in measurement methods by specifying that automated office devices should be used in the monitoring of patients selected for the aggressive blood pres- sure goal of less than 120/80 mm Hg. Table 11–4 compares the treatment threshold and target recommendations laid out in the American, Canadian, and European guidelines. Treatment to blood pressures less than 130 mm Hg systolic seems especially important in stroke prevention. The ACCORD study examined the effect of treatment of systolic pressures to below 130–135 mm Hg in patients with diabetes; the study’s two by two factorial design addressed glycemic control as well as blood pressure con- trol. In the original analysis, the lower blood pressure treat- ment goal significantly increased the risk of serious adverse effects (with no additional gain in terms of heart, kidney, or retinal disease). There was, however, significant additional reduction in the risk of stroke, indicating that lower blood pressure targets might be justified in diabetic patients at high risk for cerebrovascular events. Post hoc analysis of the ACCORD study after 9 years of follow-up suggested that a beneficial effect of lower blood pressure in older high-risk persons (mostly on nonfatal myocardial infarctions) could be detected in the standard glycemic control group. Similarly, in the SPS3 trial in patients who have had a lacunar stroke, treating the systolic blood pressure to less than 130 mm Hg (mean systolic blood pressure of 127 mm Hg among treated versus mean systolic blood pressure 138 mm Hg among untreated patients) probably reduced the risk of recurrent stroke (and with an acceptably low rate of adverse effects from treatment). Blood pressure manage- ment in acute stroke is discussed below. »How Low To Go?Alth ough observational studies indicate that the blood pressure-risk relationship holds up at levels considerably below 120 mm Hg, there is uncertainty about whether this is true for treated blood pressure. This question was addressed in a secondary analysis of data from the ONTARGET and TRANSCEND studies in which participants with ele- vated cardiovascular risk but no history of stroke were treated with telmisartan (plus or minus ramipril) or placebo. The risk of the composite cardiovascular endpoint was lowest at a treated systolic blood pressure range between 120 mm Hg and 140 mm Hg. Increased risk was observed at blood pres- sures below and above this range. The risk of stroke was the only exception, with incremental benefit observed below a treated systolic of 120 mm Hg. With respect to diastolic blood pressure on treatment, composite risk began to increase at levels below 70 mm Hg. This suggests that the blood pressure–cardiovascular risk relationship evident in observational studies of untreated hypertension may not hold in the case of treated blood pressure and that there are grounds for a degree of caution in treating below a systolic pressure of 120 mm Hg. In seeking to simplify decision making in the treatment of hypertension, some authors have suggested that a sys- tolic blood pressure goal in the 120–130 mm Hg range would be safe and effective in high-risk patients, and a systolic blood pressure of around 130 mm Hg would bereasonable in lower-risk patients, irrespective of diastolic pressures. Diastolic blood pressure will track with systolic blood pressure; the main concern about diastolic blood pressure is that treatment will lower it too much in patients who have wider pulse pressures. However, it seems that a lower diastolic blood pressure as a consequence of treat- ment does not negate the benefits of systolic blood pressure control, even though wider pulse pressures at baseline are associated with cardiovascular mortality. »Treatment of Other Cardiovascular Risk FactorsData  from multiple studies indicate that statins should be part of the strategy to reduce overall cardiovascular risk. The HOPE3 study of persons at intermediate cardiovascu- lar risk showed that 10 mg of rosuvastatin reduced average low-density lipoprotein (LDL) cholesterol from 130 mg/dL to 90 mg/dL (3.36–2.33 mmol/L), and significantly reduced the risk of multiple cardiovascular events, including myo- cardial infarction and coronary revascularization. Low- dose aspirin (81 mg/day) is likely to be beneficial in patients older than age 50 with either target-organ damage or elevated total cardiovascular risk (greater than 20–30%). Care should be taken to ensure that blood pressure is con- trolled to the recommended levels before starting aspirin to minimize the risk of intracranial hemorrhage. Data do not support the routine use of aspirin for prophylaxis in low- risk patients, including those over 65 years of age.Böhm  M et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226. [PMID: 28390695] Ruiz-Hurtado G et al. Has the SPRINT trial introduced a new blood-pressure goal in hypertension? Nat Rev Cardiol. 2017;14:560. [PMID: 28492286] Sheppard JP et al. Benefits and harms of antihypertensive treat- ment in low-risk patients with mild hypertension. JAMA Intern Med. 2018;178:1626. [PMID: 30383082] Sobieraj P et al. Low on-treatment diastolic blood pressure and cardiovascular outcome: a post-hoc analysis using NHLBI SPRINT research materials. Sci Rep. 2019;9:13070. [PMID: 31506550] Williams B et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hyperten- sion (ESH) and the European Society of Cardiology (ESC). Blood Press. 2018;27:314. [PMID: 30380928]DR UG THERAPY: CURRENT ANTIHYPERTENSIVE AGENTSTh ere are many classes of antihypertensive drugs of which six (ACE inhibitors, ARBs, renin inhibitors, calcium channel blockers, diuretics, and beta-blockers) are suitable for initial therapy based on efficacy and tolerability. The specific classes of antihypertensive medications are discussed below, and guidelines for the choice of initial medications are offered.A.  Angiotensin-Converting Enzyme InhibitorsACE  inhibitors are commonly used as the initial medi- cation in mild to moderate hypertension (Table 11–6).CMDT22_Ch11_p0443-p0474.indd  451 29/06/21 8:37 PMChapter 11452 CMDT 2022Table 11–6. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns rnin Inibios Aliskiren Tekturna 150 mg once daily 150–300 mg once daily $7.48/150 mg $224.41 Angioedema, hypotension, hyperkalemia. Contraindicated in pregnancy.Probably metabolized by CYP3A4. Absorption is inhibited by high- fat meal.Aliskiren and HCTZ Tekturna HCT 150 mg/12.5 mg once daily150 mg/12.5 mg–300 mg/ 25 mg once daily$9.78/150 mg/ 12.5 mg$293.54 aCe Inibios Benazepril Lotensin 10 mg once daily 5–40 mg in 1 or 2 doses $0.95/20 mg $28.50 Cough, hypotension, dizziness, hyperkalemia, kidney dysfunction, angioedema; taste alteration and rash (may be more frequent with captopril); rarely, proteinuria, blood dyscrasia. Contraindicated in pregnancy.More fosinopril is excreted by the liver in patients with kidney dys- function (dose reduction may or may not be necessary). Captopril and lisinopril are active without metabolism. Captopril, enalapril, lisinopril, and quinapril are approved for heart failure.Benazepril and HCTZ Lotensin HCT 5 mg/6.25 mg once daily5 mg/6.25 mg–20 mg/ 25 mg$1.07/any dose $32.21 Benazepril and amlodipineLotrel 10 mg/2.5 mg once daily10 mg/2.5 mg–40 mg/ 10 mg$3.32/20 mg/ 10 mg$99.60 Captopril Capoten 25 mg twice daily 50–450 mg in 2 or 3 doses$0.65/25 mg $19.50 Captopril and HCTZ Capozide 25 mg/15 mg twice daily25 mg/15 mg–50 mg/ 25 mg$2.85/25 mg/ 15 mg$171.00 Enalapril Vasotec 5 mg once daily 5–40 mg in 1 or 2 doses $0.95/20 mg $28.50 Enalapril and HCTZ Vaseretic 5 mg/12.5 mg once daily5 mg/12.5 mg–10 mg/ 25 mg$1.19/10 mg/ 25 mg$35.70 Fosinopril Monopril 10 mg once daily 10–80 mg in 1 or 2 doses $0.29/20 mg $8.70 Fosinopril and HCTZ Monopril-HCT 10 mg/12.5 mg once daily10 mg/12.5 mg–20 mg/ 12.5 mg$1.48/any dose $44.40 Lisinopril Prinivil, Zestril 5–10 mg once daily 5–40 mg once daily $0.08/20 mg $2.45 Lisinopril and HCTZ Prinzide or Zestoretic10 mg/12.5 mg once daily10 mg/12.5 mg–20 mg/ 12.5 mg$0.14/20 mg/ 12.5 mg$4.20 Moexipril Univasc 7.5 mg once daily 7.5–30 mg in 1 or 2 doses $1.39/7.5 mg $41.70 Moexipril and HCTZ Uniretic 7.5 mg/12.5 mg once daily7.5 mg/12.5 mg–15 mg/ 25 mg$1.70/15 mg/ 12.5 mg$51.00CMDT22_Ch11_p0443-p0474.indd  452 29/06/21 8:37 PMSYSteMIC hYperteNSION453 CMDT 2022Perindopril Aceon 4 mg once daily 4–16 mg in 1 or 2 doses $2.80/8 mg $84.00 Perindopril and amlodipinePrestalia 3.5 mg/2.5 mg once daily3.5 mg/2.5–14 mg/10 mg once daily$6.81/7 mg/5 mg $204.30 Quinapril Accupril 10 mg once daily 10–80 mg in 1 or 2 doses $1.22/20 mg $36.60 Quinapril and HCTZ Accuretic 10 mg/12.5 mg once daily10 mg/12.5 mg–20 mg/ 25 mg$1.22/20 mg/ 12.5 mg$36.60 Ramipril Altace 2.5 mg once daily 2.5–20 mg in 1 or 2 doses $1.80/5 mg $54.00 Trandolapril Mavik 1 mg once daily 1–8 mg once daily $1.21/4 mg $36.30 Trandolapril and verapamilTarka 2 mg/180 mg ER once daily2 mg/180 mg ER–8 mg/480 mg ER$5.29/any dose $158.70 angionsin II rco Blocks Azilsartan Edarbi 40 mg once daily 40–80 mg once daily $8.80/80 mg $264.00 Hyperkalemia, kidney dysfunction, rare angioedema. Combinations have additional side effects. Contraindicated in pregnancy.Losartan has a flat dose-response curve. Valsartan and irbesartan have wider dose-response ranges and longer durations of action. Addition of low-dose diuretic (separately or as combination pills) increases the response.Azilsartan and chlorthalidoneEdarbychlor 40 mg/12.5 mg once daily40 mg/12.5–40 mg/ 25 mg once daily$8.30/any dose $249.14 Candesartan cilexitil Atacand 16 mg once daily 8–32 mg once daily $3.06/16 mg $91.80 Candesartan cilexitil and HCTZAtacand HCT 16 mg/12.5 mg once daily32 mg/12.5 mg once daily$4.72/16 mg/ 12.5 mg$141.60 Eprosartan Teveten 600 mg once daily 400–800 mg in 1–2 doses$3.43/600 mg $102.90 Irbesartan Avapro 150 mg once daily 150–300 mg once daily $0.46/150 mg $13.80 Irbesartan and HCTZ Avalide 150 mg/12.5 mg once daily150–300 mg irbesartan once daily$0.67/150 mg/ 12.5 mg$20.10 Losartan and HCTZ Hyzaar 50 mg/12.5 mg once daily50 mg/12.5 mg–100 mg/ 25 mg tablets once daily$2.47/50 mg/ 12.5 mg/tablet$74.10 Olmesartan Benicar 20 mg once daily 20–40 mg once daily $6.28/20 mg $188.40 Olmesartan and HCTZBenicar HCT 20 mg/12.5 mg once daily20 mg/12.5 mg–40 mg/ 25 mg once daily$6.28/20 mg/ 12.5 mg$188.40 Olmesartan and amlodipineAzor 20 mg/5 mg once daily20 mg/5 mg–40 mg/ 10 mg$3.03/20 mg/5 mg $90.90 Olmesartan and amlodipine and HCTZTribenzor 20 mg/5 mg/ 12.5 mg once daily20 mg/5 mg/12.5 mg– 40 mg/10 mg/25 mg once daily$4.54/20 mg/ 5 mg/12.5 mg$136.20 Telmisartan Micardis 40 mg once daily 20–80 mg once daily $4.34/40 mg $130.20 (continued )CMDT22_Ch11_p0443-p0474.indd  453 29/06/21 8:37 PMChapter 11454 CMDT 2022T elmisartan and HCTZMicardis HCT 40 mg/12.5 mg once daily40 mg/12.5 mg–80 mg/ 25 mg once daily$4.83/40 mg/ 12.5 mg$144.90 Telmisartan and amlodipineTwynsta 40 mg/5 mg once daily40 mg/5 mg–80 mg/ 10 mg once daily$5.20/any dose $156.00 Valsartan Diovan 80 mg once daily 80–320 mg once daily $2.09/160 mg $62.70 Valsartan and HCTZ Diovan HCT 80 mg/12.5 mg once daily80–320 mg valsartan once daily$4.27/160 mg/ 12.5 mg$128.10 Valsartan and amlodipineExforge 160 mg/5 mg once daily160 mg/5 mg–320 mg/ 10 mg once daily$1.71/160 mg/ 10 mg$51.30 O Combinion poducs Amlodipine and val- sartan and HCTZExforge HCT 5 mg/160 mg/ 12.5 mg once daily10 mg/320 mg/25 mg up to once daily$5.70/160 mg valsartan$171.001 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; ER, extended release; HCTZ, hydrochlorothiazide.Table 11–6. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns angionsin II rco Blocks (con.)(continued)CMDT22_Ch11_p0443-p0474.indd  454 29/06/21 8:37 PMSYSteMIC hYperteNSION455 CMDT 2022Their  primary mode of action is inhibition of the RAAS, but they also inhibit bradykinin degradation, stimulate the syn- thesis of vasodilating prostaglandins, and can reduce sym- pathetic nervous system activity. ACE inhibitors appear to be more effective in younger White patients. They are rela- tively less effective in Blacks and older persons and in pre- dominantly systolic hypertension. Although as single therapy they achieve adequate antihypertensive control in only about 40–50% of patients, the combination of an ACE inhibitor and a diuretic or calcium channel blocker is potent. ACE inhibitors are the agents of choice in persons with type 1 diabetes with frank proteinuria or evidence of kidney dysfunction because they delay the progression to end-stage renal disease. Many authorities have expanded this indication to include persons with type 1 and type 2 diabetes mellitus with microalbuminuria who do not meet the usual criteria for antihypertensive therapy. ACE inhibitors may also delay the progression of nondiabetic kidney disease. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that the ACE inhibitor ramipril reduced the number of car- diovascular deaths, nonfatal myocardial infarctions, and nonfatal strokes and also reduced the incidence of new-onset heart failure, kidney dysfunction, and new-onset diabetes in a population of patients at high risk for vascular events. Although this was not specifically a hypertensive population, the benefits were associated with a modest reduction in blood pressure, and the results inferentially support the use of ACE inhibitors in similar hypertensive patients. ACE inhibi- tors are a drug of choice (usually in conjunction with a diuretic and a beta-blocker) in patients with heart failure with reduced ejection fraction and are indicated also in asymp- tomatic patients with reduced ejection fraction. How to initiate therapy— A baseline metabolic panel should be drawn prior to starting medications that inter- fere with the RAAS, repeated 1–2 weeks after initiation of therapy to evaluate changes in creatinine and potassium. Minor dose adjustments of these medications rarely trigger significant shifts in these values. Side effects— An advantage of the ACE inhibitors is their relative freedom from troublesome side effects (Table 11–6). Severe hypotension can occur in patients with bilateral renal artery stenosis; significant increases in creatinine may ensue but are usually reversible with the discontinuation of the ACE inhibitor. Hyperkalemia may develop in patients with kidney disease and type IV renal tubular acidosis (commonly seen in patients with diabetes) and in older adults. A chronic dry cough is common, seen in 10% of patients or more, and may require stopping the drug. Skin rashes are observed with any ACE inhibitor. Angioedema is an uncommon but potentially dangerous side effect of all agents of this class because of their inhibi- tion of kininase. Exposure of the fetus to ACE inhibitors during the second and third trimesters of pregnancy has been associated with a variety of defects due to hypoten- sion and reduced renal blood flow.B.  Angiotensin II Receptor BlockersARB s can improve cardiovascular outcomes in patients with hypertension as well as in patients with related conditions, such as heart failure and type 2 diabetes with nephropathy.ARBs have not been compared with ACE inhibitors in ran- domized controlled trials in patients with hypertension, but two trials comparing losartan with captopril in heart failure and post–myocardial infarction left ventricular dysfunction showed trends toward worse outcomes in the losartan group. By contrast, valsartan seems as effective as ACE inhibitors in these settings. Within group heterogeneity of antihyperten- sive potency and duration of action might explain such observations. The Losartan Intervention for Endpoints (LIFE) trial in nearly 9000 hypertensive patients with elec- trocardiographic evidence of left ventricular hypertrophy— comparing losartan with the beta-blocker atenolol as initial therapy—demonstrated a significant reduction in stroke with losartan. Of note is that in diabetic patients, death and myocardial infarction were also reduced, and there was a lower occurrence of new-onset diabetes. In a subgroup analysis from the LIFE trial, atenolol appeared to be superior to losartan in Blacks, while the opposite was the case in non- Blacks. A similar lack of efficacy of lisinopril compared to diuretics and calcium channel blockers was observed in Blacks in the Antihypertensive and Lipid-Lowering Treat- ment to Prevent Heart Attach Trial (ALLHAT), suggesting that ACE inhibitors and ARBs may not be the preferred agents in Black patients. In the treatment of hypertension, combination therapy with an ACE inhibitor and an ARB is not advised because it generally offers no advantage over monotherapy at maximum dose with addition of a comple- mentary class where necessary. Side effects— Unlike ACE inhibitors, the ARBs rarely cause cough and are less likely to be associated with skin rashes or angioedema (Table 11–6). However, as seen with ACE inhibitors, hyperkalemia can be a problem, and patients with bilateral renal artery stenosis may exhibit hypotension and worsened kidney function. Olmesartan has been linked to a sprue-like syndrome, presenting with abdominal pain, weight loss, and nausea, which subsides upon drug discon- tinuation. There is evidence from an observational study suggesting that ARBs and ACE inhibitors are less likely to be associated with depression than calcium channel block- ers and beta-blockers.C.  Renin InhibitorsSi nce renin cleavage of angiotensinogen is the rate-limiting step in the renin-angiotensin cascade, the most efficient inac- tivation of this system would be expected with renin inhibi- tion. Conventional ACE inhibitors and ARBs probably offer incomplete blockade, even in combination. Aliskiren, a renin inhibitor, binds the proteolytic site of renin, thereby prevent- ing cleavage of angiotensinogen. Aliskiren effectively lowers blood pressure, reduces albuminuria, and limits left ventricu- lar hypertrophy, but it has yet to be established as a first-line drug based on outcomes data. The combination of aliskiren with ACE inhibitors or ARBs in persons with type 2 diabetes mellitus offers no advantage and might even increase the risk of adverse cardiac or renal consequences.D . Calcium Channel Blocking AgentsThese  agents act by causing peripheral vasodilation but with less reflex tachycardia and fluid retention than otherCMDT22_Ch11_p0443-p0474.indd  455 29/06/21 8:37 PMChapter 11456 CMDT 2022vasodilators.  They are effective as single-drug therapy in approximately 60% of patients in all demographic groups and all grades of hypertension (Table 11–7). For these rea- sons, they may be preferable to beta-blockers and ACE inhibitors in Blacks and older persons. Verapamil and dil- tiazem should be combined cautiously with beta-blockers because of their potential for depressing atrioventricular (AV) conduction and sinus node automaticity as well as contractility. Calcium channel blockers are equivalent to ACE inhibi- tors and thiazide diuretics in prevention of coronary heart disease, major cardiovascular events, cardiovascular death, and total mortality. A protective effect against stroke with calcium channel blockers is well established, and in two trials (ALLHAT and the Systolic Hypertension in Europe trial), these agents appeared to be more effective than diuretic-based therapy. Side effects— The most common side effects of calcium channel blockers are headache, peripheral edema, brady- cardia, and constipation (especially with verapamil in older adults) (Table 11–7). The dihydropyridine agents— nifedipine, nicardipine, isradipine, felodipine, nisoldipine, and amlodipine—are more likely to produce symptoms of vasodilation, such as headache, flushing, palpitations, and peripheral edema. Edema is minimized by coadministra- tion of an ACE inhibitor or ARB. Calcium channel block- ers have negative inotropic effects and should be used cautiously in patients with cardiac dysfunction. Amlodip- ine is the only calcium channel blocker with established safety in patients with severe heart failure.E.  DiureticsThia zide diuretics (Table 11–8) are the antihypertensives that have been most extensively studied and most consis- tently effective in clinical trials. They lower blood pressure initially by decreasing plasma volume, but during long-term therapy, their major hemodynamic effect is reduction of peripheral vascular resistance. Most of the antihypertensive effect of these agents is achieved at lower dosages (typically, 12.5 mg of hydrochlorothiazide or equivalent), but their biochemical and metabolic effects are dose related. Chlortha- lidone has the advantage of better 24-hour blood pressure control than hydrochlorothiazide in clinical trials. Thiazides may be used at higher doses if plasma potassium is above 4.5 mmol/L. The loop diuretics (such as furosemide) may lead to electrolyte and volume depletion more readily than the thiazides and have short durations of action. Because of these adverse effects, loop diuretics should be reserved for use in patients with kidney dysfunction (serum creatinine greater than 2.5 mg/dL [208.3 mcmol/L]; estimated glo- merular filtration rate [eGFR] less than 30 mL/min/1.73 m2) in which case they are more effective than thiazides. Relative to beta-blockers and ACE inhibitors, diuretics are more potent in Blacks, older individuals, the obese, and other subgroups with increased plasma volume or low plasma renin activity (or both). They are relatively more effective in smokers than in nonsmokers. Long-term thiazide adminis- tration also mitigates the loss of bone mineral content in older women at risk for osteoporosis.Overall, diuretics administered alone control blood pressure in 50% of patients with mild to moderate hyper- tension and can be used effectively in combination with all other agents. They are also useful for lowering isolated or predominantly systolic hypertension. Side effects— The adverse effects of diuretics relate primar- ily to the metabolic changes listed in Table 11–8. Erectile dysfunction, skin rashes, and photosensitivity are less fre- quent. Hypokalemia has been a concern but is uncommon at the recommended dosages. The risk can be minimized by limiting dietary salt or increasing dietary potassium; potassium replacement is not usually required to maintain serum K+at greater than 3.5 mmol/L. Higher serum K+ levels are prudent in patients at special risk from intracel- lular potassium depletion, such as those taking digoxin or with a history of ventricular arrhythmias in which case a potassium-sparing agent could be used. Compared with ACE inhibitors and ARBs, diuretic therapy is associated with a slightly higher incidence of mild new-onset diabe- tes. Diuretics also increase serum uric acid and may pre- cipitate gout. Increases in blood glucose, triglycerides, and LDL cholesterol may occur but are relatively minor during long-term low-dose therapy. The potential for worsening of diabetes is outweighed by the advantages of blood pres- sure control, and diuretics should not be withheld from diabetic patients.F . Aldosterone Receptor AntagonistsSp ironolactone and eplerenone are natriuretic in sodium- retaining states, such as heart failure and cirrhosis, but only very weakly so in hypertension. These drugs have reemerged in the treatment of hypertension, particularly in resistant patients and are helpful additions to most other antihyper- tensive medications. Consistent with the increasingly appreciated importance of aldosterone in essential hyper- tension, the aldosterone receptor blockers are effective at lowering blood pressure in all hypertensive patients regard- less of renin level and are also effective in Blacks. Aldoste- rone plays a central role in target-organ damage, including the development of ventricular and vascular hypertrophy and renal fibrosis. Aldosterone receptor antagonists amelio- rate these consequences of hypertension, to some extent independently of effects on blood pressure. Side effects— Spironolactone can cause breast pain and gyne- comastia in men through activity at the progesterone receptor, an effect not seen with the more specific eplerenone. Hyper- kalemia is a problem with both drugs, chiefly in patients with chronic kidney disease. Hyperkalemia is more likely if the pretreatment plasma potassium exceeds 4.5 mmol/L.G.  Beta-Adrenergic Blocking AgentsT hese drugs are effective in hypertension because they decrease the heart rate and cardiac output. The beta-blockers also decrease renin release and are more efficacious in populations with elevated plasma renin activity, such as younger White patients. They neutralize the reflex tachycar- dia caused by vasodilators and are especially useful in patients with associated conditions that benefit from the cardioprotective effects of these agents.CMDT22_Ch11_p0443-p0474.indd  456 29/06/21 8:37 PMSYSteMIC hYperteNSION457 CMDT 2022Table 11–7. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Nondiydoyidin agns Diltiazem Cardizem SR 90 mg twice daily 180–360 mg in 2 doses$283.20 (120 mg twice daily)++ ↓↓  ↓↓ Edema, headache, bradycardia, bloating and constipation, dizziness, AV block, heart failure, urinary frequency.Also approved for angina. Cardizem CD 180 mg ER once daily180–360 mg ER once daily$46.80 (240 mg once daily) Cartia XT 180 or 240 mg ER once daily180–480 mg ER once daily$46.80 (240 mg once daily) Dilacor XR 180 or 240 mg ER once daily180–540 mg ER once daily$39.00 (240 mg once daily) Dilt-CD 180 or 240 mg ER once daily180–480 mg ER once daily$46.80 (240 mg once daily) Diltia XT 180 or 240 mg ER once daily180–540 mg ER once daily$46.80 (240 mg once daily) Taztia XT 120 or 180 mg ER once daily120–540 mg ER once daily$53.40 (240 mg once daily) Tiazac 120 or 240 mg ER once daily120–540 mg ER once daily$53.40 (240 mg once daily) Verapamil Calan 80 mg three times daily80–480 mg in 3 divided doses$35.10 (80 mg three times daily)++ ↓↓↓  ↓↓↓ Same as diltiazem but more likely to cause constipation and heart failure.Also approved for angina and arrhythmias. Calan SR 180 mg ER once daily180–480 mg ER in 1 or 2 doses$36.60 (240 mg once daily) Verelan 120 or 240 mg ER once daily240–480 mg ER once daily$68.70 (240 mg once daily) Verelan PM 100 or 200 mg ER once daily100–400 mg ER once daily$75.90 (200 mg once daily) (continued )CMDT22_Ch11_p0443-p0474.indd  457 29/06/21 8:37 PMChapter 11458 CMDT 2022Table 11–7. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Diydoyidins Amlodipine Norvasc 2.5 mg once daily 2.5–10 mg once daily$3.00 (10 mg once daily)+++ ↓/0 ↓/0 Edema, dizziness, palpitations, flushing, headache, hypoten- sion, tachycardia, bloating and consti- pation, urinary frequency.Amlodipine, nicar- dipine, and nife- dipine also approved for angina. Amlodipine and atorvastatinCaduet 2.5 mg/10 mg once daily10 mg/80 mg once daily$281.10 (10 mg/ 40 mg daily)+++ ↓/0 ↓/0 Edema (amlodipine), myopathy and hepa- totoxicity (atorvastatin). Felodipine Plendil 5 mg ER once daily 5–10 mg ER once daily$81.60 (10 mg ER daily)+++ ↓/0 ↓/0 Isradipine DynaCirc 2.5 mg twice daily 2.5–5 mg twice daily$120.00 (5 mg twice daily)+++ ↓/0 ↓ Nicardipine Cardene 20 mg three times daily20–40 mg three times daily$52.20 (20 mg three times daily)+++ ↓/0 ↓ Nifedipine Adalat CC 30 mg ER once daily 30–90 mg ER once daily$67.50/60 mg daily +++ ↓  ↓↓ Procardia XL 30 or 60 mg ER once daily30–120 mg ER once daily$60.30/60 mg daily Nisoldipine Sular 17 mg daily 17–34 mg daily $251.70 (34 mg once daily)+++ ↓/0 ↓1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. AV, atrioventricular; ER, extended release; GI, gastrointestinal.(continued)CMDT22_Ch11_p0443-p0474.indd  458 29/06/21 8:37 PMSYSteMIC hYperteNSION459 CMDT 2022Table 11–8. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns tizids nd rld Diuics Hydrochloro- thiazide (HCTZ)Esidrix, Microzide12.5 or 25 mg once daily12.5–50 mg once daily$0.08/25 mg $2.40 ↓K+,↓Mg2+,↑Ca2+,↓Na+, ↑uric acid, ↑glucose, ↑LDL cholesterol, ↑triglycerides; rash, erectile dysfunction.Low dosages effective in many patients with- out associated metabolic abnormalities Chlorthalidone Thalitone 12.5 or 25 mg once daily12.5–50 mg once daily$1.21/25 mg $36.30  Better 24-hour blood pressure control than HCTZ because of longer half-life Metolazone Zaroxolyn 1.25 or 2.5 mg once daily1.25–5 mg once daily$1.51/5 mg $45.30  More effective with concurrent kidney disease Indapamide Lozol 2.5 mg once daily2.5–5 mg once daily$0.83/2.5 mg $24.90  Does not alter serum lipid levels Bendroflume- thiazideAprinox Neo-Naclex2.5 mg once daily— — —  Not available in United States Loo Diuics Furosemide Lasix 20 mg twice daily40–320 mg in 2 or 3 doses$0.16/40 mg $9.60 Same as thiazides, but with higher risk of excessive diuresis and electrolyte imbalance. Increases calcium excretion.Short duration of action a disadvantage; should be reserved for patients with kidney disease or fluid retention. Poor antihypertensive. Ethacrynic acid Edecrin 50 mg once daily50–100 mg once or twice daily$23.95/25 mg $1437.00 Bumetanide (generic) 0.25 mg twice daily0.5–10 mg in 2 or 3 doses$0.54/1 mg $32.40 Torsemide Demadex 5 mg once daily5–10 mg once daily$0.70/10 mg $21.00  Effective blood pressure medication at low dosage. (continued )CMDT22_Ch11_p0443-p0474.indd  459 29/06/21 8:37 PMChapter 11460 CMDT 2022Table 11–8. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns aldoson rco Blocks Spironolactone Aldactone 12.5 or 25 mg once daily12.5–100 mg once daily$0.19/25 mg $5.70 Hyperkalemia, metabolic acidosis, gynecomastia.Can be useful add-on therapy in patients with refractory hypertension. Amiloride (generic) 5 mg once daily5–10 mg once daily$1.25/5 mg $37.50 Eplerenone Inspra 25 mg once daily25–100 mg once daily$4.10/25 mg $123.00 Combinion poducs HCTZ and triamtereneDyazide, Maxzide-25 (25/37.5 mg)1 tab once daily1 or 2 tabs once daily$0.27 $8.10 Same as thiazides plus GI disturbances, hyperkalemia rather than hypokalemia, headache; triamterene can cause kidney stones and kidney dysfunction; spirono- lactone causes gynecomastia. Hyperkale- mia can occur if this combination is used in patients with advanced kidney disease or those taking ACE inhibitors.Use should be limited to patients with demonstrable need for a potassium- sparing agent. HCTZ and amiloride(generic) (50/5 mg)½ tab once daily1 or 2 tabs once daily$1.16 $34.80 HCTZ and spironolac- toneAldactazide (25/25 mg; 50/50 mg)1 tab (25/25 mg) once daily1–4 tabs once daily$1.24/ (25/25 mg)$37.201 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; GI, gastrointestinal; LDL, low-density lipoprotein.(continued)CMDT22_Ch11_p0443-p0474.indd  460 29/06/21 8:37 PMSYSteMIC hYperteNSION461 CMDT 2022Th ese include individuals with angina pectoris, previous myo- cardial infarction, and stable heart failure as well as those with migraine headaches and somatic manifestations of anxiety. Although all beta-blockers appear to be similar in anti- hypertensive potency, they differ in a number of pharma- cologic properties (these differences are summarized in Table 11–9), including specificity to the cardiac beta- 1-receptors (cardioselectivity) and whether they also block the beta-2-receptors in the bronchi and vasculature ; at higher dosages, however, all agents are nonselective. The beta-blockers also differ in their pharmacokinetics, lipid solubility—which determines whether they cross the blood- brain barrier predisposing to central nervous system side effects—and route of metabolism. Metoprolol reduces mor- tality and morbidity in patients with chronic stable heart failure with reduced ejection fraction (see Chapter 10). Carvedilol and nebivolol maintain cardiac output and are beneficial in patients with left ventricular systolic dysfunc- tion. Carvedilol and nebivolol may reduce peripheral vas- cular resistance by concomitant alpha-blockade (carvedilol) and increased nitric oxide release (nebivolol). Because of the lack of efficacy in primary prevention of myocardial infarction and inferiority compared with other drugs in prevention of stroke and left ventricular hypertrophy, tra- ditional beta-blockers should not be used as first-line agents in the treatment of hypertension without specific compelling indications (such as active coronary artery disease). Vasodilating beta-blockers may emerge as alter- native first-line antihypertensives, but this possibility has yet to be rigorously tested in outcome studies. Side effects— The side effects of beta-blockers include inducing or exacerbating bronchospasm in predisposed patients; sinus node dysfunction and AV conduction depres- sion (resulting in bradycardia or AV block); nasal conges- tion; Raynaud phenomenon; and central nervous system symptoms with nightmares, excitement, depression, and confusion. Fatigue, lethargy, and erectile dysfunction may occur. The traditional beta-blockers (but not the vasodilator beta-blockers carvedilol and nebivolol) have an adverse effect on lipids and glucose metabolism. Beta-blockers are used cautiously in patients with type 1 diabetes, since they can mask the symptoms of hypoglycemia and prolong these episodes by inhibiting gluconeogenesis. These drugs should also be used with caution in patients with advanced periph- eral vascular disease associated with rest pain or nonhealing ulcers, but they are generally well tolerated in patients with mild claudication. Nebivolol can be safely used in patients with stage II claudication (claudication at 200 m). In treatment of pheochromocytoma, beta-blockers should not be administered until alpha-blockade (eg, phentolamine) has been established . Otherwise, blockade of vasodilatory beta-2-adrenergic receptors will allow unopposed vasocon- strictor alpha-adrenergic receptor activation with worsening of hypertension. For the same reason, beta-blockers should not be used to treat hypertension arising from cocaine use . Great care should be exercised if the decision is made, in the absence of compelling indications, to remove beta- blockers from the treatment regimen because abrupt with- drawal can precipitate acute coronary events and severe increases in blood pressure.H. Alpha-Adrenoceptor AntagonistsPrazosin,  terazosin, and doxazosin (Table 11–10) block postsynaptic alpha-receptors, relax smooth muscle, and reduce blood pressure by lowering peripheral vascular resistance. These agents are effective as single-drug therapy in some individuals, but tachyphylaxis may appear during long-term therapy. Unlike beta-blockers and diuretics, alpha-blockers have no adverse effect on serum lipid levels. In fact, alpha-blockers increase HDL cholesterol while reducing total cholesterol; whether this is beneficial in the long term has not been established. Side effects— Side effects are relatively common (Table 11–10). These include marked hypotension after the first dose which, therefore, should be small and given at bedtime. Post-dosing palpitations, headache, and nervous- ness may continue to occur during long-term therapy; these symptoms may be less frequent or severe with doxa- zosin because of its more gradual onset of action. In ALL- HAT, persons receiving doxazosin as initial therapy had a significant increase in heart failure hospitalizations and a higher incidence of stroke relative to those receiving diuret- ics, prompting discontinuation of this arm of the study. Cata- ractectomy in patients exposed to alpha-blockers can be complicated by the floppy iris syndrome, even after discon- tinuation of the drug, so the ophthalmologist should be alerted that the patient has been taking the drug prior to surgery. To summarize, alpha-blockers should generally not be used as initial agents to treat hypertension—except perhaps in men with symptomatic prostatism or nightmares linked to posttraumatic stress disorder.I.  Drugs With Central Sympatholytic ActionMet hyldopa, clonidine, guanabenz, and guanfacine (Table 11–10) lower blood pressure by stimulating alpha- adrenergic receptors in the central nervous system, thus reducing efferent peripheral sympathetic outflow. There is considerable experience with methyldopa in pregnant women, and it is still used for this population. Clonidine is available in patches, which may have particular value in noncompliant patients. All of these central sympatholytic agents are effective as single therapy in some patients, but they are usually used as second- or third-line agents because of the high frequency of drug intolerance. Side effects— Side effects include sedation, fatigue, dry mouth, postural hypotension, and erectile dysfunction. An important concern is rebound hypertension following withdrawal. Methyldopa also causes hepatitis and hemo- lytic anemia and should be restricted to individuals who have already tolerated long-term therapy.J.  Peripheral Sympathetic InhibitorsTh ese agents are usually used only in refractory hypertension. Reserpine remains a cost-effective antihypertensive agent (Table 11–10). Its reputation for inducing mental depres- sion and its other side effects—sedation, nasal stuffiness, sleep disturbances, and peptic ulcers—has made it unpop- ular, though these problems are uncommon at low dosages.CMDT22_Ch11_p0443-p0474.indd  461 29/06/21 8:37 PMChapter 11462 CMDT 2022Table 11–9. Antihypertensive drugs: beta-adrenergic blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos  UniCos of 30 Dys of tmn (Bsd on avg Dosg)1Scil pois Commns5B-1 Slciviy2ISa3MSa4Liid Solubiliyrnl vs hic eliminion Acebutolol Sectral 400 mg once daily200–1200 mg in 1 or 2 doses$1.34/400 mg $40.20 + + + + H > R Positive ANA; rare LE syndrome; also indicated for arrhythmias. Doses > 800 mg have beta-1 and beta-2 effects. Atenolol Tenormin 25 mg once daily25–100 mg once daily$0.79/50 mg $23.70 + 0 0 0 R Also indicated for angina and post-MI. Doses > 100 mg have beta-1 and beta-2 effects. Atenolol/ chlorthalidoneTenoretic 50 mg/25 mg once daily50 mg/25 mg– 100 mg/25 mg once daily$1.88/50 mg/ 25 mg$56.40 + 0 0 0 R Betaxolol Kerlone 10 mg once daily10–40 mg once daily$0.78/10 mg $23.40 + 0 0 + H > R Bisoprolol Zebeta 5 mg once daily5–20 mg once daily$1.22/10 mg $36.60 + 0 0 0 R = H Also effective for heart failure. Bisoprolol and HCTZZiac 2.5 mg/ 6.25 mg once daily2.5 mg/6.25 mg– 10 mg/6.25 mg once daily$1.14/2.5/ 6.25 mg$34.20 + 0 0 0 R = H Low-dose combination approved for initial therapy. Carvedilol Coreg Coreg CR6.25 mg twice daily 20 mg ER once daily12.5–50 mg in 2 doses 20–80 mg ER once daily$0.09/25 mg $9.91/any tablet$5.40 (25 mg twice a day) $297.300 0 0 +++ H > R Alpha:beta blocking activity 1:9; may cause ortho- static symptoms; effec- tive for heart failure. Nitric oxide potentiating vasodilatory activity. Labetalol Trandate 100 mg twice daily200–2400 mg in 2 doses$0.39/200 mg $23.40 0 0/+ 0 ++ H Alpha:beta blocking activity 1:3; more orthostatic hypotension, fever, hepatotoxicity.CMDT22_Ch11_p0443-p0474.indd  462 29/06/21 8:37 PMSYSteMIC hYperteNSION463 CMDT 2022Metoprolol Lopressor Toprol-XL (SR prepara- tion)50 mg twice daily 25 mg once daily50–200 mg twice daily 25–400 mg once daily$0.03/50 mg $1.50/100 mg$1.80 $45.00+ 0 + +++ H Also indicated for angina and post-MI. Approved for heart failure. Doses > 100 mg have beta-1 and beta-2 effects. Metoprolol and HCTZLopressor HCT50 mg/ 12.5 mg twice daily50 mg/25 mg– 200 mg/50 mg$1.77/100 mg/ 25 mg$106.20 + 0 + +++ H Nadolol Corgard 20 mg once daily20–320 mg once daily$3.96/40 mg $118.80 0 0 0 0 R Nadolol and bendroflumeth- azideCorzide 40 mg/5 mg once daily40 mg/5 mg– 80 mg/5 mg once daily6.14/80 mg/ 5 mg$184.20 Nebivolol Bystolic 5 mg once daily40 mg once daily $6.32/5 mg $189.60 + 0 0 ++ H Nitric oxide potentiating vasodilatory activity. Pindolol Visken 5 mg twice daily10–60 mg in 2 doses$1.10/5 mg $66.00 0 ++ + + H > R In adults, 35% renal clearance. Propranolol Inderal Inderal LA InnoPran XL20 mg twice daily 80 mg ER once daily 80 mg ER once nightly40–640 mg in 2 doses 120–640 mg ER once daily 80–120 mg ER once nightly$0.41/40 mg $2.98/120 mg $30.20/ 120 mg$24.60 $89.40 $906.000 0 ++ +++ H Also indicated for angina and post-MI. Propranolol and HCTZ(generic) 40 mg/25 mg twice daily80 mg/25 mg twice daily$1.41/80 mg/ 25 mg$84.60 0 0 ++ +++ H Timolol (generic) 5 mg twice daily10–60 mg in 2 doses$1.70/10 mg $102.00 0 0 0 ++ H > R Also indicated for post-MI; 80% hepatic clearance.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.2 Agents with beta-1 selectivity are less likely to precipitate bronchospasm and decrease peripheral blood flow in low doses, but selectivity is only relative.3 Agents with ISA cause less resting bradycardia and lipid changes.4 MSA generally occurs at concentrations greater than those necessary for beta-adrenergic blockade. The clinical importance of MS A by beta-blockers has not been defined.5 Adverse effects of all beta-blockers: bronchospasm, fatigue, sleep disturbance and nightmares, bradycardia and atrioventricular block, worsening of heart failure, cold extremities, gastrointestinal disturbances, erectile dysfunction, ↑triglycerides, ↓high-density lipoprotein cholesterol, rare blood dyscrasias. ANA, antinuclear antibody; ER, extended release; HCTZ, hydrochlorothiazide; ISA, intrinsic sympathomimetic activity; LE, lupus erythematosus; MI, myocardial infarction; MSA, membrane-stabilizing activity; SR, sustained release; 0, no effect; +, some effect; ++, moderate effect; +++, most effect.CMDT22_Ch11_p0443-p0474.indd  463 29/06/21 8:37 PMChapter 11464 CMDT 2022Table 11–10. Alpha-adrenoceptor blocking agents, sympatholytics, and vasodilators.Dug poiy Nms Iniil Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns al-adnoco Blocks Doxazosin Cardura Cardura XL1 mg at bedtime 4 mg ER once daily1–16 mg once daily 4–8 mg ER once daily$0.29/4 mg $7.07/4 mg ER$8.70 (4 mg once daily) $212.10 (4 mg ER once daily)Syncope with first dose; postural hypotension, dizziness, palpitations, headache, weakness, drowsiness, sexual dys- function, anticholinergic effects, urinary inconti- nence; first-dose effects may be less with doxazosin.May↑HDL and ↓LDL cholesterol. May provide short-term relief of obstructive prostatic symptoms. Less effective in preventing car- diovascular events than diuretics.Prazosin Minipress 1 mg at bedtime 2–20 mg in 2 or 3 doses$0.95/5 mg $57.00 (5 mg twice daily) Terazosin Hytrin 1 mg at bedtime 1–20 mg in 1 or 2 doses$1.60/1, 2, 5, 10 mg$48.00 (5 mg once daily) Cnl Symolyics Clonidine Catapres Catapres TTS (transdermal patch)0.1 mg twice daily 0.1 mg/day patch weekly0.2–0.6 mg in 2 doses 0.1–0.3 mg/day patch weekly$0.21/0.1 mg $55.77/0.2 mg patch$12.60 (0.1 mg twice daily) $223.08 (0.2 mg weekly)Sedation, dry mouth, sex- ual dysfunction, head- ache, bradyarrhythmias; side effects may be less with guanfacine. Contact dermatitis with clonidine patch.“Rebound” hypertension may occur even after gradual withdrawal. Clonidine and chlorthalidoneClorpres 0.1 mg/15 mg one to three times daily0.1 mg/15 mg– 0.3 mg/15 mg$2.77/0.1 mg/ 15 mg$166.20/0.1 mg/ 15 mg twice daily Guanfacine Tenex 1 mg once daily 1–3 mg once daily $0.87/1 mg $26.10 (1 mg once daily) Methyldopa Aldochlor 250 mg twice daily 500–2000 mg in 2 doses$0.66/500 mg $39.60 (500 mg twice daily)Hepatitis, hemolytic ane- mia, fever.Avoid in favor of safer agents.CMDT22_Ch11_p0443-p0474.indd  464 29/06/21 8:37 PMSYSteMIC hYperteNSION465 CMDT 2022pil Nuonl angoniss Reserpine (generic) 0.05 mg once daily 0.05–0.25 mg once daily$1.19/0.1 mg $35.70 (0.1 mg once daily)Depression (less likely at low dosages, ie, < 0.25 mg), night terrors, nasal stuffi- ness, drowsiness, peptic disease, GI disturbances, bradycardia. Dic Vsodilos Hydralazine Apresoline 25 mg twice daily 50–300 mg in 2–4 doses$0.15/25 mg $9.00 (25 mg twice daily)GI disturbances, tachycar- dia, headache, nasal congestion, rash, LE-like syndrome.May worsen or precipitate angina. Minoxidil (generic) 5 mg once daily 10–40 mg once daily $1.28/10 mg $38.40 (10 mg once daily)Tachycardia, fluid retention, headache, hirsutism, pericardial effusion, thrombocytopenia.Should be used in combination with beta-blocker and diuretic.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ER, extended release; GI, gastrointestinal; LE, lupus erythematosus.CMDT22_Ch11_p0443-p0474.indd  465 29/06/21 8:37 PMChapter 11466 CMDT 2022Guanethidine and guana drel inhibit catecholamine release from peripheral neurons but frequently cause orthostatic hypotension (especially in the morning or after exercise), diarrhea, and fluid retention.K.  Arteriolar DilatorsH ydralazine and minoxidil (Table 11–10) relax vascular smooth muscle and produce peripheral vasodilation. When given alone, they stimulate reflex tachycardia; increase myocardial contractility; and cause headache, palpitations, and fluid retention. To counteract these effects, the agents are usually given in combination with diuretics and beta-blockers in resistant patients. Hydrala- zine produces frequent gastrointestinal disturbances and may induce a lupus-like syndrome. Minoxidil causes hir- sutism and marked fluid retention; this very potent agent is reserved for the most refractory of cases. »Antihypertensive Medications & the Risk of CancerA  number of observational studies have examined the association between long-term exposure to antihyperten- sive medications and cancer. Weak associations have been suggested by some of these studies, but results have been very mixed. In the absence of large-scale prospective studies with cancer as a prespecified outcome measure, the effect of antihypertensive drugs on the risk of cancer remains uncertain. By contrast, the beneficial effect of these drugs on cardiovascular outcomes has been clearly established. Concern about increased risk of cancer should not be minimized, but at present there are no compelling data to prompt a change in prescribing patterns.Hicks  BM et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. [PMID: 30355745] Su KA et al. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br J Dermatol. 2018;179:1088. [PMID: 29723931] Wright CM et al. Calcium channel blockers and breast cancer incidence: an updated systematic review and meta-analysis of the evidence. Cancer Epidemiol. 2017;50:113. [PMID: 28866282] »Procedures That Modulate the Activity of the Autonomic Nervous SystemBefore the adv ent of antihypertensive medications, lumbar sympathectomy was used to lower blood pressure. In a more specific and less invasive approach, the renal sympa- thetic nerves can be ablated using radiofrequency energy applied to the luminal surface of the renal arteries. How- ever, the Symplicity HTN-3 study of renal sympathetic denervation did not show any difference in blood pressure reduction compared to a sham procedure group. Subse- quently, the SPYRAL HTN-OFF MED study, using a more intensive and closely controlled ablation strategy, demon- strated clinically meaningful blood pressure reductions compared to the sham control group. Although not yetaccepted in general clinical practice, it seems probable that renal sympathetic nerve ablation will emerge as an alterna- tive or adjunctive modality in the treatment of hyperten- sion and may become useful in the management of resistant hypertension and drug intolerance.Böhm  M et al; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444. [PMID: 32234534] Hermida RC et al; Hygia Project Investigators. Bedtime hyper- tension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41: 4565. [PMID: 31641769] »Developing an Antihypertensive RegimenHisto rically, data from large placebo-controlled trials sup- ported the overall conclusion that antihypertensive therapy with diuretics and beta-blockers had a major beneficial effect on a broad spectrum of cardiovascular outcomes, reducing the incidence of stroke by 30–50% and of heart failure by 40–50%, and halting progression to accelerated hypertension syndromes. The decreases in fatal and nonfa- tal coronary heart disease and cardiovascular and total mortality were less dramatic, ranging from 10% to 15%. Similar placebo-controlled data pertaining to the newer agents are generally lacking, except for stroke reduction with the calcium channel blocker nitrendipine in the Sys- tolic Hypertension in Europe trial. However, there is sub- stantial evidence that ACE inhibitors, and to a lesser extent ARBs, reduce adverse cardiovascular outcomes in other related populations (eg, patients with diabetic nephropa- thy, heart failure, or postmyocardial infarction and indi- viduals at high risk for cardiovascular events). Most large clinical trials that have compared outcomes in relatively unselected patients have failed to show a difference between newer agents—such as ACE inhibitors, calcium channel block- ers, and ARBs—and the older diuretic-based regimens with regard to survival, myocardial infarction, and stroke. Where differences have been observed, they have mostly been attrib- utable to subtle asymmetries in blood pressure control rather than to any inherent advantages of one agent over another. Recommendations for initial treatment identify ACE inhibi- tors, ARBs, and calcium channel blockers as valid choices. Because of their adverse metabolic profile, initial therapy with thiazides might best be restricted to older patients. Thiazides are acceptable as first-line therapy in Blacks because of specific efficacy in this group. As discussed above, beta-blockers are not ideal first-line drugs in the treatment of hypertension without compelling indications for their use (such as active coronary artery disease and heart failure). Vasodilator beta-blockers (such as carvedilol and nebivolol) may produce better outcomes than traditional beta-blockers; however, this possibility remains a theoretical consideration. The American Diabetes Association has advocated eve- ning dosing of one or more antihypertensive medications to restore nocturnal blood pressure dipping. The HYGIACMDT22_Ch11_p0443-p0474.indd  466 29/06/21 8:37 PMSYSteMIC hYperteNSION467 CMDT 2022trial  compared the effect of nighttime dosing of at least one antihypertensive medication with morning dosing of all antihypertensive medications in 19,000 participants with median follow-up 6.3 years, and demonstrated improved ambulatory blood pressure and nocturnal dipping, and a significant decline in major cardiovascular events in the nighttime dosing group. Participants were monitored via ambulatory blood pressure measurement, and the inci- dence of nocturnal hypotension in the HYGIA trial was very low. However, profound nocturnal hypotension might not be detected in the absence of ambulatory blood pres- sure monitoring, and ischemic optic neuropathy or other low perfusion complications would be a concern. Drugs that interrupt the renin-angiotensin cascade are more effective in young, White persons, in whom renin tends to be higher. Calcium channel blockers and diuretics are more effective in older or Black persons, in whom renin levels are generally lower. Many patients require two or more medications and even then a sub- stantial proportion fail to achieve the goal blood pres- sure. A stepped care approach to the drug treatment of hypertension is outlined in Table 11–11. In diabetic patients, three or four drugs are usually required to reduce systolic blood pressure to goal. In many patients, blood pressure cannot be adequately controlled with any combination. As a result, debating the appropriate first-line agent is less relevant than determining the most appropriate combinations of agents. The mnemonic ABCD can be used to remember four classes of antihypertensive medications. These four classes can be divided into two categories: AB and CD. AB refers to drugs that block the RAAS ( ACE/ARB and beta-blockers). CD refers to those that work in other pathways ( calcium channel blockers and diuretics). Combinations of drugs between the two categories are more potent than combina- tions from within a category. Many experts recommend the use of fixed-dose combination (between two categories) antihypertensive agents as first-line therapy in patientswith substantially elevated systolic pressures (greater than 160/100 mm Hg) or difficult-to-control hypertension (which is often associated with diabetes or kidney dysfunc- tion). In light of unwanted metabolic effects, calcium chan- nel blockers might be preferable to thiazides in the younger hypertensive patient requiring a second antihypertensive drug following initiation of therapy with an ACE inhibitor or ARB. Furthermore, based on the results from the ACCOMPLISH trial, a combination of ACE inhibitor and calcium channel blocker may also prove optimal for patients at high risk for cardiovascular events. The initial use of low-dose combinations allows faster blood pressure reduction without substantially higher intolerance rates and is likely to be better accepted by patients. Data from the ALTITUDE study (in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease or both) indicate that the addition of aliskiren to either ARB or ACE inhibitor was associated with worse outcomes and cannot be recommended, at least in this population. A suggested approach to treatment, tailored to patient demographics, is outlined in Table 11–12. In sum, as a prelude to treatment, the patient should be informed of common side effects and the need for diligent compliance. In patients with blood pressure less than 160/90 mm Hg in whom pharmacotherapy is indicated, treatment should start with a single agent or two-drug combination at a low dose. Follow-up visits usually should be at 4- to 6-week intervals to allow for full medication effects to be established (especially with diuretics) before further titration or adjustment. If, after titration to usual doses, the patient has shown a discernible but incomplete response and a good tolerance of the initial drug, another medication should be added. See Goals of Treatment, above. As a rule of thumb, a blood pressure reduction of 10 mm Hg can be expected for each antihypertensive agent added to the regimen and titrated to the optimum dose. In those with more severe hypertension, or with comorbidi- ties (such as diabetes) that are likely to render them Table 11–11. A step care approach to the initiation and titration of antihypertension medications.1,2Step  1 ACE inhibitor/ARB or3Calcium  channel blocker or Thiazide diuretic4Step  2 ACE inhibitor/ARB plus Calcium channel blocker orthiazide diuretic5Step  3 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic Step 4 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic plus spironolactone6 1Allow 2 weeks to reach full effect of each drug. Proceed through steps until target blood pressure is attained.2 Beta-blockers can be used at any stage if specifically indicated, eg, heart failure or angina.3 The European guidelines recommend starting with low-dose combination of two antihypertensive drugs in all but low-risk grade 1 hyper- tension (140–159/90–99 mm Hg). American guidelines suggest initiation with dual therapy for stage 2 hypertension (> 140/90 mm H g).4 Thiazide or calcium channel blocker is more effective initial therapy in older people and Blacks.5 If required, add a calcium channel blocker rather than diuretic in younger patients to avoid long-term exposure to metabolic si de effects of diuretics.6 Alternatives to spironolactone include eplerenone, amiloride, or triamterene. Watch for hyperkalemia, especially if also receiv ing ACE inhibitor/ ARB. Avoid potassium-sparing diuretics in advanced CKD. If more than three drugs are required at maximum dose, consider special ist referral. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD, chronic kidney disease.CMDT22_Ch11_p0443-p0474.indd  467 29/06/21 8:37 PMChapter 11468 CMDT 2022T able 11–12. Choice of antihypertensive agent based on demographic considerations.1,2 Blck, all ags all Os, ag < 55 Ys all Os, ag > 55 Ys Fis-lin CCB or diuretic ACE inhibitor or ARB3or CCB or diuretic4CCB or diuretic5Scond-lin  ARB3or ACE inhibitor6or vasodilating beta-blocker6Vasodilating beta-blocker ACE inhibitor or ARB3or vasodilating beta-blocker7rsisn  ynsion Aldosterone receptor blocker Aldosterone receptor blocker Aldosterone receptor blocker addiionl oions Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8 1Compelling indications may alter the selection of an antihypertensive drug.2 Start with full dose of one agent, or lower doses of combination therapy. In more severe hypertension (≥ 140/90 mm Hg), conside r initiat- ing therapy with a fixed dose combination.3 Women of childbearing age should avoid ACE inhibitors and ARBs or discontinue as soon as pregnancy is diagnosed.4 The adverse metabolic effects of thiazide diuretics and beta-blockers should be considered in younger patients but may be less important in the older patient.5 For patients with significant kidney dysfunction, use loop diuretic instead of thiazide.6 Despite the elevated risk of angioedema and cough in Blacks, ACE inhibitors are generally well tolerated and are a useful adjun ct.7 There are theoretical advantages in the use of vasodilating beta-blockers such as carvedilol and nebivolol.8 Alpha-antagonists may precipitate or exacerbate orthostatic hypotension in older adults. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.resistan t to treatment, initiation with combination therapy is advised and more frequent follow-up is indicated. Patients who are compliant with their medications and who do not respond to conventional combination regi- mens should usually be evaluated for secondary hyperten- sion before proceeding to more complex regimens. »Medication NonadherenceAdher ence to antihypertensive treatment is alarmingly poor. In one European study of antihypertensive medica- tion compliance, there was a 40% discontinuation rate at 1 year after initiation. Collaborative care, using clinicians, pharmacists, social workers, and nurses to encourage com- pliance, has had a variable and often rather modest effect on blood pressure control. Adherence is enhanced by patient education and by use of home blood pressure mea- surement. The choice of antihypertensive medication is important. Better compliance has been reported for patients whose medications could be taken once daily or as combination pills. Adherence is best with ACE inhibitors and ARBs, and worse with beta-blockers and diuretics. »Consideration of Gender in HypertensionBecause  of the preponderance of male recruitment into large-scale clinical trials, the impact of gender on the evaluation and management of hypertension remains uncertain. The limited data that exist suggest a steeper relationship in women between 24-hour ambulatory and night time systolic blood pressure and the risk of cardio- vascular events. There are many gender-specific effects on the mechanisms and end organ impact of hypertension. In younger adults, men are more likely to be hypertensive than women, a relationship that reverses in later life.Regression of left ventricular hypertrophy in response to ACE inhibitors is less pronounced in women. Women are more likely to have isolated systolic hypertension, probably because they develop more active left ventricular systolic function and greater vascular stiffness than men. Fibro- muscular dysplasia of the renal artery is much more com- mon in women than men. The side effects of many antihypertensive drugs are more pronounced in women than men, including ACE inhibitor–associated cough and hyponatremia and hypokalemia in response to diuretics. Conversely, thiazides can help preserve bone density. Dependent edema due to amlodipine is more likely in women, and women are more sensitive to beta-blockers. There are no data to support a different blood pressure target in women, but this question has not been examined in dedicated clinical trials. »Treatment of Hypertension in DiabetesH ypertensive patients with diabetes are at particularly high risk for cardiovascular events. Data from the ACCORD study of diabetic patients demonstrated that most of the benefits of blood pressure lowering were seen with a systolic target of less than 140 mm Hg. Although there was a reduc- tion in stroke risk at a systolic target below 120/70 mm Hg, treatment to this lower target was associated with an increased risk of serious adverse effects. US and Canadian guidelines recommend a blood pressure goal of less than 130/80 mm Hg in diabetic patients. Because of the benefi- cial effects of ACE inhibitors in diabetic nephropathy, they should be part of the initial treatment regimen. ARBs or perhaps renin inhibitors may be substituted in those intol- erant of ACE inhibitors. While the ONTARGET study showed that combinations of ACE inhibitors and ARBs in persons with atherosclerosis or type 2 diabetes withCMDT22_Ch11_p0443-p0474.indd  468 29/06/21 8:37 PMSYSteMIC hYperteNSION469 CMDT 2022end-orga n damage appeared to minimize proteinuria, this strategy slightly increased the risks of progression to dialy- sis and of death; thus, it is not recommended. Most dia- betic patients require combinations of three to five agents to achieve target blood pressure, usually including a diuretic and a calcium channel blocker or beta-blocker. Canagliflozin improves glycemic control through inhibition of the sodium-glucose co-transporter 2 (SGLT2) and, in addition, generally lowers blood pressure by 3–4 mm Hg. This drug was associated with improved renal outcomes and reduced cardiovascular risk in the CREDENCE trial of patients with diabetic nephropathy and can be consid- ered when additional blood pressure control is needed in patients with type 2 diabetes. In addition to rigorous blood pressure control, treatment of persons with diabe- tes should include aggressive treatment of other risk factors. »Treatment of Hypertension in Chronic Kidney DiseaseH ypertension is present in 40% of patients with a GFR of 60–90 mL/min/1.73 m2, and 75% of patients with a GFR less than 30 mL/min/1.73 m2. The rate of progression of chronic kidney disease is markedly slowed by treatment of hypertension. In the SPRINT trial, the reduction in cardio- vascular risk associated with lower blood pressure targets was also observed in the subgroup with a GFR of less than 60 mL/min/1.73 m2. However, an effect of lower blood pressure targets on the slowing of chronic kidney disease progression appears to be restricted to those with pro- nounced proteinuria. In the SPRINT trial, the lower blood pressure goal was associated with increased risk of acute kidney injury, but this was generally reversible and not associated with elevated biomarkers for ischemic injury. Most experts recommend a blood pressure target of less than 130/80 mm Hg in patients with chronic kidney dis- ease, with consideration of more intensive lowering if pro- teinuria greater than 1 g per 24 hours is present. Medications that interrupt the renin-angiotensin cascade can slow the progression of kidney disease and are preferred for initial therapy, especially in those with albuminuria of greater than 300 mg/g creatinine. Transition from thiazide to loop diuretic is often necessary to control volume expansion as the eGFR falls below 30 mL/min/1.73 m2. ACE inhibitors remain protective and safe in kidney disease associated with significant proteinuria and serum creatinine as high as 5 mg/dL (380 mcmol/L). However, the use of drugs blocking the RAAS cascade in patients with advanced chronic kidney disease should be supervised by a nephrol- ogist. Kidney function and electrolytes should be measured 1 week after initiating treatment and subsequently moni- tored carefully in patients with kidney disease. An increase in creatinine of 20–30% is acceptable and expected; more exaggerated responses suggest the possibility of renal artery stenosis or volume contraction. Although lower blood pressure levels are associated with acute decreases in GFR, this appears not to translate into an increased risk of developing end-stage renal disease in the long term. Persis- tence with ACE inhibitor or ARB therapy as the serum potassium level exceeds 5.5 mEq/L is probably notwarranted, since other antihypertensive medications are renoprotective as long as goal blood pressures are main- tained. However, diuretics can often be helpful in control- ling mild hyperkalemia, and there are novel cation exchange polymers (such as patiromer) that sequester potassium in the gut and are more effective and better tol- erated than sodium polystyrene sulfonate. »Treatment of Hypertension in BlacksSubstan tial evidence indicates that Blacks in the United States are not only more likely to become hypertensive and more susceptible to the cardiovascular and renal complica- tions of hypertension—they also respond differently to many antihypertensive medications. The REGARDS study illustrates these differences. At systolic blood pressures less than 120 mm Hg, Black and White participants between 45 and 64 years of age had equal risk of stroke. For a 10 mm Hg increase in systolic blood pressure, the risk of stroke was threefold higher in Black participants. At levels above 140–159/90–99 mm Hg, the hazard ratio for stroke in Black compared to White participants between 45 and 64 years of age was 2.35. This increased susceptibility may reflect genetic differences in the cause of hypertension or the subsequent responses to it, differences in occurrence of comorbid conditions such as diabetes or obesity, or envi- ronmental factors such as diet, activity, stress, or access to health care services. In any case, as in all persons with hypertension, a multifaceted program of education and lifestyle modification is warranted. Early introduction of combination therapy has been advocated, but there are no clinical trial data to support a lower than usual blood pres- sure goal in Blacks. Because it appears that ACE inhibitors and ARBs—in the absence of concomitant diuretics—are less effective in Blacks than in Whites, initial therapy should generally be a diuretic or a diuretic in combination with a calcium channel blocker. However, inhibitors of the RAAS do lower blood pressure in Black patients, are useful adjuncts to the recommended diuretic and calcium chan- nel blockers, and should be used in patients with hyperten- sion and compelling indications such as heart failure and kidney disease (especially in the presence of proteinuria) (Table 11–13). Black patients have an elevated risk of ACE inhibitor–associated angioedema and cough, so ARBs would be the preferred choice. »Treating Hypertension in Older AdultsSeveral  studies in persons over 60 years of age have con- firmed that antihypertensive therapy prevents fatal and nonfatal myocardial infarction and reduces overall cardio- vascular mortality. The HYVET study indicated that a reasonable ultimate blood pressure goal is 150/80 mm Hg. Updated guidelines suggest that blood pressure goals should not generally be influenced by age alone. An explor- atory subgroup analysis of the SPRINT study found that people older than age 75 years showed benefit at the 120 mm Hg systolic treatment target. Importantly, these benefits were also evident in patients classified as frail. This more aggressive approach was, however, associated with greater risk of falls and worsening kidney function,CMDT22_Ch11_p0443-p0474.indd  469 29/06/21 8:37 PMChapter 11470 CMDT 2022indicating  that close monitoring is required in elderly patients treated to lower blood pressure goals. It is also important to note the exclusion criteria of the SPRINT study, which included diabetes mellitus, stroke, and ortho- static hypotension. Blood pressure treatment goals should be individual- ized in the very elderly. In the SPRINT MIND study, the lower systolic blood pressure target of 120 mm Hg was associated with a 15% reduction in the incidence of mild cognitive impairment and probable all cause dementia compared to the 140 mm Hg in the target group. Based upon this data, aggressive control of hypertension in high- risk individuals would have a significant impact on the prevalence of dementia. As discussed above, it is important to note that blood pressure measurements in the SPRINT study were made by automated devices, which are known to read lower than conventional office measurements. How to initiate antihypertensive therapy in older patients— The same medications are used in older patients but at 50% lower doses. Pressure should be reduced more gradually with a safe intermediate systolic blood pressure goal of 160 mm Hg. As treatment is initiated, older patients should be carefully monitored for orthostasis, altered cog- nition, and electrolyte disturbances. The elderly are espe- cially susceptible to problems associated with polypharmacy, including drug interactions and dosing errors. »Management of Supine Hypertension in Patients With Orthostatic HypotensionSup ine hypertension is common in patients with ortho- static hypotension and is associated with increased cardio- vascular risk. Treatment of orthostasis can exacerbate supine hypertension and vice versa. Life expectancy is often reduced in patients with profound autonomic ner- vous system dysfunction. In those whose life expectancy is at least several years, though, treatment of nocturnal hypertension might be considered with the use of shorter acting agents (eg, captopril, hydralazine, losartan, or quick- release nifedipine). In patients with supine hypertension, medications used to increase blood pressure during the day should not be given within 5 hours of bedtime.»Follow-Up of Patients Receiving Hypertension TherapyOnc e blood pressure is controlled on a well-tolerated regi- men, follow-up visits can be infrequent and laboratory test- ing limited to those appropriate for the patient and the medications used. Y early monitoring of blood lipids is rec- ommended, and an electrocardiogram could be repeated at 2- to 4-year intervals depending on whether initial abnor- malities are present and on the presence of coronary risk factors. Patients who have had excellent blood pressure control for several years, especially if they have lost weight and initiated favorable lifestyle modifications, might be con- sidered for a trial of reduced antihypertensive medications.Carnethon  MR et al; American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Func- tional Genomics and Translational Biology; and Stroke Coun- cil. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393. [PMID: 29061565] Perkovic V et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295. [PMID: 30990260] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] Wenger NK et al. Hypertension across a woman’s life cycle. J Am Coll Cardiol. 2018;71:1797. [PMID: 29673470]RE SISTANT HYPERTENSIONResistant  hypertension is defined as the failure to reach blood pressure control in patients who are adherent to full doses of an appropriate three-drug regimen (including a diuretic). In the approach to resistant hypertension, the clinician should first confirm compliance and rule out “white coat hypertension, ” ideally using ambulatory or home-based measurement of blood pressure. Exacerbating factors should be considered (as outlined above). Finally, identifiable causes of resistant hypertension should be sought (Table 11–14). The clinician should pay particularTable 11–13. Recommended antihypertensive medications for coexisting indications.Indicion aniynsiv Mdicion Diuic B-Block aCe Inibio arBClcium Cnnl Blockaldoson angonis Heart failure √ √ √ √  √ Following MI  √ √  √ High coronary disease risk √ √ √  √ Diabetes √ √ √ √ √ Chronic kidney disease  √ √ Recurrent stroke prevention √  √ ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; MI, myocardial infarction.CMDT22_Ch11_p0443-p0474.indd  470 29/06/21 8:37 PMSYSteMIC hYperteNSION471 CMDT 2022at tention to the type of diuretic being used in relation to the patient’s kidney function. Aldosterone may play an important role in resistant hypertension and aldosterone receptor blockers can be very useful. If goal blood pressure cannot be achieved following completion of these steps, consultation with a hypertension specialist should be con- sidered. Renal sympathetic nerve ablation is a consider- ation for these patients in the absence of other options, but further trials are needed before this procedure can be rou- tinely integrated into clinical practice.W ei FF et al. Diagnosis and management of resistant hyperten- sion: state of the art. Nat Rev Nephrol. 2018;14:428. [PMID: 29700488]HY PERTENSIVE URGENCIES & EMERGENCIESH ypertensive urgencies are situations in which blood pressure must be reduced within a few hours. These include patients with asymptomatic severe hypertension (systolic blood pressure greater than 220 mm Hg or dia- stolic pressure greater than 125 mm Hg that persists after a period of observation) and those with optic disk edema, progressive target-organ complications, and severe periop- erative hypertension. Elevated blood pressure levels alone—in the absence of symptoms of new or progressive target-organ damage—rarely require emergency therapy. Parenteral drug therapy is not usually required; partial reduction of blood pressure with relief of symptoms is thegoal. Effective oral agents are clonidine, captopril, and slow-release nifedipine. Hypertensive emergencies require substantial reduction of blood pressure within 1 hour to avoid the risk of serious morbidity or death. Although blood pressure is usually strik- ingly elevated (diastolic pressure greater than 130 mm Hg), the correlation between pressure and end-organ damage is often poor. It is the presence of critical multiple end-organ injury that determines the seriousness of the emergency and the approach to treatment. Emergencies include hyperten- sive encephalopathy (headache, irritability, confusion, and altered mental status due to cerebrovascular spasm), hyper- tensive nephropathy (hematuria, proteinuria, and acute kidney injury due to arteriolar necrosis and intimal hyper- plasia of the interlobular arteries), intracranial hemorrhage, aortic dissection, preeclampsia-eclampsia, pulmonary edema, unstable angina, or myocardial infarction. Encepha- lopathy or nephropathy accompanying hypertensive reti- nopathy has historically been called malignant hypertension, but the therapeutic approach is identical to that used in other hypertensive emergencies. Parenteral therapy is indicated in most hypertensive emergencies, especially if encephalopathy is present. The initial goal in hypertensive emergencies is to reduce the pres- sure by no more than 25% (within minutes to 1 or 2 hours) and then toward a level of 160/100 mm Hg within 2–6 hours. Excessive reductions in pressure may precipitate coronary, cerebral, or renal ischemia. To avoid such declines, the use of agents that have a predictable, dose-dependent, tran- sient, and progressive antihypertensive effect is preferable (Table 11–15). In that regard, the use of sublingual or oral fast-acting nifedipine preparations is best avoided. Acute ischemic stroke is often associated with marked elevation of blood pressure, which will usually fall sponta- neously. In such cases, antihypertensives should only be used if the systolic blood pressure exceeds 180–200 mm Hg, and blood pressure should be reduced cautiously by 10–15% (Table 11–15). If thrombolytics are to be given, blood pres- sure should be maintained at less than 185/110 mm Hg during treatment and for 24 hours following treatment. Inintracerebral hemorrhage, the aim is to minimize bleeding by reducing the systolic blood pressure in most patients to 130–140 mm Hg within the first 6 hours. In acute subarachnoid hemorrhage, as long as the bleeding source remains uncorrected, a compromise must be struck between preventing further bleeding and maintaining cere- bral perfusion in the face of cerebral vasospasm. In this situ- ation, blood pressure goals depend on the patient’s usual blood pressure. In previously normotensive patients, the tar- get should be a systolic blood pressure of 110–120 mm Hg; in hypertensive patients, blood pressure should be treated to 20% below baseline pressure. In the treatment of hyper- tensive emergencies complicated by (or precipitated by) central nervous system injury, labetalol or nicardipine are good choices, since they are nonsedating and do not appear to cause significant increases in cerebral blood flow or intracranial pressure. Patients with subarachnoid hemor- rhage should receive nimodipine for 3 weeks following presentation to minimize cerebral vasospasm. In hyperten- sive emergencies arising from catecholaminergic mechanisms,Table 11–14. Causes of resistant hypertension.Improper  blood pressure measurement Nonadherence Volume overload and pseudotolerance Excess sodium intake Volume retention from kidney disease Inadequate diuretic therapy Drug-induced or other causes Inadequate doses Inappropriate combinations Nonsteroidal anti-inflammatory drugs; cyclooxygenase-2 inhibitors Cocaine, amphetamines, other illicit drugs Sympathomimetics (decongestants, anorectics) Oral contraceptives Adrenal steroids Cyclosporine and tacrolimus Erythropoietin Licorice (including some chewing tobacco) Selected over-the-counter dietary supplements and medicines (eg, ephedra, ma huang, bitter orange) Associated conditions Obesity Excess alcohol intake Identifiable causes of hypertension (see Table 11–2) Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560.CMDT22_Ch11_p0443-p0474.indd  471 29/06/21 8:37 PMChapter 11472 CMDT 2022T able 11–15. Treatment of hypertensive emergency depending on primary site of end-organ damage. See Table 11–16 for dosages.t y of hynsiv emgncyrcommndd Dug Oions nd Combinions Dugs o avoid Myocardial ischemia and infarction Nicardipine plus esmolol1Nitroglycerin  plus labetalol Nitroglycerin plus esmolol1Hydralazine, diazoxide, minoxidil, nitroprusside Acute kidney injury Fenoldopam Nicardipine Clevidipine Aortic dissection Esmolol plus nicardipine Esmolol plus clevidipine Labetalol Esmolol plus nitroprussideHydralazine, diazoxide, minoxidil Acute pulmonary edema, LV systolic dysfunction Nicardipine plus nitroglycerin2plus a loop diuretic Clevidipine plus nitroglycerin2plus a loop diureticHydralazine, diazoxide, beta-blockers Acute pulmonary edema, diastolic dysfunction Esmolol plus low-dose nitroglycerin plus a loop diuretic Labetalol plus low-dose nitroglycerin plus a loop diuretic Ischemic stroke (systolic blood pressure > 180–200 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Intracerebral hemorrhage (systolic blood pressure > 140–160 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Hyperadrenergic states, including cocaine use Nicardipine plus a benzodiazepine Clevidipine plus a benzodiazepine Phentolamine LabetalolBeta-blockers Preeclampsia, eclampsia Labetalol NicardipineDiuretics, ACE inhibitors1 Avoid if there is LV systolic dysfunction.2 Drug of choice if LV systolic dysfunction is associated with ischemia. ACE, angiotensin-converting enzyme; LV, left ventricular.suc h as pheochromocytoma or cocaine use, beta-blockers can worsen the hypertension because of unopposed peripheral vasoconstriction; nicardipine, clevidipine, or phentolamine is preferred . Labetalol is useful in these patients if the heart rate must be controlled. Table 11–15 provides guidelines for the choice of antihypertensive agent based on the site of end- organ damage. ACE inhibitors are specifically indicated for hypertensive crisis from systemic sclerosis (scleroderma). In acute aortic dissection, systolic blood pressure and heart rate should be reduced within 30 minutes to below 120 mm Hg and less than 60 beats per minute, using a combination of vasodilation and beta-blockade. »Pharmacologic ManagementA.  Parenteral AgentsSodiu m nitroprusside is no longer the treatment of choice for acute hypertensive problems; in most situations, appropriatecontrol of blood pressure is best achieved using combinations of nicardipine or clevidipine plus labetalol or esmolol . (Table 11–16 lists drugs, dosages, and adverse effects.) 1. Nicardipine— Intravenous nicardipine is the most potent and the longest acting of the parenteral calcium channel blockers. As a primarily arterial vasodilator, it has the potential to precipitate reflex tachycardia, and for that reason it should not be used without a beta-blocker in patients with coronary artery disease. 2. Clevidipine— Intravenous clevidipine is an L-type cal- cium channel blocker with a 1-minute half-life, which facilitates swift and tight control of severe hypertension. It acts on arterial resistance vessels and is devoid of venodila- tory or cardiodepressant effects. 3. Labetalol— This combined beta- and alpha-blocking agent is the most potent adrenergic blocker for rapid bloodCMDT22_Ch11_p0443-p0474.indd  472 29/06/21 8:37 PMSYSteMIC hYperteNSION473 CMDT 2022Table 11–16. Drugs for hypertensive emergencies and urgencies (in descending order of preference).agn acion Dosg Ons Duion advs effcs Commns hynsiv emgncis Nicardipine (Cardene)Calcium channel blocker5 mg/h intravenously; may increase by 1–2.5 mg/h every 15 minutes to 15 mg/h1–5 minutes 3–6 hours Hypotension, tachycardia, headache. May precipitate myocardial ischemia. Clevidipine (Cleviprex)Calcium channel blocker1–2 mg/h intravenously initially; double rate every 90 seconds until near goal, then by smaller amounts every 5–10 minutes to a maximum of 32 mg/h2–4 minutes 5–15 minutes Headache, nausea, vomiting. Lipid emulsion: contraindicated in patients with allergy to soy or egg. Labetalol (Trandate)Beta- and alpha-blocker20–40 mg intravenously every 10 minutes to 300 mg; 2 mg/min infusion5–10 minutes 3–6 hours Nausea, hypotension, bronchospasm, bradycardia, heart block.Avoid in acute LV systolic dysfunction, asthma. May be continued orally. Esmolol (Brevibloc) Beta-blocker Loading dose 500 mcg/kg intravenously over 1 minute; maintenance, 25–200 mcg/kg/min1–2 minutes 10–30 minutes Bradycardia, nausea. Avoid in acute LV systolic dysfunction, asthma. Weak antihypertensive. Fenoldopam (Corlopam)Dopamine receptor agonist0.1–1.6 mcg/kg/min intravenously 4–5 minutes < 10 minutes Reflex tachycardia, hypotension, increased intraocular pressure.May protect kidney function. Enalaprilat (Vasotec)ACE inhibitor 1.25 mg intravenously every 6 hours 15 minutes 6 hours or moreExcessive hypotension. Additive with diuretics; may be contin- ued orally. Furosemide (Lasix) Diuretic 10–80 mg orally or intravenously 15 minutes 4 hours Hypokalemia, hypotension. Adjunct to vasodilator. Hydralazine (Apresoline)Vasodilator 5–20 mg intravenously; may repeat after 20 minutes10–30 minutes 2–6 hours Tachycardia, headache, vomiting, diarrheaAvoid in coronary artery disease, dissec- tion. Rarely used except in pregnancy. Nitroglycerin Vasodilator 0.25–5 mcg/kg/min intravenously 2–5 minutes 3–5 minutes Headache, nausea, hypotension, bradycardia.Tolerance may develop. Useful primar- ily with myocardial ischemia. Nitroprusside (Nitropress)Vasodilator 0.25–10 mcg/kg/min intravenously Seconds 3–5 minutes Anxiety, increased intracranial pressure, vomiting, bowel obstruction; thiocyanate and cyanide toxicity, especially with kid- ney and liver dysfunction; hypotension. Coronary steal, decreased cerebral blood flow, increased intracranial pressure.No longer the first-line agent. hynsiv Ugncis Clonidine (Catapres)Central sympatholytic0.1–0.2 mg orally initially; then 0.1 mg every hour to 0.8 mg orally30–60 minutes 6–8 hours Sedation. Rebound may occur. Captopril (Capoten) ACE inhibitor 12.5–25 mg orally 15–30 minutes 4–6 hours Excessive hypotension. Nifedipine (Adalat, Procardia)Calcium channel blocker10 mg orally initially; may be repeated after 30 minutes15 minutes 2–6 hours Excessive hypotension, tachycardia, head- ache, angina, myocardial infarction, stroke.Response unpredictable. ACE, angiotensin-converting enzyme; CNS, central nervous system; GI, gastrointestinal; LV, left ventricular.CMDT22_Ch11_p0443-p0474.indd  473 29/06/21 8:37 PMChapter 11474 CMDT 2022pres sure reduction. Other beta-blockers are far less potent. Excessive blood pressure drops are unusual. Experience with this agent in hypertensive syndromes associated with pregnancy has been favorable. 4. Esmolol— This rapidly acting beta-blocker is approved only for treatment of supraventricular tachycardia, but is often used for lowering blood pressure. It is less potent than labetalol and should be reserved for patients in whom there is particular concern about serious adverse events related to beta-blockers. 5. Fenoldopam— Fenoldopam is a peripheral dopamine-1 (DA1) receptor agonist that causes a dose-dependent reduction in arterial pressure without evidence of toler- ance, rebound, withdrawal, or deterioration of kidney function. In higher dosage ranges, tachycardia may occur. This drug is natriuretic, which may simplify volume man- agement in acute kidney injury. 6. Enalaprilat— This is the active form of the oral ACE inhibi- tor enalapril. The onset of action is usually within 15 minutes, but the peak effect may be delayed for up to 6 hours. Thus, enalaprilat is used primarily as an adjunctive agent. 7. Diuretics— Intravenous loop diuretics can be very help- ful when the patient has signs of heart failure or fluid reten- tion, but the onset of their hypotensive response is slow, making them an adjunct rather than a primary agent for hypertensive emergencies. Low dosages should be used initially (furosemide, 20 mg, or bumetanide, 0.5 mg). They facilitate the response to vasodilators, which often stimu- late fluid retention. 8. Hydralazine— Hydralazine can be given intravenously or intramuscularly, but its effect is less predictable than that of other drugs in this group. It produces reflex tachycardia and should not be given without beta-blockers in patients with possible coronary disease or aortic dissection. Hydral- azine is used primarily in pregnancy and in children, but even in these situations, it is not a first-line drug. 9. Nitroglycerin, intravenous— This agent should be reserved for patients with accompanying acute coronary ischemic syndromes. 10. Nitroprusside sodium— This agent is given by con- trolled intravenous infusion gradually titrated to thedesired effect. It lowers the blood pressure within seconds by direct arteriolar and venous dilation. Monitoring with an intra-arterial line avoids hypotension. Nitroprusside— in combination with a beta-blocker—is useful in patients with aortic dissection.B.  Oral AgentsPa tients with less severe acute hypertensive syndromes can often be treated with oral therapy. Suitable drugs will reduce the blood pressure over a period of hours. In those presenting as a consequence of noncompliance, it is usually sufficient to restore the patient’s previously established oral regimen. 1. Clonidine— Clonidine, 0.2 mg orally initially, followed by 0.1 mg every hour to a total of 0.8 mg, will usually lower blood pressure over a period of several hours. Sedation is frequent, and rebound hypertension may occur if the drug is stopped. 2. Captopril— Captopril, 12.5–25 mg orally, will also lower blood pressure in 15–30 minutes. The response is variable and may be excessive. Captopril is the drug of choice in the management of systemic sclerosis hypertensive crisis. 3. Nifedipine— The effect of fast-acting nifedipine cap- sules is unpredictable and may be excessive, resulting in hypotension and reflex tachycardia. Because myocardial infarction and stroke have been reported in this setting, the use of sublingual nifedipine is not advised. Nifedipine retard, 20 mg orally, appears to be safe and effective.C.  Subsequent TherapyWhen  the blood pressure has been brought under control, combinations of oral antihypertensive agents can be added as parenteral drugs are tapered off over a period of 2–3 days.Co rdonnier C et al. Intracerebral haemorrhage: current approaches to acute management. Lancet. 2018;392:1257. [PMID: 30319113] Ipek E et al. Hypertensive crisis: an update on clinical approach and management. Curr Opin Cardiol. 2017;32:397. [PMID: 28306673] Peixoto AJ. Acute severe hypertension. N Engl J Med. 2019;381:1843. [PMID: 31693807]CMDT22_Ch11_p0443-p0474.indd  474 29/06/21 8:37 PM475 CMDT 2022 ºATHEROSCLEROTIC PERIPHERAL VASCULAR DISEASE OCCLUSIVE DISEASE: AORTA & ILIAC ARTERIESE S S E N T I A L S  O F  D I A G N O S I S »Claudication: cramping pain or tiredness in the calf, thigh, or hip while walking. »Diminished femoral pulses. »Tissue loss (ulceration, gangrene) or rest pain. »General ConsiderationsOlusive  atherslerti lesins develping in the extrem- ities, r peripheral artery disease (PAD), is evidene f a systemi atherslerti press. The prevalene f PAD is 30% in patients wh are 70 years ld withut ther risk fatrs, r 50 years ld with risk fatrs suh as diabetes mellitus r tba use. Pathlgi hanges f athersle- rsis may be diffuse, but flw-limiting stenses ur seg- mentally. In the lwer extremities, stenses lassially ur in three anatmi segments: the artilia segment, femral-ppliteal segment, and the infrappliteal r tibial segment f the arterial tree. Lesins in the distal arta and prximal mmn ilia arteries lassially ur in White male smkers aged 50–60 years. Disease prgressin may lead t mplete lusin f ne r bth mmn ilia arteries, whih an preipitate lusin f the entire abdminal arta t the level f the renal arteries. »Clinical FindingsA.  Symptoms and SignsA pprximately tw-thirds f patients with PAD are either asymptmati r d nt have lassi symptms. Intermit- tent laudiatin, whih is pain with ambulatin that urs frm insuffiient bld flw relative t demand, is typially12Warren J. Gasper, MD James C. Iannuzzi, MD, MPH Meshell D. Johnson, MDBlood Vessel & Lymphatic Disordersdesribed as severe and  ramping and primarily in the alf musles. The pain frm artilia lesins may extend int the thigh and buttks and eretile dysfuntin may ur frm bilateral mmn ilia disease. Rarely, patients m- plain nly f weakness in the legs when walking, r simply extreme limb fatigue. The symptms are relieved with rest and are reprduible when the patient walks again. Femral pulses and distal pulses are absent r very weak. Bruits may be heard ver the arta, ilia, and femral arteries.B.  Doppler and Vascular FindingsThe  rati f systli bld pressure deteted by Dppler examinatin at the ankle mpared with the brahial artery (referred t as the ankle-brahial index [ABI]) is redued t belw 0.9 (nrmal rati is 0.9–1.2); this differene is exag- gerated by exerise. Bth the drsalis pedis and the psterir tibial arteries are measured and the higher f the tw artery pressures is used fr alulatin. Segmental wavefrms r pulse vlume rerdings btained by strain gauge tehnl- gy thrugh bld pressure uffs demnstrate blunting f the arterial inflw thrughut the lwer extremity.C.  ImagingCT  angigraphy (CTA) and magneti resnane angigra- phy (MRA) an identify the anatmi latin f disease. Due t verlying bwel, duplex ultrasund has a limited rle in imaging the artilia segment. Imaging is required nly when symptms neessitate interventin, sine a his- try and physial examinatin with vasular testing shuld apprpriately identify the invlved levels f the arterial tree. »TreatmentA.  Medical and Exercise TherapyThe  rnerstnes f PAD treatment are ardivasular risk fatr redutin and a supervised r strutured exerise prgram. Essential elements inlude smking essatin, antiplatelet therapy, lipid and bld pressure management, and weight lss. Nitine replaement therapy, buprpin, and vareniline have established benefits in smking essa- tin (see Chapter 1). Antiplatelet agents (aspirin, 81 mg rally daily, r lpidgrel, 75 mg rally daily) redue verallCMDT22_Ch12_p0475-p0501.indd  475 29/06/21 8:37 PMCHAPTER 12476 CMDT 2022ar divasular mrbidity. Lw-dse rivarxaban (2.5 mg rally twie daily) with aspirin 100 mg rally daily redues bth majr ardivasular and limb-related adverse events in symptmati patients. All patients with PAD shuld reeive high-dse statin (eg, atrvastatin 80 mg daily if tler- ated) t treat hyperhlesterlemia and inflammatin. A trial f ilstazl 100 mg rally twie a day, may imprve walking distane in apprximately tw-thirds f patients. Supervised exerise prgrams fr PAD prvide signifi- ant imprvements in pain, walking distane, and quality f life and may be mre effetive than an endvasular treatment alne. A minimum training gal is a walking sessin f 30–45 minutes at least 3 days per week fr a minimum f 12 weeks. Strutured mmunity r hme- based exerise prgrams as well as alternative exerises (yling, upper-bdy ergmetry) may als be effetive.B.  Endovascular TherapyWhen  the atherslerti lesins are fal, they an be effetively treated with angiplasty and stenting. This apprah mathes the results f surgery fr single stenses but bth effetiveness and durability derease with lnger r multiple stenses.C.  Surgical InterventionA  prstheti art-femral bypass graft that bypasses the diseased artery segments is a highly effetive and durable treatment fr this disease. Patients may als be treated with a graft frm the axillary artery t the femral arteries (axill-femral bypass graft) r with a graft frm the n- tralateral femral artery (femral-femral bypass) when ilia disease is limited t ne side. The perative risk f axill-femral and femral-t-femral bypass grafts is lwer beause the abdminal avity is nt entered and the arta is nt rss-lamped, but the grafts are less durable. »ComplicationsThe  mpliatins f the art-femral bypass are thse f any majr abdminal surgery in a patient ppulatin with a high prevalene f ardivasular disease. Mrtality is lw (2–3%), but mrbidity is higher and inludes a 5–10% rate f myardial infartin. While endvasular apprahes are safer and the mpliatin rate is 1–3%, they are less durable with extensive disease. »PrognosisPa tients with islated artilia disease may have a further redutin in walking distane withut interventin, but symptms rarely prgress t rest pain r threatened limb lss. Life expetany is limited by their attendant ardi- vasular disease with a mrtality rate f 25–40% at 5 years. Symptmati relief is generally exellent with super- vised exerise r after interventin. After art-femral bypass, a pateny rate f 90% at 5 years is mmn. End- vasular pateny rates and symptm relief fr patients with shrt stenses are als gd with 80% symptm free at 3 years. Reurrene rates fllwing endvasular treatment f extensive disease are 30–50%.»When to ReferPa tients with prgressive redutin in walking distane in spite f risk fatr mdifiatin and supervised exerise prgrams and thse with limitatins that interfere with their ativities f daily living shuld be referred fr nsul- tatin t a vasular surgen.Bnaa M P et al. Rivarxa ban in peripheral artery disease after revasularizatin. N Engl J Med. 2020;382:1994. [PMID: 32222135] MDermtt MM. Medial management f funtinal impair- ment in peripheral artery disease: a review. Prg Cardivas Dis. 2018;60:586. [PMID: 29727608] Mrs R et al. The evlving treatment f peripheral arterial disease thrugh guideline-direted remmendatins. J Clin Med. 2018;7:9. [PMID: 29315259]OCC LUSIVE DISEASE: FEMORAL & POPLITEAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S »Cramping pain or tiredness in the calf with exercise. »Reduced popliteal and pedal pulses. »Foot pain at rest, relieved by dependency. »Foot gangrene or ischemic ulcers. »General ConsiderationsThe  superfiial femral artery is the peripheral artery mst mmnly luded by atherslersis. Atherslersis f the femral-ppliteal segment usually urs abut a deade after the develpment f artilia disease, has an even gender distributin, and mmnly affets Blak and Hispani patients. The disease frequently urs where the superfiial femral artery passes thrugh the abdutr magnus tendn in the distal thigh (Hunter anal). The mmn femral artery and the ppliteal artery are less ften diseased but lesins in these vessels are debilitating, resulting in shrt-distane laudiatin. »Clinical FindingsA.  Symptoms and SignsSymp tms f intermittent laudiatin aused by lesins f the mmn femral artery, superfiial femral artery, and ppliteal artery are nfined t the alf. Claudiatin urs at 2–4 blks when there is lusin r stensis f the superfiial femral artery at the addutr anal, pr- vided gd llateral vessels frm the prfunda femris are maintained. Hwever, with nmitant disease f the prfunda femris r the ppliteal artery, muh shrter distanes may trigger symptms. With shrt-distane lau- diatin, dependent rubr f the ft with blanhing n elevatin may be present. Chrni lw bld flw states will als ause atrphi hanges in the lwer leg and ftCMDT22_Ch12_p0475-p0501.indd  476 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS477 CMDT 2022with  lss f hair, thinning f the skin and subutaneus tissues, and disuse atrphy f the musles. With segmental lusive disease f the superfiial femral artery, the m- mn femral pulsatin is nrmal, but the ppliteal and pedal pulses are redued.B.  Doppler and Vascular FindingsABI  values less than 0.9 are diagnsti f PAD and levels belw 0.4 suggest hrni limb-threatening ishemia (fr- merly ritial limb ishemia). ABI readings depend n arterial mpressin. Sine the vessels may be alified in diabetes mellitus, hrni kidney disease, and in lder adults, ABIs an be misleading. In suh patients, the te- brahial index is usually reliable with a value less than 0.7 nsidered diagnsti f PAD. Pulse vlume rerdings with uffs plaed at the high thigh, mid-thigh, alf, and ankle will delineate the levels f bstrutin with redued pressures and blunted wavefrms.C.  ImagingDuplex  ultrasngraphy, CTA, and MRA all adequately shw the anatmi latin f the bstrutive lesins and are dne nly if revasularizatin is planned. »TreatmentA.  Medical and Exercise TherapyA s with artilia disease, risk fatr redutin, medial pti- mizatin with a high-dse statin, and exerise treatment are the rnerstne f therapy. Cilstazl, 100 mg rally twie a day, may imprve intermittent laudiatin symptms.B.  Surgical InterventionIn terventin is indiated if laudiatin is prgressive, ina- paitating, r interferes signifiantly with essential daily ativities r emplyment. Interventin is mandatry if there is ishemi rest pain r ishemi ulers threaten the ft. 1. Bypass surgery— The mst effetive and durable treat- ment fr lesins f the superfiial femral artery is a femral- ppliteal bypass with autlgus saphenus vein. Syntheti material, usually plytetraflurethylene (PTFE), an be used, but these grafts d nt have the durability f vein bypass. 2. Endovascular surgery— Endvasular tehniques, suh as angiplasty and stenting, are ften used fr lesins f the superfiial femral artery. These tehniques have lwer mrbidity than bypass surgery but als have lwer rates f durability. Endvasular therapy is mst effetive in patients underging aggressive risk fatr mdifiatin in whm lesins measure less than 10 m lng. Palitaxel-eluting stents r palitaxel-ated ballns ffer mdest imprve- ment ver bare metal stents and nnated ballns, but the effet is nt as rbust as in the rnary arteries. The 1-year pateny rate is 50% fr balln angiplasty, 70% fr drug-ated ballns, and 80% fr stents. Hwever, by 3 years, the pateny rates are signifiantly wrse fr all three tehniques and reinterventin fr restensis is mmn.After a meta-analysis f linial trial data shwed inreased mrtality at 3–5 years after treatment with palitaxel-ated devies, the US FDA perfrmed an independent review and remmends judiius use f the devies. Onging trials, suh as SWEDEPAD, are expeted t prvide additinal data n the risks and benefits f palitaxel devies. 3. Thromboendarterectomy— Remval f the athersle- rti plaque is limited t the lesins f the mmn fem- ral and the prfunda femris arteries where bypass grafts and endvasular tehniques have a mre limited rle. »ComplicationsOpen  surgial predures f the lwer extremities, partiu- larly lng bypasses with vein harvest, have a risk f wund infetin that is higher than in ther areas f the bdy. Wund infetin r serma an ur in as many as 10–15% f ases. Myardial infartin rates after pen surgery are 5–10%, with a 1–4% mrtality rate. Cmplia- tin rates f endvasular surgery are 1–5%, making these therapies attrative despite their lwer durability. »PrognosisThe p rgnsis fr mtivated patients with islated superfi- ial femral artery disease is exellent, and surgery is nt remmended fr mild r mderate laudiatin in these patients. Hwever, when laudiatin signifiantly limits daily ativity undermining quality f life and ardivasu- lar health, interventin may be warranted. All interven- tins require lse pstpredure fllw-up with repeated ultrasund surveillane s that reurrent narrwing an be treated prmptly with angiplasty r bypass t prevent mplete lusin. The reprted pateny rate f bypass grafts f the femral artery, superfiial femral artery, and ppliteal artery is 65–70% at 3 years, whereas the pateny f angiplasty is less than 50% at 3 years. Beause f the extensive atherslerti disease, inlud- ing assiated rnary lesins, 5-year survival with lwer extremity PAD is 70% and dereases t 50% when there is invlvement f the tibial arteries. Hwever, with aggressive risk fatr mdifiatin, substantial imprvement in ln- gevity has been reprted. »When to ReferPa tients with prgressive symptms, shrt-distane laudi- atin, rest pain, r any uleratin shuld be referred t a peripheral vasular speialist.Hiram t JS et al. Interventins fr lwer extremity peripheral artery disease. Nat Rev Cardil. 2018;15:332. [PMID: 29679023] Katsans K et al. Risk f death fllwing appliatin f pali- taxel-ated ballns and stents in the femrppliteal artery f the leg: a systemati review and meta-analysis f randm- ized ntrlled trials. J Am Heart Ass. 2018;7:e011245. [PMID: 30561254] Nrdanstig J et al. Mrtality with palitaxel-ated devies in peripheral artery disease. N Engl J Med. 2020;383:2538. [PMID: 33296560]CMDT22_Ch12_p0475-p0501.indd  477 29/06/21 8:37 PMCHAPTER 12478 CMDT 2022Rha-Singh KJ  et al; VIVA Physiians, In. Patient-level meta- analysis f 999 laudiants underging primary femrppli- teal nitinl stent implantatin. Catheter Cardivas Interv. 2017;89:1250. [PMID: 28303688]OCC LUSIVE DISEASE: TIBIAL & PEDAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S »Severe pain of the forefoot that is relieved by dependency (ischemic rest pain). »Pain or numbness of the foot with walking. »Ulcer or gangrene, and not claudication, is a frequent initial manifestation. »Pallor when the foot is elevated. »General ConsiderationsO lusive presses f the tibial arteries f the lwer leg and pedal arteries in the ft ur primarily in patients with dia- betes. There ften is extensive alifiatin f the artery wall. »Clinical FindingsA.  Symptoms and SignsU nless there are nmitant lesins in the artilia r femral/superfiial femral artery segments, the first man- ifestatin f leg ishemia due t tibial artery disease is fre- quently an ishemi uler r ft gangrene, rather than laudiatin. The presene f ishemi rest pain r ulers is termed chronic limb-threatening ischemia and is assi- ated with the highest rate f amputatin. Classially, ish- emi rest pain is nfined t the drsum f the ft and is relieved with dependeny: the pain des nt ur with standing, sitting, r dangling the leg ver the edge f the bed. It is severe and burning in harater, and beause it is present nly when reumbent, it may awaken the patient frm sleep. On examinatin, femral and ppliteal pulses may r may nt be present depending n disease extent, but pal- pable pedal pulses will be absent. Dependent rubr may be prminent with pallr n elevatin. The skin f the ft is generally l, atrphi, and hairless.B.  Doppler and Vascular FindingsThe  ABI is ften belw 0.4; hwever, the ABI may be falsely elevated due t alifiatin f the arterial media layer (Mönkeberg medial alifi slersis) and may nt be mpressible. Te-brahial indexes are preferred fr assess- ing perfusin and prediting wund healing.C.  ImagingDig ital subtratin angigraphy is the gld standard methd t delineate the anatmy f the tibial-pplitealsegment. MRA r CTA is less helpful fr detetin f lesins in this latin due t the small vasulature and ther tehnial issues related t image reslutin. »Differential DiagnosisBeause  f the high inidene f neurpathy in these patients, it is imprtant t differentiate rest pain frm dia- beti neurpathi dysesthesia. Leg night ramps ause pain in the leg rather than the ft and shuld nt be nfused with ishemi rest pain. Dependent rubr in the presene f a te wund an ften be mistaken fr ellulitis; pallr n elevatin helps nfirm the diagnsis f rubr. »TreatmentGd  ft are may prevent ulers, and mst diabeti patients will d well with a nservative regimen. Hwever, if uleratins appear and there is n signifiant healing within 2–3 weeks, bld flw studies (ankle-brahial index/te-brahial index) are indiated. Pr bld flw and a ft uler r nightly ishemi rest pain requires expe- ditius revasularizatin t avid a majr amputatin.A.  Bypass and Endovascular TechniquesBypass  with vein t the distal tibial r pedal arteries is an effetive therapy t treat rest pain and heal ishemi ulers f the ft. Beause the ft ften has relative sparing f vasular disease, these bypasses have had adequate pateny rates (70% at 3 years). Frtunately, in nearly all series, limb preservatin rates are muh higher than pateny rates. Endvasular treatment with plain balln angiplasty is effetive fr shrt segment lesins. The tehnial failure and relusin rates inrease drastially with lng seg- ment disease in multiple tibial arteries. Stents and drug- ated ballns have nt been suessful in the tibial vessels t date.B.  AmputationPa tients with ishemi rest pain r ulers have a 30–40% 1-year risk fr majr amputatin that inreases if revasu- larizatin annt be dne. Patients with diabetes and PAD have a 4-fld risk f hrni limb-threatening ishemia mpared with nndiabeti patients with PAD and have a risk f amputatin up t 20-fld when mpared t an age- mathed ppulatin. Many patients wh have belw-the- knee r abve-the-knee amputatins due t vasular insuffiieny never regain independent ambulatry status and ften need assisted-living failities. These fatrs m- bine t demand revasularizatin whenever pssible t preserve the limb. »ComplicationsThe  mpliatins f interventin are similar t thse listed fr superfiial femral artery disease with evidene that the verall ardivasular risk f interventin inreases with dereasing ABI. Patients with hrni limb-threatening ishemia require aggressive risk fatr mdifiatin. Wund infetin rates after bypass are higher if there is an pen wund in the ft.CMDT22_Ch12_p0475-p0501.indd  478 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS479 CMDT 2022 »PrognosisPa tients with tibial atherslersis have extensive ather- slerti burden and a high prevalene f diabetes. Their prgnsis withut interventin is pr and mpliated by the risk f amputatin. »When to ReferPa tients with diabetes and ft ulers shuld be referred fr a frmal vasular evaluatin. Interventin may nt be neessary but the severity f the disease will be quantified, whih has impliatins fr future symptm develpment. Any patient with an uler and a diabeti ft infetin shuld be evaluated fr an emergent perative inisin and drainage. Brad-spetrum intravenus antibitis shuld be given empirially; fr example, vanmyin shuld be given t ver methiillin-resistant Staphylococcus aureus (MRSA) and ertapenem r piperaillin/tazbatam shuld be given t ver gram-negative and anaerbi rganisms. Centers that have a multidisiplinary limb preservatin enter staffed with vasular surgens, pdiatrists, plasti and rthpedi surgens, prsthetis and rthti speial- ists, and diabetes speialists shuld be sught.Cnte  MS et al. Glbal vasular guidelines n the management f hrni limb-threatening ishemia. J Vas Surg. 2019;69:3. [PMID: 31159978] Farber A et al. The urrent state f ritial limb ishemia: a sys- temati review. JAMA Surg. 2016;151:1070. [PMID: 27551978]ACU TE ARTERIAL OCCLUSION OF A LIMBE S S E N T I A L S  O F  D I A G N O S I S »Sudden pain in a limb with absent limb pulses. »Usually some neurologic dysfunction with numb- ness, weakness, or complete paralysis. »Loss of light touch sensation requires revascular- ization within 3 hours for limb viability. »General ConsiderationsAu te lusin may be due t an emblus r t thrmb- sis f a diseased atherslerti segment. Embli large enugh t lude prximal arteries in the lwer extremi- ties are almst always frm the heart and are related t atrial fibrillatin. Over 50% f the embli frm the heart g t the lwer extremities, 20% t the erebrvasular iru- latin, and the remainder t the upper extremities and mesenteri and renal irulatin. Atrial fibrillatin is the mst mmn ause f ardia thrmbus frmatin; ther auses are valvular disease r thrmbus frmatin n the ventriular surfae f a large anterir myardial infart. Embli frm arterial sures suh as arterial uleratins r alified exresenes are usually small and g t the distal arterial tree (tes).The typial patient with primary thrmbsis has had a histry f laudiatin and nw has an aute lusin. If the stensis is hrni, llateral bld vessels will develp, and the resulting lusin may ause nly minimal inrease in symptms. »Clinical FindingsA.  Symptoms and SignsTh e sudden nset f extremity pain, with lss r redutin in pulses, is diagnsti f aute arterial lusin. This ften will be ampanied by neurlgi dysfuntin, suh as numb- ness r paralysis in extreme ases. With ppliteal lusin, symptms may affet nly the ft. With prximal lusins, the whle leg may be affeted. Signs f severe arterial ishemia inlude pallr, lness f the extremity, and mttling. Impaired neurlgi funtin prgressing t anesthesia with paralysis indiates irreversible injury requiring amputatin.B.  Doppler and Laboratory FindingsThere  will be little r n flw fund with Dppler examina- tin f the distal vessels. Imaging, if dne, may shw an abrupt utff f ntrast with embli lusin. Bld wrk may shw myglbinemia and metabli aidsis.C.  ImagingW henever pssible, imaging shuld be dne in the perating rm beause btaining angigraphy, MRA, r CTA may delay revasularizatin and jepardize the viability f the extremity. Hwever, in ases with nly mdest symptms and where light tuh f the extremity is maintained, imaging may be helpful in planning the revasularizatin predure. »TreatmentImm ediate revasularizatin is required in all ases f symptmati aute arterial thrmbsis. Evidence of neuro- logic injury, including loss of light touch sensation, indicates that collateral flow is inadequate to maintain limb viability and revascularization should be accomplished within 3 hours. Lnger delays arry a signifiant risk f irreversible tissue damage. This risk apprahes 100% at 6 hurs.A.  HeparinAs  sn as the diagnsis is made, unfratinated heparin shuld be administered (5000–10,000 units) intravenusly, fllwed by a heparin infusin t maintain the ativated partial thrmbplastin time (aPTT) in the therapeuti range (60–85 sends) (12–18 units/kg/h). This helps pre- vent lt prpagatin and may als help relieve assiated vessel spasm. Antiagulatin may imprve symptms, but revasularizatin will still be required.B.  Endovascular TechniquesPharmame hanial thrmbetmy atheters an ahieve rapid revasularizatin and are mst effetive fr the smaller arteries f the lwer leg. Catheter-direted hemi- al thrmblysis int the lt with tissue plasmingen ativatr (TPA) may be dne but ften requires 24 hurs rCMDT22_Ch12_p0475-p0501.indd  479 29/06/21 8:37 PMCHAPTER 12480 CMDT 2022lnger  t fully lyse the thrmbus. This apprah an be taken nly in patients with an intat neurlgi examina- tin withut abslute ntraindiatins, suh as bleeding diathesis, gastrintestinal bleeding, intraranial trauma, r neursurgery within the past 3 mnths. Heparin is admin- istered systemially t prevent thrmbus frmatin arund the sheath. Frequent vasular and aess site examinatins are required during the thrmblyti predure t guard against the develpment f a hematma.C.  Surgical InterventionGeneral  anesthesia is usually indiated; lal anesthesia may be used in extremely high-risk patients if the explra- tin is t be limited t the mmn femral artery. In extreme ases, it may be neessary t perfrm thrmb- embletmy frm the femral, ppliteal, and even the pedal vessels t revasularize the limb. The mbined use f devies that pulverize and aspirate lt and intrapera- tive thrmblysis with TPA imprves utmes. »ComplicationsCm pliatins f revasularizatin f an autely ishemi limb an inlude severe metabli aidsis, hyperkalemia, aute kidney injury, and ardia arrest. In ases where sev- eral hurs have elapsed but revery f viable tissue may still be pssible, signifiant levels f lati aid, ptassium, and ther harmful agents suh as myglbin may be released int the irulatin during revasularizatin. Administering sdium biarbnate (150 mEq NaHCO3in 1 L f dextrse 5% in water) prir t reestablishing arterial flw is required. Surgery in the presene f thrmblyti agents and heparin arries a high risk f pstperative wund hematma. »PrognosisThere  is a 10–25% risk f amputatin with an aute arterial embli lusin, and a 25% r higher in-hspital mrtal- ity rate. Prgnsis fr aute thrmbti lusin f an atherslerti segment is generally better beause the l- lateral flw an maintain extremity viability. The lnger- term survival reflets the verall nditin f the patient. In high-risk patients, an aute arterial lusin is assi- ated with a dismal prgnsis.OCC LUSIVE CEREBROVASCULAR DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of weakness and numbness of an extremity or the face, aphasia, dysarthria, or uni- lateral blindness (amaurosis fugax). »Bruit heard loudest in the mid neck. »General ConsiderationsU nlike the ther vasular territries, symptms f ishemi erebrvasular disease are predminantly due t embli. The ishemia is reversible (transient ishemi attaks[TIAs]) when llateral flw reestablishes perfusin, but is a sign that the risk f additinal embli and a strke is high. Mst ishemi strkes are due t embli frm the heart. One-quarter f all ishemi strkes may be due t embli frm an arterial sure; apprximately 90% f these embli riginate frm the prximal internal artid artery, an area uniquely prne t the develpment f athersler- sis. Intraranial atherslerti lesins are unmmn in western ppulatins but are the mst frequent latin f erebrvasular disease in Asian ppulatins. »Clinical FindingsA.  Symptoms and SignsGenerally , the symptms f a TIA last nly a few sends t minutes (but may ntinue up t 24 hurs) while a strke is defined as persistent symptms beynd 24 hurs. The mst mmn lesins assiated with artid disease invlve the anterir irulatin in the rtex with bth mtr and sensry invlvement. Embli t the retinal artery ause unilateral blindness; transient mnular blindness is termed “amaursis fugax. ” Psterir irula- tin symptms referable t the brainstem, erebellum, and visual regins f the brain may be due t atherslersis f the vertebral basilar systems and are muh less mmn. Signs f erebrvasular disease may inlude artid artery bruits. Hwever, there is pr rrelatin between the degree f stensis and the presene f the bruit. Further- mre, the presene f a bruit des nt rrelate with strke risk. Nnfal symptms, suh as dizziness and unsteadi- ness, seldm are related t erebrvasular atherslersis.B.  ImagingDuplex ultrasngrap hy is the imaging mdality f hie with high speifiity and sensitivity fr deteting and grad- ing the degree f stensis at the artid bifuratin (see Chapter 24). Exellent depitin f the full anatmy f the erebr- vasular irulatin frm arti arh t ranium an be btained with either MRA r CTA. Eah f the mdalities may have false-psitive r false-negative findings. Sine the deisin t intervene in ases f artid stensis depends n an aurate assessment f the degree f stensis, it is rem- mended that at least tw mdalities be used t nfirm the degree f stensis. Diagnsti erebral angigraphy is reserved fr ases where artid artery stenting (CAS) is t be dne. »TreatmentSee  Chapter 24 fr a disussin f the medial manage- ment f lusive erebrvasular disease.A.  Asymptomatic PatientsLar ge studies have shwn a 5-year redutin in strke rate frm 11.5% t 5.0% with surgial treatment f asymptmati artid stensis that is greater than 60%; patients with asymptmati artid stensis may benefit frm artid interventin if their risk frm interventin is lw and their expeted survival is lnger than 5 years. Aggressive riskCMDT22_Ch12_p0475-p0501.indd  480 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS481 CMDT 2022fat r mdifiatin, inluding high-pteny statins, may be as valuable as surgial interventin in these patients; the large NIH-spnsred CREST2 study is examining this issue. Mild t mderate disease (30–50% stensis) indiates the need fr nging mnitring and aggressive risk fatr mdifiatin. Patients with artid stensis that suddenly wrsens are thught t have an unstable plaque and are at partiularly high risk fr embli strke.B.  Symptomatic PatientsLa rge randmized trials have shwn that patients with TIAs r strkes frm whih they have mpletely r nearly m- pletely revered will benefit frm artid interventin if the ipsilateral artid artery has a stensis f mre than 70% (Figure 12–1), and they are likely t benefit if the artery has a stensis f 50–69%. In these situatins, artid endartere- tmy (CEA) and, in seleted ases, CAS have been shwn t have a durable effet in preventing further events. In symp- tmati patients, interventin shuld ideally be planned within 2 weeks sine delays inrease the risk f a send event. »ComplicationsThe  mst mmn mpliatin frm artid interventin is ranial nerve injury, while the mst dreaded mplia- tin is strke frm emblizatin r artid lusin. The Amerian Heart Assiatin’s remmendatins fr upper limits f aeptable mbined mrbidity and mrtality fr these interventins is 3% fr patients with asymptmati artid stensis, 5% fr thse with TIAs, and 7% fr patients with previus strke. Higher rates f mrbidityand mrtality negate the therapeuti benefit f artid interventin.A.  Carotid EndarterectomyIn  the 2010 CREST study the strke risk fr CEA was 2.3%. CEA als arries a 1–2% risk f permanent ranial nerve injury (usually the vagus nerve). There is als the risk f pstperative nek hematma, whih an ause aute air- way mprmise. Crnary artery disease is a mrbidity in mst f these patients. Myardial infartin rates after CEA are apprximately 2–6%.B.  Carotid Angioplasty and StentingCAS  had a strke risk f 4.1% in the 2010 CREST study; patients ver 70 years f age as well as wmen had higher strke rates with CAS than with CEA. Hwever, the risk f myardial infartin was lwer with CAS mpared t CEA (1.1% vs 2.3%). CAS is indiated fr reperative ases, prir nek radiatin, and high artid bifuratins nt therwise aessible surgially. Nnetheless, embli are mre mmn during transfemral CAS in spite f embli prtetin devies, espeially when the artid artery is trtuus and heavily alified. Transervial artid stent- ing, perfrmed thrugh a small inisin at the base f the nek, avids artery trtusity and has lwer emblizatin rates than transfemral artid stenting. »PrognosisT wenty-five perent f patients presenting with artid stensis and a TIA r small strke will have further brain ishemia within 18 mnths with mst f the events ur- ring within the first 6 mnths. Histrially, patients with asymptmati artid stensis are believed t have an annual strke rate f just ver 2% but this may be lwer in the statin era. Prspetive ultrasund sreening at least annually is remmended in asymptmati patients with knwn artid stensis t identify thse wh have evidene f plaque prgressin, whih inreases strke risk. Cn- mitant rnary artery disease is mmn and is an imprtant fatr in these patients bth fr periperative risk and lng-term prgnsis. Aggressive risk fatr mdi- fiatin shuld be presribed fr patients with erebrvas- ular disease regardless f planned interventin. »When to ReferAsym ptmati r symptmati patients with a artid ste- nsis f mre than 70% and patients with artid stensis f less than 70% with symptms f a TIA r strke shuld be referred t a vasular speialist fr nsultatin.Br tt TG et al; CREST Investigatrs. Lng-term results f stent- ing versus endarteretmy fr artid-artery stensis. N Engl J Med. 2016;374:1021. [PMID: 26890472] Mresli P et al. Cartid stenting versus endarteretmy fr asymptmati artid artery stensis: a systemati review and meta-analysis. Strke. 2017;48:2150. [PMID: 28679848] Paraskevas KI et al. An updated systemati review and meta- analysis f results f transervial artid artery stenting with flw reversal. J Vas Surg. 2020;72:1489. [PMID: 32422272] ▲Figure 12–1. Digital subtraction angiography of a high-grade (90%) stenosis of the internal carotid artery with ulceration (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  481 29/06/21 8:37 PMCHAPTER 12482 CMDT 2022VI SCERAL ARTERY INSUFFICIENCY (Intestinal Angina)E S S E N T I A L S  O F  D I A G N O S I S »Severe postprandial abdominal pain. »Weight loss with a “fear of eating.” »Acute mesenteric ischemia: severe abdominal pain yet minimal findings on physical examination. »General ConsiderationsA cute mesenteric ischemia results frm lusive mesen- teri arterial disease, either embli lusin r primary thrmbsis f at least ne majr mesenteri artery. Ishemia an als result frm nonocclusive mesenteric ischemia, whih is generally seen in patients with lw flw states, suh as severe heart failure, sepsis, r hyptensin. Chronic mesenteric ischemia, als alled intestinal angina, urs when inreased flw demands during feeding are nt met resulting in abdminal pain. Beause f the rih llateral mesenteri netwrk, generally at least tw f the three majr viseral vessels (elia, superir mesenteri, inferir mesenteri arteries) are affeted befre symptms develp. Ischemic colitis, a variant f mesenteri ishemia, usually urs in the distributin f the inferir mesenteri artery. The intestinal musa is the mst sensitive t ishemia and will slugh if underperfused. »Clinical FindingsA.  Symptoms and Signs1.  Acute mesenteric ischemia— Viseral arterial emblism presents autely with severe abdminal pain. In ntrast, patients with primary viseral arterial thrmbsis ften give an anteedent histry nsistent with hrni mesen- teri ishemia. The key finding with aute mesenteri ishemia is severe, steady, diffuse abdminal pain with an absene f fal tenderness r distentin. This “pain ut f prprtin” t physial examinatin findings urs beause ishemia initially is musal and des nt impat the peritneum until transmural ishemia inflames the peritneal lining. A high white bld ell unt, lati ai- dsis, hyptensin, and abdminal distentin may aid in the diagnsis. 2. Chronic mesenteric ischemia— Patients are generally ver 45 years f age and may have evidene f athersle- rsis in ther vasular beds. Symptms nsist f epigastri r periumbilial pstprandial pain lasting 1–3 hurs. T avid the pain, patients limit fd intake and may develp a fear f eating. Weight lss is universal. 3. Ischemic colitis— Charateristi symptms are left lwer quadrant pain and tenderness, abdminal ramping, and mild diarrhea. Retal disharge will appear muus-like r bldy and shuld prmpt further evaluatin.B. Imaging and ColonoscopyCntrast-enhaned  CT is highly aurate at determining the presene f ishemi intestine. In patients with aute r hrni mesenteri ishemia, a CTA r MRA an demn- strate narrwing f the prximal viseral vessels. In aute mesenteri ishemia frm a nnlusive lw flw state, angigraphy is needed t display the typial “pruned tree” appearane f the distal viseral vasular bed. Ultrasund sanning f the mesenteri vessels may shw prximal bstruting lesins. In patients with ishemi litis, flexible sigmidspy shuld be perfrmed t assess the grade f ishemia that urs mst ften in watershed areas, suh as the retal sigmid and spleni flexure. »TreatmentA  high suspiin f aute mesenteri ishemia ditates immediate explratin t assess bwel viability. If the bwel remains viable, arterial bypass using a prstheti nduit an be dne either frm the supra-elia arta r mmn ilia artery t the elia and the superir mesen- tery artery. In ases where bwel viability is questinable r bwel resetin will be required, the bypass an be dne with autlgus vein t avid the use f prstheti nduits in a ptentially ntaminated field. Angiplasty and stent- ing f the arteries an be used but des nt avid a surgial evaluatin f bwel viability. In hrni mesenteri ishemia, angiplasty and stenting f the prximal vessel may be benefiial depending n the anatmy f the stensis. Shuld an endvasular slutin nt be available, an art-viseral artery bypass is the pre- ferred management. The lng-term results are highly dura- ble. Viseral artery endarteretmy is reserved fr ases with multiple lesins where bypass wuld be diffiult. The mainstay f treatment f ishemi litis is mainte- nane f bld pressure and perfusin until llateral ir- ulatin bemes well established. The patient must be mnitred lsely fr evidene f perfratin neessitating resetin. »PrognosisThe  mbined mrbidity and mrtality rates are 10–15% frm surgial interventin in part due t malnutritin and frailty in patients preeding hrni mesenteri ishemia. Hwever, withut interventin bth nditins are uni- frmly fatal. Adequate llateral irulatin usually devel- ps in thse wh have ishemi litis, and the prgnsis fr this entity is better than hrni mesenteri ishemia. »When to ReferAny  patient in whm there is a suspiin f mesenteri ishemia shuld be urgently referred fr imaging and ps- sible interventin.Alahdab F et al.  A systemati review and meta-analysis f end- vasular versus pen surgial revasularizatin fr hrni mesenteri ishemia. J Vas Surg. 2018;67:1598. [PMID: 29571626]CMDT22_Ch12_p0475-p0501.indd  482 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS483 CMDT 2022Clair  DG et al. Mesenteri ishemia. N Engl J Med. 2016;374:959. [PMID: 26962730] Lim S et al. Cntemprary management f aute mesenteri ishemia in the endvasular era. Vas Endvasular Surg. 2019;53:42. [PMID: 30360689]ACU TE MESENTERIC VEIN OCCLUSIONThe h allmarks f aute mesenteri vein lusin are pst- prandial pain and evidene f a hyperagulable state. Aute mesenteri vein lusin presents similarly t the arterial lusive syndrmes but is muh less mmn. Patients at risk inlude thse with parxysmal nturnal hemglbinuria; prtein C, prtein S, r antithrmbin defiienies; r the JAK2 mutatin. These lesins are diffi- ult t treat surgially, and thrmblysis is the mainstay f therapy. Aggressive lng-term antiagulatin is required fr these patients. ºNONATHEROSCLEROTIC VASCULAR DISEASE THROMBOANGIITIS OBLITERANS (Buerger Disease)E S S E N T I A L S  O F  D I A G N O S I S »Typically occurs in male cigarette smokers. »Distal extremities involved with severe ischemia, progressing to tissue loss. »Thrombosis of the superficial veins may occur. »Smoking cessation is essential to stop disease progression. »General ConsiderationsBuerger  disease is a segmental, inflammatry, and thrm- bti press f the distal-mst arteries and asinally veins f the extremities. Pathlgi examinatin reveals arteritis in the affeted vessels. The ause is nt knwn but it is rarely seen in patients wh d nt smke igarettes. Arteries mst mmnly affeted are the plantar and digi- tal vessels f the ft and lwer leg. In advaned stages, the fingers and hands may beme invlved. The inidene f Buerger disease has dereased dramatially. »Clinical FindingsA.  Symptoms and SignsBuerger  disease may be initially diffiult t differentiate frm rutine peripheral vasular disease, but in mst ases, the lesins are n the tes and the patient is yunger than 40 years f age. The bservatin f superfiial thrmb- phlebitis may aid the diagnsis. Beause the distal vessels are usually affeted, intermittent laudiatin is nt m- mn with Buerger disease, but rest pain, partiularly painin the distal mst extremity (ie, tes), is frequent. This pain ften prgresses t tissue lss and amputatin, unless the patient stps smking. The prgressin f the disease seems t be intermittent with aute and dramati episdes fllwed by sme perids f remissin.B.  ImagingMRA  r invasive angigraphy an demnstrate the blit- eratin f the distal arterial tree typial f Buerger disease. »Differential DiagnosisIn  atherslerti peripheral vasular disease, the nset f tissue ishemia tends t be less dramati than in Buerger disease, and symptms f prximal arterial invlvement, suh as laudiatin, predminate. Symptms f Raynaud disease may be diffiult t dif- ferentiate frm Buerger disease and are ften existent in 40% f patients. Repetitive atherembli may als mimi Buerger disease and may be diffiult t differentiate. It may be neessary t image the prximal arterial tree t rule ut sures f arterial mirembli. »TreatmentSmking essatin is the mainstay f therapy and will  halt the disease in mst ases. As the distal arterial tree is luded, revasularizatin is ften nt pssible. Sympa- thetmy is rarely effetive. »PrognosisIf  smking essatin an be ahieved, the utlk fr Buerger disease may be better than in patients with premature periph- eral vasular disease. If smking essatin is nt ahieved, then the prgnsis is generally pr, with amputatin f bth lwer and upper extremities a pssible utme.Le  Jnur A et al; Frenh Buerger’s Netwrk. Lng-term utme and prgnsti fatrs f mpliatins in thrmbangiitis bliterans (Buerger’s disease): a multienter study f 224 patients. J Am Heart Ass. 2018;7:e010677. [PMID: 30571594] ºARTERIAL ANEURYSMS ABDOMINAL AORTIC ANEURYSME S S E N T I A L S  O F  D I A G N O S I S »Most aortic aneurysms are asymptomatic until rupture. »80% of abdominal aortic aneurysms measuring 5 cm are palpable; the usual threshold for treat- ment is 5.5 cm. »Back or abdominal pain with aneurysmal tender- ness may precede rupture. »Rupture is catastrophic: excruciating abdominal pain that radiates to the back; hypotension.CMDT22_Ch12_p0475-p0501.indd  483 29/06/21 8:37 PMCHAPTER 12484 CMDT 2022 »General ConsiderationsDilatati n f the infrarenal arta is a nrmal part f aging. The arta f a healthy yung man measures apprximately 2 m. An aneurysm is nsidered present when the arti diameter exeeds 3 m, but aneurysms rarely rupture until their diameter exeeds 5 m. Abdminal arti aneurysms are fund in 2% f men ver 55 years f age; the male t female rati is 4:1. Ninety perent f abdminal athersle- rti aneurysms riginate belw the renal arteries. The aneurysms usually invlve the arti bifuratin and ften invlve the mmn ilia arteries. Inflammatry aneurysms are an unusual variant. These have an inflammatry peel (similar t the inflammatin seen with retrperitneal fibrsis) that surrunds the aneurysm and enases adjaent retrperitneal strutures, suh as the dudenum and, asinally, the ureters. »Clinical FindingsA.  Symptoms and Signs1.  Asymptomatic— Althugh 80% f 5-m infrarenal aneurysms are palpable n rutine physial examinatin, mst aneurysms are disvered n ultrasund r CT imag- ing as part f a sreening prgram r during the evaluatin f unrelated abdminal symptms. 2. Symptomatic— a. Pain— Aneurysmal expansin may be ampanied by pain that is mild t severe midabdminal dismfrt ften radiating t the lwer bak. The pain may be nstant r intermittent and is exaerbated by even gentle pressure n the aneurysm sak. Pain may als ampany inflamma- try aneurysms. Mst aneurysms have a thik layer f thrmbus lining the aneurysmal sa, but emblizatin t the lwer extremities is rarely seen. b. Rupture— The sudden esape f bld int the retr- peritneal spae auses severe pain and hyptensin. Free rupture int the peritneal avity is a lethal event.B.  Laboratory FindingsIn  aute ases f a ntained rupture, the hematrit may be nrmal, sine there has been n pprtunity fr hemdilutin. Patients with aneurysms may als have rnary artery disease, artid disease, kidney impairment, and emphysema, whih are typially seen in elderly men wh smke igarettes. Preperative testing may indiate the presene f these mrbid nditins, whih inrease the risk f interventin.C.  ImagingA bdminal ultrasngraphy is the diagnsti study f hie fr initial sreening fr the presene f an aneu- rysm. In apprximately three-quarters f patients with aneurysms, urvilinear alifiatins utlining prtins f the aneurysm wall may be visible n plain radigraphs f the abdmen r bak. CT sans prvide a mre reliable assessment f aneurysm diameter and shuld be dne when the aneurysm nears the diameter threshld (5.5 m)fr treatment. Cntrast-enhaned CT sans shw the arter- ies abve and belw the aneurysm. The visualizatin f this vasulature is essential fr planning repair. CT imaging will ften demnstrate mural thrmbus within the aneurysm and is nt an indiatin fr antiagulatin. One an aneurysm is identified, rutine fllw-up with ultrasund will determine size and grwth rate. The fre- queny f imaging depends n aneurysm size ranging frm every 2 years fr aneurysms smaller than 4 m t every 6 mnths fr aneurysms at r apprahing 5 m. When an aneurysm measures apprximately 5 m, a CTA with ntrast shuld be dne t mre aurately assess the size f the aneurysm and define the anatmy. »ScreeningGuidelines  remmend abdminal ultrasund sreening in men 65–75 years ld with expsure t 100 r mre life- time igarettes but nflit n whether wmen with the same expsure shuld be sreened. Guidelines d nt re- mmend repeated sreening if the arta shws n enlarge- ment. While patients are mnitred, smking essatin and treatment f underlying hypertensin, hyperlipidemia, and diabetes shuld be nsidered. »TreatmentA.  Elective RepairTh e risk f rupture inreases with aneurysm diameter. In gen- eral, eletive repair is indiated fr arti aneurysms 5.5 m r larger in diameter r aneurysms that demnstrate rapid expan- sin (mre than 0.5 m in 6 mnths). Symptms suh as pain r tenderness may indiate impending rupture and require urgent repair regardless f the aneurysm’s diameter.B.  Aneurysmal RuptureA  ruptured aneurysm is a lethal event. Apprximately half the patients exsanguinate prir t reahing a hspital. In the remainder, bleeding may be temprarily ntained in the retrperitneum (ntained rupture), allwing the patient t underg emergent surgery. Hwever, nly half f thse patients will survive. Endvasular repair is available fr ruptured aneurysm treatment in mst majr vasular en- ters, with the results ffering sme imprvement ver pen repair fr these ritially ill patients.C.  Inflammatory AneurysmThe  presene f periarti inflammatin (inflammatry aneurysm) is nt an indiatin fr surgial treatment, unless there is assiated mpressin f retrperitneal strutures, suh as the ureter r pain upn palpatin f the aneurysm. Interestingly, the inflammatin that enases an inflammatry aneurysm reedes after either endvasular r pen surgial aneurysm repair.D . Assessment of Operative RiskAneurysms  appear t be a variant f systemi athersler- sis. Patients with aneurysms have a high rate f rnary disease but a 2004 trial demnstrated minimal value inCMDT22_Ch12_p0475-p0501.indd  484 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS485 CMDT 2022addressing  stable rnary artery disease prir t aneu- rysm resetin. Hwever, in patients with signifiant symptms f rnary disease, the rnary disease shuld be treated first. Aneurysm repair shuld fllw shrtly thereafter beause there is a slightly inreased risk f aneu- rysm rupture after the rnary predures.E.  Open Surgical Resection Versus Endovascular RepairIn  pen surgial aneurysm repair, a graft is sutured t the nn-dilated vessels abve and belw the aneurysm. This invlves an abdminal inisin, extensive dissetin, and interruptin f arti bld flw. The mrtality rate is lw (2–5%) in enters that have a high vlume fr this pre- dure and when it is perfrmed in gd-risk patients. Older, siker patients may nt tlerate the ardipulmnary stresses f the peratin. With endvasular arti repair, a stent-graft is intrdued thrugh small inisins ver the femral arteries and psitined within the arta under flurspi guidane. The stent must be able t seal seurely against the wall f the arta abve and belw the aneurysm, thereby exluding bld frm flwing int the aneurysm sa. T suessfully treat an aneurysm, the ana- tmi requirements fr endvasular repairs are mre preise than fr pen repairs. Mst studies have fund that endvasular arti repair ffers patients redued pera- tive mrbidity and mrtality as well as shrter revery perids. Lng-term survival is equivalent between the tw tehniques. Patients wh underg endvasular repair, hwever, likely need additinal interventins and need lifelng mnitring, sine there is a 10–15% inidene f ntinued aneurysm grwth after endvasular repair. »ComplicationsM yocardial infarction, the mst mmn mpliatin, urs in up t 10% f patients wh underg pen aneurysm repair. The inidene f myardial infartin is substantially lwer with endvasular repair. Fr rutine infrarenal aneu- rysms, renal injury is unusual; hwever, when it des ur, r if the baseline reatinine is elevated, it is a signifiant m- pliating fatr in the pstperative perid. Respiratry mpliatins are similar t thse seen in mst majr abdminal surgery. Gastrintestinal hemrrhage, even years after arti surgeries, suggests the pssibility f graft enteric fistula, mst mmnly between the arta and the distal dudenum; the inidene f this mpliatin is higher when the initial surgery is perfrmed n an emergeny basis. »PrognosisThe m rtality rate fr an pen eletive surgial resetin is 1–5%, and the mrtality rate fr endvasular therapy is 0.5–2%. Of thse wh survive surgery, apprximately 60% are alive at 5 years; myardial infartin is the leading ause f death. The lng-term survival (5 years r mre) after pen and endvasular repairs is equivalent. Mrtality rates f untreated aneurysms vary with aneu- rysm diameter. The mrtality rate amng patients with large aneurysms has been defined as fllws: 12% annual risk f rupture with an aneurysm larger than 6 m indiameter and a 25% annual risk f rupture in aneurysms f mre than 7 m diameter. In general, a patient with an arti aneurysm larger than 5.5 m has a threefld greater hane f dying f a nsequene f rupture f the aneu- rysm than f dying f the surgial resetin. At present, endvasular aneurysm repair may be less definitive than pen surgial repair and requires lse fl- lw up with an imaging predure. Devie migratin, mpnent separatin, and graft limb thrmbsis r kink- ing are mmn reasns fr repeat interventin. With mplete exlusin f bld frm the aneurysm sa, the pressure is lwered, whih auses the aneurysm t shrink. An “endleak” frm the tp r bttm seal znes (type 1) r thrugh a graft defet (type 3) is assiated with a per- sistent risk f rupture. Indiret leakage f bld thrugh lumbar and inferir mesenteri branhes f the aneurysm (type-2 endleak) prdues an intermediate piture with smewhat redued pressure in the sa, slw shrinkage, and lw rupture risk. Hwever, type-2 endleak warrants lse bservatin as aneurysm dilatatin an hange aneurysm mrphlgy leading t type-1 endleak and rupture. »When to Refer• Any patient with a 4.5-m r larger arti aneurysm shuld be referred t a vasular speialist fr bserva- tin and assessment. •Urgent referrals shuld be made if the patient m- plains f pain and gentle palpatin f the aneurysm nfirms that it is the sure, regardless f the aneurys- mal size. »When to Admit• Patients with a tender aneurysm t palpatin r signs f arti rupture require emergent hspital admissin. •Evidene f infetin after repair.O ’Dnnell TFX et al. Abdminal arti aneurysm sreening guidelines: United States Preventive Servies Task Fre and Siety fr Vasular Surgery. J Vas Surg. 2020;71:1457. [PMID: 32334726] Jin J. Sreening fr abdminal arti aneurysm. JAMA Patient Page. JAMA. 2019;322:2256. [PMID: 31821432] Lederle FA et al; OVER Veterans Affairs Cperative Study Grup. Open versus endvasular repair f abdminal arti aneurysm. N Engl J Med. 2019;380:2126. [PMID: 31141634] US Preventive Servies Task Fre; Owens DK et al. Sreening fr abdminal arti aneurysm: US Preventive Servies Task Fre Remmendatin Statement. JAMA. 2019;322:2211. [PMID: 31821437]TH ORACIC AORTIC ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S »Widened mediastinum on chest radiograph. »With rupture, sudden onset of chest pain radiating to the back.CMDT22_Ch12_p0475-p0501.indd  485 29/06/21 8:37 PMCHAPTER 12486 CMDT 2022 »General ConsiderationsMs t thrai arti aneurysms are due t atherslersis; syphilis is a rare ause. Disrders f nnetive tissue and Ehlers-Danls and Marfan syndrmes als are rare auses but have imprtant therapeuti impliatins. Traumati, false aneurysms, aused by partial tearing f the arti wall with deeleratin injuries, may ur just beynd the ri- gin f the left sublavian artery. Less than 10% f arti aneurysms ur in the thrai arta. »Clinical FindingsA.  Symptoms and SignsMs t thrai aneurysms are asymptmati. When symp- tms ur, they depend largely n the size and the psi- tin f the aneurysm and its rate f grwth. Substernal bak r nek pain may ur. Pressure n the trahea, esphagus, r superir vena ava an result in the fllwing symptms and signs: dyspnea, stridr r brassy ugh, dysphagia, and edema in the nek and arms as well as dis- tended nek veins. Strething f the left reurrent laryngeal nerve auses harseness. With aneurysms f the asending arta, arti regurgitatin may be present due t dilatin f the arti valve annulus. Rupture f a thrai aneurysm is atastrphi beause bleeding is rarely ntained, allwing n time fr emergent repair.B.  ImagingThe  aneurysm may be diagnsed n hest radigraph by the alified utline f the dilated arta. CT sanning with ntrast enhanement is the mdality f hie, but MRA an be used t demnstrate the anatmy and aneurysmal size and t exlude lesins that an mimi aneurysms, suh as neplasms r substernal giter. There is n lw-st alternative (eg, ultrasngraphy) fr sreening r surveil- lane. Cardia atheterizatin and ehardigraphy may be required t desribe the relatinship f the rnary vessels t an aneurysm f the asending arta. »TreatmentIn diatins fr repair depend n the latin f dilatin, rate f grwth, assiated symptms, and verall nditin f the patient. Desending thrai aneurysms measuring 6 m r larger may be nsidered fr repair, sine there is a 5-year survival f 54% in these patients. Aneurysms f the desend- ing thrai arta are treated rutinely by endvasular grafting. Repair f arh aneurysms shuld be undertaken nly if there is a skilled surgial team with an aeptable rerd f utmes fr these mplex predures. The avail- ability f thrai arti endgraft tehnique using mplex branhed endvasular renstrutins fr aneurysms invlving the arh r viseral arta (ustm-made grafts with branhes t the vessels invlved in the aneurysm) des nt hange the indiatins fr aneurysm repair. Aneurysms that invlve the prximal arti arh r asending arta repre- sent partiularly hallenging prblems and may be nsid- ered fr repair when they measure 5.5 m. Open surgery is usually required, arrying substantial risk f mrbidity (inluding strke, diffuse neurlgi injury, and intelletualimpairment) beause interruptin f arh bld flw is required. »ComplicationsW ith the exeptin f endvasular repair fr disrete sa- ular aneurysms f the desending thrai arta, the mrbidity and mrtality f thrai aneurysm repair is higher than fr infra-renal abdminal arti aneurysm repair. Paraplegia remains a devastating mpliatin. Mst large series reprt apprximately 4–10% rate f paraplegia fllwing endvasular repair f thrai arti aneurysms. The spinal arterial supply is segmental thrugh interstal branhes f the arta with variable degrees f intersegmental nnetin. Therefre, the mre extensive the aneurysm, the greater is the risk f paraplegia with repair. Prir infrarenal abdminal arti surgery, subla- vian r internal ilia artery lusin, and hyptensin all inrease the paraplegia risk. Invlvement f the arti arh als inreases the risk f strke, even when the aneurysm des nt diretly affet the artid artery. »PrognosisGenerally , degenerative aneurysms f the thrai arta will enlarge (n average 0.1 m/y) and require repair t prevent death frm rupture. Saular aneurysms, partiu- larly thse distal t the left sublavian artery and the desending thrai arta, have gd results with endvas- ular repair. Resetin f aneurysms f the arti arh requires a skilled surgial team and shuld be attempted nly in lw-risk patients. Branhed r fenestrated endvas- ular grafting tehnlgy has demnstrated redued mr- bidity and mrtality. »When to Refer• Asending arti aneurysms larger than 4.5 m shuld be referred t a ardia surgen fr bservatin and assessment and nsidered fr repair at 5.5 m. •Desending thrai arti aneurysm shuld be referred t a vasular speialist when they reah 5 m fr bser- vatin and assessment and nsidered fr repair at 6 m. »When to Admit• Any patient with hest r bak pain with a knwn r suspeted thrai arta aneurysm must be brught t the hspital and underg urgent imaging studies t rule ut the aneurysm as a ause f the pain.Gasper  WJ et al. Assessing the anatmi appliability f the multibranhed endvasular repair f thraabdminal arti aneurysm tehnique. J Vas Surg. 2013;57:1553. [PMID: 23395201] Uphurh GR et al. Siety fr Vasular Surgery linial pratie guidelines f thrai endvasular arti repair fr desend- ing thrai arti aneurysms. J Vas Surg. 2021;73:55S. [PMID: 32628988] Werlin EC et al. Multibranhed endvasular arti aneurysm repair in patients with and withut hrni arti dissetins. J Vas Surg. 2019;70:1419. [PMID: 31327618]CMDT22_Ch12_p0475-p0501.indd  486 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS487 CMDT 2022PE RIPHERAL ARTERY ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S »Widened, prominent pulses. »Acute leg or foot pain and paresthesias with loss of distal pulses. »High association of popliteal aneurysms with abdominal aortic aneurysms. »General ConsiderationsLike  arti aneurysms, peripheral artery aneurysms are silent until ritially symptmati. Hwever, unlike arti aneurysms, the presenting manifestatins are due t peripheral emblizatin and thrmbsis. Ppliteal artery aneurysms aunt fr 70% f peripheral arterial aneu- rysms. Ppliteal aneurysms may emblize repetitively ver time and lude distal arteries. Due t the redundant parallel arterial supply t the ft, ishemia des nt ur until a final emblus ludes flw. Primary femral artery aneurysms are muh less m- mn. Hwever, pseudaneurysms f the femral artery fllwing arterial puntures fr arterigraphy and ardia atheterizatin ur with an inidene ranging frm 0.05% t 6% f arterial puntures. »Clinical FindingsA.  Symptoms and SignsThe  patient may be aware f a pulsatile mass when the aneurysm is in the grin, but ppliteal aneurysms are ften undeteted by the patient and liniian. Rarely, peripheral aneurysms may prdue symptms by mpressing the lal vein r nerve. The first symptm may be due t ish- emia f aute arterial lusin. The symptms range frm sudden-nset pain and paralysis t shrt-distane laudi- atin that slwly lessens as llateral irulatin develps. Symptms frm reurrent emblizatin t the leg are ften transient, if they ur at all. Sudden ishemia may appear in a te r part f the ft, fllwed by slw reslutin, and the true diagnsis may be elusive. The nset f reurrent episdes f pain in the ft, partiularly if ampanied by yansis, suggests emblizatin and requires investigatin f the heart and prximal arterial tree. Beause ppliteal pulses are smewhat diffiult t pal- pate even in nrmal individuals, a partiularly prminent r easily felt pulse is suggestive f aneurysm and shuld be investigated by ultrasund. Sine ppliteal aneurysms are bilateral in 60% f ases, the diagnsis f thrmbsis f a ppliteal aneurysm is ften aided by the palpatin f a pulsatile aneurysm in the ntralateral ppliteal spae. Apprximately 50% f patients with ppliteal aneurysms have an aneurysmal abdminal arta.B.  Imaging StudiesDuplex lr ultrasun d is the mst effiient investigatin t nfirm the diagnsis f peripheral aneurysm, measureits size and nfiguratin, and demnstrate mural thrm- bus. MRA r CTA is required t define the aneurysm and lal arterial anatmy fr renstrutin. Arterigraphy is nt remmended beause mural thrmbus redues the apparent diameter f the lumen n angigraphy. Patients with ppliteal aneurysms shuld underg abdminal ultra- sngraphy t determine whether an abdminal arti aneurysm is als present. »TreatmentT  prevent limb lss frm thrmbsis r emblizatin, surgery is indiated when an aneurysm is assiated with any peripheral emblizatin, the aneurysm is larger than 2 m, r a mural thrmbus is present. Immediate r urgent surgery is indiated when aute emblizatin r thrmbsis has aused aute ishemia. Open surgial bypass is gener- ally indiated. Endvasular exlusin f the aneurysm an be dne but has anatmi nstraints and is reserved fr high-risk patients. Intra-arterial thrmblysis may be dne in the setting f aute ishemia, if examinatin (light tuh) remains intat, suggesting that immediate surgery is nt imperative. Aute pseudaneurysms f the femral artery due t arterial puntures an be suessfully treated using ultrasund-guided mpressin r thrmbin injetin. Open surgery with prstheti interpsitin grafting is pre- ferred fr primary aneurysms f the femral artery. »PrognosisA pprximately ne-third f untreated patients will require an amputatin. The lng-term pateny f bypass grafts fr femral and ppliteal aneurysms is generally exellent but depends n the adequay f the utflw trat. Late graft lusin is less mmn than in similar surgeries fr lusive disease. »When to Refer• Peripheral arterial aneurysms measuring 2 m r with ultrasund evidene f thrmbus within the aneurysm shuld be referred t prevent prgressin t limb- threatening ishemia. »When to Admit• Patients with symptms f ishemia r any signs f emblizatin shuld be admitted and referred t a vas- ular speialist.AOR TIC DISSECTIONE S S E N T I A L S  O F  D I A G N O S I S »Sudden searing chest pain with radiation to the back, abdomen, or neck in a hypertensive patient. »Widened mediastinum on chest radiograph. »Pulse discrepancy in the extremities. »Acute aortic regurgitation may develop.CMDT22_Ch12_p0475-p0501.indd  487 29/06/21 8:37 PMCHAPTER 12488 CMDT 2022 »General ConsiderationsA rti dissetin urs when a spntaneus intimal tear develps and bld dissets int the media f the arta. The tear an result frm repetitive trque applied t the asend- ing and prximal desending arta during the ardia yle; hypertensin is an imprtant mpnent f this disease press. Dissetins are lassified by the entry pint and distal extent. Type A dissection invlves the arh prximal t the left sublavian artery, and type B dissection urs in the prximal desending thrai arta typially just beynd the left sublavian artery. Dissetins may ur in the absene f hypertensin but abnrmalities f smth musle, elasti tissue, r llagen are mre mmn in these patients. Pregnany, biuspid arti valve, and artatin als are assiated with inreased risk f dissetin. Bld entering the intimal tear may extend the dissetin int the abdminal arta, the lwer extremities, the artid arteries, r less mmnly, the sublavian arteries. Bth abs- lute pressure levels and the pulse pressure are imprtant in prpagatin f dissetin. Aortic dissection is a true emer- gency and requires immediate control of blood pressure to limit the extent of the dissection. With type A dissetin, whih has the wrse prgnsis, death may ur within hurs due t rupture f the dissetin int the periardial sa r dissetin int the rnary arteries, resulting in myardial infartin. Rupture int the pleural avity is als pssible. The intimal/ medial flap f the arti wall reated by the dissetin may lude majr arti branhes, resulting in ishemia f the brain, intestines, kidney, r extremities. »Clinical FindingsA.  Symptoms and SignsSe vere persistent hest pain f sudden nset radiating dwn the bak r pssibly int the anterir hest is harateristi. Radiatin f the pain int the nek may als ur. The patient is usually hypertensive. Synpe, hemiplegia, r paralysis f the lwer extremities may ur. Mesenteri ishemia r kidney injury may develp. Peripheral pulses may be diminished r unequal. A diastli murmur may develp as a result f a dis- setin in the asending arta lse t the arti valve, ausing valvular regurgitatin, heart failure, and ardia tampnade.B.  Electrocardiographic FindingsLeft  ventriular hypertrphy frm lng-standing hyperten- sin is ften present. Aute hanges suggesting myardial ishemia d nt develp unless dissetin invlves the rnary artery stium. Classially, inferir wall abnr- malities predminate sine dissetin leads t mprmise f the right rather than the left rnary artery. In sme patients, the ECG may be mpletely nrmal.C.  ImagingA  multiplanar CT san with ntrast enhanement is the immediate diagnsti imaging mdality f hie; lini- ians shuld have a lw threshld fr btaining a CT san in any hypertensive patient with hest pain and equival findings n ECG. The CT san shuld inlude bth the hest and abdmen t fully delineate the extent f thedisseted arta. MRA is an exellent imaging mdality fr hrni dissetins, but in the aute situatin, the lnger imaging time and the diffiulty f mnitring patients in the MRI sanner make the CT san preferable. Chest radi- graphs may reveal an abnrmal arti ntur r widened superir mediastinum. Althugh transesphageal ehar- digraphy (TEE) is an exellent diagnsti imaging methd, it is generally nt readily available in the aute setting. »Differential DiagnosisA rti dissetin is mst mmnly misdiagnsed as my- ardial infartin r ther auses f hest pain suh as pulmnary emblizatin. Dissetins may ur with minimal pain; branh vessel lusin f the lwer extrem- ity an mimi arterial emblus. »TreatmentA.  MedicalAg gressive measures t lwer bld pressure shuld ur when an arti dissetin is suspeted, even befre the diag- nsti studies have been mpleted. Treatment requires a simultaneus redutin f the systli bld pressure t 100– 120 mm Hg and pulse pressure. Beta-blkers have the mst desirable effet f reduing the left ventriular ejetin fre that ntinues t weaken the arterial wall and shuld be first- line therapy. Labetall, bth an alpha- and beta-blker, lw- ers pulse pressure and ahieves rapid bld pressure ntrl. Give 20 mg ver 2 minutes by intravenus injetin. Addi- tinal dses f 40–80 mg intravenusly an be given every 10 minutes (maximum dse 300 mg) until the desired bld pressure has been reahed. Alternatively, 2 mg/min may be given by intravenus infusin, titrated t desired effet. In patients wh have asthma, bradyardia, r ther nditins that neessitate the patient’s reatin t beta-blkers be tested, esmll is a reasnable hie beause f its shrt half-life. Give a lading dse f esmll, 0.5 mg/kg intravenusly ver 1 minute, fllwed by an infusin f 0.0025–0.02 mg/kg/min. Titrate the infusin t a gal heart rate f 60–70 beats/min. If beta-blkade alne des nt ntrl the hypertensin, nitrprusside may be added as fllws: 50 mg f nitrprus- side in 1000 mL f 5% dextrse and water, infused at a rate f 0.5 mL/min fr a 70-kg persn (0.3 mg/kg/min); the infu- sin rate is inreased by 0.5 mL every 5 minutes until adequate ntrl f the pressure has been ahieved. In patients with asthma, while there are n data supprting the use f the al- ium hannel antagnists, diltiazem and verapamil are pten- tial alternatives t treatment with beta-blking drugs. Mrphine sulfate is the apprpriate drug t use fr pain relief. Lng-term medial are f patients shuld inlude beta- blkers in their antihypertensive regimen.B.  Surgical Intervention1.  Type A dissection— Urgent surgical intervention is required for all type A dissections. If a skilled ardivasular team is nt available, the patient shuld be transferred t an appr- priate faility. The predure invlves grafting and replaing the diseased prtin f the arh and brahiephali vessels as neessary. Replaement f the arti valve may be required with reattahment f the rnary arteries.CMDT22_Ch12_p0475-p0501.indd  488 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS489 CMDT 20222. T ype B dissection with malperfusion— Urgent surgery is required fr type B dissetins if there is arti branh mprmise resulting in malperfusin f the renal, vis- eral, r extremity vessels. The immediate gal f surgery is t restre flw t the ishemi tissue. Endvasular stenting f the entry tear at the level f the sublavian artery may result in bliteratin f the false lumen and restre flw int the branh vessel frm the true lumen. The results, hwever, are unpreditable and shuld nly be attempted by an experiened team. 3. Type B dissection without malperfusion— Fr aute type B dissetins withut malperfusin, bld pressure ntrl is the primary treatment. Lng-term arti-speifi survival and late aneurysm frmatin rates are imprved with early thrai stent graft repair, espeially in healthy patients with high-risk anatmi features (arti diameter greater than 4 m r partial false lumen thrmbsis). »Prognosis & Follow-UpThe  mrtality rate fr untreated type A dissetins is apprximately 1% per hur fr 72 hurs and ver 90% at 3 mnths. Mrtality is als extremely high fr untreated type B dissetins with malperfusin r rupture. The surgial and endvasular therapies fr these patients are tehnially demanding and require an experiened team t ahieve periperative mrtalities f less than 10%. Aneurysmal enlargement f the residual false lumen may develp despite adequate antihypertensive therapy. Y early CT sans are required t mnitr fr aneurysm develpment. Indiatins fr late aneurysm repair are determined by aneurysm size (6 m r larger), similar t undisseted thrai aneurysms. »When to Admit• All patients with an aute dissetin shuld be hspital- ized fr bld pressure management and bservatin. •Urgent surgial repair is indiated fr all type A disse- tins and fr type B dissetins with malperfusin, rupture, r persistent symptms.Bssne E  et al. Aute arti syndrmes: diagnsis and manage- ment, an update. Eur Heart J. 2018;39:739. [PMID: 29106452] Evangelista A et al; IRAD Investigatrs. Insights frm the Interna- tinal Registry f Aute Arti Dissetin: a 20-year experiene f llabrative linial researh. Cirulatin. 2018;137:1846. [PMID: 29685932] ºVENOUS DISEASES VARICOSE VEINSE S S E N T I A L S  O F  D I A G N O S I S »Dilated, tortuous superficial veins in the legs. »Asymptomatic or there may be aching discomfort or pain. »Often hereditary. »Increased frequency after pregnancy.»General ConsiderationsV arise veins develp in the lwer extremities. Perids f high venus pressure related t prlnged standing r heavy lifting are ntributing fatrs, but the highest ini- dene urs in wmen after pregnany. Varisities develp in ver 20% f all adults. The mbinatin f prgressive venus reflux and venus hypertensin is the hallmark f hrni venus disease. The superfiial veins are invlved, typially the great saphenus vein and its tributaries, but the shrt saphenus vein (psterir lwer leg) may als be affeted. Distentin f the vein prevents the valve leaflets frm apting, reating inmpetene and reflux f bld tward the ft. Fal venus dilatin and reflux leads t inreased pressure and distentin f the vein segment belw that valve, whih in turn auses prgressive failure f the next lwer valve. Perfrating veins that nnet the deep and superfiial systems may beme inmpetent, allwing bld t reflux int the superfiial veins frm the deep system, inreasing venus pressure and distentin. Sendary varisities an develp as a result f bstrutive hanges and valve damage in the deep venus system fllwing thrmbphlebitis, r rarely as a result f prximal venus lusin due t neplasm r fibrsis. Cngenital r aquired arterivenus fistulas r venus malfrmatins are als assiated with varisities and shuld be nsidered in yung patients with varisities. »Clinical FindingsA.  Symptoms and SignsSymp tm severity is nt rrelated with the number and size f the varisities; extensive varise veins may pr- due n subjetive symptms, whereas minimal varisi- ties may prdue many symptms. Dull, ahing heaviness r a feeling f fatigue f the legs brught n by perids f standing is the mst mmn mplaint. Ithing frm venus ezema may ur either abve the ankle r diretly verlying large varisities. Dilated, trtuus veins f the thigh and alf are visible and palpable when the patient is standing. Lngstanding varise veins may prgress t hrni venus insuffiieny with assiated ankle edema, brwnish skin hyperpigmen- tatin, and hrni skin induratin r fibrsis. A bruit r thrill is never fund with primary varise veins and, when fund, alerts the liniian t the presene f an arterive- nus fistula r malfrmatin.B.  ImagingThe identifiatin  f the sure f venus reflux that feeds the symptmati veins is neessary fr effetive surgial treatment. Duplex ultrasngraphy by a tehniian experi- ened in the diagnsis and lalizatin f venus reflux is the test f hie fr planning therapy. In mst ases, reflux will arise frm the greater saphenus vein. »Differential DiagnosisV arise veins due t primary superfiial venus reflux shuld be differentiated frm thse sendary t previusCMDT22_Ch12_p0475-p0501.indd  489 29/06/21 8:37 PMCHAPTER 12490 CMDT 2022r  nging bstrutin f the deep veins (pst-thrmbti syndrme). Pain r dismfrt sendary t neurpathy shuld be distinguished frm symptms assiated with existent varise veins. Similarly, vein symptms shuld be distinguished frm pain due t intermittent laudia- tin, whih urs after a preditable amunt f exerise and reslves with rest. In adlesent patients with varise veins, imaging f the deep venus system is bligatry t exlude a ngenital malfrmatin r atresia f the deep veins. Surgical treatment of varicose veins in these patients is contraindicated because the varicosities may play a signifi- cant role in venous drainage of the limb. »ComplicationsSuperfiial  thrmbphlebitis f varise veins is unm- mn. The typial presentatin is aute lalized pain with tender, firm veins. The press is usually self-limiting, reslving within several weeks. The risk f deep venus thrmbsis (DVT) r emblizatin is very lw unless the thrmbphlebitis extends int the great saphenus vein in the upper medial thigh. Predispsing nditins inlude pregnany, lal trauma, r prlnged perids f sitting. In lder patients, superfiial varisities may bleed with even minr trauma. The amunt f bleeding an be alarm- ing as the pressure in the varisity is high. »TreatmentA.  Nonsurgical MeasuresN nsurgial treatment is effetive. Elasti graduated m- pressin stkings (20–30 mm Hg pressure) redue the venus pressure in the leg and may prevent the prgressin f disease. Gd ntrl f symptms an be ahieved when stkings are wrn daily during waking hurs and legs are elevated, espeially at night. Cmpressin stk- ings are well-suited fr elderly patients r patients wh d nt want surgery.B.  Varicose Vein SclerotherapyDiret  injetin f a slersing agent indues permanent fibrsis and bliteratin f the target veins. Chemial irri- tants (eg, glyerin) r hypertni saline are ften used fr small, less-than-4-mm retiular veins r telangietasias. Fam slertherapy is used t treat the great saphenus vein, varise veins larger than 4 mm, and perfrating veins. Slertherapy f varise veins withut treatment f underlying saphenus vein reflux is assiated with vari- sity reurrene rates ver 50% as unrreted reflux prgressively dilates adjaent veins. Cmpliatins suh as phlebitis, tissue nersis, r infetin may ur with any slersing agent.C.  Surgical Reflux TreatmentT reatment ptins fr reflux arising frm the great saphenus vein inlude surgial vein stripping (remval) r endvenus treatments using thermal devies (laser r radifrequeny atheter), yanarylate glue injetin, r fam slersant injetin. Endvenus treatments an ften be perfrmed with lal anesthesia alne and theearly suess is equal t vein stripping. Lng-term suess is highest with vein stripping and thermal treatments while the lng-term durability f yanarylate glue and fam is unknwn. One majr mpliatin f thermal treatments inludes endthermal heat-indued thrmbsis f the deep vein and may require prlnged antiagulatin. Less mmn sures f reflux inlude the small saphenus vein (fr varisities in the psterir alf) and inmpetent perfratr veins arising diretly frm the deep venus sys- tem. Crretin f reflux is perfrmed at the same time as exisin f the symptmati varise veins. When superfi- ial venus reflux is present, nmitant reflux in the deep venus system is ften sendary t vlume verlad, whih will reslve with rretin f the superfiial reflux. »PrognosisSurgial  treatment f superfiial vein reflux and exisin f varise veins prvide exellent results. The 5-year suess rate (as defined as lak f pain and reurrent varisities) is 85–90%. Simple exisin (phlebetmy) r injetin slertherapy withut rretin f reflux is assiated with reurrene rates ver 50%. Even after adequate treat- ment, sendary tissue hanges may persist. »When to Refer• Abslute indiatins fr referral fr saphenus ablatin inlude thrmbphlebitis and bleeding. •Pain and smeti nerns are respnsible fr the majrity f referrals fr ablatin.Kabnik  LS et al. Classifiatin and treatment f endthermal heat-indued thrmbsis: remmendatins frm the Amerian Venus Frum and the Siety fr Vasular Sur- gery. J Vas Surg Venus Lymphat Disrd. 2021;9:6. [PMID: 33012690] DePpas E et al. Varise veins and lwer extremity venus insuffiieny. Semin Intervent Radil. 2018;35:56. [PMID: 29628617]SU PERFICIAL VENOUS THROMBOPHLEBITISE S S E N T I A L S  O F  D I A G N O S I S »Red, painful induration along a superficial vein, usually at the site of a recent intravenous line. »Marked swelling of the extremity may not occur. »General ConsiderationsShrt-term venus a theterizatin f superfiial arm veins as well as the use f lnger-term peripherally inserted en- tral atheter (PICC) lines are the mst mmn ause f superfiial thrmbphlebitis. Intravenus atheter sites shuld be bserved daily fr signs f lal inflammatin and shuld be remved if a lal reatin develps in the vein. Serius thrmbti r septi mpliatins an ur if this pliy is nt fllwed; S aureus is the mst mmnCMDT22_Ch12_p0475-p0501.indd  490 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS491 CMDT 2022pathgen.  Other rganisms, inluding fungi, may als be respnsible. Superfiial thrmbphlebitis may ur spntaneusly, ften in pregnant r pstpartum wmen r in individuals with varise veins, r it may be assiated with trauma, as with a blw t the leg r fllwing intravenus therapy with irritating slutins. It als may be a manifestatin f systemi hyperagulability sendary t abdminal an- er suh as arinma f the panreas and may be the earli- est sign f these nditins. Superfiial thrmbphlebitis may be assiated with ult DVT in abut 20% f ases. Pulmnary embli are exeedingly rare and ur frm an assiated DVT. (See Chapters 9 and 14 fr disussin n deep venus thrmbsis.) »Clinical FindingsIn  spntaneus superfiial thrmbphlebitis, the great saphenus vein is mst ften invlved. The patient usually experienes a dull pain in the regin f the invlved vein. Lal findings nsist f induratin, redness, and tender- ness alng the urse f a vein. The press may be lal- ized, r it may invlve mst f the great saphenus vein and its tributaries. The inflammatry reatin generally subsides in 1–2 weeks; a firm rd may remain fr a muh lnger perid. Edema f the extremity is unmmn. Lalized redness and induratin at the site f a reent intravenus line requires urgent attentin. Prximal exten- sin f the induratin and pain with hills and high fever suggest septi phlebitis and requires urgent treatment. »Differential DiagnosisThe linear ra ther than irular nature f the lesin and the distributin alng the urse f a superfiial vein serve t differentiate superfiial phlebitis frm ellulitis, erythema ndsum, erythema induratum, panniulitis, and fibrsi- tis. Lymphangitis and deep thrmbphlebitis must als be nsidered. »TreatmentF r spntaneus thrmbphlebitis if the press is well lalized and nt near the saphenfemral juntin, lal heat and nnsteridal anti-inflammatry mediatins are usually effetive in limiting the press. If the induratin is extensive r is prgressing tward the saphenfemral juntin (leg) r ephal-axillary juntin (arm), ligatin and divisin f the vein at the juntin f the deep and superfiial veins is indiated. Antiagulatin therapy is usually nt required fr fal presses. Prphylati dse lw-mleular-weight heparin r fndaparinux is remmended fr 5 m r ln- ger superfiial thrmbphlebitis f the lwer limb veins (Table 14–14) and full antiagulatin is reserved fr dis- ease that is rapidly prgressing r if there is nern fr extensin int the deep system (Table 14–16). Septi superfiial thrmbphlebitis is an intravasular absess and requires urgent treatment with heparin r fndaparinux (see Table 14–16) t limit further thrmbus frmatin and remval f the ffending atheter in atheter- related infetins (see Chapter 30). Treat with antibitis(eg, vanmyin, 15 mg/kg intravenusly every 12 hurs, plus eftriaxne, 1 g intravenusly every 24 hurs). If ul- tures are psitive, therapy shuld be ntinued fr 7–10 days r fr 4–6 weeks if mpliating endarditis annt be exluded. Surgial exisin f the invlved vein may als be neessary t ntrl the infetin. »PrognosisW ith spntaneus thrmbphlebitis, the urse is gener- ally benign and brief. In patients with phlebitis sendary t varise veins, reurrent episdes are likely unless r- retin f the underlying venus reflux and exisin f varisities is dne. In ntrast, the mrtality frm septi thrmbphlebitis is 20% r higher and requires aggressive treatment. Hwever, if the invlvement is lalized, the mrtality is lw and prgnsis is exellent with early treatment.Di  Nisi M et al. Treatment fr superfiial thrmbphlebitis f the leg. Chrane Database Syst Rev. 2018;2:CD004982. [PMID: 29478266]CH RONIC VENOUS INSUFFICIENCYE S S E N T I A L S  O F  D I A G N O S I S »History of prior DVT or leg injury. »Edema, (brawny) skin hyperpigmentation, subcu- taneous lipodermosclerosis in the lower leg. »Venous ulcers: large ulcerations at or above the medial ankle. »General ConsiderationsChrni  venus insuffiieny is a severe manifestatin f venus hypertensin. One f the mst mmn etilgies is prir deep venus thrmbphlebitis, althugh abut 25% f patients d nt have a knwn histry f DVT. In these ases, there may be a histry f leg trauma r surgery; besity is ften a mpliating fatr. Prgressive superfi- ial venus reflux is als a mmn ause. Other auses inlude ngenital r neplasti bstrutin f the pelvi veins r a ngenital r aquired arterivenus fistula. The basi pathlgy is aused by valve leaflets that d nt apt beause they are either thikened and sarred (pst-thrmbti syndrme) r in a dilated vein and are therefre funtinally inadequate. Prximal venus bstrutin due t hrni thrmbus r sarring m- punds the prblem. With the valves unable t stp venus bld frm returning t the ft (venus reflux), the leg develps venus hypertensin and an abnrmally high hydrstati fre is transmitted t the subutaneus veins and tissues f the lwer leg. The resulting edema results in dramati and deleterius sendary hanges. The stigmata f hrni venus insuffiieny inlude fibrsis f the sub- utaneus tissue and skin, pigmentatin f skin (hemsid- erin taken up by the dermal marphages), and, later,CMDT22_Ch12_p0475-p0501.indd  491 29/06/21 8:37 PMCHAPTER 12492 CMDT 2022uleratin,  whih is extremely slw t heal. Ithing may preipitate the frmatin f uleratin r lal wund el- lulitis. Dilatin f the superfiial veins may ur, leading t varisities. Althugh surgial treatment fr venus reflux an imprve symptms, ntrlling edema and the sendary skin hanges usually require lifelng mpres- sin therapy. »Clinical FindingsA.  Symptoms and SignsPrgr essive pitting edema f the leg (partiularly the lwer leg) is the primary presenting symptm. Sendary hanges in the skin and subutaneus tissues develp ver time (Figure 12–2). The usual symptms are ithing, a dull dis- mfrt made wrse by perids f standing, and pain if an uleratin is present. The skin at the ankle is usually taut frm swelling, shiny, and a brwnish pigmentatin (hem- siderin) ften develps. If the nditin is lngstanding, the subutaneus tissues beme thik and fibrus. Uler- atins may ur, usually just abve the ankle, n the medial r anterir aspet f the leg. Healing results in a thin sar n a fibrti base that ften breaks dwn with minr trauma r further buts f leg swelling. Varisities may appear (Figure 12–3) that are assiated with inm- petent perfrating veins. Cellulitis, whih is ften diffiult t distinguish frm the hemsiderin pigmentatin, may be diagnsed by blanhing erythema with pain.B.  ImagingPa tients with pst-thrmbti syndrme r signs f hrni venus insuffiieny shuld underg duplex ultrasngra- phy t determine whether superfiial reflux is present and t evaluate the degree f deep reflux and bstrutin. »Differential DiagnosisPa tients with heart failure, hrni kidney disease, r dem- pensated liver disease may have bilateral edema f the lwer extremities. Many mediatins an ause edema (eg, al- ium hannel blkers, nnsteridal anti-inflammatry agents, thiazlidinedines). Swelling frm lymphedema invlves the feet and may be unilateral, but varisities are absent. Edema frm these auses pits easily and brawny dislratin is rare. Lipedema is a disrder f adipse tissue that urs almst exlusively in wmen, is bilateral and symmetri, and is haraterized by stpping at a distint line just abve the ankles. Primary varise veins may be diffiult t differentiate frm the sendary varisities f pst-thrmbti syn- drme r venus bstrutin. Other nditins assiated with hrni ulers f the leg inlude neurpathi ulers usually frm diabetes mel- litus, arterial insuffiieny (ften manifests as painful lat- eral ankle ulers with absent pulses; medial ankle ulers, n ▲Figure 12–2. Bilateral pretibial edema and erythema consistent with stasis dermatitis (sometimes mimicking cellulitis) in chronic venous insufficiency. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.) ▲Figure 12–3. Varicose veins, manifested as blue, subcutaneous, tortuous veins more than 3 mm in diam- eter. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  492 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS493 CMDT 2022the  ther hand, are usually due t venus insuffiieny), autimmune diseases (eg, Felty syndrme), sikle ell ane- mia, erythema induratum (bilateral and usually n the psterir aspet f the lwer part f the leg), and fungal infetins. »PreventionI rreversible tissue hanges and assiated mpliatins in the lwer legs an be redued thrugh early and aggressive antiagulatin f aute DVT t minimize the valve damages and by presribing mpressin stkings if hrni edema develps after the DVT has reslved. Treatment f aute ilifemral DVT with atheter-direted thrmblysis r mehanial thrmbetmy des nt redue pst-thrmbti syndrme and hrni venus insuffiieny. »TreatmentA.  General MeasuresFitted , graduated mpressin stkings (20–30 mm Hg pressure r higher) wrn frm the ft t just belw the knee during the day and evening are the mainstays f treat- ment and are usually suffiient. When they are nt, addi- tinal measures, suh as avidane f lng perids f sitting r standing, intermittent elevatins f the invlved leg, and sleeping with the legs kept abve the level f the heart, may be neessary t ntrl the swelling. Pneumati mpressin f the leg, whih an pump the fluid ut f the leg, is used in refratry ases.B.  UlcerationAs  the primary pathlgy is edema and venus hyperten- sin, healing f the uler will nt ur until the edema is ntrlled and mpressin is applied. Cirumferential nnelasti bandages n the lwer leg enhane the pumping atin f the alf musles n venus bld flw ut f the alf. A lesin an ften be treated n an ambulatry basis by means f a semi-rigid gauze bt made with Unna paste (Gelast, Medipaste) r a multi-layer mpressin dressing (eg, Prfre). Initially, the uler needs t be debrided and the bt hanged every 2–3 days t ntrl uler drainage. As the edema and drainage subside, pti- mal healing is ahieved when the bt is kept in plae fr 5–7 days. The uler, tendns, and bny prminenes must be adequately padded. Alternatively, knee-high graduated mpressin stkings with an absrbent dressing may be used, if wund drainage is minimal. Hme mpressin therapy with a pneumati mpressin devie is used in refratry ases, but many patients have severe pain with the “milking” atin f the pump devie. Sme patients will require admissin fr mplete bed rest and leg elevatin t ahieve uler healing. After the uler has healed, daily graduated mpressin stking therapy is mandatry t prevent uler reurrene.C.  Vein Treatment Reflux or ObstructionT reatment f superfiial vein reflux (see Varise Veins se- tin, abve) has been shwn t derease the reurrene rate f venus ulers. Where there is substantial bstrutin fthe femral and ppliteal deep venus system, superfiial varisities supply the venus return and they shuld nt be remved. Venus stents as treatment f hrni ilia deep vein stensis r bstrutin may imprve venus uler healing and redue the uler reurrene rate in severe ases. »PrognosisIndivid uals with hrni venus insuffiieny ften have reurrent edema, partiularly if they d nt nsistently wear supprt stkings that have at least 20–30 mm Hg mpressin. »When to Refer• Patients with signifiant saphenus reflux shuld be evaluated fr ablatin. •Patients with ulers shuld be mnitred by an interdis- iplinary wund are team s that these hallenging wunds reeive aggressive are.Raffett  JD. Pathphysilgy f hrni venus disease and venus ulers. Surg Clin Nrth Am. 2018;98:337. [PMID: 29502775] Vedantham S et al; ATTRACT Trial Investigatrs. Pharmam- ehanial atheter-direted thrmblysis fr deep-vein thrmbsis. N Engl J Med. 2017;377:2240. [PMID: 29211671]SU PERIOR VENA CAVAL OBSTRUCTIONE S S E N T I A L S  O F  D I A G N O S I S »Swelling of the neck, face, and upper extremities. »Dilated veins over the upper chest and neck. »General ConsiderationsP artial r mplete bstrutin f the superir vena ava is a relatively rare nditin that is usually sendary t neplas- ti r inflammatry presses in the superir mediastinum. The mst frequent auses are (1) neplasms, suh as lymph- mas, primary malignant mediastinal tumrs, r arinma f the lung with diret extensin (ver 80%); (2) hrni fibrti mediastinitis, either f unknwn rigin r sendary t tuberulsis, histplasmsis, pygeni infetins, r drugs, espeially methysergide; (3) DVT, ften by extensin f the press frm the axillary r sublavian vein int the innmi- nate vein and vena ava assiated with atheterizatin f these veins fr dialysis r fr hyperalimentatin; (4) aneu- rysm f the arti arh; and (5) nstritive periarditis. »Clinical FindingsA.  Symptoms and SignsThe  nset f symptms is aute r subaute. Symptms inlude swelling f the nek and fae and upper extremities. Symptms are ften pereived as ngestin and present asCMDT22_Ch12_p0475-p0501.indd  493 29/06/21 8:38 PMCHAPTER 12494 CMDT 2022heada he, dizziness, visual disturbanes, stupr, synpe, r ugh. There is prgressive bstrutin f the venus drainage f the head, nek, and upper extremities. The uta- neus veins f the upper hest and lwer nek beme dilated, and flushing f the fae and nek develps. Brawny edema f the fae, nek, and arms urs later, and yansis f these areas then appears. Cerebral and laryngeal edema ultimately result in impaired funtin f the brain as well as respiratry insuffiieny. Bending ver r lying dwn aentuates the symptms; sitting quietly is generally pre- ferred. The manifestatins are mre severe if the bstru- tin develps rapidly and if the azygs juntin r the vena ava between that vein and the heart is bstruted.B.  Laboratory FindingsThe ven us pressure is elevated (ften mre than 20 m f water) in the arm and is nrmal in the leg. Sine lung aner is a mmn ause, brnhspy is ften perfrmed; transbrnhial bipsy, hwever, is relatively ntraindiated beause f venus hypertensin and the risk f bleeding.C.  ImagingChest  radigraphs and a CT san an define the latin and ften the nature f the bstrutive press, and n- trast vengraphy r magneti resnane vengraphy (MRV) will map ut the extent and degree f the venus bstrutin and the llateral irulatin. Brahial veng- raphy r radinulide sanning fllwing intravenus injetin f tehnetium (T-99m) pertehnetate demn- strates a blk t the flw f ntrast material int the right heart and enlarged llateral veins. These tehniques als allw estimatin f bld flw arund the lusin as well as serial evaluatin f the respnse t therapy. »TreatmentCnser vative measures, suh as elevatin f the head f the bed and lifestyle mdifiatin t avid bending ver, are useful. Balln angiplasty f the bstruted aval segment mbined with stent plaement prvides prmpt relief f symptms and is the predure f hie fr all etilgies. Oasinally, antiagulatin is needed, while thrmbly- sis is rarely needed. Urgent treatment fr neplasm nsists f (1) autius use f intravenus diuretis and (2) mediastinal irradia- tin, starting within 24 hurs, with a treatment plan designed t give a high daily dse but a shrt ttal urse f therapy t rapidly shrink the lal tumr. Intensive m- bined therapy will palliate the press in up t 90% f patients. In patients with a subaute presentatin, radiatin therapy alne usually suffies. Chemtherapy is added if lymphma r small-ell arinma is diagnsed. Lng-term utme is mpliated by risk f re-lusin frm either thrmbsis r neplasm grwth. Surgial pre- dures t bypass the bstrutin are mpliated by bleed- ing frm high venus pressure. In ases where the thrmbsis is sendary t an indwelling atheter, thrm- blysis may be attempted. Clinial judgment is required sine a lng-standing lt may be fibrti and the risk f bleeding an utweigh the ptential benefit.»PrognosisThe  prgnsis depends n the nature and degree f bstrutin and its speed f nset. Slwly develping frms sendary t fibrsis may be tlerated fr years. A high degree f bstrutin f rapid nset sendary t aner is ften fatal in a few days r weeks beause f inreased intraranial pressure and erebral hemrrhage, but treat- ment f the tumr with radiatin and hemtherapeuti drugs may result in signifiant palliatin. Balln angi- plasty and stenting prvide gd relief but may require re- treatment fr reurrent symptms sendary t thrmbsis r restensis. »When to Refer• Any patient with prgressive head and nek swelling shuld be referred t rule ut superir vena ava syndrme. »When to Admit• Any patient with aute edema f the head and nek r with signs and symptms f airway mprmise, suh as harseness r stridr, shuld be admitted.Kalra  M et al. Endvenus and perative treatment f superir vena ava syndrme. Surg Clin Nrth Am. 2018;98:321. [PMID: 29502774] ºDISEASES OF THE LYMPHATIC CHANNELS LYMPHANGITIS & LYMPHADENITISE S S E N T I A L S  O F  D I A G N O S I S »Red streak from wound or cellulitis toward regional lymph nodes, which are usually enlarged and tender. »Chills, fever, and malaise may be present. »General ConsiderationsL ymphangitis and lymphadenitis are mmn manifesta- tins f a baterial infetin that is usually aused by hemlyti strepti r S aureus (r by bth rganisms) and bemes invasive, generally frm an infeted wund, ellulitis, r an absess. The wund may be very small r superfiial, r an established absess may be present, feed- ing bateria int the lymphatis. The invlvement f the lymphatis is ften manifested by a red streak in the skin extending in the diretin f the reginal lymph ndes. »Clinical FindingsA.  Symptoms and SignsThrbb ing pain is usually present at the site f baterial invasin frm a wund, ellulitis, r absess. Malaise,CMDT22_Ch12_p0475-p0501.indd  494 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS495 CMDT 2022anr exia, sweating, hills, and fever f 38–40°C develp quikly, ften with a rapid pulse. The red streak, when present, may be definite r may be faint and easily missed, espeially in dark-skinned patients. The invlved reginal lymph ndes may be signifiantly enlarged and are usually quite tender. The infetin may prgress rapidly, ften in a matter f hurs, and may lead t septiemia and death.B.  Laboratory FindingsLeukytsis with  a left shift is usually present. Bld ul- tures may be psitive, mst ften fr staphylal r streptal speies. Culture and sensitivity studies f the wund exudate r pus may be helpful in treatment f the mre severe r refratry infetins but are ften diffiult t interpret beause f skin ntaminants. »Differential DiagnosisTh e erythema and induratin f superfiial thrmbphlebitis are lalized in and arund the thrmbsed vein. Venus thrmbsis is nt assiated with lymphadenitis, and a wund f entrane with sendary ellulitis is generally absent. Cat-srath fever (Bartonella henselae) is a ause f lymphadenitis; the ndes, thugh ften very large, are rela- tively nntender. Expsure t ats is mmn, but the patient may have frgtten abut the srath. It is extremely important to differentiate cellulitis from acute streptococcal hemolytic gangrene or a necrotizing soft tissue infection. These are deeper infetins that may be extensive and are ptentially lethal. Patients are mre seriusly ill; there may be redness due t leakage f red ells, reating a nn- blanhing erythema; subutaneus repitus, a late finding, may be palpated r ausultated; and subutaneus air may be present n radigraphy r CT san. Immediate surgial n- sultatin is needed fr wide debridement f all invlved deep tissues if a nertizing infetin is suspeted. »TreatmentA.  General MeasuresPr mpt treatment shuld inlude heat (ht, mist m- presses r heating pad), elevatin when feasible, and immbilizatin f the infeted area. Analgesis may be presribed fr pain.B.  Specific MeasuresEmp iri antibiti therapy fr hemlyti strepti r S aureus (r bth rganisms) shuld always be instituted. Cephalsprins r extended-spetrum peniillins are m- mnly used (eg, ephalexin, 0.5 g rally fur times daily fr 7–10 days; see Table 30–6). Trimethprim-sulfamethxa- zle (tw duble-strength tablets rally twie daily fr 7–10 days) shuld be nsidered when there is nern that the pathgen is MRSA (see Tables 30–4 and 30–6).C.  Wound CareAny  wund that is the initiating site f lymphangitis shuld be treated aggressively. Any nerti tissue must be debrided and lulated pus drained.»PrognosisW ith prper therapy inluding an antibiti effetive against the invading bateria, ntrl f the infetin an usually be ahieved in a few days. Delayed r inadequate therapy an lead t verwhelming infetin with septiemia. »When to Admit• Infetins ausing lymphangitis shuld be treated in the hspital with intravenus antibitis. •Debridement may be required and prmpt surgial nsultatin is prudent.L YMPHEDEMAE S S E N T I A L S  O F  D I A G N O S I S »Painless persistent edema of one or both lower extremities, primarily in young women. »Pitting edema without ulceration, varicosities, or stasis pigmentation. »Lymphangitis and cellulitis may occur. »General ConsiderationsWhen  lymphedema is due t ngenital develpmental abnrmalities nsisting f hypplasti r hyperplasti invlvement f the prximal r distal lymphatis, it is referred t as the primary form . The bstrutin may be in the pelvi r lumbar lymph hannels and ndes when the disease is extensive and prgressive. The secondary form f lymphedema invlves inflammatry r mehani- al lymphati bstrutin frm trauma, reginal lymph nde resetin r irradiatin, r extensive invlvement f reginal ndes by malignant disease r filariasis. Lymph- edema may ur fllwing surgial remval f the lymph ndes in the grin r axillae. Sendary dilatin f the lymphatis that urs in bth frms leads t inmpe- tene f the valve system, disrupts the rderly flw alng the lymph vessels, and results in prgressive stasis f a prtein-rih fluid. Episdes f aute and hrni inflam- matin may be superimpsed, with further stasis and se- ndary fibrsis. »Clinical FindingsH ypertrphy f the limb results, with markedly thikened and fibrti skin and subutaneus tissue (Figure 12–4) in very advaned ases. T2–weighted MRI has been used t identify lymphatis and prximal bstruting masses. Lymphangigraphy and radiative istpe studies may identify fal defets in lymph flw but are f little value in planning therapy. »TreatmentSine there is n  effetive ure fr lymphedema, the treat- ment strategies are designed t ntrl the prblem andCMDT22_Ch12_p0475-p0501.indd  495 29/06/21 8:38 PMCHAPTER 12496 CMDT 2022allw  nrmal ativity and funtin. Mst patients an be treated with sme f the fllwing measures: (1) The flw f lymph ut f the extremity an be aided thrugh inter- mittent elevatin f the extremity, espeially during the sleeping hurs (ft f bed elevated 15–20 degrees, ahieved by plaing pillws beneath the mattress); the nstant use f graduated elasti mpressin stkings; and massage tward the trunk—either by hand r by means f pneumati pressure devies designed t milk edema ut f an extremity. Wund are enters speializ- ing in the are f patients with lymphedema may be help- ful. (2) Sendary ellulitis shuld be avided by means f gd hygiene and treatment f any trihphytsis f the tes. One an infetin starts, it shuld be treated by peri- ds f elevatin and antibiti therapy that vers Staphy- lococcus and Streptococcus rganisms (see Table 30–6). Infetins an be a serius and reurring prblem and are ften diffiult t ntrl. Prphylati antibitis have nt been shwn t be f benefit. (3) Intermittent urses f diureti therapy, espeially in thse with premenstrual r seasnal exaerbatins, are rarely helpful. (4) Amputatin is used nly fr the rare mpliatin f lymphangisar- ma in the extremity. »PrognosisW ith aggressive treatment, inluding pneumati mpres- sin devies, gd relief f symptms an be ahieved. The lng-term utlk is ditated by the assiated nditins and avidane f reurrent ellulitis.Chen  K et al. Surgial management f pstmastetmy lymph- edema and review f the literature. Ann Plast Surg. 2021;86: S173. [PMID: 33346539] ▲Figure 12–4. Lymphedema with a dorsal pedal hump and exaggerated skin folds near the ankle. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)ºSHOCKE S S E N T I A L S  O F  D I A G N O S I S »Hypotension, tachycardia, oliguria, altered mental status. »Peripheral hypoperfusion and impaired oxygen delivery. »Four classifications: hypovolemic, cardiogenic, obstructive, or distributive. »General ConsiderationsShk  urs when the rate f arterial bld flw is inad- equate t meet tissue metabli needs. This results in reginal hypxia and subsequent lati aidsis frm anaerbi metablism in peripheral tissues as well as even- tual end-rgan damage and failure. »ClassificationT able 12–1 utlines mmn auses and mehanisms ass- iated with eah type f shk.A.  Hypovolemic ShockH ypvlemi shk results frm dereased intravasular vlume sendary t lss f bld r fluids and eletr- lytes. The etilgy may be suggested by the linial setting (eg, trauma) r by signs and symptms f bld lss (eg, gastrintestinal bleeding) r dehydratin (eg, vmiting r diarrhea). Cmpensatry vasnstritin may transiently maintain the bld pressure but unreplaed lsses f ver 15% f the intravasular vlume an result in hyptensin and prgressive tissue hypxia.B.  Cardiogenic ShockCardigeni  shk results frm ardia failure with the resultant inability f the heart t maintain adequate tissue perfusin. The linial definitin f ardigeni shk is evidene f tissue hypxia due t dereased ardia utput (ardia index less than 2.2 L/min/m2) in the presene f adequate intravasular vlume. This is mst ften aused by myardial infartin but an als be due t ardimy- pathy, myardial ntusin, valvular inmpetene r stensis, r arrhythmias. See Chapter 10.C.  Obstructive ShockPe riardial tampnade, tensin pneumthrax, and mas- sive pulmnary emblism an ause an aute derease in ardia utput resulting in shk. These are medial emer- genies requiring prmpt diagnsis and treatment.D . Distributive ShockDistributiv e r vasdilatry shk has many auses inlud- ing sepsis, anaphylaxis, traumati spinal rd injury, rCMDT22_Ch12_p0475-p0501.indd  496 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS497 CMDT 2022aute  adrenal insuffiieny. The redutin in systemi vasular resistane results in inadequate ardia utput and tissue hypperfusin despite nrmal irulatry vlume. 1. Septic shock— Sepsis is the mst mmn ause f dis- tributive shk and arries a mrtality rate f 20–50%. TheSiety f Critial Care Mediine and the Eurpean Siety f Intensive Care Mediine’s 2016 definitin fr sepsis is life-threatening rgan dysfuntin aused by a dysregu- lated hst respnse t infetin frm any rganism (bate- rial, viral, r fungal). Septic shock is linially defined as sepsis with fluid-unrespnsive hyptensin (systli bld pressure less than 100 mm Hg), serum latate level higher than 2 mml/L, and a need fr vaspressrs t keep mean arterial pressure (MAP) abve 65 mm Hg. The mst m- mn ause f septi shk in hspitalized patients is infe- tin with gram-psitive r gram-negative rganisms, with a grwing inidene f infetin frm multidrug-resistant rganisms. Sepsis frm viral and fungal rganisms is inreasing but remain less than that fr baterial infetins. Risk fatrs fr septi shk inlude bateremia, extremes f age, diabetes, aner, immunsuppressin, and histry f a reent invasive predure. a. Clinical tools to identify sepsis and septic shock— The Third Internatinal Cnsensus Definitins fr Sepsis and Septi Shk (SEPSIS-3) remmend using the Sequential Organ Failure Assessment (SOFA) sre t define sepsis (https://en.wikipedia.rg/wiki/SOFA_sre); an inrease f 2 r mre SOFA sre pints in a patient with infetin is diagnsti f sepsis with a predited 10% mrtality. The SEPSIS-3 grup als intrdued the quik SOFA (qSOFA) sring system (https://en.wikipedia.rg/ wiki/SOFA_sre); 1 pint eah is assigned fr hypten- sin (systli bld pressure belw 100 mm Hg), altered mental status, r tahypnea (respiratry rate mre than 22 breaths per minute). A qSOFA sre f 2 r mre in a patient with suspeted infetin suggests wrsened linial utmes and may influene triage deisins fr intensive are unit (ICU)-level are. b. Systemic inflammatory response syndrome (SIRS)— Defined as a systemi respnse t a nnspeifi infetius r nninfetius insult resulting in at least tw f the fllwing findings: (1) bdy temperature higher than 38°C (100.4°F) r lwer than 36°C (96.8°F), (2) heart rate faster than 90 beats per minute, (3) respiratry rate mre than 20 breaths per minute r hyperventilatin with an arterial arbn dixide tensin (Paco2) less than 32 mm Hg, r (4) abnrmal white bld ell unt (greater than 12,000/mL r less than 4000/mL r greater than 10% immature [band] frms). Vasdilatry shk frm SIRS is ften due t burns; panreatitis; autimmune disrders, suh as vasulitis r inflammatry litis; air r amniti fluid emblus; ishemia; r trauma. SIRS is nt inluded in the 2016 frmal diagnsti riteria f sepsis. A 2018 meta- analysis demnstrated that SIRS riteria have higher sensi- tivity than qSOFA and may therefre identify patients with sepsis befre ther tests, suggesting that SIRS may be a better sreening tl fr sepsis, while qSOFA may be better used as a preditr f ICU mrtality. Studies are nging t desribe the ptimal patient ppulatins (emergeny department vs hspitalized nn-ICU patients) where SIRS and qSOFA sring systems shuld be used. 2. Neurogenic shock— Neurgeni shk is aused by traumati spinal rd injury r effets f an epidural r spinal anestheti. This results in lss f sympatheti tneTable 12–1. Classification of shock by mechanism and common causes.Hypovolemic  shock Blood loss Traumatic hemorrhage Exsanguination Hemothorax Hemoperitoneum Fracture (femur and pelvis) Nontraumatic hemorrhage Gastrointestinal bleed AAA rupture Ectopic pregnancy rupture Volume loss Burns Skin integrity loss (toxic epidermal necrolysis) Vomiting Diarrhea Hyperosmolar states (diabetic ketoacidosis) Third spacing (eg, ascites, pancreatitis) Decreased intake Cardiogenic shock Dysrhythmia Bradycardias and blocks Tachycardias Myocardial disease Left or right ventricular infarction Dilated cardiomyopathy Mechanical Valvular Aortic regurgitation from dissection Papillary muscle rupture from ischemia Acute valvular rupture from abscess Ventricular aneurysm rupture Ventricular septum rupture Free wall ventricle rupture Obstructive shock Tension pneumothorax Pericardial disease Pericardial tamponade Constrictive pericarditis High-risk (massive) pulmonary embolism Severe pulmonary hypertension Auto PEEP from mechanical ventilation Distributive (vasodilatory) shock Anaphylactic shock Septic shock Neurogenic shock Drug-induced vasodilation Adrenal insufficiency Modified, with permission, from Stone CK, Humphries RL (editors). Current Emergency Diagnosis & Treatment , 7th ed. McGraw-Hill, 2011. AAA, abdominal aortic aneurysm; PEEP , positive end expiratory pressure.CMDT22_Ch12_p0475-p0501.indd  497 29/06/21 8:38 PMCHAPTER 12498 CMDT 2022with a redutin  in systemi vasular resistane and hyp- tensin withut a mpensatry tahyardia. Reflex vagal parasympatheti stimulatin evked by pain, gastri dila- tin, r fright may simulate neurgeni shk, prduing hyptensin, bradyardia, and synpe. 3. Endocrine shock— Endrine shk an arise frm hyperthyridism, hypthyridism, r adrenal insuffi- ieny. Adrenal insuffiieny mst ften urs with abrupt essatin f lng-term rtisterid use, but it an als be preipitated by infetin, trauma, surgery, r pitu- itary injury (leading t sendary adrenal insuffiieny). In additin t hyptensin, symptms inlude weakness, nausea, abdminal pain, and nfusin. Hypthyridism an lead t myxedema ma, presenting with vasdilatin and depressed ardia utput. Shk frm hyperthyrid- ism mst ften prdues high-utput ardia failure. »Clinical FindingsA.  Symptoms and SignsHyp otension is traditinally defined as a systli bld pressure f 90 mm Hg r less r a MAP f less than 60–65 mm Hg but must be evaluated relative t the patient’s nrmal bld pressure. A drp in systli pressure f greater than 10–20 mm Hg r an inrease in pulse f mre than 15 beats per minute with psitinal hange sug- gests depleted intravasular vlume. Hwever, bld pres- sure is ften nt the best indiatr f end-rgan perfusin beause mpensatry mehanisms, suh as inreased heart rate, inreased ardia ntratility, and vasnstritin an ur t prevent hyptensin. Patients with hypten- sin ften have l r mttled extremities and weak r thready peripheral pulses. Splanhni vasnstritin may lead t liguria, bwel ishemia, and liver dysfuntin, whih an ultimately result in multirgan failure. Mentatin may be nrmal r patients may beme restless, agitated, nfused, lethargi, r matse as a result f inadequate perfusin f the brain. Hypovolemic shock is evident when signs f hypper- fusin, suh as liguria, altered mental status, and l extremities, are present. Jugular venus pressure is lw, and there is a narrw pulse pressure indiative f redued strke vlume. Rapid replaement f fluids an restre tis- sue perfusin. In cardiogenic shock, there are als signs f glbal hypperfusin with liguria, altered mental status, and l extremities. Jugular venus pressure is elevated and there may be evidene f pulmnary edema with respi- ratry mprmise in the setting f left-sided heart failure. A transthoracic echocardiogram (TTE) or a transesophageal echocardiogram (TEE) is an effective diagnostic tool to dif- ferentiate hypovolemic from cardiogenic shock. In hypvle- mi shk, the left ventrile will be small beause f dereased filling, but ntratility is ften preserved. In ardigeni shk, there is a derease in left ventriular ntratility. The left ventrile may appear dilated and full beause f the inability f the left ventrile t ejet a suffi- ient strke vlume. Inobstructive shock , the entral venus pressure may be elevated but the TTE r TEE may shw redued left ventriular filling, a periardial effusin in the ase ftampnade, thikened periardium in the ase f periar- ditis, r right ventriular dysfuntin in the ase f massive pulmnary emblism. Periardientesis r periardial windw fr periardial tampnade, hest tube plaement fr tensin pneumthrax, r atheter-direted thrmb- lyti therapy fr massive pulmnary emblism an be life- saving in ases f bstrutive shk. Indistributive shock, signs inlude hyperdynami heart sunds, warm extremities initially, and a wide pulse pres- sure indiative f large strke vlume. The ehardigram may shw a hyperdynami left ventrile. Septic shock is diagnsed when there is linial evidene f infetin in the setting f persistent hyptensin and evidene f rgan hypperfusin, suh as lati aidsis, dereased urinary utput, r altered mental status despite adequate vlume resusitatin. Neurogenic shock is diagnsed when there is evidene f entral nervus system injury and persistent hyptensin despite adequate vlume resusitatin. A his- try f lng-term rtisterid use r thyrid disease an inrease the likelihd f endocrine shock.B.  Laboratory Findings and ImagingBld  speimens shuld be evaluated fr mplete bld unt, eletrlytes, gluse, arterial bld gas determina- tins, agulatin parameters, latate levels, typing and rss-mathing, and baterial ultures. An eletrardi- gram and hest radigraph shuld als be part f the initial assessment. Pint-f-are ultrasngraphy an rapidly assess glbal ardia funtin, presene f periardial effu- sin, and intravasular vlume status via inferir vena ava inspetin in ases f undifferentiated hyptensin. A TTE an mre frmally assess right- and left-sided filling pres- sures and ardia utput. »TreatmentA.  General MeasuresT reatment depends n prmpt diagnsis and an aurate appraisal f initing nditins. Initial management n- sists f basi life supprt with an assessment f the patient’s irulatin, airway, and breathing. This may entail airway intubatin and mehanial ventilatin. Ven- tilatry failure shuld be antiipated in patients with severe metabli aidsis due t shk. Mehanial venti- latin alng with sedatin an derease respiratry musle xygen demand and allw imprved xygen delivery t hypperfused tissues. Intravenus aess and fluid resus- itatin shuld be instituted alng with ardia mnitr- ing and assessment f hemdynami parameters suh as bld pressure and heart rate. Cardia mnitring an detet myardial ishemia r malignant arrhythmias, whih an be treated by standard advaned ardia life supprt (ACLS) prtls. Unrespnsive r minimally respnsive patients shuld have their gluse heked immediately, and if their gluse levels are lw, 1 ampule f 50% dextrse intravenusly shuld be given. An arterial line shuld be plaed fr n- tinuus bld pressure measurement, and an indwelling urinary atheter shuld be inserted t mnitr urinary utput.CMDT22_Ch12_p0475-p0501.indd  498 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS499 CMDT 2022B.  Hemodynamic MeasurementsEarly  nsideratin is given t plaement f a entral venus atheter (CVC) fr infusin f fluids and media- tins and fr hemdynami pressure measurements. A CVC an prvide measurements f the entral venus pressure (CVP) and the entral venus xygen saturatin (SvO2), bth f whih an be used t manage septi and ardigeni shk. Pulmnary artery atheters (PACs) allw measurement f the pulmnary artery pressure, left- sided filling pressure r the pulmnary apillary wedge pressure (PCWP), the mixed venus xygen saturatin (SvO2), and ardia utput. Multiple studies suggest that PACs d nt inrease verall mrtality r length f hspital stay but are assiated with higher use f intrpes and intravenus vasdilatrs in selet grups f ritially ill patients. The attendant risks assiated with PACs (infe- tin, arrhythmias, vein thrmbsis, and pulmnary artery rupture) an be as high as 4–9%; thus, the rutine use f PACs annt be remmended. Hwever, in mplex situ- atins, PACs may be useful in distinguishing between ar- digeni and septi shk, s the value f the infrmatin they might prvide must be arefully weighed in eah patient. TTE is a nninvasive alternative t the PAC. TTE an prvide infrmatin abut the pulmnary artery pres- sure and urrent ardia funtin, inluding ardia ut- put. The SvO2, whih is btained thrugh the CVC, an be used as a surrgate fr the SvO2, whih is btained thrugh the PAC. Pulse pressure variatin, as determined by arterial wavefrm analysis, r strke vlume variatin is muh mre sensitive than CVP as dynami measures f fluid respnsiveness in vlume resusitatin, but these measure- ments have nly been validated in patients wh are mehanially ventilated with tidal vlumes f 8 mL/kg, nt triggering the ventilatr, and in nrmal sinus rhythm. Pint-f-are ultrasund measurements f the inferir vena ava (IVC) an suggest intravasular vlume status and guide fluid replaement. If the patient is mehanially ventilated and the IVC dilates ~15–20% with respiratins, they are likely t respnd t intravenus fluids. If the patient is spntaneusly breathing, they may be fluid- respnsive if their IVC is less than 2 m in diameter and llapses by mre than 50% with eah breath. A CVP less than 5 mm Hg suggests hypvlemia, and a CVP greater than 18 mm Hg suggests vlume verlad, ardia failure, tampnade, r pulmnary hypertensin. A ardia index lwer than 2 L/min/m2indiates a need fr intrpi supprt. A ardia index higher than 4 L/min/m2 in a hyptensive patient is nsistent with early septi shk. The systemi vasular resistane is lw (less than 800 dynes · s/m–5) in sepsis and neurgeni shk and high (greater than 1500 dynes · s/m–5) in hypvlemi and ardigeni shk. Treatment is direted at maintaining a CVP f 8–12 mm Hg, a MAP f 65 mm Hg r higher, a ardia index f 2–4 L/min/m2, and a SvO2greater than 70%.C.  Volume ReplacementV lume replaement is ritial in the initial management f shk. Hemorrhagic shock is treated with immediateeffrts t ahieve hemstasis and rapid infusins f bld substitutes, suh as type-speifi r type O negative paked red bld ells (PRBCs) r whle bld, whih prvides extra vlume and ltting fatrs. Eah unit f PRBC r whle bld is expeted t raise the hematrit by 3%. Hypovolemic shock sendary t dehydratin is managed with rapid bluses f istni rystallid slutins, usually in 1-L inrements. Cardiogenic shock in the absene f fluid verlad requires smaller fluid hallenges, usually in inrements f 250 mL. Septic shock usually requires large vlumes f fluid fr resusitatin (typially 30 mL/kg) as the assiated apillary leak releases fluid int the extravas- ular spae. Caution must be used in cases of large-volume resuscitation with unwarmed fluids because this can produce hypothermia, which can lead to hypothermia-induced coag- ulopathy. Warming f fluids befre administratin an avid this mpliatin. Crystallid slutin is the resusitatin fluid f hie in mst settings. Histrially, 0.9% saline was the mst widely used rystallid slutin in resusitatin. Data sug- gest that balaned rystallids, like latated Ringer slutin r Plasma-Lyte, are assiated with less kidney injury, fewer instanes f hyperhlremi metabli aidsis, and dereased verall mrtality. Cmparisns f 0.9% saline and llid (albumin) slutins in ritially ill patients fund n differene in utme exept in patients with traumati brain injury, where albumin resusitatin led t higher mrtality. Thus, the use f balaned rystallid slutins fr vlume resusitatin in shk is favred. If the patient des nt respnd t fluid resusitatin, early use f vaspressrs shuld be nsidered.D . Early Goal-Directed TherapyCmpensat ed shk an ur in the setting f nrmalized hemdynami parameters with nging glbal tissue hypxia. Traditinal endpints f resusitatin suh as bld pressure, heart rate, urinary utput, mental status, and skin perfusin an therefre be misleading. Fllwing set prtls fr the treatment f septi shk by adjusting the use f fluids, vaspressrs, and intrpes as well as by using bld transfusins t meet hemdynami targets (MAP 65 mm Hg r higher, CVP 8–12 mm Hg, SvO2 greater than 70%) is termed early goal-directed therapy (EGDT). Latate learane f mre than 10% an be used as a substitute fr SvO2riteria if SvO2mnitring is nt available. Tw large randmized trials published in 2014 (Pr- CESS and ARISE) demnstrated n mrtality benefit frm the institutin f the riginal algrithm fr EGDT, but this may have been due t earlier administratin f antibitis, mpnents f EGDT beming part f the “usual are” that liniians deliver, and the effetiveness f eduatin abut deteting and treating sepsis in a timely fashin. The Surviving Sepsis Campaign’s remmendatins fr patients with sepsis r septi shk are t measure latate level; btain bld ultures prir t administratin f brad-spetrum antibitis, which should occur within 1 hour of sepsis diagnosis; and administer 30 mL/kg rystal- lid fr hyptensin r latate greater than 4 mml/L within the first 3 hurs f presentatin. SmallerCMDT22_Ch12_p0475-p0501.indd  499 29/06/21 8:38 PMCHAPTER 12500 CMDT 2022resusita tin vlumes may be apprpriate fr patients with heart failure, irrhsis, r advaned kidney disease. Vas- pressrs shuld be administered fr hyptensin nt respnsive t initial fluid resusitatin t maintain MAP 65 mm Hg r higher. Remeasure latate if initial level was high, and reassess vlume status and tissue perfusin fre- quently. A meta-analysis f hemdynami ptimizatin trials suggests that early treatment befre the develpment f rgan failure results in imprved survival, and patients wh respnd well t initial effrts demnstrate a survival advantage ver nnrespnders.E.  Medications1.  Vasoactive therapy— Vaspressrs and intrpi agents are administered nly after adequate fluid resusitatin. Chie f vasative therapy depends n the presumed etilgy f shk as well as ardia utput. If there is n- tinued hyptensin with evidene f high ardia utput after adequate vlume resusitatin, then vaspressr sup- prt is needed t imprve vasmtr tne. If there is evi- dene f lw ardia utput with high filling pressures, intrpi supprt is needed t imprve ntratility. a. Distributive (vasodilatory) shock— When inreased vasnstritin is required t maintain an ade- quate perfusin pressure, alpha-adrenergi atehlamine agnists (suh as nrepinephrine and phenylephrine) are generally used. Althugh nrepinephrine is bth an alpha- adrenergi and beta-adrenergi agnist, it preferentially inreases MAP ver ardia utput. The initial dse is 1–2 mg/min as an intravenus infusin, titrated t main- tain MAP at 65 mm Hg r higher. The usual maintenane dse is 2–4 mg/min intravenusly (maximum dse is 30 mg/min). Patients with refratry shk may require dsages f 10–30 mg/min intravenusly. Epinephrine, als with bth alpha-adrenergi and beta-adrenergi effets, may be used in severe shk and during aute resusitatin. It is the vaspressr f hie fr anaphylati shk. Fr severe shk, give 1 mg/min as a ntinuus intravenus infusin initially and titrate t hemdynami respnse; the usual dsage range is 1–10 mg/min intravenusly. Dpamine has variable effets arding t dsage. At lw dses (2–5 mg/kg/min intravenusly), stimulatin f dpaminergi and beta-adrenergi reeptrs prdues inreased glmerular filtratin, heart rate, and ntratil- ity. At dses f 5–10 mg/kg/min, beta-1-adrenergi effets predminate, resulting in an inrease in heart rate and ardia ntratility. At higher dses (greater than 10 mg/ kg/min), alpha-adrenergi effets predminate, resulting in peripheral vasnstritin. The maximum dse is typi- ally 50 mg/kg/min. There is n evidene dumenting a survival benefit frm, r the superirity f, a partiular vaspressr in septi shk. Nrepinephrine is the initial vaspressr f hie in septi shk t maintain the MAP at 65 mm Hg r higher. Phenylephrine an be used fr hyperdynami septi shk if dysrhythmias r tahyardias prevent the use f agents with beta-adrenergi ativity. In meta-analyses, the use f dpamine as a first-line vaspressr in septi shk resulted in an increase in 28-day mrtality and a higher inidene farrhythmi events. Dpamine shuld nly be used as an alternative t nrepinephrine in selet patients with septi shk, inluding patients with signifiant bradyardia r lw ptential fr tahyarrhythmias. Vaspressin (antidiureti hrmne r ADH) is ften used as an adjuntive therapy t atehlamine vaspres- srs in the treatment f distributive shk. Vaspressin auses peripheral vasnstritin via V1 reeptrs lated n smth musle ells. Vaspressin als ptentiates the effets f atehlamines n the vasulature and stimulates rtisl prdutin. Intravenus infusin f vaspressin at a lw dse (0.01–0.04 unit/min) as a send agent t nr- epinephrine has been benefiial in septi patients with hyptensin refratry t fluid resusitatin and nven- tinal atehlamine vaspressrs. Higher dses f vas- pressin derease ardia utput and may put patients at greater risk fr splanhni and rnary artery ishemia. Studies d nt favr the use f vaspressin as first-line therapy. Angitensin II, a mpnent f the renin-angitensin- aldsterne system axis, is a ptent diret vasnstritr that ats n the arteries and veins t inrease bld pres- sure. Angitensin II (marketed as Giapreza) an be nsid- ered as an additional agent in vasdilatry shk that is refratry t atehlamines and vaspressin. The rem- mended starting dse is 20 ng/kg/min via ntinuus intra- venus infusin thrugh a entral venus line. It an be titrated every 5 minutes by inrements f up t 15 ng/kg/ min as needed t ahieve MAP gals, but nt t exeed 80 ng/kg/min during the first 3 hurs f use. Maintenane dses shuld nt exeed 40 ng/kg/min. Cnurrent venus thrmbemblism (VTE) prphylaxis is indiated as studies revealed a higher inidene f VTE with angitensin II use. b. Cardiogenic shock— Given meta-analyses du- menting dereased mrtality, expert pinin suggests nr- epinephrine be the first-line vaspressr fr ardigeni shk. Dbutamine, a predminantly beta-adrenergi ag- nist, inreases ntratility and dereases afterlad. It is used fr patients with lw ardia utput and high PCWP but wh d nt have hyptensin. Dbutamine an be added t a vaspressr if there is redued myardial fun- tin (dereased ardia utput and elevated PCWP), r if there are signs f hypperfusin despite adequate vlume resusitatin and an adequate MAP . The initial dse is 0.1–0.5 mg/kg/min intravenus infusin, whih an be titrated every few minutes t hemdynami effet; the usual dsage range is 2–20 mg/kg/min intravenusly. Tahyphylaxis an ur after 48 hurs sendary t the dwn-regulatin f beta-adrenergi reeptrs. Amrinne and milrinne are phsphdiesterase inhibitrs that an be substituted fr dbutamine. These drugs inrease yli AMP levels and inrease ardia ntratility, bypassing the beta-adrenergi reeptr. Vasdilatin is a side effet f bth amrinne and milrinne. 2. Antibiotics— Definitive therapy fr septi shk inludes early initiatin f empiri brad-spetrum antibitis after apprpriate ultures have been btained and within 1 hur f regnitin f septi shk. Imaging studies may prve useful t attempt lalizatin f sures f infetin.CMDT22_Ch12_p0475-p0501.indd  500 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS501 CMDT 2022Surgial  management may als be neessary if nerti tis- sue r lulated infetins are present in attempts t n- trl the sure f infetin (see Table 30–5). 3. Corticosteroids— Crtisterids are the treatment f hie in patients with shk sendary t adrenal insuf- fiieny, defined as a rtisl respnse f 9 mg/dL r less after ne injetin f 250 mg f rtitrpin. Studies supprting rtisterid use in patients with shk frm sepsis r ther etilgies are mixed. Trials where either high r lw dses f rtisterids were administered t patients in septi shk did nt nsistently shw imprved survival. The ADRENAL study demnstrated shrter time t shk reslutin (3 days vs 4 days) but n differene in 90-day mrtality. The APROCCHSS study demnstrated lwer 90-day all-ause mrtality, exept fr thse reeiving hydrrtisne plus fludrrtisne. Ntably, sme wrse utmes were bserved frm inreased rates f sendary infetins. Crtisterids an be administered in refra- try shk t derease shk duratin; the urrent rem- mended regimen is hydrrtisne 50 mg intravenusly every 6 hurs fr 5–7 days.F . Other Treatment ModalitiesCardia  failure may require use f transutaneus r trans- venus paing r plaement f an intra-arterial balln pump r left ventriular assist devie. Emergent revasu- larizatin by perutaneus angiplasty r rnary arterybypass surgery appears t imprve lng-term utme with inreased survival mpared with initial medial sta- bilizatin fr patients with myardial ishemia leading t ardigeni shk (see Chapter 10). Urgent renal replae- ment therapy may be indiated fr maintenane f fluid and eletrlyte balane during aute kidney injury result- ing in shk frm multiple mdalities.Annane  D et al; CRICS-TRIGGERSEP Netwrk. Hydrrti- sne plus fludrrtisne fr adults with septi shk. N Engl J Med. 2018;378:809. [PMID: 29490185] Gand S et al; Japanese Assiatin fr Aute Mediine (JAAM) Sepsis Prgnstiatin in Intensive Care Unit and Emergeny Rm (SPICE) (JAAM SPICE) Study Grup. The SIRS riteria have better perfrmane fr prediting infetin than qSOFA sres in the emergeny department. Si Rep. 2020;10:8095. [PMID: 32415144] Khanna A et al; ATHOS-3 Investigatrs. Angitensin II fr the treatment f vasdilatry shk. N Engl J Med. 2017;377:419. [PMID: 28528561] Rhdes A et al. Surviving Sepsis Campaign: internatinal guide- lines fr management f sepsis and septi shk: 2016. Crit Care Med. 2017;45:486. [PMID: 28098591] Thiele H et al. Management f ardigeni shk mpliating myardial infartin: an update 2019. Eur Heart J. 2019;40:2671. [PMID: 31274157] Venkatesh B et al; ADRENAL Trial Investigatrs and the Australian–New Zealand Intensive Care Siety Clinial Trials Grup. Adjuntive glurtiid therapy in patients with septi shk. N Engl J Med. 2018;378:797. [PMID: 29347874]CMDT22_Ch12_p0475-p0501.indd  501 29/06/21 8:38 PM502 CMDT 2022 ºANEMIAS »General Approach to AnemiasAnemia is presen t in adults if the hematocrit is below 41% (hemoglobin less than 13.6 g/dL [135 g/L]) in males or below 36% (hemoglobin less than 12 g/dL [120 g/L]) in females. Congenital anemia is suggested by the patient’s personal and family history. The most common cause of anemia is iron deficiency. Poor diet may result in folic acid deficiency and contribute to iron deficiency, but bleeding is the most common cause of iron deficiency in adults. Physi- cal examination demonstrates pallor. Attention to physical signs of primary hematologic diseases (lymphadenopathy; hepatosplenomegaly; or bone tenderness, especially in the sternum or anterior tibia) is important. Mucosal changes such as a smooth tongue suggest megaloblastic anemia. Anemias are classified according to their pathophysiologic basis, ie, whether related to diminished production (relative or absolute reticulocytopenia) or to increased production due to accelerated loss of red blood cells (reticulocytosis) (Table 13–1), and according to red blood cell size (Table 13–2). A reticulocy- tosis occurs in one of three pathophysiologic states: acute blood loss, recent replacement of a missing erythropoietic nutrient, or reduced red blood cell survival (ie, hemolysis). A severely microcytic anemia (mean corpuscular volume [MCV] less than 70 fL) is due either to iron deficiency or thalassemia, while a severely macrocytic anemia (MCV greater than 120 fL) is almost always due to either megaloblastic anemia or to cold agglutinins in blood analyzed at room temperature. A bone marrow biopsy is generally needed to complete the evaluation of anemia when the blood laboratory evaluation fails to reveal an etiology, when there are additional cytopenias present, or when an underlying primary or secondary bone marrow pro- cess is suspected.IR ON DEFICIENCY ANEMIAE S S E N T I A L S  O F  D I A G N O S I S »Iron deficiency: serum ferritin is < 12 ng/mL (27 pmol/L) or < 30 ng/mL (67 pmol/L) if also anemic.13Lloyd E. Damon, MD Charalambos Babis Andreadis, MD, MSCEBlood Disorders »Caused by bleeding unless proved otherwise. »Responds to iron therapy. »General ConsiderationsIro n deficiency is the most common cause of anemia worldwide. The causes are listed in Table 13–3. Aside from circulating red blood cells, the major location of iron in the body is the storage pool as ferritin or as hemosiderin in macrophages. The average American diet contains 10–15 mg of iron per day. About 10% of this amount is absorbed in the stomach, duodenum, and upper jejunum under acidic conditions. Dietary iron present as heme is efficiently absorbed (10–20%) but nonheme iron less so (1–5%), largely because of interfer- ence by phosphates, tannins, and other food constituents. The major iron transporter from the diet across the intestinal lumen is ferroportin, which also facilitates the transport of iron to apotransferrin in macrophages for delivery to ery- throid progenitor cells in the bone marrow prepared to syn- thesize hemoglobin. Hepcidin, which is increasingly produced during inflammation, negatively regulates iron transport by promoting the degradation of ferroportin. Small amounts of iron—approximately 1 mg/day—are normally lost through exfoliation of skin and gastrointestinal mucosal cells. Menstrual blood loss plays a major role in iron metabo- lism. The average monthly menstrual blood loss is approxi- mately 50 mL but may be five times greater in some individuals. Women with heavy menstrual losses must absorb 3–4 mg of iron from the diet each day to maintain adequate iron stores, which is not commonly achieved. Women with menorrhagia of this degree will almost always become iron deficient without iron supplementation. In general, iron metabolism is balanced between absorp- tion of 1 mg/day and loss of 1 mg/day. Pregnancy and lacta- tion upset the iron balance, since requirements increase to 2–5 mg of iron per day. Normal dietary iron cannot supply these requirements, and medicinal iron is needed during pregnancy and lactation. Decreased iron absorption can also cause iron deficiency, such as in people affected by celiac disease (gluten enteropathy), and it also commonly occurs after gastric resection or jejunal bypass surgery.CMDT22_Ch13_p0502-p0547.indd  502 29/06/21 8:38 PM",
                  "Chapter 11444 CMDT 2022Elev ated BP reading (office, home or pharmacy) No hypertension6White coat  hypertension6HypertensionDedicated office visit1Mean of fice BP ≥ 180/110 mm Hg No Diabetes Diabetes31 .AOBP2≥ 135/85 mm Hg (preferred) 2.Non-AOBP2≥ 140/90 mm Hg (if AOBP unavailable)AOBP or non-AOBP2≥ 1 30/80 mm HgOR Out-of-office measurement41 .ABPM (preferred) Daytime mean ≥ 135/85 mm Hg 24-hour mean ≥ 130/80 mm Hg 2.Home BP series5 Mean ≥ 135/85 mm HgORYes YesNo NoYesNo1. If AOBP is used, use the mean calculated and displayed by the device. If non-AOBP is used, take at least three readings, discard the first and calculate the mean of the remaining measurements. A history and physical examination should be performed and diagnostic tests ordered. 2.AOBP is performed with the patient unattended in a private area. Non-AOBP is performed using an electronic upper arm device with the provider in the room. 3. Diagnostic thresholds for AOBP, ABPM, and home BP in patients with diabetes have yet to be established (and may be lower than 130/80 mm Hg). 4. Serial office measurements over 3–5 visits can be used if ABPM or home measurement not available. 5. Home BP series: Two readings taken each morning and evening for 7 days (28 total). Discard first day readings and average the last 6 days. 6. Annual BP measurement is recommended to detect progression to hypertension.Notes: ▲Figure 11–1. According to these recommendations, if AOBP measurements are not available, blood pressures recorded manually in the office may be substituted if taken as the mean of the last two readings of three consecu- tive readings. Note that the blood pressure threshold for diagnosing hypertension is higher if recorded manually in these guidelines. If home blood pressure monitoring is unavailable, office measurements recorded over three to five separate visits can be substituted. ABPM, ambulatory blood pressure measurement; AOBP , automated office blood pressure; BP , blood pressure. (Reproduced, with permission, from Leung AA et al; Hypertension Canada. Hyper- tension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. Copyright © 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.) Table 11–1. Corresponding blood pressure values across a range of blood pressure measurement methods.Mnul  Msumn in Clinic1hom Blood pssu Msumnambuloy Blood pssu Msumn (Dyim)ambuloy Blood pssu Msumn (Nigim)ambuloy Blood pssu Msumn (24-hou) 120/80 mm Hg 120/80 mm Hg 120/80 mm Hg 100/65 mm Hg 115/75 mm Hg 130/80 mm Hg 130/80 mm Hg 130/80 mm Hg 110/65 mm Hg 125/75 mm Hg 140/90 mm Hg 135/85 mm Hg 135/85 mm Hg 120/70 mm Hg 130/80 mm Hg 160/100 mm Hg 145/90 mm Hg 145/90 mm Hg 140/85 mm Hg 145/90 mm Hg1 Clinic manual blood pressures are critically dependent on technique. The use of automated devices in an unattended setting typi cally result in systolic blood pressures 9–13 mm Hg lower than clinic manual pressures. Data abstracted from Greenland P et al. The New 2017 ACC/AHA Guidelines “up the pressure” on diagnosis and treatment of hyperten sion. JAMA. 2017;318:2083.CMDT22_Ch11_p0443-p0474.indd  444 29/06/21 8:37 PMSYSteMIC hYperteNSION445 CMDT 2022I t is important to recognize that the diagnosis of hyper- tension does not automatically entail drug treatment; this decision depends on the clinical setting and evaluation of cardiovascular risk, as discussed below.Greenland  P et al. The New 2017 ACC/AHA Guidelines “up the pressure” on diagnosis and treatment of hypertension. JAMA. 2017;318:2083. [PMID: 29159417] Jin J. JAMA patient page. Checking blood pressure at home. JAMA. 2017;318:310. [PMID: 28719694] Leung AA et al; Hypertension Canada. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. [PMID: 28449828] Melville S et al. Out-of-office blood pressure monitoring in 2018. JAMA. 2018;320:1805. [PMID: 30398589] Myers MG. Automated office blood pressure—incorporating SPRINT into clinical practice. Am J Hypertens. 2017;30:8. [PMID: 27551025]AP PROACH TO HYPERTENSION »Etiology & ClassificationA.  Primary Essential Hypertension“Essential  hypertension” is the term applied to the 95% of hypertensive patients in which elevated blood pressure results from complex interactions between multiple genetic and environmental factors. Blood pressure elevation above 140/90 mm Hg occurs in 10–15% of White adults and 20–30% of Black adults in the United States. The onset is usually between ages 25 and 50 years; it is uncommon before age 20 years. The best understood pathways under- lying hypertension include overactivation of the sympa- thetic nervous and renin-angiotensin-aldosterone systems (RAAS), blunting of the pressure-natriuresis relationship, variation in cardiovascular and renal development, and elevated intracellular sodium and calcium levels. Exacerbating factors include obesity, sleep apnea, increased salt intake, excessive alcohol use, cigarette smok- ing, polycythemia, nonsteroidal anti-inflammatory drug (NSAID) therapy, and low potassium intake. Obesity is associated with an increase in intravascular volume, ele- vated cardiac output, activation of the renin-angiotensin system, and, probably, increased sympathetic outflow. Life- style-driven weight reduction lowers blood pressure mod- estly, but the dramatic weight reduction following bariatric surgery results in improved blood pressure in most patients, and actual remission of hypertension in 20–40% of cases. In patients with sleep apnea, treatment with continuous posi- tive airway pressure (CPAP) has been associated with improvements in blood pressure. Increased salt intake probably elevates blood pressure in some individuals so dietary salt restriction is recommended in patients with hypertension. Excessive use of alcohol also raises blood pressure, perhaps by increasing plasma catecholamines. Hypertension can be difficult to control in patients who consume more than 40 g of ethanol (two drinks) daily or drink in “binges. ” Cigarette smoking raises blood pressure by increasing plasma norepinephrine. Although the long- term effect of smoking on blood pressure is less clear, the synergistic effects of smoking and high blood pressure oncardiovascular risk are well documented. The relationship of exercise to hypertension is variable. Aerobic exercise low- ers blood pressure in previously sedentary individuals, but increasingly strenuous exercise in already active subjects has less effect. The relationship between stress and hyper- tension is not established. Polycythemia, whether primary, drug-induced, or due to diminished plasma volume, increases blood viscosity and may raise blood pressure. NSAIDs produce increases in blood pressure averaging 5 mm Hg and are best avoided in patients with borderline or elevated blood pressures. Low potassium intake is associ- ated with higher blood pressure in some patients; an intake of 90 mmol/day is recommended. The complex of abnormalities termed the “metabolic syndrome” (upper body obesity, insulin resistance, and hypertriglyceridemia) is associated with both the develop- ment of hypertension and an increased risk of adverse cardiovascular outcomes. Affected patients usually also have low high-density lipoprotein (HDL) cholesterol levels and elevated catecholamines and inflammatory markers such as C-reactive protein.B.  Secondary HypertensionA pproximately 5% of patients have hypertension second- ary to identifiable specific causes (Table 11–2). Secondary hypertension should be suspected in patients in whom hypertension develops at an early age or after the age of 50 years, and in those previously well controlled who become refractory to treatment. Hypertension resistant to maximum doses of three medications is another clue, although multiple medications are usually required to con- trol hypertension in persons with diabetes. 1. Genetic causes— Hypertension can be caused by muta- tions in single genes, inherited on a Mendelian basis. Although rare, these conditions provide important insight into blood pressure regulation and possibly the genetic basis of essential hypertension. Glucocorticoid remediable aldosteronism is an autosomal dominant cause of early- onset hypertension with normal or high aldosterone and low renin levels. The syndrome of hypertension exacer- bated in pregnancy is inherited as an autosomal dominant trait. In these patients, a mutation in the mineralocorticoid receptor makes it abnormally responsive to progesterone and, paradoxically, to spironolactone. 2. Kidney disease— Renal parenchymal disease is the most common cause of secondary hypertension, which results from increased intravascular volume and increased activity of the RAAS. Increased sympathetic nerve activity may also contribute. 3. Renal vascular hypertension— Renal artery stenosis is present in 1–2% of hypertensive patients. The most com- mon cause is atherosclerosis, but fibromuscular dysplasia should be suspected in women under 50 years of age. Excessive renin release occurs due to reduction in renal perfusion pressure, while attenuation of pressure natriure- sis contributes to hypertension in patients with a single kidney or bilateral lesions. Activation of the renal sympa- thetic nerves may also be important.CMDT22_Ch11_p0443-p0474.indd  445 29/06/21 8:37 PMChapter 11446 CMDT 2022Renal vascula r hypertension should be suspected in the following circumstances: (1) the documented onset is before age 20 or after age 50 years, (2) the hypertension is resistant to three or more drugs, (3) there are epigastric or renal artery bruits, (4) there is atherosclerotic disease of the aorta or peripheral arteries (15–25% of patients with symp- tomatic lower limb atherosclerotic vascular disease have renal artery stenosis), (5) there is an abrupt increase (more than 25%) in the level of serum creatinine after administra- tion of angiotensin-converting enzyme (ACE) inhibitors, or (6) episodes of pulmonary edema are associated with abrupt surges in blood pressure. (See Renal Artery Stenosis, Chapter 22.) 4. Primary hyperaldosteronism— Hyperaldosteronism should be considered in people with resistant hypertension, blood pressures consistently greater than 150/100 mm Hg, hypokalemia (although this is often absent), or adrenal incidentaloma, and in those with a family history of hyper- aldosteronism. Mild hypernatremia and metabolic alkalo- sis may also occur. Hypersecretion of aldosterone is estimated to be present in 5–10% of hypertensive patientsand, besides noncompliance, is the most common cause of resistant hypertension. The initial screening step is the simultaneous measurement of aldosterone and renin in blood in a morning sample collected after 30 minutes qui- etly seated. Hyperaldosteronism is suggested when the plasma aldosterone concentration is elevated (normal: 1–16 ng/dL) in association with suppression of plasma renin activity (normal: 1–2.5 ng/mL/h). However, the plasma aldosterone/renin ratio (normal less than 30) is not highly specific as a screening test. This is because renin levels may approach zero, which leads to exponential increases in the plasma aldosterone/renin ratio even when aldosterone levels are normal. Hence, an elevated plasma aldosterone/renin ratio should probably not be taken as evidence of hyperaldosteronism unless the aldosterone level is actually elevated. During the workup for hyperaldosteronism, an initial plasma aldosterone/renin ratio can be measured while the patient continues taking usual medications. If under these circumstances the ratio proves normal or equivocal, medica- tions that alter renin and aldosterone levels, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, beta-blockers, and clonidine, should be discontinued for 2 weeks before repeating the plasma aldosterone/renin ratio; spironolactone and eplerenone should be held for 4 weeks. Slow-release verapamil and alpha-receptor blockers can be used to control blood pressure during this drug washout period. Patients with a plasma aldosterone level greater than 16 ng/dL and an aldosterone/renin ratio of 30 or more might require further evaluation for primary hyperaldosteronism. The lesion responsible for hyperaldosteronism is an adrenal adenoma or bilateral adrenal hyperplasia. 5. Cushing syndrome— Hypertension occurs in about 80% of patients with spontaneous Cushing syndrome. Excess glucocorticoid may act through salt and water retention (via mineralocorticoid effects), increased angiotensinogen lev- els, or permissive effects in the regulation of vascular tone. Diagnosis and treatment of Cushing syndrome are dis- cussed in Chapter 26. 6. Pheochromocytoma— Pheochromocytomas are uncom- mon; they are probably found in less than 0.1% of all patients with hypertension and in approximately two indi- viduals per million population. Chronic vasoconstriction of the arterial and venous beds leads to a reduction in plasma volume and predisposes to postural hypotension. Glucose intolerance develops in some patients. Hypertensive crisis in pheochromocytoma may be precipitated by a variety of drugs, including tricyclic antidepressants, antidopaminer- gic agents, metoclopramide, and naloxone. The diagnosis and treatment of pheochromocytoma are discussed in Chapter 26. 7. Coarctation of the aorta— This uncommon cause of hypertension is discussed in Chapter 10. Evidence of radial-femoral delay should be sought in all younger patients with hypertension. 8. Hypertension associated with pregnancy— Hypertension occurring de novo or worsening during pregnancy, includ- ing preeclampsia and eclampsia, is one of the most commonTable 11–2. Causes of secondary hypertension.endocin Conn syndrome (hyperaldosteronism) Licorice Cushing syndrome (hypercortisolism) Thyroid disease Pheochromocytoma Acromegaly Mutations in steroid gene regulatory domains Hypercalcemia rnl Parenchymal kidney disease Polycystic kidney disease Systemic sclerosis (scleroderma) Page kidney Mutations in genes encoding ion transport proteins Vscul Renal artery stenosis Coarctation auonomic Stress Neurogenic Mdicions Nonsteroidal anti-inflammatory drugs Corticosteroids Calcineurin inhibitors Stimulants Decongestants Angiogenesis inhibitors Tyrosine kinase inhibitors Estrogen Erythropoietin Alcohol, cocaine Gemcitabine Atypical antipsychotics Monoamine oxidase inhibitors O Obstructive sleep apnea PregnancyCMDT22_Ch11_p0443-p0474.indd  446 29/06/21 8:37 PMSYSteMIC hYperteNSION447 CMDT 2022cau ses of maternal and fetal morbidity and mortality (see Chapter 19). Autoantibodies with the potential to activate the angiotensin II type 1 receptor have been caus- ally implicated in preeclampsia, in resistant hypertension, and in progressive systemic sclerosis. 9. Estrogen use— A small increase in blood pressure occurs in most women taking oral contraceptives. A more significant increase of 8/6 mm Hg systolic/diastolic is noted in about 5% of women, mostly in obese individuals older than age 35 who have been treated for more than 5 years. This is caused by increased hepatic synthesis of angiotensinogen. The lower dose of postmenopausal estro- gen does not generally cause hypertension but rather main- tains endothelium-mediated vasodilation. 10. Other causes of secondary hypertension— Hypertension has been associated with hypercalcemia, acromegaly, hyper- thyroidism, hypothyroidism, baroreceptor denervation, com- pression of the rostral ventrolateral medulla, and increased intracranial pressure. Certain medications may cause or exac- erbate hypertension—most importantly cyclosporine, tacroli- mus, angiogenesis inhibitors, and erythrocyte-stimulating agents (such as erythropoietin). Decongestants, NSAIDs, cocaine, and alcohol should also be considered. Over-the- counter products should not be overlooked, eg, a dietary sup- plement marketed to enhance libido was found to contain yohimbine, an alpha-2–antagonist, which can produce severe rebound hypertension in patients taking clonidine. »When to ReferReferra l to a hypertension specialist should be considered in cases of severe, resistant or early-/late-onset hypertension or when secondary hypertension is suggested by screening.Byrd  JB et al. Primary aldosteronism. Circulation. 2018;138:823. [PMID: 30359120] Herrmann SM et al. Renovascular hypertension. Endocrinol Metab Clin North Am. 2019;48:765. [PMID: 31655775] »Complications of Untreated HypertensionM ost of the adverse outcomes in hypertension are associated with thrombosis rather than bleeding, possibly because increased vascular shear stress converts the normally antico- agulant endothelium to a prothrombotic state. The excess morbidity and mortality related to hypertension approxi- mately doubles for each 6 mm Hg increase in diastolic blood pressure. However, target-organ damage varies markedly between individuals with similar levels of office hyperten- sion; home and ambulatory pressures are superior to office readings in the prediction of end-organ damage (Table 11–1).A.  Hypertensive Cardiovascular DiseaseCardiac  complications are the major causes of morbidity and mortality in primary (essential) hypertension. For any level of blood pressure, left ventricular hypertrophy is asso- ciated with incremental cardiovascular risk in association with heart failure (through systolic or diastolic dysfunc- tion), ventricular arrhythmias, myocardial ischemia, and sudden death.The occurrence of heart failure is reduced by 50% with antihypertensive therapy. Hypertensive left ventricular hypertrophy regresses with therapy and is most closely related to the degree of systolic blood pressure reduction. Diuretics have produced equal or greater reductions of left ventricular mass when compared with other drug classes. Conventional beta-blockers are less effective in reducing left ventricular hypertrophy but play a specific role in patients with established coronary artery disease or impaired left ventricular function.B.  Hypertensive Cerebrovascular Disease and DementiaH ypertension is the major predisposing cause of hemor- rhagic and ischemic stroke. Cerebrovascular complications are more closely correlated with systolic than diastolic blood pressure. The incidence of these complications is markedly reduced by antihypertensive therapy. Preceding hypertension is associated with a higher incidence of sub- sequent dementia of both vascular and Alzheimer types. Home and ambulatory blood pressure may be a better predictor of cognitive decline than office readings in older people. Effective blood pressure control reduces the risk of cognitive dysfunction developing later in life.C.  Hypertensive Kidney DiseaseCh ronic hypertension is associated with injury to vascular, glomerular, and tubulointerstitial compartments within the kidney, accounting for about 25% of end-stage kidney disease. Nephrosclerosis is particularly prevalent in Blacks, in whom susceptibility is linked to APOL1 mutations and hypertension results from kidney disease rather than causing it.D . Aortic DissectionH ypertension is a contributing factor in many patients with dissection of the aorta. Its diagnosis and treatment are discussed in Chapter 12.E.  Atherosclerotic ComplicationsMost  Americans with hypertension die of complications of atherosclerosis, but antihypertensive therapy seems to have a lesser impact on atherosclerotic complications compared with heart failure, stroke, and kidney disease. Prevention of cardiovascular outcomes related to atherosclerosis proba- bly requires control of multiple risk factors, of which hypertension is only one.Seccia TM  et al. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35:205. [PMID: 27782909] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] »Clinical FindingsThe  clinical and laboratory findings are mainly referable to involvement of the target organs: heart, brain, kidneys, eyes, and peripheral arteries.CMDT22_Ch11_p0443-p0474.indd  447 29/06/21 8:37 PMChapter 11448 CMDT 2022A.  SymptomsMild  to moderate primary (essential) hypertension is largely asymptomatic for many years. The most frequent symptom, headache, is also nonspecific. Accelerated hyper- tension is associated with somnolence, confusion, visual disturbances, and nausea and vomiting (hypertensive encephalopathy). Hypertension in patients with pheochromocytomas that secrete predominantly norepinephrine is usually sustained but may be episodic. The typical attack lasts from minutes to hours and is associated with headache, anxiety, palpitation, profuse perspiration, pallor, tremor, and nausea and vomit- ing. Blood pressure is markedly elevated, and angina or acute pulmonary edema may occur. In primary aldosteron- ism, patients may have muscular weakness, polyuria, and nocturia due to hypokalemia; hypertensive emergency is rare. Chronic hypertension often leads to left ventricular hypertrophy and diastolic dysfunction, which can present with exertional and paroxysmal nocturnal dyspnea. Cerebral involvement causes stroke due to thrombosis or hemorrhage from microaneurysms of small penetrating intracranial arteries. Hypertensive encephalopathy is probably caused by acute capillary congestion and exudation with cerebral edema and may present as posterior reversible encephalopa- thy syndrome, comprising headache, visual disturbances, altered mental state, and seizures. These symptoms usually improve rapidly with control of hypertension.B.  SignsLike  symptoms, physical findings depend on the cause of hypertension, its duration and severity, and the degree of effect on target organs. 1. Blood pressure— Blood pressure is taken in both arms and, if lower extremity pulses are diminished or delayed, in the legs to exclude coarctation of the aorta. If blood pres- sure differs between right and left arms, the higher reading should be recorded as the actual blood pressure and subcla- vian stenosis suspected in the other arm. An orthostatic drop of at least 20/10 mm Hg is often present in pheochro- mocytoma. Older patients may have falsely elevated read- ings by sphygmomanometry because of noncompressible vessels. This may be suspected in the presence of Osler sign—a palpable brachial or radial artery when the cuff is inflated above systolic pressure. Occasionally, it may be necessary to make direct measurements of intra-arterial pressure, especially in patients with apparent severe hyper- tension who do not tolerate therapy. 2. Retinas— Narrowing of arterial diameter to less than 50% of venous diameter, copper or silver wire appearance, exudates, hemorrhages, and hypertensive retinopathy are associated with a worse prognosis. The typical changes of severe hypertensive retinopathy are shown in Figure 11–2 (see Chapter 7). 3. Heart— A left ventricular heave indicates severe hyper- trophy. Aortic regurgitation may be auscultated in up to 5% of patients, and hemodynamically insignificant aortic regurgitation can be detected by Doppler echocardiogra- phy in 10–20%. A presystolic (S4) gallop due to decreasedcompliance of the left ventricle is quite common in patients in sinus rhythm. 4. Pulses— Radial-femoral delay suggests coarctation of the aorta; loss of peripheral pulses occurs due to atherosclero- sis, less commonly aortic dissection, and rarely Takayasu arteritis, all of which can involve the renal arteries.C.  Laboratory FindingsRecommended  testing includes hemoglobin; serum elec- trolytes and serum creatinine; fasting blood sugar level (hypertension is a risk factor for the development of diabe- tes, and hyperglycemia can be a presenting feature of pheo- chromocytoma); plasma lipids (necessary to calculate cardiovascular risk and as a modifiable risk factor); serum uric acid (hyperuricemia is a relative contraindication to diuretic therapy); and urinalysis.D . Electrocardiography and Chest RadiographsElectrocardiographic  criteria are highly specific but not very sensitive for left ventricular hypertrophy. The “strain” pattern of ST–T wave changes is a sign of more advanced disease and is associated with a poor prognosis. A chest radiograph is not necessary in the workup for uncompli- cated hypertension.E.  EchocardiographyThe primary  role of echocardiography should be to evalu- ate patients with clinical symptoms or signs of cardiac disease.F . Diagnostic StudiesAddi tional diagnostic studies are indicated only if the clini- cal presentation or routine tests suggest secondary or com- plicated hypertension. These may include 24-hour urine free cortisol, urine or plasma metanephrines, and plasma ▲Figure 11–2. Severe, chronic hypertensive retinopa- thy with hard exudates, increased vessel light reflexes, and sausage-shaped veins. (Used, with permission, from Richard E. Wyszynski, MD, in Knoop KJ, Stack LB, Storrow AB, Thurman RJ. The Atlas of Emergency Medicine , 4th ed. McGraw-Hill, 2016.)CMDT22_Ch11_p0443-p0474.indd  448 29/06/21 8:37 PMSYSteMIC hYperteNSION449 CMDT 2022aldostero ne and renin concentrations to screen for endo- crine causes of hypertension. Renal ultrasound will detect structural changes (such as polycystic kidneys, asymmetry, and hydronephrosis); echogenicity and reduced cortical volume are reliable indicators of advanced chronic kidney disease. Evaluation for renal artery stenosis should be undertaken in concert with subspecialist consultation.G.  SummarySince  most hypertension is essential or primary, few studies are necessary beyond those listed above. If conventional therapy is unsuccessful or if secondary hypertension is suspected, further studies and perhaps referral to a hyper- tension specialist are indicated. »Nonpharmacologic TherapyLife style modification is recommended in all patients with elevated blood pressure. A diet rich in fruits, vegeta- bles, and low-fat dairy foods and low in saturated and total fats (DASH diet) has been shown to lower blood pressure. Increased dietary fiber lowers blood pressure. For every 7 g of dietary fiber ingested, cardiovascular risk could be lowered by 9%. The effect of diet on blood pres- sure may be mediated by shifts in the microbial species in the gut, the intestinal microbiota. Hand squeezing exer- cises three times a week can lower systolic blood pressure by 6 mm Hg. The protocol comprises four repeats of 2 minutes at 30% of maximum force (using a handheld dynamometer) with 1- to 3-minute rest intervals between squeezes. The acute increase in systolic blood pressure during vigorous exercise, known as the exercise pressor response, is around 50 mm Hg in normal individuals. In hypertensive persons, the exercise pressor response is elevated to about 75 mm Hg above resting systolic blood pressure. This exaggerated response is not reduced by antihypertensive medications, even in those with other- wise controlled hypertension, and is exacerbated by increased dietary sodium intake. Additional lifestyle changes, listed in Table 11–3, can prevent or mitigate hypertension or its cardiovascular consequences.Fu J et  al. Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension. J Am Heart Assoc. 2020;9:e016804. [PMID: 32975166] Smart NA et al. An evidence-based analysis of managing hyper- tension with isometric resistance exercise—are the guidelines current? Hypertens Res. 2020;43:249. [PMID: 31758166] »Who Should Be Treated With Medications?T reatment should be offered to all persons in whom blood pressure reduction, irrespective of initial blood pressure levels, will reduce cardiovascular risk with an acceptably low rate of medication-associated adverse effects. The American College of Cardiology and the American Heart Association (ACC/ AHA), Hypertension Canada (HC), and the European Soci- ety of Hypertension and European Society of Cardiology(ESH/ESC) have developed independent guidelines for the evaluation and management of hypertension. There is broad agreement that drug treatment is necessary in those with office-based blood pressures exceeding 160/100 mm Hg, irrespective of cardiac risk. Similarly, the American, Canadian, and European guidelines agree that treatment thresholds should be lower in the presence of elevated car- diovascular risk. American guidelines stand apart in recom- mending initiation of antihypertensive pharmacotherapy in those with blood pressure of 140–159/90–99 mm Hg, even if cardiovascular risk is not elevated. By contrast, the Cana- dian guidelines suggest lifestyle modifications in this low- cardiovascular-risk group, while the European guidelines recommend initiation of pharmacotherapy only if elevated pressure in this low-risk population persists after lifestyle modification. There is no outcomes evidence that mortal- ity or risk of cardiovascular events can be reduced by treat- ing mild hypertension (140/90–160/100 mm Hg) in low-risk individuals. Table 11–4 compares these three sets of guidelines. Since evaluation of total cardiovascular risk (Table 11–5) is important in deciding who to treat with antihypertensive medications, risk calculators are essential clinical tools. The ACC has an online toolkit relevant to primary prevention (https://tools.acc.org/ascvd-risk- estimator-plus/#!/calculate/estimate/), and an associated app called ASCVD Risk Estimator Plus (downloadable at https://www.acc.org/ASCVDApp). »Goals of TreatmentT raditionally, the most widely accepted goal for blood pres- sure management has been less than 140/90 mm Hg. How- ever, observational studies suggest that there does not seem to be a blood pressure level below which decrements in cardiovascular risk taper off, and a number of randomized controlled trials have suggested that treatment to bloodTable 11–3. The impact of lifestyle modifications.Modific- ion Invnionrsuling Dcs in Blood pssu Weight loss Target BMI 18.5–24.9 5–20 mm Hg/ 10-kg loss DASH diet Fruit, vegetables, low fat dairy8–14 mm Hg Sodium intake< 100 mmol/day (< 6 g salt)2–8 mm Hg Alcohol intakeMale ≤ 2 drinks/day Female ≤ 1 drink/day4 mm Hg Exercise Aerobic 30 min/day Dynamic 90-150 min/week Isometric (hand grip 4 rep- etitions 3 times/week)5–10 mm Hg Mindfulness Meditation and breathing control5 mm Hg BMI, body mass index; DASH, Dietary Approaches to Stop Hypertension.CMDT22_Ch11_p0443-p0474.indd  449 29/06/21 8:37 PMChapter 11450 CMDT 2022pres sure targets considerably below 140 mm Hg may ben- efit certain patient groups. The SPRINT study suggests that outcomes improve in nondiabetic patients with considerably elevated cardiovascu- lar risk when treatment lowers systolic pressure to less than 120 mm Hg compared to less than 140 mm Hg. On the other hand, in the HOPE3 study of largely nondiabetic patients at somewhat lower risk than those in SPRINT, reducing blood pressure by an average of 6/3 mm Hg systolic/diastolic from a baseline of 138/82 mm Hg provided no significant out- comes benefits. Therefore, it appears that blood pressure targets should be lower in people at greater estimated cardio- vascular risk. In response to the SPRINT study, the 2018 Hypertension Canada guidelines urge prescribers to consider a blood pressure goal of less than 120/80 mm Hg in patients considered at elevated risk for cardiovascular events. The 2017 ACC/AHA guidelines take a different approach by defining a 130/80 mm Hg goal as “reasonable” in nonelevated risk patients, strengthening this to “recommended” in ele- vated risk hypertensive patients. The 2018 ESH/ESC guide- lines specify a target of less than 140 mm Hg systolic for all, and less than 130 mm Hg for most if tolerated. There is a trend toward recommending similar treatment targets in the elderly; this topic is discussed in greater detail below. Some experts note that manual office measurements of around 130/80 mm Hg are likely to approximate the lower blood pressure targets specified in the SPRINT study, which used automated office blood pressure measuring devices that have been demonstrated to read as much as 16/7 mm Hg lowerTable 11–4. Comparison of blood pressure treatment thresholds from the 2017 ACC/AHA guidelines, the 2018 Hypertension Canada guidelines, and the 2018 ESH/ESC guidelines.Guidlins 1Cdiovscul risktsold fo pmcoy (mm hg) tg (mm hg) ACC/AHA Not increased > 140/90 < 130/80 (reasonable) Hypertension Canada Not increased > 160/100 < 140/90 (< 130/80 for diabetes) ESH/ESC Not increased > 140/902All < 140/90, most < 130/80, not < 120 ACC/AHA Increased < 130/80 < 130/80 (recommended) Hypertension Canada Increased > 140 systolic3< 120 systolic ESH/ESC Increased > 130/803120–130/< 80 ACC/AHA > 65 yr Risk due to advanced age > 130/80 < 130 systolic Hypertension Canada4Increased Not specified4Not specified4ESH/ESC  > 65 yr Not increased > 140/905130–140/> 806 1In all three sets of guidelines, blood pressure values are based upon nonautomated office blood pressure readings.2 Consider drug treatment if lifestyle changes fail to control blood pressure.3 Consider drug treatment if very high risk, eg, established cardiovascular disease, especially coronary disease. Note: The > 130/80 mm Hg threshold for treatment of high-risk patients in the Canadian guidelines refers to automated blood pressure readings, which are lower than nonautomated readings.4 Recommendations for persons > 75 years are not explicitly stated in the Hypertension Canada guidelines. They removed separate g oals for the elderly but consider age > 75 years to be a risk signifier triggering an approach that many would view as overly aggres sive in the extremely old.5 The European guidelines indicate a slightly more conservative treatment threshold of > 160/90 mm Hg for those > 80 years.6 This target range is also suggested in the European guidelines for patients > 80 years. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; ESH, European Societ y of Hypertension.T able 11–5. Cardiovascular risk factors.Mjo  isk fcos Hypertension1 Cigarette smoking Obesity (BMI ≥ 30)1 Physical inactivity Dyslipidemia1 Diabetes mellitus1 Microalbuminuria or estimated GFR < 60 mL/min/1.73 m2 Age (> 55 years for men, > 65 years for women) Family history of premature cardiovascular disease (< 55 years for men, < 65 years for women) tg-ogn dmg Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart failure Brain Stroke or transient ischemic attack Chronic kidney disease Peripheral arterial disease Retinopathy1 Components of the metabolic syndrome. BMI, body mass index; GFR, glomerular filtration rate. Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560–72.CMDT22_Ch11_p0443-p0474.indd  450 29/06/21 8:37 PMSYSteMIC hYperteNSION451 CMDT 2022th an manual office readings. The 2018 Canadian guidelines acknowledge this disparity in measurement methods by specifying that automated office devices should be used in the monitoring of patients selected for the aggressive blood pres- sure goal of less than 120/80 mm Hg. Table 11–4 compares the treatment threshold and target recommendations laid out in the American, Canadian, and European guidelines. Treatment to blood pressures less than 130 mm Hg systolic seems especially important in stroke prevention. The ACCORD study examined the effect of treatment of systolic pressures to below 130–135 mm Hg in patients with diabetes; the study’s two by two factorial design addressed glycemic control as well as blood pressure con- trol. In the original analysis, the lower blood pressure treat- ment goal significantly increased the risk of serious adverse effects (with no additional gain in terms of heart, kidney, or retinal disease). There was, however, significant additional reduction in the risk of stroke, indicating that lower blood pressure targets might be justified in diabetic patients at high risk for cerebrovascular events. Post hoc analysis of the ACCORD study after 9 years of follow-up suggested that a beneficial effect of lower blood pressure in older high-risk persons (mostly on nonfatal myocardial infarctions) could be detected in the standard glycemic control group. Similarly, in the SPS3 trial in patients who have had a lacunar stroke, treating the systolic blood pressure to less than 130 mm Hg (mean systolic blood pressure of 127 mm Hg among treated versus mean systolic blood pressure 138 mm Hg among untreated patients) probably reduced the risk of recurrent stroke (and with an acceptably low rate of adverse effects from treatment). Blood pressure manage- ment in acute stroke is discussed below. »How Low To Go?Alth ough observational studies indicate that the blood pressure-risk relationship holds up at levels considerably below 120 mm Hg, there is uncertainty about whether this is true for treated blood pressure. This question was addressed in a secondary analysis of data from the ONTARGET and TRANSCEND studies in which participants with ele- vated cardiovascular risk but no history of stroke were treated with telmisartan (plus or minus ramipril) or placebo. The risk of the composite cardiovascular endpoint was lowest at a treated systolic blood pressure range between 120 mm Hg and 140 mm Hg. Increased risk was observed at blood pres- sures below and above this range. The risk of stroke was the only exception, with incremental benefit observed below a treated systolic of 120 mm Hg. With respect to diastolic blood pressure on treatment, composite risk began to increase at levels below 70 mm Hg. This suggests that the blood pressure–cardiovascular risk relationship evident in observational studies of untreated hypertension may not hold in the case of treated blood pressure and that there are grounds for a degree of caution in treating below a systolic pressure of 120 mm Hg. In seeking to simplify decision making in the treatment of hypertension, some authors have suggested that a sys- tolic blood pressure goal in the 120–130 mm Hg range would be safe and effective in high-risk patients, and a systolic blood pressure of around 130 mm Hg would bereasonable in lower-risk patients, irrespective of diastolic pressures. Diastolic blood pressure will track with systolic blood pressure; the main concern about diastolic blood pressure is that treatment will lower it too much in patients who have wider pulse pressures. However, it seems that a lower diastolic blood pressure as a consequence of treat- ment does not negate the benefits of systolic blood pressure control, even though wider pulse pressures at baseline are associated with cardiovascular mortality. »Treatment of Other Cardiovascular Risk FactorsData  from multiple studies indicate that statins should be part of the strategy to reduce overall cardiovascular risk. The HOPE3 study of persons at intermediate cardiovascu- lar risk showed that 10 mg of rosuvastatin reduced average low-density lipoprotein (LDL) cholesterol from 130 mg/dL to 90 mg/dL (3.36–2.33 mmol/L), and significantly reduced the risk of multiple cardiovascular events, including myo- cardial infarction and coronary revascularization. Low- dose aspirin (81 mg/day) is likely to be beneficial in patients older than age 50 with either target-organ damage or elevated total cardiovascular risk (greater than 20–30%). Care should be taken to ensure that blood pressure is con- trolled to the recommended levels before starting aspirin to minimize the risk of intracranial hemorrhage. Data do not support the routine use of aspirin for prophylaxis in low- risk patients, including those over 65 years of age.Böhm  M et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226. [PMID: 28390695] Ruiz-Hurtado G et al. Has the SPRINT trial introduced a new blood-pressure goal in hypertension? Nat Rev Cardiol. 2017;14:560. [PMID: 28492286] Sheppard JP et al. Benefits and harms of antihypertensive treat- ment in low-risk patients with mild hypertension. JAMA Intern Med. 2018;178:1626. [PMID: 30383082] Sobieraj P et al. Low on-treatment diastolic blood pressure and cardiovascular outcome: a post-hoc analysis using NHLBI SPRINT research materials. Sci Rep. 2019;9:13070. [PMID: 31506550] Williams B et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hyperten- sion (ESH) and the European Society of Cardiology (ESC). Blood Press. 2018;27:314. [PMID: 30380928]DR UG THERAPY: CURRENT ANTIHYPERTENSIVE AGENTSTh ere are many classes of antihypertensive drugs of which six (ACE inhibitors, ARBs, renin inhibitors, calcium channel blockers, diuretics, and beta-blockers) are suitable for initial therapy based on efficacy and tolerability. The specific classes of antihypertensive medications are discussed below, and guidelines for the choice of initial medications are offered.A.  Angiotensin-Converting Enzyme InhibitorsACE  inhibitors are commonly used as the initial medi- cation in mild to moderate hypertension (Table 11–6).CMDT22_Ch11_p0443-p0474.indd  451 29/06/21 8:37 PMChapter 11452 CMDT 2022Table 11–6. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns rnin Inibios Aliskiren Tekturna 150 mg once daily 150–300 mg once daily $7.48/150 mg $224.41 Angioedema, hypotension, hyperkalemia. Contraindicated in pregnancy.Probably metabolized by CYP3A4. Absorption is inhibited by high- fat meal.Aliskiren and HCTZ Tekturna HCT 150 mg/12.5 mg once daily150 mg/12.5 mg–300 mg/ 25 mg once daily$9.78/150 mg/ 12.5 mg$293.54 aCe Inibios Benazepril Lotensin 10 mg once daily 5–40 mg in 1 or 2 doses $0.95/20 mg $28.50 Cough, hypotension, dizziness, hyperkalemia, kidney dysfunction, angioedema; taste alteration and rash (may be more frequent with captopril); rarely, proteinuria, blood dyscrasia. Contraindicated in pregnancy.More fosinopril is excreted by the liver in patients with kidney dys- function (dose reduction may or may not be necessary). Captopril and lisinopril are active without metabolism. Captopril, enalapril, lisinopril, and quinapril are approved for heart failure.Benazepril and HCTZ Lotensin HCT 5 mg/6.25 mg once daily5 mg/6.25 mg–20 mg/ 25 mg$1.07/any dose $32.21 Benazepril and amlodipineLotrel 10 mg/2.5 mg once daily10 mg/2.5 mg–40 mg/ 10 mg$3.32/20 mg/ 10 mg$99.60 Captopril Capoten 25 mg twice daily 50–450 mg in 2 or 3 doses$0.65/25 mg $19.50 Captopril and HCTZ Capozide 25 mg/15 mg twice daily25 mg/15 mg–50 mg/ 25 mg$2.85/25 mg/ 15 mg$171.00 Enalapril Vasotec 5 mg once daily 5–40 mg in 1 or 2 doses $0.95/20 mg $28.50 Enalapril and HCTZ Vaseretic 5 mg/12.5 mg once daily5 mg/12.5 mg–10 mg/ 25 mg$1.19/10 mg/ 25 mg$35.70 Fosinopril Monopril 10 mg once daily 10–80 mg in 1 or 2 doses $0.29/20 mg $8.70 Fosinopril and HCTZ Monopril-HCT 10 mg/12.5 mg once daily10 mg/12.5 mg–20 mg/ 12.5 mg$1.48/any dose $44.40 Lisinopril Prinivil, Zestril 5–10 mg once daily 5–40 mg once daily $0.08/20 mg $2.45 Lisinopril and HCTZ Prinzide or Zestoretic10 mg/12.5 mg once daily10 mg/12.5 mg–20 mg/ 12.5 mg$0.14/20 mg/ 12.5 mg$4.20 Moexipril Univasc 7.5 mg once daily 7.5–30 mg in 1 or 2 doses $1.39/7.5 mg $41.70 Moexipril and HCTZ Uniretic 7.5 mg/12.5 mg once daily7.5 mg/12.5 mg–15 mg/ 25 mg$1.70/15 mg/ 12.5 mg$51.00CMDT22_Ch11_p0443-p0474.indd  452 29/06/21 8:37 PMSYSteMIC hYperteNSION453 CMDT 2022Perindopril Aceon 4 mg once daily 4–16 mg in 1 or 2 doses $2.80/8 mg $84.00 Perindopril and amlodipinePrestalia 3.5 mg/2.5 mg once daily3.5 mg/2.5–14 mg/10 mg once daily$6.81/7 mg/5 mg $204.30 Quinapril Accupril 10 mg once daily 10–80 mg in 1 or 2 doses $1.22/20 mg $36.60 Quinapril and HCTZ Accuretic 10 mg/12.5 mg once daily10 mg/12.5 mg–20 mg/ 25 mg$1.22/20 mg/ 12.5 mg$36.60 Ramipril Altace 2.5 mg once daily 2.5–20 mg in 1 or 2 doses $1.80/5 mg $54.00 Trandolapril Mavik 1 mg once daily 1–8 mg once daily $1.21/4 mg $36.30 Trandolapril and verapamilTarka 2 mg/180 mg ER once daily2 mg/180 mg ER–8 mg/480 mg ER$5.29/any dose $158.70 angionsin II rco Blocks Azilsartan Edarbi 40 mg once daily 40–80 mg once daily $8.80/80 mg $264.00 Hyperkalemia, kidney dysfunction, rare angioedema. Combinations have additional side effects. Contraindicated in pregnancy.Losartan has a flat dose-response curve. Valsartan and irbesartan have wider dose-response ranges and longer durations of action. Addition of low-dose diuretic (separately or as combination pills) increases the response.Azilsartan and chlorthalidoneEdarbychlor 40 mg/12.5 mg once daily40 mg/12.5–40 mg/ 25 mg once daily$8.30/any dose $249.14 Candesartan cilexitil Atacand 16 mg once daily 8–32 mg once daily $3.06/16 mg $91.80 Candesartan cilexitil and HCTZAtacand HCT 16 mg/12.5 mg once daily32 mg/12.5 mg once daily$4.72/16 mg/ 12.5 mg$141.60 Eprosartan Teveten 600 mg once daily 400–800 mg in 1–2 doses$3.43/600 mg $102.90 Irbesartan Avapro 150 mg once daily 150–300 mg once daily $0.46/150 mg $13.80 Irbesartan and HCTZ Avalide 150 mg/12.5 mg once daily150–300 mg irbesartan once daily$0.67/150 mg/ 12.5 mg$20.10 Losartan and HCTZ Hyzaar 50 mg/12.5 mg once daily50 mg/12.5 mg–100 mg/ 25 mg tablets once daily$2.47/50 mg/ 12.5 mg/tablet$74.10 Olmesartan Benicar 20 mg once daily 20–40 mg once daily $6.28/20 mg $188.40 Olmesartan and HCTZBenicar HCT 20 mg/12.5 mg once daily20 mg/12.5 mg–40 mg/ 25 mg once daily$6.28/20 mg/ 12.5 mg$188.40 Olmesartan and amlodipineAzor 20 mg/5 mg once daily20 mg/5 mg–40 mg/ 10 mg$3.03/20 mg/5 mg $90.90 Olmesartan and amlodipine and HCTZTribenzor 20 mg/5 mg/ 12.5 mg once daily20 mg/5 mg/12.5 mg– 40 mg/10 mg/25 mg once daily$4.54/20 mg/ 5 mg/12.5 mg$136.20 Telmisartan Micardis 40 mg once daily 20–80 mg once daily $4.34/40 mg $130.20 (continued )CMDT22_Ch11_p0443-p0474.indd  453 29/06/21 8:37 PMChapter 11454 CMDT 2022T elmisartan and HCTZMicardis HCT 40 mg/12.5 mg once daily40 mg/12.5 mg–80 mg/ 25 mg once daily$4.83/40 mg/ 12.5 mg$144.90 Telmisartan and amlodipineTwynsta 40 mg/5 mg once daily40 mg/5 mg–80 mg/ 10 mg once daily$5.20/any dose $156.00 Valsartan Diovan 80 mg once daily 80–320 mg once daily $2.09/160 mg $62.70 Valsartan and HCTZ Diovan HCT 80 mg/12.5 mg once daily80–320 mg valsartan once daily$4.27/160 mg/ 12.5 mg$128.10 Valsartan and amlodipineExforge 160 mg/5 mg once daily160 mg/5 mg–320 mg/ 10 mg once daily$1.71/160 mg/ 10 mg$51.30 O Combinion poducs Amlodipine and val- sartan and HCTZExforge HCT 5 mg/160 mg/ 12.5 mg once daily10 mg/320 mg/25 mg up to once daily$5.70/160 mg valsartan$171.001 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; ER, extended release; HCTZ, hydrochlorothiazide.Table 11–6. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns angionsin II rco Blocks (con.)(continued)CMDT22_Ch11_p0443-p0474.indd  454 29/06/21 8:37 PMSYSteMIC hYperteNSION455 CMDT 2022Their  primary mode of action is inhibition of the RAAS, but they also inhibit bradykinin degradation, stimulate the syn- thesis of vasodilating prostaglandins, and can reduce sym- pathetic nervous system activity. ACE inhibitors appear to be more effective in younger White patients. They are rela- tively less effective in Blacks and older persons and in pre- dominantly systolic hypertension. Although as single therapy they achieve adequate antihypertensive control in only about 40–50% of patients, the combination of an ACE inhibitor and a diuretic or calcium channel blocker is potent. ACE inhibitors are the agents of choice in persons with type 1 diabetes with frank proteinuria or evidence of kidney dysfunction because they delay the progression to end-stage renal disease. Many authorities have expanded this indication to include persons with type 1 and type 2 diabetes mellitus with microalbuminuria who do not meet the usual criteria for antihypertensive therapy. ACE inhibitors may also delay the progression of nondiabetic kidney disease. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that the ACE inhibitor ramipril reduced the number of car- diovascular deaths, nonfatal myocardial infarctions, and nonfatal strokes and also reduced the incidence of new-onset heart failure, kidney dysfunction, and new-onset diabetes in a population of patients at high risk for vascular events. Although this was not specifically a hypertensive population, the benefits were associated with a modest reduction in blood pressure, and the results inferentially support the use of ACE inhibitors in similar hypertensive patients. ACE inhibi- tors are a drug of choice (usually in conjunction with a diuretic and a beta-blocker) in patients with heart failure with reduced ejection fraction and are indicated also in asymp- tomatic patients with reduced ejection fraction. How to initiate therapy— A baseline metabolic panel should be drawn prior to starting medications that inter- fere with the RAAS, repeated 1–2 weeks after initiation of therapy to evaluate changes in creatinine and potassium. Minor dose adjustments of these medications rarely trigger significant shifts in these values. Side effects— An advantage of the ACE inhibitors is their relative freedom from troublesome side effects (Table 11–6). Severe hypotension can occur in patients with bilateral renal artery stenosis; significant increases in creatinine may ensue but are usually reversible with the discontinuation of the ACE inhibitor. Hyperkalemia may develop in patients with kidney disease and type IV renal tubular acidosis (commonly seen in patients with diabetes) and in older adults. A chronic dry cough is common, seen in 10% of patients or more, and may require stopping the drug. Skin rashes are observed with any ACE inhibitor. Angioedema is an uncommon but potentially dangerous side effect of all agents of this class because of their inhibi- tion of kininase. Exposure of the fetus to ACE inhibitors during the second and third trimesters of pregnancy has been associated with a variety of defects due to hypoten- sion and reduced renal blood flow.B.  Angiotensin II Receptor BlockersARB s can improve cardiovascular outcomes in patients with hypertension as well as in patients with related conditions, such as heart failure and type 2 diabetes with nephropathy.ARBs have not been compared with ACE inhibitors in ran- domized controlled trials in patients with hypertension, but two trials comparing losartan with captopril in heart failure and post–myocardial infarction left ventricular dysfunction showed trends toward worse outcomes in the losartan group. By contrast, valsartan seems as effective as ACE inhibitors in these settings. Within group heterogeneity of antihyperten- sive potency and duration of action might explain such observations. The Losartan Intervention for Endpoints (LIFE) trial in nearly 9000 hypertensive patients with elec- trocardiographic evidence of left ventricular hypertrophy— comparing losartan with the beta-blocker atenolol as initial therapy—demonstrated a significant reduction in stroke with losartan. Of note is that in diabetic patients, death and myocardial infarction were also reduced, and there was a lower occurrence of new-onset diabetes. In a subgroup analysis from the LIFE trial, atenolol appeared to be superior to losartan in Blacks, while the opposite was the case in non- Blacks. A similar lack of efficacy of lisinopril compared to diuretics and calcium channel blockers was observed in Blacks in the Antihypertensive and Lipid-Lowering Treat- ment to Prevent Heart Attach Trial (ALLHAT), suggesting that ACE inhibitors and ARBs may not be the preferred agents in Black patients. In the treatment of hypertension, combination therapy with an ACE inhibitor and an ARB is not advised because it generally offers no advantage over monotherapy at maximum dose with addition of a comple- mentary class where necessary. Side effects— Unlike ACE inhibitors, the ARBs rarely cause cough and are less likely to be associated with skin rashes or angioedema (Table 11–6). However, as seen with ACE inhibitors, hyperkalemia can be a problem, and patients with bilateral renal artery stenosis may exhibit hypotension and worsened kidney function. Olmesartan has been linked to a sprue-like syndrome, presenting with abdominal pain, weight loss, and nausea, which subsides upon drug discon- tinuation. There is evidence from an observational study suggesting that ARBs and ACE inhibitors are less likely to be associated with depression than calcium channel block- ers and beta-blockers.C.  Renin InhibitorsSi nce renin cleavage of angiotensinogen is the rate-limiting step in the renin-angiotensin cascade, the most efficient inac- tivation of this system would be expected with renin inhibi- tion. Conventional ACE inhibitors and ARBs probably offer incomplete blockade, even in combination. Aliskiren, a renin inhibitor, binds the proteolytic site of renin, thereby prevent- ing cleavage of angiotensinogen. Aliskiren effectively lowers blood pressure, reduces albuminuria, and limits left ventricu- lar hypertrophy, but it has yet to be established as a first-line drug based on outcomes data. The combination of aliskiren with ACE inhibitors or ARBs in persons with type 2 diabetes mellitus offers no advantage and might even increase the risk of adverse cardiac or renal consequences.D . Calcium Channel Blocking AgentsThese  agents act by causing peripheral vasodilation but with less reflex tachycardia and fluid retention than otherCMDT22_Ch11_p0443-p0474.indd  455 29/06/21 8:37 PMChapter 11456 CMDT 2022vasodilators.  They are effective as single-drug therapy in approximately 60% of patients in all demographic groups and all grades of hypertension (Table 11–7). For these rea- sons, they may be preferable to beta-blockers and ACE inhibitors in Blacks and older persons. Verapamil and dil- tiazem should be combined cautiously with beta-blockers because of their potential for depressing atrioventricular (AV) conduction and sinus node automaticity as well as contractility. Calcium channel blockers are equivalent to ACE inhibi- tors and thiazide diuretics in prevention of coronary heart disease, major cardiovascular events, cardiovascular death, and total mortality. A protective effect against stroke with calcium channel blockers is well established, and in two trials (ALLHAT and the Systolic Hypertension in Europe trial), these agents appeared to be more effective than diuretic-based therapy. Side effects— The most common side effects of calcium channel blockers are headache, peripheral edema, brady- cardia, and constipation (especially with verapamil in older adults) (Table 11–7). The dihydropyridine agents— nifedipine, nicardipine, isradipine, felodipine, nisoldipine, and amlodipine—are more likely to produce symptoms of vasodilation, such as headache, flushing, palpitations, and peripheral edema. Edema is minimized by coadministra- tion of an ACE inhibitor or ARB. Calcium channel block- ers have negative inotropic effects and should be used cautiously in patients with cardiac dysfunction. Amlodip- ine is the only calcium channel blocker with established safety in patients with severe heart failure.E.  DiureticsThia zide diuretics (Table 11–8) are the antihypertensives that have been most extensively studied and most consis- tently effective in clinical trials. They lower blood pressure initially by decreasing plasma volume, but during long-term therapy, their major hemodynamic effect is reduction of peripheral vascular resistance. Most of the antihypertensive effect of these agents is achieved at lower dosages (typically, 12.5 mg of hydrochlorothiazide or equivalent), but their biochemical and metabolic effects are dose related. Chlortha- lidone has the advantage of better 24-hour blood pressure control than hydrochlorothiazide in clinical trials. Thiazides may be used at higher doses if plasma potassium is above 4.5 mmol/L. The loop diuretics (such as furosemide) may lead to electrolyte and volume depletion more readily than the thiazides and have short durations of action. Because of these adverse effects, loop diuretics should be reserved for use in patients with kidney dysfunction (serum creatinine greater than 2.5 mg/dL [208.3 mcmol/L]; estimated glo- merular filtration rate [eGFR] less than 30 mL/min/1.73 m2) in which case they are more effective than thiazides. Relative to beta-blockers and ACE inhibitors, diuretics are more potent in Blacks, older individuals, the obese, and other subgroups with increased plasma volume or low plasma renin activity (or both). They are relatively more effective in smokers than in nonsmokers. Long-term thiazide adminis- tration also mitigates the loss of bone mineral content in older women at risk for osteoporosis.Overall, diuretics administered alone control blood pressure in 50% of patients with mild to moderate hyper- tension and can be used effectively in combination with all other agents. They are also useful for lowering isolated or predominantly systolic hypertension. Side effects— The adverse effects of diuretics relate primar- ily to the metabolic changes listed in Table 11–8. Erectile dysfunction, skin rashes, and photosensitivity are less fre- quent. Hypokalemia has been a concern but is uncommon at the recommended dosages. The risk can be minimized by limiting dietary salt or increasing dietary potassium; potassium replacement is not usually required to maintain serum K+at greater than 3.5 mmol/L. Higher serum K+ levels are prudent in patients at special risk from intracel- lular potassium depletion, such as those taking digoxin or with a history of ventricular arrhythmias in which case a potassium-sparing agent could be used. Compared with ACE inhibitors and ARBs, diuretic therapy is associated with a slightly higher incidence of mild new-onset diabe- tes. Diuretics also increase serum uric acid and may pre- cipitate gout. Increases in blood glucose, triglycerides, and LDL cholesterol may occur but are relatively minor during long-term low-dose therapy. The potential for worsening of diabetes is outweighed by the advantages of blood pres- sure control, and diuretics should not be withheld from diabetic patients.F . Aldosterone Receptor AntagonistsSp ironolactone and eplerenone are natriuretic in sodium- retaining states, such as heart failure and cirrhosis, but only very weakly so in hypertension. These drugs have reemerged in the treatment of hypertension, particularly in resistant patients and are helpful additions to most other antihyper- tensive medications. Consistent with the increasingly appreciated importance of aldosterone in essential hyper- tension, the aldosterone receptor blockers are effective at lowering blood pressure in all hypertensive patients regard- less of renin level and are also effective in Blacks. Aldoste- rone plays a central role in target-organ damage, including the development of ventricular and vascular hypertrophy and renal fibrosis. Aldosterone receptor antagonists amelio- rate these consequences of hypertension, to some extent independently of effects on blood pressure. Side effects— Spironolactone can cause breast pain and gyne- comastia in men through activity at the progesterone receptor, an effect not seen with the more specific eplerenone. Hyper- kalemia is a problem with both drugs, chiefly in patients with chronic kidney disease. Hyperkalemia is more likely if the pretreatment plasma potassium exceeds 4.5 mmol/L.G.  Beta-Adrenergic Blocking AgentsT hese drugs are effective in hypertension because they decrease the heart rate and cardiac output. The beta-blockers also decrease renin release and are more efficacious in populations with elevated plasma renin activity, such as younger White patients. They neutralize the reflex tachycar- dia caused by vasodilators and are especially useful in patients with associated conditions that benefit from the cardioprotective effects of these agents.CMDT22_Ch11_p0443-p0474.indd  456 29/06/21 8:37 PMSYSteMIC hYperteNSION457 CMDT 2022Table 11–7. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Nondiydoyidin agns Diltiazem Cardizem SR 90 mg twice daily 180–360 mg in 2 doses$283.20 (120 mg twice daily)++ ↓↓  ↓↓ Edema, headache, bradycardia, bloating and constipation, dizziness, AV block, heart failure, urinary frequency.Also approved for angina. Cardizem CD 180 mg ER once daily180–360 mg ER once daily$46.80 (240 mg once daily) Cartia XT 180 or 240 mg ER once daily180–480 mg ER once daily$46.80 (240 mg once daily) Dilacor XR 180 or 240 mg ER once daily180–540 mg ER once daily$39.00 (240 mg once daily) Dilt-CD 180 or 240 mg ER once daily180–480 mg ER once daily$46.80 (240 mg once daily) Diltia XT 180 or 240 mg ER once daily180–540 mg ER once daily$46.80 (240 mg once daily) Taztia XT 120 or 180 mg ER once daily120–540 mg ER once daily$53.40 (240 mg once daily) Tiazac 120 or 240 mg ER once daily120–540 mg ER once daily$53.40 (240 mg once daily) Verapamil Calan 80 mg three times daily80–480 mg in 3 divided doses$35.10 (80 mg three times daily)++ ↓↓↓  ↓↓↓ Same as diltiazem but more likely to cause constipation and heart failure.Also approved for angina and arrhythmias. Calan SR 180 mg ER once daily180–480 mg ER in 1 or 2 doses$36.60 (240 mg once daily) Verelan 120 or 240 mg ER once daily240–480 mg ER once daily$68.70 (240 mg once daily) Verelan PM 100 or 200 mg ER once daily100–400 mg ER once daily$75.90 (200 mg once daily) (continued )CMDT22_Ch11_p0443-p0474.indd  457 29/06/21 8:37 PMChapter 11458 CMDT 2022Table 11–7. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Diydoyidins Amlodipine Norvasc 2.5 mg once daily 2.5–10 mg once daily$3.00 (10 mg once daily)+++ ↓/0 ↓/0 Edema, dizziness, palpitations, flushing, headache, hypoten- sion, tachycardia, bloating and consti- pation, urinary frequency.Amlodipine, nicar- dipine, and nife- dipine also approved for angina. Amlodipine and atorvastatinCaduet 2.5 mg/10 mg once daily10 mg/80 mg once daily$281.10 (10 mg/ 40 mg daily)+++ ↓/0 ↓/0 Edema (amlodipine), myopathy and hepa- totoxicity (atorvastatin). Felodipine Plendil 5 mg ER once daily 5–10 mg ER once daily$81.60 (10 mg ER daily)+++ ↓/0 ↓/0 Isradipine DynaCirc 2.5 mg twice daily 2.5–5 mg twice daily$120.00 (5 mg twice daily)+++ ↓/0 ↓ Nicardipine Cardene 20 mg three times daily20–40 mg three times daily$52.20 (20 mg three times daily)+++ ↓/0 ↓ Nifedipine Adalat CC 30 mg ER once daily 30–90 mg ER once daily$67.50/60 mg daily +++ ↓  ↓↓ Procardia XL 30 or 60 mg ER once daily30–120 mg ER once daily$60.30/60 mg daily Nisoldipine Sular 17 mg daily 17–34 mg daily $251.70 (34 mg once daily)+++ ↓/0 ↓1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. AV, atrioventricular; ER, extended release; GI, gastrointestinal.(continued)CMDT22_Ch11_p0443-p0474.indd  458 29/06/21 8:37 PMSYSteMIC hYperteNSION459 CMDT 2022Table 11–8. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns tizids nd rld Diuics Hydrochloro- thiazide (HCTZ)Esidrix, Microzide12.5 or 25 mg once daily12.5–50 mg once daily$0.08/25 mg $2.40 ↓K+,↓Mg2+,↑Ca2+,↓Na+, ↑uric acid, ↑glucose, ↑LDL cholesterol, ↑triglycerides; rash, erectile dysfunction.Low dosages effective in many patients with- out associated metabolic abnormalities Chlorthalidone Thalitone 12.5 or 25 mg once daily12.5–50 mg once daily$1.21/25 mg $36.30  Better 24-hour blood pressure control than HCTZ because of longer half-life Metolazone Zaroxolyn 1.25 or 2.5 mg once daily1.25–5 mg once daily$1.51/5 mg $45.30  More effective with concurrent kidney disease Indapamide Lozol 2.5 mg once daily2.5–5 mg once daily$0.83/2.5 mg $24.90  Does not alter serum lipid levels Bendroflume- thiazideAprinox Neo-Naclex2.5 mg once daily— — —  Not available in United States Loo Diuics Furosemide Lasix 20 mg twice daily40–320 mg in 2 or 3 doses$0.16/40 mg $9.60 Same as thiazides, but with higher risk of excessive diuresis and electrolyte imbalance. Increases calcium excretion.Short duration of action a disadvantage; should be reserved for patients with kidney disease or fluid retention. Poor antihypertensive. Ethacrynic acid Edecrin 50 mg once daily50–100 mg once or twice daily$23.95/25 mg $1437.00 Bumetanide (generic) 0.25 mg twice daily0.5–10 mg in 2 or 3 doses$0.54/1 mg $32.40 Torsemide Demadex 5 mg once daily5–10 mg once daily$0.70/10 mg $21.00  Effective blood pressure medication at low dosage. (continued )CMDT22_Ch11_p0443-p0474.indd  459 29/06/21 8:37 PMChapter 11460 CMDT 2022Table 11–8. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns aldoson rco Blocks Spironolactone Aldactone 12.5 or 25 mg once daily12.5–100 mg once daily$0.19/25 mg $5.70 Hyperkalemia, metabolic acidosis, gynecomastia.Can be useful add-on therapy in patients with refractory hypertension. Amiloride (generic) 5 mg once daily5–10 mg once daily$1.25/5 mg $37.50 Eplerenone Inspra 25 mg once daily25–100 mg once daily$4.10/25 mg $123.00 Combinion poducs HCTZ and triamtereneDyazide, Maxzide-25 (25/37.5 mg)1 tab once daily1 or 2 tabs once daily$0.27 $8.10 Same as thiazides plus GI disturbances, hyperkalemia rather than hypokalemia, headache; triamterene can cause kidney stones and kidney dysfunction; spirono- lactone causes gynecomastia. Hyperkale- mia can occur if this combination is used in patients with advanced kidney disease or those taking ACE inhibitors.Use should be limited to patients with demonstrable need for a potassium- sparing agent. HCTZ and amiloride(generic) (50/5 mg)½ tab once daily1 or 2 tabs once daily$1.16 $34.80 HCTZ and spironolac- toneAldactazide (25/25 mg; 50/50 mg)1 tab (25/25 mg) once daily1–4 tabs once daily$1.24/ (25/25 mg)$37.201 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; GI, gastrointestinal; LDL, low-density lipoprotein.(continued)CMDT22_Ch11_p0443-p0474.indd  460 29/06/21 8:37 PMSYSteMIC hYperteNSION461 CMDT 2022Th ese include individuals with angina pectoris, previous myo- cardial infarction, and stable heart failure as well as those with migraine headaches and somatic manifestations of anxiety. Although all beta-blockers appear to be similar in anti- hypertensive potency, they differ in a number of pharma- cologic properties (these differences are summarized in Table 11–9), including specificity to the cardiac beta- 1-receptors (cardioselectivity) and whether they also block the beta-2-receptors in the bronchi and vasculature ; at higher dosages, however, all agents are nonselective. The beta-blockers also differ in their pharmacokinetics, lipid solubility—which determines whether they cross the blood- brain barrier predisposing to central nervous system side effects—and route of metabolism. Metoprolol reduces mor- tality and morbidity in patients with chronic stable heart failure with reduced ejection fraction (see Chapter 10). Carvedilol and nebivolol maintain cardiac output and are beneficial in patients with left ventricular systolic dysfunc- tion. Carvedilol and nebivolol may reduce peripheral vas- cular resistance by concomitant alpha-blockade (carvedilol) and increased nitric oxide release (nebivolol). Because of the lack of efficacy in primary prevention of myocardial infarction and inferiority compared with other drugs in prevention of stroke and left ventricular hypertrophy, tra- ditional beta-blockers should not be used as first-line agents in the treatment of hypertension without specific compelling indications (such as active coronary artery disease). Vasodilating beta-blockers may emerge as alter- native first-line antihypertensives, but this possibility has yet to be rigorously tested in outcome studies. Side effects— The side effects of beta-blockers include inducing or exacerbating bronchospasm in predisposed patients; sinus node dysfunction and AV conduction depres- sion (resulting in bradycardia or AV block); nasal conges- tion; Raynaud phenomenon; and central nervous system symptoms with nightmares, excitement, depression, and confusion. Fatigue, lethargy, and erectile dysfunction may occur. The traditional beta-blockers (but not the vasodilator beta-blockers carvedilol and nebivolol) have an adverse effect on lipids and glucose metabolism. Beta-blockers are used cautiously in patients with type 1 diabetes, since they can mask the symptoms of hypoglycemia and prolong these episodes by inhibiting gluconeogenesis. These drugs should also be used with caution in patients with advanced periph- eral vascular disease associated with rest pain or nonhealing ulcers, but they are generally well tolerated in patients with mild claudication. Nebivolol can be safely used in patients with stage II claudication (claudication at 200 m). In treatment of pheochromocytoma, beta-blockers should not be administered until alpha-blockade (eg, phentolamine) has been established . Otherwise, blockade of vasodilatory beta-2-adrenergic receptors will allow unopposed vasocon- strictor alpha-adrenergic receptor activation with worsening of hypertension. For the same reason, beta-blockers should not be used to treat hypertension arising from cocaine use . Great care should be exercised if the decision is made, in the absence of compelling indications, to remove beta- blockers from the treatment regimen because abrupt with- drawal can precipitate acute coronary events and severe increases in blood pressure.H. Alpha-Adrenoceptor AntagonistsPrazosin,  terazosin, and doxazosin (Table 11–10) block postsynaptic alpha-receptors, relax smooth muscle, and reduce blood pressure by lowering peripheral vascular resistance. These agents are effective as single-drug therapy in some individuals, but tachyphylaxis may appear during long-term therapy. Unlike beta-blockers and diuretics, alpha-blockers have no adverse effect on serum lipid levels. In fact, alpha-blockers increase HDL cholesterol while reducing total cholesterol; whether this is beneficial in the long term has not been established. Side effects— Side effects are relatively common (Table 11–10). These include marked hypotension after the first dose which, therefore, should be small and given at bedtime. Post-dosing palpitations, headache, and nervous- ness may continue to occur during long-term therapy; these symptoms may be less frequent or severe with doxa- zosin because of its more gradual onset of action. In ALL- HAT, persons receiving doxazosin as initial therapy had a significant increase in heart failure hospitalizations and a higher incidence of stroke relative to those receiving diuret- ics, prompting discontinuation of this arm of the study. Cata- ractectomy in patients exposed to alpha-blockers can be complicated by the floppy iris syndrome, even after discon- tinuation of the drug, so the ophthalmologist should be alerted that the patient has been taking the drug prior to surgery. To summarize, alpha-blockers should generally not be used as initial agents to treat hypertension—except perhaps in men with symptomatic prostatism or nightmares linked to posttraumatic stress disorder.I.  Drugs With Central Sympatholytic ActionMet hyldopa, clonidine, guanabenz, and guanfacine (Table 11–10) lower blood pressure by stimulating alpha- adrenergic receptors in the central nervous system, thus reducing efferent peripheral sympathetic outflow. There is considerable experience with methyldopa in pregnant women, and it is still used for this population. Clonidine is available in patches, which may have particular value in noncompliant patients. All of these central sympatholytic agents are effective as single therapy in some patients, but they are usually used as second- or third-line agents because of the high frequency of drug intolerance. Side effects— Side effects include sedation, fatigue, dry mouth, postural hypotension, and erectile dysfunction. An important concern is rebound hypertension following withdrawal. Methyldopa also causes hepatitis and hemo- lytic anemia and should be restricted to individuals who have already tolerated long-term therapy.J.  Peripheral Sympathetic InhibitorsTh ese agents are usually used only in refractory hypertension. Reserpine remains a cost-effective antihypertensive agent (Table 11–10). Its reputation for inducing mental depres- sion and its other side effects—sedation, nasal stuffiness, sleep disturbances, and peptic ulcers—has made it unpop- ular, though these problems are uncommon at low dosages.CMDT22_Ch11_p0443-p0474.indd  461 29/06/21 8:37 PMChapter 11462 CMDT 2022Table 11–9. Antihypertensive drugs: beta-adrenergic blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos  UniCos of 30 Dys of tmn (Bsd on avg Dosg)1Scil pois Commns5B-1 Slciviy2ISa3MSa4Liid Solubiliyrnl vs hic eliminion Acebutolol Sectral 400 mg once daily200–1200 mg in 1 or 2 doses$1.34/400 mg $40.20 + + + + H > R Positive ANA; rare LE syndrome; also indicated for arrhythmias. Doses > 800 mg have beta-1 and beta-2 effects. Atenolol Tenormin 25 mg once daily25–100 mg once daily$0.79/50 mg $23.70 + 0 0 0 R Also indicated for angina and post-MI. Doses > 100 mg have beta-1 and beta-2 effects. Atenolol/ chlorthalidoneTenoretic 50 mg/25 mg once daily50 mg/25 mg– 100 mg/25 mg once daily$1.88/50 mg/ 25 mg$56.40 + 0 0 0 R Betaxolol Kerlone 10 mg once daily10–40 mg once daily$0.78/10 mg $23.40 + 0 0 + H > R Bisoprolol Zebeta 5 mg once daily5–20 mg once daily$1.22/10 mg $36.60 + 0 0 0 R = H Also effective for heart failure. Bisoprolol and HCTZZiac 2.5 mg/ 6.25 mg once daily2.5 mg/6.25 mg– 10 mg/6.25 mg once daily$1.14/2.5/ 6.25 mg$34.20 + 0 0 0 R = H Low-dose combination approved for initial therapy. Carvedilol Coreg Coreg CR6.25 mg twice daily 20 mg ER once daily12.5–50 mg in 2 doses 20–80 mg ER once daily$0.09/25 mg $9.91/any tablet$5.40 (25 mg twice a day) $297.300 0 0 +++ H > R Alpha:beta blocking activity 1:9; may cause ortho- static symptoms; effec- tive for heart failure. Nitric oxide potentiating vasodilatory activity. Labetalol Trandate 100 mg twice daily200–2400 mg in 2 doses$0.39/200 mg $23.40 0 0/+ 0 ++ H Alpha:beta blocking activity 1:3; more orthostatic hypotension, fever, hepatotoxicity.CMDT22_Ch11_p0443-p0474.indd  462 29/06/21 8:37 PMSYSteMIC hYperteNSION463 CMDT 2022Metoprolol Lopressor Toprol-XL (SR prepara- tion)50 mg twice daily 25 mg once daily50–200 mg twice daily 25–400 mg once daily$0.03/50 mg $1.50/100 mg$1.80 $45.00+ 0 + +++ H Also indicated for angina and post-MI. Approved for heart failure. Doses > 100 mg have beta-1 and beta-2 effects. Metoprolol and HCTZLopressor HCT50 mg/ 12.5 mg twice daily50 mg/25 mg– 200 mg/50 mg$1.77/100 mg/ 25 mg$106.20 + 0 + +++ H Nadolol Corgard 20 mg once daily20–320 mg once daily$3.96/40 mg $118.80 0 0 0 0 R Nadolol and bendroflumeth- azideCorzide 40 mg/5 mg once daily40 mg/5 mg– 80 mg/5 mg once daily6.14/80 mg/ 5 mg$184.20 Nebivolol Bystolic 5 mg once daily40 mg once daily $6.32/5 mg $189.60 + 0 0 ++ H Nitric oxide potentiating vasodilatory activity. Pindolol Visken 5 mg twice daily10–60 mg in 2 doses$1.10/5 mg $66.00 0 ++ + + H > R In adults, 35% renal clearance. Propranolol Inderal Inderal LA InnoPran XL20 mg twice daily 80 mg ER once daily 80 mg ER once nightly40–640 mg in 2 doses 120–640 mg ER once daily 80–120 mg ER once nightly$0.41/40 mg $2.98/120 mg $30.20/ 120 mg$24.60 $89.40 $906.000 0 ++ +++ H Also indicated for angina and post-MI. Propranolol and HCTZ(generic) 40 mg/25 mg twice daily80 mg/25 mg twice daily$1.41/80 mg/ 25 mg$84.60 0 0 ++ +++ H Timolol (generic) 5 mg twice daily10–60 mg in 2 doses$1.70/10 mg $102.00 0 0 0 ++ H > R Also indicated for post-MI; 80% hepatic clearance.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.2 Agents with beta-1 selectivity are less likely to precipitate bronchospasm and decrease peripheral blood flow in low doses, but selectivity is only relative.3 Agents with ISA cause less resting bradycardia and lipid changes.4 MSA generally occurs at concentrations greater than those necessary for beta-adrenergic blockade. The clinical importance of MS A by beta-blockers has not been defined.5 Adverse effects of all beta-blockers: bronchospasm, fatigue, sleep disturbance and nightmares, bradycardia and atrioventricular block, worsening of heart failure, cold extremities, gastrointestinal disturbances, erectile dysfunction, ↑triglycerides, ↓high-density lipoprotein cholesterol, rare blood dyscrasias. ANA, antinuclear antibody; ER, extended release; HCTZ, hydrochlorothiazide; ISA, intrinsic sympathomimetic activity; LE, lupus erythematosus; MI, myocardial infarction; MSA, membrane-stabilizing activity; SR, sustained release; 0, no effect; +, some effect; ++, moderate effect; +++, most effect.CMDT22_Ch11_p0443-p0474.indd  463 29/06/21 8:37 PMChapter 11464 CMDT 2022Table 11–10. Alpha-adrenoceptor blocking agents, sympatholytics, and vasodilators.Dug poiy Nms Iniil Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns al-adnoco Blocks Doxazosin Cardura Cardura XL1 mg at bedtime 4 mg ER once daily1–16 mg once daily 4–8 mg ER once daily$0.29/4 mg $7.07/4 mg ER$8.70 (4 mg once daily) $212.10 (4 mg ER once daily)Syncope with first dose; postural hypotension, dizziness, palpitations, headache, weakness, drowsiness, sexual dys- function, anticholinergic effects, urinary inconti- nence; first-dose effects may be less with doxazosin.May↑HDL and ↓LDL cholesterol. May provide short-term relief of obstructive prostatic symptoms. Less effective in preventing car- diovascular events than diuretics.Prazosin Minipress 1 mg at bedtime 2–20 mg in 2 or 3 doses$0.95/5 mg $57.00 (5 mg twice daily) Terazosin Hytrin 1 mg at bedtime 1–20 mg in 1 or 2 doses$1.60/1, 2, 5, 10 mg$48.00 (5 mg once daily) Cnl Symolyics Clonidine Catapres Catapres TTS (transdermal patch)0.1 mg twice daily 0.1 mg/day patch weekly0.2–0.6 mg in 2 doses 0.1–0.3 mg/day patch weekly$0.21/0.1 mg $55.77/0.2 mg patch$12.60 (0.1 mg twice daily) $223.08 (0.2 mg weekly)Sedation, dry mouth, sex- ual dysfunction, head- ache, bradyarrhythmias; side effects may be less with guanfacine. Contact dermatitis with clonidine patch.“Rebound” hypertension may occur even after gradual withdrawal. Clonidine and chlorthalidoneClorpres 0.1 mg/15 mg one to three times daily0.1 mg/15 mg– 0.3 mg/15 mg$2.77/0.1 mg/ 15 mg$166.20/0.1 mg/ 15 mg twice daily Guanfacine Tenex 1 mg once daily 1–3 mg once daily $0.87/1 mg $26.10 (1 mg once daily) Methyldopa Aldochlor 250 mg twice daily 500–2000 mg in 2 doses$0.66/500 mg $39.60 (500 mg twice daily)Hepatitis, hemolytic ane- mia, fever.Avoid in favor of safer agents.CMDT22_Ch11_p0443-p0474.indd  464 29/06/21 8:37 PMSYSteMIC hYperteNSION465 CMDT 2022pil Nuonl angoniss Reserpine (generic) 0.05 mg once daily 0.05–0.25 mg once daily$1.19/0.1 mg $35.70 (0.1 mg once daily)Depression (less likely at low dosages, ie, < 0.25 mg), night terrors, nasal stuffi- ness, drowsiness, peptic disease, GI disturbances, bradycardia. Dic Vsodilos Hydralazine Apresoline 25 mg twice daily 50–300 mg in 2–4 doses$0.15/25 mg $9.00 (25 mg twice daily)GI disturbances, tachycar- dia, headache, nasal congestion, rash, LE-like syndrome.May worsen or precipitate angina. Minoxidil (generic) 5 mg once daily 10–40 mg once daily $1.28/10 mg $38.40 (10 mg once daily)Tachycardia, fluid retention, headache, hirsutism, pericardial effusion, thrombocytopenia.Should be used in combination with beta-blocker and diuretic.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ER, extended release; GI, gastrointestinal; LE, lupus erythematosus.CMDT22_Ch11_p0443-p0474.indd  465 29/06/21 8:37 PMChapter 11466 CMDT 2022Guanethidine and guana drel inhibit catecholamine release from peripheral neurons but frequently cause orthostatic hypotension (especially in the morning or after exercise), diarrhea, and fluid retention.K.  Arteriolar DilatorsH ydralazine and minoxidil (Table 11–10) relax vascular smooth muscle and produce peripheral vasodilation. When given alone, they stimulate reflex tachycardia; increase myocardial contractility; and cause headache, palpitations, and fluid retention. To counteract these effects, the agents are usually given in combination with diuretics and beta-blockers in resistant patients. Hydrala- zine produces frequent gastrointestinal disturbances and may induce a lupus-like syndrome. Minoxidil causes hir- sutism and marked fluid retention; this very potent agent is reserved for the most refractory of cases. »Antihypertensive Medications & the Risk of CancerA  number of observational studies have examined the association between long-term exposure to antihyperten- sive medications and cancer. Weak associations have been suggested by some of these studies, but results have been very mixed. In the absence of large-scale prospective studies with cancer as a prespecified outcome measure, the effect of antihypertensive drugs on the risk of cancer remains uncertain. By contrast, the beneficial effect of these drugs on cardiovascular outcomes has been clearly established. Concern about increased risk of cancer should not be minimized, but at present there are no compelling data to prompt a change in prescribing patterns.Hicks  BM et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. [PMID: 30355745] Su KA et al. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br J Dermatol. 2018;179:1088. [PMID: 29723931] Wright CM et al. Calcium channel blockers and breast cancer incidence: an updated systematic review and meta-analysis of the evidence. Cancer Epidemiol. 2017;50:113. [PMID: 28866282] »Procedures That Modulate the Activity of the Autonomic Nervous SystemBefore the adv ent of antihypertensive medications, lumbar sympathectomy was used to lower blood pressure. In a more specific and less invasive approach, the renal sympa- thetic nerves can be ablated using radiofrequency energy applied to the luminal surface of the renal arteries. How- ever, the Symplicity HTN-3 study of renal sympathetic denervation did not show any difference in blood pressure reduction compared to a sham procedure group. Subse- quently, the SPYRAL HTN-OFF MED study, using a more intensive and closely controlled ablation strategy, demon- strated clinically meaningful blood pressure reductions compared to the sham control group. Although not yetaccepted in general clinical practice, it seems probable that renal sympathetic nerve ablation will emerge as an alterna- tive or adjunctive modality in the treatment of hyperten- sion and may become useful in the management of resistant hypertension and drug intolerance.Böhm  M et al; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444. [PMID: 32234534] Hermida RC et al; Hygia Project Investigators. Bedtime hyper- tension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41: 4565. [PMID: 31641769] »Developing an Antihypertensive RegimenHisto rically, data from large placebo-controlled trials sup- ported the overall conclusion that antihypertensive therapy with diuretics and beta-blockers had a major beneficial effect on a broad spectrum of cardiovascular outcomes, reducing the incidence of stroke by 30–50% and of heart failure by 40–50%, and halting progression to accelerated hypertension syndromes. The decreases in fatal and nonfa- tal coronary heart disease and cardiovascular and total mortality were less dramatic, ranging from 10% to 15%. Similar placebo-controlled data pertaining to the newer agents are generally lacking, except for stroke reduction with the calcium channel blocker nitrendipine in the Sys- tolic Hypertension in Europe trial. However, there is sub- stantial evidence that ACE inhibitors, and to a lesser extent ARBs, reduce adverse cardiovascular outcomes in other related populations (eg, patients with diabetic nephropa- thy, heart failure, or postmyocardial infarction and indi- viduals at high risk for cardiovascular events). Most large clinical trials that have compared outcomes in relatively unselected patients have failed to show a difference between newer agents—such as ACE inhibitors, calcium channel block- ers, and ARBs—and the older diuretic-based regimens with regard to survival, myocardial infarction, and stroke. Where differences have been observed, they have mostly been attrib- utable to subtle asymmetries in blood pressure control rather than to any inherent advantages of one agent over another. Recommendations for initial treatment identify ACE inhibi- tors, ARBs, and calcium channel blockers as valid choices. Because of their adverse metabolic profile, initial therapy with thiazides might best be restricted to older patients. Thiazides are acceptable as first-line therapy in Blacks because of specific efficacy in this group. As discussed above, beta-blockers are not ideal first-line drugs in the treatment of hypertension without compelling indications for their use (such as active coronary artery disease and heart failure). Vasodilator beta-blockers (such as carvedilol and nebivolol) may produce better outcomes than traditional beta-blockers; however, this possibility remains a theoretical consideration. The American Diabetes Association has advocated eve- ning dosing of one or more antihypertensive medications to restore nocturnal blood pressure dipping. The HYGIACMDT22_Ch11_p0443-p0474.indd  466 29/06/21 8:37 PMSYSteMIC hYperteNSION467 CMDT 2022trial  compared the effect of nighttime dosing of at least one antihypertensive medication with morning dosing of all antihypertensive medications in 19,000 participants with median follow-up 6.3 years, and demonstrated improved ambulatory blood pressure and nocturnal dipping, and a significant decline in major cardiovascular events in the nighttime dosing group. Participants were monitored via ambulatory blood pressure measurement, and the inci- dence of nocturnal hypotension in the HYGIA trial was very low. However, profound nocturnal hypotension might not be detected in the absence of ambulatory blood pres- sure monitoring, and ischemic optic neuropathy or other low perfusion complications would be a concern. Drugs that interrupt the renin-angiotensin cascade are more effective in young, White persons, in whom renin tends to be higher. Calcium channel blockers and diuretics are more effective in older or Black persons, in whom renin levels are generally lower. Many patients require two or more medications and even then a sub- stantial proportion fail to achieve the goal blood pres- sure. A stepped care approach to the drug treatment of hypertension is outlined in Table 11–11. In diabetic patients, three or four drugs are usually required to reduce systolic blood pressure to goal. In many patients, blood pressure cannot be adequately controlled with any combination. As a result, debating the appropriate first-line agent is less relevant than determining the most appropriate combinations of agents. The mnemonic ABCD can be used to remember four classes of antihypertensive medications. These four classes can be divided into two categories: AB and CD. AB refers to drugs that block the RAAS ( ACE/ARB and beta-blockers). CD refers to those that work in other pathways ( calcium channel blockers and diuretics). Combinations of drugs between the two categories are more potent than combina- tions from within a category. Many experts recommend the use of fixed-dose combination (between two categories) antihypertensive agents as first-line therapy in patientswith substantially elevated systolic pressures (greater than 160/100 mm Hg) or difficult-to-control hypertension (which is often associated with diabetes or kidney dysfunc- tion). In light of unwanted metabolic effects, calcium chan- nel blockers might be preferable to thiazides in the younger hypertensive patient requiring a second antihypertensive drug following initiation of therapy with an ACE inhibitor or ARB. Furthermore, based on the results from the ACCOMPLISH trial, a combination of ACE inhibitor and calcium channel blocker may also prove optimal for patients at high risk for cardiovascular events. The initial use of low-dose combinations allows faster blood pressure reduction without substantially higher intolerance rates and is likely to be better accepted by patients. Data from the ALTITUDE study (in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease or both) indicate that the addition of aliskiren to either ARB or ACE inhibitor was associated with worse outcomes and cannot be recommended, at least in this population. A suggested approach to treatment, tailored to patient demographics, is outlined in Table 11–12. In sum, as a prelude to treatment, the patient should be informed of common side effects and the need for diligent compliance. In patients with blood pressure less than 160/90 mm Hg in whom pharmacotherapy is indicated, treatment should start with a single agent or two-drug combination at a low dose. Follow-up visits usually should be at 4- to 6-week intervals to allow for full medication effects to be established (especially with diuretics) before further titration or adjustment. If, after titration to usual doses, the patient has shown a discernible but incomplete response and a good tolerance of the initial drug, another medication should be added. See Goals of Treatment, above. As a rule of thumb, a blood pressure reduction of 10 mm Hg can be expected for each antihypertensive agent added to the regimen and titrated to the optimum dose. In those with more severe hypertension, or with comorbidi- ties (such as diabetes) that are likely to render them Table 11–11. A step care approach to the initiation and titration of antihypertension medications.1,2Step  1 ACE inhibitor/ARB or3Calcium  channel blocker or Thiazide diuretic4Step  2 ACE inhibitor/ARB plus Calcium channel blocker orthiazide diuretic5Step  3 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic Step 4 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic plus spironolactone6 1Allow 2 weeks to reach full effect of each drug. Proceed through steps until target blood pressure is attained.2 Beta-blockers can be used at any stage if specifically indicated, eg, heart failure or angina.3 The European guidelines recommend starting with low-dose combination of two antihypertensive drugs in all but low-risk grade 1 hyper- tension (140–159/90–99 mm Hg). American guidelines suggest initiation with dual therapy for stage 2 hypertension (> 140/90 mm H g).4 Thiazide or calcium channel blocker is more effective initial therapy in older people and Blacks.5 If required, add a calcium channel blocker rather than diuretic in younger patients to avoid long-term exposure to metabolic si de effects of diuretics.6 Alternatives to spironolactone include eplerenone, amiloride, or triamterene. Watch for hyperkalemia, especially if also receiv ing ACE inhibitor/ ARB. Avoid potassium-sparing diuretics in advanced CKD. If more than three drugs are required at maximum dose, consider special ist referral. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD, chronic kidney disease.CMDT22_Ch11_p0443-p0474.indd  467 29/06/21 8:37 PMChapter 11468 CMDT 2022T able 11–12. Choice of antihypertensive agent based on demographic considerations.1,2 Blck, all ags all Os, ag < 55 Ys all Os, ag > 55 Ys Fis-lin CCB or diuretic ACE inhibitor or ARB3or CCB or diuretic4CCB or diuretic5Scond-lin  ARB3or ACE inhibitor6or vasodilating beta-blocker6Vasodilating beta-blocker ACE inhibitor or ARB3or vasodilating beta-blocker7rsisn  ynsion Aldosterone receptor blocker Aldosterone receptor blocker Aldosterone receptor blocker addiionl oions Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8 1Compelling indications may alter the selection of an antihypertensive drug.2 Start with full dose of one agent, or lower doses of combination therapy. In more severe hypertension (≥ 140/90 mm Hg), conside r initiat- ing therapy with a fixed dose combination.3 Women of childbearing age should avoid ACE inhibitors and ARBs or discontinue as soon as pregnancy is diagnosed.4 The adverse metabolic effects of thiazide diuretics and beta-blockers should be considered in younger patients but may be less important in the older patient.5 For patients with significant kidney dysfunction, use loop diuretic instead of thiazide.6 Despite the elevated risk of angioedema and cough in Blacks, ACE inhibitors are generally well tolerated and are a useful adjun ct.7 There are theoretical advantages in the use of vasodilating beta-blockers such as carvedilol and nebivolol.8 Alpha-antagonists may precipitate or exacerbate orthostatic hypotension in older adults. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.resistan t to treatment, initiation with combination therapy is advised and more frequent follow-up is indicated. Patients who are compliant with their medications and who do not respond to conventional combination regi- mens should usually be evaluated for secondary hyperten- sion before proceeding to more complex regimens. »Medication NonadherenceAdher ence to antihypertensive treatment is alarmingly poor. In one European study of antihypertensive medica- tion compliance, there was a 40% discontinuation rate at 1 year after initiation. Collaborative care, using clinicians, pharmacists, social workers, and nurses to encourage com- pliance, has had a variable and often rather modest effect on blood pressure control. Adherence is enhanced by patient education and by use of home blood pressure mea- surement. The choice of antihypertensive medication is important. Better compliance has been reported for patients whose medications could be taken once daily or as combination pills. Adherence is best with ACE inhibitors and ARBs, and worse with beta-blockers and diuretics. »Consideration of Gender in HypertensionBecause  of the preponderance of male recruitment into large-scale clinical trials, the impact of gender on the evaluation and management of hypertension remains uncertain. The limited data that exist suggest a steeper relationship in women between 24-hour ambulatory and night time systolic blood pressure and the risk of cardio- vascular events. There are many gender-specific effects on the mechanisms and end organ impact of hypertension. In younger adults, men are more likely to be hypertensive than women, a relationship that reverses in later life.Regression of left ventricular hypertrophy in response to ACE inhibitors is less pronounced in women. Women are more likely to have isolated systolic hypertension, probably because they develop more active left ventricular systolic function and greater vascular stiffness than men. Fibro- muscular dysplasia of the renal artery is much more com- mon in women than men. The side effects of many antihypertensive drugs are more pronounced in women than men, including ACE inhibitor–associated cough and hyponatremia and hypokalemia in response to diuretics. Conversely, thiazides can help preserve bone density. Dependent edema due to amlodipine is more likely in women, and women are more sensitive to beta-blockers. There are no data to support a different blood pressure target in women, but this question has not been examined in dedicated clinical trials. »Treatment of Hypertension in DiabetesH ypertensive patients with diabetes are at particularly high risk for cardiovascular events. Data from the ACCORD study of diabetic patients demonstrated that most of the benefits of blood pressure lowering were seen with a systolic target of less than 140 mm Hg. Although there was a reduc- tion in stroke risk at a systolic target below 120/70 mm Hg, treatment to this lower target was associated with an increased risk of serious adverse effects. US and Canadian guidelines recommend a blood pressure goal of less than 130/80 mm Hg in diabetic patients. Because of the benefi- cial effects of ACE inhibitors in diabetic nephropathy, they should be part of the initial treatment regimen. ARBs or perhaps renin inhibitors may be substituted in those intol- erant of ACE inhibitors. While the ONTARGET study showed that combinations of ACE inhibitors and ARBs in persons with atherosclerosis or type 2 diabetes withCMDT22_Ch11_p0443-p0474.indd  468 29/06/21 8:37 PMSYSteMIC hYperteNSION469 CMDT 2022end-orga n damage appeared to minimize proteinuria, this strategy slightly increased the risks of progression to dialy- sis and of death; thus, it is not recommended. Most dia- betic patients require combinations of three to five agents to achieve target blood pressure, usually including a diuretic and a calcium channel blocker or beta-blocker. Canagliflozin improves glycemic control through inhibition of the sodium-glucose co-transporter 2 (SGLT2) and, in addition, generally lowers blood pressure by 3–4 mm Hg. This drug was associated with improved renal outcomes and reduced cardiovascular risk in the CREDENCE trial of patients with diabetic nephropathy and can be consid- ered when additional blood pressure control is needed in patients with type 2 diabetes. In addition to rigorous blood pressure control, treatment of persons with diabe- tes should include aggressive treatment of other risk factors. »Treatment of Hypertension in Chronic Kidney DiseaseH ypertension is present in 40% of patients with a GFR of 60–90 mL/min/1.73 m2, and 75% of patients with a GFR less than 30 mL/min/1.73 m2. The rate of progression of chronic kidney disease is markedly slowed by treatment of hypertension. In the SPRINT trial, the reduction in cardio- vascular risk associated with lower blood pressure targets was also observed in the subgroup with a GFR of less than 60 mL/min/1.73 m2. However, an effect of lower blood pressure targets on the slowing of chronic kidney disease progression appears to be restricted to those with pro- nounced proteinuria. In the SPRINT trial, the lower blood pressure goal was associated with increased risk of acute kidney injury, but this was generally reversible and not associated with elevated biomarkers for ischemic injury. Most experts recommend a blood pressure target of less than 130/80 mm Hg in patients with chronic kidney dis- ease, with consideration of more intensive lowering if pro- teinuria greater than 1 g per 24 hours is present. Medications that interrupt the renin-angiotensin cascade can slow the progression of kidney disease and are preferred for initial therapy, especially in those with albuminuria of greater than 300 mg/g creatinine. Transition from thiazide to loop diuretic is often necessary to control volume expansion as the eGFR falls below 30 mL/min/1.73 m2. ACE inhibitors remain protective and safe in kidney disease associated with significant proteinuria and serum creatinine as high as 5 mg/dL (380 mcmol/L). However, the use of drugs blocking the RAAS cascade in patients with advanced chronic kidney disease should be supervised by a nephrol- ogist. Kidney function and electrolytes should be measured 1 week after initiating treatment and subsequently moni- tored carefully in patients with kidney disease. An increase in creatinine of 20–30% is acceptable and expected; more exaggerated responses suggest the possibility of renal artery stenosis or volume contraction. Although lower blood pressure levels are associated with acute decreases in GFR, this appears not to translate into an increased risk of developing end-stage renal disease in the long term. Persis- tence with ACE inhibitor or ARB therapy as the serum potassium level exceeds 5.5 mEq/L is probably notwarranted, since other antihypertensive medications are renoprotective as long as goal blood pressures are main- tained. However, diuretics can often be helpful in control- ling mild hyperkalemia, and there are novel cation exchange polymers (such as patiromer) that sequester potassium in the gut and are more effective and better tol- erated than sodium polystyrene sulfonate. »Treatment of Hypertension in BlacksSubstan tial evidence indicates that Blacks in the United States are not only more likely to become hypertensive and more susceptible to the cardiovascular and renal complica- tions of hypertension—they also respond differently to many antihypertensive medications. The REGARDS study illustrates these differences. At systolic blood pressures less than 120 mm Hg, Black and White participants between 45 and 64 years of age had equal risk of stroke. For a 10 mm Hg increase in systolic blood pressure, the risk of stroke was threefold higher in Black participants. At levels above 140–159/90–99 mm Hg, the hazard ratio for stroke in Black compared to White participants between 45 and 64 years of age was 2.35. This increased susceptibility may reflect genetic differences in the cause of hypertension or the subsequent responses to it, differences in occurrence of comorbid conditions such as diabetes or obesity, or envi- ronmental factors such as diet, activity, stress, or access to health care services. In any case, as in all persons with hypertension, a multifaceted program of education and lifestyle modification is warranted. Early introduction of combination therapy has been advocated, but there are no clinical trial data to support a lower than usual blood pres- sure goal in Blacks. Because it appears that ACE inhibitors and ARBs—in the absence of concomitant diuretics—are less effective in Blacks than in Whites, initial therapy should generally be a diuretic or a diuretic in combination with a calcium channel blocker. However, inhibitors of the RAAS do lower blood pressure in Black patients, are useful adjuncts to the recommended diuretic and calcium chan- nel blockers, and should be used in patients with hyperten- sion and compelling indications such as heart failure and kidney disease (especially in the presence of proteinuria) (Table 11–13). Black patients have an elevated risk of ACE inhibitor–associated angioedema and cough, so ARBs would be the preferred choice. »Treating Hypertension in Older AdultsSeveral  studies in persons over 60 years of age have con- firmed that antihypertensive therapy prevents fatal and nonfatal myocardial infarction and reduces overall cardio- vascular mortality. The HYVET study indicated that a reasonable ultimate blood pressure goal is 150/80 mm Hg. Updated guidelines suggest that blood pressure goals should not generally be influenced by age alone. An explor- atory subgroup analysis of the SPRINT study found that people older than age 75 years showed benefit at the 120 mm Hg systolic treatment target. Importantly, these benefits were also evident in patients classified as frail. This more aggressive approach was, however, associated with greater risk of falls and worsening kidney function,CMDT22_Ch11_p0443-p0474.indd  469 29/06/21 8:37 PMChapter 11470 CMDT 2022indicating  that close monitoring is required in elderly patients treated to lower blood pressure goals. It is also important to note the exclusion criteria of the SPRINT study, which included diabetes mellitus, stroke, and ortho- static hypotension. Blood pressure treatment goals should be individual- ized in the very elderly. In the SPRINT MIND study, the lower systolic blood pressure target of 120 mm Hg was associated with a 15% reduction in the incidence of mild cognitive impairment and probable all cause dementia compared to the 140 mm Hg in the target group. Based upon this data, aggressive control of hypertension in high- risk individuals would have a significant impact on the prevalence of dementia. As discussed above, it is important to note that blood pressure measurements in the SPRINT study were made by automated devices, which are known to read lower than conventional office measurements. How to initiate antihypertensive therapy in older patients— The same medications are used in older patients but at 50% lower doses. Pressure should be reduced more gradually with a safe intermediate systolic blood pressure goal of 160 mm Hg. As treatment is initiated, older patients should be carefully monitored for orthostasis, altered cog- nition, and electrolyte disturbances. The elderly are espe- cially susceptible to problems associated with polypharmacy, including drug interactions and dosing errors. »Management of Supine Hypertension in Patients With Orthostatic HypotensionSup ine hypertension is common in patients with ortho- static hypotension and is associated with increased cardio- vascular risk. Treatment of orthostasis can exacerbate supine hypertension and vice versa. Life expectancy is often reduced in patients with profound autonomic ner- vous system dysfunction. In those whose life expectancy is at least several years, though, treatment of nocturnal hypertension might be considered with the use of shorter acting agents (eg, captopril, hydralazine, losartan, or quick- release nifedipine). In patients with supine hypertension, medications used to increase blood pressure during the day should not be given within 5 hours of bedtime.»Follow-Up of Patients Receiving Hypertension TherapyOnc e blood pressure is controlled on a well-tolerated regi- men, follow-up visits can be infrequent and laboratory test- ing limited to those appropriate for the patient and the medications used. Y early monitoring of blood lipids is rec- ommended, and an electrocardiogram could be repeated at 2- to 4-year intervals depending on whether initial abnor- malities are present and on the presence of coronary risk factors. Patients who have had excellent blood pressure control for several years, especially if they have lost weight and initiated favorable lifestyle modifications, might be con- sidered for a trial of reduced antihypertensive medications.Carnethon  MR et al; American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Func- tional Genomics and Translational Biology; and Stroke Coun- cil. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393. [PMID: 29061565] Perkovic V et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295. [PMID: 30990260] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] Wenger NK et al. Hypertension across a woman’s life cycle. J Am Coll Cardiol. 2018;71:1797. [PMID: 29673470]RE SISTANT HYPERTENSIONResistant  hypertension is defined as the failure to reach blood pressure control in patients who are adherent to full doses of an appropriate three-drug regimen (including a diuretic). In the approach to resistant hypertension, the clinician should first confirm compliance and rule out “white coat hypertension, ” ideally using ambulatory or home-based measurement of blood pressure. Exacerbating factors should be considered (as outlined above). Finally, identifiable causes of resistant hypertension should be sought (Table 11–14). The clinician should pay particularTable 11–13. Recommended antihypertensive medications for coexisting indications.Indicion aniynsiv Mdicion Diuic B-Block aCe Inibio arBClcium Cnnl Blockaldoson angonis Heart failure √ √ √ √  √ Following MI  √ √  √ High coronary disease risk √ √ √  √ Diabetes √ √ √ √ √ Chronic kidney disease  √ √ Recurrent stroke prevention √  √ ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; MI, myocardial infarction.CMDT22_Ch11_p0443-p0474.indd  470 29/06/21 8:37 PMSYSteMIC hYperteNSION471 CMDT 2022at tention to the type of diuretic being used in relation to the patient’s kidney function. Aldosterone may play an important role in resistant hypertension and aldosterone receptor blockers can be very useful. If goal blood pressure cannot be achieved following completion of these steps, consultation with a hypertension specialist should be con- sidered. Renal sympathetic nerve ablation is a consider- ation for these patients in the absence of other options, but further trials are needed before this procedure can be rou- tinely integrated into clinical practice.W ei FF et al. Diagnosis and management of resistant hyperten- sion: state of the art. Nat Rev Nephrol. 2018;14:428. [PMID: 29700488]HY PERTENSIVE URGENCIES & EMERGENCIESH ypertensive urgencies are situations in which blood pressure must be reduced within a few hours. These include patients with asymptomatic severe hypertension (systolic blood pressure greater than 220 mm Hg or dia- stolic pressure greater than 125 mm Hg that persists after a period of observation) and those with optic disk edema, progressive target-organ complications, and severe periop- erative hypertension. Elevated blood pressure levels alone—in the absence of symptoms of new or progressive target-organ damage—rarely require emergency therapy. Parenteral drug therapy is not usually required; partial reduction of blood pressure with relief of symptoms is thegoal. Effective oral agents are clonidine, captopril, and slow-release nifedipine. Hypertensive emergencies require substantial reduction of blood pressure within 1 hour to avoid the risk of serious morbidity or death. Although blood pressure is usually strik- ingly elevated (diastolic pressure greater than 130 mm Hg), the correlation between pressure and end-organ damage is often poor. It is the presence of critical multiple end-organ injury that determines the seriousness of the emergency and the approach to treatment. Emergencies include hyperten- sive encephalopathy (headache, irritability, confusion, and altered mental status due to cerebrovascular spasm), hyper- tensive nephropathy (hematuria, proteinuria, and acute kidney injury due to arteriolar necrosis and intimal hyper- plasia of the interlobular arteries), intracranial hemorrhage, aortic dissection, preeclampsia-eclampsia, pulmonary edema, unstable angina, or myocardial infarction. Encepha- lopathy or nephropathy accompanying hypertensive reti- nopathy has historically been called malignant hypertension, but the therapeutic approach is identical to that used in other hypertensive emergencies. Parenteral therapy is indicated in most hypertensive emergencies, especially if encephalopathy is present. The initial goal in hypertensive emergencies is to reduce the pres- sure by no more than 25% (within minutes to 1 or 2 hours) and then toward a level of 160/100 mm Hg within 2–6 hours. Excessive reductions in pressure may precipitate coronary, cerebral, or renal ischemia. To avoid such declines, the use of agents that have a predictable, dose-dependent, tran- sient, and progressive antihypertensive effect is preferable (Table 11–15). In that regard, the use of sublingual or oral fast-acting nifedipine preparations is best avoided. Acute ischemic stroke is often associated with marked elevation of blood pressure, which will usually fall sponta- neously. In such cases, antihypertensives should only be used if the systolic blood pressure exceeds 180–200 mm Hg, and blood pressure should be reduced cautiously by 10–15% (Table 11–15). If thrombolytics are to be given, blood pres- sure should be maintained at less than 185/110 mm Hg during treatment and for 24 hours following treatment. Inintracerebral hemorrhage, the aim is to minimize bleeding by reducing the systolic blood pressure in most patients to 130–140 mm Hg within the first 6 hours. In acute subarachnoid hemorrhage, as long as the bleeding source remains uncorrected, a compromise must be struck between preventing further bleeding and maintaining cere- bral perfusion in the face of cerebral vasospasm. In this situ- ation, blood pressure goals depend on the patient’s usual blood pressure. In previously normotensive patients, the tar- get should be a systolic blood pressure of 110–120 mm Hg; in hypertensive patients, blood pressure should be treated to 20% below baseline pressure. In the treatment of hyper- tensive emergencies complicated by (or precipitated by) central nervous system injury, labetalol or nicardipine are good choices, since they are nonsedating and do not appear to cause significant increases in cerebral blood flow or intracranial pressure. Patients with subarachnoid hemor- rhage should receive nimodipine for 3 weeks following presentation to minimize cerebral vasospasm. In hyperten- sive emergencies arising from catecholaminergic mechanisms,Table 11–14. Causes of resistant hypertension.Improper  blood pressure measurement Nonadherence Volume overload and pseudotolerance Excess sodium intake Volume retention from kidney disease Inadequate diuretic therapy Drug-induced or other causes Inadequate doses Inappropriate combinations Nonsteroidal anti-inflammatory drugs; cyclooxygenase-2 inhibitors Cocaine, amphetamines, other illicit drugs Sympathomimetics (decongestants, anorectics) Oral contraceptives Adrenal steroids Cyclosporine and tacrolimus Erythropoietin Licorice (including some chewing tobacco) Selected over-the-counter dietary supplements and medicines (eg, ephedra, ma huang, bitter orange) Associated conditions Obesity Excess alcohol intake Identifiable causes of hypertension (see Table 11–2) Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560.CMDT22_Ch11_p0443-p0474.indd  471 29/06/21 8:37 PMChapter 11472 CMDT 2022T able 11–15. Treatment of hypertensive emergency depending on primary site of end-organ damage. See Table 11–16 for dosages.t y of hynsiv emgncyrcommndd Dug Oions nd Combinions Dugs o avoid Myocardial ischemia and infarction Nicardipine plus esmolol1Nitroglycerin  plus labetalol Nitroglycerin plus esmolol1Hydralazine, diazoxide, minoxidil, nitroprusside Acute kidney injury Fenoldopam Nicardipine Clevidipine Aortic dissection Esmolol plus nicardipine Esmolol plus clevidipine Labetalol Esmolol plus nitroprussideHydralazine, diazoxide, minoxidil Acute pulmonary edema, LV systolic dysfunction Nicardipine plus nitroglycerin2plus a loop diuretic Clevidipine plus nitroglycerin2plus a loop diureticHydralazine, diazoxide, beta-blockers Acute pulmonary edema, diastolic dysfunction Esmolol plus low-dose nitroglycerin plus a loop diuretic Labetalol plus low-dose nitroglycerin plus a loop diuretic Ischemic stroke (systolic blood pressure > 180–200 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Intracerebral hemorrhage (systolic blood pressure > 140–160 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Hyperadrenergic states, including cocaine use Nicardipine plus a benzodiazepine Clevidipine plus a benzodiazepine Phentolamine LabetalolBeta-blockers Preeclampsia, eclampsia Labetalol NicardipineDiuretics, ACE inhibitors1 Avoid if there is LV systolic dysfunction.2 Drug of choice if LV systolic dysfunction is associated with ischemia. ACE, angiotensin-converting enzyme; LV, left ventricular.suc h as pheochromocytoma or cocaine use, beta-blockers can worsen the hypertension because of unopposed peripheral vasoconstriction; nicardipine, clevidipine, or phentolamine is preferred . Labetalol is useful in these patients if the heart rate must be controlled. Table 11–15 provides guidelines for the choice of antihypertensive agent based on the site of end- organ damage. ACE inhibitors are specifically indicated for hypertensive crisis from systemic sclerosis (scleroderma). In acute aortic dissection, systolic blood pressure and heart rate should be reduced within 30 minutes to below 120 mm Hg and less than 60 beats per minute, using a combination of vasodilation and beta-blockade. »Pharmacologic ManagementA.  Parenteral AgentsSodiu m nitroprusside is no longer the treatment of choice for acute hypertensive problems; in most situations, appropriatecontrol of blood pressure is best achieved using combinations of nicardipine or clevidipine plus labetalol or esmolol . (Table 11–16 lists drugs, dosages, and adverse effects.) 1. Nicardipine— Intravenous nicardipine is the most potent and the longest acting of the parenteral calcium channel blockers. As a primarily arterial vasodilator, it has the potential to precipitate reflex tachycardia, and for that reason it should not be used without a beta-blocker in patients with coronary artery disease. 2. Clevidipine— Intravenous clevidipine is an L-type cal- cium channel blocker with a 1-minute half-life, which facilitates swift and tight control of severe hypertension. It acts on arterial resistance vessels and is devoid of venodila- tory or cardiodepressant effects. 3. Labetalol— This combined beta- and alpha-blocking agent is the most potent adrenergic blocker for rapid bloodCMDT22_Ch11_p0443-p0474.indd  472 29/06/21 8:37 PMSYSteMIC hYperteNSION473 CMDT 2022Table 11–16. Drugs for hypertensive emergencies and urgencies (in descending order of preference).agn acion Dosg Ons Duion advs effcs Commns hynsiv emgncis Nicardipine (Cardene)Calcium channel blocker5 mg/h intravenously; may increase by 1–2.5 mg/h every 15 minutes to 15 mg/h1–5 minutes 3–6 hours Hypotension, tachycardia, headache. May precipitate myocardial ischemia. Clevidipine (Cleviprex)Calcium channel blocker1–2 mg/h intravenously initially; double rate every 90 seconds until near goal, then by smaller amounts every 5–10 minutes to a maximum of 32 mg/h2–4 minutes 5–15 minutes Headache, nausea, vomiting. Lipid emulsion: contraindicated in patients with allergy to soy or egg. Labetalol (Trandate)Beta- and alpha-blocker20–40 mg intravenously every 10 minutes to 300 mg; 2 mg/min infusion5–10 minutes 3–6 hours Nausea, hypotension, bronchospasm, bradycardia, heart block.Avoid in acute LV systolic dysfunction, asthma. May be continued orally. Esmolol (Brevibloc) Beta-blocker Loading dose 500 mcg/kg intravenously over 1 minute; maintenance, 25–200 mcg/kg/min1–2 minutes 10–30 minutes Bradycardia, nausea. Avoid in acute LV systolic dysfunction, asthma. Weak antihypertensive. Fenoldopam (Corlopam)Dopamine receptor agonist0.1–1.6 mcg/kg/min intravenously 4–5 minutes < 10 minutes Reflex tachycardia, hypotension, increased intraocular pressure.May protect kidney function. Enalaprilat (Vasotec)ACE inhibitor 1.25 mg intravenously every 6 hours 15 minutes 6 hours or moreExcessive hypotension. Additive with diuretics; may be contin- ued orally. Furosemide (Lasix) Diuretic 10–80 mg orally or intravenously 15 minutes 4 hours Hypokalemia, hypotension. Adjunct to vasodilator. Hydralazine (Apresoline)Vasodilator 5–20 mg intravenously; may repeat after 20 minutes10–30 minutes 2–6 hours Tachycardia, headache, vomiting, diarrheaAvoid in coronary artery disease, dissec- tion. Rarely used except in pregnancy. Nitroglycerin Vasodilator 0.25–5 mcg/kg/min intravenously 2–5 minutes 3–5 minutes Headache, nausea, hypotension, bradycardia.Tolerance may develop. Useful primar- ily with myocardial ischemia. Nitroprusside (Nitropress)Vasodilator 0.25–10 mcg/kg/min intravenously Seconds 3–5 minutes Anxiety, increased intracranial pressure, vomiting, bowel obstruction; thiocyanate and cyanide toxicity, especially with kid- ney and liver dysfunction; hypotension. Coronary steal, decreased cerebral blood flow, increased intracranial pressure.No longer the first-line agent. hynsiv Ugncis Clonidine (Catapres)Central sympatholytic0.1–0.2 mg orally initially; then 0.1 mg every hour to 0.8 mg orally30–60 minutes 6–8 hours Sedation. Rebound may occur. Captopril (Capoten) ACE inhibitor 12.5–25 mg orally 15–30 minutes 4–6 hours Excessive hypotension. Nifedipine (Adalat, Procardia)Calcium channel blocker10 mg orally initially; may be repeated after 30 minutes15 minutes 2–6 hours Excessive hypotension, tachycardia, head- ache, angina, myocardial infarction, stroke.Response unpredictable. ACE, angiotensin-converting enzyme; CNS, central nervous system; GI, gastrointestinal; LV, left ventricular.CMDT22_Ch11_p0443-p0474.indd  473 29/06/21 8:37 PMChapter 11474 CMDT 2022pres sure reduction. Other beta-blockers are far less potent. Excessive blood pressure drops are unusual. Experience with this agent in hypertensive syndromes associated with pregnancy has been favorable. 4. Esmolol— This rapidly acting beta-blocker is approved only for treatment of supraventricular tachycardia, but is often used for lowering blood pressure. It is less potent than labetalol and should be reserved for patients in whom there is particular concern about serious adverse events related to beta-blockers. 5. Fenoldopam— Fenoldopam is a peripheral dopamine-1 (DA1) receptor agonist that causes a dose-dependent reduction in arterial pressure without evidence of toler- ance, rebound, withdrawal, or deterioration of kidney function. In higher dosage ranges, tachycardia may occur. This drug is natriuretic, which may simplify volume man- agement in acute kidney injury. 6. Enalaprilat— This is the active form of the oral ACE inhibi- tor enalapril. The onset of action is usually within 15 minutes, but the peak effect may be delayed for up to 6 hours. Thus, enalaprilat is used primarily as an adjunctive agent. 7. Diuretics— Intravenous loop diuretics can be very help- ful when the patient has signs of heart failure or fluid reten- tion, but the onset of their hypotensive response is slow, making them an adjunct rather than a primary agent for hypertensive emergencies. Low dosages should be used initially (furosemide, 20 mg, or bumetanide, 0.5 mg). They facilitate the response to vasodilators, which often stimu- late fluid retention. 8. Hydralazine— Hydralazine can be given intravenously or intramuscularly, but its effect is less predictable than that of other drugs in this group. It produces reflex tachycardia and should not be given without beta-blockers in patients with possible coronary disease or aortic dissection. Hydral- azine is used primarily in pregnancy and in children, but even in these situations, it is not a first-line drug. 9. Nitroglycerin, intravenous— This agent should be reserved for patients with accompanying acute coronary ischemic syndromes. 10. Nitroprusside sodium— This agent is given by con- trolled intravenous infusion gradually titrated to thedesired effect. It lowers the blood pressure within seconds by direct arteriolar and venous dilation. Monitoring with an intra-arterial line avoids hypotension. Nitroprusside— in combination with a beta-blocker—is useful in patients with aortic dissection.B.  Oral AgentsPa tients with less severe acute hypertensive syndromes can often be treated with oral therapy. Suitable drugs will reduce the blood pressure over a period of hours. In those presenting as a consequence of noncompliance, it is usually sufficient to restore the patient’s previously established oral regimen. 1. Clonidine— Clonidine, 0.2 mg orally initially, followed by 0.1 mg every hour to a total of 0.8 mg, will usually lower blood pressure over a period of several hours. Sedation is frequent, and rebound hypertension may occur if the drug is stopped. 2. Captopril— Captopril, 12.5–25 mg orally, will also lower blood pressure in 15–30 minutes. The response is variable and may be excessive. Captopril is the drug of choice in the management of systemic sclerosis hypertensive crisis. 3. Nifedipine— The effect of fast-acting nifedipine cap- sules is unpredictable and may be excessive, resulting in hypotension and reflex tachycardia. Because myocardial infarction and stroke have been reported in this setting, the use of sublingual nifedipine is not advised. Nifedipine retard, 20 mg orally, appears to be safe and effective.C.  Subsequent TherapyWhen  the blood pressure has been brought under control, combinations of oral antihypertensive agents can be added as parenteral drugs are tapered off over a period of 2–3 days.Co rdonnier C et al. Intracerebral haemorrhage: current approaches to acute management. Lancet. 2018;392:1257. [PMID: 30319113] Ipek E et al. Hypertensive crisis: an update on clinical approach and management. Curr Opin Cardiol. 2017;32:397. [PMID: 28306673] Peixoto AJ. Acute severe hypertension. N Engl J Med. 2019;381:1843. [PMID: 31693807]CMDT22_Ch11_p0443-p0474.indd  474 29/06/21 8:37 PM475 CMDT 2022 ºATHEROSCLEROTIC PERIPHERAL VASCULAR DISEASE OCCLUSIVE DISEASE: AORTA & ILIAC ARTERIESE S S E N T I A L S  O F  D I A G N O S I S »Claudication: cramping pain or tiredness in the calf, thigh, or hip while walking. »Diminished femoral pulses. »Tissue loss (ulceration, gangrene) or rest pain. »General ConsiderationsOlusive  atherslerti lesins develping in the extrem- ities, r peripheral artery disease (PAD), is evidene f a systemi atherslerti press. The prevalene f PAD is 30% in patients wh are 70 years ld withut ther risk fatrs, r 50 years ld with risk fatrs suh as diabetes mellitus r tba use. Pathlgi hanges f athersle- rsis may be diffuse, but flw-limiting stenses ur seg- mentally. In the lwer extremities, stenses lassially ur in three anatmi segments: the artilia segment, femral-ppliteal segment, and the infrappliteal r tibial segment f the arterial tree. Lesins in the distal arta and prximal mmn ilia arteries lassially ur in White male smkers aged 50–60 years. Disease prgressin may lead t mplete lusin f ne r bth mmn ilia arteries, whih an preipitate lusin f the entire abdminal arta t the level f the renal arteries. »Clinical FindingsA.  Symptoms and SignsA pprximately tw-thirds f patients with PAD are either asymptmati r d nt have lassi symptms. Intermit- tent laudiatin, whih is pain with ambulatin that urs frm insuffiient bld flw relative t demand, is typially12Warren J. Gasper, MD James C. Iannuzzi, MD, MPH Meshell D. Johnson, MDBlood Vessel & Lymphatic Disordersdesribed as severe and  ramping and primarily in the alf musles. The pain frm artilia lesins may extend int the thigh and buttks and eretile dysfuntin may ur frm bilateral mmn ilia disease. Rarely, patients m- plain nly f weakness in the legs when walking, r simply extreme limb fatigue. The symptms are relieved with rest and are reprduible when the patient walks again. Femral pulses and distal pulses are absent r very weak. Bruits may be heard ver the arta, ilia, and femral arteries.B.  Doppler and Vascular FindingsThe  rati f systli bld pressure deteted by Dppler examinatin at the ankle mpared with the brahial artery (referred t as the ankle-brahial index [ABI]) is redued t belw 0.9 (nrmal rati is 0.9–1.2); this differene is exag- gerated by exerise. Bth the drsalis pedis and the psterir tibial arteries are measured and the higher f the tw artery pressures is used fr alulatin. Segmental wavefrms r pulse vlume rerdings btained by strain gauge tehnl- gy thrugh bld pressure uffs demnstrate blunting f the arterial inflw thrughut the lwer extremity.C.  ImagingCT  angigraphy (CTA) and magneti resnane angigra- phy (MRA) an identify the anatmi latin f disease. Due t verlying bwel, duplex ultrasund has a limited rle in imaging the artilia segment. Imaging is required nly when symptms neessitate interventin, sine a his- try and physial examinatin with vasular testing shuld apprpriately identify the invlved levels f the arterial tree. »TreatmentA.  Medical and Exercise TherapyThe  rnerstnes f PAD treatment are ardivasular risk fatr redutin and a supervised r strutured exerise prgram. Essential elements inlude smking essatin, antiplatelet therapy, lipid and bld pressure management, and weight lss. Nitine replaement therapy, buprpin, and vareniline have established benefits in smking essa- tin (see Chapter 1). Antiplatelet agents (aspirin, 81 mg rally daily, r lpidgrel, 75 mg rally daily) redue verallCMDT22_Ch12_p0475-p0501.indd  475 29/06/21 8:37 PMCHAPTER 12476 CMDT 2022ar divasular mrbidity. Lw-dse rivarxaban (2.5 mg rally twie daily) with aspirin 100 mg rally daily redues bth majr ardivasular and limb-related adverse events in symptmati patients. All patients with PAD shuld reeive high-dse statin (eg, atrvastatin 80 mg daily if tler- ated) t treat hyperhlesterlemia and inflammatin. A trial f ilstazl 100 mg rally twie a day, may imprve walking distane in apprximately tw-thirds f patients. Supervised exerise prgrams fr PAD prvide signifi- ant imprvements in pain, walking distane, and quality f life and may be mre effetive than an endvasular treatment alne. A minimum training gal is a walking sessin f 30–45 minutes at least 3 days per week fr a minimum f 12 weeks. Strutured mmunity r hme- based exerise prgrams as well as alternative exerises (yling, upper-bdy ergmetry) may als be effetive.B.  Endovascular TherapyWhen  the atherslerti lesins are fal, they an be effetively treated with angiplasty and stenting. This apprah mathes the results f surgery fr single stenses but bth effetiveness and durability derease with lnger r multiple stenses.C.  Surgical InterventionA  prstheti art-femral bypass graft that bypasses the diseased artery segments is a highly effetive and durable treatment fr this disease. Patients may als be treated with a graft frm the axillary artery t the femral arteries (axill-femral bypass graft) r with a graft frm the n- tralateral femral artery (femral-femral bypass) when ilia disease is limited t ne side. The perative risk f axill-femral and femral-t-femral bypass grafts is lwer beause the abdminal avity is nt entered and the arta is nt rss-lamped, but the grafts are less durable. »ComplicationsThe  mpliatins f the art-femral bypass are thse f any majr abdminal surgery in a patient ppulatin with a high prevalene f ardivasular disease. Mrtality is lw (2–3%), but mrbidity is higher and inludes a 5–10% rate f myardial infartin. While endvasular apprahes are safer and the mpliatin rate is 1–3%, they are less durable with extensive disease. »PrognosisPa tients with islated artilia disease may have a further redutin in walking distane withut interventin, but symptms rarely prgress t rest pain r threatened limb lss. Life expetany is limited by their attendant ardi- vasular disease with a mrtality rate f 25–40% at 5 years. Symptmati relief is generally exellent with super- vised exerise r after interventin. After art-femral bypass, a pateny rate f 90% at 5 years is mmn. End- vasular pateny rates and symptm relief fr patients with shrt stenses are als gd with 80% symptm free at 3 years. Reurrene rates fllwing endvasular treatment f extensive disease are 30–50%.»When to ReferPa tients with prgressive redutin in walking distane in spite f risk fatr mdifiatin and supervised exerise prgrams and thse with limitatins that interfere with their ativities f daily living shuld be referred fr nsul- tatin t a vasular surgen.Bnaa M P et al. Rivarxa ban in peripheral artery disease after revasularizatin. N Engl J Med. 2020;382:1994. [PMID: 32222135] MDermtt MM. Medial management f funtinal impair- ment in peripheral artery disease: a review. Prg Cardivas Dis. 2018;60:586. [PMID: 29727608] Mrs R et al. The evlving treatment f peripheral arterial disease thrugh guideline-direted remmendatins. J Clin Med. 2018;7:9. [PMID: 29315259]OCC LUSIVE DISEASE: FEMORAL & POPLITEAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S »Cramping pain or tiredness in the calf with exercise. »Reduced popliteal and pedal pulses. »Foot pain at rest, relieved by dependency. »Foot gangrene or ischemic ulcers. »General ConsiderationsThe  superfiial femral artery is the peripheral artery mst mmnly luded by atherslersis. Atherslersis f the femral-ppliteal segment usually urs abut a deade after the develpment f artilia disease, has an even gender distributin, and mmnly affets Blak and Hispani patients. The disease frequently urs where the superfiial femral artery passes thrugh the abdutr magnus tendn in the distal thigh (Hunter anal). The mmn femral artery and the ppliteal artery are less ften diseased but lesins in these vessels are debilitating, resulting in shrt-distane laudiatin. »Clinical FindingsA.  Symptoms and SignsSymp tms f intermittent laudiatin aused by lesins f the mmn femral artery, superfiial femral artery, and ppliteal artery are nfined t the alf. Claudiatin urs at 2–4 blks when there is lusin r stensis f the superfiial femral artery at the addutr anal, pr- vided gd llateral vessels frm the prfunda femris are maintained. Hwever, with nmitant disease f the prfunda femris r the ppliteal artery, muh shrter distanes may trigger symptms. With shrt-distane lau- diatin, dependent rubr f the ft with blanhing n elevatin may be present. Chrni lw bld flw states will als ause atrphi hanges in the lwer leg and ftCMDT22_Ch12_p0475-p0501.indd  476 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS477 CMDT 2022with  lss f hair, thinning f the skin and subutaneus tissues, and disuse atrphy f the musles. With segmental lusive disease f the superfiial femral artery, the m- mn femral pulsatin is nrmal, but the ppliteal and pedal pulses are redued.B.  Doppler and Vascular FindingsABI  values less than 0.9 are diagnsti f PAD and levels belw 0.4 suggest hrni limb-threatening ishemia (fr- merly ritial limb ishemia). ABI readings depend n arterial mpressin. Sine the vessels may be alified in diabetes mellitus, hrni kidney disease, and in lder adults, ABIs an be misleading. In suh patients, the te- brahial index is usually reliable with a value less than 0.7 nsidered diagnsti f PAD. Pulse vlume rerdings with uffs plaed at the high thigh, mid-thigh, alf, and ankle will delineate the levels f bstrutin with redued pressures and blunted wavefrms.C.  ImagingDuplex  ultrasngraphy, CTA, and MRA all adequately shw the anatmi latin f the bstrutive lesins and are dne nly if revasularizatin is planned. »TreatmentA.  Medical and Exercise TherapyA s with artilia disease, risk fatr redutin, medial pti- mizatin with a high-dse statin, and exerise treatment are the rnerstne f therapy. Cilstazl, 100 mg rally twie a day, may imprve intermittent laudiatin symptms.B.  Surgical InterventionIn terventin is indiated if laudiatin is prgressive, ina- paitating, r interferes signifiantly with essential daily ativities r emplyment. Interventin is mandatry if there is ishemi rest pain r ishemi ulers threaten the ft. 1. Bypass surgery— The mst effetive and durable treat- ment fr lesins f the superfiial femral artery is a femral- ppliteal bypass with autlgus saphenus vein. Syntheti material, usually plytetraflurethylene (PTFE), an be used, but these grafts d nt have the durability f vein bypass. 2. Endovascular surgery— Endvasular tehniques, suh as angiplasty and stenting, are ften used fr lesins f the superfiial femral artery. These tehniques have lwer mrbidity than bypass surgery but als have lwer rates f durability. Endvasular therapy is mst effetive in patients underging aggressive risk fatr mdifiatin in whm lesins measure less than 10 m lng. Palitaxel-eluting stents r palitaxel-ated ballns ffer mdest imprve- ment ver bare metal stents and nnated ballns, but the effet is nt as rbust as in the rnary arteries. The 1-year pateny rate is 50% fr balln angiplasty, 70% fr drug-ated ballns, and 80% fr stents. Hwever, by 3 years, the pateny rates are signifiantly wrse fr all three tehniques and reinterventin fr restensis is mmn.After a meta-analysis f linial trial data shwed inreased mrtality at 3–5 years after treatment with palitaxel-ated devies, the US FDA perfrmed an independent review and remmends judiius use f the devies. Onging trials, suh as SWEDEPAD, are expeted t prvide additinal data n the risks and benefits f palitaxel devies. 3. Thromboendarterectomy— Remval f the athersle- rti plaque is limited t the lesins f the mmn fem- ral and the prfunda femris arteries where bypass grafts and endvasular tehniques have a mre limited rle. »ComplicationsOpen  surgial predures f the lwer extremities, partiu- larly lng bypasses with vein harvest, have a risk f wund infetin that is higher than in ther areas f the bdy. Wund infetin r serma an ur in as many as 10–15% f ases. Myardial infartin rates after pen surgery are 5–10%, with a 1–4% mrtality rate. Cmplia- tin rates f endvasular surgery are 1–5%, making these therapies attrative despite their lwer durability. »PrognosisThe p rgnsis fr mtivated patients with islated superfi- ial femral artery disease is exellent, and surgery is nt remmended fr mild r mderate laudiatin in these patients. Hwever, when laudiatin signifiantly limits daily ativity undermining quality f life and ardivasu- lar health, interventin may be warranted. All interven- tins require lse pstpredure fllw-up with repeated ultrasund surveillane s that reurrent narrwing an be treated prmptly with angiplasty r bypass t prevent mplete lusin. The reprted pateny rate f bypass grafts f the femral artery, superfiial femral artery, and ppliteal artery is 65–70% at 3 years, whereas the pateny f angiplasty is less than 50% at 3 years. Beause f the extensive atherslerti disease, inlud- ing assiated rnary lesins, 5-year survival with lwer extremity PAD is 70% and dereases t 50% when there is invlvement f the tibial arteries. Hwever, with aggressive risk fatr mdifiatin, substantial imprvement in ln- gevity has been reprted. »When to ReferPa tients with prgressive symptms, shrt-distane laudi- atin, rest pain, r any uleratin shuld be referred t a peripheral vasular speialist.Hiram t JS et al. Interventins fr lwer extremity peripheral artery disease. Nat Rev Cardil. 2018;15:332. [PMID: 29679023] Katsans K et al. Risk f death fllwing appliatin f pali- taxel-ated ballns and stents in the femrppliteal artery f the leg: a systemati review and meta-analysis f randm- ized ntrlled trials. J Am Heart Ass. 2018;7:e011245. [PMID: 30561254] Nrdanstig J et al. Mrtality with palitaxel-ated devies in peripheral artery disease. N Engl J Med. 2020;383:2538. [PMID: 33296560]CMDT22_Ch12_p0475-p0501.indd  477 29/06/21 8:37 PMCHAPTER 12478 CMDT 2022Rha-Singh KJ  et al; VIVA Physiians, In. Patient-level meta- analysis f 999 laudiants underging primary femrppli- teal nitinl stent implantatin. Catheter Cardivas Interv. 2017;89:1250. [PMID: 28303688]OCC LUSIVE DISEASE: TIBIAL & PEDAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S »Severe pain of the forefoot that is relieved by dependency (ischemic rest pain). »Pain or numbness of the foot with walking. »Ulcer or gangrene, and not claudication, is a frequent initial manifestation. »Pallor when the foot is elevated. »General ConsiderationsO lusive presses f the tibial arteries f the lwer leg and pedal arteries in the ft ur primarily in patients with dia- betes. There ften is extensive alifiatin f the artery wall. »Clinical FindingsA.  Symptoms and SignsU nless there are nmitant lesins in the artilia r femral/superfiial femral artery segments, the first man- ifestatin f leg ishemia due t tibial artery disease is fre- quently an ishemi uler r ft gangrene, rather than laudiatin. The presene f ishemi rest pain r ulers is termed chronic limb-threatening ischemia and is assi- ated with the highest rate f amputatin. Classially, ish- emi rest pain is nfined t the drsum f the ft and is relieved with dependeny: the pain des nt ur with standing, sitting, r dangling the leg ver the edge f the bed. It is severe and burning in harater, and beause it is present nly when reumbent, it may awaken the patient frm sleep. On examinatin, femral and ppliteal pulses may r may nt be present depending n disease extent, but pal- pable pedal pulses will be absent. Dependent rubr may be prminent with pallr n elevatin. The skin f the ft is generally l, atrphi, and hairless.B.  Doppler and Vascular FindingsThe  ABI is ften belw 0.4; hwever, the ABI may be falsely elevated due t alifiatin f the arterial media layer (Mönkeberg medial alifi slersis) and may nt be mpressible. Te-brahial indexes are preferred fr assess- ing perfusin and prediting wund healing.C.  ImagingDig ital subtratin angigraphy is the gld standard methd t delineate the anatmy f the tibial-pplitealsegment. MRA r CTA is less helpful fr detetin f lesins in this latin due t the small vasulature and ther tehnial issues related t image reslutin. »Differential DiagnosisBeause  f the high inidene f neurpathy in these patients, it is imprtant t differentiate rest pain frm dia- beti neurpathi dysesthesia. Leg night ramps ause pain in the leg rather than the ft and shuld nt be nfused with ishemi rest pain. Dependent rubr in the presene f a te wund an ften be mistaken fr ellulitis; pallr n elevatin helps nfirm the diagnsis f rubr. »TreatmentGd  ft are may prevent ulers, and mst diabeti patients will d well with a nservative regimen. Hwever, if uleratins appear and there is n signifiant healing within 2–3 weeks, bld flw studies (ankle-brahial index/te-brahial index) are indiated. Pr bld flw and a ft uler r nightly ishemi rest pain requires expe- ditius revasularizatin t avid a majr amputatin.A.  Bypass and Endovascular TechniquesBypass  with vein t the distal tibial r pedal arteries is an effetive therapy t treat rest pain and heal ishemi ulers f the ft. Beause the ft ften has relative sparing f vasular disease, these bypasses have had adequate pateny rates (70% at 3 years). Frtunately, in nearly all series, limb preservatin rates are muh higher than pateny rates. Endvasular treatment with plain balln angiplasty is effetive fr shrt segment lesins. The tehnial failure and relusin rates inrease drastially with lng seg- ment disease in multiple tibial arteries. Stents and drug- ated ballns have nt been suessful in the tibial vessels t date.B.  AmputationPa tients with ishemi rest pain r ulers have a 30–40% 1-year risk fr majr amputatin that inreases if revasu- larizatin annt be dne. Patients with diabetes and PAD have a 4-fld risk f hrni limb-threatening ishemia mpared with nndiabeti patients with PAD and have a risk f amputatin up t 20-fld when mpared t an age- mathed ppulatin. Many patients wh have belw-the- knee r abve-the-knee amputatins due t vasular insuffiieny never regain independent ambulatry status and ften need assisted-living failities. These fatrs m- bine t demand revasularizatin whenever pssible t preserve the limb. »ComplicationsThe  mpliatins f interventin are similar t thse listed fr superfiial femral artery disease with evidene that the verall ardivasular risk f interventin inreases with dereasing ABI. Patients with hrni limb-threatening ishemia require aggressive risk fatr mdifiatin. Wund infetin rates after bypass are higher if there is an pen wund in the ft.CMDT22_Ch12_p0475-p0501.indd  478 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS479 CMDT 2022 »PrognosisPa tients with tibial atherslersis have extensive ather- slerti burden and a high prevalene f diabetes. Their prgnsis withut interventin is pr and mpliated by the risk f amputatin. »When to ReferPa tients with diabetes and ft ulers shuld be referred fr a frmal vasular evaluatin. Interventin may nt be neessary but the severity f the disease will be quantified, whih has impliatins fr future symptm develpment. Any patient with an uler and a diabeti ft infetin shuld be evaluated fr an emergent perative inisin and drainage. Brad-spetrum intravenus antibitis shuld be given empirially; fr example, vanmyin shuld be given t ver methiillin-resistant Staphylococcus aureus (MRSA) and ertapenem r piperaillin/tazbatam shuld be given t ver gram-negative and anaerbi rganisms. Centers that have a multidisiplinary limb preservatin enter staffed with vasular surgens, pdiatrists, plasti and rthpedi surgens, prsthetis and rthti speial- ists, and diabetes speialists shuld be sught.Cnte  MS et al. Glbal vasular guidelines n the management f hrni limb-threatening ishemia. J Vas Surg. 2019;69:3. [PMID: 31159978] Farber A et al. The urrent state f ritial limb ishemia: a sys- temati review. JAMA Surg. 2016;151:1070. [PMID: 27551978]ACU TE ARTERIAL OCCLUSION OF A LIMBE S S E N T I A L S  O F  D I A G N O S I S »Sudden pain in a limb with absent limb pulses. »Usually some neurologic dysfunction with numb- ness, weakness, or complete paralysis. »Loss of light touch sensation requires revascular- ization within 3 hours for limb viability. »General ConsiderationsAu te lusin may be due t an emblus r t thrmb- sis f a diseased atherslerti segment. Embli large enugh t lude prximal arteries in the lwer extremi- ties are almst always frm the heart and are related t atrial fibrillatin. Over 50% f the embli frm the heart g t the lwer extremities, 20% t the erebrvasular iru- latin, and the remainder t the upper extremities and mesenteri and renal irulatin. Atrial fibrillatin is the mst mmn ause f ardia thrmbus frmatin; ther auses are valvular disease r thrmbus frmatin n the ventriular surfae f a large anterir myardial infart. Embli frm arterial sures suh as arterial uleratins r alified exresenes are usually small and g t the distal arterial tree (tes).The typial patient with primary thrmbsis has had a histry f laudiatin and nw has an aute lusin. If the stensis is hrni, llateral bld vessels will develp, and the resulting lusin may ause nly minimal inrease in symptms. »Clinical FindingsA.  Symptoms and SignsTh e sudden nset f extremity pain, with lss r redutin in pulses, is diagnsti f aute arterial lusin. This ften will be ampanied by neurlgi dysfuntin, suh as numb- ness r paralysis in extreme ases. With ppliteal lusin, symptms may affet nly the ft. With prximal lusins, the whle leg may be affeted. Signs f severe arterial ishemia inlude pallr, lness f the extremity, and mttling. Impaired neurlgi funtin prgressing t anesthesia with paralysis indiates irreversible injury requiring amputatin.B.  Doppler and Laboratory FindingsThere  will be little r n flw fund with Dppler examina- tin f the distal vessels. Imaging, if dne, may shw an abrupt utff f ntrast with embli lusin. Bld wrk may shw myglbinemia and metabli aidsis.C.  ImagingW henever pssible, imaging shuld be dne in the perating rm beause btaining angigraphy, MRA, r CTA may delay revasularizatin and jepardize the viability f the extremity. Hwever, in ases with nly mdest symptms and where light tuh f the extremity is maintained, imaging may be helpful in planning the revasularizatin predure. »TreatmentImm ediate revasularizatin is required in all ases f symptmati aute arterial thrmbsis. Evidence of neuro- logic injury, including loss of light touch sensation, indicates that collateral flow is inadequate to maintain limb viability and revascularization should be accomplished within 3 hours. Lnger delays arry a signifiant risk f irreversible tissue damage. This risk apprahes 100% at 6 hurs.A.  HeparinAs  sn as the diagnsis is made, unfratinated heparin shuld be administered (5000–10,000 units) intravenusly, fllwed by a heparin infusin t maintain the ativated partial thrmbplastin time (aPTT) in the therapeuti range (60–85 sends) (12–18 units/kg/h). This helps pre- vent lt prpagatin and may als help relieve assiated vessel spasm. Antiagulatin may imprve symptms, but revasularizatin will still be required.B.  Endovascular TechniquesPharmame hanial thrmbetmy atheters an ahieve rapid revasularizatin and are mst effetive fr the smaller arteries f the lwer leg. Catheter-direted hemi- al thrmblysis int the lt with tissue plasmingen ativatr (TPA) may be dne but ften requires 24 hurs rCMDT22_Ch12_p0475-p0501.indd  479 29/06/21 8:37 PMCHAPTER 12480 CMDT 2022lnger  t fully lyse the thrmbus. This apprah an be taken nly in patients with an intat neurlgi examina- tin withut abslute ntraindiatins, suh as bleeding diathesis, gastrintestinal bleeding, intraranial trauma, r neursurgery within the past 3 mnths. Heparin is admin- istered systemially t prevent thrmbus frmatin arund the sheath. Frequent vasular and aess site examinatins are required during the thrmblyti predure t guard against the develpment f a hematma.C.  Surgical InterventionGeneral  anesthesia is usually indiated; lal anesthesia may be used in extremely high-risk patients if the explra- tin is t be limited t the mmn femral artery. In extreme ases, it may be neessary t perfrm thrmb- embletmy frm the femral, ppliteal, and even the pedal vessels t revasularize the limb. The mbined use f devies that pulverize and aspirate lt and intrapera- tive thrmblysis with TPA imprves utmes. »ComplicationsCm pliatins f revasularizatin f an autely ishemi limb an inlude severe metabli aidsis, hyperkalemia, aute kidney injury, and ardia arrest. In ases where sev- eral hurs have elapsed but revery f viable tissue may still be pssible, signifiant levels f lati aid, ptassium, and ther harmful agents suh as myglbin may be released int the irulatin during revasularizatin. Administering sdium biarbnate (150 mEq NaHCO3in 1 L f dextrse 5% in water) prir t reestablishing arterial flw is required. Surgery in the presene f thrmblyti agents and heparin arries a high risk f pstperative wund hematma. »PrognosisThere  is a 10–25% risk f amputatin with an aute arterial embli lusin, and a 25% r higher in-hspital mrtal- ity rate. Prgnsis fr aute thrmbti lusin f an atherslerti segment is generally better beause the l- lateral flw an maintain extremity viability. The lnger- term survival reflets the verall nditin f the patient. In high-risk patients, an aute arterial lusin is assi- ated with a dismal prgnsis.OCC LUSIVE CEREBROVASCULAR DISEASEE S S E N T I A L S  O F  D I A G N O S I S »Sudden onset of weakness and numbness of an extremity or the face, aphasia, dysarthria, or uni- lateral blindness (amaurosis fugax). »Bruit heard loudest in the mid neck. »General ConsiderationsU nlike the ther vasular territries, symptms f ishemi erebrvasular disease are predminantly due t embli. The ishemia is reversible (transient ishemi attaks[TIAs]) when llateral flw reestablishes perfusin, but is a sign that the risk f additinal embli and a strke is high. Mst ishemi strkes are due t embli frm the heart. One-quarter f all ishemi strkes may be due t embli frm an arterial sure; apprximately 90% f these embli riginate frm the prximal internal artid artery, an area uniquely prne t the develpment f athersler- sis. Intraranial atherslerti lesins are unmmn in western ppulatins but are the mst frequent latin f erebrvasular disease in Asian ppulatins. »Clinical FindingsA.  Symptoms and SignsGenerally , the symptms f a TIA last nly a few sends t minutes (but may ntinue up t 24 hurs) while a strke is defined as persistent symptms beynd 24 hurs. The mst mmn lesins assiated with artid disease invlve the anterir irulatin in the rtex with bth mtr and sensry invlvement. Embli t the retinal artery ause unilateral blindness; transient mnular blindness is termed “amaursis fugax. ” Psterir irula- tin symptms referable t the brainstem, erebellum, and visual regins f the brain may be due t atherslersis f the vertebral basilar systems and are muh less mmn. Signs f erebrvasular disease may inlude artid artery bruits. Hwever, there is pr rrelatin between the degree f stensis and the presene f the bruit. Further- mre, the presene f a bruit des nt rrelate with strke risk. Nnfal symptms, suh as dizziness and unsteadi- ness, seldm are related t erebrvasular atherslersis.B.  ImagingDuplex ultrasngrap hy is the imaging mdality f hie with high speifiity and sensitivity fr deteting and grad- ing the degree f stensis at the artid bifuratin (see Chapter 24). Exellent depitin f the full anatmy f the erebr- vasular irulatin frm arti arh t ranium an be btained with either MRA r CTA. Eah f the mdalities may have false-psitive r false-negative findings. Sine the deisin t intervene in ases f artid stensis depends n an aurate assessment f the degree f stensis, it is rem- mended that at least tw mdalities be used t nfirm the degree f stensis. Diagnsti erebral angigraphy is reserved fr ases where artid artery stenting (CAS) is t be dne. »TreatmentSee  Chapter 24 fr a disussin f the medial manage- ment f lusive erebrvasular disease.A.  Asymptomatic PatientsLar ge studies have shwn a 5-year redutin in strke rate frm 11.5% t 5.0% with surgial treatment f asymptmati artid stensis that is greater than 60%; patients with asymptmati artid stensis may benefit frm artid interventin if their risk frm interventin is lw and their expeted survival is lnger than 5 years. Aggressive riskCMDT22_Ch12_p0475-p0501.indd  480 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS481 CMDT 2022fat r mdifiatin, inluding high-pteny statins, may be as valuable as surgial interventin in these patients; the large NIH-spnsred CREST2 study is examining this issue. Mild t mderate disease (30–50% stensis) indiates the need fr nging mnitring and aggressive risk fatr mdifiatin. Patients with artid stensis that suddenly wrsens are thught t have an unstable plaque and are at partiularly high risk fr embli strke.B.  Symptomatic PatientsLa rge randmized trials have shwn that patients with TIAs r strkes frm whih they have mpletely r nearly m- pletely revered will benefit frm artid interventin if the ipsilateral artid artery has a stensis f mre than 70% (Figure 12–1), and they are likely t benefit if the artery has a stensis f 50–69%. In these situatins, artid endartere- tmy (CEA) and, in seleted ases, CAS have been shwn t have a durable effet in preventing further events. In symp- tmati patients, interventin shuld ideally be planned within 2 weeks sine delays inrease the risk f a send event. »ComplicationsThe  mst mmn mpliatin frm artid interventin is ranial nerve injury, while the mst dreaded mplia- tin is strke frm emblizatin r artid lusin. The Amerian Heart Assiatin’s remmendatins fr upper limits f aeptable mbined mrbidity and mrtality fr these interventins is 3% fr patients with asymptmati artid stensis, 5% fr thse with TIAs, and 7% fr patients with previus strke. Higher rates f mrbidityand mrtality negate the therapeuti benefit f artid interventin.A.  Carotid EndarterectomyIn  the 2010 CREST study the strke risk fr CEA was 2.3%. CEA als arries a 1–2% risk f permanent ranial nerve injury (usually the vagus nerve). There is als the risk f pstperative nek hematma, whih an ause aute air- way mprmise. Crnary artery disease is a mrbidity in mst f these patients. Myardial infartin rates after CEA are apprximately 2–6%.B.  Carotid Angioplasty and StentingCAS  had a strke risk f 4.1% in the 2010 CREST study; patients ver 70 years f age as well as wmen had higher strke rates with CAS than with CEA. Hwever, the risk f myardial infartin was lwer with CAS mpared t CEA (1.1% vs 2.3%). CAS is indiated fr reperative ases, prir nek radiatin, and high artid bifuratins nt therwise aessible surgially. Nnetheless, embli are mre mmn during transfemral CAS in spite f embli prtetin devies, espeially when the artid artery is trtuus and heavily alified. Transervial artid stent- ing, perfrmed thrugh a small inisin at the base f the nek, avids artery trtusity and has lwer emblizatin rates than transfemral artid stenting. »PrognosisT wenty-five perent f patients presenting with artid stensis and a TIA r small strke will have further brain ishemia within 18 mnths with mst f the events ur- ring within the first 6 mnths. Histrially, patients with asymptmati artid stensis are believed t have an annual strke rate f just ver 2% but this may be lwer in the statin era. Prspetive ultrasund sreening at least annually is remmended in asymptmati patients with knwn artid stensis t identify thse wh have evidene f plaque prgressin, whih inreases strke risk. Cn- mitant rnary artery disease is mmn and is an imprtant fatr in these patients bth fr periperative risk and lng-term prgnsis. Aggressive risk fatr mdi- fiatin shuld be presribed fr patients with erebrvas- ular disease regardless f planned interventin. »When to ReferAsym ptmati r symptmati patients with a artid ste- nsis f mre than 70% and patients with artid stensis f less than 70% with symptms f a TIA r strke shuld be referred t a vasular speialist fr nsultatin.Br tt TG et al; CREST Investigatrs. Lng-term results f stent- ing versus endarteretmy fr artid-artery stensis. N Engl J Med. 2016;374:1021. [PMID: 26890472] Mresli P et al. Cartid stenting versus endarteretmy fr asymptmati artid artery stensis: a systemati review and meta-analysis. Strke. 2017;48:2150. [PMID: 28679848] Paraskevas KI et al. An updated systemati review and meta- analysis f results f transervial artid artery stenting with flw reversal. J Vas Surg. 2020;72:1489. [PMID: 32422272] ▲Figure 12–1. Digital subtraction angiography of a high-grade (90%) stenosis of the internal carotid artery with ulceration (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  481 29/06/21 8:37 PMCHAPTER 12482 CMDT 2022VI SCERAL ARTERY INSUFFICIENCY (Intestinal Angina)E S S E N T I A L S  O F  D I A G N O S I S »Severe postprandial abdominal pain. »Weight loss with a “fear of eating.” »Acute mesenteric ischemia: severe abdominal pain yet minimal findings on physical examination. »General ConsiderationsA cute mesenteric ischemia results frm lusive mesen- teri arterial disease, either embli lusin r primary thrmbsis f at least ne majr mesenteri artery. Ishemia an als result frm nonocclusive mesenteric ischemia, whih is generally seen in patients with lw flw states, suh as severe heart failure, sepsis, r hyptensin. Chronic mesenteric ischemia, als alled intestinal angina, urs when inreased flw demands during feeding are nt met resulting in abdminal pain. Beause f the rih llateral mesenteri netwrk, generally at least tw f the three majr viseral vessels (elia, superir mesenteri, inferir mesenteri arteries) are affeted befre symptms develp. Ischemic colitis, a variant f mesenteri ishemia, usually urs in the distributin f the inferir mesenteri artery. The intestinal musa is the mst sensitive t ishemia and will slugh if underperfused. »Clinical FindingsA.  Symptoms and Signs1.  Acute mesenteric ischemia— Viseral arterial emblism presents autely with severe abdminal pain. In ntrast, patients with primary viseral arterial thrmbsis ften give an anteedent histry nsistent with hrni mesen- teri ishemia. The key finding with aute mesenteri ishemia is severe, steady, diffuse abdminal pain with an absene f fal tenderness r distentin. This “pain ut f prprtin” t physial examinatin findings urs beause ishemia initially is musal and des nt impat the peritneum until transmural ishemia inflames the peritneal lining. A high white bld ell unt, lati ai- dsis, hyptensin, and abdminal distentin may aid in the diagnsis. 2. Chronic mesenteric ischemia— Patients are generally ver 45 years f age and may have evidene f athersle- rsis in ther vasular beds. Symptms nsist f epigastri r periumbilial pstprandial pain lasting 1–3 hurs. T avid the pain, patients limit fd intake and may develp a fear f eating. Weight lss is universal. 3. Ischemic colitis— Charateristi symptms are left lwer quadrant pain and tenderness, abdminal ramping, and mild diarrhea. Retal disharge will appear muus-like r bldy and shuld prmpt further evaluatin.B. Imaging and ColonoscopyCntrast-enhaned  CT is highly aurate at determining the presene f ishemi intestine. In patients with aute r hrni mesenteri ishemia, a CTA r MRA an demn- strate narrwing f the prximal viseral vessels. In aute mesenteri ishemia frm a nnlusive lw flw state, angigraphy is needed t display the typial “pruned tree” appearane f the distal viseral vasular bed. Ultrasund sanning f the mesenteri vessels may shw prximal bstruting lesins. In patients with ishemi litis, flexible sigmidspy shuld be perfrmed t assess the grade f ishemia that urs mst ften in watershed areas, suh as the retal sigmid and spleni flexure. »TreatmentA  high suspiin f aute mesenteri ishemia ditates immediate explratin t assess bwel viability. If the bwel remains viable, arterial bypass using a prstheti nduit an be dne either frm the supra-elia arta r mmn ilia artery t the elia and the superir mesen- tery artery. In ases where bwel viability is questinable r bwel resetin will be required, the bypass an be dne with autlgus vein t avid the use f prstheti nduits in a ptentially ntaminated field. Angiplasty and stent- ing f the arteries an be used but des nt avid a surgial evaluatin f bwel viability. In hrni mesenteri ishemia, angiplasty and stenting f the prximal vessel may be benefiial depending n the anatmy f the stensis. Shuld an endvasular slutin nt be available, an art-viseral artery bypass is the pre- ferred management. The lng-term results are highly dura- ble. Viseral artery endarteretmy is reserved fr ases with multiple lesins where bypass wuld be diffiult. The mainstay f treatment f ishemi litis is mainte- nane f bld pressure and perfusin until llateral ir- ulatin bemes well established. The patient must be mnitred lsely fr evidene f perfratin neessitating resetin. »PrognosisThe  mbined mrbidity and mrtality rates are 10–15% frm surgial interventin in part due t malnutritin and frailty in patients preeding hrni mesenteri ishemia. Hwever, withut interventin bth nditins are uni- frmly fatal. Adequate llateral irulatin usually devel- ps in thse wh have ishemi litis, and the prgnsis fr this entity is better than hrni mesenteri ishemia. »When to ReferAny  patient in whm there is a suspiin f mesenteri ishemia shuld be urgently referred fr imaging and ps- sible interventin.Alahdab F et al.  A systemati review and meta-analysis f end- vasular versus pen surgial revasularizatin fr hrni mesenteri ishemia. J Vas Surg. 2018;67:1598. [PMID: 29571626]CMDT22_Ch12_p0475-p0501.indd  482 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS483 CMDT 2022Clair  DG et al. Mesenteri ishemia. N Engl J Med. 2016;374:959. [PMID: 26962730] Lim S et al. Cntemprary management f aute mesenteri ishemia in the endvasular era. Vas Endvasular Surg. 2019;53:42. [PMID: 30360689]ACU TE MESENTERIC VEIN OCCLUSIONThe h allmarks f aute mesenteri vein lusin are pst- prandial pain and evidene f a hyperagulable state. Aute mesenteri vein lusin presents similarly t the arterial lusive syndrmes but is muh less mmn. Patients at risk inlude thse with parxysmal nturnal hemglbinuria; prtein C, prtein S, r antithrmbin defiienies; r the JAK2 mutatin. These lesins are diffi- ult t treat surgially, and thrmblysis is the mainstay f therapy. Aggressive lng-term antiagulatin is required fr these patients. ºNONATHEROSCLEROTIC VASCULAR DISEASE THROMBOANGIITIS OBLITERANS (Buerger Disease)E S S E N T I A L S  O F  D I A G N O S I S »Typically occurs in male cigarette smokers. »Distal extremities involved with severe ischemia, progressing to tissue loss. »Thrombosis of the superficial veins may occur. »Smoking cessation is essential to stop disease progression. »General ConsiderationsBuerger  disease is a segmental, inflammatry, and thrm- bti press f the distal-mst arteries and asinally veins f the extremities. Pathlgi examinatin reveals arteritis in the affeted vessels. The ause is nt knwn but it is rarely seen in patients wh d nt smke igarettes. Arteries mst mmnly affeted are the plantar and digi- tal vessels f the ft and lwer leg. In advaned stages, the fingers and hands may beme invlved. The inidene f Buerger disease has dereased dramatially. »Clinical FindingsA.  Symptoms and SignsBuerger  disease may be initially diffiult t differentiate frm rutine peripheral vasular disease, but in mst ases, the lesins are n the tes and the patient is yunger than 40 years f age. The bservatin f superfiial thrmb- phlebitis may aid the diagnsis. Beause the distal vessels are usually affeted, intermittent laudiatin is nt m- mn with Buerger disease, but rest pain, partiularly painin the distal mst extremity (ie, tes), is frequent. This pain ften prgresses t tissue lss and amputatin, unless the patient stps smking. The prgressin f the disease seems t be intermittent with aute and dramati episdes fllwed by sme perids f remissin.B.  ImagingMRA  r invasive angigraphy an demnstrate the blit- eratin f the distal arterial tree typial f Buerger disease. »Differential DiagnosisIn  atherslerti peripheral vasular disease, the nset f tissue ishemia tends t be less dramati than in Buerger disease, and symptms f prximal arterial invlvement, suh as laudiatin, predminate. Symptms f Raynaud disease may be diffiult t dif- ferentiate frm Buerger disease and are ften existent in 40% f patients. Repetitive atherembli may als mimi Buerger disease and may be diffiult t differentiate. It may be neessary t image the prximal arterial tree t rule ut sures f arterial mirembli. »TreatmentSmking essatin is the mainstay f therapy and will  halt the disease in mst ases. As the distal arterial tree is luded, revasularizatin is ften nt pssible. Sympa- thetmy is rarely effetive. »PrognosisIf  smking essatin an be ahieved, the utlk fr Buerger disease may be better than in patients with premature periph- eral vasular disease. If smking essatin is nt ahieved, then the prgnsis is generally pr, with amputatin f bth lwer and upper extremities a pssible utme.Le  Jnur A et al; Frenh Buerger’s Netwrk. Lng-term utme and prgnsti fatrs f mpliatins in thrmbangiitis bliterans (Buerger’s disease): a multienter study f 224 patients. J Am Heart Ass. 2018;7:e010677. [PMID: 30571594] ºARTERIAL ANEURYSMS ABDOMINAL AORTIC ANEURYSME S S E N T I A L S  O F  D I A G N O S I S »Most aortic aneurysms are asymptomatic until rupture. »80% of abdominal aortic aneurysms measuring 5 cm are palpable; the usual threshold for treat- ment is 5.5 cm. »Back or abdominal pain with aneurysmal tender- ness may precede rupture. »Rupture is catastrophic: excruciating abdominal pain that radiates to the back; hypotension.CMDT22_Ch12_p0475-p0501.indd  483 29/06/21 8:37 PMCHAPTER 12484 CMDT 2022 »General ConsiderationsDilatati n f the infrarenal arta is a nrmal part f aging. The arta f a healthy yung man measures apprximately 2 m. An aneurysm is nsidered present when the arti diameter exeeds 3 m, but aneurysms rarely rupture until their diameter exeeds 5 m. Abdminal arti aneurysms are fund in 2% f men ver 55 years f age; the male t female rati is 4:1. Ninety perent f abdminal athersle- rti aneurysms riginate belw the renal arteries. The aneurysms usually invlve the arti bifuratin and ften invlve the mmn ilia arteries. Inflammatry aneurysms are an unusual variant. These have an inflammatry peel (similar t the inflammatin seen with retrperitneal fibrsis) that surrunds the aneurysm and enases adjaent retrperitneal strutures, suh as the dudenum and, asinally, the ureters. »Clinical FindingsA.  Symptoms and Signs1.  Asymptomatic— Althugh 80% f 5-m infrarenal aneurysms are palpable n rutine physial examinatin, mst aneurysms are disvered n ultrasund r CT imag- ing as part f a sreening prgram r during the evaluatin f unrelated abdminal symptms. 2. Symptomatic— a. Pain— Aneurysmal expansin may be ampanied by pain that is mild t severe midabdminal dismfrt ften radiating t the lwer bak. The pain may be nstant r intermittent and is exaerbated by even gentle pressure n the aneurysm sak. Pain may als ampany inflamma- try aneurysms. Mst aneurysms have a thik layer f thrmbus lining the aneurysmal sa, but emblizatin t the lwer extremities is rarely seen. b. Rupture— The sudden esape f bld int the retr- peritneal spae auses severe pain and hyptensin. Free rupture int the peritneal avity is a lethal event.B.  Laboratory FindingsIn  aute ases f a ntained rupture, the hematrit may be nrmal, sine there has been n pprtunity fr hemdilutin. Patients with aneurysms may als have rnary artery disease, artid disease, kidney impairment, and emphysema, whih are typially seen in elderly men wh smke igarettes. Preperative testing may indiate the presene f these mrbid nditins, whih inrease the risk f interventin.C.  ImagingA bdminal ultrasngraphy is the diagnsti study f hie fr initial sreening fr the presene f an aneu- rysm. In apprximately three-quarters f patients with aneurysms, urvilinear alifiatins utlining prtins f the aneurysm wall may be visible n plain radigraphs f the abdmen r bak. CT sans prvide a mre reliable assessment f aneurysm diameter and shuld be dne when the aneurysm nears the diameter threshld (5.5 m)fr treatment. Cntrast-enhaned CT sans shw the arter- ies abve and belw the aneurysm. The visualizatin f this vasulature is essential fr planning repair. CT imaging will ften demnstrate mural thrmbus within the aneurysm and is nt an indiatin fr antiagulatin. One an aneurysm is identified, rutine fllw-up with ultrasund will determine size and grwth rate. The fre- queny f imaging depends n aneurysm size ranging frm every 2 years fr aneurysms smaller than 4 m t every 6 mnths fr aneurysms at r apprahing 5 m. When an aneurysm measures apprximately 5 m, a CTA with ntrast shuld be dne t mre aurately assess the size f the aneurysm and define the anatmy. »ScreeningGuidelines  remmend abdminal ultrasund sreening in men 65–75 years ld with expsure t 100 r mre life- time igarettes but nflit n whether wmen with the same expsure shuld be sreened. Guidelines d nt re- mmend repeated sreening if the arta shws n enlarge- ment. While patients are mnitred, smking essatin and treatment f underlying hypertensin, hyperlipidemia, and diabetes shuld be nsidered. »TreatmentA.  Elective RepairTh e risk f rupture inreases with aneurysm diameter. In gen- eral, eletive repair is indiated fr arti aneurysms 5.5 m r larger in diameter r aneurysms that demnstrate rapid expan- sin (mre than 0.5 m in 6 mnths). Symptms suh as pain r tenderness may indiate impending rupture and require urgent repair regardless f the aneurysm’s diameter.B.  Aneurysmal RuptureA  ruptured aneurysm is a lethal event. Apprximately half the patients exsanguinate prir t reahing a hspital. In the remainder, bleeding may be temprarily ntained in the retrperitneum (ntained rupture), allwing the patient t underg emergent surgery. Hwever, nly half f thse patients will survive. Endvasular repair is available fr ruptured aneurysm treatment in mst majr vasular en- ters, with the results ffering sme imprvement ver pen repair fr these ritially ill patients.C.  Inflammatory AneurysmThe  presene f periarti inflammatin (inflammatry aneurysm) is nt an indiatin fr surgial treatment, unless there is assiated mpressin f retrperitneal strutures, suh as the ureter r pain upn palpatin f the aneurysm. Interestingly, the inflammatin that enases an inflammatry aneurysm reedes after either endvasular r pen surgial aneurysm repair.D . Assessment of Operative RiskAneurysms  appear t be a variant f systemi athersler- sis. Patients with aneurysms have a high rate f rnary disease but a 2004 trial demnstrated minimal value inCMDT22_Ch12_p0475-p0501.indd  484 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS485 CMDT 2022addressing  stable rnary artery disease prir t aneu- rysm resetin. Hwever, in patients with signifiant symptms f rnary disease, the rnary disease shuld be treated first. Aneurysm repair shuld fllw shrtly thereafter beause there is a slightly inreased risk f aneu- rysm rupture after the rnary predures.E.  Open Surgical Resection Versus Endovascular RepairIn  pen surgial aneurysm repair, a graft is sutured t the nn-dilated vessels abve and belw the aneurysm. This invlves an abdminal inisin, extensive dissetin, and interruptin f arti bld flw. The mrtality rate is lw (2–5%) in enters that have a high vlume fr this pre- dure and when it is perfrmed in gd-risk patients. Older, siker patients may nt tlerate the ardipulmnary stresses f the peratin. With endvasular arti repair, a stent-graft is intrdued thrugh small inisins ver the femral arteries and psitined within the arta under flurspi guidane. The stent must be able t seal seurely against the wall f the arta abve and belw the aneurysm, thereby exluding bld frm flwing int the aneurysm sa. T suessfully treat an aneurysm, the ana- tmi requirements fr endvasular repairs are mre preise than fr pen repairs. Mst studies have fund that endvasular arti repair ffers patients redued pera- tive mrbidity and mrtality as well as shrter revery perids. Lng-term survival is equivalent between the tw tehniques. Patients wh underg endvasular repair, hwever, likely need additinal interventins and need lifelng mnitring, sine there is a 10–15% inidene f ntinued aneurysm grwth after endvasular repair. »ComplicationsM yocardial infarction, the mst mmn mpliatin, urs in up t 10% f patients wh underg pen aneurysm repair. The inidene f myardial infartin is substantially lwer with endvasular repair. Fr rutine infrarenal aneu- rysms, renal injury is unusual; hwever, when it des ur, r if the baseline reatinine is elevated, it is a signifiant m- pliating fatr in the pstperative perid. Respiratry mpliatins are similar t thse seen in mst majr abdminal surgery. Gastrintestinal hemrrhage, even years after arti surgeries, suggests the pssibility f graft enteric fistula, mst mmnly between the arta and the distal dudenum; the inidene f this mpliatin is higher when the initial surgery is perfrmed n an emergeny basis. »PrognosisThe m rtality rate fr an pen eletive surgial resetin is 1–5%, and the mrtality rate fr endvasular therapy is 0.5–2%. Of thse wh survive surgery, apprximately 60% are alive at 5 years; myardial infartin is the leading ause f death. The lng-term survival (5 years r mre) after pen and endvasular repairs is equivalent. Mrtality rates f untreated aneurysms vary with aneu- rysm diameter. The mrtality rate amng patients with large aneurysms has been defined as fllws: 12% annual risk f rupture with an aneurysm larger than 6 m indiameter and a 25% annual risk f rupture in aneurysms f mre than 7 m diameter. In general, a patient with an arti aneurysm larger than 5.5 m has a threefld greater hane f dying f a nsequene f rupture f the aneu- rysm than f dying f the surgial resetin. At present, endvasular aneurysm repair may be less definitive than pen surgial repair and requires lse fl- lw up with an imaging predure. Devie migratin, mpnent separatin, and graft limb thrmbsis r kink- ing are mmn reasns fr repeat interventin. With mplete exlusin f bld frm the aneurysm sa, the pressure is lwered, whih auses the aneurysm t shrink. An “endleak” frm the tp r bttm seal znes (type 1) r thrugh a graft defet (type 3) is assiated with a per- sistent risk f rupture. Indiret leakage f bld thrugh lumbar and inferir mesenteri branhes f the aneurysm (type-2 endleak) prdues an intermediate piture with smewhat redued pressure in the sa, slw shrinkage, and lw rupture risk. Hwever, type-2 endleak warrants lse bservatin as aneurysm dilatatin an hange aneurysm mrphlgy leading t type-1 endleak and rupture. »When to Refer• Any patient with a 4.5-m r larger arti aneurysm shuld be referred t a vasular speialist fr bserva- tin and assessment. •Urgent referrals shuld be made if the patient m- plains f pain and gentle palpatin f the aneurysm nfirms that it is the sure, regardless f the aneurys- mal size. »When to Admit• Patients with a tender aneurysm t palpatin r signs f arti rupture require emergent hspital admissin. •Evidene f infetin after repair.O ’Dnnell TFX et al. Abdminal arti aneurysm sreening guidelines: United States Preventive Servies Task Fre and Siety fr Vasular Surgery. J Vas Surg. 2020;71:1457. [PMID: 32334726] Jin J. Sreening fr abdminal arti aneurysm. JAMA Patient Page. JAMA. 2019;322:2256. [PMID: 31821432] Lederle FA et al; OVER Veterans Affairs Cperative Study Grup. Open versus endvasular repair f abdminal arti aneurysm. N Engl J Med. 2019;380:2126. [PMID: 31141634] US Preventive Servies Task Fre; Owens DK et al. Sreening fr abdminal arti aneurysm: US Preventive Servies Task Fre Remmendatin Statement. JAMA. 2019;322:2211. [PMID: 31821437]TH ORACIC AORTIC ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S »Widened mediastinum on chest radiograph. »With rupture, sudden onset of chest pain radiating to the back.CMDT22_Ch12_p0475-p0501.indd  485 29/06/21 8:37 PMCHAPTER 12486 CMDT 2022 »General ConsiderationsMs t thrai arti aneurysms are due t atherslersis; syphilis is a rare ause. Disrders f nnetive tissue and Ehlers-Danls and Marfan syndrmes als are rare auses but have imprtant therapeuti impliatins. Traumati, false aneurysms, aused by partial tearing f the arti wall with deeleratin injuries, may ur just beynd the ri- gin f the left sublavian artery. Less than 10% f arti aneurysms ur in the thrai arta. »Clinical FindingsA.  Symptoms and SignsMs t thrai aneurysms are asymptmati. When symp- tms ur, they depend largely n the size and the psi- tin f the aneurysm and its rate f grwth. Substernal bak r nek pain may ur. Pressure n the trahea, esphagus, r superir vena ava an result in the fllwing symptms and signs: dyspnea, stridr r brassy ugh, dysphagia, and edema in the nek and arms as well as dis- tended nek veins. Strething f the left reurrent laryngeal nerve auses harseness. With aneurysms f the asending arta, arti regurgitatin may be present due t dilatin f the arti valve annulus. Rupture f a thrai aneurysm is atastrphi beause bleeding is rarely ntained, allwing n time fr emergent repair.B.  ImagingThe  aneurysm may be diagnsed n hest radigraph by the alified utline f the dilated arta. CT sanning with ntrast enhanement is the mdality f hie, but MRA an be used t demnstrate the anatmy and aneurysmal size and t exlude lesins that an mimi aneurysms, suh as neplasms r substernal giter. There is n lw-st alternative (eg, ultrasngraphy) fr sreening r surveil- lane. Cardia atheterizatin and ehardigraphy may be required t desribe the relatinship f the rnary vessels t an aneurysm f the asending arta. »TreatmentIn diatins fr repair depend n the latin f dilatin, rate f grwth, assiated symptms, and verall nditin f the patient. Desending thrai aneurysms measuring 6 m r larger may be nsidered fr repair, sine there is a 5-year survival f 54% in these patients. Aneurysms f the desend- ing thrai arta are treated rutinely by endvasular grafting. Repair f arh aneurysms shuld be undertaken nly if there is a skilled surgial team with an aeptable rerd f utmes fr these mplex predures. The avail- ability f thrai arti endgraft tehnique using mplex branhed endvasular renstrutins fr aneurysms invlving the arh r viseral arta (ustm-made grafts with branhes t the vessels invlved in the aneurysm) des nt hange the indiatins fr aneurysm repair. Aneurysms that invlve the prximal arti arh r asending arta repre- sent partiularly hallenging prblems and may be nsid- ered fr repair when they measure 5.5 m. Open surgery is usually required, arrying substantial risk f mrbidity (inluding strke, diffuse neurlgi injury, and intelletualimpairment) beause interruptin f arh bld flw is required. »ComplicationsW ith the exeptin f endvasular repair fr disrete sa- ular aneurysms f the desending thrai arta, the mrbidity and mrtality f thrai aneurysm repair is higher than fr infra-renal abdminal arti aneurysm repair. Paraplegia remains a devastating mpliatin. Mst large series reprt apprximately 4–10% rate f paraplegia fllwing endvasular repair f thrai arti aneurysms. The spinal arterial supply is segmental thrugh interstal branhes f the arta with variable degrees f intersegmental nnetin. Therefre, the mre extensive the aneurysm, the greater is the risk f paraplegia with repair. Prir infrarenal abdminal arti surgery, subla- vian r internal ilia artery lusin, and hyptensin all inrease the paraplegia risk. Invlvement f the arti arh als inreases the risk f strke, even when the aneurysm des nt diretly affet the artid artery. »PrognosisGenerally , degenerative aneurysms f the thrai arta will enlarge (n average 0.1 m/y) and require repair t prevent death frm rupture. Saular aneurysms, partiu- larly thse distal t the left sublavian artery and the desending thrai arta, have gd results with endvas- ular repair. Resetin f aneurysms f the arti arh requires a skilled surgial team and shuld be attempted nly in lw-risk patients. Branhed r fenestrated endvas- ular grafting tehnlgy has demnstrated redued mr- bidity and mrtality. »When to Refer• Asending arti aneurysms larger than 4.5 m shuld be referred t a ardia surgen fr bservatin and assessment and nsidered fr repair at 5.5 m. •Desending thrai arti aneurysm shuld be referred t a vasular speialist when they reah 5 m fr bser- vatin and assessment and nsidered fr repair at 6 m. »When to Admit• Any patient with hest r bak pain with a knwn r suspeted thrai arta aneurysm must be brught t the hspital and underg urgent imaging studies t rule ut the aneurysm as a ause f the pain.Gasper  WJ et al. Assessing the anatmi appliability f the multibranhed endvasular repair f thraabdminal arti aneurysm tehnique. J Vas Surg. 2013;57:1553. [PMID: 23395201] Uphurh GR et al. Siety fr Vasular Surgery linial pratie guidelines f thrai endvasular arti repair fr desend- ing thrai arti aneurysms. J Vas Surg. 2021;73:55S. [PMID: 32628988] Werlin EC et al. Multibranhed endvasular arti aneurysm repair in patients with and withut hrni arti dissetins. J Vas Surg. 2019;70:1419. [PMID: 31327618]CMDT22_Ch12_p0475-p0501.indd  486 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS487 CMDT 2022PE RIPHERAL ARTERY ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S »Widened, prominent pulses. »Acute leg or foot pain and paresthesias with loss of distal pulses. »High association of popliteal aneurysms with abdominal aortic aneurysms. »General ConsiderationsLike  arti aneurysms, peripheral artery aneurysms are silent until ritially symptmati. Hwever, unlike arti aneurysms, the presenting manifestatins are due t peripheral emblizatin and thrmbsis. Ppliteal artery aneurysms aunt fr 70% f peripheral arterial aneu- rysms. Ppliteal aneurysms may emblize repetitively ver time and lude distal arteries. Due t the redundant parallel arterial supply t the ft, ishemia des nt ur until a final emblus ludes flw. Primary femral artery aneurysms are muh less m- mn. Hwever, pseudaneurysms f the femral artery fllwing arterial puntures fr arterigraphy and ardia atheterizatin ur with an inidene ranging frm 0.05% t 6% f arterial puntures. »Clinical FindingsA.  Symptoms and SignsThe  patient may be aware f a pulsatile mass when the aneurysm is in the grin, but ppliteal aneurysms are ften undeteted by the patient and liniian. Rarely, peripheral aneurysms may prdue symptms by mpressing the lal vein r nerve. The first symptm may be due t ish- emia f aute arterial lusin. The symptms range frm sudden-nset pain and paralysis t shrt-distane laudi- atin that slwly lessens as llateral irulatin develps. Symptms frm reurrent emblizatin t the leg are ften transient, if they ur at all. Sudden ishemia may appear in a te r part f the ft, fllwed by slw reslutin, and the true diagnsis may be elusive. The nset f reurrent episdes f pain in the ft, partiularly if ampanied by yansis, suggests emblizatin and requires investigatin f the heart and prximal arterial tree. Beause ppliteal pulses are smewhat diffiult t pal- pate even in nrmal individuals, a partiularly prminent r easily felt pulse is suggestive f aneurysm and shuld be investigated by ultrasund. Sine ppliteal aneurysms are bilateral in 60% f ases, the diagnsis f thrmbsis f a ppliteal aneurysm is ften aided by the palpatin f a pulsatile aneurysm in the ntralateral ppliteal spae. Apprximately 50% f patients with ppliteal aneurysms have an aneurysmal abdminal arta.B.  Imaging StudiesDuplex lr ultrasun d is the mst effiient investigatin t nfirm the diagnsis f peripheral aneurysm, measureits size and nfiguratin, and demnstrate mural thrm- bus. MRA r CTA is required t define the aneurysm and lal arterial anatmy fr renstrutin. Arterigraphy is nt remmended beause mural thrmbus redues the apparent diameter f the lumen n angigraphy. Patients with ppliteal aneurysms shuld underg abdminal ultra- sngraphy t determine whether an abdminal arti aneurysm is als present. »TreatmentT  prevent limb lss frm thrmbsis r emblizatin, surgery is indiated when an aneurysm is assiated with any peripheral emblizatin, the aneurysm is larger than 2 m, r a mural thrmbus is present. Immediate r urgent surgery is indiated when aute emblizatin r thrmbsis has aused aute ishemia. Open surgial bypass is gener- ally indiated. Endvasular exlusin f the aneurysm an be dne but has anatmi nstraints and is reserved fr high-risk patients. Intra-arterial thrmblysis may be dne in the setting f aute ishemia, if examinatin (light tuh) remains intat, suggesting that immediate surgery is nt imperative. Aute pseudaneurysms f the femral artery due t arterial puntures an be suessfully treated using ultrasund-guided mpressin r thrmbin injetin. Open surgery with prstheti interpsitin grafting is pre- ferred fr primary aneurysms f the femral artery. »PrognosisA pprximately ne-third f untreated patients will require an amputatin. The lng-term pateny f bypass grafts fr femral and ppliteal aneurysms is generally exellent but depends n the adequay f the utflw trat. Late graft lusin is less mmn than in similar surgeries fr lusive disease. »When to Refer• Peripheral arterial aneurysms measuring 2 m r with ultrasund evidene f thrmbus within the aneurysm shuld be referred t prevent prgressin t limb- threatening ishemia. »When to Admit• Patients with symptms f ishemia r any signs f emblizatin shuld be admitted and referred t a vas- ular speialist.AOR TIC DISSECTIONE S S E N T I A L S  O F  D I A G N O S I S »Sudden searing chest pain with radiation to the back, abdomen, or neck in a hypertensive patient. »Widened mediastinum on chest radiograph. »Pulse discrepancy in the extremities. »Acute aortic regurgitation may develop.CMDT22_Ch12_p0475-p0501.indd  487 29/06/21 8:37 PMCHAPTER 12488 CMDT 2022 »General ConsiderationsA rti dissetin urs when a spntaneus intimal tear develps and bld dissets int the media f the arta. The tear an result frm repetitive trque applied t the asend- ing and prximal desending arta during the ardia yle; hypertensin is an imprtant mpnent f this disease press. Dissetins are lassified by the entry pint and distal extent. Type A dissection invlves the arh prximal t the left sublavian artery, and type B dissection urs in the prximal desending thrai arta typially just beynd the left sublavian artery. Dissetins may ur in the absene f hypertensin but abnrmalities f smth musle, elasti tissue, r llagen are mre mmn in these patients. Pregnany, biuspid arti valve, and artatin als are assiated with inreased risk f dissetin. Bld entering the intimal tear may extend the dissetin int the abdminal arta, the lwer extremities, the artid arteries, r less mmnly, the sublavian arteries. Bth abs- lute pressure levels and the pulse pressure are imprtant in prpagatin f dissetin. Aortic dissection is a true emer- gency and requires immediate control of blood pressure to limit the extent of the dissection. With type A dissetin, whih has the wrse prgnsis, death may ur within hurs due t rupture f the dissetin int the periardial sa r dissetin int the rnary arteries, resulting in myardial infartin. Rupture int the pleural avity is als pssible. The intimal/ medial flap f the arti wall reated by the dissetin may lude majr arti branhes, resulting in ishemia f the brain, intestines, kidney, r extremities. »Clinical FindingsA.  Symptoms and SignsSe vere persistent hest pain f sudden nset radiating dwn the bak r pssibly int the anterir hest is harateristi. Radiatin f the pain int the nek may als ur. The patient is usually hypertensive. Synpe, hemiplegia, r paralysis f the lwer extremities may ur. Mesenteri ishemia r kidney injury may develp. Peripheral pulses may be diminished r unequal. A diastli murmur may develp as a result f a dis- setin in the asending arta lse t the arti valve, ausing valvular regurgitatin, heart failure, and ardia tampnade.B.  Electrocardiographic FindingsLeft  ventriular hypertrphy frm lng-standing hyperten- sin is ften present. Aute hanges suggesting myardial ishemia d nt develp unless dissetin invlves the rnary artery stium. Classially, inferir wall abnr- malities predminate sine dissetin leads t mprmise f the right rather than the left rnary artery. In sme patients, the ECG may be mpletely nrmal.C.  ImagingA  multiplanar CT san with ntrast enhanement is the immediate diagnsti imaging mdality f hie; lini- ians shuld have a lw threshld fr btaining a CT san in any hypertensive patient with hest pain and equival findings n ECG. The CT san shuld inlude bth the hest and abdmen t fully delineate the extent f thedisseted arta. MRA is an exellent imaging mdality fr hrni dissetins, but in the aute situatin, the lnger imaging time and the diffiulty f mnitring patients in the MRI sanner make the CT san preferable. Chest radi- graphs may reveal an abnrmal arti ntur r widened superir mediastinum. Althugh transesphageal ehar- digraphy (TEE) is an exellent diagnsti imaging methd, it is generally nt readily available in the aute setting. »Differential DiagnosisA rti dissetin is mst mmnly misdiagnsed as my- ardial infartin r ther auses f hest pain suh as pulmnary emblizatin. Dissetins may ur with minimal pain; branh vessel lusin f the lwer extrem- ity an mimi arterial emblus. »TreatmentA.  MedicalAg gressive measures t lwer bld pressure shuld ur when an arti dissetin is suspeted, even befre the diag- nsti studies have been mpleted. Treatment requires a simultaneus redutin f the systli bld pressure t 100– 120 mm Hg and pulse pressure. Beta-blkers have the mst desirable effet f reduing the left ventriular ejetin fre that ntinues t weaken the arterial wall and shuld be first- line therapy. Labetall, bth an alpha- and beta-blker, lw- ers pulse pressure and ahieves rapid bld pressure ntrl. Give 20 mg ver 2 minutes by intravenus injetin. Addi- tinal dses f 40–80 mg intravenusly an be given every 10 minutes (maximum dse 300 mg) until the desired bld pressure has been reahed. Alternatively, 2 mg/min may be given by intravenus infusin, titrated t desired effet. In patients wh have asthma, bradyardia, r ther nditins that neessitate the patient’s reatin t beta-blkers be tested, esmll is a reasnable hie beause f its shrt half-life. Give a lading dse f esmll, 0.5 mg/kg intravenusly ver 1 minute, fllwed by an infusin f 0.0025–0.02 mg/kg/min. Titrate the infusin t a gal heart rate f 60–70 beats/min. If beta-blkade alne des nt ntrl the hypertensin, nitrprusside may be added as fllws: 50 mg f nitrprus- side in 1000 mL f 5% dextrse and water, infused at a rate f 0.5 mL/min fr a 70-kg persn (0.3 mg/kg/min); the infu- sin rate is inreased by 0.5 mL every 5 minutes until adequate ntrl f the pressure has been ahieved. In patients with asthma, while there are n data supprting the use f the al- ium hannel antagnists, diltiazem and verapamil are pten- tial alternatives t treatment with beta-blking drugs. Mrphine sulfate is the apprpriate drug t use fr pain relief. Lng-term medial are f patients shuld inlude beta- blkers in their antihypertensive regimen.B.  Surgical Intervention1.  Type A dissection— Urgent surgical intervention is required for all type A dissections. If a skilled ardivasular team is nt available, the patient shuld be transferred t an appr- priate faility. The predure invlves grafting and replaing the diseased prtin f the arh and brahiephali vessels as neessary. Replaement f the arti valve may be required with reattahment f the rnary arteries.CMDT22_Ch12_p0475-p0501.indd  488 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS489 CMDT 20222. T ype B dissection with malperfusion— Urgent surgery is required fr type B dissetins if there is arti branh mprmise resulting in malperfusin f the renal, vis- eral, r extremity vessels. The immediate gal f surgery is t restre flw t the ishemi tissue. Endvasular stenting f the entry tear at the level f the sublavian artery may result in bliteratin f the false lumen and restre flw int the branh vessel frm the true lumen. The results, hwever, are unpreditable and shuld nly be attempted by an experiened team. 3. Type B dissection without malperfusion— Fr aute type B dissetins withut malperfusin, bld pressure ntrl is the primary treatment. Lng-term arti-speifi survival and late aneurysm frmatin rates are imprved with early thrai stent graft repair, espeially in healthy patients with high-risk anatmi features (arti diameter greater than 4 m r partial false lumen thrmbsis). »Prognosis & Follow-UpThe  mrtality rate fr untreated type A dissetins is apprximately 1% per hur fr 72 hurs and ver 90% at 3 mnths. Mrtality is als extremely high fr untreated type B dissetins with malperfusin r rupture. The surgial and endvasular therapies fr these patients are tehnially demanding and require an experiened team t ahieve periperative mrtalities f less than 10%. Aneurysmal enlargement f the residual false lumen may develp despite adequate antihypertensive therapy. Y early CT sans are required t mnitr fr aneurysm develpment. Indiatins fr late aneurysm repair are determined by aneurysm size (6 m r larger), similar t undisseted thrai aneurysms. »When to Admit• All patients with an aute dissetin shuld be hspital- ized fr bld pressure management and bservatin. •Urgent surgial repair is indiated fr all type A disse- tins and fr type B dissetins with malperfusin, rupture, r persistent symptms.Bssne E  et al. Aute arti syndrmes: diagnsis and manage- ment, an update. Eur Heart J. 2018;39:739. [PMID: 29106452] Evangelista A et al; IRAD Investigatrs. Insights frm the Interna- tinal Registry f Aute Arti Dissetin: a 20-year experiene f llabrative linial researh. Cirulatin. 2018;137:1846. [PMID: 29685932] ºVENOUS DISEASES VARICOSE VEINSE S S E N T I A L S  O F  D I A G N O S I S »Dilated, tortuous superficial veins in the legs. »Asymptomatic or there may be aching discomfort or pain. »Often hereditary. »Increased frequency after pregnancy.»General ConsiderationsV arise veins develp in the lwer extremities. Perids f high venus pressure related t prlnged standing r heavy lifting are ntributing fatrs, but the highest ini- dene urs in wmen after pregnany. Varisities develp in ver 20% f all adults. The mbinatin f prgressive venus reflux and venus hypertensin is the hallmark f hrni venus disease. The superfiial veins are invlved, typially the great saphenus vein and its tributaries, but the shrt saphenus vein (psterir lwer leg) may als be affeted. Distentin f the vein prevents the valve leaflets frm apting, reating inmpetene and reflux f bld tward the ft. Fal venus dilatin and reflux leads t inreased pressure and distentin f the vein segment belw that valve, whih in turn auses prgressive failure f the next lwer valve. Perfrating veins that nnet the deep and superfiial systems may beme inmpetent, allwing bld t reflux int the superfiial veins frm the deep system, inreasing venus pressure and distentin. Sendary varisities an develp as a result f bstrutive hanges and valve damage in the deep venus system fllwing thrmbphlebitis, r rarely as a result f prximal venus lusin due t neplasm r fibrsis. Cngenital r aquired arterivenus fistulas r venus malfrmatins are als assiated with varisities and shuld be nsidered in yung patients with varisities. »Clinical FindingsA.  Symptoms and SignsSymp tm severity is nt rrelated with the number and size f the varisities; extensive varise veins may pr- due n subjetive symptms, whereas minimal varisi- ties may prdue many symptms. Dull, ahing heaviness r a feeling f fatigue f the legs brught n by perids f standing is the mst mmn mplaint. Ithing frm venus ezema may ur either abve the ankle r diretly verlying large varisities. Dilated, trtuus veins f the thigh and alf are visible and palpable when the patient is standing. Lngstanding varise veins may prgress t hrni venus insuffiieny with assiated ankle edema, brwnish skin hyperpigmen- tatin, and hrni skin induratin r fibrsis. A bruit r thrill is never fund with primary varise veins and, when fund, alerts the liniian t the presene f an arterive- nus fistula r malfrmatin.B.  ImagingThe identifiatin  f the sure f venus reflux that feeds the symptmati veins is neessary fr effetive surgial treatment. Duplex ultrasngraphy by a tehniian experi- ened in the diagnsis and lalizatin f venus reflux is the test f hie fr planning therapy. In mst ases, reflux will arise frm the greater saphenus vein. »Differential DiagnosisV arise veins due t primary superfiial venus reflux shuld be differentiated frm thse sendary t previusCMDT22_Ch12_p0475-p0501.indd  489 29/06/21 8:37 PMCHAPTER 12490 CMDT 2022r  nging bstrutin f the deep veins (pst-thrmbti syndrme). Pain r dismfrt sendary t neurpathy shuld be distinguished frm symptms assiated with existent varise veins. Similarly, vein symptms shuld be distinguished frm pain due t intermittent laudia- tin, whih urs after a preditable amunt f exerise and reslves with rest. In adlesent patients with varise veins, imaging f the deep venus system is bligatry t exlude a ngenital malfrmatin r atresia f the deep veins. Surgical treatment of varicose veins in these patients is contraindicated because the varicosities may play a signifi- cant role in venous drainage of the limb. »ComplicationsSuperfiial  thrmbphlebitis f varise veins is unm- mn. The typial presentatin is aute lalized pain with tender, firm veins. The press is usually self-limiting, reslving within several weeks. The risk f deep venus thrmbsis (DVT) r emblizatin is very lw unless the thrmbphlebitis extends int the great saphenus vein in the upper medial thigh. Predispsing nditins inlude pregnany, lal trauma, r prlnged perids f sitting. In lder patients, superfiial varisities may bleed with even minr trauma. The amunt f bleeding an be alarm- ing as the pressure in the varisity is high. »TreatmentA.  Nonsurgical MeasuresN nsurgial treatment is effetive. Elasti graduated m- pressin stkings (20–30 mm Hg pressure) redue the venus pressure in the leg and may prevent the prgressin f disease. Gd ntrl f symptms an be ahieved when stkings are wrn daily during waking hurs and legs are elevated, espeially at night. Cmpressin stk- ings are well-suited fr elderly patients r patients wh d nt want surgery.B.  Varicose Vein SclerotherapyDiret  injetin f a slersing agent indues permanent fibrsis and bliteratin f the target veins. Chemial irri- tants (eg, glyerin) r hypertni saline are ften used fr small, less-than-4-mm retiular veins r telangietasias. Fam slertherapy is used t treat the great saphenus vein, varise veins larger than 4 mm, and perfrating veins. Slertherapy f varise veins withut treatment f underlying saphenus vein reflux is assiated with vari- sity reurrene rates ver 50% as unrreted reflux prgressively dilates adjaent veins. Cmpliatins suh as phlebitis, tissue nersis, r infetin may ur with any slersing agent.C.  Surgical Reflux TreatmentT reatment ptins fr reflux arising frm the great saphenus vein inlude surgial vein stripping (remval) r endvenus treatments using thermal devies (laser r radifrequeny atheter), yanarylate glue injetin, r fam slersant injetin. Endvenus treatments an ften be perfrmed with lal anesthesia alne and theearly suess is equal t vein stripping. Lng-term suess is highest with vein stripping and thermal treatments while the lng-term durability f yanarylate glue and fam is unknwn. One majr mpliatin f thermal treatments inludes endthermal heat-indued thrmbsis f the deep vein and may require prlnged antiagulatin. Less mmn sures f reflux inlude the small saphenus vein (fr varisities in the psterir alf) and inmpetent perfratr veins arising diretly frm the deep venus sys- tem. Crretin f reflux is perfrmed at the same time as exisin f the symptmati varise veins. When superfi- ial venus reflux is present, nmitant reflux in the deep venus system is ften sendary t vlume verlad, whih will reslve with rretin f the superfiial reflux. »PrognosisSurgial  treatment f superfiial vein reflux and exisin f varise veins prvide exellent results. The 5-year suess rate (as defined as lak f pain and reurrent varisities) is 85–90%. Simple exisin (phlebetmy) r injetin slertherapy withut rretin f reflux is assiated with reurrene rates ver 50%. Even after adequate treat- ment, sendary tissue hanges may persist. »When to Refer• Abslute indiatins fr referral fr saphenus ablatin inlude thrmbphlebitis and bleeding. •Pain and smeti nerns are respnsible fr the majrity f referrals fr ablatin.Kabnik  LS et al. Classifiatin and treatment f endthermal heat-indued thrmbsis: remmendatins frm the Amerian Venus Frum and the Siety fr Vasular Sur- gery. J Vas Surg Venus Lymphat Disrd. 2021;9:6. [PMID: 33012690] DePpas E et al. Varise veins and lwer extremity venus insuffiieny. Semin Intervent Radil. 2018;35:56. [PMID: 29628617]SU PERFICIAL VENOUS THROMBOPHLEBITISE S S E N T I A L S  O F  D I A G N O S I S »Red, painful induration along a superficial vein, usually at the site of a recent intravenous line. »Marked swelling of the extremity may not occur. »General ConsiderationsShrt-term venus a theterizatin f superfiial arm veins as well as the use f lnger-term peripherally inserted en- tral atheter (PICC) lines are the mst mmn ause f superfiial thrmbphlebitis. Intravenus atheter sites shuld be bserved daily fr signs f lal inflammatin and shuld be remved if a lal reatin develps in the vein. Serius thrmbti r septi mpliatins an ur if this pliy is nt fllwed; S aureus is the mst mmnCMDT22_Ch12_p0475-p0501.indd  490 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS491 CMDT 2022pathgen.  Other rganisms, inluding fungi, may als be respnsible. Superfiial thrmbphlebitis may ur spntaneusly, ften in pregnant r pstpartum wmen r in individuals with varise veins, r it may be assiated with trauma, as with a blw t the leg r fllwing intravenus therapy with irritating slutins. It als may be a manifestatin f systemi hyperagulability sendary t abdminal an- er suh as arinma f the panreas and may be the earli- est sign f these nditins. Superfiial thrmbphlebitis may be assiated with ult DVT in abut 20% f ases. Pulmnary embli are exeedingly rare and ur frm an assiated DVT. (See Chapters 9 and 14 fr disussin n deep venus thrmbsis.) »Clinical FindingsIn  spntaneus superfiial thrmbphlebitis, the great saphenus vein is mst ften invlved. The patient usually experienes a dull pain in the regin f the invlved vein. Lal findings nsist f induratin, redness, and tender- ness alng the urse f a vein. The press may be lal- ized, r it may invlve mst f the great saphenus vein and its tributaries. The inflammatry reatin generally subsides in 1–2 weeks; a firm rd may remain fr a muh lnger perid. Edema f the extremity is unmmn. Lalized redness and induratin at the site f a reent intravenus line requires urgent attentin. Prximal exten- sin f the induratin and pain with hills and high fever suggest septi phlebitis and requires urgent treatment. »Differential DiagnosisThe linear ra ther than irular nature f the lesin and the distributin alng the urse f a superfiial vein serve t differentiate superfiial phlebitis frm ellulitis, erythema ndsum, erythema induratum, panniulitis, and fibrsi- tis. Lymphangitis and deep thrmbphlebitis must als be nsidered. »TreatmentF r spntaneus thrmbphlebitis if the press is well lalized and nt near the saphenfemral juntin, lal heat and nnsteridal anti-inflammatry mediatins are usually effetive in limiting the press. If the induratin is extensive r is prgressing tward the saphenfemral juntin (leg) r ephal-axillary juntin (arm), ligatin and divisin f the vein at the juntin f the deep and superfiial veins is indiated. Antiagulatin therapy is usually nt required fr fal presses. Prphylati dse lw-mleular-weight heparin r fndaparinux is remmended fr 5 m r ln- ger superfiial thrmbphlebitis f the lwer limb veins (Table 14–14) and full antiagulatin is reserved fr dis- ease that is rapidly prgressing r if there is nern fr extensin int the deep system (Table 14–16). Septi superfiial thrmbphlebitis is an intravasular absess and requires urgent treatment with heparin r fndaparinux (see Table 14–16) t limit further thrmbus frmatin and remval f the ffending atheter in atheter- related infetins (see Chapter 30). Treat with antibitis(eg, vanmyin, 15 mg/kg intravenusly every 12 hurs, plus eftriaxne, 1 g intravenusly every 24 hurs). If ul- tures are psitive, therapy shuld be ntinued fr 7–10 days r fr 4–6 weeks if mpliating endarditis annt be exluded. Surgial exisin f the invlved vein may als be neessary t ntrl the infetin. »PrognosisW ith spntaneus thrmbphlebitis, the urse is gener- ally benign and brief. In patients with phlebitis sendary t varise veins, reurrent episdes are likely unless r- retin f the underlying venus reflux and exisin f varisities is dne. In ntrast, the mrtality frm septi thrmbphlebitis is 20% r higher and requires aggressive treatment. Hwever, if the invlvement is lalized, the mrtality is lw and prgnsis is exellent with early treatment.Di  Nisi M et al. Treatment fr superfiial thrmbphlebitis f the leg. Chrane Database Syst Rev. 2018;2:CD004982. [PMID: 29478266]CH RONIC VENOUS INSUFFICIENCYE S S E N T I A L S  O F  D I A G N O S I S »History of prior DVT or leg injury. »Edema, (brawny) skin hyperpigmentation, subcu- taneous lipodermosclerosis in the lower leg. »Venous ulcers: large ulcerations at or above the medial ankle. »General ConsiderationsChrni  venus insuffiieny is a severe manifestatin f venus hypertensin. One f the mst mmn etilgies is prir deep venus thrmbphlebitis, althugh abut 25% f patients d nt have a knwn histry f DVT. In these ases, there may be a histry f leg trauma r surgery; besity is ften a mpliating fatr. Prgressive superfi- ial venus reflux is als a mmn ause. Other auses inlude ngenital r neplasti bstrutin f the pelvi veins r a ngenital r aquired arterivenus fistula. The basi pathlgy is aused by valve leaflets that d nt apt beause they are either thikened and sarred (pst-thrmbti syndrme) r in a dilated vein and are therefre funtinally inadequate. Prximal venus bstrutin due t hrni thrmbus r sarring m- punds the prblem. With the valves unable t stp venus bld frm returning t the ft (venus reflux), the leg develps venus hypertensin and an abnrmally high hydrstati fre is transmitted t the subutaneus veins and tissues f the lwer leg. The resulting edema results in dramati and deleterius sendary hanges. The stigmata f hrni venus insuffiieny inlude fibrsis f the sub- utaneus tissue and skin, pigmentatin f skin (hemsid- erin taken up by the dermal marphages), and, later,CMDT22_Ch12_p0475-p0501.indd  491 29/06/21 8:37 PMCHAPTER 12492 CMDT 2022uleratin,  whih is extremely slw t heal. Ithing may preipitate the frmatin f uleratin r lal wund el- lulitis. Dilatin f the superfiial veins may ur, leading t varisities. Althugh surgial treatment fr venus reflux an imprve symptms, ntrlling edema and the sendary skin hanges usually require lifelng mpres- sin therapy. »Clinical FindingsA.  Symptoms and SignsPrgr essive pitting edema f the leg (partiularly the lwer leg) is the primary presenting symptm. Sendary hanges in the skin and subutaneus tissues develp ver time (Figure 12–2). The usual symptms are ithing, a dull dis- mfrt made wrse by perids f standing, and pain if an uleratin is present. The skin at the ankle is usually taut frm swelling, shiny, and a brwnish pigmentatin (hem- siderin) ften develps. If the nditin is lngstanding, the subutaneus tissues beme thik and fibrus. Uler- atins may ur, usually just abve the ankle, n the medial r anterir aspet f the leg. Healing results in a thin sar n a fibrti base that ften breaks dwn with minr trauma r further buts f leg swelling. Varisities may appear (Figure 12–3) that are assiated with inm- petent perfrating veins. Cellulitis, whih is ften diffiult t distinguish frm the hemsiderin pigmentatin, may be diagnsed by blanhing erythema with pain.B.  ImagingPa tients with pst-thrmbti syndrme r signs f hrni venus insuffiieny shuld underg duplex ultrasngra- phy t determine whether superfiial reflux is present and t evaluate the degree f deep reflux and bstrutin. »Differential DiagnosisPa tients with heart failure, hrni kidney disease, r dem- pensated liver disease may have bilateral edema f the lwer extremities. Many mediatins an ause edema (eg, al- ium hannel blkers, nnsteridal anti-inflammatry agents, thiazlidinedines). Swelling frm lymphedema invlves the feet and may be unilateral, but varisities are absent. Edema frm these auses pits easily and brawny dislratin is rare. Lipedema is a disrder f adipse tissue that urs almst exlusively in wmen, is bilateral and symmetri, and is haraterized by stpping at a distint line just abve the ankles. Primary varise veins may be diffiult t differentiate frm the sendary varisities f pst-thrmbti syn- drme r venus bstrutin. Other nditins assiated with hrni ulers f the leg inlude neurpathi ulers usually frm diabetes mel- litus, arterial insuffiieny (ften manifests as painful lat- eral ankle ulers with absent pulses; medial ankle ulers, n ▲Figure 12–2. Bilateral pretibial edema and erythema consistent with stasis dermatitis (sometimes mimicking cellulitis) in chronic venous insufficiency. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.) ▲Figure 12–3. Varicose veins, manifested as blue, subcutaneous, tortuous veins more than 3 mm in diam- eter. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  492 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS493 CMDT 2022the  ther hand, are usually due t venus insuffiieny), autimmune diseases (eg, Felty syndrme), sikle ell ane- mia, erythema induratum (bilateral and usually n the psterir aspet f the lwer part f the leg), and fungal infetins. »PreventionI rreversible tissue hanges and assiated mpliatins in the lwer legs an be redued thrugh early and aggressive antiagulatin f aute DVT t minimize the valve damages and by presribing mpressin stkings if hrni edema develps after the DVT has reslved. Treatment f aute ilifemral DVT with atheter-direted thrmblysis r mehanial thrmbetmy des nt redue pst-thrmbti syndrme and hrni venus insuffiieny. »TreatmentA.  General MeasuresFitted , graduated mpressin stkings (20–30 mm Hg pressure r higher) wrn frm the ft t just belw the knee during the day and evening are the mainstays f treat- ment and are usually suffiient. When they are nt, addi- tinal measures, suh as avidane f lng perids f sitting r standing, intermittent elevatins f the invlved leg, and sleeping with the legs kept abve the level f the heart, may be neessary t ntrl the swelling. Pneumati mpressin f the leg, whih an pump the fluid ut f the leg, is used in refratry ases.B.  UlcerationAs  the primary pathlgy is edema and venus hyperten- sin, healing f the uler will nt ur until the edema is ntrlled and mpressin is applied. Cirumferential nnelasti bandages n the lwer leg enhane the pumping atin f the alf musles n venus bld flw ut f the alf. A lesin an ften be treated n an ambulatry basis by means f a semi-rigid gauze bt made with Unna paste (Gelast, Medipaste) r a multi-layer mpressin dressing (eg, Prfre). Initially, the uler needs t be debrided and the bt hanged every 2–3 days t ntrl uler drainage. As the edema and drainage subside, pti- mal healing is ahieved when the bt is kept in plae fr 5–7 days. The uler, tendns, and bny prminenes must be adequately padded. Alternatively, knee-high graduated mpressin stkings with an absrbent dressing may be used, if wund drainage is minimal. Hme mpressin therapy with a pneumati mpressin devie is used in refratry ases, but many patients have severe pain with the “milking” atin f the pump devie. Sme patients will require admissin fr mplete bed rest and leg elevatin t ahieve uler healing. After the uler has healed, daily graduated mpressin stking therapy is mandatry t prevent uler reurrene.C.  Vein Treatment Reflux or ObstructionT reatment f superfiial vein reflux (see Varise Veins se- tin, abve) has been shwn t derease the reurrene rate f venus ulers. Where there is substantial bstrutin fthe femral and ppliteal deep venus system, superfiial varisities supply the venus return and they shuld nt be remved. Venus stents as treatment f hrni ilia deep vein stensis r bstrutin may imprve venus uler healing and redue the uler reurrene rate in severe ases. »PrognosisIndivid uals with hrni venus insuffiieny ften have reurrent edema, partiularly if they d nt nsistently wear supprt stkings that have at least 20–30 mm Hg mpressin. »When to Refer• Patients with signifiant saphenus reflux shuld be evaluated fr ablatin. •Patients with ulers shuld be mnitred by an interdis- iplinary wund are team s that these hallenging wunds reeive aggressive are.Raffett  JD. Pathphysilgy f hrni venus disease and venus ulers. Surg Clin Nrth Am. 2018;98:337. [PMID: 29502775] Vedantham S et al; ATTRACT Trial Investigatrs. Pharmam- ehanial atheter-direted thrmblysis fr deep-vein thrmbsis. N Engl J Med. 2017;377:2240. [PMID: 29211671]SU PERIOR VENA CAVAL OBSTRUCTIONE S S E N T I A L S  O F  D I A G N O S I S »Swelling of the neck, face, and upper extremities. »Dilated veins over the upper chest and neck. »General ConsiderationsP artial r mplete bstrutin f the superir vena ava is a relatively rare nditin that is usually sendary t neplas- ti r inflammatry presses in the superir mediastinum. The mst frequent auses are (1) neplasms, suh as lymph- mas, primary malignant mediastinal tumrs, r arinma f the lung with diret extensin (ver 80%); (2) hrni fibrti mediastinitis, either f unknwn rigin r sendary t tuberulsis, histplasmsis, pygeni infetins, r drugs, espeially methysergide; (3) DVT, ften by extensin f the press frm the axillary r sublavian vein int the innmi- nate vein and vena ava assiated with atheterizatin f these veins fr dialysis r fr hyperalimentatin; (4) aneu- rysm f the arti arh; and (5) nstritive periarditis. »Clinical FindingsA.  Symptoms and SignsThe  nset f symptms is aute r subaute. Symptms inlude swelling f the nek and fae and upper extremities. Symptms are ften pereived as ngestin and present asCMDT22_Ch12_p0475-p0501.indd  493 29/06/21 8:38 PMCHAPTER 12494 CMDT 2022heada he, dizziness, visual disturbanes, stupr, synpe, r ugh. There is prgressive bstrutin f the venus drainage f the head, nek, and upper extremities. The uta- neus veins f the upper hest and lwer nek beme dilated, and flushing f the fae and nek develps. Brawny edema f the fae, nek, and arms urs later, and yansis f these areas then appears. Cerebral and laryngeal edema ultimately result in impaired funtin f the brain as well as respiratry insuffiieny. Bending ver r lying dwn aentuates the symptms; sitting quietly is generally pre- ferred. The manifestatins are mre severe if the bstru- tin develps rapidly and if the azygs juntin r the vena ava between that vein and the heart is bstruted.B.  Laboratory FindingsThe ven us pressure is elevated (ften mre than 20 m f water) in the arm and is nrmal in the leg. Sine lung aner is a mmn ause, brnhspy is ften perfrmed; transbrnhial bipsy, hwever, is relatively ntraindiated beause f venus hypertensin and the risk f bleeding.C.  ImagingChest  radigraphs and a CT san an define the latin and ften the nature f the bstrutive press, and n- trast vengraphy r magneti resnane vengraphy (MRV) will map ut the extent and degree f the venus bstrutin and the llateral irulatin. Brahial veng- raphy r radinulide sanning fllwing intravenus injetin f tehnetium (T-99m) pertehnetate demn- strates a blk t the flw f ntrast material int the right heart and enlarged llateral veins. These tehniques als allw estimatin f bld flw arund the lusin as well as serial evaluatin f the respnse t therapy. »TreatmentCnser vative measures, suh as elevatin f the head f the bed and lifestyle mdifiatin t avid bending ver, are useful. Balln angiplasty f the bstruted aval segment mbined with stent plaement prvides prmpt relief f symptms and is the predure f hie fr all etilgies. Oasinally, antiagulatin is needed, while thrmbly- sis is rarely needed. Urgent treatment fr neplasm nsists f (1) autius use f intravenus diuretis and (2) mediastinal irradia- tin, starting within 24 hurs, with a treatment plan designed t give a high daily dse but a shrt ttal urse f therapy t rapidly shrink the lal tumr. Intensive m- bined therapy will palliate the press in up t 90% f patients. In patients with a subaute presentatin, radiatin therapy alne usually suffies. Chemtherapy is added if lymphma r small-ell arinma is diagnsed. Lng-term utme is mpliated by risk f re-lusin frm either thrmbsis r neplasm grwth. Surgial pre- dures t bypass the bstrutin are mpliated by bleed- ing frm high venus pressure. In ases where the thrmbsis is sendary t an indwelling atheter, thrm- blysis may be attempted. Clinial judgment is required sine a lng-standing lt may be fibrti and the risk f bleeding an utweigh the ptential benefit.»PrognosisThe  prgnsis depends n the nature and degree f bstrutin and its speed f nset. Slwly develping frms sendary t fibrsis may be tlerated fr years. A high degree f bstrutin f rapid nset sendary t aner is ften fatal in a few days r weeks beause f inreased intraranial pressure and erebral hemrrhage, but treat- ment f the tumr with radiatin and hemtherapeuti drugs may result in signifiant palliatin. Balln angi- plasty and stenting prvide gd relief but may require re- treatment fr reurrent symptms sendary t thrmbsis r restensis. »When to Refer• Any patient with prgressive head and nek swelling shuld be referred t rule ut superir vena ava syndrme. »When to Admit• Any patient with aute edema f the head and nek r with signs and symptms f airway mprmise, suh as harseness r stridr, shuld be admitted.Kalra  M et al. Endvenus and perative treatment f superir vena ava syndrme. Surg Clin Nrth Am. 2018;98:321. [PMID: 29502774] ºDISEASES OF THE LYMPHATIC CHANNELS LYMPHANGITIS & LYMPHADENITISE S S E N T I A L S  O F  D I A G N O S I S »Red streak from wound or cellulitis toward regional lymph nodes, which are usually enlarged and tender. »Chills, fever, and malaise may be present. »General ConsiderationsL ymphangitis and lymphadenitis are mmn manifesta- tins f a baterial infetin that is usually aused by hemlyti strepti r S aureus (r by bth rganisms) and bemes invasive, generally frm an infeted wund, ellulitis, r an absess. The wund may be very small r superfiial, r an established absess may be present, feed- ing bateria int the lymphatis. The invlvement f the lymphatis is ften manifested by a red streak in the skin extending in the diretin f the reginal lymph ndes. »Clinical FindingsA.  Symptoms and SignsThrbb ing pain is usually present at the site f baterial invasin frm a wund, ellulitis, r absess. Malaise,CMDT22_Ch12_p0475-p0501.indd  494 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS495 CMDT 2022anr exia, sweating, hills, and fever f 38–40°C develp quikly, ften with a rapid pulse. The red streak, when present, may be definite r may be faint and easily missed, espeially in dark-skinned patients. The invlved reginal lymph ndes may be signifiantly enlarged and are usually quite tender. The infetin may prgress rapidly, ften in a matter f hurs, and may lead t septiemia and death.B.  Laboratory FindingsLeukytsis with  a left shift is usually present. Bld ul- tures may be psitive, mst ften fr staphylal r streptal speies. Culture and sensitivity studies f the wund exudate r pus may be helpful in treatment f the mre severe r refratry infetins but are ften diffiult t interpret beause f skin ntaminants. »Differential DiagnosisTh e erythema and induratin f superfiial thrmbphlebitis are lalized in and arund the thrmbsed vein. Venus thrmbsis is nt assiated with lymphadenitis, and a wund f entrane with sendary ellulitis is generally absent. Cat-srath fever (Bartonella henselae) is a ause f lymphadenitis; the ndes, thugh ften very large, are rela- tively nntender. Expsure t ats is mmn, but the patient may have frgtten abut the srath. It is extremely important to differentiate cellulitis from acute streptococcal hemolytic gangrene or a necrotizing soft tissue infection. These are deeper infetins that may be extensive and are ptentially lethal. Patients are mre seriusly ill; there may be redness due t leakage f red ells, reating a nn- blanhing erythema; subutaneus repitus, a late finding, may be palpated r ausultated; and subutaneus air may be present n radigraphy r CT san. Immediate surgial n- sultatin is needed fr wide debridement f all invlved deep tissues if a nertizing infetin is suspeted. »TreatmentA.  General MeasuresPr mpt treatment shuld inlude heat (ht, mist m- presses r heating pad), elevatin when feasible, and immbilizatin f the infeted area. Analgesis may be presribed fr pain.B.  Specific MeasuresEmp iri antibiti therapy fr hemlyti strepti r S aureus (r bth rganisms) shuld always be instituted. Cephalsprins r extended-spetrum peniillins are m- mnly used (eg, ephalexin, 0.5 g rally fur times daily fr 7–10 days; see Table 30–6). Trimethprim-sulfamethxa- zle (tw duble-strength tablets rally twie daily fr 7–10 days) shuld be nsidered when there is nern that the pathgen is MRSA (see Tables 30–4 and 30–6).C.  Wound CareAny  wund that is the initiating site f lymphangitis shuld be treated aggressively. Any nerti tissue must be debrided and lulated pus drained.»PrognosisW ith prper therapy inluding an antibiti effetive against the invading bateria, ntrl f the infetin an usually be ahieved in a few days. Delayed r inadequate therapy an lead t verwhelming infetin with septiemia. »When to Admit• Infetins ausing lymphangitis shuld be treated in the hspital with intravenus antibitis. •Debridement may be required and prmpt surgial nsultatin is prudent.L YMPHEDEMAE S S E N T I A L S  O F  D I A G N O S I S »Painless persistent edema of one or both lower extremities, primarily in young women. »Pitting edema without ulceration, varicosities, or stasis pigmentation. »Lymphangitis and cellulitis may occur. »General ConsiderationsWhen  lymphedema is due t ngenital develpmental abnrmalities nsisting f hypplasti r hyperplasti invlvement f the prximal r distal lymphatis, it is referred t as the primary form . The bstrutin may be in the pelvi r lumbar lymph hannels and ndes when the disease is extensive and prgressive. The secondary form f lymphedema invlves inflammatry r mehani- al lymphati bstrutin frm trauma, reginal lymph nde resetin r irradiatin, r extensive invlvement f reginal ndes by malignant disease r filariasis. Lymph- edema may ur fllwing surgial remval f the lymph ndes in the grin r axillae. Sendary dilatin f the lymphatis that urs in bth frms leads t inmpe- tene f the valve system, disrupts the rderly flw alng the lymph vessels, and results in prgressive stasis f a prtein-rih fluid. Episdes f aute and hrni inflam- matin may be superimpsed, with further stasis and se- ndary fibrsis. »Clinical FindingsH ypertrphy f the limb results, with markedly thikened and fibrti skin and subutaneus tissue (Figure 12–4) in very advaned ases. T2–weighted MRI has been used t identify lymphatis and prximal bstruting masses. Lymphangigraphy and radiative istpe studies may identify fal defets in lymph flw but are f little value in planning therapy. »TreatmentSine there is n  effetive ure fr lymphedema, the treat- ment strategies are designed t ntrl the prblem andCMDT22_Ch12_p0475-p0501.indd  495 29/06/21 8:38 PMCHAPTER 12496 CMDT 2022allw  nrmal ativity and funtin. Mst patients an be treated with sme f the fllwing measures: (1) The flw f lymph ut f the extremity an be aided thrugh inter- mittent elevatin f the extremity, espeially during the sleeping hurs (ft f bed elevated 15–20 degrees, ahieved by plaing pillws beneath the mattress); the nstant use f graduated elasti mpressin stkings; and massage tward the trunk—either by hand r by means f pneumati pressure devies designed t milk edema ut f an extremity. Wund are enters speializ- ing in the are f patients with lymphedema may be help- ful. (2) Sendary ellulitis shuld be avided by means f gd hygiene and treatment f any trihphytsis f the tes. One an infetin starts, it shuld be treated by peri- ds f elevatin and antibiti therapy that vers Staphy- lococcus and Streptococcus rganisms (see Table 30–6). Infetins an be a serius and reurring prblem and are ften diffiult t ntrl. Prphylati antibitis have nt been shwn t be f benefit. (3) Intermittent urses f diureti therapy, espeially in thse with premenstrual r seasnal exaerbatins, are rarely helpful. (4) Amputatin is used nly fr the rare mpliatin f lymphangisar- ma in the extremity. »PrognosisW ith aggressive treatment, inluding pneumati mpres- sin devies, gd relief f symptms an be ahieved. The lng-term utlk is ditated by the assiated nditins and avidane f reurrent ellulitis.Chen  K et al. Surgial management f pstmastetmy lymph- edema and review f the literature. Ann Plast Surg. 2021;86: S173. [PMID: 33346539] ▲Figure 12–4. Lymphedema with a dorsal pedal hump and exaggerated skin folds near the ankle. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)ºSHOCKE S S E N T I A L S  O F  D I A G N O S I S »Hypotension, tachycardia, oliguria, altered mental status. »Peripheral hypoperfusion and impaired oxygen delivery. »Four classifications: hypovolemic, cardiogenic, obstructive, or distributive. »General ConsiderationsShk  urs when the rate f arterial bld flw is inad- equate t meet tissue metabli needs. This results in reginal hypxia and subsequent lati aidsis frm anaerbi metablism in peripheral tissues as well as even- tual end-rgan damage and failure. »ClassificationT able 12–1 utlines mmn auses and mehanisms ass- iated with eah type f shk.A.  Hypovolemic ShockH ypvlemi shk results frm dereased intravasular vlume sendary t lss f bld r fluids and eletr- lytes. The etilgy may be suggested by the linial setting (eg, trauma) r by signs and symptms f bld lss (eg, gastrintestinal bleeding) r dehydratin (eg, vmiting r diarrhea). Cmpensatry vasnstritin may transiently maintain the bld pressure but unreplaed lsses f ver 15% f the intravasular vlume an result in hyptensin and prgressive tissue hypxia.B.  Cardiogenic ShockCardigeni  shk results frm ardia failure with the resultant inability f the heart t maintain adequate tissue perfusin. The linial definitin f ardigeni shk is evidene f tissue hypxia due t dereased ardia utput (ardia index less than 2.2 L/min/m2) in the presene f adequate intravasular vlume. This is mst ften aused by myardial infartin but an als be due t ardimy- pathy, myardial ntusin, valvular inmpetene r stensis, r arrhythmias. See Chapter 10.C.  Obstructive ShockPe riardial tampnade, tensin pneumthrax, and mas- sive pulmnary emblism an ause an aute derease in ardia utput resulting in shk. These are medial emer- genies requiring prmpt diagnsis and treatment.D . Distributive ShockDistributiv e r vasdilatry shk has many auses inlud- ing sepsis, anaphylaxis, traumati spinal rd injury, rCMDT22_Ch12_p0475-p0501.indd  496 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS497 CMDT 2022aute  adrenal insuffiieny. The redutin in systemi vasular resistane results in inadequate ardia utput and tissue hypperfusin despite nrmal irulatry vlume. 1. Septic shock— Sepsis is the mst mmn ause f dis- tributive shk and arries a mrtality rate f 20–50%. TheSiety f Critial Care Mediine and the Eurpean Siety f Intensive Care Mediine’s 2016 definitin fr sepsis is life-threatening rgan dysfuntin aused by a dysregu- lated hst respnse t infetin frm any rganism (bate- rial, viral, r fungal). Septic shock is linially defined as sepsis with fluid-unrespnsive hyptensin (systli bld pressure less than 100 mm Hg), serum latate level higher than 2 mml/L, and a need fr vaspressrs t keep mean arterial pressure (MAP) abve 65 mm Hg. The mst m- mn ause f septi shk in hspitalized patients is infe- tin with gram-psitive r gram-negative rganisms, with a grwing inidene f infetin frm multidrug-resistant rganisms. Sepsis frm viral and fungal rganisms is inreasing but remain less than that fr baterial infetins. Risk fatrs fr septi shk inlude bateremia, extremes f age, diabetes, aner, immunsuppressin, and histry f a reent invasive predure. a. Clinical tools to identify sepsis and septic shock— The Third Internatinal Cnsensus Definitins fr Sepsis and Septi Shk (SEPSIS-3) remmend using the Sequential Organ Failure Assessment (SOFA) sre t define sepsis (https://en.wikipedia.rg/wiki/SOFA_sre); an inrease f 2 r mre SOFA sre pints in a patient with infetin is diagnsti f sepsis with a predited 10% mrtality. The SEPSIS-3 grup als intrdued the quik SOFA (qSOFA) sring system (https://en.wikipedia.rg/ wiki/SOFA_sre); 1 pint eah is assigned fr hypten- sin (systli bld pressure belw 100 mm Hg), altered mental status, r tahypnea (respiratry rate mre than 22 breaths per minute). A qSOFA sre f 2 r mre in a patient with suspeted infetin suggests wrsened linial utmes and may influene triage deisins fr intensive are unit (ICU)-level are. b. Systemic inflammatory response syndrome (SIRS)— Defined as a systemi respnse t a nnspeifi infetius r nninfetius insult resulting in at least tw f the fllwing findings: (1) bdy temperature higher than 38°C (100.4°F) r lwer than 36°C (96.8°F), (2) heart rate faster than 90 beats per minute, (3) respiratry rate mre than 20 breaths per minute r hyperventilatin with an arterial arbn dixide tensin (Paco2) less than 32 mm Hg, r (4) abnrmal white bld ell unt (greater than 12,000/mL r less than 4000/mL r greater than 10% immature [band] frms). Vasdilatry shk frm SIRS is ften due t burns; panreatitis; autimmune disrders, suh as vasulitis r inflammatry litis; air r amniti fluid emblus; ishemia; r trauma. SIRS is nt inluded in the 2016 frmal diagnsti riteria f sepsis. A 2018 meta- analysis demnstrated that SIRS riteria have higher sensi- tivity than qSOFA and may therefre identify patients with sepsis befre ther tests, suggesting that SIRS may be a better sreening tl fr sepsis, while qSOFA may be better used as a preditr f ICU mrtality. Studies are nging t desribe the ptimal patient ppulatins (emergeny department vs hspitalized nn-ICU patients) where SIRS and qSOFA sring systems shuld be used. 2. Neurogenic shock— Neurgeni shk is aused by traumati spinal rd injury r effets f an epidural r spinal anestheti. This results in lss f sympatheti tneTable 12–1. Classification of shock by mechanism and common causes.Hypovolemic  shock Blood loss Traumatic hemorrhage Exsanguination Hemothorax Hemoperitoneum Fracture (femur and pelvis) Nontraumatic hemorrhage Gastrointestinal bleed AAA rupture Ectopic pregnancy rupture Volume loss Burns Skin integrity loss (toxic epidermal necrolysis) Vomiting Diarrhea Hyperosmolar states (diabetic ketoacidosis) Third spacing (eg, ascites, pancreatitis) Decreased intake Cardiogenic shock Dysrhythmia Bradycardias and blocks Tachycardias Myocardial disease Left or right ventricular infarction Dilated cardiomyopathy Mechanical Valvular Aortic regurgitation from dissection Papillary muscle rupture from ischemia Acute valvular rupture from abscess Ventricular aneurysm rupture Ventricular septum rupture Free wall ventricle rupture Obstructive shock Tension pneumothorax Pericardial disease Pericardial tamponade Constrictive pericarditis High-risk (massive) pulmonary embolism Severe pulmonary hypertension Auto PEEP from mechanical ventilation Distributive (vasodilatory) shock Anaphylactic shock Septic shock Neurogenic shock Drug-induced vasodilation Adrenal insufficiency Modified, with permission, from Stone CK, Humphries RL (editors). Current Emergency Diagnosis & Treatment , 7th ed. McGraw-Hill, 2011. AAA, abdominal aortic aneurysm; PEEP , positive end expiratory pressure.CMDT22_Ch12_p0475-p0501.indd  497 29/06/21 8:38 PMCHAPTER 12498 CMDT 2022with a redutin  in systemi vasular resistane and hyp- tensin withut a mpensatry tahyardia. Reflex vagal parasympatheti stimulatin evked by pain, gastri dila- tin, r fright may simulate neurgeni shk, prduing hyptensin, bradyardia, and synpe. 3. Endocrine shock— Endrine shk an arise frm hyperthyridism, hypthyridism, r adrenal insuffi- ieny. Adrenal insuffiieny mst ften urs with abrupt essatin f lng-term rtisterid use, but it an als be preipitated by infetin, trauma, surgery, r pitu- itary injury (leading t sendary adrenal insuffiieny). In additin t hyptensin, symptms inlude weakness, nausea, abdminal pain, and nfusin. Hypthyridism an lead t myxedema ma, presenting with vasdilatin and depressed ardia utput. Shk frm hyperthyrid- ism mst ften prdues high-utput ardia failure. »Clinical FindingsA.  Symptoms and SignsHyp otension is traditinally defined as a systli bld pressure f 90 mm Hg r less r a MAP f less than 60–65 mm Hg but must be evaluated relative t the patient’s nrmal bld pressure. A drp in systli pressure f greater than 10–20 mm Hg r an inrease in pulse f mre than 15 beats per minute with psitinal hange sug- gests depleted intravasular vlume. Hwever, bld pres- sure is ften nt the best indiatr f end-rgan perfusin beause mpensatry mehanisms, suh as inreased heart rate, inreased ardia ntratility, and vasnstritin an ur t prevent hyptensin. Patients with hypten- sin ften have l r mttled extremities and weak r thready peripheral pulses. Splanhni vasnstritin may lead t liguria, bwel ishemia, and liver dysfuntin, whih an ultimately result in multirgan failure. Mentatin may be nrmal r patients may beme restless, agitated, nfused, lethargi, r matse as a result f inadequate perfusin f the brain. Hypovolemic shock is evident when signs f hypper- fusin, suh as liguria, altered mental status, and l extremities, are present. Jugular venus pressure is lw, and there is a narrw pulse pressure indiative f redued strke vlume. Rapid replaement f fluids an restre tis- sue perfusin. In cardiogenic shock, there are als signs f glbal hypperfusin with liguria, altered mental status, and l extremities. Jugular venus pressure is elevated and there may be evidene f pulmnary edema with respi- ratry mprmise in the setting f left-sided heart failure. A transthoracic echocardiogram (TTE) or a transesophageal echocardiogram (TEE) is an effective diagnostic tool to dif- ferentiate hypovolemic from cardiogenic shock. In hypvle- mi shk, the left ventrile will be small beause f dereased filling, but ntratility is ften preserved. In ardigeni shk, there is a derease in left ventriular ntratility. The left ventrile may appear dilated and full beause f the inability f the left ventrile t ejet a suffi- ient strke vlume. Inobstructive shock , the entral venus pressure may be elevated but the TTE r TEE may shw redued left ventriular filling, a periardial effusin in the ase ftampnade, thikened periardium in the ase f periar- ditis, r right ventriular dysfuntin in the ase f massive pulmnary emblism. Periardientesis r periardial windw fr periardial tampnade, hest tube plaement fr tensin pneumthrax, r atheter-direted thrmb- lyti therapy fr massive pulmnary emblism an be life- saving in ases f bstrutive shk. Indistributive shock, signs inlude hyperdynami heart sunds, warm extremities initially, and a wide pulse pres- sure indiative f large strke vlume. The ehardigram may shw a hyperdynami left ventrile. Septic shock is diagnsed when there is linial evidene f infetin in the setting f persistent hyptensin and evidene f rgan hypperfusin, suh as lati aidsis, dereased urinary utput, r altered mental status despite adequate vlume resusitatin. Neurogenic shock is diagnsed when there is evidene f entral nervus system injury and persistent hyptensin despite adequate vlume resusitatin. A his- try f lng-term rtisterid use r thyrid disease an inrease the likelihd f endocrine shock.B.  Laboratory Findings and ImagingBld  speimens shuld be evaluated fr mplete bld unt, eletrlytes, gluse, arterial bld gas determina- tins, agulatin parameters, latate levels, typing and rss-mathing, and baterial ultures. An eletrardi- gram and hest radigraph shuld als be part f the initial assessment. Pint-f-are ultrasngraphy an rapidly assess glbal ardia funtin, presene f periardial effu- sin, and intravasular vlume status via inferir vena ava inspetin in ases f undifferentiated hyptensin. A TTE an mre frmally assess right- and left-sided filling pres- sures and ardia utput. »TreatmentA.  General MeasuresT reatment depends n prmpt diagnsis and an aurate appraisal f initing nditins. Initial management n- sists f basi life supprt with an assessment f the patient’s irulatin, airway, and breathing. This may entail airway intubatin and mehanial ventilatin. Ven- tilatry failure shuld be antiipated in patients with severe metabli aidsis due t shk. Mehanial venti- latin alng with sedatin an derease respiratry musle xygen demand and allw imprved xygen delivery t hypperfused tissues. Intravenus aess and fluid resus- itatin shuld be instituted alng with ardia mnitr- ing and assessment f hemdynami parameters suh as bld pressure and heart rate. Cardia mnitring an detet myardial ishemia r malignant arrhythmias, whih an be treated by standard advaned ardia life supprt (ACLS) prtls. Unrespnsive r minimally respnsive patients shuld have their gluse heked immediately, and if their gluse levels are lw, 1 ampule f 50% dextrse intravenusly shuld be given. An arterial line shuld be plaed fr n- tinuus bld pressure measurement, and an indwelling urinary atheter shuld be inserted t mnitr urinary utput.CMDT22_Ch12_p0475-p0501.indd  498 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS499 CMDT 2022B.  Hemodynamic MeasurementsEarly  nsideratin is given t plaement f a entral venus atheter (CVC) fr infusin f fluids and media- tins and fr hemdynami pressure measurements. A CVC an prvide measurements f the entral venus pressure (CVP) and the entral venus xygen saturatin (SvO2), bth f whih an be used t manage septi and ardigeni shk. Pulmnary artery atheters (PACs) allw measurement f the pulmnary artery pressure, left- sided filling pressure r the pulmnary apillary wedge pressure (PCWP), the mixed venus xygen saturatin (SvO2), and ardia utput. Multiple studies suggest that PACs d nt inrease verall mrtality r length f hspital stay but are assiated with higher use f intrpes and intravenus vasdilatrs in selet grups f ritially ill patients. The attendant risks assiated with PACs (infe- tin, arrhythmias, vein thrmbsis, and pulmnary artery rupture) an be as high as 4–9%; thus, the rutine use f PACs annt be remmended. Hwever, in mplex situ- atins, PACs may be useful in distinguishing between ar- digeni and septi shk, s the value f the infrmatin they might prvide must be arefully weighed in eah patient. TTE is a nninvasive alternative t the PAC. TTE an prvide infrmatin abut the pulmnary artery pres- sure and urrent ardia funtin, inluding ardia ut- put. The SvO2, whih is btained thrugh the CVC, an be used as a surrgate fr the SvO2, whih is btained thrugh the PAC. Pulse pressure variatin, as determined by arterial wavefrm analysis, r strke vlume variatin is muh mre sensitive than CVP as dynami measures f fluid respnsiveness in vlume resusitatin, but these measure- ments have nly been validated in patients wh are mehanially ventilated with tidal vlumes f 8 mL/kg, nt triggering the ventilatr, and in nrmal sinus rhythm. Pint-f-are ultrasund measurements f the inferir vena ava (IVC) an suggest intravasular vlume status and guide fluid replaement. If the patient is mehanially ventilated and the IVC dilates ~15–20% with respiratins, they are likely t respnd t intravenus fluids. If the patient is spntaneusly breathing, they may be fluid- respnsive if their IVC is less than 2 m in diameter and llapses by mre than 50% with eah breath. A CVP less than 5 mm Hg suggests hypvlemia, and a CVP greater than 18 mm Hg suggests vlume verlad, ardia failure, tampnade, r pulmnary hypertensin. A ardia index lwer than 2 L/min/m2indiates a need fr intrpi supprt. A ardia index higher than 4 L/min/m2 in a hyptensive patient is nsistent with early septi shk. The systemi vasular resistane is lw (less than 800 dynes · s/m–5) in sepsis and neurgeni shk and high (greater than 1500 dynes · s/m–5) in hypvlemi and ardigeni shk. Treatment is direted at maintaining a CVP f 8–12 mm Hg, a MAP f 65 mm Hg r higher, a ardia index f 2–4 L/min/m2, and a SvO2greater than 70%.C.  Volume ReplacementV lume replaement is ritial in the initial management f shk. Hemorrhagic shock is treated with immediateeffrts t ahieve hemstasis and rapid infusins f bld substitutes, suh as type-speifi r type O negative paked red bld ells (PRBCs) r whle bld, whih prvides extra vlume and ltting fatrs. Eah unit f PRBC r whle bld is expeted t raise the hematrit by 3%. Hypovolemic shock sendary t dehydratin is managed with rapid bluses f istni rystallid slutins, usually in 1-L inrements. Cardiogenic shock in the absene f fluid verlad requires smaller fluid hallenges, usually in inrements f 250 mL. Septic shock usually requires large vlumes f fluid fr resusitatin (typially 30 mL/kg) as the assiated apillary leak releases fluid int the extravas- ular spae. Caution must be used in cases of large-volume resuscitation with unwarmed fluids because this can produce hypothermia, which can lead to hypothermia-induced coag- ulopathy. Warming f fluids befre administratin an avid this mpliatin. Crystallid slutin is the resusitatin fluid f hie in mst settings. Histrially, 0.9% saline was the mst widely used rystallid slutin in resusitatin. Data sug- gest that balaned rystallids, like latated Ringer slutin r Plasma-Lyte, are assiated with less kidney injury, fewer instanes f hyperhlremi metabli aidsis, and dereased verall mrtality. Cmparisns f 0.9% saline and llid (albumin) slutins in ritially ill patients fund n differene in utme exept in patients with traumati brain injury, where albumin resusitatin led t higher mrtality. Thus, the use f balaned rystallid slutins fr vlume resusitatin in shk is favred. If the patient des nt respnd t fluid resusitatin, early use f vaspressrs shuld be nsidered.D . Early Goal-Directed TherapyCmpensat ed shk an ur in the setting f nrmalized hemdynami parameters with nging glbal tissue hypxia. Traditinal endpints f resusitatin suh as bld pressure, heart rate, urinary utput, mental status, and skin perfusin an therefre be misleading. Fllwing set prtls fr the treatment f septi shk by adjusting the use f fluids, vaspressrs, and intrpes as well as by using bld transfusins t meet hemdynami targets (MAP 65 mm Hg r higher, CVP 8–12 mm Hg, SvO2 greater than 70%) is termed early goal-directed therapy (EGDT). Latate learane f mre than 10% an be used as a substitute fr SvO2riteria if SvO2mnitring is nt available. Tw large randmized trials published in 2014 (Pr- CESS and ARISE) demnstrated n mrtality benefit frm the institutin f the riginal algrithm fr EGDT, but this may have been due t earlier administratin f antibitis, mpnents f EGDT beming part f the “usual are” that liniians deliver, and the effetiveness f eduatin abut deteting and treating sepsis in a timely fashin. The Surviving Sepsis Campaign’s remmendatins fr patients with sepsis r septi shk are t measure latate level; btain bld ultures prir t administratin f brad-spetrum antibitis, which should occur within 1 hour of sepsis diagnosis; and administer 30 mL/kg rystal- lid fr hyptensin r latate greater than 4 mml/L within the first 3 hurs f presentatin. SmallerCMDT22_Ch12_p0475-p0501.indd  499 29/06/21 8:38 PMCHAPTER 12500 CMDT 2022resusita tin vlumes may be apprpriate fr patients with heart failure, irrhsis, r advaned kidney disease. Vas- pressrs shuld be administered fr hyptensin nt respnsive t initial fluid resusitatin t maintain MAP 65 mm Hg r higher. Remeasure latate if initial level was high, and reassess vlume status and tissue perfusin fre- quently. A meta-analysis f hemdynami ptimizatin trials suggests that early treatment befre the develpment f rgan failure results in imprved survival, and patients wh respnd well t initial effrts demnstrate a survival advantage ver nnrespnders.E.  Medications1.  Vasoactive therapy— Vaspressrs and intrpi agents are administered nly after adequate fluid resusitatin. Chie f vasative therapy depends n the presumed etilgy f shk as well as ardia utput. If there is n- tinued hyptensin with evidene f high ardia utput after adequate vlume resusitatin, then vaspressr sup- prt is needed t imprve vasmtr tne. If there is evi- dene f lw ardia utput with high filling pressures, intrpi supprt is needed t imprve ntratility. a. Distributive (vasodilatory) shock— When inreased vasnstritin is required t maintain an ade- quate perfusin pressure, alpha-adrenergi atehlamine agnists (suh as nrepinephrine and phenylephrine) are generally used. Althugh nrepinephrine is bth an alpha- adrenergi and beta-adrenergi agnist, it preferentially inreases MAP ver ardia utput. The initial dse is 1–2 mg/min as an intravenus infusin, titrated t main- tain MAP at 65 mm Hg r higher. The usual maintenane dse is 2–4 mg/min intravenusly (maximum dse is 30 mg/min). Patients with refratry shk may require dsages f 10–30 mg/min intravenusly. Epinephrine, als with bth alpha-adrenergi and beta-adrenergi effets, may be used in severe shk and during aute resusitatin. It is the vaspressr f hie fr anaphylati shk. Fr severe shk, give 1 mg/min as a ntinuus intravenus infusin initially and titrate t hemdynami respnse; the usual dsage range is 1–10 mg/min intravenusly. Dpamine has variable effets arding t dsage. At lw dses (2–5 mg/kg/min intravenusly), stimulatin f dpaminergi and beta-adrenergi reeptrs prdues inreased glmerular filtratin, heart rate, and ntratil- ity. At dses f 5–10 mg/kg/min, beta-1-adrenergi effets predminate, resulting in an inrease in heart rate and ardia ntratility. At higher dses (greater than 10 mg/ kg/min), alpha-adrenergi effets predminate, resulting in peripheral vasnstritin. The maximum dse is typi- ally 50 mg/kg/min. There is n evidene dumenting a survival benefit frm, r the superirity f, a partiular vaspressr in septi shk. Nrepinephrine is the initial vaspressr f hie in septi shk t maintain the MAP at 65 mm Hg r higher. Phenylephrine an be used fr hyperdynami septi shk if dysrhythmias r tahyardias prevent the use f agents with beta-adrenergi ativity. In meta-analyses, the use f dpamine as a first-line vaspressr in septi shk resulted in an increase in 28-day mrtality and a higher inidene farrhythmi events. Dpamine shuld nly be used as an alternative t nrepinephrine in selet patients with septi shk, inluding patients with signifiant bradyardia r lw ptential fr tahyarrhythmias. Vaspressin (antidiureti hrmne r ADH) is ften used as an adjuntive therapy t atehlamine vaspres- srs in the treatment f distributive shk. Vaspressin auses peripheral vasnstritin via V1 reeptrs lated n smth musle ells. Vaspressin als ptentiates the effets f atehlamines n the vasulature and stimulates rtisl prdutin. Intravenus infusin f vaspressin at a lw dse (0.01–0.04 unit/min) as a send agent t nr- epinephrine has been benefiial in septi patients with hyptensin refratry t fluid resusitatin and nven- tinal atehlamine vaspressrs. Higher dses f vas- pressin derease ardia utput and may put patients at greater risk fr splanhni and rnary artery ishemia. Studies d nt favr the use f vaspressin as first-line therapy. Angitensin II, a mpnent f the renin-angitensin- aldsterne system axis, is a ptent diret vasnstritr that ats n the arteries and veins t inrease bld pres- sure. Angitensin II (marketed as Giapreza) an be nsid- ered as an additional agent in vasdilatry shk that is refratry t atehlamines and vaspressin. The rem- mended starting dse is 20 ng/kg/min via ntinuus intra- venus infusin thrugh a entral venus line. It an be titrated every 5 minutes by inrements f up t 15 ng/kg/ min as needed t ahieve MAP gals, but nt t exeed 80 ng/kg/min during the first 3 hurs f use. Maintenane dses shuld nt exeed 40 ng/kg/min. Cnurrent venus thrmbemblism (VTE) prphylaxis is indiated as studies revealed a higher inidene f VTE with angitensin II use. b. Cardiogenic shock— Given meta-analyses du- menting dereased mrtality, expert pinin suggests nr- epinephrine be the first-line vaspressr fr ardigeni shk. Dbutamine, a predminantly beta-adrenergi ag- nist, inreases ntratility and dereases afterlad. It is used fr patients with lw ardia utput and high PCWP but wh d nt have hyptensin. Dbutamine an be added t a vaspressr if there is redued myardial fun- tin (dereased ardia utput and elevated PCWP), r if there are signs f hypperfusin despite adequate vlume resusitatin and an adequate MAP . The initial dse is 0.1–0.5 mg/kg/min intravenus infusin, whih an be titrated every few minutes t hemdynami effet; the usual dsage range is 2–20 mg/kg/min intravenusly. Tahyphylaxis an ur after 48 hurs sendary t the dwn-regulatin f beta-adrenergi reeptrs. Amrinne and milrinne are phsphdiesterase inhibitrs that an be substituted fr dbutamine. These drugs inrease yli AMP levels and inrease ardia ntratility, bypassing the beta-adrenergi reeptr. Vasdilatin is a side effet f bth amrinne and milrinne. 2. Antibiotics— Definitive therapy fr septi shk inludes early initiatin f empiri brad-spetrum antibitis after apprpriate ultures have been btained and within 1 hur f regnitin f septi shk. Imaging studies may prve useful t attempt lalizatin f sures f infetin.CMDT22_Ch12_p0475-p0501.indd  500 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS501 CMDT 2022Surgial  management may als be neessary if nerti tis- sue r lulated infetins are present in attempts t n- trl the sure f infetin (see Table 30–5). 3. Corticosteroids— Crtisterids are the treatment f hie in patients with shk sendary t adrenal insuf- fiieny, defined as a rtisl respnse f 9 mg/dL r less after ne injetin f 250 mg f rtitrpin. Studies supprting rtisterid use in patients with shk frm sepsis r ther etilgies are mixed. Trials where either high r lw dses f rtisterids were administered t patients in septi shk did nt nsistently shw imprved survival. The ADRENAL study demnstrated shrter time t shk reslutin (3 days vs 4 days) but n differene in 90-day mrtality. The APROCCHSS study demnstrated lwer 90-day all-ause mrtality, exept fr thse reeiving hydrrtisne plus fludrrtisne. Ntably, sme wrse utmes were bserved frm inreased rates f sendary infetins. Crtisterids an be administered in refra- try shk t derease shk duratin; the urrent rem- mended regimen is hydrrtisne 50 mg intravenusly every 6 hurs fr 5–7 days.F . Other Treatment ModalitiesCardia  failure may require use f transutaneus r trans- venus paing r plaement f an intra-arterial balln pump r left ventriular assist devie. Emergent revasu- larizatin by perutaneus angiplasty r rnary arterybypass surgery appears t imprve lng-term utme with inreased survival mpared with initial medial sta- bilizatin fr patients with myardial ishemia leading t ardigeni shk (see Chapter 10). Urgent renal replae- ment therapy may be indiated fr maintenane f fluid and eletrlyte balane during aute kidney injury result- ing in shk frm multiple mdalities.Annane  D et al; CRICS-TRIGGERSEP Netwrk. Hydrrti- sne plus fludrrtisne fr adults with septi shk. N Engl J Med. 2018;378:809. [PMID: 29490185] Gand S et al; Japanese Assiatin fr Aute Mediine (JAAM) Sepsis Prgnstiatin in Intensive Care Unit and Emergeny Rm (SPICE) (JAAM SPICE) Study Grup. The SIRS riteria have better perfrmane fr prediting infetin than qSOFA sres in the emergeny department. Si Rep. 2020;10:8095. [PMID: 32415144] Khanna A et al; ATHOS-3 Investigatrs. Angitensin II fr the treatment f vasdilatry shk. N Engl J Med. 2017;377:419. [PMID: 28528561] Rhdes A et al. Surviving Sepsis Campaign: internatinal guide- lines fr management f sepsis and septi shk: 2016. Crit Care Med. 2017;45:486. [PMID: 28098591] Thiele H et al. Management f ardigeni shk mpliating myardial infartin: an update 2019. Eur Heart J. 2019;40:2671. [PMID: 31274157] Venkatesh B et al; ADRENAL Trial Investigatrs and the Australian–New Zealand Intensive Care Siety Clinial Trials Grup. Adjuntive glurtiid therapy in patients with septi shk. N Engl J Med. 2018;378:797. [PMID: 29347874]CMDT22_Ch12_p0475-p0501.indd  501 29/06/21 8:38 PM502 CMDT 2022 ºANEMIAS »General Approach to AnemiasAnemia is presen t in adults if the hematocrit is below 41% (hemoglobin less than 13.6 g/dL [135 g/L]) in males or below 36% (hemoglobin less than 12 g/dL [120 g/L]) in females. Congenital anemia is suggested by the patient’s personal and family history. The most common cause of anemia is iron deficiency. Poor diet may result in folic acid deficiency and contribute to iron deficiency, but bleeding is the most common cause of iron deficiency in adults. Physi- cal examination demonstrates pallor. Attention to physical signs of primary hematologic diseases (lymphadenopathy; hepatosplenomegaly; or bone tenderness, especially in the sternum or anterior tibia) is important. Mucosal changes such as a smooth tongue suggest megaloblastic anemia. Anemias are classified according to their pathophysiologic basis, ie, whether related to diminished production (relative or absolute reticulocytopenia) or to increased production due to accelerated loss of red blood cells (reticulocytosis) (Table 13–1), and according to red blood cell size (Table 13–2). A reticulocy- tosis occurs in one of three pathophysiologic states: acute blood loss, recent replacement of a missing erythropoietic nutrient, or reduced red blood cell survival (ie, hemolysis). A severely microcytic anemia (mean corpuscular volume [MCV] less than 70 fL) is due either to iron deficiency or thalassemia, while a severely macrocytic anemia (MCV greater than 120 fL) is almost always due to either megaloblastic anemia or to cold agglutinins in blood analyzed at room temperature. A bone marrow biopsy is generally needed to complete the evaluation of anemia when the blood laboratory evaluation fails to reveal an etiology, when there are additional cytopenias present, or when an underlying primary or secondary bone marrow pro- cess is suspected.IR ON DEFICIENCY ANEMIAE S S E N T I A L S  O F  D I A G N O S I S »Iron deficiency: serum ferritin is < 12 ng/mL (27 pmol/L) or < 30 ng/mL (67 pmol/L) if also anemic.13Lloyd E. Damon, MD Charalambos Babis Andreadis, MD, MSCEBlood Disorders »Caused by bleeding unless proved otherwise. »Responds to iron therapy. »General ConsiderationsIro n deficiency is the most common cause of anemia worldwide. The causes are listed in Table 13–3. Aside from circulating red blood cells, the major location of iron in the body is the storage pool as ferritin or as hemosiderin in macrophages. The average American diet contains 10–15 mg of iron per day. About 10% of this amount is absorbed in the stomach, duodenum, and upper jejunum under acidic conditions. Dietary iron present as heme is efficiently absorbed (10–20%) but nonheme iron less so (1–5%), largely because of interfer- ence by phosphates, tannins, and other food constituents. The major iron transporter from the diet across the intestinal lumen is ferroportin, which also facilitates the transport of iron to apotransferrin in macrophages for delivery to ery- throid progenitor cells in the bone marrow prepared to syn- thesize hemoglobin. Hepcidin, which is increasingly produced during inflammation, negatively regulates iron transport by promoting the degradation of ferroportin. Small amounts of iron—approximately 1 mg/day—are normally lost through exfoliation of skin and gastrointestinal mucosal cells. Menstrual blood loss plays a major role in iron metabo- lism. The average monthly menstrual blood loss is approxi- mately 50 mL but may be five times greater in some individuals. Women with heavy menstrual losses must absorb 3–4 mg of iron from the diet each day to maintain adequate iron stores, which is not commonly achieved. Women with menorrhagia of this degree will almost always become iron deficient without iron supplementation. In general, iron metabolism is balanced between absorp- tion of 1 mg/day and loss of 1 mg/day. Pregnancy and lacta- tion upset the iron balance, since requirements increase to 2–5 mg of iron per day. Normal dietary iron cannot supply these requirements, and medicinal iron is needed during pregnancy and lactation. Decreased iron absorption can also cause iron deficiency, such as in people affected by celiac disease (gluten enteropathy), and it also commonly occurs after gastric resection or jejunal bypass surgery.CMDT22_Ch13_p0502-p0547.indd  502 29/06/21 8:38 PM"
                ]
              ],
              "shape": {
                "columns": 2,
                "rows": 5
              }
            },
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>string_values</th>\n",
              "      <th>spacy_doc</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>CANCER1613 CMDT 2022Office  of Disease Prevent...</td>\n",
              "      <td>(CANCER1613, CMDT, 2022Office,  , of, Disease,...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>DIABETES MELLITUS &amp; HYPOGLYCEMIA1213 CMDT 2022...</td>\n",
              "      <td>(DIABETES, MELLITUS, &amp;, HYPOGLYCEMIA1213, CMDT...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli...</td>\n",
              "      <td>(NERVOUS, SYSTEM, DISORDERS979, CMDT, 2022al...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>KIDNEY DISEASE913 CMDT 2022Thr  ar svral ...</td>\n",
              "      <td>(KIDNEY, DISEASE913, CMDT, 2022Thr,  , ar, ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Chapter 11444 CMDT 2022Elev ated BP reading (o...</td>\n",
              "      <td>(Chapter, 11444, CMDT, 2022Elev, ated, BP, rea...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                       string_values  \\\n",
              "0  CANCER1613 CMDT 2022Office  of Disease Prevent...   \n",
              "1  DIABETES MELLITUS & HYPOGLYCEMIA1213 CMDT 2022...   \n",
              "2  NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli...   \n",
              "3  KIDNEY DISEASE913 CMDT 2022Thr  ar svral ...   \n",
              "4  Chapter 11444 CMDT 2022Elev ated BP reading (o...   \n",
              "\n",
              "                                           spacy_doc  \n",
              "0  (CANCER1613, CMDT, 2022Office,  , of, Disease,...  \n",
              "1  (DIABETES, MELLITUS, &, HYPOGLYCEMIA1213, CMDT...  \n",
              "2  (NERVOUS, SYSTEM, DISORDERS979, CMDT, 2022al...  \n",
              "3  (KIDNEY, DISEASE913, CMDT, 2022Thr,  , ar, ...  \n",
              "4  (Chapter, 11444, CMDT, 2022Elev, ated, BP, rea...  "
            ]
          },
          "execution_count": 75,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 84,
      "metadata": {},
      "outputs": [],
      "source": [
        "\n",
        "doc_adj = [token.text.lower() for doc in df.spacy_doc for token in doc if token.pos_=='ADJ']\n",
        "doc_noun = [token.text.lower() for doc in df.spacy_doc for token in doc if token.pos_=='NOUN']"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 88,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[('\\ue040f', 282),\n",
              " ('high', 259),\n",
              " ('severe', 222),\n",
              " ('common', 200),\n",
              " ('less', 186),\n",
              " ('retinal', 184),\n",
              " ('such', 183),\n",
              " ('due', 183),\n",
              " ('other', 176),\n",
              " ('daily', 172),\n",
              " ('primary', 158),\n",
              " ('first', 153),\n",
              " ('present', 151),\n",
              " ('chronic', 146),\n",
              " ('-', 141),\n",
              " ('r\\ue03bnal', 140),\n",
              " ('low', 135),\n",
              " ('visual', 130),\n",
              " ('small', 129),\n",
              " ('clinical', 128),\n",
              " ('peripheral', 116),\n",
              " ('renal', 104),\n",
              " ('initial', 103),\n",
              " ('greater', 100),\n",
              " ('higher', 98),\n",
              " ('most', 96),\n",
              " ('acute', 95),\n",
              " ('su\\ue034h', 94),\n",
              " ('early', 91),\n",
              " ('urinary', 91),\n",
              " ('surgical', 87),\n",
              " ('lower', 87),\n",
              " ('similar', 86),\n",
              " ('advanced', 85),\n",
              " ('available', 81),\n",
              " ('multiple', 80),\n",
              " ('colorectal', 79),\n",
              " ('systemic', 79),\n",
              " ('many', 79),\n",
              " ('normal', 77),\n",
              " ('metastatic', 76),\n",
              " ('helpful', 76),\n",
              " ('oral', 74),\n",
              " ('gastric', 73),\n",
              " ('single', 73),\n",
              " ('large', 71),\n",
              " ('optic', 70),\n",
              " ('likely', 68),\n",
              " ('mild', 68),\n",
              " ('several', 68),\n",
              " ('long', 66),\n",
              " ('tubular', 66),\n",
              " ('upper', 65),\n",
              " ('arterial', 65),\n",
              " ('cardiovascular', 62),\n",
              " ('corneal', 61),\n",
              " ('important', 60),\n",
              " ('rare', 60),\n",
              " ('malignant', 60),\n",
              " ('free', 60),\n",
              " ('elevated', 59),\n",
              " ('central', 59),\n",
              " ('significant', 59),\n",
              " ('intraocular', 59),\n",
              " ('local', 58),\n",
              " ('bilateral', 58),\n",
              " ('few', 57),\n",
              " ('new', 56),\n",
              " ('pancreatic', 54),\n",
              " ('topical', 54),\n",
              " ('useful', 53),\n",
              " ('spinal', 53),\n",
              " ('antihypertensive', 53),\n",
              " ('anti', 52),\n",
              " ('diabetic', 51),\n",
              " ('further', 51),\n",
              " ('positive', 50),\n",
              " ('able', 50),\n",
              " ('ocular', 50),\n",
              " ('older', 50),\n",
              " ('adjuvant', 49),\n",
              " ('abdominal', 49),\n",
              " ('more', 49),\n",
              " ('hypertensive', 49),\n",
              " ('fluid', 48),\n",
              " ('effective', 48),\n",
              " ('cardiac', 48),\n",
              " ('anterior', 48),\n",
              " ('poor', 47),\n",
              " ('pleural', 46),\n",
              " ('different', 46),\n",
              " ('least', 46),\n",
              " ('macular', 46),\n",
              " ('adverse', 45),\n",
              " ('pulmonary', 44),\n",
              " ('specific', 44),\n",
              " ('deep', 44),\n",
              " ('systolic', 44),\n",
              " ('neuropathy', 43),\n",
              " ('secondary', 43),\n",
              " ('ne\\ue034essary', 43),\n",
              " ('sudden', 42),\n",
              " ('distal', 41),\n",
              " ('major', 40),\n",
              " ('third', 40),\n",
              " ('\\ue03ab\\ue048ut', 40),\n",
              " ('n\\ue040rmal', 40),\n",
              " ('inflammatory', 39),\n",
              " ('sensitive', 39),\n",
              " ('frequent', 39),\n",
              " ('extensive', 38),\n",
              " ('left', 38),\n",
              " ('vascular', 38),\n",
              " ('\\ue03and', 38),\n",
              " ('m\\ue040st', 38),\n",
              " ('red', 37),\n",
              " ('essential', 37),\n",
              " ('overall', 37),\n",
              " ('benign', 37),\n",
              " ('focal', 37),\n",
              " ('vas\\ue034ular', 37),\n",
              " ('necessary', 36),\n",
              " ('white', 35),\n",
              " ('ischemic', 35),\n",
              " ('glom\\ue03brular', 35),\n",
              " ('limited', 34),\n",
              " ('various', 34),\n",
              " ('hepatocellular', 34),\n",
              " ('partial', 34),\n",
              " ('rapid', 33),\n",
              " ('medical', 33),\n",
              " ('minimal', 33),\n",
              " ('\\ue034ardia\\ue034', 33),\n",
              " ('ing', 32),\n",
              " ('uric', 32),\n",
              " ('posterior', 32),\n",
              " ('larger', 31),\n",
              " ('progressive', 31),\n",
              " ('resistant', 31),\n",
              " ('young', 31),\n",
              " ('active', 31),\n",
              " ('pmnervous', 31),\n",
              " ('pr\\ue040ximal', 31),\n",
              " ('gastrointestinal', 30),\n",
              " ('rash', 30),\n",
              " ('median', 30),\n",
              " ('possible', 30),\n",
              " ('palliative', 30),\n",
              " ('intravenous', 30),\n",
              " ('neurologic', 30),\n",
              " ('t\\ue048', 30),\n",
              " ('cerebral', 30),\n",
              " ('diagnostic', 29),\n",
              " ('non', 29),\n",
              " ('physical', 29),\n",
              " ('complete', 29),\n",
              " ('adequate', 29),\n",
              " ('radical', 29),\n",
              " ('open', 29),\n",
              " ('hepatic', 29),\n",
              " ('vitreous', 29),\n",
              " ('distant', 28),\n",
              " ('mental', 28),\n",
              " ('better', 28),\n",
              " ('asymptomatic', 28),\n",
              " ('patient', 28),\n",
              " ('\\ue034erebr\\ue040spinal', 28),\n",
              " ('n\\ue03bphrotic', 28),\n",
              " ('ipsilateral', 27),\n",
              " ('subsequent', 27),\n",
              " ('same', 27),\n",
              " ('additional', 27),\n",
              " ('proximal', 27),\n",
              " ('ophthalmic', 27),\n",
              " ('fem\\ue040ral', 27),\n",
              " ('neoadjuvant', 26),\n",
              " ('negative', 26),\n",
              " ('familial', 26),\n",
              " ('relative', 26),\n",
              " ('aggressive', 26),\n",
              " ('good', 26),\n",
              " ('intestinal', 26),\n",
              " ('elderly', 26),\n",
              " ('esophageal', 26),\n",
              " ('variable', 26),\n",
              " ('intracranial', 26),\n",
              " ('weekly', 25),\n",
              " ('invasive', 25),\n",
              " ('smaller', 25),\n",
              " ('standard', 25),\n",
              " ('general', 25),\n",
              " ('intensive', 25),\n",
              " ('trigeminal', 25),\n",
              " ('usual', 25),\n",
              " ('t\\ue040', 25),\n",
              " ('\\ue034entral', 25),\n",
              " ('end\\ue040vas\\ue034ular', 25),\n",
              " ('total', 24),\n",
              " ('rectal', 24),\n",
              " ('maximum', 24),\n",
              " ('symptomatic', 24),\n",
              " ('external', 24),\n",
              " ('cystic', 24),\n",
              " ('absent', 24),\n",
              " ('underlying', 24),\n",
              " ('\\ue034ranial', 24),\n",
              " ('lar', 23),\n",
              " ('cutaneous', 23),\n",
              " ('persistent', 23),\n",
              " ('superior', 23),\n",
              " ('unilateral', 23),\n",
              " ('viral', 23),\n",
              " ('preferred', 23),\n",
              " ('genetic', 23),\n",
              " ('immediate', 23),\n",
              " ('urgent', 23),\n",
              " ('\\ue03av\\ue03ail\\ue03able', 23),\n",
              " ('intra\\ue034ranial', 23),\n",
              " ('ventricular', 22),\n",
              " ('regional', 22),\n",
              " ('recurrent', 22),\n",
              " ('short', 22),\n",
              " ('hereditary', 22),\n",
              " ('gross', 22),\n",
              " ('permanent', 22),\n",
              " ('reversible', 22),\n",
              " ('impaired', 22),\n",
              " ('idiopathic', 22),\n",
              " ('imp\\ue040rtant', 22),\n",
              " ('pupillary', 22),\n",
              " ('a\\ue034ute', 22),\n",
              " ('pr\\ue040gressive', 22),\n",
              " ('p\\ue040lyneur\\ue040pathy', 22),\n",
              " ('dry', 21),\n",
              " ('last', 21),\n",
              " ('full', 21),\n",
              " ('meta', 21),\n",
              " ('transient', 21),\n",
              " ('venous', 20),\n",
              " ('abnormal', 20),\n",
              " ('younger', 20),\n",
              " ('biliary', 20),\n",
              " ('painful', 20),\n",
              " ('nal', 20),\n",
              " ('individual', 20),\n",
              " ('atrial', 20),\n",
              " ('medial', 20),\n",
              " ('diuretic', 20),\n",
              " ('anal', 19),\n",
              " ('glomerular', 19),\n",
              " ('postoperative', 19),\n",
              " ('little', 19),\n",
              " ('hyper-', 19),\n",
              " ('myocardial', 19),\n",
              " ('sure', 19),\n",
              " ('s\\ue03bv\\ue03bral', 19),\n",
              " ('l\\ue03bss', 19),\n",
              " ('coronary', 19),\n",
              " ('foreign', 19),\n",
              " ('testicular', 18),\n",
              " ('therapeutic', 18),\n",
              " ('hot', 18),\n",
              " ('moderate', 18),\n",
              " ('second', 18),\n",
              " ('cranial', 18),\n",
              " ('intra-', 18),\n",
              " ('late', 18),\n",
              " ('dominant', 18),\n",
              " ('neur\\ue040pathy', 18),\n",
              " ('superfi\\ue034ial', 18),\n",
              " ('polycystic', 18),\n",
              " ('intermediate', 17),\n",
              " ('like', 17),\n",
              " ('cytotoxic', 17),\n",
              " ('light', 17),\n",
              " ('uncommon', 17),\n",
              " ('average', 17),\n",
              " ('eral', 17),\n",
              " ('mal', 17),\n",
              " ('dependent', 17),\n",
              " ('papillary', 17),\n",
              " ('urothelial', 17),\n",
              " ('nervous', 17),\n",
              " ('p\\ue040ssible', 17),\n",
              " ('lateral', 17),\n",
              " ('syst\\ue03bmic', 17),\n",
              " ('nephrotic', 17),\n",
              " ('current', 16),\n",
              " ('histologic', 16),\n",
              " ('3–4', 16),\n",
              " ('obstructive', 16),\n",
              " ('direct', 16),\n",
              " ('pre-', 16),\n",
              " ('solid', 16),\n",
              " ('worse', 16),\n",
              " ('fewer', 16),\n",
              " ('wide', 16),\n",
              " ('prostatic', 16),\n",
              " ('internal', 16),\n",
              " ('side', 16),\n",
              " ('safe', 16),\n",
              " ('simple', 16),\n",
              " ('t\\ue03able', 16),\n",
              " ('glu\\ue03c\\ue048se', 16),\n",
              " ('\\ue040ral', 16),\n",
              " ('resp\\ue040nsible', 16),\n",
              " ('abd\\ue040minal', 16),\n",
              " ('reflex', 16),\n",
              " ('int\\ue03brstitial', 16),\n",
              " ('retinopathy', 16),\n",
              " ('certain', 15),\n",
              " ('appropriate', 15),\n",
              " ('squamous', 15),\n",
              " ('epithelial', 15),\n",
              " ('right', 15),\n",
              " ('heavy', 15),\n",
              " ('improved', 15),\n",
              " ('optimal', 15),\n",
              " ('adenomatous', 15),\n",
              " ('functional', 15),\n",
              " ('abrupt', 15),\n",
              " ('toxic', 15),\n",
              " ('fatal', 15),\n",
              " ('dietary', 15),\n",
              " ('middle', 15),\n",
              " ('residual', 15),\n",
              " ('l\\ue048wer', 15),\n",
              " ('depressed', 15),\n",
              " ('capillary', 15),\n",
              " ('unresp\\ue040nsive', 15),\n",
              " ('medi\\ue034al', 15),\n",
              " ('marked', 15),\n",
              " ('giant', 15),\n",
              " ('\\ue034ervi\\ue034al', 15),\n",
              " ('fun\\ue034ti\\ue040nal', 15),\n",
              " ('tibial', 15),\n",
              " ('diab\\ue03btic', 15),\n",
              " ('aortic', 15),\n",
              " ('excessive', 15),\n",
              " ('human', 14),\n",
              " ('main', 14),\n",
              " ('sive', 14),\n",
              " ('untreated', 14),\n",
              " ('preoperative', 14),\n",
              " ('annual', 14),\n",
              " ('vein', 14),\n",
              " ('typical', 14),\n",
              " ('equal', 14),\n",
              " ('systematic', 14),\n",
              " ('segmental', 14),\n",
              " ('neu-', 14),\n",
              " ('bacterial', 14),\n",
              " ('autosomal', 14),\n",
              " ('\\ue040ther', 14),\n",
              " ('n\\ue040', 14),\n",
              " ('ven\\ue040us', 14),\n",
              " ('di\\ue03btary', 14),\n",
              " ('adrenal', 13),\n",
              " ('palpable', 13),\n",
              " ('visible', 13),\n",
              " ('mediastinal', 13),\n",
              " ('curative', 13),\n",
              " ('differential', 13),\n",
              " ('difficult', 13),\n",
              " ('intrinsic', 13),\n",
              " ('healthy', 13),\n",
              " ('fecal', 13),\n",
              " ('mixed', 13),\n",
              " ('vertebral', 13),\n",
              " ('sensory', 13),\n",
              " ('ba\\ue034k', 13),\n",
              " ('fa\\ue034ial', 13),\n",
              " ('palsy', 13),\n",
              " ('ax\\ue040nal', 13),\n",
              " ('pati\\ue03bnt', 13),\n",
              " ('n\\ue03bphropathy', 13),\n",
              " ('s\\ue03bcondary', 13),\n",
              " ('nephritic', 13),\n",
              " ('routine', 12),\n",
              " ('immune', 12),\n",
              " ('respiratory', 12),\n",
              " ('select', 12),\n",
              " ('irreversible', 12),\n",
              " ('post', 12),\n",
              " ('feasible', 12),\n",
              " ('unresectable', 12),\n",
              " ('antiviral', 12),\n",
              " ('false', 12),\n",
              " ('longer', 12),\n",
              " ('localized', 12),\n",
              " ('superficial', 12),\n",
              " ('serious', 12),\n",
              " ('gradual', 12),\n",
              " ('slow', 12),\n",
              " ('widespread', 12),\n",
              " ('apparent', 12),\n",
              " ('inadequate', 12),\n",
              " ('microscopic', 12),\n",
              " ('sub-', 12),\n",
              " ('abn\\ue040rmal', 12),\n",
              " ('ass\\ue040\\ue034iated', 12),\n",
              " ('my\\ue040\\ue034ardial', 12),\n",
              " ('bra\\ue034hial', 12),\n",
              " ('incr\\ue03bas\\ue03bd', 12),\n",
              " ('intrav\\ue03bnous', 12),\n",
              " ('m\\ue03bmbranous', 12),\n",
              " ('pmdisorders', 12),\n",
              " ('stromal', 11),\n",
              " ('definitive', 11),\n",
              " ('helical', 11),\n",
              " ('meta-', 11),\n",
              " ('prior', 11),\n",
              " ('usu-', 11),\n",
              " ('stable', 11),\n",
              " ('conventional', 11),\n",
              " ('intrahepatic', 11),\n",
              " ('latter', 11),\n",
              " ('insu-', 11),\n",
              " ('equivalent', 11),\n",
              " ('serial', 11),\n",
              " ('intermittent', 11),\n",
              " ('affected', 11),\n",
              " ('regular', 11),\n",
              " ('pelvic', 11),\n",
              " ('european', 11),\n",
              " ('epidural', 11),\n",
              " ('sexual', 11),\n",
              " ('beneficial', 11),\n",
              " ('ambulatory', 11),\n",
              " ('autonomic', 11),\n",
              " ('\\ue048ften', 11),\n",
              " ('effe\\ue034tive', 11),\n",
              " ('in\\ue034lude', 11),\n",
              " ('additi\\ue040n', 11),\n",
              " ('disturban\\ue034es', 11),\n",
              " ('resp\\ue040nsive', 11),\n",
              " ('\\ue034\\ue040mm\\ue040nly', 11),\n",
              " ('pulm\\ue040nary', 11),\n",
              " ('effe\\ue034ts', 11),\n",
              " ('weak', 11),\n",
              " ('gbm', 11),\n",
              " ('preservative', 11),\n",
              " ('allergic', 11),\n",
              " ('orbital', 11),\n",
              " ('liposomal', 10),\n",
              " ('clear', 10),\n",
              " ('corticosteroid', 10),\n",
              " ('sided', 10),\n",
              " ('cognitive', 10),\n",
              " ('unusual', 10),\n",
              " ('best', 10),\n",
              " ('absolute', 10),\n",
              " ('solitary', 10),\n",
              " ('symp-', 10),\n",
              " ('prognostic', 10),\n",
              " ('male', 10),\n",
              " ('sixth', 10),\n",
              " ('peritoneal', 10),\n",
              " ('slight', 10),\n",
              " ('profound', 10),\n",
              " ('mesenteric', 10),\n",
              " ('prolonged', 10),\n",
              " ('black', 10),\n",
              " ('potent', 10),\n",
              " ('fat', 10),\n",
              " ('refractory', 10),\n",
              " ('ill', 10),\n",
              " ('in\\ue03cre\\ue03ased', 10),\n",
              " ('d\\ue048', 10),\n",
              " ('\\ue03able', 10),\n",
              " ('\\ue046g', 10),\n",
              " ('separate', 10),\n",
              " ('repetitive', 10),\n",
              " ('\\ue040ften', 10),\n",
              " ('adjunctive', 10),\n",
              " ('generalized', 10),\n",
              " ('idi\\ue040pathi\\ue034', 10),\n",
              " ('is\\ue040lated', 10),\n",
              " ('p\\ue040stural', 10),\n",
              " ('l\\ue040w', 10),\n",
              " ('\\ue034\\ue040llateral', 10),\n",
              " ('als\\ue040', 10),\n",
              " ('mus\\ue034ular', 10),\n",
              " ('h\\ue03blpful', 10),\n",
              " ('th\\ue03bs\\ue03b', 10),\n",
              " ('ur\\ue03bmic', 10),\n",
              " ('atopic', 10),\n",
              " ('ml', 10),\n",
              " ('monocular', 10),\n",
              " ('cervical', 9),\n",
              " ('electrolyte', 9),\n",
              " ('erectile', 9),\n",
              " ('nonspecific', 9),\n",
              " ('curable', 9),\n",
              " ('blind', 9),\n",
              " ('inter-', 9),\n",
              " ('key', 9),\n",
              " ('great', 9),\n",
              " ('radia-', 9),\n",
              " ('excellent', 9)]"
            ]
          },
          "execution_count": 88,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "Counter(doc_adj).most_common(500)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 87,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[('patients', 1302),\n",
              " ('%', 1154),\n",
              " ('t\\ue040', 1050),\n",
              " ('\\ue040f', 999),\n",
              " ('disease', 653),\n",
              " ('risk', 576),\n",
              " ('treatment', 534),\n",
              " ('mg', 489),\n",
              " ('f\\ue040r', 476),\n",
              " ('cancer', 446),\n",
              " ('insulin', 437),\n",
              " ('pmid', 426),\n",
              " ('therapy', 422),\n",
              " ('pressure', 372),\n",
              " ('blood', 337),\n",
              " ('p\\ue03atients', 334),\n",
              " ('pain', 267),\n",
              " ('type', 261),\n",
              " ('patient', 223),\n",
              " ('years', 223),\n",
              " ('\\ue048f', 209),\n",
              " ('g', 208),\n",
              " ('b\\ue03b', 207),\n",
              " ('levels', 206),\n",
              " ('days', 198),\n",
              " ('nerve', 198),\n",
              " ('use', 195),\n",
              " ('age', 193),\n",
              " ('kidney', 191),\n",
              " ('\\ue048r', 186),\n",
              " ('survival', 183),\n",
              " ('s', 178),\n",
              " ('day', 175),\n",
              " ('loss', 171),\n",
              " ('t', 170),\n",
              " ('hours', 170),\n",
              " ('stage', 169),\n",
              " ('surgery', 168),\n",
              " ('hypertension', 166),\n",
              " ('t\\ue048', 166),\n",
              " ('pati\\ue03bnts', 165),\n",
              " ('tumors', 164),\n",
              " ('artery', 163),\n",
              " ('diagnosis', 160),\n",
              " ('times', 158),\n",
              " ('\\ue03and', 155),\n",
              " ('\\ue040r', 151),\n",
              " ('tumor', 149),\n",
              " ('cell', 148),\n",
              " ('agents', 147),\n",
              " ('signs', 145),\n",
              " ('weeks', 144),\n",
              " ('»', 138),\n",
              " ('cancers', 136),\n",
              " ('dose', 136),\n",
              " ('inhibitors', 136),\n",
              " ('fr\\ue040m', 136),\n",
              " ('cases', 134),\n",
              " ('injury', 134),\n",
              " ('tion', 133),\n",
              " ('symptoms', 133),\n",
              " ('seizures', 133),\n",
              " ('chemotherapy', 129),\n",
              " ('drugs', 126),\n",
              " ('term', 125),\n",
              " ('\\ue034an', 123),\n",
              " ('nausea', 120),\n",
              " ('side', 119),\n",
              " ('eye', 118),\n",
              " ('rate', 117),\n",
              " ('studies', 117),\n",
              " ('\\ue046g', 116),\n",
              " ('o', 115),\n",
              " ('weight', 114),\n",
              " ('syndrome', 112),\n",
              " ('n', 112),\n",
              " ('\\ue040n', 112),\n",
              " ('prostate', 110),\n",
              " ('level', 109),\n",
              " ('carcinoma', 108),\n",
              " ('liver', 107),\n",
              " ('02/07/21', 103),\n",
              " ('brain', 103),\n",
              " ('infection', 99),\n",
              " ('weakness', 98),\n",
              " ('system', 96),\n",
              " ('resection', 96),\n",
              " ('diabetes', 95),\n",
              " ('dis\\ue03bas\\ue03b', 94),\n",
              " ('months', 93),\n",
              " ('\\ue040\\ue034\\ue034ur', 93),\n",
              " ('men', 92),\n",
              " ('combination', 91),\n",
              " ('serum', 91),\n",
              " ('results', 91),\n",
              " ('l', 91),\n",
              " ('aneurysm', 91),\n",
              " ('year', 90),\n",
              " ('metastases', 90),\n",
              " ('effects', 90),\n",
              " ('management', 89),\n",
              " ('life', 88),\n",
              " ('beta', 88),\n",
              " ('edema', 87),\n",
              " ('drug', 87),\n",
              " ('heart', 86),\n",
              " ('fluid', 86),\n",
              " ('imaging', 86),\n",
              " ('radiation', 85),\n",
              " ('time', 83),\n",
              " ('plasma', 83),\n",
              " ('table', 82),\n",
              " ('vision', 82),\n",
              " ('lesions', 82),\n",
              " ('chapter', 82),\n",
              " ('29/06/21', 81),\n",
              " ('lung', 80),\n",
              " ('study', 80),\n",
              " ('factors', 79),\n",
              " ('aneurysms', 79),\n",
              " ('hem\\ue040rrhage', 79),\n",
              " ('dl', 78),\n",
              " ('f\\ue048r', 78),\n",
              " ('glaucoma', 78),\n",
              " ('failure', 77),\n",
              " ('dysfunction', 77),\n",
              " ('findings', 77),\n",
              " ('obstruction', 76),\n",
              " ('rates', 76),\n",
              " ('history', 76),\n",
              " ('\\ue03are', 76),\n",
              " ('findingsa.', 75),\n",
              " ('minutes', 74),\n",
              " ('p\\ue03atient', 74),\n",
              " ('adults', 73),\n",
              " ('ment', 73),\n",
              " ('head', 73),\n",
              " ('skin', 72),\n",
              " ('lesi\\ue040n', 72),\n",
              " ('trial', 71),\n",
              " ('onset', 70),\n",
              " ('et', 68),\n",
              " ('benefit', 68),\n",
              " ('inhibitor', 68),\n",
              " ('h\\ue040urs', 68),\n",
              " ('diarrhea', 67),\n",
              " ('ing', 67),\n",
              " ('vein', 67),\n",
              " ('tests', 66),\n",
              " ('th\\ue03b', 66),\n",
              " ('function', 65),\n",
              " ('cm', 65),\n",
              " ('line', 65),\n",
              " ('drop', 65),\n",
              " ('calcium', 64),\n",
              " ('screening', 64),\n",
              " ('biopsy', 63),\n",
              " ('blockers', 63),\n",
              " ('tissue', 62),\n",
              " ('status', 61),\n",
              " ('di\\ue03abetes', 61),\n",
              " ('dise\\ue03ase', 61),\n",
              " ('agent', 59),\n",
              " ('guidelines', 59),\n",
              " ('family', 59),\n",
              " ('prognosis', 58),\n",
              " ('complications', 58),\n",
              " ('death', 57),\n",
              " ('site', 57),\n",
              " ('trials', 57),\n",
              " ('control', 57),\n",
              " ('response', 57),\n",
              " ('solution', 57),\n",
              " ('analysis', 56),\n",
              " ('pmchapter', 56),\n",
              " ('d\\ue048se', 56),\n",
              " ('\\ue034ar\\ue040tid', 56),\n",
              " ('cause', 55),\n",
              " ('incidence', 55),\n",
              " ('eg', 55),\n",
              " ('colon', 54),\n",
              " ('receptor', 54),\n",
              " ('fatigue', 54),\n",
              " ('vomiting', 54),\n",
              " ('lymph', 54),\n",
              " ('progression', 54),\n",
              " ('test', 54),\n",
              " ('grade', 53),\n",
              " ('testing', 53),\n",
              " ('review', 53),\n",
              " ('anemia', 53),\n",
              " ('mm', 53),\n",
              " ('effect', 52),\n",
              " ('gene', 51),\n",
              " ('occlusion', 51),\n",
              " ('du\\ue03b', 51),\n",
              " ('tract', 50),\n",
              " ('medications', 50),\n",
              " ('di\\ue03abeti\\ue03c', 50),\n",
              " ('dis\\ue040rders', 50)]"
            ]
          },
          "execution_count": 87,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "Counter(doc_noun).most_common(200)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 57,
      "metadata": {},
      "outputs": [],
      "source": [
        "adj_list = list(set(doc_adj))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 43,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "5060\n"
          ]
        }
      ],
      "source": [
        "print(len(adj_list))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 59,
      "metadata": {},
      "outputs": [],
      "source": [
        "stop_words = [\"patient\", \"may\", \"disease\", \"cause\", \"treatment\", \"also\", \"symptom\", \"usually\", \"sign\",\n",
        "                \"diagnosis\", \"result\", \"pain\", \"include\", \"pressure\", \"lung\", \"pulmonary\", \"respiratory\",\n",
        "                \"chest\", \"fluid\", \"complication\", \"change\", \"blood\", \"infection\", \"therapy\", \"prevent\",\n",
        "                \"acute\", \"care\", \"child\", \"level\", \"air\", \"use\", \"severe\", \"help\", \"used\", \"exercise\",\n",
        "                \"normal\", \"incidence\", \"pneumonia\",\"tissue\", \"show\", \"chronic\", \"failure\", \"cast\", \"increased\",\n",
        "                \"monitor\", \"hypoxemia\", \"produce\", \"edema\", \"increase\", \"space\", \"occurs\", \"cough\", \"alveolar\", \n",
        "                \"heart\", \"pathophysiology\", \"sputum\", \"provide\", \"decreased\", \"pneumothorax\", \"test\", \"special\",\n",
        "                \"tube\", \"condition\", \"common\", \"surgery\",\"secretion\", \"fibrosis\", \"disorder\", \"pa\", \"area\", \"form\",\n",
        "                \"cell\", \"skin\", \"drainage\", \"tb\", \"year\", \"commonly\", \"check\", \"teach\", \"rest\", \"watch\", \"encourage\", \n",
        "                \"underlying\", \"consideration\", \"et\", \"early\", \"hour\", \"family\", \"need\", \"effusion\", \"body\", \"drug\", \"support\", \n",
        "                \"rate\", \"syndrome\", \"requires\", \"inflammation\", \"abg\", \"side\", \"infant\", \"however\", \"upper\", \"cor\", \"pulmonale\",\n",
        "                 \"ventilator\", \"mechanical\", \"breath\", \"maintain\" , \"foot\", \"day\", \"bed\", \"parent\", \"especially\", \"fever\", \"culture\",\n",
        "                'system', 'within', 'factor', 'amount', 'death', 'movement', 'progress', 'volume', 'one', 'stage', 'report',\n",
        "                'avoid', 'respiration', 'trauma', 'occur', 'atelectasis', 'hand', 'includes', 'weight', 'tendon', 'hypertension', \n",
        "                'le', 'time', 'lead', 'damage', 'causing', 'require', 'activity', 'injury', 'risk', 'mm', 'measure', 'examination',\n",
        "                'nerve', 'stress', 'make', 'al', 'see', 'decrease', 'age', 'hg''case', 'month', 'coughing', 'develops', 'formation', \n",
        "                'without', 'site', 'every', 'reduce', 'relieve', 'effect','percussion', 'ordered', 'develop', 'affect', 'loss', 'flow',\n",
        "                'lesion', 'technique', 'exposure', 'gas', 'finding', 'procedure', 'begin', 'wall', 'immediately', 'type', 'response', \n",
        "                'position', 'needed', 'administer', 'control', 'ass', 'increasing', 'although', 'tell', 'output', 'give', 'analysis',\n",
        "                'history', 'often' ,'week', 'home', 'perform','function', 'typically', 'frequently', 'adult', 'indicate', 'administration',\n",
        "                'explain', 'using', 'suggest', 'called', 'center', 'head', 'people', 'resulting', 'including', 'period', 'feature', 'case','pmid','tion','eg','pmchapter','med'\n",
        "                   ]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 60,
      "metadata": {},
      "outputs": [],
      "source": [
        "new_stopwords = adj_list+stop_words"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 61,
      "metadata": {},
      "outputs": [],
      "source": [
        "stpwrd = stopwords.words('english')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 62,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            " adjective words = 5060\n",
            " topic domain stop words = 222\n",
            " marge adj_list & stop_words =  5282\n",
            " english stop words = 198\n"
          ]
        }
      ],
      "source": [
        "print(f' adjective words = {len(adj_list)}')\n",
        "print(f' topic domain stop words = {len(stop_words)}')\n",
        "print(f' marge adj_list & stop_words =  {len(new_stopwords)}')\n",
        "print(f' english stop words = {len(stpwrd)}')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 63,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "after marge all of the stop words = 5480\n"
          ]
        }
      ],
      "source": [
        "stpwrd.extend(new_stopwords)\n",
        "\n",
        "print(f'after marge all of the stop words = {len(stpwrd)}')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 65,
      "metadata": {},
      "outputs": [],
      "source": [
        "wordnet_lemmatizer = WordNetLemmatizer()\n",
        "def text_preprocessing(articles):\n",
        "    tokens = word_tokenize(articles)                                            # Tokenize the article: tokens\n",
        "    lower_tokens= [t.lower() for t in tokens]                                   # Convert the tokens into lowercase: lower_tokens\n",
        "    alpha_only = [t for t in lower_tokens if t.isalpha()]                       # Retain alphabetic words: alpha_only\n",
        "    no_stops = [t for t in alpha_only if t not in stopwords.words('english')]   # Remove all stop words: no_stops\n",
        "    lemmatized = [wordnet_lemmatizer.lemmatize(t) for t in no_stops]           # Lemmatize all tokens into a new list: lemmatized\n",
        "    no_stops = [t for t in lemmatized if t not in stpwrd ]                     # Remove all stop words: no_stops\n",
        "    return no_stops\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 66,
      "metadata": {},
      "outputs": [],
      "source": [
        "bow1 = text_preprocessing(article1)\n",
        "bow2 = text_preprocessing(article2)\n",
        "bow3 = text_preprocessing(article3)\n",
        "bow4 = text_preprocessing(article4)\n",
        "bow5 = text_preprocessing(article5)\n",
        "bow6 = text_preprocessing(article6)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 68,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Counter({'kidney': 74, 'study': 71, 'given': 49, 'three': 38, 'unit': 37, 'benefit': 35, 'diabetes': 34, 'glucose': 34, 'dka': 32, 'g': 29, 'b': 25, 'pen': 25, 'egfr': 24, 'per': 23, 'either': 22, 'diet': 22, 'pmdiabetes': 21, 'required': 20, 'ldl': 20, 'nph': 20, 'islet': 19, 'mody': 19, 'united': 19, 'event': 19, 'even': 18, 'gene': 16, 'urine': 16, 'plasma': 16, 'whether': 14, 'hypoglycemia': 14, 'lin': 13, 'n': 12, 'inhibitor': 11, 'l': 11, 'cholesterol': 11, 'illness': 10, 'hg': 10, 'laboratory': 10, 'receptor': 10, 'two': 10, 'meal': 10, 'metformin': 10, 'mcg': 10, 'lipid': 9, 'medication': 9, 'ace': 9, 'e': 9, 'size': 9, 'dispensed': 9, 'agent': 9, 'despite': 8, 'action': 8, 'hdl': 8, 'dos': 8, 'unless': 8, 'prefilled': 8, 'infused': 8, 'nordisk': 8, 'vessel': 8, 'shift': 8, 'degree': 7, 'binding': 7, 'thus': 7, 'designed': 7, 'v': 7, 'seen': 7, 'fiber': 7, 'index': 7, 'state': 7, 'subcutaneously': 7, 'delivers': 7, 'lysine': 7, 'lispro': 7, 'novo': 7, 'mix': 7, 'needle': 7, 'instituted': 7, 'si': 7, 'guideline': 7, 'life': 6, 'prevention': 6, 'sample': 6, 'minimed': 6, 'lipoprotein': 6, 'slightly': 6, 'ingested': 6, 'minute': 6, 'analog': 6, 'agonist': 6, 'dinner': 6, 'titer': 6, 'men': 6, 'glargine': 6, 'delivery': 6, 'sensitivity': 6, 'acidosis': 6, 'relief': 6, 'cvd': 6, 'insensitivity': 5, 'identified': 5, 'inhibit': 5, 'pancreatitis': 5, 'intensively': 5, 'ukpds': 5, 'findingsa': 5, 'keep': 5, 'suggests': 5, 'kg': 5, 'strip': 5, 'f': 5, 'te': 5, 'abnormality': 5, 'rise': 5, 'review': 5, 'fda': 5, 'five': 5, 'peak': 5, 'rapidly': 5, 'glulisine': 5, 'syrinx': 5, 'csii': 5, 'still': 5, 'identify': 5, 'icu': 5, 'icma': 5, 'suggested': 4, 'ct': 4, 'requiring': 4, 'er': 4, 'dcct': 4, 'end': 4, 'ada': 4, 'newly': 4, 'diuresis': 4, 'figure': 4, 'plus': 4, 'highly': 4, 'set': 4, 'sweetener': 4, 'otherwise': 4, 'tablet': 4, 'pioglitazone': 4, 'lowering': 4, 'syringe': 4, 'giving': 4, 'bind': 4, 'ure': 4, 'hypersensitivity': 4, 'nine': 4, 'r': 4, 'table': 4, 'detemir': 4, 'degludec': 4, 'supply': 4, 'preparation': 4, 'lilly': 4, 'us': 4, 'management': 4, 'night': 4, 'bedtime': 4, 'issue': 4, 'value': 4, 'severity': 4, 'mri': 4, 'ketone': 4, 'ria': 4, 'proinsulin': 4, 'measurement': 4, 'pnets': 4, 'mortality': 4, 'resistance': 3, 'six': 3, 'atp': 3, 'defect': 3, 'puberty': 3, 'reverse': 3, 'diabetesthe': 3, 'ci': 3, 'subsequently': 3, 'persist': 3, 'suffered': 3, 'lens': 3, 'gresses': 3, 'quently': 3, 'tubule': 3, 'c': 3, 'fasting': 3, 'testing': 3, 'expense': 3, 'line': 3, 'http': 3, 'tend': 3, 'fruit': 3, 'primarily': 3, 'bile': 3, 'user': 3, 'flushing': 3, 'gliclazide': 3, 'noted': 3, 'repaglinide': 3, 'nateglinide': 3, 'breakfast': 3, 'release': 3, 'xr': 3, 'exenatide': 3, 'liraglutide': 3, 'delivering': 3, 'semaglutide': 3, 'take': 3, 'empagliflozin': 3, 'symlin': 3, 'reserve': 3, 'cyp': 3, 'suspended': 3, 'find': 3, 'tends': 3, 'tide': 3, 'exendin': 3, 'linked': 3, 'seek': 3, 'gliptin': 3, 'ii': 3, 'density': 3, 'eight': 3, 'fiasp': 3, 'reversed': 3, 'humalog': 3, 'sanofi': 3, 'persists': 3, 'tive': 3, 'led': 3, 'depend': 3, 'jama': 3, 'ica': 3, 'distinguish': 3, 'get': 3, 'tively': 3, 'antibody': 3, 'ent': 3, 'noninsulin': 3, 'efficacy': 3, 'based': 3, 'ckd': 3, 'igg': 3, 'tie': 3, 'penis': 3, 'preexisting': 3, 'bicarbonate': 3, 'signsthe': 3, 'ketoacidosis': 3, 'replenish': 3, 'distress': 3, 'drink': 3, 'suppressed': 3, 'vldl': 3, 'obesity': 2, 'prevents': 2, 'dna': 2, 'wolfram': 2, 'ized': 2, 'perk': 2, 'alpelisib': 2, 'hemochromatosis': 2, 'trial': 2, 'dia': 2, 'betes': 2, 'gfr': 2, 'unlike': 2, 'believed': 2, 'inhibiting': 2, 'suggesting': 2, 'shown': 2, 'depending': 2, 'fruity': 2, 'pruritus': 2, 'eruptive': 2, 'wherein': 2, 'presented': 2, 'tolerance': 2, 'permission': 2, 'mb': 2, 'bedridden': 2, 'hemoglobin': 2, 'referred': 2, 'el': 2, 'criterion': 2, 'asting': 2, 'mmol': 2, 'exists': 2, 'finger': 2, 'monitoring': 2, 'wirelessly': 2, 'insight': 2, 'freestyle': 2, 'libre': 2, 'treatmenta': 2, 'curve': 2, 'represents': 2, 'listed': 2, 'beta': 2, 'tolbutamide': 2, 'tolazamide': 2, 'acetohexamide': 2, 'chlorpropamide': 2, 'press': 2, 'dailyup': 2, 'glucotrol': 2, 'meglitinide': 2, 'mitiglinide': 2, 'glucophage': 2, 'dulaglutide': 2, 'filled': 2, 'byetta': 2, 'diluent': 2, 'reaction': 2, 'lixisenatide': 2, 'alogliptin': 2, 'taking': 2, 'sitagliptin': 2, 'canagliflozin': 2, 'bromocriptine': 2, 'colesevelam': 2, 'start': 2, 'nausea': 2, 'intestine': 2, 'ever': 2, 'iii': 2, 'iv': 2, 'gut': 2, 'suppresses': 2, 'drinking': 2, 'glutide': 2, 'express': 2, 'p': 2, 'hip': 2, 'technosphere': 2, 'formulated': 2, 'lyumjev': 2, 'protamine': 2, 'novolog': 2, 'aventis': 2, 'concentration': 2, 'npl': 2, 'length': 2, 'insulet': 2, 'deliver': 2, 'iaa': 2, 'education': 2, 'friend': 2, 'evening': 2, 'specificity': 2, 'carbohydrate': 2, 'lada': 2, 'rent': 2, 'another': 2, 'combination': 2, 'reached': 2, 'cost': 2, 'ar': 2, 'gain': 2, 'bladder': 2, 'consensus': 2, 'ther': 2, 'blunted': 2, 'target': 2, 'aim': 2, 'pregnancy': 2, 'refuse': 2, 'ige': 2, 'extent': 2, 'bmj': 2, 'iris': 2, 'feeling': 2, 'preventing': 2, 'terized': 2, 'inserted': 2, 'aspirin': 2, 'bleeding': 2, 'burden': 2, 'stiffness': 2, 'j': 2, 'iwgdf': 2, 'rev': 2, 'curr': 2, 'getting': 2, 'abetic': 2, 'hyperglycemia': 2, 'sepsis': 2, 'ensues': 2, 'alcohol': 2, 'depleted': 2, 'tients': 2, 'flux': 2, 'sodium': 2, 'kcl': 2, 'clin': 2, 'anion': 2, 'gap': 2, 'rule': 2, 'prognosisthe': 2, 'jbds': 2, 'gen': 2, 'oglycemia': 2, 'upon': 2, 'ingesting': 2, 'occult': 2, 'insulinoma': 2, 'obtain': 2, 'send': 2, 'conclude': 2, 'feeding': 2, 'among': 2, 'hypercholesterolemia': 2, 'apolipoprotein': 2, 'homozygote': 2, 'extremely': 2, 'childhood': 2, 'triglyceride': 2, 'particle': 2, 'hypertriglyceridemia': 2, 'hyperlipidemia': 2, 'atherosclerosis': 2, 'lancet': 2, 'west': 1, 'mellitust': 1, 'ype': 1, 'whenever': 1, 'wnt': 1, 'wrestler': 1, 'glucokinase': 1, 'account': 1, 'mitochondrial': 1, 'leprechaunism': 1, 'exocrine': 1, 'endocrinopathies': 1, 'klinefelter': 1, 'turner': 1, 'others': 1, 'sometimes': 1, 'hnf': 1, 'homeobox': 1, 'mutation': 1, 'trna': 1, 'leu': 1, 'uur': 1, 'inherited': 1, 'midd': 1, 'insipidus': 1, 'tus': 1, 'moad': 1, 'dus': 1, 'thy': 1, 'nent': 1, 'niacin': 1, 'sirolimus': 1, 'acromegaly': 1, 'cushing': 1, 'glucagonoma': 1, 'cirrhosis': 1, 'dystrophy': 1, 'lipodystrophy': 1, 'phenytoin': 1, 'pentamidine': 1, 'calcineurin': 1, 'somatostatinoma': 1, 'hemosiderosis': 1, 'tify': 1, 'erides': 1, 'utility': 1, 'controlfindings': 1, 'resulted': 1, 'definitely': 1, 'edic': 1, 'kingdom': 1, 'tightly': 1, 'trialsa': 1, 'diabetesat': 1, 'lived': 1, 'studied': 1, 'lifestyle': 1, 'interfering': 1, 'urination': 1, 'diverted': 1, 'consciousness': 1, 'presenting': 1, 'obstetrical': 1, 'delivered': 1, 'lb': 1, 'clinistix': 1, 'acanthosis': 1, 'nigricans': 1, 'nape': 1, 'neck': 1, 'velvety': 1, 'appearance': 1, 'umesh': 1, 'masharani': 1, 'mrcp': 1, 'uk': 1, 'vides': 1, 'thereby': 1, 'advantage': 1, 'diagnose': 1, 'load': 1, 'text': 1, 'confirmed': 1, 'repeat': 1, 'speed': 1, 'style': 1, 'link': 1, 'pling': 1, 'expired': 1, 'meter': 1, 'ingly': 1, 'inserting': 1, 'wire': 1, 'drift': 1, 'birth': 1, 'render': 1, 'dieta': 1, 'substituting': 1, 'nut': 1, 'bined': 1, 'list': 1, 'w': 1, 'il': 1, 'sit': 1, 'nutrient': 1, 'indexblood': 1, 'food': 1, 'reference': 1, 'sweetening': 1, 'bulking': 1, 'hsh': 1, 'treating': 1, 'hyperglycemiathe': 1, 'stimulate': 1, 'divide': 1, 'yet': 1, 'tiveness': 1, 'let': 1, 'dymelor': 1, 'diabinese': 1, 'amaryl': 1, 'xl': 1, 'micronase': 1, 'glynase': 1, 'tolinase': 1, 'orinase': 1, 'japan': 1, 'prandin': 1, 'hoursd': 1, 'starlix': 1, 'biguanides': 1, 'thiazolidinediones': 1, 'actos': 1, 'rosiglitazone': 1, 'avandia': 1, 'acarbose': 1, 'precose': 1, 'miglitol': 1, 'glyset': 1, 'voglibose': 1, 'trulicity': 1, 'syringeusual': 1, 'ering': 1, 'neously': 1, 'bydureon': 1, 'powder': 1, 'suspend': 1, 'provided': 1, 'inject': 1, 'victoza': 1, 'adlyxin': 1, 'lyxumia': 1, 'dosesinitial': 1, 'ozempic': 1, 'rybelsus': 1, 'water': 1, 'wait': 1, 'eat': 1, 'nesina': 1, 'linagliptin': 1, 'tradjenta': 1, 'saxagliptin': 1, 'onglyza': 1, 'januvia': 1, 'vildagliptin': 1, 'galvus': 1, 'limit': 1, 'invokana': 1, 'dapagliflozin': 1, 'farxiga': 1, 'jardiance': 1, 'ertugliflozin': 1, 'steglatro': 1, 'cycloset': 1, 'welchol': 1, 'pramlintide': 1, 'vial': 1, 'containing': 1, 'increment': 1, 'initiation': 1, 'aspartate': 1, 'aminotransferase': 1, 'estimated': 1, 'filtration': 1, 'est': 1, 'lized': 1, 'glinide': 1, 'tein': 1, 'upset': 1, 'egfrs': 1, 'interferes': 1, 'sensitize': 1, 'stent': 1, 'safety': 1, 'concern': 1, 'record': 1, 'lifted': 1, 'alt': 1, 'absorption': 1, 'digest': 1, 'undigested': 1, 'return': 1, 'subset': 1, 'design': 1, 'withdrew': 1, 'died': 1, 'versus': 1, 'advised': 1, 'experience': 1, 'existing': 1, 'ney': 1, 'gip': 1, 'teneligliptin': 1, 'issued': 1, 'freely': 1, 'filtered': 1, 'sglt': 1, 'ries': 1, 'nyha': 1, 'grene': 1, 'labeled': 1, 'iapp': 1, 'dizziness': 1, 'recommended': 1, 'actoplusmet': 1, 'oseni': 1, 'insulininsulin': 1, 'differ': 1, 'preserve': 1, 'summary': 1, 'bioavailability': 1, 'administered': 1, 'niacinamide': 1, 'treprostinil': 1, 'citrate': 1, 'interfere': 1, 'hagedorn': 1, 'isophane': 1, 'admelog': 1, 'apidra': 1, 'afrezza': 1, 'ryzodeg': 1, 'lantus': 1, 'toujeo': 1, 'basaglar': 1, 'levemir': 1, 'tresiba': 1, 'origin': 1, 'pensed': 1, 'ration': 1, 'neither': 1, 'tended': 1, 'self': 1, 'predinner': 1, 'dexterity': 1, 'method': 1, 'reused': 1, 'sterility': 1, 'reuse': 1, 'injector': 1, 'owen': 1, 'rying': 1, 'bd': 1, 'kinked': 1, 'ily': 1, 'interrupted': 1, 'closed': 1, 'loop': 1, 'devised': 1, 'iq': 1, 'vide': 1, 'referee': 1, 'whistle': 1, 'transplan': 1, 'eligibility': 1, 'pendent': 1, 'suppress': 1, 'sl': 1, 'obes': 1, 'dk': 1, 'diabetesa': 1, 'distinguishing': 1, 'diabetesan': 1, 'training': 1, 'since': 1, 'probably': 1, 'obligation': 1, 'provides': 1, 'lie': 1, 'nurse': 1, 'prevented': 1, 'hygiene': 1, 'bring': 1, 'serve': 1, 'medicationst': 1, 'setting': 1, 'marker': 1, 'glutamic': 1, 'decarboxylase': 1, 'phosphatase': 1, 'zinc': 1, 'transporter': 1, 'example': 1, 'regimen': 1, 'man': 1, 'assumes': 1, 'consuming': 1, 'approximately': 1, 'drate': 1, 'lunch': 1, 'raised': 1, 'cose': 1, 'must': 1, 'dawn': 1, 'phenomenon': 1, 'somogyi': 1, 'surge': 1, 'shifting': 1, 'sleeve': 1, 'bmi': 1, 'depends': 1, 'split': 1, 'ity': 1, 'controla': 1, 'onstrated': 1, 'regarding': 1, 'microvascular': 1, 'macrovascular': 1, 'decision': 1, 'seven': 1, 'class': 1, 'insulinsif': 1, 'reache': 1, 'except': 1, 'taken': 1, 'know': 1, 'eskd': 1, 'doubling': 1, 'creatinine': 1, 'promote': 1, 'retention': 1, 'fracture': 1, 'cancer': 1, 'vomiting': 1, 'tract': 1, 'dehydration': 1, 'algorithm': 1, 'recommendation': 1, 'panel': 1, 'association': 1, 'hunger': 1, 'tiredness': 1, 'seizure': 1, 'keeping': 1, 'rin': 1, 'blunts': 1, 'group': 1, 'achieved': 1, 'polypharmacy': 1, 'frail': 1, 'expectancypremeal': 1, 'hospitalized': 1, 'fructosamine': 1, 'reliance': 1, 'placed': 1, 'kit': 1, 'ister': 1, 'turned': 1, 'immunopathology': 1, 'iga': 1, 'igd': 1, 'sensitized': 1, 'disfiguring': 1, 'blindness': 1, 'justified': 1, 'jerk': 1, 'dulled': 1, 'feel': 1, 'arthropathy': 1, 'swelling': 1, 'surprisingly': 1, 'reserved': 1, 'distribute': 1, 'ulcer': 1, 'metatarsal': 1, 'arrow': 1, 'dean': 1, 'sm': 1, 'satiani': 1, 'abraham': 1, 'wt': 1, 'color': 1, 'atlas': 1, 'synopsis': 1, 'ive': 1, 'blister': 1, 'burning': 1, 'tyline': 1, 'sleep': 1, 'lessened': 1, 'tried': 1, 'rubbed': 1, 'cachexia': 1, 'trunk': 1, 'pupil': 1, 'neuritis': 1, 'fullness': 1, 'reflux': 1, 'lessness': 1, 'lessen': 1, 'usefulness': 1, 'distended': 1, 'severing': 1, 'persisting': 1, 'resting': 1, 'dil': 1, 'pellet': 1, 'ring': 1, 'kept': 1, 'fitted': 1, 'tilting': 1, 'etdrs': 1, 'edly': 1, 'turbulent': 1, 'gangrene': 1, 'membrane': 1, 'knee': 1, 'leg': 1, 'glistening': 1, 'shin': 1, 'bone': 1, 'tightening': 1, 'tunnel': 1, 'dupuytren': 1, 'ture': 1, 'dish': 1, 'sity': 1, 'engl': 1, 'rj': 1, 'shen': 1, 'ji': 1, 'situationsa': 1, 'hospitalh': 1, 'lenging': 1, 'vice': 1, 'ting': 1, 'view': 1, 'ie': 1, 'patientsee': 1, 'stillbirth': 1, 'severely': 1, 'utilizing': 1, 'nless': 1, 'di': 1, 'ketoacidosise': 1, 'tenderness': 1, 'findingst': 1, 'coma': 1, 'accident': 1, 'uremia': 1, 'leftover': 1, 'might': 1, 'contain': 1, 'elevate': 1, 'keto': 1, 'freezing': 1, 'na': 1, 'niques': 1, 'ter': 1, 'sheet': 1, 'replacementin': 1, 'tely': 1, 'plishes': 1, 'tered': 1, 'potassiumt': 1, 'beginning': 1, 'ecg': 1, 'u': 1, 'bicarbonatethe': 1, 'note': 1, 'liter': 1, 'hyperchloremic': 1, 'revers': 1, 'transition': 1, 'tently': 1, 'lightly': 1, 'hyp': 1, 'erglycemic': 1, 'statee': 1, 'osmolality': 1, 'considerationsth': 1, 'pathogenesisa': 1, 'signsonset': 1, 'tures': 1, 'findingssevere': 1, 'h': 1, 'replacementfluid': 1, 'id': 1, 'insulinless': 1, 'potassiumw': 1, 'ith': 1, 'driving': 1, 'istered': 1, 'phosphateif': 1, 'ten': 1, 'sip': 1, 'lac': 1, 'acidosise': 1, 'hyperventilation': 1, 'represent': 1, 'epinephrine': 1, 'melas': 1, 'ety': 1, 'ethylene': 1, 'ues': 1, 'treatmentaggressiv': 1, 'ºthe': 1, 'tumorse': 1, 'confusion': 1, 'vision': 1, 'anxiety': 1, 'convulsion': 1, 'recovery': 1, 'ninety': 1, 'prerequisite': 1, 'epilepsy': 1, 'whipple': 1, 'slurred': 1, 'field': 1, 'findingsb': 1, 'surreptitious': 1, 'bound': 1, 'act': 1, 'absence': 1, 'testsif': 1, 'sent': 1, 'energy': 1, 'screen': 1, 'assay': 1, 'hospital': 1, 'protocol': 1, 'vised': 1, 'place': 1, 'cannula': 1, 'permit': 1, 'walking': 1, 'obtained': 1, 'frequency': 1, 'fingersticks': 1, 'manifestation': 1, 'neuroglycopenia': 1, 'hydroxybutyrate': 1, 'elapsed': 1, 'followed': 1, 'intravenously': 1, 'simply': 1, 'would': 1, 'collected': 1, 'fluoride': 1, 'ice': 1, 'glycolysis': 1, 'separated': 1, 'receipt': 1, 'arrange': 1, 'tory': 1, 'run': 1, 'localization': 1, 'tumorsafter': 1, 'series': 1, 'subtypes': 1, 'lys': 1, 'hynic': 1, 'nh': 1, 'effluent': 1, 'identifies': 1, 'treatmentthe': 1, 'blindly': 1, 'behind': 1, 'prefer': 1, 'sunitinib': 1, 'nislet': 1, 'hypoglycemiathese': 1, 'stprandial': 1, 'try': 1, 'digested': 1, 'diabetesthis': 1, 'refined': 1, 'hypoglycemiap': 1, 'hla': 1, 'actitious': 1, 'hypoglycemiaf': 1, 'hypoglycemiaa': 1, 'quinine': 1, 'inhibits': 1, 'depleting': 1, 'nad': 1, 'nadh': 1, 'esis': 1, 'dilute': 1, 'gin': 1, 'ensuring': 1, 'blaha': 1, 'md': 1, 'mphthe': 1, 'hypothesis': 1, 'stating': 1, 'development': 1, 'ascvd': 1, 'widely': 1, 'throughout': 1, 'community': 1, 'reduction': 1, 'woman': 1, 'documented': 1, 'lowered': 1, 'data': 1, 'generally': 1, 'tent': 1, 'differing': 1, 'assist': 1, 'cians': 1, 'selecting': 1, 'predominantly': 1, 'developing': 1, 'pathogenesis': 1, 'million': 1, 'involve': 1, 'metabolism': 1, 'tions': 1, 'proprotein': 1, 'convertase': 1, 'protein': 1, 'regulates': 1, 'breakdown': 1, 'transplantation': 1, 'plasmapheresis': 1, 'correct': 1, 'appears': 1, 'confer': 1, 'lifetime': 1, 'heterozygote': 1, 'person': 1, 'caused': 1, 'lipase': 1, 'enables': 1, 'chylomicron': 1, 'chylomicronemiasyndrome': 1, 'hepatosplenomegaly': 1, 'lism': 1, 'named': 1, 'electrophoresed': 1, 'dysbetalipoproteinemia': 1, 'yk': 1, 'chylomicronemia': 1, 'characterized': 1, 'trend': 1, 'cardiovasc': 1, 'hegele': 1, 'ra': 1, 'dyslipidaemias': 1, 'phenotype': 1, 'society': 1, 'task': 1, 'force': 1, 'statement': 1, 'endocrinol': 1, 'khera': 1, 'av': 1, 'matter': 1, 'circulation': 1, 'mortensen': 1, 'infarction': 1, 'vention': 1, 'cohort': 1, 'sniderman': 1, 'ad': 1, 'narrative': 1, 'cardiol': 1, 'li': 1, 'pid': 1, 'fraction': 1, 'diseasein': 1, 'carried': 1, 'molecule': 1, 'sum': 1, 'component': 1, 'pm': 1})\n"
          ]
        }
      ],
      "source": [
        "print(Counter(bow2))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 55,
      "metadata": {},
      "outputs": [],
      "source": [
        "corpus1 = \" \".join(no_stops01)\n",
        "corpus2 = \" \".join(no_stops02)\n",
        "corpus3 = \" \".join(no_stops03)\n",
        "corpus4 = \" \".join(no_stops04)\n",
        "corpus5 = \" \".join(no_stops05)\n",
        "corpus6 = \" \".join(no_stops06)\n",
        "\n",
        "df01 = pd.DataFrame([corpus1], columns=['string_values'])\n",
        "new_row1 = pd.DataFrame({'string_values':[corpus2]})\n",
        "new_row2 = pd.DataFrame({'string_values':[corpus3]})\n",
        "new_row3 = pd.DataFrame({'string_values':[corpus4]})\n",
        "new_row4 = pd.DataFrame({'string_values':[corpus5]})\n",
        "new_row5 = pd.DataFrame({'string_values':[corpus6]})\n",
        "\n",
        "df01 = pd.concat([df01, new_row1], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row2], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row3], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row4], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row5], ignore_index=True)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 56,
      "metadata": {},
      "outputs": [],
      "source": [
        "df = pd.DataFrame([article1], columns=['string_values'])  \n",
        "new_row1 = pd.DataFrame({'string_values':[article2]})\n",
        "new_row2 = pd.DataFrame({'string_values':[article3]})\n",
        "new_row3 = pd.DataFrame({'string_values':[article4]})\n",
        "new_row4 = pd.DataFrame({'string_values':[article5]})\n",
        "new_row5 = pd.DataFrame({'string_values':[article6]})\n",
        "\n",
        "df = pd.concat([df, new_row1], ignore_index=True)\n",
        "df = pd.concat([df, new_row2], ignore_index=True)\n",
        "df = pd.concat([df, new_row3], ignore_index=True)\n",
        "df = pd.concat([df, new_row4], ignore_index=True)\n",
        "df = pd.concat([df, new_row5], ignore_index=True)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 58,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>string_values</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>prevention health promotion tobacco tobacco ht...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>diabetes life islet west diabetes mellitust yp...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>beverage brainstem aura blindness field thria ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>kidney proteinuria found overload proteinuria ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>chapter ated bp reading office pharmacy coat o...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                       string_values\n",
              "0  prevention health promotion tobacco tobacco ht...\n",
              "1  diabetes life islet west diabetes mellitust yp...\n",
              "2  beverage brainstem aura blindness field thria ...\n",
              "3  kidney proteinuria found overload proteinuria ...\n",
              "4  chapter ated bp reading office pharmacy coat o..."
            ]
          },
          "execution_count": 58,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df01.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 59,
      "metadata": {},
      "outputs": [],
      "source": [
        "df01.to_csv('Current Medical Diagnosis1.csv', index=False)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 60,
      "metadata": {},
      "outputs": [],
      "source": [
        "import pickle\n",
        "with open('Current medical diagnosis1.ob', 'wb') as fp:\n",
        "    pickle.dump(stpwrd, fp)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "accelerator": "GPU",
    "colab": {
      "gpuType": "T4",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "diagnosis",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.12.0"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
